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Abstract 
 
Increased release and activity of transglutaminase-2 (TG2) in the tubulointerstitial space has 
been correlated with the progression of kidney fibrosis during chronic kidney disease (CKD), 
a condition for which there is no cure. TG2 extracellular activity contributes to kidney fibrosis 
by determining matrix deposition and resistance to degradation, through calcium dependent 
protein transamidation and matrix recruitment of latent TGF-β1, however, the mechanism of 
TG2 secretion from kidney cells is still unknown. This study aims at elucidating the mechanism 
of TG2 trafficking in CKD as a way to control its release and ultimately limit fibrosis progression.  
The murine unilateral ureteric obstruction (UUO) model of renal fibrosis was employed. Firstly, 
the UUO proteome was resolved and the effect of TG2-KO elucidated by quantitative 
proteomics of kidney homogenates. This led to the identification of markers of CKD strongly 
upregulated at an advanced stage of UUO, some of which were dysregulated in TG2-null 
kidneys, and allowed to set a background for subsequent analyses. Secondly, the TG2 
interactome was generated by developing an original approach, based on quantitative mass 
spectrometry of TG2 immunoprecipitates. This highlighted a significant association of TG2 
with a large cluster of vesicular proteins which increased post-UUO, forming the hypothesis 
that TG2 could be secreted by extracellular vesicles (EV) in CKD. The hypothesis was tested in 
a model of established tubular epithelial cells (TEC), which revealed TG2 in EV mainly of 
intraluminal origin (exosomes). The involvement of cell surface heparan sulfate proteoglycan 
(HSPG) syndecan-4 in the secretion pathway of TG2 was also investigated, and a dual role was 
ascribed to the proteoglycan, supporting both TG2 secretion and extracellular retention of the 
enzyme, with promotion of TGF-β1 activation. 
In conclusion, this study has shown a novel Sdc4-dependent secretion pathway for TG2 by 
TECs via extracellular vesicles, which is relevant to CKD condition. 
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Chapter I: General introduction 
 
1.1 CHRONIC KIDNEY DISEASE (CKD) AND KIDNEY FIBROSIS 
 
1.1.1 Chronic kidney disease  
Chronic kidney disease (CKD) is a pathology characterised by progressive loss of kidney 
structure and function over time. It is a general term defining a heterogeneous group of 
disorders affecting kidney structure and function through different mechanisms (Levey and 
Coresh 2012).  
The most common measurement of kidney function in diagnostic is the glomerular filtration 
rate (GFR), that measures the flow rate of plasma filtration through the kidney. Normally, GFR 
is approximated by a measure of creatinine clearance (estimated GFR, eGFR), calculated as the 
ratio between creatinine concentration in the collected urine and its plasma concentration, 
multiplied for urine flow rate. Cystatin C (CysC) has also been highlighted as a possible marker 
for GFR, with a more stable rate of production by the body and a better correlation with the 
loss of filtration ability (Lopez-Giacoman and Madero 2015, Shlipak, Mattes and Peralta 2013). 
The eGFR formula is normally corrected to normalise the results depending on people’s body 
size, age, ethnicity and sex (Levey, et al. 2009, Levey, et al. 1999).  As a customary practice, the 
eGFR is divided for the body size area of an average man (1.73 m2) and expressed in 
ml/min/1.73 m2. In physiological conditions, GFR is normally around 100-130 mL/min/1.73 
m2 in men and 90-120 ml/min/1.73 m2 in women. Interestingly, after age 40, GFR tends to 
naturally decrease of 0.4-1.2 mL/min per year, which approximately means a reduction of 
kidney function of the 0.5-1% per year (Bochud 2015). 
Five stages of CKD have been defined depending on the GFR: as the disease progresses, GFR 
goes from values ≥ 90 ml/min/1.73 m2 (stage 1) to 60-89 ml/min/1.73 m2 (stage 2), 30-59 
ml/min/1.73 m2 (stage 3), 15-29 ml/min/1.73 m2 (stage 4), and finally to GFR < 15 
ml/min/1.73m2 (stage 5), which is considered as an end stage kidney failure (ESKF), requiring 
replacement therapy (Eknoyan, et al. 2013). Urine abnormalities such as albuminuria 
(Eknoyan, et al. 2013) and proteinuria are also employed to define the gravity of the disease. 
As a general rule, individuals with GFR <60 ml/min/1.73 m2 (stage 3) for at least 3 months are 
regarded as patients with CKD, independently from the presence of kidney damage (Eknoyan, 
et al. 2013, Inker, et al. 2014). 
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CKD is a significant health issue worldwide, as it affects more than the 10% of the world’s 
population, an epidemic comparable with the one of diabetes (Eckardt, et al. 2013) . In Europe, 
CKD prevalence goes from 5.1 to 7.0% for stages 1 and 2 combined, from 4.5 to 5.3% for stage 
3, from 0.1 to 0.4% for the last stages.  Similar numbers can be detected in the United States 
(Coresh, et al. 2007, de Jong, et al. 2008). The more exposed groups are the elderly, given the 
natural loss of kidney function with the progression of age, leading to an approximate loss of 
30% of kidney function as the age of 70 (Bochud 2015). Some ethnic groups are also more 
prone to the disease, such as the Afro-Caribbean groups, probably because of a genetic 
predisposition, and this is connected to a higher risk of hypertension in these groups  (Kopp, 
et al. 2011, Kao, et al. 2008).  
There is no cure for CKD, and the only treatments for end-stage CKD patients are dialysis or 
kidney transplant. Even if only a low percentage CKD patients are at the end stage, CKD 
treatment is a socio-economic burden for the health system, given the extremely high costs of 
replacement therapy and dialysis, and the disrupting effect that these treatments have on the 
life of a patient (Klein, et al. 2011). Typically, at the initial stages there are no symptoms, and 
the early signs of the disease are generally underestimated or not diagnosed.   
 
Despite being mainly known for their function in the urinary system, kidneys play a series roles 
in the regulation of body functions, being directly related to the balance of blood composition 
and pressure (Schnaper and Kopp 2003). Kidney function goes beyond the well-known 
excretory one: through plasma filtering, excretion of waste and reabsorption of water and 
nutrients, kidneys play a crucial part in maintaining body balance, controlling blood osmolality 
in response to antidiuretic hormone (ADH, secreted by the pituitary gland, hypothalamus), 
acid-base balance (reabsorption of bicarbonate from urine, excrete hydrogen ions H+ and NH4+ 
into urine), clearing of toxins, etc. (Schnaper and Kopp 2003). In addition to these roles, 
kidneys perform endocrine functions secreting a series of hormones such calcitriol, 
erythropoietin and renin, the latter involved in the regulation of angiotensin and aldosterone 
level and blood pressure through the renin-angiotensin-aldosterone system (RAAS). 
 
Given the crucial roles of kidneys in the maintenance of body homeostasis and clearing of 
circulating toxic molecules, it is well known that CKD can have damaging effects not only on 
the excretory system. In particular, CKD affects the cardiovascular system even at its earliest 
stages, when not many visible symptoms of renal damage are present (Herzog, et al. 2011, 
Gansevoort, et al. 2013). 
Because the kidney is involved in many other physiological and pathological processes in the 
body, kidney diseases are classically divided in primary diseases, originating in the kidney or 
mainly located in the kidney, and secondary diseases, which have other origins but lead to CKD. 
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Examples of primary kidney disease are congenital diseases (e.g. mutations affecting mesangial 
cells or podocytes), some kinds of diabetic-independent glomerulonephritis, urinary tract 
infection, etc. (Eckardt, et al. 2013). Most end-stage patients are affected by monogenic 
disorders such as polycystic kidney disease, which is the main genetic cause of CKD (Devuyst, 
et al. 2012). 
 
The nephrons are the structural and functional units of the kidneys (Fig. 1.1). Each nephron is 
composed of a corpuscle, that filters the blood and is composed by a capillary tuft called 
glomerulus and a surrounding Bowman’s capsule, and a tubule, that perform both the functions 
of secretion and reabsorption (Fig. 1.1, Table 1.1). Kidney diseases can be distinguished into 
glomerular conditions, if they initially affect the glomerular portion of the nephron, and tubular 
diseases, if they start from the tubules (Fig. 1.1). Glomerular diseases are the large majority of 
the diseases leading to CKD, as the glomerulus is the filtering part of the nephron receiving the 
blood from the system. Even if starting from the glomerulus, the disease eventually 
compromises the tubular portion during its progression (Kaissling, LeHir and Kriz 2013).  
On the other side, few primarily tubular diseases have been reported, which are generally 
triggered by a form of acute kidney injury whose repair processes become chronic and lead to 
the formation foci of tubulointerstitial fibrosis (Kaissling, LeHir and Kriz 2013). Some toxic 
substances, ischemia and ureteric obstruction are considered causes of tubular diseases 
(Kaissling, LeHir and Kriz 2013).  
  
Diabetic nephropathy (DN) and hypertension-associated CKD are the most common causes of 
ESKF in developed societies (Maezawa, Takemoto and Yokote 2015, Levey and Coresh 2012, 
Eckardt, et al. 2013). DN is perhaps the most studied type of CKD, given its frequency in the 
population and its importance in public health. Hyperglycaemia can lead to kidney damage 
through many ways: it affects the integrity of endothelial basement membrane of glomerulus, 
the production of nitric oxide, it promotes the activation of RAAS, the release of reactive oxygen 
species (ROS) and the upregulation of cytokine mediators such as transforming growth factor- 
β (TGF-β) and vascular endothelial growth factor (VEGF) (Nakagawa, et al. 2011, Broekhuizen, 
et al. 2010, Nieuwdorp, et al. 2006, Kuwabara, et al. 2010). Hypertension produces a renal 
damage by increasing blood pressure in the renal capillaries, and ROS production.  
Because of its effect on diabetes and hypertension, obesity may be regarded as an important 
risk factor for CKD (Chen, et al. 2004, Hsu, et al. 2009). 
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Figure 1.1: Kidney structure and main components. (A) Location and anatomy of the human kidney: 
The kidneys are “beans shaped” multi-lobed organs located at the back of the abdomen outside the 
peritoneal cavity. On longitudinal section, the kidney can be distinct into a cortical area, on the outside, 
and a medullar area in the inside. Picture adapted from (Marieb and Hoehn 2007). Internal anatomy of 
the kidney, obtained from Encyclopaedia Britannica (www.britannica.com). (B) Representative 
structure of the nephron and distinction between cortical nephrons and juxtamedullary nephrons, from 
(Marieb and Hoehn 2007). (C) Structure of the renal corpuscle: renal corpuscles occupy only 3 -5% of 
the total kidney (Schnaper and Kopp 2003). They are characterised by a capillary tuft called glomerulus 
that receives blood-to-filter from the renal afferent arterioles, filters it through a process of 
ultrafiltration driven by the high pressure in the capillaries, and drains the filtered blood in into an 
efferent arteriole. The external part of the renal corpuscle is known as the Bowman's capsule and 
receives the filtered material (ultrafiltrate) that will subsequently flow along the renal tubule (Patton 
2015). Distinction into three filtration layers: capillary endothelial cells, characterised by pores 
(fenestrae); the thick glomerular basement membrane (GBM) characterised by a large glycocalyx, acting 
as a negatively charged barrier protecting form the filtration of negative molecules such as serum 
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albumin;  the podocyte layer, specialized foot processed (pedicels) cells that surround the capillary tuft. 
Mesangial cells are specialised cells with characteristics between macrophages and vascular smooth 
muscle cells (Schnaper and Kopp 2003, Patton 2015) located in the interstitial space between capillaries 
and involved in glomerular contraction. Pictures obtained from (Marieb and Hoehn 2007) and (Lee, et 
al. 2015a). Permission to reproduce the picture on the right has been granted by John Wiley and Sons. 
(D) Schematic representation of the renal tubule and collecting duct, with distinctive pattern of 
reabsorption and secretion: at the proximal convoluted tubule (PCT) mostly reabsorption happens, and 
salts, water and molecules such as glucose and amino acids are reabsorbed into peritubular capillaries. 
At the level of the loop of Henle the water and salt exchange takes place: the descending limb of the loop 
of Henle, permeable to water, allows water to exit freely by osmosis into the interstitial space until tonic 
equilibrium. The thin ascending limb, impermeable to water, is characterised by a series of transporters 
that actively pump sodium (Na+) and other ions out from the filtrate into the interstitial capillaries 
(reabsorption) (Patton 2015). At the level of distal convoluted tubule (DCT), active transport of ions in 
both directions happens, and is generally is controlled by hormones. Potassium (K+) is secreted from the 
blood to the ultrafiltrate, while calcium (Ca2+) and Na+ (controlled by aldosterone) are generally 
reabsorbed in the blood stream (Patton 2015). Exchanges of hydrogen (H+) and ammonium (NH4) 
(secreted) and bicarbonate ions (HCO3-, reabsorbed) also happen at this level and control plasma pH. 
The collecting duct system departs from the distal tubules and descends into the medullar area, where 
high levels of Na+ drive water reabsorption through ADH-controlled aquaporins, leading to urine 
concentration (Patton 2015). Picture obtained from (Marieb and Hoehn 2007).  
 
 
 
Table 1.1: Cellular components of the nephron. All cells of the nephron can be affected by CKD.  
Location Cellular types 
Renal corpuscle 
 Mesangial cells (intraglomerular, between capillaries) 
 Fenestrated endothelial cells (capillaries) 
 Podocytes (outer layer of glomerulus) 
 Epithelial cells (Bowman's capsule) 
Tubules 
 Tubular epithelial cells (TECs). 
o Proximal convoluted tubule (PCT): cuboidal epithelial cells with brush 
border (microvilli). Bigger than DCT cells. 
o Descending limb of Loop of Henle: cuboidal epithelial cells (thick) + 
Squamous epithelial cells (thin). 
o Ascending limb of Loop of Henle: cuboidal epithelial cells (thick) + 
Squamous epithelial cells (thin). 
o Distal convoluted tubule (DCT): cuboidal epithelial cells without brush 
border (microvilli). Smaller than PCT cells. 
 Interstitial Fibroblasts /Myofibroblast 
Juxtaglomerular 
apparatus 
(Located between afferent 
arteriole and DCT) 
 Juxtaglomerular cells: specialised smooth muscle cells (known to secrete renin). 
 Epithelial cells (Macula densa – cortical ascending loop of Henle). 
 Mesangial cells (extraglomerular) 
Vascular system 
 Endothelial cells 
 Smooth muscle cells 
 Leucocytes 
 Platelets 
 
 
In summary, several factors can determine CKD, going from diabetes, increase in intravascular 
pressure (hypertension), ureteric obstruction, toxic molecules, immune complexes, 
mechanical insult, genetic mutations, etc.  However, even if the aetiologies of CKD are multiple, 
the main feature that unites all these diseases is a progressive scarring, or fibrosis, of the 
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kidney, that can initiate in any part of the nephron and leads to progressive disruption of renal 
parenchyma and to the organ functional loss, being the main event associated with the 
progression of CKD to ESKF (Liu 2006).  
 
  
1.1.2 Kidney fibrosis 
There is a general agreement in literature that kidney fibrosis is the main common event that 
characterize the progression of virtually any kind of CKD to its end stages and is considered 
the main cause of the progressive kidney function loss observed in CKD (Liu 2006). Kidney 
fibrosis is a progressive and irreversible pathological process which, as any other type of tissue 
fibrosis, may be regarded as an abnormal wound healing process, determined by chronic insult 
of the organ and inflammation. The main characteristics of kidney fibrosis are the accumulation 
of sclerotic tissue and collapse of renal parenchyma that lead to kidney failure (Duffield 2014). 
Fibrotic kidneys show an excessive accumulation and deposition of a pathological extracellular 
matrix (ECM), mainly consisting of collagen I and III, but also collagen IV (deposited in the 
basement membrane) and V, fibronectin (FN), laminin, and heparan sulphate proteoglycans 
(HSPGs). Matrix build up is accompanied by a progressive loss of functional cells and 
vasculature that lead to the loss of renal parenchyma (Hewitson 2012, Liu 2006, Duffield 
2014). While in physiological conditions, ECM synthesis is part of a reparative process, upon 
CKD the excessive synthesis and deposition results in an accumulation of scarring tissue that 
is destructive for the organ function. Parenchyma collapse is caused by cell loss as well as 
accumulation and contraction of ECM fibres, leading to a smaller size of the fibrotic organ, in 
which the scarring tissue results more concentrated (Hewitson 2009).  
As causes of CKD are multiple, and can principally affect the glomerulus, the tubules, and the 
vascular system, renal fibrosis can start in different parts of the nephron depending on the 
initial site of insult. Generally, kidney fibrosis can be distinguished into glomerulosclerosis, if 
it affects the glomerulus, or tubulointerstitial fibrosis, if it affects the tubular interstitium 
(Table 1.2). Since most of nephron volume is made by the tubule (~95%), renal fibrosis is 
generally observed as a tubulointerstitial fibrosis, that happens simultaneously with the 
tubular structure loss (Kaissling, LeHir and Kriz 2013).  
Glomerulosclerosis is characterised by  the thickening of the glomerular basement membrane, 
mesangial cells proliferation and matrix accumulation in the mesangial space (mainly collagen 
IV) and podocyte loss. Matrix accumulation impairs the filtration function of the glomerulus 
and leads to a general hardening of the glomerulus with progressive occlusion. 
Tubulointerstitial fibrosis is instead characterised by accumulation of interstitial matrix, 
fibroblast proliferation and activation, tubular damage and tubular atrophy, as well as capillary 
loss. Accumulation of interstitial matrix within tubules and capillaries impairs their 
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reabsorption/secretion functions (Table 1.2). In some cases, vascular sclerosis can be 
observed, with matrix accumulation, thickening of the tunica media, smooth muscle cells 
proliferation and loss of elasticity (Table 1.2). 
As the disease progresses, leading to ESKF, fibrosis affects all parts of the nephron resulting 
into widespread fibrotic lesions at glomerular, tubular and vascular level. 
 
Table 1.2: Main events in kidney fibrosis. 
Location Progression End stage 
Renal corpuscle 
(Glomerulosclerosis) 
 Mesangial cells proliferation 
 Thickening glomerular basement membrane (GBM) 
 Thickening of Bowman’s capsule 
 Podocyte loss 
 Matrix accumulation in the glomerulus (“hardening”)  
 Progressive occlusion by fibrous tissue accumulation at the 
proximal tubular level 
 Capillary loss 
 Complete 
occlusion of the 
glomerulus 
 Fibrotic “hard” 
glomerulus.  
 Loss of cells 
Tubules 
(Tubulointerstitial 
Fibrosis) 
 Fibroblast/myofibroblast proliferation 
 EMT and EndMT 
 Tubular epithelial cell loss 
 Thickening tubular basement membrane (TBM) 
 Matrix accumulation in the interstitial space.  
 Expansion of interstitial space  
 Tubular atrophy 
 Capillary loss 
 Tubular loss 
 Virtually a-cellular 
sclerotic tissue  
Vascular system 
(Vascular Sclerosis) 
 Matrix accumulation inside the vessel 
 Thickening of the tunica media,  
 Smooth muscle cells proliferation 
 Loss of elasticity of the vessel 
 Vascular calcification can be observed 
 Sclerotic vessels 
 Calcified vessels 
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1.1.2.1 Cellular mechanisms of kidney fibrosis 
At a cellular level, the mechanism of fibrosis shares most pathways with wound healing 
(Verderio, Johnson and Griffin 2004). The main difference is that, in this case, the continuous 
insult and inflammation (chronic) lead to a perpetuation of the healing response, that results 
in an excessive accumulation of ECM beyond the level occurring in the normal wound healing 
response, as well as disruption of the cellular systems.  
The main events that characterize kidney fibrosis can be distinguished into inflammatory 
infiltration, fibrogenic response (glomerulosclerosis and tubulointerstitial fibrosis) and cell 
death (with tubular atrophy, capillary loss and podocyte loss), and eventually lead to 
parenchymal disruption (Liu 2006).  
After the initial injury (insult), kidney resident cells activate and start an inflammatory 
response, with production and secretion of proinflammatory cytokines and chemokines. 
Proinflammatory cytokines and chemokines recruit inflammatory cells by chemotactic 
gradient, leading to infiltration of neutrophils, monocytes/macrophages as well as T cells. 
These cells produce both inflammatory and pro-fibrotic cytokines and injurious molecules 
such as reactive oxygen species (ROS). Main pro-fibrotic cytokines are thought to be TGF-β 
[1.1.2.2] and platelet-derived growth factor (PDGF) (Hewitson 2012). These cytokines mainly 
act in the profibrotic response; however, they are also suggested to contribute to macrophage 
recruitment in the site of injury. Being the process regarded as an uncontrolled wound 
response, other factors might co-participate, such as fibroblast growth factors 1 (FGF1, acidic) 
and 2 (FGF2, basic) and vascular endothelial growth factor (VEGF), interleukins (IL) and 
tumour necrosis factor α (TNFα) (Grazul-Bilska et al., 2003; Schultz & Wysocki, 2009; Werner 
& Grose, 2003).  
 
Pro-fibrotic cytokines and growth factors stimulate the activation of the resident mesenchymal 
cells, their proliferation, and influence ECM-proteins synthesis by these cells. In all kidney 
compartments, fibrosis is associated with at least one type of mesenchymal cells: the 
interstitial fibroblast, the glomerular mesangial cells and vascular smooth muscle cells (Liu 
2006, Hewitson 2012); these cells are phenotypically similar and, when activated, both 
mesangial cells and fibroblasts acquire smooth muscle cells features with de novo synthesis of 
smooth muscle actin (α-SMA)(Darby and Hewitson 2007, Johnson, et al. 1991). These activated 
cells are the principal source of ECM components, in particular collagens I and III and FN (Liu 
2006) and also provide mechanical strength for the contraction of the ECM, thus increasing its 
density (Hewitson 2012). In addition to α-SMA, intermediate filaments proteins are associated 
with the mesenchymal phenotype, such as desmin and vimentin (Raats and Bloemendal 1992). 
Particularly important are the activated renal interstitial fibroblast, regarded as myofibroblast. 
Myofibroblast are recognized by α-SMA (stress fibres) and elevated contractile proprieties and 
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are identified virtually all types of kidney fibrosis. α-SMA is crucial for cell adhesion and 
maturation of focal adhesion sites (Hinz, et al. 2003) and is fundamental for the contractile 
proprieties of myofibroblasts (Hinz, et al. 2001b, Hinz, et al. 2001a). Contraction of 
myofibroblasts seems to depend on a Rho-Kinase pathway that involves myosin phosphatases 
(Tomasek, et al. 2002). 
Myofibroblast expression is largely correlated with the progression of the disease (Hewitson 
2012). While in normal wound healing they contribute to the mechanical tension required for 
wound closure, but disappear by apoptosis as the scar is formed, during kidney fibrosis they 
remain and proliferate in the tissue, leading matrix synthesis and deposition as well as tissue 
contraction (Darby and Hewitson 2007).  
Interestingly, resident interstitial peritubular fibroblasts have been suggested not to be the 
only fount of myofibroblast activation, as other cells such as pericytes/perivascular fibroblasts 
and bone marrow derived cells (fibrocytes) can be activated to myofibroblasts (Meran and 
Steadman 2011, Lin, et al. 2008) .   
 
Phenotypical activation of resident cells is not the only source of myofibroblasts in kidney 
fibrosis. In the context of fibrosis, when the pro-fibrotic stimuli are intense and maintained for 
long times, they not only promote fibroblast activation in a way that is similar to wound-
healing, but also induce transition of tubular epithelial cells (TECs) to mesenchymal features 
through a process that is referred as epithelial to mesenchymal transition (EMT) (Quaggin and 
Kapus 2011). EMT is a mechanism through which the epithelial cells, in this case the tubular 
ones, loose adhesion as well as cell polarity and acquire mesenchymal features with the ability 
to migrate and invade the area. The process of EMT starts with the loss of adhesive proprieties 
in the stimulated (or injured) epithelial cells, followed by expression of α-SMA and cytoskeletal 
modifications, disruption of tubular basement membrane and finally migration and invasion 
(Liu 2004). EMT is characterized by loss of epithelial markers such as E-cadherin, desmoplakin, 
cytokeratin, and de novo expression of mesenchymal markers such as α-SMA, N-cadherin, OB-
cadherin (a better marker of activated fibroblasts), vimentin and fibroblast specific protein 
1(FSP1, or S100A4)(Zeisberg and Neilson 2009). Translocation of β-catenin from the 
membrane to the cytosol and then to the nucleus, where it is involved in transcriptional 
regulation, is another symptom of cells undergoing EMT (Zeisberg and Neilson 2009).   
Interestingly, also injured endothelial cells have been suggested to transition to mesenchymal 
features through similar mechanism. Endothelial to mesenchymal transition (EndMT) has 
been observed in different types of renal fibrosis model such as the unilateral ureteric 
obstruction (UUO), the streptozotocin-induced DN as well as in diabetic kidney biopsies (Li and 
Bertram 2010, Zeisberg, et al. 2008).  
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While myofibroblastic activation of the resident cells is an early response of the kidney tissue 
to pro-fibrotic stimuli and it is also observed in wound healing processes, transition (EMT) of 
the TECs is thought to happen at a later time (Liu 2006, Efstratiadis, et al. 2009).  
 
Proliferative mesenchymal myofibroblastic cells deriving from both processes produce a 
substantial amount of collagen (mainly of subtypes I and III) and FN and have contractile 
proprieties (α-SMA). Continuous deposition of ECM protein by these cells result in the 
progressive accumulation of a fibrous scar. The fibrous scar as well as the myofibroblast 
contraction is thought to induce mechanical injury in the kidney, that determine reduced 
vascularisation (capillary loss), cell atrophy and death and finally parenchymal collapse.  
Pro-fibrotic cytokines and growth factors are not only produced by infiltrating leucocytes but 
also by stimulated epithelial cells, endothelial cells, and by fibroblasts/myofibroblasts, thus 
perpetuating the fibrotic response. Interestingly it has been seen that, if kidney injury is 
chronic or persistent, as in many cases of CKD, injured epithelial cells show an arrest in cell 
cycle between the G2 and M phase and that G2/M-arrested proximal tubular epithelial cells 
(TECs) can upregulate the production of profibrotic cytokines (especially TGF-β) via a JNK (c-
jun NH2-terminal kinase) signalling pathway  (Yang, et al. 2010). 
 
Reduced vascularisation is a consequence of tissue fibrosis and leads to hypoxia, which itself 
has been suggested to act as a profibrotic stimulus, mostly by aim of the hypoxia-inducible 
factor-1 (HIF1), being involved in both EMT and TGF-β activation. This favours the progression 
of the disease through a positive feedback loop in which hypoxia is both effect and promoter 
of fibrosis (Tanaka and Nangaku 2010, Kimura, et al. 2008, Higgins, et al. 2007, Zhang, et al. 
2003, Higgins, et al. 2008).  
Proteinuria is another well-known consequence of kidney disease, frequently employed as a 
marker of renal function loss: the breakage of the glomerular barrier leads to leakage of 
proteins into the urine. At the same time, uremic proteins might be adequately filtered and 
might accumulate in blood; as these proteins are toxic, they can result in tubular inflammation 
in a self-sustained loop that promotes fibrosis (Hewitson 2012, Ihle, et al. 1989).  
 
In many CKD conditions, vascular calcification can also be observed and has been linked with 
elevated risk of mortality. Vascular calcification can be observed in 30-65% of patients with 
stage 3-5 CKD and in most end stage patients (Moe and Chen 2008).  It is considered as a 
response to hyperphosphatemia, uraemia, inflammation and hyperglycaemia, in which 
vascular smooth muscle cells acquire chondrocyte/osteoblast-like features and produce 
“matrix vesicles” from which calcification starts. This process is usually referred as Chronic 
Kidney Disease-Mineral Bone Disorder (CKD-MBD) (Moe and Chen 2008). Reduced Calcitriol 
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production by proximal tubular cells is a cause of vascular calcification, as calcitriol is and 
activated form of Vitamin D that controls calcium absorption and phosphate secretion by the 
kidney.  
Other complications of CKD include anaemia, due to a reduced production of erythropoietin by 
interstitial fibroblasts around the proximal tubule of the kidney.  
 
1.1.2.2 Transforming growth factor β (TGF-β): the main pro-fibrotic cytokine in kidney 
fibrosis  
Transforming growth factor β (TGF-β1, -β2, -β3) is a family of growth factors necessary for 
several cellular processes including wound healing, fibrosis and metastatic cancers. TGF-β is 
synthesized as an immature pro-peptide composed by an N-terminal signal peptide, a latency 
associated peptide (LAP), and the TGF-β peptide. By proteolysis, mature TGF-β is produced, 
dimerizes as an ~25 kDa dimer and remains connected with the LAP peptide by non-covalent 
bonds, forming in what is called small latent TGF-β complex (Annes, Munger and Rifkin 2003, 
Worthington, Klementowicz and Travis 2011). This complex associates to a larger peptide 
called latent TGF-β binding protein (LTBP), which is required for secretion, by disulphide 
bonds. As a result, TGF-β is secreted  and accumulates in the matrix as an inactive latent 
complex referred to as the large latent TGF-β complex, in which the cytokine is complexed with 
the two other proteins, LAP and LTBP (Annes, Munger and Rifkin 2003, Worthington, 
Klementowicz and Travis 2011). This complex is unable to bind cell surface receptors, and 
TGF-β must be released from LAP to be activated.   
TGF-β activation by release of the protein can be mediated by different processes, with 
integrin-mediated activation being the more described. LAP contains Arg-Gly-Asp (RGD) 
domains for integrin binding, and integrins are known as the main inducers of TGF-β 
activation, by promoting mechanical tension or by simultaneously binding proteases and LAP 
(Wipff and Hinz 2008, Hinz 2015, Worthington, Klementowicz and Travis 2011). Moreover, 
activation can be mediated by proteolytic cleavage of LAP, performed by proteases such as 
plasmin or matrix metalloproteases (MMPs), ROS-mediated structural modification of LAP and 
thrombospondin interaction with TGF-β (Annes, Munger and Rifkin 2003). Thrombospondin 
is a matrix glycoprotein known to be upregulated by TGF-β and has been involved in its 
activation upon kidney disease (Daniel, et al. 2004). Acid treatment that denatures LAP leads 
to TGF-β activation in vitro (Annes, Munger and Rifkin 2003). 
Once activated, TGF-β binds two serine/threonine kinase receptors (TGFβRI and TGFβRII) 
resulting in TGFβRI phosphorylation by TβRII, which is constitutively phosphorylated. 
Phosphorylation of the receptor leads to signal transduction by activation of the Smad 
signalling pathway, involved in the transcriptional regulation of several proteins. Briefly, the 
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phosphorylated TGFβRI receptor recruits and phosphorylates R-Smads (receptor regulated 
Smads: Smad2 or Smad3). Smad2/3 then associate to Smad4 (common Smad) and form a 
heterodimer that enters the nucleus and acts as a transcription factor. The TGF-β/Smad 
signalling is regulated at different stages, both pre-receptor and post-receptor, by regulation 
of TGF-β gene expression, activation through different mechanisms, receptor expression and 
post receptor Smad signalling. 
Genes upregulated by TGF-β through Smads are FN, collagen, HSPGs (Kolm, et al. 1996), 
transglutaminase-2 (TG2) and other wound healing - associated proteins such as 
thrombospondin and tenascin, while it downregulates proteins associated with matrix 
degradation, such as some MMPs and plasmin (Varga, Rosenbloom and Jimenez 1987, Ignotz 
and Massague 1986, Roberts, et al. 1990). 
Upregulation of TGF-β has been identified in virtually any kind of CKD. It has been proven to 
stimulate activation of both mesangial cells and interstitial fibroblasts, and transition of TECs 
to myofibroblast in vitro (Fan, et al. 1999, Liu 2006, Liu 2004). Exogenous TGF-β has been 
shown to lead to renal fibrosis, while its inhibition has a protective role in CKD (Liu 2006).  
In kidney disease, both TGF-β expression and activation by release from the latent complex are 
upregulated, and also the expression of TGF-β receptors has been suggested to be increased 
(Böttinger 2007, Bottinger and Bitzer 2002, Lan 2011). All these elements lead to an 
upregulation of TGF-β/Smad signalling. Moreover, some Smad corepressors, known to control 
the effect of Smad signalling in healthy kidneys, have been suggested to be downregulated upon 
kidney fibrosis (Yang, et al. 2003), further increasing the cytokine mediated signalling 
response. TECs express the largest number of TGF-β receptors, hence they have been suggested 
to be the main target of the cytokine, leading to EMT (Liu 2004).  
Glucose and angiotensin II (AngII) have been suggested as possible TGF-β inducers, as well as 
proteinuria and ischemia, while other profibrotic factors, such as connective tissue growth 
factor (CTGF), have been suggested as downstream effectors of TGF-β. CTGF has been 
suggested to be induced by TGF-β and determine myofibroblast differentiation and 
proliferation  (Duncan, et al. 1999, Gupta, et al. 2000, Kothapalli, et al. 1997). 
 
1.1.2.3 Other factors in kidney fibrosis 
Beyond cytokines and growth factors, other molecules can be involved in the promotion of 
kidney fibrosis. For example, as reported before, there is a direct association between diabetes 
and CKD, as an increased glucose concentration is known to determine a fibrotic response 
(Lam, et al. 2003, Li, et al. 2003). Kidney fibrosis has also been suggested to be under the control 
of the RAAS, putting the pathological process in correlation with blood pressure and 
hypertension.  
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There is an association between cardiovascular diseases and kidney fibrosis, which is both 
direct and indirect. On a side, in fact, fibroblast proliferation and ECM deposition is upregulated 
by AngII, that also has inflammatory proprieties and induces TGF-β (Ruiz-Ortega and Egido 
1997, Ruster and Wolf 2006), but also aldosterone and renin have been proposed to play 
profibrotic / profibrogenic roles independently from hypertension (Ruster and Wolf 2006). On 
the other side, hypertension itself induces stress injury in the kidney tissues, indirectly leading 
to fibrosis. In line with these findings, the control of blood pressure has been suggested to be 
renoprotective in models of kidney fibrosis (Lewis, et al. 2001).  
Studies of hypertensive kidney disease have highlighted the presence of renal oxidative stress 
leading to promotion of fibrotic matrix accumulation, and that the oxidative stress is induced 
by prolonged exposure to AngII (Zhao, et al. 2008). Moreover, uremic proteins retained when 
the kidney progressed to failure have been suggested to be toxic in the context of cardiac 
disease (Vanholder, et al. 2003). 
MMPs and plasminogen/plasmin are proteins involved in matrix remodelling and resolution 
of the wound healing process. During wound healing, MMPs are released together with their 
inhibitors (tissue inhibitors of matrix metalloproteases, TIMPs) and control matrix 
remodelling by degrading existing matrix (Schultz and Wysocki 2009). However, some 
extracellular proteases have been associated with the progression of kidney fibrosis by acting 
as signalling molecules, more than simple degrading enzymes (Zhao, et al. 2013). For example, 
gelatinase-A (MMP-2) has been suggested to promote EMT in vitro, and to determine fibrosis 
if overexpressed in mice (Zhao, et al. 2013). Also, MMP-3 has been involved in the process, by 
activating Rac1 small GTPase, which leads to the production of ROS (Zhao, et al. 2013). TGF-β 
-induced shedding of E-cadherin by MMPs has been suggested to induce a signalling pathway 
mediated by β-catenin, which promotes EMT (Zheng, et al. 2009). Increased MMP-9 activity 
has been involved in disruption of tubular basement membrane, which promotes EMT of TECs, 
and tissue-type plasminogen activator (tPA) has been suggested to induce MMP-9 activation 
(Cheng and Lovett 2003, Radisky, et al. 2005, Yang, et al. 2002, Zheng, et al. 2009). 
 
1.1.2.4 Fibronectin (FN) in cell adhesion and matrix accumulation 
FN is a principal component of ECM, necessary for cell adhesion, migration and adhesion-
associated signal transduction. FN is a matrix glycoprotein that organises into insoluble fibres 
though self-association sites; by arranging itself into an insoluble extracellular matrix, FN 
provides a structure on which cells can adhere and spread.  
FN can bind cell surface adhesion receptors such as integrins, through its RGD domains, and 
heparan sulphate (HS) chains of HSPGs, though its heparin-binding sites. This interaction leads 
to the activation of adhesion dependent signalling pathways on the cells, that promote 
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cytoskeletal remodelling necessary for the cell movement. Engagement of FN by cell surface 
HSPG syndecan-4 (Sdc4) triggers focal adhesion and stress fibres formation, providing the 
contractile strength for cell movements, through signalling routes that largely depend on 
protein kinase Cα (PKCα) activation. A specific description of HSPGs involvement in cell matrix 
adhesion and signal transduction will be provided in Chapter VI.  
In addition to its importance in cell adhesion, adhesion-associated signal transduction and cell 
spreading, FN binding to cell surface receptors is also needed for FN polymerisation from 
soluble FN dimers into insoluble FN fibrils. Adhesion-mediated cell mechanical contraction, 
stimulated by Rho family of small GTPases, favours FN assembly into a fibrillar matrix by 
inducing ECM tension, FN stretching and subsequent exposure of otherwise hidden self-
assembly sites (Zhong, et al. 1998, Huveneers, et al. 2008).  
 
In inflammatory conditions, fragmentation of FN leads to release of free RGD sequences, that 
interfere with FN matrix binding to integrins and lead to cell detachment and detachment-
associated cell death, also known as anoikis (Hadden and Henke 2000); this also promotes 
apoptosis by activating caspase-3 (Buckley, et al. 1999). These free RGD peptides are normally 
released in large number during matrix remodelling, necessary in both wound healing and 
angiogenesis, and they are sharply released in kidney fibrosis, due to the activity of specific 
MMPs (Wang, et al. 2010, Verderio, et al. 2003).  
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1.1.3 Experimental models of chronic kidney disease inducing fibrosis 
As reported before, CKD represents a heterogeneous group of diseases with many aetiologies, 
characterised by recurrent or progressive injury of the glomerulus, the tubulointerstitium or 
the vasculature. The most disparate events can affect kidney physiology, ranging from immune 
events, to inflammatory responses, to toxic substances, to metabolic impairment or genetic 
predisposition. For this reason, many animal experimental models of CKD exist in renal 
research, that employ one or more CKD causes to induce the fibrotic response (Table 1.3).  
Animal models of CKD can be distinguished into spontaneous models and acquired models. 
Spontaneous models are generally characterised by a low reproducibility and elevated gender 
and strain bias (Yang, Zuo and Fogo 2010). Some spontaneous models, for example, employ the 
simply aging of animals, mostly rats, which is linked to a natural decrease of renal functionality 
(Goldstein, Tarloff and Hook 1988). Aging of experimental animals primarily determines 
glomerulosclerosis, with thickening of the GBM, followed by tubulointerstitial disease and 
tubular atrophy, at a rate that is gender and genetic background - dependent and is not always 
reproducible (Schmitt, et al. 2009). Other models involve for example mice with Lupus 
nephritis, an immune complex – mediated glomerular disease le followed by interstitial 
responses, or spontaneously hypertensive rats (SHR), rats characterised by hyper-contracting 
smooth muscle vascular cells leading to excessive vasoconstriction and developing 
glomerulosclerosis and tubulointerstitial fibrosis as a secondary disease (Santiago-Raber, et al. 
2004, Ofstad and Iversen 2005).  
Some genetic engineered models have also been produced to mimic specific CKD conditions,  
as in case of transgenic animals with toxin-induced podocyte depletion (comparable to a 
genetic focal and segmental glomerulosclerosis, FSGS) or the HIV-associated nephropathy 
(HIVAN) transgenic mice model, both determining glomerular damage and sclerosis as a 
primary effect.  
Generally reproducible and reliable are the acquired models of CKD. Many acquired models 
have been developed in the last decades, simulating different types of human conditions lading 
to fibrosis. Ablation models, obstructive models, and metabolic models mimicking DN are 
among the more largely employed.  
Subtotal nephrectomy (SNx), also regarded as a 5/6 nephrectomy model, is a model inducing 
glomerulosclerosis by removal of one kidney and ablation of 2/3 of the other, and is sometimes 
referred to as the “remnant kidney model” (Shimamura and Morrison 1975, Anderson, et al. 
1985, Griffin, Picken and Bidani 1994, Kren and Hostetter 1999). Generally, in this model, 
hypertension and strong upregulation of the RAAS system are observed (Anderson, et al. 1985, 
Griffin, Picken and Bidani 1994, Greene, Kren and Hostetter 1996, Remuzzi, et al. 2005). 
Normally, glomerular sclerosis resembling to FSGS and early interstitial fibrosis can be 
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observed 8 weeks post SNx, while high levels of glomerular sclerosis and tubulointerstitial 
fibrosis are detected at 3 months post-ablation (Ma, et al. 2005, Johnson, et al. 1997b, Burhan, 
et al. 2016). Progressive renal insufficiency and hypertension are observed in this model, and 
detectable by an increases in proteinuria, serum creatinine and systolic blood pressure, with 
proteinuria strongly correlating with scarring index  (Johnson, et al. 1997b).  
Unilateral ureteric obstruction (UUO) model is one of the main models employed in the study 
of CKD, as it allows rapid induction of a tubulointerstitial response (Chevalier, Forbes and 
Thornhill 2009). In this model, surgical obstruction of one ureter determines urine retention 
and reduced blood flow, with a rapid (days to weeks) development of tubulointerstitial 
inflammation and fibrosis, and end stage kidney failure reached in less than a month (Ucero, et 
al. 2014, Chevalier, Forbes and Thornhill 2009, Scarpellini, et al. 2014). Specific description of 
this CKD model will be provided in chapter III.  
Aristolochic acid nephropathy (AAN) model is a good model of CKD in mice, with mechanisms 
resembling to the human disease (Huang, et al. 2013, Scarpellini, et al. 2014). AAN is a disease 
characterised progressive renal interstitial fibrosis often linked with urothelial cancer and 
associated with aristolochic acid (AA) containing plant extracts (Aristolochia spp.), reported to 
be nephrotoxic and carcinogenic since last century (Gokmen and Lord 2012, Debelle, 
Vanherweghem and Nortier 2008). It was first described in 1993 in a Belgian study on women 
developing tubulointerstitial fibrosis after assumption of a slimming regimen containing 
extracts from this family (Vanherweghem, et al. 1993). It is sometimes referred as Chinese 
herbs nephropathy given the frequent substitution of botanical products AA-containing herbs 
in Chinese. Murine AAN models with administration of a series of AA doses induce an early 
tubulointerstitial fibrosis, with the proximal tubule being the main target of AA and male being 
more affected that female (Huang, et al. 2013, Lebeau, et al. 2005).  
Other animal models of CKD might involve the employment of puromycin aminonucleoside 
(PAN), inducing nephrotic syndrome or Cyclosporine A, determining kidney fibrosis by 
upregulation of pro-fibrotic pathways such as RAAS system and TGF-β signalling pathway 
(Gherardi, Vecchia and Calandra 1980, Bing, et al. 2006).  
Animal models of diabetes have also been employed to study fibrotic development [reviewed 
in (Rüster and Wolf 2010, Alpers and Hudkins 2011)]. Glomerular injury and endothelial 
dysfunction are the main effects of diabetes in kidney, however, also tubulointerstitial effects 
can be observed (Nakagawa, et al. 2011). One of the most used models of DN is the 
Streptozotocin (STZ) - induced model of Type I diabetes (Tesch and Allen 2007). STZ is a 
chemical known to be particularly toxic to the pancreatic beta-cells; STZ treatment determines 
hyperglycaemia, oxidative stress, and albuminuria in a dose-dependent manner. A number of 
low concentration doses, instead of a single more concentrated dose, are required to produce 
an effect comparable to diabetes, as STZ has been shown to produce nephrotoxic effects 
CHAPTER I – INTRODUCTION 
 
18 
 
independently from its effect on hyperglycaemia, making the interpretation of results difficult 
when high levels are employed (Tesch and Allen 2007).  
The db/db mouse model, on the other side, is characterized by of leptin receptor deficiency, 
and is one of the mostly employed model of Type II diabetes in the study of DN (Sharma, McCue 
and Dunn 2003).  
 
Table 1.3: Experimental models of CKD. 
Model Principle 
Initial fibrotic 
effect 
Advantages Disadvantages 
Ageing 
Spontaneous, loss of kidney 
function with age 
Glomerulosclerosis Spontaneous 
Gender and strain 
dependent. Not 
reproducible. 
Lupus nephritis 
Spontaneous, immune complex-
mediated 
Glomerulosclerosis Spontaneous 
Gender and strain 
dependent. 
spontaneously 
hypertensive 
rats (SHR) 
Spontaneous, excessive 
vasoconstriction 
Glomerulosclerosis 
and 
tubulointerstitial 
fibrosis as 
secondary effect 
Spontaneous 
Gender and strain 
dependent. Fibrosis 
as secondary effect. 
Toxin-induced 
podocyte 
depletion 
Genetically engineered model, 
loss of podocyte barrier. 
Glomerulosclerosis 
(FSGS) 
Good model for podocyte 
loss - glomerular 
damage 
Employment of 
drugs /toxins. 
HIV-associated 
nephropathy 
(HIVAN) 
Genetically engineered model, 
mimics nephropathy resulting 
from kidney infection with HIV or 
from antiretroviral drugs effect 
Glomerulosclerosis 
(FSGS) 
- 
Gender and strain 
dependent. 
Subtotal 
nephrectomy 
(SNx) or 5/6 
nephrectomy 
model 
Acquired model, ablation 
(removal of one kidney and 
ablation of 2/3 of the other) 
Glomerulosclerosis 
(FSGS) 
Reproducible, well 
described by proteinuria, 
does not require 
drugs/toxins 
Slow, elevated 
hypertension 
observed. 
Unilateral 
ureteric 
obstruction 
(UUO) 
Acquired model, surgical 
obstruction of one ureter 
Tubulointerstitial 
fibrosis 
Reproducible, Rapid, 
does not require drugs 
/toxins. Determines 
tubular damage as a 
primary result. Presence 
of contralateral kidney as 
a control. 
Does not reflect the 
slow progression of 
kidney fibrosis hat 
generally happens 
in clinical 
conditions. Urine 
accumulation affect 
detection. 
Aristolochic acid 
nephropathy 
(AAN) 
Acquired model, nephrotoxic 
effect of aristolochic acid (AA) 
Tubulointerstitial 
fibrosis 
Reproducible, well 
representative of human 
conditions. Determines 
tubular damage as a 
primary result. 
Employment of 
drugs /toxins. Can 
also determine a 
carcinogenic 
response. 
Puromycin 
aminonucleoside 
(PAN) 
Acquired model, nephrotoxic 
(nephrotic syndrome), podocyte 
loss.  
Glomerulosclerosis  
Reproducible, 
Representative of 
podocyte loss and 
glomerular alterations 
Employment of 
drugs /toxins. 
Cyclosporine A 
Acquired model, induction of 
pro-fibrotic pathways (mainly 
RAAS, ROS and TGF-β) 
Tubulointerstitial 
fibrosis and 
endothelial 
dysfunction.  
Reproducible, activates 
main pathways leading 
to kidney fibrosis.  
Employment of 
drugs /toxins, 
secondary effects. 
Requires low last 
diet.  
Streptozotocin 
(STZ) - induced 
model 
Acquired model, type I diabetes. 
STZ is toxic for pancreatic β 
cells.  
Glomerulosclerosis 
(DN) 
Reproducible DN model. 
Well correlates with 
hyperglycaemia and loss 
of kidney function/kidney 
damage.  
Employment of 
drugs /toxins. Can 
also determine 
nephrotoxicity 
independently from 
diabetes.  
db/db model 
Genetically engineered model, 
type II diabetes. Model of leptin 
receptor deficiency.  
Glomerulosclerosis 
(DN) 
Reproducible DN model - 
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1.2 TRANSGLUTAMINASE FAMILY 
 
1.2.1 The transglutaminase family (TG) 
The transglutaminase (TG) family (EC 2.3.2.13, “Protein-glutamine γ-glutamyltransferase”) is 
a family of enzymes with calcium (Ca2+)-dependent transamidating activity, which leads to post 
translational modification of proteins (Table 1.4). In humans, nine TGs have been identified, 
of which eight are catalytically active (TG1-7 and Factor XIII) and one is catalytically inactive 
(Erythrocyte membrane protein band 4.2) (Eckert, et al. 2014). TG isoforms originated by an 
early gene duplication event that gave rise to two separate lineages, one containing TG1, TG4 
and FXIII, more closely related, and one containing the other TG members (Lorand and Graham 
2003a).  
Of the TG members, transglutaminase-2 (TG2) has been the most characterised, as 
ubiquitously expressed and generally present in cells in higher amount. Availability of TG 
genetic knock out models have contributed to the understanding of specific gene functions, but 
also highlighted the complexity if their role and regulation. In the following pages, the 
enzymatic reaction catalysed by the TG family is reviewed and the roles of the individual 
isozymes summarised with an emphasis on the TG2 family member.  
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Table 1.4: Members of the transglutaminase (TG) family. Members of the transglutaminase family 
and proprieties in human. Adapted from (Eckert et al., 2014). Proteins identified as expressed in rat 
kidney by our group (Burhan, et al. 2016) are highlighted (Kidney) 
 
Protein name 
Protein 
ID 
Alternative names Gene 
Gene 
locus 
MW 
(kDa) 
Main location in 
humans 
Main 
function(s) 
Transglutaminase-
1 
TG1 
Keratinocyte TG, 
TGk,  particulate TG 
tgm1 14q11.2 110 
Epidermis, 
squamous 
epithelia 
(Membrane-bound 
keratinocytes) 
Kidney 
Keratinocyte 
Differentiation, 
Cornified 
envelope 
formation 
Transglutaminase- 
2 
TG2 
Tissue TG, TGc, 
liver TG, endothelial 
TG, erythrocyte TG, 
Ghα 
tgm2 20q11-12 77 
Ubiquitous 
Kidney 
Cell 
adhesion, matrix 
stabilization, cell 
death, signal 
transduction, 
etc. 
Transglutaminase-
3 
TG3 
Epidermal TG, TGE, 
callus TG,  
hair follicle TG, 
bovine snout TG  
tgm3 20q11-12 77 
Hair follicle, 
epidermis, brain 
(keratinocytes) 
Kidney 
Keratinocyte 
differentiation, 
Cornified 
envelop 
stabilization, hair 
growth 
Transglutaminase-
4 
TG4 
Prostate TG. TGp 
androgen-regulated 
major 
secretory protein, 
vesiculase, 
dorsal prostate 
protein 1 
tgm4 3q21-22 77 Prostate 
Reproduction, 
(semen 
coagulation) – in 
rodents. 
Prostate cancer 
(EMT) 
Transglutaminase-
5 
TG5 TGx tgm5 15q15.2 81 
Foreskin 
keratinocytes, 
epithelial 
barrier lining, 
skeletal 
muscular striatum 
Keratinocyte 
Differentiation, 
Cornified 
envelope 
formation 
Transglutaminase-
6 
TG6 TGy tgm6 20q11 78 
Testis, lung, brain 
Kidney 
Poorly 
understood, 
Cancer 
Transglutaminase-
7 
TG7 TGz tgm7 15q15.2 81 
Ubiquitous but 
predominately in 
testis and lung 
Kidney 
Poorly 
understood, 
Cancer 
Factor XIIIa FXIIIA 
Fibrin-stabilizing 
factor, fibrinoligase, 
plasma TG, Laki-
Lorand factor 
f13a1 6q24-25 83 
Platelets, placenta, 
synovial fluid, 
chondrocytes, 
astrocytes, 
macrophages, 
osteoclasts 
and osteoblasts 
Blood 
coagulation, 
wound 
healing, bone 
synthesis 
Erythrocyte 
membrane protein 
band 4.2  
Band4.2 
B4.2, ATP-binding 
erythrocyte 
membrane protein 
band 4.2 
epb42 15q15.2 72 
Erythrocyte 
membranes, cone 
marrow, spleen 
Membrane 
integrity, cell 
attachment, 
signal 
transduction 
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1.2.2 Transglutaminase reactions 
TG members catalyse the formation of intra- or inter-molecular covalent isopeptide bonds 
between the ε-amine group of a peptide-bound lysine residue (Lys) and the γ-carboxamide 
group of a peptide-bound glutamine (Gln) residue, with release of ammonia (NH3). This 
reaction is also known as crosslinking reaction and the resulting ε-(γ-glutamyl)lysine 
isopeptide bond is highly resistant to proteolysis (Lorand and Graham 2003b).  
The catalytic reaction that characterise the TG family relies on a well-conserved catalytic site, 
is identical between all enzymatically active TGs, of which cysteine is the most important 
residue (Fig. 1.2A). Interestingly, some cysteine proteases, such as papain, cathepsin and 
caspase I also share a similar catalytic domain (Takahashi, Takahashi and Putnam 1986).  
The crosslinking reaction consists of two steps: upon calcium activation, cysteine (Cys) -SH 
group attacks the free acyl group of the glutamine residues (γ-carboxamide group) and forms 
an intermediate thioester with release of NH3, then the thioester reacts with the free amino 
group of the acyl acceptor lysine (Fig. 1.2B). All enzymatically active TGs can also accept free 
primary amines/polyamines as donors, mediating amine incorporation and polyamination 
(Fig. 1.2B). Moreover, in presence of H2O, they catalyse deamidation of glutamine residues to 
glutamate in the absence of amine donors (Fig. 1.2B) (Lorand and Graham 2003b).  
Some TG, such as TG1, can also perform an esterification reaction, that can link a Gln residue 
to the aliphatic chain of ceramide and fatty acid (Nemes, et al. 1999) (Fig. 1.2B).  
An isopeptidase activity, that reverts the crosslinking one, has been observed only in vitro 
(Lorand and Graham 2003b, Király, et al. 2016).  
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Figure 1.2: The transglutaminase (TG) family. (A) The transamidating catalytic site is conserved 
among TG members, with exclusion of inactive TG Erythrocyte membrane protein band 4.2 (Band 4.2). 
Catalytic Cysteine is highlighted in yellow and identified by an arrow. Picture adapted from (Eckert, et 
al. 2014). Permission to reproduce this picture has been granted by The American Physiological Society. 
(B) Enzymatic reactions catalysed by the TG family, described in [1.2.2]. Picture adapted from (Klöck, 
DiRaimondo and Khosla 2012). Enz=Enzyme (TG), P = Peptide or Protein. Permission to reproduce this 
picture has been granted by Springer. 
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1.2.3 Transglutaminase 1 (TG1) 
Transglutaminase-1 (TG1), or Keratinocyte TG, is a membrane-bound protein mainly located 
in keratinocytes of squamous epithelia, lower female genital tract and upper digestive tract. 
TG1 is associated with the inner side of the plasma membrane via an amino-terminal lipid 
(fatty acid) linkage that anchors it to the inner side of the plasma membrane (Phillips, et al. 
1993).  
TG1 is upregulated at the last stages of keratinocytes differentiation and its activity is 
fundamental for the formation of the cornified envelope on the cytosolic side of the plasma 
membrane at these stages, promoting the formation of large protein complexes by crosslinking 
(Steinert, Chung and Kim 1996, Kalinin, Kajava and Steinert 2002).  
Besides being activated by calcium, as all the enzyme members of TG family, TG1 is also 
activated by proteolysis, resulting in 3 fragments of 10, 33 and 67 kDa which are released in 
the cytosol (Kim, Chung and Steinert 1995, Sturniolo, et al. 2003, Eckert, et al. 2009, Steinert, 
Chung and Kim 1996). The proteolysis has been suggested to be mediated by proteins such as 
the cytosolic calcium-dependent calpain ant the lysosomal cathepsin D (Kim and Bae 1998, 
Egberts, et al. 2004). The tumour suppressor protein tazarotene-induced gene 3 (TIG3) is a 
known activator of TG1 in epidermis (Sturniolo, et al. 2003, Eckert, et al. 2009). 
TG1 gene mutations lead to lamellar ichthyosis, an autosomal recessive skin disorder 
characterised by abnormal cornification (Huber, et al. 1995, Candi, et al. 1998, Matsuki, et al. 
1998). Even if also TG3 and TG5 are localised in the same area and known to contribute to 
keratinocyte differentiation and formation of the cornified envelope, they fail to compensate 
the cornified envelope defects of TG1-null mice (Hitomi 2005). Because of the loss of the skin 
barrier function, TG1-knock out is lethal in neonatal mice (Matsuki, et al. 1998).  
 
1.2.4 Transglutaminase-3 (TG3) 
Transglutaminase-3 (TG3), also known as epidermal TG, is mainly identified in epidermis, hair 
follicle and brain (Hitomi, et al. 2001). Together with TG1 and TG5, it is well expressed in 
differentiating keratinocytes (Hitomi, et al. 2001, Candi, Schmidt and Melino 2005, Hitomi 
2005). It participates to the stabilisation of the cornified envelope together with TG1 (Candi, 
Schmidt and Melino 2005), even if its presence is not crucial for the formation of a skin barrier 
(John, et al. 2012). Importantly, it crosslinks keratin and other proteins at the hair follicle 
supporting hair growth. TG3-null mice have thinner hair, but no significant difference in 
barrier function or wound healing (John, et al. 2012). TG3 appears to be downregulated during 
psoriasis, a skin disease associated with altered keratinocyte differentiation, and lamellar 
ichthyosis (Candi, et al. 2002).   
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Similarly, to TG1, TG3 is activated by proteolysis, which is mediated by Cathepsin L and 
controlled by the cysteine protease inhibitor cystatin M/E (Cheng, et al. 2006). The 77 kDa 
precursor protein is cleaved into two domains (50 + 27 kDa), that remain non/covalently 
joined in the active enzyme (Kim, et al. 1990, Hitomi, Ikeda and Maki 2003). Similarly to TG2, 
TG3 is able to bind and hydrolyse GTP (Ahvazi, et al. 2004) and, in certain conditions, it has 
been shown to be secreted by the cells (Sardy, et al. 2002).  
 
1.2.5 Transglutaminase-4 (TG4) 
Transglutaminase-4 (TG4), or prostate TG, is specifically present in prostate, prostatic fluids 
and seminal plasma (Dubbink, et al. 1998, Jiang and Ablin 2011). The enzyme is involved in the 
formation of the copulatory plug, and TG4-null mice experience lower fertility (Jiang and Ablin 
2011). Similarly to TG2 and FXIIIa, TG4 can be secreted (Lorand and Graham 2003b, Jiang and 
Ablin 2011). TG4 has been correlated with the malignancy of prostate cancer cells and has been 
associated with EMT in prostate cancer (Jiang and Ablin 2011).   
 
1.2.6 Transglutaminase-5 (TG5) 
Transglutaminase-5 (TG5) is mainly localised in keratinocytes and skeletal muscle cells, even 
if it has been suggested to be present in other tissues (Candi, et al. 2002, Candi, et al. 2004). It 
is probably involved in the formation of cornified cell envelope and keratinocyte 
differentiation together with TG1 and TG3 (Candi, et al. 2001). TG5 appears to be upregulated 
in both ichthyosis vulgaris and lamellar ichthyosis skin syndromes (Candi, et al. 2002). 
Mutations in Tgm5 gene causing enzyme inactivation determine the “peeling skin syndrome” 
(Cassidy, et al. 2005).  
Similarly to TG1 and TG3, TG5 is activated by proteolysis of an 81kDa precursor, resulting in a 
53 kDa active peptide (Pietroni, et al. 2008). Similarly to TG2, also TG5 shows GTP binding, and 
its transamidating activity is inhibited by both GTP and ATP binding (Candi, et al. 2004).  
 
1.2.7 Transglutaminase-6 (TG6) and transglutaminase-7 (TG7) 
Transglutaminase-6 (TG6) and transglutaminase-7 (TG7) are less understood TG isoforms. 
Both are localised in human testes and lungs, and have been detected in mice brain (Eckert, et 
al. 2014). Both have been also involved in cancer: TG6 has been detected in human tumour 
cells with neuronal morphology (Thomas, et al. 2013), while TG7 has been associated with a 
poor outcome of breast cancer (Jiang, et al. 2003).  
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1.2.8 Factor XIIIa (FXIIIa)  
Factor XIIIa (FXIIIa) is one of the most studied TG members and is found in plasma and 
platelets, but also in macrophages, astrocytes, chondrocyte, dermal dendritic cells, osteoblasts, 
hearth cells and eyes and synovial fluid (Eckert, et al. 2014). The enzyme is mainly known for 
its crucial role in the blood coagulation cascade (Ariens, et al. 2002).   
FXIII is 83 kDa and is expressed as an heterotetramer composed of two catalytically active 
subunits (FXIIIa) and two non-catalytic subunits (FXIIIb) that act as carrier proteins. By 
thrombin-initiated proteolysis mechanism, supported by Ca2+, the catalytical subunit is 
dissociated from the carrier one, resulting in an active enzyme. The resulting catalytically free 
“a” subunit is activated by Ca2+ (as the other TG members) and plays an important role in blood 
clot formation by crosslinking of fibrin (Ariens, et al. 2002), which is itself converted from 
fibrinogen by thrombin.  
To promote stabilisation of the fibrin matrix, FXIIIa crosslinks the plasminogen activator 
inhibitor-2 (PAI2) and α2-antiplasmin (α2-AP), two inhibitors of fibrinolysis, to fibrin, 
localising them in the blood clot area where they interfere with to plasmin-mediated lysis 
(Ritchie, et al. 2000). FXIIIa has also been shown to be able to crosslink thymosin-β4 (Tβ4) in 
the ECM after the release of the protein by thrombin-activated platelets. In this way Tβ4 can 
be held in the matrix where it contributes to different wound healing steps and promotes the 
activation of TGF-β (Huff, et al. 2002, Telci and Griffin 2006).  
Together with its well-known role in blood coagulation, FXIII has also been suggested to be 
involved in inflammatory responses: FXIIIa, for example, plays a role in hypertension-
associated angiogenesis by mediating monocyte adhesion (AbdAlla, et al. 2004).   
Importantly, as TG2 and TG4, Factor XIIIa can be found in extracellular space where it performs 
its catalytic activity supported by high calcium levels. The mechanism of FXIII secretion has not 
been elucidated yet, it might involve action of the “b” subunit or might be only dependent on 
passive stress-induced cell leakage (Muszbek, et al. 2011).  
FXIIIa-null mice are characterised by uncontrolled bleeding and, similarly to TG2-null mice, 
impaired wound healing. They also experience reduced angiogenesis and tissue remodelling 
defects, in a way that is similar to TG2-null mice (Koseki-Kuno, et al. 2003, Muszbek, et al. 2011, 
Dardik, Loscalzo and Inbal 2006, Inbal and Dardik 2006).  
 
1.2.9 Erythrocyte membrane protein band 4.2 
Erythrocyte membrane protein band 4.2 (Band 4.2) is a 72-kDa catalytically inactive TG 
member. It lacks the active cysteine that characterises the catalytic site of the other TG 
isoforms, which is substituted by an alanine (Satchwell, et al. 2009, Eckert, et al. 2014) (Fig. 
1.2A).  
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It is a component of the membrane-proximal cytoskeleton of erythrocytes; together with 
proteins such as spectrin, ankyrin and band 3 (anion exchanger 1, to which band4.2 interacts 
in living red blood cells), it mediates cortical cytoskeleton attachment to the membrane,  
playing an important role in the stabilisation of cell and the maintenance of membrane 
integrity (Satchwell, et al. 2009). Defects in 4.2 expression are involved in hereditary 
spherocytosis an haemolytic anaemia form of blood disease characterized by the production of 
spherical blood cells (spherocytes) rather than bi-concave. Band 4.2-null mice are 
characterised by spherocytosis and defects in ion transport in the cells, by altered regulation 
of anion exchanger function (band 3) (Peters, et al. 1999, Satchwell, et al. 2009).   
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1.3 TRANSGLUTAMINASE-2 (TG2) 
 
1.3.1 Transglutaminase-2 (TG2) structure and function in the cell 
TG2, or tissue transglutaminase, is the most ubiquitous isoenzyme of the TG family, present 
virtually in all tissues and cell types and involved in a large spectrum of physiological and 
pathological events. TG2 was the first described member of the TG family (Mycek, et al. 1959) 
and, as all the members of the family, it is characterised by a Ca2+-dependent transamidation 
activity that mediates post translational modification of protein through crosslinking, as well 
as amine incorporation and deamidation. In addition to the well-known transamidating role of 
TG2, the enzyme is characterised by Ca2+-independent enzymatic activities, such as GTP and 
ATP binding and hydrolysis, kinase and protein disulphide isomerase, and non-enzymatic roles 
as a structural protein in the ECM.  
As a result of its multiple function and ubiquity, TG2 has been involved in disparate 
pathophysiological processes and in a large spectrum of human diseases. As we will see in the 
next paragraphs, TG2 enzymatic activity has been suggested to be largely controlled by the 
cells and activated in response to specific stimuli. In physiological conditions, TG2 knock-out 
mice appear viable, fertile and do not show any developmental abnormality (De Laurenzi and 
Melino 2001, Nanda, et al. 2001), suggesting that, in vivo, TG2 activation is mainly a response 
to transient or chronic stress condition.  
 
1.3.1.1 TG2 localisation in the cell 
Even if TG2 has been described as mainly cytosolic, the enzyme has also been shown to be 
located on the cell surface and extracellular space, where it contributes to the stabilisation and 
the deposition of the extracellular matrix (Upchurch, et al. 1991, Barsigian, Stern and Martinez 
1991, Belkin 2011, Zemskov, et al. 2006). TG2 lacks a leader peptide (signal peptide) necessary 
for endoplasmic reticulum (ER) targeting and ER-to-Golgi classical protein secretion (Ichinose, 
et al. 1990, Ikura, et al. 1988), and also lacks Golgi associated protein modifications such as 
acetylation and glycosylation (Ichinose, et al. 1990, Ikura, et al. 1988). For these reasons, TG2 
has been suggested to be secreted though a non-classical pathway that has not yet completely 
elucidated (Chou, et al. 2011, Belkin 2011). Shading light on the mechanism of TG2 export by 
living cells will be one of the main focuses of this Thesis and the description of the state of 
research on TG2 unconventional secretion will be provided in Chapter V.  
Localisation of TG2 has also been reported in the nucleus and in mitochondria (Grazia Farrace, 
et al. 2002, Furutani, et al. 2016). It has been seen that, in some cell lines  such as neuroblastoma 
cells, TG2 is largely found in the nucleus and can reach up to the 7% of the total enzyme (Lesort, 
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et al. 1998). Moreover, histones have been shown to be substrates for TG2 activity (Kim, et al. 
2002, Mishra, et al. 2006, Ballestar, Boix-Chornet and Franco 2001).  
 
1.3.1.2 TG2 structure and key domains 
In humans, the TG2 gene (Tgm2) is composed by a total of 13 exons and 12 introns. The most 
commonly expressed form of TG2 and the only reported in literature as endogenously 
expressed at a protein level is sometimes referred as TGM2_V1 (Phatak, et al. 2013), or full 
length TG2. This is a 687 amino acids long monomeric protein of ~78 kDa. TG2 is characterised 
by four domains: the N-terminal β-Sandwich domain covers the residues from 1 to 139 and 
does not include a signal peptide for ER-targeting, the α/β catalytic domain, from residue 140 
to 454, and two C-terminal β-barrel domains, β1 from residue 479 to residue 585 and β2 from 
586 to the C terminal end (Fig. 1.3).  
The N-terminal β-sandwich domain has been associated with cell adhesion and migration 
functions of TG2 and does not have enzymatic activity. The N-terminal β-sandwich domain 
contains a specific binding site for FN in which peptide 88-WTATVVDQQDCTLSLQLTT-106  has 
been suggested to be crucial for the binding and probably important for the enzyme secretion  
(Jeong, et al. 1995, Gaudry, et al. 1999, Hang, et al. 2005, Chou, et al. 2011).  
The catalytic domain of TG2 is well conserved among the members of the TG family. A catalytic 
triad formed by Cys277-His335-Asp358 forms the catalytic core (Fesus and Piacentini 2002). 
Tryptophan residue Trp241 is also situated close to the catalytic core and is important for TG2 
transamidating activity, as it has been involved in the stabilisation of reaction intermediates, 
and is also conserved in other TG members (Iismaa, et al. 2003). Trp-332, on the other side, 
might be involved in the negative regulation of the activity (Murthy, et al. 2002).  
The C- terminal β-barrel domain 1 is involved in binding and hydrolysation of both GTP and 
ATP, and, together with the core domain and the C- terminal β-barrel 2, regulates the G-protein 
function of TG2 (Liu, Cerione and Clardy 2002, Kanchan, Fuxreiter and Fésüs 2015, Nakaoka, 
et al. 1994). TG2 has been shown to be able to bind ATP in the same binding pocket of GTP: the 
residues Arg476, Arg478, Val479 and Tyr583 have been shown to bind both ATP and GDP by 
hydrogen bonds, while Ser482 and Arg580 bind only GTP, and Cys230 and Cys370 only ATP 
(Han, et al. 2010). Kojima and colleagues have recently proposed the sequences responsible 
for TG2 shuttling between nucleus and cytosol in an hepatocellular carcinoma (HCC) cell line, 
locating them in the β-barrel domains: a nuclear localization signal (NLS) in the β barrel-1 
domain of TG2 (466-AEKEETGMAMRIRV-479) and a leucine-rich nuclear export signal (NES) 
β barrel-2 domain (657-LHMGLHKL-664) (Shrestha, et al. 2015).  
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Figure 1.3: TG2 structure and domains. Schematic of TG2 domains with their localisation and 
associated functions. Important aminoacidic residues have been highlighted. Adapted from (Kanchan, 
Fuxreiter and Fésüs 2015). Permission to reproduce this picture has been granted by Springer. 
 
 
TG2 is characterized by at least 4 different isoforms or splice forms, determined by alternative 
splicing of the transcript. In addition to the canonical full length TG2, or TGM2_V1, 3 isoforms 
have been reported in literature at mRNA level and have been recently renamed by Phatak and 
colleagues as TGM2_V2 (short), TGM2_V3 (very short) and TGM2_V4 (a and b, deleted form) 
(Phatak, et al. 2013). TGM2_V2 and TGM2_V3 are generated by intron retention and result in 
truncated isoforms with a different C-terminus: TGM2_V2 is a 548 amino acids long protein 
with a molecular mass of ~62 kDa, TGM2_V3 is a 349 amino acids long protein with a predicted 
molecular mass of ~38 kDa (Fraij, et al. 1992, Fraij and Gonzales 1996, Antonyak, et al. 2006). 
TGM2_V4 isoforms a and b are generated by an atypical splicing event resulting in a protein 
with a size similar to the full length TG2 but with a different C-terminal side (Lai, et al. 2007). 
In humans, the alterative isoforms lack the C-terminal GTP regulatory domain that controls the 
access of Ca2+ to the active site, and consequently the enzyme is predicted to be constitutively 
active (Begg, et al. 2006).  
Only few studies have been conducted on the role of TG2 isoforms in disease: a higher isoforms 
expression was detected at mRNA level in cancer cells compared to the normal cells, suggesting 
an increased level of alternative splicing (Phatak, et al. 2013). Moreover, higher levels of 
TGM2_V2 expression have been reported upon Alzheimer’s disease, in parallel with an increase 
in crosslinking activity (Citron, et al. 2001). In the rat SNx model of chronic kidney disease 
generating fibrosis, our group recently demonstrated an upregulation of TG2 alternative 
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isoform at a transcript level, as well as the canonical TG2 transcript, during the progression of 
kidney fibrosis (Burhan, et al. 2016).  
 
1.3.1.3 TG2 enzymatic activities in the cell 
TG2 possesses multiple activities although it is mostly known for protein transamidation. 
Several substrate proteins of TG2- mediated transamidation have been reported and collected 
in the TRANSDAB database (http://genomics.dote.hu/wiki/) (Csősz, Meskó and Fésüs 2009), 
which currently contains 161 substrates for TG2 enzymatic activity (Appendix , Table I).  
TG2-crosslinked products are highly resistant to proteolytic degradation and mechanical 
tension, and can reach large molecular sizes (Griffin, Casadio and Bergamini 2002). In addition 
to protein crosslinking with formation of ε-(γ-glutamyl)lysine bonds, the transamidation 
activity of TG2 also determines amine incorporation, typically by incorporating polyamines 
into peptide-bound glutamine residues. TG2 has also well-known deamidation activity, which 
has been largely implicated in the modification of gluten peptide gliadin, leading to immune T-
cell response in celiac disease (Dørum, et al. 2009, Sollid and Jabri 2011, Anderson, et al. 2000, 
Klöck, DiRaimondo and Khosla 2012, Arentz-Hansen, et al. 2000).  
 
In addition to its calcium-dependent crosslinking activity, TG2 is able to bind and hydrolyse 
GTP, acting as a G-protein (referred as Gh) (Nakaoka, et al. 1994). As a G-protein, TG2 has been 
involved in the regulation phospholipase C (PLCδ1). When not hydrolysing GTP, TG2 has been 
reported to bind PLCδ1 and inhibit its phospholipase activity, while GTP binding to TG2 allows 
the dissociation of the two proteins and PLCδ1 activation (Feng, Rhee and Im 1996). TG2 has 
been shown to couple different receptors to PLC, such as α1b- and α1d-adrenoreceptors, 
thromboxane and oxytocin receptors. Interestingly, the GTPase activity of TG2 in the activation 
of PLC has been suggested to contribute to fibroblast adhesion and spreading during wound 
healing, independently from the crosslinking and non-enzymatic TG2 extracellular roles 
(Stephens, et al. 2004).  
 
Studies have proposed that TG2 can also act as a protein disulphide isomerase (PDI) in 
physiological conditions, and that this specific function is involved, in mitochondria, with the 
correct assembly and folding of the complexes of the respiratory chain (Hasegawa, et al. 2003, 
Mastroberardino, et al. 2006). Specific substrates are in complex I (NADH–ubiquinone 
oxidoreductase), complex II (succinate–ubiquinone oxidoreductase) and complex IV 
(cytochrome c oxidase). This function does not require calcium, hence it would function also 
when the crosslinking activity of the enzyme is inhibited (Mastroberardino, et al. 2006, 
Hasegawa, et al. 2003). In support of this notion, TG2-null mice have been reported to have 
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altered number of disulphide bonds in the respiratory chain complexes, that results in a 
reduced ATP productions and lethargy of the mice (Mastroberardino, et al. 2006). Accordingly, 
TG2 overexpression has been proved to induce mitochondrial hyperpolarisation, while its loss 
determines results in a loss of balance between complex I and II of mitochondrial respiratory 
system (Grazia Farrace, et al. 2002, Battaglia, et al. 2007). A possible physiological role for TG2 
in the context of glucose tolerance was suggested, as TG2-null mice were shown to have a 
weakened insulin secretion upon glucose simulation, similar to some diabetic responses. This 
role of TG2 was associated with its involvement in the regulation in the respiratory chain 
activation lading to ATP production, through its  disulphide isomerase function (Bernassola, et 
al. 2002, Mastroberardino, et al. 2006).  
 
Mishra and colleagues firstly proposed that TG2 is also able to perform serine-kinase activity 
and phosphorylate insulin-like growth factor-binding protein-3 in breast cancer cells, with a 
possible anti-apoptotic role (Mishra and Murphy 2004). This activity, again, is not dependent 
on calcium binding, and even seems to be inhibited by the Ca2+-dependent crosslinking activity 
of the enzyme (Mishra and Murphy 2004). TG2 kinase activity has been proposed to be induced 
by protein kinase A (PKA)-mediated phosphorylation, which would also interfere with the 
enzyme transamidating activity (Mishra, Melino and Murphy 2007). TG2 phosphorylation at 
serine-216 by PKA has been suggested to create a binding site for 14-3-3 protein family 
members, with possible roles in signal transduction and apoptosis and a possible involvement 
in TG2 regulation itself (Mishra and Murphy 2006).  
 
 
1.3.1.4 The allosteric regulation of TG2 enzymatic activity by calcium, GTP and redox 
proteins 
In the past few decades, several studies have focused on the conformational regulation of TG2 
structure by mutually exclusive binding of Ca2+ or GTP. TG2 transamidating activity has been 
suggested to depend on an enzyme “open” tertiary conformation with exposed catalytic 
domain, which is promoted by Ca2+ ions, while GTP binding instead favours TG2 maintenance 
in a “closed”, inactive, conformation (Fig. 1.4).  
In absence of calcium or at a low calcium level (<100 µM), the active site of TG2 is hidden in a 
cleft between the N-terminal region and the C-terminal region, covered by the β-barrel domain 
and hence inaccessible to glutamine donors (Casadio, et al. 1999, Jang, et al. 2014, Liu, Cerione 
and Clardy 2002) (Fig. 1.4). This conformation is regarded as a “close”, inactive, TG2 
conformation.  
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Calcium binding determines a “relaxation” of the molecule, to an “open”, active, conformation 
exposing the active sites to substrates (Casadio, et al. 1999, Jang, et al. 2014, Liu, Cerione and 
Clardy 2002). TG2 can bind 6 Ca2+ ions on 6 negatively charged asparagine (Asp) and glutamine 
(Gln) -rich binding sites. It has been suggested that calcium binding does not determine a 
complete opening of the TG2 structure, but allows a destabilisation of the structure and the 
opening of a deep “substrate channel” where glutamine substrates can access to the catalytic 
core. Binding of glutamine substrates and formation of the acyl-enzyme intermediate allow 
further opening of the structure to permit correct positioning of the amine donor (Pinkas, et al. 
2007, Király, Demény and Fésüs 2011).   
GTP binding negatively regulates transamidating activity of TG2 by binding the enzyme in its 
closed conformation (Liu, Cerione and Clardy 2002, Jang, et al. 2014). Differently from calcium, 
GTP binding does not directly induce conformational changes in the proteins, but stabilises 
TG2 into the close structure, that can be reversed by Ca2+- binding, when present at an adequate 
concentration (>100 µM) (Di Venere, et al. 2000, Casadio, et al. 1999). GTP binding favours 
stability by masking the “destabilizing residue” Arg579 and favouring the maintenance of the 
closed conformation, also secured by a Cys277–Tyr516 hydrogen bond (Begg, et al. 2006); on 
the contrary, Ca2+ binding allows destabilisation of the molecular structure and subsequent 
relaxation by exposing Arg579 and breaking the hydrogen bond (Király, Demény and Fésüs 
2011). To note, ATP can also bind TG2 in its close conformation possibly contributing to the 
stability of the structure (Han, et al. 2010).  
The intracellular environment has a relatively high concentration of GTP (50 - 300µM) and ATP 
(8-11 mM) (Smethurst and Griffin 1996, Király, Demény and Fésüs 2011), and relatively low 
concentrations of Ca2+ (~100nM) (Bronner 2001), hence TG2 crosslinking activity is thought 
to be inhibited in the cytosol, where TG2 would be acting as a G-protein or be inactive. Only 
when levels of Ca2+ are raised to about 100 µM, the transamidating activity of the enzyme can 
be detected (Smethurst and Griffin 1996).  
Extracellular calcium levels, on the other side, reach millimolar concentrations (~1-1.5 mM) 
(Bronner 2001, Király, Demény and Fésüs 2011), thus allowing TG2 activation. However, 
despite the high extracellular levels of calcium and the low GTP, extracellular TG2 has been 
suggested to be mostly enzymatically inactive in vivo in unstressed conditions, and to be almost 
exclusively activated upon injury or mechanical stress (Siegel, et al. 2008). This is in line with 
the theory of a TG2 association with stress conditions, supported by the healthy phenotype of 
TG2-null mice in physiological conditions (De Laurenzi and Melino 2001).  
One of the reasons of TG2 inactivity in the extracellular space is the reversible oxidation of 
“open” TG2 at three cysteine residues (Cys230, Cys370 and Cys371), with formation of a 
disulphide bond between Cys370 and Cys371 (Stamnaes, et al. 2010), that can happen in the 
highly oxidizing extracellular environment. These disulphide bonds inhibit Ca2+ binding to one 
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of the sites, and stabilize an inactive, oxidised conformation of TG2. TG2 oxidation is almost 
exclusively localised in the extracellular space: intracellularly, the reducing environment as 
well as the abundance of reduced glutathione tend to interfere with the formation of disulphide 
bonds (Fig. 1.4).  
Moreover, nitric oxide can inhibit TG2 activity by determining cysteine S-nitrosylation (S-
nitrosothiols formation), in a process that is controlled by extracellular calcium levels (Lai, et 
al. 2001). This modification has been shown to prevent TG2 activity both in vitro and in vivo in 
blood vessels, where it limits TG2 dependent vascular calcification and hypertension (Lai, et al. 
2001, Santhanam, et al. 2010). Nitrosylation can affect also tyrosine residues of TG2 and was 
suggested to inhibit its activity in fibroblasts (Telci, et al. 2009) (Fig. 1.4).   
Thiol reductases such as thioredoxin have been demonstrated to be able to activate TG2 in the 
extracellular matrix by reducing the Cys disulphide bonds (Jin, et al. 2011). Interestingly, 
thioredoxin can be secreted by monocytes in response to interferon-γ (IFN-γ), a pro-
inflammatory cytokine, and is sufficient to activate the extracellular TG2 (Jin, et al. 2011). In 
line with this, the employment of the reducing agent DTT has been shown to revers TG2 
inactivation caused by oxidation (Stamnaes, et al. 2010) (Fig. 1.4). In addition to reducing 
agents, also mechanical stress associated with cell contraction has been suggested to induce 
changes on extracellular TG2 conformation, favouring its activation (Huelsz-Prince, et al. 2013, 
Belkin 2011).  
 
 
Figure 1.4: The allosteric regulation of TG2 catalytic activity by calcium, nucleosides and redox 
reactions. Adapted from (Eckert, et al. 2014, Pinkas, et al. 2007). Permission to reproduce these pictures 
has been granted by The American Physiological Society and Rowena Matthews (Michigan, USA).  
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1.3.1.5 Regulation of TG2 expression 
Even if detected in many cell types, TG2 has been frequently regarded as a stress-associated 
protein, the expression of which is upregulated by several physiological and pathological 
stress-associated factors. Many growth factors and inflammatory cytokines have been shown 
to induce transcription of TG2 mRNA.  
TGF-β1, the main pro-fibrotic cytokine involved in the processes of wound healing and fibrosis, 
upregulates TG2 expression in different cell types (George, et al. 1990, Quan, et al. 2005), and 
the effect is observable even at low levels of cytokine (1ng/ml) (Quan, et al. 2005). Similarly, 
cytokines such as interleukin 6 (IL6) and tumour necrosis factor α (TNFα) have also been 
associated with the enzyme transcription, the latter through induction of nuclear factor κB 
(NFκB) transcription factor, to which TG2 transcription promoter is sensitive (Suto, Ikura and 
Sasaki 1993, Kuncio, et al. 1996, Ikura, et al. 1994).   
TG2 promoter has an NF-κB binding motif that induces TG2 transcription. Moreover, TG2 is 
itself able to activate NF-kB through induction of polymerization of NF-κB inhibitory protein, 
IκBa, with a role in stress response and in the promotion of cell survival in cancer cells; indeed, 
TG2 inhibition reduces NF-κB activation (Ientile, Caccamo and Griffin 2007, Cao, et al. 2008).  
TG2 is upregulated in response to glutamate receptor activation and oxidative stress with 
release of ROS, which are features neurodegenerative diseases such as Alzheimer’s disease and 
Huntington’s disease (Campisi, et al. 2003, Ientile, Caccamo and Griffin 2007).  
Other molecules known to induce TG2 transcription are retinoids such as retinoic acid 
(Piacentini, et al. 1992, Nagy, et al. 1996), and the hypoxia inducible factor HIF-1 (Jang, et al. 
2010), which is upregulated upon low oxygen conditions. HIF-1 increases TG2 expression with 
anti-apoptotic consequences on hypoxic tumour cells, and TG2 has been shown to be 
upregulated in response to ischemia or hypoxia in different models (Jang, et al. 2010, Filiano, 
et al. 2010, Tolentino, et al. 2004).  
 
1.3.2 Intracellular TG2 is involved in the regulation of cell death 
TG2 has been for long time associated with apoptotic processes inside the cells. TG2 expression 
and activity has been shown to be upregulated in cells undergoing apoptosis (Piacentini, et al. 
2005). Pro-apoptotic stimuli, such as retinoic acid, increase TG2 expression, and TG2 inhibition 
in the presence of calcium has been suggested to be protective against dell death, in presence 
of the same stimuli (Oliverio, et al. 1999).  
TG2-dependent crosslinking, following increases in intracellular calcium, has been suggested 
to be involved in the stabilisation of dying cells, preventing loss of intracellular components. 
The type of cell death induced by TG2 has been suggested to be independent from the normal 
pathways of apoptosis and necrosis, as the cells are not characterised by classical apoptotic 
CHAPTER I – INTRODUCTION 
 
35 
 
features (cell shrinkage, chromatin condensation, etc.) neither show fragmentation of DNA 
(Verderio, et al. 1998, Nicholas, et al. 2003). TG2 determines cell death by inducing cross-
linking of intracellular proteins in the presence of calcium.  
In the context of renal scarring (Section 1.4), it was observed how TG2 determines intracellular 
crosslinking in TECs, that were dead but did not show apoptotic morphology and DNA 
fragmentation (Johnson, et al. 1997a).  
In 2003, Nicholas and colleagues showed how intracellular TG2 crosslinking activity happens 
in response to necrotic stimuli associated with inflammation and wound healing/fibrosis 
(Nicholas, et al. 2003). Loss of calcium homeostasis during inflammation and wound repair 
(increase in intracellular Ca2+) led to induction of TG2 crosslinking activity inside the cells, that 
was mostly localised in the perinuclear area and inside the nucleus. This crosslinking activity 
was suggested to form shell-like structures around the nuclei, that were comparable to micro-
scars or to the TG1-mediated cornified envelope, and were proposed to help trapping the DNA 
and avert its fragmentation, thus preventing necrotic death and tissue disruption, in a 
mechanism that is alternative and independent from cell apoptosis (Nicholas, et al. 2003). 
Similar results were obtained upon UV light - induced upregulation of TG2 activity in dermal 
fibroblasts (Gross, Balklava and Griffin 2003). This is particularly important in situation of 
inflammation and tissue repair, limiting necrosis and inflammation and promoting the 
preservation of the tissue integrity after damage. In hepatic cells, TG2 has been suggested to 
induce apoptosis through crosslinking and inactivation of the transcription factor SP1 in the 
nucleus (Tatsukawa, et al. 2009).  
Increased intracellular calcium levels and subsequent increase in intracellular TG2-mediated 
crosslinking and amine incorporation have been associated with different conditions of the 
brain such as ageing, Alzheimer’s disease and Huntington’s disease (Jeitner, et al. 2009).  
 
Some authors have suggested that TG2 might be protective against apoptosis in a GTP-
dependent manner, favouring survival (Antonyak, et al. 2001, Antonyak, et al. 2006). This 
might mean that, at the initial stages of infection, when calcium balance is conserved, TG2 
upregulation might contribute to cell survival, while, if the stimulus is kept and induces 
intracellular rise in calcium, TG2 might lead to specific crosslinking-dependent cell death 
(Nicholas, et al. 2003). In general, TG2 transamidating activity has been suggested to either 
facilitate or inhibit apoptosis, depending on the tissue and the specific stimuli, while the 
GTPase function of TG2 has been shown to generally inhibit apoptosis (Fésüs and Szondy 
2005). 
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1.3.3 Extracellular TG2 plays both enzymatic and non-enzymatic roles 
As reported before, even if most of TG2 expression is localised in the cytoplasm, a relatively 
consistent portion of the TG2 (10-20%) is found in the extracellular space, both on the cell 
surface and extracellular matrix (Zemskov, et al. 2006). In a study on Swiss 3T3 fibroblasts 
with TG2 expression controlled by a tet-inducible promoter, Dr Verderio and colleagues 
showed that increased expression of TG2 leads to an increased export and localisation in the 
extracellular space (Verderio, et al. 1998). Even if in some cases a stress-induced, passive 
release of TG2 as result of cell damage has been observed (Kawai, et al. 2008), this is thought 
not to be the only mechanism of TG2 release, as TG2 export has been observed from living and 
healthy cells in vitro (Verderio, et al. 1998).  
TG2 is known to be exported by the cells through a still not completely clarified unconventional 
secretion (Belkin 2011): a description of current hypotheses of TG2 unconventional export will 
be provided in Chapter V.  
Once exported, the enzyme can be found both on the cell surface and extracellular matrix 
where TG2 co-localises with FN and acts as a Ca2+-dependent transamidating protein (Gaudry, 
et al. 1999, Verderio, et al. 1998). It also has a structural non-enzymatic role in the ECM, as a 
protein scaffold with direct consequences on cell adhesion, spreading and survival (Kanchan, 
Fuxreiter and Fésüs 2015, Belkin 2011) (Fig. 1.5).  
 
1.3.3.1 Crosslinking activity of TG2 in the extracellular space is necessary for ECM deposition 
and resistance 
Extracellular TG2 has been shown to covalently crosslink ECM proteins, contributing to ECM 
deposition and resistance (Aeschlimann and Thomazy 2000). FN, collagens (I, II, III, V, XI), 
fibrinogen/fibrin, laminin and nidogen are well known substrates of TG2 transamidating 
activity in the extracellular matrix and cell basement membrane (Verderio, Johnson and Griffin 
2004, Barsigian, Stern and Martinez 1991, Verderio, et al. 1998, Jones, et al. 1997, Chau, et al. 
2005, Aeschlimann and Paulsson 1991). Particularly important in this context is the role for 
TG2 in the deposition of a FN matrix by crosslinking soluble monomers, as it provides an 
environment for cell adhesion and spreading (Jones, et al. 1997, Verderio, et al. 1998). 
Crosslinking activity of ECM proteins by TG2 has been involved in the promotion of matrix 
stabilisation, deposition and resistance to proteolytic decay, as well as in the regulation of cell 
adhesion and movement, by providing a platform of adhesion and migration of cells, like 
fibroblast or endothelial cells. Since FN matrix assembly acts as start for the polymerisation of 
other structures, such as fibrillin, TG2 has been suggested to favour not only remodelling of 
existing matrix, but also initial assembly of novel ECM.  
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Interestingly, TG2 has also been suggested to crosslink itself to vascular endothelial growth 
factor receptor (VEGFR), with a role in the modulation of endothelial cell response to VEGF and 
a potential role in angiogenesis (Dardik and Inbal 2006). 
It is important to remember that, while crosslinking activity of TG2 can be well detected in vitro 
upon TG2 export (Verderio, et al. 1998), extracellular TG2 activity in vivo is likely to be mostly 
silent in physiological conditions, due to oxidation/nitrosylation in non-reducing environment, 
and it is thought to be transiently activated by stress signals or mechanical tension when TG2 
is released in the ECM.  
 
1.3.3.2 Non enzymatic roles of extracellular TG2: a scaffold protein necessary for RGD 
independent adhesion and spreading 
The process of cell adhesion and subsequent migration requires the interaction between cell 
surface receptors, of which the most characterized are Integrins and syndecans, and the 
extracellular matrix proteins such as FN (RGD cell binding site). Cell surface-matrix interaction 
leads to different signalling pathways involved in cytoskeletal reorganization, with formation 
of focal adhesion (FA) and stress fibres. Integrin binding and clustering mediate the process of 
cell attachment by inducing focal adhesion kinase (FAK) auto-phosphorylation (Tyr397), 
which in turn leads to FAK activation by further phosphorylation at Tyr576 and Tyr577, by 
creating a binding site for Src kinase. Autophosphorylation alone does not support FA, which 
require formation of FAK-Src complex and subsequent Src-mediated activation of the protein.  
FAK activation, subsequently, regulates both small GTPases Rac and Rho activation (Huveneers 
and Danen 2009), which are important for migration and stress fibre formation. Transient 
RhoA downregulation by FAK though activation of small GTPase activating protein 
p190RhoGAP (Ren, et al. 2000, Arthur and Burridge 2001, Holinstat, et al. 2006) is necessary 
for transient release of adhesion tension during cell migration.  
Cell surface HSPG syndecan-4 (Sdc4) binding to matrix proteins has been involved in the 
Tyr397-phosphorylation of FAK (Wilcox-Adelman, Denhez and Goetinck 2002), and might also 
indirectly activate Src-dependent phosphorylation of FAK through PKCα activation (Gatesman, 
et al. 2004); an outline of HSPGs/Sdc4 involvement in focal adhesion and spreading will be 
provided on Chapter VI. 
 
In the extracellular space, TG2 can contribute to cell-matrix adhesion and adhesion-dependent 
signalling through a non-enzymatic “scaffold” role that involves forming a complex with FN, an 
additional extracellular TG2 function which is independent from its transamidating activity or 
any other enzymatic activity (Verderio, et al. 2003). TG2 binding site for FN is located on its N-
terminal beta sandwich domain (Jeong, et al. 1995, Gaudry, et al. 1999, Hang, et al. 2005). 
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Extracellular TG2 is able to bind soluble FN at 2:1 stoichiometry on the FN N-terminal gelatin 
binding domain (Radek, et al. 1993). TG2 promotes FN auto-assembly as well as crosslinking-
dependent deposition in the extracellular space in response to stimuli such as TGF-β, and in 
cooperation with α5β1 integrins (Akimov and Belkin 2001b). Furthermore, TG2 binding to FN 
has been suggested to protect the enzyme from proteolytic degradation that in the extracellular 
environment is thought to be mediated specifically by membrane-type MMPs (MT-MMPs 
subtypes 1-3)(Belkin, et al. 2001) 
The TG2-FN matrix complex has been suggested to play an important role in mediating RGD-
independent cell adhesion by counteracting stress- or tissue remodelling-associated loss of cell 
adhesion, and resulting in increased cell survival despite matrix fragmentation (Verderio, et al. 
2003). TG2-FN heterocomplex promotes RGD independent cell adhesion by binding to cell 
surface HSPGs chains and inducing adhesion-dependent cell signalling such as FAK activation 
(Verderio, et al. 2003). Both integrins and cell surface proteoglycans have been suggested to 
cooperate with TG2 in the promotion of RGD independent cell adhesion to FN (Fig. 1.5). 
Binding of matrix TG2 to cell surface HSPG Sdc4 induces receptor clustering and subsequent 
protein kinase Cα (PKCα)- induced signalling (Wang, et al. 2010, Telci, et al. 2008), which in 
turn would induce β1-integrin clustering and co-signalling (Wang, et al. 2010, Telci, et al. 
2008). Indirect association with another HSPG, syndecan-2 (Sdc2), has been reported to be 
involved the process of cell adhesion in HOB cells, and promote cytoskeletal regulation and FN 
deposition (Wang, et al. 2010, Wang, Telci and Griffin 2011) (Fig. 1.5).  
The group of Alex Belkin has proposed that TG2 is also able to directly bind integrins (β1 and 
β3 mainly) at 1:1 stoichiometry, and, when complexed to extracellular FN, TG2 would act as an 
integrin-associated co-receptor for the gelatin domain of FN, promoting RGD-independent cell 
attachment and integrin-dependent cell signalling in this way (Akimov, et al. 2000) (Fig. 1.5).  
 
On the cell surface, TG2 has also been shown to interact with other receptors. For example, it 
has been suggested to bind platelet-derived growth factor receptor (PDGFR) and link it to β1 
integrins. Though this function TG2 was proposed to favour receptor clustering, that in turn 
regulate cell migration (Zemskov, et al. 2009) (Fig. 1.5).  
Low density lipoprotein (LDL) receptor-related proteins 5 and 6 (LRP5, LRP6) have also been 
suggested to interact with TG2 on smooth muscle cells, and TG2 binding to these proteins has 
been suggested to activate the β-catenin signalling pathway, favouring calcification (Faverman, 
et al. 2008) (Fig. 1.5).  
LRP1, another member of the family, is an interesting partner of TG2 on the cell surface and a 
well-known endocytic receptor. TG2 binding to LRP1 has been suggested to promote the 
enzyme internalisation and degradation through clathrin and/or caveolae-lipid rafts mediated 
endocytosis (Fig. 1.5). Its deletion leads to TG2 upregulation on the cell surface and increased 
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adhesion and cell-matrix interactions (Zemskov, et al. 2007). LRP1 also regulates endocytosis 
of other TG2 associated partners such as FN and β1/β3 integrins (Salicioni, et al. 2004, 
Salicioni, et al. 2002). Localisation of TG2 and β1-integrins in lipid rafts and caveolae might 
increase the interaction of these particular endocytosis-associated cell domains to the matrix 
(Zemskov, et al. 2007, Eckert, et al. 2014).  
G-protein coupled receptor GPR56 is another binding partner of TG2 on the cell surface, with 
a role in cancer regulation. GPR56 overexpression has been suggested to inhibit cancer 
proliferation through a TG2 dependent mechanism which also involves NF-κB (Xu, et al. 2006, 
Kausar, et al. 2010).  
 
TG2 non-enzymatic interactions are not exclusively associated with adhesion, survival and 
spreading: the protein has also been suggested to interact with several partners both outside 
(ECM, cell surface) and inside the cells (cytosol, nucleus), in relation to cell signalling and 
inflammatory response, and to the control of TG2 activity itself, either directly or by regulation 
of calcium levels. An exhaustive list of TG2 binding partners and proposed consequences of this 
interaction has been recently reviewed by Kanchan and colleagues (Kanchan, Fuxreiter and 
Fésüs 2015) (Appendix , Table II). TG2 has also been involved in the regulation of expression 
and activity of matrix metalloproteases (MMPs) through a non-enzymatic function. For 
example, TG2 expression was suggested to inhibit MMP-9 transcription by binding c-Jun in the 
nucleus and inhibiting the Jun-Fos complex binding to the AP-1 transcription site (Ahn, et al. 
2008).   
 
 
Figure 1.5: Some non-enzymatic functions of TG2 in the extracellular space. From (Belkin 2011). 
Permission to reproduce this picture has been granted by John Wiley and Sons.  
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1.3.4 TG2 as a key wound healing protein 
In the past few decades, many studies have demonstrated the importance of transglutaminase 
family members in wound healing, with particular interest on TG2 implication in the process.  
Firstly, TG2 is induced and secreted upon tissue injury. Early work in a human fibroblasts 
monolayer showed that TG2 is deposited in the matrix and associates with FN upon simulation 
of wound (Upchurch, et al. 1991), where it persists for hours.  
Secondly, TG2 expression is upregulated by a series of cytokines that are also induced by 
platelets and inflammatory cells upon wound repair. Among these, TGF-β, interleukins and 
TNF-α are well known. Haroon et al. showed a TG2 upregulation in rats upon wound in parallel 
with cytokine production such as TGF-β, VEGF, TNF-α, IL-6, etc. TG2 deposited in the site of 
wound already one day after injury in the provisional fibrin matrix, where it performs its 
crosslinking activity (Haroon, et al. 1999). 
Thirdly, on fibroblast monolayer, TGF-β treatment leads to upregulation of both TG2 and FN 
and stabilizes tissue inflammation by promoting the formation of a proliferative FN matrix 
(granulation tissue) by crosslinking (Quan, et al. 2005). When acting as a matrix crosslinking 
enzyme, TG2 has been shown to confer higher stability to the tissue and resistance to both 
mechanical and chemical matrix degradation (Johnson, et al. 1999).  
Extracellular TG2 crosslinking of FN mediates deposition and stabilisation of the granulation 
tissue, favouring the stabilisation of the inflammatory wound and providing a matrix for 
fibroblast migration  (Quan, et al. 2005). 
The crosslinking activity of TG2 is known to play roles also at the earlier stages of wound 
healing by crosslinking fibrin and FN, as well as at the last stages of scar formation, by 
crosslinking different collagen isotypes. TG2 has been shown to stabilise the Factor XIII-
deposited fibrin blood clot, as non-reducible glutamyl-lysine bounds produced by TG2 have 
been identified both in the provisional matrix after blood coagulation and during inflammation, 
and in the granulation tissue produced by fibroblasts to stabilize the inflammatory response. 
Therefore, TG2 can act at different stages of the wound healing process, targeting different 
mechanisms associated with tissue repair (Table 1.5). Particularly important is the role for 
TG2 in the proliferative phase of wound healing, where it has been shown to play roles in 
granulation tissue formation and fibroblast migration, as well as angiogenesis and 
epithelization. 
The importance for TG2 in the wound healing process has been confirmed by knockout studies, 
in which TG2-null mice showed delayed wound healing and impaired adhesion of isolated 
fibroblasts (De Laurenzi and Melino 2001, Nanda, et al. 2001).  
TG2 is released by both macrophages and endothelial cells invading the fibrin clot (Haroon, et 
al. 1999, Murthy, et al. 1991) and has been shown to be upregulated by increased local 
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concentration of thrombin in endothelial cells (Auld, et al. 2001). Differently from FXIIIa, TG2 
does not need thrombin for its activation, therefore can continue its crosslinking activity even 
after thrombin disappears from the healing area (Verderio, Johnson and Griffin 2004). In line 
with this is the finding that XIIIa deficiency does not lead to a strong wound healing impairment 
(~15%) (Muszbek, Yee and Hevessy 1999).  
TG2 has also been shown to support scar formation by crosslinking collagen I, II and III as well 
as promoting lysyl oxidase (LOX) - independent crosslinking of collagen V and XI (Verderio, 
Johnson and Griffin 2004, Kleman, et al. 1995), leading to collagen matrix remodelling and 
formation of large collagen bundles, providing resistance to mechanical tension as well as 
conferring resistance to proteolytic degradation by at least some MMP such as MMP-1 
(Johnson, et al. 1999).  
TG2 is also known to perform non-enzymatic roles in wound healing, promoting adhesion and 
migration of fibroblasts on FN in an RGD independent manner (Balklava, et al. 2002, Verderio, 
et al. 2003, Telci, et al. 2008, Wang, et al. 2010), which is particularly crucial in the context of 
injury and tissue remodelling, when the activation of proteases for matrix reorganisation leads 
to the release of numerous interfering RGD- fragments from FN.  
TG2 has also been suggested to promote angiogenesis during wound repair (Haroon, et al. 
1999), even if a correct balance of the enzyme concentration and activity is necessary for this 
function. A downregulation of TG2 was observed at the first hours of capillary formation by 
endothelial cells in a 3D collagen matrix, suggesting that the maintenance of low TG2 is 
required at the beginning of angiogenesis (Bell, et al. 2001). In line with this finding, excessive 
TG2 activity inhibits angiogenesis by promoting matrix accumulation (Griffin, et al. 2002, Jones, 
et al. 2006).  
In addition to the abovementioned roles of TG2 in matrix deposition and stabilisation or 
fibroblast migration, TG2 also plays a role in the inflammatory phase of wound healing with 
both anti-inflammatory and pro-inflammatory functions. In a non-enzymatic manner, acting as 
a scaffold protein, TG2 has been seen to promote monocyte recruitment in the site of wound, 
by favouring their migration on the FN matrix (Akimov and Belkin 2001a). TG2 is particularly 
expressed in macrophages and, in these cells, has been shown to be important for phagocytosis 
of dead cells and subsequent release of TGF-β (Szondy, et al. 2003). By intracellular Ca2+-
mediated crosslinking, TG2 can contribute to contain inflammation, preventing/limiting 
leaking from dying cells (Verderio, et al. 1998, Nicholas, et al. 2003). 
Interestingly, TG2 has also been suggested to act as a promoting agent for inflammation at the 
very initial stages after damage. In fact, it TG2 promotes the activation of the secretory 
phospholipase A2 (sPLA2) by crosslinking or amine incorporation (Cordella-Miele, Miele and 
Mukherjee 1990, Cordella-Miele, et al. 1993). sPLA2 is an important enzyme in the 
inflammatory response, as it catalyses the production of arachidonic acid from cell membrane 
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phospholipids, necessary to produce inflammatory and thrombogenic eicosanoids by the 
cyclooxygenase pathway.   
 
Table 1.5: Main factions of TG2 and other members of TG family in the wound repair process.  
PHASES of 
WOUND REPAIR 
KNOWN FUNCTIONS OF TG2 
KNOWN FUNCTIONS OF OTHER 
TG FAMILY MEMBERS 
Haemostasis 
 Stabilisation of provisional matrix of Fibrin 
and FN . 
 Matrix incorporation of Plasminogen 
inhibitors (PAI2, α2-AP). 
 Fibrin clot formation (FXIIIa). 
 Matrix incorporation of 
Plasminogen inhibitors (PAI2, α2-
AP) (FXIIIa). 
Inflammation 
 Monocyte adhesion and migration. 
 TGF-β activation. 
 Activation of sPLA2. 
 
Proliferation / Matrix 
deposition 
 Crosslinking and stabilisation of extracellular 
matrix (Collagen and FN). 
 Resistance to / prevention of matrix protease 
digestion. 
 Promotion of cell adhesion, migration and 
proliferation (Fibroblasts). 
 RDG-independent cell adhesion prevents cell 
death and favours spreading. 
 TGF-β activation. 
 Regulation of angiogenesis. 
 Re-epithelisation by promoting 
keratinocyte differentiation (TG1, 
TG3, TG5). 
Remodelling and 
resolution of the 
wound 
 Stabilisation of ECM (collagen mainly). 
 Resistance to / prevention of matrix protease 
digestion. 
 Cell death (intracellular crosslinking). 
 
 
 
1.3.5 TG2 roles in disease 
TG2 has been associated with a series of pathological conditions, such as celiac disease, cystic 
fibrosis, heart fibrosis, lung fibrosis, hepatic disease, arthritis, cardiovascular diseases and 
artherosclerosis etc. (Iismaa, et al. 2009). Several reports have involved TG2 in the 
development of chronic kidney disease, as will be described in section 1.4.  
In the nervous system, TG2 has been attributed roles in neuronal differentiation, synaptic 
modulation, release of neurotransmitters, and long-term potentiation (Jeitner, et al. 2009). TG2 
has been associated with neurodegenerative diseases such as Alzheimer Disease (Wilhelmus, 
et al. 2009) and Huntington disease (Mastroberardino, et al. 2002), as well as in ischemic 
neuronal loss (Ientile, et al. 2004). The involvement of TG2 in neurodegenerative diseases has 
been suggested to be associated with the promotion of accumulation of insoluble protein 
aggregates in both cytoplasm and nucleus. Through similar processes, TG2 has been involved 
in Parkinson’s disease (Junn, et al. 2003).  
Even though TG2 has been for long regarded as a pro-apoptotic factor, in the past few decades, 
several studies have described a role for TG2 in cancer [reviewed in (Mangala and Mehta 2005, 
Eckert, et al. 2014)], where it promotes malignancy and proliferation by having both anti-
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anoikis effects and anti-apoptotic effects, ultimately favouring cell survival (Mangala, et al. 
2007, Mann, et al. 2006, Verma and Mehta 2007, Verderio, et al. 2003).  
TG2 expression in cancer is related with enhanced drug-resistance, invasion and migration and 
has been strongly associated with the promotion of  EMT, with evidences in breast and ovarian 
cancer, and human epidermal cancer stem cells (Fisher, et al. 2015, Shao, et al. 2009, Cao, et al. 
2012, Kumar, et al. 2012, Eckert, et al. 2015). The closed, GTP-binding structure of TG2 has 
been suggested to be necessary for the events (Fisher, et al. 2015, Kumar, et al. 2012, Eckert, 
et al. 2015). TG2 has also been suggested to control MMP-2 (Gelatinase A) in ovarian cancer 
(Satpathy, et al. 2009), which has been highlighted as a mediator of cancer cells invasiveness 
and promotion of metastasis (Kenny, et al. 2008).  
Interestingly, TG2 activation of NF-κB has been implicated many of the TG2-mediated events 
in cancer promotion, including EMT and  survival /drug resistance (Mann, et al. 2006, Verma 
and Mehta 2007, Shao, et al. 2009, Jang, et al. 2010, Cao, et al. 2008). In many tumour cell lines, 
TG2 expression is induced by the hypoxic environment in an HIF-1 dependent manner (Jang, 
et al. 2010), which promotes malignant cell growth in solid tumours.  
In the extracellular space, TG2 promotes cancer cells cell survival and spreading, especially by 
its scaffold role and interaction with ECM. Recently, Matei and colleagues revealed the 
importance of TG2-mediated modifications of the ECM in aggressive pancreatic cancer (Lee, et 
al. 2015b). TG2 secretion and large collagen crosslinking in the pancreatic stroma was 
suggested to induce ECM-mechanical tension leading to specific signal transduction for the 
promotion of mesenchymal cells proliferation (Lee, et al. 2015b). As a confirmation, TG2-KO in 
pancreatic cancer cells significantly reduces xenograft tumour size in mice, compared to WT 
cancer cells (Lee, et al. 2015b).  
At the light of the more recent findings, it is clear that many disorders in which TG2 has been 
implicated are driven by changes introduced by increased TG2 synthesis and export in the 
ECM.  
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1.4 TRANSGLUTAMINASE-2 IN KIDNEY FIBROSIS 
 
In the past few decades, TG2 has been associated with kidney fibrosis through a series of 
processes involving extracellular matrix accumulation and stabilization, activation of the 
profibrotic cytokine TGF-β, cell death, etc. This section will provide a comprehensive outline of 
the main studies of TG2 involvement in kidney disease (Table 1.6-1.7). A summary of TG2 
main roles in Kidney fibrosis progression is found in Table 1.8.  
 
1.4.1 Transglutaminase-2 expression in kidney  
In a healthy kidney TG2 is the more expressed member of the TG family, even if other members 
of the family, such as TG1, TG3, TG6 and TG7, have been identified in the organ both at an mRNA 
level and protein level (Deasey, Shanmugasundaram and Nurminskaya 2013, Burhan, et al. 
2016). 
A recent work from our group employing a rat model of SNx, showed how, even if other 
members of TG family are expressed in kidney and upregulated upon kidney fibrosis (mainly 
TG1 and TG3), TG2 is the most expressed TG isoform in kidney and significantly correlates with 
the loss of renal function (Burhan, et al. 2016). Even if implicated in the process of wound 
healing in other organs, FXIIIa was not detected as expressed in kidney in this study (Burhan, 
et al. 2016).  
Apart from TG2, the only other member of TG family studied in kidneys is TG1, that has been 
shown to localize on cadherin-based adherens junctions of kidney TECs (Hiiragi, et al. 1999) 
and to be important in the regulation of their proliferation through the JAK2-Stat-3 signalling 
pathway (Zhang, et al. 2009, Ponnusamy, et al. 2009).  
As reported before, TG2-null mice are phenotypically normal (De Laurenzi and Melino 2001); 
the disruption of the gene also does not affect the renal phenotype, as TG2-null mice have 
normal sized kidneys, no histological differences, and GFR is similar to WT mice (Shweke, et al. 
2008). This, in line with our previous general observations, suggests that TG2 has mostly a 
pathological role in kidney. TG1, however, results upregulated in TG2-null mice (Deasey, 
Shanmugasundaram and Nurminskaya 2013), suggesting a possible compensatory role. 
Moreover, levels of TG1, 3, 6 and 7 have been shown to increase in response to TG2 KO in mice 
(unpublished data TS Johnson/E Verderio). 
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1.4.2 Transglutaminase-2 association with kidney fibrosis models 
In the past few decades, a number of studied have suggested an association between TG2 and 
the development of kidney fibrosis upon CKD (Table 1.6). In all these studies, TG2 has been 
observed to localize and perform its crosslinking activity in the interstitial space, and, 
depending on the type of kidney damage, to act in both tubular and glomerular area. 
The first suggestion on the involvement of TG2 in the pathological process of kidney fibrosis 
was published in 1997 by Johnson and colleagues employing a rat SNx model (Johnson, et al. 
1997b). In this model, an increase in both TG2 expression and activity was observed as the 
disease progressed, and the authors hypothesized that TG2 could introduce qualitative 
changes in the ECM that could slow down matrix degradation by proteases (Johnson, et al. 
1997b). In this way, TG2 could shift the extracellular equilibrium to matrix deposition, 
reducing the proteolytic turnover. As employment of paraffin embedded section, in which the 
fixation is performed prior to immunohistochemical staining, was suggested to be unsuitable 
for extracellular TG2 detection (Verderio, et al. 1998), in 1999, the same group  (Johnson, et al. 
1999) performed TG2 staining on SNx kidney cryosections, proven to be better for detection 
of extracellular TG2 (Verderio, et al. 1998), together with an in situ TG activity assay developed 
by Verderio and colleagues (Verderio, et al. 1998). They showed that TG2 antigen and activity 
were abundantly located in the extracellular space in the SNx model, colocalising with the 
expanded ECM (Johnson, et al. 1999). By addition of exogenous enzyme, TG2 was suggested to 
stabilise the extracellular collagen against degradation by the action of MMP-1. In the same 
study, analysis of TG2 expression by mRNA hybridisation suggested that TG2 was mainly 
produced by proximal TECs and less by the glomerular cells. TG2 was also shown to be 
expressed by renal fibroblast that proliferate in the tubular interstitium after injury, while the 
presence of TG2 in blood vessels didn’t correlate with the disease (Johnson, et al. 1999). 
Interestingly, in a retrospective study on the rat SNx model, our group showed that all TG 
members known to be expressed in kidney steadily increased upon SNx, with a peak at 90 days 
post-treatment, in line with the loss of renal function. However, at this time-point TG2 
expression largely exceeded the other TGs, confirming the leading role of this enzyme (Burhan, 
et al. 2016). 
In a rat model of DN induced by STZ, TG2 was observed to be accumulated in the ECM (Skill, et 
al. 2001). As DN is primarily a glomerular disease, glomeruli were isolated and analysed for 
TG2 antigen and ε-(γ-glutamyl)lysine crosslink bound accumulation, identifying an accretion 
of active TG2 in the glomerular basement membrane (GBM). Even if both tubules and glomeruli 
showed an increase in TG2 activity [ε-(γ-glutamyl)lysine crosslink] after injury, in the tubules 
no overall changes in TG2 expression was noticed, meaning that the increase in the 
extracellular activity was not associated with a de novo synthesis of TG2 protein but probably 
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only to an increase in the enzyme export (Skill, et al. 2001). The same authors developed an in 
vitro model of diabetic nephropathy induced by high glucose levels on opossum kidney (OK) 
proximal TECs (up to 36 mM, for 96 h), and showed an increase in TG2 expression and 
crosslinking products upon glucose stress, together with the increase deposition of several 
ECM proteins, especially FN and total collagen (Skill, et al. 2004). The increase in ECM 
deposition induced by glucose appeared significantly correlated with the increase in ε-(γ-
glutamyl)lysine crosslink bounds, confirming the involvement of the enzyme in matrix 
accumulation (Skill, et al. 2004). 
Some years later, the STZ model was induced on uninephrectomized (UNx) rats by Huang and 
colleagues, to accelerate the process of kidney fibrosis. In this model, both tubulointerstitial 
fibrosis and glomerulosclerosis were detected, and increased progressively up to eight months 
post administration of STZ; TG2 activity was several-fold increased at eight months post 
treatment, with progressive accumulation of crosslinking products, and was significantly 
higher than control rats and UNx untreated rats (Huang, et al. 2009). Employment of a specific 
TG inhibitor was shown to be protective against the progression of disease in this model 
(Huang, et al. 2009). 
In a rat model of FSGS by injection of PAN, the induction of disease led to an increase of TG2 
expression and crosslinking activity mainly in the glomeruli, and was accompanied by an 
increase in FN deposition and reduction in MMP-9 activation (Liu, et al. 2006).  
The UUO model on C57BL/6 mice (described in Chapter III) was also employed in the analysis 
of TG2 implications on CKD by different groups. This model was shown to induce 
tubulointerstitial fibrosis in only 12 days after treatment, and the development of disease was 
accompanied by a significant increase in TG2 expression that appeared strongly increased in 
both tubulointerstitium and periglomerular area (Shweke, et al. 2008). The expression of TG2 
correlated with the development of tubulointerstitial fibrosis, detected by an increase in 
collagen I expression and deposition, myofibroblasts infiltration monocyte adhesion and 
macrophage infiltration (Shweke, et al. 2008). Interestingly, TG2 was shown to partially co-
localise with infiltrated macrophages upon UUO, suggesting that the enzyme could be secreted 
by different cell types during CKD (Shweke, et al. 2008).  
Importantly, an increased expression of TG2 in in renal tubular cells and deposition in the 
tubulointerstitial space was also identified when the same surgery was performed in Wistar 
rats, in parallel with increased immunostaining of CTGF, which was suggested to partially co-
localize with the enzyme in the tubulointerstitium, and FN (Chen, Huang and Yu 2005). 
In a recent study by our group, both UUO model, which induce a rapid tubulointerstitial 
fibrosis, and AAN model, which induces a tubulointerstitial fibrosis more similar to the human 
disease (Huang, et al. 2013), were analysed on the C57BL/6 mice strain. In both models, a 
progressive accumulation of TG2 was detected in the tubulointerstitial space. Increase in 
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tubulointerstitial TG2 was suggested to result from an augmented export of the enzyme and 
re-distribution of the protein from the cytosol to the extracellular space, as its total level, when 
detected by Western blot, was found to not significantly vary upon treatment (Scarpellini, et 
al. 2014). 
As reported above, vascular calcification can be detected on advanced CKD, and it is typical of 
the mineral bone disorder- associated CKD (CKD-MBD)(Moe, et al. 2009). When arterial 
calcification was induced using the Cy/+ rat model, that spontaneously develops CKD with all 
the features of CKD-MBD, TG2 expression and activity of TG2 was shown to be upregulated in 
both vascular smooth muscle cells and pathological matrix vesicles derived by these cells 
(Chen, et al. 2013). TG2 was shown to be involved in the calcification of both cells and vesicles, 
as the general TG inhibitor cystamine slowed down calcification in smooth muscle vascular 
cells, matrix vesicles and aorta rings isolated from these rats (Chen, et al. 2013). 
 
1.4.3 Transglutaminase-2 in CKD patients 
The importance of TG2 in the development of kidney fibrosis has been reported not only in 
animal models of CKD, but also in human pathology, using biopsies from patients with various 
kinds of CKD (Table 1.6).  
The first study to investigate TG2 expression and activity in human biopsies was published in 
2003 by Johnson and colleagues. In this study, they examined changes in both TG2 expression 
and products of TG2 post-translational modification [ε-(γ-glutamyl)lysine crosslink] in renal 
scarring using biopsies by a number of patients with different nephropathies, both 
proliferative and non-proliferative, with different levels of scarring. Diseases considered 
included crescentic glomerulonephritis (CGN), DN, IgA nephropathy (IgAN), FSGS and ESKF, to 
mention some (Johnson, et al. 2003). A significant correlation between the level of interstitial 
fibrosis (evaluated by Masson’s trichrome - MT staining) and TG2 extracellular expression/in 
situ activity was identified in biopsies characterized by diverse levels of tissue scarring (from 
mild to severe) (Johnson, et al. 2003). Upregulation of TG2 mRNA was detected in mainly in 
TECs, but also in interstitial and mesangial cells from these patients, and was associated with 
an increased expression of soluble TG2, that well correlated with the level of tissue scarring 
especially in proliferative diseases.  
In 2004, a further study employed renal biopsies from 16 DN patients, that showed an increase 
in TG2 and ε-(γ-glutamyl)lysine crosslink compared to the healthy kidney, as detected by 
immunofluorescent staining and confocal microscopy. Both TG2 antigen and activity 
correlated with the level of tissue scarring measured by MT staining, and localised in 
peritubular and periglomerular areas of the kidneys (El Nahas, et al. 2004).  
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Interestingly, in both studies mentioned, some level of intracellular TG2 crosslinking activity 
was detected in TECs upon fibrosis, that suggests a TG2-mediated cell death upon kidney injury 
(Johnson, et al. 2003, El Nahas, et al. 2004), as a cellular response to loss of calcium homeostasis 
(Verderio, et al. 1998, Nicholas, et al. 2003). This agrees with what already observed by 
Johnson and colleagues in 1997, that first proposed a TG2-induced/mediated cell death of 
tubular cells in the ablation model of CKD (Johnson, et al. 1997b).  
Other studies of TG2 expression on human kidney biopsies were undertaken on patients with 
IgAN, which is a well-known type of proliferative glomerulopathy. In a first study (Ikee, et al. 
2007), glomerular staining of TG2 correlated well with  the loss of kidney function as detected 
in different ways (creatinine clearance and serum creatinine, protein excretion, 
glomerulosclerosis, mesangial cell proliferation), and tubular staining of TG2 was well 
identified and significantly correlated with markers of tubular dysfunction such as N-acetyl-β-
glucosaminidase (Bazzi, et al. 2002) and urinary β2-microglobulin (Peterson, Evrin and 
Berggard 1969). TG2 staining was shown to be high in interstitial fibrotic lesions and in the 
proximity of vascular poles, as well as on glomerular crescents, that sometimes form in this 
kind of disease (Tumlin, Lohavichan and Hennigar 2003).  
Whereas it correlated with a series of markers of renal function, TG2 expression didn’t 
correlate with TGF-β staining (Ikee, et al. 2007). In a mouse model of the same disease, TG2 
was suggested to be involved in mesangial cells activation by promoting the deposition of IgA 
on the mesangial cell surface, in a complex with the soluble CD89 protein, which directly binds 
transferrin receptor. This binding, in turn, induces TG2 expression on the mesangial cell 
surface which upregulates transferrin receptor, in a positive loop that potentiates mesangial 
activation upon IgA - CD89 administration (Berthelot, et al. 2012).  
In a study of kidney biopsies from patients affected by membranous nephropathy (MN), a 
primary cause of glomerular disease and one of the common causes of nephrotic syndrome in 
adults, TG2 expression was increased and preceded the development of fibrosis. However, it 
was not affected by an immunosuppressive treatment (Papasotiriou, et al. 2012).  
TG2 was also analysed as a potential early marker of chronic allograft dysfunction after kidney 
transplant, which is similar to other forms of CKD and characterised by chronic inflammation 
and development of fibrosis. Chronic allograft nephropathy (CAN) can be detected in up to 40% 
of grafts already few months after transplant and is the most common cause transplant failure. 
It is usually detected too late, by allograft fibrosis, which is led by ECM expansion. To determine 
if TG2 could be a potential early marker of allograft rejection and subsequent CAN, TG2 
expression was examined on sequential biopsies at different stages post-kidney transplant 
(Johnson, et al. 2004). TG2 and its crosslinking products were shown to be absent in kidney 
biopsies at implantation, but increased early after transplantation in the tubulointerstitium 
and mesangium of almost half of the biopsies, and were present in all patients with established 
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CAN (Johnson, et al. 2004). Importantly, increase in TG2 was detectable before fibrosis and 
better correlated with the outcome of kidney transplant than other predictors such as collagen 
staining, α-SMA and MT staining, at the implantation and early after transplant. For this reason, 
it was suggested to be a potential marker of allograft scarring at the earlier stages of disease 
(Johnson, et al. 2004). In a subsequent study with a larger cohort, TG2 expression was reported 
to increase with allograft scarring, observed as a rise in tubulointerstitial fibrosis and tubular 
atrophy. Its expression was suggested to correlate with both increased expression of TGF-β 
and with the tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), suggesting that both 
matrix deposition and reduced degradation contribute to the development of interstitial 
fibrosis and tubular atrophy in this conditions (Mengel, et al. 2008). 
Interestingly, the role of TG2 in chronic allograft rejection has also been studied in vivo 
employing an animal model of allogenic renal transplantation, where kidneys were 
transplanted from a donor Lewis rat to a receiver Fisher rat (allografts), or to another Lewis 
rat as a control (isographs) (Shrestha, et al. 2014). In this model, allogenic transplant led to a 
progressive dysregulation in the parameters of renal function, such as loss of creatinine 
clearance, increased serum creatinine, hypertension, etc. In parallel, a rise in TG2 
expression/activity was observed in the allografts, with increased export in the 
tubulointerstitium and periglomerular space, and a distribution that mirrored the one of 
myofibroblasts, while no changes where observed in the controls (Shrestha, et al. 2014). 
Intriguingly, for the first time, ε-(γ-glutamyl)lysine crosslinked products were also observed 
be progressively excreted in the allograft urine (Shrestha, et al. 2014), suggesting TG2 activity 
as a possible easily detectable marker of renal stress.  
There is growing interest in urinary biomarkers of CKD as possible predictors of the disease at 
its early stages, as most of the current markers are mainly representative of the later stages of 
established disease. In a recent study from Johnson’s group, TG2 expression was analysed on 
urine samples of ~300 patients with distinct types of CKD followed for a minimum of three 
years (da Silva Lodge, El Nahas and Johnson 2013). Urinary TG2 expression was analysed by 
sandwich ELISA and was found to be on average 41 times greater than the controls. Higher 
expression was identified in diabetic nephropathy patients and in general patients with 
progressive or rapidly progressive disease were showing to have higher TG2 excretion than 
individuals with non-progressive CKD (da Silva Lodge, El Nahas and Johnson 2013). Increase 
in TG2 urinary expression could be detected at the early stages of the disease (stage 2), 
suggesting the enzyme as a possible early marker; moreover, from the statistical analysis of 
the data, the ratio of TG2:creatinine resulted as an even better predictor of progressive CKD 
than the ratio of albumin over creatinine (da Silva Lodge, El Nahas and Johnson 2013).  
In summary, these studies showed how TG2 is expressed and exported in the interstitial space 
in in patients affected by a variety of CKDs, and is active as a matrix crosslinker, contributing 
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to ECM stabilisation. For this reason, TG2 was suggested as a potential clinical target against 
the development of fibrosis. In the next paragraph, a series of studies involving TG2 deletion 
or TG chemical inhibition will be shown, which confirmed a potential protective role of TG2 
targeting against CKD..  
 
Table 1.6: Studies of transglutaminase-2 in CKD.  
 Models of CKD with upregulated extracellular TG2  
expression and  / or activity 
Reference 
E
X
P
E
R
IM
E
N
T
A
L
 M
O
D
E
L
 
Subtotal Nephrectomy (SNx) in Rat 
(Johnson et al. 1997) 
(Johnson et al. 1999) 
(Johnson et al. 2007) 
(Burhan et al., 2016) 
Unilateral Ureteric Obstruction (UUO) in Rat (Chen et al. 2005) 
Unilateral Ureteric Obstruction (UUO) in mouse 
(Shweke et al. 2008) 
(Scarpellini et al. 2014) 
Aristolochic Acid Nephropathy (AAN) in mouse (Scarpellini et al. 2014) 
CKD-Mineral Bone Disorder (CKD-MBD), Cy/+ rat (Chen et al. 2013) 
STZ- induction of diabetic nephropathy in Rat 
(Skill et al. 2001) 
(Huang et al. 2009) 
(Huang et al. 2010) 
Rat Fisher-Lewis model of chronic allograft nephropathy (Shrestha et al. 2014) 
Puromycin aminonucleoside (PAN)-induced rat model of focal and segmental 
glomerulosclerosis 
(Liu et al. 2006) 
H
U
M
A
N
 B
IO
P
S
IE
S
 Human biopsies with different types of CKD (Johnson et al. 2003) 
Human biopsies at different stages of diabetic nephropathy 
(Johnson et al. 2003) 
(El Nahas et al. 2004) 
Human biopsies at different stages of allograft rejection (Johnson et al. 2004) 
Human biopsies at different stages of Membranous Nephropathy (MN) (Papasotiriou et al. 2012) 
Human biopsies of IgA nephropathy (IgAN) 
(Johnson et al. 2003) 
(Ikee et al. 2007) 
C
E
L
L
 
S
Y
S
T
E
M
S
 
Tubular epithelial cells (TEC) 
(Skill et al. 2004) 
(Fisher et al. 2009) 
(Huang et al. 2010) 
(Chou et al. 2011) 
Vascular smooth muscle cells (VSMC) from Cy/+ rat (Chen et al. 2013) 
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1.4.4 Transglutaminase inhibition and TG2 specific knock out have a 
protective role against the progression of CKD 
Given the involvement of TG2 in the process of kidney fibrosis, a number of studies have tested 
its potential as a clinical target against the progression of disease either by employing TG 
inhibitors or by knocking down the protein, in both in vivo and in vitro experimental models 
(Table 1.7).  
The first study on the possible effect of TG inhibition on kidney fibrosis was performed by Skill 
and colleagues on an in vitro OK TECs model of DN induced by high glucose levels, where 
contemporaneous increase in TG2 extracellular expression/activity and matrix deposition 
were observed (Skill, et al. 2004). In this study, they employed two pan-inhibitors of TGs: one, 
1,3-dimethyl-2[(oxopropyl)thio]-imidazolium (synthesized in house and named NTU283), is a 
potent TG inhibitor with no specificity for any TG family member over another and initially 
developed by Merk as a FXIIIa inhibitor (Castelhano, et al. 1990, Freund, et al. 1994). NTU283 
is suggested to be highly cell soluble and to easily enter the cells. The second one, a 
carboxybenzoyl-glutamylglycine analogue [N-benzyloxycarbonyl-L-phenylalanyl-6-
dimethylsulfonium-5-oxo-L-norleucine or NTU281), was developed by Griffin’s group as pan-
inhibitor of TGs (Griffin, Coutts and Saint 2004); it is less cell permeable, hence mostly limited 
to the extracellular space. Application of these TG inhibitors suggested for the first time a direct 
implication of TG in matrix deposition and stabilisation, with collagen III suggested as the main 
target of the enzymes’ crosslinking activity (Skill, et al. 2004). The same compounds were 
employed on the experimental rat ablation model of CKD (SNx). These compounds were 
delivered locally to the kidney by intra renal infusion with a subcutaneous osmotic mini-pump, 
and confirmed a protective effect of TG inhibition against both glomerulosclerosis and 
tubulointerstitial fibrosis (detected by collagen deposition and MT staining), interstitial cell 
proliferation, and loss of renal function (detected by creatinine clearance, proteinuria and 
albuminuria) (Johnson, et al. 2007).  
Few years later, Huang and colleagues employed NTU281 on the STZ model of DN performed 
on UNx rats (Huang, et al. 2009), delivering the compound to the animals by direct intrarenal 
infusion for eight months. While untreated animals presented extensive renal fibrosis, and 
were showing ESKF at the end of the experimental time, rats treated with NTU281 showed a 
significant reduction of glomerulosclerosis and tubulointerstitial fibrosis detected by MT 
staining and collagen accumulation, accompanied by a significant amelioration of kidney 
function (Huang, et al. 2009). 
Despite the employment of these TG inhibitors were shown to have positive effect against the 
development of fibrosis in animal models or cultured cells, they are not specific for TG2, and 
might lead to other pathologic effects by affecting other members of the TG family, if delivered 
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systemically. For example, by inhibiting TG1, these compounds were shown to impede 
terminal differentiation of keratinocytes that could cause parakeratosis (Harrison, et al. 2007). 
Similarly, attempts to use these inhibitors systemically have resulted in longer bleeding times 
in some analysed animals (TS Johnson personal communication).   
 
In addition to these pan-inhibitor studies, a series of studies employing specific knock out of 
TG2 (TG2-KO) confirmed that TG2 inhibition alone was sufficient to slow down the 
development of fibrosis. In a model of mice UUO, specific TG2-KO appeared protective against 
the progression of tubulointerstitial fibrosis (Shweke, et al. 2008). The knock out led to a 
reduced collagen deposition and myofibroblasts / macrophage infiltration, that were 
associated with a lowered activation of TGF-β (Shweke, et al. 2008). The effect of TG2-KO was 
also studied in vitro using primary TECs from TG2-null mice and was paired to an analysis of 
TG2 overexpression in opossum kidney (OK) TECs (Fisher, et al. 2009). From this study, TG2 
was proven to accelerate ECM deposition with higher resistance to proteolytic digestion, as 
both features were increased in TG2 overexpressing cells and reduced by TG2-KO (Fisher, et 
al. 2009). Similar positive effects of TG2-KO against fibrosis were observed in other organs 
such as in lung and liver (Olsen, et al. 2011, Zhao, et al. 2011), suggesting a conserved 
mechanism in different fibrotic conditions.  
 
Taken altogether, these studies propose TG2 as a possible target against the development of 
kidney fibrosis. For this reason, the development of a specific inhibitor of TG2 activity was 
suggested to be important to provide a potentially highly effective clinical tool against the 
development of fibrosis. Unfortunately, however, the pharmacological development of this 
inhibitor is extremely challenging, given the high homology of TG2 catalytic domain with the 
other members of TG family, and the conserved catalytic core. In the past few decades, several 
academic groups and R&D companies have registered patents on TG2 small molecule 
inhibitors, while more recently the development of antibodies as TG2 inhibitors has appeared 
promising [reviewed in (Verderio, et al. 2015)].  
As an increased export of the enzyme has been observed upon fibrosis, an alternative approach 
would be to block the enzyme trafficking to the cell surface, interfering with TG2 binding to 
potential secretion partners.  
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Table 1.7:  Studies of transglutaminase inhibition or TG2-deletion in CKD progression. 
 
Type of treatment Reference 
TG inhibitors 
(Skill et al. 2004) 
(Chen et al. 2005) 
(Johnson et al. 2007) 
(Huang et al. 2009) 
(Huang et al. 2010) 
(Chen et al. 2013) 
TG2 knock-out 
(Shweke et al. 2008) 
(Fisher et al. 2009) 
(Scarpellini et al. 2014) 
 
 
1.4.5 TG2 mediated TGF-β activation and its importance in progressive 
kidney scarring 
TG2 crosslinking activity has been suggested to play a double fibrogenic role in the 
development of fibrosis: one is a direct role in the stabilization of ECM, already mentioned in 
the previous paragraphs, while the second is a role in the recruitment of large latent TGF-β 
complex to the matrix and activation of TGF-β.  
Since the end of the last century, TG2 has been known to be involved in the recruitment of the 
large latent TGF-β1 complex  and TGF-β1 activation by crosslinking of LTBP-1 large binding 
protein to the extracellular matrix (Nunes, et al. 1997, Kojima, Nara and Rifkin 1993, Verderio, 
et al. 1999). Interestingly, in fibroblasts, TG2 has also been suggested to induce TGF-β 
expression at mRNA and protein level through NF-κB activation and subsequent 
transcriptional regulation (Telci, et al. 2009). Treatment of TG2-expressing Swiss 3T3 
fibroblasts with TG inhibitors or inhibition of TG2 activity by nitric oxide (NO) resulted in 
reduction in NF-κB activation and TGF-β1 expression and activation, and subsequent lowering 
of ECM protein synthesis and deposition (Telci, et al. 2009). In addition, TGF-β1 has been 
suggested to upregulate TG2 expression in different cell types (George, et al. 1990, Quan, et al. 
2005). This suggest that both TG2 and TGF-β1 are involved in a positive feedback loop in which 
they reciprocally induce their expression and activation (Belkin 2011).  
The hypothesis of TG2 involvement in the upregulation of TGF-β activation during CKD arised 
from different studies involving KO of the enzyme. Initial findings were provided by Shweke 
and colleagues on the UUO mice model of experimental kidney fibrosis (Shweke, et al. 2008). 
While in healthy control mice the TG2-KO didn’t significantly affect the amount of activated 
TGF-β1, when measured by Quantikine TGF-β1 ELISA kit by R&D Systems, upon UUO (12 days 
post-surgery), the development of renal fibrosis was associated with a consistent increase in 
active TGF-β1, that was significantly lower in TG2-null mice subjected to the same treatment 
(Shweke, et al. 2008). Comparable results were obtained by Fisher and colleagues using TG2-
null primary TECs and TG2-overexpressing TECs (Fisher, et al. 2009), where TG2 modulation 
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was shown to significantly affect TGF-β activation when measured by mink lung epithelial cells 
(MLEC) bioassay (Abe, et al. 1994).  
A significant increase in TGF-β was also observed by our group in the AAN model of kidney 
fibrosis in a recent study (Scarpellini et al. 2014). Interestingly, in this study, the knock out of 
the HSPG Sdc4 was accompanied by a decrease in TGF-β1 activity in fibrotic mice (Scarpellini 
et al. 2014). Even if a possible role for cell surface HSPGs such as Sdc4 in TGF-β activation has 
been suggested, for example by regulating the distribution of the large latent complex, the 
importance of Sdc4 for the cytokine regulation was suggested to be indirect, by promoting TG2 
externalisation and retention, which in turn promotes TGF-β activation. In support to this, in 
recent work by our group, addition of exogenous TG2 on tubular epithelial cells was shown to 
be sufficient to induce TGF-β activation, and the effect was reduced by employment of a 
chemical antagonist of HS chains (Burhan, et al. 2016).  
Recent findings on the role of HSPGs interaction with TG2 in progressive renal scarring will be 
described in the next section. However, the significance of this interaction for the enzyme 
trafficking and extracellular retention by kidney cells has not yet been completely understood, 
and will be the focus of Chapter VI.  
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Table 1.8: Summary of the main roles of transglutaminase-2 in the progression of kidney fibrosis 
 
Roles of transglutaminase-2 in CKD Reference 
Formation of ε-(γ-glutamyl)lysine crosslinks (detected by exhaustive 
proteolytic digestion) 
(Johnson et al. 1997) 
(Skill et al. 2001) 
(Skill et al. 2004) 
(Shrestha et al. 2014) 
Formation of ε-(γ-glutamyl)lysine crosslinks (detected by 
immunocytochemistry/immunofluorescence) 
(Johnson et al. 1997) 
(Johnson et al. 1999) 
(Skill et al. 2001) 
(Johnson et al. 2003) 
(El Nahas et al. 2004) 
(Johnson et al. 2004) 
(Liu et al. 2006) 
(Chen et al. 2013) 
(Shrestha et al. 2014) 
Extracellular transamidating activity (amine incorporation assay) 
(Johnson et al. 1999) 
(Skill et al. 2001) 
(Johnson et al. 2003) 
(Johnson et al. 2004) 
(Liu et al. 2006) 
(Johnson et al. 2007) 
(Shweke et al. 2008) 
(Huang et al. 2009) 
ECM deposition 
(Skill et al. 2004) 
(Chen et al. 2005) 
(Johnson et al. 2007) 
(Shweke et al. 2008) 
(Fisher et al. 2009) 
(Huang et al. 2009) 
(Chen et al. 2013) (Vascular 
calcification) 
(Scarpellini et al. 2014) 
Matrix resistance to proteolytic turnover 
(Johnson et al. 1999) 
(Fisher et al. 2009) 
Myofibroblasts infiltration 
(Johnson et al. 2007) 
(Shweke et al. 2008) 
(Huang et al. 2009) 
Immune cell infiltration 
(Johnson et al. 2007) 
(Shweke et al. 2008) 
Intracellular protein crosslinking 
(Johnson et al. 1997) 
(El Nahas et al. 2004) 
(Johnson et al. 2004) 
Activation of TGF-β 
(Shweke et al. 2008) 
(Fisher et al. 2009) 
(Huang et al. 2010) 
(Scarpellini et al. 2014) 
(Burhan et al. 2016) 
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1.5 TRANSGLUTAMINASE-2 INTERACTION WITH HEPARAN SULPHATE 
PROTEOGLYCANS AND INVOLVEMENT IN KIDNEY FIBROSIS 
 
1.5.1 The families of heparan sulfate proteoglycans (HSPGs) 
Heparan sulfate proteoglycans (HSPGs) are a cell surface/ECM superfamily of proteoglycans 
characterised by a core protein associated with one or more covalently attached heparan 
sulfate (HS) chains, a specific type of glycosaminoglycan (GAG) chain (Esko, Kimata and Lindahl 
2009).  In mammals, approximately 17 HS proteoglycans have been identified and can be 
distinguished into nine families depending on their location, core protein and type of HS/GAG 
chains (Sarrazin, Lamanna and Esko 2011). In general, HSPGs can be divided into two large 
categories, cell surface membrane-associated proteoglycans and secreted extracellular matrix 
HSPGs (located in the basement membrane) (Table 1.9).  
The most well-known cell surface HSPGs are the syndecans (four members, Sdc1-4) and the 
glypicans (six members, Gpc1-6). Syndecans are a family of transmembrane proteoglycans 
characterised by a small cytoplasmic domain, a transmembrane portion and a larger 
extracellular domain with two – to – five GAG chains, that are mainly HS but can include one or 
two chondroitin sulfate (CS) chains (Sdc1 an Sdc3), a different type of sulfated GAG chain. 
Glypicans, on the other side, are covalently bound to the cell surface by a 
glycosylphosphatidylinositol (GPI) phospholipid linkage. The core protein has a globular 
cysteine rich structure and is characterised by only HS chains in number of one to three (Esko, 
Kimata and Lindahl 2009, Tumova, Woods and Couchman 2000). Minor forms of cell surface 
HSPGs include fibroblasts’ betaglycan, or TGF-β receptor III (TGFBR3), a large part-time 
proteoglycan with HS and CS chains, CD44v3, an isoform of CD44 antigen in limphocytes, 
characterised by one HS chain (Sarrazin, Lamanna and Esko 2011), and Neuropilin-1, another 
large part-time proteoglycan characterised by HS or CS chains that act as co-receptor in VEGF 
signalling (Table 1.9).    
Extracellular matrix (secreted) HSPGs are located in the basement membrane of different cell 
types and include perlecan, agrin, and collagen type XVIII (endostatin) (Sarrazin, Lamanna and 
Esko 2011). Perlecan is a large HSPG with a protein core of 400 kDa and one-to-four HS chains. 
In rare cases CS chains have been observed on perlecan (Kvist, et al. 2006). Agrin is smaller 
and characterised by only HS chains; it is localised in the basement membrane and is regarded 
to as the main component of the kidney glomerular basement membrane in humans (Groffen, 
et al. 1998). Collagen XVIII is a particular basement membrane collagen with one-to-three HS 
chains, that can be cleaved to form endostatin, a short fragment involved in angiogenesis 
inhibition (Table 1.8).  
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Interestingly, one last HSPG family, serglycin, is a family of small (10-19 kDa) proteoglycans 
localised on cytoplasmic storage granules and secretory vesicles of hematopoietic cells, mast 
cells and endothelial cells (Kolset and Tveit 2008, Pejler, Åbrink and Wernersson 2009). 
Serglycin is characterised by the presence of CS chains and, notably, it is the only HSPG to show 
heparin chains (Schaefer, et al. 2004) (Table 1.9).  
 
Table 1.9: Heparan sulfate proteoglycans (HSPGs). Table adapted from (Sarrazin, Lamanna and Esko 
2011). HS = Heparan sulfate, CS = Chondroitin sulfate. Numbers in brackets indicate the number of 
chains.  
 
 
 
 
1.5.2 HSPGs in wound healing, fibrosis and kidney disease 
Syndecan family has been suggested to play many roles in the process of tissue repair after 
injury. Sdc4 and Sdc1 have been well described as upregulated during inflammatory 
conditions, leading to angiogenesis and wound repair (Gallo, et al. 1997). Moreover, Sdc2 has 
also been suggested to play a role in wound healing by modulation of TGF-β signalling (Chen, 
Klass and Woods 2004). Growth factors such as FGF2 have been shown to be key mediators of 
wound healing by interaction with both Syndecans and tyrosine receptors.  
Sdc4 activity in wound healing is directly correlated with its ligand-mediated oligomerisation 
and activation of specific small GTPases in cooperation with β1 integrins. In case of injury, Sdc4 
supports cell proliferation and migration to close the wound: the increase of Sdc4 expression 
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in the wound area correlates with an increase in cell proliferation, that depends on growth 
factor stimulation (FGF2 binding) and subsequent PKCα activation (Chapter VI).   
Sdc1 role in wound healing, on the other side, is associated with the promotion of cell adhesion 
and negative control of mesenchymal transformation.  
Both Sdc4 and Sdc1-null mice show defects in wound healing. Sdc4-null mice show delayed 
wound healing, which in general depends on altered proliferation and motility of fibroblasts. 
Sdc4-null mice are unable to produce a proper granulation tissue and novel vascularisation 
(angiogenesis) in the wound area during the healing process, which depends on a loss of the 
proliferative capacity of the cells (Echtermeyer, et al. 2001). On the other side, Sdc1-KO mice 
show defects in wound healing mostly determined by dysregulated re-epithelisation (Stepp, et 
al. 2002). 
Syndecan shedding has been shown to be involved in the regulation of wound healing. During 
inflammation, HS chains of Syndecans can bind chemokines, which can induce MMP-dependent 
shedding of Syndecan ectodomains. Apparently, both Sdc1 and Sdc4 shedded ectodomains 
have been found to accumulate in dermal wound fluids (Subramanian, Fitzgerald and Bernfield 
1997), but their involvement in the healing process were suggested as different. Sdc1 shed 
ectodomains, produced for example by MMP-7, favour cell migration and facilitate wound 
closure, while at the same time promoting re-epithelisation (Chen, et al. 2009, Endo, et al. 2003, 
Su, et al. 2008). Sdc4 shedding, on the other side, reduces proliferation and controls FGF2 
signalling (Bass and Humphries 2002).   
 
As tissue scarring can be described as an uncontrolled wound healing, it appears likely that 
Syndecans could be involved in the regulation of tissue fibrosis.  
The involvement of Syndecans in tissue fibrosis has been well-studied in heart disease 
(infarction, hypertension, etc.) and associated with cardiac fibrosis. During cardiac fibrosis, 
Sdc1 and Sdc4 have been suggested to be upregulated by inflammatory response and to 
contribute to pro-fibrotic signalling (cell migration/proliferation/adhesion) by binding ECM 
proteins such as cytokines and growth factors but also FN and collagens, and transducing the 
signal to the intracellular space. On the other side, ectodomain shedding during inflammation 
leads to cardiac rupture by ECM degradation, and directly correlates with a bad outcome of 
myocardial infarction (Schellings, et al. 2010, Lunde, et al. 2016).  
In pulmonary fibrosis, shedding of Sdc1 promotes neutrophil chemotaxis and fibrogenesis.  
Sdc4 has been suggested to be required for the formation of a myofibroblast phenotype in 
fibrosis and to induce ECM contraction mediated by fibroblast, transducing TGF-β signalling 
and activating ERK response during chronic fibrosis (Chen, et al. 2005, Matsui, et al. 2011). 
 
CHAPTER I – INTRODUCTION 
 
59 
 
In kidneys, expression of Sdc1, Sdc2 and Sdc4 has been detected, among which Sdc4 was 
reported to be the most abundant syndecan of kidney tissue, Sdc1 was described as highly 
expressed and Sdc2 as less expressed (Kim, et al. 1994).  
Association of Sdc4/HSPGs with CKD has been reported in the past (Yung, et al. 2001, Morita, 
et al. 1994, Fan, et al. 2003). Loss of endothelial glycocalyx is another feature of CKD and has 
been shown to be largely associated with Sdc1 shedding in CKD (Padberg, et al. 2014, Zeng, et 
al. 2014).  
Importantly, also Sdc2 has been shown to be upregulated in some studies of kidney fibrosis: 
the expression of Sdc2 was increased in parallel with TGF-β upon DN, moreover, it was shown 
to be upregulated in a model of unilateral nephrectomy where Sdc4 expression was abolished, 
suggesting a compensatory effect of this family member (Ruiz, et al. 2012, Chen, Klass and 
Woods 2004).  
Recently, in a rat model of CKD obtained by SNx, Sdc4 appeared as the highest expressed 
syndecan in fibrotic kidneys, increasing in parallel with the loss of kidney function and peaking 
at a level of advanced fibrosis (90 days post-SNx), when the process becomes irreversible 
(Burhan, et al. 2016). Knockout of Sdc4 in two mouse model of CKD obtained by UUO or AAN 
resulted in a striking reduction of fibrosis compared to WT mice (Scarpellini, et al. 2014).  
Altogether, these findings suggest that Sdc4 is overexpressed during the progression of CKD 
and might play a role in supporting fibrosis, which is in line with the protective role of its knock 
out and the reduced wound healing in Sdc4-null cells (Echtermeyer, et al. 2001).  
A recent work has suggested a significant role for HS chain sulfation state in the binding and 
extracellular localisation of cytokines and growth factors and in promoting their association 
with their receptors during kidney disease. In this study, the level of sulfation was associated 
with the progression of kidney fibrosis in the context of chronic allograft rejection after kidney 
transplant. They suggested that the level of 6-O-sulfated glucosamine residues is upregulated 
by in kidney TECs upon allograft rejection, that associates with an increased binding of FGF2 
and ERK activation. In the same study, the increase in 6-O-sulfation in fibrotic kidneys was 
confirmed employing a mouse UUO model (Alhasan, et al. 2014).  
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1.5.3 TG2 interaction with HSPGs is involved in TG2 extracellular roles and in 
the enzyme release 
Lately, different studies have focused on the relationship between extracellular TG2 and cell 
surface HSPGs.   
Different studies from our group at NTU suggested that TG2 is able to bind HS chains / heparin 
with high affinity (comparable with the affinity of TG2 for FN) and that the interaction of TG2 
with cell surface HS chains of syndecans has two main consequences: it mediates the RDG-
independent cell adhesion to FN-TG2 heterocomplex and it favours cell surface trafficking and 
ECM distribution of TG2 (Scarpellini, et al. 2009, Verderio, Scarpellini and Johnson 2009, 
Verderio and Scarpellini 2010).  
Between 2003 and 2008, works from Griffin’s group suggested that, in case of apoptosis 
mediated by matrix fragmentation with loss of RGD-dependent cell adhesion (anoikis), TG2 is 
able to rescue cell adhesion of fibroblasts and epithelial cells by promoting RGD-independent 
cell adhesion to FN, and that this critically depends on TG2-FN heterocomplex binding to Sdc4 
HS chains, leading to PKCα activation and FAK signalling (Verderio, et al. 2003, Telci, et al. 
2008), which requires β1-integrins (Wilcox-Adelman, Denhez and Goetinck 2002).  
The role of HSPG in cell adhesion is particularly important in situations of cell stress that 
determine an over-secretion of TG2 and an over-deposition in the ECM. This happens during 
pathophysiological events such as wound healing, organ fibrosis or cancer development.  
Other studies form Griffin’s group confirmed the requirement of Sdc4 for RGD-independent 
cell adhesion to TG2-FN heterocomplex, while proposing a that also Sdc2 was required for the 
process, as its deletion was leading to reduced cell attachment and spreading both in control 
cell or cells cultured in presence of RGD peptide, that TG2-FN homodimer alone couldn’t 
compensate. Interestingly, however, they suggested that Sdc2 didn’t directly bind TG2 but 
acted as a downstream PKCα -dependent signal that regulates actin cytoskeleton (Wang, Telci 
and Griffin 2011, Wang, et al. 2010)  .  
In an in vitro study employing mouse dermal fibroblast (MDFs), Scarpellini and colleagues 
showed an elevated affinity of TG2 for HS chains and heparin. They suggested that cell surface 
HSPGs could act as receptors for TG2 via HS chains, and that binding to cell surface HSPGs 
significantly controls TG2 trafficking to the cell surface, allowing its extracellular activity 
(Scarpellini, et al. 2009, Scarpellini 2009). Sdc4 null-MDFs showed a significant abolishment of 
TG2 export, as well as treatment with a HS chemical antagonist (Surfen) (Schuksz, et al. 2008) 
or HS digestion by bacterial Heparitinase (Scarpellini, et al. 2009, Scarpellini 2009). 
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1.5.4 TG2 interaction with HSPGs in models of CKD 
Knowing the pivotal role of TG2 export to the cell surface during the progression of CKD, shown 
in the previous section, the effect of Sdc4 on TG2 trafficking and development of fibrosis was 
studied in vivo employing Sdc4 null mice subjected to 2 two different experimental models of 
CKD in mice: UUO and AAN. In these models, knock-out of Sdc4 appeared to be protective 
against the progression of CKD and specifically against the accumulation of fibrotic tissue, by 
negatively controlling TG2 export and activity on the cell surface (Scarpellini, et al. 2014).  
In a recent work, our group analysed expression levels of TG and syndecan family members in 
a rat model of kidney fibrosis obtained by SNx (Burhan, et al. 2016), showing a correlation 
between Sdc4 and TG2 expression during the progression of the disease, as well as a co-
localisation of the two in the interstitial space and peritubular area of fibrotic kidney tissue, 
which was abolished by interference with HS chains.  
Moreover, in both studies, a possible role for Sdc4 in favouring TG2-mediated TGF-β activation 
was investigated by measuring the percentage of activated TGF-β via MLEC bioassay (Abe, et 
al. 1994) in Sdc4-null tissues or after pre-treatment with the Hs antagonist Surfen (Scarpellini, 
et al. 2014, Burhan, et al. 2016).   
Taken altogether, these results confirm a direct binding between TG2 and HS chains of HSPGs 
and specifically suggested Sdc4 as the main receptor of TG2 on the cell surface, favouring TG2 
secretion to the cell surface and localisation in the extracellular space upon injury, where it can 
perform its enzymatic and non-enzymatic activities in the promotion of fibrosis progression, 
including TGF-β activation (Verderio, et al. 2015). Once exported, TG2 can probably interact 
with the HS chains of other extracellular HSPGs such as basement membrane Perlecan or 
directly with matrix FN, that are likely to contribute to the enzyme trafficking in the 
extracellular space and localisation in the matrix.  
Until now, the importance of HSPGs/Sdc4 for cell surface trafficking of TG2 has been studied 
in vitro in dermal fibroblasts or in vivo in models of kidney disease. However, the specific 
mechanism of TG2-HS/Sdc4 interaction and involvement in the enzyme export has never been 
investigated employing kidney cell lines. Analysis of HSPGs/Sdc4 role in TG2 export in renal 
cell types is the aim of Chapter VI and will be described further on.  
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1.6 HYPOTHESES AND SPECIFIC OBJECTIVES 
 
In this chapter, we have provided some background on the role of TG2 in ECM remodelling and 
deposition in the context of CKD. TG2 was defined as a possible clinical target against the 
progression of kidney fibrosis, and the hypothesis of a therapy against CKD targeting TG2 
secretion from kidney cells was arisen. As TG2 is characterized by a still not completely 
clarified unconventional secretion, that might involve TG2 association with different molecular 
partners and pathways for protein release, we believe that the elucidation of TG2 network of 
interactions (interactome) in kidneys at the cell-matrix interface would be the quickest 
conceivable way to identify TG2 - associated partners on its way to secretion by kidney cells. 
To achieve this purpose, we defined an original proteomic approach that combines TG2-
immunoprecipitation (IP) with a high-resolution mass spectrometry (MS) approach. The 
highly descriptive SWATH data independent acquisition (DIA) was chosen as the MS data 
collection approach for this study.  
We hypothesised that this approach would allow us to define specific TG2-associated partners 
in the context of kidney fibrosis and that, among these partners, some would lead us to deduce 
hypotheses for TG2 unconventional secretion from kidney cells in CKD conditions, that would 
subsequently be tested in vitro using kidney immortalized cell lines. As a number of studies 
from our group have highlighted HSPGs, and specifically Sdc4, as binding partners for TG2, and 
have suggested an involvement of Sdc4 in TG2 trafficking from kidney cells in in vivo models of 
CKD, we also hypothesised that HSPGs/Sdc4 could be key participants in the pathway of TG2 
unconventional secretion from kidney cells.  
The main objectives of this studies are:  
 The definition of the kidney proteome by SWATH acquisition MS in an experimental model 
of CKD, that serves to elucidate the context for the subsequent analyses of TG2 associated 
partners. The experimental model chosen for this study is the UUO model of 
tubulointerstitial fibrosis. 
 The production of the TG2 interactome in in the same experimental model using the 
abovementioned approach, combining TG2-IP and high-resolution SWATH acquisition MS.  
 The analysis of functional distribution and pathway representation of TG2 specifically 
associated partners at the cell-matrix interface, in order to produce possible hypotheses 
for the pathway of TG2 unconventional secretion from kidney cells in the context of CKD.  
 The in vitro validation of the produced hypothesis/hypotheses for TG2 unconventional 
secretion from kidney cells by, employment of immortalised cell lines.  
 The in vitro validation of the possible involvement of HSPGs/Sdc4 in TG2 secretion from 
kidney cells and extracellular retention in vitro by employment of immortalised cell lines. 
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Chapter II: General material and methods 
 
2.1 REAGENTS AND MATERIAL 
 
2.1.1 Cell culture reagents and material 
2.1.1.1 Reagents 
 
Table 2.1: Reagents employed for cell culture. 
Reagent 
Product 
code 
Company Storage 
D-Glucose G8270 Sigma RT 
DMEM with 1 g/L glucose w/o L-Glutamine BE12-707F Lonza 4°C 
DMEM with 4.5 g/L glucose w/o L-Glutamine BE12-614F Lonza 4°C 
DMEM:F-12 1:1 Mixture w/15mM Hepes, w L-
Glutamine 
BE12-719F Lonza 4°C 
Ethylenediaminetetraacetic acid solution 0.5 M pH 
8.0 
3690 Sigma 4°C 
G418 (Geneticin) (CAS: 108321-42-2) 100 mg/ml 
solution in HEPES 
ant-gn-5 Invivogen -20°C 
G418 Sulfate (lyophilised powder)  [potency = 800 
µg/mg] 
345810 Merk 
Stock solution 100 mg/ml in 
sterile distilled water, filtered 
(stored at -20°C) 
Gibco TM Foetal Bovine Serum, qualified, E.U.-
approved, South America origin 
11573397 
Thermo Fisher 
Scientific 
-20°C 
L-Glutamine solution [200 mM L-glutamine (100X)] G7513 Sigma -20°C 
MycoAlert Plus Mycoplasma Detection Kit LT07-701 Lonza 4°C, -20°C once prepared 
Mycoplasma removal agent (MRA) [50 µg/ml] BUF035 AbD Serotec RT 
Penicillin-Streptomycin (Pen/Strep) [10,000 
units/ml penicillin and 10 mg/ml streptomycin 
(100X)] 
P4333 Sigma -20°C 
Trypan Blue solution 93595 Sigma RT 
Trypsin solution [2.5% (v/w) trypsin (10X)] 59427C Sigma -20°C 
Zeocin (lyophilised powder) ant-zn-1p Invivogen 
Stock solution 100 mg/ml in 
sterile distilled water, filtered 
(stored at -20°C) 
 
2.1.1.2 Plasticware 
 Sterile plastic serological pipettes, Pasteur pipettes and pipette tips were supplied by 
Sarstedt.  
 T25, T75 and T155 flasks were supplied by Sarstedt.  
 Cryotube vials were supplied by Sarstedt. 
 Lab-Tek 8-well (0.82cm²/well) radiation sterilised glass chamber slides were supplied by 
Thermo Scientific Nunc (10051021, Fisher) 
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2.1.2 Laboratory reagents 
2.1.2.1 Enzymes 
 Guinea pig liver TG2 (T5398, Sigma): Purity of powder = 85% (850 μg/mg). Units of 
enzymatic activity = 2.5 U/mg (1U = formation of 1 μM hydroxamate/min from N-alpha-
CBZ-GLN-GLY and hydroxylamine,  at pH 6.0, 37°C (GROSSOWICZ, et al. 1950). A 1mg/ml 
pure TG2 solution (2,5 U/ml) was prepared in ultrapure water, taking into account protein 
purity, and stored at -20°C.  
 Recombinant human hexahistidine-tagged human TG2 produced in E.coli (His6-rhTG2) 
(T002, Zedira, Germany). Purity of powder = 90% (900 μg/mg). Units of enzymatic activity 
=  0.59 U/mg /mg (1U = formation of 1.0 μM hydroxamate/min from N-alpha-CBZ-GLN-
GLY and hydroxylamine,  at pH 6.0, 37°C). A 1mg/ml pure TG2 solution (590 mU/ml) was 
prepared in ultrapure water, taking into account protein purity,  and stored at -20°C.  
 Heparinase III (or Heparitinase I, HepI) from Flavobacterium heparinum (CAS: 37290-86-
1) (H8891 Sigma): Units of enzymatic activity = 30 Sigma Units (U)/mg (1U = formation of 
1 μM of unsaturated uronic acid /h using bovine kidney Heparan Sulfate as substrate, at pH 
7.5, 25°C), equivalent to 0.05 IU/mg (1 IU = 600 Sigma U). A 5 IU/ml stock solution in an 
appropriate Hep I buffer [20 mM Tris-HCl, 50 mM NaCl, 4 mM CaCl, 0.01% (w/v) BSA, pH 
7.5] as suggested by the manufacturer and stored at -80°C.  
 
2.1.2.2 Antibodies 
Table 2.2:  Primary antibodies. Rb=Rabbit, Ms=Mouse WB= Western Blot, IF=Immunofluorescence, 
NE=Not employed 
 
Antigen Antibody Code Company WB IF 
Phospho-(Ser) PKC Substrate (P-
S3-101) 
Rb monoclonal 6967 
Cell Signalling 
Technology 
1:1000 NE 
Actin Rb polyclonal A2066 Sigma 1:2500 NE 
Clathrin Heavy Chain (D3C6) Rb monoclonal 4796 
Cell Signalling 
Technology 
1:500 1:400 
Collagen 1 Rb polyclonal ab34710 Abcam NE 1:500 
Cyclophilin-A Rb polyclonal ab41684 Abcam 1:1000 NE 
EGFP Rb polyclonal ab290 Abcam 1:2500 1:500 
Flotillin 2 Ms monoclonal 610383 
BD Transduction 
Laboratories 
1:5000 NE 
Hemagglutinin (HA) Rb polyclonal C29F4 
Cell Signalling 
Technology 
1:1000 1:500 
His6-Peroxidase Ms monoclonal 
11965085001 R
OCHE 
Roche, Sigma 1:1000 NE 
phospho(pSer425)-Smad3 Rb polyclonal SAB4300253 Sigma NE 1:75 
Phospho-(Ser) CDKs Substrate 
(P-S2-100) 
Rb monoclonal 9477 
Cell Signaling 
Technology 
1:1000 NE 
Phospho-(Ser/Thr) ATM/ATR 
Substrate (S*/T*QG) (P-S/T2-100) 
Rb monoclonal 6966 
Cell Signaling 
Technology 
1:1000 NE 
Phospho-(Ser/Thr)AMPK 
Substrate (P-S/T2-102) 
Rb monoclonal 5759 
Cell Signaling 
Technology 
1:1000 NE 
Phospho-Akt Substrate 
(RXRXXS/T)(110B7E) 
Rb monoclonal 9614 
Cell Signaling 
Technology 
1:1000 NE 
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Phospho-PKA Substrate (RRXS/T) 
(100G7E) 
Rb monoclonal 9624 
Cell Signalling 
Technology 
1:1000 NE 
Phospho-tyrosine Ms monoclonal 610430 
BD Transduction 
Laboratories 
1:250 NE 
Smad 3 Rb polyclonal 9513 
Cell Signalling 
Technology 
NE 1:75 
Syndecan-4 (Sdc4) Rb polyclonal ab24511 Abcam 1:500 1:50 
Transglutaminase 2 (TG2) Rb polyclonal ab80563 Abcam 1:1000 NE 
Transglutaminase 2 (TG2) Rb polyclonal ab421 Abcam 1:500 NE 
Transglutaminase 2 (TG2) - IA12 Ms monoclonal IA12 
University of 
Sheffield, UK 
1:5000 1:400 
Transglutaminase 2 
(TG2)[Cub7402] 
Ms monoclonal ab2386 Abcam NE 1:150 
α-Smooth muscle actin  [1A4] Ms monoclonal ab7817 Abcam 1:1000 NE 
β-Tubulin Rb polyclonal ab6046 Abcam 1:2000 NE 
 
 
Table 2.3:  Secondary antibodies 
Secondary antibodies for Western Blot Product code Company Dilution 
Donkey anti-rabbit IgG HRP P0448 Dako 1:2000 
Donkey anti-mouse IgG-HRP  P0447 Dako 1:1000 
Goat anti-rabbit IgG HRP  7074 Cell Signalling Technology  1:2000 
 
Secondary antibodies for 
Immunofluorescence 
Product 
code 
Company Dilution Excitation Emission 
Donkey anti-rabbit IgG H&L (Alexa 
Fluor®488) 
A21206 
Molecular 
probes / 
Invitrogen 
1:1000 499 519 Green 
Donkey anti-rabbit IgG H&L (Alexa 
Fluor®568)  
A10042 
Molecular 
probes / 
Invitrogen 
1:1000 579 603 Red 
Goat anti-mouse IgG DyLight®594  A11032 
Molecular 
probes / 
Invitrogen 
1:1000 591 618 Red 
Sheep anti-mouse - FITC 76257 Sigma 1:250 495 519 Green 
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2.1.2.3 Chemicals and reagents 
General chemicals were obtained from Sigma or Melford unless otherwise stated. Table 2.4 
reports the list of Chemicals, Kits and Reagents employed for this thesis. Composition of the 
main Buffers is reported in the Appendix of this thesis (Table III).  
 
Table 2.4: Chemicals and reagents. NA = Not available, RT = Room temperature 
Name 
CAS  
Number 
Product 
code 
Company Form 
Storing 
T(°C) 
Notes 
1,4-Dithiothreitol (DTT) 578517 MB1015 Melford 
lyophilized 
powder 
4°C  
Stock 100 mM in water 
(-20°C) 
1,4-Dithiothreitol (DTT) 
(Molecular grade) 
578517 
18064-
014 
Invitrogen 
Solution 
(0.1M) 
-20 °C 
In SuperScript® II 
Reverse Transcriptase 
kit 
100 bp DNA Ladder NA G2101 Promega Solution -20 °C 
Ready-to-load ladder 
stock by mixing 1:4:1 
volumes of 100bp DNA 
ladder,  ultrapure water 
and Blue/Orange 6X 
Loading Dye (Primega) 
3,3′,5,5′-tetramethylbenzidine 
(TMB)  
54827-17-7 T9281 Sigma 
lyophilized 
powder 
4°C  
Stock solution 10mg/ml 
in DMSO (stored at 
4°C) 
Agarose 9012-36-6 AGR100 
Web 
Scientific 
lyophilized 
powder 
RT   
Albumine fom Bovine Serum 
(BSA) Purity > 96% 
9048-46-8 A4503 Sigma 
lyophilized 
powder 
4°C 
 Heat inactivated at 
56°C/30 min 
Amaxa Nucleofector™ kit V  NA 
VCA 
1003 
Lonza Solution kit 4°C    
Amiloride hydrochloride 
hydrate 
2016-88-8 A7410 Sigma 
lyophilized 
powder 
RT 
Stock solution 25 mg/ml 
(94 mM) in water 
(stored at -20°C) 
Ammonium Persulfate (APS) 7727-54-0 A0502 Melford 
lyophilized 
powder 
RT   
Ampicillin 7177-48-2 A9518 Sigma 
lyophilized 
powder 
4°C  
Stock solution 100 
mg/ml in sterile water 
(stored at -20°C) 
BCA Assay Kit Reagent A / 
Bicinchoninic Acid Solution 
[1% (w/v) BCA, 2%(w/v) 
Na2CO3, 0.16% (w/v) NaK 
tartrate, 0.4%(w/v) NaOH,  
0.95%(w/v) NaHCO3] 
NA B9643 Sigma Solution RT   
BCA Assay Kit Reagent B [4% 
(w/v) CuSO4] 
7758-98-7 C2284 Sigma Solution RT   
Bio-Safe Coomassie Stain  6104-58-1 161-0786 Bio-Rad Solution RT 
Based on Coomassie 
brilliant blue G-250 
Biotin Cadaverine or N-(5-
Aminopentyl)biotinamide 
trifluoroacetate salt 
NA A5348 Sigma 
lyophilized 
powder 
4°C  
50 mM in DMSO (stored 
at 4°C) 
bis-2-methyl-4-amino-quinolyl-
6-carbamide or Surfen hydrate 
NA S6951 Sigma  
lyophilized 
powder 
4°C 
Stock solution 30 mM in 
DMSO (stored at -20°C 
in the dark in glass 
containers) 
Blue/Orange 6X Loading Dye NA G1881 Promega Solution -20 °C   
Bradford Reagent NA B6916 Sigma Solution 4°C 
Based on Coomassie 
brilliant blue G-250 
Bromophenol Blue  115-39-9 B5525 Sigma 
lyophilized 
powder 
RT   
Calcium Chloride (CaCl2) 10043-52-4 C3881 Sigma 
lyophilized 
powder 
RT   
cOmplete EDTA-free Protease 
Inhibitors  
NA 
0000000
1187358
0001 
Roche 
Sigma Tablets 4°C 
Dissolve 1 tablet in 50 
ml 
Deoxycholic Acid (Sodium 
Deoxycholate) 
302-95-4 D6750 Sigma 
lyophilized 
powder 
RT 
0.1 %(w/v) deoxycholic 
acid in PBS (stored at -
20°C) 
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DharmaFECT I ®  NA 
T-2001-
01 
Thermo 
Scientific 
Solution 4°C   
Diethylpyrocarbonate (DEPC) 1609-47-8 D5758 Sigma Solution 4°C    
Dimethyl sulfoxide (DMSO)  67-68-5 FIND FIND Solution RT   
dNTPs mix NA U1511  Promea Solution -20 °C   
Ethanol (Nuclease free) 64-17-5 D7023 Sigma Solution RT   
Ethidium Bromide 1239-45-8 1510 Sigma Solution RT   
Ethylenediaminetetraacetic 
acid (EDTA) 
60-00-4 ED Sigma 
lyophilized 
powder 
RT 
Stock solution 500 mM 
pH 8 (stored at RT) 
ExtrAvidin®−Peroxidase  NA E2886 Sigma Solution 4°C    
EZ-Chemiluminescence 
Detection Kit for HRP  
NA K1-0170 Geneflow 
Solution 
KIT 
4°C   
Fibronectin from human 
plasma 
86088-83-7 F1056 Sigma 
lyophilized 
powder 
-20 °C 
Stock 1mg/ml solution 
in ultrapure water was 
dissolved by incubation 
at 37 °C for 30 minutes 
(stored at -20°C) 
First-Strand buffer, 5X NA 
18064-
014 
Invitrogen Solution -20 °C 
In SuperScript® II 
Reverse Transcriptase 
kit 
Fluorescein isothiocianate 
(FITC) - Cadaverine 
NA A10466 Invitrogen 
lyophilized 
powder 
4°C  Stock solution 50 mM 
Glacial Acetic Acid 64-19-7 
A360OB
17 
Fisher Solution RT   
Glycerol 56-81-5 G5516 Sigma Solution RT   
Glycine 56-40-6 G0709 Melford 
lyophilized 
powder 
RT   
GW4869 6823-69-4 D1692 Sigma  
lyophilized 
powder 
RT 
Stock solution 5 mM in 
DMSO (stored at -20°C) 
Hydrogen peroxide H2O2 7722-84-1 H1009 Sigma Solution 4°C    
IGEPAL CA-630 9002-93-1 I8896 Sigma Solution RT   
Imipramine hydrochloride 113-52-0 I0899 Sigma  
lyophilized 
powder 
RT 
Stock slution 50 mg/ml 
(158 mM) in sterile 
water (stored at -20°C) 
iQ™ SYBR® Green Supermix  NA 170-8880 Biorad Solution -20 °C   
Isopropanol 67-63-0 P749017 Fisher Solution RT   
Kanamycin 25389-94-0 H815 Gibco 
lyophilized 
powder 
4°C  
Stock solution 25 mg/ml 
in sterile water  (stored 
at -20°C) 
LB Broth, Lennox  NA BP1427 
Fisher 
Scientific 
lyophilized 
powder 
RT   
Methanol  67-56-1 M40017 Fisher Solution RT   
N,N,N′,N′-
Tetramethylethylenediamine 
(Temed) 
110-18-9 T9281 Sigma Solution RT   
N-ethylmaleimide  128-53-0 E3876 Sigma  
lyophilized 
powder 
RT 
Stock solution 100 mM  
(12.5 mg/ml) (stored at  
-20°C) 
Nitrocellulose membrane  9004-70-0 1620115 Bio-Rad Membrane RT   
N-Octyl-Beta-Glucopyranoside 
(OGP)  
29836-26-8 O8001 Sigma 
lyophilized 
powder 
RT   
Paraformaldehyde (PFA) 30525-89-4 P6148 Sigma 
lyophilized 
powder 
RT 
3% (w/v) solution in 
PBS pH 7.4 (dissolves 
at approx. 60°C) 
Phosphatase Inhibitor Cocktail 
2 
NA P5726  Sigma  Solution 4°C    
Phosphatase Inhibitor Cocktail 
3 
NA P0044  Sigma  Solution 4°C    
Phosphate-Citrate Buffer with 
Urea Hydrogen Peroxide 
NA P4560 Sigma Tablets 4°C  
Dissolve 1 tablet in 10 
ml 
Pierce™ Crosslink Magnetic 
IP/Co-IP Kit 
NA 88805 
Thermo 
Scientific 
Kit 4°C   
Pierce™ LDH Cytotoxicity 
Assay kit 
NA 88953 
Thermo 
Scientific 
Kit 
-20 °C, 
4°C 
 
PIP Strips™ Membranes  NA P-23750 
Molecular 
Probes® - 
Thermo 
Scientific 
Phospholipi
d 
Membrane 
4°C    
Ponceau S  6226-79-5 P3504  Sigma 
lyophilized 
powder 
RT   
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Potassium Chloride (KCl) 7447-40-7 P9541 Sigma 
lyophilized 
powder 
RT   
Potassium dihydrogen 
phosphate 
7778-77-0 P5504 Sigma 
lyophilized 
powder 
RT   
Prism Ultra Protein Ladder 
(10-245 kDa) 
NA 
ab11602
8 
Abcam Solution -20 °C   
Protease inhibitor cocktail NA P8340 Sigma  
DMSO 
Solution 
-20°C   
ProteaseMAX™ Surfactant  NA V2071 Promega 
lyophilized 
powder 
-20 °C 
1% (w/v) in 50 mM 
TEAB (stored at -20°C 
in small volume aliquots 
- avoid thaw-freeze 
cycles) 
Protogel - 30% 
Acrylamide/Bis-
acrylamidesolution (37.5:1 
ratio) 
79-06-1 A2-0072 Geneflow Solution RT   
QIAGEN Plasmid Midi Kit  NA 12143 Qiagen 
Solution 
KIT 
RT 
RNase A- 
supplemented Buffer P1 
stored at 4°C 
QIAprep Spin Miniprep Kit  NA 27104 Qiagen 
Solution 
KIT 
RT 
RNase A- 
supplemented Buffer P1 
stored at 4°C 
Random primers NA C1181 Promega Solution -20 °C   
siRNA Buffer, 5X NA 
B-
002000-
UB 
Thermo 
Scientific 
Solution 4°C   
Sodium Cloride (NaCl)  7647-14-5 S7653 Sigma 
lyophilized 
powder 
RT 
Stock solution 1M in  
water (stored at RT) 
Sodium Dodecyl Sulphate 
(SDS) 
151-21-3 B2008 Melford  
lyophilized 
powder 
RT   
Sodium Hydroxide (NaOH) 1310-73-2 50523 
Duchefa 
Biochemie 
lyophilized 
powder 
RT 
Stock solution 1M in  
water (stored at RT) 
Sodium Phosphate Dibasic 
Heptahydrate (Na2HPO4) 
7782-85-6 S2317 Melford 
lyophilized 
powder 
RT 
1M solution in distilled 
water (dissolves at 
approx. 50°C) 
Sulphuric acid H2SO4 7664-93-9 59160PB Fisher Solution RT   
SuperScript® II Reverse 
Transcriptase  
NA 
18064-
014 
Invitrogen Solution -20 °C   
TGF-β Recombinant NA 240B 
RD 
Systems 
Solution -80°C   
Tissue Transglutaminase 
Pico-Assay Kit  
NA M003 Zedira Kit 4°C    
tri-ethyl ammonium 
bicarbonate (TEAB) [1M 
solution] 
15715-58-9 T7408  Sigma Solution RT   
Triton-X100 9002-93-1 X100 Sigma Solution RT   
Trizma Base / TRIS 
[Tris(hydroxymethyl) 
aminomethane] 
77-86-1 B2005 Melford 
lyophilized 
powder 
RT   
Trypsin, MS Grade   V5280 Promega 
lyophilized 
powder 
-20 °C 
1 mg/ml in 50 mM 
acetic acid (stored at -
20°C of -80°C for long 
term storage) 
Tween® -20  9005-64-5 P1379 Sigma Solution RT   
Urea 57-13-6 U5128 Sigma 
lyophilized 
powder 
RT   
VECTASHIELD® Mounting 
Medium  
NA H-1000 Vectorlab Solution 4°C    
VECTASHIELD® Mounting 
Medium with DAPI  
NA H-1200 Vectorlab Solution 4°C    
β-Mercaptoethanol or 2-
Mercaptoethanol 
60-24-2 M3148 Sigma Solution 4°C    
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2.1.3 Laboratory equipment 
Table 2.5: Laboratory equipment. 
Instrument Company 
Amaxa Nucleofactor electroporation machine Lonza 
Amaxa® Nucleofactor™  Device Lonza 
Avanti J 301 High speed centrifuge Beckman Coulter 
Corbett Research Thermal Cycler Qiagen 
Electrophoresis kit MultiSUB Choice 15x15cm SLS 
Electrophoresis tank Multi SUB Mini Geneflow 
Eppendorf refrigerated centrifuge 5417R Eppendorf 
GyroStir 280H Magnetic Hotplate Stirrer Sciquip 
Harrier 18/80 Centrifuge Sanyo 
Heating Block QBT4 Grant 
LAS4000 imaging system  GE Healthcare 
Leica TCS confocal microscope  Leica 
Mini PROTEAN® Gel casting system  Bio-Rad 
Mini PROTEAN® Tetra Cell Bio-Rad 
Model 680 Spectrophotometer (plate reader) Biorad 
MSH280 Pro Stirrer Sciquip 
NanoDrop® 8000  Thermo Scientific 
Olympus BX61 fluorescent microscope Olympus 
Optima L100 XP Ultracentrifuge Beckman Coulter 
Polarstar Optima Luminometer BMG Labtech 
Power pack Bio-Rad 
SciQuip Orbital Shaker Basic O3  Sciquip 
Soniprep 150 Sonicator MSE 
Syngene U:Genius transilluminator Genflow 
TC 3000X Thermocycler Techne 
Triple TOF 5600 +  Sciex 
Ts100 Eclipse Optical Microscope Nikon 
U:Genius transilluminator Syngene 
Ultra Turrax T25 homogeniser Merk 
Water bath Grant 
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2.1.4 List of companies 
Table 2.6: Companies. 
Company Address 
Abcam Cambridge, UK 
AbD Serotec Oxford, UK 
BD Biosciences Oxford, UK 
Beckman Coulter High Wycombe 
Bemis Londonderry, UK 
Bio-Rad Hemel Hempstead, UK 
BMG Labtech Ortenberg, Germany 
BMG Labtech Aylesbury, UK 
Cell Signaling Technology Laiden,The Netherlands 
DakoCytomation Glostrup, Denmark 
Eksigent California, USA 
Eppendorf UK Stevenage, UK 
Fisher Scientific  Loughborough, UK 
GE Healthcare Bucks, UK 
Geneflow Lichfield, UK 
Invitrogen  Paisley, UK 
Invivogen Toulouse, France 
Leica Solms, Germany 
Life Technologies  Paisley, UK 
Lonza Wokingham, UK 
Melford Ipswich, UK 
Merk Millipore Nottingham, UK 
New England Biolabs  Hitchin, UK 
New Objective Inc. Massachusetts, USA 
Promega Southampton, UK 
Qiagen Crawley, UK 
Reytest Straubenhardt, Germany 
Sarstedt Leicester, UK 
Sartorius Stedim Epsom, UK 
Scientific Laboratory Supplies Nottingham, UK 
SCIEX Canada 
Sciquip Shrewsbury , UK 
Sigma Dorset, UK 
Syngene Cambridge, UK 
Thermo Scientific Paisley, UK 
Vectorlab Peterborough, UK 
VWR  Lutterworth, UK 
Web Scientific Cheshire, UK 
Zedira GmbH Darmstadt, Germany 
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2.2 METHODS 
 
2.2.1 Cell culture 
2.2.1.1 Cell lines 
For the in vitro experiments performed in this thesis, two commercially available immortalised 
rat renal cell lines were employed: NRK52E tubular epithelial cells (TECs), an immortalised 
cell line of adherent epithelial cells obtained from rat proximal renal tubules, and NRK49F 
fibroblasts, an adherent cell line of rat kidney fibroblasts obtained by isolation from the same 
mixed culture from which the NRK52E are produced. Both NRK52E TECs and NRK49F renal 
fibroblasts were obtained from the European Collection of Authenticated Cell Cultures 
(ECACC) (UK).  
In some experiments, a stable cell line of NRK52E clones overexpressing EGFP-tagged TG2 was 
employed (referred as EGFP-TG2 overexpressing clones or EGFP-TG2 clones). These clones 
were produced in Dr Verderio Laboratory (NTU) by former Research Assistant Raghavendran 
Ramaswamy, by stably transfecting NRK52E cells with a specific pEGFP-N1-TG2 plasmid 
(Appendix, Fig. II), expressing a human TG2 cDNA chimeric protein with a C-terminal EGFP 
tag, with green fluorescence. Briefly, NRK52E wild type (WT) cells were transfected by 
electroporation with 10μg of pEGFP-N1-TG2 plasmid, and clones resistant to the selective 
antibiotic G418 (Geneticin®, an analogue of neomycin, was employed in this case) were 
isolated and screened for TG2 expression and activity. In this thesis, specifically, clones #C5 
and clone #E6 were employed: these clones had already been fully characterized in Dr Verderio 
laboratory (NTU). For the aims of this thesis, characterisation of TG2 expression and activity 
was repeated for the clones employed to confirm the preservation of their characteristics.   
 
2.2.1.2 Culture conditions 
NRK52E cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 4.5 g/L 
glucose supplemented with 5% (v/v) filtered (0.2 µm) heat-inactivated Foetal Bovine Serum 
(FBS), 2mM L-glutamine, 100 IU/mL penicillin and 100 μg/mL streptomycin. This medium 
composition will be referred as complete medium throughout the thesis.  
EGFP-TG2 overexpressing clones were maintained in the same medium, with the addition of 
700 µg/ml G418 (Geneticin®) to preserve the stringency of the clonal selection.  
NRK49F cells were cultured in the same DMEM medium supplemented with 10% (v/v) filtered 
(0.2 µm) heat inactivated FBS, 2mM L-glutamine 100 IU/mL penicillin and 100 μg/ml. All 
cultures were kept at 37°C and 5% CO2 in air. 
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Culture conditions could vary in specific experiments, by keeping the cells in lower glucose 
concentration employing Dulbecco’s modified Eagle’s medium (DMEM) with 1 g/L glucose 
(Lonza) or using lower concentrations of FBS to slow down cell growth. siRNA transfections 
were performed in absence of antibiotics (no penicillin, streptomycin or selective antibiotics) 
and the corresponding medium is regarded as complete antibiotic-free medium.  
 
2.2.1.3 Cell passaging 
90-95% confluent cell monolayers cells were washed one time with pre-warmed (37°C) sterile 
PBS pH 7.4 [137mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 1.8mM KH2PO4, pH 7.4 (autoclaved 
at 121 °C for 20 min)] and incubated with trypsin/EDTA solution [0.25% (w/v) trypsin, 2 mM 
EDTA in PBS, pH 7.4] for 5 min at 37°C (approximately 1 ml for a T75 flask). Trypsin solution 
was prepared by diluting 2.5% (w/v) trypsin stock solution with nine volumes of sterile PBS 
pH 7.4 and adding 1:250 of 500 mM sterile EDTA solution. Solution was sterile filtered (0.2 µm) 
and aliquots (~10 ml) were stored at -20°C until needed. In-use solution can be kept in the 
fridge for a short amount of time.  
After incubation with trypsin/EDTA solution, cells were dislodged by gently tapping the flask 
and at least five volumes of complete medium were added to inactivate trypsin. Cell suspension 
was transferred to a 15ml conical bottom tube and cells were pelleted by centrifugation at 500g 
for 5 minutes. Cell pellet was re-suspended in 1 ml complete medium and the desired dilution 
of cells was re-seeded in a new flask containing fresh culture medium. For routine culture of 
NRK49F and NRK52E cells, cell passaging was usually performed at 1:10 dilution, and cells 
were again confluent in approximately three days.  
 
 
2.2.1.4 Cell counting 
Cell counting was performed using an Improved Neubauer Chamber hemocytometer of 0.1 mm 
thickness (HAE2112, Scientific Laboratory Supplies). 10µl of cell suspension were loaded in 
the chamber after placing an appropriate cover slip. Cells were counted under the microscope 
at 10x magnification, and at least four 4x4 quadrants at the angles (yellow in Fig.2.1) were 
considered. Average number of cells was calculated for all quadrants considered, and the 
number of cells per ml was approximated by multiplying the average number by 104 (Fig.2.1).  
In specific experiments where high precision was necessary, cell suspension was diluted in 
nine volumes of trypan blue before counting. In this case, the final cell number takes into count 
the dilution factor and the resulting number was multiplied by 105.  
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Figure 2.1: Hematocytometer grid employed for cell counting and cell number calculation. The 
chamber has a thickness of 0.1 mm. It is characterized by nine big squares of 1 mm2 (volume of 0.1 mm3 
= 10-4 ml). 4 quadrants (yellow) were counted for each measurement and averaged. The cell counted in 
each quadrant (number of cells for 0.1 mm2 = number of cells in 10-4 ml) were multiplied for 104 (10,000) 
to have a reliable approximation of the number of cells per ml.  
 
 
2.2.1.5 Cryopreservation of cells and resuscitation of frozen cells 
In order to freeze cells for cryopreservation, approximately 1 million cells were pelleted by 
centrifugation as described above. All supernatant was carefully removed and the pellets re-
suspended in 1ml of freezing solution [10% dimethyl sulfoxide in FBS; sterile filtered (0.2 µm)]. 
Cell suspension was transferred into sterile cryovials and frozen at -80°C for a day, before 
moving them to liquid nitrogen for long term storage. This gradual freezing prevents 
substantial cell death due to thermic shock.  
In order to thaw frozen cells stored in liquid nitrogen, cryovials were recovered from the liquid 
nitrogen storage and quickly defrosted at 37°C until little ice remained. The outside of the vial 
was sterilised with 70% (v/v) ethanol, then the thawed mixture was transferred to 10 ml pre-
warmed complete medium. Cells were recovered by centrifugation (500g for 5 min), then 
medium was carefully removed and pelleted cells were transferred to a T25 flask containing 
fresh complete medium. Medium was changed the day after to remove every trace of DMSO. 
 
2.2.1.6 Routine test for mycoplasma detection 
In order to check cultured cells for mycoplasma contamination, MycoAlert Plus Mycoplasma 
Detection Kit from Lonza was employed, following the manufacturer’s instructions. Briefly, the 
cells were kept in culture for at least 2 days before collecting the conditioned medium for 
testing. Medium was quickly centrifuged at 200g for 5 min to pellet floating cells and 100 µl of 
cleared supernatant where transferred in a white 96-well plate suitable for luminescence. 100 
µl MycoAlert® PLUS Reagent was added, the plate was incubated for 5 min in the dark at room 
temperature, then luminescence was read (Read A - spontaneous luminescence) using 
Polarstar Optima Luminometer (BMG Labtech). 100 µl MycoAlert® PLUS Substrate was then 
added on the top and the plate incubated again for 10 min in the dark at room temperature. 
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Luminescence was read for the second time (Read B) and the ratio Read B / Read A calculated. 
A ratio lower than 1 signifies absence of mycoplasma while a ratio higher than 1.2 means 
mycoplasma contamination. A value between 1 and 1.2 requires quarantine of the cells and re-
testing in one or two days.  
In case of mycoplasma contamination, 0.5 μg/ml Mycoplasma Removal Agent (MRA) (AbD 
Serotec) was added to culture medium for a week and maintained at each cell passaging. After 
the end of the week, cells were cultured in the absence of MRA for another week before re-
testing for mycoplasma.  
 
2.2.1.7 LDH cytotoxicity assay 
To assess cytotoxicity of specific compounds, LDH assay was performed using Pierce LDH 
Cytotoxicity Assay kit (Thermo Scientific) and following the manufacturer’s protocol. LDH 
Cytotoxicity assay is based on the detection of the activity of lactate dehydrogenase (LDH) in 
the conditioned medium, as LDH is a cytosolic enzyme released in the culture media as a 
consequence of plasma membrane damage. The assay is based on two reactions: the 
conversion of lactate to pyruvate by LDH, with production of NADH, and the reduction of 
tetrazolium salt (INT) to a red formazan product, which employs the produced NADH and is 
catalysed by the enzyme diaphorase. Red formazan absorbs at 490 nm, and its level is directly 
proportional to the amount of LDH released by the cells.  
To determine the optimal number of cells to employ, a serial dilution of cells (0-20,000 
cells/well) was either untreated or lysed with the appropriate lysis buffer provided by the kit. 
The assay was performed on the conditioned medium following the manufacturer’s 
instruction, and absorbance was measured at 490 nm (red formazan, signal) using a plate 
reader spectrophotometer. Absorbance at 680 nm was measured as well and subtracted from 
the Abs490 as the background signal. Abs 490nm – Abs 680 is the measure of LDH release; LDH 
release from untreated cells is regarded as spontaneous LDH release, while LDH release in the 
medium of lysed cells is regarded as the maximum LDH release for the specific number of cells, 
and should be proportional to the cell number.  
LDH release values were plotted against the initial number of cells and the optimal number of 
cells was chosen within the area of linear growth of the maximum LDH - spontaneous LDH 
trendline.   
To perform cytotoxicity assay, 7,500 cells/well were cultured in a 96-well plate in presence of 
the treatment required by the specific experiment (e.g. chemical compound with unknown 
cytotoxicity), the assay was performed on the conditioned medium following the manufacturer 
instruction and LDH release was measured as Abs490 – Abs 680 nm.  
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2.2.2 Kidney material 
For the aims of this thesis either C57BL/6J mice kidneys (Chapter III, IV and VI) or Wistar rats 
kidneys (Chapter VI) were employed. All animals were bred at Nottingham Trent University 
(NTU) animal house by licenced technicians. TG2-/- (TG2-null) C57BL/6J mice (De Laurenzi and 
Melino 2001) were obtained from Prof. Gerry Melino (University of Tor Vergata, Rome) and 
backcrossed with WT mice at NTU animal house by licenced technicians. After sacrifice, 
kidneys were stored in Liquid nitrogen.  
 
 
2.2.3 Total protein extraction  
2.2.3.1 Lysis buffers 
Cell lysates or tissue lysates utilised in this thesis were produced in different lysis buffers 
depending on the specific requirements of the subsequent experiments. Composition of lysis 
buffers and associated experimental procedures are reported in Table 2.7.   
 
Table 2.7: Specific composition of the lysis buffers employed and corresponding subsequent 
experimental procedures. WB=Western Blot, IP=Immunoprecipitation, MS=Mass Spectrometry.  
 
Name Composition 
Employed for 
WB IP 
Activity 
assay 
MS 
IGEPAL- containing Lysis 
Buffer 
20 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, 1% (v/v) 
IGEPAL CA-630, 0.5% (w/v) deoxycholic acid, 0.1% 
(w/v) SDS, pH 7.4 
    
Radioimmunoprecipitation 
assay buffer (RIPA buffer) 
50 mM Tris HCl, 150 mM NaCl, 1% (vv) NP40, 0.5% 
Sodium Deoxicholate, 0.1% SDS, pH 8 
    
Sucrose – Based Lysis 
buffer 
250 mM sucrose, 2 mM EDTA, and 5 mM Tris-HCl, 
pH 7.4 
    
IP Lysis/Wash buffer 
(Thermoscientific) 
250mM Tris-HCl, 150mM NaCl, 1mM EDTA, 1% 
NP40, 5% glycerol pH 7.4 
    
Proteomics Lysis Buffer 9.5 M urea, 2%(w/v) DTT, 1% (w/v) N-Octyl-Beta-
Glucopyranoside (OGP)  
    
 
2.2.3.2 Total protein extraction from cells 
In order to obtain total protein extract from kidney cells, 80-90% confluent monolayers were 
washed with PBS pH 7.4 and harvested by either trypsinization or cell scraping depending on 
the experiments. Cell scraping was performed with disposable cell scrapers in a small layer of 
PBS pH 7.4 (0.5-3 ml depending on the dimension of the culture flask) to favour detachment 
and is advisable in the experiments where the preservation of membrane proteins is necessary.  
Cell pellet was collected by centrifugation at 500 g for 5 min and re-suspended in 200µl - 1 ml 
of the appropriate lysis buffer containing protease inhibitors. Unless otherwise stated, 1:100 
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dilution of Protease Inhibitor Cocktail (P8340, Sigma) was employed. Cells were incubated for 
15 minutes on ice, sonicated on ice (3 repetition for 5 sec, 1 min hold) using a probe sonicator 
with amplitude set to 5 µm. Lysate was incubated again for 20 min on ice, then a brief 
centrifugation (1,000 g for 5 min) was employed to remove un-lysed particulate material.  If 
not immediately used, cell lysates were stored at -80°C.  
 
2.2.3.3 Total protein extraction from mouse or rat kidney tissue 
10% (w/v) mouse or rat kidney homogenates were produced by either grinding the organ in 
liquid nitrogen or by mechanical homogenisation using an Ultra Turrax T25 tissue 
homogenizer (Merck). To perform homogenisation in liquid nitrogen, kidneys or kidney 
portions were grinded with cold sterile pestle and mortar making sure the tissue was always 
maintained under a liquid nitrogen coat. The paste obtained was collected with a sterile scalpel 
and transferred in a new microcentrifuge tube containing the appropriate volume of lysis 
buffer (100 µl for each mg of kidney tissue).  
Mechanical homogenisation with Ultra Turrax T25 tissue homogenizer (Merck) was 
performed in an appropriate volume of lysis buffer (100 µl for each mg of kidney tissue) on ice, 
3 times for 10 sec or until complete homogenization.  
In both cases, the mixture was incubated on ice for 20 min, then centrifuged at 4°C for 10 min 
at 1000 g remove un-lysed particulate material. If not immediately used, tissue homogenates 
were stored at -80°C.  
 
 
2.2.4 Protein quantification 
2.2.4.1 Preparation of bovine serum albumin (BSA) standard curve 
A standard curve of known protein concentrations was produced prior to each protein 
quantification assay  by preparing a serial dilution of bovine serum albumin (BSA) to 1 mg/ml, 
0.75 mg/ml, 0.5 mg/ml, 0.25 mg/ml, 0.125 mg/ml and 0 mg/ml (blank) in cell lysis buffer.  
 
2.2.4.2 Bicinchoninic acid (BCA) protein quantification assay 
BCA quantification assay was performed using a commercially available BCA quantification 
assay reagents kit. BCA working solution was prepared immediately before the assay by 
combining Reagent A [1% (w/v) BCA, 2%(w/v) Na2CO3, 0.16% (w/v) NaK tartrate, 0.4%(w/v) 
NaOH, 0.95%(w/v) NaHCO3] and Reagent B [4% (w/v) CuSO4] in 50:1 proportion. 25 µl of 
samples (in triplicates) or BSA standards (0-1 mg/ml) (in duplicates) were incubated with 200 
µl of BCA working solution in a 96/well plate. The plate was incubated 30 min at 37°C in the 
dark and the absorbance was measured at 570 nm using a 96 well plate reader 
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(spectrophotometer).  The unknown sample concentration was obtained by plotting the 
absorbance values on the BSA standard curve of known protein concentration.  
 
2.2.4.3 Bradford protein quantification assay 
Bradford quantification assay was performed using the commercially available Bradford 
reagent from Sigma. 5 µl of samples (in triplicates) or BSA standards (0-1 mg/ml) (in 
duplicates) were incubated with 250 µl of Bradford reagent in a 96/well plate. The plate was 
incubated 15 min at room temperature in the dark and the absorbance is measured at 570 nm 
using a 96 well plate reader (spectrophotometer).  The unknown sample concentration was 
obtained by plotting the absorbance values on the BSA standard curve of known protein 
concentration.  
 
2.2.5 Immunoprecipitation (IP) 
Immunoprecipitation (IP) is a procedure used to precipitate a desired antigen from a pool of 
proteins. IP was performed using PierceTM Crosslink Magnetic IP/Co-IP Kit (88805, Thermo 
Scientific), following the Manufacturer’s protocol with some modifications in the length of the 
incubation steps.  
Briefly, 2.5 µg of antibody against the desired protein were incubated with 20 µl of 10mg/mL 
(200 µg) Pierce Protein A/G Magnetic Beads for one hour at room temperature in constant 
rotation, then covalently attached to the beads by crosslinking, using 20µM disuccinimidyl 
suberate (DSS) crosslinker provided in the kit for 3 h at room temperature in constant rotation.  
Cell or tissue lysates were produced using the specific IP Lysis/Wash Buffer provided by the 
kit. Equal amounts of total proteins (0.75-1 mg cell lysate/kidney tissue lysate, depending on 
the experiment) were the applied on the beads overnight (15 h) at 4°C in constant rotation to 
allow the antigen to bind, then the bound antigen was eluted in 40-90 µl elution buffer pH 2.0, 
provided by the kit, for 5 min at room temperature. 0.1 volumes of neutralisation buffer pH 8.5 
were added to neutralize the pH of the elution. The final solution contains the target protein 
(precipitated) and the co-associated ones (co-precipitated). Ideally, the antibody 
(Immunoglobulins) would not be eluted since it is covalently linked to the magnetic beads. If 
not immediately used, immunoprecipitated (IP) proteins were stored at -80°C. 
 
2.2.6 SDS - polyacrylamide gel electrophoresis (SDS-PAGE) 
In order to separate proteins depending on theirs size, denaturing SDS - Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) was performed using the Mini PROTEAN® cell for 1-D vertical 
mini gel (8.3 x 7.3 cm) electrophoresis system from Bio-Rad.  
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2.2.6.1 Preparation of polyacrylamide gel for SDS-PAGE 
1.5 mm thick mini SDS-polyacrylamide gels (83 x 73 x 1.5 mm) were prepared on a Mini 
PROTEAN® gel casting system (Bio-Rad). 8-12% (w/v) acrylamide/bis-acrylamide resolving 
gel solution was prepared immediately before gel casting as described in Table 2.8, poured 
between Mini PROTEAN® III glass plates (a 1.5 mm thick spacer plate and a short plate) (Web 
Scientific) until 1.5/2 cm from the top, covered with 1 ml of isopropanol, and let polymerize 
for 15-20 min or until completely solid. Approximately 8 ml of resolving solution is required 
for each gel.  
 
Table 2.8: Composition of one SDS-PAGE resolving gel containing either 8%, 10% or 12% 
acrylamide/bis-acrylamide. 8 ml were used to prepare one mini PROTEAN® gel.  
 
Composition of one 1.5 mm thick Resolving gel (8 ml) 
Components 
ml 
8% 10% 12% 
ProtoGel (30%) (30% acrylamide / bisacrylamide solution at 37.5:1 Ratio) (Geneflow) 2.1 2.7 3.2 
Resolving buffer 4X [1.5 mM Tris HCl, 0.4% SDS, pH 8.8] 2.0 2.0 2.0 
Distilled H2O 3.9 3.3 2.8 
10% (w/v) ammonium persulphate (APS) 0.08 0.08 0.08 
N,N,N′,N′-Tetramethylethylenediamine (TEMED) (Sigma) 0.008 0.008 0.008 
 
 
Isopropanol was removed, then 5% (w/v) acrylamide/bis-acrylamide stacking gel (prepared 
as described in Table 2.9) was poured on the top. 10-well combs (Bio-Rad) were immediately 
inserted to form the sample wells and stacking gel was let to polymerize until solid 
(approximately 15-20 min). Approximately 2.5 ml of stacking solution is necessary for each 
gel. 
 
Table 2.9: Composition of one SDS-PAGE stacking gel containing 5% acrylamide/bis-acrylamide. 
3 ml were used to prepare one mini PROTEAN® gel.  
 
Composition of one 1.5 mm thick Stacking gel (3 ml) 
Components 
ml 
5% 
ProtoGel (30%) (30% acrylamide / bisacrylamide solution at 37.5:1 Ratio) (Geneflow) 0.5 
Stacking buffer 4X [0.5 M Tris HCl, 0.4% SDS, pH 6.8] 0.8 
Distilled H2O 1.8 
10% (w/v) ammonium persulphate (APS) 0.03 
N,N,N′,N′-Tetramethylethylenediamine (TEMED) (Sigma) 0.003 
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2.2.6.2 Preparation of samples for SDS-PAGE electrophoresis in reducing conditions 
Ready-to-load samples were prepared by adding 1/3 volume of 4X reducing and denaturing 
sample buffer [4X Laemmli buffer: 250 mM Tris-HCl pH 6.8; 40% (v/v) glycerol; 8% (v/v) SDS; 
20%(v/v) β-mercaptoethanol (β-ME); 0.008%(w/v) bromophenol blue] to protein samples 
and warming them up at 98C for 10 min on a heating block. Samples were cooled at room 
temperature and briefly spun to collect all material before loading.  
 
2.2.6.3 Protein separation by gel electrophoresis 
SDS-PAGE gels were placed into the appropriate Mini PROTEAN® running modules and 
inserted into the buffer tank containing electrophoresis buffer [25mM Tris-HCl, 192mM 
glycine; 0.1%(w/v) SDS]. Samples were loaded into the gel wells, together with approximately 
2.5 µl of pre-stained protein ladder [Prism Ultra Protein Ladder (10-245 kDa) (ab116028)] 
was also added on a lane. Samples were separated by electrophoresis, first at a constant voltage 
of 100V till the samples surpass the stacking gel, then at a constant voltage of 150V until the 
end. 
 
2.2.6.4 Coomassie blue staining of SDS-PAGE protein gels 
To visualize the protein resolved by SDS-PAGE, some gels were stained using BioSafeTM 
Coomassie Stain from Bio-Rad, following the manufacturer’s instructions.  
 
 
2.2.7 Western blot 
In order to determine the expression of target proteins in specific lysates, proteins separated 
by SDS-PAGE were screened for expression of particular antigens by Western blot (WB). 
 
2.2.7.1 Protein transfer to a nitrocellulose membrane 
The proteins separated by SDS-PAGE were transferred electrophoretically from the SDS-
polyacrylamide gel  onto a 0.45 µm pore–size nitrocellulose membrane (1620115, Bio-Rad) 
using a Rad Mini Trans-Blot® wet blotting system (Bio-Rad). To assemble the transfer 
“sandwich” necessary for wet blotting, six pieces of 3 mm Whatman® cellulose 
chromatography paper (WHA3030861, Sigma) and one piece of nitrocellulose were cut big 
enough to have the same size as the gel (approximately 9 cm x 7 cm). Nitrocellulose membrane 
was hydrated in ultrapure water for 5 min, then, together with Whatman® papers and two 
fibre pads, was pre-saturated in transfer buffer [48 mM Tris, 39 mM glycine, 0.0375% (w/v) 
SDS, 20% (v/v) methanol] for few minutes. Transfer buffer was freshly prepared from a 10X 
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stock buffer [480 mM Tris, 390 mM glycine,0.375% (w/v) SDS] by adding 20% (v/v) methanol 
(200 ml on one litre of final buffer) on the day of use. Elements were assembled in the mini gel 
holder (Bio-Rad) in this order, starting from the negative electrode (black): fibre pad, three 
papers, protein gel, nitrocellulose, three papers, and fibre pad. The gel holder was then placed 
in the Mini Trans-Blot Central Core (Bio-Rad), making sure to pair negative and positive sides, 
and the structure placed in the buffer tank filled with transfer buffer, together with a Bio-Ice 
cooling unit to keep the system cold during transfer. Electrophoretic transfer of the samples 
was then performed at the constant current of 180 mA for 75 min.  
 
2.2.7.2 Membrane staining with Ponceau red 
To reveal the bands on the nitrocellulose membrane, Ponceau red staining [0.1% (w/v) 
Ponceau S, 5% (v/v) glacial acetic acid] was used, immersing the membranes for 2 min in the 
solution and then quickly rinsing it with water to wash out the excessive stain.  
Membranes were then washed with Tris buffered saline buffer (TBS) [25 mM Tris-HCl, 150 
mM NaCl and 2 mM KCl, pH 7.4] to remove the stain before the blocking step. 
 
2.2.7.3 Immunoprobing 
Nitrocellulose membranes with transferred proteins were incubated in blocking buffer, 5% 
(w/v) non-fat milk in TBST [25mM Tris-HCl, 150mM NaCl, 2mM KCl, 0.1%(v/v) Tween-20], for 
one hour at room temperature in constant shaking. The blocking step is necessary to prevent 
the aspecific binding of the antibody in the subsequent steps.  
After blocking, membranes were incubated with the appropriate dilution of primary antibody 
(Table 2.2) in blocking buffer, overnight (15 h) at 4°C in gentle rotation.  
The following day the antibody in blocking buffer was recovered (primary antibodies in 
blocking buffer were stored at -20°C and re-used few times before disposal); membranes were 
washed three times for 10 min with TBST and incubated with the appropriate dilution of 
horseradish peroxidase (HRP)-conjugated secondary antibody in blocking buffer (Table 2.3) 
for 2 h at room temperature in gentle rotation. In some experiment, an HRP-conjugated 
primary antibody was used. In this case the incubation was performed for 2 h at room 
temperature or overnight (15 h) at 4°C in gentle rotation. 
The membrane was then washed again with TBST (3 times/10 min each) and the 
immunoreactive bands developed by enhanced chemiluminescence (ECL) using EZ-
Chemiluminescence Detection Kit for HRP (K1-0170) from Geneflow, following the 
manufacturer’s instructions. EZ-ECL substrate needs to be prepared fresh before membrane 
development: for a full size membrane (approximately 9 cm x 7 cm), approximately 500 µl of 
reagent A (luminol and enhancer) were mixed with the same amount of reagent B (stable 
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peroxide solution) and let equilibrate for 5 min before employment. Nitrocellulose membrane 
was placed protein-side facing upwards on a dark background in the LAS4000 imaging system 
(GE Healthcare), EZ-ECL mixture was pipetted on it homogeneously and incubated  for 1 min 
in the dark. Excessive solution was drained out and chemiluminescent image acquisition was 
performed in the LAS4000 imaging system with exposure time going from 30 sec to 30 min, 
depending on the specific experiment. 
 
2.2.7.4 Stripping and re-probing 
Membrane stripping is a procedure employed to remove the antibodies bound to specific 
proteins transferred on the nitrocellulose  membrane, allowing to re-probe the same proteins 
with a second antibody. Different stripping buffers exist in biochemistry, with variable 
strength. For the aims of this thesis, a 0.5 M NaOH solution was employed as a quick stripping 
buffer. After development, membranes were incubated for 8 min with the solution in constant 
rotation at room temperature, then washed with TBST, the first time quickly to remove all 
NaOH, followed by 3 times for 5 min. Stripped membranes need to be blocked again in blocking 
buffer for 1 h before proceeding with immunoprobing as described above.   
 
2.2.7.5 Quantification of protein expression by gel densitometry 
The intensity of selected bands was evaluated by using 2D densitometry evaluation on AIDA 
(Advanced image Data Analyser) image analyser (Raytest, Germany) and following the 
manufacturer’s instruction. Intensity of the target protein in the sample was normalised for 
band intensity of a loading control protein, which expression was not affected by the treatment 
(housekeeping protein). Loading controls employed in this thesis were β-tubulin, actin or 
cyclophilin-A (Table 2.2), deepening on the specific experiment performed.  
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2.2.8 Immunofluorescent staining of cell monolayers 
2.2.8.1 Cell culture in an 8-well chamber slide 
In order to immunodetect specific antigens in kidney cell monolayers, fluorescent 
immunostaining (IF) was performed. To perform fluorescent immunostaining, kidney cells 
were cultured in an 8-well chamber slide: approximately 20,000 cells were seeded in each well 
in approximately 300 µl culture medium, treatments were performed as required by the 
specific experiments, and cells were allowed to grow until approximately 90% confluent. 
 
2.2.8.2 Fixation of cells with or without permeabilization 
Once cells reached the desired confluence, medium was removed and cells washed with 
approximately 500µl of sterile PBS pH 7.4, 3 times for 5 min. After washing, cells were either 
fixed with paraformaldehyde [3% (w/v) PFA] but not permeabilized or fixed with 3% (w/v) 
PFA and permeabilized with Triton-X100 depending on the specific aim of the experiment. In 
the first case, in fact, only the antigen present extracellularly and on the cell surface would be 
immunodetected by the antibodies, while in the second case, cells would be permeable to the 
antibody itself, allowing the detection of intracellular antigen.  
As PFA is not soluble at room temperature (dissolves at approximately 60°C in PBS), 3% (w/v) 
PFA solution was prepared fresh before the experiment by mixing the appropriate amount of 
paraformaldehyde powder in PBS pH 7.4 and letting it dissolve using a magnetic stirrer on an 
hot plate, under the chemical hood (PFA fumes might be toxic if inhaled), until completely clear. 
The solution was let to cool down to room temperature before using it to fix the cells.  
Fixation of cells without permeabilization was performed incubating the cells with 200µl/well 
of 3%(w/v) PFA solution for 8 min at room temperature. Cell monolayer was washed with PBS 
pH 7.4 (3 x 5min) before proceeding with the blocking step.  
Fixation and permeabilization was instead performed by incubating the cells with 200µl/well 
of 3%(w/v) PFA solution for 20 min at room temperature. Cell monolayer was washed two 
times with PBS pH 7.4, then incubated with 200 µl/well of 0.1% (v/v) Triton X100 in PBS pH 
7.4 for 15 min at room temperature. Cell monolayer was washed with PBS pH 7.4 (3 x 5min) 
before proceeding with the blocking step.  
 
2.2.8.3 Immunoprobing 
After fixation / fixation-permeabilization of the cell monolayer, chamber slides were saturated 
with 200µl/well of blocking buffer [3%(w/v) BSA in PBS pH7.4] for one hour at room 
temperature or 30 min at 37°C. The blocking step is necessary to prevent the aspecific binding 
of the antibody in the subsequent steps.  
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After blocking, cell monolayers were incubated with ~100 µl/well of the appropriate dilution 
of primary antibody (Table 2.2, dilutions for IF) in blocking buffer, overnight (15 h) at 4°C. The 
following day the cell monolayers were washed with PBS pH 7.4 (3 x 5 min, as described above) 
and incubated with the appropriate dilution of fluorochrome-conjugated secondary antibody 
in blocking buffer (Table 2.3, fluorochrome-conjugated secondary antibodies) with emission 
at a specific wavelength, for 2 h at room temperature, protected from light. After incubation, 
chamber slide was washed again three times with PBS pH 7.4 and the wells removed, leaving 
the glass slide.  
The slide was then mounted using few microliters of a 1:1 dilution of 
VECTASHIELD® mounting medium with DAPI and without DAPI (Vectorlab), enough to cover 
all wells. Using this solution, the cell nuclei will be stained with DAPI (4',6-diamidino-2-
phenylindole) and appear blue on the fluorescent microscope. Slides were stored in the dark 
at 4°C for short-term storage and at -20°C for long-term storage.  
As a negative control, to rule out any aspecific staining, primary antibody was omitted from 
one well / treatment, and cells incubated with the secondary antibody alone. Absence of a 
fluorescent signal after washing-out of the antibody would confirm the specificity of the signal 
observed in the other wells.  
Images were acquired using a Leica TCS confocal microscope (Leica, Germany) at a 
magnification going from 10X magnification in dry conditions to 63X magnification with 
immersion oil. Quantification of fluorescent signals was performed with ImageJ open source 
software (Schindelin, et al. 2015) on at least eight non-overlapping images per treatment. 
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2.2.9 Transglutaminase activity assay 
2.2.9.1 Total TG2 activity assay 
In order to determine the TG2 activity of cell and tissue lysates, TG transamination activity was 
assessed by measuring the enzyme ability of incorporating biotinylated cadaverine (BTC) on 
immobilised fibronectin (FN), using a modification of the established method by Jones and 
colleagues (Jones, et al. 1997) (Fig. 2.2).  
To perform the assay, a 96-well plate was coated with 100µl/well of 5µg/ml human plasma 
fibronectin (FN) (Sigma) in 50 mM Tris-HCl pH 7.4, overnight (15 h) at 4°C. The plates were 
washed 3 times with 200 µl/well Tris-HCl pH 7.4, then blocked with 100µl of 3% (w/v) BSA in 
50mM Tris-HCl pH 7.4 for 30 min at 37°C or 1h at RT (Fig. 2.2A).  
In the meantime, protein samples for TG2 activity assay were prepared following the standard 
lysis protocol and employing a sucrose based lysis buffer [250 mM sucrose, 2 mM EDTA, and 
50 mM Tris-HCl, pH 7.4] containing protease inhibitors (1:100 dilution of Protease Inhibitor 
Cocktail, Sigma). Together with protein samples, also a standard curve of known 
concentrations of guinea pig liver TG2 (gplTG2) was prepared by performing a serial dilution 
of stock TG2 (Sigma) to obtain 100, 75, 50, 25, 12.5, 6.25, 3.125 and 0 ng/well. This standard 
curve would be necessary to relate the specific absorbance to pure TG2 transamidation 
activity.  
After blocking with BSA, the plate was washed again three times with 50 mM Tris-HCl pH 7.4, 
then 60 µg/well of cell lysate were incubated in triplicates in presence of freshly added 0.1 mM 
biotin cadaverine [BTC, or N-(5-Aminopentyl)biotinamide trifluoroacetate salt] for 2 h at 37°C 
in Reaction buffer containing calcium [5 mM CaCl2, 10 mM 1,4-Dithiothreitol (DTT), 50mM 
Tris-HCl pH 7.4 + 0.1 mM BTC]  in a final volume of 100µl/well. Background activity (to be 
subtracted from the TG2 activity) was measured for each sample in triplicates by replacing 
CaCl2 with 5 mM EDTA [5 mM EDTA, 10 mM DTT, 50mM Tris-HCl pH 7.4 + 0.1 mM BTC]. 
Standard curve (0-100 ng/well) was also loaded in duplicates in both reaction buffers in a final 
volume of 100µl/well and incubated as well for 2 h at 37°C (Fig. 2.2B).  
After a wash with 10 mM EDTA in PBS to stop the reaction and three washes with Tris-HCl pH 
7.4, the amount of cross-linked BTC was revealed by incubation with 100 µl of a 1:5000 dilution 
of ExtrAvidin®−Peroxidase in blocking buffer, followed by three  other washes with Tris-HCl 
pH 7.4 (Fig. 2.2C).  
Subsequently, the plate was equilibrated for 10 min with 100µl of 50mM phosphate-citrate 
buffer, containing 0.014% (v/v) H2O2, pH 5.0. Buffer was prepared fresh for each experiment 
by dissolving one tablet Phosphate-citrate buffer/urea H2O2 (Sigma) in 10 ml distilled H2O. At 
the end of equilibration, the buffer was substituted with 100µl developing solution [50 mM 
phosphate-citrate buffer, 0.014% (v/v) H2O2 pH 5.0 containing 7.5% w/v 3,3′,5,5′-
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tetramethylbenzidine (TMB)]. Developing solution was prepared freshly before development 
by adding 75 µl of 10mg/ml 3,3′,5,5′-tetramethylbenzidine TMB stock solution in DMSO to 10 
ml of 50 mM phosphate-citrate buffer, 0.014% (v/v) H2O2 pH 5.0 (Fig.2D). If the phosphate-
citrate buffer containing H2O2 (Sigma) was old, 10 ml of developing solution were also 
supplemented with 5µl of 30% H2O2. The development was observed by the colour of the 
solution shifting to blue (Fig.2.2D), and was stopped by adding 0.5 volumes of 2.5N sulphuric 
acid (H2SO4), that turns the solution to a stable yellow colour (Fig. 2.2E).  
The absorbance was then measured at 450 nm using a 96-well plate reader 
(spectrophotometer).  The specific activity of TG2 in mU was calculated by subtracting the 
mean absorbance value in presence of EDTA from the mean absorbance value in presence of 
calcium, and plotting the unknown samples resulting values on the gplTG2 standard curve of 
known concentrations to infer the amount of TG2 specific activity (mU/ml).  
 
2.2.9.2 Extracellular TG2 activity assay 
In order to measure TG2 activity outside the cells, extracellular TG2 activity assay (sometimes 
regarded as cell surface TG2 activity assay) was performed according to (Jones, et al. 1997). 
The principle of the experiment is identical to the Total TG2 activity assay. In this case, 
however, the ability of TG2 of incorporating biotin cadaverine (BTC) (Fig.2.2) in FN is 
measured on living cells, limiting the TG2 activity detected to the cell surface/extracellular one.  
To perform the assay, a 96-well plate was coated with 50µl/well of 5 µg/ml human plasma FN 
in 50mM Tris-HCl pH 7.4, overnight (15 h) at 4°C. The wells were washed three times with 200 
µl/well Tris-HCl pH 7.4, then blocked with 100µl of 3% (w/v) BSA in 50mM Tris-HCl pH 7.4 for 
30 min at 37°C or 1h at room temperature (Fig.2.2A).  
To harvest cells for the assay, approximately 80-90% confluent cell monolayers were washed 
once with PBS pH 7.4 then detached with a trypsin-free buffer [5 mM EDTA in sterile PBS pH 
7.4] in gentle shaking at 37°C. Reaction was stopped with complete culture medium and cell 
pellet collected by centrifugation at 500g for 5 min. A cells suspension of 200,000 cells/ml in 
serum free-medium containing 10mM 1,4-Dithiothreitol (DTT) prepared ready to be 
supplemented with BTC and loaded on the plate.  
Once blocking step was over, wells were washed two times with 50mM Tris-HCl pH 7.4 and a 
last one with serum-free culture medium. Appropriate amount of cell suspension was 
supplemented with 0.1 mM BTC, and 100 µl/well (corresponding to 20,000 cells/well) were 
incubated in triplicates or quadruplicates, depending on the experiment, for 2 h at 37°C, to 
allow the amine incorporation reaction to happen (Fig. 2.2B). As a negative control, serum free 
medium with 10 mM DTT was applied in triplicates and incubated as above.  
The reaction was stopped with 2 washes with sterile PBS pH 7.4, and cell monolayer was 
incubated for 10 min with freshly prepared 0.1% (w/v) sodium deoxycholate in PBS pH 7.4 in 
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gentle rotation, to lyse the cells and leave only the FN-BTC extracellular matrix. After three 
washes with Tris-HCl pH 7.4, the amount of cross-linked BTC was revealed by incubation with 
100 µl of a 1:5000 dilution of ExtrAvidin®−Peroxidase (E2886, Sigma) in 50 mM Tris-HCl pH 
7.4 containing 1.5 % (w/v) BSA for 1 h at 37°C followed by three other washes with Tris-HCl 
pH 7.4 (Fig.2.2C).  
The plate was developed with 100µl developing solution [50 mM phosphate-citrate buffer, 
0.014% v/v H2O2 pH 5.0 containing 7.5% w/v 3,3′,5,5′-tetramethylbenzidine (TMB)] as 
described before (Fig.2.2D). The development was detected by the colour of the solution 
shifting to blue, and was stopped by adding 0.5 volumes of 2.5N Sulphuric acid (H2SO4), that 
turns the solution to a stable yellow colour (Fig.2.2E). The absorbance was then measured at 
450 nm using a 96-well plate reader (spectrophotometer).  
 
2.2.9.3 In situ TG2 activity assay 
In order to visualise TG2 activity in situ, incorporation of fluorescein isothiocianate (FITC) - 
conjugated cadaverine by a cell monolayer was measured as described by Verderio and 
colleagues (Verderio, et al. 1998). Briefly, approximately 20,000 cells/well were seeded in an 
8-well chamber slide and cultured in 300 µl culture medium until ~70% confluent. Medium 
was replaced with 250 µl/well of complete medium containing 0.5 mM FITC-cadaverine and 
cells were incubated for 4 -15 h (ON) depending on the experiment. Cell monolayer was gently 
washed three times with 500 µl PBS pH 7.4 for 5 min, then cell fixed with 200 µl cold 90% (v/v) 
methanol in PBS pH 7.4 at -20°C for 10 min. After fixation, chamber slide was washed 4 times 
with PBS pH 7.4 for 8 min and slide mounted with 1:1 dilution of VECTASHIELD® mounting 
medium with DAPI and without DAPI as described before [2.2.8.2] 
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Figure 2.2: Outline of TG2 activity plate assay performed in this thesis. A= Fibronectin (FN) coating; 
B=Amine (BTC) incorporation by TG2; C=Incubation with ExtrAvidin® peroxidase that binds biotin; 
D=Development with TMB substrate (peroxidase-dependent colorimetric reaction that turns the 
solution blue); E = Reaction stopped with sulphuric acid (H2SO4) that turns the solution to a stable yellow 
colour (read at 450 nm).  
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2.2.10 Cell transfection 
2.2.10.1 Transfection of plasmid DNA by electroporation 
In specific experiments, cell transfection of cDNA was performed to induce expression of 
specific proteins by the cells. Electroporation is an easy method used to introduce DNA in the 
cells by applying a transient electrical field that briefly opens the pores of the cells, allowing 
exogenous DNA to enter. Amaxa® NucleofectorTM  technology, in particular, is a cell-type 
specific transfection technique based on electroporation, that allows a delivery of DNA directly 
to the nucleus, transiently opening also the nuclear membrane, hence allowing a higher 
transfection efficiency.  
Following Amaxa® Nucleofector™ manufacturer’s suggestions, one million of exponentially 
growing NRK52E cells or EGFP-TG2 overexpressing NRK52E clones were harvested by 
centrifugation as described before and re-suspended in 100 µl of supplemented Nucleofector™ 
solution V form Amaxa Nucleofector™ kit V. Supplemented Nucleofector™ solution was 
prepared at room temperature shortly before the experiment by mixing one volume of 
supplement to 4.5 volumes of Nucleofector™ solution V. For a single reaction, 82 μl of 
Nucleofector™ solution V  were supplemented with 18 μl of supplement, to have 100 μl of total 
reaction volume. 
5 µg of the chosen mammalian transfection plasmid (Table 2.10) were added to the cell 
suspension and the whole suspension transferred in the certified electroporation cuvette 
provided in the kit. As a control, a mock transfection (no plasmid added) was performed, 
following the same procedure.  When performing transient transfections of TG2 and TG2 
mutants with the pEGFP-N1-TG2 plasmid (Chapter VI), a control transfection with the empty 
pEGFP-N1 vector (ClonTech #6085-1), in addition to the mock transfection, was performed.  
The cuvette was placed in the cuvette holder of the Amaxa® Nucleofactor™ device and the 
electric field was transiently applied. Program T-027 of the electroporation device was 
employed for transfection, as suggested by the manufacturer for this specific cell line. The 
cuvette was carefully removed and 500 µl of complete DMEM was quickly added on the 
mixture.  Without re-suspending, the sample was gently transferred into a 6-well plate 
containing 2 ml of pre-warmed complete DMEM medium using the supplied sterile plastic 
pipettes. Expression of the plasmid was allowed to proceed for 48 h at 37°C in 5% CO2 before 
harvesting the cells.  
In every experiment, a transfection with 5 µg of pEGFP-N1 empty vector (Clonetech) was 
carried out to evaluate the transfection efficiency: after 48 h cells were observed under 
confocal fluorescent microscope and the ratio between fluorescent cells (green emission) and 
total cells (bright field) was calculated. Generally, transfection efficiency comprised between 
65 and 85% was obtained. Moreover, the efficiency of the specific cDNA transfection was 
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assessed at transcript level by quantitative real time PCR (qRT-PCR) or at protein level by 
Western blot.   
 
Table 2.10: Mammalian transfection plasmids employed in this thesis for transfection of NR52E 
cells. 
cDNA Transfection plasmid  
Antibiotic 
resistance  
Human Syndecan 4 (Sdc4) pcDNA3.1(+)_Sdc4 (Scarpellini, 2009) Ampicillin 
Human Syndecan 4 tagged with Hemagglutinin 
(HA-Sdc4) 
pcDNA3_HA-Sdc4 (unpublished)  Ampicillin 
Human Transglutaminase 2 tagged with 
Enhanched Green fluorescent protein (EGFP-TG2 
(sometimes referred as EGFP.-TG2(WT)] 
pEGFP-N1-TG2(WT) (Scarpellini, 2009) Kanamycicn 
Heparin binding mutant Human Transglutaminase 
2 (mutation M1c, Lortat-Jacob et al, 2012) tagged 
with Enhanched Green fluorescent protein [EGFP-
TG2(M1c)] 
pEGFP-N1-TG2(M1c) 
(Unpublished) 
Kanamycicn 
Heparin binding mutant Human Transglutaminase 
2 (mutation M3, Lortat-Jacob et al, 2012) tagged 
with Enhanched Green fluorescent protein [EGFP-
TG2(M3)] 
pEGFP-N1-TG2(M3) (Unpublished) Kanamycicn 
Enhanched Green fluorescent protein alone 
(Transfection control) 
EGFP-N1 plasmid (6085-1, Clontech, 
California, US) 
Kanamycicn 
None (Control) Mock transfection / 
 
 
2.2.10.2 Transfection of siRNA  
Small interfering RNA (siRNA) transfection is a cell transfection technique used to transiently 
interfere with the expression of selected genes. In this case, a vector-free approach of siRNA 
transfection, based on DharmaFECT® 1 transfection reagent, was used. In order to perform 
knock out of selected gene expression on NRK52E cells or NRK52E EGFP-TG2 overexpressing 
clones, approximately 300,000 cells/well were plated in a 6-well plate and cultured overnight 
(15 h) in an antibiotic-free DMEM medium specifically prepared for siRNA transfection [DMEM 
containing 4.5 g/L glucose, 5%(v/v) FBS and 2 mM L-glutamine].  
The day after, a transfection solution containing 100 nM siRNA (Table 2.11) and 
DharmaFECT® 1 was prepared; volumes reported in the protocol are considered for the 
preparation of a 4 ml final transfection solution, which was enough to transfect tree wells of a 
6-well plate (approximately 1.3 ml/well). Preparation of siRNA transfection solutions was 
performed in nuclease-free conditions, and, when necessary, nuclease-free water 
[diethylpyrocarbonate (DEPC)- treated water prepared by incubation of distilled H2O with 
0.1% (v/v) DEPC overnight under the chemical hood, followed by autoclaving at 121 °C for 20 
min] was employed to dilute siRNA stocks and reagents.  
Briefly, a 2 µM solution of the specific siRNA employed (Table 2.11) was prepared in 200 µl of 
siRNA Buffer [60 mM KCl, 6 mM HEPES-pH 7.5, 200 uM MgCl2, diluted from 5X siRNA buffer 
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stock (B-002000-UB, GE Dharmacon, Thermo Scientific) with nuclease-free water], then 
further diluted to 1µM by adding one volume (200 µl) of serum free DMEM. At the same time, 
400 µl of 2.5% (v/v) DharmaFECT® 1 solution in serum-free DMEM was prepared by mixing 
10 µl of DharmaFECT® 1 transfection reagent (T-2001-01, GE Dharmacon, Thermo Scientific) 
to 390 µl of medium. The two separate solutions were incubated for 5 min at room 
temperature, then combined 1:1 (total volume = 800 µl) and incubated again 20 min at room 
temperature. The final solution was diluted 5 times with 3.2 ml of complete antibiotics-free 
DMEM medium. Culture medium was removed from the cultured cells and replaced with 
approximately 1.3 ml of transfection medium. Following transfection, incubation was 
protracted for 24 or 48 h depending on the experiment.  
In all experiments performed, both a specific gene-targeting siRNA and a non-targeting control 
scrambled siRNA (Table 2.11) were used, to rule out any effect on gene expression determined 
by the transfection procedure itself. After transfection, the efficiency of knock down at a 
transcript level or at a protein level was assessed.  
 
Table 2.11: siRNA employed in this thesis for transfection of NRK52E cells.  
Knock – out of SiRNA 
Rat Syndecan 4 (Sdc4) 
Rat Sdc4 Targeting siRNA [ON-TARGETplus Rat Sdc4 (24771) siRNA - 
Individual (J-087816-05-0005, Dharmacon,Thermo Scientific)] 
Rat Clathrin (Cltc) 
Rat Cltc Targeting siRNA [ON-TARGETplus Rat Cltc (54241) siRNA – 
SMARTpool (L-090659-02-0005, Dharmacon, Thermo Scientific)] 
/ (Control) 
Non-targeting scrambled control siRNA [ON-TARGETplus Non-targeting siRNA 
#1 (D-001810-01-05, Dharmacon, Thermo Scientific)] 
 
 
2.2.11 Amplification of plasmid DNA  
2.2.11.1  Preparation of LB Broth (Lennox) culture medium and LB-Agar plates 
Lennox lysogeny broth (LB, sometimes referred as Luria Bertani broth) (Bertani 1951) was 
prepared by mixing 20 g of granulated Fisher BioReagents™ LB Broth Lennox to 1 L of distilled 
water and autoclaving it (121 °C for 20 min). The final solution contained 5 g/L yeast extract, 
10 g/L tryptone and 5g/L NaCl, and its pH was approximately 7.  
LB-agar plates containing specific selective antibiotics were also prepared. To prepare 20 Agar 
plates, 500 ml of LB Broth [0.5% (w/v) yeast extract, 1% (w/v) tryptone and 0.5% (w/v) NaCl, 
pH~7] were mixed with 1.5% (w/v) of agarose. The mixture was autoclaved (121 °C for 20 
min) to sterilise it and dissolve the agarose, and let cool down to approximately 50°C before 
adding the antibiotics. Autoclaved solution was opened in sterile conditions (over Bunsen 
flame) and the appropriate amount of the selective antibiotic [100 µg/ml ampicillin or 50 
µg/ml kanamycin depending on the specific antibiotic resistance carried by the plasmid the 
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cells were transformed with, Table 2.10] was added. Rapidly, the mixture was poured in 
bacterial culture Petri dishes (~25 ml/dish) and let solidify at room temperature in sterile 
conditions. Plates were incubated cover side- down at 37°C for 1 h to avoid contaminations. If 
not used immediately, plates were sealed with Parafilm M® (Bemis) and stored cover side - 
down at 4°C in the dark, wrapped in aluminium foil, for no longer than one month. On the day 
of use, plates were pre-warmed at 37°C for approximately 30 min before employment.  
 
2.2.11.2 Transformation of DH5α competent cells with plasmid DNA 
In order to transform bacterial E.coli cells with plasmid DNA and allow plasmid DNA 
replication in this system, 50 µl of Subcloning Efficiency™ chemically competent DH5α™ cells 
(18265-017, Invitrogen) were taken from -80°C storage and slowly thawed on ice. Once 
defrosted, cells were incubated with approximately 20 ng of desired expression plasmid 
(Table 2.10), on ice for 30 min. After this time, a heat shock of exactly 45 sec at 42°C was 
performed in a water bath, followed by a 2 min incubation on ice. 950 µl of pre-warmed LB b 
broth was added on the top, and the tube was incubated for one hour at 37°C at 200 rpm 
constant shaking. Different volumes of the transformed cells (200-50 µl) were then plated on 
LB Agar plates containing the selective antibiotic (Table 2.10) and plates were incubated 
cover-side down at 37°C overnight. Antibiotic-resistant colonies were observed the day after. 
A mock transformation (no plasmid added) was performed every time to confirm whether the 
antibiotic resistance was carried by the plasmid.   
 
2.2.11.3 Glycerol stock of bacterial colonies 
In order to store transformed bacteria, an isolated antibiotic-resistant bacterial colony was 
picked with a sterile tip to inoculate 10 ml of LB broth containing the selective antibiotic [100 
µg/ml ampicillin or 50 µg/ml kanamycin depending on the specific resistance carried by the 
plasmid used (Table 2.10)] in an appropriate sized container (must be at least 5 times bigger 
than the medium volume, to allow enough oxygen to be available). The preparation was then 
incubated overnight at 37°C at 200 rpm constant shaking. The resulting bacterial culture was 
used to prepare 1 ml  frozen stocks containing 15% (v/v) glycerol in sterile cryovials (850 µl 
bacterial culture + 150 µl glycerol), stored at -80°C.   
When transformed bacteria were needed, the glycerol stock was gently thawed on ice and, 
when still partially frozen, a small portion was taken with a sterile loop and used to inoculate 
selective LB broth.  
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2.2.11.4 Amplification and extraction of plasmid DNA  
2.2.11.4.1 Miniprep of plasmid DNA:  
A single bacterial colony from agar plate or glycerol stock was used to inoculate 5 ml of 
selective LB broth [100 µg/ml ampicillin or 50 µg/ml kanamycin depending on the specific 
resistance carried by the plasmid used (Table 2.10)], and incubated 6-8 h at 37°C at 200 rpm 
constant shaking. Bacteria were pelleted by centrifugation (6000g for 15 min at 4°C), then 
plasmid were isolated using the QIAprep Spin Miniprep Kit (Qiagen), following the 
manufacturer protocol. Plasmid DNA was eluted in 50 µl nuclease-free distilled water unless 
otherwise stated. Concentration was measured by NanoDrop® 8000 spectrophotometer 
(Thermo Scientific).  
Purity of the plasmid preparation was also assessed with the NanoDrop® 8000 
spectrophotometer by the 260/280 and 260/230 absorbance ratio. All nucleotides (RNA, 
ssDNA and dsDNA) absorb at 260 nm, while proteins, ethanol and other possible contaminants 
of the extracted plasmid absorb around 280 nm; EDTA and carbohydrate absorb around 230 
nm, while phenol contributes to both 230 nm and 280 nm absorbance. DNA preparations with 
260/280 around 1.8 and 260/230 ratio around 2-2.2 were regarded as pure (Thermo Fisher 
Scientific, NanoDrop products 2008).  
 
2.2.11.4.2 Midiprep of plasmid DNA:  
A single bacterial colony from agar plate or glycerol stock was used to inoculate 5 ml of 
selective LB broth [100 µg/ml ampicillin or 50 µg/ml kanamycin depending on the specific 
resistance carried by the plasmid used (Table 2.10)], and incubated 6-8 hr at 37°C at 200 rpm 
constant shaking. The whole bacterial culture was then transferred in a bigger flask containing 
100 ml selective LB broth and left at the same conditions overnight (15 h). Bacteria were 
pelleted by centrifugation (6000g for 15 min at 4°C), then plasmid were isolated using the 
Qiagen Plasmid Midi Kit (12143, Qiagen) and following the manufacturer protocol. Plasmid 
DNA was eluted in 40 µl Tris-EDTA (TE) Buffer [10 mM Tris-HCl, 1 mM EDTA, pH 8.0] unless 
otherwise stated. Concentration and purity of DNA was measured by NanoDrop® 8000.  
 
2.2.11.5 Sequencing of plasmid DNA 
To confirm the correct sequence of plasmid DNA, purified plasmids were sequenced by Sanger 
sequencing by Source BioScience Overnight Service™ (EVCHT50, Source BioScience).  
A minimum of  5 µl of 100 ng/µl plasmid DNA, in either 10 mM Tris HCl pH 8.5  or nuclease – 
free water, were sent for sequencing. Sequencing primers were provided by the company and 
depended on the specific vector employed. Sequencing results were analysed by BLAST (Basic 
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Local Alignment Search Tool, https://blast.ncbi.nlm.nih.gov/Blast.cgi) or Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo) open source sequencing tools.  
 
2.2.12 Total RNA extraction from kidney cells 
In order to measure the level of transcription of particular genes, total RNA was extracted from 
cells. RNA extraction was performed using GenElute™ Mammalian Total RNA Miniprep Kit 
(Sigma), a column-based RNA purification kit, following the manufacturer’s instructions.  
To extract RNA, approximately 5 million of exponentially growing cells were employed. Cells 
were detached by trypsinization as described above, and centrifuged at 500 g for 5 min to 
obtain cell pellets. Traces of serum were carefully removed by washing the cell pellet once with 
sterile PBS pH 7.4, and pelleting them again by centrifugation. Cell pellet was lysed with 250 
μL of the lysis solution containing β-ME (provided by the kit), and filtered through GenElute 
filtration column by centrifugation at ~16,000 × g for 2 min. Lysate was supplemented with 
250 μl of 70% (v/v) ethanol and placed into a GenElute binding column. A series of brief high 
speed spins and washes were performed as required by the protocol, and the RNA was eluted 
in 50 μL of the elution solution by ~16,000 × g centrifugation for 1 min. Extracted RNA was 
stored at -80°C.  
After purification, the amount and quality of the RNA obtained was determined by NanoDrop® 
8000 (Thermo Scientific). Between 10 and 20 μg RNA were usually obtained from 1 million 
cultured cells. RNA preparations with 260/280 ration around 2 and 260/230 ratio around 2-
2.2 were regarded as pure (Thermo Fisher Scientific, NanoDrop products 2008).  
 
2.2.13 Reverse transcription  
2 µg of total RNA obtained was reverse transcribed using “random primers” (C1181 Promega) 
and 200 units (100U/µg RNA) of SuperScript® II reverse transcriptase (Invitrogen) at 42°C for 
50 min.  
Briefly, for each reaction (final volume 20 µl), 2 µg of total RNA was incubated with 25 µg/ml 
of random primers (Promega) and 250 µM dNTP’s (Promega) in a total volume 13 µl at 65°C 
for 5 min, then quickly chilled on ice. 4 µl of 5X First-Strand buffer and 2 µl of 0.1 M DTT (final 
concentration 10mM), provided with the transcriptase, were added, and the solution incubated 
at 25°C for 2 min. 200 units (1 µl) of SuperScript® II reverse transcriptase (18064-014, 
Invitrogen) were then added, to a final volume of 20 µl. The mixture was incubated in a table 
top standard thermocycler at 25°C for 10 min, then 42°C for 50 min, and finally at 70°C for 15 
min, to allow for reverse transcription. The reverse transcribed cDNA was stored at -20°C until 
needed.  
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2.2.14 Quantitative real time PCR (qRT-PCR) 
2.2.14.1 qRT-PCR Reaction 
To measure the level of expression of the gene of interest, equal volumes of cDNA obtained by 
reverse transcription were amplified by quantitative PCR (qPCR) using iQ™ SYBR® Green 
Supermix (170-8880, Biorad). This ready-to-use mix is 2X concentrated and contains 50 U/ml 
hot-start iTaq™ DNA polymerase, 6 mM MgCl2, 0.4 mM dNTPs, SYBR® Green I dye, enhancers, 
stabilizers and fluorescein.  
Primers for specific gene amplification were found from literature (Brucato, et al. 2000, Kim, 
et al. 1994, Ahmad, et al. 2007), checked for quality and melting proprieties using Sigma 
OligoEvaluator™ (http://www.oligoevaluator.com) and obtained from Sigma as customized 
Easy Oligos (OLIGOS, Sigma). Lyophilized primers were resuspended in nuclease-free water at 
a 100µM stock concentration. These solutions where then further diluted in nuclease-free 
water at a 20µM working concentration. The specific primers employed in this thesis are 
reported in Table 2.12.   
1µl of cDNA was added to 6.25 µl of 2X iQ™ SYBR® Green Supermix (Biorad), 400 nM forward 
primer and 400 nM reverse primer in nuclease free water (DEPC-treated), to the final volume 
of 12.5 µl, into suitable nuclease free Strip tubes (981103, Qiagen). The amplification was 
performed in triplicates. A no-template control reaction (in triplicates) was included to rule 
out any buffer contamination. cyclophilin-A (CycA) (Table 2.12) was selected as housekeeping 
gene, employed to normalize the values and perform a relative quantification.  
PCR reactions were carried out in a Corbett Rotor-Gene 6000 rotary analyser (Qiagen). 
Thermal cycles performed for the specific amplifications presented in this thesis are reported 
in Table 2.13: an initial denaturation of 10 min at 95°C was followed by 40 cycles of 
denaturation at 95°C for 30 sec, annealing at 58°C for 20 sec and elongation at 72°C for 20 sec. 
At the end of the last cycle, a ramp temperature rise from 72°C to 95°C (5 seconds each °C) was 
performed to produce melting curves. Melting curves are fundamental to confirm the 
specificity of the amplification and the absence of contamination in the reagents (no-template 
control).  
Once the last step was over, fluorescence (SYBR Green) data were obtained as graphs of 
fluorescence signal accumulation over cycle. A fluorescence threshold (background level) was 
arbitrarily chosen in every experiment and “cycle threshold” (Ct) values were calculated by the 
software as the intersection points of the fluorescence curves with the threshold chosen. The 
Ct value can be defined as the number of cycles necessary for the fluorescent signal to cross the 
threshold, and is proportional to the amount target cDNA in the sample: the higher is the gene 
expression in the sample analysed, the lower will be the Ct value, and vice versa.  
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In some cases, the amplification product (end-point) of the PCR reaction was further analysed 
by agarose gel electrophoresis [2% (w/v)] to confirm the specificity of the amplification as well 
as the absence of contamination in the reagents (no-template control).  
 
Table 2.12: Primers employed for specific gene amplification by qRT-PCR. Primers were checked 
for quality and melting proprieties using Sigma OligoEvaluator™ (http://www.oligoevaluator.com) and 
obtained from Sigma as 100 µM customed Easy Oligos.  
 
Primers 
Target 
Gene 
Name Sequence 5’-3’ Tm 
Product 
size 
Reference 
Syndecan-
4 Sdc4 
Sdc4 FW 5’-GAGTCGATTCGAGAGACTGA-3’  54 
366 bp 
(Kim, et al. 1994, Brucato, 
et al. 2000) 
Sdc4 RV 5’-AAAAATGTTGCTGCCCTG-3’ 56 
Cyclophilin-
A (CycA) 
Rat CycA FW 5’-AGCATACAGGTCCTGGCATC-3’ 54 
127 bp 
(Ahmad, et al. 2007) 
Rat CycA RV 5’-TTCACCTTCCCAAAGACCAC-3’ 52 
 
 
Table 2.13: Thermal cycles employed for specific gene amplification by qRT-PCR using primers 
reported in Table 2.12. PCR reactions were carried out in a Corbett Rotor-Gene 6000 rotary analyser 
(Qiagen).  
 
Thermocycler conditions 
Cycles Step T (°C) Time 
1 Denaturation 95°C 10 min 
40 
Denaturation 95°C 30 sec 
Annealing 58 °C 20 sec 
Elongation 72 °C 20 sec 
1 Melt  72 - 95°C Hold sec on 1
st
 step, hold 5 sec on next steps 
 
 
2.2.14.2  Relative quantification of transcript expression 
Once Ct values were obtained for each replica of each sample, the 2-ΔΔCt relative quantification 
method (Livak and Schmittgen 2001) was manually applied to calculate the level of expression 
of the target gene.   
Ct values obtained were averaged within the 3 replicas of each sample. Mean Ct values for the 
housekeeping gene (that is proportional the total cDNA loaded, hence should be constant 
among the different samples) was subtracted from the mean Ct values for the target gene, 
obtaining a normalised ΔCt value (1). Subsequently, a ΔΔCt value was calculated as the 
difference between the gene of interest and a calibrator (2), which is arbitrarily chosen and can 
be, for example, the untreated sample; the final result will be the level of expression of each 
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sample relatively to this calibrator. Finally, the relative expression from the calibrator was 
calculated as 2-ΔΔCT (3). Standard errors were calculated as described in (Livak and Schmittgen 
2001).   
 
(1) ∆𝐶𝑡 = 𝐶𝑡𝑡𝑎𝑟𝑔𝑒𝑡 𝑔𝑒𝑛𝑒 − 𝐶𝑡ℎ𝑜𝑢𝑠𝑒𝑘𝑒𝑒𝑝𝑖𝑛𝑔 𝑔𝑒𝑛𝑒  →  ∆𝐶𝑡𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝐶𝑦𝑐𝐴 = 𝐶𝑡𝑡𝑎𝑟𝑔𝑒𝑡 𝑔𝑒𝑛𝑒 − 𝐶𝑡𝐶𝑦𝑐𝐴   
(2) ∆∆𝐶𝑡 = ∆𝐶𝑡 − ∆𝐶𝑡𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑜𝑟 
(3) % 𝐸𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑡𝑎𝑟𝑔𝑒𝑡 𝑔𝑒𝑛𝑒 𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒𝑙𝑦 𝑡𝑜 𝑡ℎ𝑒 𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑜𝑟 =  2
−∆∆𝐶𝑡 ∙ 100 
 
 
2.2.15 Preparation and loading of an electrophoresis agarose gel 
In order to separate amplified DNA samples depending on their size, DNA electrophoresis was 
performed on an agarose gel.  
Agarose gel was prepared by mixing 2% (w/v) agarose to a volume of Tris-acetate-EDTA (TAE) 
buffer (40mM Tris, 20mM acetic acid, 1mM EDTA, pH 8.5) sufficient to fill the gel casting tray. 
Agarose was dissolved by warming up the mixture in the microwave and, after cooling down 
the final solution to approximately 50°C, ethidium bromide (10 mg/ml, Sigma) was added to a 
final concentration of 0.5 µg/ml (5 µl in 100 ml of gel mixture). The gel was then poured into 
the gel tray containing the well combs and let solidify.  
Once solidified, the gel was placed in the electrophoresis chamber, containing a suitable 
amount of TAE buffer, loading the wells on the negative side (black, as DNA is negatively 
charged and runs to the positive side). Samples amplified with iQ™ SYBR® Green Supermix are 
already in a blue loading buffer, in other cases, samples to load were prepared by adding a 1:5 
dilution of Blue/Orange 6X loading dye (G1881, Promega). DNA samples were loaded in the 
wells and electrophoresis was performed by applying a constant voltage of 100 -150 V for at 
least 30 min.  
Together with the samples, 6µl of 100kb DNA ladder was run. 100kb DNA ladder was prepared 
as suggested by the manufacturer, by mixing 1:4:1 volumes of 100 bp DNA ladder (G2101, 
Promega), ultrapure water and Blue/Orange 6X loading dye and is necessary to determine the 
size of the separated fragments and an approximate concentration. Once the run was 
completed, DNA fragments were visualized under UV light (U:Genius transilluminator, 
Syngene).  
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2.2.16 Statistical analysis 
All experiments were undertaken at least three times (three independent experiments) unless 
otherwise stated. Data were expressed as means ± standard deviation (SD), unless otherwise 
stated. Statistical analysis of the differences between data sets was performed on Office Excel 
by Student’s t-test (two-tailed distribution, unequal variance), unless otherwise stated. A p-
value lower than 0.05 was regarded as significant (* = p<0.05, ** = p<0.01, *** = p<0.001, **** 
= p<0.0001).  
 
2.2.17 Protein and nucleotide sequence alignments 
Protein and nucleotide sequence alignments were performed employing the distinct functions 
available on the SDSC (San Diego Supercomputer Centre) Biology Workbench bioinformatic 
platform (http://workbench.sdsc.edu).   
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Chapter III: Proteomic analysis of differentially expressed proteins 
in the unilateral ureteric obstruction (UUO) model of CKD 
 
3.1 AIMS OF THE CHAPTER  
 
The aim of this chapter is to perform a proteomic analysis of the UUO model by employing 
quantitative mass spectrometry and, in this manner, identify proteins significantly 
overexpressed or underexpressed upon obstructive nephropathy. Functional enrichment 
analysis will give an idea of the functional classes and biological pathways affected by the 
disease, while interaction analysis will provide a picture of the possible connections between 
the proteins. This novel library of proteins differentially expressed by UUO will be a valuable 
tool for the identification of markers of advanced tubulointerstitial fibrosis. Furthermore, it 
will be useful to set a baseline for the TG2-interactome analysis described Chapter IV.  
Given the protective role of TG2-KO against the progression of fibrosis observed both in vitro 
and in vivo in different models of kidney disease, the analysis of possible variations in protein 
expression in the TG2-null phenotype subjected to UUO is another aim of this chapter, that 
might provide information on the role of TG2 in the progression of disease. 
 
 
3.2 INTRODUCTION 
 
3.2.1 Unilateral ureteric obstruction (UUO) model of CKD  
The unilateral ureteric obstruction (UUO) is an experimental model of CKD largely employed 
in rodents (Chevalier, Forbes and Thornhill 2009). It is a good model to produce a rapid tubular 
and interstitial response, with proliferation and activation of interstitial fibroblasts, increased 
deposition of an interstitial matrix mainly composed of collagen I, III, IV, fibronectin (FN) and 
heparan sulphate proteoglycans (HSPGs), interstitial fibrosis and tubular atrophy (Nagle, et al. 
1973, Sharma, et al. 1993). The UUO procedure mimics the effect of human congenital 
obstructive nephropathy, one of the most important causes of renal impairment in the children 
(Seikaly, et al. 2003).  
While the majority of models of CKD including the ablation models and the diabetic 
nephropathy models generally lead to glomerular injury and glomerulosclerosis as a primary 
response, less models have been designed to determine a primary tubulointerstitial disease, 
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which is particularly important, taking into consideration that  the progression of renal 
insufficiency better correlates with this tubulointerstitial fibrosis, comparing to the glomerular 
response (Schainuck, et al. 1970). UUO is the best known experimental model with a primary 
tubulointerstitial effect, even if other experimental models, including ischemia/reperfusion or 
employment of specific nephrotoxins and immune complexes have been suggested to 
determine a fibrotic response starting from the tubules (Chevalier, Forbes and Thornhill 2009). 
Advantages of UUO are the absence of toxins and the availability of the contralateral kidney as 
a genetically identical control (Chevalier, Forbes and Thornhill 2009). 
UUO is produced by surgical incision of abdomen and exposure and obstruction of one of the 
ureters, usually the left, with two separate knots (one proximal and one distal) or by 
employment of surgical clips, generally cutting the space between the obstructions (Ucero, et 
al. 2014). The obstructed kidney experience urine retention and quickly develops the 
tubulointerstitial injury while the contralateral kidney (non-obstructed kidney) undergoes a 
series of compensatory changes (Ucero, et al. 2014). The contralateral kidney can be employed 
as a control but it cannot be employed as a healthy non-treated control, as it compensates for 
the organ loss (Chevalier 1990). For this reason, a Sham operation, in which the ureter is 
exposed but not ligated, is usually employed as a healthy control (Ucero, et al. 2014).  
The procedure induces extremely rapid responses, with reduced GFR and blood flow already 
observable within one day, and hydronephrosis, large immune response and cell death within 
a week (Chevalier, Forbes and Thornhill 2009, Vaughan, et al. 2004). 
The organ responses to the UUO leading to a rapid development of CKD in the experimental 
animals can be divided into three phases: inflammatory response, tubular cell injury and cell 
death (by both apoptosis and necrosis), and tubulointerstitial fibrosis (Chevalier, Forbes and 
Thornhill 2009, Ucero, et al. 2014) (Fig. 3.1).  
Inflammatory response starts immediately after obstruction (~12 h) and is mainly 
characterized by macrophage infiltration and activation in the interstitial space. Infiltrated 
macrophages produce a large number of cytokines responsible for fibroblast recruitment and 
activation as well as for tubular cell death. Two population of macrophages can be observed in 
this model: the classically activated (M1) and the alternatively activated (M2) (Duffield 2014, 
Ricardo, van Goor and Eddy 2008). The firsts have a classical inflammatory phenotype and are 
involved in the promotion of cell death, while the others are involved in tissue healing and 
resolution of the inflammation, and mediate cell proliferation as well as ECM deposition and 
sclerotic tissue accumulation (Duffield 2014, Ricardo, van Goor and Eddy 2008).  
Upregulation of AngII has also been observed as an early response to UUO (Klahr and 
Morrissey 1998), with production of reactive oxygen species (ROS) and upregulation of NF-κB 
(Esteban, et al. 2004), and has been directly involved in the development of tubular injury and 
tubulointerstitial fibrosis (Ishidoya, et al. 1995, Kaneto, et al. 1994).  
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TNF-α upregulation by M1 macrophages is also observed and associated with tubular cell 
death (Misseri, et al. 2005) and NF-κB activation (Meldrum, et al. 2006). NF-κB activation, in 
turn, promotes macrophage infiltration and upregulates the expression of cytokines and 
growth factors (Sanz et al., 2010), with TGF-β as the most important factor upregulated in this 
system (Kaneto, Morrissey and Klahr 1993, Scarpellini, et al. 2014).   
TGF-β favours both tubular epithelial cell death and EMT / EndMT, leading to myofibroblast 
proliferation and fibrosis through Smad3 activation (Sato, et al. 2003, Inazaki, et al. 2004, 
Ucero, et al. 2014, Chevalier, Forbes and Thornhill 2009).  
Tubular cell death is already observed 24 h post-UUO, and involves both apoptotic and necrotic 
pathways (Ucero, et al. 2014). Tubular dilatation with loss of parenchymal structure is largely 
evident two weeks post-UUO, sometimes preceded by G2/M cell cycle arrest with abnormal 
deposition of extracellular matrix (Yang, et al. 2010).  
Substantial interstitial fibroblast proliferation and differentiation/activation of interstitial 
fibroblasts is already evident few days post-surgery (Eddy, et al. 2012, Matsuo, et al. 2005), 
with expression of myofibroblast markers by day three post-UUO. Subsequently, the tubules 
undergo a process of dilatation, with deposition of ECM and expansion of the interstitial space, 
and atrophy, with apoptotic flattened epithelial cells and exposed remnant tubular basement 
membrane (TBM) where the epithelial cells are lost. Blood vessels might look widened as well, 
as endothelial cells undergo apoptosis and transformation, with consequent capillary loss and 
ischemia/hypoxia in the organ.  
The presence of glomerular injury and glomerulosclerosis upon UUO remains controversial: 
having been always regarded as a tubulointerstitial model, an effect on the glomerulus has 
been generally unheeded. However, in some works, development of proteinuria suggests a 
secondary glomerular injury, contributing to the outcome of disease (Tapmeier, et al. 2008, 
Chevalier, Forbes and Thornhill 2009). An effect in the glomeruli is sometimes absent or less 
evident, mostly characterized by thickening of Bowman’s capsule and reduction in the 
glomerular size, that happens after tubular fibrosis is established and the disease approaches 
end-stage (around three weeks post-surgery) (Scarpellini, et al. 2014).  
In conclusion, the UUO model is a highly reproducible model leading to tubular injury and 
extended fibrosis in a relatively short period. Early apoptotic and fibrotic response can be 
already observed at three days post-UUO, including large fibroblast proliferation and 
activation and a significant increase in collagen expression. By day seven, a significant loss of 
tubular integrity and accumulation of deposited extracellular collagen are observable (early-
CKD) and an established fibrosis with parenchymal damage is present at two weeks post-UUO 
(late-CKD) (Eddy, et al. 2012, Shweke, et al. 2008). At 21 days, an established kidney fibrosis 
and parenchymal loss, comparable to the last stages of CKD, can be observed (Scarpellini, et al. 
2014, Zhao, et al. 2015a).  
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Upon histological observation, UUO kidneys are generally characterised by a large interstitial 
space rich of matrix, with detection of fibroblasts/myofibroblasts and inflammatory cells. 
Epithelial cells undergoing atrophy usually look flattened or disappear showing the TBM.  Also 
the blood vessels are widened, while the glomeruli are less affected by the process. Only when 
the disease reaches its end-stages, a glomerular loss and reduction in size, with podocyte death 
and exposed glomerular basement membrane (GBM) might be observed (Ucero, et al. 2014, 
Scarpellini, et al. 2014).   
 
 
Figure 3.1: Cellular response to unilateral ureteric obstruction (UUO) leading to 
tubulointerstitial fibrosis and tubular injury. Activation of interstitial macrophages with cytokine 
release and induction of the renin-angiotensin system (RAS), with AngII production, are key elements in 
the development of interstitial fibrosis and renal failure upon UUO. The figure represents the main 
cellular responses to inflammation and AngII rise leading to both epithelial and endothelial cell loss and 
interstitial fibroblast recruitment, proliferation and activation. Epithelial and endothelial cell transition 
(EMT and EndMT) contribute to myofibroblast proliferation. Increased deposition of ECM by activated 
fibroblasts leads to accumulation of sclerotic tissue. Proteases inhibitors and activators such as 
plasminogen activator (tPA) and plasminogen activator inhibitor (PAI) are involved in the control of 
matrix degradation. Picture obtained from (Chevalier, Forbes and Thornhill 2009). Permission to 
reproduce this picture has been granted by Elsevier. 
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3.2.2 Proteomic studies of CKD employing mass spectrometry (MS) 
Despite a large number of studies have aimed to analyse kidney fibrosis progression and 
identify early or late biomarkers of disease, few works have been published employing a non-
hypothesis driven proteomic approach, by mass spectrometric (MS) analysis of kidney tissue 
or urine (Klein, et al. 2011). In this section, some representative MS analyses of CKD models 
will be presented, with particular focus on the most recent proteomic studies of the UUO model 
(Table 3.1).  
In 2008, a study aimed to determine possible urinary biomarkers of glomerulosclerosis was 
performed on patients with different diseases targeting the glomerulus (diabetic nephropathy 
or DN, focal and segmental glomerulosclerosis or FSGS, lupus nephritis, membranous 
nephropathy) (Varghese, et al. 2007). 2-D gel electrophoresis (2-DE) followed by protein spot 
quantification, and statistical analysis employing the artificial neural network (ANN) 
algorithm, led to the individuation of 21 possible spots as predictor biomarkers of glomerular 
diseases, that were identified by MS using either matrix-assisted laser desorption/ionization 
(MALDI) – time of flight (TOF) tandem MS (MS/MS) approach or linear ion trap quadrupole 
(LTQ) MS.  Most of these proteins were plasma proteins, possibly due to blood leakage into the 
urine, such as α-1 antitrypsin, transferrin, albumin, and α-1 microglobulin (Varghese, et al. 
2007).   
In 2009, a proteomic study performed on whole kidney lysates of streptozotocin (STZ)-treated 
diabetic rats, employing isobaric tag for relative and absolute quantitation (i-TRAQ™) labelling 
and liquid chromatography tandem ms (LC-MS/MS), identified 330 proteins in diabetic 
kidneys, of which 88 were significantly altered by DN (Gong, et al. 2009). importantly, a 
number of proteins associated with redox regulation were either upregulated or 
downregulated by the disease in this model, including subtypes of glutathione s-transferase 
and glutathione peroxidase. Basement membrane (BM)-associated proteins such as collagen 
VI and the hspg perlecan were upregulated by the disease, as well as the cytoskeletal protein 
actinin. Proteins involved in apoptosis were also identified, such as clusterin and voltage 
dependent anion selective channel 1 (Gong, et al. 2009).  
In 2010, Cummings and colleagues performed a MS analysis to define mediators of 
tubulointerstitial fibrosis and tubular damage in DN, employing a transgenic OVE26 mice 
model of type 1 diabetes (Cummins, et al. 2010), a model of progressive DN showing TGF-β -
mediated tubulointerstitial fibrosis (Powell, et al. 2009). 2-DE followed by an LC-MS/MS 
analysis of tubule extracts from kidneys with pro-fibrotic / fibrotic phenotypes led the group 
to the identification of 476 proteins differentially expressed upon fibrosis. The main finding of 
this study was the identification of TGF-β -related proteins among the differentially expressed 
candidates, such as β-catenin (downregulated) and glycogen synthase kinase 3 (GSK3)-β, 
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together with TGF-β upregulation itself. Grb2-related adaptor protein (GRAP) was upregulated 
upon disease in the tubules and identified for the first time as a member of the TGF-β signalling 
pathway by an in vitro validation (Cummins, et al. 2010). A number of proteins associated with 
metabolism and oxidative stress were also highlighted by this study (Cummins, et al. 2010). 
Interestingly, the redox protein thioredoxin (TXN) was also upregulated in kidney in these 
diabetic mice (Cummins, et al. 2010).  
On a similar model, few years before, another group identified 41 proteins differentially 
expressed in diabetic disease by 2-D gel and MS on whole kidney tissues (Thongboonkerd, et 
al. 2004). Among these proteins, they highlighted a downregulation of elastase IIIB and an 
upregulation of monocyte/neutrophil elastase inhibitor, suggesting an increase in elastin 
deposition in the kidney (Thongboonkerd, et al. 2004). Subsequent biochemical analysis 
indeed confirmed the alterations in the renal elastin-elastase system in type 1 diabetic 
nephropathy (Thongboonkerd, et al. 2004). Other interesting findings were the upregulation 
of proteins associated with myofibroblast activation (vimentin, tropomyosin, myosin, etc.) and 
protease inhibitors (antithrombin-IIIb, serine protease inhibitor EIA or serpin, etc.), as well as 
the identification of complement proteins (inflammatory response) and calcium binding 
proteins such as calmodulin and calbindin (Thongboonkerd, et al. 2004). 
In a study employing the rat SNx model of CKD, in 2005, Xu and colleagues performed MS on 
isolated glomerular tissue collected by laser capture microdissection (LCM) (Xu, et al. 2005). 
MALDI-MS led to the detection of 1473 distinct protein peaks, of which 251 were identified as 
significantly differentially expressed protein compared to the controls. Among these proteins, 
thymosin-β4 was identified as the main protein marker of sclerosis, with a proposed  direct 
involvement in the fibrotic process (Xu, et al. 2005). 
 
3.2.2.1  Mass spectrometric studies of the UUO model 
Few proteomic studies employing MS have been performed in the UUO model in recent years 
and, as far as we are concerned, none of these works has been performed employing the highly 
sensitive and quantitative SWATH data acquisition approach employed in this Thesis (Table 
3.1).  
In 2015, Yuan et al. published a study in Scientific Reports (Yuan, et al. 2015) with the aim of 
identifying specific urinary biomarkers of obstructive nephropathy. In their study, they 
employed male Sprague-Dawley rats in which UUO was performed in the left kidney, and Sham 
operated rats that were used as controls. The expression of proteins was analysed by MS at one 
week and three weeks post-surgery on three randomly selected male rats per treatment and 
exclusively on urinary proteins, obtained by acetone precipitation of cleared urine, collected at 
the abovementioned time-points from the residual left ureter. Data were collected by LC-
MS/MS using a shotgun approach on a Triple TOF 5600 mass spectrometer (SCIEX). To 
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determine which proteins were significantly altered by UUO, fold change analysis on spectral 
counts was performed, and proteins with a p-value ≤ 0.05 and at least 2-fold change from the 
control were regarded as significantly altered by UUO. They identified 7 proteins significantly 
increased by UUO after one week and 19 significantly overexpressed at three weeks, compared 
to the sham operated control. Only two proteins were found upregulated both after one week 
and three weeks. They considered the proteins upregulated at one week as possible 
biomarkers of renal tubular injury, while the ones overexpressed at three weeks, when the 
development of CKD has already reached a high grade of severity, were considered as markers 
of UUO-induced renal interstitial fibrosis. Among these proteins, the main urine biomarkers 
highlighted by the study were vimentin, α-actinin-1, moesin, annexin a1 and clusterin, all 
correlated with the progression of disease. Vimentin is a marker of EMT and mesenchymal cell 
activation. α-actinin-1 has been described as a marker of a series of nephropathies and is an 
element of the glomerular filtration barrier (Renaudineau, et al. 2007). Moesin is a cytoskeletal 
protein recently associated with CKD (Chen, et al. 2014), while annexin A1 is involved in 
inflammatory processes as well as in apoptosis. Clusterin has been associated with both acute 
kidney injury and aging of the organ (Fuchs and Hewitt 2011, Trougakos and Gonos 2006).  
In the same year, Zhao and colleagues published a study on the International Journal of Clinical 
Experimental Pathology (Zhao, et al. 2015b). Also this study was performed in Sprague-Dawley 
rats, of both sexes in this case, but the rats were subjected to UUO of left kidney for a shorter 
time (12, 24 and 72 h)(Sham operation as control) and MS was performed on whole kidney 
tissue rather than urine. Total lysates of six left kidneys/treatment were pooled together and 
separated by 2-D gels in three replicas, and relative volume of spots (% of total volume) was 
quantified by 2-D gel analysis software. The spots with a significant (p ≤ 0.05) alteration in size 
of at least 1.5-fold were analysed by MALDI-TOF/TOF MS and, as a result, 39 proteins were 
identified as significantly differentially expressed upon UUO, of which some were individuated 
as underexpressed and some as overexpressed. The proteins identified were associated with 
cytoskeletal regulation, signalling, apoptosis etc. However, a number of proteins associated 
with mitochondrial energy production and glucose metabolism were recognised, which are 
typical of a healthy living and proliferating cell.  
The main result of this paper was the identification of a number of antioxidant proteins, such 
as glutathione S-transferase, glutathione peroxidase, peroxiredoxin and aldose reductases, 
upregulated at the earlier time points (12 and 24 h). The authors explained this as the effect of 
an immediate oxidative stress due to a reduction in blood/oxygen supply (hypoxia or 
ischemia), which leads to release of ROS. This antioxidative response of the cell appeared to 
happen early after obstruction. On the contrary, no sign of upregulation of antioxidant proteins 
was identified at 72 h post-UUO, and even a downregulation of glutathione S-transferase and 
peroxidase was reported at this time-point.  
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Table 3.1: Some representative proteomic studies of CKD employing MS, with number (nº diff) 
of differentially expressed proteins detected upon disease.  
 
Reference 
Animal and 
Treatment 
Sample 
N 
(samples) 
Technique 
nº 
diff 
Main findings 
Varghese et al., 
2007 
Human, patients 
with 
Either diabetic 
nephropathy, 
FSGS, lupus 
nephritis, 
membranous 
nephropathy and 
proteinuria >3 g/d 
Urine 32 
2-DE + 
MALDI-TOF 
MS/MS or 
2-DE+ LTQ 
linear ion 
trap MS a 
20 
Plasma proteins 
in urine 
Gong et al., 
2009 
Mice, STZ-Treated Tissue 4/group 
iTRAQ
TM
 
labelling 
+ LC-
MS/MS 
88 
Redox regulation, 
Apoptosis, ECM 
proteins 
Thongboonkerd 
et al., 2004 
Mice, OVE26 type 1 
diabetic (Diabetic 
nephropathy) 
Tissue 5/group 
2-DE + 
MALDI-TOF 
41 
Elastin 
accumulation, 
Myofibroblast 
actovation, 
chaperone 
proteins 
Cummins et al., 
2010 
Mice, OVE26 type 1 
diabetic (Diabetic 
nephropathy) 
Tissue 
(Tubules) 
2/group 
2-DE + LC-
MS/MS 
476 
TGF-β signalling 
pathway 
Xu et al., 2005 
Rat, SNx 
12 weeks 
Tissue 
(Glomeruli) 
6 Rats 
30-50 
glomeruli/group 
MALDI-MS 251 Thymosin β4 
Yuan et al., 
2015 
Rats, UUO 
1 week and 3 weeks 
Urine 3/group LC-MS/MS 23 
Vimentin, Alpha-
actinin-1, Moesin, 
Annexin A1 and 
Clusterin 
Zhao et al., 
2015 
Rats, UUO 
12, 24 and 72 hours 
Tissue 3/group 
2-DE+ 
MALDI-
TOF/TOF 
39 
Antioxidant 
proteins 
(Glutathione S-
transferase, 
Glutathione 
peroxidase, 
Peroxiredoxin 
and Aldose 
reductases) 
upregulated at 
the earlier time 
points 
 
2-DE: 2-dimension gel electrophoresis; MS: Mass spectrometry; MS/MS: Tandem mass spectrometry; LC: 
Liquid chromatography; iTRAQ™: Isobaric Tag for Relative and Absolute Quantitation; MALDI: Matrix-
Assisted Laser Desorption/Ionization; TOF: Time of Flight  
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 3.3 EXPERIMENTAL PROCEDURES 
 
3.3.1 Experimental model  
3.3.1.1 TG2-null (TG2-KO) mice and wild type (WT) inbred C57BL/6J mice 
In this study both TG2-null (TG2-KO) mice and wild type (WT) inbred C57BL/6J mice were 
employed. TG2-null mice were obtained with an homologous recombination approach as 
reported by De Laurenzi and Melino in 2001 (De Laurenzi and Melino 2001). This approach is 
based on the employment of a targeting pPNT plasmid with neomycin (Geneticin) resistance 
that deletes a portion of exon 5, exon 6, all intron 5 and the beginning of intron 6 of Tgm2 
sequence (Fig. 3.2). In order to produce TG2-null mice, the linearized vector needs to be 
inserted into embryonic stem cells, that are then selected with neomycin and ganciclovir. 
Positive clones are injected into C57BL/6J blastocysts and then transferred into pseudo-
pregnant females (De Laurenzi and Melino 2001). Mice were obtained from Prof. Gerry Melino, 
they were backcrossed at least six times with WT mice at the Nottingham Trent University 
(NTU) animal house by licenced technicians, then genotyped in house by Dr Alessandra 
Scarpellini. All experimental procedures were carried out under licence in accordance with 
regulations laid down by Her Majesty’s Government, UK (animals scientific procedures act 
ASPA, 1986), and were approved by NTU ethical review committee (ASPA ethical review 
process).  
 
 
Figure 3.2: Obtainment of TG2-null mice using an homologous recombination approach. The 
figure, obtained from De Lurenzi and Melino (De Laurenzi and Melino 2001), shows how TGM2 sequence 
appears in WT mice (wild type) and in TG2-null mice (recombinant), where a part of the sequence, 
namely all intron 5 and exon 6 and a portion of exon 5 and intron 6, has been deleted. The targeting 
vector necessary for recombination is shown as well. Permission to reproduce this picture has been 
granted by The American Society for Microbiology.  
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3.3.1.2 Execution of unilateral ureteric obstruction (UUO) on WT and TG2-KO mice 
Experimental UUO was performed on both strains as described by Vielhauer et al. (Vielhauer, 
et al. 2001). The procedure was carried out at University of Sheffield (UK) by alicenced 
technician (Dr Linghong Huang). Mice were anaesthetized with 5% (v/v) fluorothane and the 
anaesthesia was maintained with 2% (v/v) fluorothane during the surgical process, the left 
ureter of the mice was obstructed using a ligating clip (Hemoclip Plus, Weck Closure Systems), 
while the muscle wall was sealed with single cross-over stitching using dissolvable stitches. 
ADEPT® adhesion reduction solution [4%(w/v) icodextrin] (Baxter Healthcare, Illinois, USA) 
was dispensed in the peritoneum in order to prevent post-surgical adhesions prior to closing. 
After the procedure, buprenorphine, an opioid-derivate, was administered to the mice at 10 
mg/kg for 40 h for pain-relief. The animals were allowed to eat and drink without restrictions. 
Mice were sacrificed and kidneys harvested 21 days post-operation. Kidneys were snap-frozen 
and stored in liquid nitrogen until needed. When needed, left kidneys were removed from 
liquid nitrogen and employed for the different experiments as described in 3.3.1.3.  
All experimental procedures were carried out under licence in accordance with regulations 
laid down by Her Majesty’s Government, UK (animals scientific procedures act ASPA, 1986), 
and were approved by the University of Sheffield animal ethical review committee (ASPA 
ethical review process). 
 
3.3.1.3 Numerical dimension of the study  
For the aims of this thesis, a total of 32 WT and 32 TG2-KO inbred C57BL/6J mice were 
employed. Half of these mice (16 WT and 16 TG2-KO) were subjected to UUO and the remaining 
to a Sham operation for 21 days. Samples were distributed as follows in the different 
experiments (Fig. 3.3):   
1. Validation of the UUO model: 6 WT Sham operated kidneys (3 females and 3 males), 6 
WT UUO kidneys (3 females and 3 males), 6 TG2-KO Sham operated kidneys (3 females and 
3 males) and 6 TG2-KO UUO kidneys (3 females and 3 males), all randomly selected, were 
employed for the validation of the UUO model. Specifically:  
a. One WT female Sham operated kidney quarter, one WT female UUO kidney quarter, 
one TG2-KO female Sham operated kidney quarter and one TG2-KO female UUO 
kidney quarter were paraffin embedded, sectioned and stained for histological 
analysis as described in 3.3.2.  
b. Six WT Sham operated kidney quarters (three females and three males), six WT 
UUO kidney quarters (three females and three males), six TG2-KO Sham operated 
kidney quarters (three females and three males) and six TG2-KO UUO kidney 
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quarters (three females and three males) were homogenized and employed for 
Western blotting as described in 3.3.3.  
c. Three WT Male Sham operated kidney quarters, three WT Male Sham operated 
kidney quarters, three TG2-KO Male Sham operated kidney quarters and three 
TG2-KO Male UUO kidney quarters were homogenized and tested for TGF-β1 
activity as described in 3.3.4.  
2. Proteomic analysis of the UUO model: Halves from four WT Sham operated kidneys 
(three females and one male), four WT UUO kidneys (three females and one male), four 
TG2-KO Sham operated kidneys (three females and one male) and four WT TG2-KO kidneys 
(three females and one male ) were employed for the SWATH-MS proteomic analysis of the 
UUO model on total kidney lysate described in paragraphs 3.3.5 and 3.3.6, in order to have 
4 biological replicas to compare for each group.   
3. TG2-interactome in the UUO model (described in Chapter IV): for this study, only male 
mice were employed to reduce gender/hormonal bias. A total 12 WT Sham operated 
kidneys, 12 WT UUO kidneys, 12 TG2-KO Sham operated kidneys (necessary as Sham 
operated background for the analysis) and 12 TG2-KO UUO kidneys (necessary as UUO-
background for the analysis) were homogenized, fractionated, pooled in pairs and TG2-
immunoprecipitated (TG2-IP) as described in the next chapter. SWATH acquisition-MS 
proteomic analysis was then performed on 5 TG2-IP samples while the sixth ones of each 
group were combined and used for the production of the spectral library.  
 
As this was the first time a proteomic study was performed on the UUO model of kidney fibrosis 
employing the highly sensitive SWATH-data independent acquisition approach, no data were 
available to perform a power calculation prior to the experiments, in order to determine the 
minimal number of required biological replicas. For this reason, an arbitrary number of 
kidneys was chosen for each MS experiment basing on the advice of the NTU proteomic group 
of John Van Geest Cancer Research Centre and the limited number of kidneys available. Power 
calculation was performed a posteriori to confirm the adequacy of the employed sample size 
as described in 3.3.9.  
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Figure 3.3: Distribution of kidney samples in the different experiment performed. Graphical 
representation of distribution of the 32 WT kidneys (16 Sham-operated and 16 UUO, 21 days) and the 
32 TG2-null kidneys (16 Sham-operated and 16 UUO, 21 days) in the SWATH - MS experiments described 
in Chapter III (UUO-Proteome) and IV (TG2-interactome in UUO) as well as in the validation histological 
and biochemical experiments described in Chapter III. In the validation experiments, portions from the 
same kidneys used in the SWATH acquisition-MS experiments were employed. Legend:* = quarters of 
the same kidneys used for the SWATH proteomic analysis of UUO (3 females). ** = a quarter from the 
same kidney used for the SWATH proteomic analysis of UUO (1 male) was employed while the other 2 
kidney replicas were portions of kidneys used for the SWATH TG2-interactome study of Chapter IV.  
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3.3.2 Haematoxylin and eosin (H&E) staining and Masson’s trichrome (MT) 
staining  
Haematoxylin and eosin (H&E) staining is one of the main type of staining employed in 
histology, allowing a general detection of tissue morphology. Haematoxylin is a blue/purple 
natural stain derived from the Logwood tree wood. In its original form, haematoxylin has a low 
staining capacity, hence it is usually oxidised to haematein and combined with aluminium, used 
as a mordant for the dye, to form haemalum. Most haematoxylin stainings [Mayer (Mayer 
1891), Ehrlich's (Ehrlich 1886), Harris (Harris 1900), Gill’s (Gill, Frost and Miller 1974) etc.], 
are based on the formation of this metal-dye complex. In other cases, such as Weigert's 
haematoxylin (Weigert 1904), the metal employed is iron; these are used when the subsequent 
stains are acidic. Haematoxylin binds acidic and negatively charged compounds such as DNA 
and RNA (basophils), that will be stained in blue/purple. Other basophil compounds in the cells 
will have a purple-red colour. Eosin is a synthetic pink/red staining derived from fluorescein. 
It is an acidic compound that binds to basic and cationic complexes such as positively charged 
aminoacidic chains (eosinophiles); for this reason, it mainly stains cytoplasm and extracellular 
compounds: cytoplasm and muscular fibres are stained in red or dark red, while collagen and 
mitochondria will have a pink colour.  
Masson’s trichrome (MT) staining is a three-colour staining procedure and it is one of the most 
common stainings employed for the detection of organ fibrosis. This staining allows to detect 
simultaneously nuclei, cytoplasm and collagen/bone and determine the accumulation of the 
last over the others. It is based on three different stainings: first, the abovementioned Weigert's 
iron haematoxylin (Weigert 1904), that stains the nuclei in brown/dark blue, a second solution, 
containing acid fuchsin and xylidine Ponceau, is used to stain the cytoplasm in pink, and finally 
a third staining, that can be green or blue, will stain the fibrillar collagen.  
H&E staining and MT staining were performed on paraffin-embedded kidney sections. 
Normally, kidneys, or kidney portions, should be fixed in formalin from fresh, as soon as they 
are extracted from the mice. This is because a freezing-thawing process might introduce 
ruptures in the kidney tissue that will affect the integrity of the final section. In this case, 
unfortunately, not having freshly extracted kidneys, we had to employ frozen samples (kidney 
quarters) stored in liquid nitrogen. To make the thawing process as delicate as possible, we 
proceeded as follows: kidneys were removed from liquid nitrogen and directly placed in dry 
ice (-78.5°C) for transferring to the freezer. The organs were kept at -80°C for 1 h, then placed 
in dry ice (-78.5°C) and transferred at -40°C for 2 h and finally at -20°C for 2 h. Transfers from 
freezers were as quick as possible, and performed in ice. Kidneys were then left to thaw on ice 
for 45 min and in the fridge (4°C) for 30 min. Finally, they were allowed to reach room 
temperature on the bench for additional 30 min. Once defrosted, kidneys were fixed in 10% 
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formalin [4% (w/v) PFA] in PBS pH 7.4 for 36 h, at room temperature and in gentle rotation 
(60 rpm). After fixation, they were washed 3 times with PBS pH 7.4 and left in PBS until paraffin 
embedding. The day after, samples were delivered to the University of Sheffield (UK), where 
paraffin embedding, sectioning and staining were carried out at the Department of Infection, 
Immunity & Cardiovascular Disease by Dr Fiona J. Wright.  
Pictures of stained kidney slides were taken by the author at NTU with an Olympus BX61 
fluorescent microscope (Olympus, Japan), set on bright field acquisition, with Cell^F imaging 
system software (Olympus, Japan). For quantification of kidney fibrosis from MT staining, the 
% area of the different colours (dark blue, red/pink, light blue) was quantified on Cell^F 
following the manufacturer’s guidelines, on at least 24 different fields per treatment, making 
sure to include both tubular and glomerular areas of the kidney. The “phase selection” function 
of the software was used to determine the areas and the level of fibrosis was measured either 
as a ratio of phase 2 (collagen, light blue) over phase 1 (cytoplasm, red/pink) or as a ratio of 
phase 2 (collagen, light blue) over phase 3 (nuclei, dark blue). 
 
3.3.3 Immunoprobing of TG2 and the fibrosis marker α-smooth muscle actin 
in kidney lysates 
10% (w/v) kidney homogenates were prepared in a sucrose based lysis buffer [0.32 M sucrose, 
5mM Tris-HCl, 2mM EDTA, pH 7.4] containing 1:100 (v/v) protease inhibitors cocktail (P8340, 
Sigma). Mechanical homogenization was performed on ice using an Ultra Turrax T25 
Homogenizer (Merck).  
Equal amounts of proteins were resolved by 12% (w/v) acrylamide/bis-acrylamide SDS-PAGE 
under reducing condition. Immunodetection of the proteins of interest was performed by 
Western blot as described in the general methods using the antibodies reported in Table 3.2 
in blocking buffer [5% (w/v) non-fat milk in TBST pH 7.4]. Immunoreactive bands were 
detected by enhanced chemiluminescence (EZ-Chemiluminescence Detection Kit for HRP, 
Geneflow) after incubation with an appropriate HRP-conjugated secondary antibody (Table 
3.2) in blocking buffer as described in the general methods. Image acquisition was performed 
with a LAS4000 imaging system (GE Heathcare) and comparison of protein band intensity was 
obtained by Aida Image Analyzer v.4.03 (Raytest, Germany), following the manufacturer’s 
instructions.  
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Table 3.2: List of antibodies employed on whole kidney lysates to validate the UUO model on WT 
and TG2-null mice. The table shows the details of primary and secondary antibodies employed for 
Western blot immunodetection on whole kidney lysates. Details of dilution used in blocking buffer [5% 
(w/v) non-fat milk in TBST pH 7.4] are reported in the table. 
Primary antibodies Company Dilution 
Mouse monoclonal anti-transglutaminase-2 (TG2) (IA12) University of Sheffield (UK) 1: 5000 
Mouse monoclonal anti-alpha-smooth muscle actin (α-SMA) 
[1A4] (ab7817) 
Abcam (UK) 1:1000 
Rabbit polyclonal anti-cyclophilin-A (ab41684) Abcam (UK) 1:1000 
Rabbit polyclonal anti-β-tubulin (ab6046) Abcam (UK) 1:2000 
Secondary antibodies Company Dilution 
Goat anti-rabbit IgG HRP-conjugated Dako (Denmark) 1:2000 
Goat anti-mouse IgG HRP-conjugated Dako (Denmark) 1:1000 
 
  
3.3.4 Detection of TGF-β1 activity in kidney homogenates by mink lung 
epithelial cell (MLEC) bioassay  
In order to measure TGF-β1 activity of the total kidney homogenates, the mink lung epithelial 
cell (MLEC) bioassay (Abe, et al. 1994) was performed as described before (Scarpellini, et al. 
2014, Huang, et al. 2010a). A 10% (w/v) kidney homogenate was prepared in homogenization 
buffer [0.25 M sucrose, 10 mM Tris-HCl, 1 mM MgCl2, 2 mM EDTA, pH 7.4] containing 1:100 
(v/v) protease inhibitors cocktail (P8340, Sigma). Mechanical homogenization was performed 
on ice using an Ultra Turrax T25 homogenizer (Merck). Each homogenate was centrifuged at 
1000 g for 5 min at 4°C to remove large particulates, then the supernatant diluted 1:10 in 
sterile-filtered (2 µm, Sartorius Stedim) serum-free DMEM with 0.1% (w/v) BSA. 100 µl of this 
solution was applied to the MLEC in a 96-well plate (5x104 cells/well) and incubated for 22 h. 
Cells were then washed twice with PBS and lysed in 1X Reporter Lysis Buffer (Promega). 50 µl 
of cell lysate were mixed to an equal volume of luciferase substrate (Promega) and light 
emission was measured with Polarstar Optima luminometer (BMG Labtech). Total TGF-β1 was 
also measured by acid treatment of the kidney homogenate prior incubation with the MLEC 
system (Van Waarde, et al. 1997). The experiments were performed by Dr. Nina Schroeder at 
NTU, analysis and interpretation of results was performed by the author.  
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3.3.5 Sample preparation for mass spectrometry (MS) analysis in whole 
kidney lysates 
Sham operated and UUO kidneys from both WT and TG2-KO mice (four per treatment, of both 
genders) were collected from the liquid nitrogen storage and quickly ground in liquid nitrogen 
using pestle and mortar, in sterile conditions and avoiding cross-contamination. A 10% (w/v) 
tissue homogenate was prepared in “proteomics lysis buffer” containing 9.5 M urea, 
2%(w/v) DTT, 1% (w/v) N-Octyl-Beta-Glucopyranoside (OGP) and protease inhibitors 
(Sigma). Sonication (amplitude 5 µm, 5 sec, 3 times) was performed to induce mechanical 
breakage of the tissue. Equal amounts of total protein extracts (50 µg) were diluted in 50 mM 
tri-ethyl ammonium bicarbonate (TEAB) containing a final concentration of 0.02% (w/v) 
ProteaseMAX™ surfactant trypsin enhancer (Promega). Proteins were subjected to reduction 
(5 mM DTT, 56°C for 20 min) and alkylation (15 mM iodoacetamide at room temperature for 
15 min), then trypsin digested overnight at 37°C using 0.02 mg/ml MS grade trypsin (Promega) 
and 0.01% (w/v) ProteaseMAX™ surfactant in a thermomixer. Samples were vacuum 
concentrated to dryness and resuspended in 20 µl of 5% (v/v) acetonitrile/0.1% (v/v) formic 
acid for MS analysis. 
 
3.3.6 Mass spectrometry (MS) 
3.3.6.1 Mass spectrometry (MS), library production and SWATH data independent 
acquisition (DIA) 
The samples were analysed by reverse-phase high-performance liquid chromatography 
electrospray ionization tandem mass spectrometry (RP-HPLC-ESI-MS/MS) using the 
TripleTOF 5600+ mass spectrometer from SCIEX (Canada). The instrument is available for 
university staff and students at the proteomics facility lab of the John Van Geest Cancer 
Research Centre, NTU, and MS runs have been performed by Dr David Boocock, assisted by 
Clare Coveney and Dr Amanda Miles, using the samples prepared by the author.  
The mass spectrometer was used in two different modalities depending on the stage of the 
experiment: shotgun data dependent acquisition (DDA) was employed for spectral library 
construction, while SWATH - data independent acquisition (DIA) [described in (Gillet, et al. 
2012)] was used for the acquisition of quantitative data.  
Regarding the liquid chromatography, RP-HPLC mobile phases were solvent A [2% (v/v) 
acetonitrile, 5% (v/v) DMSO in 0.1% (v/v) formic acid in LC/MS grade water] and solvent B 
[LC/MS grade acetonitrile containing 5% (v/v) DMSO and 0.1% (v/v) formic acid]. Samples 
were directly injected onto an YMC Triart-C18 column (25 cm, 2µm, 300 um i.d) at 5 µl/min 
using microflow LC system (Eksigent ekspert nano LC 425) using an increasing linear gradient 
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of solvent B over solvent A going from 2% to 40% in a total time of 60 min (SWATH-DIA) or 
120 min (spectral library production by DDA). Regeneration and re-equilibration of the column 
were performed by loading 90% solvent B for 10 mins followed by 5% solvent B for 10 min. 
Auto calibration was performed by the MS every 4 samples using an injection of a standard of 
25 pmol β-Galactosidase digest. The electrospray ionisation, then, was carried out using 
PicoTip® nanospray emitters uncoated SilicaTips™ (New Objective Inc., USA), with voltage set 
to +2400 V. 
First, a spectral library was produced by DDA on a pool of all samples in high sensitivity mode. 
DDA mass spectrometry files were searched using ProteinPilot 5 (SCIEX, Canada): the analysis 
was conducted by the software with an exhaustive identification strategy, searching the 
UniProt Swiss-Prot database (January 2015 release) for murine species. The generated file was 
imported into PeakView 2.0 software (SCIEX, Canada) as an ion library and spiked in iRT 
retention time standards (Biognosys, Switzerland), after filtering for false discovery rate (FDR) 
of 1% and excluding shared peptides.  
SWATH-DIA was then performed on 4 kidney extracts per phenotype and treatment (WT or 
TG2-KO, UUO or Sham). Data independent detection was performed using 40 variable SWATH 
windows: during different cycles, the initial survey scan (TOF-MS) is performed for each 
window (SWATH), and the following MS/MS experiment is carried on the totality of the 
precursors detected in the SWATH using ion collision energy [reference for the method is 
provided in (Gillet, et al. 2012)]. Spectral alignment and targeted data extraction from the 
SWATH data was performed in PeakView 2.0 using the abovementioned reference spectral 
library generated by DDA. SWATH data was processed using an extraction window of 5 min 
and applying these parameters: maximum 6 peptides/protein, maximum 6 transitions, peptide 
confidence of >99%, exclude shared peptides, and XIC width set at 75 ppm.  
 
3.3.6.2 Targeted data extraction and fold change analysis 
Quantitation and fold change analysis between the different phenotype/treatment 
combinations were carried out using the OneOmics cloud processing software from SCIEX, 
employing weighted average of proteins spectral results among the different biological replica 
to calculate fold change and relative significance. The outcome of the experiment is a list of 
protein identification names (IDs), with log2 of fold change (FC) values (1), absolute FC values 
(2), p-values of FC [p-value(FC)] and confidence level of FC [C(FC)], all calculated by the 
software.  
 
log2[𝐹𝐶 𝐴 𝑣𝑠 𝐵 (𝑋)] =  log2
𝑀𝑒𝑎𝑛 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑋 𝑖𝑛 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝐴
𝑀𝑒𝑎𝑛 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑋 𝑖𝑛 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝐵
 
𝐴𝑏𝑠 𝐹𝐶𝐴 𝑣𝑠 𝐵(𝑋) = 2
|log2[𝐹𝐶 𝐴 𝑣𝑠 𝐵 (𝑋)]| 
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Under suggestion of Dr David Boocock and the SCIEX technical assistance for the software, 
confidence level was chosen to be a better measurement of the significance of the fold change, 
over the most commonly used p-value. In fact, in the software, the C(FC) takes into account the 
variance among the values and the number of peptides identified per protein, while the p-
value(FC), which is calculated in an unweighted manner, does not. While in the confidence level 
all the values are weighted by their variance (obtained by multiple linear regression, MLR), in 
the case of the p-values all the values are considered equally, regardless of the variance 
between measurements. This means that, in cases where there is a large variance between 
measures or the number measures are low, lower p-values might be an artefact of the high 
variance among the measurements and not the effect of the change itself, while in the case of 
confidence all the values that have low reproducibility are weighted out. As a general rule, fold 
changes with a C(FC) higher than the 0.80 (80%) were regarded as highly significant.  Values 
with confidence between 0.80 (80%) and 0.5 (50%) were acceptable but less significant, and 
values with C(FC) lower than 0.5 should not be considered as significant. In the analyses 
performed in this thesis, data were regarded as significantly differentially expressed upon 
treatment at C(FC) higher than 0.80 (80%).  
 
3.3.7 Bioinformatic analysis 
Once a list of significant proteins was obtained, it was analysed with a series of bioinformatics 
approaches aimed to define the overrepresented functions, biological process and pathways 
for the differentially expressed proteins, and determine protein-protein interactions.  
Full names of the proteins were obtained by manual search of protein IDs on UniProtKB 
(http://www.uniprot.org/uniprot) database.  
Functional classification and functional overrepresentation analysis were performed using 
two different open source bioinformatics resources: DAVID (Database for Annotation, 
Visualization, and Integrated Discovery) bioinformatics resource 6.7 
(http://david.abcc.ncifcrf.gov) (Dennis, et al. 2003) and PANTHER (Protein ANalysis THrough 
Evolutionary Relationships) database (http://www.pantherdb.org) (Mi, Muruganujan and 
Thomas 2013). In both cases, the whole Mus musculus genome was employed as background 
gene list.  
 
3.3.7.1 Functional classification  
Functional classification was performed using the Gene Ontology (GO) terms for Biological 
Process, Molecular Function and Cellular Component in addition to PANTHER Protein Class 
terms and PANTHER pathways. Gene Ontology (GO, http://geneontology.org) is a project that 
unifies the scientific terminology of gene product attributes / proprieties across the different 
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species. It provides a clear and organized vocabulary (ontology) of terms representing gene 
product properties. These terms are defined, standardized and associated with specific codes, 
so that gene products are clearly associated with a series of specific annotations depending on 
their functions.  GO contains roughly 25,000 terms, that are species-aspecific, hence can be 
applied to a wide range of species both bacterial or eukaryotic. GO terms are organised in larger 
general groups in which are nested narrower groups of more specific terms (child terms). At 
the top level, GO terms are divided in three different major ontologies, describing:  
 Biological Processes: multi-step complete processes performed by groups of molecules 
having specific function and acting together. Metabolic processes, cell organization 
processes, signalling events etc. are part of this group.  
 Molecular Functions: differently from biological processes, are single elemental activities 
that are performed by a molecule. For example, catalytic activity, binding, hydrolysis, 
kinase activity etc. are in this group.  
 Cellular components: portions of the cell or the extracellular environment in which the 
gene products can be detected.  
GO terms associated with the proteins in the list were identified using PANTHER and were 
visualized in pie charts as percentage of representation of the specific GO annotation term (hits 
of that specific annotation term, or class) over the total number of class hits (for all the 
annotation terms individuated in the list of proteins.  
It is important to remember that the percentage of representation is considered over the total 
class hits and not over the total amount of proteins: in fact, since a protein ID might fit in more 
than one GO annotation (class hit) or in no one, the total number of class hits is generally 
different from the total number of proteins.  
The same analysis was performed using PANTHER Protein Class annotation terms, a set of 
descriptors that identify classes of proteins (for example Cytoskeletal proteins, Kinases, 
Transcription factors, Chaperones, Signalling molecules, etc.) and PANTHER pathways, 
annotation terms associated with biological pathways at the whole organism level. For both 
groups, the different terms/keywords have been searched and organised using PANTHER 
bioinformatics tool and even if they generally overlap (protein can fall in different terms) and 
interact, they are not nested in classes and sub-classes or pathways and sub-pathways.  
 
3.3.7.2 Statistical overrepresentation test  
Functional overrepresentation test was performed in PANTHER using the same GO terms 
(Biological Process, Molecular Function, Cellular Component), PANTHER Protein class and 
PANTHER Pathways annotations, to determine the enrichment of specific classes comparing 
to the same terms representation in the entire Mus musculus genome (Mi, et al. 2013).  
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The overrepresentation analysis allows, given a list of proteins uploaded by the user, to 
determine which annotation terms are significantly over-represented or under-represented. It 
is also referred as enrichment analysis.  
The statistical overrepresentation test is based on the comparison of annotation terms’ 
distribution in the user’s list of proteins with the distribution of the same annotation terms in 
the reference list, that is usually the organism genome and should contain all the proteins in 
the user’s list. An expected value (which represent the null hypothesis H0) (1) and an observed 
value (2) are calculated for each annotation term X individuated by the user’s list, as follows. 
Being N the total number of genes in the reference list, K the total number of genes in the user’s 
uploaded list, n(X) the number of genes belonging to annotation term X in the reference list 
and k(X) the number of genes belonging to the annotation term X in the user’s list, the values 
are calculated as:  
 
(1) 𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑  𝑣𝑎𝑙𝑢𝑒 𝑓𝑜𝑟  𝑋 =
𝑁 𝑔𝑒𝑛𝑒𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑙𝑖𝑠𝑡 𝜖 𝑋
𝑡𝑜𝑡 𝑁 𝑔𝑒𝑛𝑒𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑙𝑖𝑠𝑡
∙ 𝑡𝑜𝑡 𝑁 𝑔𝑒𝑛𝑒𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑢𝑠𝑒𝑟′𝑠 𝑙𝑖𝑠𝑡 
=
𝑛(𝑋)
𝑁
∙ 𝐾 
(2) 𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 𝑓𝑜𝑟 𝑋 =  𝑁 𝑔𝑒𝑛𝑒𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑢𝑠𝑒𝑟′𝑠 𝑙𝑖𝑠𝑡 𝜖 𝑋 = 𝑘(𝑋)  
 
At this point the H0 hypothesis is that the annotation term X is distributed in the same way in 
the User’s list and in the reference list, hence 
𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 𝑓𝑜𝑟 𝑋
𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 𝑓𝑜𝑟 𝑋
= 1 .  
If  
𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 𝑓𝑜𝑟 𝑋
𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 𝑓𝑜𝑟 𝑋
> 1 there is an overrepresentation, or enrichment, if 
𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 𝑓𝑜𝑟 𝑋
𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 𝑓𝑜𝑟 𝑋
<
1 there is an underrepresentation.  
The statistical method used to calculate if this change is significant is called binomial test.  
The null hypothesis H0 (3) of this test is that the annotation term is distributed equally in the 
reference and in the User’s list, hence probability P(X) of finding a gene from the annotation 
term X in the User’s list is the same probability of finding the annotation term in the Reference 
list.  
(3) 𝐻0: 𝑃(𝑋) =
𝑁 𝑔𝑒𝑛𝑒𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑙𝑖𝑠𝑡 𝜖 𝑋
𝑡𝑜𝑡 𝑁 𝑔𝑒𝑛𝑒𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑙𝑖𝑠𝑡
=
𝑛(𝑥)
𝑁
  
Knowing the hypothesis, the p-value (p) of the difference is calculated using this formula for a 
binomial distribution (4).  
(4)  𝑝 =  ∑ (
𝐾
𝑘(𝑥)
) 𝑃(𝑋)𝑘(𝑋)(1 − 𝑃(𝑋))
𝐾−𝑘(𝑋)
 
 
In this thesis, a p-value lower than 0.05 was regarded as significant.  
To confirm the findings obtained with PANTHER, ranking of significantly enriched functions, 
with fold change enrichment and relative p-value, was also obtained on DAVID bioinformatic 
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tool by statistical overrepresentation analysis, selecting the GO terms for Biological Process 
(GOTERM_BP_FAT), Molecular Function (GOTERM_MF_FAT) and Cellular Component 
(GOTERM_CC_FAT). Again, a p-value lower than 0.05 was considered significant.  
Pathway overrepresentation analysis was performed as well in DAVID comparing the 
representation of the different Kyoto Encyclopaedia of Genes and Genomes (KEGG, 
http://www.genome.jp/kegg) terms (KEGG_PATHWAY) in the user’s list to the expected 
pathway representation in mice. This analysis was coupled to the statistical 
overrepresentation analysis performed with PANTHER using the PANTHER Pathway 
keywords.  
 
3.3.7.3 Investigation of protein interactions using STRING 
In order to identify clusters and networks of interacting proteins, known and reported protein-
protein interactions in the list of candidates were analysed using STRING (Search Tool for the 
Retrieval of Interacting Genes/Proteins) v10 database (http://string-db.org) (Szklarczyk, et al. 
2015), that contains both known and predicted and both direct and indirect protein 
interactions. The network was produced by using confidence level greater than 0.4 (mild 
confidence, set by default by the software) and by removing all the unconnected proteins. The 
network was exported, and re-organized using the open source software Cytoscape v. 3.0.2 
(http://www.cytoscape.org).  
 
 
3.3.8 Statistical residual analysis in the protein spectral data obtained by 
SWATH-MS acquisition.  
3.3.8.1 Linear regression  
In statistics, a linear regression analysis is an analysis performed to identify the relationship 
between a dependent variable y and an independent, or explanatory, variable x, and, secondly, 
to infer how strongly dependent variable y can be predicted from an independent variable x. 
Given a series of n paired x and y numerical data, represented by points in the cartesian plane, 
the linear regression analysis individuates the best-fitting straight line through the points, 
called regression line (1). This line gives the predicted value y’ for a given independent variable 
x.  
𝑡: 𝑦′ = 𝑓(𝑥)               𝑡: 𝑦′ = 𝑚𝑥 + 𝑞 
 
The vertical distance between the point 𝑃𝑖(𝑥𝑖; 𝑦𝑖) and t is the error from the predicted value 
and is called residual (2). The regression line is defined as the line that minimizes the mean of 
the squared residuals (3).  
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𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙 = 𝑦 − 𝑦′ 
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙𝑠 =
∑ (𝑦𝑖 − 𝑦
′
𝑖)
2𝑛
𝑖=1
𝑛⁄  
 
The coefficient of correlation r is a key descriptor of the strength of the linear correlation 
between x and y and is defined as the mean of the product of standardized values for x and y 
(4, 5). The coefficient of correlation r is a value that goes from -1 to 1.  
 
𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑧𝑒𝑑 𝑥𝑖 =  𝑥𝑖
∗ =
𝑥𝑖−𝑎𝑣𝑒𝑟𝑎𝑔𝑒(𝑥)
𝑠𝑑(𝑥)
 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑧𝑒𝑑 𝑦𝑖 =  𝑦𝑖
∗ =
𝑦𝑖−𝑎𝑣𝑒𝑟𝑎𝑔𝑒(𝑦)
𝑠𝑑(𝑦)
 
𝑐𝑜𝑟𝑟𝑒𝑎𝑡𝑖𝑜𝑛 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑟 =  
∑ (𝑥𝑖
∗ ∙ 𝑦𝑖
∗)𝑛𝑖=1
𝑛⁄  
 
In normal linear model, the square root of r (called R2 or R-squared) is the fraction of variance 
explained (variance of the population-error variance). The higher is the value, the higher is the 
dependency of y from x.  
 
3.3.8.2 Analysis of residuals  
The analysis of residuals can be used to determine how significant is the difference of given y 
from its predicted value y’. For this reason, for the aims of this study, it can be used an 
alternative method, different from the fold change analysis, to determine which proteins are 
significantly altered in the UUO model compared to the Sham.   
To achieve this purpose, the protein intensity data obtained by quantitation with the 
abovementioned OneOmics cloud processing software (SCIEX) were first normalized within 
each sample dataset in order to be comparable among samples. For the aims of this thesis, UUO 
values for a given protein were considered as dependent variables (y) and Sham operated 
values for the same protein as the independent variables (x). Regression plots were produced 
in excel for each pair of samples (UUO-1 vs Sham-1, … , UUO-4 vs Sham-1, UUO-1 vs Sham-2, … 
, UUO-4 vs Sham-2, … , UUO-4 vs Sham-4;  a total of 16 pairs) and standardized residuals plots 
(difference between standardized y and standardized y’, calculated for each protein) were 
obtained as well for each samples. The mean standardized residual of every protein was 
calculated by averaging the standard residuals of all 16 pairs of samples for each protein in the 
list (6).   
𝑀𝑒𝑎𝑛 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙 (𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑋) =
∑ (𝑦𝑋,𝑖
∗ − 𝑦′𝑋,𝑖
∗ )216𝑖=1
16
⁄  
 
The distribution of residuals in the group of proteins approximates a normal standard Gaussian 
distribution (𝑚 = 0;  𝜎 = 1). The more distant the mean standard residuals are from m=0 the 
more significant will be the difference from the predicted values. Because of the proprieties of 
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the normal standard distribution, a value of higher than 1.96 or lower than -1.96 means a p-
value of approximately 0.05 (it is exactly 0.05 if we have 𝑛 → ∞ number of samples).  
The absolutes of the mean residuals can be plotted on a normal standard distribution in Office 
Excel (NORM.S.DIST function) to infer probability values (p-values).  
For this specific study on protein expression, the outcome of the residual analysis can be 
interpreted in this way: positive mean of residuals indicates that the protein is overexpressed 
in UUO (dependent variable y) compared to its predicted value, negative mean of residuals 
implies that the protein is underexpressed in UUO compared to its predicted value, p-value 
lower than 0.05 means that this difference is significant.  
 
3.3.9 Power analysis 
In statistics, the power of an experiment is the ability of the experiment to detect an effect if it 
exists and it is defined as the probability that the experiment to rejects 𝐻0 (null hypothesis, no 
effect) if 𝐻1 (alternative hypothesis, effect) is true.  
The power is equal to 1 − 𝛽, where 𝛽 is the probability of type II error, a false negative, that 
means the probability to accept 𝐻0 (null hypothesis, no effect) even if 𝐻1 is true. The higher is 
the power of the experiment, the higher will be the ability of that particular experimental 
design to properly detect the effect the researcher is investigating, if that effect exists, and 
consequentially, the lower will be the rate of false negatives.  
The power calculation, or power analysis, is a test usually performed during the experimental 
design, to determine a priori the minimum sample size necessary to have a trustable result, 
before sacrificing any sample. The power analysis is based on these six variables:  
 The effect size of the biological process 
 The standard deviation 
 The significance level (usually α = 0.05) 
 The desired power of the experiment, usually between 95 and 80% 
 The sample size 
 The alternative hypothesis (one-sided test vs two-sided test)  
Knowing this, the test is employed to calculate the minimum sample size knowing all the other 
variables and the desired power of the experiment. This kind of test is performed a priori, and 
the necessary information are obtained from previous studies on the same biological effect 
(literature). A series of statistical software and on-line tools allow to perform the power 
analysis automatically, by introducing some key statistical descriptors obtained by previous 
literature, mainly standard deviations, means and correlations, the significance level (usually 
α = 0.05) and the desired power of the experiment, which is usually higher than 80%. Knowing 
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these values a priori, the outcome of the test is the minimal number of samples necessary to 
get the desired power.  
Unfortunately, in some cases, no previous data are available for carrying out an a priori power 
calculation before sacrificing any sample.  This is the case of the SWATH-MS proteomic study 
on UUO performed in this thesis, because no proteomic studies have been performed before in 
this model with such a sensitive system. In addition to this, when working with large spectral 
datasets, information such as standard deviations are difficult to obtain from literature, or even 
to analyse all together, as to every single protein detected is associated with its own standard 
deviation among the different experimental replica, and the total number of proteins detected 
by SWATH-DIA can easily reach thousands. In these cases, a pilot study must be performed 
with an arbitrary number of individuals, and the power calculation has to be performed a 
posteriori using the outcome of this study, to determine if it allows a sufficient power, knowing 
the statistical variables obtained from the study itself (standard deviation, means, correlation 
between treated and untreated response, etc.…), or whether more individuals are necessary.  
The SWATH-MS experiment performed in this chapter on four independent kidneys/treatment 
can be considered as a pilot study performed by arbitrarily choosing the sample size. After the 
list of significantly overexpressed/underexpressed proteins was obtained in the study, a 
power analysis was performed on series of candidates, to determine the power of the 
experiment and decide whether the number of samples were enough for the study to be 
statistically acceptable. The power calculation was performed using the Dell Statistica software 
(Dell, Texas, USA) and asking the software to compare two different means (UUO or Sham) of 
dependent samples by T-test.  
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3.4 RESULTS 
 
3.4.1 Validation of kidney fibrosis in the UUO model by histological analysis 
As described above in this chapter, UUO leads to a rapid development of tubulointerstitial 
fibrosis, with enlarged and atrophied tubules, exposed basement membrane and accumulation 
of extracellular matrix in the interstitium. Given the rapidity of the process, clear differences 
should be seen by histological stainings of kidney sections between Sham Operated and UUO 
kidneys at 21 days post-operation, comparable to advanced-to-end stage level of kidney 
disease.  
To observe morphological changes and fibrotic tissue accumulation between healthy and 
fibrotic kidneys in C57BL/6J mice subjected to 21 days UUO, both H&E staining and MT 
staining were performed. In 2014, our group already demonstrated the development of 
fibrosis on a similar model of UUO performed for 21 days on the same mice strain, by MT 
staining as well as collagen staining, and results are published (Scarpellini, et al. 2014). For this 
reason, this analysis has merely validating purposes, aimed to provide a confirmation of a 
developed fibrosis in our samples.  
 
3.4.1.1 Haematoxylin and eosin (H&E) staining of UUO and Sham-operated kidney sections 
In order to qualitatively observe differences in kidney morphology upon UUO, H&E staining of 
paraffin embedded sections was performed and pictures were obtained as described in 3.3.2. 
In order to cover as much renal parenchyma as possible, pictures were taken both on the renal 
cortex and on the renal medulla. The staining highlighted a neat alteration in the organ 
morphology upon 21 days UUO (Fig. 3.4).  
In Sham operated kidneys (21 days), histology of the organ appeared healthy in both its 
glomerular and tubular portion (Fig. 3.4A). Renal corpuscle (Fig. 3.4A black square bracket; 
Fig. 3.4C, SHAM) appeared normally shaped: glomerulus was well vascularized with 
observable mesangial cells, while Bowman’s capsule appeared normal, with an intact podocyte 
layer and a clear undisrupted Bowman’s space (black arrow individuates one). In some cases, 
a continuum with the proximal convoluted tubule was seen.  
Proximal (P) and distal (D) convoluted tubules, in the cortical area, were normally shaped (Fig. 
3.4A) and a tight association of tubules could be observed. At a closer look (Fig 3.4D), proximal 
tubules (P) were roughly bean-shaped with a strong eosinophilic stain, while distal tubules (D) 
appeared round in section and with a more intense nuclear stain.  In the renal medulla (Fig. 
3.4A, M), descending and ascending loops of Henle and collecting ducts were clearly 
distinguishable and outlined by epithelial cells. In general, Sham-operated kidneys appeared 
CHAPTER III – RESULTS 
 
124 
 
well vascularised, with clear peritubular and glomerular capillaries outlined by endothelial 
cells.  
As expected, sections from kidneys at 21 days post-UUO showed a disruption of the renal 
structure typical of an advanced-to-end stage tubulointerstitial fibrosis (Fig. 3.4B). Cortical 
tubules (Fig. 3.4B; Fig. 3.4D, UUO) were mostly atrophied and lost their tight association, with 
formation of empty spaces between them, loss of a clear epithelial border and a larger 
interstitial space. Medullar tubules (Fig. 3.4B, M), as well, completely lost their structure and 
tight association, making difficult to distinguish the different parts. A general paler pink colour 
characterized the totality of UUO sections (Fig. 3.4B; Fig. 3.4C-D, UUO) and this is in 
agreement with the fact that H&E typically stains fibrillary collagen in a lighter red/pink, 
comparing to the darker red of cytoplasmic staining (Fischer, et al. 2008). Considering this, a 
paler colour would reflect the general cell flattening/loss and contemporaneous ECM 
accumulation. Peritubular capillaries were not as distinguishable as before. As reported before, 
the effect of UUO on glomerular cells is generally slower, being a model that affects primarily 
the tubules. In line with the theory, in the sections obtained a part of renal corpuscles (Fig. 
3.4B black square bracket individuates one, Fig. 3.4C-UUO) were still showing the typical 
structure and a clear vascularisation, even if they were perhaps experiencing a process of 
podocyte atrophy and scarring, hence displaying a lighter eosinophilic staining. Some 
glomeruli (Fig. 3.4B, Fig. 3.4C-UUO, asterisk to identify one) showed a focal 
glomerulosclerosis, with loss of capillary structure and typical glomerular sclerotic area rich 
in fibrous tissue.  
In conclusion, H&E staining allowed to detect obvious differences in renal morphology at 21-
days post UUO, compared to the Sham operated controls, with tubular atrophy and structural 
loss being the main observable features. The level of kidney damage can be considered similar 
to the later stages of an obstructive kidney disease (Huang, et al. 2006), even if, given the 
particular technique and the rapidity of the process, comparison with human disease is difficult 
(Chevalier, Forbes and Thornhill 2009). At the same time, from the histological appearance of 
the kidney tissue, Sham operated mice seem to have physiologically normal nephron structures 
and vascularisation, and can be safely referred as healthy mice, while UUO mice at 21 days can 
be referred as fibrotic mice.  
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Figure 3.4: Haematoxylin and Eosin (H&E) staining of kidney sections from UUO and Sham 
operated kidneys at 21 days post-surgery. H&E staining of paraffin sections was performed at the 
Department of Infection, Immunity & Cardiovascular Disease of the University of Sheffield by Dr Fiona J. 
Wright. Pictures were taken with an Olympus BX61 fluorescent microscope with Cell^F imaging system 
software (Olympus, Japan). (A,B) Representative images at 20X magnification of Sham (A) and UUO (B) 
kidneys at 21 days post-surgery. (C) Close up (80X) of Glomeruli. (D) Close Up (80X) of Proximal and 
Distal convoluted tubules in the cortical area. Legend: 1,2 = mostly cortical area;  3,4 = mostly medullar 
area; square bracket = renal corpuscle; arrow = Bowman’s space; P = proximal convoluted tubule; D = 
distal convoluted tubule; M = medulla; * = sclerotic glomerulus. 
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3.4.1.2 Masson’s trichrome (MT) staining of UUO and Sham-operated kidney sections 
Masson’s Trichrome (MT) staining, a well-established method to quantify the level of scarring 
in diseased kidneys, was performed on Sham-operated and UUO mice at 21 days post-surgery 
and pictures were obtained using an Olympus BX61 microscope as described in 3.3.2. Focus 
was put on both cortical and medullar area, making sure to include sufficient glomeruli and 
tubules in the pictures (Fig. 3.5). Similarly to the H&E staining, MT confirmed a substantial 
alteration in the organ morphology. In addition, dual-staining of collagen and plasma or 
collagen and nuclei allows to perform a quantification of kidney fibrosis (fibrotic tissue) as a 
result of fibrillary collagen accumulation and simultaneous flattening and/or loss of structural 
cells (Fig. 3.6).  
In Sham operated kidneys (21 days), normal glomeruli and tubules were observed (Fig. 3.5A), 
with the typical morphology of a healthy organ, as described in the previous section. Large red 
staining identified the cellular structures; tubules were tightly associated and had a clear 
epithelial border in both the cortical and the medullar area (Fig. 3.5A; Fig 3.5D). The renal 
corpuscle (Fig. 3.5A - black square bracket identifies one, Fig. 3.5C) was characterized by 
properly distributed mesangial cells and podocytes, in red, around the well vascularized 
capillary system of the glomerulus and enclosed in the typical Bowman’s space (black arrow). 
Kidneys appeared well vascularised both in the glomeruli and around the tubules. Little blue 
staining for fibrillary tissue was noted, limited to the interstitial space (Fig. 3.5A; Fig. 3.5D - 
white thick arrows identifies an example), the intramesangial ECM (Fig. 3.5A; Fig. 3.5C - white 
thin arrows identifies an example) and the basement membranes of both TECs and glomerular 
cells (Fig. 3.5A; Fig. 3.5C - white triangles identify some examples).  
Upon fibrosis (21 days post-UUO), a clear disruption of kidney parenchyma was observed in 
the MT staining (Fig. 3.5B). The plasma staining (red) was strongly reduced compared to the 
Sham operated kidneys: flattening and loss of tubular cells, and consequent tubular atrophy, 
was evident, while the reduced staining in the glomeruli might identify a loss in mesangial cells 
and podocytes. Tubules which lost their tight association and peritubular capillaries borders 
were less distinguishable from the remnant tubules and appeared enlarged (Fig. 3.5B, Fig. 
3.5C).  
Signs of glomerulosclerosis and corpuscular loss were evident in the cortex with loss of 
capillary structure and accumulation of sclerotic fibrillary tissue (white thin arrows to identify 
an example) among the few remnant mesangial cells. However, as shown with the H&E 
staining, glomerular sclerosis and loss is slower than tubulointerstitial fibrosis in this model, 
and some intact glomeruli were still present at 21 days post-UUO (black square bracket 
individuates one)(Fig. 3.5B, Fig. 3.5C). The blue staining was strongly augmented in UUO 
sections, in both cortical and medullar area, and revealed an accumulation of fibrous tissue 
mostly in the tubulointerstitial space (Fig. 3.5B, Fig. 3.5D - white thick arrows identify an 
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example), but also in atrophied corpuscles (Fig. 3.5B, Fig. 3.5C - white thin arrows to identify 
an example). Following cell loss (TECs and podocytes), exposed basement membranes (white 
triangles identify an example) were also evident in both tubular and glomerular sections. At a 
close look (Fig. 3.5, Fig. 3.5D), the location of cells, identified by dark brown stained nuclei, 
was also altered by fibrosis, possibly showing fibroblasts/myofibroblasts in the interstitial 
space, where they produce abundant matrix, as well as loss of the tubular epithelial border.  
Quantification of the different staining colours was performed with Cell^F software and the 
ratio of collagen over cytoplasm was measured to evaluate the accumulation of fibrotic tissue 
(Fig. 3.6A).  Significant collagen accumulation was identified at 21 days post-UUO (10.76±3.13 
fold from WT Sham, equalised to 1; p=0.002 **). A similar result was obtained by quantifying 
the level of collagen over the number of cells (brown staining of the nuclei) (Fig. 3.6B), with a 
3.19 ± 0.68 -fold increase in collagen deposition at 21 days post-UUO compared to Sham-
operated healthy controls (p=0.0003 ***).  
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Figure 3.5: Masson’s Trichrome (MT) staining of kidney sections from UUO and Sham operated 
kidneys at 21 days post-surgery. MT staining of paraffin sections was performed at the Department 
of Infection, Immunity & Cardiovascular Disease of the University of Sheffield by Dr Fiona J. Wright. 
Pictures were taken with an Olympus BX61 fluorescent microscope with Cell^F imaging system software 
(Olympus, Japan). (A,B) Representative images at 20X magnification of Sham (A) and UUO (B) kidneys 
at 21 days post-surgery.  (C) Close up (80X) of Glomeruli. (D) Close Up (80X) of Proximal and Distal 
convoluted tubules in the cortical area. Legend: 1,2 = mostly cortical area; 3,4 = mostly medullar area; 
square bracket = renal corpuscle; arrow = Bowman’s space; P = proximal convoluted tubule; D = distal 
convoluted tubule; * = sclerotic glomerulus; thick white arrow = interstitial space; thin white arrow = 
intraglomerular matrix; white triangles = basement membrane. 
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Figure 3.6: Quantification of renal fibrosis by Masson’s trichrome (MT) staining. In order to 
quantify the level of fibrosis WT mice subjected to UUO, quantification of MT-stained sections was 
performed with Cell^F imaging system software (Olympus, Japan). The level of fibrosis was measured 
as (A) ratio of phase 2 (collagen, light blue) over phase 1 (cytoplasm, pink) or as (B) ratio of phase 2 
(collagen, light blue) over phase 3 (nuclei, brown).  Data represent mean ratio values expressed relative 
to the WT Sham operated control (equalised to 1) ± SEM, n=24 different fields per treatment covering 
both cortical and medullar areas. Significance of the differences between treatments was determined by 
T-test: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
 
 
3.4.2 Expression of the fibrosis marker α-smooth muscle actin (α-SMA) in 
kidneys subjected to UUO 
α-SMA is a well-established marker of myofibroblasts proliferation during fibrosis 
progression. In order to validate the development of fibrosis in wild type kidneys subjected to 
UUO (21 days), whole kidney lysates were immunoprobed for α-SMA by Western blotting. At 
the same time, the expression TG2 was measured on the same lysates using a specific mouse 
monoclonal anti-TG2 antibody. In all experiments, constitutively expressed cyclophilin-A 
(CypA) was employed as a loading control.  
Previous studies on CKD have reported a predisposition to fibrosis development in adult males 
comparing to females. A series of studies have showed in the past that the progression of some 
non-diabetic renal diseases is faster in men then in women of the same age (Seliger, Davis and 
Stehman-Breen 2001, Neugarten 2002, Silbiger and Neugarten 2008), suggesting a possible 
involvement of male sex hormones in the process or a possible protective role of female 
hormones. Similar gender bias was also observed in aging animals and other spontaneous in 
vivo rodent models of CKD [reviewed in (Herrera 2010)]. This is generally not the same in 
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diabetic kidney diseases, where the impact of sex on the outcome in kidney is much more 
variable and might be associated with altered hormone levels during diabetes in either genders 
(Maric 2009). With this in mind, gender bias in protein expression was investigated as well by 
probing N=3 randomly selected kidneys per treatment from each sex.  
 
3.4.2.1 TG2 expression in whole kidney lysates 
In male mice, UUO determined a small but not significant increase in the expression of TG2 at 
21-days post-surgery comparing to the healthy mice (Fig. 3.7A,B): a 1.39 ± 1.14 fold change 
increase, in fact, was measured comparing to the sham operated control (equalized to 1) 
(p=0.61 not significant). In females (Fig. 3.7D,E), again, a small increase in TG2 signal was 
observed at 21-days post UUO, corresponding to a 1.51 ± 0.19 -fold change comparing to the 
sham-operated control. Again, the difference was not significant by T-test (p=0.16).  
These data suggest that, even if TG2 protein expression might increase upon fibrosis, the 
enzyme is not necessarily up-regulated in a significant manner upon CKD, in agreement with a 
previous study performed by our group in the UUO and AAN model of kidney fibrosis 
(Scarpellini, et al. 2014).  
Curiously, in some cases, and especially in female mice, a double band between 75 and 80 kDa 
was observed with the employed antibody, of which only the bottom band, more intense 
(asterisk), should be specific for the full length form of TG2.  
 
3.4.2.2 α-SMA expression in whole kidney lysates 
α-SMA signal was up-regulated at 21-days post-UUO in WT mice of both genders. α-SMA signal 
(~37 kDa) was absent or minimal in Sham operated kidneys, and strongly increased upon 
treatment. This is in agreement with previous studies where the myofibroblast marker was 
investigated in UUO [eg. (Xue, et al. 2003, Inazaki, et al. 2004)].  
In male mice (Fig. 3.7 A,C), 21-days UUO determined an average 22-fold increase in α-SMA 
expression comparing to the healthy controls, and varied in a range from ~12 to ~32-fold 
changes from Sham in the different samples (mean fold increase = 22.7±8.99-fold change from 
Sham, p=0.05). In female mice (Fig. 3.6 D,F), UUO showed a ~5-fold increase in α-SMA 
comparing with the Sham operated control (4.83±2.21), that was however not significant 
(p=0.24) given the variability of expression. The lower expression of α-SMA in female mice 
might reflect a gender bias in fibrosis development in this model, with a partial protection in 
female.  
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Figure 3.7: Expression of TG2 and fibrosis marker α smooth muscle actin (α-SMA) in kidney 
lysates from the UUO model at 21-days. Expression of TG2 and fibrosis marker α-SMA was detected 
by Western blot using the specific antibodies reported in Table 3.2. Experiment was performed on three 
different male kidneys/treatment (A-C) or three different female kidneys/treatment (D-F). Specific blots 
are shown on the left (A,D). Intensity of immunoreactive bands was quantified by densitometric analysis 
and normalised to constitutively expressed cyclophilin-A (CypA). The graphs represent mean 
normalised densitometric measurements expressed relative to the Sham operated control (equalised to 
1) ± SD, n = 3 kidney lysates per group, in either male (B,C) or female (D,F) mice. Significance of the 
differences between treatments was determined by T-test: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = 
p<0.0001, ns = not significant. 
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3.4.3 TGF-β activation in the UUO model  
TGF-β1 is a known mediator of tubulointerstitial fibrosis, influencing the expression of a 
number of fibrogenesis-associated proteins. TGF-β activity is known to be increased during 
fibrosis and sustain the progression of fibrosis (Roberts, et al. 1986, Böttinger 2007). In order 
to validate the increased activation of the cytokine upon UUO, the TGF-β activity bioassay on 
the mink lung epithelial cells (MLEC) system was performed on whole kidney lysates from both 
WT and TG2-null mice, subjected to UUO or Sham operation (Fig. 3.8). As expected, TGF-β 
activation, measured as active TGF-β / total TGF-β, was virtually null in sham operated kidneys. 
In fact, TGF-β is usually secreted the interstitial space as a response to inflammation, with 
infiltration of inflammatory cells that release the cytokine, a phenomenon that is generally 
transient or limited in physiological conditions. UUO for 21 days determined a strong 
significant increase in TGF-β activity, in agreement with previous measurement performed in 
the same model (Scarpellini, et al. 2014, Shweke, et al. 2008).  
 
 
Figure 3.8: Level of active TGF-β in kidney lysates from the UUO model in WT mice. In order to 
measure the activation of TGF-β in the UUO model (21 days), active and total TGF-β were assessed using 
100 µl of 10% (w/v) kidney lysate or acid-treated lysate, both 10 times diluted, on the MLEC system, as 
described in 3.3.4. The experimental data was collected by Dr Nina Schroeder at NTU. Data represent 
the mean % of active TGF-β ± SD, N=3. Significance of the differences between treatments was 
determined by T-test: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001 
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3.4.4 Proteomic analysis by SWATH-MS reveals a series of proteins 
differentially expressed in UUO mice 
3.4.4.1 Definition of a list of proteins differentially expressed by UUO 
Quantitative MS analysis employing a SWATH-DIA approach allows to achieve a large coverage 
of a sample’s proteome, with a much higher sensitivity than the targeted data acquisition 
approach or the shotgun-DDA approach and allowing to perform quantification of protein 
expression and quantitative comparisons among different samples (Gillet, et al. 2012). 
With the aim of determining proteins differentially expressed by UUO, SWATH-MS was 
performed on four randomly selected Sham operated kidneys and four randomly selected UUO 
kidneys, all harvested at 21 days post-surgery and belonging to both genders. Samples 
preparation and SWATH acquisition-MS was performed as described in 3.3.6, and the spectral 
analysis resulted in the detection of 2106 proteins expressed in the different samples.  
Fold change (FC) in proteins’ expression between UUO and Sham operated mice were 
calculated by SCIEX OneOmics processing software. The outcome of the OneOmics FC analysis 
between UUO and Sham operated samples, at a confidence of fold change [C(FC)] up to 0.5, can 
be found in the Supplementary information of this thesis (Suppl. Table 3.1).  
A C(FC) threshold of 0.8 (80%) was chosen to define the list of significant differentially 
expressed proteins upon UUO, when compared to the Sham operated control.  As a result, of 
the 2106 proteins expressed in the different samples, as detected by SWATH acquisition-MS, 
653 were identified as differentially expressed at 21 days post-UUO [C(FC) ≥0.8]. Of these 
proteins, 195 were upregulated upon UUO (Suppl. Table 3.5), while 458 (Suppl. Table 3.6) 
were downregulated by the treatment. Protein IDs were manually searched on UniProtKB and 
full protein names included in the lists.  
Table 3.3 and 3.4 highlight some of the most interesting proteins arose from a preliminary 
overview of the differentially expressed proteins at 21 days post-UUO.  
 
3.4.4.2 Preliminary observation of the UUO-overexpressed proteins 
Even before performing any kind of functional analysis on the proteins, it was already evident 
that many of the 195 proteins upregulated upon UUO were directly associated with the process 
of kidney fibrosis (highlighted in Table 3.3).  
As expected, collagens were identified as upregulated by UUO (Table 3.3 and Fig. 3.9A). 
Among the collagen subtypes identified, collagen type XII (COCA1_MOUSE), which is known to 
interact with collagen I, was identified as the most upregulated at 21 days post-UUO, with an 
~16 fold increase from the Sham operated controls, followed by collagen I and collagen III, both 
approximately 7.7-fold upregulated. Relative protein quantification performed by the 
software, basing on the normalized protein spectra, highlighted collagen I as the more 
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expressed collagen in UUO kidneys, followed by collagen III and collagen IV, the mayor 
structural component of the GBM (Fig. 3.9A). ECM glycoproteins fibronectin (FN, 
FINC_MOUSE), fibrillins and fibulins were all strongly upregulated by the disease, with fold 
increase from the Sham operated conditions going from ~6 (FBLN5_MOUSE) to ~11 
(FBN1_MOUSE) (Table 3.3). The strong fibulin 1 upregulation agrees with previous studies of 
mice UUO (Schaefer, et al. 2004). Among these matrix glycoproteins, “EGF-containing fibulin-
like protein” (FBLN3_MOUSE), also known as fibulin 3, is able to bind epithelial growth factor 
receptor (EGFR) activating EGFR-signalling pathway, possibly acting as a profibrotic cytokine 
in the promotion of kidney fibrosis. Fibronectin and fibrillin 1 showed the highest expression 
in the group, when relative protein expression was investigated (Fig. 3.9A). Interestingly, 
small leucin rich matrix proteoglycan (SLRP) biglycan was upregulated, together with other 
SLRPs mimecan and lumican (Table 3.3, Fig. 3.9A), in agreement with previous findings on 
mice subjected to UUO (Schaefer, et al. 2004), and in human biopsies, were it was present both 
in the glomerulus and in areas of tubulointerstitial fibrosis (Stokes, et al. 2000). Basement 
membrane laminins, nidogen and HSPGs, including agrin, known to be the main HSPG in the 
GBM (Groffen, et al. 1998), perlecan, and collagen XVIII /endostatin, were also upregulated by 
the disease (Table 3.3, Fig. 3.9A). Basement membrane HSPGs have been suggested to be 
involved in the maintenance of the glomerular filtration barrier (Kvist, et al. 2006, Morita, et 
al. 2005, Miosge, et al. 2003), and may be upregulated in response to injury.   
A few proteases and proteases inhibitors, as expected, were overexpressed upon UUO (Table 
3.3) and might be involved in matrix remodeling and stabilization. Among these, antitrypsin 
was highly overexpressed (~8 -fold) and known to be upregulated in models of kidney disease  
(Bergin, et al. 2012, Navarro-Munoz, et al. 2012).  
Several markers of fibroblast proliferation and myofibroblast activation were also identified 
as upregulated at 21 days post-UUO in our model (Table 3.3). In agreement with previous 
studies (Xue, et al. 2003, Inazaki, et al. 2004), as well as with the protein immunoprobing in 
whole kidney lysates [3.4.2], α-SMA (ACTA_MOUSE) was upregulated in UUO (Table 3.3). 
Moreover, other markers such as vimentin (Yuasa, et al. 2014, Grone, et al. 1987, Johnson, et 
al. 1991, Ofstad and Iversen 2005, Zou, et al. 2006), desmin (Zou, et al. 2006, Johnson, et al. 
1991, Yuasa, et al. 2014) and vinculin (a marker of focal adhesion sites)/talin (Humphries, et 
al. 2007) were significantly induced at 21-days post-UUO in this model (Table 3.3). Calponin 
is another marker of myofibroblast proliferation (Yuasa, et al. 2014, Choi, Nam and Cha 2014, 
Lee, et al. 2010, Sugenoya, et al. 2002) with a possible protective role in the glomerulus 
(Sugenoya, et al. 2002), and one of its isoforms (CNN1_MOUSE) resulted more than 8-fold 
upregulated upon UUO at 21-days post UUO. Different tropomyosins and myosins were also 
overexpressed in UUO kidneys, in agreement with their role in cell contraction (Tomasek, et al. 
2002) (Table 3.3). Relative protein quantification performed by the software, basing on the 
CHAPTER III – RESULTS 
 
135 
 
normalized spectra, highlighted vimentin as the more expressed marker in UUO kidneys, 
followed by α-SMA (Fig. 3.9B). 
Other proteins that might be directly associated with the progression of fibrosis upon UUO are 
lipid binding proteins such as apolipoproteins (Table 3.3). Expression of APOA and mutations 
in APOE have been associated with the progression of CKD in different models (Kopp, et al. 
2011, Boes, et al. 2006, Hsu, et al. 2005). APOE might have a protective function in the 
glomerulus (Hsu, et al. 2005). Clusterin (CLUS_MOUSE) is an apolipoprotein suggested to be 
upregulated different types of acute and chronic kidney diseases, where it might play and 
antiapoptotic role (Chevalier, et al. 1996), and was more than 5-fold increased in the model 
(Table 3.3). Fatty acid binding protein, a lipid binding protein already shown to be upregulated 
in serum upon kidney disease (Górski, et al. 1997, Yamamoto, et al. 2007) was also identified 
in this model (Table 3.3). 
Proteins involved in inflammatory response appeared upregulated in response to UUO at 21-
days, among which complement proteins C3 and C4 (Stegall, Chedid and Cornell 2012, Welch, 
Beischel and Witte 1993) and numerous members of the annexin family were identified (Table 
3.3). Annexin 1-6 were all upregulated at 21 days post-UUO; annexin 1 was strongly 
overexpressed (ANXA1_MOUSE, 8-fold overexpressed) and is known to be involved in 
inflammatory response as well as being a marker of cells undergoing apoptosis (Arur, et al. 
2003). Also annexin 5 (ANXA5_MOUSE) is frequently employed as a marker of apoptotic cells 
in commercial kits and has also been involved in coagulation; similarly, annexin 4 
(ANXA4_MOUSE) has been suggested as an early marker of apoptosis (Herzog, et al. 2004). 
Above all, annexin 2 (ANXA2_MOUSE) is an interesting protein in the context of kidney injury 
as well as being characterized by an unconventional secretory route [reviewed in Chapter V]. 
It has been suggested to bind and control plasmin (Ma and Fogo 2009, Fitzpatrick, et al. 2000) 
and to be upregulated in models of tubular injury and necrosis (Cheng, et al. 2005) 
A number of serum proteins were overexpressed in the UUO proteome (Table 3.3), in line with 
previous studies (Filip, et al. 2015). In particular, serum β-2-microglobulin has been 
demonstrated to markedly increase in patients with chronic renal failure (Blumberg and Burgi 
1987, Peterson, Evrin and Berggard 1969, Varghese, et al. 2007). To note, other 
immunoglobulins were upregulated by UUO and are displayed in Suppl. Table 3.5.  
Uromodulin appeared as the most overexpressed protein in our UUO model at 21 days post-
surgery (UROM_MOUSE, more than 16-fold overexpressed) (Table 3.3). The upregulation of 
this protein in kidneys upon CKD is a novel finding, as the protein is involved in the regulation 
of tubular structures and is normally present in physiological conditions. However, as 
uromodulin is the most common protein in the urine of healthy individuals (Bleyer, Zivna and 
Kmoch 2011, Devuyst 2013, Nagaraj and Mann 2011), urine retention determined by the UUO 
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procedure might lead to a strong accumulation of the protein in the kidney, which has been 
associated with forms of CKD (Scolari, et al. 2004, Rampoldi, et al. 2003).  
An interesting protein showing a strong increase in expression upon UUO was transgelin 
(TAGL_MOUSE), more than 9-times upregulated in comparison with the Sham operated control 
(Table 3.3). Transglelin has been recently suggested as a marker of proliferating cells, 
upregulated during the progression of fibrosis in both glomerular and tubular cells in different 
models of kidney disease, including obstructive nephropathy (Inomata, et al. 2011, Gerolymos, 
et al. 2011, Sakamaki, et al. 2011, Daniel, et al. 2012, Karagianni, et al. 2013).  Periostin was 
also strongly overexpressed at 21-days post UUO: this protein has been largely studied in the 
context of renal disease and associated with both glomerulosclerotic and tubulointerstitial 
kidney diseases (Guerrot, et al. 2012, Mael-Ainin, et al. 2014, Sen, et al. 2011, Wallace, et al. 
2014, Satirapoj, et al. 2012) (Table 3.3). 
Moesin, galectin-1, retinol-binding protein and myoferlin were among the other interesting 
proteins overexpressed in the UUO proteome when compared to Sham operated conditions 
(Table 3.3), in agreement with their proposed involvement in CKD models (Henderson, et al. 
2008, Chen, et al. 2014, Pallet, et al. 2014). Thymosin β-4 is known to promote stabilisation of 
fibrin clots in wound repair (Huff, et al. 2002, Telci and Griffin 2006), and was as well 
overexpressed in the disease together with fibrinogen isoforms (Table 3.3).  
In summary, these first general observations are already indicatory of the development of a 
large tubulointerstitial fibrosis upon UUO, highlighting most of the main markers and 
structural molecules. Interestingly, TG2 (TGM2_MOUSE) was detected as significantly 
overexpressed by UUO with this technique, even if with only a small fold increase from the 
Sham operated healthy conditions (FC= +1.71) (Table 3.3). 
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Table 3.3: Highlight of interesting protein groups identified as significantly overexpressed in 
kidneys at 21 days post-UUO. Comprehensive list of protein can be found in the Supplementary 
material (Suppl. Table 3.5). In increasing shades of red the absolute fold change increase of UUO from 
Sham operated condition, in increasing shades of yellow the confident of fold change C(FC). A C(FC) 
higher than 80% (0.8) was regarded as significant. 
 
Highlighted  Examples 
FC 
(UUO/Sham)  
C(FC) 
Collagens 
Collagen alpha-1(I) chain CO1A1_MOUSE 7.61 0.96 
Collagen alpha-1(III) chain CO3A1_MOUSE 7.72 0.92 
Collagen alpha-1(IV) chain CO4A1_MOUSE 2.67 0.88 
Collagen alpha-2(IV) chain CO4A2_MOUSE 4.50 0.80 
Collagen alpha-1(VI) chain CO6A1_MOUSE 4.78 0.88 
Collagen alpha-2(VI) chain CO6A2_MOUSE 4.76 0.94 
Collagen alpha-1(XII) chain COCA1_MOUSE 15.92 0.82 
Collagen alpha-1(XIV) chain COEA1_MOUSE 4.62 0.81 
Extracellular 
Matrix 
glycoproteins 
Fibronectin FINC_MOUSE 7.85 0.84 
Fibrillin-1 FBN1_MOUSE 10.84 0.89 
Fibrillin-2 FBN2_MOUSE 7.26 0.94 
Fibulin-2 FBLN2_MOUSE 9.65 0.81 
Fibulin-5 FBLN5_MOUSE 5.81 0.84 
EGF-containing fibulin-like extracellular matrix 
protein 1 (Fibulin 3) 
FBLN3_MOUSE 6.33 0.80 
Emilin-1 EMIL1_MOUSE 4.42 0.82 
Biglycan PGS1_MOUSE 8.73 0.86 
Mimecan MIME_MOUSE 6.67 0.83 
Lumican LUM_MOUSE 6.55 0.87 
Basement 
membrane 
Laminin subunit alpha-5 LAMA5_MOUSE 2.26 0.83 
Laminin subunit beta-1 LAMB1_MOUSE 1.85 0.85 
Laminin subunit gamma-1 LAMC1_MOUSE 1.85 0.93 
Nidogen-1 NID1_MOUSE 2.10 0.92 
Agrin AGRIN_MOUSE 2.16 0.92 
Basement membrane-specific heparan sulfate 
proteoglycan core protein 
PGBM_MOUSE 1.80 0.81 
Collagen alpha-1(XVIII) chain COIA1_MOUSE 2.57 0.96 
Proteases 
Cathepsin D CATD_MOUSE 2.65 0.82 
Cathepsin Z CATZ_MOUSE 2.53 0.86 
Hemopexin HEMO_MOUSE 4.60 0.86 
Protease 
inhibitor 
Alpha-1-antitrypsin 1-1 A1AT1_MOUSE 3.07 0.86 
Alpha-1-antitrypsin 1-2 A1AT2_MOUSE 7.86 0.82 
Alpha-1-antitrypsin 1-4 A1AT4_MOUSE 2.72 0.83 
Antithrombin-III ANT3_MOUSE 2.27 0.86 
Kininogen-1 KNG1_MOUSE 3.09 0.91 
Serpin B6 SPB6_MOUSE 3.56 0.89 
Serpin H1 SERPH_MOUSE 6.19 0.94 
Marker 
Myofibroblasts 
Actin, aortic smooth muscle ACTA_MOUSE 3.17 0.94 
Vimentin VIME_MOUSE 8.56 0.90 
Desmin DESM_MOUSE 5.98 0.94 
Vinculin VINC_MOUSE 2.33 0.94 
Talin-1 TLN1_MOUSE 1.78 0.82 
Calponin-1 CNN1_MOUSE 8.59 0.80 
Calponin-2 CNN2_MOUSE 6.15 0.80 
Tropomyosin alpha-1 chain TPM1_MOUSE 4.28 0.84 
Tropomyosin alpha-4 chain TPM4_MOUSE 4.19 0.91 
Myosin light chain kinase, smooth muscle MYLK_MOUSE 2.59 0.80 
Myosin light polypeptide 6 MYL6_MOUSE 2.53 0.92 
Myosin regulatory light chain 12B ML12B_MOUSE 2.33 0.83 
Myosin regulatory light polypeptide 9 MYL9_MOUSE 3.08 0.98 
Myosin-9 MYH9_MOUSE 2.61 0.99 
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Myosin-10 MYH10_MOUSE 3.27 0.85 
Myosin-11 MYH11_MOUSE 3.28 0.87 
Lipid-binding 
proteins 
Apolipoprotein A-I APOA1_MOUSE 2.46 0.92 
Apolipoprotein A-IV APOA4_MOUSE 2.50 0.82 
Apolipoprotein E APOE_MOUSE 3.31 0.87 
Beta-2-glycoprotein 1 (Apolipoprotein H) APOH_MOUSE 2.50 0.80 
Clusterin (Apolipoprotein J) CLUS_MOUSE 5.35 0.81 
Fatty acid-binding protein, adipocyte FABP4_MOUSE 1.82 0.85 
Inflammation 
Complement C3 CO3_MOUSE 2.59 0.87 
Complement C4-B CO4B_MOUSE 3.44 0.86 
H-2 class II histocompatibility antigen, A-U 
alpha chain 
HA2U_MOUSE 8.32 0.80 
Annexin A1 ANXA1_MOUSE 8.17 0.84 
Annexin A2 ANXA2_MOUSE 3.76 0.90 
Annexin A3 ANXA3_MOUSE 4.73 0.83 
Annexin A4 ANXA4_MOUSE 1.78 0.85 
Annexin A5 ANXA5_MOUSE 2.29 0.84 
Annexin A6 ANXA6_MOUSE 2.71 0.89 
Plasma proteins  
Beta-2-microglobulin B2MG_MOUSE 2.88 0.82 
Serotransferrin TRFE_MOUSE 3.78 0.91 
Creatine kinase B-type KCRB_MOUSE 7.56 0.83 
Serum albumin ALBU_MOUSE 2.98 0.92 
Vitamin D-binding protein VTDB_MOUSE 3.13 0.93 
Other  
Uromodulin UROM_MOUSE 16.34 0.85 
Transgelin TAGL_MOUSE 9.27 0.89 
Transgelin-2 TAGL2_MOUSE 3.04 0.88 
Periostin POSTN_MOUSE 8.04 0.80 
Moesin MOES_MOUSE 1.52 0.81 
Galectin-1 LEG1_MOUSE 6.15 0.87 
Retinol-binding protein 1 RET1_MOUSE 5.56 0.83 
Myoferlin MYOF_MOUSE 4.99 0.86 
Fibrinogen alpha chain FIBA_MOUSE 4.64 0.90 
Fibrinogen beta chain FIBB_MOUSE 4.00 0.86 
Fibrinogen gamma chain FIBG_MOUSE 4.45 0.85 
Thymosin beta-4 TYB4_MOUSE 4.35 0.88 
Transglutminase 2 TGM2_MOUSE 1.71 0.90 
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Figure 3.9: Relative protein expression of markers of fibrotic tissue deposition and 
myofibroblasts proliferation identified as overexpressed in mice subjected to 21 days – UUO. 
Column charts show the mean relative intensity as calculated by OneOmics software from the SWATH-
MS data (SCIEX, Canada) ± SD, N=4 samples per treatment. (A) Extracellular matrix and basement 
membrane proteins: collagens, ECM glycoproteins and basement membrane components including 
HSPGs. (B) Markers of fibroblast proliferation and myofibroblasts differentiation. Significance of the 
differences between spectral means was determined by T-test; all differences resulted significant at 
p<0.01 
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3.4.4.3 Preliminary observation of the UUO-underexpressed proteins 
The 458 proteins identified as underexpressed at 21 days post-UUO (Suppl. Table 3.6), 
appeared mostly metabolic and in large part associated with mitochondrial functions. They 
included a great number of enzymes involved in glycolysis / Krebs cycle, cytochrome subunits, 
ATP and NAD(P)H metabolism but also fatty acid and lipid metabolism. Some metabolic 
proteins such as glucose-6-phosphatase (G6PC_MOUSE), mitochondrial kynurenine/alpha-
aminoadipate aminotransferase (AADAT_MOUSE) or hydroxyacid oxidase 2 (HAOX2_MOUSE) 
were more than 40-fold underexpressed in UUO conditions (Suppl. Table 3.6).  
The strong downregulation of a large number of metabolic and regulative proteins is possibly 
linked to a substantial loss in kidney cells by apoptosis/necrosis, that happens during the 
progression of experimental UUO (Ucero, et al. 2014, Chevalier, Forbes and Thornhill 2009) 
and is highly established at this time point (21 days). However, few groups of proteins were 
selected from the list as interesting in the context of kidney physiology and are displayed in 
Table 3.4.   
A number of UUO-downregulated proteins, for examples, were found associated with the 
control of normal kidney functions. A number of them were involved in transport through the 
tubular membrane: solute carrier family proteins (S12A1_MOUSE, S13A3_MOUSE, 
S22AI_MOUSE, S22A2_MOUSE, GTR1_MOUSE) can mediate the uptake of proteins, drugs and 
neurotransmitters from the blood to the tubular cells, while sodium/glucose cotransporter 2 
and Na(+)/H(+) exchange regulatory cofactor NHE-RF3 and chloride intracellular channel 
protein 5 are important for ion transport along the tubule (Table 3.4).  
The calcium-binding protein calbindin (CALB1_MOUSE) was also strongly downregulated in 
this model upon UUO (Table 3.4); it is known to be downregulated by ageing of or nephrotoxic 
stress on the kidney (Steiner, et al. 1996, Armbrecht, et al. 1989, Sooy, Kohut and Christakos 
2000, Hoffmann, et al. 2010) and might be involved in the control of physiological renal calcium 
absorption.  
Tubular osmolality - associated proteins such as aquaporins (involved in the regulation of 
tubular water permeability) and L-xylulose reductase were also underexpressed at 21-days 
post UUO, together with other proteins in different ways associated with the control of kidney 
excretion (PGES2_MOUSE, PTGR2_MOUSE, ST1D1_MOUSE) (Table 3.4).  
A considerable underexpression in proteins involved in the control of blood pressure and 
Angiotensin metabolism was also noted upon 21 days UUO. Argininosuccinate synthase and 
cystathionine gamma-lyase were both strongly downregulated by UUO, as well as angiotensin-
converting enzymes (ACE_MOUSE and TMM27_MOUSE) and angiotensin-processing enzymes 
(AMPN_MOUSE, AMPE_MOUSE and NEP_MOUSE) (Table 3.4). The latter are possibly linked to 
a dysregulation of the RAAS system upon UUO (Klahr and Morrissey 1998, Chevalier, Forbes 
and Thornhill 2009, Ucero, et al. 2014).  
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Interestingly, a substantial number of antioxidant enzymes was found underexpressed at 21 
days post-UUO, including glutathione synthases, s-transferases, reductases, peroxidases, as 
well as thioredoxins, superoxide dismutase species, peroxidases and catalase (Table 3.4).  
Few proteins know to be involved ECM digestion, such as meprin and basigin, were several-
fold underexpressed in UUO mice at 21 days compared to the Sham operated control (Table 
3.4), and also alpha-enolase, reported to promote both plasminogen activation and hypoxia 
tolerance, was more than 2-fold downregulated (Table 3.4).  
Cadherin-16, known as kidney-specific cadherin, was also downregulated by UUO in a 
substantial manner (Table 3.4), and, being involved in the maintenance of tissue structure, 
might be associated with a large epithelial cell loss and transition.  
Curiously, to conclude, while moesin was identified as upregulated by UUO, ezrin and radixin, 
the other two ERM-proteins, involved in cytoskeletal-plasma membrane association, were 
found significantly downregulated. A recent proteomic study on STZ-treated diabetic rats 
similarly highlighted ezrin downregulation upon disease, in line with our observations (Gong, 
et al. 2009).  
To summarize, the proteins identified as underexpressed in mice kidneys subjected to 21-days 
UUO were represented by a large percentage of proteins in different ways associated with cell 
metabolism and energy production, but also included a few proteins directly involved in the 
control of kidney functionality and physiological response to stress. Among these, the 
substantial downregulation of antioxidant protein is an interesting finding that might be worth 
investigating in future, to understand if it is correct considering it a genuine stress response to 
UUO or it is more likely to be a mere effect of cell death.  
In the next sections, a functional analysis of the proteins overexpressed and underexpressed 
in the UUO-associated proteome will be provided, with the aim of highlighting specific clusters 
of proteins significantly upregulated or downregulated in the model.   
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Table 3.4: Highlight of interesting protein groups identified as significantly underexpressed in 
kidneys at 21 days post-UUO. Comprehensive list of protein can be found in the Supplementary 
material (Suppl. Table 3.6). In increasing shades of red the absolute fold change decrease of UUO from 
Sham operated condition, in increasing shades of yellow the confident of fold change C(FC). A C(FC) 
higher than 80% (0.8) was regarded as significant 
 
Highlighted  Examples 
FC 
(Sham/UUO)  
C(FC) 
Kidney Function  
Solute carrier family 12 member 1 S12A1_MOUSE 6.91 0.96 
Solute carrier family 13 member 3 S13A3_MOUSE 9.52 0.88 
Solute carrier family 22 member 18 S22AI_MOUSE 9.86 0.90 
Solute carrier family 22 member 2 S22A2_MOUSE 12.29 0.81 
Solute carrier family 2, facilitated glucose 
transporter member 1 
GTR1_MOUSE 2.58 0.80 
Sodium/glucose cotransporter 2 SC5A2_MOUSE 16.23 0.80 
Na(+)/H(+) exchange regulatory cofactor 
NHE-RF3 
NHRF3_MOUSE 10.71 0.86 
Chloride intracellular channel protein 5 CLIC5_MOUSE 4.18 0.85 
Calbindin CALB1_MOUSE 32.07 0.91 
Aquaporin-1 AQP1_MOUSE 6.91 0.80 
Aquaporin-3 AQP3_MOUSE 6.51 0.90 
L-xylulose reductase DCXR_MOUSE 5.92 0.88 
Prostaglandin E synthase 2 PGES2_MOUSE 6.29 0.89 
Prostaglandin reductase 2 PTGR2_MOUSE 3.79 0.89 
Sulfotransferase 1 family member D1 ST1D1_MOUSE 13.74 0.85 
Blood pressure - 
RAAS independent 
Argininosuccinate synthase ASSY_MOUSE 21.28 0.88 
Cystathionine gamma-lyase CGL_MOUSE 16.04 0.86 
Control Angiotensin 
Angiotensin-converting enzyme ACE_MOUSE 12.66 0.91 
Collectrin TMM27_MOUSE 14.41 0.85 
Aminopeptidase N AMPN_MOUSE 3.83 0.95 
Glutamyl aminopeptidase AMPE_MOUSE 4.21 0.87 
Neprilysin NEP_MOUSE 8.05 0.90 
Antioxidant enzymes 
Catalase CATA_MOUSE 12.62 0.94 
Glutathione peroxidase 1 GPX1_MOUSE 3.45 0.92 
Glutathione peroxidase 3 GPX3_MOUSE 1.54 0.83 
Glutathione reductase, mitochondrial GSHR_MOUSE 2.33 0.80 
Glutathione S-transferase A2 GSTA2_MOUSE 17.14 0.85 
Glutathione S-transferase A3 GSTA3_MOUSE 10.63 0.81 
Glutathione S-transferase A4 GSTA4_MOUSE 3.61 0.86 
Glutathione S-transferase kappa 1 GSTK1_MOUSE 12.27 0.82 
Glutathione S-transferase Mu 1 GSTM1_MOUSE 2.37 0.89 
Glutathione S-transferase Mu 5 GSTM5_MOUSE 3.27 0.87 
Glutathione S-transferase P 1 GSTP1_MOUSE 1.77 0.94 
Glutathione S-transferase theta-2 GSTT2_MOUSE 5.84 0.87 
Glutathione synthetase GSHB_MOUSE 5.17 0.82 
Microsomal glutathione S-transferase 3 MGST3_MOUSE 7.12 0.84 
Peroxiredoxin-1 PRDX1_MOUSE 2.03 0.91 
Peroxiredoxin-5, mitochondrial PRDX5_MOUSE 6.30 0.91 
Peroxiredoxin-6 PRDX6_MOUSE 2.23 0.94 
Superoxide dismutase [Cu-Zn] SODC_MOUSE 3.33 0.94 
Superoxide dismutase [Mn], 
mitochondrial 
SODM_MOUSE 11.66 0.93 
Copper chaperone for superoxide 
dismutase 
CCS_MOUSE 2.75 0.99 
Thioredoxin reductase 2, mitochondrial TRXR2_MOUSE 4.29 0.83 
Thioredoxin, mitochondrial THIOM_MOUSE 4.90 0.90 
Thioredoxin-dependent peroxide 
reductase, mitochondrial 
PRDX3_MOUSE 5.23 0.90 
Anti-fibrotic 
Meprin A subunit alpha MEP1A_MOUSE 7.15 0.88 
Meprin A subunit beta MEP1B_MOUSE 14.72 0.82 
Basigin BASI_MOUSE 4.09 0.87 
Alpha-enolase ENOA_MOUSE 2.51 0.98 
Other  
Cadherin-16 CAD16_MOUSE 19.54 0.92 
Radixin RADI_MOUSE 2.79 0.83 
Ezrin EZRI_MOUSE 3.13 0.96 
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3.4.4.4 Functional distribution of UUO-overexpressed and -underexpressed proteins 
Functional classification of the differentially expressed proteins identified by SWATH-MS was 
performed in PANTHER as described in 3.3.7, investigating the GO terms for Biological 
Processes, Molecular Functions and Cellular Components as well as the PANTHER Protein class 
terms. Results were visualized in pie charts as percentage of representation of the different 
annotation classes in the list.  
The GO annotations for Biological Processes (Fig. 3.10A) revealed that the majority of proteins 
significantly lowered by UUO have a role in metabolism: 69.9% of the proteins underexpressed 
by UUO were falling into the “metabolic process” (GO:0008152) annotation term. This was 
more than the half (55.2%) of the total class hits, which means that most of the metabolic 
proteins were only associated with this annotation term (Fig. 3.10A). On the other side, the 
45.9% of the UUO- overexpressed proteins were in some way associated with metabolic 
processes, but they represent only the 17.5% of the total annotation term hits (Fig. 3.10A): 
this means that these proteins were associated not exclusively with metabolism but also to 
other processes (they fall in more than one annotation term). Among the Biological processes 
more represented in UUO, “cellular component organization or biogenesis” (GO:0071840) and 
cellular process (GO:0009987) covered more than a quarter of the total class hits [10.1% 
(26.5% of proteins) and 20.1% (53.0% of proteins), respectively], while they were less 
represented among the 458 proteins underexpressed in UUO [2.6% (3,3% of the proteins) and 
11.6% (14.7% of the proteins), respectively] (Fig. 3.10A). Interestingly, there was also a higher 
amount of proteins associated with immune system [immune system process (GO:0002376) 
11.4%], apoptosis [apoptotic process (GO:0006915), 2.7%] and adhesion [biological adhesion 
(GO:0022610), 10.8%] upon UUO induction, which were lower in the list of UUO-
underexpressed proteins (Fig. 3.10A).  
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Among the GO terms for Molecular Functions (Fig.3.10B), a high percentage of proteins 
(31.9%) was associated with structural activity [structural molecule activity (GO:0005198)] in 
the UUO model and was possibly mostly associated with the substantial amount of proteins 
attributable to the cytoskeleton (Suppl. Table 3.5) and to the smooth muscle/mesenchymal 
phenotype of the cells (Table 3.8); they represented the 22.9% of total class hits among the 
UUO-overexpressed proteins, in contrast to only the 5.7% in the UUO-underexpressed list 
(Fig.3.10B). “Binding” (GO:0005488) molecular function was also associated with the UUO-
overexpressed proteins, covering the 42.2% of the proteins (30.2% of total class hits) against 
the 10.5% of the opposite group (11.1% of total class hits) (Fig.3.10B). This might be directly 
linked to many adhesion proteins and proteins involved in nuclear acid binding among the 
UUO-overexpressed members of the proteome (Suppl. Table 3.5).  
As expected, “Catalytic activity” (GO:0003824) function was less represented in the group of 
proteins overexpressed in the UUO model (29.7% of the proteins, 21.3% of total class hits) in 
comparison to a substantial representation in the UUO-underexpressed proteins, where the 
61.4% of members belong to this annotation term (64.9% of total class hits) (Fig.3.10B). In 
addition, ability to be involved in antioxidant response is also lowered by the UUO, with the 
“antioxidant activity” (GO:0016209) annotation term being present only in the list of UUO-
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underexpressed proteins (2.1% of total class hits) (Fig.3.10B), in line with previous 
observations [3.4.4.3].  
 
 
 
Cellular compartments were also analyzed (Fig.3.10C) with the same approach. The UUO-
overexpressed proteins were characterized by a substantial amount of proteins belonging to 
extracellular region (GO:0005576) (17.6% of total class hits) or extracellular matrix 
(GO:0031012) (9.3% of total class hits), that were considerably lower among the UUO-
underexpressed proteins (1.9% and 1.3% respectively) (Fig.3.10C). In the latter group, on the 
other hand, a great amount of proteins was not associated at all with any cell component 
(around the 65% of proteins) and the remaining were belonging mostly to membranes 
(GO:0016020, 15.0% of total class hits), organelles (GO:0043226, 23.1% of total class hits) and 
cell parts, including the plasma membrane (GO:0044464, 45.0% of total class hits) (Fig.3.10C).  
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Finally, PANTHER Protein Class annotation terms (Fig.3.10D) allowed to determine more 
specifically to which functional group the proteins were belonging. The four classes more 
represented in the UUO-overexpressed list were “extracellular matrix protein” (PC00102, 
8.3%), “receptor” (PC00197, 8.3%, almost exclusively for cytokines), “enzyme modulator” 
(PC00095, 10.3%) and, above all, “cytoskeletal protein” (PC00085, 20.2%) (Fig.3.10D).   
In line with the previous findings, the PANTHER Protein classes more represented among the 
UUO-underexpressed proteins were mostly oxidoreductases (PC00176, 24.5%), together with 
other metabolism-associated proteins such as transferases (PC00220, 12.4%), hydrolases 
(PC00121, 11.0%) and transporters (PC00227, 8.2%), of which most are associated with the 
mitochondrial membrane (Fig.3.10D).   
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Figure 3.10: Functional distribution of UUO-overexpressed and -underexpressed proteins. 
(starts in previous pages) Functional distribution of UUO-Overexpressed and -Underexpressed 
proteins was investigated by PANTHER (http://www.pantherdb.org) using the annotation term 
ontologies for (A) PANTHER GO-slim Biological Process, (B) PANTHER GO-slim Molecular Function, (C) 
PANTHER GO-slim Cellular Component, (D) PANTHER Protein Class. Labels to be read as: % proteins 
belonging to the class over the number of proteins in the list, annotation term (Class), % proteins 
belonging to the class over the total number of class hits (for all the annotation terms individuated in 
the list of proteins = 100%). For PANTHER protein class only annotation term (Class) and % proteins 
belonging to the class over the total number of class hits are displayed. Red circles indicate terms more 
represented in the UUO-overexpressed protein list, green circles indicate terms more represented in 
UUO-underexpressed protein list, black circles indicate terms similarly represented in both lists. 
 
The distribution of different biological pathways was also investigated using the PANTHER 
Pathways annotation terms on PANTHER Database (Table 3.5, Table 3.6).  
In order of coverage, the more represented pathways among the UUO-overexpressed proteins 
at 21 days post-surgery (Table 3.5) were “Integrin signaling pathway” (P00034, 15.5%), 
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“Inflammation mediated by chemokine and cytokine signaling pathway” (P00031, 12.7%), 
“Cytoskeletal regulation by Rho GTPase” (P00016, 9.2%) and “Blood coagulation” (P00011, 
6.3%), while in the UUO-underexpressed the main pathways (Table 3.6) were “Glycolysis” 
(P00024, 6.4%), “Huntington disease” (P00029, 5.7%), “TCA cycle” (P00051, 5.7%) and “De 
novo purine biosynthesis” (P02738, 4.5%). 
 
Table 3.5: PANTHER Pathways representation in UUO-overexpressed proteins. Pathways 
represented in UUO-overexpressed proteins were investigated by PANTHER 
(http://www.pantherdb.org) using the annotation term ontologies for PANTHER Pathways. The table 
shows the pathways distribution in UUO-overexpressed proteins. The number of proteins belonging to 
the class and the percentage of representation over the total class hits are in increasing shades of red 
(the higher, the more intense). 
PANTHER Pathways  n % 
Integrin signaling pathway (P00034) 22 15.50% 
Inflammation mediated by chemokine and cytokine signaling pathway (P00031) 18 12.70% 
Cytoskeletal regulation by Rho GTPase (P00016) 13 9.20% 
Blood coagulation (P00011) 9 6.30% 
Huntington disease (P00029) 7 4.90% 
Nicotinic acetylcholine receptor signalling pathway (P00044) 6 4.20% 
Gonadotropin releasing hormone receptor pathway (P06664) 5 3.50% 
Alzheimer disease-presenilin pathway (P00004) 4 2.80% 
Cadherin signaling pathway (P00012) 4 2.80% 
Nicotine pharmacodynamics pathway (P06587) 3 2.10% 
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway (P00026) 3 2.10% 
Wnt signaling pathway (P00057) 3 2.10% 
FAS signaling pathway (P00020) 3 2.10% 
Dopamine receptor mediated signaling pathway (P05912) 3 2.10% 
CCKR signaling map (P06959) 3 2.10% 
Metabotropic glutamate receptor group III pathway (P00039) 2 1.40% 
5HT1 type receptor mediated signaling pathway (P04373) 2 1.40% 
Heterotrimeric G-protein signaling pathway-rod outer segment phototransduction (P00028) 2 1.40% 
Plasminogen activating cascade (P00050) 2 1.40% 
Endothelin signaling pathway (P00019) 2 1.40% 
Enkephalin release (P05913) 2 1.40% 
Muscarinic acetylcholine receptor 2 and 4 signaling pathway (P00043) 2 1.40% 
Metabotropic glutamate receptor group II pathway (P00040) 2 1.40% 
Beta2 adrenergic receptor signaling pathway (P04378) 1 0.70% 
Axon guidance mediated by semaphorins (P00007) 1 0.70% 
Beta1 adrenergic receptor signaling pathway (P04377) 1 0.70% 
GABA-B_receptor_II_signaling (P05731) 1 0.70% 
p53 pathway (P00059) 1 0.70% 
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway (P00027) 1 0.70% 
Vitamin D metabolism and pathway (P04396) 1 0.70% 
Vasopressin synthesis (P04395) 1 0.70% 
General transcription by RNA polymerase I (P00022) 1 0.70% 
FGF signaling pathway (P00021) 1 0.70% 
EGF receptor signaling pathway (P00018) 1 0.70% 
Parkinson disease (P00049) 1 0.70% 
Opioid proopiomelanocortin pathway (P05917) 1 0.70% 
Opioid prodynorphin pathway (P05916) 1 0.70% 
Histamine H2 receptor mediated signaling pathway (P04386) 1 0.70% 
Opioid proenkephalin pathway (P05915) 1 0.70% 
Cell cycle (P00013) 1 0.70% 
Metabotropic glutamate receptor group I pathway (P00041) 1 0.70% 
Cortocotropin releasing factor receptor signaling pathway (P04380) 1 0.70% 
Pyrimidine Metabolism (P02771) 1 0.70% 
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Table 3.6: PANTHER Pathways representation in UUO-underexpressed proteins. Pathways 
represented in UUO-underexpressed proteins were investigated by PANTHER 
(http://www.pantherdb.org) using the annotation term ontologies for PANTHER Pathways. The table 
shows the pathways distribution in UUO-underexpressed proteins. The number of proteins belonging to 
the class and the percentage of representation over the total class hits are in increasing shades of green 
(the higher, the more intense). 
PANTHER Pathways N % 
Glycolysis (P00024) 10 6.40% 
Huntington disease (P00029) 9 5.70% 
TCA cycle (P00051) 9 5.70% 
De novo purine biosynthesis (P02738) 7 4.50% 
ATP synthesis (P02721) 6 3.80% 
Wnt signaling pathway (P00057) 5 3.20% 
Cadherin signaling pathway (P00012) 5 3.20% 
Fructose galactose metabolism (P02744) 5 3.20% 
Pyruvate metabolism (P02772) 5 3.20% 
Alzheimer disease-presenilin pathway (P00004) 4 2.50% 
Inflammation mediated by chemokine and cytokine signaling pathway (P00031) 4 2.50% 
Parkinson disease (P00049) 4 2.50% 
Cytoskeletal regulation by Rho GTPase (P00016) 4 2.50% 
Apoptosis signaling pathway (P00006) 3 1.90% 
Arginine biosynthesis (P02728) 3 1.90% 
N-acetylglucosamine metabolism (P02756) 3 1.90% 
Methylmalonyl pathway (P02755) 3 1.90% 
Nicotinic acetylcholine receptor signaling pathway (P00044) 3 1.90% 
De novo pyrmidine ribonucleotides biosythesis (P02740) 3 1.90% 
Pyrimidine Metabolism (P02771) 3 1.90% 
De novo pyrimidine deoxyribonucleotide biosynthesis (P02739) 2 1.30% 
Integrin signalling pathway (P00034) 2 1.30% 
Pentose phosphate pathway (P02762) 2 1.30% 
Asparagine and aspartate biosynthesis (P02730) 2 1.30% 
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway (P00026) 2 1.30% 
Aminobutyrate degradation (P02726) 2 1.30% 
O-antigen biosynthesis (P02757) 2 1.30% 
Vitamin B6 metabolism (P02787) 2 1.30% 
Leucine biosynthesis (P02749) 2 1.30% 
Heme biosynthesis (P02746) 2 1.30% 
Gamma-aminobutyric acid synthesis (P04384) 2 1.30% 
Succinate to proprionate conversion (P02777) 2 1.30% 
Glutamine glutamate conversion (P02745) 2 1.30% 
Dopamine receptor mediated signaling pathway (P05912) 2 1.30% 
Salvage pyrimidine ribonucleotides (P02775) 2 1.30% 
Coenzyme A biosynthesis (P02736) 1 0.60% 
Phenylethylamine degradation (P02766) 1 0.60% 
Hypoxia response via HIF activation (P00030) 1 0.60% 
Nicotine pharmacodynamics pathway (P06587) 1 0.60% 
Ascorbate degradation (P02729) 1 0.60% 
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway (P00027) 1 0.60% 
Vitamin D metabolism and pathway (P04396) 1 0.60% 
Transcription regulation by bZIP transcription factor (P00055) 1 0.60% 
Alanine biosynthesis (P02724) 1 0.60% 
Methylcitrate cycle (P02754) 1 0.60% 
FGF signaling pathway (P00021) 1 0.60% 
Acetate utilization (P02722) 1 0.60% 
Valine biosynthesis (P02785) 1 0.60% 
TGF-beta signaling pathway (P00052) 1 0.60% 
Methionine biosynthesis (P02753) 1 0.60% 
FAS signaling pathway (P00020) 1 0.60% 
Tryptophan biosynthesis (P02783) 1 0.60% 
Plasminogen activating cascade (P00050) 1 0.60% 
Threonine biosynthesis (P02781) 1 0.60% 
Endothelin signaling pathway (P00019) 1 0.60% 
EGF receptor signaling pathway (P00018) 1 0.60% 
Isoleucine biosynthesis (P02748) 1 0.60% 
Blood coagulation (P00011) 1 0.60% 
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Formyltetrahydroformate biosynthesis (P02743) 1 0.60% 
Angiotensin II-stimulated signaling through G proteins and beta-arrestin (P05911) 1 0.60% 
Salvage pyrimidine deoxyribonucleotides (P02774) 1 0.60% 
CCKR signaling map (P06959) 1 0.60% 
Pyridoxal phosphate salvage pathway (P02770) 1 0.60% 
Gonadotropin releasing hormone receptor pathway (P06664) 1 0.60% 
 
 
3.4.4.5 Statistical overrepresentation test on UUO-overexpressed and -underexpressed 
proteins 
In order to determine which GO terms were significantly enriched or downregulated upon UUO 
in comparison with their distribution in the whole Mus Musculus gene expression, a statistical 
overrepresentation test was performed employing both PANTHER and DAVID bioinformatics 
tools. Results from the test performed by PANTHER are shown in Table 3.7 – 3.10. As for the 
previous paragraph, the GO terms for Biological Process, Molecular Function and Cellular 
Component, in addition to PANTHER Protein Class terms, were analysed.  A series of 
annotation terms were found significantly enriched upon UUO (in the list of UUO-
overexpressed proteins) with a p-value of the analysis lower than 0.05 (in bold in the different 
tables). Other terms were significantly enriched among the UUO-underexpressed protein 
(p≤0.05), therefore we can consider them significantly reduced by UUO at 21-days post-
surgery.  
Within the Biological Processes, a number of terms were significantly enriched upon UUO 
(p≤0.05) (in bold in Table 3.7). Several terms were found associated with cell adhesion (black 
arrows), a feature that is strongly represented in interstitial fibroblast/myofibroblasts, RNA 
modification/translation (grey arrows) and inflammation mediated by cytokines (white 
arrows). A significant reduction, in line with the previous results reported in 3.4.4.3-3.4.4.4, 
was found in a series of catalytic/metabolic processes (asterisks, *).  
Molecular Functions (Table 3.8) significantly enriched by UUO where associated with 
cytoskeletal organisation and actin binding (black arrows) and regulation of enzymatic 
activities in cells (white arrows), which were mostly proteolytic. Significantly enriched were 
also “extracellular matrix structural constituent” GO term (GO:0005201) (light grey arrow) 
and the "mRNA binding” function (GO:0003729) (dark grey arrow), which is in line with the 
previous annotation terms identified above for Biological processes and associated with 
splicing and translation mechanisms. Reduced proteins were again mostly metabolic 
(asterisks, *), and some of them were directly related to redox regulation (**).  
Cellular components overrepresented in the list of proteins differentially expressed by UUO 
are displayed in Table 3.9. This analysis clearly identified that cytoskeletal (dark arrows) and 
extracellular proteins (grey arrows), most of which belonging to the ECM, were enriched upon 
UUO, confirming what seen by a preliminary examination of protein names [3.4.4.2]. On the 
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other hand, UUO-underexpressed protein significantly represented the cytoplasmic and 
mitochondrial compartments of the cells (asterisk, *), in line with previous speculations 
[3.4.4.3]. 
Finally, PANTHER Protein classes significantly modulated by UUO were investigated, and 
results are shown in Table 3.10. PANTHER classes enriched by UUO were again associated 
with cytoskeletal organisation and actin binding (black arrows) and extracellular matrix 
composition and organisation (light grey arrow). In addition to these, also regulation of 
proteolytic activity (white arrows) and mRNA splicing/processing (dark grey arrows) were 
enriched by UUO. Classes of proteins whose annotation keys were significantly lowered during 
UUO were as usual metabolic (asterisks, *) and in part associated with redox regulation (**).  
Similar outcomes were also obtained by investigating the GO terms in DAVID bioinformatics 
resource, and results can be found in the appendix of this thesis (Suppl. Table 3.7 – 3.12).  
In conclusion, these analyses statistically confirmed that functions associated with cytoskeletal 
assembly and regulation, extracellular matrix dynamics, cell adhesion, inflammatory response 
and transcriptional modulation are significantly enriched at 21 days post-UUO, while 
significantly underrepresented in the model are functions associated with cell metabolism and 
redox regulation.   
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Table 3.7: GO Biological Process overrepresentation test on UUO-overexpressed and -
underexpressed proteins performed by PANTHER. Statistical overrepresentation test was 
performed by PANTHER (http://www.pantherdb.org) using the annotation terms for PANTHER GO-
slim Biological Process. Legend: Black arrows =terms associated with cell adhesion; grey arrows = terms 
associated with RNA modification and translation; white arrows = terms associated with inflammation. 
* = terms associated with catalytic/metabolic processes. +, red = overrepresented term (fold change 
from expected value H0 >1); -, green = underrepresented term (fold change from expected value H0 <1). 
In increasing shades of grey = fold change from the expected value H0 (the more intense, the higher the 
fold change). In increasing shades of blue = p-value (the more intense, the lower the p-value). A p-value 
lower than 0.05 was regarded as significant. 
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Table 3.8: GO Molecular Function overrepresentation test on UUO-overexpressed and -
underexpressed proteins performed by PANTHER. Statistical overrepresentation test was 
performed by PANTHER (http://www.pantherdb.org) using the annotation terms for PANTHER GO-
slim Molecular Function. Legend: Black arrows = terms associated with cytoskeletal organisation and 
actin binding; white arrows = terms associated with regulation of enzymatic activities in cells; light grey 
arrow = “extracellular matrix structural constituent”; Dark grey arrow = "mRNA binding”; * = metabolic 
terms; ** = redox regulation-associated terms.  +, red = overrepresented term (fold change from 
expected value H0 >1); -, green = underrepresented term (fold change from expected value H0 <1). In 
increasing shades of grey = fold change from the expected value H0 (the more intense, the higher the fold 
change). In increasing shades of blue = p-value (the more intense, the lower the p-value). A p-value lower 
than 0.05 was regarded as significant. 
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Table 3.9: GO Cellular Component overrepresentation test on UUO-overexpressed and -
underexpressed proteins, performed by PANTHER. Statistical overrepresentation test was 
performed by PANTHER (http://www.pantherdb.org) using the annotation terms for PANTHER GO-
slim Cellular Component. Legend: Dark arrows = cytoskeletal proteins; grey arrows = extracellular 
proteins; * = cytoplasmic and mitochondrial proteins. +, red = overrepresented term (fold change from 
expected value H0 >1); -, green = underrepresented term (fold change from expected value H0 <1). In 
increasing shades of grey = fold change from the expected value H0 (the more intense, the higher the fold 
change). In increasing shades of blue = p-value (the more intense, the lower the p-value). A p-value lower 
than 0.05 was regarded as significant. 
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Table 3.10: PANTHER Protein Class overrepresentation test on UUO-overexpressed and -
underexpressed proteins, performed by PANTHER. Statistical overrepresentation test was 
performed by PANTHER (http://www.pantherdb.org) using the annotation terms for PANTHER Protein 
Class. Legend: Black arrows = terms associated with cytoskeletal organisation and actin binding; light 
grey arrows = terms associated with extracellular matrix composition and organisation; white arrows = 
proteolytic activity; dark grey arrows = mRNA splicing/processing. * = metabolic terms; ** = redox 
regulation-associated terms. +, red = overrepresented term (fold change from expected value H0 >1); -, 
green = underrepresented term (fold change from expected value H0 <1). In increasing shades of grey = 
fold change from the expected value H0 (the more intense, the higher the fold change). In increasing 
shades of blue = p-value (the more intense, the lower the p-value). A p-value lower than 0.05 was 
regarded as significant. 
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3.4.4.6 Statistical overrepresentation test of PANTHER Pathways and KEGG Pathways 
upregulated or downregulated upon UUO 
In order to determine which molecular pathways were significantly enriched by UUO, 
statistical overrepresentation analysis was carried out using both PANTHER Pathways 
annotation terms of PANTHER bioinformatic tool and KEGG pathways annotation terms on 
DAVID database (Table 3.11, 3.12).  
PANTHER Pathways significantly enriched by UUO (Table 3.11) were “Integrin signalling 
pathway” (P00034), “Cytoskeletal regulation by Rho GTPase” (P00016), “Inflammation 
mediated by chemokine and cytokine signalling pathway” (P00031), “Blood coagulation” 
(P00011) and “Nicotinic acetylcholine receptor signalling pathway” (P00044). Pathways 
significantly underexpressed (Table 3.11) were almost exclusively related to metabolism 
aimed to energy production. Examples of these were “Fructose galactose metabolism” 
(P02744), “ATP synthesis” (P02721), “Glycolysis” (P00024) and, as the more significant, “TCA 
cycle” (P00051).  
 
Table 3.11: PANTHER Pathway overrepresentation test on UUO-overexpressed and -
underexpressed proteins.  Statistical overrepresentation test was performed by PANTHER 
(http://www.pantherdb.org) using the annotation terms ontologies for PANTHER Pathways. Legend: +, 
red = overrepresented term (fold change from expected value H0 >1); -, green = underrepresented term 
(fold change from expected value H0 <1). In increasing shades of grey = fold change from the expected 
value H0 (the more intense, the higher the fold change). In increasing shades of blue = p-value (the more 
intense, the lower the p-value). A p-value lower than 0.05 was regarded as significant. 
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Overrepresented KEGG Pathways when analyzed by DAVID (Table 3.12) were in line with the 
previous analysis of PANTHER Pathways. The most enriched pathways upon UUO (Table 
3.12A) were associated with cell adhesion and cytoskeletal dynamics [Focal adhesion 
(mmu04510), Tight junction (mmu04530), Regulation of actin cytoskeleton (mmu04810)], to 
the extracellular matrix system [ECM-receptor interaction (mmu04512)], to mRNA splicing 
[Spliceosome (mmu03040)] and to inflammation and wound healing [Complement and 
coagulation cascades (mmu04610), Leukocyte transendothelial migration (mmu04670), Fc 
gamma R-mediated phagocytosis (mmu04666)]. A series of disease pathways that can be 
related to inflammation and scarring were also enriched in this model, these pathways were 
associated with heart diseases [Dilated cardiomyopathy (mmu05414), Viral myocarditis 
(mmu05416), Hypertrophic cardiomyopathy (mmu05410)] or other pathologies [Small cell 
lung cancer (mmu05222), Systemic lupus erythematosus (mmu05322)]. Vascular smooth 
muscle contraction (mmu04270) pathway was also enriched by UUO, possibly related to the 
mesenchymal cells activation and contraction characterizing fibrosis.   
KEGG pathways underexpressed by UUO (Table 3.12B) were again mostly metabolic and 
associated with energy supply to the organism, including sugar, lipids and aminoacid 
metabolism [for example, Glycolysis/Gluconeogenesis (mmu00010), TCA cycle (mmu00020), 
Oxidative phosphorylation (mmu00190), Starch and sucrose metabolism (mmu00500), 
Fructose and mannose metabolism (mmu00051), Fatty acid metabolism (mmu00071), 
Synthesis and degradation of ketone bodies (mmu00072), Arginine and proline metabolism 
(mmu00330), Tryptophan metabolism (mmu00380) etc.]. This is in agreement with findings 
in section 3.4.4.4 and 3.4.4.5. Some disease pathways were also found downregulated by UUO 
(enriched in UUO-underexpressed group): specifically, these were Parkinson's disease 
(mmu05012), Huntington's disease (mmu05016) and Alzheimer's disease (mmu05010).  
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Table 3.12: KEGG overrepresentation test on UUO-overexpressed and -underexpressed proteins 
performed on DAVID. Statistical overrepresentation test was performed in DAVID 
(http://david.abcc.ncifcrf.gov) using the annotation terms ontologies KEGG Pathways. The number of 
proteins belonging to the annotation term and fold change from the expected value H0 are in increasing 
shades of red for the UUO-overexpressed proteins (the higher the more intense)(A) and of green for the 
UUO-underrepresented proteins (the higher the more intense)(B). The p-value is shown in increasing 
shades of blue (the more intense, the lower the p-value). A p-value lower than 0.05 was regarded as 
significant. 
 
 
 
CHAPTER III – RESULTS 
 
159 
 
3.4.4.7 Protein-protein interaction analysis performed on String 
To determine if the proteins overexpressed or underexpressed in UUO, and possibly belonging 
to some key significantly altered classes or pathways, were also able to directly or indirectly 
interact between themselves, interactions among the UUO- underexpressed or overexpressed 
proteins were investigated using the STRING bioinformatic tool, a database that collects all the 
known and reported protein-protein interactions.  
The network of interaction obtained for the UUO-overexpressed proteins is reported in Fig. 
3.11. Among the proteins enriched in UUO, a series of clusters of interacting proteins was 
detected. To confirm our initial observations [3.4.4.2], a significant group of interacting ECM 
components was identified, composed by a large cluster of collagens (a), but also including a 
number of fibrillins, fibulins (b), laminins (c), and FN (d). The already mentioned small 
extracellular proteoglycans and HSPGs (e), the latter associated with the glomerular and 
tubular basement membrane, were directly associated with the other matrix proteins in the 
network.   
By functional analysis, cytoskeletal organisation and regulation of actin polymerisation were 
highlighted as a significantly represented protein functions among the UUO-overexpressed 
proteins [3.4.4.4 – 3.4.4.5], suggesting a substantial promotion of cytoskeletal remodelling in 
fibrotic conditions. In agreement with this, a large cluster of proteins associable to cytoskeletal 
organisation was identified, consisting of mostly actin types or proteins directly associated 
with actins (f). Among these proteins, some are known markers of mesenchymal cells such as 
α-SMA, vimentin and desmin (g),  in agreement with fibroblasts proliferation and activation to 
myofibroblasts phenotype associated with the rapid fibrosis progression in UUO.  
Hubs of proteins associated with inflammation, such as complement proteins (h) as well as a 
considerable group of annexins (i), are also identified by the network, in agreement with their 
suggested involvement in stress response or cell death during the progression of kidney 
fibrosis [3.4.4.1]. In line with what we already highlighted in Table 3.3, a significant cluster of 
serine protease inhibitors of the serpin superfamily was also identified (j), and might suggest 
a role for these proteins in the promotion of fibrosis by slowing down fibrolytic processes.  
Finally, a node of proteins involved in RNA binding, regulation of mRNA maturation and 
splicing is evident in the interaction network (k) as already suggested by functional analysis 
[3.4.4.4 – 3.4.4.5] and might highlight an altered or even alternative regulation of protein 
expression upon CKD.  
When protein-protein interactions in UUO-underexpressed proteins were analyzed (Fig. 
3.12), the resulting network was extremely rich in interactions compared to the interactions 
in UUO-overexpressed proteins. A main cluster of metabolic proteins, mostly cytoplasmic or 
mitochondrial, with few sparse protein connections around, was obtained, suggesting that the 
metabolism-associated proteins are the most altered in the fibrotic kidney. 
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Figure 3.11: Network of protein-protein interactions of UUO-overexpressed proteins. Network of 
known and predicted protein-protein interactions was designed in STRING (http://string-db.org)  using 
the list of proteins overexpressed in UUO kidney. A confidence of at least 0.4 (middle confidence in 
STRING) was chosen as threshold for the interactions identified. Results were exported on Cytoscape 
(http://www.cytoscape.org) for graphical visualisation.   
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Figure 3.12: Network of protein-protein interactions of UUO-underexpressed proteins. Network 
of known and predicted protein-protein interactions was designed in STRING (http://string-db.org)  
using the list of proteins underexpressed in UUO. A confidence of at least 0.4 (middle confidence in 
STRING) was chosen as threshold for the interactions identified. Results were exported on Cytoscape 
(http://www.cytoscape.org) for graphical visualisation. 
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3.4.5 SWATH-MS approach allows to identify a larger amount of proteins 
significantly altered in UUO kidneys in comparison with previous studies  
The UUO-differentially expressed proteins were compared to those obtained previously in rat 
in the same model of CKD (Table 3.13). 
 
Table 3.13: Summary of the most recent proteomic studies performed on UUO models. 
Protein list 
from 
Treatment Sample Technique 
Total 
proteins 
detected 
UUO differentially 
expressed proteins 
Of which 
Overexpressed 
Yuan et al. 
(Sci Rep, 
2015)  
UUO 
1 week and 
3 weeks 
Urine 
LC-MS/MS DDA (Triple 
TOF 5600 mass 
spectrometer - SCIEX, 
Canada) 
 500 
proteins 
23 
 (7 after 1 week and 18 
after 3 weeks 
23 
Zhao et al. 
(Int.J Clin 
Exp Path, 
2015) 
UUO 
12, 24 and 
72 hours 
Tissue 
2-DE + MALDI-
TOF/TOF (ABI 4800 
Proteomics Analyzer 
mass spectrometer, 
Applied Biosystems, 
USA). 
~ 800 
spots/ gel 
39 
 (21 after 12 hr,  
9 after 24 hr and 
12 after 72 hr)  
31 
Current 
Study 
UUO 
3 weeks 
Tissue 
LC-MS/MS 
SWATH-DIA  
(Triple TOF 5600 mass 
spectrometer - SCIEX, 
Canada) 
2106 653 195 
  
 
Table 3.14 displays all the proteins identified as differentially expressed in UUO by Yuan and 
colleagues and Zhao and colleagues (Yuan, et al. 2015, Zhao, et al. 2015b) and investigates their 
identification in the current proteomic study.  
Of the 23 proteins identified as overexpressed in UUO by Yuan et al. (Yuan, et al. 2015), 10 were 
also identified as overexpressed in our model, of which seven at a significant level (confidence 
> 80%) and three at a less significant level (50<confidence<80, displayed in Suppl. Table 3.1) 
(Table 3.14). Four proteins were instead found underexpressed in the current study, of which 
one, aminopeptidase N, at a significant level. This is understandable if we consider that 
aminopeptidase N is an early urine marker for this study (Yuan, et al. 2015) and can either be 
downregulated at later stages of the disease or be mainly identified in urine upon UUO.  
At 21 days post-UUO, which is the same time-point of advanced fibrosis employed in the 
current study, 18 were the proteins identified by Yuan et al. (Yuan, et al. 2015) of which eight 
were identified by the current study, six at a significant level and two at a confidence level 
between 50 and 80% (Table 3.14). In general, the 30.4% of proteins suggested as urinary 
markers by Yuan et al. were significantly identified in the UUO model by SWATH-MS, number 
that rises to 43.5% if we consider also the less significant proteins (confidence <0.8). If we 
narrow the analysis to the sole proteins upregulated in urine at 21 days, 33.3% of proteins 
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were significantly (confidence≥0.8) identified by SWATH-MS which rises to 44.4% if we lower 
the confidence level to 50% (Table 3.14).  
A different situation was found when the current study was compared to the list of proteins 
identified by Zhao et al. in 2015 (Zhao, et al. 2015b) (Table 3.14). In this latter work, in fact, 
despite whole kidney lysates were employed as in the current study, early time points were 
used (less than a week), ending up with the identification of early marker of inflammatory or 
ischemic reaction and not markers of an advanced fibrosis. Of the 31 proteins found 
overexpressed in the UUO model at either 12, 24 or 72 h by Zhao and colleagues, only 10 
(32.2%) were found overexpressed in our SWATH-MS analysis at 21 days post UUO, of which 
7 in a significant manner (22.6%)(Table 3.14). Interestingly, 19 proteins were found 
underexpressed in our model (61.3%), of which 15 in a significant manner (48.4%), and three 
at a confidence between 0.5 and 0.8 (9.7%) (Table 3.14). These proteins were mostly markers 
of the earlier time-points (12-24 h), and are likely to be proteins overexpressed as an 
immediate inflammatory response or antioxidant response to ischemia, then underexpressed 
when the fibrosis is at its late stages. Only two proteins (6.4%) were not detected at all (Table 
3.14).  Zhao and colleagues also identified nine proteins as significantly underexpressed in 
UUO (two at 24 hr and 7 at 72 h); of these proteins, seven (77.8%) were found significantly 
downregulated also by SWATH-MS, while two were found overexpressed, one significantly at 
a confidence higher than 0.8 and one less significantly (confidence 0.77) (Table 3.14).  
The comparison of the current study with both papers was collected in Suppl. Table 3.13, that 
provides an alternative way to see the results, showing only the proteins detected by SWATH-
MS and the corresponding expression in previous literature. Suppl. Table 3.14 summarizes 
the overlap between the previous analyses and the UUO-overexpressed proteins in the current 
study.  
In summary, of the 54 proteins found overexpressed in UUO either in urine or in tissue by the 
two recent papers using a less sensitive technique, 19 were detected also SWATH-MS, of which 
13 in a significant manner [C(FC)≥0.8]. These proteins represent approximately the 8% of all 
the proteins detected by SWATH-MS. 23 of these proteins were instead found underexpressed 
in our model, of which 15 were significant (80% confidence).  
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Table 3.14: List of proteins reported as differentially expressed in the UUO model from recent 
literature and corresponding detection in the current study. Legend: +, red = overexpressed 
proteins in the study (positive fold change from the Sham operated control); -, green =underexpressed 
proteins in the study (negative fold change from the Sham operated control); in increasing shades of 
grey = absolute fold change from the sham operated control in the current study (the more intense, the 
more overexpressed or underexpressed depending on the direction of difference) ; bright yellow = 
confidence ≥ 0.8 in the current study  (considered significant in the current study); pale yellow = 0.5 > 
confidence < 0.8 in the current study;  * = A1AT1 as example value, but also other isoforms (A1AT2, 
A1AT4 and A1AT5) were detected as overexpressed ** = MUP2 as example value, but also MUP6 was 
detected as overexpressed, while MUP3 was detected as underexpressed. 
Proteins Identified as differentially expressed in UUO by Yuan et al., 2015      
IN URINE Current study 
Name days post UUO 
Direction of 
difference 
FC 
(UUO/Sham) C(FC) 
Alpha-actinin 1 ACTN1 21 + + 4.22 0.96 
Alpha-actinin 4 ACTN4 21 + + 1.46 0.70 
Aminopeptidase N AMPN 7 + - 3.83 0.95 
Annexin A1 ANXA1 21 + + 8.17 0.84 
Cathepsin D CATD 7 + + 2.65 0.82 
Clusterin CLUS 21 + + 5.35 0.81 
Complement component C9 CO9 21 +    
Golgi resident protein GCP-60 GCP60 21 +    
Cluster of Histone H1-4 H14 21 + - 1.32 0.18 
Intraflagellar transport protein 172 homolog IF172 7 +    
Ig gamma-1 chain C region IGHG1 21 +    
Galectin 3 - binding protein LG3BP 7 + + 5.78 0.67 
Lumican LUM 21 + + 6.55 0.87 
Moesin MOES 21 + + 1.52 0.81 
Periaxin PRAX 21 +    
Glycogen phosphorylase PYGM 7, 21 +    
Protein S100-A8 S10A8 21 +    
Protein S100-A9 S10A9 7, 21 + + 3.03 0.54 
Solute carrier family 12 member 7 S12A7 7 +    
Extracellular Superoxide dismutase SODE 21 + - 1.30 0.31 
Serine protease Inhibitor A3N SPA3N 21 +    
Transaldolase TALDO 21 + - 1.34 0.57 
Cluster of Vimentin VIME 21 + + 8.56 0.90 
 
Proteins IdentifIed as differentially expressed in UUO by Zhao et al., 2015           
 IN KIDNEY TISSUE 
Current study 
Name 
days post 
UUO 
Direction of 
difference 
Fold change 
UUO/Sham 
Confidence 
3-hydroxyantharanilate 3,4-dioxygenase 3HAO 72 + - 15.56 0.85 
Alpha-1 antiproteinase A1AT 72 + + 3.07 * 0.86 
abhydrolase domain-containing protein 14B ABHEB 12 + - 5.57 0.93 
Actin, aortic smooth muscle ACTA 72 - + 3.17 0.94 
Aspartoacylase-2 ACY3 72 - - 12.43 0.80 
Alanine glyoxylate aminotransferae 2, mitochondrial AGT2 12 + - 9.01 0.71 
4'-Trimethylaminobutyraldehyde dehydrogenase AL9A1 24 - - 5.76 0.94 
Serum albumin ALBU 72 + + 2.98 0.92 
Aldose reductase related protein 1  ALD1 24 + + 3.96 0.44 
Annexin A1 ANXA1 12 + + 8.17 0.84 
Annexin A2 ANXA2 12 + + 3.76 0.90 
Annexin A4 ANXA4 72 + + 1.78 0.85 
Aflatoxyn B1 aldheyde reductase member 3 ARK73 12 +       
ATP synthase subunit D, mitochondrial ATP5H 12 + - 7.21 0.93 
ATP synthase subunit beta, mitochondrial ATPB 12 + - 6.55 0.94 
Branched chain anìmino acid aminotransferase, 
mitochondrial 
BCAT2 12 + - 4.38 0.89 
Macboxymethylenebutenolidase homolog CMBL 72 - - 5.38 0.85 
Electron transfer flavoprotein subunit beta ETFB 12 + - 8.13 0.91 
Fibronogen beta chain FIBB 12 + + 4.00 0.86 
Glycine aminotransferase, mitochondrial GATM 24 + - 13.91 0.87 
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Guanine nucleotide binding protein G(I)/G(S)/G(T) subunit 
beta-2 
GBB2 12 + - 1.38 0.47 
Gamma glutamyltranspeptidase  GGT1 24 + - 13.58 0.89 
Gluthatione peroxydase 1 GPX1 72 - - 3.45 0.92 
Phospholipid hydroperoxide glutathione peroxidase, 
mitochondrial 
GPX41 12 + - 4.18 0.52 
Gluthatione S-transferase Mu 2 GSTM2 12 + + 1.29 0.17 
Gluthatione S transferase P GSTP1 24 + - 1.77 0.94 
Gluthatione S-transferase P GSTP1 72 - - 1.77 0.94 
Isocitrate dehydrogenase (NAD) subunit alpha, 
mitochondrial.  
IDH3A 24 - - 4.86 0.91 
Adenylate kinase isoenxyme 4, mitochondrial KAD4 24 + - 19.83 0.89 
Meprin A subunit alpha MEP1A 12 + - 7.15 0.88 
Mayor urinary protein MUP 72 - + 2.79 ** 0.77 
2-oxoisovalerate dehydrogenase subunit alpha, 
mitochondrial 
ODBA 12 + - 10.29 0.64 
Pyruvate dehydrogenaseE1 component subunit beta, 
mitochondrial 
ODPB 72 - - 6.05 0.96 
Protein disulfide isomerase A6 PDIA6 12 + + 1.68 0.90 
Phosphatidylethanolamine binding protein 1 PEBP1 12 + - 1.92 0.92 
Peroxiredoxin  PRDX1 12 + - 2.03 0.91 
Etherogenous nuclear ribonucleoproteinsA2/B1 ROA2 24 + + 1.27 0.38 
Serine protease inhibitor A3N SPA3N 12, 24, 72 +       
Thiosulfate sulfutransferase THTR 12 + - 7.75 0.89 
Voltage dependent anion selective channel protein 2 VDAC2 12 + - 2.84 0.94 
 
 
3.4.6 Residual analysis of SWATH-MS protein spectral results gives a lower 
number of protein significantly altered from prediction.  
In parallel with the fold change analysis performed by OneOmics cloud processing software 
(SCIEX, Canada), an analysis of residuals from the linear regression lines between WT UUO and 
WT Sham operated spectral data was performed, as described in 3.3.8.  
First, regression lines were drawn using protein intensity values in UUO (dependent variable 
y) and protein intensity values in Sham operated conditions (independent variable x) foreach 
protein hit, for every of the 16 combinations of kidney samples as described in 3.3.8. Sixteen 
non-overlapping regression lines were obtained, with a slope between ~0.49 and  ~0.63 (Fig. 
3.13A). A second regression line using the mean spectral values of the four UUO WT mice and 
the four Sham operated WT mice was produced as well, showing a slope of 0.58 and an R2 value 
of 0.43 (Fig. 3.13B). From these results, a low correlation (R-squared between 0.30 and 0.55) 
was observed between the treatments, and the relationship was biased towards higher values 
for the Sham operated kidneys, since the slope of the regression curves was lower than one, 
and always around 0.5-0.6. This reflects a generally higher expression of proteins in the healthy 
kidney (below y=x, red dashed line), compared to the proteins overexpressed by UUO (above 
y=x, red dashed line), which can be associated with an increased cell death or to a more difficult 
homogenization of a fibrotic tissue.  
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Figure 3.13: Regression lines between spectral values of UUO and Sham operated wild type mice. 
Regression analysis was performed on (A) every of the 16 combinations of UUO (dependent variable y) 
and Sham operated mice (independent variable x) normalized intensity values of every protein detected 
by SWATH-MS. Single protein points (x=intensity in Sham; y=intensity in UUO) and regression lines are 
shown in the graph for each combination of samples. Two representative regression line equations and 
R-squared values are displayed. (B) The same analysis was performed using the mean values of the 4 
UUO and Sham operated biological replicas. Mean protein points (x= mean intensity in Sham; y=mean 
intensity in UUO) with relative error bars (standard deviations) are shown. The regression line is shown 
in black and the corresponding equation and R-squared value are displayed. In both graphs, the red 
dashed line is the bisector of the 1st nd 3rd quadrant, corresponding to the y=x. 
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Residual analysis was then performed as described in the Experimental procedure. As it can be 
seen in Table 3.15, 48 proteins were identified as significantly (p≤0.05) different from the 
predicted value in UUO (predicted value = y’, obtained from the regression line). The exact half 
of these proteins (24 proteins) had positive mean of standardized residual (in increasing 
shades of red) and p-value lower than 0.05, and were regarded as significantly higher than the 
prediction. The other 24 proteins had negative mean of standardized residual (decreasing 
shades of green) and p-value lower than 0.05, and were considered significantly lower than the 
prediction.  
In order to see if these variations were overlapping with the list of UUO-differentially 
expressed proteins reported in the previous paragraphs, the same proteins were searched in 
the fold change dataset obtained with OneOmics (SCIEX, Canada) (last 2 columns of Table 
3.15). The number of proteins identified in this way by residual analysis was much smaller. No 
complete overlap was identified between the 2 analyses, especially for what it concerns the 
proteins whose residuals were significantly higher than the regression line. This is because the 
fold change analysis is based on the identification of proteins significantly different from an 
y=x assumption (bisector of the first/third quadrant, red dashed line in Fig. 3.13) while the 
residual analysis is based on the identification of proteins whose spectral value significantly 
different from the prediction, determined by the regression line, that, in this case, has a much 
lower slope (~0.5-0.6). A graphical view is presented in Fig. 3.14 showing the regression line 
obtained from the mean spectral values, as well as the y=x red dashed line. In red are shown 
some proteins identified as significantly higher than the prediction (mean standard residual 
≥0, p≤0.05) that were also identified as significantly overexpressed upon UUO (FC > 1 or  
log2(FC) > 0 , C(FC) ≥ 0.8). These proteins are all located above both the regression line and 
the y=x line. In green there are some proteins identified as significantly lower than the 
prediction (mean standard residual ≤ 0, p≤0.05) that were also identified as significantly 
underexpressed upon UUO (FC <1 or log2(FC) <0 , C(FC)≥ 0.8). These proteins are all located 
below the regression line. Finally, in blue are shown some of proteins that, however identified 
as significantly higher than the prediction by residual analysis (mean standard residual ≥0, 
p≤0.05), were not significantly overexpressed during UUO. These proteins can generally be 
found between the regression line and the y=x line (see PPIA_MOUSE or EF1A1_MOUSE) or 
anyway near the bisector (such as the histone proteins H2B1P_MOUSE and H4_MOUSE) and 
might have a high variability in protein intensity among replicas (large error bars, as it can be 
seen for haemoglobin HBA_MOUSE).  
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Table 3.15: List of proteins identified by SWATH-MS on wild type (WT) mice having a spectral 
intensity significantly different from the predicted value on the regression line. Regression 
analysis was performed for each of the 16 possible combinations of UUO and Sham operated WT mice, 
and mean standard residuals were obtained for every protein identified by SWATH-MS. P-values were 
obtained by plotting the mean standard residuals on a normal standard distribution, and a p-value lower 
than 0.05 was regarded as significant. The table reports the proteins with residuals significantly positive 
(spectral values significantly higher than the predicted y’), in increasing shades of red, or negative 
(spectral values significantly lower than the predicted y’), in decreasing  shades of green. Significand p-
values are reported in increasing shades of blue, the more intense the more significant. The last two 
columns show the fold change values obtained for the given protein with the OneOmics software (SCIEX, 
Canada) (in increasing shades of red the positive log2 of the fold change and in decreasing shades of 
green negative log2 of the fold change) with the corresponding confidence highlighted in yellow if 
accepted as significant (higher than 0.8). 
Residual analysis UUO vs SHAM 
Fold Change 
Analysis  
Protein ID Name 
Mean  
Residual 
P-value 
Log2 
(FC) 
C(FC) 
ALBU_MOUSE Serum albumin 25.66 4.67E-144 1.58 0.92 
HBA_MOUSE Hemoglobin subunit alpha 14.42 2.77E-46 0.44 0.71 
ACTB_MOUSE Actin, cytoplasmic 1 11.56 4.02E-30 0.64 0.93 
UROM_MOUSE Uromodulin 7.46 3.25E-13 4.03 0.85 
CO1A1_MOUSE Collagen alpha-1(I) chain 7.19 2.38E-12 2.93 0.96 
VIME_MOUSE Vimentin 6.46 3.47E-10 3.10 0.90 
H2B1P_MOUSE Histone H2B type 1-P 6.28 1.12E-09 0.34 0.17 
H4_MOUSE Histone H4 5.50 1.07E-07 0.38 0.10 
CO3A1_MOUSE Collagen alpha-1(III) chain 5.22 4.74E-07 2.95 0.92 
CO4A2_MOUSE Collagen alpha-2(IV) chain 5.07 1.05E-06 2.17 0.80 
TAGL2_MOUSE Transgelin-2 4.50 1.60E-05 1.60 0.88 
TPM4_MOUSE Tropomyosin alpha-4 chain 2.98 4.64E-03 2.07 0.91 
APOA1_MOUSE Apolipoprotein A-I 2.97 4.87E-03 1.30 0.92 
PPIA_MOUSE Peptidyl-prolyl cis-trans isomerase A 2.89 6.21E-03 -0.23 0.32 
ACTA_MOUSE Actin, aortic smooth muscle 2.87 6.58E-03 1.67 0.94 
CO1A2_MOUSE Collagen alpha-2(I) chain 2.85 6.95E-03 3.09 0.79 
MYL6_MOUSE Myosin light polypeptide 6 2.61 1.31E-02 1.34 0.92 
PROF1_MOUSE Profilin-1 2.33 2.64E-02 1.07 0.89 
EF1A1_MOUSE Elongation factor 1-alpha 1 2.31 2.78E-02 -0.32 0.35 
ABCB7_MOUSE ATP-binding cassette sub-family B member 7, mitochondrial 2.30 2.83E-02 0.92 0.89 
ECHD3_MOUSE Enoyl-CoA hydratase domain-containing protein 3, mitochondrial 2.27 3.05E-02 -2.46 0.67 
K2C8_MOUSE Keratin, type II cytoskeletal 8 2.23 3.34E-02 2.30 0.89 
LEG1_MOUSE Galectin-1 2.22 3.41E-02 2.62 0.87 
TAGL_MOUSE Transgelin 2.06 4.78E-02 3.21 0.89 
COX5B_MOUSE Cytochrome c oxidase subunit 5B, mitochondrial -2.08 4.58E-02 -3.04 0.91 
F16P1_MOUSE Fructose-1,6-bisphosphatase 1 -2.27 3.01E-02 -4.38 0.81 
CALB1_MOUSE Calbindin -2.39 2.29E-02 -5.00 0.91 
COX5A_MOUSE Cytochrome c oxidase subunit 5A, mitochondrial -2.55 1.54E-02 -3.18 0.94 
COX41_MOUSE Cytochrome c oxidase subunit 4 isoform 1, mitochondrial -2.56 1.50E-02 -2.90 0.94 
ACADM_MOUSE Medium-chain specific acyl-CoA dehydrogenase, mitochondrial -2.61 1.32E-02 -3.86 0.86 
MMSA_MOUSE 
Methylmalonate-semialdehyde dehydrogenase [acylating], 
mitochondrial 
-2.67 1.14E-02 -3.79 0.88 
MDHM_MOUSE Malate dehydrogenase, mitochondrial -2.71 1.03E-02 -2.73 0.96 
COX2_MOUSE Cytochrome c oxidase subunit 2 -2.76 8.87E-03 -3.00 0.87 
S100G_MOUSE Protein S100-G -2.85 6.93E-03 -4.05 0.90 
AT1B1_MOUSE Sodium/potassium-transporting ATPase subunit beta-1 -3.03 4.00E-03 -4.29 0.87 
AADAT_MOUSE Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial -3.06 3.65E-03 -5.59 0.84 
ECHP_MOUSE Peroxisomal bifunctional enzyme -3.06 3.64E-03 -4.32 0.84 
ACSM2_MOUSE Acyl-coenzyme A synthetase ACSM2, mitochondrial -3.11 3.14E-03 -4.33 0.86 
MDHC_MOUSE Malate dehydrogenase, cytoplasmic -3.13 2.97E-03 -2.30 0.95 
AK1A1_MOUSE Alcohol dehydrogenase [NADP(+)] -3.42 1.14E-03 -3.40 0.91 
ASSY_MOUSE Argininosuccinate synthase -3.50 8.60E-04 -4.41 0.88 
ADT2_MOUSE ADP/ATP translocase 2 -3.56 7.17E-04 -2.82 0.81 
UK114_MOUSE Ribonuclease UK114 -4.02 1.23E-04 -3.67 0.94 
ALDOB_MOUSE Fructose-bisphosphate aldolase B -4.95 1.87E-06 -3.83 0.93 
PRDX5_MOUSE Peroxiredoxin-5, mitochondrial -5.07 1.03E-06 -2.65 0.91 
AT1A1_MOUSE Sodium/potassium-transporting ATPase subunit alpha-1 -5.10 8.80E-07 -3.72 0.93 
ATPB_MOUSE ATP synthase subunit beta, mitochondrial -5.65 4.59E-08 -2.71 0.94 
ATPA_MOUSE ATP synthase subunit alpha, mitochondrial -9.15 2.72E-19 -2.69 0.96 
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Figure 3.14: Location of specific candidates identified by residual analysis on the cartesian plane, 
with respect to the regression line and the y=x quadrant bisector line. Regression analysis was 
performed on Office Excel using the mean values of the 4 UUO and Sham operated biological replicas. 
Mean protein points P(x= mean intensity in Sham; y=mean intensity in UUO) with relative error bars 
(standard deviations) are shown. The regression line is shown in black while bisector of the quadrant, 
corresponding to the y=x line, is shown as a red dashed line. The name of specific proteins is shown in 
red (proteins with positive significant standard residuals, p≤0.05, and significantly overexpressed in 
UUO, confidence ≥ 0.8), blue (proteins with positive significant standard residuals, p≤0.05, but not 
significantly overexpressed in UUO) or green (proteins with negative significant standard residuals, 
p≤0.05, and significantly underexpressed in UUO, confidence ≥ 0.8).  
 
In this chapter, residual analysis was employed as an alternative method to the fold change 
analysis to determine which proteins were significantly altered in the UUO comparing to the 
Sham operated condition. However, given the fact that the regression curves had a slope much 
lower than the y=x bisector curve (slope = 1), the outcome of both analyses resulted not to be 
comparable. The lower  slope of regression curve is probably due to the fact that in the healthy 
(Sham) condition the proteins detected by the machine in equal amounts of total protein (from 
a 1 µg/µl sample concentration) were more evenly distributed in their relative intensity, while 
in the UUO condition the same amount of total lysate (from the same 1 µg/µl sample 
concentration) was represented by few highly abundant proteins, with albumin above all, and 
a more elevated number of less abundant proteins. Therefore, while the analysis of residuals 
gave us only an idea of which protein intensity in the UUO condition were significantly different 
from their predicted value y’ obtained by the regression line, the fold change analysis 
performed using SCIEX OneOmics gave us a more convincing idea of which proteins were 
differentially expressed by UUO compared to the Sham operated condition. Production of a 
regression line, however, was still useful to visualize how the protein intensity were 
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distributed and which were the more extremely expressed protein (highly abundant or lowly 
abundant) such as serum albumin.  
 
 
3.4.7 Analysis of the effect of TG2-KO in the UUO model of kidney fibrosis 
For the aims of Chapter IV, where the interactome of TG2 in the UUO model of kidney fibrosis 
will be produced, use of TG2-null inbred mice next to the WT individuals was necessary. In the 
past, a protective role of TG2-KO in kidney fibrosis has been suggested in TG2-KO, employing 
different models of CKD including the UUO itself (Fisher, et al. 2009, Shweke, et al. 2008).   
In this section an analysis of fibrosis development and UUO-differentially expressed proteins 
in TG2-KO mice subjected to UUO or Sham operation for 21 days will be provided, comparing 
it with the same treatments in WT mice.  
 
3.4.7.1 Histological staining of kidney samples from UUO and Sham-operated TG2-null mice 
and comparison with WT 
In order to qualitatively observe differences in kidney morphology in both WT and TG2-KO at 
21 days post-UUO (advanced/end stage fibrosis), H&E staining was performed as described 
above (3.3.2) and some representative pictures are shown in Fig. 3.15. In Sham operated 
kidneys (Fig. 3.15 a,b) no differences in renal morphology could be observed in TG2-KO mice 
(b) in comparison with the WT conditions (a) (described in the 3.4.1.1 section of this chapter). 
In TG2-null mice (b), glomeruli appeared well vascularised, normally shaped and rich in 
mesangial cells while tubules were healthy, tightly associated and clearly bordered by 
epithelial cells with no differences from the Sham operated WT mice (a). Vascularisation 
appeared not dissimilar from the WT (Fig. 3.15 a,b).   
Upon UUO (21 days), H&E highlighted a clear alteration in the organ morphology in both WT 
and TG2-null mice (Fig. 3.15, c-d). To the naked eye, no obvious difference was observed in 
TG2-KO mice undergoing fibrosis (d) comparing to the WT mice subjected to UUO (c) 
(described in 3.4.1.1). In both cases, signs of advanced-to-end stage fibrosis were highlighted, 
with general loss of renal structure, tubular atrophy and loss of tight tubular association, as 
well an advanced level of glomerulosclerosis in some glomeruli (individuated by an asterisk in 
Fig. 3.15). Eosinophilic pink staining was similar in TG2-null (d) and WT mice (c) subjected to 
21 days UUO and was clearly paler than the Sham operated controls in both tubular and 
glomerular fractions.  
These findings suggest a comparable development of fibrosis in both TG2-KO and WT mice at 
21 days post-UUO, with no evident effect of TG2-KO on the level of fibrosis at 21 days post-UUO 
with this qualitative approach.  
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Figure 3.15: Haematoxylin and eosin (H&E) staining of kidney sections from the 21 days-UUO 
model in WT and TG2-KO mice. H&E staining of paraffin sections was performed at the Department 
of Infection, Immunity & Cardiovascular Disease of the University of Sheffield by Dr Fiona J. Wright. 
Pictures were taken with an Olympus BX61 fluorescent microscope with Cell^F imaging system software 
(Olympus, Japan). Representative images at 20X magnification are here shown. Legend: 1,2 = mostly 
cortical area; 3,4 = mostly medullar area; square bracket = renal corpuscule; arrow = Bowman’s space; 
P = proximal convoluted tubule; D = distal convoluted tubule; M = medulla; * = sclerotic glomerulus. 
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In order to visualize fibrotic tissue accumulation in TG2-null mice subjected to UUO and 
compare it with the WT condition, MT staining of paraffin embedded sections was performed 
(Fig. 3.16) and the relative accumulation of fibrillary collagen was quantified as described in 
3.3.2 (Fig. 3.17).  
In Sham operated kidneys (Fig. 3.16 a,b), no differences in renal morphology and collagen 
accumulation (blue staining) was observed between TG2-null mice (b) and WT mice (a) 
(described in 3.4.1.2). In both cases, diffuse red staining highlighted healthy and tightly 
associated renal structures while minimal blue staining was limited to the interstitial space, 
intraglomerular space or basement membranes. No significant alteration in collagen 
deposition was observed between TG2-null (b) and WT (a) Sham operated mice when the blue 
staining corresponding to fibrillary collagen was compared to cytoplasm staining (red, Fig. 
3.17A) (1.41±0.36, p=0.15) or nuclear staining (brown, Fig. 3.17B) (1.17±0.21, p=0.38). 
Upon ureteral obstruction (21 days post-UUO), the level of fibrosis observed in TG2-KO mice 
by MT staining was similar to the one of WT mice subjected the same treatment (described in 
3.4.1.2) and was comparable to and advanced/final stage of CKD (Fig. 3.16 c,d). Morphological 
alterations in fibrotic TG2-null mice (d) could be observed in both corpuscular and tubular 
portions and were comparable with what seen in WT mice subjected to UUO (c) (3.4.1.2 for 
description). In both cases, the cytosolic red staining was heavily reduced and substituted by a 
clear increase in fibrillary blue staining that accumulated in the areas of fibrotic 
tubulointerstitium and in sclerotic disrupted glomeruli. When quantification of the different 
staining colours was performed with Cell^F software (Fig. 3.17), the ratio of collagen over 
cytoplasm revealed a significant collagen accumulation upon UUO in both WT (10.76±3.13 fold 
from WT Sham, equalised to 1; p=0.002 **) and TG2-KO mice (10.08±2.70 from WT Sham, 
p=0.0003 ***; 7.15±2.48 fold from its own Sham operated control, P=0.0005 ***), with no 
significant change in collagen deposition determined by TG2-KO in UUO (p=0.99) (Fig. 3.17A).  
When, however, the accumulation of collagen was measured as ratio of collagen over the total 
number of cells (nuclear staining, Fig. 3.17B), a significant (p=0.007 **) reduction in fibrotic 
tissue accumulation was observed in TG2-KO mice subjected to UUO, compared to the 
corresponding WT mice. In TG2-KO mice, in fact, collagen accumulation was 1.64±0.30 – fold 
higher than the Sham operated WT (p=0.008 **) and only 1.40±0.19 higher than its own TG2-
KO Sham operated control (p=0.02 *). This value was significantly (p=0.007 **) lower than the 
collagen accumulation in WT mice at 21 days post-UUO when it was measured with the same 
method (3.19±0.68, p=0.0003 ***) (Fig. 3.17B) and might suggest a possible protective role of 
TG2-KO against the progression of fibrosis, that was however difficult to observe by eye at this 
level of advanced disease.  
In summary, by histological staining TG2-KO mice appeared to develop a level of fibrosis at 21-
days post UUO that can be regarded as an advanced-to-end stage fibrosis and was similar to 
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WT mice subjected to the same treatment. Quantification of collagen accumulation over the 
total number of living cells (Fig. 3.17B), however, revealed a significant reduction in TG2-KO 
UUO mice compared to the fibrotic WT, that might suggest a protective role of TG2 abolishment 
in UUO. This is in line with previous findings in the same model, where however an earlier time 
point was employed (12 days UUO) (Shweke, et al. 2008).  
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Figure 3.16: Masson’s trichrome (MT) staining of kidney sections from the 21 days- UUO model 
in WT and TG2-KO mice. In order to visualise and quantify the development of fibrosis, MT staining of 
paraffin sections were performed at the Department of Infection, Immunity & Cardiovascular Disease of 
the University of Sheffield by Dr Fiona J. Wright.  Pictures were taken with an Olympus BX61 fluorescent 
microscope with Cell^F imaging system software (Olympus, Japan). Representative images at 20X 
magnification are here shown. Legend: 1,2 = mostly cortical area;  3,4 = mostly medullar area; square 
bracket = renal corpuscule; arrow = Bowman’s space; P = proximal convoluted tubule; D = distal 
convoluted tubule; * = sclerotic glomerulus; thick white arrow = interstitial space; thin white arrow = 
intraglomerular matrix;  white triangles = basement membrane. 
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Figure 3.17: Quantification of renal fibrosis by Masson’s trichrome (MT) staining. In order to 
quantify the level of fibrosis in WT and TG2-KO mice subjected to 21 days UUO (Fig. 3.16), quantification 
of MT-stained sections was performed with Cell^F imaging system software (Olympus, Japan). The level 
of fibrosis was measured as (A) ratio of phase 2 (collagen, light blue) over phase 1 (cytoplasm, pink) or 
as (B) ratio of phase 2 (collagen, light blue) over phase 3 (nuclei, brown). Data represent mean values 
expressed relative to the WT sham operated control (equalised to 1) ± SEM, n=24 different fields per 
treatment covering both cortical and medullar areas. Significance of the differences between 
treatments/phenotypes was determined by T-test: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = 
p<0.0001. 
 
 
3.4.7.2 Investigation of α-SMA expression and TGF-β1 activation in TG2-null kidneys 
subjected to UUO 
In order to verify the knock-out of TG2 at a protein level, kidney lysates from TG2-KO mice 
subjected to UUO or Sham-operation (21 days) were immunoprobed for TG2 by western 
blotting as described in 3.3.3. Subsequently, the expression of the mesenchymal marker α-SMA 
was investigated in TG2-null kidneys at 21-days post-UUO by probing the same kidney lysates.  
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In both cases, both male (N=3) and female (N=3) randomly selected kidney samples were 
tested in order to examine a possible gender bias in protein expression. In all experiments, 
constitutively expressed cyclophilin-A (CypA) was employed as loading control.  
TG2 expression was virtually absent in TG2-KO male mice subjected either to Sham operation 
or UUO (Fig. 3.18A, B), while a clear signal was observed in the WT. In females (Fig. 3.18D, E) 
TG2-immunoprobing revealed a weak signal in the TG2-null mice (Fig. 3.18D, asterisk), that 
should have a complete knock out of TG2 at a protein level (De Laurenzi and Melino 2001). 
This signal observed in TG2-KO females is likely to result from unspecific binding of the 
antibody employed to another protein, that could be also noticed in WT females, where a 
double band was evident (Fig. 3.18D, asterisk) in both UUO and Sham operated condition.  
When the same samples were probed for α-SMA, the signal was absent or low in Sham operated 
kidneys of both TG2-null male (Fig. 3.18A, C) and female (Fig. 3.18D,F) mice; it was 
comparable to the one observed in WT mice subjected to the same procedure and described 
before in 3.4.2.2, however a small (not significant) increase in signal upon TG2-KO when band 
intensity was measured by densitometry.  
At 21-days post-UUO, the α-SMA immunoreactive band at ~37 kDa was detected in TG2-KO 
mice of both genders (Fig. 3.18A, C, D, F) in line with fibrosis progression. In male mice (Fig. 
3.18A, C) α-SMA expression in TG2-KO upon 21 days-UUO was 12.55 ± 5.93 – fold higher than 
the sham operated WT control (p=0.08, not significant), normalized to 1 in the graph, and 7.14 
± 4.70-fold higher than their own TG2-null control (p=0.08, not significant). The raise in α-SMA 
expression upon UUO was lower in mice devoid of TG2 compared to the WT ones, characterized 
by an average 22-fold increase in α-SMA signal, but the difference didn’t appear significant by 
T-test (p=0.19) (Fig. 3.18 A, C). The noticeable drop in the fibrosis marker expression in TG2-
KO mice subjected to UUO, compared to WT mice, might suggest protective role of TG2 deletion 
against the progression of fibrosis, in agreement with previous studies using both general TG 
inhibitors (Skill, et al. 2004, Johnson, et al. 2007, Huang, et al. 2009) or specific TG2-KO 
(Shweke, et al. 2008, Fisher, et al. 2009). 
In female mice (Fig. 3.18 D, F), again, an increase in α-SMA could be appreciated in both WT 
and TG2-KO individuals subjected to 21-days UUO. In TG2 null mice, the increase was 3.57 ± 
1.14 – fold higher than the sham operated WT control (p=0.19, not significant), normalized to 
1 in the graph, and 2.17 ± 0.79 – fold higher than its own TG2-null control (p=0.24, not 
significant). Again, the α-SMA expression was in average lower than the signal observed in WT 
mice subjected to the same procedure, but the difference wasn’t regarded as significant when 
analyzed by T test(p=0.57). The effect was less evident in female mice than in male, and might 
suggest a gender bias in the rate of fibrosis development and/or in the protective effect of TG2 
deletion. 
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Figure 3.18: Expression of TG2 and fibrosis marker α-smooth muscle actin (α-SMA) in WT and 
TG2-KO kidney lysates from the UUO model at 21-days. Expression of TG2 and fibrosis marker α-
SMA was detected by Western blot using the specific antibodies reported in Table 3.2. Experiment was 
performed on 3 different male kidneys (A-C) or 3 different female kidneys (D-F). Specific blots are shown 
on the left (A,D). Intensity of immunoreactive bands was quantified by densitometric analysis and 
normalised to constitutively expressed Cyclophilin A (CycA). The graphs represent mean values 
expressed relative to the Sham operated control (equalised to 1) ± SD, n = 3 kidney lysates per group for 
either male (B,C) or female (D,F) mice. Significance of the differences between treatments/phenotypes 
was determined by T-test: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
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TGF-β activation is a known marker of fibrosis progression, already shown to be increased by 
UUO procedure and to be significantly inhibited by TG2-KO in a model of UUO of lower severity 
(12 days)(Shweke, et al. 2008). In line with those findings, in this chapter, we have shown how 
UUO for 21 days led to a strong increase in TGF-β1 activation [3.4.3]. In order to investigate the 
effect of TG2-KO in our model of established UUO, a TGF-β activity bioassay was performed on 
TG2-null mice subjected to UUO (21 days) or Sham operation, as described in 3.3.4.  
TGF-β activation was almost absent in Sham operated TG2-null kidneys (Fig. 3.19) and not 
different from the WT mice subjected to the same procedure. As described before in 3.4.3, UUO 
treatment for 21 days determined a strong increase of TGF-β activity in WT mice, that was 
almost 30-fold higher than the control (p<0.0001, ****). Interestingly, this activation was 
significantly driven back to basal levels (~1) in UUO TG2-KO mice (p<0.0001, ****) (Fig. 3.19). 
This confirms a crucial role for TG2 in TGF-β activation (Kojima, Nara and Rifkin 1993, Nunes, 
et al. 1997, Huang, et al. 2010b) while supporting the idea of a protective role of TG2-KO in this 
model of CKD, involving a reduced activation of the cytokine (Shweke, et al. 2008).  
 
 
Figure 3.19: Level of active TGF-β in kidney lysates from the UUO model in WT and TG2-KO mice. 
In order to measure the activation of TGF-β on WT ad TG2-null mice at 21 days post-UUO, active and 
total TGF-β were assessed using 100 µl of 10% (w/v) kidney lysate or acid-treated lysate, both 10 times 
diluted, on the MLEC system. Data represent the mean % of active TGF-β ± SD, N=3. Significance of the 
differences between treatments/phenotypes was determined by T-test: * = p<0.05, ** = p<0.01, *** = 
p<0.001, **** = p<0.0001.  
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3.4.7.3 SWATH-MS proteomic analysis of proteins differentially expressed upon TG2-KO 
shows minimal alteration due to TG2 deletion.  
In order to determine which were significantly altered in expression by TG2-KO in either 
healthy or fibrotic conditions, four randomly selected Sham operated TG2-null kidneys and 
four randomly selected UUO TG2-null kidneys, at 21 days post-surgery and of both genders, 
were analyzed by SWATH-MS as described in 3.3.6 and FC analysis was performed by 
OneOmics [3.3.6.2] against the spectral results of WT mice subjected to the same treatments 
(Fig. 3.20). In this way, differences between TG2-KO mice and WT mice were measured as fold 
change in protein expression, and, to keep consistency with the previous analysis, a confidence 
of fold change ≥0.8 was regarded as significant for variation.  The outcome of the FC analyses 
between TG2-null and WT at a confidence of fold change [C(FC)] up to 0.5, can be found in the 
Supplementary information of this thesis (Suppl. Table 3.2 = TG2-null and WT, Sham 
operated; Suppl. Table 3.3= TG2-null and WT, UUO).  
 
 
Figure 3.20: SWATH-MS Experimental setup to identify proteins significantly altered by TG2 
knock-out in healthy (Sham) or fibrotic (UUO) C57BL/6J mice. (1) = Proteins significantly altered 
upon TG2-KO in Sham operated mice - Results in Table 3.16A; (2) = Proteins significantly altered upon 
TG2-KO in UUO mice - Results in Table 3.16B 
 
Of the 2106 proteins detected by SWATH acquisition in the different samples, few  were 
identified as differentially expressed upon TG2-KO at the chosen confidence level (C(FC)≥0.8) 
and are displayed in Tables 3.16 and 3.17.  
Only 4 proteins appeared altered in TG2-null mice in Sham operated conditions, when 
compared to healthy WT mice (Table 3.16), while 31 were altered in TG2-KO mice subjected 
to 21 days – UUO, when compared to the WT counterpart (Table 3.16). In both cases, as 
expected, TG2 was significantly underexpressed, at a confidence higher than 80%.  
In Sham operated conditions (Table 3.16), three proteins were overexpressed in TG2-KO 
animals compared to the WT: one ribosomal protein (RL24_MOUSE), one histone protein 
(H14_MOUSE) and another protein called calcium-binding protein 39 (CAB39_MOUSE), a 
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protein involved in the stimulation of the activity of serine/threonine kinases activities such as 
liver kinase B1 (LKB1), which has been involved in control of  metabolism and proliferation in 
kidney cells and to be downregulated upon CKD, where its loss is associated with a pro-fibrotic 
phenotype of cells (Han, et al. 2016, Alexander and Walker 2011). TG2 (TGM2_MOUSE) was 
the only underexpressed protein, and was 9 times underexpressed comparing to WT, 
confirming the knock-out of the enzyme in this system (Table 3.16).  
In order to investigate whether other proteins were differentially expressed by TG2-KO at a 
lower confidence of fold change, the outcome of the FC analysis between TG2-null and WT 
healthy mice (Sham operated) was analysed to a confidence of 0.5 (Suppl. Table 3.2). 50 
proteins resulted increased by TG2-KO at this level of confidence, of which 26 proteins were 
either ribosomes or histone proteins [C(FC) generally ≥0.6]. The others were mostly associated 
with cell metabolism, however, few keratins resulted increased by TG2 deletions. The protein 
fermitin (URP2_MOUSE), involved in cell adhesion by binding integrin, was almost 6-times 
increased comparing to the healthy WT mice, and might reveal a compensatory effect or the 
KO, in response to loss of cellular adhesion. A number of proteins involved in intracellular 
vesicular trafficking, lysosome targeting and retromer transport were also identified.  
The downregulated proteins [log2FC (TG2-KO/WT)]<0 were only 22 at this level of confidence. 
They included for example the exosome protein transmembrane protein 256 (TM256_MOUSE) 
as 1.5-fold increased compared to the WT; this might suggest a role for TG2 in the promotion 
of exosome trafficking.  
 
Table 3.16: List of proteins differentially expressed (confidence ≥ 0.8) in the TG2-KO mice in 
Sham operated conditions, and corresponding fold change from the WT. In red the positive 
logarithm of FC from the WT mice (overexpression in TG2-KO comparing to WT) while in green the 
negative logarithm of FC (underexpression in TG2-KO comparing to WT). In shades of yellow the 
confidence of the change. A confidence ≥ 0.8 was regarded as significant 
Proteins significantly modulated by TG2-KO in Sham operated mice (21 days) 
Protein ID Name  
Log2 FC (TG2-KO 
Sham/ WT Sham) 
Abs FC (TG2-KO 
Sham/ WT Sham) 
C(FC) 
CAB39_MOUSE Calcium-binding protein 39 1.88 3.69 0.81 
RL24_MOUSE 60S ribosomal protein L24 0.85 1.81 0.90 
H14_MOUSE Histone H1.4 0.81 1.75 0.84 
TGM2_MOUSE Transglutaminase 2 -3.16 8.94 0.84 
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In UUO conditions (Table 3.17), the situation observed was slightly different, with a higher 
amount of overexpressed proteins as a consequence of TG2-KO at a confidence level of 0.8. In 
this case, in fact, 28 proteins were upregulated in TG2-null mice compared to the WT ones. 
Interestingly majority of these proteins, 19, were ribosomal, while 7 were histone proteins 
(Table 3.17). RL24_MOUSE and H14_MOUSE, that were the only ribosomal protein and the 
only histone protein overexpressed in TG2-null Sham operated mice (Table 3.17), were 
detected also in this list (Table 3.17) at C(FC)≥0.8. The remaining two proteins overexpressed 
in TG2-KO UUO mice compared to WT were translocator protein (TSPO_MOUSE) and 
mitochondrial import receptor subunit TOM5 homolog (TOM5_MOUSE), which are both 
mitochondrial import proteins necessary for translocation of lipids or peptides from the 
cytosol to the inside of the mitochondria (Table 3.17).  
The proteins underexpressed in TG2-null mice were only two, in addition to TG2 which was 
more than 30-fold underexpressed: these were ATP-binding cassette sub-family B member 7 
(ABCB7_MOUSE), which is mitochondrial and is involved in the export from mitochondria (the 
opposite direction), and fatty acid-binding protein (FABP4_MOUSE), that was already 
mentioned before as a protein upregulated by kidney disease (Górski, et al. 1997, Yamamoto, 
et al. 2007) (Table 3.17).  
The proteins significantly altered by TG2-KO in mice subjected to UUO were analysed on 
STRING v10 to define possible interactions. As shown in Fig. 3.21, at a middle confidence level 
(0.4), two clear clusters of ribosomal and histone proteins were identified by STRING, while 
the other proteins, including TG2, were showing no interaction between themselves (not 
described nor predicted) or the clusters.  
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Table 3.17: List of proteins differentially expressed (confidence ≥ 0.8) in the TG2-KO mice at 21- 
UUO conditions, and corresponding fold change from the WT. In red the positive logarithm of FC 
from the WT mice (overexpression in TG2-KO comparing to WT) while in green the negative logarithm 
of FC (underexpression in TG2-KO comparing to WT). In shades of yellow the confidence of the change. 
A confidence ≥ 0.8 was regarded as significant 
Proteins significantly modulated by TG2-KO in mice subjected to UUO (21 days) 
Protein ID Name  
Log2 FC (TG2-KO 
 UUO/ WT UUO) 
Abs FC (TG2-KO 
UUO/ WT UUO) 
Confidence 
TSPO_MOUSE Translocator protein 1.79 3.46 1.00 
H12_MOUSE Histone H1.2 1.55 2.92 0.94 
RL19_MOUSE 60S ribosomal protein L19 1.45 2.73 0.85 
H10_MOUSE Histone H1.0 1.44 2.72 0.82 
H14_MOUSE Histone H1.4 1.41 2.66 0.95 
RL24_MOUSE 60S ribosomal protein L24 1.31 2.49 0.92 
RL13_MOUSE 60S ribosomal protein L13 1.26 2.39 0.89 
H15_MOUSE Histone H1.5 1.24 2.35 0.88 
H11_MOUSE Histone H1.1 1.22 2.34 0.97 
RL8_MOUSE 60S ribosomal protein L8 1.17 2.25 0.84 
TOM5_MOUSE 
Mitochondrial import receptor subunit TOM5 
homolog 
1.17 2.25 0.97 
RL14_MOUSE 60S ribosomal protein L14 1.15 2.22 0.93 
RL7A_MOUSE 60S ribosomal protein L7a 1.14 2.21 0.86 
RS30_MOUSE 40S ribosomal protein S30 1.14 2.21 0.91 
RS24_MOUSE 40S ribosomal protein S24 1.10 2.15 0.92 
RL4_MOUSE 60S ribosomal protein L4 1.09 2.14 0.86 
RL27_MOUSE 60S ribosomal protein L27 1.09 2.14 0.83 
RL36_MOUSE 60S ribosomal protein L36 1.02 2.03 0.89 
RL13A_MOUSE 60S ribosomal protein L13a 0.89 1.85 0.81 
H4_MOUSE Histone H4 0.89 1.85 0.82 
RL17_MOUSE 60S ribosomal protein L17 0.87 1.82 0.85 
RL7_MOUSE 60S ribosomal protein L7 0.85 1.80 0.91 
RS18_MOUSE 40S ribosomal protein S18 0.81 1.75 0.87 
RL18_MOUSE 60S ribosomal protein L18 0.79 1.73 0.87 
RS29_MOUSE 40S ribosomal protein S29 0.74 1.67 0.80 
RS13_MOUSE 40S ribosomal protein S13 0.68 1.60 0.86 
RS25_MOUSE 40S ribosomal protein S25 0.66 1.59 0.84 
H2B1P_MOUSE Histone H2B type 1-P 0.57 1.48 0.83 
ABCB7_MOUSE 
ATP-binding cassette sub-family B member 7, 
mitochondrial 
-0.39 1.31 0.88 
FABP4_MOUSE Fatty acid-binding protein, adipocyte -1.06 2.08 0.87 
TGM2_MOUSE Transglutaminase 2 -4.97 31.44 0.85 
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Figure 3.21: Network of protein-protein interactions of TG2-KO differentially expressed proteins 
in UUO mice (21 days). Network of known and predicted protein-protein interactions was designed in 
STRING (http://string-db.org) using the list of differentially expressed proteins of TG2-null mice 
subjected to UUO reported in Table 13B. A confidence of at least 0.4 (middle confidence in STRING) was 
chosen as threshold for the interactions identified. 
 
When we considered a broader confidence level, higher than the 50% (displayed in Suppl. 
Table 3.3), numerous other proteins were identified as upregulated by TG2 deletion  in UUO 
conditions. Of the 69 proteins having a positive fold change from the WT conditions at this level 
of confidence, 58 were either ribosomal or histone proteins, while only 11 were associated 
with other functions.  These proteins were mostly mitochondrial and associated with cell 
metabolism, which might be correlated to an increased cell viability when TG2 was deleted.   
At the same confidence threshold, 77 proteins appeared downregulated by TG2-KO in mice 
subjected to 21-days UUO. Among these proteins, only two ribosome subunits and no histone 
were identified. All the other proteins were associated with a plethora of intracellular and 
extracellular processes, and a number of them can be correlated to a bad outcome of CKD by 
being involved in matrix deposition, inflammation, apoptotic response, cytokine activation etc. 
(Suppl. Table 3.3), supporting the idea of a protective action of TG2 in the context of fibrosis. 
To cite only few examples, both collagen VI and collagen XVIII (HSPG-endostatin) were 
identified as downregulated by TG2-KO at a confidence higher than 60%. A number of 
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fibrinogen chains (FIBA_MOUSE, FIBB_MOUSE, FIBG_MOUSE) were ~2-fold downregulated at 
a C(FC)≥0.6, suggesting a role for TG2 on all stages of wound healing/fibrotic process (Suppl. 
Table 3.3). Thrombospondin (TSP1_MOUSE), a matrix glycoprotein known to be upregulated 
by TGF-β and to be significantly involved in its activation upon kidney disease (Hugo, Kang and 
Johnson 2002, Daniel, et al. 2004, Murphy-Ullrich, et al. 2002) was also downregulated by TG2-
KO at C(FC)=0.74 (Suppl. Table 3.3). Cell signalling protein calmodulin (CALM_MOUSE) 
(C(FC)=0.76) and proteins of the 14-3-3 family [C(FC) ~0.6], known to bind phosphorylated 
TG2 with a possible role in cell signalling (Mishra and Murphy 2006) were also underexpressed 
upon KO when a lower level of significance was considered (Suppl. Table 3.3). Other proteins 
were associated with cytoskeletal remodelling and cell adhesion, and some were even involved 
in intracellular vesicular trafficking (Suppl. Table 3.3). Finally, the well-known marker of 
exosomal vesicles CD63 (CD63_MOUSE) was minimally downregulated by the KO [C(FC)>0.7] 
(Suppl. Table 3.3), suggesting a possible correlation between TG2 expression and exosome 
formation.  
 
In summary, MS analysis of protein expression in TG2-KO mice in comparison with WT mice, 
in both healthy and fibrotic conditions, revealed minimal changes in protein expression at an 
high level of FC confidence, mostly involving an upregulation of ribosomal and histone proteins 
when mice were deprived of the enzyme. However, observation of expression variations at 
lower level of confidence highlighted a number of proteins that can be associated with a 
protective role for TG2 in disease, such as extracellular matrix proteins, cytoskeletal elements 
and signalling proteins that might control the localisation and activity of pro-fibrotic factors 
and cytokines. A possible involvement of TG2 in signalling and vesicular transport was also 
underlined by this analysis.  
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3.4.7.4 SWATH-MS proteomic analysis of proteins differentially expressed upon UUO in 
TG2-KO mice and comparison with the same analysis performed in WT mice.  
Being interested in defining if the TG2-KO was determining an alteration in the list of proteins 
differentially expressed upon UUO, SWATH acquisition-MS was performed on 4 TG2-KO Sham 
operated kidneys and 4 TG2-KO UUO kidneys at 21 days post-operation, and data were 
acquired as described in 3.3.6. Fold change variations in proteins’ expression between UUO 
and Sham operated TG2-null mice were calculated by OneOmics processing software, in the 
same way as the analysis performed in WT mice and reported in 3.4.4 (Fig. 3.22, 1). The 
outcome of the FC analysis between UUO and Sham operated samples in TG2-null mice, at a 
confidence [C(FC)] higher than 0.5, can be found in the supplementary information of this 
thesis (Suppl. Table 3.4). Likewise the analysis performed in WT mice, candidates were 
regarded as significantly overexpressed or underexpressed upon UUO in TG2-null mice 
(comparing to the sham operated control in the same phenotype) at a C(FC) ≥ 0.8.  
 
 
Figure 3.22: SWATH-MS experimental setup to identify proteins significantly altered by UUO in 
TG2-KO C57BL/6J mice. (1) = Proteins significantly altered upon UUO in WT mice – Results in 3.4.4, 
Lists in Suppl. Tables 3.5 and 3.6; (2) = Proteins significantly altered upon UUO in TG2-null mice – 
Results in Suppl. Tables 3.15 and 16; (3) = Comparison of the outcomes of the Analysis 1 and 2 - Results 
in Suppl. Tables 17 and 18. 
 
Of the 2106 proteins detected by SWATH-MS, 668 were identified as differentially expressed 
in the UUO model in TG2-null mice in a significant manner (confidence ≥ 0.8), of which 186 
were upregulated post UUO (Suppl. Table 3.15) while 482 (Suppl. Table 3.16) were 
downregulated post-UUO.  These numbers were comparable, but not identical, to the number 
of proteins identified as significantly overexpressed (N=195, Suppl. Table 3.5) or 
underexpressed (N=458, Suppl. Table 3.6) in WT mice subjected to 21 days-UUO [3.3.4].  
To determine if the proteins differentially expressed upon UUO in WT mice (fully analysed in 
3.4.4 and listed in Suppl. Table 3.5 and 3.6) were similarly modulated in TG2-KO mice, and at 
CHAPTER III – RESULTS 
 
186 
 
the same time whether new proteins were identified as significantly altered by UUO in the TG2-
null phenotype, the outcomes of the 2 analyses were compared (Fig. 3.22, 3) and results were 
collected in Suppl. Table 3.17 (UUO-Overexpressed proteins) and Suppl. Table 3.18 (UUO-
Underexpressed proteins). A summary of protein numbers and detection overlaps is reported 
in Table 3.18.  
 
Table 3.18: Comparison of abundance (N) of UUO-differentially expressed proteins between WT 
and TG2-KO mice.  
Phenotype: WT TG2-KO 
Total/Unique proteins Total N  Unique N Total N Unique N 
Proteins detected 2106 0 2106 0 
Differentially expressed by UUO 
(confidence >0.8) 
653 132 668 147 
UUO-Overexpressed 
(confidence >0.8) 
195 56 186 47 
UUO-Underexpressed 
(confidence >0.8) 
458 76 482 100 
 
The main findings obtained from this comparison are reported in Table 3.19 and Table 3.20. 
Among the 195 UUO-overexpressed proteins identified in WT mice at a confidence level of 0.8, 
139 were also identified as significantly overexpressed after 21 days-UUO in TG2 null mice 
(labelled as COMMON in Suppl. Table 3.17), while 56 appeared significantly upregulated 
uniquely in the WT phenotype (labelled as WT ONLY in Suppl. Table 3.17). On the other side, 
47 proteins were detected as upregulated at a confidence level higher than 0.8 only in the TG2-
null mice (labelled as TG2-KO ONLY in Suppl. Table 3.17).  
Among the UUO overexpressed proteins in both phenotypes, the more interesting finding was 
tapasin (TPSN_MOUSE) characterized by a substantial 36.41-fold increase in expression 
compared to sham operated control in WT mice at a confidence of 0.76, that can be regarded 
as significant, versus a more than 5-times lower fold increase upon UUO in TG2-null mice (6.71-
fold from sham, confidence 0.89) (Table 3.19). Uromodulin (UROM_MOUSE) was more 
overexpressed in WT mice subjected to UUO compared to TG2-null mice (16.84 vs 9.78 – fold 
higher than the Sham operated control) as well as Fibrillin 1 (FBN1_MOUSE, 10.84 vs 8.05 -
fold) (Table 3.19).   
Some proteins recognised as UUO-overexpressed in WT mice were not significantly varying 
upon UUO in TG2-null mice, such as alpha-1-antitrypsin 1-2 (A1AT2_MOUSE), fibulin 2 
(FBLN2_MOUSE) and metallothionein-2 (MT2_MOUSE). Fatty acid-binding protein 
(FABP4_MOUSE), even appeared downregulated (log2FC<0) by the UUO in TG2-null mice at a 
confidence close to 0.8 (Table 3.19). As a confirmation of the TG2-KO, TG2-null mice showed 
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no significant variation of TG2 expression upon UUO, while an overexpression was observable 
in WT mice (Table 3.19, Fig 3.23).  
On the other side, collagen alpha-1(XII) chain (COCA1_MOUSE) was more overexpressed in 
TG2-deprived UUO mice (26.15-fold) than in WT mice (15.92 fold), and a similar difference 
was detected in fibrillin 2 (FBN2_MOUSE), with an overexpression upon UUO in TG2 null mice 
(14.52 -fold) that was almost twice the one detected in WT (7.26-fold) (Table 3.19).  
Some proteins resulted significantly overexpressed exclusively in TG2-null mice and with a 
fold increase calculated from Sham higher than the WT. Examples were protein S100-A6 
(S10A6_MOUSE), that was 10.94-fold overexpressed in TG2-KO UUO mice and Major urinary 
protein 6 (MUP6_MOUSE), 7.80-fold overexpressed (Table 3.19). In line with previous 
observation, moreover, a portion of the 47 proteins with positive fold increase significant in 
“TG2-KO only” at C(FC)≥0.8 were histone proteins: histone H1.5 (H15_MOUSE), histone H1.1 
(H11_MOUSE), histone H2A type 1-H (H2A1H_MOUSE), histone H1.2 (H12_MOUSE), histone 
H2AX (H2AX_MOUSE), histone H2B type 1-P (H2B1P_MOUSE) (Suppl. Table 3.17), some of 
which already reported as significantly overexpressed upon TG2-KO in UUO mice in 3.4.7.3 
section (Table 3.17),  H12_MOUSE, H15_MOUSE, H11_MOUSE and H2B1P_MOUSE.  
 
Table 3.19. Proteins significantly overexpressed (Confidence ≥ 0.8) in either WT or TG2-KO 
kidneys subjected to UUO (21 days) that show clear differences between phenotypes. In increasing 
shade of red the positive log2 (Log2FC) of fold change from the sham operated condition (the more 
intense, the more overexpressed), in decreasing shades of green the negative log2 (Log2FC) of fold 
change from the sham operated condition (the more intense, the more underexpressed), in increasing 
shades of grey the absolute fold change from the sham operated condition (ABS FC, absolute increase or 
decrease depending of the sign of Log2FC) while in shades of yellow the confidence of the change.  
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TPSN Tapasin 5.19 36.41 0.76 2.75 6.71 0.89 
UROM Uromodulin 4.03 16.34 0.85 3.29 9.78 0.88 
FBN1 Fibrillin-1 3.44 10.84 0.89 3.01 8.05 0.89 
FBLN2 Fibulin-2 3.27 9.65 0.81 2.32 4.99 0.54 
K1C19 Keratin, type I cytoskeletal 19 3.26 9.57 0.86 2.99 7.95 0.89 
C1QB Complement C1q subcomponent subunit B 3.24 9.42 0.70 2.12 4.35 0.91 
TAGL Transgelin 3.21 9.27 0.89 2.78 6.86 0.89 
VIME Vimentin 3.10 8.56 0.90 2.74 6.67 0.91 
MT2 Metallothionein-2 3.02 8.11 0.84 -3.36 10.27 0.09 
A1AT2 Alpha-1-antitrypsin 1-2 2.97 7.86 0.82 1.31 2.48 0.48 
PLSL Plastin-2 2.93 7.63 0.85 2.25 4.77 0.82 
E41L2 Band 4.1-like protein 2 2.70 6.51 0.77 1.69 3.22 0.88 
CNN2 Calponin-2 2.62 6.15 0.80 2.04 4.11 0.84 
LG3BP Galectin-3-binding protein 2.53 5.78 0.67 1.70 3.26 0.81 
FIBA Fibrinogen alpha chain 2.21 4.64 0.90 0.93 1.91 0.69 
CO4A2 Collagen alpha-2(IV) chain 2.17 4.50 0.80 1.45 2.73 0.79 
FIBG Fibrinogen gamma chain 2.15 4.45 0.85 1.50 2.82 0.74 
FIBB Fibrinogen beta chain 2.00 4.00 0.86 0.96 1.95 0.71 
K2C79 Keratin, type II cytoskeletal 79 1.61 3.05 0.91 0.65 1.57 0.56 
AGRIN Agrin 1.11 2.16 0.92 0.73 1.66 0.67 
FABP4 Fatty acid-binding protein, adipocyte 0.86 1.82 0.85 -0.76 1.69 0.78 
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TGM2 Transglutminase 2 0.78 1.71 0.90 -1.49 2.81 0.17 
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 COCA1 Collagen alpha-1(XII) chain 3.99 15.92 0.82 4.71 26.15 0.83 
FBN2 Fibrillin-2 2.86 7.26 0.94 3.86 14.52 0.89 
RCN3 Reticulocalbin-3 2.73 6.65 0.74 3.22 9.30 0.84 
ELN Elastin 1.88 3.69 0.61 2.53 5.78 0.83 
MUP6 Major urinary protein 6 1.56 2.94 0.62 2.96 7.80 0.95 
S10A6 Protein S100-A6 1.50 2.82 0.65 3.45 10.94 0.81 
 
Figure 3.23: Relative quantification of TG2 expression based on normalised calculated protein 
spectra as detected upon UUO or Sham operation in WT or TG2-null mice by SWATH-MS data 
acquisition. Column show the mean normalised protein area as calculated by the software ± SD, N=4 
samples per treatment. Significance of the differences between spectral means was determined by T-
test: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001.  
 
Among the 458 UUO-underexpressed proteins identified in WT mice at a confidence level of 
0.8, 382 were also identified as significantly underexpressed after 21 days-UUO in TG2 null 
mice at the same confidence level (labelled as COMMON in Suppl. Table 3.18), while 76, even 
if having a negative logarithm of fold change in both phenotypes, appeared significantly 
underexpressed uniquely in the WT phenotype (labelled as WT ONLY in Suppl. Table 3.18). 
On the other side,  100 proteins were detected as upregulated at a confidence level higher than 
0.8 only in the TG2-null mice (labelled as TG2-KO ONLY in Suppl. Table 3.18). Few examples 
of proteins with different levels of underexpression between WT and TG2-KO phenotypes 
subjected to UUO are reported in Table 3.20.  
The 3 most underexpressed proteins in WT mice subjected to UUO, Glucose-6-phosphatase 
(G6PC_MOUSE), mitochondrial Kynurenine/alpha-aminoadipate aminotransferase 
(AADAT_MOUSE), and Hydroxyacid oxidase (HAOX2_MOUSE), all involved in metabolic 
processes and energy production in the cell, were much less downregulated TG2-null 
individuals subjected to the same treatment. Particularly evident was the difference in the first 
2 proteins, with more than 70-fold increase in WT versus less than 11 in TG2-KO 
(G6PC_MOUSE) and 48 -fold increase versus 11.59 (AADAT_MOUSE) (Table 3.20). Calbindin 
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(CALB1_MOUSE), an interesting protein in the context of kidney fibrosis (Steiner, et al. 1996, 
Armbrecht, et al. 1989, Sooy, Kohut and Christakos 2000, Hoffmann, et al. 2010), was also less 
downregulated in TG2-null mice. Another protein more underexpressed upon UUO in WT mice 
was the already mentioned mitochondrial import receptor subunit TOM5 homolog 
(TOM5_MOUSE)(7.94-fold increased in UUO WT mice versus 2.69 in TG2-null), already 
identified as significantly upregulated upon knock out of TG2 in UUO mice as reported in 3.4.7.3 
section (Table 3.17). Some proteins, such as translocator protein (TSPO_MOUSE) and 40S 
ribosomal protein S24 (RS24_MOUSE) were not significantly altered by the UUO in TG2-null 
mice. On the other side, a number of proteins were showing a higher downregulation upon 
TG2-KO. The more evident examples were the bifunctional epoxide hydrolase 2 protein 
(HYES_MOUSE), 25.06-times underexpressed in TG2-null mice versus only 4.85-fold decrease 
in WT, and PDZK1-interacting protein 1, more than 90-times downregulated in the TG2-null 
mice subjected to UUO.      
 
Table 3.20. Proteins significantly Underexpressed (Confidence ≥ 0.8) in either WT or TG2-KO 
kidneys subjected to UUO (21 days) that show clear differences between phenotypes. In increasing 
shade of red the positive log2 (Log2FC) of fold change from the sham operated condition (the more 
intense, the more overexpressed), in decreasing shades of green the negative log2 (Log2FC) of fold 
change from the sham operated condition (the more intense, the more underexpressed), in increasing 
shades of grey the absolute fold change from the sham operated condition (ABS FC, absolute increase or 
decrease depending of the sign of Log2FC) while in shades of yellow the confidence of the change.  
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G6PC Glucose-6-phosphatase -6.17 72.24 0.86 -3.43 10.79 0.83 
AADAT 
Kynurenine/alpha-aminoadipate 
aminotransferase, mitochondrial 
-5.59 48.00 0.84 -3.54 11.59 0.80 
HAOX2 Hydroxyacid oxidase 2 -5.47 44.28 0.85 -4.18 18.08 0.88 
CALB1 Calbindin -5.00 32.07 0.91 -4.40 21.18 0.92 
PXMP2 Peroxisomal membrane protein 2 -3.78 13.77 0.81 -2.90 7.48 0.55 
ACE Angiotensin-converting enzyme -3.66 12.66 0.91 -3.21 9.27 0.79 
TOM5 
Mitochondrial import receptor subunit 
TOM5 homolog 
-2.99 7.94 1.00 -1.43 2.69 0.88 
COASY Bifunctional coenzyme A synthase -2.97 7.83 0.85 -2.68 6.41 0.77 
TAU Microtubule-associated protein tau -2.96 7.76 0.83 -2.26 4.79 0.77 
PPA6 Lysophosphatidic acid phosphatase type 6 -2.95 7.74 0.85 -2.28 4.87 0.69 
MRP2 
Canalicular multispecific organic anion 
transporter 1 
-2.59 6.03 0.82 -1.17 2.25 0.24 
TSPO Translocator protein -1.87 3.66 0.98 0.84 1.79 0.56 
RS24 40S ribosomal protein S24 -0.99 1.99 0.88 0.81 1.75 0.37 
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PDZ1I PDZK1-interacting protein 1 -5.52 45.76 0.84 -6.50 90.53 0.79 
SC5A3 Sodium/myo-inositol cotransporter -3.86 14.51 0.63 -4.79 27.69 0.86 
HYES Bifunctional epoxide hydrolase 2 -2.28 4.85 0.81 -4.65 25.06 0.84 
CX6A1 
Cytochrome c oxidase subunit 6A1, 
mitochondrial 
-3.57 11.91 0.74 -4.43 21.54 0.80 
GATM Glycine amidinotransferase, mitochondrial -3.80 13.91 0.87 -4.39 20.94 0.88 
DHAK Triokinase/FMN cyclase -3.56 11.77 0.80 -4.16 17.82 0.79 
ACOX1 Peroxisomal acyl-coenzyme A oxidase 1 -2.33 5.01 0.78 -3.86 14.52 0.88 
BDH2 3-hydroxybutyrate dehydrogenase type 2 -3.02 8.13 0.82 -3.48 11.18 0.80 
GLNA Glutamine synthetase -1.97 3.91 0.83 -3.14 8.84 0.83 
CHAPTER III – RESULTS 
 
190 
 
In conclusion, the analysis of the protein differentially expressed by UUO in TG2-null mice 
compared with the differentially expressed proteins in the WT phenotype highlighted few 
proteins whose expression might be affected by TG2 expression in UUO.  
For example, despite the pattern of protein alteration at 21 days-post UUO in TG2-null mice 
was generally similar to the WT mice, extracellular matrix proteins such as fibrillin-1, fibulin-
2, and collagen IV, and proteins involved in wound healing and fibrosis progression such as 
transgelin, vimentin and fibrinogen, were more strongly upregulated by UUO in WT mice 
compared to the mice with TG2 depletion, suggesting a protective role of the enzyme knock-
out during the progression of fibrosis in mice.  
 
 
3.4.8 Power calculation confirms that a sufficient number of 
kidneys/treatment were employed in the SWATH-MS study.  
The power calculation was performed using the Dell Statistica software (Dell, Texas, USA) 
comparing for each detected protein the different means and standard deviation of UUO or 
Sham operated kidneys (T-test for dependent samples). Being unmanageable to analyse 
standard deviation and means of all identified proteins, nine proteins were chosen for the 
analysis:  
1. The UUO-Overexpressed protein with lower confidence (~0.8) (FUS_MOUSE) 
2. The UUO-Overexpressed protein with higher confidence (MYH9_MOUSE) 
3. The UUO-Overexpressed protein with lower fold change (LAMP1_MOUSE) 
4. The UUO-Overexpressed protein with higher fold change (UROM_MOUSE) 
5. The UUO-Underexpressed protein with lower confidence (~0.8) (FBX50_MOUSE) 
6. The UUO-Underexpressed protein with higher confidence (TOM5_MOUSE) 
7. The UUO-Underexpressed protein with lower fold change (CLH1_MOUSE) 
8. The UUO-Underexpressed protein with higher fold change (G6PC_MOUSE) 
9. Transglutaminase 2 (TGM2_MOUSE) 
In order to determine the minimum sample size N, the desired power was set to the 90% and 
the desired type I error rate α to 0.05. For most of the analysed proteins (Fig. 3.24, tables on 
the left and graphs in the centre), the minimum N necessary for a power higher or equal to 90% 
was equal or lower than 4 individuals, and most proteins were requiring a sample size of at 
least 3 sample, with minimal (broken line in the graph) or no change (flat line in the graph) in 
the power of the experiment by increasing the dimension of the group analysed. The only 
exception was given by clathrin (heavy chain 1, CLH1_MOUSE), which is the protein with the 
lowest absolute fold change among the UUO-underexpressed proteins, that gave a minimum 
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sample size N of 5 with power threshold set to 90%, although N=4 was still identified by a 
power of the experiment higher than the 80%, which is statistically acceptable (asterisk in the 
corresponding graph).  
The trend of minimum sample size N with respect to the probability of false positive (Type I 
error rate α) was also analysed (Fig. 3.24, graphs on the right). Setting the desired power to 
90%, all proteins were showing an N≤4 when α was 0.05 or lower. The only exception was 
again Clathrin, where the α of 0.05 was requiring a sample size of at least 5. Again, this could 
be lowered down by setting the power to 0.8 in the software (data not shown).  
In summary, results confirmed that the experiment had a high prediction power that was 
always higher than 80% when using 4 samples. For this reason, a number of biological samples 
equal to N=4 was considered sufficient and the results of the SWATH-MS experiment 
statistically reliable.  
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Figure 3.24: Power analysis of a representative portion of proteins identified as differentially 
expressed upon UUO by SWATH-MS. Power calculation was performed on Dell Statistica software 
(Dell, Texas, USA) comparing 2 different means (UUO or Sham) of dependent samples by T-test. Nine 
representative proteins were chosen for the analysis and the values obtained from four experimental 
replicas (mean, standard deviation, correlation) of Sham (Group 1 in the power analysis) and UUO 
(Group 2 in the power analysis) mice were used for the calculations. Tables on the left show the details 
of the calculation, with the means, standard deviation and correlation values inserted by the user and 
the power goal and the type I error rate fixed to 0.9 and 0.05 by the user. All the other values were 
calculated by the program to determine the required sample size N and its actual power. The graphs in 
the central column represent the required sample size (axis of ordinates) depending on the Power goal 
(axis of abscissae). The graphs in the right column represent the required sample size (axis of ordinates) 
depending on the Type I error rate (axis of abscissae). 
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3.5 DISCUSSION  
 
CKD is a major healthcare problem, usually asymptomatic in the initial phases, before it 
progresses to a late stage of disease where it requires organ transplant. Currently classification 
and prognosis relies mainly on markers of renal function such as the glomerular filtration rate 
(eGFR) and the measure of proteinuria (specifically albuminuria). These methods, however, 
are have been criticized for having insufficient predictive capacity, as they are not sensitive at 
the early stages and highly subjected to on many factors going from age, sex and genetic 
background to the specific etiology of CKD and the presence of other clinical issues (Inker, et 
al. 2014, Levey, et al. 2009b, Levey, et al. 2009a, Rule, et al. 2004).   Despite many studies have 
been produced in the past decades, there is still a need for the definitions of new biomarkers 
in CKD that could complement the current markers of renal function and even be addressed as 
possible clinical targets against the development of disease.  
For this reason, there is a strong interest in clinical research for the identification of novel 
biomarker of CKD with a good correlation to fibrosis progression, early diagnostic potential 
and predictive capacity (Brosius and Pennathur 2013, Merchant 2015, Fassett, et al. 2011). In 
recent years, quantitative high resolution MS techniques have becomed a more and more 
suitable tool for the unbiased discovery of novel biomarkers in CKD. However, given the large 
spectrum of CKD causes and co-associated diseases (diabetes, hypertension, metabolic 
disrders, etc.) no marker has yet been confirmed as a potential clinical tool allowing early 
diagnostic and prediction of outcome, adding information to the current kidney function 
diagnostic markers (Hsu, et al. 2017).  
As fibrosis is the main event associated with the progression of CKD to its late stage, novel 
biomarkers of CKD might be identified among the proteins associated with this pathological 
process, either promoters of renal scarring, such as proteins associated with inflammation, 
pro-fibrotic cytokines, markers of mesenchymal activation, transcription factors, etc., or 
products of renal scarring, such as extracellular matrix proteins and glycoproteins.  
 
As it is well established that the progression of renal insufficiency better correlates with 
tubulointerstitial fibrosis than with glomerulosclerosis (Schainuck, et al. 1970), in this Chapter, 
we employed a well-established model of tubulointerstitial fibrosis induced by unilateral 
ureteric obstruction (UUO) to investigate, by a quantitative mass spectrometric approach, 
possible biomarkers of CKD. A blind approach should be employed in order not to miss possible 
markers due to the bias determined by the researcher’s pre-knowledge of the pathological 
processes involved. A mouse model of UUO induced by 21 days surgical ligation of the left 
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ureter in C57BL/6J mice was used, which was compared to Sham operated mice sacrificed at 
the same timepoint.  
 
Given the rapidity of this model, 21 days-UUO should be comparable to an end stage CKD, with 
large accumulation of fibrotic tissue and loss of parenchyma integrity (Eddy, et al. 2012, Zhao, 
et al. 2015a). However, the animal responses to the surgery might vary, and the progression of 
disease might be slower or faster.  
For this reason, as a first analysis in this chapter, a validation of fibrosis development in 
randomly selected kidney samples was performed by both histological staining and 
biochemical analysis of two well-known biomarkers of the fibrotic process: α-smooth muscle 
actin (α-SMA) expression, as an indication of myofibroblast activation, and TGF-β activation, 
as a key pro-fibrotic mediator CKD. From a histological point of view, when mice were 
subjected to 21-days UUO, kidneys morphology and fibrotic tissue accumulation were 
comparable to a level of advanced kidney fibrosis. They showed a substantial loss in kidney 
compact structure, with parenchymal disruption, tubular atrophy, and expanded interstitial 
space. Sham operated mice showed healthy and functional kidneys, with no signs of structural 
alterations. MTstaining for fibrillar collagen deposition confirmed a significant accumulation 
of fibrotic tissue in kidneys from UUO-mice at this timepoint, with a collagen/cytoplasm ratio 
more than 10-fold higher than the sham operated mice (Fig. 3.5 – 3.6).  The activity of the pro-
fibrotic cytokine TGF-β was markedly upregulated in kidney lysates from UUO mice, while it 
was almost absent in Sham operated sample (less than 1% of total TGF-β, measured upon acid 
treatment of the lysate) (Fig. 3.8). These findings are in agreement with the characterization 
of a similar model of UUO obtained in our lab few years ago on the same mice strain, where the 
large accumulation of fibrillar collagen was regarded as being similar to the late stages of CKD, 
and a large upregulation of TGF-β activity was observed, when UUO was progressing for 21 
days (Scarpellini, et al. 2014). The expression of α-SMA was also assessed in both UUO and 
Sham operated mice as a measure of myofibroblast proliferation, which is known to be a key 
feature of tubulointerstitial fibrosis and contribute to the large deposition of fibrillar matrix 
(Ucero, et al. 2014). As shown in Fig. 3.7, α-SMA was virtually absent in Sham operated mice, 
while clear expression was observed in kidneys upon 21-days UUO. In male mice, the 
upregulation of α-SMA appeared higher and more significant than in female mice subjected to 
the same treatment. This might be in agreement with a suggested slower rate fibrosis 
development in the female sex in some CKD models, as previous studies have highlighted some 
predisposition of male to a faster progression of  non-diabetic CKD (Silbiger and Neugarten 
2008, Neugarten 2002, Hu, et al. 2009, Stringer, et al. 2005); however, the analysis of more 
samples and different time points would be necessary to support this hypothesis.  
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Altogether, the analysis of the 21 days -UUO model produced for this study confirmed the 
development of an elevated level of CKD in the treated mice, that will be referred to as “fibrotic” 
mice, and the absence of any fibrotic responses in the Sham operated ones, that can be referred 
to as “healthy” mice.   
 
Afterwards, the UUO proteome was identified by quantitative mass spectrometry, performed 
employing a high-resolution SWATH data independent acquisition (DIA) approach, followed 
by targeted data extraction from a spectral library produced “a priori”.  SWATH-DIA approach 
is a fairly recent and increasingly applied technology in MS-based proteomics. By allowing to 
detect all the fragment ion spectra of all the precursors in a series of sequential windows of 
m/z size, and to extract quantitative data by comparing them to a spectral library, this method 
goes beyond the discovery based shotgun proteomics or the classical targeted proteomics, as 
it provides a comprehensive coverage of the proteome, high reproducibility and quantitative, 
comparable, results (Gillet, et al. 2012, Collins, et al. 2016). Analysis of whole kidney 
preparations led to the identification of 2016 proteins. Analysis of the UUO and control 
proteome led to the identification of several proteins differentially expressed upon UUO. 195 
proteins were identified as significantly upregulated upon UUO at a confidence higher than 
80%, while a larger number, 458, were identified as significantly underexpressed in fibrotic 
kidneys at this advanced stage of disease (Suppl. Table 3.5, 3.6). Among these proteins, 
possible markers of the disease progression could be identified, as defined by a high fold 
increase at an elevated confidence.  
 
Many proteins directly associated with the progression of fibrosis were identified as 
overexpressed in the UUO kidney (Table 3.3). ECM-associated proteins and structural 
constituents of the ECM, were strongly enriched GO terms and protein classes at 21 days post-
UUO (3.4.4.4-3.4.4.5). Matrix structural proteins included an elevated number of collagens, 
among which collagen XII, a fibril-associated collagen, was the most upregulated at 21 days 
post-surgery. As expected, collagen I (more than 7-fold overexpressed) was the collagen with 
the highest expression, followed by collagen III and IV, all significantly upregulated by disease 
(Fig. 3.9). Other matrix proteins significantly associated with the progression of UUO in terms 
of upregulation were the matrix glycoproteins FN, fibrillin, fibulin and biglycan, with fibrillin 1 
and biglycan being among the more strongly induced proteins post-UUO, therefore possible 
biomarkers of CKD, in agreement with previous findings (Schaefer, et al. 2004). Fibulin 2, a 
glycoprotein associated with the basement membrane and known to interact with fibrillin 1 
itself (Reinhardt, et al. 1996), was almost 10-fold overexpressed in the UUO model in this study. 
Interestingly, all basement membrane HSPGs, known to play a role in the filtration barrier of 
kidney glomeruli, were also found to be induced by the UUO in the current analysis, possibly 
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as an effect of increased basement membrane matrix deposition, also observed in the 
histological specimens. However, the cell surface HSPG syndecan-4 was not induced post UUO.  
Annotation terms associated with the regulation of the protease activity were also significantly 
enriched in the list of UUO proteins. In particular, the upregulation of a number of serine 
protease inhibitors (serpins) was an important finding of this study and might be an interesting 
prognostic marker to evaluate the progression of CKD in patients. In agreement with this, the 
combination of the analysis of matrix proteins expression and their modification by proteases 
(with exposure or not of specific epitopes), has been recently suggested as possible marker of 
fibrosis, able to distinguish progressive from stable fibrosis (Genovese, et al. 2014) 
 
As a possible consequence of fibroblast proliferation and myofibroblast activation, 
cytoskeletal-associated and cell adhesion functions were among the most significantly 
enriched GO terms and PANTHER protein classes. A number of mesenchymal cell markers were 
identified in the list of UUO overexpressed proteins, and included αSMA. The more 
overexpressed markers, however, were in this model vimentin and calponin 1. Transgelin, an 
actin-crosslinking protein expressed in proliferating cells (fibroblasts, smooth muscle), was 
also strongly upregulated in the disease. This might be an interesting marker of CKD, as 
transgelin upregulation was seen in previous studies in different models of CKD, in both 
glomerular and tubular fibrosis (Inomata, et al. 2011, Gerolymos, et al. 2011, Sakamaki, et al. 
2011, Daniel, et al. 2012, Karagianni, et al. 2013).  
Proteins involved in inflammatory response and apoptosis were also overexpressed post-UUO 
as well as proteins involved in transcription regulation suggesting active gene expression. The 
most significant pathways (KEGG and PANTHER) overrepresented in the UUO were associated 
with ECM-receptor interaction and integrin signaling, focal adhesion, cytoskeletal regulation 
by Rho GTPase and cytokine-mediated inflammatory response, in line with the notion that 
fibrosis is an abnormal wound healing process.  
 
As reported before, in search of possible markers, the proteins with higher fold increase were 
analyzed. At a confidence level of 0.8, the protein having the highest expression was the tubulo-
associated protein Uromodulin, followed by the abovementioned collagen XII and fibrillin-1. 
Uromodulin, however, does not appear as an interesting marker of CKD progression, as its 
strong upregulation in kidney lysates is more likely to be an effect of urine retention due to the 
ureteric obstruction process itself, being Uromodulin the more concentrated protein in urine 
(Bleyer, Zivna and Kmoch 2011, Devuyst 2013).   
At a higher confidence level, such as 95%, only 7 proteins appeared upregulated by the UUO in 
this study [myosin-9, myosin regulatory light polypeptide 9, collagen alpha-1(I) chain, collagen 
alpha-1(XVIII) chain, alpha-actinin-1, tubulin alpha-1a chain and carboxylesterase 1C], while 
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38 appeared downregulated by the treatment and were in large part mitochondrial metabolic 
proteins.  
At a confidence level higher than 70% tenascin (TENA_MOUSE), alpha-1-acid glycoprotein 
(A1AG1_MOUSE), neutrophil gelatinase–associated lipocalin (NGAL_MOUSE) and tapasin 
(TPSN_MOUSE) emerged as interesting markers of CKD progression.  
Tenascin, an extracellular matrix glycoprotein for long known as a marker of mesenchymal 
transition in embryonic kidney (Aufderheide, Chiquet-Ehrismann and Ekblom 1987), was the 
most overexpressed protein of the whole proteome (79-fold overexpression post UUO at 
confidence of 71%). Its upregulation in CKD with different aetiologies was reported before in 
hypothesis-driven studies (Horstrup, et al. 2002, Masaki, et al. 1998, Truong, et al. 1994, 
Truong, et al. 1996) and at the time of writing this thesis Fu et al. (2016) confirmed its strong 
upregulation in two animal models of CKD, the UUO and the ischemia-reperfusion model, and 
suggested it to be crucial for the proliferation of fibroblasts. Knock down of tenascin gene is 
protective against fibroblast proliferation and fibrosis accumulation (Fu, et al. 2016).  
Alpha-1-acid glycoprotein was as well more than 70 fold overexpressed, it is a plasma alpha 
globulin glycoprotein and a known acute phase protein upregulated in response to 
inflammation. This protein is involved in the transport of different proteins in blood, including 
protease inhibitors, and it has been known for a long time that the serum level of the protein is 
increased in patients with CKD (Docci, et al. 1985, Vasson, et al. 1991).  
Notably, neutrophil gelatinase–associated lipocalin (NGAL_MOUSE) was identified as more 
than 9 times upregulated in UUO at 79% confidence. This is a marker of different models of 
kidney fibrosis also involved in cancer and cardiovascular diseases (Cernaro, et al. 2016), and 
the protein has been recently suggested as mediator of cell proliferation in kidney by aim of 
EGFR mitogenic signalling and a possible biomarker of CKD progression, with a patent filed for 
the study of an NGAL inhibitors (Terzi, et al. 2016). 
Perhaps the most intriguing finding in this chapter was the identification of tapasin a 
transmembrane protein strongly induced post UUO (by 36 fold, with 76% confidence). Tapasin 
is mainly known to regulate ER-loading of the major histocompatibility complex I, but it is also 
detected on the cell surface (Teng, et al. 2002).  To our knowledge, this is the first time that 
tapasin has emerged as a possible candidate biomarker of CKD.  
 
The vast majority of proteins significantly underexpressed post UUO and related pathways 
were associated with metabolic pathways and energy production by the cells (Suppl. Table 
3.6 and Table 3.11). This could be a consequence of diffuse cell death by apoptosis or necrosis 
likely at an advanced stage of fibrosis.  In agreement with this, markers of cell death such as 
annexins were upregulated post UUO and a generally lower protein expression was identified 
in UUO kidneys compared to the sham operated ones, as underlined by residual analysis (Fig. 
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3.14- 3.15). A substantial number of proteins underexpressed at 21-days UUO were having an 
antioxidant role (highlighted in Table 3.4) as dysregulation of antioxidant enzymes has been 
reported in diabetic and non-diabetic CKD before. Furthermore, downregulation of catalase 
and glutathione peroxidase activity have been correlated to the bad outcomes of different 
kidney diseases (Mimic-Oka, et al. 1999, Ceriello, et al. 2000, Ceballos-Picot, et al. 1996). 
Moreover, in models hypertensive renal disease, AngII upregulation has been suggested to 
induce renal oxidative stress by reducing Superoxide dismutase in the kidney (Zhao, et al. 
2008).  
 
Comparison of this study with two recent proteomic studies of the UUO using different MS 
acquisition approaches (Yuan, et al. 2015, Zhao, et al. 2015b) showed how the application of a 
SWATH-MS allows to the identification of a larger number of proteins differentially expressed 
upon UUO progression, as only ~8% of all the proteins detected by SWATH-MS as significantly 
overexpressed by UUO had been identified in the previous studies.  One (Yuan, et al. 2015), was 
a study in late UUO (21 days), but employing urine as a sample, while the second (Zhao, et al. 
2015b) was performed on whole kidney lysates as the current one, but at much earlier time 
point when different cellular responses take place, mainly associated with inflammation. So 
far, this is to our knowledge the first attempt to solve the UUO proteome at a late stage of the 
disease model. 
 
An established protein implicated in CKD pathogenesis through fibrosis progression, by 
alteration of matrix homeostasis via protein cross-linking and recruitment of latent TGF is 
type 2 transglutaminase (TG2). The enzyme has been object of intense research in our group 
at NTU and may represent a novel therapeutic target for fibrosis treatment.  Our unbiased 
analysis of UUO proteome revealed a small but significant increase in transglutaminase-2 
(TG2) post UUO (~1.71-fold increased). This is in agreement with the notion that the effect of 
extracellular TG2 in wound healing and fibrosis is mostly relying on an increased TG2 release 
from tubular epithelial cells, rather than increased  expression (Scarpellini, et al. 2009, 
Scarpellini, et al. 2014). Although in other CKD models, including those established by us, such 
as the rat subtotal nephrectomy, TG2 was also found to be induced in expression (Burhan, et 
al. 2016), the most prominent feature related to TG2 was the increased protein crosslinking in 
the ECM consequent to TG2 secretion post insult (Scarpellini, et al. 2014). To establish the role 
played by TG2 in experimental fibrosis, UUO or a Sham operation was performed in the TG2-
knockout mouse in parallel to that performed in WT mice.  
The level of fibrosis developed in this phenotype upon UUO was lower when compared with 
the one observed in WT mice. A possible protective role of TG2-KO was suggested by 
biochemical analyses, with a trend in α-SMA reduction (Fig. 3.18) and a clear abolishment of 
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TGF-β activation upon UUO (Fig. 3.19). The inhibition of TGF-β activity in TG2-null mice 
subjected to UUO confirms the pivotal role for TG2 in the activation of the enzyme (Nunes, et 
al. 1997, Verderio, et al. 1999), which becomes especially important when the cytokine is 
activated in the context of fibrosis. A protective effect if TG2 KO in a CKD model was reported 
before  and findings presented here substantially confirm and corroborate what previously 
reported , giving strength to the importance of TG2 in disease progression (Fisher, et al. 2009, 
Shweke, et al. 2008). 
Analysis of the TG2-KO proteome revealed a modest alteration in protein expression between 
WT-proteome and TG2-null proteomes in sham operated kidneys (Table 3.16, Suppl. Table 
3.2). No compensatory effect from other TG family members was observed in either Sham 
operated and UUO conditions.  
There was a consistent upregulation of a number of Ribosomal subunits and histone proteins 
when TG2 was removed, that was particularly strong when kidneys were in fibrotic conditions. 
TG2 is known to be able to both crosslink and phosphorylate histone proteins (Ballestar, Boix-
Chornet and Franco 2001, Kim, et al. 2002, Mishra, et al. 2006).  
Among the proteins upregulated in Sham operated kidneys by TG2-KO were calcium binding 
protein 39 and the protein fermitin. The latter is a protein located in focal adhesion sites and 
involved in cell adhesion by interacting with integrins, and was strongly upregulated in TG2-
null mice, hence possibly involved in a compensatory effect on cell adhesion, when TG2 is 
removed. Elimination of TG2 led to a the downregulation of a number of proteins otherwise 
overexpressed in the WT UUO kidney such as collagens VI, the HSPG collagen XVIII, a number 
of fibrinogen chains and thrombospondin, a protein involved in the activation of TGF-β (Hugo, 
Kang and Johnson 2002, Daniel, et al. 2004), as well as signalling proteins possibly associated 
with the enzyme activity in the cell (3.4.7.3).  
One of the main finding was a clear reduction in tapasin overexpression in TG2-null mice post 
UUO compared to WT post UUO (Table 3.19) corroborating the idea of a synergy between TG2 
and tapasin in CKD. This is particularly interesting in the light of independent findings by Prof. 
Johnson’s group who recently identified tapasin as a binding partner for TG2 on the N-terminal 
β-sandwich domain, by employing a yeast-two-hybrid screening approach. The protein has 
been shown to co-localise with TG2 on the plasma membrane of renal tubular epithelial cells 
and knock out of the protein has been suggested to prevent TG2 export from these cells 
(Personal communication of Prof Timothy Johnson).  
Fibrillin 1 and uromodulin, but also proteins associated with the mesenchymal phenotype such 
as vimentin and transgelin were less induced post UUO upon TG2 KO, proving that they 
potentially act in synergy with TG2 in disease progression. Fibulin 2 overexpression was 
significant only in WT mice, as well as the member of the serpin family α-1-antitrypsin (Table 
3.19). Protein S100-A6, known to complex with annexin2 and be involved in plasmin 
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regulation and CKD (Cheng, et al. 2005), was more overexpressed in TG2-null mice upon UUO 
than in WT ones, where the protein resulted not significant. Similarly, mayor urinary protein 
6, a small urinary globin, was also upregulated by UUO only in absence of TG2. These proteins, 
and other proteins differentially regulated in the TG2-null mice and reported in Tables 3.19-
3.20, might all be associated with the protective role of TG2 in CKD, and more investigation 
will be needed to understand possible mechanisms involved.  
In Conclusion, the establishment of UUO model of renal fibrosis and quantitative proteomics 
by SWATH-MS have highlighted a number of known candidate markers of fibrosis, including 
TG2. Knockout of TG2 in UUO has confirmed the protective role of TG2 deletion in CKD 
development, and quantitative proteomics has for the first time highlighted changes in UUO 
proteome consequent to TG2 KO in kidney. Data have revealed biomarkers of renal fibrosis 
which may act in synergy with TG2 in disease development. 
The availability of the WT and TG2 KO proteome at a high level of resolution forms the basis of 
further investigations presented in the next Chapter aimed at identifying the TG2 interactome 
in plasma membranes isolated from UUO kidneys. 
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Chapter IV: The cell-matrix interactome of transglutaminase-2 in 
kidney fibrosis 
 
4.1 AIMS OF THE CHAPTER  
 
Starting from a TG2 immunoprecipitation (IP) method combined with a SWATH acquisition 
mass spectrometry analysis, the aim of this chapter is to define the interactome of TG2 in 
kidney fibrotic membranes.  
It is anticipated that TG2-interacting partners will emerge that might be associated with TG2 
trafficking and externalisation, leading to hypotheses on the mechanism(s) of TG2 secretion in 
CKD.  
 
 
4.2 INTRODUCTION 
 
4.2.1 A novel immunoprecipitation approach for the detection of TG2-
associated proteins in kidney cell membranes 
With the aim of analysing possible partners of TG2 secretion from kidney cells, few years ago, 
a preliminary MS analysis of TG2-associated proteins in kidney cell membranes was performed 
by our group at NTU, employing kidneys from healthy C57BL/6J mice.  
The novel approach proposed by our group combined a TG2 immunoprecipitation (TG2-IP) 
from healthy kidneys with iTRAQ® labelling, followed by LC−MALDI-TOF/TOF analysis of the 
tagged samples. Importantly, it included the analysis of TG2-IPs from TG2-null mice (De 
Laurenzi and Melino 2001) as a background, to rule out possible false positive detections.  
By comparing 5 IPs from wild type (WT) and TG2-KO mice, Dr Alessandra Scarpellini, at NTU, 
identified 24 proteins as significantly associated with TG2 in kidney membrane extracts (Table 
4.1), because absent in the TG2-IP from TG2-null mice or having an intensity at least 5 fold 
higher in the WT than the TG2-KO (WT/TG2-KO>5), in at least 4 out of 5 IP samples. 
Preliminary analysis of the results was presented at the Renal Association Conference in 
Newcastle in 2012 by Dr Elisabetta Verderio (Elisabetta Verderio, et al. 2012), but never 
published. The main finding of this study was the association of TG2 with extracellular heparan 
sulfate proteoglycans (HSPGs)  perlecan and collagen XIII (endostatin), but also the association 
CHAPTER IV – RESULTS 
 
204 
with the basement membrane glycoproteins nidogen-1/2 and to numerous cytoskeletal 
proteins (actin, myosins, plectin, vimentin, spectrins, etc.) that might be involved in the control 
of the enzyme’s trafficking. Moreover, clathrin association was regarded as interesting at the 
time, being the protein involved in vesicular transport (Elisabetta Verderio, et al. 2012), and 
glutathione peroxidase, which is and antioxidant protein, hence possibly involved in the 
maintenance of the enzyme reduced-active state (Stamnaes, et al. 2010, van den Akker, et al. 
2011).  
This was the first attempt of identifying the TG2 interaction network in kidney samples, and 
set the experimental bases for the approach employed in the current study, allowing to 
produce results described in this chapter.  
 
 
Table 4.1: TG2-associated proteins identified in healthy mice kidneys by iTRAQ® labelling and 
LC−MALDI-TOF/TOF. 
 
Protein ID Name 
ACTG_MOUSE Actin, cytoplasmic 2 
ATPB_MOUSE ATP synthase subunit beta, mitochondrial 
PGBM_MOUSE Basement membrane-specific heparan sulfate proteoglycan core protein (Perlecan) 
CLH_MOUSE Clathrin heavy chain 1 
COIA1_MOUSE Collagen alpha-1(XVIII) chain 
C1QB_MOUSE Complement C1q subcomponent subunit B 
FLNB_MOUSE Filamin-B 
GPX3_MOUSE Glutathione peroxidase 3 
HSP7C_MOUSE Heat shock cognate 71 kDa protein 
ML12B_MOUSE Myosin regulatory light chain 12B 
MYH10_MOUSE Myosin-10 
MYH11_MOUSE Myosin-11 
MYH14_MOUSE Myosin-14 
MYH9_MOUSE Myosin-9 
NID1_MOUSE Nidogen-1 
NID2_MOUSE Nidogen-2 
PLEC_MOUSE Plectin 
SERPH_MOUSE Serpin H1 
AT1A1_MOUSE Sodium/potassium-transporting ATPase subunit alpha-1 
SPTA2_MOUSE Spectrin alpha chain, brain 
SPTB2_MOUSE Spectrin beta chain, brain 1 
TPM3_MOUSE Tropomyosin alpha-3 chain 
VILI_MOUSE Villin-1 
VIME_MOUSE Vimentin 
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4.2.2 Preliminary work for the creation of a TG2 interactome in kidney 
fibrosis 
This Chapter focuses on the identification of the TG2-associated proteins in the 21 days- UUO 
model of kidney fibrosis and their network of interactions during disease (interactome). In the 
preliminary work performed by our group and Prof Johnson at Nottingham Trent University 
and Sheffield university, a TG2 immunoprecipitation (IP) approach from UUO kidneys was 
combined with quantitative SWATH-Mass spectrometry (MS) (Fig. 4.1A).  
Briefly, WT inbred mice were subjected to UUO (12 mice) or a sham operation (12 mice), and 
kidneys were harvested at 21-day post-surgery. To obtain a negative control for TG2-IP, TG2-
null mice (TG2-KO) were also subjected to UUO (Fig. 4.1A). All kidneys were lysed by 
mechanical homogenisation in an appropriate immunoprecipitation-suitable buffer and 
fractionated by high speed centrifugation to separate the crude membrane extracts from the 
cytosolic fraction. In order to validate the appropriate fractionation of the kidney 
homogenates, expression of plasma membrane marker sodium potassium ATPase (Na+/K+ 
ATPase) in the different fractions was investigated by Western blot: as expected, an intense 
band at ~112kDa, corresponding to Na+/K+ ATPase, was detected in the pelleted fraction 
(crude membrane extract) and was completely absent in the supernatant (cytosolic extract), 
confirming that all the membrane fraction was collected by centrifugation, with no trace left in 
the cytosolic fraction (Fig. 4.1B).   
After fractionation, extracts were combined in pairs (two extracts/sample) to increase protein 
amount. A total of six biological replicas per fraction were produced in this way, and TG2-
associated proteins were isolated by immunoprecipitation with an anti-TG2 monoclonal 
antibody (IA12, University of Sheffield) crosslinked to magnetic beads. An appropriate and 
specific immunoprecipitation of TG2 with this antibody was confirmed by Western blot: 
probing of TG2 in the TG2-precipitates, in fact, confirmed the correct immunoprecipitation of 
TG2 in WT mice, in both cytosolic and membranous fractions while no signal, as expected, was 
detected in TG2-KO mice (Fig. 1C). Coomassie staining of the same precipitates revealed a 
series of proteins specifically co-precipitated in WT mice, as they were absent in the TG2-null 
(TG2-KO) individuals (Fig. 4.1D). These proteins were directly or indirectly interacting with 
the enzyme and, in theory, they could be detected in the subsequent mass spectrometry (MS) 
experiments (Fig. 4.1A).  
The TG2-IP samples were analyzed by reverse-phase high-pressure liquid chromatography 
electrospray ionization tandem mass spectrometry (RP-HPLC-ESI-MS/MS) using the 
TripleTOF 5600+ mass spectrometer from SCIEX (Canada). The instrument is available for 
University staff and students at the proteomics facility lab of the John Van Geest cancer 
research center at Nottingham Trent University (Clifton Campus, Nottingham, UK), and mass 
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spectrometry runs were performed by Dr. David Boocock, assisted by Dr. Nina Schroeder, Miss 
Clare Coveney and Dr. Amanda Miles. In order to obtain the most quantitative and reliable 
results, the modern SWATH-data independent acquisition (DIA) approach (Gillet, et al. 2012) 
was employed for MS data acquisition (Fig. 4.1A). In order to ensure the most generalizable 
and quantitative data, five independent SWATH-MS experiment were performed, each one 
comparing WT and TG2-KO mice. To avoid gender bias, only male mice were employed. The 
different samples were subjected to cyclic data independent acquisition (DIA) using 34 Static 
SWATH acquisition windows of fixed dimension (m/z = 15 Da/mass) covering a mass range 
from 400 to 900 Da. Practically, during different cycles, an initial survey scan (TOF-MS) is 
performed for each window, then the following MS/MS experiments carried on the totality of 
the precursors detected in the window using ion collision energy, allowing to obtain the largest 
possible coverage of detectable proteins (Gillet, et al. 2012). After acquisition, spectral 
alignment and targeted data extraction was performed with an appropriate software 
(PeakView 2.0 SCIEX) using a reference spectral library previously generated by shotgun-MS 
(data dependent acquisition, DDA; FDR = 1%) on a pool of TG2-IP samples (one 
sample/condition) and necessary for the extrapolation of protein intensities and the 
production of quantitative results (Fig. 4.1A)a. The output of the analysis consisted of 3 
different quantification files representing the intensity of the individual ions (the area under 
the intensity curve), of the different peptides (cumulative intensity of the ions) and of the 
proteins (cumulative intensity of the peptides).  
The third file was the one used for the subsequent statistical analysis, aimed at identifying the 
TG2-associated proteins in UUO and Sham operated kidneys and ultimately producing the TG2 
interactome in kidney fibrosis: this is the part of the analysis performed for this thesis, and the 
focus of this chapter.   
                                                             
a SWATH data was processed using an extraction window of 12 min and applying these parameters: 100 peptides, 
5 transitions, peptide confidence of >99%, exclude shared peptides, and XIC width set at 50 ppm. 
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Figure 4.1: Preliminary work for the production of the TG2 interactome in kidney fibrosis. (A) 
Schematic outline of the experimental design for the identification of the TG2 interactome in kidney 
fibrosis. (B) 10% (w/v) kidney homogenates were prepared for both WT and TG2-KO sham operated 
and UUO kidneys. Kidneys were lysed in homogenization buffer (0.25 M sucrose, 10 mM Tris-HCl, 1 mM 
MgCl2, 2 mM EDTA, pH 7.4) containing protease inhibitors (Sigma) by mechanical homogenisation (Ultra 
Turrax T25 homogeniser, Merck). The whole homogenate was centrifuged at 1000g for 5 min at 4°C to 
pellet down and remove larger particulates, then membranes (M) were separated from the cytosolic (C) 
fraction by centrifugation at 200,000 g at 4°C for 30 min. The pellet (crude membrane fraction, M) was 
re-suspended in immunoprecipitation (IP) buffer [25 mM Tris.HCl, 150 mM NaCl, 1 mM EDTA, 1% (v/v) 
NP40, 5% glycerol (v/v), pH 7.4] containing protease inhibitors (Sigma). Equal volumes of proteins were 
resolved by 12% (w/v) acrylamide SDS-PAGE under reducing condition and proteins were 
immunoprobed for TG2 [mouse monoclonal anti TG2 (IA12, University of Sheffield, UK)], the plasma 
membrane marker Na+/K+ ATPase [Mouse monoclonal anti-alpha 1 sodium potassium ATPase antibody 
[464.6] - plasma membrane marker (ab7671 Abcam)]and the loading control β-tubulin [Rabbit 
polyclonal anti β-tubulin (ab6046, Abcam)]. Immunoreactive bands were detected by enhanced 
chemiluminescence (Geneflow) after incubation with appropriate HRP-conjugated secondary 
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antibodies in blocking buffer. Image acquisition was performed with a LAS4000 imaging system (GE 
Heathcare). (C,D) Immunoprecipitation of TG2-associated protein (TG2-IP) was performed with an anti-
TG2 monoclonal antibody (IA12) on both cytosolic (C) and membranous (M) fractions, using the Pierce™ 
Crosslink Magnetic IP/Co-IP Kit (Thermo Scientific) and following to the manufacturer’s instructions. 
Proteins were eluted in 50 µl of the appropriate elution buffer provided by the kit (Thermo Scientific). 
(C) Equal volumes of proteins were resolved by 12% (w/v) acrylamide SDS-PAGE under reducing 
condition and proteins were immunoprobed for TG2. Immunoreactive bands were detected by 
enhanced chemiluminescence (Geneflow) after incubation with appropriate HRP-conjugated secondary 
antibodies in blocking buffer. Image acquisition was performed with a LAS4000 imaging system (GE 
Heathcare). (D) Coomassie staining of TG2-immunoprecipiates were separated by 12%(w/v) SDS-PAGE 
and revealed a series of specifically co-precipitated proteins in WT mice. Purified guinea pig liver TG2 
was run as positive control. A black square identifies TG2.  
 
 
4.2.3 Transglutaminase-2 interactions: substrates or partners? 
Being a multifunctional and ubiquitous enzyme, a plethora of TG2 substrates have been 
identified in the literature, both in the extracellular and in the intracellular space, and including 
mitochondria and nucleus. Beside the notorious extracellular matrix components, substrates 
for TG2 crosslinking activity in the context of wound healing and scarring (fibronectin, 
collagen, elastin, vitronectin, etc.), also many cytoskeletal proteins have been suggested as 
substrates for the enzyme transamidation activity both by intramolecular and intermolecular 
modification (actin, tubulin, etc..). In the nucleus, histone proteins have been suggested to be 
crosslinked by TG2, with a role during cell death, and these are just few examples of known 
protein substrates.  
Moreover, as described before, TG2 has also a non-enzymatic role in the cells, mainly located 
in the extracellular space (Kanchan, Fuxreiter and Fésüs 2015, Belkin 2011). For this reason, 
by immunoprecipitation, not only enzyme substrates but also a number of TG2 binding 
partners are likely to be detected.  There is a growing interest in the non-enzymatic “binding” 
partners of TG2 in research, and an updated list of TG2 interacting proteins has been recently 
published on Cellular and Molecular Life Sciences by Khanchan and colleagues (Kanchan, 
Fuxreiter and Fésüs 2015). Transdab (http://genomics.dote.hu/wiki/index.php/Main_Page) 
is a database of known partners of the transglutaminase family and it collects both substrates 
and interacting partners for TG2 (Csősz, Meskó and Fésüs 2009). A list of the main TG2 
partners, distinguished into substrates and binding partners, and obtained from Transdab, is 
provided in the Appendix (Table I), while a list of interacting partners obtained from Kanchan 
et al., (Kanchan, Fuxreiter and Fésüs 2015) is provided in Appendix Table II. 
 
  
CHAPTER IV – RESULTS 
 
209 
 
4.3 EXPERIMENTAL PROCEDURES 
 
4.3.1 Z-test statistical analysis of mass spectrometric (MS) results on TG2-
immunoprecipitated proteins 
As mentioned in the introduction [4.2.2], five independent SWATH-MS experiments were 
performed, each one including an immunoprecipitation sample from each combination of mice 
(WT / TG2-KO), treatment (Sham / UUO) and fraction (cytosol / membrane). A graphical 
outline of the sample composition of each experiment is reported in Fig.4.2A. Starting from the 
five obtained datasets, in order to identify the proteins significantly associated with TG2 in 
both UUO and sham operated kidneys, a z-test statistical analysis (Cheadle, et al. 2003), which 
is conceptually similar to a t test, was performed, using the TG2-KO kidney values as 
background controls (Fig. 4.2). The TG2-KO can be considered as best possible negative 
control for this kind of immunoprecipitation-based studies: in fact, being lacking the protein 
itself, these mice will virtually not have no specifically TG2-precipitated proteins, and all the 
peptides identified in these samples by MS can be consider as an a-specific background not 
associated with TG2.  
First, raw intensity values of every detected protein were normalized within the whole 
experiment using a Z transformation: each intensity value was transformed using the natural 
log transformation and then normalized by subtracting the average of the whole population 
(µ) and dividing for the standard deviation of the whole population (σ) as shown in equation 
(1) (Fig.4.2B). ΔZ values were then calculated by subtracting TG2-KO z-score from WT z-score 
for each protein in the treatment/compartment (equation 2 in Fig.4.2B). Finally, the Z-test 
(Cheadle, et al. 2003) (equation 3a in Fig.4.2B) was performed on the ΔZ values from the 5 
experiments together in order to compare WT and TG2-KO data in the same treatment (Sham 
or UUO) and compartment (cytosol or membrane). In this case, being the null hypothesis H0: 
ΔZ = 0 (no differences in z-score between WT and KO), the test was performed by dividing the 
average of the ΔZ of the given protein in the experiments by the standard error of the ΔZ of the 
given protein in the different experiments (equation 3b in Fig.4.2B). The results of the z-test 
were plotted on a normal distribution curve to infer probability values (p-values) and identify 
protein whose intensity was significantly higher in WT than in the background condition 
[Fig.4.2B (4)]. The proteins whose p-value was lower than 0.05 in at least 4 out of 5 occasions 
(experiments)were regarded as significantly associated with TG2.   
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Figure 4.2: Z-test statistical analysis of SWATH-MS results on TG2-immunoprecipitated proteins. 
(A) Sample distribution in the 5 independent SWATH-MS experiments on TG2-immunoprecipitates, that 
were analysed by Z-test to determine TG2-associated proteins. (B) Z-test statistical analysis adapted 
from Cheadle et. al, 2003 (Cheadle, et al. 2003) for the determination of TG2 significantly associated 
proteins.  
 
 
4.3.2 Bioinformatic analysis 
4.3.2.1 Functional clustering and overrepresentation analysis 
The TG2-associated proteins identified were further analysed with a series of bioinformatics 
approaches in order to define protein functions and determine protein-protein interactions. 
Initially, protein IDs where searched on UniprotKB (http://www.uniprot.org/uniprot) 
database to identify protein names and gather information about their functions and 
localisation. Based on these information, TG2-associated proteins were manually grouped into 
functional clusters depending on their general functions, and colour-coded to make the 
differences easier to observe.  
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Similarly to what was done for the UUO proteome and described more exhaustively in the 
previous chapter, functional classification and functional overrepresentation analysis were 
performed using both DAVID v6.7 (http://david.abcc.ncifcrf.gov) and PANTHER Database 
(http://www.pantherdb.org) bioinformatics resources, employing the Mus Musculus genome 
as background gene list.  
Functional classification was performed using the Gene Ontology (GO) terms for “Biological 
Process”, “Molecular Function” and “Cellular Component” in addition to PANTHER Protein 
Class terms and PANTHER pathways. The terms represented in the TG2-associated list in both 
UUO and sham operated conditions were visualized in pie charts as percentage of 
representation of the specific GO annotation term over the total number of class hits.  
Functional overrepresentation test was performed in PANTHER using the same GO terms 
(“Biological Process”, “Molecular Function”, “Cellular Component”) and PANTHER Protein class 
annotations. The specific description of the overrepresentation test is provided in Chapter III. 
A p-value lower than 0.05 was regarded as significant. To confirm the findings obtained with 
PANTHER, functional overrepresentation analysis was performed also by DAVID bioinformatic 
tool, selecting the GO terms for “Biological Process” (GOTERM_BP_FAT), “Molecular Function” 
(GOTERM_MF_FAT) and “Cellular Component” (GOTERM_CC_FAT). A p-value lower than 0.05 
was considered significant. In order to determine which pathways were significantly 
overrepresented in the list of TG2-associated proteins, PANTHER Pathways 
overrepresentation test was carried out by PANTHER; while the same analysis using KEGG 
Pathway keywords was performed in DAVID.  
 
4.3.2.2 Investigation of protein-protein interactions using STRING 
The interactome of TG2 in kidney fibrosis was drawn using STRING v10.0 database 
(http://string-db.org). STRING allows one to identify known and predicted protein-protein 
interactions in the list of TG2-associated proteins. The network of interaction was obtained 
using a confidence level greater than 0.4 and all the unconnected proteins were removed from 
the final scheme. The network file was imported in Cytoscape v. 3.0.2 
(http://www.cytoscape.org) to organize protein localisation and colour-code them depending 
on their specific functional cluster defined as above. In this way, clear clusters can be 
distinguished if present.  
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4.4 RESULTS 
 
4.4.1 Identification of TG2 interacting proteins from SWATH acquisition 
mass spectrometry of TG2-precipitates  
In order to identify a list of proteins that associated with TG2 in healthy and fibrotic conditions, 
SWATH-MS analysis was performed as described in the introduction (4.2.3). Between 800 and 
1200 proteins were identified in each experiment. A total of 886 proteins were detected in at 
least 3 out of 5 experiments, of which 746 were detected in 4 or more experimental replicas. 
All the proteins identified in at least 4 out of 5 experiments and significantly more expressed 
(p-value lower than 0.05) than the background TG2-null control when analysed by z-test 
[4.3.1] were regarded as significantly associated with TG2. From this statistical analysis, 489 
candidates were found significantly associated with TG2 in either UUO or sham operated 
conditions (243 in cytosol and 306 in crude membrane extracts, 60 in common between 
compartments) (Fig. 4.3A). Of these candidates, 243 were found significantly associated with 
TG2 in sham operated conditions (of which 110 in cytosol and 158 in membranes) and 316 in 
fibrotic conditions (UUO) (160 in cytosol and 192 in membranes). Only 70 proteins were found 
associated with TG2 in both conditions (35 in cytosol and 53 in membranes), suggesting that 
these proteins interact with the enzyme unrelatedly from the fibrosis development.  
To identify the interactions involved in TG2 trafficking and extracellular activity, the proteins 
associated with TG2 in crude membrane extracts were analysed in detail. The TG2-associated 
proteins of the cytosolic fraction were collected in a separate list and are shown in Suppl. 
Table 4.1 (Cytosolic fraction from UUO kidneys – 21 days) and Suppl. Table 4.2 (Cytosolic 
fraction from sham operated kidneys-21 days).   
Moreover, as we wanted to focus on TG2 partners at the cell-matrix interface, membrane 
proteins previously reported to be exclusively located in nucleus, mitochondrial or 
peroxisomal membranes were identified by their subcellular location as defined on UniprotKB 
database (Subcellular Localisation) and placed in a separate list. Nuclear proteins are displayed 
in Suppl. Table 4.3, while mitochondrial and peroxisomal are displayed in Suppl. Table 4.4 
(A=TG2 -associated proteins in UUO kidneys, B=TG2-associated proteins in sham operated 
kidneys). Ribosomal proteins and IgGs found in the membrane preparation were collected as 
well in a separate list and are reported in Suppl. Table 4.5 (A=TG2 -associated proteins in UUO 
kidneys, B=TG2-associated proteins in sham operated kidneys).  
Based on these criteria, 217 proteins were identified as significantly associated with TG2 
(p≤0.05, n≥4) with a recorded plasma membrane or plasma membrane-associated or ECM 
compartmentalisation (referred to as “cell-matrix” proteins), or else a location in biological 
fluids (Fig. 4.3B). Of these proteins, 97 were found uniquely associated with TG2 in UUO 
CHAPTER IV – RESULTS 
 
213 
 
membranes, while 95 were uniquely associated with sham operated conditions. Only 25 
proteins were found significantly associated with TG2 in both conditions. This little overlap 
suggests a marked change in TG2 interactions on kidney membranes when animals were 
subjected to UUO for 21 days.  
 
 
Figure 4.3: Number of TG2-associated proteins in UUO or Sham operated kidneys at 21-days post 
operation. (A) Number of protein identified as TG2-associated upon UUO or sham operation (21 days) 
by Z-test (p≤0.05 N≥4) in both cytosolic or membranous compartments. (B) Number of protein 
identified as TG2-associated in UUO or sham operated membranes (21 days) by Z analysis (p≤0.05 N≥4) 
after removal of specifically nuclear, mitochondrial and ribosomal proteins (reported in Suppl. Tables 
4.3-4.5). Intersections of circles identify common proteins between the groups. 
 
 
 
The TG2-associated candidates (p≤0.05, n≥4) in UUO and Sham operated kidney membranes 
(21 days) are presented in Table 4.2 and Table 4.3: Table 4.2 displays the list of 122 TG2-
associated proteins in UUO (fibrotic) membranes at 21 days post-surgery, while Table 4.2 
shows the list of 120 TG2-associated proteins in sham operated, healthy, conditions at 21 days 
post-surgery.  
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Table 4.2: List of proteins significantly associated with TG2 in UUO kidney membranes (21 days). 
This table shows all the proteins identified as TG2-associated in UUO membranes (21 days) by z-analysis  
(p≤0.05 N≥4) after removal of specifically nuclear, mitochondrial and ribosomal proteins (reported in 
Suppl. Tables Suppl. Tables 4.3-4.5). In increasing shades of blue, the p-value of TG2 association 
obtained by z-analysis. U (red) = Uniquely expressed in UUO, C (yellow) = common between UUO and 
Sham.  
 
TG2-associated proteins in UUO kidney membranes 
Sample ID Name N P value 
Unique/ 
Common 
DESP_MOUSE Desmoplakin 5 1.22E-13 U 
HSP7C_MOUSE Heat shock cognate 71 kDa protein 5 7.67E-10 U 
CALM_MOUSE Calmodulin 5 1.83E-08 C 
CAZA2_MOUSE F-actin-capping protein subunit alpha-2 5 1.97E-08 U 
GPX1_MOUSE Glutathione peroxidase 1 5 4.52E-07 U 
ADH1_MOUSE Alcohol dehydrogenase 1 5 9.40E-07 C 
POSTN_MOUSE Periostin 4 1.03E-06 U 
MYO1D_MOUSE Unconventional myosin-Id 5 3.52E-06 U 
GLRX1_MOUSE Glutaredoxin 1 4 5.61E-06 U 
GLRX3_MOUSE Glutaredoxin-3 5 1.40E-05 U 
PROF1_MOUSE Profilin-1 5 1.89E-05 U 
TGM2_MOUSE Transglutaminase 2 5 3.31E-05 C 
HSPB1_MOUSE Heat shock protein beta-1 5 3.68E-05 U 
VATH_MOUSE V-type proton ATPase subunit H 5 5.98E-05 U 
ADDG_MOUSE Gamma-adducin 5 6.66E-05 U 
AT2A2_MOUSE Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 5 8.58E-05 U 
SVIL_MOUSE Supervillin 4 1.01E-04 U 
COR1C_MOUSE Coronin-1C 5 1.38E-04 U 
IQGA1_MOUSE Ras GTPase-activating-like protein IQGAP1 5 1.50E-04 C 
TCPE_MOUSE T-complex protein 1 5 3.17E-04 U 
UBP5_MOUSE Ubiquitin carboxyl-terminal hydrolase 5 5 4.59E-04 U 
FLOT2_MOUSE Flotillin-2 4 5.38E-04 U 
NAMPT_MOUSE Nicotinamide phosphoribosyltransferase 5 6.56E-04 C 
PCKGC_MOUSE Phosphoenolpyruvate carboxykinase 5 8.93E-04 C 
RAB1A_MOUSE Ras-related protein Rab-1A 5 9.16E-04 U 
SDC4_MOUSE Syndecan-4 5 9.34E-04 U 
LDHA_MOUSE L-lactate dehydrogenase A chain 4 1.04E-03 U 
MYO1G_MOUSE Unconventional myosin-Ig 5 1.21E-03 U 
K1C20_MOUSE Keratin, type I cytoskeletal 20 4 1.35E-03 U 
COEA1_MOUSE Collagen alpha-1(XIV) chain 5 1.64E-03 U 
COCA1_MOUSE Collagen alpha-1(XII) chain 4 1.68E-03 U 
HIP1_MOUSE Huntingtin-interacting protein 1 4 1.86E-03 U 
LIMS1_MOUSE LIM and senescent cell antigen-like-containing domain protein 1 5 2.47E-03 C 
SAR1B_MOUSE GTP-binding protein SAR1b 5 2.79E-03 U 
SPTA1_MOUSE Spectrin alpha chain, erythrocytic 1 5 2.92E-03 C 
FLNA_MOUSE Filamin-A 5 2.98E-03 U 
ANK3_MOUSE Ankyrin-3 5 3.03E-03 U 
PSD11_MOUSE 26S proteasome non-ATPase regulatory subunit 11 5 3.09E-03 U 
PGBM_MOUSE 
Basement membrane-specific heparan sulfate proteoglycan core 
protein (Perlecan) 
5 3.16E-03 U 
LSP1_MOUSE Lymphocyte-specific protein 1 5 3.53E-03 U 
GELS_MOUSE Gelsolin 5 4.61E-03 U 
YKT6_MOUSE Synaptobrevin homolog YKT6 5 4.72E-03 U 
PTN6_MOUSE Tyrosine-protein phosphatase non-receptor type 6 4 4.84E-03 C 
FLNB_MOUSE Filamin-B 5 5.03E-03 U 
TLN2_MOUSE Talin-2 5 5.28E-03 U 
PGK1_MOUSE Phosphoglycerate kinase 1 4 5.39E-03 C 
PICAL_MOUSE Phosphatidylinositol-binding clathrin assembly protein 4 5.65E-03 C 
F120A_MOUSE Constitutive coactivator of PPAR-gamma-like protein 1 5 6.27E-03 C 
PRDX2_MOUSE Peroxiredoxin-2 4 6.87E-03 C 
KCC2D_MOUSE Calcium/calmodulin-dependent protein kinase type II subunit delta 5 7.10E-03 U 
RTN4_MOUSE Reticulon-4 5 7.57E-03 U 
SERA_MOUSE D-3-phosphoglycerate dehydrogenase 5 7.78E-03 C 
KC1A_MOUSE Casein kinase I isoform alpha 5 8.06E-03 U 
DCTN1_MOUSE Dynactin subunit 1 5 8.52E-03 U 
ADDA_MOUSE Alpha-adducin 5 8.61E-03 U 
PGS2_MOUSE Decorin 5 1.09E-02 U 
IF4G3_MOUSE Eukaryotic translation initiation factor 4 gamma 3 5 1.11E-02 C 
RHG18_MOUSE Rho GTPase-activating protein 18 4 1.11E-02 U 
CAPZB_MOUSE F-actin-capping protein subunit beta 5 1.11E-02 U 
MVP_MOUSE Major vault protein 5 1.14E-02 U 
TERA_MOUSE Transitional endoplasmic reticulum ATPase 5 1.21E-02 C 
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ACTB_MOUSE Actin, cytoplasmic 1 5 1.24E-02 U 
PGS1_MOUSE Biglycan 5 1.30E-02 C 
K1C14_MOUSE Keratin, type I cytoskeletal 14 5 1.33E-02 U 
PLSL_MOUSE Plastin-2 5 1.34E-02 U 
AP2A2_MOUSE AP-2 complex subunit alpha-2 5 1.52E-02 U 
FINC_MOUSE Fibronectin 5 1.57E-02 C 
CLCB_MOUSE Clathrin light chain b 5 1.65E-02 U 
SNX4_MOUSE Sorting nexin-4 5 1.67E-02 U 
SPTB1_MOUSE Spectrin beta chain, erythrocytic 5 1.73E-02 U 
ZO1_MOUSE Tight junction protein ZO-1 4 1.79E-02 U 
DREB_MOUSE Drebrin 5 1.83E-02 U 
CAN1_MOUSE Calpain1 5 1.84E-02 U 
PDLI5_MOUSE PDZ and LIM domain protein 5 5 1.85E-02 U 
PUR6_MOUSE Multifunctional protein ADE2 5 1.88E-02 U 
MY18A_MOUSE Unconventional myosin-XVIIIa 5 1.93E-02 U 
CLCA_MOUSE Clathrin light chain A 5 2.07E-02 U 
IRGM1_MOUSE Immunity-related GTPase family M protein 1 5 2.09E-02 U 
NEB2_MOUSE Neurabin-2 5 2.11E-02 U 
K2C6B_MOUSE Keratin, type II cytoskeletal 6B 5 2.14E-02 U 
AP2A1_MOUSE AP-2 complex subunit alpha-1 5 2.15E-02 U 
LYPA1_MOUSE Acyl-protein thioesterase 1 5 2.18E-02 U 
PDC6I_MOUSE Programmed cell death 6-interacting protein 5 2.38E-02 C 
AP2B1_MOUSE AP-2 complex subunit beta 5 2.43E-02 U 
K1C19_MOUSE Keratin, type I cytoskeletal 19 5 2.58E-02 U 
GRP78_MOUSE 78 kDa glucose-regulated protein 5 2.59E-02 U 
ARK72_MOUSE Aflatoxin B1 aldehyde reductase member 2 5 2.61E-02 U 
SNTB2_MOUSE Beta-2-syntrophin 5 2.63E-02 U 
MYO1B_MOUSE Unconventional myosin-Ib 5 2.67E-02 U 
K6PP_MOUSE ATP-dependent 6-phosphofructokinase, platelet type 5 2.67E-02 U 
C1QB_MOUSE Complement C1q subcomponent subunit B 5 2.71E-02 U 
F213A_MOUSE Redox-regulatory protein FAM213A 5 2.79E-02 C 
HS90A_MOUSE Heat shock protein HSP 90-alpha 5 2.85E-02 U 
GAK_MOUSE Cyclin-G-associated kinase 5 2.86E-02 U 
SPTN1_MOUSE Spectrin alpha chain, non-erythrocytic 1 5 3.08E-02 C 
UCK1_MOUSE Uridine-cytidine kinase 1 5 3.12E-02 U 
ECHP_MOUSE Peroxisomal bifunctional enzyme 5 3.15E-02 C 
ES8L2_MOUSE Epidermal growth factor receptor kinase substrate 8-like protein 2 4 3.29E-02 U 
MOES_MOUSE Moesin 5 3.33E-02 U 
PNCB_MOUSE Nicotinate phosphoribosyltransferase 5 3.34E-02 U 
MYH10_MOUSE Myosin-10 5 3.59E-02 U 
RBGPR_MOUSE Rab3 GTPase-activating protein non-catalytic subunit 5 3.65E-02 U 
VIME_MOUSE Vimentin 5 3.66E-02 U 
SERPH_MOUSE Serpin H1 5 3.81E-02 U 
RPN1_MOUSE 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
subunit 1 
4 3.89E-02 U 
LAMB2_MOUSE Laminin subunit beta-2 4 3.92E-02 C 
GSTT1_MOUSE Glutathione S-transferase theta-1 5 3.95E-02 U 
TCPQ_MOUSE T-complex protein 1 5 3.96E-02 U 
TCPZ_MOUSE T-complex protein 1 5 4.23E-02 C 
IRAK4_MOUSE Interleukin-1 receptor-associated kinase 4 5 4.24E-02 U 
C1TC_MOUSE C-1-tetrahydrofolate synthase 5 4.28E-02 U 
ARC1B_MOUSE Actin-related protein 2/3 complex subunit 1B 5 4.28E-02 U 
SCFD1_MOUSE Sec1 family domain-containing protein 1 5 4.30E-02 C 
COPB2_MOUSE Coatomer subunit beta 5 4.42E-02 U 
FA49B_MOUSE Protein FAM49B 5 4.62E-02 U 
MYH14_MOUSE Myosin-14 5 4.79E-02 U 
SNX1_MOUSE Sorting nexin-1 4 4.81E-02 U 
PLST_MOUSE Plastin-3 5 4.82E-02 U 
GBP2_MOUSE Interferon-induced guanylate-binding protein 2 5 5.00E-02 U 
SYEP_MOUSE Bifunctional glutamate/proline--tRNA ligase 5 5.17E-02 U 
TCPA_MOUSE T-complex protein 1 5 5.25E-02 U 
CLIC1_MOUSE Chloride intracellular channel protein 1 5 5.33E-02 U 
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Table 4.3: List of proteins significantly associated with TG2 in Sham operated kidney membranes 
(21 days). This table shows all the proteins identified as TG2-associated in sham operated membranes 
(21 days) by z-analysis (p≤0.05 N≥4) after removal of specifically nuclear, mitochondrial and ribosomal 
proteins (reported in Suppl. Tables 4.3-4.5). In increasing shades of blue, the p-value of TG2 association 
obtained by z-analysis. U (green) = Uniquely expressed in Sham, C (yellow) = common between UUO and 
Sham. 
 
TG2-associated proteins in Sham operated kidney membranes 
Sample ID Name N p-value 
Unique/ 
Common 
PRS4_MOUSE 26S protease regulatory subunit 4 5 5.22E-09 U 
PSME1_MOUSE Proteasome activator complex subunit 1 5 8.91E-07 U 
NEDD4_MOUSE E3 ubiquitin-protein ligase NEDD4 5 3.03E-05 U 
K2C1B_MOUSE Keratin, type II cytoskeletal 1b 4 8.40E-05 U 
UN45A_MOUSE Protein unc-45 homolog A 5 1.04E-04 U 
TGM2_MOUSE Transglutaminase 2 5 1.21E-04 C 
PRUNE_MOUSE Protein prune homolog 5 1.31E-04 U 
NIBL1_MOUSE Niban-like protein 1 5 1.41E-04 U 
PLEC_MOUSE Plectin 5 1.80E-04 U 
IF4G3_MOUSE Eukaryotic translation initiation factor 4 gamma 3 5 1.82E-04 C 
SERA_MOUSE D-3-phosphoglycerate dehydrogenase 5 1.85E-04 C 
TERA_MOUSE Transitional endoplasmic reticulum ATPase 5 2.49E-04 C 
PH4H_MOUSE Phenylalanine-4-hydroxylase 5 2.67E-04 U 
TOM1_MOUSE Target of Myb protein 1 4 3.37E-04 U 
PTN6_MOUSE Tyrosine-protein phosphatase non-receptor type 6 4 4.04E-04 C 
ACY3_MOUSE N-acyl-aromatic-L-amino acid amidohydrolase 4 5.54E-04 U 
TCPZ_MOUSE T-complex protein 1 5 6.52E-04 C 
DEST_MOUSE Destrin 5 8.51E-04 U 
UB2D3_MOUSE Ubiquitin-conjugating enzyme E2 D3 5 9.25E-04 U 
KAD1_MOUSE Adenylate kinase isoenzyme 1 5 9.92E-04 U 
G3P_MOUSE Glyceraldehyde-3-phosphate dehydrogenase 5 1.05E-03 U 
USP9X_MOUSE Probable ubiquitin carboxyl-terminal hydrolase FAF-X 5 1.27E-03 U 
PDIA1_MOUSE Protein disulfide-isomerase 4 1.40E-03 U 
CASP3_MOUSE Caspase-3 4 1.42E-03 U 
UBP24_MOUSE Ubiquitin carboxyl-terminal hydrolase 24 4 1.43E-03 U 
MEP1A_MOUSE Meprin A subunit alpha 5 1.68E-03 U 
ARF6_MOUSE ADP-ribosylation factor 6 5 1.88E-03 U 
SPTA1_MOUSE Spectrin alpha chain, erythrocytic 1 5 1.97E-03 C 
TM55B_MOUSE Type 1 phosphatidylinositol 4,5-bisphosphate 4-phosphatase 4 3.22E-03 U 
KCRB_MOUSE Creatine kinase B-type 5 4.11E-03 U 
RHEB_MOUSE GTP-binding protein Rheb 5 4.12E-03 U 
SCFD1_MOUSE Sec1 family domain-containing protein 1 5 4.24E-03 C 
ST1A1_MOUSE Sulfotransferase 1A1 5 4.51E-03 U 
ANXA2_MOUSE Annexin A2 5 5.38E-03 U 
CALM_MOUSE Calmodulin 5 5.39E-03 C 
F120A_MOUSE Constitutive coactivator of PPAR-gamma-like protein 1 5 5.77E-03 C 
OLFM4_MOUSE Olfactomedin-4 5 5.80E-03 U 
IST1_MOUSE IST1 homolog 5 6.01E-03 U 
PRDX2_MOUSE Peroxiredoxin-2 4 6.07E-03 C 
PP1A_MOUSE 
Serine/threonine-protein phosphatase PP1-alpha catalytic 
subunit 
4 6.08E-03 U 
NLTP_MOUSE Non-specific lipid-transfer protein 5 6.29E-03 U 
PPBT_MOUSE Alkaline phosphatase, tissue-nonspecific isozyme 5 6.39E-03 U 
PDC6I_MOUSE Programmed cell death 6-interacting protein 5 6.41E-03 C 
ENOA_MOUSE Alpha-enolase 4 6.90E-03 U 
FBLN1_MOUSE Fibulin-1 5 7.33E-03 U 
LIMS1_MOUSE LIM and senescent cell antigen-like-containing domain protein 1 5 7.55E-03 C 
TCPG_MOUSE T-complex protein 1 subunit gamma 5 7.61E-03 U 
GGA1_MOUSE ADP-ribosylation factor-binding protein GGA1 5 8.30E-03 U 
IRF3_MOUSE Interferon regulatory factor 3 4 8.39E-03 U 
TBB5_MOUSE Tubulin beta-5 chain 5 8.92E-03 U 
FARP1_MOUSE FERM, RhoGEF and pleckstrin domain-containing protein 1 5 9.63E-03 U 
DJB11_MOUSE DnaJ homolog subfamily B member 11 4 1.03E-02 U 
ARF5_MOUSE ADP-ribosylation factor 5 5 1.03E-02 U 
ARPC5_MOUSE Actin-related protein 2/3 complex subunit 5 4 1.06E-02 U 
ARHGC_MOUSE Rho guanine nucleotide exchange factor 12 5 1.10E-02 U 
ARL2_MOUSE ADP-ribosylation factor-like protein 2 5 1.14E-02 U 
AT1B1_MOUSE Sodium/potassium-transporting ATPase subunit beta-1 5 1.21E-02 U 
MGST3_MOUSE Microsomal glutathione S-transferase 3 5 1.21E-02 U 
NSF_MOUSE Vesicle-fusing ATPase 5 1.28E-02 U 
PGK1_MOUSE Phosphoglycerate kinase 1 4 1.38E-02 C 
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ARL1_MOUSE ADP-ribosylation factor-like protein 1 5 1.42E-02 U 
AT1A1_MOUSE Sodium/potassium-transporting ATPase subunit alpha-1 5 1.43E-02 U 
CUL5_MOUSE Cullin-5 5 1.43E-02 U 
VILI_MOUSE Villin-1 5 1.51E-02 U 
S12A3_MOUSE Solute carrier family 12 member 3 5 1.55E-02 U 
KS6A3_MOUSE Ribosomal protein S6 kinase alpha-3 5 1.58E-02 U 
TBA4A_MOUSE Tubulin alpha-4A chain 5 1.62E-02 U 
VATA_MOUSE V-type proton ATPase catalytic subunit A 5 1.70E-02 U 
SYWC_MOUSE Tryptophan--tRNA ligase 5 1.75E-02 U 
CAH9_MOUSE Carbonic anhydrase 9 4 1.76E-02 U 
RAC2_MOUSE Ras-related C3 botulinum toxin substrate 2 5 1.85E-02 U 
HBA_MOUSE Hemoglobin subunit alpha 5 1.88E-02 U 
RAB10_MOUSE Ras-related protein Rab-10 5 1.98E-02 U 
PCKGC_MOUSE Phosphoenolpyruvate carboxykinase 5 2.08E-02 C 
NRK1_MOUSE Nicotinamide riboside kinase 1 5 2.11E-02 U 
VPS35_MOUSE Vacuolar protein sorting-associated protein 35 5 2.25E-02 U 
SNX3_MOUSE Sorting nexin-3 5 2.27E-02 U 
ACSA_MOUSE Acetyl-coenzyme A synthetase 5 2.29E-02 U 
DNJA2_MOUSE DnaJ homolog subfamily A member 2 5 2.29E-02 U 
ST1D1_MOUSE Sulfotransferase 1 family member D1 5 2.40E-02 U 
ANFY1_MOUSE Rabankyrin-5 5 2.42E-02 U 
GLCTK_MOUSE Glycerate kinase 5 2.42E-02 U 
ARC1A_MOUSE Actin-related protein 2/3 complex subunit 1A 5 2.42E-02 U 
PDIA6_MOUSE Protein disulfide-isomerase A6 5 2.53E-02 U 
VATB2_MOUSE V-type proton ATPase subunit B 5 2.59E-02 U 
GCYA3_MOUSE Guanylate cyclase soluble subunit alpha-3 5 2.67E-02 U 
LYPA2_MOUSE Acyl-protein thioesterase 2 5 2.68E-02 U 
RUFY3_MOUSE Protein RUFY3 4 2.72E-02 U 
PICAL_MOUSE Phosphatidylinositol-binding clathrin assembly protein 4 2.73E-02 C 
TBC9B_MOUSE TBC1 domain family member 9B 5 2.78E-02 U 
IQGA1_MOUSE Ras GTPase-activating-like protein IQGAP1 5 2.99E-02 C 
RCN1_MOUSE Reticulocalbin-1 4 3.03E-02 U 
ARP3_MOUSE Actin-related protein 3 5 3.04E-02 U 
PGS1_MOUSE Biglycan 5 3.18E-02 C 
NAMPT_MOUSE Nicotinamide phosphoribosyltransferase 5 3.20E-02 C 
ECHP_MOUSE Peroxisomal bifunctional enzyme 5 3.21E-02 C 
HS90B_MOUSE Heat shock protein HSP 90-beta 5 3.38E-02 U 
ITM2B_MOUSE Integral membrane protein 2B 5 3.60E-02 U 
MP2K2_MOUSE Dual specificity mitogen-activated protein kinase kinase 2 5 3.62E-02 U 
DHRS4_MOUSE Dehydrogenase/reductase SDR family member 4 4 3.62E-02 U 
TBA1A_MOUSE Tubulin alpha-1A chain 5 3.66E-02 U 
IF4A1_MOUSE Eukaryotic initiation factor 4A-I 5 3.68E-02 U 
OXSR1_MOUSE Serine/threonine-protein kinase OSR1 5 3.69E-02 U 
F213A_MOUSE Redox-regulatory protein FAM213A 5 3.76E-02 C 
CLIC4_MOUSE Chloride intracellular channel protein 4 5 3.82E-02 U 
VDAC1_MOUSE Voltage-dependent anion-selective channel protein 1 5 3.87E-02 U 
CAN2_MOUSE Calpain-2 catalytic subunit 5 3.95E-02 U 
NDRG3_MOUSE Protein NDRG3 5 4.06E-02 U 
CLH1_MOUSE Clathrin heavy chain 1 5 4.11E-02 U 
LAMB2_MOUSE Laminin subunit beta-2 4 4.21E-02 C 
FINC_MOUSE Fibronectin 5 4.27E-02 C 
TS101_MOUSE Tumor susceptibility gene 101 protein 4 4.31E-02 U 
DPYL3_MOUSE Dihydropyrimidinase-related protein 3 5 4.39E-02 U 
ISG15_MOUSE Ubiquitin-like protein ISG15 5 4.53E-02 U 
DRG2_MOUSE Developmentally-regulated GTP-binding protein 2 5 4.71E-02 U 
RN213_MOUSE E3 ubiquitin-protein ligase RNF213 4 4.73E-02 U 
BAX_MOUSE Apoptosis regulator BAX 5 4.73E-02 U 
ADH1_MOUSE Alcohol dehydrogenase 1 5 4.74E-02 C 
SPTN1_MOUSE Spectrin alpha chain, non-erythrocytic 1 5 5.25E-02 C 
EF1A1_MOUSE Elongation factor 1-alpha 1 5 5.34E-02 U 
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Among the proteins associated with TG2 in either fibrotic or sham operated kidney membranes 
(Table 4.2, 4.3), some had been previously reported to interact with the enzyme (full list of 
TG2 main partners in the Appendix, Table I). These were either reported as known substrates 
of the enzyme’s catalytic activity or known interacting/binding partners of TG2 non-enzymatic 
activity by Transdab database of TG partners (Csősz, Meskó and Fésüs 2009), and are displayed 
in Table 4.4 (A,B).  
Of the TG2 significantly associated proteins in UUO kidney membranes, as detected by TG2-IP 
and SWATH-MS in the current study (p≤0.05, n≥4), 39 had a reported interaction with the 
enzyme in literature (Table 4.4A), while 83 appeared as novel partners. Most of previously 
identified TG2-partners in UUO conditions were structural components of the ECM or adhesion 
proteins, with collagens (COCA1_MOUSE, COEA1_MOUSE), fibronectin (FN) (FINC_MOUSE) 
and the cell surface HSPGs syndecan4 (SDC4_MOUSE) among the more prominent, but many 
cortical cytoskeleton proteins were also identified. These included actin (ACTB_MOUSE), 
Filamin (FLNA_MOUSE), as substrates, and talin (TLN2_MOUSE), which is a known focal 
adhesion protein linking vinculin, integrin and actin cytoskeleton, as a binding partner. 
Ankyrin (ANK3_MOUSE) and number of spectrin chains were also identified, and are known to 
be substrates of TG2 crosslinking activity on the inner side of the plasma membrane, which is 
likely to be a result of the loss of cell integrity, and associated with a TG2-mediated cell death 
preventing inflammation (Orru, et al. 2003). A few chaperone proteins of the heat shock 
protein (HSP) family and subunits of T-complex protein 1 were also known TG2 partners 
identified in our study as TG2 immunoprecipitated from kidney fibrotic membranes (p≤0.05, 
N=4).  
Of the TG2 significantly associated proteins in healthy (Sham operated) kidney membranes, as 
detected by TG2-IP and SWATH-MS in the current study (p≤0.05, n≥4), 27 had already been 
associated with the enzyme in literature (Table 4.4B), leaving out 93 possible novel partners 
of the enzyme. In these conditions, the only ECM protein and adhesion protein identified and 
already reported in literature was FN (Table 4.4B): no HSPG or collagen was found associated 
with TG2 in healthy kidney membranes, and TG2 association with FN was lower in significance 
compared to the UUO kidney (p=0.043 against p= 0.016). Many already reported cytoskeletal 
protein partners of the enzyme were identified as well in this list of candidates, of which some 
were Tubulins (Table 4.4B). Tubulins were associated with TG2 only in healthy conditions, 
which might be interesting, considering that TG2 has been shown to polyaminate tubulin with 
a role in microtubule stabilisation in brain (Song, et al. 2013). In addition, some known TG2 
partners involved in cell signalling and stress response were identified as TG2-coprecipitated 
in the sham operated kidney membranes.  
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Table 4.4: TG2-immunoprecipitated candidates in UUO kidney membranes (21-days) or Sham 
operated membranes (p≤0.05 N≥4) with a previously reported association with TG2 (Transdab 
database). The two tables shows all the proteins identified as TG2-associated in UUO (A) or Sham 
operated (B) kidney membranes (p≤0.05 N≥4) which have already been reported as substrate or 
interacting partners (binding) for the enzyme, according to the Transdab database (Csősz, Meskó and 
Fésüs 2009). Some proteins were similar or closely related to the TG2 partners reported in the database; 
in this case, the name of the reported TG2-associated partner from Transdab database is provided in the 
legend.  
 
A) Candidates in UUO kidney membranes with a previously reported interaction with TG2 
Sample ID Name p-value 
Reported interaction 
with TG2 
Note 
ACTB Actin, cytoplasmic 1 1.24E-02 Substrate  
ANK3 Ankyrin-3 3.03E-03 Substrate  
CAN1 Calpain1 1.84E-02 Substrate  
CLCA Clathrin light chain A 2.07E-02 Substrate (1) 
CLCB Clathrin light chain b 1.65E-02 Substrate (1) 
COCA1 Collagen alpha-1(XII) chain 1.68E-03 Substrate  
COEA1 Collagen alpha-1(XIV) chain 1.64E-03 Substrate  
FLNA Filamin-A 2.98E-03 Substrate  
HSP7C Heat shock cognate 71 kDa protein 7.67E-10 Substrate  
HS90A Heat shock protein HSP 90-alpha 2.85E-02 Substrate  
HIP1 Huntingtin-interacting protein 1 1.86E-03 Substrate (2) 
MYH10 Myosin-10 3.59E-02 Substrate  
MYH14 Myosin-14 4.79E-02 Substrate  
SPTA1 Spectrin alpha chain, erythrocytic 1 2.92E-03 Substrate  
SPTN1 Spectrin alpha chain, non-erythrocytic 1 3.08E-02 Substrate  
SPTB1 Spectrin beta chain, erythrocytic 1.73E-02 Substrate  
TCPE T-complex protein 1 3.17E-04 Substrate  
TCPQ T-complex protein 1 3.96E-02 Substrate  
TCPZ T-complex protein 1 4.23E-02 Substrate  
TCPA T-complex protein 1 5.25E-02 Substrate  
MYO1B Unconventional myosin-Ib 2.67E-02 Substrate (3) 
MYO1D Unconventional myosin-Id 3.52E-06 Substrate (3) 
MYO1G Unconventional myosin-Ig 1.21E-03 Substrate (3) 
MY18A Unconventional myosin-XVIIIa 1.93E-02 Substrate (3) 
VIME Vimentin 3.66E-02 Substrate  
FINC Fibronectin 1.57E-02 Substrate and Binding  
GSTT1 Glutathione S-transferase theta-1 3.95E-02 Substrate and Binding  
HSPB1 Heat shock protein beta-1 3.68E-05 Substrate and Binding  
TGM2 Transglutaminase 2 3.31E-05 Substrate and Binding  
KCC2D 
Calcium/calmodulin-dependent protein kinase type 
II subunit delta 
7.10E-03 Binding  
CALM Calmodulin 1.83E-08 Binding  
COPB2 Coatomer subunit beta 4.42E-02 Binding  
IF4G3 Eukaryotic translation initiation factor 4 gamma 3 1.11E-02 Binding (4) 
MVP Major vault protein 1.14E-02 Binding  
MOES Moesin 3.33E-02 Binding (5) 
PRDX2 Peroxiredoxin-2 6.87E-03 Binding (6) 
IQGA1 Ras GTPase-activating-like protein IQGAP1 1.50E-04 Binding  
SDC4 Syndecan-4 9.34E-04 Binding  
TLN2 Talin-2 5.28E-03 Binding  
 
B) Candidates in Sham operated kidney membranes with a previously reported interaction with TG2 
Sample ID Name p-value 
Reported interaction 
with TG2 
note 
ANXA2 Annexin A2 5.38E-03 Substrate (7) 
CAN2 Calpain-2 catalytic subunit 3.95E-02 Substrate  
CASP3 Caspase-3 1.42E-03 Substrate  
CLH1 Clathrin heavy chain 1 4.11E-02 Substrate  
DPYL3 Dihydropyrimidinase-related protein 3 4.39E-02 Substrate  
EF1A1 Elongation factor 1-alpha 1 5.34E-02 Substrate  
IF4A1 Eukaryotic initiation factor 4A-I 3.68E-02 Substrate (8) 
G3P Glyceraldehyde-3-phosphate dehydrogenase 1.05E-03 Substrate  
HS90B Heat shock protein HSP 90-beta 3.38E-02 Substrate  
SPTA1 Spectrin alpha chain, erythrocytic 1 1.97E-03 Substrate  
SPTN1 Spectrin alpha chain, non-erythrocytic 1 5.25E-02 Substrate  
TCPG T-complex protein 1 7.61E-03 Substrate  
ISG15 Ubiquitin-like protein ISG15 4.53E-02 Substrate (9) 
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FINC Fibronectin 4.27E-02 Substrate and Binding  
MGST3 Microsomal glutathione S-transferase 3 1.21E-02 Substrate and Binding  
TGM2 Transglutaminase 2 1.21E-04 Substrate and Binding  
TBB5 Tubulin beta-5 chain 8.92E-03 Substrate and Binding  
PRS4 26S protease regulatory subunit 4 5.22E-09 Binding  
BAX Apoptosis regulator BAX 4.73E-02 Binding  
CALM Calmodulin 5.39E-03 Binding  
IF4G3 Eukaryotic translation initiation factor 4 gamma 3 1.82E-04 Binding (4) 
PRDX2 Peroxiredoxin-2 6.07E-03 Binding (6) 
IQGA1 Ras GTPase-activating-like protein IQGAP1 2.99E-02 Binding  
RAC2 Ras-related C3 botulinum toxin substrate 2 1.85E-02 Binding  
PP1A 
Serine/threonine-protein phosphatase PP1-alpha 
catalytic subunit 
6.08E-03 Binding  
TBA1A Tubulin alpha-1A chain 3.66E-02 Binding  
TBA4A Tubulin alpha-4A chain 1.62E-02 Binding  
 
(1) Clathrin Heavy Chain, (2) Huntingtin, (3) Myosin,  (4) Eukaryotic translation initiation factor 5A-1, (5) 
Ezrin-Radixin-Moesin binding phosphoprotein 50, (6) Peroxiredoxin-1, (7) Annexin 1, (8) Eukaryotic 
initiation factor 4F (eIF-4F), (9) Ubiquitin 
 
 
4.4.2  Functional clusters of TG2-associated proteins in UUO and Sham 
operated kidney membranes 
After a list of TG2-associated proteins was obtained for both fibrotic (UUO) and healthy (Sham) 
membranes (Table 4.2 and Table 4.3), manual search of the proprieties and functions of every 
of them was performed, to associate each one with wide-ranging clusters depending on its role 
in the cell. The association of each protein with a general “functional cluster” is presented in 
Suppl. Tables 4.6 – 4.8: Suppl. Table 4.6 displays functional clusters of the 97 proteins 
uniquely associated with TG2 in UUO kidney membranes, Suppl. Table 4.7 the functional 
clusters of the 95 proteins uniquely associated with TG2 in sham operated kidney membranes, 
and Suppl. Table 4.8 the functional clusters of the 25 proteins significantly associated 
withTG2 in both conditions (Common proteins). Functional clusters such as “Cytoskeletal and 
actin regulation”, “Cell adhesion”, “Vesicular Trafficking” and “Metabolism” were defined as 
general groups of proteins, to describe the main role/function of each TG2-associated partner 
in the cell.   
A graphical representation of the resulting functional clustering is provided in Figures 4.4-4.6. 
In these charts the TG2-associated proteins uniquely identified in UUO kidney membranes 
(n=97, Fig. 4.4), in sham operated kidney membranes (n=95, Fig. 4.5), or found in both 
conditions (n=25, Fig. 4.6) were grouped depending on the functional cluster which the 
proteins were associated with.  Each column is proportional to the significance of TG2 
association as it represents the p-value in reversed logarithmic scale: the higher, the more 
significant the association with TG2.  
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Figure 4.4: TG2-associated proteins identified uniquely in UUO kidney membranes, grouped 
depending on their general functions. Bars represent p-value of TG2 association (determined by z-
test) of each protein identified as significantly associated with TG2 uniquely in UUO kidney membranes 
at 21 days post operation (p≤0.05 N≥4, marked with “U” in Table 4.2). Proteins were grouped and color-
coded depending the general functional cluster they were associated with (Suppl.Table 4.6). Nuclear, 
mitochondrial and ribosomal proteins were removed from the list.   
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Figure 4.5: TG2-associated proteins identified uniquely in Sham operated kidney membranes, 
grouped depending on their general functions. Bars represent p-value of TG2 association 
(determined by z-test) of each protein identified as significantly associated with TG2 uniquely in sham 
operated kidney membranes at 21 days post operation (p≤0.05 N≥4, marked with “U” in Table 4.3). 
Proteins were grouped and color-coded depending the general functional cluster they were associated 
with (Suppl.Table 4.7). Nuclear, mitochondrial and ribosomal proteins were removed from the list.   
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Figure 4.6: TG2-associated proteins identified in both UUO and Sham operated kidney 
membranes (common), grouped depending on their general functions. Bars represent p-value of 
TG2 association (determined by z-test) of each protein identified as significantly associated with TG2 in 
both UUO and sham operated kidney membranes at 21 days post operation (p≤0.05 N≥4, marked with 
“C” in Tables 4.2 and 4.3). Proteins were grouped and color-coded depending the general functional 
cluster they were associated with (Suppl.Table 4.8). Solid fill color represent the p-values for the 
healthy membranes, striped patterned colors represent p-values in UUO membranes. Nuclear, 
mitochondrial and ribosomal proteins were removed from the list. 
 
 
Comparing in the same chart the TG2-associated proteins belonging to the same functional 
cluster, in either UUO or Sham operated kidney membranes (Fig. 4.7), allowed to investigate 
possible biases in the proteins’ biological roles in association with TG2, in an established 
fibrotic condition comparing to a healthy state. When the numbers of TG2-associated proteins 
belonging to each functional cluster were presented in a pie chart as percentage of proteins in 
the cluster over the total number of proteins (Fig. 4.8), a clear difference in protein 
representation was evident, with different distribution of the biological functions in UUO 
comparing to the healthy conditions.  
 
The first evidence was that a higher number of cytoskeletal proteins was associated with TG2 
in the UUO conditions compared to the healthy status (Fig. 4.7A, 4.8). “Cytoskeletal and Actin 
dynamics” was the more represented functional cluster among the TG2-associated proteins in 
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fibrotic (UUO) conditions, covering the 21% of all the TG2-associated proteins in UUO kidney 
membranes (Fig. 4.8A), while in Sham operated membranes only 12% of the proteins 
belonged to this functional cluster (Fig. 4.8B). This cluster included both structural elements 
of the cytoskeleton and proteins involved in its remodelling, the latter important to support a 
series of cellular processes, going from focal adhesion and cell locomotion, endocytic and 
exocytic processes and intracellular movements of vesicles. In membrane extracts from 
kidneys subjected to 21 days-UUO (Fig. 4.7A), these proteins comprised actin (ACTB_MOUSE) 
and proteins associated with its polymerisation and remodelling proteins such as capping 
proteins (CAPZB_MOUSE, CAZA2_MOUSE), actin-related protein 2/3 complex 
(ARC1B_MOUSE), gelsolin (GELS_MOUSE), profilin (PROF1_MOUSE), etc. Other proteins, such 
as adducin (ADDA_MOUSE, ADDG_MOUSE), filamin (FLNA_MOUSE, FLNB_MOUSE), ankyrin 
(ANK3_MOUSE), moesin (MOES_MOUSE), and supervillin (SVIL_MOUSE) (Fig. 4.7A) are 
known to be present in the cortical cytoskeleton and connect it to the plasma membrane, and 
are frequently involved in the regulation of adhesion and plasma membrane movements. The 
intermediate filament protein vimentin (VIME_MOUSE), a protein specifically known as a 
marker of mesenchymal cells, was also associated with TG2 uniquely in UUO conditions. 
Myosin subtypes were also represented upon UUO, with a possible involvement in cell 
contraction. An increased association of TG2 with keratins (K1C14_MOUSE, K1C19_MOUSE, 
K1C20_MOUSE, K2C6B_MOUSE) upon kidney fibrosis is novel (Fig. 4.7A).   
In Sham operated kidney membrane, the lower number of TG2-associated cytoskeletal 
proteins included mostly actin remodelling proteins such as actin-related protein 2/3 complex 
components (ARC1A_MOUSE, ARPC5_MOUSE, ARP3_MOUSE), destrin (DEST_MOUSE) and 
villin (VILI_MOUSE) (Fig. 4.7A), the latter mainly associated with the brush border of epithelial 
cells, that might be strongly lost upon induction of fibrosis. As stated before, interesting is the 
association of TG2 with tubulins (TBA1A_MOUSE, TBA4A_MOUSE and TBB5_MOUSE) 
exclusively in healthy kidney membranes (Fig. 4.7A). Plectin (PLEC_MOUSE), a large protein 
involved in the maintenance of cytoskeletal structure by connecting the different cytoskeletal 
filaments between them and to the plasma membrane, also lost its association with TG2 in 
kidney membranes when mice were subjected UUO (Fig. 4.7A). Spectrins appeared associated 
with TG2 in kidney membranes in both UUO and Sham operated conditions (Fig. 4.7A). 
 
As expected, other functional clusters more represented in the group of TG2-associated 
candidates in the UUO conditions compared to the healthy state were “Cell adhesion” (5% 
against 3% in sham operated membranes) and “Extracellular Organisation” (6% against 2% in 
sham operated membranes) (Fig. 4.8), suggesting a specific upregulation of TG2 function at 
the cell-matrix interface upon established UUO. Matrix proteins such as FN and collagens were 
identified as TG2-associated in fibrotic kidney membranes, together with small matrix 
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proteoglycans known to be associated with CKD progression such as biglycan (PGS1_MOUSE) 
and decorin (PGS2_MOUSE) (Stokes, et al. 2000, Schaefer, et al. 2004) (Fig. 4.7B). Importantly, 
the cell surface HSPGs syndecan-4 (Sdc4, SDC4_MOUSE) and the basement membrane HSPG 
perlecan (PGBM_MOUSE), were recognised as uniquely associated with TG2 in fibrotic 
membranes (Fig. 4.7B), which is in line with previously suggested importance of HSPGs in 
models of kidney fibrosis, including the UUO itself (Yung, et al. 2001, Morita, et al. 1994, Fan, et 
al. 2003, Scarpellini, et al. 2014). Besides Sdc4, cell adhesion proteins also included talin 
(TLN2_MOUSE), important element of focal adhesion to the matrix, and periostin 
(POSTN_MOUSE), an adhesion protein known to interact with integrins (Fig. 4.7B). However, 
highly significant appeared the interaction between TG2 and desmosome protein desmoplakin 
(DESP_MOUSE) in UUO kidney membranes, which, together with the tight junction protein 
ZO1, suggests an involvement for the enzyme in the regulation of cell-cell adhesion in the 
context of fibrosis, that might be associated with a reepithelization process ongoing in localised 
sites of acute insult in the UUO kidney at this stage of disease.  
 
Another interesting finding is the fact that redox and specifically antioxidant proteins were 
found associated with the enzyme mainly in UUO conditions. “Redox Regulation” proteins 
covered 5% of the TG2-interacting proteins in UUO membranes, against 2% in control 
membranes (Fig. 4.8). These proteins were mostly antioxidant proteins and included 
glutaredoxins (GLRX1_MOUSE, GLRX3_MOUSE), glutathione peroxidase (GPX1_MOUSE) and 
glutathione S-transferase (GSTT1_MOUSE), and peroxiredoxin (PRDX2_MOUSE) (Fig. 4.7C), 
and might be involved in the enzyme reduction and activation in the context of kidney fibrosis.  
 
The most intriguing finding, however, was the association of TG2 with a series of proteins 
involved vesicular trafficking. A substantial percentage of TG2 interacting partners in UUO 
kidney membranes (21%) were proteins involved in different mechanisms of intracellular and 
extracellular vesicular trafficking, that instead represented only the 15% of the TG2-associated 
proteins in Sham operated conditions, suggesting that TG2 is more dynamic post UUO 
induction. Vesicular associated proteins included for example clathrins (CLCA_MOUSE, 
CLCB_MOUSE, CLH1_MOUSE) and clathin-associated proteins such as adaptor proteins 
(AP2A1_MOUSE, AP2A2_MOUSE, AP2B1_MOUSE), sorting nexins (SNX1_MOUSE, 
SNX4_MOUSE), but also known markers of extracellular vesicles such as tumour susceptibility 
gene 101 (TS101_MOUSE), programmed cell death 6-interacting protein/alix (PDC6I_MOUSE) 
and flotillin (FLOT2_MOUSE). Description of the main functions of the vesicular proteins 
identified as associated with TG2 is provided in a small supplement at the end of this thesis 
(Appendix) while a table summarizing the main proprieties is provided later in this chapter.  
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When the proteins less associated with TG2 in UUO kidney membranes compared to the 
healthy kidneys were, a general reduction in the number of metabolic proteins was observed 
as interacting with the enzyme (Fig. 4.7E). Metabolic proteins were more represented in the 
TG2-associated proteins in Sham operated kidney membranes (22%) compared to the fibrotic 
kidney membranes (12%) (Fig. 4.8). This might be correlated to the large underexpression of 
metabolic proteins at 21 days post-UUO, as described in Chapter III. “Cell regulation” proteins 
were associated with TG2 on kidney membranes almost uniquely in sham operated conditions 
(11%), while only one protein was identified as TG2-associated in UUO membranes (Fig. 4.8). 
Similarly, “Ion transport” (6% in sham against 2% in UUO membranes) and “Ubiquitination 
and Proteasome” (5% in sham against 2% in UUO membranes) were less associated with TG2 
in UUO conditions compared to the healthy ones (Fig. 4.8). Functional clusters such as 
“Signalling and stress response” and “Translational regulation” seemed equally distributed 
among the TG2-associated protein in either sham and UUO fibrotic membranes, with no bias 
toward a specific treatment (Fig. 4.8).  
 
In conclusion, while cytoskeletal components, adhesion proteins, ECM elements, antioxidants 
and vesicular proteins appeared more represented in the list of TG2-associated partners at 21-
days post UUO, and might be involved in the enzyme’s transport and pro-fibrotic activity 
during CKD, less metabolic proteins or proteins associated with cell functions and regulation 
were identified upon fibrosis when compared to the sham operated TG2 precipitates.  
For the aims of this thesis, the main finding is the identification of a substantial number of 
vesicular proteins, that points the finger to a possible involvement of a vesicular trafficking 
pathway for the enzyme secretion in conditions of fibrosis.  
 
CHAPTER IV – RESULTS 
 
227 
 
 
Figure 4.7: Candidate proteins significantly associated with TG2 in either Sham operated and 
UUO kidney membranes, grouped basing on their general functional cluster and ordered basing 
on their p-values. Bars represent p-value of TG2 association (determined by z-test) of each protein 
identified as significantly associated with TG2 in either UUO or Sham operated kidney membranes at 21 
days post operation (p≤0.05 N≥4, Listed in Table 4.2 and 4.3). Each graph represents a specific 
functional cluster, as identified in Suppl. Tables 4.6- 4.8. TG2-associated proteins in UUO kidney 
membranes are in red, while TG2-associated proteins in sham operated kidney membranes are in grey.  
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Figure 4.8: Distribution of the general functions in UUO and Sham operated kidney membranes. 
pie chart representing the distribution of the TG2-associated proteins in the different functional clusters 
(as identified in Suppl. Tables 4-6 – 4.8) for either UUO (A) or sham operated (B) kidney membranes 
at 21 days post operation (p≤0.05 N≥4).  Each sector individuates the number and % of proteins in the 
functional cluster over the total of number of proteins). Both unique and common proteins were 
considered for each treatment. TG2 was excluded from the analysis. nuclear, mitochondrial and 
ribosomal proteins were removed from the list. Red circles indicate terms more represented as 
associated with TG2 in fibrotic conditions (UUO 21 days), green circles terms more represented as 
associated with TG2 in healthy conditions (Sham 21 days) and black circles indicate terms similarly 
represented in both lists. 
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4.4.3  Functional classification of TG2-associated proteins in UUO and Sham 
operated kidney membranes using Gene Ontology (GO) and PANTHER 
annotation terms 
Functional classification of the different gene products (protein IDs) associated with TG2 was 
also performed in PANTHER, as described above in 4.3.2.1. GO terms for “Biological Processes”, 
“Molecular Functions” and “Cellular Components”, as well as PANTHER Protein class terms, 
were investigated, and results were visualized in pie charts as percentage of representation of 
the different annotation terms over the total class hits (Fig. 4.9). 
For what it concerns the GO annotations terms for “Biological Processes” (Fig. 4.9A), the term 
“Cellular component organization or biogenesis” (GO:0071840) covered approximately 21% 
of the total class hits and 39% of the total elements of the list of TG2-associated proteins in 
fibrotic kidney membranes (UUO). This means that more than a third of TG2-associated 
proteins in UUO kidney membranes was associated with this annotation term, which is a 
general ancestor term that includes more specific descendant “child” terms such as 
“Extracellular structure organization” (GO:0043062), “Membrane and endomembrane system 
organization” (GO:0061024, GO:0010256), “Actin filament organization” (GO:0007015) and 
“Vesicle tethering” (GO:0099022). In Sham operated kidney membranes, the same term 
covered only 7.6% of the total number of class hits, and the 13.1% of the TG2-associated 
candidates (Fig. 4.9A). This finding is consistent with the manual clustering described before 
(4.4.2). On the other hand, a Biological Process GO term that was less represented among TG2-
associated proteins in UUO kidney membranes, compared to the healthy ones, was “Metabolic 
process” (GO:0008152), in line with the functional cluster described before (4.4.2). This term 
covered the 22.4% of the total class hits in healthy kidney membranes, and more than a third 
of the total number of TG2-associated proteins in this condition (38.5%). In UUO kidney 
membranes, less TG2 partners were associated with this term (27.6%), that represented the 
14.8% of total class hits (Fig. 4.9A).  
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When the GO terms for “Molecular Functions” were analysed using the same approach (Fig. 
4.9B), an elevated presence of TG2 protein partners associated with the annotation terms 
“Binding” (GO:0005488) and “Structural molecule activity” (GO:0005198) were identified 
fibrotic kidney membranes (36% and 24% of total class hits, respectively, and 39% and 26% 
of total number of proteins). “Binding” Molecular Function GO term is a general annotation that 
includes a large spectrum of more specific molecular functions such as ion binding 
(GO:0043167), hormone binding (GO:0042562) and extracellular matrix binding 
(GO:0050840), while “Structural molecule activity” term includes all the gene products 
implicated in the structural constitution of the cell and the extracellular space (cytoskeleton, 
extracellular matrix, ribosomes etc.). These functions were less represented in Sham operated 
kidney membranes, especially for what it concerns “Structural molecule activity” term, that 
was more than 2-times less represented in healthy conditions (11.5% of proteins or 11.3% of 
total class hits) compared to UUO (Fig. 4.9B). “Catalytic activity” (GO:0003824), on the other 
hand, was the more represented in healthy membranes, covering almost the half of the total 
proteins in the list (43.4%). In UUO membranes, even if still considerable, this annotation term 
was less represented, covering 32.3% of all the TG2-associated proteins in the list (Fig. 4.9B).  
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To investigate the localization of the different kidney membrane fraction TG2-associated 
proteins in the cells, in healthy or fibrotic conditions, GO terms for “Cellular Components” were 
analyzed with the same approach (Fig. 4.9C). Even if the distribution of the proteins in the 
different cellular compartments appeared similar in UUO and Sham operated conditions, some 
bias was noticed toward membranous and extracellular compartments for the TG2-associated 
proteins in UUO membranes [“Membrane” (GO:0016020) =13.0% of proteins against 4.9% in 
sham;  “Extracellular matrix” (GO:0031012) = 2.4% against 0.8% in sham; “Extracellular 
region” (GO:0005576) = 4.1% against 2.5% in sham; “Cell junction” (GO:0030054) = only 
detected in UUO membranes, 4.9%], that were also showing an higher number of 
“Organelle”(GO:0043226) proteins (30.9% of proteins against 16.4% in sham) (Fig. 4.9C). In 
Sham operated kidneys, a series of proteins (at least 28%) were not associated with any 
annotation term for Cellular Components by the software, and the ones associated were mostly 
related to “Cell part” (GO:0044464) ontology, that identifies basically every intracellular 
component of the cell and include the plasma membrane. In healthy conditions, this term 
covered more than half of the total class hits, 50.6%, and the 36.1% of proteins in the list of 
TG2-associated proteins. In UUO kidney membranes the same term covered “only” 44.4% of 
total class hits, but was actually associated with more than 50% of protein candidates (Fig. 
4.9C).  
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Finally, PANTHER Protein Class annotation terms analysis (Fig.4.9D) allowed us to determine 
more specifically to which functional group the proteins were belonging. The most represented 
“Protein Class” among TG2-associated proteins in UUO conditions was “Cytoskeletal protein” 
(PC00085), that covered almost a third of proteins (31.7%) and 25.2% of total class hits. This 
class was much less represented in Sham operated membranes, involving only 11.5% of 
proteins, or 10.5% of total class hits (Fig. 4.9D). TG2-associated proteins in Sham operated 
membranes appeared more equally distributed among the different classes. Classes involved 
in metabolic reactions were the more described in Sham operated conditions, and above all 
“Hydrolase” (PC00121) proteins represented 11.3% of the total class hits against only 3.2% in 
UUO. Transferases (PC00220, 8.3% vs 6.5% in UUO), transporter proteins (PC00227, 6.8% vs 
3.2% in UUO) and ligases (PC00142, 4.5% vs 1.9% in UUO) were also more represented in 
healthy conditions (Fig. 4.9D). An exception was given by “Oxidoreductase” (PC00176) 
proteins, that were similar in both conditions, even if slightly more represented in fibrotic 
membranes (6.8% of total class hits in sham operated membranes and 7.1% in UUO) (Fig. 
4.9D).  
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Figure 4.9: Gene Ontology (GO) annotation terms and PANTHER protein classes functional 
analysis of TG2-associated proteins in UUO or Sham operated kidney membranes. Functional 
analysis of TG2-associated candidates in UUO and Sham operated kidney membranes at 21 days post-
operation was performed by PANTHER (http://www.pantherdb.org) using the annotation terms 
ontologies for (A) PANTHER GO-slim Biological Process, (B) PANTHER GO-slim Molecular Function, (C) 
PANTHER GO-slim Cellular Component, (D) PANTHER Protein Class. Labels must be read this way: % 
proteins belonging to the class over the number of proteins in the list; name of the annotation term; % 
proteins belonging to the class over the total number of class hits (for all the annotation terms 
individuated in the list of proteins = 100%). Red circles indicate terms more represented as associated 
with TG2 in fibrotic conditions (UUO 21 days), green circles terms more represented as associated with 
TG2 in healthy conditions (Sham 21 days), black circles indicate terms similarly represented in both 
lists. 
 
 
The distribution of different biological pathways among TG2-associated proteins was 
investigated using the PANTHER Pathways annotation terms on PANTHER Database (Table 
4.5, Table 4.6). Among the pathways identified by TG2-associated proteins in UUO 
membranes (Table 4.5), the more represented were “Integrin signaling pathway” (P00034), 
“Huntington disease” (P00029), “Inflammation mediated by chemokine and cytokine signalling 
pathway” (P00031) and “Nicotinic acetylcholine receptor signalling pathway” (P00044) 
(Table 4.5, black arrows).  
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Table 4.5: Pathways representation of TG2-associated proteins in UUO kidney membranes. 
Pathways represented among TG2-associated proteins in UUO kidneys at 21 days post-operation were 
analysed by PANTHER (http://www.pantherdb.org) using the annotation terms for PANTHER 
Pathways. The table shows the pathways represented, the number of proteins belonging to the pathway 
and the corresponding coverage over the total classes identified: the number of proteins belonging to 
the class and the percentage of representation over the total class hits are in increasing shades of red 
(the higher, the more intense). Black arrows identify the more represented PANTHER Pathways in the 
list.  
 
 
 
In Sham operated membranes, instead, the more represented PANTHER pathways (Table 4.6) 
were, in order, “Huntington disease” (P00029), “Integrin signalling pathway” (P00034), “B cell 
activation” (P00010) and “CCKR signaling map” (P06959) (Table 4.6, black arrows). 
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Table 4.6: Pathways representation of TG2-associated proteins in Sham operated kidney 
membranes. Pathways represented among TG2-associated proteins in sham operated kidneys at 21 
days post-operation were analysed by PANTHER (http://www.pantherdb.org) using the annotation 
terms for PANTHER Pathways. The table shows the pathways represented, the number of proteins 
belonging to the pathway and the corresponding coverage over the total classes identified: the number 
of proteins belonging to the class and the percentage of representation over the total class hits are in 
increasing shades of green (the higher, the more intense). Black arrows identify the more represented 
PANTHER Pathways in the list.  
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In order to determine which GO terms were significantly enriched among the TG2-associated 
candidates in either fibrotic (21 days UUO) or healthy (21 days sham) conditions, a statistical 
overrepresentation test was performed employing both PANTHER and DAVID bioinformatics 
tools, as described in the experimental procedures (4.3.2.1). For this test, both the list of TG2-
associated proteins in UUO kidney membranes (n=122, Table 4.2) and list of TG2-associated 
proteins in Sham operated kidney membranes (n=120, Table 4.3) were analyzed, and the 
annotation terms’ representation in the lists was compared with the terms’ distribution in the 
whole Mus musculus genome to define significantly (p≤0.05) enriched classes.  
Results from the test performed using PANTHER bioinformatic tool are shown in Table 4.7: as 
for the functional classification described above, the GO terms for “Biological Process”, 
“Molecular Function” and “Cellular Component”, in addition to PANTHER Protein Class terms, 
were analysed. A series of annotation terms were found significantly enriched (p-value lower 
than 0.05) and associated with TG2 in UUO conditions (in the list of UUO-overexpressed 
proteins). Other terms were significantly enriched among the TG2-associated proteins in sham 
operated kidney membranes (p<0.05).  
 
Seventeen GO “Biological Process” annotation terms were identified as significantly enriched 
in the group of TG2-associated proteins upon UUO (p≤0.05), while only five were found 
significantly overexpressed in Sham operated kidneys (Table 4.7A). The “Biological Process” 
terms enriched in UUO membranes at 21-days post operation could be included into three 
main ancestral groups: “Cellular component organization or biogenesis” (GO:0071840) (4.93- 
fold enriched in UUO, p=3.03∙10-19), “Cellular process” (GO:0009987) (1.46 fold enriched in 
UUO, p=0.01) and “Localization” (GO:0051179) (2.25- fold enriched in UUO, p=0.01). To this 
last group belong a series of sub-annotation terms (child terms) associated with intracellular 
transport and vesicular transport that were identified as significantly enriched among TG2-
associated proteins in UUO membranes and might be involved in the enzyme movements and 
export (Table 4.7A, grey arrows). In support to this hypothesis, “Vesicle-mediated transport” 
(GO:0016192) was 4.54-fold enriched in UUO with a high significance of overrepresentation 
(p=3.07 ∙10-7). The same function was significantly enriched also in sham operated kidney 
membranes, but with a lower fold increase and at a lower significance (3.38-fold enriched, 
p=0.003). Terms associated with protein transport were also enriched in Sham operated 
membranes, at a p-value that was similar or lower than the one of TG2-associated candidates 
in UUO (an asterisk identifies these terms in Table 4.7A).  
 
GO “Molecular Functions” (Table 4.7B) significantly enriched among TG2-associated proteins 
in UUO kidney membranes were related to the cytoskeletal structure and actin dynamics (black 
arrows): “Structural constituent of cytoskeleton” (GO:0005200) was more than 10-fold 
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enriched at a strongly significant level (p=7.68∙10-21). The term was almost 4-fold enriched also 
in Sham operated membranes (** in Table 4.7B), but at a much lower level of significance 
(p=0.01). Other terms significantly enriched in UUO membranes and involved in cytoskeletal 
dynamics (black arrows in Table 4.7B) were: “Actin binding” (GO:0003779) (18.34-fold 
enriched, p=2.84∙10-16), “Cytoskeletal protein binding” (GO:0008092) (14.49-fold enriched, 
p=4.30 ∙10-16), “Structural molecule activity” (GO:0005198) (6.29-fold enriched, p=8.03 ∙10-15), 
in line with our previous observations on the list of proteins (4.4.2).   
Two other Molecular Functions were significantly enriched in the list of TG2-associated 
proteins in healthy Sham operated conditions: “Catalytic activity” (GO:0003824, indicated by 
one circle in Table 4.7B) was identified as 1.89-fold overexpressed (p=8.79∙10-5) while “Anion 
channel activity” (GO:0005253, indicated by two circles in Table 4.7B) was 14.35-fold 
enriched (p=0.03). 
 
GO “Cellular components” overrepresented in the list of TG2-associated proteins are shown in 
Table 4.7C. In UUO kidney membranes, cytoskeletal proteins were enriched at an elevated 
significant level (black arrows in Table 4.7C). These were associated with terms such as “Actin 
cytoskeleton” (GO:0015629), more than 16-fold overrepresented (p=1.43∙10-17), 
“Cytoskeleton” (GO:0005856) (7.59-fold enriched, p=5.03∙10-14), “Intermediate filament 
cytoskeleton” (GO:0045111) (12.60-fold enriched, p=0.003). The first two terms were 
enriched also in Sham operated membranes, but the significance of enrichment was lower, 
between 0.05 and 0.01. Interestingly, “Tubulin complex” (GO:0045298) term was enriched and 
associated with TG2 only in sham operated kidney membranes (27.45-fold enriched, p=0.01) 
in line with our previous observations (4.4.1-4.4.2). Other cellular components enriched 
among TG2-associated proteins in UUO membranes were related to vesicular compartments 
(grey arrows in Table 4.7C). In particular, “Vesicle coat” (GO:0030120) annotation term was 
17.71 fold enriched (p=0.005). In addition, it was curious to note that transmembrane proteins 
(“Integral to membrane”, GO:0016021) were significantly underrepresented among TG2-
associated proteins in both condition (white arrowhead in Table 4.7C).  
Similar outcomes were also found by performing an overrepresentation test on the GO terms 
in DAVID bioinformatics resource, and results can be found in Suppl. Table 4.9 – 4.14.  
 
Finally, PANTHER Protein classes significantly overrepresented were investigated in 
PANTHER bioinformatics resource using the same approach (Table 4.7D). “Protein classes” 
significantly overrepresented among TG2-associated proteins in kidney membranes at 21 days 
post-UUO were involved in both cytoskeletal dynamics (black arrows in Table 4.7D) and 
vesicular transport (gray arrows in Table 4.7D). The “cytoskeletal protein” (PC00085) 
annotation term was almost 10 times enriched in UUO membrane, with a p-value of 9.35∙10-24. 
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This annotation term resulted enriched also in healthy membranes (** in Table 7D), but at a 
lower confidence level (p=0.015). Terms enriched uniquely in UUO membranes were proteins 
of the actin family (PC00041), intermediate filament proteins (PC00129) and actin binding 
proteins (PC00165, PC00040). The protein class of tubulins (PC00228), on the other side, was 
significantly enriched uniquely in sham operated kidneys (27.45-fold enriched, p=0.04), in 
agreement with the GO terms for “Cellular Components” described above and our previous 
observations (4.4.1-4.4.2). Trafficking and vesicular transport classes significantly enriched 
among TG2-associated proteins in kidney fibrotic membranes (gray arrows in Table 4.7D) 
were “Membrane traffic protein” (PC00150) annotation term, 5.28-fold enriched (p=0.005), 
and “Vesicle coat protein” (PC00235) annotation term, more than 17-times overrepresented 
(p=0.018). Interestingly, the protein classes identifying G-proteins (PC00020) and small 
GTPases (PC00208) were significantly enriched and associated with TG2 only in healthy 
kidney membranes at 21 days post Sham operation (3 circles in Table 4.7D), and might be 
involved in different functions of TG2 in physiological conditions.  
 
To summarize, the annotation terms associated with both cytoskeletal organization and cell 
trafficking, especially vesicular, were identified as associated with TG2 in kidney fibrotic 
membranes and significantly enriched in this condition when compared to their expression in 
the whole Mus musculus genome. These significantly enriched proteins classes or functions 
might be involved in TG2 trafficking and extracellular activity during the progression of CKD. 
Functional classes overrepresented in Sham operated kidney were less, and mostly associated 
with cell regulation and metabolism. 
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Table 4.7:  Functional Classes Overrepresentation test on TG2-associated proteins in UUO and 
Sham operated kidneys, performed by PANTHER. Statistical overrepresentation test was performed 
in PANTHER (http://www.pantherdb.org) using the annotation terms terms ontologies for (A) 
PANTHER GO-slim Biological Process, (B) PANTHER GO-slim Molecular Function, (C) PANTHER GO-slim 
Cellular Component, (D) PANTHER Protein Class. Legend: Grey arrows = Terms associated with 
intracellular trafficking and vesicular transport and enriched in UUO kidney membranes; * = Terms 
associated with intracellular trafficking and vesicular transport and enriched in Sham operated kidney 
membranes; Black arrows = terms associated with cytoskeletal organisation and actin binding and 
enriched in UUO kidney membranes; ** = terms associated with cytoskeletal organisation and actin 
binding and enriched in Sham operated kidney membranes; o = terms associated with catalytic activity 
and enriched in Sham operated kidney membranes; oo = terms associated with anion channel and 
enriched in Sham operated kidney membranes; ooo = terms associated with G-proteins or Small GTPases 
and enriched in Sham operated kidney membranes; White arrowhead = terms associated with 
transmembrane proteins significantly underrepresented in UUO and Sham operated kidney membranes.  
+, Red = overrepresented term (fold change from expected value H0 >1); -, Green = underrepresented 
term (fold change from expected value H0 <1). In increasing shades of grey = fold change from the 
expected value H0 (the more intense, the higher the fold change). In increasing shades of blue = p-value 
(the more intense, the lower the p-value). A p-value lower than 0.05 was regarded as significant.  
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To determine which molecular pathways were significantly enriched among the TG2-
associated proteins identified in this study (at a p-value lower than 0.05), statistical 
overrepresentation analysis was carried out using both PANTHER Pathways annotation terms 
on PANTHER bioinformatic tools and KEGG pathways annotation terms on DAVID database 
(Table 4.8 and 4.9). 
PANTHER Pathways significantly enriched among TG2-associated proteins at 21 days post-
UUO (Table 4.8) were, in order of significance (lower p-value): “Integrin signalling pathway” 
(P00034, 9.5-fold enriched, p=2.07∙10-5), “Huntington disease” (P00029, 11.26-fold enriched, 
p=2.07∙10-5), “Nicotinic acetylcholine receptor signalling pathway” (P00044, 13.37-fold 
enriched, 1.84E∙10-4) and “Cytoskeletal regulation by Rho GTPase” (P00016, 11.49-fold 
enriched, p=0.01). The overrepresentation of “Nicotinic acetylcholine receptor signalling 
pathway” is difficult to interpret, but is known to involve myosin and actin proteins, that are 
well represented in the list of TG2-associated proteins. PANTHER Pathways significantly 
enriched among TG2-associated proteins in Sham operated conditions (Table 4.8) were again 
“Huntington disease” (P00029, 13.88-fold enriched, p=9.94∙10-8), “Integrin signalling pathway” 
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(P00034, 8.62-fold enriched, p=1.99∙10-4), but also “B cell activation” (P00010, 15.46-fold 
enriched, 4.82∙10-4) and “T cell activation” (P00053, 9.94-fold enriched, p=0.03).  
As it can be seen, integrin signalling pathway was significantly enriched in both conditions and 
slightly more significant in UUO kidney membranes, but curiously no integrin subunit was 
identified in the list. The fact that the pathway was still identified as enriched is probably due 
to the presence of a series of proteins interacting with integrins and identified in the lists of 
TG2-associated proteins such as actin-associated proteins, HSPGs, fibronectin, periostin, and 
TG2 itself. The presence of Huntington disease was similarly curious, but consistently 
identified as enriched in both conditions.  
 
Table 4.8: PANTHER Pathway overrepresentation test on TG2-associated proteins in UUO and 
Sham operated kidneys. Statistical overrepresentation test was performed in PANTHER 
(http://www.pantherdb.org) using the annotation terms ontologies for PANTHER Pathways. Legend: +, 
Red = overrepresented term (fold change from expected value H0 >1); -, Green = underrepresented term 
(fold change from expected value H0 <1). In increasing shades of grey = fold change from the expected 
value H0 (the more intense, the higher the fold change). In increasing shades of blue = p-value (the more 
intense, the lower the p-value). A p-value lower than 0.05 was regarded as significant. 
 
 
Overrepresented KEGG Pathways, when analyzed by DAVID (Table 4.9), were only partially in 
line with the previous analysis of PANTHER Pathways (Table 4.8). The most enriched 
pathways (lower p-value) associated with TG2 in UUO kidney membranes (Table 4.9A) were 
“Huntington's disease” (mmu05016, 4.87-fold enriched, p=3.98∙10-4) and “Regulation of actin 
cytoskeleton” (mmu04810, 4.10-fold enriched, p=0.0012), but also 
“Glycolysis/Gluconeogenesis” (mmu00010) KEGG pathway was identified as significantly 7-
fold enriched, at a p-value equal to 0.0045. The other pathways significantly enriched, at a p-
value between 0.05 and 0.01 were “Endocytosis” (mmu04144), “Adherens junction” 
(mmu04520) and “Focal adhesion” (mmu04510) in agreement with our previous observation 
of protein functions and localisation at the cortical cytoskeleton and plasma membrane, as well 
as with the significant presence of clathrin and clathrin-associated proteins.  
In Sham operated conditions (Table 4.9B), the most significantly enriched pathways (lower p-
value) were “Glycolysis / Gluconeogenesis” (mmu00010, 8.17-fold enriched, p=7.17∙10-4), in 
line with the previous results, followed by “Regulation of actin cytoskeleton” (mmu04810, 
7.21-times overrepresented, p=0.008). The other pathways enriched in Sham operated 
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conditions were different from the UUO ones and were “Gap junction” (mmu04540), “Long-
term potentiation” (mmu04720) and “Vascular smooth muscle contraction” (mmu04270), all 
overrepresented with a p-value between 0.05 and 0.01.  
 
In summary, TG2-associated proteins in fibrotic kidney membranes were significantly (lower 
p-value) fitting in molecular pathways involved in both cytoskeletal organization, cell-matrix 
and cell-cell adhesion and vesicular trafficking. Glycolysis-Gluconeogenesis pathways, even if 
enriched in fibrotic conditions, was present and more overrepresented in sham operated 
membranes. 
 
Table 4.9: KEGG overrepresentation test on TG2-associated proteins in UUO and Sham operated 
kidneys performed by DAVID. Statistical overrepresentation test was performed by DAVID 
(http://david.abcc.ncifcrf.gov) using the annotation terms ontologies KEGG Pathways. The number of 
proteins belonging to the annotation term and fold change from the expected value H0 are in increasing 
shades of red for the UUO condition (the higher the more intense) (A) and of green for the Sham operated 
condition (the higher the more intense)(B). The p-value is shown in increasing shades of blue (the more 
intense, the lower the p-value). A p-value lower than 0.05 was regarded as significant. 
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4.4.4 The interactome of TG2 in fibrotic kidney membranes and healthy 
kidney membranes 
The interactions existing between the TG2-coprecipitated partners in both fibrotic and healthy 
conditions was investigated using STRING v10.0 database tool (http://string-db.org), as 
described in the Experimental Procedure (4.3.2.2). The analysis was performed on the two lists 
of TG2-associated proteins, in UUO kidney membranes (n=122, Table 4.2) and Sham operated 
kidney membranes (n=120, Table 4.3), and the presence of both known and predicted protein-
protein interactions was investigated at a confidence level of at least 0.4 (middle confidence), 
which is the default confidence level employed by STRING. STRING analysis converts the 
protein IDs uploaded into gene names, that are hence shown in the final interactome. The 
correspondence between gene names and protein IDs is shown in Suppl. Table 4.15.  
The network of TG2 molecular interactions, or TG2-interactome, was obtained in both fibrotic 
(Fig. 4.10) and healthy kidney membranes (Fig. 4.11). Both networks were edited using 
Cytoscape, to isolate clear hubs of interacting proteins and colour code the candidates 
depending on their specific functions, as assigned in Suppl. Tables 4.6-4.8 (functional 
clustering).  
 
4.4.4.1  The interactome of TG2 in kidney fibrotic membranes 
The interactome of TG2 in kidney fibrotic membranes is displayed in Figure 4.10. The picture 
shows an intense network of interactions between the TG2-associated proteins in fibrotic 
kidney membranes. The network is characterised by four main clusters of functionally-
correlated proteins (Fig 4.10A-D) interconnected by a series of chaperone proteins (light 
green) or cell regulation/signalling proteins (purple/violet) that are in different ways relating 
to the separate clusters. Heat shock proteins (HSPs) appear to be central in the interactome, 
strongly associating to a series of candidates involved in different functions in the cell. The 
identified heat shock proteins include the chaperone proteins heat shock protein HSP 90-α 
(Hsp90aa1, HS90A_MOUSE) and 78 kDa glucose-regulated protein (Hspa5, GRP78_MOUSE), 
the stress-associated protein heat shock protein β-1 (Hspb1, HSPB1_MOUSE) and the 
extracellular vesicle typical protein heat shock cognate 71 kDa protein (Hspa8, 
HSP7C_MOUSE).  
A large group of strongly interconnected cytoskeletal and actin associated proteins is present 
(Fig. 4.10A, orange). The main node is actin (Actb, ACTB_MOUSE), that is associated with many 
other proteins, not only cytoskeletal but also associated with cell regulation (purple), signalling 
and stress response (violet) such as calmodulin (Calm1, CALM_MOUSE), coronin 1C (Coro1c, 
COR1C_mouse), plastin 2 and 3 (Lcp1, PLSL_MOUSE; Pls3, PLST_MOUSE) and Ras GTPase-
activating-like protein (Iqgap1, IQGA1_MOUSE). Actin also directly interacted with all the 
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abovementioned heat shock proteins. Other cytoskeletal proteins (Fig. 4.10A, orange) that 
form largely interconnecting nodes of the cluster are spectrins (Spna1, SPTA1_MOUSE; Spna2, 
SPTN1_MOUSE and Spnb1, SPTB1_MOUSE). These proteins directly interact with actin and 
other cytoskeletal proteins and might be interesting for their role at the interface with the 
plasma membrane, with a possible involvement in secretion (De Matteis and Morrow 2000). 
Important nodes are also denoted by gelsolin (Gsn, GELS_MOUSE) and vimentin (Vim, 
VIME_MOUSE), that provide the main connection between cytoskeletal proteins (Fig. 4.10A, 
orange) and proteins associated with cell adhesion and extracellular organisation (Fig. 4.10B, 
brown/yellow). Keratins are also present in the network of TG2-associated proteins in fibrotic 
membranes, of which one, keratin 14 (Krt14, K1C14_MOUSE) is directly interacting with TG2 
itself.  
A further protein hub identified by the interactome of TG2-associated proteins in UUO 
membranes is characterised by a number of cell adhesion and extracellular organisation 
proteins (Fig. 4.10B, brown/yellow), directly interacting with each other and in the same 
cluster with TG2 (white square). Of these proteins, fibronectin (Fn1, FINC_MOUSE) and the 
HSPG syndecan-4 (Sdc4, SDC4_MOUSE) are directly interacting with TG2 (Fig. 4.10B, 
brown/yellow). Another interesting HSPG specifically relating with Sdc4 in the network is the 
basement membrane-specific HSPG perlecan (Hspg2, PGBM_MOUSE). The HSPGs Sdc4 and 
perlecan are interacting with TG2 uniquely in membranes from kidneys subjected to UUO in 
this study, suggesting a TG2 association to these proteins upon disease. Other important 
proteins of the cluster are the cell adhesion protein periostin (Postn, POSTN_MOUSE), the 
extracellular proteoglycans biglycan and decorin (Bgn, PGS1_MOUSE; Dcn, PGS2_MOUSE), and 
collagens (Col12a1, COCA1_MOUSE; Col14a1, COEA1_MOUSE). The extracellular protease 
inhibitor serpin H1 (Serpinh1, SERPH_MOUSE) acts as a connection between this cluster and 
the rest of the interactome, by interacting directly with all four of the abovementioned heat 
shock proteins (HSPs) (Fig. 4.10B, brown/yellow).  
A further small hub of redox related proteins is found associated with TG2 in UUO kidney 
membranes (Fig. 4.10C, pink), is linked to the network mainly by interacting with chaperone 
proteins (light green), including HSPs. These redox proteins are peroxiredoxin-2 (Prdx2, 
PRDX2_MOUSE), glutaredoxin 1 (Glrx, GLRX1_MOUSE), glutaredoxin-3 (Glrx3, 
GLRX3_MOUSE), glutathione peroxidase 1 (Gpx1, GPX1_MOUSE) and glutathione S-transferase 
theta-1 (Gstt1, GSTT1_MOUSE) (Fig. 4.10C, pink).  
Interestingly, a main cluster identified is made of several vesicular trafficking -associated 
proteins (Fig. 4.10D, Blue). One key node of the cluster is formed by clathrin and adaptor 
proteins (Clta, CLCA_MOUSE; Cltb, CLCB_MOUSE; Ap2a1, AP2A1_MOUSE; Ap2a2, 
AP2A2_MOUSE; Ap2b1, AP2B1_MOUSE), phosphatidylinositol-binding clathrin assembly 
protein (Picalm, PICAL_MOUSE) and coatomer subunit beta (Copb2, COPB2_MOUSE). These 
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interact with the rest of the network through vesicular-associated proteins such as cyclin-G-
associated kinase (Gak, GAK_MOUSE), huntingtin-interacting protein 1 (Hip1, HIP1_MOUSE) 
and the central heat shock cognate 71 kDa protein (Hspa8, HSP7C_MOUSE) (Fig. 4.10D, Blue). 
Elements of the retromer transport such as dynactin and sorting nexins can be observed in the 
same hub (Dctn1, DCTN1_MOUSE; Snx1, SNX1_MOUSE; Snx4, SNX4_MOUSE) (Fig. 4.10D, Blue). 
Unconventional myosins are known to be involved in intracellular transport and endocytic 
processes (Tuxworth and Titus 2000) and are part of the cluster (Myo1b, MYO1B_MOUSE; 
Myo1d, MYO1D_MOUSE; Myo1g; MYO1G_MOUSE; Myo18a, MY18A_MOUSE) (Fig. 4.10D, Blue), 
even if more intensely connected with the cytoskeletal proteins than with the vesicular ones. 
The proteins programmed cell death 6-interacting protein/alix (Pdcd6ip, PDC6I_MOUSE) and 
flotillin-2 (Flot2, FLOT2_MOUSE) are markers of extracellular vesicles and are both present in 
exosomes (See Appendix and Chapter V for more details). These proteins are both identified in 
the network of TG2-associated protein in fibrotic kidney membranes (Fig. 4.10D, Blue).  
 
In conclusion, the network of interaction produced using STRING allowed to identify clusters 
of interacting proteins associated with TG2, or even directly interacting with TG2 in kidney 
membranes under fibrotic conditions induced by 21 days UUO. Four main groups of proteins 
were identified, cytoskeletal proteins, cell adhesion and extracellular organisation proteins, 
redox regulation proteins and vesicular proteins, and might all be involved in TG2 trafficking 
and pro-fibrotic activity during disease. In addition, heat shock proteins and signalling proteins 
involved in the regulation of cytoskeletal dynamics, such as plastin, coronin and calpain 
(Capn1, CAN1_MOUSE) are important elements in the network structure.  
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Figure 4.10: Network of protein-protein interactions of TG2-associated proteins in Fibrotic 
kidney membranes (UUO, 21 days). Network of known and predicted protein-protein interactions 
was designed in STRING (http://string-db.org)  using the list of TG2-associated proteins in UUO kidney 
membranes. A confidence of at least 0.4 (middle confidence in STRING) was chosen as threshold for the 
interactions identified. Results were exported on Cytoscape (http://www.cytoscape.org) for graphical 
visualisation and colour coded depending on the specific functional cluster (Suppl.Table 4.6, 4.8). 
Thickness of the lines reflects the confidence of the interaction (from 0.4 to 0.99).  
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4.4.4.2  The interactome of TG2 in healthy kidney membranes 
The interactome of TG2 in Sham operated (healthy) kidney membranes is shown in Figure 
4.11. Similarly to what seen in the TG2-interactome in UUO conditions, a dense interrelation 
of proteins is observed. However, the four main clusters of functionally-correlated proteins 
identified in fibrotic conditions (Fig.4.11 A-D) are less evident in sham operated conditions, 
or even absent.  
A series of cell regulation and cell signalling proteins are identified in the network and linking 
the different groups of cytoskeletal (Fig. 4.11A, Orange), metabolic (Fig. 4.11C, red) and 
vesicular proteins (Fig. 4.11E, Blue). At the centre of the network heat shock protein HSP90-β 
(Hsp90ab1, HS90B_MOUSE) is connected with the majority of the proteins in the network. 
Caspase-3 (Casp3, CASP3_MOUSE) forms another important node, connecting to cytoskeletal, 
metabolic and other signalling proteins, as well as directly interacting with TG2. Also Ras-
related C3 botulinum toxin substrate 2 (Rac2, RAC2_MOUSE) is a cell signalling protein which 
represents a key node of the network, directly interacting with plasma membrane proteins and 
with Fibronectin. A series of chaperone proteins are also evident in the network, and in 
particular T-complex protein 1 subunit gamma (Cct3, TCPG_MOUSE) directly interacts with 
TG2.  
A cluster of cytoskeletal proteins is recognized in the network (Fig. 4.11A, Orange). The cluster 
is smaller and less dense in comparison with the UUO one (Fig. 4.11A, Orange) and actin is not 
present as the central node. However, actin-associated proteins are present in the network 
(actin-related protein 2/3 complex subunit 1A - Arpc1a, ARC1A_MOUSE; actin-related protein 
2/3 complex subunit 5 - Arpc5, ARPC5_MOUSE; actin-related protein 3 -Actr3, ARP3_MOUSE) 
and also two spectrin isotypes are identified and are in common with the TG2-interactome in 
fibrotic membranes (Spna1, SPTA1_MOUSE and Spna2, SPTN1_MOUSE). Interestingly, tubulins 
(tubulin alpha-1A chain - Tuba1a, TBA1A_MOUSE; tubulin alpha-4A chain - Tuba4a, 
TBA4A_MOUSE and tubulin beta-5 chain - Tubb5; TBB5_MOUSE) are present in the network 
and are uniquely associated with TG2 in Sham operated conditions.  
Very few proteins involved in cell adhesion and extracellular organisation are identified in the 
network (Fig. 4.11B, Brown/yellow), of which FN (Fn1, FINC_MOUSE) was directly interacting 
with TG2. Unlike the network of TG2-associated proteins in fibrotic conditions, in this case no 
cluster of redox-associated proteins is identified, and only peroxiredoxin 2 (Prdx2, 
PRDX2_MOUSE) is directly connected to the main network.  
Metabolic proteins are also forming a small hub of interacting candidates connected to the 
main network of TG2-associated proteins (Fig. 4.11C, Red). Among these, glyceraldehyde-3-
phosphate dehydrogenase Gapdh (Gapdh, G3P_MOUSE) is central in the network and directly 
interacting with TG2.  N-acyl-aromatic-L-amino acid amidohydrolase (aminoacylase Acy3, 
ACY3_MOUSE), a protein known for playing a role in kidney proximal tubules (Lindner, Täfler-
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Naumann and Röhm 2008, Smith, et al. 2013, Newman, et al. 2007), is also present in the cluster 
and directly associates to both Gapdh and TG2 (Fig. 4.11C, Red).  
A series of proteins associated to protein degradation by ubiquitination and proteasome (Fig. 
4.11D, dark blue-green) are also identified in the network and form a separate hub of proteins 
partially interconnected with both vesicular markers and signalling proteins. E3 ubiquitin-
protein ligase NEDD4 (Nedd4, NEDD4_MOUSE) and 26S proteasome regulatory subunit 4 
(Psmc1, PRS4_MOUSE) are the main nodes of the cluster, followed by ubiquitin-conjugating 
enzyme E2 D3 (Ube2d3, UB2D3_MOUSE) and proteasome activator complex subunit 1 (Psme1, 
PSME1_MOUSE). Cullin 5 (Cul5, CUL5_MOUSE) is also present in the cluster. The ubiquitin-like 
signalling protein ubiquitin-like protein Isg15 (ISG15_MOUSE) represents the main connection 
between this cluster and the other members of the interactome, especially to vesicular-
associated candidates Fig. 4.11D, dark blue-green).  
Vesicular proteins (Fig. 4.11E, Blue) are more sparse in the network of TG2-associated 
proteins in healthy kidney and are forming a small protein cluster that included the vesicular 
trafficking regulators ADP-ribosylation factors Arf5 and Arf6 (Arf5, ARF5_MOUSE and Arf6, 
ARF6_MOUSE), the ADP-ribosylation factor-binding protein GGA1 (Gga1, GGA1_MOUSE), 
Rab10 (Rab10, RAB10_MOUSE), the vesicular protein clathrin (heavy chain Cltc, 
CLH1_MOUSE), phosphatidylinositol-binding clathrin assembly protein (Picalm, 
PICAL_MOUSE, common with UUO), and retromer-associated proteins such Vps35 and Snx3 
(VPS35_MOUSE; SNX3_MOUSE) (Fig. 4.11E, Blue). In addition to these proteins, the 
programmed cell death 6-interacting protein/alix (Pdcd6ip, PDC6I_MOUSE) and the tumor 
susceptibility gene 101 protein (Tsg101, TS101_MOUSE), which are markers of extracellular 
vesicles and known to be both detectable in exosomes (See Chapter V for more details), are 
both present in the network of TG2-associated protein in Sham operated kidney membranes 
(Fig. 4.11E, Blue).  
 
In conclusion, TG2-associated proteins in healthy kidney membranes form a clear network of 
proteins associated with different functions, and the predominance of cytoskeletal and 
adhesion proteins identified in fibrotic condition is reduced, as well as the presence of 
antioxidant proteins. Vesicular proteins are present in the network, forming a more diffuse 
cluster of interacting proteins. Metabolic proteins and candidates involved in proteasome 
degradative pathway were well represented in the network. TG2 itself is directly associated 
with five proteins with different roles: extracellular adhesion proteins such as FN, metabolic 
proteins such as Gapdh and aminoacylase Acy3, caspase 3, involved in signalling, and a T-
complex chaperone protein. 
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Figure 4.11: Network of protein-protein interactions of TG2-associated proteins in healthy 
kidney membranes (Sham operated, 21 days). Network of known and predicted protein-protein 
interactions was designed in STRING (http://string-db.org) using the list TG2-associated proteins in 
sham operated kidney membranes. A confidence of at least 0.4 (middle confidence in STRING) was 
chosen as threshold for the interactions identified. Results were exported on Cytoscape 
(http://www.cytoscape.org) for graphical visualisation and colour coded depending on the specific 
functional cluster (Suppl.Table 4.6, 4.8). Thickness of the lines reflects the confidence of the interaction 
(from 0.4 to 0.99).  
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4.4.5 TG2 association with vesicle-mediated trafficking at the cell-matrix 
interface 
4.4.5.1 A list of TG2-associated proteins involved in vesicular trafficking 
In the previous sections, it was underlined how many TG2 interacting partners were associated 
with vesicle-mediated trafficking in the cells. Given the interest in the possible TG2 partners in 
the enzyme’s unconventional secretion by kidney cells during the progression of disease, the 
TG2-associated proteins involved in vesicle-mediated trafficking were manually investigated 
in literature to identify their specific function and their possible roles in secretion. The main 
findings of this search are reported in Table 4.10, displaying the main functions of each protein 
identified as TG2-associated in this study and having a reported involved in vesicular 
trafficking. A more extensive description the protein functions can be found in the Appendix.  
Some the proteins were recognized as mainly linked to endocytosis mechanisms, while others 
have been associated with exocytosis or recycling. Moreover, a number of proteins were 
identified as involved in the retromer trafficking from the endosome to the Golgi and/or to the 
plasma membrane.   
 
Table 4.10: List of TG2-associated proteins involved in vesicular trafficking. The proteins identified 
as TG2-associated partners by SWATH-acquisition MS and known to play a role in intracellular and/or 
extracellular vesicular trafficking have been listed in this table. A more extensive description the protein 
functions can be found in the Appendix. For each protein, the table provides protein ID (_MOUSE), the 
gene name, the full protein name, and the main function associated with vesicular trafficking. Additional 
comments are also given for specific proteins, whose other functions might be interesting for the aims 
of this thesis. Finally, the conditions in which the protein has been identified as associated with TG2 in 
kidney membranes (Sham operated or UUO mice, or both) are provided in the last column. 
Abbreviations: ER=Endoplasmatic reticulum; TGN = Trans-Golgi network; PM = Plasma membrane; MVB 
= Multivesicular bodies.  
 
Prot ID Gene Name Main role Other comments 
SHAM/ 
UUO 
ANFY1 Ankfy1 Rabankyrin-5 
Endocytosis (Clathrin-
mediated and 
Macropinocytosis) 
Also involved in retromer 
regulation via Rab5 -
GTPase 
SHAM 
ANXA2 Anxa2 Annexin A2 Endocytosis 
Acts by association with 
actin; Present in 
exosomes 
SHAM 
AP2A1 Ap2a1 
AP-2 complex subunit 
alpha-1 
Endocytosis (Clathrin - 
mediated) 
 
Plasma membrane-
specific adaptor 
 
UUO 
 
AP2A2 Ap2a2 
AP-2 complex subunit 
alpha-2 
AP2B1 Ap2b1 
AP-2 complex subunit 
beta 
ARF5 Arf5 ADP-ribosylation factor 5 Golgi Trafficking 
Also been associated with 
endocytosis of α5β1 
integrins 
SHAM 
ARF6 Arf6 ADP-ribosylation factor 6 Endocytosis  SHAM 
CLCA Clta Clathrin light chain A 
Endocytosis (Clathrin - 
mediated) 
 UUO 
CLCB Cltb Clathrin light chain b 
Endocytosis (Clathrin - 
mediated) 
 UUO 
CLH1 Cltc Clathrin heavy chain 1 
Endocytosis (Clathrin - 
mediated) 
 SHAM 
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COPB2 Copb2 Coatomer subunit beta 
Trafficking through Golgi 
+ Golgi to ER retrograde 
transport (COPI) 
 UUO 
DCTN1 Dctn1 Dynactin subunit 1 Retromer transport 
Retrograde transport 
along microtubules, not 
only retromer 
UUO 
FLOT2 Flot2 Flotillin-2 
Endocytosis (Clathrin 
independent: Caveolae,  
Phagocytosis) 
Associated with every 
membrane, also present in 
exosomes 
UUO 
GAK Gak 
Cyclin-G-associated 
kinase 
Endocytosis (Clathrin - 
mediated) 
Clathrin uncoating, 
Interacts with Hsc70 
UUO 
GGA1 Gga1 
ADP-ribosylation factor-
binding protein GGA1 
Trafficking of Clathrin 
coated vesicles from 
TGN to 
endosomes/lysosomes 
 SHAM 
HIP1 Hip1 
Huntingtin-interacting 
protein 1 
Endocytosis (Clathrin - 
mediated) 
 UUO 
HSP7C Hspa8 
Heat shock cognate 71 
kDa protein 
Endocytosis (Clathrin - 
mediated) + Chaperone 
Known to be present in 
exosomes and enriched 
upon stress 
UUO 
IST1 Ist1 IST1 homolog Element of ESCR IIII 
Frequent in urinary 
exosomes 
SHAM 
MY18A Myo18a 
Unconventional myosin-
XVIIIa 
Unconvetional myosins - 
Golgi regulation / vesicle 
budding 
Membrane tension/ 
deformation 
UUO 
MYO1B Myo1b 
Unconventional myosin-
Ib Unconvetional myosins - 
intracellular vesicular 
movements and 
movements at the PM 
 
Golgi to PM movements, 
endocytosis and 
exocytosis; Involved in 
membrane 
tension/deformation 
 
UUO 
 
MYO1D Myo1d 
Unconventional myosin-
Id 
MYO1G Myo1g 
Unconventional myosin-
Ig 
NSF Nsf Vesicle-fusing ATPase 
Membrane fusion events 
- Exocytosis (SNAREs) 
Suggested to be mportant 
for TG2 export 
SHAM 
PDC6I Pdcd6ip 
Programmed cell death 
6-interacting protein 
(ALIX) 
MVB biogenesis 
(ESCRT)- Exosome 
biogenesis 
Exosome marker, 
Associates with syndecan 
in exoxomes biogenesis 
COMMON 
PICAL Picalm 
Phosphatidylinositol-
binding clathrin 
assembly protein 
Endocytosis (Clathrin - 
mediated) 
 COMMON 
RAB10 Rab10 
Ras-related protein Rab-
10 
Golgi to PM trafficking 
regulation 
Also involved in Golgi to 
PM transport 
SHAM 
RAB1A Rab1A 
Ras-related protein Rab-
1A 
ER To Golgi trafficking 
regulation (COPII) 
 UUO 
RBGPR 
Rab3ga
p2 
Rab3 GTPase-activating 
protein non-catalytic 
subunit 
Regulated Exocytosis  UUO 
SAR1B Sar1b 
GTP-binding protein 
SAR1b 
ER To Golgi trafficking 
regulation (COPII) 
 UUO 
SCFD1 Scfd1 
Sec1 family domain-
containing protein 1 
Exocytosis (SNAREs)  COMMON 
SNX1 Snx1 Sorting nexin-1 Retromer transport  UUO 
SNX3 Snx3 Sorting nexin-3 Retromer transport 
Retromer transport 
independent from SNX-
BAR 
SHAM 
SNX4 Snx4 Sorting nexin-4 Endocytic recycling 
Interacts with Flot2 in 
endosomes recycling 
UUO 
TBC9B Tbc1d9b 
TBC1 domain family 
member 9B 
Regulation Rab 
GTPases (Deactivation) 
 SHAM 
TERA Vcp 
Transitional endoplasmic 
reticulum ATPase 
ER-associated Protein 
degradation (ERAD) 
 COMMON 
TOM1 Tom1 Target of Myb protein 1 
Ubiquintated protein 
degradation by clathrin 
vesicles 
 SHAM 
TS101 Tsg101 
Tumor susceptibility 
gene 101 protein 
MVB biogenesis 
(ESCRT)- Exosome 
biogenesis 
Might be required for 
Syndecan release in 
exosomes 
SHAM 
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VATH Atp6v1h 
V-type proton ATPase 
subunit H 
Endocytosis (Clathrin - 
mediated) 
Acidification of organelles 
and vesicular 
compartments 
UUO 
VPS35 Vps35 
Vacuolar protein sorting-
associated protein 35 
Retromer transport  SHAM 
YKT6 Ykt6 
Synaptobrevin homolog 
YKT6 
Membrane fusion events 
in ER-to Golgi / 
Endosome to Golgi 
(SNAREs) 
Might be involved in 
exocytosis 
UUO 
 
4.4.5.2 Search of TG2-associated candidates in the Exocarta database  
As many proteins identified as TG2-associated were found to be involved in exocytosis, the top 
100 exosome markers (more frequently identified in literature) per the Exocarta database 
(http://www.exocarta.org/) were searched among the TG2-associated partners obtained by 
SWATH-MS. Many top exosomal proteins were identified in the TG2 interactomes, with almost 
50% (47/100) of proteins detected (Table. 4.11). Specifically, 28% of the proteins were 
identified in healthy conditions (Sham) in either cytosol or membranes, while 30% were 
detected in fibrotic conditions (UUO) in either cytosol or membranes. Among these proteins, 
the well-established exosome marker alix (PDC6I) was identified as TG2-associated in both 
healthy and fibrotic conditions, while heat shock proteins such as heat shock cognate 71 kD 
protein (HSP7C) and heat shock protein HSP90 (HS90A_MOUSE), as well as flotillin (FLOT) 
were detected only in fibrotic conditions (Table. 4.11, red circles). Tumour susceptibility gene 
101 protein (TS101) was detected only in healthy membranes (Table. 4.11, green circles). 
Interestingly, none of the exosome typical tetraspanins (CD9, CD63, CD81) was detected among 
the TG2-associated proteins (Table. 4.11).  In order to see if other of the proteins associated 
with TG2 in kidney fibrotic cell membranes had been previously reported in literature as 
detected in the exosomal fraction of mouse or other species (human, rat, cow) even if not 
belonging to the top 100 markers, all the proteins identified as TG2-associated in kidney UUO 
membranes by SWATH-MS were manually searched in the Exocarta database (Suppl. Table 
4.16). Interestingly, when this analysis was performed, almost all the TG2-associated proteins 
in UUO kidney membranes were also reported by the Exocarta database as previously 
identified in the exosome compartment in literature, in at least one of the species (115/122, 
94%) (Suppl. Table 4.16). Importantly, the proteins reported as present in exosomes by the 
Exocarta database included TG2 itself (Suppl. Table 4.16), previously identified in exosomes 
produced by a number of human cell lines such as hepatocellular carcinoma cells, melanoma 
cells, ovarian cancer cells, prostate cancer cells (He, et al. 2015, Lazar, et al. 2015, Liang, et al. 
2013, Kharaziha, et al. 2015), as well as thymic tissue and urine (Gonzales, et al. 2009, 
Skogberg, et al. 2013), and by rat adipocytes (Lee, et al. 2015).  
In conclusion, most of the proteins identified as TG2-associated in kidney fibrotic membranes 
had been reported to have a location in the exosomes in at least another study (Suppl. Table 
4.16), and almost a sixth of TG2-associated proteins in either UUO or Sham operated kidney 
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membranes were identified as belonging to the list of top 100 exosome markers (Table 4.11). 
These results formed the hypothesis that TG2 could be secreted via exosomes by kidney cells.   
 
Table 4.11: Top-100 exosome protein markers detection in the kidney Interactome of TG2. The 
top-100 proteins identified in the exosomes per the Exocarta database (http://www.exocarta.org/) 
were searched in the lists of TG2-associated partners obtained by SWATH-MS in both Sham operated 
and UUO kidneys. C= Cytosolic fraction; M= Crude membrane extract. Red circles identify examples of 
exosome markers that have been detected as TG2 partners in fibrotic conditions, green circles exosome 
markers that have been detected as TG2 partners uniquely in healthy conditions. * = The FLOT2 isoform 
identified in UUO crude membrane extracts.  
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4.4.6 Are TG2-associated proteins upon UUO significantly overexpressed by 
the UUO itself? A comparison between the TG2 interactome in UUO and the 
UUO-proteome 
Once a list of TG2-associated proteins in fibrotic kidney membranes was obtained and analysed 
using the different bioinformatics approaches, a useful last investigation to perform was a 
comparison of the outcome of this TG2-immunoprecipitation study on kidney fibrotic 
membranes (Table 4.2) with the proteomic study carried out on whole kidney tissues 
subjected to the same treatment and shown in the previous chapter (Suppl. Table 3.1).  
In this way, it was possible to identify which protein were at the same time upregulated in the 
21 days-UUO proteome and associated with TG2 at 21-days post UUO, and which proteins were 
instead associated with TG2 upon UUO but not significantly altered in fibrotic conditions or 
even underexpressed upon UUO. The comparison of the two proteomic analyses on the UUO 
model is shown in Fig 4.12 and Table 4.12.  
From the comparison it could immediately be seen how TG2-associated proteins in UUO 
conditions were not necessarily significantly overexpressed in the UUO model at 21 days post 
UUO (Fig. 4.12). In fact, only 17 of the 122 TG2-associated proteins in fibrotic kidney 
membranes were found significantly overexpressed in the UUO proteome by SWATH-MS and 
fold change analysis from the Sham operated conditions [confidence of fold change C(FC)≥ 0.8]. 
These proteins, marked with a red arrow in Table 4.12 and a red square in Fig. 4.12, were 
mostly associated with cytoskeletal regulation and extracellular organisation and included 
TG2 (TGM2_MOUSE) itself. Of these proteins, nine were cytoskeletal: profilin 1 
(PROF1_MOUSE), gelsolin (GELS_MOUSE), vimentin (VIME_MOUSE), actin-related protein 2/3 
(ARC1B_MOUSE), F-actin-capping protein (CAPZB_MOUSE), moesin (MOES_MOUSE), filamin-
A (FLNA_MOUSE), keratin 19 (K1C19_MOUSE) and myosin 10 (MYO10_MOUSE).  Other five, 
biglycan (PGS1_MOUSE), perlecan (PGBM_MOUSE), Fibronectin (FINC_MOUSE), Collagen 
(COCA1_MOUSE) and periostin (POSTN_MOUSE), were associated with either extracellular 
organisation or cell adhesion, and two, plastin-2 (PLSL_MOUSE) and coronin-1C 
(COR1C_MOUSE), were signalling proteins associated with cytoskeletal changes (Table 4.12, 
red arrows; Fig. 4.12, red squares).  
Other 33 TG2-associated proteins in fibrotic kidney membranes were still more expressed in 
UUO kidney lysates compared to the sham operated conditions, but at a non-significant 
C(FC)(confidence lower than 0.8, marked with an asterisk in Table 4.12), hence were not 
present in the list of UUO-overexpressed proteins (Suppl. Table 3.5). Of these proteins, 16 had 
a confidence level ≥ 0.5 and are reported on the right side of the graph in Fig. 4.12, with no 
squares.  
Interestingly, 12 proteins significantly associated with TG2 in kidney fibrotic membranes were 
identified as significantly underexpressed in whole kidney lysates under the same conditions 
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(green arrow in Table 4.12, green squares in Fig. 4.12). The majority of these proteins were 
metabolic: nicotinamide phosphoribosyltransferase (NAMPT_MOUSE), phosphoglycerate 
kinase 1 (PGK1_MOUSE), acyl-protein thioesterase 1 (LYPA1_MOUSE), aflatoxin B1 aldehyde 
reductase member 2 (ARK72_MOUSE), peroxisomal bifunctional enzyme (ECHP_MOUSE) and 
C-1-tetrahydrofolate synthase (C1TC_MOUSE). The redox protein glutathione peroxidase 
(GPX1_MOUSE) and the redox-regulatory protein FAM213A (F213A_MOUSE) were also among 
these proteins, together with the cytoskeletal proteins akyrin-3 (ANK3_MOUSE) and spectrin 
(SPTN1_MOUSE), the vesicular protein V-type proton ATPase subunit H (VATH_MOUSE) and 
the heat shock protein HSP 90-α (HS90A_MOUSE). Other 13 proteins resulted underexpressed 
at C(FC) between 0.5 and 0.8, and are reported on the left side of the graph in Fig. 4.12, with 
no squares. 
In conclusion, only few of the TG2-associated proteins in fibrotic kidney membranes were 
found overexpressed in the UUO proteome itself when using whole kidney lysates, while a 
series of other proteins were found not significantly altered in the fibrotic kidney or even 
underexpressed. This might mean that the progression of UUO determines an increased 
association of the enzyme with its protein partners, and not necessarily an increase in the 
partners’ expression. An interesting finding is that most of the vesicular partners of TG2 in UUO 
kidney membranes was not detected as differentially expressed in the UUO proteome, and that 
many antioxidant proteins were increasingly associated with the enzyme even if 
downregulated by the disease.  
The same analysis was performed also on the list of TG2-associated proteins in healthy 
conditions, and results are provided in Suppl. Table 4.17.  
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Figure 4.12: Comparison of TG2 interactome in fibrotic (UUO) kidney membranes (p≤0.05) with 
UUO Proteome (confidence ≥ 0.5). In order to see if the proteins significantly associated with TG2 in 
the UUO model were also upregulated in the whole UUO proteome, the two analyses were combined in 
a plot. The 122 Proteins associated with TG2 in UUO kidney membranes were plotted on the ordinate 
axis per the p-value of TG2-association in UUO kidney membranes (to a maximum p-value ≤ 0.05), and 
on the abscissa according to the log2 of the fold change (log2 FC) in the UUO proteome comparing to 
sham operated kidneys. A positive x value indicates overexpression upon UUO, a negative value indicates 
underexpression upon UUO; for this analysis, a confidence of FC ≥ 0.5 were employed, instead of the 
otherwise employed confidence of 0.8. Red squares identify proteins significantly overexpressed in the 
UUO proteome compared to the sham operated proteome at a C(FC) higher than 80%. Green squares 
identify proteins significantly underexpressed in the UUO proteome compared to the sham operated 
proteome at a C(FC) higher than 80%. 
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Table 4.10: Comparison of TG2 interactome in kidney fibrotic membranes (p≤0.05) with UUO 
Proteome. In order to see if the proteins significantly associated with TG2 in the UUO model were also 
overexpressed in the model itself, the two analysis in were combined in this heat-map table. On the left 
side, the list of TG2-associated proteins in UUO kidney membranes (21 days); in scale of blue, the p-value 
of TG2 association as calculated by z-test. A p-value ≤0.05 was considered as significant. On the right, 
the fold change from sham and confidence values for the same proteins in the UUO proteomic analysis 
performed on whole tissue; in red, the positive fold change (FC) in the UUO, that means overexpression, 
and in green the negative fold change, that means underexpression. In yellow, the level of confidence of 
this second analysis, bright yellow ≥ 0.8 and light yellow 0.5 ≤ C < 0.8.  A confidence ≥ 0.8 was considered 
as significant. Legend: U=Unique; C= Common (associated with TG2 in both UUO and sham operated 
mice). Red arrows = proteins significantly overexpressed upon UUO; Asterisks = proteins with increase 
expression upon UUO but in a not significant manner (confidence < 0.8); Green arrows = proteins 
significantly underexpressed upon UUO.  
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4.5 DISCUSSION 
 
In the past few decades, several studies have highlighted the involvement of TG2 in the 
progression of CKD. Increased TG2 release and extracellular activity have been shown to be 
associated with the progression of kidney fibrosis in different models of CKD as well as in 
clinical biopsies. Increased extracellular TG2 expression and activity are known to contribute 
to kidney fibrosis by supporting matrix accumulation and resistance, TGF-β activation, and by 
promoting cell adhesion and contraction, acting as a structural adhesive protein.  
In the previous chapter, TG2 was identified as a potential marker of fibrosis in the UUO-
proteome, when compared to Sham operated conditions. The analysis of TG2-KO mice 
supported the idea of a protective role of TG2 inhibition against the progression of fibrosis in 
the UUO model, in agreement with previous studies employing both TG2-KO (Fisher, et al. 
2009, Shweke, et al. 2008) or general TG inhibitors in animal models (Skill, et al. 2004, Huang, 
et al. 2010, Huang, et al. 2009, Johnson, et al. 2007).  
TG2 has been suggested as a possible pharmacological target against the development of 
fibrosis, however, clinical application of a direct TG2 inhibitor is difficult, given the highly 
conserved catalytic core of this protein, compared to the other members of the family. One 
fascinating possibility would be not to aim at the inhibition of the enzymatic activity of TG2 but 
at the TG2 release from kidney cells into the interstitial space, where the enzyme contributes 
to the accumulation of fibrosis. TG2 is known to be secreted through a still not clarified 
unconventional secretion pathway by kidney cells (Chou, et al. 2011), which is likely to be 
specific for TG2 and require the interaction with certain molecular partners, with the 
possibility of becoming a specific target of intervention against the extracellular accumulation 
of the enzyme.  
Given the little knowledge of TG2 export mechanism from kidney cells during CKD, we believe 
that the identification of the TG2 interactome on fibrotic kidney membranes is an important 
step to perform to accelerate the process of resolution of TG2 externalization mechanism and 
extracellular activity in CKD.  
To achieve this purpose, in the current study, TG2-associated proteins were investigated by an 
original proteomic strategy that combines TG2-immunoprecipitation from whole kidney 
membrane preparations of  WT kidneys, with negative control immunoprecipitation from TG2-
null kidneys from inbred mice, in both fibrotic (21 days UUO) and Sham operated conditions, 
followed by a quantitative, high-throughput, MS analysis performed by SWATH-DIA. The 
employment of a the TG2-null background control is particularly important in the analysis and 
is a strength of this investigation approach, as it allows to discriminate between proteins 
significantly associated with the enzyme and contaminant proteins un-specifically 
precipitated. This, to our knowledge, represents the first unbiased (hypothesis-free) global 
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analysis of TG2 interacting proteins in a model of CKD. The proposed strategy could be adapted 
for precision targeted proteomics for the analysis of other systems. 
In this Chapter, the TG2 interactome in kidney fibrotic membranes was investigated, starting 
from the data obtained by SWATH-MS acquisition of the TG2-IP samples. A z-test statistical 
analysis, conceptually similar to a T-test, was employed, to identify a list of protein significantly 
associated with TG2, using the TG2-null data as a background control.  
 
Of the 746 proteins detected as TG2-immunoprecipited in at least 4 out of 5 experiments, 217 
were proteins identified as significantly (p≤0.05) associated with TG2 in kidney membranes 
by z-test, when protein expression was compared to the TG2-null IP backgrounds. Among these 
proteins, 97 were identified associated with TG2 uniquely in UUO, while 95 were found 
exclusively in Sham operated membranes (Fig. 4.3). Only a small overlap (25 proteins), was 
found between the two conditions, suggesting a marked change of TG2 interaction on kidney 
membranes at this stage of UUO (Fig. 4.3).  
When the outcome of the current SWATH-DIA analysis was compared with the TG2-associated 
proteins previously identified in TG2-IPs of healthy C57BL/6J mice kidney membranes by a 
relative quantification approach combining iTRAQ labelling and shotgun LC-MS/MS with DDA 
(described in 4.1.1), SWATH approach appeared as a more sensitive technology for the 
detection of TG2-associated proteins. Of the 24 proteins previously highlighted, 17 were also 
identified as significantly TG2-associated in the current study.  
Among the TG2-associated proteins identified in both fibrotic or healthy conditions, only 
approximately ¼ had an already reported interaction with TG2 in literature, according to the 
Transdab database (Table 4.4), suggesting that the large majority of TG2-associated 
candidates identified with this method were novel. However, being an immunoprecipitation-
based technique, some of the proteins identified as TG2-associated candidates might not be 
direct binding partners the enzyme, but be indirectly associated with TG2 through interaction 
with other TG2-binding proteins.   
 
It was anticipated that the analysis of TG2-interacting proteins in fibrotic kidney membranes 
at the cell-matrix interface could lead to the discovery of candidates involved in the enzyme 
secretion from kidney cells and extracellular activity during the progression of fibrosis, and 
possibly contribute to the elucidation of the mechanism of the CKD-induced unconventional 
release of TG2 from kidney cells.  
To examine the functional distribution of the TG2 interacting candidates in our list, as well as 
investigate possible pathways involved, a functional classification was performed, both 
manually (4.4.2) and by employment of bioinformatics supports allowing analysis of 
GO/PANTHER annotation terms (4.4.3-4.4.4).  
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Proteins involved in cytoskeletal organisation and remodelling, cell adhesion, ECM 
organisation and redox regulation appeared more represented among the TG2-associated 
proteins in fibrotic kidney membranes, compared with TG2 partners in healthy membranes 
(Fig. 4.7, 4.8), suggesting their involvement in TG2 pro-fibrotic roles during CKD.  
 
Importantly, among the ECM organisation and adhesion proteins, the HSPGs Sdc4 and perlecan 
were identified in the interactome of TG2 uniquely in fibrotic conditions, in the same cluster 
with FN and other adhesion proteins (Fig. 4.10). This implies that the association of TG2 with 
HSPGs is induced by CKD, in line with previous findings suggesting a crucial role for HS chains 
in TG2 extracellular localisation and activity during the progression of fibrosis (Scarpellini, et 
al. 2014, Burhan, et al. 2016). The importance of Sdc4/HSPGs in CKD has been reported (Yung, 
et al. 2001, Morita, et al. 1994, Fan, et al. 2003) and the protective role of Sdc4-KO against the 
development of kidney fibrosis has been previously suggested by our group (Scarpellini, et al. 
2014). Upregulation of both Sdc4 and TG2 expression during the progression of CKD has been 
recently shown by our group in a rat model of CKD determined by SNx, with large co-
localisation of the two proteins in the interstitium of fibrotic tubules, dependent on HS chains. 
However, Sdc4 was not found upregulated in the UUO proteome generated in the kidney 
lysates (Table 4.12), suggesting that an increased association with TG2, more than an 
increased expression of the proteoglycan, is observed in UUO at this end-stage level.  
 
A significant enrichment in TG2 association with cytoskeletal proteins was identified in UUO 
kidney membranes compared to the Sham operated ones. Indeed, many proteins involved in 
cytoskeleton remodelling were identified, that were mostly related to actin remodelling (actin 
related protein 2/3 complex, profilin, gelsolin, etc.) and located at the cortical cytoskeleton, at 
the interface with the plasma membrane (adducin, filamin, ankyrin, moesin, etc.). Vimentin 
was identified in the list, and already revealed in Chapter III as a largely upregulated marker 
of mesenchymal cells in the UUO model (Fig. 4.6-4.7), while α-SMA was identified as a TG2 
partner in the UUO cytosol (Suppl. Table 6.1). Association with these proteins leads to the 
hypothesis of TG2 being directly involved in the large cytoskeletal reorganisation happening 
during the fibrotic process. Moreover, increased intracellular TG2 crosslinking activity, which 
is likely to target cytoskeletal proteins such as actin and vimentin (Shin, et al. 2008), has 
already been identified in the past as a feature of fibrosis progression in models of CKD 
(Johnson, et al. 1997, Johnson, et al. 2003, El Nahas, et al. 2004), contributing to the cell death 
(Verderio, et al. 1998) observed at the late stages. Curiously, while TG2 association with 
myosin was identified mainly in UUO kidney membranes, and can be explained by a larger 
population of cells with “smooth muscle” phenotype, tubulins were identified as associated 
with TG2 uniquely in healthy kidney membranes. This might be associated with a role for TG2 
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in the cytoskeletal stabilisation, that might be lost upon UUO; in fact, TG2 has been shown to 
polyaminate tubulin in neural cells, resulting in neural microtubule stabilisation and decrease 
in neural plasticity both in vitro and in vivo (Song, et al. 2013). Keratins were also strongly 
associated with TG2 in UUO fibrotic membranes, consistent with their reported upregulation 
in tubular cells upon CKD (Djudjaj, et al. 2016), which was confirmed in our model (Chapter 
III).  
 
The identification of a number of antioxidant proteins uniquely associated with TG2 in fibrotic 
kidney membranes is another interesting result. Proteins with antioxidant proprieties such as  
glutaredoxins, glutathione peroxidase, glutathione S-transferase and peroxiredoxin, form a 
significant cluster in the TG2 interactome in kidney fibrotic membranes and are likely to 
contribute to the preservation of the enzyme reduced-active state in the interstitial space upon 
CKD. Interestingly, the same proteins were found as significantly downregulated in the UUO 
proteome at 21 days post-surgery (Chapter III and Table 4.12), allowing to speculate that an 
increase association with TG2 with these proteins is still happening even if the redox control 
in the organ is strongly dysregulated. This is probably a consequence of the late stages of 
disease, as antioxidant proteins were found upregulated in kidney lysates at the earliest stages 
of UUO (Zhao, et al. 2015), supporting a cooperative effect in the promotion of TG2 
extracellular activity.  
 
The most interesting finding obtained from the investigation of the TG2 interactome is the 
identification of a substantial number of proteins with a reported role in vesicle-mediated 
transport. This class of proteins was significantly enriched among the TG2 partners in both 
UUO and sham operated conditions (Table 4.7), however, protein representation was higher 
(21% vs 15%) (Fig. 4.7) and more significant in fibrotic conditions, forming a significant 
cluster of interacting proteins in the TG2-interactome (Fig. 4.10).  
As a key aim of this study is the identification of potential partners of TG2 in kidney membranes 
that might contribute to its unconventional secretion in the interstitial space, these proteins 
were regarded as particularly significant, and were investigated in detail (4.4.5) (Table 4.10).   
It was highlighted that many TG2-associated proteins on kidney membranes were well-known 
exosome markers (Table 4.11). Exosomes are small extracellular vesicles (EV) (generally < 
100 nm). They form at the late endosome by intraluminal vesicle budding that generate the so 
called multivesicular bodies (MVB), which then fuse with the plasma membrane releasing the 
exosomes. Among the top exosome markers obtained by the Exocarta database (Simpson, 
Kalra and Mathivanan 2012, Keerthikumar, et al. 2016), Alix (programmed cell death 6 – 
interacting protein), involved in intraluminal vesicle budding at the late exosome and 
responsible for exosome biogenesis through interaction with syntenin and syndecan (Hurley 
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and Odorizzi 2012, Colombo, et al. 2013, Ghossoub, et al. 2014, Baietti, et al. 2012), Hsp7c, a 
chaperone found in exosomes of most cells, and flotillin, a lipid raft associated protein, were 
found associated with TG2 in UUO kidney membranes, while the endosomal sorting complexes 
required for transport (ESCRT) machinery protein Tsg101 (Tumour susceptibility gene 101) 
was identified as a TG2 partner in healthy membranes. Interestingly, when a more 
comprehensive analysis was performed, more than 90% of the proteins identified as TG2-
associated with kidney fibrotic membranes were found reported in the exosomal fraction in at 
least another study, and included TG2 itself (Suppl. Table 4.16).  
Matching the TG2-associated proteins with the UUO proteome showed that the TG2 partners 
involved with vesicle-mediated transport and exocytosis were not increased post-UUO, 
suggesting a specific role in trafficking of TG2 upon disease (Table 4.12). On the contrary, a 
group of proteins involved in ECM-receptor organisation, including FN and periostin, 
significantly overexpressed in the UUO kidneys, were also all partners of TG2 (Table 4.12).  
These findings suggest the existence of a pathway of TG2 secretion during fibrosis progression 
driven by a vesicular trafficking which is specific for TG2, and its subsequent association with 
an UUO-upregulated protein network responsible for ECM dynamics resulting in matrix 
accumulation.  
We hypothesized that TG2 unconventional secretion from kidney cells to the extracellular 
interstitial space might be dependent on exosomes, introducing a link between TG2 and EVs in 
the UUO kidney. The identification of a few proteins involved in SNARE-mediated membrane 
fusion events, including NSF-ATPase, might support this hypothesis, as membrane fusion is 
required for exosome secretion. In this context, association of TG2 with several proteins 
mediating actin remodelling as well as signalling proteins leading to cytoskeletal 
reorganisation, such as plastin, coronin and calpain, which were particularly significant in 
kidney fibrotic membranes, might be involved in some alterations in the actin cytoskeleton 
suggested to favour vesicular trafficking. 
 
In the next chapter, the hypothesis of a TG2 unconventional secretion mediated by EVs, and in 
particular exosomes, will be tested in vitro employing tubular epithelial cells (TECs). 
Subsequently, the involvement of HS chains / Sdc4 in the process will also be investigated on 
the same cells, given the specific association of this HSPG with TG2 in UUO and other models 
of CKD.  
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Chapter V: Analysis of TG2 unconventional secretion in tubular 
epithelial cells 
 
5.1 AIMS OF THE CHAPTER  
 
Work described in Chapter IV has resulted in the identification of partners of TG2 in normal 
and fibrotic kidney. A number of proteins involved in protein trafficking were recognised, 
which might play a role in the enzyme’s unconventional secretion during the progression of 
CKD. As tubular epithelial cells (TECs) have been reported to express and release most of TG2 
secreted during the progression of CKD (Johnson, et al. 1999, Johnson, et al. 2003), the aim of 
this chapter is to investigate the mechanism of TG2 unconventional secretion in renal TECs. To 
achieve this purpose, immortalised cell lines of rat TECs are utilised as a cell model of TG2 
release in the present chapter. A number of unconventional secretion models are tested.  
 
 
5.2 INTRODUCTION  
5.2.1 Vesicular trafficking in the cell 
In the eukaryotic cell, upon protein synthesis at the ribosome, proteins can be either secreted 
or retained into the cell. The majority of the secreted proteins are characterised by a signal 
peptide that determines their access into the endoplasmic reticulum (ER) for secretion 
(Wickner and Lodish 1985). These proteins are generally referred to as “conventionally 
secreted proteins”. The signal peptide (leader peptide) is a short N-terminal amino acidic 
sequence that is added at the beginning of the protein at the moment of synthesis and directs 
the protein to a particular translocation channel of the ER (translocon or Sec61/TRAP/TRAM 
heterocomplex) (Osborne, Rapoport and van den Berg 2005, Johnson and van Waes 1999). By 
crossing the traslocon, proteins enter the ER and the signal peptide is then cleaved by a specific 
peptidase (Bussey 1988). 
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5.2.1.1 Intracellular trafficking 
From the ER, the majority of the conventionally secreted proteins move to the cis-Golgi 
network, then to the trans-Golgi network (TGN) and finally to the cell surface via a well 
organised classical vesicular transport. Proteins are released from the ER into coat protein II 
(COPII)-coated vesicles (Szul and Sztul 2011). Inside the Golgi cisternae, a series of enzymes 
determine post translational modification of the cargo proteins that are  then trafficked to the 
trans Golgi network (TGN) inside coat protein I (COPI)-coated vesicles, wich also mediate 
retrograde transport of membranes and enzymes back to the cis side of the Golgi and to ER. 
From the TGN, cargo proteins are released into clathrin coated vesicles. 
These vesicles can be directly secreted through the plasma membrane, while others cargo-
containing vesicles fuse with the late endosome (multivesicular Bodies, MVB) compartments 
for secretion (exosome) or degradation in the lysosome.  
The endosomal compartment of the cell is a membranous compartment that sorts the different 
vesicles to the appropriate destination, such as lysosome (for degradation), plasma membrane 
(for secretion / recycling) or TGN (by retromer transport).  
 
The endosome can be distinguished into three different compartments: the early endosome, 
the late endosome and the recycling endosome. Once an endocytic vesicle has formed, it 
generally fuses with the early endosome compartment, characterised by markers such as small 
GTPases Rab 4 and Rab 5 as well as early endosome antigen 1 (EEA1) and phosphatidylinositol 
3-phosphate (PI3P). From the early endosome, the cargoes destined for recycling are sorted 
into the recycling endosome, while the remaining part of early endosome matures into the late 
endosome. At the late endosome, cargoes are sorted in small (< 100 nm) intraluminal vesicles 
(ILV) by inward budding into the lumen of the endosome, giving rise to what is called 
multivesicular body (MVB) or multivesicular endosome (MVE).  These late endosomes / MVB 
either fuse with the lysosome for degradation of ILV-cargoes or with the plasma membrane for 
ILVs secretion as exosomes. It is believed that at last two different populations of MVBs co-
exist in the same cells, which are partially dissimilar in lipid composition (Mobius, et al. 2002, 
Wubbolts, et al. 2003): one ”en route” for degradation and one “en route” for exosome secretion 
(Raposo and Stoorvogel 2013). The pathway necessary for the formation of MVBs directed to 
lysosome has been well described and involved the so called ESCRT (endosomal sorting 
complex responsible for transport) machinery. This machinery is characterised by four distinct 
multiprotein complexes (ESCRT-0 to ESCRT-III) and accessory proteins such as Alix and VPS4 
(Wollert and Hurley 2010, Henne, Buchkovich and Emr 2011).  
 
The retromer complex is an important component in the pathway of endosomal protein sorting 
(Seaman 2012). Normally, retromer complex controls the transport of proteins from the 
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endosomes back to the trans Golgi network, however, a role of retromer complex in protein 
recycling form the endosome to the plasma membrane has also being identified and might 
represent a different mechanism of protein secretion (Seaman 2012).  
The two main elements of the retromer complex are the cargo-selective trimer (CST), 
constituted of three vacuolar sorting proteins (Vps35, Vps26 and Vps29), and the Snx-BAR 
dimer, constituted of a couple of sorting nexin proteins (Snx1 or Snx2 with Snx5 or Snx6) (van 
Weering, Verkade and Cullen 2010, Cullen and Korswagen 2012) and binding PI3P on the 
endosome suface. The CST recruitment to the endosomal membrane seems to be dependent 
on both the actions of the small GTPase Rab7a (Seaman, et al. 2009, Harrison, et al. 2014) and 
the Sorting nexin protein Snx3. Another protein that has been shown to possibly regulate the 
endosome to TGN trafficking mediated by the retromer is the EHD1-interacting protein 
rabankyrin-5, that binds CST and is likely to have a regulatory function, being a Rab5 effector 
(Zhang, Naslavsky and Caplan 2012, Zhang, et al. 2012). Snx5/Snx6 are able to bind dynactin 
(subunit 1, DCTN1) and connecting the endosomal tubule to the microtubules, thus directing 
the elongating endosomal tubule along them (Hong, et al. 2009, Wassmer, et al. 2009). 
Morover, clathrin might be associated to retromer transport, together with the molecular 
chaperone heat shock cognate 71 kDa protein (Hsp7c) (Popoff, et al. 2009).  
Interestingly for the context of protein secretion, CST has also been reported to interact with 
the WASH complex through its Vps35 subuit. The WASH complex is a multimolecular complex 
localised on the endosomes and involved in the activation of the actin nucleation complex 
Arp2/3 and subsequent induction of branched actin networks formation (Puthenveedu, et al. 
2010, Derivery and Gautreau 2010). WASH complex has been proposed to be central for 
recycling of specific proteins from the endosome to the plasma membrane through endosomal 
tubules elongation and budding, with crucial involvement of actin remodelling processes 
mediared by Arp2/3 and actin-capping proteins.  Examples of proteins recycled to the plasma 
membrane by this WASH-dpendent mechanisma are the are the G-protein-coupled (GPCR) β2-
adrenergic receptor, in a process that involves also the activity of another Snx protein, 
Snx27(Temkin, et al. 2011), and α5β1 integrins (Zech, et al. 2011). Also, vacuolar ATPase 
(VATH) recycling to the lysosome has been suggested to be mediated by WASH (Carnell, et al. 
2011).  
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5.2.1.2 Endocytic mechanisms 
Different mechanisms of endocytosis have been identified in mammalian cells, that can be 
generally subdivided into two categories: phagocytosis (“cell eating”/solid phase uptake) and 
pinocytosis (“cell drinking”/fluid phase uptake)(Conner and Schmid 2003). While 
phagocytosis happens only in some cells, such as leucocytes / macrophages, pinocytosis 
happens in all cell types and can be further subdivided into four main mechanisms (Conner 
and Schmid 2003): (1) clathrin mediated endocytosis (CME), (2) caveolae or lipid raft -
mediated endocytosis, (3) caveolae and clathrin - independent endocytosis and (4) 
macropinocytosis.  
CME is involved in receptor/ligand recycling, signalling and degradation by uploading into 
clathrin coated vesicles (CCV). The process requires adaptor proteins (AP2), associated at the 
membrane with phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2] and dynamin 
(Kirchhausen, Owen and Harrison 2014). Actin dynamics also play a role in the vesicle 
formation (Mooren, Galletta and Cooper 2012, Grassart, et al. 2014), while auxilin and heat 
shock cognate 70 (HSC70) have been show to act in clathrin uncoating after budding 
(Kirchhausen, Owen and Harrison 2014). Lipid raft -mediated endocytosis is driven by 
invagination of small plasma membrane lipid microdomains regarded as caveolae or caveolin-
containing lipid rafts, enriched in cholesterol and usually containing the cholesterol-binding 
protein caveolin (Matveev, et al. 2001, Parton and Richards 2003, Mayor, Parton and 
Donaldson 2014). Calveolae are particularly abundant in endothelial cells, fibroblasts and 
smooth muscle cells (Krajewska and Maslowska 2004). Also caveolae mediated endocytosis 
requires dynamin and and cortical actin dynamics contribution (Parton and Richards 2003, 
Mayor, Parton and Donaldson 2014). Pathways not involving clathrin nor caveolin are are 
involved for example in the endocytosis of (GPI)-anchored proteins and β1-integrins recycling. 
These pathways are usually also dynamin independent while they depend on different GTP-
ases such as the plasma membrane Arf6 GTPase (Brown, et al. 2001, Sabharanjak, et al. 2002, 
Naslavsky, Weigert and Donaldson 2004). Finally, macropinocytosis is characterised by the 
formation of large cell surface ruffling/engulfment that includes large amount of liquid and 
solutes and result in big intracellular vacuoles named macropinosomes (Lim and Gleeson 2011, 
Jones 2007). Macropinosomes are generally lager and can reach up to five µm in diameter 
(Khalil, et al. 2006). The mechanism is similar to what happens in phagocytosis of solid 
particles / phagosome formation, and they are both primarily regulated by remodelling of 
cortical actin (Lim and Gleeson 2011, Jones 2007).  
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5.2.1.3 Extracellular vesicles (EV) 
Cells release different kinds of vesicles in the extracellular space, generally referred to as 
extracellular vesicles (EVs). The two main categories of EVs released from living cells are 
Exosomes and Ectosomes, differing from each other on biogenesis, size and molecular markers 
(Table 5.1).  
 
5.2.1.3.1 Exosomes 
Exosomes originate in the context of the endosomal network as cargo-containing intraluminal 
vesicles (ILVs) of the multivesicular body (MVB) and are released by fusion of the limiting 
membrane of the MVB with the plasma membrane (Kowal, Tkach and Thery 2014, Cocucci and 
Meldolesi 2015). Exosomes size is identical to the ILVs and is generally between 30 and 100 
nm of diameter, even if in some cases larger and smaller exosomes have been detected (Raposo 
and Stoorvogel 2013, Akers, et al. 2013). The biogenesis of the intraluminal vesicles of the MVB 
that is en route to secretion is similar to the biogenesis of intraluminal vesicles of the MVB 
destined to lysosome degradation. In the first case, secretory MVBs subsequently fuse with the 
plasma membrane to release exosomes, while the seconds, degradative MVBs, are destined to 
fusion with the lysosome (Raposo and Stoorvogel 2013, Cocucci and Meldolesi 2015).  
An unified mechanism for secretory ILVs inward budding/exosome biogenesis has not been 
defined yet, as it is likely that different exosome population exist in nature and are generated 
through different mechanisms starting at the endosomes. Some elements of the ESCRT 
machinery have been shown to be also involved in the biogenesis of some exosomes (Colombo, 
et al. 2013): this is regarded as the ESCRT-dependent mechanism of exosomes formation. 
Proteins such as the ESCRTI subunit Tsg101, as well as the accessory proteins Alix and ATPase 
VPS4 were identified as enriched in some exosomes purifications (Thery, et al. 2001, Pisitkun, 
Shen and Knepper 2004, Colombo, et al. 2013) and suggested to be important for secretory ILV 
formation (Géminard, et al. 2004, Hurley and Odorizzi 2012, Colombo, et al. 2013). In 
particular, Alix has been suggested to be important for the formation of the HSPG syndecans 
(Sdc1-4) -baring exosomes through interaction with the Sdc - adaptor syntenin (Baietti, et al. 
2012, Hurley and Odorizzi 2012) and is, togeher with Tsg101, an important marker of 
exosomal EVs. The recruitment of proteins into ILVs/exosomes might involve the activity of 
chaperone proteins such as heat shock cognate 71 kDa protein (Hsc70) (Geminard, et al. 2001, 
Géminard, et al. 2004), that is also regarded as a frequent marker of exosomes by the Exocarta 
database.   
In addition to ESCRT-associated mechanisms for exosome biogenesis and relese, also ESCRT-
independent mechanisms of MVE biogenesis have been suggested to exist in mammalian cells 
(Stuffers, et al. 2009). First of all, a lipid-mediated mechanism of exosome formation has been 
suggested: a lipid enrichment on the the late endosomal membrane, in fact, has been associated 
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with the formation of ILVs, and lipid raft domains have been suggested to be present on the 
endosomes in the areas of exosome formation (de Gassart, et al. 2003). The maturation of the 
late endosome to MVB is characterised by formation of lipid enriched domains containing 
cholesterol, sphingomyelin and its hydrolysis product, ceramide, that also characterize the 
membrane of the exosome itself (Brouwers, et al. 2013, Wubbolts, et al. 2003). The 
sphingolipid ceramide, in particular, has been shown to be involved in the inward budding of 
ILV/exosome biogenesis in a mouse oligodendroglial cell line and is considered to drive an 
ESCRT-independent mechanism of exosome formation (ceramide-dependent mechanism) 
(Trajkovic, et al. 2008, Raposo and Stoorvogel 2013). The process is controlled by neutral 
sphingomyelinase (N-SMase), that catalyses the formation or sphingolipid ceramide from 
endosomal sphingomyelin (SM). A second ESCRT-independent mechanism for exosome 
generation involves the formation of endosomal membrane domains enriched in particular 
transmembrane proteins named tetraspanins (tertraspanins enriched domains – 
TEMs)(Hemler 2003), of which some of the most studied in the context of exosome biogenesis 
are CD63, CD81, CD83 an CD4 (van Niel, et al. 2011, Perez-Hernandez, et al. 2013). 
The final step of outer MVB membrane fusion with the plasma membrane has been suggested 
to require a SNARE membrane fusion complex and NSF-ATPase (N-ethylmaleimide-sensitive 
factor). Vamp7 V-SNARE and Ykt6 R-SNARE have been for example identified as important for 
exosomal release (Fader, et al. 2009, Gross, et al. 2012). Morover, V0 subunit of vacuolar 
ATPase has also been suggested to play a role in membrane fusion events leading to exosome 
release, possibly in association with SNAREs (Marshansky and Futai 2008).   
 
5.2.1.3.2 Ectosomes or microvesicles (MVs) 
Ectosomes, also referred to as microvesicles (MVs) or shedding vesicles, are larger vesicles 
originating by direct budding from the plasma membrane. They are generally bigger than the 
exosomes, between 100 and 2000 nm of diameter, even if smaller vesicles can bud from the 
plasma membrane (down to 50 nm). Given the possible overlap in sizes, the biogenesis of the 
vesicle and the vesicle markers are the main distinction between the two types of EVs (Akers, 
et al. 2013, Cocucci and Meldolesi 2015). The outward budding that determines the formation 
of ectosomes is regulated and happens at small plasma membrane domains with a 
characteristic phospholipid distribution (Akers, et al. 2013). The formation and budding of 
ectosomes depends on both plasma membrane phospholipids and cortical cytoskeleton. 
Plasma membrane asymmetry seems to play a role in membrane budding leading to 
microvesicle release (Hugel, et al. 2005, Akers, et al. 2013, Cocucci and Meldolesi 2015): 
Aminophospholipid phosphatidylserine (PS) is generally located on the inner leaflet of the 
plasma membrane while other lipids such as phosphatidylcholine and sphingomyelin are more 
represented on the outer side. PS translocation to the outer side by plasma membrane and 
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randomization of lipid distribution between the two layers, with subsequent loss of 
asymmetry, is mediated by tranlocases and scramblases, which activation is calcium 
dependent (increase in calcium influx triggers vesicular release). This process has been 
suggested to play a fundamental role in budding of ectosomal vesicles from the cell.  
At the same time, vesicle shedding has been suggested to be assisted by cytoskeletal 
remodelling at the plasma membrane (contraction/releasing), mediated for example by 
myosins. Rho GTPases have been suggested to be involved in the process  (de Curtis and 
Meldolesi 2012, Antonyak, Wilson and Cerione 2012), and in particular ADP-rybosilation 
factor ARF6 has been suggested to determine myosin activation through phospholipase D 
(PLD) that is itself involved in actomyosin contraction necessary for ectosome shedding 
(Muralidharan-Chari, et al. 2009, Nightingale, Cutler and Cramer 2012, Akers, et al. 2013). It 
has also been seen that the plasma microdomains from which ectosomes shed are, similarly to 
the MVB ones, enriched in cholesterol, sphingomyelin, and its product ceramide, that 
contribute to the process of vesicle budding itself. In glial cells, it has been seen that ectosome 
formation is controlled by acid sphingomyelinase (A-SMase), that catalyse the formation or 
sphingolipid ceramide from membrane SM (Bianco, et al. 2009, Antonucci, et al. 2012).   
It is important to remember that, in general, ectosome release is quicker than exosome one, 
not requiring exocytosis. In most cells, the release starts in few seconds after the secretion 
stimulus (ATP, Calcium influx/membrane depolarisation, etc…), whereas it generally takes 
minutes for the exosomes to be released (Cocucci and Meldolesi 2015) 
 
5.2.1.3.3 Destiny of EVs after release 
After release, EVs can either reach another cell or dissolve in the extracellular space releasing 
their content (Cocucci and Meldolesi 2015). This communication and transferring of 
information to another cell is crucial in several processes, such as cell immune 
response/inflammation, nervous system/synapsis, blood coagulation and cancer (Raposo and 
Stoorvogel 2013). In some cases, travelling vesicles have also a role in the modulation of the 
extracellular matrix (ECM) itself while they move, through their transmembrane proteases 
that distrupt the matrix; this might allow an easier invasion by cancer cells or macrophages 
(Muralidharan-Chari, et al. 2010, Cocucci and Meldolesi 2015). A number of vesicles are able 
to travel short or long distances (navigating EVs) into biological fluid such as blood and 
cerebrospinal fluid, and reach target cells, where they release their content (Cocucci and 
Meldolesi 2015). It is believed that target cell binding is quite specific for the different secreted 
vesicles and might depend on adhesion proteins such as integrins and tetraspanins on their 
surface (Hemler 2003, Rana, et al. 2012), as well as membrane bound glycoproteins such as 
galectins (Klibi, et al. 2009, Barres, et al. 2010). HSPGs have also been suggested to play a role 
in the process (Christianson, et al. 2013).  
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When the EVs reach the target cell, they can fuse with the plasma membrane or be internalised 
by endocytosis/phagocytosis (Raposo and Stoorvogel 2013). Fusion of EVs with the plasma 
membrane happens through a mechanism that does not involve SNAREs (Cocucci and 
Meldolesi 2015) and is activated by cell surface fusogen proteins. At the moment, the retroviral 
proteins syncytins, that can bind receptors on the cell membrane, have been suggested as 
fusogen proteins for exosome fusion to the target cell (Aguilar, et al. 2013, Pérez-Vargas, et al. 
2014, Vargas, et al. 2014). Currently, it is not sure that the same fusion mechanism employing 
syncytins is valid also for shedded ectosomes (Cocucci and Meldolesi 2015).  
In other cases, an endocytic mechanism determines the internalisation of the vesicle. 
Endocytosis may be clathrin mediated or involve micropinocytosis and phagocytosis, and it is 
likely that larger vesicles employ one of the latter two mechanisms to be internalised (Feng, et 
al. 2010, Fitzner, et al. 2011, Tian, et al. 2014). Actin cytoskeletal proteins, phosphatilinositol-
3-kinase and dynamin (Tian, et al. 2014, Barres, et al. 2010, Raposo and Stoorvogel 2013) are 
involved in the process of EV-endocytosis by target cells. Once endocytosed, EVs generally fuse 
with endosome or phagosome. From the endosome, they can release their content the 
cytoplasm by back fusion with the endosomal membrane or can be targeted to the lysosome to 
be degraded.   
Some vesicles, however, dissolve in the extracellular space once secreted releasing their 
content. Examples are the vesicles containing IL-1β or growth factors such as FGF2 or 
transforming growth factor beta (TGFβ) (Cocucci and Meldolesi 2015).  
 
5.2.1.3.4 Markers of EVs 
As suggested before, exosomes and ectosomes are also characterised by different molecular 
markers. The databases ExoCarta (http://www.exocarta.org) (Simpson, Kalra and Mathivanan 
2012, Mathivanan and Simpson 2009, Keerthikumar, et al. 2016) and Vesiclepedia 
(http://www.microvesicles.org) (Kalra, et al. 2012) represent collections of proteins, but also 
lipids and RNAs associated with exosomes and ectosomes from different species and biological 
tissues and are useful tools to investigate EV-markers.  
Given their origin from the late endosomal compartments / MVB, typical markers of the 
exosomes are proteins associated with MVB biogenesis, such as ESCRT machinery components 
(Alix, Tsg101, etc…) (Thery, et al. 2001, Pisitkun, Shen and Knepper 2004, Colombo, et al. 2013) 
as well as Hsc70 (Thery, et al. 2001, Géminard, et al. 2004) and annexins (Thery, et al. 1999, 
Thery, et al. 2001). Proteins derived from membrane microdomains have also been found 
significantly enriched in the exosomes: these include both tetraspanins from TEMs (CD9, CD63, 
CD81, etc…) (Kleijmeer, et al. 1998, Bobrie, et al. 2011) and lipid raft markers such as flotillin 
and GPI-anchored proteins (Wubbolts, et al. 2003). Moving to the lipid compositions, exosomes  
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are also rich in cholesterol, sphingomyelin and ceramide (Wubbolts, et al. 2003, Brouwers, et 
al. 2013) (Table 5.1). Ectosome typical markers are generally less described, as they mostly 
vary depending on the protein and lipid composition of the plasma membrane domain they 
originate from. It is known, for example, that flotillin can generally be used as a marker of both 
ectosomes and exosomes, being associated with lipid raft domains on both endosomes and 
plasma membrane (Table 5.1). Sphingomyelin and ceramide, as well, have been described in 
both contexts. Some ectosomes have been suggested to be specifically enriched in membrane-
associated proteins such as Integrins, Arf6 and vesicle-associated membrane protein 3 
(VAMP3), or even specific matrix metalloproteases (Dolo, et al. 1998, Taraboletti, et al. 2002, 
Muralidharan-Chari, et al. 2009, Akers, et al. 2013). Other studies have suggested the virus-like 
particle TyA and complement components C1a and C1q as possible ectosomes markers 
(Cocucci and Meldolesi 2015, Meldolesi 2016) (Table 5.1).  
 
5.2.1.3.5 Apoptotic bodies 
In addition to ectosomes and exosomes, another form of extracellular vesicle can be detected. 
These vesicles, named apoptotic bodies or apoptosomes, are released uniquely by cells 
undergoing programmed cell death and apoptosis, through a mechanism of membrane 
blebbing (Akers, et al. 2013). These vesicles are generally larger than both ectosomes and 
exosomes (500-5000 nm of diameter), but in some cases, smaller apoptotic vesicles between 
50 and 500 nm have been identified (Akers, et al. 2013, Simpson and Mathivanan 2012). The 
main marker of apoptotic bodies is Annexin V, bound to PS on the plasma membrane (Akers, 
et al. 2013). Moreover, thrombospondin (TSP) and Complement component C3b have been 
proposed as apoptotic bodies markers (Akers, et al. 2013). Generally, once released, apoptotic 
bodies are phagocyted by macrophages (Elmore 2007). 
 
Table 5.1: Extracellular vesicles (EVs). Abbreviations: PM = Plasma membrane; MVB = Multivesicular 
bodies. 
 
EXTRACELLULAR VESICLES 
Name Biogenesis Diameter Markers 
Exosomes 
MVBs: fusion of the limiting 
membrane of the MVB with 
PM 
~ 30 - 100 nm 
Proteins: CD9, CD63, 
CD81, Alix, Tsg101, Hsp70, 
Flotillin etc… 
Lipids: Sphyngomyelin, 
Ceramide 
Ectosomes or 
Microvesicles 
Shedding from plasma 
membrane – Living cells 
~ 100- 2000 nm 
Proteins: Dependent on 
origin PM - Flotillin, Vamp3, 
Integrins, TyA, C1a/C1q 
etc.; Lipids: 
Phosphatidylserine (PS), 
Sphingomyelin, Ceramide 
Apoptotic bodies 
Shedding from plasma 
membrane – necrotic cells 
~ 500-5000 nm Annexin V, TSP, C3b 
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5.2.2 Mechanisms of unconventional protein secretion 
5.2.2.1 Unconventionally secreted proteins 
A nuber of secreted proteins have been shown to lack an N-terminal ER signal peptide and to 
reach the cell surface by an ER-and Golgi independent pathway (Muesch, et al. 1990). These 
proteins are identified as “unconventionally secreted proteins” and are a group of cell surface 
bound, matrix-associated or soluble proteins often involved in particular in the regulation of 
cell growth, differentiation and immune response (Nickel 2003, Nickel and Seedorf 2008, 
Nickel and Rabouille 2009, Nickel 2010). Examples of unconventionally secreted proteins are 
fibroblast growth factor 2 or basic fibroblast growth factor (FGF2) (Mignatti, Morimoto and 
Rifkin 1992), some specific interleukins (IL) (Lopez-Castejon and Brough 2011), galectins 
(Sato, Burdett and Hughes 1993) and the characteristic acyl-coenzyme A (CoA) - binding 
protein (AcbA) from yeast or Dictyostelium discoideum (Manjithaya, et al. 2010a). Other less 
studied unconventionally secreted proteins are thioredoxin (Rubartelli, et al. 1992, Nickel 
2003), and peroxiredoxin 1, the export of which is regulated by cytokines such as TGF-β1 
(Chang, et al. 2006). Brefeldin A (BFA), a drug that completely blocks Golgi trafficking (Orcl, et 
al. 1991), does not affect the export of any of these signal-peptide lacking proteins (Nickel 
2003). In addition, these proteins are generally characterised by not having post-translational 
modifications proper of the ER/Golgi space such as N-glycosylation, even if they might have 
consensus sites for glycosylation (Nickel 2003).  
Unconventional secretion mechanisms can be distinguished between non-vesicular and 
vesicular mechanisms (Rabouille, Malhotra and Nickel 2012) (Table 5.2, Fig. 5.1). Non-
vesicular mechanisms happen by direct translocation through the plasma membrane and can 
involve phospholipid binding and formation of channels, as in the case of the FGF2 
unconventional secretion, or protein transporters. Vesicular mechanisms involve instead 
different types of membranous intermediates that carry the protein cargo: this includes the 
formation of internal cargo-containing vesicles in the endosome (MVB) and exosome secretion, 
MV direct formation at the plasma membrane, and particular secretory lysosomes.  
Interleukin (IL) 1β secretion is associated with the inflammasome activity and has been 
initially suggested to employ a vesicular pathway of unconventional secretion for its export 
(Andrei, et al. 1999, Andrei, et al. 2004, Qu, et al. 2007). More recently, however, a non-vesicular 
unconventional export has been proposed for IL-1β, involving the permeabilisation of the 
plasma membrane (Shirasaki, et al. 2014, Martín-Sánchez, et al. 2016).  
Alternative pathways such as that involving autophagosome processes might lead to 
unconventional secretion (Rabouille, Malhotra and Nickel 2012), as reported for the AcbA 
secretion (Manjithaya and Subramani 2010, Manjithaya, et al. 2010a). Proteolytic cleavage by 
cysteine proteases such as caspase-1 and calpain can be involved in the unconventional 
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secretion of a protein, as exemplified by the inflammasome/caspase-1 dependent secretion of 
IL-1β and for the IL-1α secretion (Brough, et al. 2003, Brough and Rothwell 2007, Keller, et al. 
2008, Groß, et al. 2012).  
 
Another small group of unconventionally secreted proteins exists in nature (Nickel and 
Rabouille 2009, Nickel and Seedorf 2008, Rabouille, Malhotra and Nickel 2012) which possess 
the leader sequence and are driven into the ER but reach the surface either in a Golgi 
independent manner (Baldwin and Ostergaard 2002) or in a COPII independent manner (Fatal, 
et al. 2004, Karhinen, et al. 2005). Examples of Golgi-independent leader peptide-containing 
unconventionally secreted proteins are cystic fibrosis transmembrane conductance regulator 
(CFTR) (Yoo, et al. 2002, Wang, et al. 2004) and Drosphila melanogaster alpha-integrins 
(Schotman, Karhinen and Rabouille 2008). 
 
 
Table 5.2: Mechanisms of unconventional protein secretion.  
 
KNOWN UNCONVENTIONAL SECRETION MECHANISMS 
Pathway Main unconventionally secreted proteins 
1) NON – VESICULAR MECHANISMS OF UNCONVENTIONAL PROTEIN SECRETION (LEADERLESS PROTEINS) 
Direct translocation across the plasma membrane 
Fibroblast growth factor 2 (FGF2) [Ref. in 5.2.2.2.1]; 
Fibroblast growth factor 1 (FGF1) [Ref. in 5.2.2.2.3]; 
Galectins [Ref. in 5.2.2.2.2]; Interleukin -1α (IL-1α) [Ref. in 
5.2.2.2.3] Annexin A2 [Ref. in 5.2.2.2.4]; Interleukin 1β (IL-
1β) [Ref. in 5.2.2.3.2]; Thioredoxin [Ref. in 5.2.2.1] 
Plasma membrane transporters (ABC) 
Yeast pheromone a-factor; Leishmania spp. acylated 
surface protein B (HASPB); Drosophila germ cell attractants 
[Ref. in 5.2.1.2.5] etc… 
2) VESICULAR MECHANISM OF UNCONVENTIONAL PROTEIN SECRETION (LEADERLESS PROTEINS) 
Autophagosome-like structures / CUPS Dictyostelium AcbA /Yeast Acb1 [Ref. in 5.2.2.3.1]  
Secretory lysosomes / Multivesicular bodies 
Interleukin 1β (IL-1β) [Ref. in 5.2.2.3.2]; Transglutaminase-2 
(TG2) [Ref. in 5.3.3]? 
Shedding microvesicles 
Interleukin 1β (IL-1β) [Ref. in 5.2.2.3.2]; Transglutaminase-2 
(TG2) [Ref. in 5.3.3]? 
3) UNCONVENTIONAL SECRETION OF LEADER-CONTAINING PROTEINS 
Golgi bypass 
Cystic fibrosis transmembrane conductance regulator 
(CFTR); CD45; yeast Ist2; Drosophila α integrin (Nickel and 
Rabouille, 2009; Rabouille et al., 2012) 
COPII bypass 
Yeast heat-shock protein 150 (Hsp150) (Nickel and 
Rabouille, 2009) 
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Figure 5.1: Mechanisms of unconventional protein secretion.  
 
 
5.2.2.2 Non-vesicular mechanisms of unconventional protein secretion  
5.2.2.2.1 Fibroblast growth factor 2 (FGF2) 
The extracellular growth factor FGF2 is a protein belonging to the fibroblast growth factor 
family of heparin binding proteins and is involved in different functions outside the cells such 
as angiogenesis, wound healing, differentiation and migration (Nugent and Iozzo 2000). FGF2s 
lacks a signal peptide and was suggested to be secreted by an unconventional secretory 
pathway more than 20 years ago (Mignatti, Morimoto and Rifkin 1992). FGF2 has been 
reported to be secreted through a peculiar unconventional pathway that does not involve 
vesicular compartments (Schafer, et al. 2004, Nickel 2011, La Venuta, et al. 2015). The 
mechanism has been recently elucidated. FGF2 is exported by direct translocation through the 
plasma membrane and the process involves binding to plasma membrane phosphoinositides 
(PIPs) and heparan sulphate proteoglycans (HSPGs) (Temmerman, et al. 2008, Zehe, et al. 
2006, Nickel 2007). According to Nickel and colleagues (Steringer, et al. 2012), FGF2 binding 
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to phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2] on the inner side of the plasma 
membrane (Temmerman, et al. 2008) is the first main step: this is not only fundamental for the 
protein’s targeting to the membrane, but also induces the oligomerisation of the protein and 
its inclusion in the lipidic bi-layer, with formation of an hydrophilic pore that disturbs the 
permeability barrier of the plasma membrane (Steringer, et al. 2012, Nickel 2011). Thereafter, 
HSPGs in the membrane proximity,on the extracellular surface of the plasma membrane, bind 
FGF2 though their long HS chains and facilitate the transport across the pore and towards the 
outside by means of a trapping mechanism (Zehe, et al. 2006, Nickel 2007). Curiously, FGF2 
needs to be fully-folded to bind PI(4,5)P2, and through the whole process FGF2 remains in a 
fully-folded tertiary structure, while, normally, proteins that are transferred through 
conventional protein channels need be unfolded for translocation (Backhaus, et al. 2004, 
Torrado, et al. 2009).  
FGF2 phosphorylation (Tyr83) has been suggested as a further key step to initiate the secretion 
of the protein. Phosphorylation is performed by a specific Tec non-receptor tyrosine kinase 
and might be determinant for the protein binding to phosphoinositides and translocation to 
the inner side of the plasma membrane (Ebert, et al. 2010, La Venuta, et al. 2016). Tec Kinase 
activity is itself controlled by Src- tyrosine kinases, that determine the activation of Tec and its 
translocation to the inner side of the plasma membrane by aims of the Tec kinase PH (plakstrin 
homology) domain that binds phosphoinositides (Nickel 2011). Recently, also 
sodium/potassium ATPase ATP1A1 has been shown to be involved in the export mechanisms 
by recruiting FGF2 at the inner leaflet of the plasma membrane (Zacherl, et al. 2015, La Venuta, 
et al. 2015).  
In addition to the FGF2, other unconventionally secreted proteins have been suggested to 
follow a non-vesicular secretory mechanism. Among these proteins we can cite the other 
member of FGF family fibroblast growth factor 1 (FGF1), the plasma membrane associated 
proteins annexins A1 and A2 (Anxa1, Anxa2), cell surface/ECM lectins and the Leishmania 
hydrophilic acylated surface protein B (HASPB), that were suggested in the past to be 
synthesized in the cytosol and secreted by translocation across the plasma membrane that 
does not involve vesicular formation (Stegmayer, et al. 2005, Deora, et al. 2004, Rabouille, 
Malhotra and Nickel 2012, Seelenmeyer, Stegmayer and Nickel 2008). These less understood 
pathways are described in the next section. 
 
5.2.2.2.2 Galectins 
Lectins are a family of carbohydrate binding proteins. Among them, galectins specifically 
bind β-galactoside sugars and can be observed in the extracellular matrix (ECM) in association 
with ECM β-galactoside-containing glycoproteins or glycolipids and cell surface β-galactoside-
containing counter receptors. In the extracellular space, they are involved in functions such as 
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receptor-mediated signalling, cell adhesion and apoptosis (Liu and Rabinovich 2005). In the 
past, extracellular trafficking of galectins was seen to involve blebbing of EVs from the plasma 
membrane (Cooper and Barondes 1990, Mehul and Hughes 1997, Hughes 1999), but more 
recently the formation of vesicles (either by direct blebbing or exosomes formation) was 
excluded at least for galectin 1 (Gal-1). Binding to cell surface β-galactoside containing 
glycoproteins or glycolipids (counter receptors) has been shown to be necessary for Gal-1 
export across the plasma membrane with a process that might be similar to the HSPGs-FGF2 
interaction. Glycoprotein/Gal-1 binding however might occur inside the cell and act in a 
different way in the export of the lectin (Seelenmeyer, et al. 2005). Similarly to FGF2, the export 
of Gal-1 happens in a fully folded state (Backhaus, et al. 2004).  
 
5.2.2.2.3 Fibroblast growth factor 1 (FGF1) 
FGF1 is a member of the fibroblast grow factor family mainly known for its role in angiogenesis 
and, similarly to FGF2, is characterised by an ER/Golgi-independent secretion. Differently from 
FGF2, that is generally secreted by the cells without the necessity of a stimulus (Florkiewicz, et 
al. 1995), FGF1 is secreted by the cells as a consequence of different stresses, first of all the heat 
shock (Jackson, et al. 1992, Jackson, et al. 1995). FGF1 was suggested to be exported by non-
vesicular translocation across the plasma membrane following heat shock triggering, and to be 
released by the cells as a biologically inactive homodimer, formed as a result of cysteine (Cys) 
oxydation, which seems to be necessary for the protein secretion (Jackson, et al. 1995, 
Tarantini, et al. 1995). FGF1 protein is exported as part of an S100 release complex:  upon 
stress, FGF1 is translocated in the proximity of the plasma membrane, and binding to the 
release complex precedes and determines the export of the protein itself (Prudovsky, et al. 
2002). The complex requires S100A13, which is also an unconventionally secreted protein, 
structurally similar to calmodulin (Landriscina, et al. 2001). Other fundamental components 
are leader-less proteins 40kDa portion of synaptotagamin 1 (Syt1) (Tarantini, et al. 1998) and 
sphingosine kinase 1 (Soldi, et al. 2007). The stress-induced aggregation of the multiprotein 
complex at the inner side of the plasma membrane has been suggested to be copper(Cu2+) - 
dependent and the components of the complex itself are all Cu2+-binding proteins. Once the 
complex of FGF1 is formed, the translocation across the plasma membrane has been shown to 
happen through a complex-induced phosphatidylserine (PS) “flipping mechanism”(Kirov, et al. 
2012).  Similarly to FGF2, FGF1 and the components of the complex have been shown to bind 
acidic phospholipids such as PS and PIPs with high affinity on the inner side of the plasma 
membrane and induce membrane destabilisation upon binding to specific 
phosphatidylcholine-free membrane domains(Graziani, et al. 2006).  
Interleukin -1α (IL-1α) has been reported to share most of the characteristics of FGF1 
secretion, including the copper-dependent complex formation with S100A13 and phospholipid 
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binding- dependent translocation, however, the protein is secreted as a monomer and the 
secretion complex does not include Syt1. An alternative component of the complex which has 
been identified is calpain, another calcium binding protein that associates with annexin 2 at 
the plasma membrane inner side. For a reference, see (Prudovsky, et al. 2003).  
 
5.2.2.2.4 Annexin A2 
Annexin A2 (Anxa2) is a membrane binding member of the annexin family with a role in signal 
transduction and stress response. Anxa2 is known to bind directly PI(4,5)P2 
phosphoinositides at the inner side of the plasma membrane in a calcium dependent manner 
(Rescher, et al. 2004) and to determine the phospholipid clustering in microdomains (Gokhale, 
et al. 2005, Menke, Gerke and Steinem 2005). Similarly to FGF1, Anxa2 forms an 
heterotetramer with the S100 protein member S100A10, which is bound to the plasma 
membrane through PIP2-Anxa2 binding in a Tyr phosphorylation dependent manner (Deora, 
et al. 2004). Also , Anxa2 is known to be able to form oligomers with FGF1-release complex, 
and the formation of oligomers might be involved in the process of protein translocation or 
FGF1 targeting to the plasma membrane (Prudovsky, et al. 2003, Prudovsky, et al. 2008, 
Rabouille, Malhotra and Nickel 2012).  
There is no complete agreement on Anxa2 unconventional secretion, as some studies have also 
suggested a vesicular export through incorporation into intraluminal vesicles of MVB and 
subsequent release as exosomes(Valapala and Vishwanatha 2011, Deora, et al. 2004) or 
interaction with SNAREs (Danielsen, van Deurs and Hansen 2003).  
 
5.2.2.2.5 Proteins employing ABC transporters for translocation 
Translocation across the plasma membrane in a vesicle-independent manner is mediated by 
plasma membrane ATP-binding cassette (ABC) transporters. The general characteristic of 
proteins released through ABC transporters is to be lipidated (Rabouille, Malhotra and Nickel 
2012) and the lipid chain might function for protein targeting to the inner leaflet of the plasma 
membrane in close proximity to the trasporter. For example, pheromone a-factor from yeast, a 
farnesylated protein, is externalized through the ABC transporter Ste6p (Kuchler, Sterne and 
Thorner 1989, Michaelis 1993). Other unconventionally secreted proteins from different 
eukaryotic species have been reported to be lipidated and secreted through ABC transporters, 
not only yeast and proteozoan parasites but also species of higher complexity such as 
Drosophila spp. (Ricardo and Lehmann 2009) suggesting ABC-transporter translocation as a 
common conserved mechanism of protein secretion across the plasma membrane.  
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5.2.2.3 Vesicular mechanisms of unconventional protein secretion 
Differently from the proteins described in the previous paragraphs which follow a non-
vesicular transport mechanism, a second group of leaderless proteins have been suggested to 
follow an unconventional secretion mechanism that involves vesicular intermediates.  The two 
more characteristic proteins in this group are the acyl-CoA binding protein (AcbA) from 
Dictyostelium spp (Cabral, et al. 2010) and IL-1β.  
 
5.2.2.3.1 Acyl-CoA binding protein (AcbA/Acb1)  
AcbA is secreted by Dictyostelium spp. cells upon starvation, and is subsequently subjected to 
cleavage in the extracellular space to produce SDF-2, a smaller peptide involved in signalling 
and necessary for formation of spores (Richardson, Loomis and Kimmel 1994). The secretion 
of AcbA and its yeast homologue Acb1 has been reported to require vesicular fusion and does 
not involve cell surface transporters (Cabral, et al. 2010, Kinseth, et al. 2007). The secretion of 
AcbA/Acb1 involves a number of factors proper of autophagosome biogenesis 
[phosphatidylinositol (3,4,5)-trisphosphate PI(3,4,5)P3 and autophagy-related proteins (Atg) 
are the main examples], suggesting that the export of the AcbA/Acb1 happens through 
autophagosome-like vesicles (Duran, et al. 2010, Manjithaya, et al. 2010b). However, a series 
of elements involved in MVBs formation and endosomal fusion through SNAREs were also 
identified as key elements in the process (Duran, et al. 2010, Manjithaya, et al. 2010b), as well 
as the Golgi reassembly-stacking proteins (GRASPs, Grh1 in yeast) (Kinseth, et al. 2007, Duran, 
et al. 2010, Bruns, et al. 2011), primarily involved in vesicle fusion with Golgi and stacking of 
Golgi cisternae.  
Secretion pathway starts from the formation of “cup-shaped” membranes, named CUPS 
(compartment for unconventional protein secretion) which form at the proximity of Sec13-
containing ER exit in a starvation-dependent manner, are rich in PI(3,4,5)P3 phospholipids and 
contain GRASPs as well as autophagy-related proteins such as Atg9 and Atg8 (Bruns, et al. 
2011, Malhotra 2013). AcbA/Acb1 are recruited in this area possibly via acylation, then the 
cargo containing vesicle detaches from CUPS (Malhotra 2013), reaches endosomal MVB 
compartment in a process that is dependent from the t-SNARE Tlg2, the Rab family GTPase 
Ypt6/Rab6 and ESCRT-I protein Vps24 (Duran, et al. 2010), and it is likely to be internalised as 
a luminal vesicle of the endosome (Malhotra 2013). While starvation dependent degradative 
autophagosomes end up fusing with the vacuole, these CUPS-derived secretion 
autophagosomes/MVBs fuse with the plasma membrane for secretion, in a process involving a 
specific plasma membrane tSNARE (Sso1) (Bruns, et al. 2011).  
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5.2.2.3.2 Interleukin 1β (IL-1β) 
Interleukin 1β is another well studied unconventional secreted protein (Rubartelli, et al. 1990) 
and a central mediator in inflammatory response induced by inflammasome activation, also 
known to contribute to chronic diseases and tissue injury (Latz 2010).  The main secretory 
stimulus is the ATP-dependent activation of purinergic receptor P2X7, a nucleotide-gated ion 
channel that induces inflammasome assembly and is necessary for IL-1β secretion (Ferrari, et 
al. 2006, Pelegrin, Barroso-Gutierrez and Surprenant 2008), supported by K+ efflux from the 
channel, which is the necessary signal that triggers inflammasome assembly, and Ca2+ and Na+ 
influx, involved in membrane depolarization and intracellular signalling. In particular, calcium 
influx has been proven to be necessary for microvesicle formation through depolarisation of 
the plasma membrane (loss of asymmetry) and dissociation of cytoskeletal actin from 
membrane glycoproteins (Burnier, et al. 2009). P2X7 also drives the formation of a “membrane 
pore”, that allows the passage of larger cations through the membrane (Ferrari, et al. 2006, 
Browne, et al. 2013).  
The inflammasome is a multi-molecular complex and its assembly determines auto-processing 
of pro-caspase 1 to activated caspase 1 (Kahlenberg and Dubyak 2004). The cleaveage of pro-
IL-1β to active IL-1β is performed by active caspase-1 (Martinon, Burns and Tschopp 2002, 
Brough and Rothwell 2007, Denes, Lopez-Castejon and Brough 2012), which is itself activated 
by cleaveage upon iflammasome assembly (Ferrari, et al. 2006), and is thought to be important 
for IL-1β secretion.  
In the last decades, a series of vesicular secretion pathways have been suggested for IL-1β. One 
involves formation of “lysosome-like” structures regarded as secretory lysosomes, lysosomes 
that instead of undergoing degradation are secreted at the level of the plasma membrane and 
contain both activated IL-1β and caspase 1 (Andrei, et al. 1999, Andrei, et al. 2004). Autophagy 
was also suggested to play a role in the formation of this secretory lysosomal structures 
(Harris, et al. 2011). In other cases, the formation of MVB and release of exosomes was 
suggested for IL-1β secretion (Qu, et al. 2007), while some authors where pointing at MV 
shedding preceded by phosphatidylserine (PS) flipping at the outer side of the membrane as a 
possible mechanism (MacKenzie, et al. 2001).  
More recently, however, a different mechanism was suggested for IL-1β secretion, a 
mechanism that does not involve a vesicular compartment formation (Harris, et al. 2011), but 
instead happens by direct translocation through an hyperpermeabilised plasma membrane 
domain (Shirasaki, et al. 2014, Martín-Sánchez, et al. 2016), with phosphatidylserine (PS) 
flipping induced by P2X7 receptor activation, and can be due to a caspase dependent apoptotic 
process named pyroptosis (Martín-Sánchez, et al. 2016, Brough and Rothwell 2007), known to 
lead to protein leaking during inflammation (Brough and Rothwell 2007).  
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It is important to see that both IL-1β and the abovementioned IL-1α are synthesised by the 
cells as precursor proteins of the same length (31 kDa), but only IL-1β needs to be cleaved to 
be activated and bind the specific interleukin receptor IL-1RI, while IL-1α is active in its 
unprocessed form (Dinarello 1996). Calcium dependent calpain seems to be involved, instead, 
in IL-1α cleaveage and secretion (Groß, et al. 2012, Brough, et al. 2003). Even if not directly 
involved in IL-1α claveage, however, inflammasome activation and subsequent Caspase-1 
activation seem to be necessary for the process of IL-1α secretion either by determining 
Calpain activiation (Groß, et al. 2012) or by direct cleavage of pro-IL-1α (Keller, et al. 2008). In 
addition to this, caspase 1 has been suggetsed to play a role in other protein secretion, such as 
FGF2, annexin A2, galectin 3 and peroxiredoxin 1 (Keller, et al. 2008).  
 
5.2.3 Transglutaminase 2 is an unconventionally secreted protein 
As described in Chapter I, transglutaminase-2 (TG2) is an enzyme primarily located in the 
cytoplasm of the cells, but it can also be localized in the plasma membrane and extracellular 
environment and, as a consequence, it is involved in several ECM processes. Despite being 
clearly released by living cells, TG2 lacks a signal peptide necessary for ER/Golgi conventional 
secretion (Ichinose, et al. 1990, Ikura, et al. 1988).  
The TG2 unconventional secretory route has been the focus of research of different groups for 
many years now. Some elements have been identified in literature as important for TG2 
secretion even if a complete mechanism was not elucidated.  
An intact FN binding N-terminal β-sandwich domanin was suggested to be crucial for TG2 
secretion (Gaudry, et al. 1999, Chou, et al. 2011). TG2 binds FN with high affinity and the 
binding site is located on the N-terminal side of the β-sandwich domain of TG2, independent 
from TG2 conformation and activity (Jeong, et al. 1995).  Removal of these aminoacids was 
shown to prevent TG2 secretion to the cell surface of both an inducible system of Swiss 3T3 
fibroblast and NRK52E renal tubular epithelial cells (Gaudry, et al. 1999, Chou, et al. 2011), 
however, secretion was proven not to be dependent on FN binding, as FN deletion was not 
affecting the export (Chou, et al. 2011). Interestingly, the motif detected (aminoacids 88-106) 
(Chou, et al. 2011) determines the formation of an “hairpin structure” exposed on the surface 
of TG2, that was suggested to be crucial for TG2 correct folding in a tertiary structure necessary 
for the enzyme secretion (Chou, et al. 2011). Active state conformation was found to be 
important for TG2 secretion in transfected 3T3 finroblasts (Balklava, et al. 2002). Moreover, 
TG2 binds HSPGs with high affinity, and this interaction has been proven to be central for TG2 
secretion and localisation on the cell surface by our group (Scarpellini, et al. 2009, Lortat-Jacob, 
et al. 2012) and confirmed by others (Wang, et al. 2012).  
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Overall, three routes for TG2 unconventional secretion were proposed in the past few years. 
Belkin and colleagues showed that N-ethylmaleimide NEM, a specific inhibitor of NSF ATPase 
(an enzyme involved in membrane fusion), or NSF-mutant clones, led to impaired TG2 release 
in the ECM by NIH3T3 fibroblasts and concluded that TG2 is more likely to be secreted though 
an intracellular vesicular intermediate (Zemskov, et al. 2011). Indeed, it was previously shown 
that nitric oxide (NO) -mediated inhibition of membrane fusion, via nitrosylation of NSF-
ATPase, interfered with TG2 secretion (Santhanam, Berkowitz and Belkin 2011, Jandu, et al. 
2013).  By immunofluorescent stainings and immunoprecipitation approaches on a model of 
transfected NIH3T3 fibroblasts with inducible TG2 sinthesis, it was suggested that TG2 is 
recruited after synthesis at the level of the Peri Nuclear Recycling Compartment (PNRC) and 
delivered into recycling vesicles. The small GTPase Rab11, that regulates recycling endosomes 
formation and delivery to the plasma membrane, was localized in the proximity of TG2 and 
was confirmed necessary for its secretion by siRNA tranfection, together with specific SNAREs 
associated with endosome-to-plasma membrane movements. The authors also suggested that 
phosphinositide binding [mainly PI(3)P and PI(4)P]  was necessary for TG2 loading into 
vesicles at the level of PNRC. A phosphoinisitides binding site for TG2 was mapped in the 
sequence 590-KIRILGEPKQRKK-602 (Zemskov, et al. 2011), that contained the basic positively 
charged cluster subsequently suggested for Heparin sulphate (Lortat-Jacob, et al. 2012). By 
fluorescent immunostaining and immunoprecipitation, TG2 was found into the same recycling 
vesicles of internalized α5β1. Integrins were not necessary for TG2 loading, although the two 
elements were exported in complex on the cell surface (Zemskov, et al. 2011) .  
J. van den Akker and co-authors from the university of Amsterdam proposed that TG2 was 
released from cells by microvesicle formation by smooth mucle cells, though a mechanism 
likely to depend on the crosslinking activity of TG2 (van den Akker, et al. 2012). TG2 
crosslinking activity was suggested to be necessary for the release of these TG2-containing 
vesicles from the cell surface, probably involving a process of cytoskeletal remodelling 
necessary for the formation of the microvesicle itself (van den Akker, et al. 2012). This 
observation is consistent with the requirement of Ca2+ for TG2 secretion also reported by 
others (Zemskov, et al. 2011). Furthermore, a necessary stimulus for TG2 secretion in this 
model was TG2 redox state (Glutahione S-transferase, Thioredoxin reductase etc.) that breaks 
Cys-Cys disulphide bonds and allows conformational changes necessary for the Ca2+ dependent 
activation (van den Akker, et al. 2011, van den Akker, et al. 2012).  
Cerione’s group in the context of cancer-associated microvesicle formation (Antonyak, et al. 
2011) also identified TG2 as associated with microvesicles through a MS-proteomic approach, 
and identified secretory microvesicles containing TG2 as independent from the conventional 
ER-Golgi trafficking as well as from the MVB formation. TG2 was mainly found localised on the 
outer side of the vesicles and FN was co-localised with TG2 on these vesicles. The authors 
CHAPTER V -  RESULTS 
 
282 
 
suggested that, despite TG2 was loaded into these vesicles, the formation of the vesicles as well 
as their shedding was independent from the protein itself and its catalytic activity (Antonyak, 
et al. 2011).  
Recently, Aeschlimann’s group has employed differentiated macrophages known to secrete IL-
1β in a P2X7 receptor (P2X7R)/inflammasome – dependent manner, and suggested that the 
purinergic P2X7 receptor was necessary TG2 secretion as well (Adamczyk, et al. 2015). Using 
a combination of an ATP homologue for P2X7 receptor stimulation and P2X7R inhibitors, as 
well as transfection of P2X7R in cells naturally lacking P2X receptors, it was proposed that TG2 
secretion is dependent on P2X7-receptor activation. The Ca2+ dependent catalytic activity of 
TG2 was found not to be crucial for the enzyme secretion. According to this model, although 
P2X7R stimulation determines an increase in extracellular vesicle secretion (shedded 
microvesicles/ectosomes), TG2 was secreted in soluble form and TG2 release was independent 
from microvesicle shedding (which is dependent on Ca2+ influx through P2X7R) and exosome 
formation. In particular, cell surface protrusions co-localised with TG2 were observed but were 
not detaching from the plasma membrane. Despite being attributed to P2X7R activation, TG2 
release didn’t involve inflammasome assemblation processes or cleaveage, neither involved 
the P2X7R Ca2+ channel function necessary for microvesicle shedding. Instead, the proposed 
secretion pathway involved the pore formation function of P2X7 receptor induced by ATP 
binding and regulated by calcium levels, and direct tranlocation of TG2 through the pore, in a 
catalytic activity-independent manner (Adamczyk, et al. 2015). Moreover, they suggested that 
Thioredoxin 1, an unconventionally secreted protein involved in redox activation of TG2 
(Chapter I) was exported as well through the pore together with TG2 and might function as 
TG2 chaperone through secretion (Adamczyk, et al. 2015).   
 
In conclusion, different mechanisms have been suggested for TG2 unconventional secretion in 
cell ines, however, no complete understanding has been obtained yet. Moreover, no 
investigation has been undertaken to study release in vivo. The association of TG2 with 
vesicular compartment seems to suggest a vesicular transport for TG2, however it was also 
shown in other systems that TG2 might not be associated directly with the vesicles.  
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Table 5.3: Hypotheses of TG2 unconventional secretion.  
HYPOTHESES OF TG2 UNCONVENTIONAL SECRETION 
Zemskov et al., 2011; 
Santhanam et al, 2011  
Recycling endosome – 
derived secretion 
Dependent on Rab11, phosphinositide binding 
[PI(3)P, PI(4)P], Calcium influx, NSF-ATPase.  
Co-localise with integrin α5β1 in vesicles.  
van den Akker et al., 2012 
Shedding microvesicles 
 
Release dependent on TG2 activity, dependent on 
reducing agent for TG2.  
Antonyak et al., 2011 
Independent from TG2 catalytic activity, co-localise 
with Fibronectin in vesicles. 
Adamczyk et al., 2015 
Direct translocation through 
membrane pore 
Dependent on P2X7 receptor, Independent from 
Calcium/ TG2 activity. Co-localise with Thioredoxin 1 
during export.  
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5.3 EXPERIMENTAL PROCEDURES 
 
5.3.1 Experimental design  
 As proteins involved in SNARE-mediated membrane fusion-exocytosis were identified in 
the TG2 interactome in kidney membranes, the need for membrane fusion for TG2 release 
is investigated in this chapter by employment of an NSF-ATPase inhibitor on TECs (Fig. 
5.2A).  
 As a number of TG2-associated proteins in kidney membranes have been found to belong 
to EV, mainly exosomes, this chapter also reports on the isolation of EV subpopulations and 
characterisation of TG2 in exosomes and ectosomes, with employment of inhibitors of EV 
biogenesis (Fig. 5.2B).  
 Analysis of the known mechanisms of unconventional secretion, presented in the 
introduction of this chapter, has shown that many unconventionally secreted proteins are 
targeted to specific membranes by binding to acidic phospholipids; moreover, specific 
proteins’ phosphorylation events were recognized to be involved in the export of some 
unconventionally secreted protein. For this reason, an initial analysis of both the binding 
capacity of TG2 to membrane phospholipids and and the degree of phosphorylation of TG2 
in immunoprecipitates from TECs is provided in this chapter, as outlined in Fig. 5.2C-D.  
 Lastly, having clathrin and CCV-associated proteins been found to be largely associated 
with TG2 in its interactome, the role of clathrin extracellular TG2 localisation and 
abundance will be examined (Fig. 5.2E).  
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Figure 5.2: Experimental design for the investigation of TG2 unconventional secretion from TECs.  
 
 
5.3.2 N-ethylmaleimide (NEM) treatment of kidney TECs 
N-ethylmaleimide (NEM) is a specific inhibitor of NSF (N-ethylmaleimide-sensitive factor) 
ATPase, a protein necessary for the majority of intracellular vesicular trafficking and 
membrane fusion events. NSF-ATPase is an ATPase necessary for membrane fusion mediated 
by SNAREs (Zhao, Slevin and Whiteheart 2007) and is involved in both intracellular membrane 
fusion and secretion, including ER-Golgi derived vesicles (Block, et al. 1988, Beckers, et al. 
1989), endosome membrane fusion and recycling endosomes (Rodriguez, Stirling and 
Woodman 1994, Mallard, et al. 2002), secretion of granules from platelets (Polgar and Reed 
1999), and, importantly for the current study, exosome secretion by MVB fusion (Fader, et al. 
2009). As its main function, NSF ATPase acts together with SNAPs and employs the energy of 
ATP hydrolysis to disassemble SNARE complexes after membrane fusion, allowing their 
recycling (Barnard, Morgan and Burgoyne 1997, Ryu, Jahn and Yoon 2016). 
In order to test the effect of NSF ATPase inhibition on TG2 release, NRK52E WT or EGFP-TG2 
overexpressing NRK52E (clone #C5) cells were cultured in normal culture conditions as 
described in 2.2.1, either in T-25 flasks (for biotin-cadaverine incorporation assay) or in 8-
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wells chamber slides (for immunofluorescent staining), until 90% confluent. At this point, 
medium was supplemented with 0.6 mM NEM (E3876, Sigma) and cells were incubated for 30 
min at 37°C in the presence of the inhibitor, as suggested by previous literature (Zemskov, et 
al. 2011). NEM stock solution was prepared in sterile water at a 100 mM concentration (12.5 
mg/ml), and stored at -20°C. Aqueous solutions are reported to be instable (Sigma guidelines) 
hence, the solution was stored for short periods of time, and prepared fresh if older than a 
week.  
After incubation, cell viability was measured by LDH bioassay (2.2.1.7), while the effect on 
extracellular TG2 was measured by either biotin-cadaverine incorporation assay performed on 
living cells or immunofluorescent staining of extracellular TG2, as described in the general 
methods (2.2.8 - 2.2.9).  
 
 
5.3.3 Isolation of extracellular vesicles (EVs) from cell medium by 
differential centrifugation 
In order to investigate the possible release of TG2 into vesicular compartments, EVs have been 
isolated from cell medium by differential centrifugation, by adapting the method described by 
Bianco and colleagues in 2009 (Bianco, et al. 2009). The different stages of the isolation are 
summarized in Fig. 5.3.  
 
5.3.3.1 Cell culture and treatments 
For EVs isolation from conditioned medium, NRK52E WT, NRK49F WT and EGFP-TG2 
overexpressing NRK52E (clone #C5) cells were cultured in T-175 flasks, in the normal culture 
conditions described in the general methods (2.2.1.1), until 80% confluent. At this stage, cell 
monolayers were washed twice with PBS to remove every FBS trace, as animal serum contains 
vesicular components (exosomes, ectosomes and apoptotic bodies) that might interfere with 
the analysis (Shelke, et al. 2014, Eitan, et al. 2015). After washing, the medium was replaced 
with serum-free DMEM and cells were cultured for additional 36 hours.  
In some cases, cells were stimulated by adding recombinant TGF-1 (10 ng/ml) to the serum-
free medium during the 36 hours of incubation, to simulate a pro-fibrotic condition in vitro. In 
other cases, glucose stress was performed by culturing the cells in a T175 culture flask in 
DMEM medium containing 5.5 mM D-Glucose (low glucose, physiological condition) and 
supplemented with 2% (v/v) heat-inactivated FBS, 2mM L-glutamine and 100 IU/mL penicillin 
- 100 μg/mL streptomycin until 80% confluent. The cells were then washed twice with PBS pH 
7.4, the medium was replaced with serum-free medium containing either 5 mM (low) or 30 
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mM (high) glucose and cells were grown for a further 36 h. In specific experiments, vesicular 
trafficking inhibitors reported in paragraph 5.3.5 were added to the serum-free medium, and 
incubations were performed over appropriate times.   
 
5.3.3.2 EVs Isolation by differential centrifugation  
After incubation, conditioned medium was collected and supplemented with protease 
inhibitors (cOmplete™ EDTA-free protease inhibitors from Sigma). Cells monolayer was 
washed twice with PBS pH 7.4, scraped in PBS and the pellet collected by centrifugation at 500 
g for 5 min. Pelleted cells were lysed in radiommunoprecipitation assay (RIPA) buffer [50 mM 
Tris-HCl pH 8, 150 mM NaCl, 1% (v/v) NP40, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) 
SDS] following the lysis protocol reported in 2.2.3 (Fig.5.3).  
Conditioned medium was centrifuged 3 times at 300 g for 10 min at 4°C to remove remaining 
cells (P1), and supernatant (S1) was centrifuged at 1,200 g for 20 min at 4°C to remove large 
cell debris and apoptotic bodies (P2). Supernatant (S2) was centrifuged 10,000 g for 30 min at 
4°C to collect the microvesicular/ectosomal portion (P3), and the supernatant (S3) was 
centrifuged at 110,000 g for 1 h at 4°C in order to collect the exosomes (P4). All pellets obtained 
were resuspended in equal volumes (40 µl) of RIPA buffer (Fig.5.3).  
After the last centrifuge, the remaining EV-free medium (S4) was collected and residual 
proteins were precipitated using trichloroacetic acid (TCA) as it follows: 1:10 volume of TCA 
was added to the medium, mixed well, and the mixture was incubated for at least one hour on 
ice. The mixture was then divided into single conic bottom Eppendorf tubes and centrifuged 
for 5 min at 13,000 rpm. The supernatant was discarded and pellet was washed with cold 
acetone (1 ml/pellet) by centrifuging it again for 5 min at 13,000 rpm. The obtained pellet was 
air-dried and resuspended in 40 µl of RIPA buffer (Fig.5.3).  
 
5.3.3.3 Immunoprobing of specific proteins in cell and EVs lysates  
Depending on the specific experiment, equal amounts (15-25 µg) or equal volumes (40 µl) of 
proteins were resolved by 12% (w/v) acrylamide/bis-acrylamide SDS-PAGE under reducing 
condition. Immunodetection of the proteins of interest was performed by Western blot 
(described in Chapter II, 2.2.7) using the antibodies reported in Table 5.4 in blocking buffer 
[5% (w/v) non-fat milk in TBST pH 7.4]. Flotillin-2 (Flot2) is a lipid raft protein and was 
employed as a marker for both ectosome and exosomes (Wubbolts, et al. 2003, Antonyak, et al. 
2011). Immunoreactive bands were detected by enhanced chemiluminescence after 
incubation with an appropriate HRP-conjugated secondary antibody (Table 5.4) in blocking 
buffer as described in the general methods. Image acquisition was performed with a LAS4000 
imaging system (GE Heathcare). 
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Figure 5.3: Outline of the experimental procedure for extracellular vesicles isolation by 
differential centrifugation. Method adapted from (Bianco, et al. 2009).  
 
 
Table 5.4: Antibodies employed for extracellular vesicles (EVs) analysis. The table shows the 
primary and secondary antibodies employed for the immunodetection of specific proteins in cell lysates 
and EV fraction lysates. Antibodies’ dilutions in blocking buffer [5% (w/v) non-fat milk in TBST pH 7.4] 
are also shown.   
 
Primary antibodies  Company Dilution  
Rabbit polyclonal to Transglutaminase 2 (TG2) (ab421) Abcam  1:500 
Rabbit polyclonal anti-GFP (ab290) Abcam  1:2500 
Mouse Monoclonal anti-Flotillin 2 (610383) BD Transduction Laboratories  1:5000 
Secondary antibodies Company Dilution  
Goat anti-rabbit IgG HRP conjugated  Dako  1:2000 
Goat anti-mouse IgG HRP conjugated  Dako  1:1000 
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5.3.4 Measure of EV size by qNANO™ 
In order to characterize the size of the EV subpopulations obtained by differential 
centrifugation using the protocol described in the previous section (5.3.3.2), nanoparticle 
analyisis was performed by technical staff at the Institite of Neuroscience of the National 
Centre of Research (CNR) in Milan (Italy), using a qNANO™ (iZON, New Zeland) particle 
analyser (Garza-Licudine, et al. 2010). qNANO™ allows nano-scale particle analysis of 
biological vesicles by employing a tunable resistive pulse sensing (tRPS) method, that consents 
the measurement of each particle in suspension as they are passing, one at a time, though 
adjustable nanopores (Garza-Licudine, et al. 2010).  
For the characterisation of MV size by qNANO™, EGFP-TG2 overexpressing NRK52E TECs were 
cultured as described in 5.3.3.1 and 36h-conditioned medium was collected and sent overnight, 
in ice, to the abovementioned Institite of Neuroscience. Here, EVs were isolated by differential 
centrifugation by technical staff, following the same method described in 5.3.3.2, and 
nanoparticle analysis was performed by qNANO™ on the collected EV fractions.  
 
 
5.3.5 Inhibition of extracellular vesicles (EVs) release 
Sphingomyelinase (SMase) is an enzyme involved in the production of ceramide by the cell, by 
catalysing the hydrolysis of sphingomyelin (SM) with production 
of phosphocholine and ceramide. Different kinds of SMases exist in nature, depending on their 
specific location and the pH that favours their enzymatic activity. In particular, is important to 
mention both neutral SMase (nSMase) and acid SMase (aSMase) in the context of lipid-induced 
EV formation. It has been suggested that nSMase plays a role in exosome formation (ILV 
budding in secretory MVBs) (Trajkovic, et al. 2008), while aSMase might be involved in MV 
shedding (Bianco, et al. 2009).  
The following inhibitors were employed to modulate EV formation.  
The inhibitor N,N′-Bis[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-3,3′-p-phenylene-bis-
acrylamide dihydrochloride, generally referred to as GW4869 (D1692, Sigma), was employed 
as a cell-permeable inhibitor of nSMase (Luberto, et al. 2002) and inhibitor of exosome 
biogenesis (Trajkovic, et al. 2008).  
Imipramine hydrochloride, or 10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-
propanamine hydrochloride (I0899, Sigma), a specific inhibitor of aSMase, was employed as a 
possible inhibitor of ectosome budding (Bianco, et al. 2009). It is also important to remember 
that aSMase has also been involved in endocytic pathways by micropinocytosis, and 
imipramine has been suggested to inhibit micropinocytosis in different cell models (Serrano, 
et al. 2012, Miller, et al. 2012).  
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Amiloride hydrochloride [N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide 
hydrochloride hydrate] (A7410 Sigma) is an inhibitor of membrane depolarisation suggested 
to interfere with both EV release and macropinocytosis.  This compound has been proposed to 
inhibit both Na+/Ca2+ exchangers, involved in stimulated calcium influx and depolarisation, and 
H+/Na+ exchangers. Amiloride / N-ethyl-N-isopropyl amiloride has as mainly been involved in 
the inhibition of micropinocytosis, which is favoured by H+/Na+ exchange (Stelmach, Rusak 
and Tomasiak 2002, Koivusalo, et al. 2010). It is not yet clear wether amiloride effect on 
exocytosis is to associate with a lower exosome secretion by blocking channel activity (Savina, 
et al. 2003, Chalmin, et al. 2010, Merendino, et al. 2010), or with an inhibition of MV shedding 
(Stelmach, Rusak and Tomasiak 2002).  
Prior to EVs extraction, treatment with the different inhibitors was performed in serum-free 
DMEM medium at 37°C in EGFP-TG2 overexpressing NRK52 cells (clone #C5), using the 
specific working concentrations and incubation times reported in Table 5.5. After incubation, 
isolation of the different vesicle subpopulations from the medium was performed following the 
procedure described the previous paragraph (5.3.3.2), and equal volumes (40 µl) of each 
fraction was analysed for TG2/EGFP-TG2 expression as described in 5.3.3.3.  
 
Table 5.5: Inhibitors of extracellular vesicles (EVs) formation. Inhibitors used in this study to 
selectively interfere with EVs formation. GW4869 (N,N′-Bis[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-
3,3′-p-phenylene-bis-acrylamide dihydrochloride) was re-suspended in DMSO at stock concentration of 
5 mM.  Imipramine hydrochloride (10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine 
hydochloride) and amiloride hydrochloride (N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide 
hydrochloride hydrate) were re-suspended in water at a stock concentration of 50 and 25 mg/ml 
respectively (158 mM and 94 mM). All reagents were obtained from Sigma. nSMase = neutral 
sphingomyelinase, aSMase = acid sphingomyelinase 
 
Inhibitor Inhibition of [ ] 
Incubation 
time 
Control 
GW4869 
(D1692 Sigma) 
Selective inhibitor of nSMase 10 µM 16 h 
Serum free DMEM + 0.2% 
(v/v) DMSO 
Imipramine hydrochloride 
(I0899 Sigma) 
Selective inhibitor of aSMase 30 µM 30 min Serum free DMEM 
Amiloride hydrochloride 
(A7410 Sigma) 
Inhibitor of Na
+
/H
+ 
and
 
Na
+
/Ca
2+
 antiporter 
1 mM 10 min Serum free DMEM 
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5.3.6 Immunofluorescent staining of extracellular EGFP-TG2 
Immunofluorescent staining of extracellular EGFP-TG2 was performed on EGFP-TG2 
overexpressing NRK52E cells (Clone #C5) after treatment with specific EVs inhibitors. For 
these experiments, 50,000 EGFP-TG2 NRK52E cells/well were grown in an 8-well chamber 
slide in normal conditions for 24 h or until 80% confluent. At this stage, cells were treated as 
appropriate with vesicular trafficking inhibitors and/or with 10 ng/ml of recombinant TGF-β1 
in complete DMEM medium, and incubated at 37°C for the times reported in Table 5.5.  
After incubation, medium was removed carefully and cells were straight away fixed (non 
permeabilised) without any preliminary wash, to perturb the vesicles as little as possible. The 
full protocol followed for cell fixation and extracellular EGFP immunofluorescent staining (on 
non-permeabilised cells) is reported in the general methods (Chapter II).  
 
5.3.7 Measurement of TG2 activity in EVs  
In order to determine TG2 activity of the different extracellular vesicle subpopulations, 
measurement of TG2 activity was performed on both lysed and non lysed EVs of EGFP-TG2 
overexpressing NRK52E TECs. EVs were isolated by differential centrifugation as described in 
5.3.3, however, pellets were not lysed in RIPA buffer, but they were either lysed in a milder 
sucrose-based lysis buffer [0.25M sucrose, 2 mM EDTA, and 5 mM Tris-HCl, pH 7.4] (that lyses 
the membranous compartments but is more suitable for enzyme activity assays), or just re-
suspended as whole EVs in 50 mM Tris-HCl, pH 7.4 or serum free medium. In the first case the 
TG2 activity detected is that of the full vesicle, while in the second case, by not lysing the EVs, 
the activity detected is limited to the vesicles surface.  
TG2 activity was assessed using either the in-house total TG2 activity assay described in 2.2.9.1, 
or a more sensitive commercial TG2 activity “pico” assay obtained from Zedira. In both cases, 
assay plates were kept in gentle slow shaking during the TG2 reaction step, to make sure that 
all sides of the vesicles were in contact with the substrate-coated surface.  
 
5.3.7.1 Tissue transglutaminase pico-assay 
The tissue transglutaminase pico-assay kit (M003 Zedira) is a commercial kit suitable for a 
precise quantification of TG2 activity. The principle of the kit is very similar to the in-house 
total TG2 activity plate assay described in Chapter II: it is based on the employment of a plate 
coated with high molecular weight glutamine donor substrate (HA-HMS), and biotin-
cadaverine as a primary amine, that is crosslinked to the substrate by catalytically active TG2 
(in presence of adequate calcium and dithiothreitol – DTT). Streptavidin conjugated to 
horseradish peroxidase (HRP) is employed to detect biotinylated cadaverine incorporated on 
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the substrate and finally 3, 3', 5, 5'-tetramethylbenzidine (TMB) is used to develop the plate, 
through a colorimetric reaction with HRP in presence of hydrogen peroxide (H2O2).  
50 µL of re-suspended pellet in sucrose-based lysis buffer or 50 mM Tris-HCl, pH 7.4 (both 
supplemented with 10 mM DTT), were tested following the manufacturer’s instructions. 
Absorbance was read at 450 nm (TG2-activity) and 620 nm (background). TG2 activity of the 
given samples was measured by extrapolation from the calibration curve produced using the 
TG standards provided by the kit (from 0 to 10 ng/ml of TG2 or 0-500 pg/well as 50 µL are 
loaded per well). Calibration curve design and TG2 activity calculation for the MV extracts was 
performed using the statistical software GraphPad Prism 7 (http://www.graphpad.com). 
 
 
5.3.8 TG2 binding to phospholipids 
To analyse the ability of recombinant human TG2 to bind intracellular phospholipids, PIP 
Strips™ Membranes (P-23750, Molecular Probes®) were employed. PIP Strips™ are 6 cm 
nitrocellulose membrane containing 15 spots of different phospholipids (100 pmol each) plus 
a blank sample. These membranes are incubated together with the selected protein, in this case 
a purified TG2, and the binding to phospholipids is measured after specific washes using a dot 
blot – like developing approach.  
First, the PIP Strips™ membrane was incubated for 1 h at room temperature using the 
appropriate blocking buffer (3% BSA in TBST), with gentle shaking. After blocking, the 
membrane was incubated overnight (15 h) at 4°C in gentle agitation with 0.5 µg/ml of 
commercially available recombinant human hexahistidine-tagged human TG2 produced in 
E.coli (His6-rhTG2) (T002, Zedira), in blocking buffer and in the presence of 2mM of calcium 
chelator EDTA, to keep TG2 in the closed conformation typical of the intracellular space 
(Pinkas, et al. 2007). After the incubation, the membrane was washed three times with blocking 
buffer (10 min wash in gentle agitation) and re-incubated as above with 0.5 µg/ml His6-rhTG2 
in blocking buffer supplemented with 2mM EDTA overnight (15 h) at 4°C in gentle shaking. 
Washing was performed again as above and then phospholipid bound TG2 was developped by 
incubating the membrane with 1:1000 (v/v) dilution of mouse monoclonal anti-His6-antibody 
conjugated to peroxidase (Roche, Sigma) in blocking buffer at 4°C for 15 h. After incubation, 
the membrane was washed three times with TBST (10 min per wash in gentle agitation) and 
chemiluminescent spots detected by enhanced chemiluminescence (EZ-Chemiluminescence 
Detection Kit for HRP, Geneflow). Image acquisition was performed with a LAS4000 imaging 
system (GE Heathcare).  
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5.3.9 Detection of phosphorylation in TG2 and TG2-immunoprecipitated 
proteins 
To determine if TG2 or TG2-associated proteins could be phosphorylated in normal conditions 
and upon pro-fibrotic stress, immunoprecipitation(IP) of TG2 was performed in cells subjected 
to glucose stress. EGFP-tagged TG2 was immunoprecipitated from the EGFP-TG2 
overexpresing clones as described in 2.2.5 using a rabbit polyclonal anti-GFP antibody. An 
outline of the experimental procedure is reported in Fig.5.4.  
Glucose stress to simulate a condition of diabetic nephropathy was performed in cells of NRK52 
EGFP-TG2 clone #C5. Previous work from our group has proven that glucose stress determines 
an increase in TG2 export in this cell line, in both WT and EGFP-TG2 overexpressing NRK52E 
cells (Huang et al., 2016, in preparation). 2∙106 cells were seeded in a T75 culture flask in 
complete DMEM medium but containing only 5.5 mM D-glucose (low glucose, physiological 
condition) and 2% (v/v) heat-inactivated FBS.  After 24 h, the medium was replaced with the 
same medium containing either 5.5 mM (low glucose, physiological condition) or 30 mM (high 
glucose – “diabetic” condition) D-glucose, and grown for further 48 h. Cell lysates were 
produced in 500 µl of IP Lysis/Wash buffer (Thermo Scientific) as described in the general 
methods (2.2.5). In addition to 1% (v/v) protease inhibitors cocktail (P8340 Sigma), 1%(v/v) 
phosphatase inhibitors [phosphatase inhibitor cocktail 2 (P5726 Sigma) and phosphatase 
inhibitor cocktail 3 (P0044 Sigma)] were also added to the lysate to inhibit dephosphorylation.  
EGFP-immunoprecipitation was performed in equal amounts of proteins (750 µg) with 2.5 µg 
of rabbit polyclonal anti-GFP antibody (Ab 290, Abcam), using the Pierce™ Crosslink Magnetic 
IP/Co-IP Kit (Thermo Scientific), and following the protocol for IP reported in general methods 
(2.2.5). As a negative control, the same procedure was performed in the absence of antibody 
(referred to as “beads” only control). Proteins were eluted in 75 µl of acidiic elution buffer and 
neutralised with 7.5 µl of neutralization buffer, both from the kit.  
To investigate protein phosphorylation a Western blot analysis was performed, using a range 
of antibodies detecting phosphotyrosine or phospho-serine/threonine at specific sites, 
reported in Table 5.6.  In each blot, equal volumes of GFP-precipitates and “beads only”-
precipitates were analysed for both treatments (41 µl elution product and 14 µl of 4X Laemmli 
buffer, deriving from 375 µg of cell lysate). As a positive control, equal amounts (37.5 µg) of 
total cell lysates were loaded.  
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Figure 5.4: Outline of the procedure employed to investigate phosphorylation of TG2 / TG2-
associated proteins, in GFP-immunoprecipitates from EGFP-TG2 overexpressing clones 
subjected to glucose stress.  
 
 
Table 5.6: Antibodies employed to investigate phosphorylation of TG2 / TG2-associated proteins. 
The table shows the primary and secondary antibodies employed for Western blot immunodetection of 
tyrosine or serine/threonine phosphorylation, as well as the anti-GFP antibody employed to confirm the 
immunoprecipitation itself. Antibodies dilutions used in blocking buffer [5% (w/v) non-fat milk in TBST 
pH 7.4] are also shown. 
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5.3.10 SiRNA knock down of clathrin 
Clathrin knock down was performed in both NRK52E WT and EGFP-TG2 overexpressing 
NRK52E (clone #C5) TECs, by transient transfection of rat clathrin-targeting siRNA, following 
the protocol for siRNA transfection reported in Chapter II (2.2.10.2).  
For this specific experiment, 2∙105 cells/well were cultured in a 6-well plate in antibiotic-free 
DMEM (Lonza, Switzerland) supplemented with 5% (v/v) heat-inactivated FBS (Gibco) and 
2mM L-glutamine (Sigma) for 24 h. The day after, cells were transfected with either 100 nM 
rat clathrin-targeting siRNA [ON-TARGETplus Rat Cltc (54241) siRNA – SMARTpool (L-
090659-02-0005) from Dharmacon, Thermo Scientific)] or non-targeting scrambled control 
siRNA [ON-TARGETplus Non-targeting siRNA #1 (D-001810-01-05) from Dharmacon], using 
DharmaFECT 1 (Dharmacon) as transfection reagent. After transfection, cells were grown for 
additional 24 hours.  
The knock down at a protein level was measured by western blot using antibodies against 
clathrin [Rb monoclonal anti-clathrin heavy chain (D3C6) XP®, 4796, Cell Signalling – dilution 
1:500), TG2 (Rb polyclonal anti-TG2, Ab421, Abcam – dilution 1:500) and β-tubulin (Rb 
Polyclonal anti-β-tubulin, Ab6046, Abcam– dilution 1:5000) as a loading control.  
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5.4 RESULTS  
 
5.4.1 Membrane fusion events appear to be necessary for TG2 export from 
TECs 
As described in Chapter IV, several proteins involved in intracellular vesicular trafficking have 
been found as significantly associated with TG2 in kidney membranes by SWATH™-MS in both 
healthy and fibrotic kidneys. Among these proteins, NSF-ATPase, that is required for 
intracellular SNARE-mediated membrane fusion events, including exocytosis, was itself 
specifically identified as TG2-associated in kidney membranes. NEM a specific inhibitor of NSF 
ATPase (Zhao, Slevin and Whiteheart 2007), had already been suggested to significantly 
interfere with TG2 secretion by Zemskov and colleagues in 2011 (Zemskov, et al. 2011). 
Knowing this, it was interesting to assess the effect of NSF ATPase inhibition by NEM on TG2 
export by kidney TECs.  
To achieve this purpose, NRK52E WT or EGFP-TG2 overexpressing NRK52E cells were 
employed. EGFP-TG2 overexpressing NRK52E clones had already been fully characterized in 
Dr Verderio laboratory (NTU) (Huang et al., 2016 manuscript in preparation), but the 
validation of the clones employed in this thesis, which are clone #C5, in this chapter, and both 
#C5 and #E6, in the next one, was repeated to confirm that the overexpression of EGF-TG2 
chimera was maintained and was resulting in an higher extracellular TG2 expression compared 
to the wild type TECs (Suppl. Fig. 5.1).  
NRK52E WT or EGFP-TG2 overexpressing NRK52E cells (clone #C5) were treated with 0.6 mM 
NEM for 30 min as described 5.3.2. Membrane integrity, measured by LDH cytotoxicity assay 
assay, was not significantly affected by NEM at this concentration and incubation time, in both 
cell lines (Fig. 5.5A, black arrow). Optimisation of the LDH assay for the cell lines employed 
was performed prior to the cytotoxicity assay as described in 2.2.1.7, and the optimal number 
of cells to employ was chosen depending on the results as described in Suppl. Fig. 5.2.  
Subsequently, the effect of NEM treatment on TG2 export was assessed by biotin-cadaverine 
incorporation assay in FN, performed on living cells as described in 2.2.9.1 (Fig. 5.4B), for 2, 4 
or 6 h. The optimal number of cells to employ (20,000) was chosen based on previous literature 
(Jones, et al. 1997) and confirmed on this line of TECs by preliminary test on a serial dilution 
of cells (Suppl. Fig. 5.2).  
Results showed a progressive increase in biotinylated cadaverine incorporation (product of 
extracellular TG activity) with time (Fig. 5.5B). At each time point, pre-incubation with NEM 
resulted in a significant reduction of TG2 outside the cells in NRK52E WT TECs. Similarly, also 
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EGFP-TG2 overexpressing clones were characterised by a reduction of TG2 export upon 
treatment with NEM, which was significant at 2 and 4 h culture (Fig. 5.5B).   
To support these observation, after NEM treatment, immunofluorescent staining of 
extracellular TG2 or EGFP-TG2 was performed in not permeabilised cells following the 
protocol reported in chapter II (2.2.8). NRK52E WT cells showed a punctate pattern of 
extracelluar TG2 antigen (red) staining that was significantly reduced upon NEM treatment 
(~50% of the control, p<0.05, *) (Fig. 5.5C). Similarly, also the EGFP-TG2 overexpressing cells 
displayed a level of extracellular EGFP-TG2 (red), which was significantly (p<0.05, *) reduced 
after NEM treatment; however, this inhibition was not as strong as the one seen in WT cells, 
being extracellular TG2 expression only approximately 10% lower thenthe untreated cells 
(Fig. 5.5C). 
 
In summary, from these experiments, TG2 release appeared to be partially dependent on NSF-
ATPase function, being significantly reduced by the employment of NEM. The effect appeared 
to be clearer on WT cells compared with the EGFP-TG2 overexpressing clone. Results suggest 
that vesicle fusion events requiring NSF-ATPase are at least in part involved in TG2 
unconventional export from TECs, in agreement with previous findings on other cell models 
(Zemskov, et al. 2011).  
This finding, together with the identification of several exosomal markers within the list of 
TG2-associated proteins in kidney membranes (shown in Chapter IV), raised the hypothesis of 
TG2 being secreted by the cells as an exosome cargo, by fusion of MVB outer membrane to the 
plasma membrane. To test this hypothesis, in the next section, TG2 presence in EV fractions 
was investigated.  
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Figure 5.5: N-ethylmaleimide (NEM) treatment leads to a reduction in extracellular TG2 in kidney 
TECs. (A) WT or EGFP-TG2 overexpressing NRK52E TECs were incubated with different concentrations 
(0 to 1 µM) of N-ethylmaleimide (NEM) for 30 min. After incubation, cell viability was measured by LDH 
assay as described in 2.2.1.7. Data are presented as spontaneous LDH Release (Abs  490 nm – Abs 
680nm) at each concentration for each cell line ± SD. Total LDH release of untreated cells (Abs  490 nm 
– Abs 680 nm, after cell lysis) ± SD, is also shown in the picture. (B) WT or EGFP-TG2 overexpressing 
NRK52E TECs were pre-treated with 0.6 mM NEM for 30 min. 20,000 cells/well were seeded in a 96-
well plate in quadruplicates and extracellular TG2 was detected as described in 2.2.9.2, for 2, 4 and 6 h. 
Non-treated cells were used as a control. The values are the average Abs (450 nm) of three independent 
experiments, each undertaken in quadruplicates, normalised for the relative control (equalised to 1) ± 
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SD, N=3. (C, D) NRK52E WT TECs (C) and EGFP-TG2 overexpressing NRK52E TECs (D) were incubated 
with 0.6 µM (NEM) for 30 min. Immunofluorescent staining of estracellular TG2 or EGFP-TG2 was 
performed as described in 2.2.8: extracellular TG2 (C) was detected on fixed (3%PFA) but not 
permeabilised NRK52E WT cells using a by mouse monoclonal anti-TG2 antibody (IA12) followed by a 
secondary goat anti-mouse antibody Alexa Fluor® 598, with red emission. Extracellular EGFP-TG2 
chimera (D) was detected on fixed (3%PFA) but not permeabilised cells using a Rb polyclonal anti-GFP 
antibody (Abcam) followed by a donkey anti-rabbit Alexa Fluor® 568 antibody, with red fluorescence 
(D). Nuclei were stained with DAPI. Representative pictures at 200X magnification are here shown. 
Extracellular TG2 (C) was quantified by ImageJ intensity analysis on at least 8 non-overlapping fields 
per treatment and presented as mean relative intensity of red over blue (nuclei), expressed relative to 
the control cells without NEM (equalised to 1) ± SEM.  Extracellular EGFP-TG2 (D) was quantified by 
ImageJ intensity analysis on at least 8 non-overlapping fields per treatment and presented as mean 
relative intensity of red over green (total EGFP-TG2), expressed relative to the control cells without NEM 
(equalised to 1) ± SEM. Significance of the differences between treatments was determined by T-test: * 
= p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
 
 
5.4.2 The hypothesis of a TG2 vesicular export from TECs 
5.4.2.1 Extracellular vesicles isolation from TECs 
To investigate the possibility of TG2 being exported from kidney cells through EVs release, 
exosomes and ectosomes were isolated from TECs allowed to grow in serum-free medium for 
36 h, following the protocol described in 5.3.3. qNANO™ analysis of particle sizes was 
performed on the different fractions as described in 5.3.4 and confirmed both the presence of 
EV subpopulation in the conditioned medium of this line of TECs and a correct separation of 
vesicles subpopulations with this method of isolation (Fig. 5.6A). Ectosomes were recovered 
in the P3 fraction with a mean size of 205±99.3 nm at a concentation of 2.97 x 107 prt/ml 
medium) and exosomes from the P4 fraction with a mean size of 129±50.8 nm at a 
concentration of 5.89 x 107 prt/ml medium) (Fig. 5.6A).  
To confirm the expression of the lipid rafts marker flotillin-2 in all EV fractions produced by 
this cell line, the isolated pellets were lysed as described in 5.3.3 and equal amounts of proteins 
were subjected to Western blot analysis using a monoclonal antibody against Flot2 as reported 
in 5.3.3.3 (Fig. 5.6B). The expected molecular weight for Flot2 is was ~42 kDa. Flot2 
expression was detectable in all isolated fractions, including a high expression in the cell lysate 
and a little expression in P2 fraction. A higher expression of Flot2 was detected in the exosomal 
fraction (P4) compared to the ectosomal (P3) one (Fig. 5.6B). As expected, no signal was 
detected in the vesicle-deproved medium after TCA-precipitation of proteins (S4) (Fig 5.6B).    
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Figure 5.6: A differential centrifugation approach for the isolation of extracellular vesicles 
subpopulations. (A) Analysis of microparticle size distribution in fraction P3 and P4 was performed by 
nanoparticle tracking analysis with qNano™ (Izon) of the differential centrifugation products obtained 
from the conditioned medium of EGFP-TG2 overexpressing NRK52E cells, as described in 5.3.3. 
Ectosomes were recovered in the P3 and exosomes from the P4 fraction. (B) Expression of flotillin-2 
(Flot2) was measured by Western blotting on equal amounts of the differential centrifugation products 
obtained from the conditioned medium of NRK52E cells , cultured for 36 h in serum–free conditions as 
described in 5.3.3.  
 
 
5.4.2.2 Detection of TG2 in extracellular vesicle (EVs) fractions in TECs subjected to pro-
fibrotic stimuli 
To test the presence of TG2 in EVs isolated from TECs, equal amounts of proteins from the 
ectosome (P3) and exosome fractions (P4) of EGFP-TG2 overexpressing NRK52E cells, as well 
as from the vesicles-deprived medium (S4), were investigated by Western blot, following the 
protocol reported in 5.3.3.  
The results revealed the presence of TG2 in the exosomes and ectosome fractions, as both 
EGFP-TG2 chimera at ~100 kDa (Fig. 5.7A, black arrow) and endogenous TG2 at ~80 kDa (Fig. 
5.7A, grey arrow) were detected. Flot2 was probed as well as a lipid raft marker detectable in 
both exosomal and endosomal fraction, but not in soluble extracellular form.  
Densitometric analysis of TG2, relative to Flot2, revealed a trend of enrichment of TG2 in the 
exosome fraction (P4) in the 36 h - conditioned medium compared to the ectosome (P3) (Fig 
5.7A), suggesting a location of the enzyme predominantly in these vesicles. 
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Both TG2 and exogenous EGFP-TG2 were also detectable in the P2 fraction in this cell line, 
together with Flot2 (data not shown); this might either signify that the enzyme is present in 
apoptotic bodies shedding from cells undergoing programmed death or in debris of these cells 
present in the medium.   
The same cells were also stimulated by recombinant TGF-1 (10ng/ml) to simulate conditions 
of fibrogenesis in vitro, as described in 5.3.3.1 (Fig 5.7B). Incubation with recombinant TGF-
1 did not change the level of TG2 in the total cell lysate (TL), but determined an increase in 
the exosome-associated TG2, that was expecially evident for the endogenous enzyme (Fig. 
5.6B). The cytokine did increase the expression of Flot2 in the TL but it did not alter Flot2 
expression in the EV subpopulations, suggesting that it did not increase the exosome 
production in our conditions (Fig 5.7B). The vesicle-deprived medium was also collected and 
proteins recovered by TCA precipitation. The results show that a small amount of TG2 (mainly 
endogenous) is also present free in the culture medium but was not increased by TGF1 
(Fig.5.7B). 
The same experiment was performed also on WT NRK52E cells rather than in the clonal cell 
line to rule out artefacts determined by the exogenous protein chimera (Fig. 5.7C). Equal 
amounts of each extracted fraction as well as the vesicles-free medium proteins, was 
immunoprobed using antibodies against TG2 and Flot2 (Fig. 5.7C). Similarly to what observed 
in the EGFP-TG2 clone, TG2 was detectable in both exosomes (P4) and ectosomes (P3), with a 
prevalence in the exosomes (P4) (Fig.5.7C, grey arrow). Again, treatment with TGF-1 clearly 
increased TG2 relative to Flot2 expression in the exosomal fraction and reduced TG2 in the cell 
lysate, without altering the level of Flot2 (Fig. 5.7C). A little amount of protein was also 
detected in the vesicle deprived medium (S4). Interestingly, a second band at higher molecular 
weight (~180 kDa) was also identified in the vesicle-deprived medium in this condition (Fig. 
5.7C, asterisk), suggesting that free TG2 is unstable and either self-polymerises or becomes 
incorporated in circulating proteins. Alternatively, it might also be a product of TG2 
complexing with some high molecular weight proteins in the matrix, such as perlecan or FN. 
TG2 expression in the medium was extremely variable (Fig. 5.7A-C) and we attribute this 
inconsistency to the experimental variability or to occasional cell leakage. This fraction was 
not increased by TGF-1 (Fig. 5.7A-C).  
Subsequently, to determine whether the location of TG2 was specific for the TEC cell lines, 
exosomes and ectosomes were also isolated from an established cell line of renal fibroblasts 
(NRK49F). Equal amounts of cells and EV fractions were probed for TG2, and also in this 
specific cell line TG2 was enriched in both endosomal (P3) and exosomal (P4) subpopulations, 
with a prevalence in the exosomal one (Fig.5.7D, grey arrow). TGF-1 lowered TG2 in the total 
cell lysate and increased it in the exosomal and ectosomal fraction. Interestingly, Flot2 
appeared to be highly expressed in the ectosomal (P3) fraction in this cell line (Fig.5.7D).   
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Finally, to check the effect of a different pro-fibrotic stress on TG2 location in the EV 
subpopulations, EGFP-TG2 overexpressing NRK52E cells were subjected to a glycaemic stress 
(30 mM glucose/36 h) to simulate conditions of diabetic nephropathy in vitro (Fig.5.7E). Equal 
amounts of proteins from the cellular, the ectosomal (P3) and the exosomal fractions (P4), as 
well as from the vesicles-free medium after TCA protein precipitation (S4), were probed for 
the EGFP-tag of EGFP-TG2, TG2 and Flot2, as described above. EGFP-TG2 chimera (Fig. 5.7E, 
black arrow) and endogenous TG2 (Fig. 5.7E, gray arrow) were identified in the ectosome (P3) 
and ectosome (P4) fractions, with a prevalence in the exosomal one in the 36 h - conditioned 
medium. In this case, however, the glucose stress didn’t lead to an increase in the exosome-
associated TG2 (Fig.5.7E). On the other side, an increase in soluble EGFP-TG2 was noticed in 
the vesicle-deprived medium (S4) as well as a small rise in the amount of endogenous TG2 
(Fig.5.7E), suggesting an alternative release of the protein. 
In conclusion, TG2 was suggested to be present in extracellular vesicles and to be mainly 
located in exosomal vesicles (P4) comparing to the shedded microvesicles in both TECs and 
kidney fibroblasts from rat. TGF-1 treatment lowered TG2 in the total cell lysate and 
increased it in the exosomal fraction in all cell lines analysed. However, when a glucose stress 
was employed instead of TGF-1, a similar effect could not be observed, suggesting that glucose 
is not a stimulus for TG2 loading in the vesicles.  
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Figure 5.7: TG2 in extracellular vesicles (EV) fractions. Cells of NRK52E EGFP-TG2 stable clone #C5 
(A, B), NRK52E cells (C) and NRK49F cells were grown in serum-free medium for 36 h without (A) and 
with supplementation of 10 ng/ml TGF-β1 (B-D). Alternatively, to simulate a glycaemic stress on the 
cells, NRK52E EGFP-TG2 overexpressing cells were also cultured in DMEM containing 5 mM glucose 
(Low glucose) for 48 h, then medium was replaced with serum-free medium containing either 5 mM (-) 
or 30 mM (+) glucose and grown for additional 36 h (D).  After incubation, culture medium was collected 
and vesicular fraction separated by serial centrifugation as described in 5.3.3. Proteins from vesicles-
deprived medium were concentrated by TCA precipitation (S4). Equal amounts of cell lysate (total 
lysate, TL), EV fraction lysates and vesicle-deprived medium (15 to 25 µg depending on the experiment) 
were separated by 12%SDS PAGE and immunoprobed for TG2 and flotillin-2 (Flot2) using the specific 
antibodies reported in Table 5.4. NRK52E EGFP-TG2 cells fractions (A,B,D) were also probed for the 
EGFP tag of EGFP-TG2 exogenous chimera using a Rb anti-GFP antibody (Abcam). All fractions were 
immunoprobed for TG2 and Flot2. NRK52E EGFP-TG2 cells fractions (A,B,D) were also probed for the 
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EGFP tag of TG2. (A-C) Intensity of immunoreactive bands was quantified by densitometric analysis and 
normalised to Flot2 expression. Densitometric data represent mean values of 3 (A) or 2 (B, C) 
independent experiments expressed relative to the untreated cells (equalised to 1) ± SD. Significance of 
the differences between treatments/fractions was determined by T-test: * = p<0.05, ** = p<0.01, *** = 
p<0.001, **** = p<0.0001. 
 
 
To gain insights on the location of TG2 within EV, we devised an experiment aimed at 
measuring the catalytic activity of TG2 of whole EV and lysed EV.  
To determine TG2 activity in EV-subpopulations isolated by differential centrifugation, an in-
house TG activity assay was performed on equal volumes of the different fractions (20 µl) 
obtained from EGFP-TG2 overexpressing NRK52E cells, as described in 5.3.7. In this case, the 
fractions obtained where either lysed in a mild sucrose-based lysis buffer or kept intact by re-
suspending them in fresh sterile serum-free medium.  From the assay, it was evident that, even 
if the higher amount of TG activity was localised in the cells or on the cell surface (Fig.5.8A, 
cells), a small level of transamidating activity was also measurable in the conditioned medium 
EV subpopulations in both lysed (Fig.5.8A, inset) and intact conditions (Fig.5.8B, inset). In 
both cases, in the conditioned medium obtained (P3+P4+S4), most of the TG2 activity was 
localised in the exosomal fraction (P4), while less could be observed in the ectosomes (P3) and 
very little activity was detectable free in the medium (Fig. 5.8A,B). Interestingly, in the case of 
intact vesicles, the exosomal fraction was the only one that was showing a level of activity 
higher than the background activity of clean non-conditioned serum free medium in which the 
vesicles were re-suspended for the analysis (5.3% of the cell activity, 0.053, red dashed line in 
the inset of Fig.5.8B), while in the ectosomal fraction (P3) and the vesicle deprived condition 
medium (S4) where showing a TG2 activity lower than the threshold (Fig. 5.8B, inset).  
Treatment TGF-1 didn’t affect the total TG2 activity in lysed cells, and even a small, non-
significant decrease was observed in the total TG2 activity of treated EV fractions when these 
were lysed (Fig. 5.8A). On the contrary, when the transamidating activity of intact fractions 
was analysed, TGF-1 appeared to significantly enhance (p≈0.05) the activity of TG2 on the cell 
surface of the intact cells (Fig. 5.8B). The activity of TG2 was not significantly altered in intact 
ectosomes (P3) and vesicle-free medium (S4), while an increase in the enzyme activity, even if 
not statistically significant, could be measured in the exosomal fraction (Fig. 5.8B).  
In order to better understand whether TG2 was more likely to be located inside or outside the 
extracellular vesicles of TECs, a more sensitive commercially available TG activity assay (tissue 
transglutaminase pico-assay kit from Zedira) was performed analysing simultaneously the 
activity of TG2 from lysed (in sucrose based lysis buffer) and intact (re-suspended in 50 mM 
Tris-HCl pH 7.4) EV-fractions, obtained from the same flask of 36 h - cultured EGFP-TG2 
overexpressing TECs (Fig. 5.8C) as reported in 5.3.7.1. The experiment showed how the 
activity of TG2 is likely to be located mostly on the surface of these vesicles, rather than in their 
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inside, as the activity of intact vesicles (P3, P4) was not significantly different, and even a bit 
higher, than the lysed ones (Fig. 5.8C). Again, the activity was higher in the exosome 
compartment, followed by the ectosome, while no activity was detected in the medium by this 
assay (lower than the background) (Fig. 5.8C). Interestingly, when the cells were observed, 
most of the activity was again likely to locate on the cell surface of the cells, since the activity 
of lysed cells was only the 3% higher than the intact ones (Fig. 5.8C). This is in line with 
previous observations that TG2 is mostly in its closed catalytically inactive conformation in the 
intracellular environment in physiological conditions and it is typically activated after release 
(Pinkas, et al. 2007).  
 
 
 
 
Figure 5.8: TG2 activity on intact or lysed extracellular vesicles subpopulations. (A) EGFP-TG2 
overexpressing NRK52E cells (clone #C5) were grown in serum-free medium ± 10 ng/ml TGF-β1 for 36 
h. Vesicular fractions were separated by serial centrifugation from culture medium and the different 
fractions were either lysed in a mild lysis buffer (Lysed, A) or re-suspended in serum-free sterile DMEM 
medium (Intact, B) depending on the expriment. Transamidating activity was measured on these 
extracts by In-house TG2 activity assay as described in 2.2.9.1. Data represent mean absorbance values 
(Abs 450 nm) expressed relative to the untreated cells (equalised to 1) ± SD. (G) NRK52E EGFP-TG2 
clone #C5 cells were grown in serum-free medium for 36 h. Conditioned medium was collected and 
dived into two identical replicas of the same volume, one necessary to produce lysed EV fractions and 
one necessary for intact fractions. Vesicular fractions were separated by serial centrifugation as 
decribed in 5.3.2.2 and cells and EVs were either lysed in a mild lysis buffer (Lysed) or re-suspended in 
50 mM Tris-HCl pH 7.4 (Intact, F). The transamidating activity was measured by Tissue 
Transglutaminase Pico-Assay (Zedira) as described in 5.3.7.1. Data represent mean TG2 activity values 
in µU/well expressed relative to the activity of lysed cells (equalised to 1). Significance of the differences 
between treatments and fractions was determined by T-test: * = p<0.05, ** = p<0.01, *** = p<0.001, **** 
= p<0.0001. 
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5.4.2.3 Effect of specific nSMase inhibitor GW4869  
In several mammalian cell types, the biogenesis of exosomes depends on neutral 
sphingomyelinase activity for the production of ceramide of which exosomes are rich 
(Trajkovic, et al. 2008). We therefore investigated whether GW4869, which blocks neutral 
SMase (nSMase), affected exosome release of TG2.  
EGFP-TG2 overexpressing NRK52E cells were incubated with 10µM GW4869 in serum free 
medium for 16 h as reported in 5.3.5.  After incubation, extracellular vesicles were isolated by 
differential centrifugation and equal volumes (40 µl) of lysates were analysed for TG2/EGFP-
TG2 expression and Flot2 expression by Western blot as described in 5.3.3.3. As a control, total 
cell lysed (50 µg) form treated and untreated cells were also analysed (Fig. 5.9A-B).   
Upon 16 h treatment with 10µM GW4869 the expression of flotillin-2 was decreased in the 
exosomal fraction (P4), consistent with a reduction of total exosome release, and this was 
accompanied by a marked reduction of TG2 in the same fraction (Fig 5.9A). GW4869 produced 
no change in ectosome production (P3) and no difference in the ectosome release of TG2 was 
observed, which remained lower than the exosomal one (Fig 5.9A). A small reduction upon 
treatment was observed in the cell lysate (TL). When the total amount of proteins was 
quantified by BCA assay, the treatment with 10µM GW4869 didn’t significantly change protein 
concentration in the cell lysate, while, in the ectosomes, the total amount of proteins appeared 
even increased. The exosomal proteins were just minimally reduced in this conditions, 
suggesting that not all the exosome production is based on the ceramide -dependent pathway.  
In order to visually observe the location of extracellular EGFP-TG2, immunofluorescence 
staining of EGFP was performed on non-permeabilised cells as described in 5.3.6, on cells 
treated with 10 ng/ml of recombinant TGF-β1 and/or 10µM GW4869 (Fig. 5.9C). Total EGFP-
TG2 (intracellular + extracellular) has spontaneous green fluorescence and is shown in green 
in the pictures, while extracellular EGFP, detected by immunoprobing using a red fluorocrome 
-conjugated secondary antibody, is show in red in the pictures.  
Minimum washing of the monolayer before fixation to prevent exosome loss revealed an 
intense punctate pattern at the apical and basal sides of the cells (red) accompanied by bigger 
spots of EGFP-TG2 signal (Fig. 5.9C), mainly located on the apical and lateral sides of the cells.  
Suppl. Fig 5.4A shows the specific location of the signal on the cells. Specificity of the red signal 
for EGFP-TG2 was confirmed by providing a negative control via incubation of the non-
permeabilised cell monolayer with only the secondary red fluorocrome conjugated antibody, 
in absence of the anti-GFP primary antibody. As expected, no red signal was observed in this 
condition (Suppl. Fig 5.4B). 
Treatment of cells with TGF-β1 significantly increased the vesicular export of the EGFP-TG2 
(1.56-fold higher than the untreated control, p=0.01,**), that appeared as localised in several  
“puncta” around the cells (Fig. 5.9C). Treatment with GW4869 markedly inhibited TG2 export 
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in a significant manner (65.8% of the untreated control, p=0.04, *), and clearly interfered with 
TGF-β1 – stimulated TG2 export, bringing exported TG2 down to the basal level (42.3% of the 
TGF-β1 treated control, 0.0002, ***) (Fig. 5.9C).  
In synthesis, these data suggests that the employment of GW4869 at 10µM concentration 
significantly interferes with the extracellular trafficking of the EGFP-TG2 from transfected 
NRK52E cells and that, given the proprieties of the inhibitor itself and the characteristics of 
TG2 expression in EV fractions, the inhibition is likely to happen by interfering with TG2 
loading on the exosome (P4) fraction during biogenesis.   
 
Figure 5.9. Inhibitor of exosome biogenesis GW4869 affects TG2 presence in EVs: (A,B) EGFP-TG2 
overexpressing NRK52E cells (clone #C5) were grown in complete medium until 80% confluent, the 
cells were washed with PBS and medium replaced with serum-free medium ± 10 µM GW4869 for 16 h. 
After incubation, conditioned medium was collected and vesicular fraction separated by differential 
centrifugation as described in 5.3.3. (A) All fractions were immunoprobed for EGFP and Flot2 using the 
antibodies reported in Table 5.4. A representative blot is shown. Densitometric analysis of band 
intensity/area is shown at the bottom of the graph. (B) Total protein quantification was performed on 
cell lysate and vesicular fractions  by BCA assay, as described in the general methods, and reported as 
protein concentration in mg/ml ±SD  (C) EGFP-TG2 overexpressing NRK52E cells were grown in an 8 
well chamber slide until 80% confluent, then medium was replaced with complete medium ± 10 ng/ml 
TGF-β1 ± 10 µM GW4869 for 16 h. Extracellular EGFP-TG2 chimera was detected on fixed (3%PFA) but 
not permeabilised cells as described in 2.2.8 using a rabbit polyclonal anti-GFP antibody (Abcam) 
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followed by a donkey anti rabbit Alexa Fluor® 568 antibody, with red fluorescence. Nuclei were stained 
with DAPI. Representative pictures at 200X magnification are here shown. Extracellular EGFP-TG2 was 
quantified by ImageJ intensity analysis on at least 8 non-overlapping fields per treatment and presented 
as mean relative intensity of red over green (total EGFP-TG2) ± SEM, expressed relative to the control 
cells without TGF-β1 (equalised to 1). Significance of the differences between treatments was 
determined by T-test: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
 
 
5.4.2.4 Effect of two possible inhibitors of ectosome formation 
As described before, acid sphingomyelinase (aSMase) has been involved in microvesicle 
shedding from plasma membrane(Bianco, et al. 2009), the possibility that TG2 is partly 
released by ceramide-mediated microvesicle shedding was investigated using the aSMase 
inhibitor imipramine hydrochloride. Another inhibitor employed to interfere with ectosomes 
secretion was the inhibitor of Na+/H+ exchanges amiloride hydrochloride. Amiloride is a 
known inhibitor of calcium influx dependent micropinocytosis and some types of regulated 
exocytosis. To investigate a possible inhibitory effect of these inhibitors on TG2 secretion by 
microvesicular fraction, EGFP-TG2 overexpressing cells were incubated with either 30 µM 
imipramine for 30 min or 1 mM amiloride for 10 min, as reported in 5.3.5.  
First, extracellular TG2 activity of cells incubated with these two inhibitors was measured by 
biotin cadaverine incorporation assay performed on living cells, and results were compared 
with the extracellular TG2 activity of untreated cells (Fig.5.10A). Incubation with both 
imipramine and amiloride lead to a significant reduction of extracellular TG2 activity 
comparing to the control (~ 80% of the control, p = 0.0002, *** and  ~86% of the control, p = 
0.003 **, respectively) (Fig. 5.10A). Interestingly, when the effect of GW4869 on extracellular 
TG2 activity was tested with the same approach, no difference was observed between 
treatment and control (Fig. 5.10A). This is probably due to the short incubation time with 
biotinylated cadaverine after GW4869 incubation, that might not be long enough to observe 
the exosomes contribution to the extracellular space, as they take longer to be secreted after 
cells attach (Cocucci and Meldolesi 2015). 
Given the ability of both imipramine and amiloride to partially reduce the level of extracellular 
TG2, analysis of EV fractions was performed after treatment with both inhibitors (Fig.5.10B-
C). First, cells were treated with 30 µM imipramine for 30 min; identically to what done with 
GW4869 inhibitor and described in 5.4.2.3, equal volumes of treated/untreated EV fractions 
(40 µl) were analysed by Western blot, together with equal amounts of cell lysates as a control 
(20 µg) (Fig.5.10B). At this short time, ectosomes formed in a greater proportion than 
exosomes, as previously shown(Cocucci and Meldolesi 2015). Treatment with 30 µM 
imipramine for 30 min didn’t appear to alter the level of Flot2 in any fraction (Fig. 5.10B). The 
expression of EGFP-TG2, that was particularly high in the ectosomal fraction (P3, - ) of control 
cells after 30 min compared to the exosomal one (P4, - ), was strongly reduced by treatment 
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with imipramine (P3, +) (Fig.5.10B, black arrow). This might suggest an effect of the inhibitor 
on the enzyme loading in MVs by regulating the formation of ceramide. Interestingly, however, 
employment of the inhibitor also resulted in a lower amount of EGFP-TG2 in the cell lysate 
(Fig.5.10B). No real explanation for this can be given for the moment and might reflect the 
effect of imipramine in the endocytosis of the protein by macropinocytosis (Serrano, et al. 
2012, Miller, et al. 2012).  
 
To test the effect of amiloride treatment on EGFP-TG2 location in the different EV fractions, 
EGFP-TG2 overexpressing cells were incubated with 1 mM amiloride for a short time (10 min), 
as suggested by previously published protocols reported in 5.3.5. After incubation, 
extracellular vesicles were isolated from the conditioned medium, and the expression of EGFP-
TG2 and Flot2 was analysed by western blot on equal volumes of EV fractions as above (Fig. 
5.9C). At only 10 min after medium change, ectosomes subpopulation is usually more 
abundant than exosomes (Cocucci and Meldolesi 2015): in agreement with this, in normal 
conditions, Flot2 was more expressed in the ectosomal (P3, - ) fraction compared to the 
exosomal fraction (P4, - ), where was minimal. In line with flotillin expression, also EGFP-TG2 
expression was enriched in the ectosomes of untreated cells (P3, - ) compared to the exosomes 
(P4, -) (Fig. 5.10C, black arrow). Amiloride incubation led to a small decrease in Flot2 in the 
ectosomes (P3, +) consistent with its proposed role as an inhibitor of microvesicles formation 
(Stelmach, Rusak and Tomasiak 2002), and a similar decrease in EGFP-TG2 in the same fraction 
(Fig. 5.10C, black arrow).  No variation in both EGFP-TG2 and flotillin expression was observed 
under the same condition in the exosome fraction (P4, +).  An increase of EGFP-TG2 was 
observed upon treatment in the total cell lysate, possibly underlying enzyme retention inside 
the cells (Fig. 5.10C, black arrow).   
Identically to what was done with GW4869 treatment, immunofluorescent staining of 
extracellular EGFP-TG2 was performed on the cells after treatment with the two 
abovementioned inhibitors: EGFP-TG2 overexpressing TECs were treated with either with 30 
µM imipramine/30 min or 1mM amiloride/10 min while a pro-fibrotic stimulus to was 
provided by with 10 ng/ml of recombinant TGF-β1. Immunofluorescent detection of EGFP was 
performed as described in the previus section. Extracellular EGFP-TG2 signal appeared as a 
red punctate pattern around the cells, accompanied by bigger spots of TG2 signal (Fig. 5.10D-
E).  
The first set of experiments performed after treatment with TGF-β1 and/or imipramine for 30 
min (Fig. 5.10D) confirmed a significant effect of TGF-β1 stimulus on TG2 export in untreated 
cells also at this shorter incubation time, in line with what seen after 16 h treatment in Fig. 
5.9C: treatment of cells with TGF-β1 significantly increased the vesicular export of the EGFP-
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TG2 (1.47-fold higher than the untreated control, p=0.01,**), that appeared as a dense punctate 
pattern around the cells (Fig. 5.10D).  
Exposure of cells to imipramine for 30 min determined only a minimal reduction of EGFP-TG2 
export in control cells (less than 7% lower than the untreated control, not significant). In TGF-
β1 stimulated conditions, treatment with imipramine led to a decrease extracellular TG2 
export produced by TGF1 (~75% of the TGF-β1 stimulated untreated cells), however, this 
reduction was variable among the cells observed and didn’t appear significant by statistical 
analysis (p=0.085, non significant) (Fig. 5.10D).   
When cells were incubated with TGF-β1 and/or amiloride for only 10 min (Fig. 5.10E), again 
TGF-β1 stimulus determined a significant increase in EGFP-TG2 export even at this shorter 
time-point in untreated cells (1.43-fold higher than the untreated control, p=0.03, *). Amiloride 
incubation decreased extracellular EGFP-TG2 immunofluorescent labelling of approximately 
the 22% in both control and TGF-1 stimulated cells. However, the differences in the 
quantification of fluorescent signal did not appear statistically significant when analysed by T-
test (p=0.16 in the control cells and 0.12 in TGF-1 stimulated cells) (Fig. 5.10E).  
In summary, data from immunofluorescent staining of EGFP-TG2 suggest that the employment 
of imipramine and amiloride might partially interfer with the extracellular trafficking of the 
EGFP-TG2 exogenous chimera from transfected NRK52E cells. However, morphometric 
quantifications did not lead to statistically significant differences between untreated cells and 
cells treated with either imipramine or amiloride, suggesting either a low release of EGFP-TG2 
in the MV/ectosomal fraction or a not complete effect of these inhibitors in the enzyme release 
through shedding ectosomes. Western blot analysis of ectosomal (P3) fractions after treatment 
with imipramine or amiloride showed a reduction in EGFP-TG2 location in this fraction 
compared to the untreated control. However, in the first case this was accompanied by a similar 
reduction of the enzyme in all fractions including the cell lysate, and was not accompanied by 
a similar reduction in Flot2 marker expression, while in the case of amiloride a reduction of 
EGFP-TG2 expression in the ectosomes was in line with the reduction of flotillin marker 
expression, suggesting an effective reduction in MV release mediated by the inhibitor.  
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Figure 5.10: Analysis of imipramine and amiloride effects of TG2 expression in EVs. (A) EGFP-TG2 
overexpressing NRK52E cells were grown in complete medium until 80% confluent, the cells were 
washed with PBS and medium replaced with complete medium ± specific inhibitors as described in 5.3.5. 
Specifically, treatments with 30 µM imipramine hydrochloride for 30 min, 1 mM amiloride 
hydrochloride for 10 min (complete medium as control), and 5 µM GW4869 for 16 h (0.1% DMSO in 
complete medium as a control) were performed. After treatment, extracellular TG2 activity was 
measured as described in 2.2.9.2. The values are the average Abs (450 nm) of five independent 
experiments, each undertaken in quadruplicates, normalised for the relative control (equalised to 1) ± 
SD. (B,C) EGFP-TG2 overexpressing NRK52E cells were grown in complete medium until 80% confluent, 
the cells were washed with PBS and medium replaced with serum-free medium ± 30 µM Imipramine 
hydrochloride for 30 min (A) or  ± 1 mM amiloride hydrochloride for 10 min (B). After incubation, 
culture medium was collected and vesicular fraction separated by differential centrifugation as 
described in 5.3.3. All fractions were immunoprobed for EGFP and Flot2 as described in 5.3.3.3. 
Representative blots are shown. (D,E) EGFP-TG2 overexpressing NRK52E cells were grown in an 8 well 
chamber slide until 80% confluent, then medium was replaced with complete medium ± 10 ng/ml TGF-
β1 ± 30 µM imipramine hydrochloride for 30 min (D) or ± 10 ng/ml TGF-β1 ±  1mM amiloride 
hydrochloride for 10 min (E). Extracellular EGFP-TG2 chimera was detected on fixed (3%PFA) but not 
permeabilised cells as described in Fig. 5.9. Representative pictures at 200X magnification are shown. 
Extracellular EGFP-TG2 was quantified by ImageJ intensity analysis on at least 8 non-overlapping fields 
per treatment and presented as mean relative intensity of red over green (total EGFP-TG2), expressed 
relative to the control cells without TGF-β1 (equalised to 1) ± SEM. Significance of the differences 
between treatments was determined by T-test: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
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5.4.3 Interaction of recombinant TG2 with immobilised phospholipids 
The ability of recombinant human TG2 (rhTG2) to bind phosphoinositides (PIPs) was 
measured employing commercially available PIP Strips™ membranes (Molecular Probes®, 
Oregon, US) as described in 5.3.8. The recombinant enzyme was kept in a closed / catalytically 
inactive conformation by incubating it in presence of the calcium chelator EDTA (Pinkas, et al. 
2007). Human TG2 bound mono-, bis- and tris- phosphorylated phosphoinositides 
immobilised on the membrane, with variable strength (Fig. 5.11, arrowheads). TG2 interacted 
with all three phosphoinositide monophosphate species (PI3P, PI4P and PI5P) with a 
preference for phosphatidylinositol 4-phosphate (PI4P), typical of the Golgi apparatus and 
important substrate for the stimulated formation of plasma membrane PI(4,5)P2 by 
phosphatidylinositol 4-phosphate 5-kinase (PIP5K) (Chong, et al. 1994, Funakoshi, Hasegawa 
and Kanaho 2011). The binding to PI3P, typical of early and recycling endosomes and 
suggested by Belkin’s group as important for the enzme’s unconventional secretion (Zemskov, 
et al. 2011), was present, but lower than the others.  
TG2 did also bind all immobilised bis-phosphorylated phosphoinositides [PI(3,4)P2, PI(3,5)P2 
and PI(4,5)P2], with PI(3,5)P2 and PI(4,5)P2 , the latter typical of the plasma membrane, binding 
being among the highest. Interestingly, PI(3,5)P2, having the highest binding to TG2, is known 
to be mainly  present on the late endosomes/MVBs and lysosomes membranes and has been 
suggested to be upregulated in events of “lysosome exocytosis” by macrophages (Samie, et al. 
2013, Li, et al. 2013).  
A low but detectable binding capacity for phosphatidylinositol 3,4,5-trisphosphate 
[PI(3,4,5)P2] was also noticed. No binding was detected for lysophosphatidic acid (LPA), 
lysophosphatidylcholine (LPC), phosphatidylinositol (PI), phosphatidylethanolamine (PE), 
phosphatidylcholine (PC), sphingosine-1-phosphate (S1P), phosphatidic acid (PA) and 
phosphatidylserine (PS) (Fig. 5.11).  
In conclusion, TG2 showed to associate with a range of phosphoinositides typical of plasma 
membrane when immobilised on nitrocellulose. As TG2 was in its calcium-deprived condition 
it is anticipated that it can bind phosphoinositides in its closed, inactive, conformation.  
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Figure 5.11: Phospholipid binding abilities of recombinant human TG2: The ability of recombinant 
His6 tagged-TG2 (T002, Zedira, Germany) to bind membrane-immobilised phospholipids was detected 
using commercially available PIP Strips™ membranes (Molecular Probes®, Oregon, US) following the 
protocol reported in 5.3.8. 2 mM EDTA was added during the reaction to keep the enzyme in the closed 
conformation. (A) Setup of the membrane: the different phospholipids immobilised on the membrane 
strip are reported in the table. (B) Phospholipid-bound recombinant TG2 was detected by incubation 
with anti-6His antibody conjugated to HRP (Roche, Switzerland). The immunoreactive spots were 
visualised by chemiluminescence after addition of ECL reagent, N=1. Arrowheads identify the 
phospholipid binding detected after membrane development.   
 
 
5.4.4 Protein phosphorylation in TG2-immunoprecipitates from TECs 
subjected to glucose stress 
5.4.4.1 Optimisation of IP protocol 
To optimise TG2 immunoprecipitation from EGFP-TG2 transfected cells (clone #C5), cell 
lysates were employed to immunoprecipitate TG2 using the EGFP tag (5.3.9). A “beads-only” 
control was included to confirm the specificity of the binding to the antibody and washes were 
collected as well to assess the quality of the experiment. Immunoprobing of EGFP confirmed 
that EGFP-TG2 is specifically immunoprecipitated as a 100 kDa chimera by the antibody and 
not by the control beads (Fig. 5.12A). Examination of the “washes” showed an intense 
immunoreaction in the “beads only” control but not in the GFP-IP, confirming specificity (Fig. 
5.12A). The heavy chain and light chain of the IgG from the antibody were also eluted with the 
GFP-immunoprecipitation and appear in the blot as two bands, one around 50kDa (IgG heavy 
chain) and one around 25 kDa (IgG light chain) (Fig. 5.12A, asterisk) 
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5.4.4.2 Analysis of protein phosphorylation in EGFP-TG2 precipitates from cells subjected to 
glucose stress 
Putative phosphorylation sites of Homo sapiens TG2 protein sequence (EC:2.3.2.13) were 
analysed using NetPhos online tool (http://www.cbs.dtu.dk/services/NetPhos) (Fig. 5.12B). 
A series of possible serine, threonine and tyrosine phosphorylation sites were identified, at 
variable levels of phosphorylation potential. Among the residues at higher phosphorylation 
potential, several serine (S) were identified (68, 216, 253, 430, 449, etc.) as well as few 
threonine (T) residues (position 73, 442 etc). Some possible tyrosine (Y) phosphorylation sites 
were also detected, with Y-369, Y-583 and Y-503 having a score higher than 0.8, but in general 
threonine and tyrosine phosphorylation sites were less in number comparing to serine (Fig. 
5.12B). TG2 documented phosphorylation sites were also searched using Phosphosite 
database (http://www.phosphosite.org) (Fig. 5.12B). A number of reported phosphorylation 
sites were obtained for the human TG2 protein using this database, of which the majority have 
been assigned to TG2 uniquely by a discovery mass spectrometric approach but have never 
been confirmed biochemically using site-specific methods. The only sites reported for TG2 in 
literature as a consequence of site-specific types of studies are Ser212, Ser215 and Ser216, 
largely investigated by Mishra’s group (Mishra and Murphy 2006).   
To study possible phosphorylation of TG2 and TG2-associated proteins under pro-fibrotic 
conditions, NRK52E EGFP-TG2 overexpressing clones were cultured at high glucose 
concentration (30mM) to simulate a diabetic status as described in 5.3.9. Previous data by the 
lab group had shown how increasing the level of glucose induced an increase in cell surface 
TG2 antigen and activity from these clones, suggesting a stress-related externalisation of the 
enzyme (Huang et al. 2016, in preparation). TG2 was immunoprecipitated from these cells by 
using the EGFP-tag, and the obtained elution was tested for phosphorylation at different 
residues/domains (Fig 5.13) as described in 5.3.9, using the antibodies reported in Table 5.6. 
Tyrosine phosphorylation (P-Y) was investigated for the precipitated EGFP-TG2, and a 
compatible signal for EGFP-TG2 chimera phosphorylation was detected at 100kDa (Fig. 5.13A, 
red circle), suggesting that TG2 could be phosphorylated by tyrosine kinases both in 
physiological and in pathological conditions.  
Serine and threonine phosphorylation (P-S; P-T) (Fig. 5.13B-G) was analysed using antibodies 
detecting specific phosphorylation on distinctive consensus sequences for a range of 
serine/threonine (S/T) kinases. Names and consensus sequence of each S/T-kinase are 
reported in Table 5.7.  
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Table 5.7: Serine-threonine kinases investigated in this study 
Kinase Main roles in the cells 
Consensus 
sequence 
Reference 
5' AMP-activated 
protein kinase 
AMPK 
Regulation of metabolism and 
cellular energy production 
(L/M)XRXX(S/T)XXXL (Hill, et al. 2016) 
Protein kinase B Akt 
Apoptosis, Cell 
migration/proliferation, Insulin 
signalling pathway, 
Angiogenesis 
RXRXX(S/T) (Alessi, et al. 1996) 
Protein Kinase A or 
cAMP-dependent 
protein kinase 
PKA 
Metabolism, Vasodilatation, 
Stimulation of transmembrane 
transport in kidney. Associates 
to some hormone receptors 
RRX(S/T) 
(Pearson and Kemp 
1991) 
Ataxia-telangiectasia 
mutated kinase / 
ATM- and RAD3-
related kinase 
ATM/ATR 
Regulation of cell cycle I 
response to DNA damage 
(S/T)QG (Kastan and Lim 2000) 
Protein kinase C PKC 
Cell signalling: cell adhesion, 
cell migration, cell contraction, 
secretion 
(R/K)(R/K)XSX(R/K) 
(Nishikawa, et al. 1997, 
Pearson and Kemp 1991) 
Cyclin-dependent 
kinase 
CDK Cell cycle regulation (K/R)SPX(K/R) 
(Holmes and Solomon 
1996) 
 
 
Possible S/T phosphorylation of TG2 by protein kinase A (PKA) and cyclin-dependent kinase 
(CDK) were identified, with CDK having a more intense signal. PKA -mediated phosphorylation 
was identified only upon glucose stress (Fig. 5.13D, red circle) while CDK-mediated 
phosphorylation was identified in both conditions, but increased upon glucose stress (Fig. 
5.13G, red circle). Interestingly, cyclin-G-associated kinase was identified as significantly 
associated with TG2 in UUO kidney membranes in the current study, as reported in Chapter IV.  
5' AMP-activated protein kinase (AMPK), protein kinase B (Akt), ataxia-telangiectasia mutated 
kinase / ATM- and RAD3-related kinase (ATM/ATR) and protein kinase C (PKC) did not appear 
to phosphorylate the enzyme as no visible band was seen at 100 kDa (black arrowhead) when 
EGFP-precipitates were probed for these kinase’s -dependent phosphorylation.  
In summary, possible phosphorylation of TG2 was detected in cells subjected to glycaemic-like 
stress and might be involved in the secretion of the enzyme. As phosphorylation has been 
implicated in the unconventional secretion of HS-modulated cytokines such as FGF2 (Steringer, 
et al. 2012, Nickel 2007), this finding suggests that also TG2, which is HS-modulated 
(Scarpellini, et al. 2009, Burhan, et al. 2016, Scarpellini, et al. 2014) might share a similar 
release pathway.  
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Figure 5.12: Optimisation of the EGFP-TG2 preciptation and identification of putative 
phosphorylation sites for TG2. (A) in order to optimize of EGFP-TG2 immunoprecipitation from EGFP-
TG2 overexpressing clones using an anti-GFP antibody, cells were cultured in standard conditions and 
EGFP was immunoprecipitated from 0.75 mg of cell homogenate using 2.5 µg of rabbit polyclonal anti-
GFP as described in 5.3.8. Beads only control was performed to confirm the specificity of the 
precipitation. Equal volumes (40 µl) of pre-elution wash (unbound proteins) and elution (IP), as well as 
100 µg of total cell lysate (Pre-IP) were screened for the expression of EGFP-TG2 chimera by Western 
blotting with rabbit polyclonal anti-GFP antibody. Immunoreactive bands were detected by enhanced 
chemiluminescence (Geneflow) after incubation with appropriate HRP-conjugated secondary antibody 
(Table 5.6) in blocking buffer. Image acquisition was performed with a LAS4000 imaging system (GE 
Heathcare). The figure shows a representative blot. Asterisk represent co-eluted IgGs (** = Heavy Chain; 
*=Light Chain). (B) Putative phosphorylation sites of Homo sapiens  TG2 protein sequence (EC:2.3.2.13) 
were analysed using NetPhos online tool (http://www.cbs.dtu.dk/services/NetPhos). Table represent 
all putative phosphorylation sites detected on human TG2 sequence (phosphorylation potential > 
threshold, set at 0.5 by default).  (C) Documented phosphorylation sites of Homo sapiens TG2 protein 
were investigated on Phosphosite database (http://www.phosphosite.org). The table shows all the 
reported phosphorylation sites on TG2, and the nuber of times they have been identified by site specific 
analysis (second columns) or uniquely by a discovery approach-based MS (third column).   
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Figure 5.13: Analysis of protein phosphorylation in EGFP-TG2 precipitates from cells subjected 
to glucose stress. NRK52E EGFP-TG2 overexpressing clones were subjected to glucose stress to 
simulate a pro-fibrotic condition (5mM glucose = - / 30 mM glucose = +) and EGFP-TG2 chimera was 
immunoprecipitated from equal amounts of cell lysate (750 µg) with a rabbit polyclonal anti-GFP 
antibody (Abcam) as described in 5.3.3 Equal volumes (40 µl) of GFP-immunoprecipitated proteins 
(IP:GFP) were screened for the presence of phosphorylated tyrosine, serine or threonine by Western 
blotting using specific antibodies reported in Table 5.6. Immunoreactive bands were detected by 
enhanced chemiluminescence (Geneflow) after incubation with appropriate HRP-conjugated secondary 
antibody (Table 5.6) in blocking buffer. Image acquisition was performed with a LAS4000 imaging 
system. The blot was then stripped and probed with Rabbit polyclonal anti-GFP (Abcam, Table 5.6) 
followed by goat anti-rabbit IgG conjugated to HRP (Dako) to confirm the immunoprecipitation (WB: 
GFP). The EGFP-TG2 chimera expected MW is 100 kDa (arrowhead). Each experiment was performed in 
duplicates or triplicates. The figure shows representative blots for each antibody employed. Asterisk 
represent co-eluted IgGs (** = Heavy Chain; *=Light Chain). Red circles identify phosphorylated EGFP-
TG2. A = Rabbit polyclonal anti-phosphotyrosine; B = Rabbit monoclonal Phospho-(Ser/Thr)AMPK;CF = 
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Rabbit monoclonal Phospho-AKT; D = Rabbit monoclonal Phospho-PKA; E = Rabbit monoclonal 
Phospho-(Ser/Thr) ATM/ATR; F = Rabbit monoclonal Phospho-(Ser) PKC; G = Rabbit monoclonal 
Phospho-(Ser) CDKs. 
 
 
5.4.5 Investigation of the importance of the endocytic protein clathrin for 
TG2 presence on the cell surface 
As reported before in chapter IV, clathrin and clathrin coated vesicles (CCV)-  associated 
proteins were identified as TG2- partners in the enzyme’s interactome by SWATH-MS in both 
healthy and fibrotic kidney membranes, hence might directly or indirectly interact with the 
enzyme itself during its trafficking. Knowing this, it was considered interesting, as an additional 
investigation, to study the effect of clathrin knock down on extracellular TG2.  
First, to investigate the the co-precipitation of clathrin with TG2 in our cell model, NRK52E 
EGFP-TG2 overexpressing clones were subjected to a glucose stress (30mM) as described in 
the previous section (5.4.4) and immunoprecipitation of the EGFP-TG2 chimera was performed 
on equal amounts of cell lysates (5.3.9).  Co-precipitation of clathrin was investigated on EGFP-
immunoprecipitated extracts by Western blot, using a specific antibody against the heavy chain 
of clathrin, with predicted size of ~180 kDa. Expression of EGFP was tested as well on the same 
lysates, and employed as a control for protein precipitation (Fig. 5.14A). Immunoprobing of 
clathrin on EGFP-TG2 immunprecipitates revealed a faint band at high molecular weight (> 
130 kDa), which is likely to be specific (Fig. 5.14A, arrowhead). Expression of this protein was 
more intense in cell stressed with high glucose, while the level of precipitated EGFP-TG2 
chimera at 100 kDa remained equal in both conditions (Fig. 5.14A, black arrow). This 
suggested that clathrin is partially associated with TG2 in EGFP-TG2 overexpressing Rat TECs, 
and that the association with the enzyme is increased by glucose stress, probably due to an 
increased amount of enzyme outside the cells.   
Immunofluorescent staining of both clathrin and TG2 was also performed on NRK52E WT cells 
following the general protocol for immunofluorescece reported in Chapter II (2.2.8). The 
staining revealed a partial co-localisation of TG2 (Fig. 5.14B, in red) with clathrin (Fig. 5.14B, 
in green) in non permeabilised cells, while it was weaker intracellularly in permeabilised cells 
(Fig. 5.14B).  
Clathrin knock down was performed on both WT and EGFP-TG2 overexpressing NRK52E cells, 
by transient transfection of rat clathrin-targeting siRNA, as described in 5.3.10. Non-targeting 
scrambled siRNA was employed as a control. Transient transfection with 100 nM rat clathrin - 
targeting siRNA for 24 h led to a visible reduction of clathrin expression at a protein level in 
both WT and EGFP-TG2 overexpressing TECs, as investigated by western blot (Fig. 5.14C, 
arrowhead). Interestingly, a reduction in TG2 expression, both exogenous EGFP-tagged (100 
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kDa, black arrow) and endogenous (75 kDa, grey arrow), was observed in EGFP-TG2 
overexpressing TECs subjected to Clathrin KO when the same lysates were probed with an anti-
TG2 antibody, and might be linked to a reduced endocytosis of the enzyme itself (Fig. 5.14 C, 
red circle).  
When extracellular TG2 activity was measured by biotin-cadaverine incorporation assay 
performed on living cells, no effect was observed on WT NRK52E cells (Fig. 5.14D). On the 
contrary, a small but significant rise (p=0.0002, ***) was detected in extracellular TG2 in EGFP-
TG2 overexpressing NRK52E cells subjected to siRNA knock down of clathrin (Fig. 5.14D, red 
circle).  
Results from clathrin knock down in EGFP-TG2 overexpressing TECs suggest a possible 
involvement of clathrin in TG2 endocytosis, with a reduced amount of TG2 inside the cells and 
an increased amout of extracellular/cell surface associated one upon knock out of clathrin. This 
is in line with previous findings of an LRP1-mediated internalisation of TG2, where the 
involvement of CCV was proposed (Zemskov, et al. 2007). However, it was not confirmed in 
WT cells in this study, suggesting that the phenomenon might happen only in conditions of TG2 
overexpression, and not at a basal level of endogenous TG2.  
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Figure 5.14: Study of interaction between Clathrin and extracellular TG2. (A) NRK52E EGFP-TG2 
overexpressing clones were subjected to glucose stress and EGFP-TG2 chimera was immunoprecipitated 
as described in Fig 5.13. Equal volumes (40 µl) of GFP-immunoprecipitated proteins (IP:GFP) were 
screened for the presence of clathrin using a rabbit monoclonal antibody described in 5.3.10. GFP was 
also probed to confirm IP of EGFP-TG2 chimera at 100kDa (black arrow). A representative blot is here 
shown. Arrowhead indicates clathrin heavy chain signal > 130 kDa.  (B) Co-Immunofluorescent staining 
of Clathrin and TG2 was performed on both non permeabilised and permeabilised NRK52E WT cells 
subjected to glucose stress (30 mM glucose), as described in 2.2.8. A rabbit monoclonal antibody against 
clathrin (4796, Cell Signalling,– dilution 1:400) followed by a donkey anti-rabbit Alexa Fluor® 488 
antibody, with green fluorescence, and a mouse monoclonal anti-TG2 antibody  (IA12, University of 
Sheffield - dilution 1:400) followed by a goat anti-mouse antibody Alexa Fluor® 598, with red emission 
were employed for the assay. White arrows indicate points of TG2 and clathrin co-localisation. (C, D) 
Clathrin knock down was performed on both NRK52E WT and EGFP-TG2 overexpressing NRK52E (clone 
#C5) cells, by transient transfection with rat clathrin-targeting siRNA, as described in 5.3.10. 24 h after 
transfection, (C) the effect of the knock down at a protein level was measured on equal amounts of 
proteins by immunoprobing clathrin, TG2 (Ab421, Abcam) and β-tubulin as a loading control. (D) The 
effect on extracellular TG2 was measured by extracellular TG2 activity assay as described in 2.2.9.2. The 
values are the average Abs (450 nm) of three independent experiments, each undertaken in 
quadruplicates, normalised for the relative scrabled siRNA control (equalised to 1) ± SD. Significance of 
the differences between treatments was determined by T-test: * = p<0.05, ** = p<0.01, *** = p<0.001, 
**** = p<0.0001. 
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5.5 DISCUSSION  
 
Extracellular TG2 has been suggested to play a number of roles on the cell surface and ECM, 
contributing to the progression of fibrosis in the context of CKD, while its inhibition in the 
extracellular environment has been found to be protective against the progression of disease. 
Despite being primarily a cytosolic enzyme, TG2 export and extracellular activity have been 
shown to significantly increase during the progression of CKD in response to pro-fibrotic 
stimuli. The enzyme is known to be unconventionally secreted in the ECM as a leaderless 
protein, through a mechanism that is still not completely clarified. Here, the main objective was 
to understand the mechanism of TG2 unconventional secretion during fibrosis progression.  
As the analysis of TG2 interactome in kidney cellular membranes highlighted a significant 
cluster of TG2 interacting proteins also located in extracellular vesicles, which increased in 
expression and complexity post UUO, it was hypothesised that TG2 could be secreted via 
extracellular vesicles.  
As kidney tubular epithelial cells (TECs) are regarded as the main source of TG2 released in 
the matrix during fibrosis development  (Johnson, et al. 1999, Johnson, et al. 2003) tubular 
epithelial cell line of NRK52E cells was selected for in vitro investigations of TG2 secretion. 
Although this established cell line expresses TG2 endogenously, rat TG2 is notoriously harder 
to detect by immunoassays than human TG2, especially in low protein preparations, therefore 
we reasoned that the EGFP reporter could facilitate the study of TG2 secretion and a clonal cell 
line of NRK52E cells expressing EGFP-tagged human TG2 was also employed.  
 
The requirement of a vesicular intermediate and membrane fusion events for TG2 export was 
demonstrated in this cell line by the requirement of NSF-ATPase for TG2 secretion (both 
antigen and cell surface activity) (Fig. 5.5). As NSF-ATPase is necessary for a variety of 
membrane fusion events mediated by SNAREs (Zhao, Slevin and Whiteheart 2007) including 
exosome secretion by MVB fusion (Fader, et al. 2009), and was identified as associated with 
TG2 in kidney membranes in the previous chapter (Chapter IV), this finding suggests that 
vesicle fusion events mediated by SNAREs and requiring NSF-ATPase are at least in part 
involved in TG2 unconventional release from TECs. Although NEM has been reported to 
interfere with TG2 catalytic activity by promoting the formation of thiol groups (Kumazawa, et 
al. 1997), the fact that also the release of TG2 protein was inhibited by NEM rules out any 
interference with TG2 activity detection (Fig. 5.5C). Therefore, extracellular TG2 could be 
secreted through a mechanism requiring vesicle-membrane fusion, such as the recycling 
endosome - to - plasma membrane pathway proposed by Zemkov and colleagues (Zemskov, et 
al. 2011), or via MVB/exosome release.  
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To investigate whether TG2 was secreted via a MVB/exosome pathway, extracellular vesicles 
were isolated by differential centrifugation from serum-free conditioned medium, according 
to well established protocols which allow the separation of exosomes from vesicles shedded 
from plasma membrane, MV or ectosomes (Bianco, et al. 2009) (Fig. 5.6A). One 
exosomal/ectosome marker was employed in this investigation, flotillin-2 (Fig. 5.6B); this is a 
well-characterised EV protein which can be reliably detected by immunoblotting; moreover 
flotillin-2 emerged as a clear partner of TG2 in the UUO, indicating a co-association, either 
direct or indirect, with TG2 in conditions favouring the enzyme export.  
TG2 presence in exosomes, as detected by Western blot on EV fractions from TECs (both WT 
and EGFP-TG2 overexpressing), and its further enrichment when a fibrosis-like condition was 
simulated in the cells by TGF-1 addition, strongly suggest that TG2 is released via EV of 
intraluminal origin (exosomes) (Fig. 5.7). Exosomes-associated TG2 was also identified in the 
conditioned medium of rat renal fibroblast (NRK49F), suggesting that TG2 release into the 
exosomal fraction is not limited to the specific cell line.  Interestingly, some TG2 was also found 
in larger vescicles shedded from the plasma membrane (ectosomes), although in lower 
amount, while the free TG2 in EV-deprived conditioned medium was generally low or absent, 
with some level of variability from preparation to preparation.  
 
TG2 association with exosomes was confirmed by employing an inhibitor of ceramide 
synthesis by nSMase, known to interfere with exosome biogenesis (Luberto, et al. 2002, 
Trajkovic, et al. 2008), which significantly reduced extracellular TG2 as detected by 
immunofluorescence, completely abolished TGF-1-stimulated release, and clearly lowered 
TG2 association with the exosomes without interfering with the microvesicle fraction (Fig 5.9).  
Employment of an inhibitor of ceramide biogenesis at the plasma membrane by aSMase, with 
a proposed inhibitory effect on ectosomes release (Bianco, et al. 2009), had a less singnificant 
consequence on TG2 relesase and a more general effect on TG2 presence in all fractions. 
Similarly, the employment of the inhibitor of Na+/H+ exchanges amiloride, suggested to 
interfer with exocytosis of micropinosomes (Falcone, et al. 2006), led to some decrease in TG2 
release, but the reduction of TG2 associated with the MV fraction (P3), though observable, was 
not particularly strong (Fig 5.9). However, amiloride specificity in the inhibition of EV 
secretion is not yet clear as amiloride / N-ethyl-N-isopropyl amiloride (EIPA) has mainly been 
involved in the inhibition of micropinocytosis, which is favoured by H+/Na+ exchange 
(Stelmach, Rusak and Tomasiak 2002, Koivusalo, et al. 2010). In the context of  EVs, only few 
studies have proposed an inhibitory effect of EIPA on ectosome release (Stelmach, Rusak and 
Tomasiak 2002) or macropinosomes release (Falcone, et al. 2006) while limited works have 
suggested that dimethyl amiloride inhibits calcium-regulated exosome secretion by blocking 
channel activity (Savina, et al. 2003, Chalmin, et al. 2010, Merendino, et al. 2010).  
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In summary, validation of TG2 association with exosome with inhibitor of ceramide synthesis 
and the finding of TG2 in EV lysate should convincingly establish that TG2 is exported via 
exosomes in the TEC cell line, consistent with the finding of abundant exosomal proteins in the 
TG2 interactome. Altogether these data suggest that, however TG2 could be identified in the 
ectosomal fraction, that was paticularly enriched of TG2 at the early minutes post-treatment 
(Fig. 5.10), is more likely to be release through an exosomal fraction from TECs.  
In agreement with this, while this thesis was in preparation,  Piacentini’s group published a 
study on human embrionic kidney cells and mouse embryonic fibroblasts suggesting that TG2 
might be secreted into exosomes and even contribute to exosome biogenesis under stress 
conditions, such as proteasome inhibition or the expression of mutant huntingtin (mHtt), an 
excessively glutaminated mutant huntingtin that is the main cause of Huntington disease (Diaz-
Hidalgo, et al. 2016). They proposed that, for its secretion, TG2 was interacting with two of the 
main proteins involved in intraluminal vesicles biogenesis: Alix and Tsg101 (Diaz-Hidalgo, et 
al. 2016). In particular, they suggested that, upon stress, TG2 was able to determine the 
assemblage of a complex including not only the two abovementioned proteins, but also the 
mutant huntingtin mHtt and the co-chaperone involved in its removal from the cells, BAG3, a 
complex that seemed to be necessary for the selective cargo loaging mHtt/BAG3 in the 
exosome (Diaz-Hidalgo, et al. 2016). Previous works have identified TG2 in exosomes 
(Skogberg, et al. 2015, Piacentini, et al. 2014), however, the latter work and the current study 
form our group are the first ones trying to provide an explanation for TG2 localisation in this 
fraction and hypothesize a secretion pathway. Interestingly, in the current study, TG2 was 
identified as significantly associated with huntingtin-interacting proteins in UUO kidney 
membranes, and “Huntington disease” pathway was identified as significantly enriched in the 
list of TG2 partners cell-matrix iterface both in fibrotic and sham operated condiions. This 
might support the idea of an exosomal pathway for TG2 secretion that might happen under 
stressed conditions in different types of diseases.  
 
There is an interest in understanding whether TG2 is present on the surface of released EVs or 
on their inside. This specific question is particularly relevant, considering that TG2 on the 
surface of vesicles can directly interact with its partners in the extracellular space such as 
HSPGs, FN, integrins etc., while, if the enzyme was uploaded inside the vesicle, it would require 
vesicle degeneration/dissolution for release in the matrix. To attempt an initial answer to his 
question, we developed an experimental approach aimed at measuring the catalytic activity of 
TG2 of whole EV and lysed EV (Fig. 5.8). Our preliminary results suggested that TG2 is likely 
to be located mostly on the surface of these vesicles, rather than in their inside, however, a 
better resolution approach would be necessary for the experiment to be conclusive. At the 
moment, we can only hypothesize that TG2 is present on the cell surface of released exosomes. 
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The fact that at the early times after cell medium is changed, and vesicles cleared-out by PBS 
wash, the exosomal fraction is minimal and substantially lower than the ectosomal, then tends 
to increase along the time made us speculate that many of the exosomes released might 
accumulate in the medium and reamain associated with the extracellular space, maybe by 
binding to cell surface receptors such as Sdc4 or integrins or ECM adhesion proteins such as 
FN. Being TG2 a known binding partner of several extracellular components, including HSPGs 
and FN, its presence on the exosome surface would contribute to a direct interaction of the 
exosomes with the matrix and their retention in the matrix. This would also explain the large 
retention of TG2 in the matrix as observed by immunofluorescence experiments in this 
Chapter.  
 
As many pathways of unconventional protein secretion have been seen to involve protein 
binding to membrane phospholipid, an analysis of recombinant TG2 binding to immbilised 
phospholipids was performed (Fig. 5.11). Preliminary data obtained showed that TG2 binds 
with good affinity PI(4,5)P2, typical of the inner side of the plasma membrane and suggested 
as key element of FGF2 secretion mechanism (Steringer, et al. 2012). In the same assay, the 
binding to recycling endosome typical PI(3)P, suggested by Zemskov and colleagues as 
importat in the context of recycling endosomes-dependent TG2 trafficking, was much lower 
(Zemskov, et al. 2011). Interestingly, in support to our findings of TG2 association with 
MVB/exosomes, PI(3,5)P2 had the highest binding to TG2 and is known to be mainly present 
on the late endosomes/MVBs and lysosomes membranes, where is upregulated in events of 
“lysosome exocytosis” by macrophages (Samie, et al. 2013, Li, et al. 2013).   
Phosphorylation of TG2 or TG2-associated proteins was also investigated in TECs, in 
conditions favouring the enzyme’s export from NRK52E cells, such as a glucose stress (Huang 
et al., manuscript in preparation) (Fig. 5.13). PKA-mediated phosphorylation was identified 
upon stress, in line with previous studies highligting TG2 phosphorilation at Ser216 by PKA 
and its effect on TG2 activity and signalling (Mishra and Murphy 2006). However, highest 
phosphorylation was obtained by cyclin dependent kinase (CDK), a kinase primarily involved 
in the regulation of cell cycle. More experiments will be required to eludcidate possible 
consequences on TG2 export.   
Finally, given the elevated numer of proteins in the TG2 interactome with a reported 
association with clathrin-mediated endocytosis, as an additional investigation the effect of 
clathrin deletion on the amount of extracellular TG2 was examined on TECs (Fig. 5.14). Results 
highlighted a possible involvement of clathrin-mediated endociytosis in the TG2 uptake from 
TECs, in line with previous studies of receptor-mediated TG2 internalisation (Zemskov, et al. 
2007).   
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In conclusion, in this chapter, the hypothesis of a TG2 unconventional secretion mediated by 
EV was investigated, and results suggested a TG2 association with the exosomal compartment, 
wich is supported by the TG2 interactome analysis in kidney membranes presented in the 
previous chapter. The hypothesis that TG2 is secreted on the surface of exosomes, and that 
TG2-bearing exosomes accumulate in the extracellular matrix by binding adhesion molecules, 
is a fascinating hypothesis, that will be able to link a possible pathway of TG2 unconventional 
secretion from TECs with TG2 adhesive and pro-fibrotic role in the ECM during the process of 
kidney fibrosis. In support to this idea, a recent comparative analisys published on Bone has 
suggested that the so called “matrix vesicles”, extracellular-membrane bound vesicles involved 
in vascular calcification, and the exosomes are homologous structures with similar markers 
and biogenesis (Shapiro, Landis and Risbud 2015). Moreover, exosomes have been shown to 
act as cell adhesion mediators in epithelial cells, fibroblasts and cancer cells, a mechanism that 
involved FN and in which we can hypotesize extracellular TG2 could play a role (Koumangoye, 
et al. 2011, Mu, Rana and Zöller 2013, Sung, et al. 2015).  
If this was the case, we could postulate the existance of a population exosomes similar to matrix 
vesicles that are released from TECs in a profibrotic cytokine - stimulated fashion, carry TG2, 
and interact twith FN and HSPGs/Sdc4 in the extracellular environment, where they contribute 
to matrix deposition and adhesion.  
As HSPGs, and in particular Sdc4, have been previously identified as important binding 
partners of TG2 for its secretion by mouse dermal fibroblast and in vivo in models of kidney 
fibrosis, including the UUO (Scarpellini, et al. 2009, Scarpellini, et al. 2014), and since the HSPGs 
Sdc4 and perlecan have been highlighted as uniquely associated with TG2 in kidney fibrotic 
membranes in the current study (Chapter IV), it would be interesting to investigate the 
involvement of cell surface HSPG Sdc4 in TG2 unconventional secretion by kidney TECs,  to try 
to define if and at which stage the HSPGs-TG2 interaction takes place. This analysis will be the 
focus of the next, and last, chapter of results.  
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Chapter VI: The role of heparan sulfate proteoglycans (HSPGs) in 
TG2 secretion and extracellular retention by TECs 
 
6.1 AIMS OF THE CHAPTER 
 
As heparan sulfate proteoglycans (HSPGs) /syndecan 4 (Sdc4) have been suggested as 
potential partners of TG2 during kidney fibrosis, and since studies from my group have 
previously proposed a role for HSPGs, and specifically for Sdc4, in TG2 trafficking in vivo in 
kidney fibrosis models and in vitro in mouse dermal fibroblasts, the hypothesis of a role for 
HSPGs/Sdc4 in the unconventional secretion of TG2 from tubular epithelial cells (TECs) has 
been raised.  The aim of this chapter is to investigate the role of HSPGs, and in particular Sdc4, 
in TG2 release and extracellular retention from kidney TECs, with a particular interest in the 
elucidation of the potential involvement of Sdc4 in the vesicular mechanism of TG2 
unconventional secretion.  
 
 
6.2 INTRODUCTION  
 
6.2.1 Heparan sulfate proteoglycan (HSPG) biosynthesis and roles in the cells 
fv6.2.1.1 Biosynthesis of HS chains in the cell 
HSPGs are characterised by HS chains, particularly long GAG carbohydrates (40–300 
monosaccharides, covering 20–150 nm), strongly anionic and characterised by different levels 
of sulfation and epimerisation (Sarrazin, Lamanna and Esko 2011). Some HSPGs are 
characterised by only one chain while others, such as syndecans, have up to five chains (Fig. 
6.1A). The basic units building the HS chains are disaccharide units of β-D-Glucuronic acid 
(GlcA) and α-D-N-acetylglucosamine (GlcNAc), however, during biosynthesis, a series of 
enzymes contribute to GlcNAc N- diacylation/sulfation, O- sulfation, and epimerisation of the 
GlcA residues to iduronic acid (IdoA) (Sugahara and Kitagawa 2002, Whitelock and Iozzo 
2005) (Fig. 6.1B). HS biosynthesis relies on a series of enzymatic steps happening in the Golgi 
apparatus and employing nucleoside-monosaccharides imported from the cytoplasm (Bishop, 
Schuksz and Esko 2007, Whitelock and Iozzo 2005), as schematically shown in Fig. 6.1B. HS 
biosynthesis starts at the GAG attachment sites of the core protein, which contain Serine-
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Glycine sequences.  The first steps of serine xylosilation and linkage region formation are in 
common between heparan sulfate (HS) and chondroitin sulfate (CS), while the following steps 
proceed differently for each type of GAG chains (Esko, Kimata and Lindahl 2009). Specific 
aminoacidic clusters around the attachment serine (e.g. contiguous Ser-Gly residues in the  
attachment sites for HS) as well as specific phosphorylation and sulfation of the linkage region 
are thought to be involved in the selection between the type of GAG chains assembled, being 
recognised by the specific enzymes involved in GAG elongation (Sugahara and Kitagawa 2002). 
HS elongation is shown in Fig. 6.1B. CS elongation is similar to HS chains, but, in this case, is 
formed of N-acetyl-galactose and glucuronic acid (Esko, Kimata and Lindahl 2009).  
As the HS chain is growing, it simultaneously undergoes a series of modifications performed 
by a range of enzymes acting in the same Golgi stacks (Sugahara and Kitagawa 2002, Whitelock 
and Iozzo 2005) such as N- deacylation/N-sulfatation of GlcNAc to GlcNS by the enzyme GlcNAc 
N-deacetylase/N-sulfotransferase (Ndst), epimerisation by uronyl-C5 epimerase, which acts 
on the GlcA residues present in the N-sulfated domains (next to GlcNS), determining the 
formation of iduronic acid (IdoA) residues, and  O-sulfation, which happens at different 
residues and is mediated by series of O-sulfotransferases (Fig. 6.1B). For example, 6-O 
sulfotransferases (Hs6st1-3), mediate the O-sulfation at C6 of N-sulfoglucosamine (GlcNS), 
with formation of GlcNS(6S). Rarely, also GlcNAc can be 6O-sufated. These modifications 
generate relatively short segments of sulfate sugars (sulfated domains) and iduronic acid 
alternated to variable lengths of unmodified domains. Because of these specific patterns and 
the strong negative charge, the HS chains can bind a great number of ligands including 
cytokines and growth factors, ECM structural proteins, enzymes, etc.  Once HSPGs are secreted 
to the cell surface or ECM, they can undergo further modifications. In fact, the number of 
sulfated groups can be altered by plasma membrane-bound endosulfatases SULF1/2, that 
selectively remove sulfate groups from the HS chain, possibly as a consequence of specific 
signalling (Bishop, Schuksz and Esko 2007). Moreover, once exported, mammalian HS chains 
can be enzymatically cleaved by a specific extracellular enzyme called heparanase (endo-β-
glucuronidases), that digests HS in specific sites (between GlcA-GlcNS located after IdoA-
GlcNAc), determining the release of chains and associated ligands in the extracellular space 
(Dreyfuss, et al. 2009).  
In addition to the typical HS chains, few cells can produce heparin, a highly sulfated HS chain. 
In heparin, more than 80% of the GlcN residues are sulfated and more than 70% GlcA is 
epimerized to IdoA (Esko, Kimata and Lindahl 2009). As a result, while HS chains contain only 
~0.8 sulfate groups per disaccharide, heparin contains approximately 2.3 (Sarrazin, Lamanna 
and Esko 2011). As a proteoglycan GAG chain, heparin is produced only in the connective tissue 
and exclusively as a serglycin-associated chain while HS is produced virtually byall cells (Esko, 
Kimata and Lindahl 2009).  
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Figure 6.1: Heparan sulfate proteoglycans (HSPGs). (A) Structure of main cell surface and secreted 
HSPGs. Pictures adapted from (Iozzo 2001, Esko, Kimata and Lindahl 2009). Permission to reproduce 
these pictures has been granted by Cold Spring Harbor Laboratory Press and the American Society for 
Clinical Investigation. (B) Structure of heparan sulfate (HS) chains and enzymes involved in HS chains 
biogenesis and modifications. HS biosynthesis starts at the GAG attachment sites of the core protein, 
which contain serine-glycine sequences. The first step is the binding of a xilose to Ser residue by aim of 
a specific enzyme named xylosyltransferase (XylT) that employs UDP-xylose as donor. The following 
step is a formation of a linkage region, a tetrasaccharide sequence determined by the stepwise addition 
of two galactoses (Gal) and one glucuronic acid [GlcA β1-3Gal β1-3Gal β1-4Xyl β1-O-Ser] performed by 
specific glycosyltransferases: β1–4 galactosyltransferase, β1–3 galactosyltransferase (GalTI and GalTII) 
and β1–3 glucuronosyltransferase (GlcAT). HS elongation from the linkage region is initiated by the 
addition of a first α1–4 GlcNAc performed by an exostoses family – like (Extl) enzyme called Extl3 
(GlcNAc transferase). Subsequently, an enzyme complex composed of the HS polymerases of the 
exostoses family (Ext), Ext1 and Ext2 (GlcA/GlcNAc Transferases), continues the HS chain elongation by 
alternatively adding GlcA and GlcNAc from the corresponding UDP sugars (Esko, Kimata and Lindahl 
2009). N- deacylation/N-sulfatation of GlcNAc to GlcNS is perfomed by the enzyme GlcNAc 
ndeacetylase/nsulfotransferases (Ndst) using 3′-phosphoadenosine 5′-phosphosulfate (PAPS) as sulfate 
donor. Uronyl C5 epimerase acts on the GlcA residues present in the N-sulfated domains (next to GlcNS), 
determining the formation of iduronic acid (IdoA) residues. O-sulfotransferases mediate O-sulfation 
employing PAPS as sulfate donor. IdoA undergoes 2O-sulfation (sulfation at C2) performed by uronyl 2-
O-sulfotransferase (Hs2st). 6-O sulfotransferases (Hs6st1-3), at the same time, mediate the O-sulfation 
at C6 of GlcNS or GlcNAc (rarely). 3-O-sulfotransferases (Hs3st1, 2, 3a,3b, 4, 5, 6) determine a less 
frequent  O-sulfation at C3 of either GlcNS, GlcNS(6S)and GlcNAc with production of GlcNS(3S), 
GlcNS(3S+6S) and GlcNAc(3S). Adapted from (Esko, Kimata and Lindahl 2009). Permission to reproduce 
this picture has been granted by Cold Spring Harbor Laboratory Press.  
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6.2.1.2 HSPGs roles in the cells  
HSPGs have been reported to bind a large number of ligands. Binding occurs mostly through 
their long HS chains, even if ligand associations with the core protein have also been described. 
For example, the core protein of syndecans is able to interact with both integrins and 
cytoskeletal elements [6.2.2-3], while long HSPGs such as perlecan are characterised by a series 
of ligand-binding independent domains (e.g. for laminin). The ability of proteins to bind HS 
generally depends on the presence of narrow pockets of positively charged basic amino acids 
(lysine, arginine and rarely histidine) on their surface in the tertiary structure (Sarrazin, 
Lamanna and Esko 2011, Dreyfuss, et al. 2009). For example, two consensus motifs have been 
proposed (XBBXBX and XBBBXXBX, where B represents a basic residue and X an hydropathic 
-neutral or hydrophobic- residue)(Cardin and Weintraub 1989), but they not necessarily 
appear on all heparin binding proteins (Dreyfuss, et al. 2009). In general, it seems that the 
specificity of the interactions of HS chains with particular proteins is associated with the 
overall organization HS chain (presence of IdoA sulfate, number of 6O sulfation, etc.) and not 
on a specific monosaccharide sequence (Kreuger, et al. 2006).   
Ligand biding of cell surface HSPGs can induce their clustering and promote cell signalling. 
Given the long HS chains, that can cross the extracellular matrix, some functions of  HSPGs 
occur both “in cis”(on the same cell) or “in trans” between neighbour cells (Bishop, Schuksz and 
Esko 2007).  The next paragraphs will provide a general description of some of the more 
described roles of HSPGs in the cell (Fig.6.2). Specific description of syndecan functions will be 
provided in the next section [6.2.2-3 ] 
HSPGs are able to bind  cytokines and growth factors such as fibroblast growth factors (FGFs), 
transforming growth factors (TGF-β1,2), vascular endothelial growth factor (VEGF), platelet 
derived growth factor (PDGF), etc. (Dreyfuss, et al. 2009, Sarrazin, Lamanna and Esko 2011) 
through the HS chains. By binding these molecule, HSPGs play a role in controlling their 
activity, stability and localisation in the matrix, regulate their clustering and provide protection 
against proteolysis (Dreyfuss, et al. 2009, Bishop, Schuksz and Esko 2007). HSPGs can function 
as storage reservoirs for cytokines and growth factors in the matrix: cytokines, chemokines, 
growth factors etc. can be held in specific positions or stored until necessary in the matrix, from 
which they can be released by heparanase cleavage or core protein shedding (Dreyfuss, et al. 
2009, Iozzo, Zoeller and Nyström 2009, Bishop, Schuksz and Esko 2007). Shedding of cell 
surface proteoglycans, specifically syndecans, by MMPs, is controlled by intracellular signalling 
pathways and can contribute to liberation of stored factors and chemokines.  
Shedding can have a duplex role in the control of inflammation by either increasing chemokine 
migration in the inflammatory area or promoting chemokine release from the inflammation 
area (Kirkpatrick and Selleck 2007).  
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HS-bound chemokine gradients on endothelial cells are involved in leukocyte recruitment 
during inflammatory response and physiological leucocyte distribution (Wang, et al. 2005). 
One of the less described cell surface HSPG, betaglycan, is able to bind TGF-β through the core 
protein and FGF2 though the HS chains. By binding TGF-β, this proteoglycan contributes to the 
storage of growth factor for TGF-receptors, without directly contributing to signal 
transduction.  
HSPGs can play a role in cellular signalling indirectly, by acting as co-receptors, or directly, by 
acting as receptor themselves. One of the more described HSPG ligands is FGF2, also known as 
basic fibroblast growth factor. Cell surface HSPGs bind FGF2 trough the HS chains, and this 
binding has been suggested to favour the protein’s unconventional secretion (Steringer, et al. 
2012, La Venuta, et al. 2015) (described in chapter V), localisation in the extracellular space, 
dimerization and protection from proteolytic degradation. Importantly, in this context, cell 
surface HSPGs have also been suggested to play a co-receptor role: it has been suggested that 
cell surface HSPGs can act as a co-receptor for FGF2 receptor tyrosine kinase (FGFR), favouring 
the formation of a ligand-receptor complex, possibly by inducing conformational changes on 
the bound proteins (dimerization), and, ultimately, promoting tyrosine kinase-dependent 
signalling (Steinfeld, Van Den Berghe and David 1996, Spivak-Kroizman, et al. 1994). The co-
receptor function of HSPGs has been extended to the other members of the FGF family 
(Dreyfuss, et al. 2009), as well as to other growth factors such as VEGF (Ashikari-Hada, et al. 
2005), PDGF (Abramsson, et al. 2007), etc. The effect of HSPGs as co-receptors can occur “in 
cis”, when HSPGs and receptors are present on the same cells, or “in trans”, when HSPGs and 
receptors are present on adjacent cells (Sarrazin, Lamanna and Esko 2011, Kramer and Yost 
2002, Jakobsson, et al. 2006).  In general, the ability of HSPGs to trans-activate adjacent cells is 
important to promote cellular interaction, signal transduction and cell differentiation 
(Sarrazin, Lamanna and Esko 2011).   
Cell surface HSPGs can also act themselves as receptors, inducing a signalling cascade in a non-
enzymatic, protein-kinase dependent manner. Particularly studied, in this context, are the 
transmembrane syndecans, characterized by specific phosphorylation sites on the cytosolic 
domain of the protein core and able to bind specific kinases. The best studied example is Sdc4 
(Simons and Horowitz 2001), described in the next section [6.2.3].  
Cell surface HSPGs, and specifically syndecans, can interact with integrins and other cell 
adhesion receptors, mediating cell adhesion and cell-cell interactions.  One of the most 
common integrin binding domain present on ECM proteins is the RGD (arginine-glycine-
aspartic acid) peptide sequence, that has been well described on FN. As cell surface HSPGs, and 
in particular syndecans, are able to bind FN on its heparin-binding domain, they can contribute 
to focal adhesion and stress fibres formation in collaboration with integrin or even as an 
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alternative cell adhesion receptor (Saoncella, et al. 1999a, Echtermeyer, et al. 1999, 
Alexopoulou, Multhaupt and Couchman 2007).   
Another interesting function of cell surface HSPGs (both syndecans and glypicans) is the ability 
to act as endocytic receptors, involved in both constitutive and ligand-induced endocytosis. 
HSPG-mediated endocytosis appears to be both clathrin, caveolin and dynamin -independent, 
to be associated with lipid rafts of specific composition and to be similar to micropinocytosis 
(Christianson and Belting 2014).  In most cases, endocytosed HSPGs are directed to the 
lysosome, where both HSPG and ligand is degraded. Particularly studied, in this case, is the 
lipoprotein degradation mediated by HS binding and endocytosis (Stanford, et al. 2010), that 
gives HSPGs a role in metabolic control. In the case of syndecans, internalisation can be 
triggered by clustering of the transmembrane and cytoplasmic domains (Fuki, et al. 1997). Cell 
surface syndecans have also been involved in the endocytosis of other molecules, such as FGF2 
internalisation by micropinocytosis mediated by Sdc4, that involves protein-core 
oligomerisation (Tkachenko, et al. 2004). In some cases, internalised HSPGs can be recycled 
(Christianson and Belting 2014). A typical example is the Syndecan recycling together with FGF 
receptor (Zimmermann, et al. 2005).  
Finally, extracellular matrix HSPGs such as perlecan, agrin and endostatin contribute to the 
definition of the basement membrane (BM) structure containing laminin, collagen and 
glycoproteins. The formation of a basement membrane not only contributes to the resistance 
of the tissue against mechanical stress, but also provide a highly charged barrier against the 
filtration of specific solutes (Iozzo 2005). For example, in the kidney, a thick glomerular 
basement membrane (GBM) rich in HS chains forms a negatively charged barrier that prevents 
anionic proteins from entering the ultrafiltrate. Loss of HS chains, in this context, leads to 
proteinuria in the urine (Raats, Van Den Born and Berden 2000).   
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Figure 6.2: Main functions of HSPGs in cells. Figure adapted from (Bishop, Schuksz and Esko 2007). 
Permission to reproduce this picture has been granted by Nature Publishing Group.  
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6.2.2 Syndecan Family 
 
6.2.2.1 Syndecan family and structure 
The syndecan (Sdc) family is  the more described family of cell surface HSPGs and is composed 
of 4 distinct members (Sdc1, Sdc2, Sdc3 and Sdc4) (Fig. 6.3A). Syndecans are type I single -
pass transmembrane core proteins with covalently bound heparan sulfate (HS) chains (and 
chondroitin sulfate -CS- in some cases). The four members of the family have evolved from the 
same gene that underwent duplication followed by divergent evolution. Based on the specific 
origin and protein homology, two subfamilies of syndecans can be distinguished, one 
containing Sdc1 and Sdc3, and one characterised by Sdc2 and Sdc4 (Carey 1997). This sub-
classification has also been suggested to reflect functional similarities: for example, Sdc2 and 
Sdc4 have been associated with cell proliferation, while Sdc1 and Sdc3 have been mainly 
related to its inhibition (Tkachenko, Rhodes and Simons 2005) (Fig. 6.3A). 
The general structure of a syndecan core protein (Fig. 6.3A) is characterised by an N-terminal 
long extracellular ectodomain, with covalently bound HS or HS/CS chains, a single-pass 
transmembrane domain, involved in Syndecan oligomerisation, and a C-terminal short 
cytoplasmic domain, involved in the interaction with cytoskeleton and signal transduction.  
The extracellular domain is a long region ending with its N-terminal signal peptide and is highly 
variable among family members (10–20% conservation)(Afratis, et al. 2016, David 1993). The 
ectodomain is characterised by a series of Ser-Gly attachment site for HS/CS covalent binding: 
both HS and CS chains can be found on Sdc1 and Sdc3, while only HS is present on Sdc2 and 
Sdc4. GAG chains can be located both at the distal and membrane proximal side of the 
ectodomain, in case of Sdc1 and Sdc3, or only in the distal part, as in Sdc2 and Sdc4 (Carey 
1997, Afratis, et al. 2016). HS chains have different lengths in syndecans, going from 50 to 150 
disaccharide units (Bernfield, et al. 1999).  
The transmembrane domain is virtually identical among family members. Its peculiarity is to 
have a high affinity for self-association. The transmembrane domain contains GXXXG motifs 
that are fundamental for the dimerization of syndecan protein cores into homodimers (Dews 
and Mackenzie 2007). This oligomerisation, in particular, has been proven important for Sdc4 
role in protein kinase C α (PKCα) activation.  
The cytoplasmic domain is a short region (30-35 aminoacids) highly conserved among the 
family members. It contains binding sites for cytoskeletal proteins and phosphorylation sites 
for specific kinases. It is characterised by three distinct regions: two conserved regions (C1 and 
C2) and one variable region (V). The C1 domain binds kinases and cytoskeletal proteins such 
as Src non-receptor tyrosine kinase, tubulin, cortactin, and ERM family proteins (ezrin, radixin, 
moesin)(Afratis, et al. 2016). The C2 domains, on the other side (C-terminal), contains two 
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tyrosine residues and an important hydrophobic motif (C-terminal EFYA motif) that binds PDZ 
(PSD-95 ⁄ Discs-large ⁄ Zonula Occludens)-domain containing proteins and mediates cell 
adhesion and Syndecan recycling. Through this motif, Syndecans bind PDZ-containing proteins 
such as calcium/calmodulin dependent serine protein kinase (CASK), syntenin, synectin, 
synbindin, etc. (Afratis, et al. 2016). The V domain is highly heterogeneous among the four 
mammalian syndecans and can contain specific binding sites (Tkachenko, Rhodes and Simons 
2005), for example, a specific sequence for phosphatidylinositol(4,5)bisphosphate has been 
observed in Sdc4 in this region.   
Because of their transmembrane location and long HS chains, syndecans are able to link the 
intracellular space, and the actin cytoskeleton in particular, to the extracellular matrix, and 
have been involved in signalling transduction between ECM and intracellular 
space/cytoskeleton (Afratis, et al. 2016). Syndecans are involved in cell adhesion and 
proliferation, independently from or by interacting with integrins. They bind ECM components 
such as collagens (I, III, V), FN, thrombospondin etc., providing structural support for the 
adhesion. Moreover, they have been reported to play a role in endocytosis, recycling, exosome 
biosynthesis and wound repair (Tkachenko, Rhodes and Simons 2005, Afratis, et al. 2016).  
Syndecans have different distribution in mammalian cells depending on the cell types and 
development stage (Couchman 2003, Kim, et al. 1994). Expression of the different Syndecans 
in cells is variably regulated by different growth factors such as TGF-β2, that upregulates Sdc4 
while downregulating Sdc1  (Dobra, Nurminen and Hjerpe 2003), FGF2 (Sdc4), mechanical 
stress, and wound healing-associated cytokines (Sdc1 and Sdc4) (Tkachenko, Rhodes and 
Simons 2005). In the next paragraphs, a brief description of the four Syndecan members will 
be provided.    
 
6.2.2.2 Syndecan-1 (Sdc1) 
Syndecan-1 (Sdc1) is a member of syndecan family largely expressed in epithelial cells, present 
in plasma cells and in minor part on fibroblast/mesenchymal cells of skin, liver, lungs and 
kidneys. It is the main Syndecan form in keratinocytes (Kim, et al. 1994, Afratis, et al. 2016).  
Sdc1 is primarily involved in cell-cell adhesion and cell-matrix adhesion. Cell-cell adhesion 
function of Sdc1 depends on its binding “in-trans” to growth factors and membrane receptors 
on neighbouring cells, through the HS chains. In general, Sdc1 expression promotes cell 
adhesion and reduced migration (Altemeier, et al. 2012) while its loss promotes the cell 
proliferation with loss of cell-cell binding (Tkachenko, Rhodes and Simons 2005); by 
supporting cell-cell adhesion, Sdc1 has been suggested to be involved in the maintenance of 
the epithelial cells shape (Couchman, Chen and Woods 2001, Kato, et al. 1995).  Sdc1 inhibition 
and heparanase HS digestion of Sdc1 has been shown to promote Epithelial-Mesenchymal 
Transition (EMT) with consequences for cell development, cancer and wound healing (Kato, et 
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al. 1995, Couchman, Chen and Woods 2001). This is particularly applicable to FGF2-dependent 
EMT induction on renal tubular epithelial cells (TECs): in renal TECs, Sdc1-HS digestion with 
heparanase facilitates EMT induced by FGF2, making it a possible clinical target against fibrosis 
(Masola, et al. 2012).  
Sdc1 has been suggested to regulate the cell surface level of E-cadherin (epithelial marker), as 
its inhibition has been shown to correlate with the loss of E-cadherin itself. It has been 
suggested that the synthesis syndecan-1 and E-cadherin are themselves downregulated by the 
initiation of EMT, promoting loss of adhesion and conversion of the cells to a fibroblast-like 
shape (Sun, et al. 1998).  
Similarly to Sdc4-KO [6.2.3], Sdc1-null mice are generally healthy and does not appear to have 
defects in development. However, defects in wound healing of the skin and cornea epithelium 
was observed in Sdc1-KO mice. (Stepp, et al. 2002, Pal-Ghosh, et al. 2008) 
Sdc1 undergoes lipid-raft dependent endocytosis upon clustering, and the endocytosis is 
mediated by a specific MKKK domain on the membrane proximal C1 region. Ligand binding to 
Sdc1 determines MKKK-dependent phosphorylation of ERK, which itself determines the 
unbinding of Sdc1 and tubulin and the localisation of Sdc1 into rafts. Subsequently, MKKK 
mediates Src kinase phosphorylation of tyrosine residues between C1 and transmembrane 
region, which determines recruitment of cortactin, a mediator of actin-dependent endocytosis 
(Chen and Williams 2013). This process is for example involved in the removal of triglyceride-
rich lipoproteins, and Sdc1 shedding impairs lipoprotein catabolism in hepatocytes 
(hypertriglyceridemia)(Deng, et al. 2012, Stanford, et al. 2009).  
 
6.2.2.3 Syndecan 2 (Sdc2) 
Syndecan-2 (fibroglycan, Sdc2) is well-expressed in endothelial cells, but also present in 
mesenchymal cells such as fibroblasts (Essner, Chen and Ekker 2006, Afratis, et al. 2016). It is 
strongly associated with the cytoskeleton, binding ERM-proteins on its C1 region  (Granés, et 
al. 2003), linking the cytoskeleton to the plasma membrane.  
Sdc2 has been involved in angiogenesis by modulation of VEGF signalling (Chen, Hermanson 
and Ekker 2004, Essner, Chen and Ekker 2006, Noguer, et al. 2009): Sdc2 shedding inhibits 
angiogenesis by “in-trans” interaction with the protein tyrosine phosphatase receptor CD148 
in nearby cells, which in turn deactivates β1-containing integrins, mediating endothelial cell 
migration (Whiteford, et al. 2011, De Rossi, et al. 2014).   
Importantly, Sdc2 has been suggested to play a role in TGF-β1 signalling: Sdc2 is in fact able to 
bind to both TGF-β1 and betaglycan (TGF-βRIII) though its core protein and facilitates TGF-β1- 
TGF-βRII binding with promotion of TGF-β1-associated Smad signalling leading to the 
expression of adhesion-associated proteins such as focal adhesion kinase (FAK) and integrin 
β1 (Chen, Klass and Woods 2004, Mytilinaiou, et al. 2013).  In renal cells, Sdc2 was shown to 
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promote an increase in TGF-β-mediated matrix deposition; moreover, an increase in Sdc2 in 
renal interstitium has been associated with diabetic nephropathy (Chen, Klass and Woods 
2004).   
 
 
6.2.2.4 Syndecan-3 (Sdc3) 
Syndecan-3 (Sdc3), also known as neural syndecan (N-syndecan) is highly expressed in neural 
cells and in developing musculoskeletal tissues (Afratis, et al. 2016). Its expression is highly 
regulated during development peaking in the first days after birth (oligodendrocyte 
differentiation and myelin formation) and declining in adults to basal levels (Carey, et al. 1997). 
Sdc3 levels in hypothalamus have been shown to regulate feeding behaviour, learning and 
memory, and Sdc3-KO resulted in reduced feeding response and learning/memory defects 
(Reizes, et al. 2001). Sdc3 knock-out has been associated with muscular dystrophy 
characterized by satellite cells hyperplasia and fibrosis, possibly associated with an excessive 
growth factor receptor activation (Cornelison, et al. 2004).  
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Figure 6.3: The Syndecan family of cell surface HSPGs and the specific structure of syndecan-4 
(Sdc4). (A) The four members of the syndecan family of transmembrane HSPGs. Adapted from 
(Couchman, et al. 2015). Permission to reproduce this picture has been granted by John Wiley and Sons.  
(B) Specific characteristics of syndecan-4 (Sdc4) domains. Adapted from (Couchman 2003). Permission 
to reproduce this picture has been granted by Nature Publishing Group.  
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6.2.3 Syndecan-4 (Sdc4) 
Syndecan-4 (Sdc4) (or ryudocan, or amphiglycan) is the most studied member of the Sdc family 
and is considered ubiquitously expressed in mammalian cells at all stages of development 
(Fig.6.3B). It is particularly rich in epithelial and fibroblastic cells, especially in liver and lungs, 
while it is lower in neuronal cells and endothelial cells. Sdc4 is considered a central mediator 
of cell adhesion and migration. It has a with a well-known role in wound healing and 
inflammatory response.  
Mechanical cell stress, tissue injury and wound healing  have been suggested to upregulate 
Sdc4 expression (Li, et al. 1997, Gallo, et al. 1997, Tkachenko, Rhodes and Simons 2005), which 
is also induced by growth factors such as TGF-β2 in epithelial cells (Dobra, Nurminen and 
Hjerpe 2003) and FGF2 (Cizmeci-Smith, et al. 1997). Expression of Sdc4 is upregulated by 
inflammation in cardiac cells and has a NF-κB response sequence on its promoter (Strand, et 
al. 2013). Expression of Sdc4 has been suggested to be important as an early inflammatory 
response, to accelerate the resolution of tissue inflammation limiting tissue injury and fibrosis, 
and for this reason it can be regarded as a possible anti-inflammatory protein (Xie, et al. 2012, 
Tanino, et al. 2012); however, inflammation- mediated shedding of Sdc4 ectodomain has been 
shown to be pro-inflammatory and to lead cell proliferation and tissue fibrosis (Strand, et al. 
2013).  
Similarly to Sdc1-KO mice, Sdc4-null mice are generally healthy, viable and fertile, and does not 
appear to have defects in development (Stepp, et al. 2002). However, defects in wound healing 
and impaired angiogenesis of the granulation tissue were shown in Sdc4-KO mice and were 
mostly associated with altered cell migration (Echtermeyer, et al. 2001).  
Moreover, altered blood clothing with thrombi formation and excessive inflammatory response 
were identified. This last effect was mediated by impaired lipopolysaccharide clearance by 
endocytosis and excessive interleukin-1β expression from macrophages, due to impaired 
recruitment of transforming growth factor-β (TGF-β)(Ishiguro, Kojima and Muramatsu 2002). 
Sdc4-KO mice showed defects in muscular reconstruction by satellite cells, that showed altered 
proliferation activation and differentiation in absence of Sdc4 (Cornelison, et al. 2004). Sdc4-
null mice also presented higher susceptibility to κ-carrageenan-induced nephropathy 
(Ishiguro, Kojima and Muramatsu 2002). 
A peculiarity of Sdc4 sits in the variable cytosolic region: the cytoplasmic variable region of 
Sdc4 has some affinity for self-association, in addition to the transmembrane domain which is 
in common with the other syndecans. This leads to the formation of a “twisted clamp” structure 
strongly involved inSdc4 intracellular signal transduction. However, this affinity is easy to 
break because of C1 chains repulsion, and can be neutralised, hence stabilised, in presence of 
acidic phospholipids such as to phosphotidylinositol(4,5)-bisphosphate (PIP2).  
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In mammalian cells, Sdc4 is known to be a constitutive element of focal adhesion (FA) sites and 
to be largely implicated in the promotion of FA, stress fibres formation and cell 
spreading/migration by controlling cytosolic signalling response and actin cytoskeleton 
remodelling. Integrins, by themselves, are able to bind ECM adhesion molecules such as FN on 
their RDG binding domain ad promote cell attachment and migration, but stabilization of focal 
adhesion sites and formation of actin stress fibres (necessary for adhesion and migration in 
non -muscle cells) require the intervention of Sdc4 and its binding to the heparin binding sites 
of FN through the HS chains (Saoncella, et al. 1999b, Woods, et al. 2000, Mahalingam, Gallagher 
and Couchman 2007).  
 
Fundamental for the mediation of FA and migration is the ability of Sdc4 to bind and activate 
protein kinase Cα (PKCα), a process that requires Sdc4 binding to PIP2 and oligomerisation. 
Briefly, upon engagement to adhesion molecules such a FN in the extracellular side, Sdc4 is 
able to bind PIP2 on its variable cytoplasmic region (LGKKPIYKK sequence, similar to a 
pleckstrin homology PH domain), which is important for the stabilisation of Sdc4 oligomers. 
Stable PIP2-associated oligomeric complexes of Sdc4 are able to bind the catalytic domain of 
PKCα on the same Sdc4 variable region, localize PKCα it in focal adhesion areas and favour its 
activation by auto phosphorylation (Oh, Woods and Couchman 1997, Oh, et al. 1998, 
Couchman, et al. 2002, Lim, et al. 2003).  
 
PKCα activation modulates the activity of the members of the Rho family of small GTPases such 
as RhoA, RhoG and Rac1 (Dovas, Yoneda and Couchman 2006, Bass, et al. 2007). RhoA is mostly 
involved in focal adhesion and stress fibres formation and is necessary for stabilisation of focal 
adhesion sites required for contraction and subsequent migration, Rac1 leads the signalling 
cascade required for cell protrusion and migration, while RhoG is involved in a series of 
processes including endocytosis and cell migration and is able to determine itself the activation 
of Rac1 (Katoh and Negishi 2003). The control of GTPase downstream signalling depends on 
Sdc4 association and PKCα-dependent phosphorylation of GTPase regulation proteins such as 
the guanine nucleotide dissociation inhibitor RhoGDIα (that interacts with Sdc4 trough 
Synectin) (Brooks, Williamson and Bass 2012, Elfenbein, et al. 2009, Dovas, et al. 2010) and 
p190Rho–guanosine triphosphatase–activating protein (RhoGAP) (Dovas, Yoneda and 
Couchman 2006, Brooks, Williamson and Bass 2012, Bass, et al. 2008). By regulating Rho 
GTPase signalling, Sdc4 is able to transduce the extracellular signal, FN binding, to the 
intracellular space and regulate the signalling cascade and cytoskeletal rearrangements 
involved in cell adhesion and protrusion.  
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The Sdc4 mediated PKCα activation is also negatively controlled by the cytoplasmic domain 
phosphorylation at a specific serine site. In fact, PIP2 binding to Sdc4 is inhibited by 
phosphorylation of Serine-183 in its cytoplasmic domain, that has been suggested to be 
mediated by another member of PKC family, PKC-δ. When Sdc4 is Ser183 phosphorylated, it 
undergoes conformational changes and is unable to bind PIP2 and form PIP2-dependent 
oligomers. Its dephosphorylation, mediated by specific phosphatases of class II, promotes PIP2 
binding to stabilise Sdc4 oligomerisation, allowing PKCα activation (Horowitz and Simons 
1998, Koo, et al. 2006, Murakami, et al. 2002).  
 
Phosphorylation-regulated binding to PIP2 is also able to control Sdc4 binding to other 
cytosolic proteins other than PKCα. For example, similarly to other Syndecans, Sdc4 is able to 
bind the PDZ domain of Syntenin on its C2 cytosolic region and the recruitment of Syntenin in 
proximity to the cell membrane is mediated by PIP2 binding to its PDZ domain, to which Sdc4 
also binds (Zimmermann, et al. 2002) and is negatively controlled by ser-183 phosphorylation 
(Koo, et al. 2006).  
 
Sdc4 has also been suggested to control cell migration and FA by regulating integrin recycling, 
in a process that is independent from PKCα activation, but is associated with syntenin binding 
and regulation of GTPse Arf6, and is controlled by Sdc4 phosphorylation by a cytosolic cSrc 
kinase (Morgan, et al. 2013). This suggests that Sdc4 is more likely to act as a regulator of 
integrins at the FA sites, rather than a co-receptor, controlling their trafficking rather than 
stabilisation, and to be crucial for the regulation of cell migration.  
Moreover, when associated with FN, Sdc4 promotes phosphorylation of focal adhesion kinase 
(FAK) (Wilcox-Adelman, Denhez and Goetinck 2002) and controls cell adhesion, migration and 
spreading. The signal appears to be mediated by Rho GTPase but not by PKCα, and it is likely 
to depend on both integrin and Sdc4 cooperative signal transduction in response to FN (Bass 
and Humphries 2002).  
 
Interestingly, FN-engaged Sdc4 oligomers are able to bind other cytoskeletal proteins such as 
α-actinin, an actin binding protein of the spectrin superfamily associated with cytoskeletal 
modulation by formation of actin microdomains, involved in adhesion and membrane 
deformation (Okina, et al. 2012, Choi, et al. 2008). Another protein that binds engaged Sdc4 
intracellularly is syndesmos, that specifically binds both C1 and V domains of Sdc4 and itself 
interacts with paxillin, involved in FA (Denhez, et al. 2002, Baciu, et al. 2000).  
 
To note, not only FN can induce Sdc4-mediated cell adhesion or spreading, but also other 
extracellular proteins, growth factors such as FGF2, and proteases. For example, Sdc4 is a cell 
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surface receptor for ADAM (a disintegrin and metalloprotease) -12, which promotes Sdc4 
oligomerisation and activation of PKCα, that determines the accumulation of activated 
β1 integrins leading to β1 integrin-dependent cell spreading and stress fibres formation, with 
RhoA-GTPase and Rac1 GTPase as a signal mediators (Thodeti, et al. 2003). This happens also 
in in cell-cell adhesion of neuronal cells, where binding of Thy-1 cell surface antigen to both HS 
chains of Sdc4 and RGD binding sites of α5β3 integrin promotes the activation of PKC followed 
by cell adhesion mediated by RhoA or cell migration involving Rac1 GTPase activation/RhoA 
inhibition if Thy1 signal is prolonged(Avalos, et al. 2009).  
 
Finally, Sdc4 has been suggested to be a major controller of calcium channels of the transient 
receptor potential canonical type (TRPC) on the cells surface. Calcium influx regulated by these 
channels is involved in cytoskeletal changes, by activation of proteins involved in actin 
modification, crosslinking, as well as of a series of calmodulin regulated enzymes. In 
myofibroblasts, Sdc4 controls TRPC inactivation (channel closure), which is dependent on PKC 
phosphorylation, and the interaction between the two proteins might involve simultaneous 
association with α-actinin. By blocking the channel, Sdc4 plays a key role in the formation of a 
myofibroblastic phenotype in these cells, characterised by α-SMA-stress fibres and focal 
adhesion points marked with OB-cadherin. In this context, Sdc4 deletion leads to loss of the 
myofibroblast mesenchymal phenotype, and to the presence of adherents junctions containing 
N-cadherin (Gopal, et al. 2015).   
 
In the last few years, a number of studies have shown an involvement of syndecans, and 
specifically Sdc4, in protein endocytosis. In particular, Sdc4 has been shown to play a role in 
FGF2 internalisation by micropinocytosis, in a process that requires Sdc4 association with lipid 
raft domains and Sdc4-medited activation of Rac1 GTPase (Elfenbein, et al. 2012, Tkachenko, 
et al. 2004). FGF2 binding induces Sdc4 clustering and shifting to non – caveolar lipid rafts, 
leading to the uptake by micropinocytosis of both molecules.  
Even if Sdc4 endocytosis has been suggested to happen synchronously with the endocytosis of 
caveolin-1 (“in tandem”), Sdc4 is not present in caveolar membrane lipid rafts (Tkachenko, 
Rhodes and Simons 2005, Tkachenko and Simons 2002). However, proximity of Sdc4 might 
induce caveolar endocytosis of nearby proteins upon HS-ligand binding leading to PKCα 
activation and activation of specific kinases (Src) or GTPases (Tkachenko, Rhodes and Simons 
2005). For example,  Sdc4 has been suggested to be involved in caveolin-mediated endocytosis 
of α5β4 integrins with a role in wound healing (Bass, et al. 2011). In this case Sdc4 supports 
endocytosis but is not endocytosed itself; it acts by mediating PKCα-dependent activation of 
RhoG upon engagement to FN (Elfenbein, et al. 2009, Bass, et al. 2011, Prieto-Sánchez, 
Berenjeno and Bustelo 2006).  
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After endocytosis, syndecans can be recycled in a process that involves alternate Syntenin – 
PDZ binding to the cytosolic tail and PIP2-syntenin association on the endosome. Arf6 is 
involved in this process by mediating PIP2 production on the endosomes trough the activation 
of a specific kinase (PIP5K). After being endocytosed, syndecan-binding to syntenin PDZ 
domains leads the HSPG to the recycling endosomal compartments, where it remains stably 
associated with syntenin as long as PIP2 levels are low. Subsequently, endosomal PIP2 
(upregulated by Arf6 activation) binding to one or both PDZ domains determines syndecan 
dissociation from syntenin and drives Sdc4 recycling back to the cell surface (Zimmermann, et 
al. 2005). During this process, syndecans can control the recycling of HS-ligands, such as the 
well-described syndecan-mediated recycling of FGF2/FGF2-receptor (Zimmermann, et al. 
2005) and β1 integrins, which affect cell spreading (Morgan, et al. 2013). Loss of Sdc2 binding 
to syntenin or syntenin inhibition lead to blockage of syndecan/syndecan cargo recycling by 
inhibiting its association with the recycling compartment, leads the proteins to degradation 
and negatively affect cell spreading. Inhibition of PIP2 binding to syntenin inhibits Syndecan 
recycling back to the surface and blocks it in the recycling compartment.  
 
6.2.4 The heparin binding site of TG2 
In 2012, three different research groups have attempted to describe the heparin binding site 
(HBS) of TG2, obtaining partially dissimilar results (Teesalu, et al. 2012b, Wang, et al. 2012, 
Lortat-Jacob, et al. 2012).  
The first group, composed of Teesalu and colleagues (Teesalu, et al. 2012b), investigated the 
heparin binding sites of TG2 using synthetic peptides of 6His-tagged human recombinant TG2. 
They investigated five different TG2 peptides of 11-14 amino acids [P1: 202-
KFLKNAGRDCSRRS-215; P2: 261-LRRWKNHGCQRVKY-274; P3: 476-RIRVGQSMNMGS-487; 
P4: 590-KIRILGEPKQKRKL-603; P5: 671-DKLKAVKGFRN-681] binding to immobilised 
heparin by surface plasmon resonance biosensor (SPR) (Fig. 6.4A).  The two peptides that 
showed higher heparin affinity were P1 (202KFLKNAGRDCSRRS215) and P2 
(261LRRWKNHGCQRVKY274), which also had a higher immunoreactivity for IgA anti-TG2 
autoantibodies from patients with celiac disease, previously suggested to interfer with TG2-HS 
binding (Teesalu, et al. 2012a). P4 (590KIRILGEPKQKRKL603) showed a small affinity to 
heparin in SPR analysis. P2 had the higher RDG-independent effect in cell attachment assays 
and contains a consensus sequence proposed for heparin binding sites of different proteins 
(261LRRWKN266 = XBBXBX)(Cardin and Weintraub 1989). The amino acids sequences of P1 
and P2 were localized in the structural model of TG2, showing that they are very close and part 
of the α-helical structures, on the surface of the catalytic domain; multiple alignment analysis 
of those sequences in different taxa and for the different human TG types revealed that they 
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were well conserved between taxa and but not among the other human TG (Teesalu, et al. 
2012b). 
 
A second group investigating TG2 HBS was Griffin’s group (Wang, et al. 2012). Basing on the 
3D arrangement of basic amino acid residues, Wang and colleagues selected two sequences, 
allowing simultaneous binding of FN, necessary for the adhesion function of TG2: 590-
KIRILGEPKQKRK-602 (HS1), located at the tip of C-terminal- β barrel 2, and 202-
KFLKNAGRDCSRRSSPVYVGR-222 plus K-387 (HS2), forming a shallow pocket lined with basic 
residues (the basic residues are in bold) (Fig. 6.4A). They suggested that that the HBS 
sequences must be in a β-sheet in order for the basic residues to face the same direction, or 
that the two basic residues must be at least 20 Å apart in an α-helix to permit the binding of 
heparin/HS. Upon structural analysis, the two clusters suggested docked well with heparin/HS 
when the enzyme was in a close conformation, while binding to the open conformation resulted 
inhibited (Wang, et al. 2012). In order to analyse the heparin binding proprieties of these 
suggested sequences, they produced TG2-expressing plasmids (pcDNA3.1-TG2) with 
mutations in the proposed HBS, substituting the basic aminoacids with alanine by site directed 
mutagenesis. As a result, they could compare WT TG2 (unmutated) with mutant HS1 (K600A, 
R601A, K602A) and mutant HS2 (K205A, R209A), that  were transfected and expressed into 
mammalian cells, including human kidney epithelial cells. TG2 binding was measured in the 
transfected cell lysates applied onto heparin-sepharose column (Wang, et al. 2012). A large 
percentage of HS2 mutants showed no binding, suggesting that the basic residues substituted 
with Ala in the TG2 HS2 mutant (K205 and R209) were critic for heparin association. Moreover, 
they demonstrated a higher affinity of heparin-sepharose to the closed form of TG2 and the 
crucial role of HS2 mutant residues in this conformation (Wang, et al. 2012).  
They subsequently produced a synthetic peptide P1, corresponding to the HS2 region from 
position 200 to position 216 of wtTG2: 200NPKFLKNAGRDCSRRSS216. The peptide represents 
the putative heparin binding site and was compared with a scrambled peptide P1s, used as a 
control. This peptide was tested in a binding-specificity assay towards Sdc4 and Sdc2. It 
strongly bound Sdc4, while Sdc2 binding resulted similar to the negative control without 
syndecans, confirming that the 200-216 TG2 region binds preferentially Sdc4. The putative 
HBS P1 peptide was also proven to support RDG-independent cell adhesion to syndecan in a 
cell attachment assay (Wang, et al. 2012). In conclusion, they suggested the region 200-
NPKFLKNAGRDCSRRSS-216 as the heparin/HS binding site, with a role in cell adhesion and 
TG2 trafficking on the cell surface in cooperation with Sdc4 (Table 6.2, Fig. 6.4B). This binding 
site is well conserved between taxa and but not among the other human TGs (Wang, et al. 
2012).  
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Finally, a third study was performed by our research group at NTU (Lortat-Jacob, et al. 2012) 
(Table 6.1, Fig. 6.4A). TG2 sequence was examined in search of basic residues organized into 
the typical consensus sequences for heparin binding (Cardin and Weintraub 1989) and two 
clusters were identified: RRWK (positions 262–265) and KQKRK (positions 598–602), which, 
even if distant on the protein sequence, are close to each other on the TG2 surface when the 
enzyme is its close conformation (GTP-bound). Further examination of the protein structure 
also revealed that three other basic residues, R19 and R28 and K634 are in close proximity to 
these two clusters in the close conformation of TG2 and could be involved in heparin 
interaction (Table 6.1, Fig. 6.4A). TG2 mutants targeting these domains were produced, 
together with other three mutants targeting K202 and K205, which form a well-exposed 
positively charged site on the opposite face of the protein, and R580, which is localised in GTP 
binding domain.  
Nine different mutant human TG2 bacterial expression plasmids [pET21a(+)TG2] were 
produced by substitution of one or more basic residues with serine, by site-directed 
mutagenesis: M1a (R262S), M1b (R263S) and M1c (K265S), independently targeting 262-
RRWK-265 cluster, M2 (K202S/K205S), M3 (K598S/K600S/R601S/K602S), M4 (R19S), M5 
(R28S), M6 (R580S) and  M7 (K634S) (Lortat-Jacob, et al. 2012) (Table 6.1, Fig. 6.4A). 
Recombinant HBM proteins were expressed and purified, and their heparin-binding ability was 
compared with WT TG2 (unmutated) by SPR. The requirement of each basic residue of the 262-
RRWK-265 cluster for heparin binding was demonstrated, as all of the M1 mutants (a-c) had a 
strong decrease in affinity to heparin, compared to the WT. At the same time, also the second 
cluster, 598-KQKRK-602, was proven very important, as the corresponding M3 mutant was 
associated with an almost complete loss of heparin binding (Lortat-Jacob, et al. 2012). The 
mutants for the single residues Arg19 (M4) and Arg28 (M5), which were considered as putative 
elements of the binding site, displayed as well a reduction in the affinity, which supports their 
role in heparin recognition and binding. Those basic residues are very close to the two 
abovementioned clusters in the tri-dimensional structure. Finally, Lys634 (M7) seemed to be 
partially involved (slower rate of binding to heparin) in the recognition and stabilization of 
heparin during binding (Lortat-Jacob, et al. 2012).  
From these results, it was deduced that the heparin-binding site of TG2 is probably composed 
of more than one element of the primary sequence, that are close to each other in the three-
dimensional structure: cluster RRWK 262-265 and KQKRK 598-602 are possibly the main 
elements (Table 6.1, blue), with the participation of the basic residues Arg19, Arg28 and 
Lys634. 
TG2 (WT or mutants) stabilisation in the open conformation determined a significant loss of 
heparin binding compared to the untreated enzyme. Heparin binding ability of a commercially 
available open-TG2, which has a stable open conformation, was tested as well and showed a 
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much lower affinity than WT TG2. In support to these finding, the two clusters RRWK 262-265 
and KQKRK 598-602 were found spatially closed in the folded conformation, but very distant 
in the open “active” one. It was concluded that the binding between TG2 and heparin/HS 
happens when TG2 is in the closed conformation and depends on the proximity of both cluster.  
The research team also investigated the role of the different mutants in RGD-independent cell 
adhesion by plating Swiss 3T3 fibroblast on FN coated plates in presence of RGD peptide. As 
expected, M1c and M3 (that had no heparin affinity) failed to support RGD-independent cell 
adhesion, while M2 and M6 allowed some residual cell attachment.  
From these results, it was concluded that the heparin binding site is made of the two clusters 
RRWK 262-265 and 598-KQKRK-602 (with K600 being the most important residue of the 
cluster). Probably the basic residues Arg19, Arg28 and Lys634 can also be involved in the 
binding (Table 6.2, Fig. 6.4B). Multiple alignment analysis of these sequences in different taxa 
and for the different TG types revealed that they are well conserved between taxa and typical 
of the TG2 (Lortat-Jacob, et al. 2012).  
 
In summary, comparison of the three studies shows that all research groups analysed TG2 
region between 200-222 as a proposed heparin binding region (Teesalu, et al. 2012b, Wang, et 
al. 2012, Lortat-Jacob, et al. 2012). Teesalu et al. considered 202-KFLKNAGRDCSRRS-215 
(peptide P1), and Wang et al. also suggested that 202-KFLKNAGRDCSRRSSPVYVGR-222 should 
form a putative binding region (Fig.6.4, Table 6.2). In particular Wang et al. found Lys-205 
and Arg-209 as critical residues for Heparin binding. Our group (Lortat-Jacob, et al. 2012) also 
considered two residues belonging to the region, Lys-202 and Lys-205 (mutant M2), explaining 
the choice with their location in the secondary structure of the protein in a well-exposed 
positively charged cluster on the surface of the protein and opposite to cluster 262RRWK265 
(M1a-c) and 598KQKRK602 (M3) (Table 6.1). This residues were not found critical for heparin 
binding, but this could suggest that maybe the most important basic residue in that region 
would be Arg209, that has been substituted by mutation in mutant HS2 of Wang et al. but not 
our mutant M2 (Teesalu, et al. 2012b, Wang, et al. 2012, Lortat-Jacob, et al. 2012) (Fig. 6.4, 
Table 6.2).  
LRRWK sequence (261-264), containing the XBBXBX consensus, was taken into consideration 
by Teesalu et al. (Peptide 2, 261-LRRWKNHGCQRVKY-274), who suggested it as a putative 
heparin binding region. Also our group (Lorat-Jacob et al.) took into consideration cluster 
262RRWK265 (M1a-c) and concluded that it is likely to be a sequence involved in Heparin and 
HS binding of TG2. In particular, here, Arg262 was suggested to have a central position in 
heparin binding. The second cluster found important for heparin binding by our group is 598-
KQKRK-602. This region overlaps with regions that were also studied by Teesalu et al. (peptide 
P4, 590KIRILGEPKQKRKL603) and Wang et al. (Mutant HS1, 590KIRILGEPKQKRK602, 
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mutations: K600A, R601A, K602A). In the first study, the region showed just a weak affinity to 
heparin while Wang et al. mutant showed no sensible differences in binding  (Teesalu, et al. 
2012b, Wang, et al. 2012, Lortat-Jacob, et al. 2012) (Fig.4, Table 6.2).  
 
Table 6.1: Putative heparin binding sites investigated by our group (Lorat-Jacob et al., 2012). The 
table shows the list of sites and regions investigated by the authors as possible heparin binding regions 
of TG2, and the mutations produced by site directed mutagenesis on full length recombinant human TG2 
in order to assess the importance of the site integrity for heparin binding.  Light blue indicates the TG2 
heparin binding site suggested by the authors (Lortat-Jacob, et al. 2012). Tri-dimensional localisation of 
the putative heparin binding sites investigated by Lorat-Jacob et al., 2012: tri-dimensional localisation 
of the sites investigated by the authors in the closed conformation of TG2. M1 and M3 sites are close to 
each other in this conformation, suggesting that heparin binding happens when TG2 is catalytically 
inactive (Lortat-Jacob, et al. 2012). Permission to reproduce this picture has been granted by the 
American Society for Biochemistry and Molecular Biology.  
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Figure 6.4: Investigation of the heparin binding site of TG2 – Comparison of investigated and 
proposed sites by three research groups (Teesalu, et al. 2012b, Wang, et al. 2012, Lortat-Jacob, et 
al. 2012). (A) Comparison of putative regions on amino acid sequence of TG2 (PDB code 3LY6) 
investigated by the three research groups  (B) Comparison of putative amino acid sequence of TG2 (PDB 
code 3LY6) proposed by the three research groups. The basic residues arginine (R) and lysine (K) are in 
bold. 
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Table 6.2: Investigation of the heparin binding site of TG2 – proposed sites by three research 
groups (Teesalu, et al. 2012b, Wang, et al. 2012, Lortat-Jacob, et al. 2012). Proposed heparin 
binding sites (HBSs) of TG2 by the three research groups in 2012. The basic residues R and K are in bold. 
The putative important basic aminoacids investigated by mutation by Wang et al.,2012 and Lorat-Jacob 
et al., 2012 are underlined; the same colour (X, X, or X) indicates the same sequence or position in human 
TG2. 
 
Paper Proposed Heparin binding site(s) of TG2 
Teesalu et al., J Pept Sci. 2012 
LRRWKNHGCQRVKY    261-274    (P2) 
KFLKNAGRDCSRRS    202-215    (P1) 
Wang et al., JBC, 2012 NPKFLKNAGRDCSRRSS 200-216 (P1) 
Lortat-Jacob et al., JBC, 2012 
RRWK 262-265 (M1) 
KQKRK 598-602 (M3) 
Other important sites:  Arg19 (M4), Arg28 (M5) and Lys634 (M7) 
 
 
In a recent study from our group, the binding proprieties of other members of the 
transglutaminase family to heparin were tested by SPR (Burhan, et al. 2016). A strong binding 
of TG1 for heparin was detected by this assay, that was higher than TG2 affinity at the same 
concentration, while TG3 and FXIIIa had only a weak affinity for heparin. The TG2 Heparin 
binding site proposed by our group [262–RRWK-265, 598–KQKRK-602] (Lortat-Jacob, et al. 
2012) has no similar sequences in TG1 and only the basic residue Arg19 was conserved and 
exposed on the surface of TG1 (Burhan, et al. 2016). The binding sites proposed by other 
groups, such as the one including the residues 202–215 (Wang, et al. 2012) are as well not 
conserved in TG1. These data suggest that the TG1 interaction with heparin/HS occurs through 
a different binding site (Burhan, et al. 2016). On the other hand, TG3 displayed two positive 
clusters similar to TG2 ones expose on the surface, that might act like a weak HBS [KNWK 259–
262 and RVRK606–609]. FXIIIa sequence showed no similarities to TG2 HBS (Burhan, et al. 
2016).  
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6.3 EXPERIMENTAL PROCEDURES 
 
6.3.1 Experimental design 
To investigate the role of HSPGs/Sdc4 in TG2 unconventional secretion in kidney cells (Fig. 
6.5), an immortalized cell line of rat TECs (NRK52E), either WT or overexpressing an EGFP-
tagged-TG2 protein, was employed. Sdc4 expression was modulated by transient transfection 
(overexpression- underexpression of Sdc4 cDNA) and inhibition of HS chains.  
In specific experiments, mutations of the putative heparin binding site of TG2 was performed. 
An in vitro approach for the simulation of abundant extracellular TG2 released in the medium 
by neighborhood cells was also employed, and the amount of TG2 retained in ECM/cell surface 
before and after Sdc4 inhibition was analyzed, with particular interest to the consequences of 
this deposition on TGF-β activation.  
Finally, the possible role of Sdc4 in the extracellular trafficking of TG2 inside vesicles has been 
analyzed by co-precipitation studies and transient transfections. Fig. 6.5 outlines the different 
approaches employed in this results chapter.  
 
Figure 6.5: Experimental design for the investigation of HSPG/Sdc4 involvement in TG2 
extracellular secretion and retention by kidney cells. 
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6.3.2 Immunoprecipitation of TG2 from whole kidney lysate  
TG2-immunoprecipitation (TG2-IP) was performed from whole mouse (healthy female 
C57BL/6) and rat (male Wistar) kidney lysate (1 mg) with 2.5 µg of a mouse monoclonal anti-
TG2 antibody (IA12) (University of Sheffield, UK), using the Pierce™ Crosslink Magnetic IP/Co-
IP Kit (Thermo Scientific) and following the protocol for IP reported in general methods 
(Chapter II). Beads with no conjugated antibody were a negative control. In selected elutions, 
HS chains of the HSPG were digested using heparitinase I (50 mU/ml) for 2 h 37°C under 
constant rotation (see 6.3.5.2 for a description). 
After IP, equal volumes of TG2-immunoprecipitates were separated by 12% (w/v) SDS-PAGE 
as described in Chapter II and immunoblotted for detection of Sdc4 using 1:500 (v/v) rabbit 
polyclonal anti-Sdc4 antibody (Ab24511 Abcam). Correct precipitation of TG2 was tested as 
well by immunoprobing with a rabbit polyclonal anti-TG2 antibody (ab80563, Abcam).  
 
 
6.3.3 Transient transfection of kidney TECs  
6.3.3.1 Cell transfection of syndecan-4 (Sdc4) cDNA 
WT and EGFP-TG2 overexpressing NRK52E cells (clone #C5 and #E6, see Chapter II for a 
characterisation of these clones) were transiently transfected with human Sdc4 cDNA using 
two different plasmids: pcDNA3_HA-Sdc4 [expression of human Sdc4 tagged with 
hemagglutinin (HA) on the N-terminus] (unpublished) and pcDNA3.1(+)_Sdc4 (human Sdc4 by 
itself) (Scarpellini 2009). These plasmids were produced by sub-cloning in Dr Verderio 
laboratory at Nottingham Trent University (NTU), by, respectively, Dr Izhar Burhan and Dr 
Alessandra Scarpellini. Plasmid maps are reported in Appendix (Fig. I).  
Plasmids were amplified by transformation of DH5α competent cells and then purified using 
the Midipep kit from Qiagen, as described in the general methods (Chapter II). Concentration 
and purity of DNA was measured by NanoDrop (Thermo scientific). In order to confirm the 
presence and the orientation of the insert in both plasmids, a diagnostic restriction digestion 
using appropriate restriction enzymes was performed.  
Transient transfection with both plasmids was performed by electroporation using 5 µg of 
plasmid and following the general method reported in Chapter II. As a control, a mock 
transfection was performed.  Quality of transfection was confirmed by simultaneous transient 
transfection of NRK52E cells with 5 µg of p-EGFP-N1 plasmid (6085-1, Clontech).  
After transfection, overexpression of Sdc4 was tested at the transcript level by quantitative real 
time PCR (qRT-PCR, see Chapter III for the method), employing the primers and thermocycling 
conditions step conditions reported in Table 6.3. After amplification, threshold cycle (Ct) 
values were obtained and averaged among replica. The 2-ΔΔCt relative quantification method 
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(Livak and Schmittgen 2001) was employed to calculate the level of expression of Sdc4.  
Efficient transfection was also assessed at a protein level by either Western blot or fluorescent 
immunostaining employing rabbit polyclonal anti-HA (C29F4, Cell Signalling Technology) and 
anti-Sdc4 (ab24511, Abcam) antibodies.  
 
Table 6.3: Primers and thermocycling conditions for the amplification of Sdc4 cDNA by 
quantitative RT-PCR.  
 
Primers 
Target Gene Name Sequence 5’-3’ Tm Product size 
Syndecan-4 Sdc4 
Sdc4 FW 5’-GAGTCGATTCGAGAGACTGA-3’  54 
366 bp 
Sdc4 RV 5’-AAAAATGTTGCTGCCCTG-3’ 56 
Cyclophilin A (CycA) 
Rat CycA FW 5’-AGCATACAGGTCCTGGCATC-3’ 54 
127 bp 
  
Rat CycA RV 5’-TTCACCTTCCCAAAGACCAC-3’ 52 
 
Thermocycling conditions 
Cycles Step T (°C) Time 
1 Denaturation 95°C 10 min 
40 
Denaturation 95°C 30 sec 
Annealing 58 °C 20 sec 
Elongation 72 °C 20 sec 
1 Melt  72 - 95°C Hold secs on 1
st
 step, hold 5 secs on next steps 
 
6.3.3.2 Cell transfection with heparin binding mutant TG2 cDNA 
NRK52 WT cells were transiently transfected with pEGFP-N1-TG2(M1c) and pEGFP-N1-
TG2(M3) plasmids, produced in Dr Verderio’s laboratory at NTU by Dr Izhar Burhan 
(unpublished) and expressing heparin binding site (HBS) - mutant TG2 in two different regions 
(Appendix, Fig II). As a TG2 control with no mutation in the heparin binding site, cells were 
transiently transfected with pEGFP-N1-TG2(WT) plasmid. This plasmid was produced in Dr 
Verderio laboratory at NTU by Dr Alessandra Scarpellini (Scarpellini 2009) (Appendix, Fig II).  
For the experimental purposes of this thesis, pEGFP-N1-TG2(WT), pEGFP-N1-TG2(M1c), 
pEGFP-N1- TG2(M3) plasmids, as well as pEGFP-N1 parental vector (p-EGFP-N1 plasmid, 
6085-1, Clontech) were amplified and purified as described in previous section. In order to 
confirm the presence and the orientation of the insert in all EGFP-TG2 and mutant EGFP-TG2 
plasmids, a diagnostic restriction digestion was performed.  
To confirm the presence of the heparin-binding mutations, the purified pEGFP-N1-EGFP-
TG2(M1c) and pEGFP-N1-EGFP-TG2(M3) plasmids were diluted in 10 mM Tris-HCl pH 8.5 at a 
concentration of 100 ng/μl and sequenced (Sanger sequencing) by Source Bioscience 
Sequencing (Nottingham, UK) using appropriate forward and reverse primers provided by the 
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company itself. The presence of the mutation was assessed in both plasmids by aligning the 
sequenced insert with WT full length TG2 cDNA on ClustalW2 web software from EMBL-EBI.  
Transient transfection with all plasmids was performed by electroporation using 5 µg of 
plasmid and following the general method reported in 2.2.10.1. As a negative control, a mock 
transfection was performed. In specific experiments, pEGFP-vector alone was employed as a 
control. Quality of transfection was confirmed by simultaneous transient transfection of 
NRK52E cells with 5 µg of p-EGFP-N1 plasmid. 
The expression of heparin-binding mutant and WT EGFP-TG2 chimera at ~100 kDa proteins 
was tested by Western blot using a rabbit polyclonal anti-GFP antibody (Ab290 Abcam).  
 
 
6.3.4 SiRNA knock down of syndecan-4 
Sdc4 knock down was performed on both WT and EGFP-TG2 overexpressing NRK52E (clone 
#C5 and #E6) cells, by transient transfection with rat Sdc4-targeting siRNA, following the 
protocol for siRNA transfection reported in 2.2.10.2. Briefly, 2∙105 cells/well were cultured in 
a 6-well plate in antibiotic-free DMEM supplemented with 5% (v/v) heat-inactivated FBS and 
2mM L-glutamine for 24 h. The day after, cells were transfected with either 100 nM rat Sdc4-
targeting siRNA [ON-TARGETplus Rat Sdc4 (24771) siRNA from Dharmacon, Thermo 
Scientific] or non-targeting scrambled control siRNA [ON-TARGETplus Non-targeting siRNA 
#1 (D-001810-01-05) from Dharmacon, Thermo Scientific], using DharmaFECT 1 (Dharmacon, 
Thermo Scientific) as transfection reagent. After transfection, cells were grown for additional 
24 hours. After transfection, knock-down of Sdc4 was tested at the transcript level by 
quantitative RT-PCR as described in 6.3.3.1 (Table 6.3).  
When knock down of Sdc4 was followed by extracellular vesicle (EVs) isolation (as described 
in Chapter V), transient transfection with rat Sdc4 - targeting siRNA/ scrambled control siRNA 
was performed on 80% confluent EGFP-TG2 overexpressing NRK52E cells cultured in a T75 
culture flask for 48 h, in 5ml antibiotic-free and serum-free medium.  
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6.3.5 Employment of Surfen and heparitinase to interfer with HS binding 
6.3.5.1 Surfen 
In order to chemically interfere with HS-binding, cells were treated with 3-12M Surfen [bis-
2-methyl-4-amino-quinolyl-6-carbamide, Sigma] (Schuksz, et al. 2008) at 37°C for 15 min or 2 
h (Scarpellini 2009, Scarpellini, et al. 2009) depending on the experiment. A 30 mM stock 
solution of Surfen was prepared in dimethyl sulfoxide (DMSO) and stored at -20°C in the dark 
in glass containers, to be diluted when necessary. In specific experiments where extracellular 
TG2 activity was measured on living cells after treatment, Surfen was applied for 10 min on a 
cell suspension kept on ice, as suggested by Esko’s group (Schuksz, et al. 2008). Briefly, cells 
were cultured in normal conditions until 80% confluent, then detached with sterile PBS 
containing 5mM EDTA in constant shaking at 37°C. Equal volumes of the cell suspension 
obtained were incubated with increasing concentration of Surfen (0, 3, 6, 9 and 12 µM) in PBS 
supplemented with 0.1% (w/v) BSA, for 10 minutes on ice.  
 
6.3.5.2 Heparitinase I 
Heparan sulfate chains of HSPGs were digested by incubation with 30mU/ml heparitinase I 
(also known as heparinase III, H8891, Sigma) at 37°C for one hour (Scarpellini 2009, 
Scarpellini, et al. 2009). Heparitinase I (Hep I) is was stored at -20°C as 5U/ml stock solution 
in an appropriate Hep I buffer [20 mM Tris-HCl, 50 mM NaCl, 4 mM CaCl2, 0.01% (w/v) BSA, 
pH 7.5], suggested by the manufacturer. When needed, the enzyme was diluted to the working 
concentration (30mU/ml) in the same Hep I buffer using either water as a solvent, for 
experiments involving cell lysates, or complete culture DMEM medium as a solvent when the 
HepI treatment was performed on living cells. In this second case, generally, a 10X 
concentrated HepI buffer was prepared [200 mM Tris-HCl, 500 mM NaCl, 40 mM CaCl2, 0.1% 
(w/v) BSA, pH 7.5], sterile filtered (0.2 µm filter), and diluted 1:9 with complete culture DMEM 
medium.  
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6.3.6 Employment of recombinant active TG2 to simulate high release of the 
enzyme in the extracellular environment  
We developed an in vitro model simulating matrix TG2 accumulation in the extracellular milieu 
of rat kidney cells, where exogenous active TG2 was added to the conditioned medium of a cell 
monolayer (Fig. 6.6). Cells were cultured in 8-well chamber slides until approximately 80% 
confluent. At this stage, cells were washed twice with serum free medium and 250µl per well 
of 5 µg/ml solution of activated recombinant human TG2 was added to the cells and incubated 
for 1 h at 37°C.  
To obtain a 5 µg/ml solution of activated TG2, 5 µg of commercially available recombinant 
human hexahistidine-tagged TG2 produced in E.coli (His6-rhTG2) (T002, Zedira) was pre-
activated with 2mM DTT in a final volume of 20µl of DMEM medium supplemented with 2% 
(v/v) heat-inactivated FBS, 2mM L-glutamine and 100 IU/mL penicillin and 100 μg/mL 
streptomycin, for 15 min on ice. After incubation, 980 µl of the same supplemented medium 
were added in order to have 1 ml of 5 µg/ml solution of activated TG2 and dilute the DTT to a 
40µM concentration, that should not interfere with cell viability.  
In specific experiments, cells were pre-incubated with either 12 µM Surfen for 15 min or 
30mU/ml Heparitinase I (HepI) for 1 h as described above. 
 
6.3.6.1 Detection of TG2 and TG2 activity in situ   
After incubation, cells were washed three times with sterile PBS pH 7.4 to remove all TG2 not 
associated with either cell surface or matrix and immunofluorescent staining of TG2 was 
performed on fixed (3% PFA/8 min) but not permeabilised cells following the general method 
for immunofluorescent staining described in Chapter II (2.2.8). Specifically, extracellular TG2 
was probed with 1:150 (v/v) dilution of a mouse monoclonal anti-TG2 antibody [Cub7402] 
(ab2386, Abcam), followed by 1:250 (v/v) dilution of a FITC conjugated sheep anti-mouse 
secondary antibody. In some experiments, also extracellular collagen type I was 
immunostained by employing a 1:500 (v/v) dilution of rabbit polyclonal anti-collagen I 
antibody (Abcam) followed by a donkey anti-rabbit-Alexa Fluor® 568, with red fluorescence.  
In order to detect TG2 activity in situ, 0.5 mM FITC - conjugated cadaverine was added to the 
medium during the incubation with 5 µg/ml recombinant active TG2, and cells were kept in 
incubation with exogenous recombinant TG2 for a longer time (6 h) to allow crosslinking 
activity to accumulate. After incubation, cell monolayer was washed carefully for three times 
with sterile PBS pH 7.4, and cells were fixed with cold methanol at -20°C for 10 min before 
mounting of the slide, as described in the general methods (2.2.9.3).  
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6.3.6.2. Immunofluorescent staining of active and total Smad3 after incubation with 
exogenously added TG2 
Cells were grown in an 8-well chamber slide until 70% confluent and treated with 12 μM Surfen  
for 15 min before addition of 20 µg/ml of pre activated Rh-TG2 for 24 h. After incubation, 
immunofluorescent staining of total Smad3 and active Smad3 (phosphorylated) was 
performed on fixed (3%PFA) and permeabilised cells [0.1% (w/v) Triton X100] following the 
general protocol reported in 2.2.8. Cells were probed with either a 1:75 (v/v) dilution of rabbit 
polyclonal anti-Smad3 antibody (#9513, Cell Signalling Technology) (total Smad3) or a 1:75 
(v/v) dilution of rabbit polyclonal anti-phospho(pSer425)-Smad3 (SAB4300253, Sigma) (active 
Smad3), both followed by a donkey anti-rabbit Alexa Fluor® 488 secondary antibody with 
green fluorescence. Total and phosphorylated Smad3 were quantified by ImageJ intensity 
analysis and expressed relative to the number of cells (DAPI staining of nuclei), and active 
Smad3 was calculated as a ratio of phosho-Smad3 over Smad3 for each one of the treatments 
performed.  
 
 
Figure 6.6: Experimental design for the simulation of abundant extracellular TG2 on a kidney cell 
monolayer and analysis of TG2 retention by kidney cells.  
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6.4 RESULTS  
 
6.4.1 Analysis of the quality of transfection plasmids 
In order to confirm the quality of transfection plasmids for transient transfection of NRK52E 
cells, both purity of DNA and presence/correct orientation of each plasmid employed in this 
chapter was analysed. Purity of plasmid DNA was measured by NanoDrop (Thermo scientific) 
and a clean DNA was confirmed for all plasmid preparations by a 260/280 ratio close to 2. 
Presence and correct orientation of the cDNA insert was confirmed in all plasmids by 
diagnostic restriction digestion (Suppl. Fig. 6.1A-B) using the appropriate restriction enzymes 
reported in the Appendix (Fig. I, II). Correct mutations of the heparin binding site were 
confirmed in pEGFP-N1-EGFP-TG2(M1c) and pEGFP-N1-EGFP-TG2(M3) plasmids by Sanger 
sequencing and ClustalW2 sequence comparison (Suppl. Fig. 6.1C). Sequence alignment 
against the TG2(WT) plasmid sequence confirmed the presence of mutation K265S in pEGFP-
N1-EGFP-TG2(M1c) and mutations K598S, K600S, R601S and K602S in pEGFP-N1-EGFP-
TG2(M3), in agreement with the transfection cDNA described by Lorat-Jacob and colleagues 
(Lorat-Jacob et al., 2012) (Suppl. Fig. 6.1C).  
 
 
6.4.2 TG2/Sdc4 co-precipitation in kidney lysates and co-localisation in 
kidney cells 
In order to investigate the interaction of TG2 with Sdc4 in kidneys, TG2-immunoprecipitation 
(TG2-IP) was performed from whole mouse (healthy female C57BL/6) and rat (male Wistar) 
kidney lysate. Immunoprecipitates were probed for the presence of Sdc4 both before (-Hep) 
and after (+ Hep) cleavage of the HS chains by digestion with heparitinase I (HepI), as described 
in the experimental procedures. A double band between 25 and 35 kDa, compatible with the 
core protein monomer size (Echtermeyer, et al. 1999) was identified as co-precipitated with 
TG2, and its detection was enhanced by  glycosaminoglycan (GAG) chains digestion with HepI 
in both mouse (Fig. 6.7A, grey arrowhead) and rat (Fig. 6.7B, grey arrowhead) kidney 
homogenates. In rat TG2-immunoprecipitates, a second band of ~40 kDa, compatible with Sdc4 
homodimer, was also visible and its detection enhanced by treatment with HepI (Fig. 6.7B, 
grey arrow). Furthermore, HepI treatment also appeared to ease the detection of TG2 itself 
(Fig. 6.7 A,B, black arrowheads).  
To visualise Sdc4, stable clones of NRK52E overexpressing EGFP-TG2 were transiently 
transfected with human Sdc4 cDNA tagged with hemagglutinin (HA), using pcDNA3_HA-Sdc4 
as described in the experimental procedures (6.3.3.1).  
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The expression of the exogenous HA-Sdc4 as a chimeric protein was confirmed by Western blot 
of lysates of NRK52E WT cells transiently transfected with pcDNA3-HA-hSdc4 for 24, 48 and 
72 h. Probing of the HA tag by Western blot confirmed expression of HA-Sdc4 starting at 24 h 
from transfection. Probing of the lysate with rabbit polyclonal anti-Sdc4 antibody confirmed 
the expression of the proteoglycan as an HA-tagged chimeric protein (Suppl. Fig. 6.2A). The 
HA tag was greatly advantageous for the detection of Sdc4, as cells transfected with a non-
tagged Sdc4 cDNA (pcDNA3.1(+)_Sdc4) and immunostained with anti-Sdc4 antibody resulted 
into a more diffuse staining (Suppl. Fig. 6.2B).  
As shown also in Suppl. Fig. 6.2B, fluorescent immunostaining of HA-Sdc4 using an anti-HA 
antibody revealed a predominant cell surface location of Sdc4 but also a strong peri-nuclear 
staining was identified in some cells (Fig. 6.7C). TG2 partially colocalised with Sdc4 in these 
compartments, as indicated by the white arrows in Fig. 6.7C (orange-yellow fluorescence), but 
it was ubiquitously expressed in the cells.  
Together, these results are compatible with TG2 association with Sdc4, as the proteoglycan is 
precipitated with TG2 and partially co-localised with TG2 on the surface and perinucleus of 
NRK52 transfected cells.  
In all experiments, transfection efficiency was confirmed by simultaneous transient 
transfection of NRK52E WT cells with 5 µg of p-EGFP-N1 plasmid, resulting in a transfection 
efficiency between 60 and 80%, depending on the experiment (Suppl. Fig. 6.3). 
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Figure 6.7: Co-precipitation of TG2 and Sdc4 from kidneys and co-localisation in kidney cells. 
(A,B) TG2-immunoprecipitation (TG2-IP) was performed on 1 mg of whole mouse (female C57BL/6) 
(A) and rat (male Wistar) (B) kidney homogenate with 2.5 µg of mouse monoclonal anti-TG2 antibody 
(IA12, University of Sheffield), using the Pierce™ Crosslink Magnetic IP/Co-IP Kit (Thermo Scientific) as 
described in 6.3.2. HS chains were digested using heparitinase I (Hep, 50 mU/ml). Elutions (TG2-IP) 
were separated by 12% (w/v) SDS-PAGE and immunoprobed with a rabbit polyclonal anti-Sdc4 
antibody (ab24511, Abcam, dilution 1:500), as well as with a rabbit polyclonal anti-TG2 antibody 
(ab80563, Abcam, dilution 1:1000). Immunoreactive bands were detected by enhanced 
chemiluminescence (Geneflow) after incubation with appropriate goat anti-rabbit IgG HRP-conjugated 
secondary antibody (dilution 1:2000, Dako) in blocking buffer. Image acquisition was performed with a 
LAS4000 imaging system (GE Healthcare). Black arrowhead indicates TG2 at ~75kDa, grey arrowhead 
the Sdc4 bands between 25 and 35 kDa of size. (C) EGFP-TG2 clones were transfected by electroporation 
using 5 µg of pcDNA-HA-hSdc4. Fixed (3%PFA) but not permeabilized EGFP-TG2 clones were incubated 
with a rabbit polyclonal anti-HA antibody (C29F4, Cell Signalling Technology– dilution 1:500) followed 
by donkey anti-rabbit IgG H&L Alexa Fluor® 568 as secondary antibody (1:1000, red), to detect cell 
surface HA-Sdc4. Nuclei were stained with DAPI. Specimens (20 μm) where scanned by confocal 
microscopy every µm, and each picture combines all the 20 levels observed. Representative pictures of 
3 fields are shown. White arrowheads indicate co’-localisation (green over red). 
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6.4.3 Effect of Sdc4 overexpression on TG2 extracellular deposition 
In order to determine the effect of Sdc4 overexpression on TG2 export by renal TECs, cells were 
transiently transfected with both pcDNA3_HA-Sdc4 and pcDNA3.1(+)_Sdc4 plasmids 
(Appendix, Fig.I).  
48 h transfection with both plasmids resulted into a several-fold increase in Sdc4 transcript as 
measured by qRT-PCR (Fig. 6.8A), confirming an increased expression of the protein 
compared to the mock transfected cells. Transfection of NRK52E WT with Sdc4 cDNA cells 
resulted in 8.72±2.22-fold increase of Sdc4 mRNA compared to the mock control when 
transfected with pcDNA3_HA-Sdc4 plasmid (p=0.03, *) and 19.93±3.41-fold increase of Sdc4 
mRNA when transfected with pcDNA3.1(+)_Sdc4 (0.001,***). Similar overexpression of Sdc4 
at the transcript level was confirmed upon transfection of EGFP-TG2 overexpressing clone #E6 
9details of this clone in Suppl. Fig. 5.1) with the same plasmids: 14.32±4.11-fold increase of 
Sdc4 mRNA compared to the mock control upon transfection with pcDNA3_HA-Sdc4 
(p=0.0006, ***) and 18.40 ± 3.87-fold increase when cells were transfected with 
pcDNA3.1(+)_Sdc4 (0.0001, ****). Transfection of EGFP-TG2 overexpressing clone #C5 with 
Sdc4 cDNA cells led to a higher increase of Sdc4 mRNA compared to the mock transfected 
control, with 44.63±4.45-fold rise when cells were transfected with pcDNA3_HA-Sdc4 
(p=0.0001, ****) and 28.94±2.04 fold increase when pcDNA3.1(+)_Sdc4 was employed 
(p=0.001, ***).  
In all cell lines analysed, Sdc4 overexpression was accompanied by a general increase in 
extracellular TG2 activity when analysed by biotin cadaverine incorporation assay on living 
cells, which was statistically significant expecially in the in two EGFP-TG2 overexpressing 
clones (Fig 6.8B). In NRK52E WT cells, only Sdc4 overexpression determined by pcDNA3_HA-
Sdc4 led to a significant increase of extracellular TG2 activity compared to the mock 
transfected control (1.21 ±0.267; p=0.03, *) while no significant variation was detected when 
the non-tagged plasmid was employed. Similarly, also in EGFP-TG2 overexpressing clone # C5 
a significant 1.68 ±0.51 -fold increase in extracellular TG2 was observed only when the HA 
plasmid was employed (p= 0.0007, ***) while transfection with pcDNA3.1(+)_Sdc4 plasmid led 
to a not significant 1.22±0.32 fold increase in TG2 export (p=0.07). The best results were 
obtained when Sdc4 was overexpressed in EGFP-TG2 overexpressing clone #E6: in this case, 
both plasmids led to a significant ~25% rise of extracellular TG2 activity (p=0.001 in the first 
case and p= 0.0005 in the second, ***). In all cases, a general variability in the experimental 
results was observed in the different experimental replica, suggesting a variable efficiency of 
each transfection performed and a variable cellular response to the overexpression itself (Fig. 
6.8, bottom chart showing the single independent experimental results). 
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Figure 6.8: Extracellular TG2 activity in NRK52 WT cells and EGFP-TG2 clones overexpressing 
Sdc4. One million WT and EGFP-TG2 overexpressing (clones #C5 and E6) NRK52E cells were 
transfected by electroporation with human Sdc4 cDNA using 5 µg of either pcDNA3_HA-Sdc4 or 
pcDNA3.1(+)_Sdc4 plasmid, and seeded in a 6- well plate. Mock transfection was employed as a control. 
48 h after transfection (A) the relative expression of Sdc4 mRNA was measured by qRT-PCR (Table 6.3) 
by 2-ΔΔCt relative quantification method (cyclophilin-A was employed as housekeeping gene). (B) 
Extracellular TG2 activity was measured as described in 2.2.9.2. Values are the average Abs (450 nm) of 
three independent experiments, each undertaken in triplicates, normalised for the relative mock 
transfected control (equalised to 1) ± SD (top graph). Individual experimental results are shown in graph 
underneath. In this case, values are the average Abs (450 nm) of three replicas of each independent 
experiment performed, normalised for the relative mock transfected control (equalised to 1) ± SD. 
Significance of the differences between treatments was determined by T-test: * = p<0.05, ** = p<0.01, 
*** = p<0.001, **** = p<0.0001. 
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6.4.4 Effect of Sdc4-underexpression or chemical inhibition on TG2 
extracellular deposition 
In order to determine the effect of Sdc4 knock down on extracellular TG2, NRK52 cells were 
transiently transfected with rat Sdc4-targeting siRNA or siRNA control for 24 h, as described 
in the experimental procedures (6.3.4). Reduction of Sdc4 expression in rat TECs was 
confirmed at transcript level by qRT-PCR (Suppl. Fig. 6.4).   There was a significant difference 
in residual Sdc4 transcript if cells were transfected twice with Sdc4 targeting siRNA (Suppl. 
Fig. 6.4), but since the residual expression was low in both cases (approximately 10% of the 
control siRNA) and  the difference in residual expression small, only one siRNA transfection 
was applied in the subsequent experiments.  
Sdc4 targeting siRNA was applied to WT NRK52 cells, resulting in 12.20 ± 0.65% of remnant 
Sdc4 transcript expression (p=0.005, **), and to EGFP-TG2-transfected clones #C5 and #E6 
(Suppl. Fig 5.1), resulting into 11.85 ± 0.44% (p=0.001. ***) residual Sdc4 in clone #C5 and an 
almost complete Sdc4 knock down in clone #E6 (0.027 ± 0.001% of residual Sdc4 expression, 
p=0.005, **) (Fig. 6.9A).  
In all cell lines analysed, Sdc4 knock down lead to a significant reduction in extracellular TG2 
activity when analysed by biotin cadaverine incorporation assay in living cells (Fig. 6.9B). In 
NRK52E WT cells, TG2 extracellular activity was 45.14 ± 11.68% of that of control cells 
transfected with scrambled siRNA (p =6.66∙10-06, ****). In EGFP-TG2 overexpressing clone #C5, 
an approximately 20% reduction in extracellular TG2 was observed (79.99 ± 10.25% of 
control,  p= 0.002, **), while, in the clone #E6, Sdc4 – targeting siRNA transfection led to ~40% 
decrease in extracellular enzyme activity (60.59 ±  12.78% of control, p=1.17∙10-05, ****), in 
three independent experiments (Fig. 6.9B).  
In order to interfere with HS-binding, cells were treated with 3-12M Surfen, an antagonist of 
HS chains of HSPGs, for 10 min on ice (Fig. 6.9C) as previously described (Schuksz, et al. 2008). 
In both WT and EGFP-TG2 overexpressing NRK52 cells, HS antagonism with Surfen (6 µM) led 
to a significant reduction in extracellular TG2 activity. NRK52 WT cells showed a statistically 
significant ~27% reduction in extracellular TG2 when cells were treated with 6 µM Surfen 
(72.69 ±25.00 % of control cells with no Surfen, p= 0.007, **), that was further reduced if Surfen 
concentration was increased, as 9 or 12 M led to, respectively, 65.26 ± 12.74% (p=4.34∙10-06, 
****) and 61.04 ±9.16% (p=3.23∙10-07, ****) residual extracellular TG2. In the EGFP-TG2 clone 
#C5, treatment with 6 µM Surfen resulted in 73.62± 24.50% remnant extracellular TG2 activity 
compared to the untreated control (p=0.04, *) which was further decreased by a 9 µM Surfen 
(67.85 ± 18.24 % of control, p= 0.002, **) and a 12 µM Surfen treatment  (59.15± 14.63% of 
control, p=0.0002, ***). Therefore, HS antagonism by Surfen led to up to a 40% reduction, 
approximately, in cell surface TG2 activity in NRK52E cells and EGFP-TG2 transfected clones. 
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LDH assay confirmed that there was no effect on cell permeability at these concentration of 
Surfen in both cell lines, excluding leaking of cytosolic components/loss of viability which may 
affect measurements of TG2 activity on the surface of cells (Suppl. Fig. 6.5A).  Also, Surfen did 
not affect the total expression of TG2, at least when used at 12 µM for 2 h at 37°C (Suppl. Fig. 
6.5B). 
In summary, the two experimental approaches for HS interference described in this section 
propose that Sdc4 knock down and HS antagonism have a negative effect on TG2 export from 
TECs, suggesting the possible involvement of HSPGs/Sdc4 in the availability of TG2 at the cell 
surface in this cellular system. 
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Figure 6.9: Extracellular TG2 activity in NRK52 WT cells and EGFP-TG2 clones after Sdc4 knock 
down. NRK52E WT and EGFP-TG2 overexpressing (clones #C5 and #E6) cells were transfected with 
100 nM rat Sdc4 – targeting siRNA for 24 h as described in 6.3.4. The same cells transfected with 100 nM 
non-targeting scrambled SiRNA were used as control. (A) the relative expression of Sdc4 mRNA was 
measured by qRT-PCR (Table 6.3) by 2-ΔΔCt relative quantification method (cyclophilin-A was employed 
as housekeeping gene). (B) Extracellular TG2 activity was measured as described in 2.2.9.2. Values are 
the average Abs (450 nm) of three independent experiments, each undertaken in triplicates, normalised 
for the relative mock transfected control (equalised to 1) ± SD. (C) NRK52E WT and EGFP-TG2 
overexpressing (clones #C5) cells were cultured in normal conditions until 80% confluent. Cells were 
detached with sterile PBS containing 5mM EDTA in constant shaking at 37°C, and equal volumes of the 
cell suspensions obtained were incubated with increasing concentration of Surfen (0, 3, 6, 9 and 12 µM) 
in PBS/0.1% (w/v) BSA, for 10 min on ice. After incubation, cells were collected by centrifugation at 500 
g/5 min and extracellular TG2 activity was measured as described in 2.2.9.2.  Values are the average Abs 
(450 nm) of three independent experiments, each undertaken in triplicates, normalised for the 
untreated control (0 µM Surfen, equalised to 1) ± SD. Significance of the differences between treatments 
was determined by T-test: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
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6.4.5 Importance of the heparin binding site of TG2 for the enzyme’s 
extracellular deposition 
The heparin-binding site (HBS) of TG2 has been mapped to two basic clusters at position 
262RRWK265 and 598KQKRK602 of TG2 by our group, forming a positively charged heparin 
binding pocket on the surface of the enzyme when it is in a close conformation (Lortat-Jacob, 
et al. 2012). The involvement of this HBS in TG2 trafficking outside the cells was investigated 
by transient transfection of WT NRK52E cells with EGFP-tagged heparin binding mutants of 
TG2 where the first (mutant M1c) and second (mutant M3) clusters were mutated by site 
directed mutagenesis. Cells were transfected with pEGFP-N1-TG2(M1c) and pEGFP-N1-
TG2(M3) plasmids, characterised by the aforementioned point mutations in the HBS (Lortat-
Jacob, et al. 2012) (Appendix, Fig. II). The first plasmid expresses a mutation in 262RRWK265 
cluster of TG2 (M1c, mutation K265S) and the second expresses four mutations in the 
598KQKRK602 of the enzyme (M3, mutations K598S, K600S, R601S and K602S) (Suppl. Fig. 
6.1C), all mutations known to inhibit the binding of purified TG2 to heparin (Lortat-Jacob, et 
al. 2012).  As a positive control, cells were transfected with pEGFP-N1-TG2(WT) plasmid, 
containing wild type human TG2 cDNA.  
Transfection efficiency was assessed by fluorescent confocal microscopy by direct count of the 
number of green fluorescent cells (transfected) over the total (nuclei) (Suppl. Fig. 6.6). 
Transfection efficiency measured in this way was 93.42 ± 6.35% of total cells for the control 
pEGFP-N1-TG2(WT) plasmid, 84.63 ± 12.56% for pEGFP-N1-TG2(M1c) and 90.15 ± 15.08% 
for pEGFP-N1-TG2(M3). No significant difference was observed between the specific plasmids 
when the efficiency was measured in this way by direct count (Suppl. Fig. 6.6). Expression of 
EGFP-TG2 chimera after transfection was also assessed by western blot, and similar amount of 
EGFP-TG2 chimera protein was detected for both mutated and wild type TG2 (Fig. 6.10A).  
Transfection of both Heparin binding mutant TG2 cDNA, by either pEGFP-N1-TG2(M1c) or 
pEGFP-N1-TG2(M3) plasmids, led to a reduction in extracellular TG2 activity compared to the 
control plasmid, when measured by biotinylated cadaverine incorporation assay on living cells 
(Fig. 6.10B). Transfection with both plasmids led to an approximate 40% reduction in 
extracellular TG2 activity, with a residual enzymatic activity of 62.15 ± 30.02 % of the control 
for M1c mutant and 61.11 ± 14.80% of the control for M3 mutant (p=7.64∙10-07, ****) (Fig. 
6.10B). 
Immunofluorescent staining of extracellular EGFP-TG2 was performed on non-permeabilised 
cells (Fig. 6.10C) and reflected the observations of the above-mentioned activity assay. 
Transient transfection with pEGFP-N1-TG2(M1c) led to a ~35% reduction in the extracellular 
EGFP-TG2 (red fluorescence) compared to the TG2(WT) control (p=0.029, *), when this was 
measured relatively to the total transfected protein (green fluorescence) (Fig. 6.10C). On the 
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other hand, transient transfection with pEGFP-N1-TG2(M3) only led to a ~20% reduction of 
extracellular EGFP-TG2 compared to the TG2(WT) control (p=0.018, *) (Fig. 6.10C). 
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Figure 6.10: Effects of mutations in TG2 heparin binding site on extracellular TG2 localisation 
and activity. (A) 1 million NRK52E WT cells were transiently transfected by electroporation with 5 µg 
of pEGFP-N1 plasmid containing either TG2(WT), TG2(M1c) and TG2(M3) as described in 6.3.3.2 and 
seeded in a 6-well plate for 48 h. Equal amounts of cell lysates (30 µg) were separated by 10% SDS-PAGE 
and immunoprobed for TG2 using a rabbit polyclonal anti-TG2 antibody (Ab80563 Abcam, dilution 
1:1000) and Actin (A5060 Sigma, dilution 1:500) as a loading control, both followed by goat anti rabbit 
IgG conjugated to HRP (Dako, dilution 1:2000). The immunoreactive bands were visualised by 
chemiluminescence after addition of ECL reagent (Biological Industries). Image acquisition was 
performed with a LAS4000 imaging system (GE Heathcare) and comparison of protein band intensity 
was obtained by Aida Image Analyzer v.4.03 (Raytest), following the manufacturer’s instructions. A 
representative blot and relative quantification normalized for the loading control and expressed relative 
to the TG2(WT) transfected control (equalized to 1) are shown. Transfected EGFP-TG2 has a molecular 
weight of ~100 kDa, while cell endogenous TG2 appears as a lower band at  ~100 kDa. (B) 1 million 
NRK52E WT cells were transiently transfected by electroporation with 5 µg of pEGFP-N1 plasmid 
containing either TG2(WT), TG2(M1c) and TG2(M3) as described in 6.3.3.2 and seeded in a 6-well plate 
for 48 h. After transfection, extracellular TG2 activity was measured as described in 2.2.9.2. Values are 
the average Abs (450 nm) of three independent experiments, each undertaken in quadruplicates, 
normalised for the control TG2(WT)-transfected cells (equalised to 1) ± SD. (C) 200,000 NRK52E WT 
cells were transiently transfected by electroporation with 5 µg of pEGFP-N1 plasmid containing either 
TG2(WT), TG2(M1c) and TG2(M3) as described in 6.3.3.2 and seeded in an 8-well chamber slide for 48 
h. Extracellular EGFP-TG2 chimera was detected by immunofluorescent staining on fixed (3%PFA) but 
not permeabilised cells by a rabbit polyclonal anti-GFP antibody (ab290,Abcam,dilution 1:500) followed 
by a donkey anti-rabbit Alexa Fluor® 568 antibody (dilution 1:1000) secondary antibody, following the 
general method described in 2.2.8. Nuclei were stained with DAPI. Representative pictures at 100X 
magnification are here shown. Cell surface and matrix bound EGFP-TG2 was quantified by ImageJ 
intensity analysis (8 non-overlapping images per section) and presented as mean relative intensity of 
red over green (total EGFP-TG2) ± SD, expressed relative to the TG2(WT) transfected cells (equalised to 
1). Significance of the differences between treatments was determined by T-test: * = p<0.05, ** = p<0.01, 
*** = p<0.001, **** = p<0.0001. 
 
 
6.4.5.1 Investigation of the effect of altered 6-O sulfation of heparan sulfate chains on the 
TG2 secretion from human kidney cells 
Recently, the distribution of 6-O sulfated groups in HS chains has been suggested to be 
important in the progression of renal fibrosis, possibly by binding specific cytokines or growth 
factors (Alhasan, et al. 2014). Alhasan and colleagues showed how two different enzyme 
families involved in 6-O sulfation of HS chains, glucosaminyl-6-O-sulfotransferases (HS6STs), 
which determine the formation of 6-O-sulfated glucosamine residues on HSPGs, and HS-6-O-
endosulfatases (SULFs), which remove them, are able to modulate fibrotic associated cell 
responses in vitro. They also showed that the level of 6-O sulfation is upregulated in vivo in the 
UUO model of kidney fibrosis (Alhasan, et al. 2014).  
Stable human kidney TECs overexpressing either SULF2 (HKC8 cells)(Alhasan, et al. 2014) or 
HS6ST (HK2 cells) (Alhasan, et al. 2014) were kindly provided by Prof Simi Ali (Newcastle 
University) and were employed to investigate whether the expression of these enzymes 
affected TG2 externalisation.  
SULF2 overexpressing HKC8 clones (SULF2#S5 and SULF2 #S11)(Alhasan, et al. 2014), as well 
as mock transfected cells, were cultured in the appropriate selective medium until confluent 
and tested for both total TG2 expression/activity and extracellular TG2 activity. SULF2 
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overexpressing clones displayed a similar level of intracellular TG2, as determined by Western 
blot (Fig.6.11A), however the control (“mock”) cells had clearly less TG2 (Fig. 6.11A), TG2 
activity measurement on whole cell lysates (total TG2 activity), when measured by biotin 
cadaverine incorporation assay, confirmed a significantly lower TG2 activity in the mock 
transfected HKC8 clones (Fig. 6.11B), while the activity of the two SULF2 overexpressing 
clones was approximately 5-fold higher (p<0.001). These data suggest that increased HS-6-O-
endosulfatases, predicted to raise the removal of HS-6-O sulfated groups, lead to increased 
expression of TG2in the cells. Alternatively, increased TG2 could be simply due to a clonal effect 
or a compensatory event.  
When cell surface TG2 activity was measured in these cells, SULF2 overexpressing clones 
displayed a significantly higher level of extracellular TG2 activity compared to the mock 
transfected control (clone #S5 was 2.39±1.96-fold higher than the mock control, p=0.024, *; 
clone #S11 was 3.42±2.63-fold higher than the mock control, p=0.003, **) (Fig.6.11C). 
However, when the extracellular TG2 activity was normalised for the total TG2 activity of the 
cells to determine the portion of TG2 activity exported, the extracellular TG2 resulted higher 
in the mock transfected control HKC8 cells compared to the SULF2 overexpressing ones, 
suggesting that HS-6-O S groups are important for TG2 export in this cell line (Fig. 6.11D).  
When the same analysis was performed in the HS6ST overexpressing HK2 clones (HS6ST #T5 
and HS6ST #T7)(Alhasan, et al. 2014) and mock transfected HK2 cells, the SULF2 
overexpressing clones displayed a ~20-25% lower TG2 compared to the stably mock 
transfected cells by western blot (Fig. 6.11E) and total TG2 activity assay (Fig. 6.11F).  When 
cell surface TG2 activity was measured in these cells, HS6ST overexpressing clones were 
showing a significantly 20-40% lower level of extracellular TG2 activity compared to the mock 
transfected control (clone #T5 was 0.81 ± 0.068 of the mock control, p =0.0002, ***, while clone 
#T7 was 0.63±0.061 of the mock control, p =2.88 ∙10-11, ****) (Fig. 6.11G). However, when the 
extracellular TG2 activity was normalised for the total TG2 activity of the cells to determine the 
portion of TG2 activity exported, the extracellular TG2 activity appeared similar between the 
HS6ST clone #T5 and the mock transfected cells, while the #T7 clone extracellular activity 
resulted still lower than the control (Fig.6.11H).  
Overall, increased sulfation of HS-6-O by HS6ST in transfected clones was not accompanied by 
increased TG2 export compared to mock transfected clones (and overall led to a reduced 
expression of TG2) while increased de-sulfation of HS-6-O by SULF2 affected the export of TG2, 
although it led to its increased expression in SULF2 transfected clones. 
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Figure 6.11: Investigation of the effect of altered 6-O sulfation of HS chains on TG2 secretion from 
human TECs.  (A – D) HKC8 mock transfected and SULF2 overexpressing clones (#S5 and #S11) were 
cultured in grown in DMEM-F12 medium supplemented with 10% (v/v) heat-inactivated FBS, 2mM L-
glutamine, 100 IU/mL penicillin, 100 μg/mL streptomycin and 400 µg/ml G418 (Invivogen). (E-H) HK2 
mock transfected and HS6ST overexpressing clones (#T5 and #T7) were cultured in DMEM-F12 medium 
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supplemented with 10% (v/v) heat-inactivated FBS, 2mM L-glutamine, 100 IU/mL penicillin, 100 μg/mL 
streptomycin and 400 µg/ml Zeocin (Invivogen). (A, B, E, F) 90% confluent cells were lysed in a mild 
lysis buffer (0.25 M sucrose, 5 mM TRIS-HCl, 2 mM EDTA, pH 7.4) (A, E) Equal amounts of protein lysate 
(100 µg) were separated by 10% SDS PAGE and immunoprobed with a rabbit polyclonal anti-TG2 
antibody (ab80563, Abcam, dilution 1:1000) as well as with a rabbit polyclonal anti-β-tubulin antibody 
(ab6046 Abcam, dilution 1:5000) as a loading control, as described in 2.2.7. 500 ng of purified guinea 
pig liver TG2 (gplTG2, Sigma) were also loaded as a standard positive control. Molecular weight of 
human TG2 immunoreactive bands is ~75kDa. (B, F) Total TG2 activity was measured on equal amounts 
of protein lysates (60 µg) as described in 2.2.9.1. Values are the average Abs (450 nm) of four replicas, 
expressed relative to the mock transfected control (equalised to 1) ± SD.  (C, G) Extracellular TG2 activity 
was measured as described in 2.2.9.2. Values are the average Abs (450 nm) of four independent 
experiments, each undertaken in quadruplicates, normalised for the relative mock transfected control 
(equalised to 1) ± SD. Significance of the differences between treatments was determined by T-test: * = 
p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. (D, H) Chart representing the extracellular TG2 
activity of each clone expressed relative to the total TG2 activity of the same cells (Extracellular TG2 
activity/ Total TG2 activity) and normalised for the relative mock transfected control (equalised to 1) ± 
SD.   
  
 
 
 
6.4.6 Role of HS chains in the cell surface retention of exogenously added 
TG2  
Having established that Sdc4 and HS can modulate the level of TG2 at the cell surface, we 
wanted to extend the investigation of this function in situations of abundant deposition of TG2 
in the ECM, which is typically found in the context of kidney fibrosis. To do so, recombinant 
TG2 was added to NRK52E and NRK49F monolayers and the amount of TG2 retained in 
ECM/cell surface with or without HS inhibition was analyzed, with particular interest to the 
consequences of this deposition on TGFβ1 activation.   
NRK52 cells were pre-incubated with the HS antagonist Surfen before extracellular addition of 
recombinant human TG2, which was pre-treated with DTT as described in 5.3.6, to allow the 
access to the enzyme active site (Stamnaes, et al. 2010). After washing, the level of TG2 retained 
to the cell surface extracellular matrix was investigated by immunofluorescence as described 
in 6.3.6.1 (Fig. 6.12A).  As the monoclonal anti-TG2 antibody CUB 7402 has no reported 
specificity for rat TG2, no or very low background fluorescence was detected in untreated cells 
(Fig. 6.12A, - Rh-TG2). Extracellularly added recombinant TG2 was retained in the pericellular 
matrix of NRK52E cells (Fig. 6.12A, + Rh-TG2).  Pre-incubation of the cell monolayer with 
surfen led to a significantly lower level of extracellular TG2 retention, which was 63% of the 
total TG2 deposited in the matrix (p= 0.04, *). 
When TG2 activity was analysed in situ by FITC-cadaverine incorporation assay (Verderio, et 
al. 1998) (Fig. 6.12B), pre-incubation of the cell monolayer with Surfen reduced extracellular 
TG2 activity in both in cells with no additional exogenous TG2 (to 35.64±1.79%, p=0.07) and 
cells with extracellularly added enzyme (to 67.89±26.33%, p=0.21). Although these differences 
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were not statistically significant, there was a clear trend of decrease in TG2 extracellular 
activity upon HS antagonism by Surfen. 
Treatment of the NRK52E matrix with heparitinase (HepI), which selectively cleaves HS chains 
at the 1-4 bounds between N-acetylglucosamine and glucuronic acid residues, led to a 
reduction in the exogenous TG2 deposition to approximately 66%, but this was not as 
significant as the reduction determined by Surfen (Fig. 6.12C).    
As fibroblast are known to produce abundant extracellular matrix (Chapter I), NRK49F 
fibroblasts were also analysed using the same approach. Extracellularly added recombinant 
TG2 strongly accumulated in the pericellular matrix of NRK49F (Fig. 13A), and partially co-
localized with collagen I, immunostained with an anti-collagen I polyclonal antibody followed 
by a secondary antibody with red fluorescence (Fig. 6.13A, red staining). When the NRK49 cell 
monolayer was pre-incubated with surfen, the amount of extracellularly retained TG2 was 
significantly reduced to 34% of the TG2 deposited in the matrix of untreated cells (p=0.0008, 
***) (Fig. 6.13A). Pre-treatment with heparitinase (HepI) determined as well a significant 
reduction in TG2 deposition in the matrix, to approximately 65% of the TG2 deposited in 
untreated cells (p≈0.05) (Fig. 6.13B). 
In summary, HS chains are important for TG2 retention in the extracellular environment once 
externalised, in an autocrine or paracrine fashion, as chemical antagonism or digestion of these 
chains had an inhibitory effect on the enzyme deposition.  
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Figure 6.12: Deposition of extracellular TG2 is reduced by employment of HS antagonist Surfen 
or digestion of HS chains in NRK52E TECs. (A) To assess retention of exogenous TG2 in the 
extracellular environment, NRK52E cells were grown in an 8-well chamber slide and treated with 12 µM 
Surfen for 15 min before addition of reduced human Rh-TG2 at a final concentration of 5 µg/ml for 1 h. 
After fixation (3%PFA), TG2 was immunostained by a mouse monoclonal anti-TG2 antibody followed by 
sheep anti-mouse-FITC. Nuclei were stained with DAPI. Representative figures at 100X magnification 
are here shown. Cell surface and matrix bound exogenous TG2 was quantified by ImageJ intensity 
analysis (8 non overlapping images per section) and presented as mean relative intensity of green over 
blue (DAPI) ± SD, expressed relative to the control without added TG2 (equalised to 1). (B) In order to 
detect TG2 extracellular activity in cells subjected to the same treatments, NRK52E cells were grown in 
an 8-well chamber slide and treated with 12 µM Surfen for 15 min before addition of reduced human 
Rh-TG2 (5 µg/ml) and FITC-conjugated cadaverine for 6 h. Cells were fixed with 90% methanol as 
described in 2.2.9.3 and nuclei were stained with DAPI. Representative figures at 100X magnification 
are here shown. Cell surface and matrix-associated TG2 activity was quantified by ImageJ intensity 
analysis (8 non overlapping images per section) and presented as mean relative intensity of green over 
blue (DAPI) ± SD, expressed relative to the control without added TG2 (equalised to 1). (C) In order to 
determine whether deposition of extracellular TG2 is reduced by digestion of HS chains in NRK52E TECs, 
these cells were grown in an 8-well chamber slide and treated with 30 mU/ml heparitinase I (Hep I) for 
1 h before addition of 5 µg/ml reduced human Rh-TG2 for 1 h. TG2 immunostaining was performed as 
described above. Representative figures at 100X magnification are here shown. Cell surface and matrix 
bound exogenous TG2 was quantified by ImageJ intensity analysis (8 non overlapping images per 
section) and presented as mean relative intensity of green over blue (DAPI) ± SD, expressed relative to 
the control without added TG2 (equalised to 1). Significance of the differences between treatments was 
determined by T-test: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
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Figure 6.13: Deposition of extracellular TG2 is inhibited by employment of HS antagonist Surfen 
or digestion of HS chains in NRK49F renal fibroblasts. (A) NRK49F cells were grown in an 8-well 
chamber slide and treated with 12 uM Surfen for 15 minutes before addition DTT-activated human Rh-
TG2 at a final concentration of 5 µg/ml for 1 h. Cells were fixed with 3% PFA. Immunostaining was 
performed by using rabbit polyclonal anti-collagen I antibody and mouse monoclonal anti-TG2 antibody 
followed by donkey anti-rabbit-Alexa Fluor® 568, with red emission, and sheep anti-mouse-FITC, with 
green emission. Nuclei were stained with DAPI. In negative controls the primary antibodies were 
omitted. Representative pictures of collagen I and extracellular TG2 stainings are shown separately (40X 
magnification) and merged (40 and 200X magnification). Cell surface and matrix bound exogenous TG2 
was quantified by ImageJ intensity analysis (8 non overlapping images per section) and presented as 
mean relative intensity of green over blue (DAPI) ± SD, expressed relative to the control without added 
TG2 (equalised to 1). (B) In order to determine whether deposition of extracellular TG2 is reduced by 
digestion of HS chains in NRK49F fibroblasts, these cells were grown in an 8-well chamber slide and 
treated with 30 mU/ml heparitinase I (Hep I) for 1 h before addition of 5 µg/ml reduced human Rh-TG2 
for 1 h. TG2 immunostaining was performed as above. Representative figures at 100X magnification are 
here shown. Cell surface and matrix bound exogenous TG2 was quantified by ImageJ intensity analysis 
(8 non overlapping images per section) and presented as mean relative intensity of green over blue 
(DAPI) ± SD, expressed relative to the control without added TG2 (equalised to 1). Significance of the 
differences between treatments was determined by T-test: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = 
p<0.0001. 
 
 
 
 
6.4.7 Interplay between HSPG and TG2 in TGF-β activation 
Having established the importance of HS chains of proteoglycans in the deposition of TG2 in 
the matrix, we asked the question whether extracellular TG2 leads to increased activation TGF-
β signalling in TECs and the function of HS-TG2 interaction in this process. Modulation of TGF-
β activity results in TGF-β receptor/ Smad3 activation, that leads to the transcriptional 
regulation of fibrosis-associated genes (Lan 2011, Inazaki, et al. 2004, Sato, et al. 2003).  
NRK52E cells monolayer was pre-treated with Surfen before incubation with recombinant 
TG2, and Smad3 phosphorylation was assessed relative to total Smad3 protein by 
immunofluorescence using specific antibodies, as described in 6.3.6.2.  
Extracellular TG2 induced Smad3 phosphorylation in the NRK52E cell monolayer (Fig. 6.14A), 
and this was greatly reduced when HS chains were blocked by Surfen (Fig. 6.14A). 
Extracellular TG2 did not change the level of total Smad3, but Surfen pre-treatment led to a 
decrease in total Smad3 (Fig. 6.14B). When the degree of Smad3 phosphorylation was 
expressed as a ratio between phosphorylated Smad3 and total expressed Smad3, Smad3 
activation was significantly increased by extracellular exogenous TG2 (3.33±1.01 times the 
control without TG2, p=3.74∙10-5, ****) (Fig.6.14C). Surfen alone did not change the level of 
Smad3 phosphorylation over total but had a strong inhibitory effect on Smad3 activation 
induced by TG2 (Fig.6.14C), which was only 1.50(±1.00)-fold the value of cells not 
supplemented with TG2 (p= 0.09) and was significantly lower than the Smad3 activation 
mediated by TG2 in cells without surfen (~43% of untreated cells, p=2.77∙10-5,****)(Fig. 
6.14C).  
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These data suggest that extracellular TG2 is sufficient to mediate TGF-β activation from TECs, 
when measured via Smad3 phosphorylation; moreover, they suggest that HS antagonism itself 
does not change the level of TGF-β activation while but TGF-β signalling is affected by 
interference between TG2-HS interaction in the matrix of NRK52E cells. 
 
 
Figure 6.14: Effect of exogenously added TG2 on TGF-β-dependent Smad3 activation. (A, B) In 
order to assess Smad3 activation, NRK52E cells were grown in an 8-well chamber slide and treated with 
12 µM Surfen for 15 minutes before addition of Rh-TG2 pre-activated with DTT, at a final concentration 
of 20 µg/ml for 24 hours. After fixation (3% PFA) and permeabilisation [0.1% (w/v) Triton X100], active 
(pSer425) (A) and total Smad3 (B) were immunostained by rabbit polyclonal antibodies reported in 
6.3.6.2, followed by donkey anti-rabbit-Alexa Fluor® 488. Nuclei were stained with DAPI. 
Representative figures at 100X magnification are here shown. Total Smad3 was quantified by ImageJ 
intensity analysis (8 non overlapping images per section) and presented as mean relative intensity of 
green over blue (DAPI) ± SD, expressed relative to the control without added TG2 (equalised to 1); little 
variation was observed in the total Smad 3 between treatments. (C) Active phosphorylated Smad 3 was 
quantified by ImageJ intensity analysis (8 non overlapping images per section) and the amount of 
activated Smad3 was presented as mean relative intensity of green over blue (DAPI) ± SD, normalised 
for the total Smad3 in the corresponding treatment and expressed relative to the control without added 
TG2 (equalised to 1). Significance of the differences between treatments was determined by T-test: * = 
p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
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6.4.8 Role of Sdc4 in the proposed pathway of TG2 unconventional 
secretion.  
In Chapter V, TG2 association with extracellular vesicles  (EV) was analysed and the release of 
TG2 from kidney cells through a vesicular type of unconventional secretion suggested. Prior 
work including that reported in this chapter have shown that HS/Sdc4 are involved in TG2 
export from kidney cells (Huang, et al. unpublished). As Sdc4 has been recently reported to 
have a role in exosome biogenesis and cargo loading by binding specific protein cargoes 
(Baietti, et al. 2012, Roucourt, et al. 2015, David and Zimmermann 2015), the hypothesis was 
formed that Sdc4 could be involved in the vesicular trafficking of TG2, with  TG2 being a Sdc4-
binding cargo in exosomes. 
To test this hypothesis, firstly, the presence of Sdc4 in EV subpopulations obtained from rat 
kidney cells was investigated by Western blotting on total lysates. Sdc4 is notoriously difficult 
to detect by Western blotting and, being a glycoprotein, would require removal of HS chains 
for its correct detection (Fig. 6.7A,B). However my work in this chapter with cells transfected 
with Sdc4 cDNA constructs showed a consistent band at ~35 kDa (Suppl. Fig. 6.2) which 
intensifies after HepI treatment (Fig. 6.7A,B).    
EGFP-TG2 overexpressing NRK52E cells were cultured in serum free medium for 36 h and the 
different vesicular fractions were isolated following the protocol described in the previous 
chapter (5.3.3) (Fig. 6.15A). Western blot analysis of the different fractions revealed an 
enrichment of Sdc4 in the exosomal fraction (P4), compared to the total cell lysate (TL), while 
a low almost undetectable level of Sdc4 was observed in the ectosomal portion (P3) and in the 
vesicle-deprived medium in the absence of Hepase treatment (Fig. 6.15A). Endogenous TG2 
and EGFP-tagged exogenous TG2 were present in these vesicular subpopulations and more 
strongly associated with the exosomal portion (P4). Both Sdc4 and TG2 values were expressed 
as percentages of EV marker flotillin-2 (Fig. 6.15A).  
Pro-fibrotic stimulus by recombinant TGF-1 (10ng/ml) did not influence Sdc4 association 
with the exosomal fraction (Fig. 6.15B). This is in contrast with TG2 that appeared more 
strongly accumulated on the exosomal fraction upon TGF-1 treatment (Chapter V).  
When the same experiment was performed in wild type NRK52E cells, Sdc4 was also found 
associated with the exosomal fraction, with no or low signal in the ectosomes (P3) and in the 
medium (S4) under the experimental conditions employed, and Sdc4 was not affected by the 
treatment with recombinant TGF-1 (Fig. 6.15C).  
To confirm Sdc4 association in exosomes from a different renal cell type, EVs were also isolated 
from renal NRK49 fibroblasts. Sdc4 was also present in the exosomes subpopulation of this cell 
line (Fig. 6.15D). 
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Altogether, within the limits of the Sdc4 detection method, these experiments suggest that in 
renal cell types, Sdc4 is not only present on the surface of cells, where it serves as a receptor, 
but also in the exosome fraction, where TG2 can be detected too (Chapter V).  
 
 
Figure 6.15: Presence of Sdc4 in extracellular vesicle (EV) fractions and cell medium. Blots from 
Fig. 5.7 of Chapter V, showing EV fractions from (A) NRK52E EGFP-TG2 clone #C5 cells (B) NRK52E 
EGFP-TG2 clone #C5 cells ± 10 ng/ml TGF-β1, (C) NRK52E WT cells ± 10 ng/ml TGF-β1 and (D) NRK49F 
cells ± 10 ng/ml TGF-β1 were stripped and re-probed for Sdc4 using a rabbit polyclonal anti-Sdc4 
antibody (ab24511, Abcam, dilution 1:500). Immunoreactive bands were detected by enhanced 
chemiluminescence (Geneflow) after incubation with appropriate HRP-conjugated secondary antibody 
(Goat anti-Rabbit IgG-HRP dilution 1:2000, Dako) in blocking buffer. Image acquisition was performed 
with a LAS4000 imaging system (GE Healthcare). For NRK52 cells, two (B,C) or three (A) independent 
experiments were performed. A representative blot is shown.  
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To investigate if TG2 and Sdc4 co-associate in these vesicles, immunoprecipitation of Sdc4 
(Sdc4-IP) was performed from lysates of EV fractions, and total cell lysates as a control, 
obtained from EGFP-TG2 overexpressing NRK52E cells (clone #C5) using a polyclonal anti-
Sdc4 antibody (Fig. 6.16A).  In exosome lysates (P4), EGFP-tagged TG2 was shown to co-
precipitate with Sdc4 (Fig. 16A, c), as it was seen to co-precipitate from IP of Sdc4 from total 
cell lysate (Fig. 6.16A, a). About 50% of the TG2 present in the P4 fraction associated with 
Sdc4, as revealed by detecting residual TG2 in the P4 “unbound” fraction (Fig. 16A, c). The 
association of TG2 with Sdc4 was proportionally lower in total cell lysate as denoted by the 
abundant unbound TG2 in cell lysate after Sdc4 IP (Fig. 6.16A, a). Sdc4 was detected via the 
usual 25-35 kDa double band. Immunoprecipitation of Sdc4 from the ectosomal (P3) lysate 
revealed that Sdc4 is indeed present in the ectosomal fraction as a 25-35 kDa double band (Fig. 
6.16A,b), although it was not clearly visible by Western blotting of total P3 lysates as shown in 
Fig. 6.15. In contrast, only the lower Sdc4-immunoreacting band was detected in the Sdc4 
immunoprecipitate from the exosomal (P4) fraction (Fig.16A, c). This band was intense and 
perhaps may result from a different degree of glycosylation of Sdc4 in exosomes (it 
corresponds to the size of the core protein, 20-22 kDa) (Fig.16A, c), although the two 
immunoreactive bands of Sdc4 were present in the total exosomal P4 lysate (as shown in 
previous Fig 6.15).   
To assess the requirement of Sdc4 for TG2 association with the vesicles, EGFP-TG2 
overexpressing NRK52E cells were transiently transfected with either rat Sdc4 targeting siRNA 
or scrambled control siRNA in serum-free antibiotic-free medium for 48 h, in order to knock 
down the expression of the proteoglycan, as described in 6.3.4. After transfection, Sdc4 
reduction was confirmed by Western blotting of total cell lysate (Fig. 6.16B) and EV fractions 
isolated as above. Immunoprobing of EGFP-TG2 exogenous chimera and endogenous TG2 in 
these fractions showed that the knock down did not alter TG2 expression in tot cell lysate, but 
reduced both endogenous (TG2) and transfected (EGFP-TG2) enzyme in the exosome (P4) 
fractions; moreover, it lowered the level of free TG2 found in the EV-free conditioned medium 
(S4) (Fig. 6.16C). TG2 association with the ectosomes (P3) was also abolished by Sdc4 knock 
out (Fig. 6.16C).  
In summary, Sdc4 was proven to associate with TG2 in extracellular vesicles, and its 
underexpression by siRNA knock downhad an inhibitory effect on TG2 association with the 
exosomal and ectosomal fraction.   
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Figure 5.16: TG2 and Sdc4 interaction in extracellular vesicle (EV) fractions and cell medium. (A) 
NRK52E EGFP-TG2 clone #C5 cells were cultured in serum-free medium for 36 h. Culture medium was 
collected, the vesicular fractions were separated by differential centrifugation as described in 5.3.3 and 
lysed in IP Lysis/Wash Buffer (Thermo Scientific). Immunoprecipitation of Sdc4 (Sdc4-IP) was 
performed on these extracts and on the total cell lysate (TL) using 2.5 µg of rabbit polyclonal anti-Sdc4 
antibody (ab24511, Abcam). Fraction lysates before immunoprecipitation (Lysate), Sdc4-IP and non-
precipitated proteins collected as a wash-out  during immunoprecipitation (Unbound) were probed for 
EGFP-TG2 chimera and Sdc4 by western blot using a rabbit polyclonal anti-Sdc4 antibody (ab24511, 
Abcam, dilution 1:500) and a rabbit polyclonal anti-GFP antibody (ab290, Abcam, dilution 1:2500) to 
investigate a possible co-precipitation of Sdc4 and EGFP-TG2 in vesicular extracts. Black arrowhead 
indicate EGFP-TG2 at ~100 kDa, grey arrowhead the Sdc4 bands between 25 and 35 kDa of size. (B,C) 
NRK52E EGFP-TG2 clone #C5 cells were transiently transfected with 100 nM rat Sdc4/targeting siRNA 
or scrambled control siRNA in serum-free antibiotic-free medium for 48 h as described in 6.3.4. After 
incubation (B) knock down of Sdc4 at a protein level was measured on equal amounts of total cell lysate 
by Western blot using a rabbit polyclonal antibody against Sdc4 (ab24511, Abcam, dilution 1:500) (C) 
culture medium was collected and vesicular fraction separated by serial centrifugation as described in 
5.3.3. Proteins and complexes from vesicles-deprived medium were precipitated by TCA and collected 
as well. Equal volumes of all fractions were separated by 12% (w/v) SDS PAGE and immunoprobed with 
a rabbit polyclonal anti-TG2 antibody (ab421, Abcam) and a rabbit polyclonal anti-GFP antibody (to 
detect the EGFP tag of EGFP-TG2 exogenous chimera), following the general method reported in 2.2.7. A 
representative blot is shown for each experiment.  
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6.5 DISCUSSION  
 
Heparan sulfate proteoglycans (HSPGs) have recently been involved in cell surface protein 
trafficking including externalisation of unconventionally secreted proteins. The HS-dependent 
pathway of FGF2 release from cells is one of the most understood example (Zehe, et al. 2006, 
Nickel 2007). TG2 has also high affinity for HS and our group was the first to report and 
characterise the association of TG2 with HS and then try and dissect its biological significance 
(Scarpellini, et al. 2009, Verderio, Scarpellini and Johnson 2009, Verderio and Scarpellini 
2010). One of the main observations was that primary dermal fibroblasts KO for syndecan-4 
(Sdc4) had a higher level of intracellular TG2 and a lower level of cell surface TG2 compared to 
wild type cells raising the hypothesis that the HS chains of Sdc4 could regulate the trafficking 
of TG2 (Scarpellini, et al. 2009). In vivo, we know that KO of Sdc4 is protective on the 
development of tubulointerstitial fibrosis (Scarpellini, et al. 2014), however a mechanism for 
this was not elucidated, as no studies have ever been performed in vitro employing renal cells.  
Work presented in this thesis has revealed that TG2 is released from cells exposed to pro-
fibrogenic TGF-β1 via extracellular vesicles, predominantly exosomes. We therefore asked 
whether Sdc4 was involved in the release of TG2 also in TEC, and hypothesised that Sdc4 could 
participate in the uptake of TG2 cargo in extracellular vesicles. 
 
Evidence for the involvement of Sdc4 in TG2 export in kidney were gained in this thesis both 
in vivo and in vitro. In vivo, it was shown that Sdc4 is part of the TG2 plasma membrane 
interactome specifically in the UUO kidney (Chapter IV) and that TG2 and Sdc4 co-precipitate 
from kidney homogenates using an anti-TG2 antibody, with increased TG2 yield upon HS 
cleavage (this chapter) (Fig. 6.7).  
In this chapter, it was shown that modulation of Sdc4 expression by cell transfection of Sdc4 
cDNA in NRK52E cells regulates the level of cell surface TG2 activity consequent to TG2 release 
(Fig. 6.8). This was observed both in wild type NRK52E cells and in stable cell lines of NRK52E 
overexpressing a EGFP-tagged TG2. Knock out of Sdc4 in the same cell lines led to a significant 
reduction of TG2 secretion, when assessed with the same method (Fig. 6.9).  
Proof that TG2 association with HS was required for secretion from cells was provided by 
evidence of lower cells surface TG2 in NRK52E cells treated with a HS antagonist (Surfen) (Fig. 
6.9) and by employment of NRK52E expressing TG2 mutants lacking the previously described 
heparin binding site of TG2 (Lortat-Jacob, et al. 2012), compared to cells expressing the wild 
type form of TG2 (Fig. 6.10).  
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Whether the HS-TG2 interaction occurred at the cell surface as previously suggested, as cells 
treated with exogenous heparitinase (which selectively cleaves HS) displayed less surface TG2 
(Scarpellini, et al. 2009), or also intracellularly still remains to be elucidated. However, in the 
current study, Sdc4 has been detected in exosomes purified from TECs, together with TG2, and 
KO of Sdc4 by siRNA led to a lower level of TG2 in the exosome fraction of TECs, suggesting a 
direct effect of Sdc4 on TG2 secretion via exosomes (Fig. 6.15 – 6.16).  
Sdc4 has been recently ascribed the function of contributing to exosome biogenesis. Work from 
Baietti et al. (2012) have proposed a role for syndecans in the biogenesis of exosomes and 
cargo loading into exosomes, in complex with syntenin and alix, an auxiliary component of 
ESCRT known to be involved in ILV formation (Baietti, et al. 2012). It was demonstrated that 
syndecan, syntenin and alix co-localise in a large population of exosomes (marked by CD63 as 
a characteristic cargo) and that ligand-mediated syndecan oligomerisation plays a central role 
the induction of syntenin-alix mediated intraluminal budding of these exosomes, by binding 
syntenin on its PDZ domain. Upon ligand binding to syndecan HS chains on the endosome, 
syndecan clustering has been shown to stimulate the recruitment of syntenin-alix complexes 
and subsequently support the budding process. Syntenin links syndecan to alix by interacting 
with alix through its N-terminal domain and with syndecan through its PDZ domain. 
Consequently, the HSPG, together with its cargoes such as FGF2 and FGFR, is found located on 
syntenin and alix enriched exosomes (Baietti, et al. 2012, Friand, David and Zimmermann 
2015).  
 
In the light of this, the present study cannot distinguish whether Sdc4 affects the release of TG2 
by interacting with the enzyme intracellularly, because of Sdc4 implication in exosome 
biogenesis and cargo selection, or exclusively outside the cell, being a strong previously 
characterised interacting partner of the enzyme on the cell surface and extracellular space.  
Whether or not TG2 interacts with Sdc4 inside the cell, it is clear that the importance of HS 
extends to the localisation/distribution of TG2 outside the cell, since treatment of kidney 
cryosections with heparitinase, which selectively cleaves HS on the surface, consistently led to 
loss in extracellular TG2 in the AAN and SNx model (Burhan, et al. 2016, Scarpellini, et al. 2014).  
 
As a key feature of CKD is a large release of TG2 in the extracellular matrix, we hypothesized 
that extracellular HS chain largely contribute to TG2 retention and distribution in the matrix.  
To confirm this, we developed an in vitro model simulating TG2 accumulation in the 
extracellular milieu of renal cells, by addition of exogenous recombinant TG2 on cell 
monolayers (Fig. 6.6). This model was employed to determine the contribution of HS chains in 
matrix retention of the recombinant enzyme, by performing antagonism of HS chain with 
Surfen (Schuksz, et al. 2008) or HS digestion by heparitinase (Fig. 6.12 – 6.13).  As secreted 
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TG2 is likely to be “distributed” in extracellular space from TG2-rich secreting cells (TECs) to 
the adjacent matrix producing cells, such as the interstitial fibroblasts, and the long HS chains 
are likely to contribute to the distribution of the enzyme in the matrix between adjacent cells 
(Verderio, Scarpellini and Johnson 2009), both TECs, known to export large TG2 during 
fibrosis, and renal fibroblasts (NRK49F), known to be rich in cell surface HSPGs (Clayton, et al. 
2001) and produce a large amount of extracellular matrix, were analysed.  
HS were confirmed to be important for the retention of extracellular TG2 in the matrix, as their 
removal led to la large wash out of the exogenously added enzyme, and was particularly 
significant on kidney fibroblasts (Fig. 6.12 – 6.13).  
 
Another relevant finding in this chapter is the evidence of increased TGF-β signalling 
(measured by downstream Smad3 phosphorylation) induced by extracellular TG2 specifically, 
when added exogenously to a NRK52 monolayer, and impairment of this process by HS 
antagonism with Surfen (Fig. 6.14). TGF-β is a central mediator of kidney fibrosis and TG2 has 
been suggested before to promote its activation by crosslinking the latent binding protein 
LTBP to the matrix (Nunes, et al. 1997, Burhan, et al. 2016). In a previous chapter of this thesis, 
TG2 was highlighted as a central mediator of TGF-β activation in kidneys subjected to UUO, as 
its KO was shown to impede cytokine activation upon disease (Chapter III). A previous 
published work from our group has shown that also Sdc4 KO results in a strong reduction in 
TGF-β1 activation and inhibition of TG2 accumulation in the matrix in experimental models of 
CKD, with a protective role against the progression of fibrosis (Scarpellini, et al. 2014).  
Here, a cooperation between HSPGs and TG2 in the activation of TGF-β from renal TECs has 
been highlighted. The inhibition of TGF-β activation upon HS antagonism observed in these 
study (Fig.6.14) led us to the hypothesis that HS regulates TGF-β activity by affecting the 
matrix deposition of TG2. Moreover, previous studies have suggested that HS chains could 
promote LTBP deposition in the matrix and its binding to FN (Chen, et al. 2007). Altogether, 
these findings led us to elucidate an interplay between TG2 and HSPGs in the activation of TGF-
β, as summarized in Fig. 6.17. In this model, HS chains contribute to TGF-β activation recruiting 
both TG2 and LTBP to the ECM in association with FN. Here, TG2, which also is a binding 
partner for FN, promotes TGF-β activation by catalysing the incorporation of LTBP in the ECM. 
Moreover, TG2 promotes matrix remodelling by crosslinking FN, conferring mechanical 
resistance to the matrix. Large LTBP crosslinking to the matrix and matrix stiffening, on a side, 
and LAP binding to cell surface integrin, on the other, are thought to be sufficient to produce 
mechanical tension necessary for TGF-β activation. In summary, these findings suggest that 
controlling matrix localisation of TG2 by HS regulation has ultimately an impact not only on 
the extracellular TG2 enzymatic activity but also on the activation of latent TGF-β. This is 
particularly crucial in conditions of fibrosis, when large TG2 is secreted at the site of injury and 
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retained by HS chains and FN in close proximity to the secreted large latent TGFβ complex, 
whose secretion is also upregulated upon CKD and its localisation in the matrix also controlled 
by HS chains trough LTBP binding.  
 
Lastly, access to clones of human TECs stably expressing SULF endosulfatases and HS6ST 
sulftransferases led us to initial data on the role of HS sulfation on TG2 availability outside the 
cells. It is possible that removal of 6-O-sulfated glucosamine residues leads to a lower level of 
TG2 release and consequent detection on the cell surface (Fig. 6.11). Vice versa, an increase in 
of 6-O-sulfation leads to a reduction in intracellular TG2 but this is not linked to a detectable 
incraese in TG2 on the cell surface (Fig. 6.11), as expected by the reasoning that 6-O-sulfation 
affects the degree of TG2 association with HS chains.   
 
In conclusion, results from this Chapter suggest that HSPG Sdc4 has at least two roles in the 
promotion of kidney fibrosis: on a side, it contributes to TG2 export by TECs, which is likely to 
happen by exosome release (Chapter V), and on the other, it controls TG2 retention and 
deposition in the matrix in proximity to the latent TGF-β complex, contributing to the cytokine 
activation by TG2. Despite the importance of HS/Sdc4 for TG2 secretion by TECs has been 
confirmed in this study, the exact mechanism by which Sdc4 contributes to the enzyme release 
into exosomes has still to be elucidated, to understand whether TG2-HS binding happens inside 
the cell and determines TG2 loading in the exosomes during their biogenesis, or exclusively 
outside the cell by a so-called “trapping mechanism”. In either case, HS binding of TG2 still 
remains an interesting clinical target against the development of disease, as its inhibition 
reduces TG2 accumulation in the tubulointerstitium as well as strongly inhibiting TG2-
mediated activation of the pro-fibrotic cytokine TGF-β.  
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Figure 6.17: Interplay of TG2 and HS in the mechanical activation of latent TGF-β. TG2 is released 
from cells in the progression of kidney fibrosis and cell surface HS are critical for its extracellular 
recruitment. By calcium-dependent transamidation, extracellular TG2 increases the general degree of 
crosslinking of the ECM (1), produces a remodelled and stiffened matrix typical of the fibrotic condition 
(2) and incorporates LTBP in the ECM, storing large latent TGF-β (3). These events are a pre-requisite 
for the mechanical release (depicted by the background orange arrow) of soluble TGF-β dimer from 
large latent TGF-β complex, occurring via LAP- integrin binding on the cell side, and LTBP binding to a 
sufficiently remodelled ECM on the extracellular side. Under these conditions, cell contraction will result 
into TGF-β release, and consequently engagement with its receptor (4). HS have been reported to 
mediate LTBP association with the matrix. We have given new evidence that antagonism of HS lowers 
the recruitment and retention of TG2 to the matrix and greatly reduces activation of TGF-β by 
extracellular TG2.  
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Chapter VII: Final discussion 
 
Transglutaminase 2 (TG2) is a multifunctional enzyme with many pathological roles in human. 
Its transamidating activity is strictly controlled by the low Ca2+/GTP ratio inside the cell in 
physiological conditions; conversely, it is induced in pathological conditions when sufficient 
Ca2+ enters the cells. Therefore, as TG2 is only activated in disease, inhibition of TG2 is 
anticipated not to have an adverse effect in normal cells, making the enzyme an attractive 
target for therapy in a number of pathological conditions.  
TG2 is a ubiquitous protein found in the cytosol, in mitochondria and in the nucleus, but it is 
also released in the extracellular environment as a leaderless unconventionally secreted 
protein, where the high Ca2+ concentration activates the protein’s transamidation activity; 
however, TG2 has also been ascribed non-enzymatic roles in the extracellular space, binding 
FN, integrins and cell surface HSPGs and acting as a scaffold protein. In the extracellular 
environment, all these functions of TG2 concur to induce wound repair and scar formation. 
Examples of diseases due to TG2 malfunction are those arising from fibrosis progression and 
evasion of proliferation control. TG2 has been implicated in lung, liver, heart and kidney 
fibrosis (Verderio, et al. 2015, Small, et al. 1999, Mirza, et al. 1997, Zhao, et al. 2011, Griffin, 
Smith and Wynne 1979, Olsen, et al. 2011) and atherosclerosis (Williams, et al. 2010, Haroon, 
et al. 2001, Bakker, Pistea and VanBavel 2008). 
Fibrosis can be regarded as a process of uncontrolled wound healing, determined by a chronic 
insult and inflammation and TG2 contributes to fibrosis in three ways: by increasing matrix 
deposition and stabilisation, which counteract matrix degradation, promoting the activation of 
TGF-β through matrix recruitment of the latent TGF-β complex, and favouring cell adhesion 
upon matrix degradation and tissue damage, with effects on both fibroblast proliferation and 
inflammatory cells recruitment.   
As the carcinogenic process can be regarded as an uncontrolled wound healing process, and 
chronic tissue injury and inflammation are an important risk factor in the progression of 
malignant tumours, wound healing and malignant cancer have been suggested to have strong 
similarities, including matrix remodelling, cell adhesion and angiogenesis. Therefore, 
dissecting the pathway of TG2 export, which was the purpose of this thesis, is not only relevant 
to CKD but also to fibrosis at large and even cancer treatment.  
 
Chronic kidney disease (CKD) is a pathology characterised by loss of kidney function over time, 
whose main feature is a progressive fibrosis of the organ, leading to kidney failure at its end 
stage (ESKF). The incidence of CKD is on the increase as it is linked with ageing and other 
conditions such as diabetes, obesity and cardiovascular diseases. Currently there is no cure for 
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CKD, and replacement therapy or dialysis are the only treatments currently available for ESKF 
patients. Moreover, risk of cardiovascular disease and death by heart failure increases with the 
progression of CKD, due to hypertension and arteriosclerosis as well as impaired renal 
filtration of uremic toxins (Herzog, et al. 2011, Sarnak, et al. 2003, Vanholder, et al. 2003, 
Lisowska-Myjak 2014, Moradi, Sica and Kalantar-Zadeh 2013). Beside dialysis and transplant 
for end stage patients, the only treatments employed at the moment are aimed to counteract 
CKD effects and associated syndromes, such as the control of blood pressure, anaemia and 
mineral bone disorder (MBD) (Yamaguchi, Tanaka and Inagi 2016, Pergola, et al. 2016, Basile, 
Brandenburg and Torres 2016, Carson, et al. 2009).   
 
In this study, the fibrotic model of CKD was used as a platform to study the mechanism of TG2 
externalisation to the extracellular matrix (ECM) as it precedes and determines the pro 
fibrogenic role of TG2. It is well established that TG2 accumulates in the tubular interstitium 
and glomerular matrix in several experimental models of CKD and in patients during the 
progression of CKD [reviewed in Chapter I and (Verderio, et al. 2015)], however, the specific 
mechanism of TG2 release from kidney cells is still largely unknown. 
Pan inhibitors of TG convincingly reduce renal fibrosis, and in the current study (Chapter III) 
we have demonstrated that TG2-KO is protective in the unilateral ureteric obstruction (UUO) 
experimental model mimicking the late stages of CKD, with advanced tubulointerstitial fibrosis, 
confirming and extending the finding that TG2-KO is protective at earlier stages (Shweke, et al. 
2008). Given the clear direct association of extracellular TG2 to the fibrotic process and the 
protective role of TG2 inhibition, TG2 can be regarded as a potential target against the 
progression of CKD. However, the creation of a specific TG2 inhibitor of TG2 extracellular 
activity is made difficult by the presence of a highly conserved catalytic core within TG family 
members and between TGs and a number of cysteine proteases. For example, defects in TG1 
activity have been shown to determine an autosomal recessive skin disorder characterised by 
abnormal cornification, known as lamellar ichthyosis  (Matsuki, et al. 1998, Huber, et al. 1995, 
Candi, et al. 1998), while Factor XIII-null animals have impaired coagulation and uncontrolled 
bleeding (Koseki-Kuno, et al. 2003). 
 
Aware of this problem and knowing the potential uniqueness of TG2 secretion pathway, in this 
thesis, we suggested to interfere with the release of TG2 from kidney cells, rather than with the 
extracellular activity of TG2, as a way to control the pro-fibrotic role TG2 in fibrosis 
development. Therefore we believe that elucidation of the mechanism of TG2 unconventional 
secretion by tubular epithelial cells is key to control the enzyme’s pathological role.  
We anticipated that unbiased analysis of all TG2-interacting proteins at the cell-matrix 
interface in kidneys subjected to experimental CKD (the UUO model) would highlight key 
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partners in the enzyme’s secretion. To achieve this, we proposed a novel experimental 
approach combining TG2 immunoprecipitation from whole kidney membrane preparations of 
WT kidneys with negative control immunoprecipitation from TG2-null kidneys from inbred 
mice (Chapter IV). TG2 associated proteins were identified with high resolution quantitative 
SWATH-MS acquisition. The proposed strategy could be adapted for precision targeted 
proteomics for the analysis of other systems. 
The proteome of the UUO kidney was fully defined at the start of the project, prior to the 
production of the TG2 interactome. This showed upregulation of established and potentially 
new markers of kidney fibrosis, including a significant increase in TG2, matrix proteins and 
known markers of fibroblast proliferation/myofibroblast activation (Chapter III). The TG2-
precipitated proteins from the UUO kidney have been identified and used to interrogate the 
UUO proteome.  
A set of vesicular proteins potentially involved in TG2 export from kidney cells clearly emerged, 
and among them a striking number were exosome-associated proteins (Chapter IV). The TG2 
partners involved with trafficking and exocytosis were not increased post-UUO, generating the 
hypothesis of their specific role in trafficking of TG2. On the contrary, a group of proteins 
involved in ECM-receptor organisation, a pathway that we report to be significantly 
overexpressed in the UUO kidneys, were also all partners of TG2. This finding is consistent with 
the existence of a pathway of TG2 secretion during fibrosis progression driven by vesicular 
trafficking specific for TG2, and its subsequent association with a protein network responsible 
for ECM dynamics leading to matrix accumulation. 
 
To validate the idea of a vesicular secretion mechanism of TG2, we relied on tubular epithelial 
cells (TECs), known to produce and secrete the largest quota of TG2 during fibrosis (Chapter V 
– VI).  Isolation and analysis of TG2 in extracellular vesicles revealed enrichment of TG2 mainly 
in vesicle of intraluminal origin (exosomes), which increases in the presence of TGF-β, 
therefore in situations of fibrosis (Chapter V). Evidence is presented which suggest that TG2 is 
located on the surface of these vesicles. Although not demonstrated in this thesis, it is possible 
that vesicular TG2 could contribute to the adherence of vesicles to the ECM once secreted. A 
portion of TG2 was also identified in larger vesicles shedded from the plasma membrane 
(ectosomes), which however were less enriched in TG2. Altogether, the results obtained 
allowed to suggest a possible secretion mechanism of TG2 from kidney cells during the 
progression of fibrosis, which is represented in Figure 7.1.   
The role of EVs in kidney is only beginning to be understood (Zhang, et al. 2016). As in other 
systems, EVs could contribute to intercellular communication and disease spreading in 
physiopathological conditions and could transfer their content including TG2 to distant cells 
even from organ to organ.  
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Another main finding in this study is the specific association of TG2 with Sdc4 in the UUO 
kidney and not in the healthy kidney, which confirms the notion that Sdc4 cooperates with TG2 
in fibrosis development (Burhan, et al. 2016, Scarpellini, et al. 2014). Here we have shown that 
Sdc4 is critical in TG2 extracellular trafficking by vesicles, as less TG2 is found in the EVs when 
Sdc4 is knocked down (Chapter VI).  
It is fascinating to hypothesize an intracellular interaction between TG2 and Sdc4-HS inside 
the cells, that would contribute to the enzyme loading into intraluminal vesicles for secretion 
(Figure 7.1). As syndecans have been recently proposed to play a role in the exosome 
biogenesis and cargo loading (Roucourt, et al. 2015, Baietti, et al. 2012, Friand, David and 
Zimmermann 2015), it is tempting to speculate that TG2 and HS chains would interact, if 
present in the same vesicle.  
Although we currently do not know if TG2 interacts with Sdc4/HS inside the cell, it is well 
established that the interaction of TG2 with HSPG/Sdc4 occurs at the cell surface/ECM, and 
that it is crucial for TG2 deposition in vivo (Burhan, et al. 2016, Scarpellini, et al. 2014) and in 
vitro (Chapter VI). Here, in TECs, requirement of TG2 interaction with HS chains for both TG2 
extracellular secretion and matrix retention has been confirmed (Chapter VI), and a 
cooperative role for HS chains and extracellular TG2 in TGF-β activation in the ECM proposed, 
with some of these data recently published in Scientific Reports (Burhan, et al. 2016).  
As we showed that TG2 is likely to be located on the surface of secreted exosomes, Sdc4 and 
other HSPGs present in the matrix (such as perlecan, another HSPG identified in the TG2 
interactome post-UUO), could contribute to the retention of TG2-containing vesicles in the area 
via TG2-HS interaction. Therefore TG2 could promote adhesion and matrix crosslinking in this 
way (Fig. 7.1). TG2 is a known adhesive protein, but to our knowledge an adhesive role of 
vesicular TG2 has never been proposed. This is in line with recent thinking ascribing to EV the 
property of releasing ECM proteins like FN and essentially be conducive of cell adhesion and 
migration  (Sung, et al. 2015).  
In terms of “TG2 treatment” one could envisage that blocking the TG2-HS interaction by means 
of small inhibitors or monoclonal antibodies could lower TG2 release and accumulation in the 
matrix. Block of TG2 inside the cell would not lead in principle to negative effects being the 
enzyme mostly silent intracellularly.  
 
TG2 is not the only matrix remodelling enzyme: lysyl oxidase proteins (LOX) and lysyl oxidase 
– like proteins (LOXL), which function as an extracellular amine oxidase in a copper dependent 
way leading to deamination of the epsilon amino group of a peptide bound lysine residue of 
collagen and monomers of elastin.  The role of LOX in renal fibrosis is less studied (Di Donato, 
et al. 1997, Grau-Bove, Ruiz-Trillo and Rodriguez-Pascual 2015, Goto, et al. 2005, Yang, et al. 
2010), however according to Mehal et al., LOXL2 has been suggested as a central element of 
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every fibrosis model, belonging to a “core pathway” of fibrosis (Mehal, Iredale and Friedman 
2011). The finding that bot h LOXL2 and TG2 are overexpressed in idiopathic pulmonary 
fibrosis (Chien, et al. 2014, Olsen, et al. 2011) suggests that the two enzymes could co-
participate to the deposition of matrix. On the other hand, it cannot be ruled out that one class 
of proteins could compete for the same residues.  
 
Future work from our group will focus on the elucidation of the role of HS/Sdc4 interaction 
intracellularly, to understand at which stage of the TG2 secretory pathway the proteoglycan is 
involved. This will allow us to implement the suggested pathway of TG2 secretion and advise 
possible targeting strategies for the inhibition of TG2 secretion.  
At the same time, a number of other proteins identified in the TG2 interactome as significantly 
associated to the enzyme upon disease might be investigated, with particular interest to the 
proteins associating to the enzyme in other compartments, such as the cytosol, the nuclear and 
the mitochondrial compartment, to understand their possible contribution to the large number 
of cellular responses happening during CKD.  
The consistent identification of a TG2 association to the cytoskeletal proteins is another 
fascinating field of study, that might reveal additional roles for TG2 in controlling cellular 
responses upon disease. For example, mechanical tension produced by cytoskeletal 
remodelling has been shown to contribute to TGF-β activation (Giacomini, et al. 2012, Wipff 
and Hinz 2008, Hinz 2009, Wells and Discher 2008). If TG2 in the cortical cytoskeleton 
determines contraction of kidney cells, that might happen by localised calcium influx and TG2-
mediated crosslinking,  a dual role for the enzyme in the activation of TGF-β may be envisaged, 
both outside and inside the cell, where it could be transiently activated by the loss of calcium 
homeostasis. 
Finally, having produced a the UUO proteome and highlighted a number of proteins 
substantially upregulated in conditions of disease, it would be useful to validate some of the 
novel ones as potential biomarkers of disease.  
Having shown that TG2 is implicated in the development of fibrosis in the UUO model, and 
proposed the way TG2 might be secreted from tubular epithelial cells, which is critical to TG2-
mediated matrix crosslinking leading to fibrosis, it would be of interest as a future work to 
confirm these findings in patients’ biopsies with a view of establishing anti TG2 therapies. 
Work from the group of Tim Johnson (Sheffield Kidney Institute) has shown that TG2 is 
upregulated in patients biopsies with CKD of different aetiologies (Johnson, et al. 2003), and  
that increased TG2 and TG2 crosslinks can be identified in urine and may be diagnostic of 
fibrosis (da Silva Lodge, El Nahas and Johnson 2013, Shrestha, et al. 2014). It is anticipated that 
refinement of the methodology to detect TG2 and its products [current methods cannot be 
routinely used in clinics as not quantitative and reproducible (TS Johnson, personal 
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communication)] might facilitate TG2 investigation in vivo in clinical samples, establishing a 
link between the abnormal activity of TG2 and disease, thus setting the basis for TG2-targeted 
treatment in fibrosis.  
 
 
CHAPTER VII – FINAL DISCUSSION 
 
393 
 
Figure 7.1: A proposed pathway for TG2 unconventional secretion and extracellular localisation 
by TECs. TG2 is secreted unconventionally by exosomes originating from late endosomes as 
multivesicular endosomes (MVB) which then fuse with the plasma membrane releasing the intraluminal 
vesicles (ILV) outside the cells (exosomes). (A) The biogenesis of TG2-bearing exosomes is mediated by 
ceramide, as the inhibitor of n-SMase GW4869 significantly reduces the presence of TG2 in the exosome 
fraction in the extracellular space (Fig. 5.8). TG2, which has high affinity for HS, is loaded on the surface 
of the ILV as a HS/SDC4 cargo, and exposed on the surface of the formed exosome. (B) Following fusion 
of the outer membrane of MVB with the plasma membrane, the TG2-bearing exosomes likely accumulate 
in the ECM by TG2 binding to ECM/cell surface protein partners in an “autocrine” or “paracrine” fashion. 
(C) Once released with exosomes, TG2 could also undergo a conformational change due to the high 
Ca2+/GTP ratio of the extracellular space, with a lowering or even loss HS affinity; the free TG2 could 
bind the HS of other proteoglycans or other ECM partners. If this theory will be confirmed, it might 
explain both TG2 secretion and increased extracellular TG2 accumulation by TECs upon CKD, connecting 
the mechanism of export with the crucial TG2 role in matrix crosslinking as well as with its involvement 
in the increased cell adhesion. (D) In the matrix TG2 acts as an adhesive protein and matrix crosslinker 
promoting fibres accumulation and latent TGF-β recruitment. In the matrix, TG2 and HS/Sdc4 cooperate 
in the activation of TGF-β, as shown in Fig. 6.17. (E) TG2 is also present in ectosomes. It is possible that 
TG2 once secreted via exosomes, it is captured by the PM and retained on ectosomes shed by the PM. 
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Supplementary data 
 
S.1 SUPPLEMENTARY DATA OF CHAPTER III 
 
S.1.1 Fold Change analysis of SWATH-MS protein expression data 
S.1.1.1 Fold change analysis of WT UUO vs WT Sham operated  
Supplementary Table 3.1: Outcome of the fold change (FC) analysis between WT UUO mice (21 
days) and WT Sham operated mice (21 days) [C(FC) ≥ 0.5].  
 
  Protein ID log2(FC) Abs(FC) C(FC) p-value (FC) 
1 sp|Q80YX1|TENA_MOUSE 6.31 79.49 0.71 4.6E-04 
2 sp|P68373|TBA1C_MOUSE 6.24 75.77 0.64 2.1E-01 
3 sp|Q60590|A1AG1_MOUSE 6.19 73.04 0.71 5.7E-01 
4 sp|Q9R233|TPSN_MOUSE 5.19 36.41 0.76 7.4E-04 
5 sp|Q07235|GDN_MOUSE 4.68 25.69 0.64 2.5E-02 
6 sp|Q08619|IFI5B_MOUSE 4.25 19.08 0.60 1.7E-06 
7 sp|Q9ET54|PALLD_MOUSE 4.07 16.84 0.57 8.7E-01 
8 sp|Q91X17|UROM_MOUSE 4.03 16.34 0.85 3.4E-03 
9 sp|Q60847|COCA1_MOUSE 3.99 15.92 0.82 9.5E-04 
10 sp|Q05144|RAC2_MOUSE 3.96 15.51 0.63 7.6E-05 
11 sp|Q9WVJ9|FBLN4_MOUSE 3.89 14.84 0.74 2.8E-05 
12 sp|O88207|CO5A1_MOUSE 3.74 13.34 0.78 2.8E-05 
13 sp|Q64449|MRC2_MOUSE 3.73 13.22 0.78 9.4E-01 
14 sp|P29416|HEXA_MOUSE 3.51 11.41 0.70 1.7E-01 
15 sp|Q61554|FBN1_MOUSE 3.44 10.84 0.89 4.4E-04 
16 sp|Q9CZH7|MXRA7_MOUSE 3.43 10.77 0.51 1.8E-02 
17 sp|P20491|FCERG_MOUSE 3.39 10.47 0.61 8.3E-01 
18 sp|A6X935|ITIH4_MOUSE 3.33 10.03 0.51 2.4E-02 
19 sp|P37889|FBLN2_MOUSE 3.27 9.65 0.81 3.3E-03 
20 sp|P19001|K1C19_MOUSE 3.26 9.57 0.86 1.2E-03 
21 sp|Q8K1B8|URP2_MOUSE 3.25 9.50 0.71 1.2E-02 
22 sp|P11672|NGAL_MOUSE 3.24 9.42 0.78 2.8E-05 
23 sp|P14106|C1QB_MOUSE 3.24 9.42 0.70 8.2E-07 
24 sp|P37804|TAGL_MOUSE 3.21 9.27 0.89 2.7E-04 
25 sp|P14483|HB2A_MOUSE 3.21 9.26 0.69 2.2E-04 
26 sp|P49710|HCLS1_MOUSE 3.14 8.84 0.69 1.2E-02 
27 sp|P28653|PGS1_MOUSE 3.13 8.73 0.86 1.6E-04 
28 sp|Q08091|CNN1_MOUSE 3.10 8.59 0.80 6.2E-03 
29 sp|P20152|VIME_MOUSE 3.10 8.56 0.90 5.4E-05 
30 sp|Q01149|CO1A2_MOUSE 3.09 8.54 0.79 2.2E-03 
31 sp|P02802|MT1_MOUSE 3.08 8.45 0.61 9.0E-02 
32 sp|P14438|HA2U_MOUSE 3.06 8.32 0.80 1.9E-02 
33 sp|P10107|ANXA1_MOUSE 3.03 8.17 0.84 2.4E-04 
34 sp|Q8C4U3|SFRP1_MOUSE 3.03 8.17 0.57 1.3E-01 
35 sp|P02798|MT2_MOUSE 3.02 8.11 0.84 3.9E-05 
36 sp|Q62009|POSTN_MOUSE 3.01 8.04 0.80 5.9E-03 
37 sp|P06800|PTPRC_MOUSE 2.99 7.95 0.78 3.3E-05 
38 sp|P82198|BGH3_MOUSE 2.99 7.94 0.71 9.4E-04 
39 sp|P22599|A1AT2_MOUSE 2.97 7.86 0.82 2.8E-04 
40 sp|P11276|FINC_MOUSE 2.97 7.85 0.84 7.7E-03 
41 sp|Q640N1|AEBP1_MOUSE 2.97 7.82 0.62 6.1E-01 
42 sp|O89053|COR1A_MOUSE 2.96 7.77 0.80 1.3E-04 
43 sp|P08121|CO3A1_MOUSE 2.95 7.72 0.92 1.0E-03 
44 sp|Q9CYG7|TOM34_MOUSE 2.94 7.67 0.58 3.5E-04 
45 sp|Q61233|PLSL_MOUSE 2.93 7.63 0.85 7.6E-05 
46 sp|Q9JLI6|SCLY_MOUSE 2.93 7.61 0.53 4.1E-03 
47 sp|P11087|CO1A1_MOUSE 2.93 7.61 0.96 9.4E-04 
48 sp|Q04447|KCRB_MOUSE 2.92 7.56 0.83 2.7E-05 
49 sp|Q71FD7|FBLI1_MOUSE 2.90 7.44 0.53 3.9E-05 
50 sp|Q60710|SAMH1_MOUSE 2.89 7.41 0.74 1.3E-02 
51 sp|Q9D8T7|SLIRP_MOUSE 2.89 7.39 0.56 7.6E-01 
SUPPLEMENTARY DATA 
 
396 
 
52 sp|Q61555|FBN2_MOUSE 2.86 7.26 0.94 6.9E-03 
53 sp|P97290|IC1_MOUSE 2.78 6.88 0.68 1.9E-02 
54 sp|Q62148|AL1A2_MOUSE 2.78 6.85 0.78 2.9E-03 
55 sp|Q61781|K1C14_MOUSE 2.75 6.75 0.75 7.9E-03 
56 sp|Q8VCC9|SPON1_MOUSE 2.75 6.74 0.63 6.9E-05 
57 sp|Q62000|MIME_MOUSE 2.74 6.67 0.83 2.4E-03 
58 sp|Q62266|SPR1A_MOUSE 2.74 6.67 0.78 8.8E-03 
59 sp|Q8BH97|RCN3_MOUSE 2.73 6.65 0.74 7.1E-05 
60 sp|O70456|1433S_MOUSE 2.72 6.59 0.75 4.2E-06 
61 sp|Q8BMK4|CKAP4_MOUSE 2.72 6.57 0.85 4.9E-02 
62 sp|P51885|LUM_MOUSE 2.71 6.55 0.87 1.8E-03 
63 sp|P28654|PGS2_MOUSE 2.70 6.52 0.79 1.4E-03 
64 sp|O70318|E41L2_MOUSE 2.70 6.51 0.77 4.4E-06 
65 sp|Q9CX80|CYGB_MOUSE 2.67 6.36 0.67 2.2E-02 
66 sp|Q8BPB5|FBLN3_MOUSE 2.66 6.33 0.80 8.3E-05 
67 sp|P35441|TSP1_MOUSE 2.64 6.23 0.79 7.0E-01 
68 sp|Q05186|RCN1_MOUSE 2.64 6.21 0.53 3.5E-03 
69 sp|P19324|SERPH_MOUSE 2.63 6.19 0.94 1.6E-04 
70 sp|Q08879|FBLN1_MOUSE 2.62 6.16 0.79 5.1E-04 
71 sp|Q8VCI0|PLBL1_MOUSE 2.62 6.15 0.58 1.3E-05 
72 sp|Q9Z247|FKBP9_MOUSE 2.62 6.15 0.53 5.9E-01 
73 sp|Q08093|CNN2_MOUSE 2.62 6.15 0.80 6.5E-04 
74 sp|P16045|LEG1_MOUSE 2.62 6.15 0.87 1.2E-04 
75 sp|P21956|MFGM_MOUSE 2.61 6.12 0.54 1.2E-01 
76 sp|O70400|PDLI1_MOUSE 2.61 6.10 0.76 3.6E-02 
77 sp|P01631|KV2A7_MOUSE 2.60 6.05 0.71 6.6E-01 
78 sp|P10923|OSTP_MOUSE 2.59 6.03 0.78 1.7E-01 
79 sp|P31001|DESM_MOUSE 2.58 5.98 0.94 1.6E-03 
80 sp|Q9D1H9|MFAP4_MOUSE 2.54 5.82 0.77 5.9E-04 
81 sp|Q9WVH9|FBLN5_MOUSE 2.54 5.81 0.84 3.8E-04 
82 sp|Q07797|LG3BP_MOUSE 2.53 5.78 0.67 6.1E-04 
83 sp|Q9R111|GUAD_MOUSE 2.53 5.77 0.54 2.3E-03 
84 sp|Q9CYL5|GAPR1_MOUSE 2.52 5.72 0.64 2.2E-03 
85 sp|P25911|LYN_MOUSE 2.51 5.70 0.71 7.0E-01 
86 sp|Q61576|FKB10_MOUSE 2.48 5.58 0.50 1.0E-02 
87 sp|Q00915|RET1_MOUSE 2.48 5.56 0.83 3.6E-04 
88 sp|P45377|ALD2_MOUSE 2.46 5.52 0.56 3.7E-06 
89 sp|Q3TJD7|PDLI7_MOUSE 2.43 5.40 0.81 2.6E-05 
90 sp|P84084|ARF5_MOUSE 2.43 5.37 0.53 9.6E-01 
91 sp|Q06890|CLUS_MOUSE 2.42 5.35 0.81 2.0E-03 
92 sp|P19973|LSP1_MOUSE 2.39 5.26 0.67 4.3E-04 
93 sp|Q922U2|K2C5_MOUSE 2.39 5.24 0.83 2.4E-03 
94 sp|O70200|AIF1_MOUSE 2.38 5.22 0.68 1.3E-03 
95 sp|Q9CQW9|IFM3_MOUSE 2.37 5.17 0.57 3.0E-02 
96 sp|Q03350|TSP2_MOUSE 2.37 5.16 0.53 8.6E-01 
97 sp|Q9JIF0|ANM1_MOUSE 2.35 5.11 0.57 3.5E-01 
98 sp|Q8BTM8|FLNA_MOUSE 2.34 5.07 0.93 1.7E-05 
99 sp|Q922F4|TBB6_MOUSE 2.33 5.04 0.53 7.3E-02 
100 sp|Q3U962|CO5A2_MOUSE 2.33 5.01 0.67 5.7E-03 
101 sp|Q91YJ2|SNX4_MOUSE 2.32 5.01 0.65 3.5E-02 
102 sp|Q69ZN7|MYOF_MOUSE 2.32 4.99 0.86 1.9E-05 
103 sp|P97821|CATC_MOUSE 2.31 4.94 0.55 4.2E-03 
104 sp|Q9Z0N1|IF2G_MOUSE 2.30 4.94 0.62 6.0E-01 
105 sp|P11679|K2C8_MOUSE 2.30 4.93 0.89 5.5E-05 
106 sp|P01901|HA1B_MOUSE 2.26 4.78 0.64 8.9E-04 
107 sp|Q04857|CO6A1_MOUSE 2.26 4.78 0.88 4.7E-03 
108 sp|Q02788|CO6A2_MOUSE 2.25 4.76 0.94 2.1E-03 
109 sp|O35639|ANXA3_MOUSE 2.24 4.73 0.83 5.7E-05 
110 sp|P11835|ITB2_MOUSE 2.22 4.67 0.54 1.0E+00 
111 sp|Q8R1G6|PDLI2_MOUSE 2.22 4.67 0.55 1.1E-01 
112 sp|E9PV24|FIBA_MOUSE 2.21 4.64 0.90 4.9E-02 
113 sp|Q80X19|COEA1_MOUSE 2.21 4.62 0.81 3.4E-04 
114 sp|Q91X72|HEMO_MOUSE 2.20 4.60 0.86 2.4E-02 
115 sp|O35114|SCRB2_MOUSE 2.18 4.52 0.50 2.3E-01 
116 sp|P97315|CSRP1_MOUSE 2.18 4.52 0.89 4.7E-05 
117 sp|Q62188|DPYL3_MOUSE 2.18 4.52 0.67 2.5E-02 
118 sp|P08122|CO4A2_MOUSE 2.17 4.50 0.80 1.3E-04 
119 sp|Q8VCM7|FIBG_MOUSE 2.15 4.45 0.85 1.2E-01 
120 sp|Q99K41|EMIL1_MOUSE 2.15 4.42 0.82 7.8E-05 
121 sp|P68369|TBA1A_MOUSE 2.14 4.41 0.96 3.8E-04 
122 sp|Q9R0P9|UCHL1_MOUSE 2.14 4.40 0.54 2.6E-02 
123 sp|Q9JK53|PRELP_MOUSE 2.13 4.38 0.79 5.6E-04 
124 sp|Q9WV54|ASAH1_MOUSE 2.12 4.36 0.79 5.0E-02 
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125 sp|P06909|CFAH_MOUSE 2.12 4.35 0.72 4.5E-02 
126 sp|P20065|TYB4_MOUSE 2.12 4.35 0.88 3.5E-07 
127 sp|P29788|VTNC_MOUSE 2.12 4.34 0.71 1.8E-02 
128 sp|P58771|TPM1_MOUSE 2.10 4.28 0.84 4.2E-02 
129 sp|Q9DCV7|K2C7_MOUSE 2.09 4.27 0.88 3.4E-05 
130 sp|Q9QXS1|PLEC_MOUSE 2.09 4.25 0.73 3.6E-02 
131 sp|P04441|HG2A_MOUSE 2.09 4.25 0.58 1.4E-01 
132 sp|P97298|PEDF_MOUSE 2.09 4.24 0.81 1.2E-03 
133 sp|Q7TPR4|ACTN1_MOUSE 2.08 4.22 0.96 8.2E-07 
134 sp|Q9QZZ6|DERM_MOUSE 2.07 4.20 0.77 1.1E-03 
135 sp|Q6IRU2|TPM4_MOUSE 2.07 4.19 0.91 2.2E-03 
136 sp|P01837|IGKC_MOUSE 2.05 4.15 0.87 3.7E-02 
137 sp|Q00898|A1AT5_MOUSE 2.04 4.10 0.65 1.2E-01 
138 sp|Q8K0E8|FIBB_MOUSE 2.00 4.00 0.86 3.6E-02 
139 sp|O35682|MYADM_MOUSE 2.00 4.00 0.87 3.5E-02 
140 sp|Q9EP71|RAI14_MOUSE 1.98 3.95 0.70 9.9E-02 
141 sp|P49300|CLC10_MOUSE 1.96 3.90 0.56 1.5E-01 
142 sp|Q8C3W1|CA198_MOUSE 1.96 3.90 0.78 2.9E-05 
143 sp|P01899|HA11_MOUSE 1.96 3.88 0.79 7.9E-03 
144 sp|Q91VW3|SH3L3_MOUSE 1.94 3.85 0.90 3.4E-03 
145 sp|O08573|LEG9_MOUSE 1.92 3.79 0.61 6.0E-04 
146 sp|P70460|VASP_MOUSE 1.92 3.79 0.54 9.7E-01 
147 sp|Q921I1|TRFE_MOUSE 1.92 3.78 0.91 1.4E-03 
148 sp|P07356|ANXA2_MOUSE 1.91 3.76 0.90 6.9E-07 
149 sp|P16110|LEG3_MOUSE 1.90 3.73 0.73 2.0E-05 
150 sp|Q8CFX1|G6PE_MOUSE 1.89 3.71 0.90 3.2E-07 
151 sp|P16015|CAH3_MOUSE 1.88 3.69 0.60 4.4E-01 
152 sp|O35887|CALU_MOUSE 1.88 3.69 0.84 1.7E-04 
153 sp|P54320|ELN_MOUSE 1.88 3.69 0.61 7.8E-04 
154 sp|P42225|STAT1_MOUSE 1.88 3.68 0.54 3.2E-02 
155 sp|P55002|MFAP2_MOUSE 1.87 3.65 0.58 1.0E-03 
156 sp|Q61599|GDIR2_MOUSE 1.86 3.64 0.73 3.6E-03 
157 sp|Q99P72|RTN4_MOUSE 1.85 3.59 0.72 5.5E-05 
158 sp|P26645|MARCS_MOUSE 1.84 3.59 0.73 5.8E-02 
159 sp|Q8CI51|PDLI5_MOUSE 1.84 3.58 0.70 1.7E-04 
160 sp|Q9JII5|DAZP1_MOUSE 1.84 3.57 0.50 6.1E-01 
161 sp|Q60854|SPB6_MOUSE 1.83 3.56 0.89 4.5E-03 
162 sp|P63254|CRIP1_MOUSE 1.83 3.55 0.90 2.0E-05 
163 sp|P29391|FRIL1_MOUSE 1.82 3.54 0.64 2.4E-02 
164 sp|Q9D8Y0|EFHD2_MOUSE 1.82 3.52 0.87 5.7E-05 
165 sp|P20918|PLMN_MOUSE 1.82 3.52 0.73 1.7E-03 
166 sp|Q3U7R1|ESYT1_MOUSE 1.81 3.52 0.82 5.6E-04 
167 sp|P48678|LMNA_MOUSE 1.80 3.49 0.94 1.0E-04 
168 sp|P01029|CO4B_MOUSE 1.78 3.44 0.86 2.1E-03 
169 sp|Q8K4G1|LTBP4_MOUSE 1.78 3.43 0.58 7.4E-05 
170 sp|Q6ZWM4|LSM8_MOUSE 1.76 3.40 0.57 8.1E-01 
171 sp|Q9WV32|ARC1B_MOUSE 1.76 3.38 0.87 1.2E-04 
172 sp|Q62048|PEA15_MOUSE 1.74 3.34 0.63 3.6E-03 
173 sp|P99024|TBB5_MOUSE 1.74 3.33 0.88 1.3E-05 
174 sp|Q8CHH9|SEPT8_MOUSE 1.73 3.32 0.61 1.9E-04 
175 sp|P08226|APOE_MOUSE 1.73 3.31 0.87 3.9E-04 
176 sp|P84096|RHOG_MOUSE 1.72 3.29 0.77 3.4E-04 
177 sp|O08638|MYH11_MOUSE 1.71 3.28 0.87 8.5E-05 
178 sp|Q61879|MYH10_MOUSE 1.71 3.27 0.85 1.6E-03 
179 sp|P29699|FETUA_MOUSE 1.71 3.27 0.90 1.6E-01 
180 sp|Q62219|TGFI1_MOUSE 1.70 3.26 0.79 1.9E-05 
181 sp|P01831|THY1_MOUSE 1.70 3.25 0.79 2.8E-05 
182 sp|Q3TZZ7|ESYT2_MOUSE 1.69 3.23 0.86 6.6E-07 
183 sp|Q9EPB4|ASC_MOUSE 1.68 3.21 0.76 3.8E-03 
184 sp|P01864|GCAB_MOUSE 1.68 3.21 0.91 5.6E-02 
185 sp|P63044|VAMP2_MOUSE 1.67 3.19 0.63 9.4E-02 
186 sp|P58774|TPM2_MOUSE 1.67 3.19 0.79 1.4E-03 
187 sp|P62737|ACTA_MOUSE 1.67 3.17 0.94 2.5E-06 
188 sp|P23198|CBX3_MOUSE 1.66 3.16 0.78 3.3E-03 
189 sp|O35206|COFA1_MOUSE 1.66 3.15 0.78 1.3E-01 
190 sp|P70202|LXN_MOUSE 1.65 3.14 0.58 8.8E-04 
191 sp|P21614|VTDB_MOUSE 1.65 3.13 0.93 1.1E-05 
192 sp|P23953|EST1C_MOUSE 1.64 3.11 0.95 1.3E-01 
193 sp|P20060|HEXB_MOUSE 1.64 3.11 0.53 1.6E-01 
194 sp|O08677|KNG1_MOUSE 1.63 3.09 0.91 1.4E-04 
195 sp|Q9CQ19|MYL9_MOUSE 1.62 3.08 0.98 7.9E-05 
196 sp|Q61703|ITIH2_MOUSE 1.62 3.08 0.57 4.8E-01 
197 sp|P50543|S10AB_MOUSE 1.62 3.08 0.88 2.7E-04 
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198 sp|P07758|A1AT1_MOUSE 1.62 3.07 0.86 1.7E-02 
199 sp|P01867|IGG2B_MOUSE 1.62 3.07 0.81 3.2E-01 
200 sp|Q9JJU8|SH3L1_MOUSE 1.61 3.06 0.86 4.1E-03 
201 sp|Q8VED5|K2C79_MOUSE 1.61 3.05 0.91 8.1E-04 
202 sp|Q9WVA4|TAGL2_MOUSE 1.60 3.04 0.88 3.9E-07 
203 sp|Q9CPW4|ARPC5_MOUSE 1.60 3.03 0.76 3.8E-02 
204 sp|P01869|IGH1M_MOUSE 1.60 3.03 0.59 9.1E-02 
205 sp|P31725|S10A9_MOUSE 1.60 3.03 0.54 1.7E-01 
206 sp|Q6IFZ6|K2C1B_MOUSE 1.59 3.02 0.61 4.6E-02 
207 sp|P05784|K1C18_MOUSE 1.58 2.99 0.94 2.3E-03 
208 sp|P07724|ALBU_MOUSE 1.58 2.98 0.92 4.1E-05 
209 sp|O54724|PTRF_MOUSE 1.57 2.96 0.84 1.6E-02 
210 sp|Q62465|VAT1_MOUSE 1.56 2.96 0.90 1.9E-05 
211 sp|O55131|SEPT7_MOUSE 1.56 2.95 0.82 1.0E-03 
212 sp|P43406|ITAV_MOUSE 1.56 2.94 0.61 2.9E-03 
213 sp|P02762|MUP6_MOUSE 1.56 2.94 0.62 2.3E-01 
214 sp|P28667|MRP_MOUSE 1.55 2.92 0.67 1.4E-03 
215 sp|Q6P5H2|NEST_MOUSE 1.55 2.92 0.70 2.5E-04 
216 sp|Q9ESB3|HRG_MOUSE 1.54 2.91 0.79 1.7E-03 
217 sp|P97372|PSME2_MOUSE 1.54 2.91 0.88 1.1E-02 
218 sp|P01887|B2MG_MOUSE 1.52 2.88 0.82 2.8E-04 
219 sp|P07091|S10A4_MOUSE 1.52 2.87 0.64 9.6E-03 
220 sp|Q61147|CERU_MOUSE 1.52 2.86 0.80 2.9E-02 
221 sp|P14602|HSPB1_MOUSE 1.51 2.85 0.72 1.0E-02 
222 sp|Q9QXS6|DREB_MOUSE 1.51 2.85 0.51 1.9E-02 
223 sp|Q8R1F1|NIBL1_MOUSE 1.51 2.84 0.56 6.4E-01 
224 sp|Q9QZ85|IIGP1_MOUSE 1.50 2.83 0.57 6.4E-02 
225 sp|P42208|SEPT2_MOUSE 1.50 2.83 0.82 7.9E-05 
226 sp|Q9EQH2|ERAP1_MOUSE 1.50 2.82 0.54 1.9E-02 
227 sp|P47753|CAZA1_MOUSE 1.50 2.82 0.57 1.6E-03 
228 sp|P14069|S10A6_MOUSE 1.50 2.82 0.65 2.4E-05 
229 sp|Q9JK48|SHLB1_MOUSE 1.49 2.80 0.57 1.4E-02 
230 sp|Q5SYD0|MYO1D_MOUSE 1.48 2.80 0.55 2.3E-01 
231 sp|P11589|MUP2_MOUSE 1.48 2.79 0.77 7.9E-02 
232 sp|P06281|RENI1_MOUSE 1.47 2.77 0.78 3.6E-01 
233 sp|P30681|HMGB2_MOUSE 1.46 2.75 0.52 8.3E-02 
234 sp|P18760|COF1_MOUSE 1.45 2.74 0.87 2.2E-04 
235 sp|P43025|TETN_MOUSE 1.45 2.74 0.76 3.3E-02 
236 sp|Q8CGP6|H2A1H_MOUSE 1.45 2.73 0.64 5.2E-03 
237 sp|P46935|NEDD4_MOUSE 1.45 2.72 0.68 1.9E-01 
238 sp|Q00897|A1AT4_MOUSE 1.44 2.72 0.83 3.1E-02 
239 sp|P14824|ANXA6_MOUSE 1.44 2.71 0.89 3.9E-04 
240 sp|Q8C1B7|SEP11_MOUSE 1.44 2.71 0.80 2.9E-06 
241 sp|P54923|ADPRH_MOUSE 1.44 2.71 0.86 3.3E-04 
242 sp|O08553|DPYL2_MOUSE 1.42 2.68 0.88 1.8E-04 
243 sp|P02463|CO4A1_MOUSE 1.42 2.67 0.88 6.6E-03 
244 sp|Q921M7|FA49B_MOUSE 1.42 2.67 0.52 1.0E-03 
245 sp|P27546|MAP4_MOUSE 1.41 2.66 0.82 2.5E-05 
246 sp|P18242|CATD_MOUSE 1.41 2.65 0.82 1.8E-03 
247 sp|P63213|GBG2_MOUSE 1.40 2.65 0.81 2.2E-03 
248 sp|A2ADY9|DDI2_MOUSE 1.40 2.64 0.58 8.5E-01 
249 sp|P49312|ROA1_MOUSE 1.40 2.63 0.88 3.4E-03 
250 sp|Q64339|ISG15_MOUSE 1.39 2.62 0.84 1.6E-01 
251 sp|Q9QXC1|FETUB_MOUSE 1.39 2.61 0.89 4.7E-05 
252 sp|Q8VDD5|MYH9_MOUSE 1.39 2.61 0.99 1.5E-06 
253 sp|P01027|CO3_MOUSE 1.38 2.59 0.87 2.3E-03 
254 sp|Q6PDN3|MYLK_MOUSE 1.37 2.59 0.80 1.1E-05 
255 sp|P08207|S10AA_MOUSE 1.37 2.59 0.86 2.3E-03 
256 sp|Q99KC8|VMA5A_MOUSE 1.37 2.58 0.86 3.2E-07 
257 sp|P39061|COIA1_MOUSE 1.36 2.57 0.96 6.1E-07 
258 sp|Q06138|CAB39_MOUSE 1.36 2.56 0.58 3.1E-01 
259 sp|P68510|1433F_MOUSE 1.35 2.55 0.68 8.8E-01 
260 sp|Q60605|MYL6_MOUSE 1.34 2.53 0.92 3.1E-04 
261 sp|Q9WUU7|CATZ_MOUSE 1.34 2.53 0.86 5.5E-05 
262 sp|Q9D554|SF3A3_MOUSE 1.34 2.53 0.52 4.7E-01 
263 sp|Q62419|SH3G1_MOUSE 1.34 2.52 0.70 3.5E-05 
264 sp|Q9ES28|ARHG7_MOUSE 1.33 2.51 0.69 3.7E-05 
265 sp|Q921M3|SF3B3_MOUSE 1.33 2.51 0.83 1.9E-04 
266 sp|P06728|APOA4_MOUSE 1.32 2.50 0.82 1.6E-01 
267 sp|P40124|CAP1_MOUSE 1.32 2.50 0.92 7.3E-07 
268 sp|Q01339|APOH_MOUSE 1.32 2.50 0.80 1.2E-03 
269 sp|Q3UW53|NIBAN_MOUSE 1.31 2.48 0.55 8.4E-01 
270 sp|Q00623|APOA1_MOUSE 1.30 2.46 0.92 4.2E-03 
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271 sp|Q9EQU5|SET_MOUSE 1.30 2.46 0.83 4.2E-02 
272 sp|P63163|RSMN_MOUSE 1.29 2.45 0.60 9.3E-02 
273 sp|Q8VIJ6|SFPQ_MOUSE 1.28 2.44 0.81 1.0E-06 
274 sp|P02535|K1C10_MOUSE 1.27 2.41 0.58 1.0E-01 
275 sp|P26350|PTMA_MOUSE 1.26 2.39 0.66 4.0E-02 
276 sp|Q921E2|RAB31_MOUSE 1.26 2.39 0.57 6.5E-01 
277 sp|Q8VE97|SRSF4_MOUSE 1.25 2.37 0.70 7.7E-03 
278 sp|O70433|FHL2_MOUSE 1.25 2.37 0.59 9.4E-05 
279 sp|P17918|PCNA_MOUSE 1.24 2.37 0.69 5.3E-02 
280 sp|Q9QZR9|CO4A4_MOUSE 1.24 2.36 0.71 1.0E-02 
281 sp|O89086|RBM3_MOUSE 1.24 2.36 0.84 5.1E-03 
282 sp|Q06770|CBG_MOUSE 1.24 2.35 0.51 9.2E-03 
283 sp|P09528|FRIH_MOUSE 1.23 2.35 0.56 4.2E-02 
284 sp|P62500|T22D1_MOUSE 1.23 2.35 0.90 1.8E-04 
285 sp|Q99PL5|RRBP1_MOUSE 1.23 2.35 0.55 3.7E-04 
286 sp|Q62318|TIF1B_MOUSE 1.22 2.33 0.83 3.1E-04 
287 sp|P13020|GELS_MOUSE 1.22 2.33 0.84 1.6E-05 
288 sp|Q9CQW2|ARL8B_MOUSE 1.22 2.33 0.54 3.0E-01 
289 sp|Q64727|VINC_MOUSE 1.22 2.33 0.94 2.7E-05 
290 sp|Q3THE2|ML12B_MOUSE 1.22 2.33 0.83 7.8E-05 
291 sp|P28665|MUG1_MOUSE 1.22 2.32 0.64 1.9E-01 
292 sp|P14733|LMNB1_MOUSE 1.20 2.30 0.86 4.4E-06 
293 sp|P53810|PIPNA_MOUSE 1.20 2.30 0.53 1.6E-03 
294 sp|P48036|ANXA5_MOUSE 1.20 2.29 0.84 2.0E-03 
295 sp|P97371|PSME1_MOUSE 1.19 2.28 0.84 9.7E-02 
296 sp|P32261|ANT3_MOUSE 1.18 2.27 0.86 8.4E-02 
297 sp|O88531|PPT1_MOUSE 1.18 2.26 0.70 7.5E-04 
298 sp|Q61001|LAMA5_MOUSE 1.17 2.26 0.83 1.6E-01 
299 sp|P21460|CYTC_MOUSE 1.16 2.23 0.69 1.1E-01 
300 sp|Q9WUM4|COR1C_MOUSE 1.16 2.23 0.83 1.3E-05 
301 sp|P47757|CAPZB_MOUSE 1.16 2.23 0.89 1.9E-03 
302 sp|P19221|THRB_MOUSE 1.15 2.22 0.54 7.5E-02 
303 sp|P56959|FUS_MOUSE 1.15 2.22 0.80 2.0E-03 
304 sp|Q9QWR8|NAGAB_MOUSE 1.14 2.21 0.72 2.6E-01 
305 sp|Q6P5E4|UGGG1_MOUSE 1.14 2.20 0.74 3.4E-01 
306 sp|Q61166|MARE1_MOUSE 1.14 2.20 0.54 3.2E-04 
307 sp|Q9JKF1|IQGA1_MOUSE 1.12 2.17 0.66 3.4E-02 
308 sp|P97822|AN32E_MOUSE 1.12 2.17 0.58 9.8E-02 
309 sp|A2ASQ1|AGRIN_MOUSE 1.11 2.16 0.92 3.3E-04 
310 sp|Q9EST5|AN32B_MOUSE 1.11 2.15 0.81 8.9E-02 
311 sp|P07759|SPA3K_MOUSE 1.11 2.15 0.79 7.6E-02 
312 sp|Q9Z172|SUMO3_MOUSE 1.10 2.14 0.55 1.2E-01 
313 sp|Q60749|KHDR1_MOUSE 1.10 2.14 0.84 6.7E-03 
314 sp|Q61292|LAMB2_MOUSE 1.09 2.13 0.76 1.3E-03 
315 sp|Q80UG5|SEPT9_MOUSE 1.09 2.13 0.52 8.3E-05 
316 sp|P43276|H15_MOUSE 1.08 2.12 0.75 1.4E-01 
317 sp|Q3UPH1|PRRC1_MOUSE 1.08 2.12 0.53 5.3E-01 
318 sp|Q9Z0E6|GBP2_MOUSE 1.08 2.12 0.56 2.8E-02 
319 sp|O88456|CPNS1_MOUSE 1.08 2.11 0.69 6.8E-03 
320 sp|P62962|PROF1_MOUSE 1.07 2.10 0.89 4.1E-04 
321 sp|P10493|NID1_MOUSE 1.07 2.10 0.92 1.2E-04 
322 sp|O08529|CAN2_MOUSE 1.06 2.09 0.54 1.0E-03 
323 sp|Q91VC3|IF4A3_MOUSE 1.05 2.07 0.50 1.4E-01 
324 sp|Q3THW5|H2AV_MOUSE 1.05 2.07 0.86 1.2E-02 
325 sp|Q9WUM3|COR1B_MOUSE 1.04 2.06 0.86 1.5E-03 
326 sp|Q9CX86|ROA0_MOUSE 1.04 2.06 0.58 1.7E-02 
327 sp|Q9CXY6|ILF2_MOUSE 1.04 2.06 0.56 8.0E-03 
328 sp|P29351|PTN6_MOUSE 1.04 2.05 0.59 2.1E-01 
329 sp|P04186|CFAB_MOUSE 1.03 2.05 0.55 5.8E-03 
330 sp|Q61838|A2M_MOUSE 1.03 2.05 0.85 1.2E-02 
331 sp|Q3UZ39|LRRF1_MOUSE 1.03 2.04 0.61 1.1E-02 
332 sp|Q9JHU9|INO1_MOUSE 1.02 2.03 0.81 7.3E-04 
333 sp|Q60972|RBBP4_MOUSE 1.02 2.02 0.57 1.3E-04 
334 sp|Q9ERG0|LIMA1_MOUSE 1.02 2.02 0.87 6.5E-03 
335 sp|P08752|GNAI2_MOUSE 1.01 2.02 0.83 3.3E-03 
336 sp|Q9JM76|ARPC3_MOUSE 1.01 2.01 0.87 2.9E-07 
337 sp|O88342|WDR1_MOUSE 1.01 2.01 0.83 7.0E-03 
338 sp|Q925B0|PAWR_MOUSE 1.00 2.00 0.54 9.2E-03 
339 sp|Q9WVB0|RBPMS_MOUSE 0.99 1.98 0.67 2.4E-02 
340 sp|P48428|TBCA_MOUSE 0.99 1.98 0.76 5.7E-01 
341 sp|P63280|UBC9_MOUSE 0.98 1.97 0.91 1.9E-06 
342 sp|Q63844|MK03_MOUSE 0.98 1.97 0.62 2.6E-04 
343 sp|P17225|PTBP1_MOUSE 0.97 1.97 0.56 3.7E-01 
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344 sp|Q07813|BAX_MOUSE 0.97 1.96 0.69 1.4E-01 
345 sp|Q91W90|TXND5_MOUSE 0.97 1.96 0.50 3.9E-01 
346 sp|P34928|APOC1_MOUSE 0.96 1.95 0.64 2.2E-01 
347 sp|O88322|NID2_MOUSE 0.96 1.95 0.68 4.9E-01 
348 sp|Q8BH43|WASF2_MOUSE 0.96 1.94 0.60 1.7E-02 
349 sp|Q3TEA8|HP1B3_MOUSE 0.95 1.94 0.83 5.5E-04 
350 sp|P47754|CAZA2_MOUSE 0.95 1.94 0.75 3.0E-02 
351 sp|Q9DBG9|TX1B3_MOUSE 0.95 1.93 0.73 5.2E-04 
352 sp|Q8C0E2|VP26B_MOUSE 0.95 1.93 0.67 1.1E-01 
353 sp|P97447|FHL1_MOUSE 0.94 1.92 0.56 1.5E-02 
354 sp|Q8BFZ3|ACTBL_MOUSE 0.93 1.91 0.84 2.4E-04 
355 sp|P09813|APOA2_MOUSE 0.93 1.90 0.63 5.9E-02 
356 sp|Q8BG05|ROA3_MOUSE 0.93 1.90 0.90 2.2E-03 
357 sp|Q91YH5|ATLA3_MOUSE 0.92 1.90 0.67 2.4E-02 
358 sp|Q8BP92|RCN2_MOUSE 0.92 1.90 0.54 6.0E-02 
359 sp|Q99K48|NONO_MOUSE 0.92 1.90 0.91 6.0E-03 
360 sp|Q61102|ABCB7_MOUSE 0.92 1.89 0.89 5.6E-05 
361 sp|Q99JY9|ARP3_MOUSE 0.92 1.89 0.95 5.5E-05 
362 sp|Q61207|SAP_MOUSE 0.91 1.88 0.75 3.3E-02 
363 sp|Q60604|ADSV_MOUSE 0.91 1.88 0.78 7.7E-03 
364 sp|Q9CVB6|ARPC2_MOUSE 0.91 1.87 0.83 3.7E-05 
365 sp|Q9D0T1|NH2L1_MOUSE 0.90 1.86 0.81 9.1E-04 
366 sp|Q8C522|ENDD1_MOUSE 0.90 1.86 0.71 4.9E-04 
367 sp|P61750|ARF4_MOUSE 0.89 1.86 0.62 7.7E-01 
368 sp|P02468|LAMC1_MOUSE 0.89 1.85 0.93 2.3E-04 
369 sp|P02469|LAMB1_MOUSE 0.89 1.85 0.85 1.4E-02 
370 sp|Q91VM5|RMXL1_MOUSE 0.89 1.85 0.65 1.1E-02 
371 sp|Q9R0P5|DEST_MOUSE 0.89 1.85 0.80 2.6E-02 
372 sp|Q62470|ITA3_MOUSE 0.89 1.85 0.66 7.4E-01 
373 sp|Q7TSV4|PGM2_MOUSE 0.88 1.84 0.79 7.5E-05 
374 sp|O35593|PSDE_MOUSE 0.87 1.83 0.56 9.9E-02 
375 sp|Q9Z204|HNRPC_MOUSE 0.87 1.82 0.76 3.0E-01 
376 sp|Q00612|G6PD1_MOUSE 0.87 1.82 0.74 4.9E-02 
377 sp|Q9Z2X1|HNRPF_MOUSE 0.87 1.82 0.83 3.1E-02 
378 sp|P04117|FABP4_MOUSE 0.86 1.82 0.85 1.4E-01 
379 sp|Q6WVG3|KCD12_MOUSE 0.86 1.82 0.70 2.5E-02 
380 sp|Q61792|LASP1_MOUSE 0.86 1.81 0.81 5.0E-01 
381 sp|P43275|H11_MOUSE 0.86 1.81 0.68 8.3E-02 
382 sp|Q80XU3|NUCKS_MOUSE 0.85 1.80 0.56 4.2E-03 
383 sp|Q05793|PGBM_MOUSE 0.85 1.80 0.81 3.2E-01 
384 sp|P84089|ERH_MOUSE 0.85 1.80 0.62 7.5E-02 
385 sp|P70372|ELAV1_MOUSE 0.85 1.80 0.68 1.2E-01 
386 sp|Q921F2|TADBP_MOUSE 0.85 1.80 0.81 1.8E-02 
387 sp|O08810|U5S1_MOUSE 0.84 1.79 0.63 6.2E-01 
388 sp|Q9EPC1|PARVA_MOUSE 0.84 1.79 0.73 1.9E-02 
389 sp|P21619|LMNB2_MOUSE 0.84 1.79 0.53 1.6E-02 
390 sp|P09405|NUCL_MOUSE 0.84 1.79 0.83 6.6E-02 
391 sp|O08807|PRDX4_MOUSE 0.83 1.78 0.73 2.6E-04 
392 sp|Q91V88|NPNT_MOUSE 0.83 1.78 0.57 5.8E-02 
393 sp|Q8BL97|SRSF7_MOUSE 0.83 1.78 0.79 1.9E-03 
394 sp|Q9Z1N5|DX39B_MOUSE 0.83 1.78 0.81 3.0E-03 
395 sp|Q7TMK9|HNRPQ_MOUSE 0.83 1.78 0.65 1.3E-01 
396 sp|P97429|ANXA4_MOUSE 0.83 1.78 0.85 1.3E-02 
397 sp|P26039|TLN1_MOUSE 0.83 1.78 0.82 1.9E-02 
398 sp|Q3U0V1|FUBP2_MOUSE 0.83 1.78 0.80 1.4E-01 
399 sp|Q8C854|MYEF2_MOUSE 0.82 1.76 0.78 1.8E-05 
400 sp|Q9QZS0|CO4A3_MOUSE 0.82 1.76 0.64 4.1E-02 
401 sp|Q6ZWX6|IF2A_MOUSE 0.82 1.76 0.52 1.7E-01 
402 sp|P61161|ARP2_MOUSE 0.81 1.76 0.88 2.3E-05 
403 sp|Q62523|ZYX_MOUSE 0.81 1.75 0.53 3.6E-01 
404 sp|P63158|HMGB1_MOUSE 0.81 1.75 0.68 8.4E-02 
405 sp|P62307|RUXF_MOUSE 0.81 1.75 0.87 1.8E-03 
406 sp|Q8R5J9|PRAF3_MOUSE 0.80 1.74 0.54 9.2E-01 
407 sp|Q9D0E1|HNRPM_MOUSE 0.80 1.74 0.86 1.4E-02 
408 sp|Q9QXA5|LSM4_MOUSE 0.79 1.73 0.79 8.4E-01 
409 sp|P97314|CSRP2_MOUSE 0.78 1.72 0.82 3.5E-03 
410 sp|Q501J6|DDX17_MOUSE 0.78 1.72 0.61 2.1E-02 
411 sp|P21981|TGM2_MOUSE 0.78 1.71 0.90 6.0E-04 
412 sp|Q9D1J3|SARNP_MOUSE 0.78 1.71 0.77 1.6E-01 
413 sp|P62996|TRA2B_MOUSE 0.78 1.71 0.59 6.4E-01 
414 sp|P59999|ARPC4_MOUSE 0.77 1.71 0.66 6.3E-03 
415 sp|Q61029|LAP2B_MOUSE 0.77 1.71 0.80 1.2E-02 
416 sp|Q62093|SRSF2_MOUSE 0.76 1.70 0.86 2.5E-02 
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417 sp|Q8C2Q3|RBM14_MOUSE 0.76 1.69 0.56 1.4E-03 
418 sp|P17047|LAMP2_MOUSE 0.76 1.69 0.77 4.1E-04 
419 sp|P11031|TCP4_MOUSE 0.75 1.69 0.62 5.2E-03 
420 sp|Q9DAW9|CNN3_MOUSE 0.75 1.68 0.56 3.1E-01 
421 sp|P24452|CAPG_MOUSE 0.75 1.68 0.77 1.9E-02 
422 sp|Q922R8|PDIA6_MOUSE 0.75 1.68 0.90 1.3E-01 
423 sp|Q8BQ47|CNPY4_MOUSE 0.74 1.68 0.63 8.0E-01 
424 sp|Q9Z2N8|ACL6A_MOUSE 0.73 1.66 0.73 6.6E-02 
425 sp|P61982|1433G_MOUSE 0.72 1.65 0.81 1.7E-01 
426 sp|Q9Z130|HNRDL_MOUSE 0.72 1.65 0.66 1.1E-02 
427 sp|O70133|DHX9_MOUSE 0.72 1.65 0.53 4.0E-02 
428 sp|Q923D2|BLVRB_MOUSE 0.72 1.65 0.70 1.9E-03 
429 sp|P62852|RS25_MOUSE 0.72 1.65 0.52 9.7E-01 
430 sp|Q9R0P4|SMAP_MOUSE 0.71 1.64 0.88 9.1E-04 
431 sp|P70168|IMB1_MOUSE 0.71 1.64 0.75 4.0E-01 
432 sp|P40240|CD9_MOUSE 0.71 1.63 0.65 1.9E-01 
433 sp|Q8CIB5|FERM2_MOUSE 0.70 1.63 0.53 2.4E-01 
434 sp|Q9Z1X4|ILF3_MOUSE 0.70 1.63 0.57 1.5E-01 
435 sp|Q61656|DDX5_MOUSE 0.70 1.63 0.80 1.7E-03 
436 sp|O55023|IMPA1_MOUSE 0.69 1.62 0.67 1.6E-01 
437 sp|P62311|LSM3_MOUSE 0.69 1.62 0.91 1.7E-04 
438 sp|Q9Z2D6|MECP2_MOUSE 0.69 1.61 0.67 2.2E-03 
439 sp|O08547|SC22B_MOUSE 0.68 1.61 0.74 1.0E-02 
440 sp|P84104|SRSF3_MOUSE 0.68 1.60 0.64 5.0E-01 
441 sp|Q62189|SNRPA_MOUSE 0.68 1.60 0.57 4.1E-03 
442 sp|O08583|THOC4_MOUSE 0.67 1.60 0.57 7.6E-02 
443 sp|Q01730|RSU1_MOUSE 0.67 1.59 0.84 4.8E-03 
444 sp|Q99KF1|TMED9_MOUSE 0.67 1.59 0.78 1.3E-03 
445 sp|Q9R0P6|SC11A_MOUSE 0.67 1.59 0.80 3.9E-01 
446 sp|Q61937|NPM_MOUSE 0.67 1.59 0.57 5.4E-01 
447 sp|Q8C166|CPNE1_MOUSE 0.67 1.59 0.52 4.5E-02 
448 sp|Q9R1Z8|VINEX_MOUSE 0.67 1.59 0.68 8.2E-02 
449 sp|P63085|MK01_MOUSE 0.66 1.58 0.73 1.2E-02 
450 sp|P60843|IF4A1_MOUSE 0.66 1.58 0.66 1.8E-02 
451 sp|P26883|FKB1A_MOUSE 0.66 1.58 0.64 9.1E-01 
452 sp|Q02257|PLAK_MOUSE 0.64 1.56 0.62 7.0E-01 
453 sp|O55222|ILK_MOUSE 0.64 1.56 0.69 9.4E-01 
454 sp|Q4KML4|ABRAL_MOUSE 0.64 1.56 0.80 3.8E-03 
455 sp|O09131|GSTO1_MOUSE 0.64 1.56 0.67 9.2E-02 
456 sp|P60710|ACTB_MOUSE 0.64 1.56 0.93 1.0E-02 
457 sp|Q8CI94|PYGB_MOUSE 0.63 1.55 0.59 2.4E-01 
458 sp|Q99JI6|RAP1B_MOUSE 0.63 1.55 0.76 5.3E-03 
459 sp|P49722|PSA2_MOUSE 0.63 1.55 0.57 2.2E-01 
460 sp|Q9D8B3|CHM4B_MOUSE 0.62 1.54 0.51 7.2E-02 
461 sp|Q9CYZ2|TPD54_MOUSE 0.62 1.54 0.50 5.9E-01 
462 sp|Q9WVA3|BUB3_MOUSE 0.62 1.54 0.52 1.6E-02 
463 sp|Q9CY50|SSRA_MOUSE 0.62 1.53 0.56 2.1E-02 
464 sp|Q8VEK3|HNRPU_MOUSE 0.61 1.53 0.85 6.6E-03 
465 sp|Q62426|CYTB_MOUSE 0.61 1.52 0.77 3.3E-01 
466 sp|P26041|MOES_MOUSE 0.60 1.52 0.81 7.1E-04 
467 sp|Q61990|PCBP2_MOUSE 0.60 1.52 0.68 2.1E-01 
468 sp|Q60598|SRC8_MOUSE 0.60 1.51 0.56 9.3E-01 
469 sp|Q99PT1|GDIR1_MOUSE 0.60 1.51 0.84 1.1E-04 
470 sp|Q9CR86|CHSP1_MOUSE 0.59 1.51 0.63 1.7E-01 
471 sp|Q8R081|HNRPL_MOUSE 0.59 1.50 0.60 2.4E-03 
472 sp|Q3TWW8|SRSF6_MOUSE 0.58 1.50 0.54 6.2E-02 
473 sp|Q61545|EWS_MOUSE 0.58 1.50 0.58 7.2E-02 
474 sp|P15864|H12_MOUSE 0.58 1.49 0.53 3.1E-01 
475 sp|P10605|CATB_MOUSE 0.58 1.49 0.79 1.5E-03 
476 sp|Q6PDM2|SRSF1_MOUSE 0.58 1.49 0.56 6.1E-03 
477 sp|P34022|RANG_MOUSE 0.57 1.49 0.53 3.4E-01 
478 sp|Q8VE37|RCC1_MOUSE 0.57 1.49 0.64 1.9E-03 
479 sp|Q9JHL1|NHRF2_MOUSE 0.57 1.49 0.54 6.5E-01 
480 sp|Q9CQV8|1433B_MOUSE 0.57 1.49 0.75 4.6E-03 
481 sp|P62320|SMD3_MOUSE 0.57 1.48 0.74 6.1E-03 
482 sp|P00493|HPRT_MOUSE 0.56 1.48 0.71 5.1E-02 
483 sp|P63024|VAMP3_MOUSE 0.56 1.48 0.78 6.6E-02 
484 sp|O35737|HNRH1_MOUSE 0.56 1.48 0.87 1.0E-04 
485 sp|Q9CQS8|SC61B_MOUSE 0.56 1.47 0.69 3.8E-02 
486 sp|P62317|SMD2_MOUSE 0.56 1.47 0.81 6.5E-03 
487 sp|Q7TNG5|EMAL2_MOUSE 0.55 1.47 0.51 5.6E-02 
488 sp|P57780|ACTN4_MOUSE 0.55 1.46 0.70 6.7E-03 
489 sp|P60867|RS20_MOUSE 0.54 1.46 0.59 2.2E-02 
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490 sp|P24369|PPIB_MOUSE 0.54 1.46 0.76 7.7E-03 
491 sp|P68254|1433T_MOUSE 0.54 1.46 0.76 7.4E-03 
492 sp|P63001|RAC1_MOUSE 0.53 1.45 0.50 9.5E-01 
493 sp|P05132|KAPCA_MOUSE 0.53 1.44 0.89 6.8E-03 
494 sp|Q9JHJ0|TMOD3_MOUSE 0.53 1.44 0.62 2.4E-01 
495 sp|P09055|ITB1_MOUSE 0.52 1.44 0.62 6.9E-01 
496 sp|Q8VBT0|TMX1_MOUSE 0.52 1.43 0.57 4.7E-02 
497 sp|P62827|RAN_MOUSE 0.51 1.43 0.64 2.1E-01 
498 sp|P08113|ENPL_MOUSE 0.50 1.42 0.73 4.1E-02 
499 sp|P62309|RUXG_MOUSE 0.50 1.42 0.70 1.4E-01 
500 sp|Q99020|ROAA_MOUSE 0.50 1.41 0.74 1.9E-02 
501 sp|Q99KP6|PRP19_MOUSE 0.49 1.40 0.58 7.2E-02 
502 sp|P08003|PDIA4_MOUSE 0.49 1.40 0.80 2.7E-01 
503 sp|P61979|HNRPK_MOUSE 0.49 1.40 0.82 3.0E-05 
504 sp|Q922Q8|LRC59_MOUSE 0.48 1.40 0.58 2.7E-04 
505 sp|Q9R0Y5|KAD1_MOUSE 0.48 1.40 0.51 3.8E-01 
506 sp|O89023|TPP1_MOUSE 0.48 1.39 0.69 6.1E-01 
507 sp|P57776|EF1D_MOUSE 0.47 1.38 0.68 5.8E-03 
508 sp|P11438|LAMP1_MOUSE 0.47 1.38 0.81 1.1E-02 
509 sp|Q99M71|EPDR1_MOUSE 0.46 1.38 0.55 1.4E-02 
510 sp|Q9D7X3|DUS3_MOUSE 0.46 1.38 0.57 7.1E-01 
511 sp|P60766|CDC42_MOUSE 0.46 1.37 0.55 5.8E-01 
512 sp|P58389|PTPA_MOUSE 0.45 1.37 0.64 6.8E-02 
513 sp|Q76MZ3|2AAA_MOUSE 0.45 1.36 0.51 6.1E-01 
514 sp|P21107|TPM3_MOUSE 0.44 1.36 0.67 4.0E-01 
515 sp|P01942|HBA_MOUSE 0.44 1.35 0.71 9.5E-01 
516 sp|P62305|RUXE_MOUSE 0.43 1.35 0.79 2.4E-01 
517 sp|Q61753|SERA_MOUSE 0.43 1.35 0.54 1.7E-01 
518 sp|Q9R1P4|PSA1_MOUSE 0.40 1.32 0.52 4.6E-04 
519 sp|Q9D8N0|EF1G_MOUSE 0.40 1.32 0.61 1.6E-01 
520 sp|P62137|PP1A_MOUSE 0.38 1.30 0.53 6.2E-02 
521 sp|Q9DCD0|6PGD_MOUSE 0.37 1.29 0.65 6.1E-02 
522 sp|P27773|PDIA3_MOUSE 0.35 1.28 0.56 7.6E-03 
523 sp|P27661|H2AX_MOUSE 0.34 1.26 0.52 6.4E-01 
524 sp|P20029|GRP78_MOUSE 0.33 1.26 0.57 3.8E-01 
525 sp|P63017|HSP7C_MOUSE -0.27 1.21 0.74 5.3E-02 
526 sp|Q61171|PRDX2_MOUSE -0.36 1.28 0.64 9.8E-02 
527 sp|P40142|TKT_MOUSE -0.40 1.32 0.51 2.4E-01 
528 sp|Q01853|TERA_MOUSE -0.40 1.32 0.52 1.1E-01 
529 sp|Q9DAS9|GBG12_MOUSE -0.40 1.32 0.51 1.7E-01 
530 sp|Q93092|TALDO_MOUSE -0.42 1.34 0.57 1.7E-02 
531 sp|Q9D1G1|RAB1B_MOUSE -0.43 1.35 0.65 5.7E-02 
532 sp|Q9EQX4|AIF1L_MOUSE -0.46 1.38 0.58 3.3E-02 
533 sp|P61205|ARF3_MOUSE -0.46 1.38 0.60 2.0E-01 
534 sp|Q9QYJ0|DNJA2_MOUSE -0.47 1.39 0.52 1.0E-01 
535 sp|O54984|ASNA_MOUSE -0.48 1.39 0.75 1.6E-03 
536 sp|Q9CQ22|LTOR1_MOUSE -0.49 1.40 0.62 2.1E-01 
537 sp|P46638|RB11B_MOUSE -0.49 1.41 0.68 3.1E-01 
538 sp|Q9Z1Z0|USO1_MOUSE -0.50 1.41 0.54 4.3E-02 
539 sp|P31428|DPEP1_MOUSE -0.51 1.43 0.76 1.1E-02 
540 sp|P17427|AP2A2_MOUSE -0.52 1.43 0.54 5.6E-03 
541 sp|P06151|LDHA_MOUSE -0.52 1.44 0.72 6.9E-02 
542 sp|P26638|SYSC_MOUSE -0.53 1.45 0.57 1.7E-01 
543 sp|Q68FD5|CLH1_MOUSE -0.56 1.47 0.88 4.2E-03 
544 sp|P84091|AP2M1_MOUSE -0.56 1.48 0.53 6.6E-01 
545 sp|Q91WG5|AAKG2_MOUSE -0.57 1.48 0.62 4.2E-01 
546 sp|P10639|THIO_MOUSE -0.57 1.49 0.75 1.6E-03 
547 sp|Q8K021|SCAM1_MOUSE -0.58 1.50 0.57 5.4E-02 
548 sp|P07901|HS90A_MOUSE -0.58 1.50 0.81 2.9E-01 
549 sp|P30416|FKBP4_MOUSE -0.61 1.53 0.68 7.1E-01 
550 sp|Q8BP67|RL24_MOUSE -0.62 1.53 0.59 6.6E-01 
551 sp|Q62446|FKBP3_MOUSE -0.62 1.53 0.67 6.1E-02 
552 sp|P46412|GPX3_MOUSE -0.63 1.54 0.83 8.4E-02 
553 sp|P62821|RAB1A_MOUSE -0.64 1.56 0.71 2.3E-02 
554 sp|Q9D819|IPYR_MOUSE -0.65 1.56 0.56 9.7E-02 
555 sp|Q9CZX8|RS19_MOUSE -0.65 1.57 0.53 9.3E-01 
556 sp|P05064|ALDOA_MOUSE -0.65 1.57 0.84 1.9E-02 
557 sp|Q91V64|ISOC1_MOUSE -0.66 1.58 0.71 9.5E-05 
558 sp|P62274|RS29_MOUSE -0.66 1.58 0.53 6.8E-01 
559 sp|O09044|SNP23_MOUSE -0.66 1.59 0.52 1.6E-01 
560 sp|Q9JMH6|TRXR1_MOUSE -0.67 1.59 0.70 2.9E-03 
561 sp|Q6P8X1|SNX6_MOUSE -0.67 1.59 0.65 2.7E-01 
562 sp|Q9CPV4|GLOD4_MOUSE -0.67 1.59 0.71 6.8E-03 
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563 sp|Q8K2C9|HACD3_MOUSE -0.67 1.60 0.74 3.1E-02 
564 sp|Q61249|IGBP1_MOUSE -0.68 1.60 0.51 8.6E-01 
565 sp|P08556|RASN_MOUSE -0.68 1.61 0.70 1.6E-03 
566 sp|P11881|ITPR1_MOUSE -0.69 1.61 0.59 5.3E-04 
567 sp|O55022|PGRC1_MOUSE -0.69 1.61 0.67 3.6E-02 
568 sp|Q8BFZ9|ERLN2_MOUSE -0.69 1.62 0.66 3.4E-02 
569 sp|Q68FH4|GALK2_MOUSE -0.70 1.62 0.58 7.7E-01 
570 sp|P40336|VP26A_MOUSE -0.70 1.63 0.79 3.9E-01 
571 sp|Q9R0N0|GALK1_MOUSE -0.71 1.64 0.85 8.3E-03 
572 sp|Q9QUH0|GLRX1_MOUSE -0.72 1.65 0.54 4.0E-02 
573 sp|Q9CR57|RL14_MOUSE -0.73 1.66 0.56 3.9E-01 
574 sp|Q9CQM5|TXD17_MOUSE -0.73 1.66 0.77 7.4E-02 
575 sp|Q8C7X2|EMC1_MOUSE -0.77 1.70 0.50 2.7E-03 
576 sp|Q3THS6|METK2_MOUSE -0.77 1.70 0.69 1.1E-01 
577 sp|Q6ZWV3|RL10_MOUSE -0.77 1.71 0.64 7.4E-01 
578 sp|P68372|TBB4B_MOUSE -0.77 1.71 0.90 2.3E-04 
579 sp|Q9CQ89|CUTA_MOUSE -0.78 1.71 0.56 6.8E-02 
580 sp|P63087|PP1G_MOUSE -0.78 1.71 0.58 5.2E-02 
581 sp|Q9CQB5|CISD2_MOUSE -0.78 1.72 0.75 8.0E-02 
582 sp|O70492|SNX3_MOUSE -0.78 1.72 0.84 6.7E-02 
583 sp|O88952|LIN7C_MOUSE -0.78 1.72 0.74 2.4E-01 
584 sp|Q9ES97|RTN3_MOUSE -0.79 1.72 0.77 1.9E-03 
585 sp|D3Z7P3|GLSK_MOUSE -0.80 1.74 0.60 6.8E-03 
586 sp|Q9CXA2|T3HPD_MOUSE -0.80 1.74 0.62 3.2E-02 
587 sp|P10922|H10_MOUSE -0.80 1.74 0.52 8.4E-01 
588 sp|Q91V92|ACLY_MOUSE -0.80 1.74 0.76 3.5E-02 
589 sp|P10630|IF4A2_MOUSE -0.80 1.74 0.64 6.9E-01 
590 sp|Q9EP69|SAC1_MOUSE -0.80 1.74 0.66 5.2E-01 
591 sp|Q9WTN6|S22AL_MOUSE -0.80 1.75 0.64 2.8E-02 
592 sp|Q920Q6|MSI2H_MOUSE -0.81 1.75 0.60 5.3E-04 
593 sp|Q60770|STXB3_MOUSE -0.81 1.75 0.70 4.9E-04 
594 sp|P61022|CHP1_MOUSE -0.81 1.76 0.68 4.8E-01 
595 sp|Q3TW96|UAP1L_MOUSE -0.81 1.76 0.84 2.8E-02 
596 sp|P47911|RL6_MOUSE -0.81 1.76 0.54 8.3E-01 
597 sp|P19157|GSTP1_MOUSE -0.82 1.77 0.94 4.1E-04 
598 sp|Q8K1R3|PNPT1_MOUSE -0.83 1.77 0.59 4.3E-01 
599 sp|Q9ERN0|SCAM2_MOUSE -0.84 1.79 0.61 4.0E-01 
600 sp|O70475|UGDH_MOUSE -0.84 1.79 0.82 7.5E-03 
601 sp|Q8R001|MARE2_MOUSE -0.84 1.79 0.53 9.6E-03 
602 sp|Q62261|SPTB2_MOUSE -0.84 1.80 0.87 1.4E-02 
603 sp|Q91V41|RAB14_MOUSE -0.85 1.80 0.74 1.6E-01 
604 sp|Q9WUA2|SYFB_MOUSE -0.85 1.81 0.59 4.9E-02 
605 sp|Q60676|PPP5_MOUSE -0.86 1.82 0.53 4.7E-02 
606 sp|Q8R2Y8|PTH2_MOUSE -0.86 1.82 0.57 1.7E-02 
607 sp|Q9CQ86|MIEN1_MOUSE -0.87 1.83 0.58 2.5E-02 
608 sp|Q921J2|RHEB_MOUSE -0.87 1.83 0.56 7.4E-03 
609 sp|Q9CQ80|VPS25_MOUSE -0.88 1.84 0.55 5.3E-01 
610 sp|Q99L47|F10A1_MOUSE -0.88 1.84 0.54 2.6E-01 
611 sp|P14148|RL7_MOUSE -0.88 1.84 0.56 7.7E-01 
612 sp|Q8R1V4|TMED4_MOUSE -0.88 1.84 0.90 2.2E-03 
613 sp|P35980|RL18_MOUSE -0.88 1.85 0.66 4.5E-01 
614 sp|P16546|SPTN1_MOUSE -0.89 1.85 0.88 5.9E-05 
615 sp|P12367|KAP2_MOUSE -0.89 1.85 0.57 2.5E-01 
616 sp|Q64471|GSTT1_MOUSE -0.91 1.87 0.80 1.0E-02 
617 sp|P45878|FKBP2_MOUSE -0.91 1.88 0.74 3.8E-03 
618 sp|Q99KI3|EMC3_MOUSE -0.91 1.88 0.57 7.5E-01 
619 sp|Q9R0X4|ACOT9_MOUSE -0.91 1.88 0.71 9.5E-02 
620 sp|Q8QZY2|GLCTK_MOUSE -0.91 1.88 0.69 1.1E-02 
621 sp|P54822|PUR8_MOUSE -0.92 1.90 0.73 7.5E-03 
622 sp|Q924M7|MPI_MOUSE -0.93 1.90 0.58 6.5E-02 
623 sp|Q9D1A2|CNDP2_MOUSE -0.93 1.90 0.77 4.7E-02 
624 sp|P35278|RAB5C_MOUSE -0.93 1.91 0.74 5.4E-01 
625 sp|Q9Z0P4|PALM_MOUSE -0.93 1.91 0.73 6.1E-03 
626 sp|Q9D1L0|CHCH2_MOUSE -0.94 1.92 0.72 5.0E-02 
627 sp|P70296|PEBP1_MOUSE -0.94 1.92 0.92 2.5E-02 
628 sp|Q99LB6|MAT2B_MOUSE -0.96 1.94 0.89 2.0E-01 
629 sp|Q9CY64|BIEA_MOUSE -0.96 1.94 0.63 2.4E-01 
630 sp|P28843|DPP4_MOUSE -0.96 1.95 0.73 2.6E-02 
631 sp|Q9CY27|TECR_MOUSE -0.97 1.95 0.65 8.6E-03 
632 sp|Q9WVE8|PACN2_MOUSE -0.97 1.96 0.85 4.3E-02 
633 sp|O35643|AP1B1_MOUSE -0.97 1.97 0.82 3.5E-03 
634 sp|Q8VDM4|PSMD2_MOUSE -0.98 1.98 0.52 1.5E-01 
635 sp|Q9D7S9|CHMP5_MOUSE -0.98 1.98 0.70 3.0E-01 
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636 sp|P15532|NDKA_MOUSE -0.99 1.98 0.88 2.9E-03 
637 sp|P62849|RS24_MOUSE -0.99 1.99 0.88 1.9E-01 
638 sp|Q8BMA6|SRP68_MOUSE -0.99 1.99 0.57 7.6E-01 
639 sp|P12970|RL7A_MOUSE -1.00 2.01 0.74 4.0E-01 
640 sp|Q9CZW5|TOM70_MOUSE -1.01 2.02 0.57 1.6E-02 
641 sp|P06745|G6PI_MOUSE -1.02 2.03 0.93 2.8E-04 
642 sp|P35700|PRDX1_MOUSE -1.02 2.03 0.91 9.7E-03 
643 sp|P55264|ADK_MOUSE -1.02 2.03 0.87 5.3E-04 
644 sp|Q5SRX1|TM1L2_MOUSE -1.02 2.03 0.74 9.0E-02 
645 sp|Q91W52|TMM19_MOUSE -1.03 2.04 0.71 7.2E-05 
646 sp|Q9D8E6|RL4_MOUSE -1.03 2.04 0.69 6.3E-01 
647 sp|Q9CPU0|LGUL_MOUSE -1.04 2.06 0.74 2.8E-02 
648 sp|P28474|ADHX_MOUSE -1.05 2.07 0.78 3.1E-03 
649 sp|Q9DCL9|PUR6_MOUSE -1.06 2.09 0.79 4.5E-02 
650 sp|P82343|RENBP_MOUSE -1.07 2.10 0.68 2.6E-03 
651 sp|Q6ZWY3|RS27L_MOUSE -1.07 2.10 0.77 1.9E-02 
652 sp|P62855|RS26_MOUSE -1.08 2.11 0.51 2.8E-01 
653 sp|Q01768|NDKB_MOUSE -1.08 2.11 0.95 8.8E-03 
654 sp|Q3UQ44|IQGA2_MOUSE -1.08 2.12 0.56 1.1E-02 
655 sp|P55258|RAB8A_MOUSE -1.10 2.15 0.74 2.1E-02 
656 sp|O35465|FKBP8_MOUSE -1.10 2.15 0.56 6.2E-01 
657 sp|Q9DBP5|KCY_MOUSE -1.14 2.21 0.75 1.5E-04 
658 sp|Q9QYA2|TOM40_MOUSE -1.15 2.22 0.57 2.1E-01 
659 sp|O08709|PRDX6_MOUSE -1.16 2.23 0.94 8.2E-03 
660 sp|P61211|ARL1_MOUSE -1.16 2.24 0.90 5.7E-03 
661 sp|P56371|RAB4A_MOUSE -1.17 2.25 0.80 3.7E-04 
662 sp|O35857|TIM44_MOUSE -1.17 2.25 0.83 4.3E-04 
663 sp|Q9Z0M5|LICH_MOUSE -1.18 2.27 0.58 9.0E-01 
664 sp|Q9CZ42|NNRD_MOUSE -1.18 2.27 0.78 4.1E-03 
665 sp|Q9CR67|TMM33_MOUSE -1.19 2.28 0.86 3.6E-03 
666 sp|Q6GQT9|NOMO1_MOUSE -1.19 2.28 0.53 2.4E-02 
667 sp|Q6ZQI3|MLEC_MOUSE -1.19 2.28 0.66 1.3E-02 
668 sp|P16858|G3P_MOUSE -1.19 2.29 0.92 6.5E-04 
669 sp|Q91WQ3|SYYC_MOUSE -1.20 2.30 0.57 4.1E-01 
670 sp|Q8K411|PREP_MOUSE -1.21 2.32 0.53 1.3E-01 
671 sp|P47791|GSHR_MOUSE -1.22 2.33 0.80 1.0E-01 
672 sp|O55234|PSB5_MOUSE -1.22 2.33 0.69 8.0E-03 
673 sp|Q9D6U8|F162A_MOUSE -1.23 2.35 0.51 4.4E-02 
674 sp|Q9QYB5|ADDG_MOUSE -1.24 2.36 0.76 1.5E-02 
675 sp|Q9QXY6|EHD3_MOUSE -1.24 2.37 0.86 6.4E-05 
676 sp|P10649|GSTM1_MOUSE -1.24 2.37 0.89 2.8E-04 
677 sp|Q9DCZ1|GMPR1_MOUSE -1.27 2.41 0.81 1.2E-06 
678 sp|O70404|VAMP8_MOUSE -1.27 2.41 0.77 4.8E-04 
679 sp|Q9DBJ1|PGAM1_MOUSE -1.27 2.41 0.97 2.1E-03 
680 sp|Q99LX0|PARK7_MOUSE -1.27 2.42 0.93 9.3E-03 
681 sp|Q8K183|PDXK_MOUSE -1.28 2.42 0.85 1.6E-02 
682 sp|P04939|MUP3_MOUSE -1.28 2.43 0.63 5.8E-01 
683 sp|P56565|S10A1_MOUSE -1.28 2.44 0.85 8.7E-03 
684 sp|Q9R022|DJC12_MOUSE -1.30 2.46 0.55 4.3E-02 
685 sp|O70439|STX7_MOUSE -1.32 2.49 0.76 5.3E-05 
686 sp|O09117|SYPL1_MOUSE -1.32 2.50 0.91 1.6E-03 
687 sp|P17182|ENOA_MOUSE -1.33 2.51 0.98 9.2E-04 
688 sp|Q8K3A0|HSC20_MOUSE -1.33 2.51 0.56 1.7E-01 
689 sp|P15947|KLK1_MOUSE -1.33 2.51 0.60 7.1E-01 
690 sp|Q8R2K1|FUCM_MOUSE -1.33 2.52 0.88 2.0E-02 
691 sp|O35988|SDC4_MOUSE -1.33 2.52 0.54 3.8E-05 
692 sp|Q9R087|GPC6_MOUSE -1.34 2.53 0.54 5.8E-01 
693 sp|O88792|JAM1_MOUSE -1.34 2.54 0.55 9.3E-01 
694 sp|Q99KQ4|NAMPT_MOUSE -1.36 2.57 0.82 1.5E-03 
695 sp|Q9WV85|NDK3_MOUSE -1.36 2.57 0.59 1.9E-02 
696 sp|P17809|GTR1_MOUSE -1.37 2.58 0.80 5.8E-05 
697 sp|Q91XU3|PI42C_MOUSE -1.37 2.58 0.57 4.6E-01 
698 sp|Q60931|VDAC3_MOUSE -1.37 2.59 0.74 1.4E-03 
699 sp|Q9D6Y9|GLGB_MOUSE -1.37 2.59 0.98 5.2E-05 
700 sp|P56394|COX17_MOUSE -1.37 2.59 0.69 6.4E-02 
701 sp|Q9CPQ3|TOM22_MOUSE -1.37 2.59 0.75 1.1E-03 
702 sp|P47740|AL3A2_MOUSE -1.38 2.61 0.79 5.9E-02 
703 sp|Q9ESE1|LRBA_MOUSE -1.41 2.65 0.53 3.9E-01 
704 sp|Q9CQ92|FIS1_MOUSE -1.41 2.65 0.89 3.0E-02 
705 sp|P17710|HXK1_MOUSE -1.41 2.66 0.91 3.3E-04 
706 sp|Q91ZJ5|UGPA_MOUSE -1.41 2.66 0.87 1.2E-03 
707 sp|O35345|IMA7_MOUSE -1.41 2.67 0.58 4.2E-01 
708 sp|Q8VDM6|HNRL1_MOUSE -1.42 2.67 0.58 2.7E-03 
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709 sp|Q8K274|KT3K_MOUSE -1.42 2.68 0.56 4.3E-02 
710 sp|Q9D5T0|ATAD1_MOUSE -1.43 2.69 0.79 4.4E-03 
711 sp|P62342|SELT_MOUSE -1.43 2.70 0.76 1.2E-02 
712 sp|Q9CYR6|AGM1_MOUSE -1.43 2.70 0.75 1.0E-02 
713 sp|P17751|TPIS_MOUSE -1.44 2.71 0.95 1.2E-03 
714 sp|Q3ULJ0|GPD1L_MOUSE -1.44 2.72 0.87 4.2E-04 
715 sp|Q9DCT1|AKCL2_MOUSE -1.45 2.73 0.93 4.0E-05 
716 sp|Q9WU84|CCS_MOUSE -1.46 2.75 0.99 3.3E-03 
717 sp|P26043|RADI_MOUSE -1.48 2.79 0.83 3.3E-03 
718 sp|P40237|CD82_MOUSE -1.48 2.79 0.56 9.4E-01 
719 sp|Q8K4Z3|NNRE_MOUSE -1.49 2.80 0.77 3.2E-03 
720 sp|P10518|HEM2_MOUSE -1.50 2.82 0.91 2.3E-06 
721 sp|Q60930|VDAC2_MOUSE -1.50 2.84 0.94 2.9E-06 
722 sp|P48193|41_MOUSE -1.51 2.84 0.85 3.7E-04 
723 sp|P27601|GNA13_MOUSE -1.52 2.86 0.80 1.1E-02 
724 sp|A3KMP2|TTC38_MOUSE -1.52 2.87 0.87 1.2E-05 
725 sp|P51906|EAA3_MOUSE -1.52 2.88 0.50 2.2E-02 
726 sp|P57016|LAD1_MOUSE -1.53 2.89 0.66 4.4E-03 
727 sp|Q3UGR5|HDHD2_MOUSE -1.53 2.90 0.82 3.9E-01 
728 sp|P59017|B2L13_MOUSE -1.55 2.93 0.67 1.8E-01 
729 sp|Q921H8|THIKA_MOUSE -1.56 2.95 0.91 3.4E-03 
730 sp|P00920|CAH2_MOUSE -1.56 2.95 0.95 5.6E-03 
731 sp|O88958|GNPI1_MOUSE -1.56 2.96 0.89 2.9E-05 
732 sp|Q60973|RBBP7_MOUSE -1.57 2.97 0.68 4.2E-01 
733 sp|Q99L04|DHRS1_MOUSE -1.57 2.97 0.79 2.7E-02 
734 sp|Q8BG51|MIRO1_MOUSE -1.57 2.97 0.76 3.1E-04 
735 sp|Q9QXW9|LAT2_MOUSE -1.57 2.98 0.57 1.8E-04 
736 sp|P50247|SAHH_MOUSE -1.58 2.99 0.91 6.2E-04 
737 sp|P28656|NP1L1_MOUSE -1.59 3.02 0.54 8.1E-01 
738 sp|P70349|HINT1_MOUSE -1.60 3.04 0.88 4.3E-04 
739 sp|Q9WVK4|EHD1_MOUSE -1.61 3.05 0.83 1.1E-04 
740 sp|Q9DD20|MET7B_MOUSE -1.62 3.07 0.59 5.3E-03 
741 sp|P97478|COQ7_MOUSE -1.62 3.07 0.53 8.1E-02 
742 sp|O35943|FRDA_MOUSE -1.64 3.11 0.55 1.0E-02 
743 sp|P56376|ACYP1_MOUSE -1.64 3.13 0.68 2.3E-03 
744 sp|P26040|EZRI_MOUSE -1.65 3.13 0.96 5.2E-01 
745 sp|P67778|PHB_MOUSE -1.65 3.13 0.92 2.3E-03 
746 sp|Q9D0F9|PGM1_MOUSE -1.65 3.13 0.90 2.1E-04 
747 sp|P46664|PURA2_MOUSE -1.65 3.13 0.68 5.7E-01 
748 sp|P03893|NU2M_MOUSE -1.67 3.19 0.69 9.4E-03 
749 sp|Q9CS42|PRPS2_MOUSE -1.68 3.20 0.85 2.6E-04 
750 sp|Q9D710|TMX2_MOUSE -1.68 3.20 0.75 4.5E-05 
751 sp|Q99J39|DCMC_MOUSE -1.68 3.21 0.62 3.2E-03 
752 sp|Q80SU7|GVIN1_MOUSE -1.69 3.22 0.83 1.0E-01 
753 sp|Q8JZQ2|AFG32_MOUSE -1.69 3.23 0.75 6.3E-03 
754 sp|P51863|VA0D1_MOUSE -1.70 3.24 0.87 2.0E-03 
755 sp|Q9D7P6|ISCU_MOUSE -1.70 3.25 0.81 3.2E-08 
756 sp|Q9QZ23|NFU1_MOUSE -1.71 3.26 0.66 6.4E-01 
757 sp|P09411|PGK1_MOUSE -1.71 3.27 0.97 3.0E-05 
758 sp|P48774|GSTM5_MOUSE -1.71 3.27 0.87 1.3E-04 
759 sp|Q9D7N9|APMAP_MOUSE -1.71 3.28 0.84 6.0E-02 
760 sp|Q9R0P3|ESTD_MOUSE -1.72 3.28 0.86 6.8E-04 
761 sp|Q64521|GPDM_MOUSE -1.73 3.31 0.67 1.1E-01 
762 sp|O09043|NAPSA_MOUSE -1.73 3.32 0.84 3.0E-01 
763 sp|P08228|SODC_MOUSE -1.74 3.33 0.94 1.1E-02 
764 sp|Q99JY0|ECHB_MOUSE -1.75 3.37 0.87 9.0E-04 
765 sp|P51660|DHB4_MOUSE -1.76 3.39 0.95 2.5E-02 
766 sp|Q9CYH2|F213A_MOUSE -1.77 3.42 0.89 2.9E-03 
767 sp|Q922B1|MACD1_MOUSE -1.78 3.44 0.59 2.1E-01 
768 sp|P11352|GPX1_MOUSE -1.79 3.45 0.92 1.3E-02 
769 sp|Q8K3J9|GPC5C_MOUSE -1.79 3.46 0.52 1.3E-02 
770 sp|Q64105|SPRE_MOUSE -1.79 3.47 0.96 6.4E-04 
771 sp|Q9JK42|PDK2_MOUSE -1.79 3.47 0.55 4.7E-04 
772 sp|Q8JZU2|TXTP_MOUSE -1.80 3.47 0.87 3.0E-04 
773 sp|P09803|CADH1_MOUSE -1.80 3.48 0.68 6.9E-03 
774 sp|Q9CZR8|EFTS_MOUSE -1.81 3.50 0.85 3.2E-04 
775 sp|P31786|ACBP_MOUSE -1.81 3.51 0.93 8.6E-04 
776 sp|Q8JZN5|ACAD9_MOUSE -1.81 3.52 0.75 1.3E-03 
777 sp|O35658|C1QBP_MOUSE -1.82 3.52 0.83 5.7E-04 
778 sp|Q9D7X8|GGCT_MOUSE -1.83 3.55 0.99 2.0E-03 
779 sp|Q3UJU9|RMD3_MOUSE -1.83 3.55 0.75 2.2E-03 
780 sp|Q9Z1G3|VATC1_MOUSE -1.83 3.55 0.83 3.1E-07 
781 sp|O70252|HMOX2_MOUSE -1.83 3.56 0.50 4.0E-01 
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782 sp|Q9CPY7|AMPL_MOUSE -1.84 3.57 0.93 2.0E-02 
783 sp|Q9DCU6|RM04_MOUSE -1.84 3.59 0.91 2.9E-06 
784 sp|Q64331|MYO6_MOUSE -1.84 3.59 0.80 2.0E-02 
785 sp|P24472|GSTA4_MOUSE -1.85 3.61 0.86 4.6E-02 
786 sp|Q8CAY6|THIC_MOUSE -1.85 3.61 0.85 2.0E-05 
787 sp|Q9CQX2|CYB5B_MOUSE -1.86 3.62 0.93 4.2E-01 
788 sp|P37040|NCPR_MOUSE -1.87 3.64 0.81 8.1E-03 
789 sp|Q8K010|OPLA_MOUSE -1.87 3.65 0.77 1.8E-04 
790 sp|Q9D9V3|ECHD1_MOUSE -1.87 3.65 0.78 7.9E-05 
791 sp|P50637|TSPO_MOUSE -1.87 3.66 0.98 1.9E-01 
792 sp|P51661|DHI2_MOUSE -1.88 3.67 0.83 2.1E-04 
793 sp|P05201|AATC_MOUSE -1.88 3.68 0.88 8.2E-04 
794 sp|Q8R519|ACMSD_MOUSE -1.88 3.69 0.69 5.3E-03 
795 sp|P70245|EBP_MOUSE -1.89 3.70 0.91 9.3E-07 
796 sp|P34884|MIF_MOUSE -1.89 3.71 0.92 1.9E-02 
797 sp|Q99LP6|GRPE1_MOUSE -1.89 3.71 0.59 5.8E-02 
798 sp|O35129|PHB2_MOUSE -1.90 3.73 0.94 1.6E-04 
799 sp|P70444|BID_MOUSE -1.90 3.74 0.74 1.0E-04 
800 sp|P35802|GPM6A_MOUSE -1.90 3.74 0.69 9.0E-05 
801 sp|Q9DCJ9|NPL_MOUSE -1.91 3.76 0.88 4.3E-03 
802 sp|Q8BGC4|ZADH2_MOUSE -1.91 3.76 0.72 2.7E-04 
803 sp|P55302|AMRP_MOUSE -1.91 3.77 0.77 3.8E-05 
804 sp|O09172|GSH0_MOUSE -1.92 3.77 0.53 4.6E-02 
805 sp|Q8VDQ1|PTGR2_MOUSE -1.92 3.79 0.89 9.8E-03 
806 sp|Q8R146|APEH_MOUSE -1.93 3.80 0.77 1.4E-03 
807 sp|P70290|EM55_MOUSE -1.93 3.82 0.91 4.5E-05 
808 sp|P48962|ADT1_MOUSE -1.93 3.82 0.83 1.0E-03 
809 sp|P97449|AMPN_MOUSE -1.94 3.83 0.95 1.8E-03 
810 sp|O35969|GAMT_MOUSE -1.94 3.83 0.64 2.0E-03 
811 sp|Q9CZU6|CISY_MOUSE -1.94 3.83 0.88 9.3E-04 
812 sp|P98197|AT11A_MOUSE -1.94 3.85 0.81 3.9E-02 
813 sp|Q9Z2Z6|MCAT_MOUSE -1.95 3.87 0.72 1.1E-01 
814 sp|Q8CIM7|CP2DQ_MOUSE -1.95 3.87 0.77 2.1E-05 
815 sp|P56395|CYB5_MOUSE -1.95 3.87 0.86 4.9E-02 
816 sp|P15105|GLNA_MOUSE -1.97 3.91 0.83 3.1E-04 
817 sp|Q9D8Y1|T126A_MOUSE -1.97 3.93 0.85 1.8E-02 
818 sp|Q3TJ91|L2GL2_MOUSE -1.98 3.94 0.71 1.0E-05 
819 sp|Q9CRD0|OCAD1_MOUSE -1.98 3.94 0.54 1.1E-02 
820 sp|Q8VCF0|MAVS_MOUSE -1.98 3.95 0.84 3.5E-04 
821 sp|P58281|OPA1_MOUSE -1.99 3.97 0.74 1.9E-02 
822 sp|Q8BIJ6|SYIM_MOUSE -1.99 3.98 0.73 4.5E-02 
823 sp|P53986|MOT1_MOUSE -1.99 3.98 0.91 6.3E-03 
824 sp|O88451|RDH7_MOUSE -1.99 3.98 0.74 2.9E-01 
825 sp|P16125|LDHB_MOUSE -2.00 3.99 0.86 1.9E-05 
826 sp|Q9JHS4|CLPX_MOUSE -2.00 3.99 0.78 2.8E-04 
827 sp|Q9Z2Y8|PROSC_MOUSE -2.00 4.01 0.90 1.8E-03 
828 sp|Q791V5|MTCH2_MOUSE -2.00 4.01 0.89 4.1E-04 
829 sp|P62073|TIM10_MOUSE -2.00 4.01 0.86 3.0E-04 
830 sp|Q99L60|VATC2_MOUSE -2.01 4.03 0.70 2.6E-04 
831 sp|Q4VAE3|TMM65_MOUSE -2.01 4.03 0.88 1.5E-02 
832 sp|Q8VCA8|SCRN2_MOUSE -2.02 4.05 0.82 5.9E-01 
833 sp|P19137|LAMA1_MOUSE -2.02 4.06 0.65 4.0E-01 
834 sp|Q571I9|A16A1_MOUSE -2.03 4.09 0.61 1.1E-03 
835 sp|P18572|BASI_MOUSE -2.03 4.09 0.87 9.2E-02 
836 sp|Q9DB29|IAH1_MOUSE -2.03 4.10 0.76 4.6E-05 
837 sp|Q9DBL1|ACDSB_MOUSE -2.04 4.10 0.93 3.9E-04 
838 sp|Q8BXK9|CLIC5_MOUSE -2.06 4.18 0.85 6.5E-03 
839 sp|O70325|GPX41_MOUSE -2.06 4.18 0.52 2.8E-04 
840 sp|Q64669|NQO1_MOUSE -2.07 4.19 0.80 2.6E-07 
841 sp|Q9CR62|M2OM_MOUSE -2.07 4.19 0.83 3.3E-03 
842 sp|P06801|MAOX_MOUSE -2.07 4.20 0.83 1.7E-02 
843 sp|Q80Y14|GLRX5_MOUSE -2.07 4.20 0.93 4.1E-04 
844 sp|P16406|AMPE_MOUSE -2.07 4.21 0.87 1.1E-02 
845 sp|P30275|KCRU_MOUSE -2.08 4.24 0.88 1.6E-04 
846 sp|Q3TMH2|SCRN3_MOUSE -2.09 4.27 0.66 4.1E-05 
847 sp|P97742|CPT1A_MOUSE -2.09 4.27 0.84 8.3E-05 
848 sp|Q9D939|ST1C2_MOUSE -2.09 4.27 0.74 4.7E-04 
849 sp|P51174|ACADL_MOUSE -2.10 4.28 0.87 1.3E-02 
850 sp|Q9JLT4|TRXR2_MOUSE -2.10 4.29 0.83 1.3E-05 
851 sp|Q925I1|ATAD3_MOUSE -2.10 4.30 0.80 2.4E-03 
852 sp|Q924X2|CPT1B_MOUSE -2.10 4.30 0.58 1.5E-03 
853 sp|P10852|4F2_MOUSE -2.12 4.34 0.91 3.5E-04 
854 sp|P26443|DHE3_MOUSE -2.13 4.37 0.92 4.0E-04 
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855 sp|O35855|BCAT2_MOUSE -2.13 4.38 0.89 1.9E-05 
856 sp|P57746|VATD_MOUSE -2.14 4.40 0.89 1.5E-07 
857 sp|Q6P1B1|XPP1_MOUSE -2.14 4.40 0.87 8.8E-03 
858 sp|Q3UMF0|COBL1_MOUSE -2.14 4.40 0.54 3.0E-03 
859 sp|Q99J99|THTM_MOUSE -2.14 4.41 0.83 3.2E-04 
860 sp|O35490|BHMT1_MOUSE -2.14 4.42 0.66 1.1E-01 
861 sp|Q8BJZ4|RT35_MOUSE -2.15 4.43 0.81 3.2E-03 
862 sp|Q9WVA2|TIM8A_MOUSE -2.15 4.45 0.67 7.1E-03 
863 sp|Q8BMS1|ECHA_MOUSE -2.16 4.46 0.97 1.5E-02 
864 sp|O35972|RM23_MOUSE -2.16 4.46 0.61 9.6E-07 
865 sp|P05063|ALDOC_MOUSE -2.16 4.47 0.70 4.0E-02 
866 sp|Q9CXT8|MPPB_MOUSE -2.17 4.51 0.71 3.9E-01 
867 sp|Q8BH59|CMC1_MOUSE -2.17 4.51 0.84 7.9E-05 
868 sp|Q8BFR5|EFTU_MOUSE -2.18 4.54 0.95 1.3E-04 
869 sp|Q99KB8|GLO2_MOUSE -2.18 4.54 0.77 3.6E-03 
870 sp|Q9CWS0|DDAH1_MOUSE -2.19 4.57 0.83 8.7E-04 
871 sp|P29758|OAT_MOUSE -2.20 4.59 0.86 4.6E-02 
872 sp|P08905|LYZ2_MOUSE -2.20 4.60 0.93 1.0E-04 
873 sp|O35143|ATIF1_MOUSE -2.21 4.61 0.83 9.7E-03 
874 sp|Q8CAQ8|MIC60_MOUSE -2.22 4.65 0.92 2.4E-03 
875 sp|Q8CGK3|LONM_MOUSE -2.22 4.66 0.90 1.6E-05 
876 sp|P50431|GLYC_MOUSE -2.22 4.67 0.77 3.0E-03 
877 sp|Q9WV98|TIM9_MOUSE -2.23 4.68 0.77 1.4E-04 
878 sp|Q8BGH2|SAM50_MOUSE -2.23 4.69 0.89 5.3E-05 
879 sp|Q78IK4|MIC27_MOUSE -2.23 4.70 0.81 3.6E-06 
880 sp|Q9DCB8|ISCA2_MOUSE -2.24 4.73 0.82 1.5E-03 
881 sp|O88844|IDHC_MOUSE -2.25 4.75 0.90 2.2E-04 
882 sp|O08756|HCD2_MOUSE -2.25 4.76 0.91 8.3E-06 
883 sp|P42125|ECI1_MOUSE -2.26 4.80 0.91 4.3E-04 
884 sp|P16331|PH4H_MOUSE -2.27 4.83 0.84 3.5E-03 
885 sp|Q9Z2I0|LETM1_MOUSE -2.27 4.84 0.79 3.2E-04 
886 sp|P28271|ACOC_MOUSE -2.28 4.84 0.94 9.1E-05 
887 sp|P34914|HYES_MOUSE -2.28 4.85 0.81 1.1E-01 
888 sp|Q60932|VDAC1_MOUSE -2.28 4.85 0.96 4.0E-04 
889 sp|Q9CQZ5|NDUA6_MOUSE -2.28 4.86 0.84 4.6E-05 
890 sp|Q9D6R2|IDH3A_MOUSE -2.28 4.86 0.91 2.7E-04 
891 sp|Q8VE95|CH082_MOUSE -2.29 4.88 0.64 2.2E-02 
892 sp|Q9JHW2|NIT2_MOUSE -2.29 4.88 0.90 7.8E-04 
893 sp|O88696|CLPP_MOUSE -2.29 4.89 0.73 3.3E-06 
894 sp|Q9DB15|RM12_MOUSE -2.29 4.89 0.91 5.8E-04 
895 sp|P97493|THIOM_MOUSE -2.29 4.90 0.90 2.4E-05 
896 sp|Q99J94|SO1A6_MOUSE -2.30 4.92 0.79 8.2E-04 
897 sp|P97364|SPS2_MOUSE -2.30 4.93 0.90 1.3E-03 
898 sp|P14152|MDHC_MOUSE -2.30 4.94 0.95 6.7E-04 
899 sp|P47934|CACP_MOUSE -2.31 4.95 0.74 1.2E-03 
900 sp|Q60648|SAP3_MOUSE -2.31 4.96 0.85 1.4E-02 
901 sp|Q9WV92|E41L3_MOUSE -2.31 4.96 0.86 8.2E-04 
902 sp|Q8CFA2|GCST_MOUSE -2.32 4.98 0.69 2.7E-02 
903 sp|Q60597|ODO1_MOUSE -2.32 5.00 0.91 4.9E-07 
904 sp|Q9R0H0|ACOX1_MOUSE -2.33 5.01 0.78 1.3E-01 
905 sp|Q8VDK1|NIT1_MOUSE -2.33 5.03 0.90 2.1E-04 
906 sp|P62077|TIM8B_MOUSE -2.33 5.03 0.80 1.6E-06 
907 sp|Q9QZA0|CAH5B_MOUSE -2.33 5.03 0.56 2.3E-01 
908 sp|Q8BTY1|KAT1_MOUSE -2.34 5.05 0.69 1.3E-04 
909 sp|Q8BVI4|DHPR_MOUSE -2.34 5.07 0.88 4.0E-04 
910 sp|Q60936|ADCK3_MOUSE -2.35 5.10 0.65 1.0E-04 
911 sp|Q9WTP7|KAD3_MOUSE -2.35 5.10 0.89 2.4E-04 
912 sp|P50544|ACADV_MOUSE -2.36 5.12 0.89 4.2E-05 
913 sp|P97823|LYPA1_MOUSE -2.36 5.13 0.90 1.4E-04 
914 sp|P51855|GSHB_MOUSE -2.37 5.17 0.82 2.8E-03 
915 sp|O89106|FHIT_MOUSE -2.37 5.18 0.58 3.5E-02 
916 sp|Q99M87|DNJA3_MOUSE -2.38 5.19 0.72 5.3E-02 
917 sp|Q9R112|SQRD_MOUSE -2.38 5.20 0.92 2.4E-04 
918 sp|Q3UP75|UD3A1_MOUSE -2.38 5.20 0.72 2.3E-04 
919 sp|P00158|CYB_MOUSE -2.38 5.20 0.67 3.0E-02 
920 sp|Q9WTP6|KAD2_MOUSE -2.38 5.21 0.86 3.5E-04 
921 sp|P20108|PRDX3_MOUSE -2.39 5.23 0.90 5.7E-04 
922 sp|Q8VHG0|FMO4_MOUSE -2.39 5.24 0.52 3.6E-04 
923 sp|Q8BMF4|ODP2_MOUSE -2.39 5.25 0.98 1.4E-04 
924 sp|Q6PB66|LPPRC_MOUSE -2.40 5.26 0.88 1.0E-03 
925 sp|P58137|ACOT8_MOUSE -2.40 5.27 0.76 1.6E-03 
926 sp|Q9DCQ2|ASPD_MOUSE -2.41 5.31 0.69 4.4E-03 
927 sp|P50518|VATE1_MOUSE -2.41 5.32 0.91 1.4E-06 
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928 sp|Q9Z2I9|SUCB1_MOUSE -2.42 5.33 0.97 2.2E-04 
929 sp|Q07417|ACADS_MOUSE -2.42 5.36 0.89 5.2E-03 
930 sp|Q9QYR9|ACOT2_MOUSE -2.43 5.38 0.79 1.9E-02 
931 sp|Q8R1G2|CMBL_MOUSE -2.43 5.38 0.85 2.7E-03 
932 sp|Q9CQ62|DECR_MOUSE -2.43 5.39 0.89 1.8E-03 
933 sp|P47802|MTX1_MOUSE -2.43 5.41 0.74 2.0E-01 
934 sp|Q8BH86|CN159_MOUSE -2.43 5.41 0.83 1.6E-02 
935 sp|Q8BMC1|VATG3_MOUSE -2.44 5.43 0.94 6.5E-04 
936 sp|Q9D1K2|VATF_MOUSE -2.45 5.45 0.90 7.0E-04 
937 sp|O35459|ECH1_MOUSE -2.45 5.46 0.97 5.0E-04 
938 sp|Q8BLF1|NCEH1_MOUSE -2.45 5.47 0.92 1.2E-02 
939 sp|Q8R3P0|ACY2_MOUSE -2.46 5.49 0.58 2.0E-03 
940 sp|P97494|GSH1_MOUSE -2.46 5.49 0.86 6.8E-03 
941 sp|Q91WN4|KMO_MOUSE -2.46 5.49 0.71 9.6E-04 
942 sp|B2RSH2|GNAI1_MOUSE -2.46 5.51 0.55 8.4E-03 
943 sp|Q68FL4|SAHH3_MOUSE -2.46 5.51 0.76 1.6E-01 
944 sp|Q9D7J9|ECHD3_MOUSE -2.46 5.51 0.67 5.7E-03 
945 sp|P62814|VATB2_MOUSE -2.47 5.52 0.85 1.2E-03 
946 sp|Q9WV69|DEMA_MOUSE -2.47 5.52 0.53 3.5E-03 
947 sp|Q9CRB9|MIC19_MOUSE -2.47 5.53 0.90 1.4E-02 
948 sp|O09111|NDUBB_MOUSE -2.47 5.53 0.90 1.5E-06 
949 sp|Q8QZS1|HIBCH_MOUSE -2.47 5.55 0.89 2.6E-04 
950 sp|P38647|GRP75_MOUSE -2.47 5.56 0.82 3.6E-02 
951 sp|Q8VCR7|ABHEB_MOUSE -2.48 5.57 0.93 3.6E-06 
952 sp|Q8VEM8|MPCP_MOUSE -2.48 5.57 0.90 1.9E-04 
953 sp|P35486|ODPA_MOUSE -2.48 5.58 0.92 7.5E-06 
954 sp|P62075|TIM13_MOUSE -2.48 5.58 0.96 1.3E-04 
955 sp|Q9CXV1|DHSD_MOUSE -2.49 5.60 0.60 1.4E-04 
956 sp|P00375|DYR_MOUSE -2.49 5.60 0.79 2.4E-02 
957 sp|O35215|DOPD_MOUSE -2.49 5.63 0.91 2.5E-03 
958 sp|O55137|ACOT1_MOUSE -2.49 5.63 0.85 3.5E-03 
959 sp|Q922Q1|MARC2_MOUSE -2.50 5.65 0.89 1.0E-04 
960 sp|P35846|FOLR1_MOUSE -2.50 5.66 0.64 2.7E-02 
961 sp|Q8BWN8|ACOT4_MOUSE -2.51 5.68 0.81 3.1E-02 
962 sp|G5E8K5|ANK3_MOUSE -2.51 5.70 0.85 2.5E-05 
963 sp|P52825|CPT2_MOUSE -2.51 5.70 0.88 9.9E-04 
964 sp|Q921G7|ETFD_MOUSE -2.52 5.74 0.89 1.6E-03 
965 sp|Q922H2|PDK3_MOUSE -2.52 5.75 0.66 4.3E-02 
966 sp|Q9JLJ2|AL9A1_MOUSE -2.53 5.76 0.94 5.2E-03 
967 sp|Q9CQZ6|NDUB3_MOUSE -2.53 5.76 0.76 3.9E-05 
968 sp|Q9QXG4|ACSA_MOUSE -2.53 5.76 0.65 8.7E-03 
969 sp|Q9CQN1|TRAP1_MOUSE -2.54 5.82 0.88 7.5E-04 
970 sp|P47738|ALDH2_MOUSE -2.54 5.82 0.95 1.3E-05 
971 sp|Q61133|GSTT2_MOUSE -2.55 5.84 0.87 2.8E-04 
972 sp|Q9D1I5|MCEE_MOUSE -2.55 5.85 0.76 5.6E-04 
973 sp|Q8BKZ9|ODPX_MOUSE -2.55 5.86 0.72 6.3E-04 
974 sp|Q8BGD8|COA6_MOUSE -2.55 5.87 0.67 2.2E-01 
975 sp|Q91X52|DCXR_MOUSE -2.57 5.92 0.88 7.7E-03 
976 sp|Q9CQ54|NDUC2_MOUSE -2.57 5.93 0.88 4.1E-07 
977 sp|Q6DYE8|ENPP3_MOUSE -2.57 5.94 0.71 6.1E-04 
978 sp|Q8BVE3|VATH_MOUSE -2.57 5.94 0.90 9.3E-03 
979 sp|Q99JB7|AMNLS_MOUSE -2.57 5.95 0.64 3.4E-01 
980 sp|P17426|AP2A1_MOUSE -2.57 5.95 0.65 3.2E-02 
981 sp|O88441|MTX2_MOUSE -2.58 5.96 0.79 1.8E-01 
982 sp|Q9D2R6|COA3_MOUSE -2.58 5.98 0.55 9.1E-05 
983 sp|Q9DCM0|ETHE1_MOUSE -2.58 5.99 0.92 3.6E-03 
984 sp|P03888|NU1M_MOUSE -2.58 6.00 0.74 6.4E-05 
985 sp|Q8VI47|MRP2_MOUSE -2.59 6.03 0.82 8.2E-04 
986 sp|Q8K0H1|S47A1_MOUSE -2.59 6.03 0.53 2.3E-02 
987 sp|P50516|VATA_MOUSE -2.59 6.04 0.92 1.3E-06 
988 sp|Q9D051|ODPB_MOUSE -2.60 6.05 0.96 7.1E-05 
989 sp|Q8BJ64|CHDH_MOUSE -2.60 6.06 0.88 8.9E-04 
990 sp|Q9DCJ5|NDUA8_MOUSE -2.60 6.07 0.91 3.7E-07 
991 sp|P50171|DHB8_MOUSE -2.60 6.07 0.87 5.5E-04 
992 sp|P05202|AATM_MOUSE -2.61 6.10 0.97 1.8E-04 
993 sp|Q9CQJ8|NDUB9_MOUSE -2.61 6.10 0.83 1.4E-04 
994 sp|O55126|NIPS2_MOUSE -2.62 6.13 0.66 2.1E-01 
995 sp|Q9Z2H5|E41L1_MOUSE -2.62 6.14 0.67 1.3E-01 
996 sp|Q64433|CH10_MOUSE -2.62 6.15 0.90 7.4E-04 
997 sp|P03899|NU3M_MOUSE -2.62 6.15 0.95 1.5E-03 
998 sp|Q9CQQ7|AT5F1_MOUSE -2.62 6.17 0.92 3.2E-04 
999 sp|Q9D2R0|AACS_MOUSE -2.64 6.24 0.60 1.1E-01 
1000 sp|Q9QXD1|ACOX2_MOUSE -2.64 6.24 0.84 6.1E-04 
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1001 sp|Q9JLF6|TGM1_MOUSE -2.65 6.27 0.77 3.7E-03 
1002 sp|Q71RI9|KAT3_MOUSE -2.65 6.29 0.81 7.8E-03 
1003 sp|P97450|ATP5J_MOUSE -2.65 6.29 0.97 2.8E-03 
1004 sp|Q8BWM0|PGES2_MOUSE -2.65 6.29 0.89 8.1E-04 
1005 sp|Q9EP89|LACTB_MOUSE -2.65 6.30 0.72 3.8E-04 
1006 sp|P99029|PRDX5_MOUSE -2.65 6.30 0.91 5.2E-04 
1007 sp|Q91YI0|ARLY_MOUSE -2.66 6.31 0.91 3.6E-04 
1008 sp|P53395|ODB2_MOUSE -2.66 6.31 0.81 1.3E-03 
1009 sp|Q9CPQ1|COX6C_MOUSE -2.66 6.33 0.91 7.0E-04 
1010 sp|Q14DH7|ACSS3_MOUSE -2.66 6.33 0.63 1.1E-01 
1011 sp|Q9DCS3|MECR_MOUSE -2.66 6.33 0.73 6.4E-03 
1012 sp|Q9D855|QCR7_MOUSE -2.66 6.34 0.89 4.4E-03 
1013 sp|Q5M8N4|D39U1_MOUSE -2.67 6.35 0.73 1.2E-02 
1014 sp|Q99JR1|SFXN1_MOUSE -2.67 6.35 0.83 1.7E-03 
1015 sp|P17665|COX7C_MOUSE -2.67 6.35 0.80 6.1E-04 
1016 sp|Q99KR7|PPIF_MOUSE -2.67 6.36 0.57 5.2E-03 
1017 sp|Q9Z1P6|NDUA7_MOUSE -2.67 6.36 0.91 8.8E-05 
1018 sp|Q9CZ13|QCR1_MOUSE -2.67 6.37 0.94 4.0E-04 
1019 sp|Q9DBX3|SUSD2_MOUSE -2.67 6.38 0.92 8.7E-04 
1020 sp|Q8R086|SUOX_MOUSE -2.68 6.39 0.56 4.0E-02 
1021 sp|Q99LB2|DHRS4_MOUSE -2.68 6.42 0.91 1.1E-01 
1022 sp|Q91WK5|GCSH_MOUSE -2.68 6.42 0.74 1.9E-03 
1023 sp|P56382|ATP5E_MOUSE -2.68 6.42 0.61 2.4E-02 
1024 sp|Q8K4F5|ABHDB_MOUSE -2.69 6.43 0.63 3.6E-06 
1025 sp|Q8VBW8|TTC36_MOUSE -2.69 6.45 0.74 1.4E-02 
1026 sp|Q03265|ATPA_MOUSE -2.69 6.46 0.96 5.8E-04 
1027 sp|Q8CC88|VWA8_MOUSE -2.69 6.46 0.82 8.0E-04 
1028 sp|Q920R6|VPP4_MOUSE -2.69 6.46 0.78 6.0E-04 
1029 sp|Q9CPP6|NDUA5_MOUSE -2.69 6.48 0.90 3.9E-04 
1030 sp|P56391|CX6B1_MOUSE -2.70 6.48 0.92 3.2E-05 
1031 sp|Q91Z53|GRHPR_MOUSE -2.70 6.49 0.79 7.7E-03 
1032 sp|Q8R2N1|AQP3_MOUSE -2.70 6.51 0.90 2.8E-03 
1033 sp|P11404|FABPH_MOUSE -2.71 6.53 0.88 1.3E-04 
1034 sp|Q99MS3|MP17L_MOUSE -2.71 6.55 0.59 1.3E-02 
1035 sp|P56480|ATPB_MOUSE -2.71 6.55 0.94 1.5E-04 
1036 sp|P97807|FUMH_MOUSE -2.71 6.56 0.89 1.3E-07 
1037 sp|P98078|DAB2_MOUSE -2.71 6.56 0.79 1.1E-03 
1038 sp|Q78IK2|USMG5_MOUSE -2.72 6.60 0.97 1.2E-03 
1039 sp|Q06185|ATP5I_MOUSE -2.73 6.62 0.90 1.2E-03 
1040 sp|P08249|MDHM_MOUSE -2.73 6.63 0.96 6.1E-05 
1041 sp|Q9DCT2|NDUS3_MOUSE -2.73 6.64 0.96 3.1E-04 
1042 sp|Q99KI0|ACON_MOUSE -2.74 6.66 0.90 8.9E-04 
1043 sp|Q8BYF6|SC5A8_MOUSE -2.74 6.69 0.58 5.5E-03 
1044 sp|Q9D172|ES1_MOUSE -2.75 6.71 0.92 3.9E-04 
1045 sp|Q91WD5|NDUS2_MOUSE -2.75 6.72 0.91 2.9E-04 
1046 sp|Q9WUR2|ECI2_MOUSE -2.75 6.73 0.85 1.8E-03 
1047 sp|A2AJL3|FGGY_MOUSE -2.75 6.73 0.85 6.8E-04 
1048 sp|Q60866|PTER_MOUSE -2.75 6.73 0.91 2.3E-05 
1049 sp|Q8VC69|S22A6_MOUSE -2.76 6.76 0.71 3.2E-02 
1050 sp|Q9Z0S1|BPNT1_MOUSE -2.77 6.81 0.87 6.4E-05 
1051 sp|Q91ZA3|PCCA_MOUSE -2.77 6.83 0.84 5.1E-04 
1052 sp|O09174|AMACR_MOUSE -2.77 6.84 0.62 8.7E-02 
1053 sp|Q9DB20|ATPO_MOUSE -2.77 6.84 0.96 1.1E-03 
1054 sp|Q9D826|SOX_MOUSE -2.77 6.84 0.76 5.1E-02 
1055 sp|Q9CQ75|NDUA2_MOUSE -2.78 6.87 0.77 4.0E-04 
1056 sp|P68368|TBA4A_MOUSE -2.79 6.89 0.88 3.0E-05 
1057 sp|Q9D2G2|ODO2_MOUSE -2.79 6.89 0.89 6.1E-05 
1058 sp|Q02013|AQP1_MOUSE -2.79 6.91 0.80 4.8E-03 
1059 sp|P55014|S12A1_MOUSE -2.79 6.91 0.96 1.9E-04 
1060 sp|Q99LC3|NDUAA_MOUSE -2.79 6.92 0.93 1.8E-04 
1061 sp|Q7TMF3|NDUAC_MOUSE -2.79 6.93 0.76 4.4E-04 
1062 sp|Q91VR2|ATPG_MOUSE -2.80 6.96 0.90 2.5E-04 
1063 sp|P03930|ATP8_MOUSE -2.80 6.97 0.90 8.4E-04 
1064 sp|Q8K3J1|NDUS8_MOUSE -2.81 7.02 0.80 4.2E-04 
1065 sp|P51881|ADT2_MOUSE -2.82 7.06 0.81 7.5E-05 
1066 sp|Q9CPX8|QCR10_MOUSE -2.83 7.11 0.80 1.4E-02 
1067 sp|Q9CPU4|MGST3_MOUSE -2.83 7.12 0.84 2.8E-02 
1068 sp|Q9CQ69|QCR8_MOUSE -2.83 7.12 0.91 1.0E-04 
1069 sp|Q922D8|C1TC_MOUSE -2.83 7.12 0.87 4.0E-05 
1070 sp|Q9DCV4|RMD1_MOUSE -2.83 7.13 0.70 1.1E-02 
1071 sp|Q9DB77|QCR2_MOUSE -2.84 7.14 0.94 2.3E-04 
1072 sp|P28825|MEP1A_MOUSE -2.84 7.15 0.88 2.4E-03 
1073 sp|Q9DBF1|AL7A1_MOUSE -2.84 7.16 0.82 2.4E-04 
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1074 sp|O08749|DLDH_MOUSE -2.84 7.18 0.94 1.2E-04 
1075 sp|Q9Z2H7|GIPC2_MOUSE -2.84 7.18 0.72 9.8E-04 
1076 sp|Q91VT4|CBR4_MOUSE -2.85 7.19 0.85 7.6E-04 
1077 sp|Q9CXZ1|NDUS4_MOUSE -2.85 7.19 0.83 2.1E-04 
1078 sp|Q9QXX4|CMC2_MOUSE -2.85 7.20 0.80 2.7E-04 
1079 sp|Q9DC50|OCTC_MOUSE -2.85 7.20 0.80 3.7E-02 
1080 sp|Q9DCX2|ATP5H_MOUSE -2.85 7.21 0.93 1.8E-03 
1081 sp|Q8BH95|ECHM_MOUSE -2.85 7.21 0.90 5.1E-05 
1082 sp|Q9CQC7|NDUB4_MOUSE -2.85 7.21 0.83 1.1E-04 
1083 sp|Q99MR8|MCCA_MOUSE -2.86 7.25 0.82 7.4E-06 
1084 sp|P16332|MUTA_MOUSE -2.86 7.27 0.81 2.3E-05 
1085 sp|P56389|CDD_MOUSE -2.86 7.28 0.81 6.7E-05 
1086 sp|Q9Z0X1|AIFM1_MOUSE -2.87 7.30 0.92 3.7E-05 
1087 sp|Q62425|NDUA4_MOUSE -2.87 7.30 0.89 5.2E-06 
1088 sp|Q9CR51|VATG1_MOUSE -2.87 7.31 0.83 5.2E-04 
1089 sp|Q8C5H8|NAKD2_MOUSE -2.87 7.33 0.95 2.5E-04 
1090 sp|Q9D7B6|ACAD8_MOUSE -2.88 7.36 0.75 1.6E-02 
1091 sp|P48771|CX7A2_MOUSE -2.88 7.37 0.92 5.2E-05 
1092 sp|Q80XL6|ACD11_MOUSE -2.89 7.41 0.80 1.3E-01 
1093 sp|P19783|COX41_MOUSE -2.90 7.46 0.94 1.4E-04 
1094 sp|Q8R404|MIC13_MOUSE -2.90 7.47 0.72 6.8E-04 
1095 sp|Q9DCS2|CP013_MOUSE -2.90 7.48 0.87 7.5E-03 
1096 sp|Q9CQX8|RT36_MOUSE -2.92 7.55 0.67 7.3E-03 
1097 sp|Q91VD9|NDUS1_MOUSE -2.92 7.55 0.94 1.1E-04 
1098 sp|Q9CZB0|C560_MOUSE -2.92 7.55 0.83 1.6E-04 
1099 sp|P63038|CH60_MOUSE -2.92 7.56 0.96 1.0E-03 
1100 sp|O09173|HGD_MOUSE -2.92 7.58 0.84 4.4E-03 
1101 sp|P56392|CX7A1_MOUSE -2.93 7.60 0.93 8.9E-05 
1102 sp|A2ARV4|LRP2_MOUSE -2.93 7.60 0.84 9.6E-04 
1103 sp|Q99KP3|CRYL1_MOUSE -2.93 7.62 0.90 3.6E-04 
1104 sp|Q91WR5|AK1CL_MOUSE -2.94 7.66 0.79 2.6E-02 
1105 sp|P41216|ACSL1_MOUSE -2.94 7.69 0.90 9.5E-03 
1106 sp|P47199|QOR_MOUSE -2.95 7.71 0.84 1.2E-04 
1107 sp|P61110|ANRE_MOUSE -2.95 7.73 0.77 1.7E-03 
1108 sp|Q8BP40|PPA6_MOUSE -2.95 7.74 0.85 3.2E-05 
1109 sp|P52196|THTR_MOUSE -2.95 7.75 0.89 4.6E-04 
1110 sp|P10637|TAU_MOUSE -2.96 7.76 0.83 2.2E-03 
1111 sp|Q99LY9|NDUS5_MOUSE -2.96 7.78 0.67 3.7E-02 
1112 sp|Q9CR61|NDUB7_MOUSE -2.96 7.79 0.84 9.2E-04 
1113 sp|P61458|PHS_MOUSE -2.96 7.81 0.80 2.5E-03 
1114 sp|P32020|NLTP_MOUSE -2.97 7.82 0.88 4.9E-02 
1115 sp|Q9DBL7|COASY_MOUSE -2.97 7.83 0.85 2.4E-03 
1116 sp|Q8C165|P20D1_MOUSE -2.97 7.83 0.53 3.9E-04 
1117 sp|Q9JLZ3|AUHM_MOUSE -2.97 7.85 0.85 1.0E-01 
1118 sp|Q9CQ91|NDUA3_MOUSE -2.98 7.86 0.89 7.5E-03 
1119 sp|Q8K023|AKC1H_MOUSE -2.98 7.87 0.56 7.5E-03 
1120 sp|O08966|S22A1_MOUSE -2.98 7.88 0.74 1.5E-01 
1121 sp|Q9CR68|UCRI_MOUSE -2.98 7.89 0.91 4.3E-04 
1122 sp|Q8BWT1|THIM_MOUSE -2.98 7.90 0.91 2.0E-03 
1123 sp|P70404|IDHG1_MOUSE -2.98 7.91 0.91 1.0E-03 
1124 sp|Q8K1Z0|COQ9_MOUSE -2.98 7.91 0.90 1.1E-04 
1125 sp|B1AXP6|TOM5_MOUSE -2.99 7.94 1.00 2.2E-03 
1126 sp|Q9DCU9|HOGA1_MOUSE -2.99 7.95 0.69 2.7E-02 
1127 sp|Q9D0M3|CY1_MOUSE -2.99 7.96 0.94 9.6E-04 
1128 sp|O55060|TPMT_MOUSE -3.00 7.98 0.93 1.3E-04 
1129 sp|Q9CQA3|SDHB_MOUSE -3.00 7.99 0.89 2.6E-04 
1130 sp|P00405|COX2_MOUSE -3.00 7.99 0.87 3.4E-03 
1131 sp|Q9DBE0|CSAD_MOUSE -3.00 8.00 0.90 6.7E-03 
1132 sp|Q9ERS2|NDUAD_MOUSE -3.00 8.00 0.89 4.1E-05 
1133 sp|Q9DCZ4|MIC26_MOUSE -3.01 8.03 0.75 4.1E-07 
1134 sp|Q61391|NEP_MOUSE -3.01 8.05 0.90 1.5E-02 
1135 sp|P70441|NHRF1_MOUSE -3.01 8.07 0.94 5.1E-03 
1136 sp|P56379|68MP_MOUSE -3.02 8.12 0.71 1.4E-03 
1137 sp|Q9DCW4|ETFB_MOUSE -3.02 8.13 0.91 4.0E-04 
1138 sp|Q8JZV9|BDH2_MOUSE -3.02 8.13 0.82 4.4E-03 
1139 sp|P46656|ADX_MOUSE -3.03 8.16 0.61 5.5E-03 
1140 sp|Q9DC70|NDUS7_MOUSE -3.03 8.16 0.94 1.4E-06 
1141 sp|Q9D8I3|GLOD5_MOUSE -3.03 8.17 0.56 2.8E-02 
1142 sp|P17563|SBP1_MOUSE -3.03 8.19 0.92 3.9E-05 
1143 sp|P54071|IDHP_MOUSE -3.04 8.21 0.93 4.2E-04 
1144 sp|O35409|FOLH1_MOUSE -3.04 8.24 0.58 2.3E-03 
1145 sp|P19536|COX5B_MOUSE -3.04 8.24 0.91 2.9E-05 
1146 sp|Q8BJ03|COX15_MOUSE -3.04 8.24 0.50 6.3E-01 
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1147 sp|O35683|NDUA1_MOUSE -3.05 8.25 0.86 2.5E-03 
1148 sp|P99028|QCR6_MOUSE -3.05 8.31 0.93 1.4E-03 
1149 sp|Q9D3D9|ATPD_MOUSE -3.06 8.32 0.98 4.6E-04 
1150 sp|P55096|ABCD3_MOUSE -3.06 8.36 0.88 5.1E-03 
1151 sp|Q9DC69|NDUA9_MOUSE -3.07 8.38 0.89 6.4E-05 
1152 sp|Q91YT0|NDUV1_MOUSE -3.07 8.43 0.90 7.9E-06 
1153 sp|Q91VM9|IPYR2_MOUSE -3.09 8.50 0.83 1.4E-01 
1154 sp|Q9D6J6|NDUV2_MOUSE -3.09 8.50 0.84 1.6E-03 
1155 sp|Q6P3A8|ODBB_MOUSE -3.09 8.53 0.78 1.2E-03 
1156 sp|Q9WUM5|SUCA_MOUSE -3.10 8.55 0.94 9.3E-04 
1157 sp|Q9DCS9|NDUBA_MOUSE -3.11 8.63 0.86 3.7E-03 
1158 sp|Q8K2B3|SDHA_MOUSE -3.11 8.64 0.98 3.4E-06 
1159 sp|Q99MZ7|PECR_MOUSE -3.11 8.65 0.87 1.9E-02 
1160 sp|P03921|NU5M_MOUSE -3.12 8.67 0.88 3.1E-02 
1161 sp|Q9D6J5|NDUB8_MOUSE -3.12 8.67 0.86 3.9E-06 
1162 sp|Q9DCC7|ISC2B_MOUSE -3.12 8.68 0.71 2.6E-03 
1163 sp|Q9R0M5|TPK1_MOUSE -3.12 8.69 0.79 6.3E-03 
1164 sp|Q80W22|THNS2_MOUSE -3.12 8.70 0.83 1.2E-03 
1165 sp|P52503|NDUS6_MOUSE -3.12 8.72 0.81 2.4E-04 
1166 sp|G3X9C2|FBX50_MOUSE -3.13 8.73 0.80 5.4E-04 
1167 sp|Q8R4N0|CLYBL_MOUSE -3.13 8.75 0.80 4.1E-04 
1168 sp|Q3TC72|FAHD2_MOUSE -3.13 8.76 0.80 5.6E-04 
1169 sp|P03911|NU4M_MOUSE -3.14 8.79 0.89 1.3E-02 
1170 sp|O55125|NIPS1_MOUSE -3.14 8.81 0.91 8.3E-04 
1171 sp|Q9CQR4|ACO13_MOUSE -3.14 8.84 0.77 4.2E-04 
1172 sp|P13707|GPDA_MOUSE -3.15 8.85 0.91 8.0E-04 
1173 sp|Q8CFZ5|S22AC_MOUSE -3.15 8.90 0.78 2.7E-01 
1174 sp|Q5U5V2|HYKK_MOUSE -3.15 8.91 0.80 1.6E-02 
1175 sp|Q99K67|AASS_MOUSE -3.16 8.94 0.73 1.9E-04 
1176 sp|P09242|PPBT_MOUSE -3.17 8.99 0.74 5.9E-03 
1177 sp|Q3UEG6|AGT2_MOUSE -3.17 9.01 0.71 6.8E-05 
1178 sp|Q3V0K9|PLSI_MOUSE -3.17 9.01 0.86 1.0E-05 
1179 sp|Q9CQH3|NDUB5_MOUSE -3.17 9.01 0.85 6.9E-07 
1180 sp|Q99LC5|ETFA_MOUSE -3.18 9.07 0.93 5.5E-05 
1181 sp|P12787|COX5A_MOUSE -3.18 9.08 0.94 1.1E-03 
1182 sp|P59158|S12A3_MOUSE -3.18 9.09 0.63 8.8E-03 
1183 sp|Q7TNG8|LDHD_MOUSE -3.19 9.10 0.88 7.4E-02 
1184 sp|P48758|CBR1_MOUSE -3.19 9.11 0.92 6.1E-02 
1185 sp|Q9D6Y7|MSRA_MOUSE -3.19 9.12 0.83 1.0E-04 
1186 sp|P56135|ATPK_MOUSE -3.20 9.17 0.80 2.6E-04 
1187 sp|Q9CR21|ACPM_MOUSE -3.20 9.19 0.92 2.3E-04 
1188 sp|P38060|HMGCL_MOUSE -3.21 9.26 0.92 1.9E-03 
1189 sp|Q8R1I1|QCR9_MOUSE -3.22 9.30 0.67 3.7E-05 
1190 sp|Q9D173|TOM7_MOUSE -3.22 9.30 0.57 1.5E-02 
1191 sp|Q9D0K2|SCOT1_MOUSE -3.22 9.34 0.92 2.1E-04 
1192 sp|Q8CI85|CAH12_MOUSE -3.24 9.46 0.58 9.8E-04 
1193 sp|Q9JIZ0|CMLO1_MOUSE -3.24 9.47 0.67 2.9E-02 
1194 sp|Q8BWF0|SSDH_MOUSE -3.24 9.47 0.88 4.5E-04 
1195 sp|P62897|CYC_MOUSE -3.25 9.49 0.92 3.4E-04 
1196 sp|Q91Y63|S13A3_MOUSE -3.25 9.52 0.88 3.6E-05 
1197 sp|Q62433|NDRG1_MOUSE -3.25 9.52 0.99 8.0E-04 
1198 sp|O88909|S22A8_MOUSE -3.25 9.52 0.80 4.6E-03 
1199 sp|Q99JW2|ACY1_MOUSE -3.26 9.59 0.77 3.3E-01 
1200 sp|Q9D8B4|NDUAB_MOUSE -3.26 9.60 0.62 7.3E-03 
1201 sp|Q9DBT9|M2GD_MOUSE -3.27 9.68 0.78 1.6E-05 
1202 sp|P62627|DLRB1_MOUSE -3.28 9.69 0.63 6.0E-01 
1203 sp|Q3UFF7|LYPL1_MOUSE -3.28 9.71 0.73 1.5E-02 
1204 sp|Q91WS0|CISD1_MOUSE -3.29 9.75 0.95 5.8E-04 
1205 sp|Q3UIU2|NDUB6_MOUSE -3.29 9.77 0.81 4.6E-03 
1206 sp|Q61425|HCDH_MOUSE -3.30 9.82 0.90 3.7E-03 
1207 sp|Q8BGS1|E41L5_MOUSE -3.30 9.84 0.77 1.3E-05 
1208 sp|Q78KK3|S22AI_MOUSE -3.30 9.86 0.90 2.0E-03 
1209 sp|Q8CG76|ARK72_MOUSE -3.30 9.87 0.87 9.6E-04 
1210 sp|P97328|KHK_MOUSE -3.31 9.90 0.83 1.1E-02 
1211 sp|Q5SWY8|SC5AA_MOUSE -3.31 9.93 0.63 9.1E-03 
1212 sp|Q8R0Y6|AL1L1_MOUSE -3.31 9.95 0.91 3.9E-04 
1213 sp|P40936|INMT_MOUSE -3.33 10.03 0.83 1.5E-01 
1214 sp|Q99LB7|SARDH_MOUSE -3.33 10.05 0.85 7.1E-07 
1215 sp|Q9WU79|PROD_MOUSE -3.33 10.05 0.81 2.3E-05 
1216 sp|Q8QZT1|THIL_MOUSE -3.34 10.10 0.95 1.9E-02 
1217 sp|Q9JHI5|IVD_MOUSE -3.34 10.14 0.88 4.2E-04 
1218 sp|Q91W43|GCSP_MOUSE -3.35 10.20 0.57 2.1E-01 
1219 sp|P50136|ODBA_MOUSE -3.36 10.29 0.64 1.0E-03 
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1220 sp|P50285|FMO1_MOUSE -3.37 10.33 0.82 3.8E-05 
1221 sp|Q8R0F8|FAHD1_MOUSE -3.38 10.39 0.84 6.0E-05 
1222 sp|Q99KR3|LACB2_MOUSE -3.38 10.39 0.82 1.2E-01 
1223 sp|Q8JZN7|MIRO2_MOUSE -3.38 10.40 0.55 2.2E-01 
1224 sp|Q9Z2I8|SUCB2_MOUSE -3.38 10.42 0.94 1.3E-04 
1225 sp|Q6ZQM8|UD17C_MOUSE -3.39 10.51 0.75 9.6E-03 
1226 sp|Q99L13|3HIDH_MOUSE -3.40 10.55 0.94 1.3E-08 
1227 sp|Q9JII6|AK1A1_MOUSE -3.40 10.56 0.91 4.1E-04 
1228 sp|Q91V76|CK054_MOUSE -3.41 10.61 0.82 2.8E-03 
1229 sp|P30115|GSTA3_MOUSE -3.41 10.63 0.81 1.2E-03 
1230 sp|Q9JIL4|NHRF3_MOUSE -3.42 10.71 0.86 8.2E-04 
1231 sp|Q8K157|GALM_MOUSE -3.43 10.75 0.74 2.1E-05 
1232 sp|Q9WVT6|CAH14_MOUSE -3.43 10.76 0.70 1.5E-04 
1233 sp|Q8K370|ACD10_MOUSE -3.43 10.77 0.86 1.5E-04 
1234 sp|Q9QZD8|DIC_MOUSE -3.44 10.83 0.83 8.4E-03 
1235 sp|Q9DCG6|PBLD1_MOUSE -3.45 10.91 0.87 4.3E-02 
1236 sp|Q3ULD5|MCCB_MOUSE -3.45 10.95 0.90 3.8E-04 
1237 sp|Q8BGA8|ACSM5_MOUSE -3.46 11.03 0.76 2.8E-05 
1238 sp|Q5F285|TM256_MOUSE -3.46 11.03 0.71 1.0E-02 
1239 sp|Q8R164|BPHL_MOUSE -3.47 11.09 0.87 1.2E-04 
1240 sp|Q91YP0|L2HDH_MOUSE -3.48 11.18 0.58 8.2E-05 
1241 sp|Q925N2|SFXN2_MOUSE -3.49 11.27 0.65 8.7E-02 
1242 sp|Q9D0S9|HINT2_MOUSE -3.49 11.27 0.98 2.6E-05 
1243 sp|P11930|NUD19_MOUSE -3.50 11.28 0.90 5.0E-02 
1244 sp|P14246|GTR2_MOUSE -3.50 11.30 0.72 5.0E-02 
1245 sp|Q9WVD5|ORNT1_MOUSE -3.50 11.32 0.79 1.3E-03 
1246 sp|P18894|OXDA_MOUSE -3.51 11.38 0.81 5.7E-04 
1247 sp|Q9CPQ8|ATP5L_MOUSE -3.53 11.54 0.80 6.2E-05 
1248 sp|O88428|PAPS2_MOUSE -3.53 11.56 0.77 2.2E-03 
1249 sp|Q9D023|MPC2_MOUSE -3.54 11.60 0.82 3.2E-04 
1250 sp|Q8R0Y8|S2542_MOUSE -3.54 11.63 0.86 1.4E-03 
1251 sp|P09671|SODM_MOUSE -3.54 11.66 0.93 6.7E-04 
1252 sp|O88533|DDC_MOUSE -3.55 11.69 0.74 3.6E-04 
1253 sp|P00397|COX1_MOUSE -3.55 11.70 0.90 1.1E-02 
1254 sp|Q8VC30|DHAK_MOUSE -3.56 11.77 0.80 1.6E-02 
1255 sp|Q62468|VILI_MOUSE -3.56 11.78 0.91 5.8E-09 
1256 sp|Q99PG0|AAAD_MOUSE -3.57 11.84 0.85 3.4E-03 
1257 sp|Q3UNZ8|QORL2_MOUSE -3.57 11.85 0.82 8.1E-02 
1258 sp|Q64516|GLPK_MOUSE -3.57 11.89 0.86 6.0E-05 
1259 sp|P43024|CX6A1_MOUSE -3.57 11.91 0.74 1.3E-03 
1260 sp|Q8VCT4|CES1D_MOUSE -3.58 11.96 0.83 2.3E-04 
1261 sp|Q8CHT0|AL4A1_MOUSE -3.61 12.17 0.93 9.9E-05 
1262 sp|Q99MN9|PCCB_MOUSE -3.61 12.22 0.96 1.3E-04 
1263 sp|Q8CAK1|CAF17_MOUSE -3.61 12.24 0.70 4.3E-02 
1264 sp|Q9DCM2|GSTK1_MOUSE -3.62 12.27 0.82 1.8E-04 
1265 sp|O70577|S22A2_MOUSE -3.62 12.29 0.81 2.2E-03 
1266 sp|Q8BK30|NDUV3_MOUSE -3.63 12.37 0.79 9.0E-04 
1267 sp|Q91XE4|ACY3_MOUSE -3.64 12.43 0.80 8.5E-02 
1268 sp|Q9D687|S6A19_MOUSE -3.64 12.51 0.74 1.5E-06 
1269 sp|P24270|CATA_MOUSE -3.66 12.62 0.94 1.0E-02 
1270 sp|Q9WV68|DECR2_MOUSE -3.66 12.62 0.90 6.7E-06 
1271 sp|P62071|RRAS2_MOUSE -3.66 12.64 0.58 4.3E-01 
1272 sp|P09470|ACE_MOUSE -3.66 12.66 0.91 3.4E-03 
1273 sp|P52760|UK114_MOUSE -3.67 12.69 0.94 5.5E-03 
1274 sp|P63030|MPC1_MOUSE -3.69 12.91 0.93 5.7E-04 
1275 sp|Q64442|DHSO_MOUSE -3.71 13.11 0.82 9.5E-04 
1276 sp|Q8VDN2|AT1A1_MOUSE -3.72 13.14 0.93 1.2E-04 
1277 sp|P35505|FAAA_MOUSE -3.72 13.16 0.92 5.2E-06 
1278 sp|Q60759|GCDH_MOUSE -3.72 13.17 0.77 3.4E-04 
1279 sp|O88343|S4A4_MOUSE -3.73 13.29 0.83 1.3E-04 
1280 sp|Q91XE0|GLYAT_MOUSE -3.75 13.43 0.88 1.7E-03 
1281 sp|O70250|PGAM2_MOUSE -3.75 13.44 0.88 6.6E-04 
1282 sp|Q9WVL0|MAAI_MOUSE -3.75 13.49 0.82 6.7E-07 
1283 sp|Q60928|GGT1_MOUSE -3.76 13.58 0.89 1.1E-03 
1284 sp|Q3UZZ6|ST1D1_MOUSE -3.78 13.74 0.85 5.3E-08 
1285 sp|P42925|PXMP2_MOUSE -3.78 13.77 0.81 2.8E-04 
1286 sp|Q9EQ20|MMSA_MOUSE -3.79 13.79 0.88 3.4E-04 
1287 sp|O88986|KBL_MOUSE -3.79 13.82 0.85 2.4E-05 
1288 sp|P61922|GABT_MOUSE -3.79 13.84 0.93 1.3E-03 
1289 sp|Q9DCN1|NUD12_MOUSE -3.80 13.88 0.59 1.0E-02 
1290 sp|Q9D964|GATM_MOUSE -3.80 13.91 0.87 1.7E-04 
1291 sp|Q8R0N6|HOT_MOUSE -3.82 14.07 0.84 1.0E-03 
1292 sp|Q91Y97|ALDOB_MOUSE -3.83 14.21 0.93 4.0E-05 
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1293 sp|Q80XN0|BDH_MOUSE -3.83 14.24 0.89 2.7E-04 
1294 sp|P85094|ISC2A_MOUSE -3.84 14.27 0.90 3.0E-04 
1295 sp|Q9Z2J0|S23A1_MOUSE -3.84 14.29 0.78 1.5E-02 
1296 sp|Q9ESG4|TMM27_MOUSE -3.85 14.41 0.85 4.2E-05 
1297 sp|P45952|ACADM_MOUSE -3.86 14.48 0.86 1.2E-04 
1298 sp|Q9JKZ2|SC5A3_MOUSE -3.86 14.51 0.63 1.1E-02 
1299 sp|Q64FW2|RETST_MOUSE -3.88 14.71 0.76 6.6E-03 
1300 sp|Q61847|MEP1B_MOUSE -3.88 14.72 0.82 2.7E-04 
1301 sp|Q9ERT9|PPR1A_MOUSE -3.89 14.87 0.68 5.2E-04 
1302 sp|O35488|S27A2_MOUSE -3.90 14.88 0.81 1.4E-03 
1303 sp|Q9QXN5|MIOX_MOUSE -3.93 15.22 0.79 2.6E-01 
1304 sp|Q78JT3|3HAO_MOUSE -3.96 15.56 0.85 3.8E-04 
1305 sp|Q60825|NPT2A_MOUSE -3.96 15.57 0.58 1.2E-03 
1306 sp|Q8BK72|RT27_MOUSE -3.97 15.65 0.79 4.2E-01 
1307 sp|Q14C51|PTCD3_MOUSE -3.98 15.77 0.60 1.8E-01 
1308 sp|Q8VCN5|CGL_MOUSE -4.00 16.04 0.86 1.7E-03 
1309 sp|Q3TLP5|ECHD2_MOUSE -4.01 16.09 0.87 3.5E-03 
1310 sp|Q923I7|SC5A2_MOUSE -4.02 16.23 0.80 1.0E-04 
1311 sp|Q9DCY0|KEG1_MOUSE -4.03 16.36 0.88 1.7E-02 
1312 sp|Q9CQN3|TOM6_MOUSE -4.04 16.46 0.65 2.5E-02 
1313 sp|Q99NB1|ACS2L_MOUSE -4.05 16.56 0.89 1.9E-04 
1314 sp|P97816|S100G_MOUSE -4.05 16.59 0.90 3.4E-03 
1315 sp|Q99N23|CAH15_MOUSE -4.06 16.64 0.59 1.4E-03 
1316 sp|Q91WG0|EST2C_MOUSE -4.06 16.66 0.69 5.3E-02 
1317 sp|Q8JZZ0|UD3A2_MOUSE -4.06 16.72 0.83 6.6E-03 
1318 sp|Q61767|3BHS4_MOUSE -4.07 16.79 0.79 1.1E-02 
1319 sp|Q04646|ATNG_MOUSE -4.07 16.80 0.90 2.8E-04 
1320 sp|Q8BH00|AL8A1_MOUSE -4.10 17.11 0.88 3.8E-05 
1321 sp|P10648|GSTA2_MOUSE -4.10 17.14 0.85 2.0E-02 
1322 sp|O54749|CP2J5_MOUSE -4.11 17.31 0.57 6.9E-01 
1323 sp|Q7TMS5|ABCG2_MOUSE -4.12 17.42 0.79 1.8E-03 
1324 sp|Q8VIM4|BSND_MOUSE -4.14 17.65 0.77 5.0E-03 
1325 sp|Q05920|PYC_MOUSE -4.17 18.04 0.87 1.5E-03 
1326 sp|Q3TNA1|XYLB_MOUSE -4.18 18.14 0.67 3.0E-02 
1327 sp|Q9WUZ9|ENTP5_MOUSE -4.19 18.28 0.75 3.3E-04 
1328 sp|Q9Z2V4|PCKGC_MOUSE -4.20 18.41 0.80 1.4E-03 
1329 sp|O88338|CAD16_MOUSE -4.29 19.54 0.92 8.5E-04 
1330 sp|P14094|AT1B1_MOUSE -4.29 19.55 0.87 6.5E-04 
1331 sp|P00416|COX3_MOUSE -4.30 19.65 0.64 1.0E-02 
1332 sp|Q9WUR9|KAD4_MOUSE -4.31 19.83 0.89 6.5E-04 
1333 sp|Q9DBM2|ECHP_MOUSE -4.32 19.92 0.84 4.8E-03 
1334 sp|Q8K0L3|ACSM2_MOUSE -4.33 20.17 0.86 6.1E-02 
1335 sp|Q91YD6|VILL_MOUSE -4.38 20.84 0.63 7.3E-01 
1336 sp|Q9QXD6|F16P1_MOUSE -4.38 20.84 0.81 1.0E-04 
1337 sp|Q91VA0|ACSM1_MOUSE -4.38 20.87 0.83 3.8E-04 
1338 sp|P16460|ASSY_MOUSE -4.41 21.28 0.88 1.4E-03 
1339 sp|Q8VEA4|MIA40_MOUSE -4.44 21.77 0.50 9.1E-03 
1340 sp|P70691|UD12_MOUSE -4.89 29.67 0.74 6.1E-03 
1341 sp|P12658|CALB1_MOUSE -5.00 32.07 0.91 1.6E-03 
1342 sp|Q8VCH0|THIKB_MOUSE -5.10 34.19 0.75 6.8E-02 
1343 sp|Q8QZW3|F151A_MOUSE -5.39 41.95 0.79 5.6E-04 
1344 sp|Q9NYQ2|HAOX2_MOUSE -5.47 44.28 0.85 2.3E-02 
1345 sp|Q9CQH0|PDZ1I_MOUSE -5.52 45.76 0.84 5.0E-03 
1346 sp|Q8C025|CHPT1_MOUSE -5.58 47.75 0.76 5.6E-03 
1347 sp|Q9WVM8|AADAT_MOUSE -5.59 48.00 0.84 1.7E-02 
1348 sp|O88576|S6A18_MOUSE -5.82 56.31 0.63 5.7E-04 
1349 sp|P35576|G6PC_MOUSE -6.17 72.24 0.86 4.1E-03 
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S.1.1.2 Fold change analysis of TG2-KO Sham operated vs WT Sham operated 
 
Supplementary Table 3.2: Outcome of the fold change (FC) analysis between TG2-KO Sham 
operated mice (21 days) and WT Sham operated mice (21 days) [C(FC) ≥ 0.5].  
 
 Protein ID log2(FC) Abs(FC) C(FC) p-value (FC) 
1 sp|Q9CYW4|HDHD3_MOUSE 3.44 10.87 0.52 4.27E-01 
2 sp|Q99J27|ACATN_MOUSE 3.40 10.52 0.57 3.32E-01 
3 sp|Q8K1B8|URP2_MOUSE 2.49 5.63 0.58 9.49E-02 
4 sp|P84084|ARF5_MOUSE 2.02 4.07 0.57 2.04E-01 
5 sp|Q06138|CAB39_MOUSE 1.88 3.69 0.81 2.96E-05 
6 sp|Q6ZWV7|RL35_MOUSE 1.63 3.11 0.57 1.57E-01 
7 sp|Q6IFZ6|K2C1B_MOUSE 1.47 2.78 0.59 1.45E-01 
8 sp|Q9QZA0|CAH5B_MOUSE 1.46 2.75 0.61 2.03E-01 
9 sp|P62717|RL18A_MOUSE 1.26 2.39 0.61 4.28E-01 
10 sp|P47915|RL29_MOUSE 1.22 2.33 0.68 6.83E-01 
11 sp|P43275|H11_MOUSE 1.05 2.07 0.58 3.34E-02 
12 sp|P15864|H12_MOUSE 0.96 1.95 0.72 1.13E-02 
13 sp|P10922|H10_MOUSE 0.94 1.92 0.77 3.76E-03 
14 sp|Q9CPR4|RL17_MOUSE 0.90 1.87 0.76 5.00E-01 
15 sp|P02535|K1C10_MOUSE 0.89 1.85 0.52 6.87E-01 
16 sp|Q9D1R9|RL34_MOUSE 0.85 1.81 0.52 7.93E-01 
17 sp|Q8BP67|RL24_MOUSE 0.85 1.81 0.90 1.08E-01 
18 sp|Q8C0E2|VP26B_MOUSE 0.82 1.77 0.57 1.89E-01 
19 sp|P43274|H14_MOUSE 0.81 1.75 0.84 3.76E-02 
20 sp|P43276|H15_MOUSE 0.79 1.73 0.66 3.15E-02 
21 sp|P47964|RL36_MOUSE 0.76 1.69 0.68 3.74E-02 
22 sp|O09167|RL21_MOUSE 0.76 1.69 0.68 1.76E-01 
23 sp|P62852|RS25_MOUSE 0.76 1.69 0.66 3.69E-01 
24 sp|P84099|RL19_MOUSE 0.72 1.65 0.52 9.68E-02 
25 sp|P62806|H4_MOUSE 0.72 1.64 0.74 1.73E-02 
26 sp|P47963|RL13_MOUSE 0.71 1.64 0.70 4.26E-01 
27 sp|P62862|RS30_MOUSE 0.70 1.62 0.69 1.79E-01 
28 sp|Q8BP40|PPA6_MOUSE 0.68 1.61 0.52 3.17E-01 
29 sp|Q9CRC0|VKOR1_MOUSE 0.68 1.60 0.68 1.30E-01 
30 sp|Q91VW3|SH3L3_MOUSE 0.64 1.56 0.58 1.40E-01 
31 sp|Q6ZWV3|RL10_MOUSE 0.64 1.55 0.56 1.03E-01 
32 sp|P24668|MPRD_MOUSE 0.63 1.55 0.56 4.23E-02 
33 sp|P62855|RS26_MOUSE 0.57 1.48 0.53 3.36E-01 
34 sp|P84228|H32_MOUSE 0.54 1.45 0.56 1.45E-02 
35 sp|P68433|H31_MOUSE 0.53 1.44 0.66 7.79E-01 
36 sp|Q3THW5|H2AV_MOUSE 0.52 1.44 0.53 6.60E-02 
37 sp|Q9DAS9|GBG12_MOUSE 0.52 1.43 0.75 2.60E-02 
38 sp|P04117|FABP4_MOUSE 0.51 1.43 0.58 1.56E-01 
39 sp|Q9QZQ8|H2AY_MOUSE 0.50 1.42 0.65 2.08E-02 
40 sp|P62880|GBB2_MOUSE 0.47 1.38 0.52 4.94E-01 
41 sp|P62301|RS13_MOUSE 0.43 1.35 0.50 6.23E-01 
42 sp|Q14DH7|ACSS3_MOUSE 0.43 1.35 0.53 7.30E-01 
43 sp|P62315|SMD1_MOUSE 0.43 1.34 0.57 4.37E-02 
44 sp|P56382|ATP5E_MOUSE 0.41 1.33 0.53 1.56E-02 
45 sp|P11404|FABPH_MOUSE 0.41 1.32 0.54 2.82E-01 
46 sp|P63024|VAMP3_MOUSE 0.34 1.27 0.50 8.92E-01 
47 sp|Q9CQ19|MYL9_MOUSE 0.32 1.24 0.63 7.37E-01 
48 sp|Q99MZ7|PECR_MOUSE 0.29 1.22 0.53 9.41E-01 
49 sp|P13707|GPDA_MOUSE 0.27 1.20 0.52 3.76E-01 
50 sp|P63276|RS17_MOUSE 0.26 1.19 0.55 1.97E-01 
51 sp|Q9DCB8|ISCA2_MOUSE -0.31 1.24 0.54 3.15E-01 
52 sp|P17563|SBP1_MOUSE -0.31 1.24 0.57 4.44E-02 
53 sp|Q9DCU6|RM04_MOUSE -0.34 1.27 0.54 7.69E-01 
54 sp|Q9DCT1|AKCL2_MOUSE -0.35 1.28 0.55 4.39E-03 
55 sp|Q61937|NPM_MOUSE -0.41 1.33 0.62 4.20E-01 
56 sp|Q9CR86|CHSP1_MOUSE -0.51 1.42 0.54 5.96E-01 
57 sp|Q9CQX2|CYB5B_MOUSE -0.51 1.43 0.80 9.52E-02 
58 sp|P51906|EAA3_MOUSE -0.52 1.43 0.52 2.67E-02 
59 sp|P05132|KAPCA_MOUSE -0.58 1.50 0.55 9.60E-01 
60 sp|Q08943|SSRP1_MOUSE -0.63 1.55 0.56 1.33E-01 
61 sp|Q5F285|TM256_MOUSE -0.66 1.58 0.73 6.36E-02 
62 sp|Q571E4|GALNS_MOUSE -0.67 1.60 0.70 4.95E-01 
63 sp|Q8BJZ4|RT35_MOUSE -0.75 1.68 0.55 7.64E-01 
64 sp|P50637|TSPO_MOUSE -0.81 1.75 0.61 1.12E-01 
65 sp|Q8CFV9|RIFK_MOUSE -0.99 1.98 0.68 4.79E-02 
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66 sp|Q8K3A0|HSC20_MOUSE -1.09 2.12 0.56 6.86E-02 
67 sp|P68373|TBA1C_MOUSE -1.12 2.17 0.67 1.47E-01 
68 sp|Q9CQN3|TOM6_MOUSE -1.24 2.37 0.62 6.39E-02 
69 sp|O70252|HMOX2_MOUSE -2.01 4.02 0.51 9.55E-01 
70 sp|Q9D173|TOM7_MOUSE -2.03 4.08 0.57 2.56E-01 
71 sp|P63087|PP1G_MOUSE -2.75 6.71 0.57 2.23E-01 
72 sp|P21981|TGM2_MOUSE -3.16 8.94 0.84 3.13E-05 
 
 
 
 
 
S.1.1.3 Fold change analysis of TG2-KO UUO vs WT UUO 
 
Supplementary Table 3.3: Outcome of the fold change (FC) analysis between TG2-KO UUO mice 
(21 days) and WT UUO mice (21 days) [C(FC) ≥ 0.5].  
 
 Protein ID log2(FC) Abs(FC) C(FC) p-value (FC) 
1 sp|Q99PG0|AAAD_MOUSE 3.08 8.48 0.51 5.25E-02 
2 sp|Q8BMF3|MAON_MOUSE 2.52 5.73 0.54 6.22E-01 
3 sp|Q9CXT8|MPPB_MOUSE 1.97 3.92 0.70 1.61E-01 
4 sp|P50637|TSPO_MOUSE 1.79 3.46 1.00 3.76E-01 
5 sp|P15864|H12_MOUSE 1.55 2.92 0.94 4.00E-02 
6 sp|O35683|NDUA1_MOUSE 1.50 2.82 0.58 1.89E-01 
7 sp|P84099|RL19_MOUSE 1.45 2.73 0.85 7.33E-02 
8 sp|P10922|H10_MOUSE 1.44 2.72 0.82 2.40E-01 
9 sp|P43274|H14_MOUSE 1.41 2.66 0.95 7.82E-02 
10 sp|Q9JHU4|DYHC1_MOUSE 1.37 2.59 0.55 4.88E-01 
11 sp|Q6GSS7|H2A2A_MOUSE 1.32 2.50 0.73 3.28E-02 
12 sp|Q8BP67|RL24_MOUSE 1.31 2.49 0.92 2.36E-01 
13 sp|P47963|RL13_MOUSE 1.26 2.39 0.89 1.24E-01 
14 sp|P43276|H15_MOUSE 1.24 2.35 0.88 8.33E-02 
15 sp|P43275|H11_MOUSE 1.22 2.34 0.97 2.30E-02 
16 sp|P61255|RL26_MOUSE 1.19 2.28 0.58 2.32E-01 
17 sp|P62918|RL8_MOUSE 1.17 2.25 0.84 8.91E-02 
18 sp|B1AXP6|TOM5_MOUSE 1.17 2.25 0.97 2.81E-01 
19 sp|Q9CR57|RL14_MOUSE 1.15 2.22 0.93 9.19E-02 
20 sp|P12970|RL7A_MOUSE 1.14 2.21 0.86 1.97E-02 
21 sp|P62862|RS30_MOUSE 1.14 2.21 0.91 7.82E-02 
22 sp|Q99LX0|PARK7_MOUSE 1.13 2.19 0.51 1.58E-01 
23 sp|P62849|RS24_MOUSE 1.10 2.15 0.92 1.41E-01 
24 sp|Q9D8E6|RL4_MOUSE 1.09 2.14 0.86 8.61E-02 
25 sp|P61358|RL27_MOUSE 1.09 2.14 0.83 2.50E-02 
26 sp|P47964|RL36_MOUSE 1.02 2.03 0.89 1.25E-01 
27 sp|P47911|RL6_MOUSE 1.02 2.02 0.78 1.35E-01 
28 sp|P41105|RL28_MOUSE 0.98 1.97 0.80 5.36E-01 
29 sp|P62843|RS15_MOUSE 0.97 1.97 0.53 1.67E-01 
30 sp|P27659|RL3_MOUSE 0.97 1.96 0.55 5.04E-01 
31 sp|Q6ZWV3|RL10_MOUSE 0.97 1.96 0.63 6.95E-01 
32 sp|Q6ZWV7|RL35_MOUSE 0.93 1.90 0.64 4.26E-02 
33 sp|P63158|HMGB1_MOUSE 0.90 1.87 0.53 7.05E-01 
34 sp|P19253|RL13A_MOUSE 0.89 1.85 0.81 9.03E-01 
35 sp|P62806|H4_MOUSE 0.89 1.85 0.82 2.25E-01 
36 sp|Q8CGP6|H2A1H_MOUSE 0.87 1.83 0.76 2.06E-01 
37 sp|Q9CPR4|RL17_MOUSE 0.87 1.82 0.85 1.71E-01 
38 sp|P62855|RS26_MOUSE 0.86 1.81 0.54 3.63E-01 
39 sp|P14148|RL7_MOUSE 0.85 1.80 0.91 7.32E-02 
40 sp|P62270|RS18_MOUSE 0.81 1.75 0.87 1.45E-02 
41 sp|Q9CZM2|RL15_MOUSE 0.81 1.75 0.61 2.10E-01 
42 sp|P35980|RL18_MOUSE 0.79 1.73 0.87 9.18E-02 
43 sp|Q6ZWN5|RS9_MOUSE 0.78 1.71 0.73 6.60E-02 
44 sp|P62717|RL18A_MOUSE 0.77 1.70 0.68 2.68E-01 
45 sp|P03987|IGHG3_MOUSE 0.76 1.69 0.66 2.92E-02 
46 sp|P62281|RS11_MOUSE 0.75 1.68 0.73 3.29E-02 
47 sp|P62274|RS29_MOUSE 0.74 1.67 0.80 2.19E-01 
48 sp|P68433|H31_MOUSE 0.74 1.67 0.71 2.58E-01 
49 sp|P62900|RL31_MOUSE 0.73 1.66 0.71 4.23E-01 
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50 sp|O09167|RL21_MOUSE 0.70 1.62 0.71 4.87E-01 
51 sp|P62315|SMD1_MOUSE 0.68 1.61 0.79 6.96E-02 
52 sp|P62301|RS13_MOUSE 0.68 1.60 0.86 3.13E-02 
53 sp|P62852|RS25_MOUSE 0.66 1.59 0.84 3.02E-02 
54 sp|P27661|H2AX_MOUSE 0.66 1.58 0.74 1.23E-01 
55 sp|P62754|RS6_MOUSE 0.66 1.58 0.60 2.75E-01 
56 sp|Q9JJI8|RL38_MOUSE 0.65 1.57 0.57 7.45E-01 
57 sp|P20065|TYB4_MOUSE 0.61 1.52 0.57 8.40E-01 
58 sp|Q3THW5|H2AV_MOUSE 0.60 1.52 0.62 9.36E-01 
59 sp|P25444|RS2_MOUSE 0.59 1.51 0.54 7.32E-01 
60 sp|Q8CGP2|H2B1P_MOUSE 0.57 1.48 0.83 1.60E-02 
61 sp|P14131|RS16_MOUSE 0.54 1.46 0.54 9.45E-02 
62 sp|P53026|RL10A_MOUSE 0.54 1.46 0.70 1.53E-01 
63 sp|P62242|RS8_MOUSE 0.46 1.38 0.74 1.70E-01 
64 sp|Q8VDM4|PSMD2_MOUSE 0.45 1.37 0.63 5.72E-01 
65 sp|P62702|RS4X_MOUSE 0.45 1.37 0.59 1.59E-01 
66 sp|Q9QZQ8|H2AY_MOUSE 0.44 1.35 0.78 2.92E-02 
67 sp|Q6ZWY3|RS27L_MOUSE 0.42 1.34 0.62 6.84E-01 
68 sp|Q9CZX8|RS19_MOUSE 0.37 1.29 0.70 3.69E-01 
69 sp|P62245|RS15A_MOUSE 0.37 1.29 0.54 4.83E-02 
70 sp|P17742|PPIA_MOUSE -0.20 1.15 0.75 6.58E-02 
71 sp|P57776|EF1D_MOUSE -0.21 1.16 0.59 1.95E-01 
72 sp|Q8VDW0|DX39A_MOUSE -0.22 1.16 0.53 7.04E-01 
73 sp|Q04857|CO6A1_MOUSE -0.22 1.17 0.50 5.97E-01 
74 sp|P61924|COPZ1_MOUSE -0.22 1.17 0.51 4.60E-01 
75 sp|P39061|COIA1_MOUSE -0.23 1.17 0.60 9.51E-03 
76 sp|Q99PT1|GDIR1_MOUSE -0.23 1.17 0.60 2.72E-01 
77 sp|Q61171|PRDX2_MOUSE -0.24 1.18 0.61 3.97E-02 
78 sp|P24369|PPIB_MOUSE -0.24 1.18 0.57 4.33E-02 
79 sp|Q05144|RAC2_MOUSE -0.25 1.19 0.55 4.62E-02 
80 sp|Q60972|RBBP4_MOUSE -0.26 1.20 0.55 1.46E-02 
81 sp|P68254|1433T_MOUSE -0.26 1.20 0.60 3.58E-01 
82 sp|Q02788|CO6A2_MOUSE -0.27 1.20 0.79 5.96E-01 
83 sp|P61205|ARF3_MOUSE -0.27 1.21 0.57 1.96E-01 
84 sp|O08547|SC22B_MOUSE -0.28 1.21 0.57 5.49E-01 
85 sp|Q9R0P6|SC11A_MOUSE -0.28 1.21 0.74 7.56E-01 
86 sp|P51859|HDGF_MOUSE -0.28 1.22 0.55 5.63E-01 
87 sp|P61982|1433G_MOUSE -0.30 1.23 0.57 5.53E-01 
88 sp|Q9CQR2|RS21_MOUSE -0.31 1.24 0.67 4.01E-03 
89 sp|Q922U2|K2C5_MOUSE -0.32 1.25 0.62 9.83E-02 
90 sp|Q8BGS7|CEPT1_MOUSE -0.32 1.25 0.50 7.76E-01 
91 sp|Q99KP6|PRP19_MOUSE -0.32 1.25 0.64 2.59E-02 
92 sp|P62309|RUXG_MOUSE -0.32 1.25 0.69 5.71E-03 
93 sp|P21460|CYTC_MOUSE -0.32 1.25 0.64 1.25E-02 
94 sp|P54923|ADPRH_MOUSE -0.32 1.25 0.53 2.06E-01 
95 sp|P21107|TPM3_MOUSE -0.32 1.25 0.54 4.81E-01 
96 sp|Q61233|PLSL_MOUSE -0.33 1.25 0.64 3.05E-02 
97 sp|P23953|EST1C_MOUSE -0.34 1.26 0.76 6.95E-01 
98 sp|Q9WUM3|COR1B_MOUSE -0.34 1.27 0.53 2.20E-01 
99 sp|P62259|1433E_MOUSE -0.35 1.27 0.57 2.62E-01 
100 sp|Q6IFZ6|K2C1B_MOUSE -0.35 1.27 0.57 9.83E-02 
101 sp|Q9CX80|CYGB_MOUSE -0.36 1.29 0.60 3.32E-01 
102 sp|P07759|SPA3K_MOUSE -0.36 1.29 0.51 9.54E-01 
103 sp|Q8CHH9|SEPT8_MOUSE -0.37 1.30 0.51 6.55E-01 
104 sp|Q3UBX0|TM109_MOUSE -0.38 1.30 0.54 8.71E-03 
105 sp|P01029|CO4B_MOUSE -0.38 1.30 0.70 9.02E-02 
106 sp|Q9ESB3|HRG_MOUSE -0.38 1.31 0.52 8.85E-01 
107 sp|Q61102|ABCB7_MOUSE -0.39 1.31 0.88 2.05E-03 
108 sp|P18760|COF1_MOUSE -0.40 1.32 0.52 2.27E-01 
109 sp|P41731|CD63_MOUSE -0.40 1.32 0.74 4.88E-02 
110 sp|Q91YH5|ATLA3_MOUSE -0.40 1.32 0.53 1.40E-01 
111 sp|O35887|CALU_MOUSE -0.42 1.34 0.62 2.21E-02 
112 sp|O88792|JAM1_MOUSE -0.43 1.34 0.53 6.16E-02 
113 sp|P21956|MFGM_MOUSE -0.43 1.35 0.55 1.84E-02 
114 sp|P68373|TBA1C_MOUSE -0.44 1.35 0.57 1.25E-01 
115 sp|Q9R0P4|SMAP_MOUSE -0.44 1.36 0.57 4.38E-01 
116 sp|Q99M71|EPDR1_MOUSE -0.46 1.38 0.61 1.22E-03 
117 sp|P01942|HBA_MOUSE -0.46 1.38 0.69 1.16E-01 
118 sp|Q62000|MIME_MOUSE -0.49 1.40 0.50 6.48E-01 
119 sp|Q99LB6|MAT2B_MOUSE -0.51 1.43 0.55 3.78E-01 
120 sp|Q00623|APOA1_MOUSE -0.52 1.43 0.62 6.97E-01 
121 sp|P35441|TSP1_MOUSE -0.52 1.43 0.74 7.86E-01 
122 sp|Q9D7X3|DUS3_MOUSE -0.53 1.44 0.52 9.79E-02 
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123 sp|P08207|S10AA_MOUSE -0.53 1.45 0.71 1.37E-01 
124 sp|Q9R0P5|DEST_MOUSE -0.56 1.48 0.72 7.50E-03 
125 sp|Q91VW3|SH3L3_MOUSE -0.57 1.48 0.60 1.57E-01 
126 sp|Q9Z130|HNRDL_MOUSE -0.66 1.58 0.54 1.26E-03 
127 sp|Q91VM9|IPYR2_MOUSE -0.68 1.60 0.53 9.55E-01 
128 sp|P62204|CALM_MOUSE -0.68 1.60 0.72 1.77E-01 
129 sp|Q9D0M5|DYL2_MOUSE -0.69 1.61 0.56 8.30E-01 
130 sp|Q9Z2W1|STK25_MOUSE -0.71 1.64 0.58 8.63E-01 
131 sp|Q9D1L9|LTOR5_MOUSE -0.78 1.71 0.64 2.58E-01 
132 sp|P19096|FAS_MOUSE -0.81 1.75 0.51 3.77E-01 
133 sp|Q8VCM7|FIBG_MOUSE -0.89 1.85 0.63 5.34E-01 
134 sp|P01878|IGHA_MOUSE -0.89 1.85 0.53 4.55E-01 
135 sp|Q8K0E8|FIBB_MOUSE -0.99 1.99 0.60 6.30E-01 
136 sp|P14069|S10A6_MOUSE -1.00 1.99 0.75 4.41E-03 
137 sp|P04117|FABP4_MOUSE -1.06 2.08 0.87 8.97E-02 
138 sp|E9PV24|FIBA_MOUSE -1.09 2.13 0.72 6.48E-01 
139 sp|Q9QZ85|IIGP1_MOUSE -1.35 2.54 0.65 7.15E-02 
140 sp|Q9D1P4|CHRD1_MOUSE -1.58 2.98 0.51 1.12E-03 
141 sp|P02798|MT2_MOUSE -1.78 3.45 0.69 6.42E-02 
142 sp|Q9D7X8|GGCT_MOUSE -1.89 3.71 0.53 5.37E-02 
143 sp|Q9JKF7|RM39_MOUSE -1.93 3.80 0.51 1.50E-01 
144 sp|P01635|KV5A3_MOUSE -4.19 18.29 0.71 6.78E-01 
145 sp|P21981|TGM2_MOUSE -4.97 31.44 0.85 9.81E-01 
146 sp|Q6AW69|CGNL1_MOUSE -7.21 148.27 0.50 8.44E-01 
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S.1.1.4 Fold change analysis of TG2-KO UUO vs TG2-KO Sham operated 
 
Supplementary Table 3.4: Outcome of the Fold change (FC) analysis between TG2-KO UUO mice 
(21 days) and TG2-KO Sham operated mice (21 days) [C(FC) ≥ 0.5].  
 
 Protein ID log2(FC) Abs(FC) C(FC) p-value (FC) 
1 sp|Q60847|COCA1_MOUSE 4.71 26.15 0.83 8.11E-03 
2 sp|Q61555|FBN2_MOUSE 3.86 14.52 0.89 9.96E-03 
3 sp|Q80YX1|TENA_MOUSE 3.81 14.03 0.72 4.74E-03 
4 sp|Q9CYG7|TOM34_MOUSE 3.55 11.73 0.70 6.13E-02 
5 sp|P14069|S10A6_MOUSE 3.45 10.94 0.81 1.97E-01 
6 sp|Q08091|CNN1_MOUSE 3.45 10.90 0.80 8.70E-04 
7 sp|P28653|PGS1_MOUSE 3.30 9.86 0.87 1.97E-04 
8 sp|Q91X17|UROM_MOUSE 3.29 9.78 0.88 1.00E-02 
9 sp|Q07235|GDN_MOUSE 3.28 9.71 0.64 4.34E-01 
10 sp|Q8BH97|RCN3_MOUSE 3.22 9.30 0.84 2.53E-09 
11 sp|P15379|CD44_MOUSE 3.18 9.05 0.56 1.55E-04 
12 sp|P82198|BGH3_MOUSE 3.18 9.04 0.75 3.72E-04 
13 sp|Q08619|IFI5B_MOUSE 3.15 8.90 0.68 4.63E-04 
14 sp|Q62009|POSTN_MOUSE 3.12 8.66 0.78 9.63E-03 
15 sp|Q62241|RU1C_MOUSE 3.06 8.36 0.57 1.18E-02 
16 sp|P10107|ANXA1_MOUSE 3.04 8.24 0.94 1.80E-05 
17 sp|Q8K4G1|LTBP4_MOUSE 3.03 8.19 0.74 2.70E-06 
18 sp|Q61554|FBN1_MOUSE 3.01 8.05 0.89 2.39E-04 
19 sp|P19001|K1C19_MOUSE 2.99 7.95 0.89 5.00E-05 
20 sp|P02762|MUP6_MOUSE 2.96 7.80 0.95 1.58E-03 
21 sp|Q62148|AL1A2_MOUSE 2.96 7.79 0.77 4.24E-03 
22 sp|P35441|TSP1_MOUSE 2.96 7.77 0.76 8.37E-02 
23 sp|P14438|HA2U_MOUSE 2.95 7.75 0.74 8.04E-02 
24 sp|O88207|CO5A1_MOUSE 2.92 7.56 0.83 1.27E-01 
25 sp|Q921M7|FA49B_MOUSE 2.91 7.53 0.70 1.80E-06 
26 sp|Q05144|RAC2_MOUSE 2.91 7.50 0.76 6.35E-02 
27 sp|Q9CZH7|MXRA7_MOUSE 2.90 7.48 0.60 3.17E-02 
28 sp|P07214|SPRC_MOUSE 2.90 7.45 0.57 7.89E-01 
29 sp|Q62000|MIME_MOUSE 2.89 7.40 0.86 4.97E-02 
30 sp|Q01149|CO1A2_MOUSE 2.86 7.25 0.71 1.56E-02 
31 sp|P97290|IC1_MOUSE 2.86 7.24 0.78 1.33E-03 
32 sp|P06800|PTPRC_MOUSE 2.84 7.17 0.78 1.52E-06 
33 sp|Q8VCC9|SPON1_MOUSE 2.78 6.87 0.58 9.14E-04 
34 sp|P37804|TAGL_MOUSE 2.78 6.86 0.89 6.99E-04 
35 sp|O89053|COR1A_MOUSE 2.77 6.83 0.82 2.01E-04 
36 sp|P51885|LUM_MOUSE 2.76 6.76 0.84 1.23E-03 
37 sp|Q9R233|TPSN_MOUSE 2.75 6.71 0.89 1.14E-04 
38 sp|Q8CHH9|SEPT8_MOUSE 2.74 6.69 0.58 4.77E-04 
39 sp|P20152|VIME_MOUSE 2.74 6.67 0.91 4.16E-04 
40 sp|P11087|CO1A1_MOUSE 2.73 6.64 0.96 1.55E-03 
41 sp|Q9ET54|PALLD_MOUSE 2.69 6.47 0.52 9.94E-02 
42 sp|Q9CYL5|GAPR1_MOUSE 2.69 6.44 0.86 6.35E-07 
43 sp|P11276|FINC_MOUSE 2.66 6.31 0.89 8.72E-02 
44 sp|P01831|THY1_MOUSE 2.66 6.30 0.72 7.83E-06 
45 sp|Q08879|FBLN1_MOUSE 2.65 6.28 0.78 1.57E-04 
46 sp|Q64449|MRC2_MOUSE 2.64 6.23 0.77 9.97E-04 
47 sp|Q8BMK4|CKAP4_MOUSE 2.63 6.18 0.73 1.84E-04 
48 sp|P06909|CFAH_MOUSE 2.63 6.17 0.81 1.83E-03 
49 sp|P08121|CO3A1_MOUSE 2.59 6.02 0.95 3.74E-03 
50 sp|Q04447|KCRB_MOUSE 2.58 5.98 0.86 3.51E-06 
51 sp|Q61576|FKB10_MOUSE 2.57 5.94 0.52 2.39E-02 
52 sp|P09528|FRIH_MOUSE 2.54 5.80 0.56 1.03E-01 
53 sp|P54320|ELN_MOUSE 2.53 5.78 0.83 3.47E-04 
54 sp|P11835|ITB2_MOUSE 2.50 5.65 0.57 4.24E-04 
55 sp|Q91XV3|BASP1_MOUSE 2.49 5.64 0.78 3.67E-04 
56 sp|Q62266|SPR1A_MOUSE 2.49 5.63 0.79 2.40E-02 
57 sp|P31725|S10A9_MOUSE 2.47 5.55 0.50 1.48E-02 
58 sp|Q61781|K1C14_MOUSE 2.47 5.55 0.81 1.45E-02 
59 sp|Q8R0X7|SGPL1_MOUSE 2.46 5.50 0.62 3.69E-01 
60 sp|P19324|SERPH_MOUSE 2.45 5.45 0.96 1.83E-03 
61 sp|P16045|LEG1_MOUSE 2.44 5.44 0.93 5.59E-04 
62 sp|Q9WVH9|FBLN5_MOUSE 2.43 5.38 0.87 4.64E-05 
63 sp|Q71FD7|FBLI1_MOUSE 2.42 5.36 0.67 2.08E-05 
64 sp|Q8BPB5|FBLN3_MOUSE 2.42 5.35 0.87 1.14E-04 
65 sp|P49710|HCLS1_MOUSE 2.41 5.33 0.70 9.48E-03 
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66 sp|Q69ZN7|MYOF_MOUSE 2.38 5.21 0.81 9.22E-07 
67 sp|P97298|PEDF_MOUSE 2.37 5.16 0.55 4.87E-02 
68 sp|Q922U2|K2C5_MOUSE 2.37 5.15 0.84 8.21E-04 
69 sp|Q3TJD7|PDLI7_MOUSE 2.36 5.13 0.64 2.59E-05 
70 sp|P11672|NGAL_MOUSE 2.35 5.11 0.73 5.22E-04 
71 sp|Q8R3Q6|CCD58_MOUSE 2.33 5.04 0.54 8.68E-01 
72 sp|Q62188|DPYL3_MOUSE 2.32 4.99 0.70 9.77E-05 
73 sp|P37889|FBLN2_MOUSE 2.32 4.99 0.54 1.35E-01 
74 sp|Q00915|RET1_MOUSE 2.31 4.95 0.78 2.61E-04 
75 sp|O70456|1433S_MOUSE 2.30 4.92 0.72 1.65E-03 
76 sp|O70400|PDLI1_MOUSE 2.28 4.85 0.59 1.90E-02 
77 sp|P21956|MFGM_MOUSE 2.26 4.79 0.52 5.61E-03 
78 sp|Q99K41|EMIL1_MOUSE 2.25 4.77 0.89 1.95E-03 
79 sp|Q61233|PLSL_MOUSE 2.25 4.77 0.82 1.00E-03 
80 sp|P84096|RHOG_MOUSE 2.24 4.71 0.60 4.35E-04 
81 sp|Q60710|SAMH1_MOUSE 2.23 4.70 0.84 4.60E-07 
82 sp|Q9JK53|PRELP_MOUSE 2.23 4.68 0.89 8.02E-03 
83 sp|P19973|LSP1_MOUSE 2.23 4.68 0.58 6.08E-05 
84 sp|P20065|TYB4_MOUSE 2.22 4.65 0.90 3.17E-03 
85 sp|P42703|LIFR_MOUSE 2.21 4.61 0.58 5.26E-03 
86 sp|P31001|DESM_MOUSE 2.20 4.60 0.94 1.98E-03 
87 sp|Q8BTM8|FLNA_MOUSE 2.19 4.56 0.95 3.61E-05 
88 sp|P14483|HB2A_MOUSE 2.19 4.55 0.60 4.72E-01 
89 sp|Q922F4|TBB6_MOUSE 2.18 4.53 0.57 1.78E-02 
90 sp|Q9D132|UPK1A_MOUSE 2.18 4.52 0.56 2.61E-01 
91 sp|Q8CGP6|H2A1H_MOUSE 2.17 4.49 0.85 5.65E-04 
92 sp|Q60590|A1AG1_MOUSE 2.16 4.46 0.51 1.80E-01 
93 sp|Q9CX80|CYGB_MOUSE 2.15 4.43 0.55 1.38E-02 
94 sp|Q3U962|CO5A2_MOUSE 2.13 4.37 0.62 1.25E-03 
95 sp|Q8K3A0|HSC20_MOUSE 2.12 4.35 0.50 9.29E-01 
96 sp|P14106|C1QB_MOUSE 2.12 4.35 0.91 3.89E-03 
97 sp|Q9WV54|ASAH1_MOUSE 2.11 4.32 0.87 2.96E-02 
98 sp|P97821|CATC_MOUSE 2.11 4.30 0.53 6.11E-01 
99 sp|Q06890|CLUS_MOUSE 2.10 4.30 0.86 3.18E-02 
100 sp|P68369|TBA1A_MOUSE 2.10 4.28 0.91 2.25E-03 
101 sp|P11679|K2C8_MOUSE 2.09 4.26 0.94 3.72E-05 
102 sp|Q9QZZ6|DERM_MOUSE 2.08 4.23 0.71 2.01E-02 
103 sp|Q61599|GDIR2_MOUSE 2.08 4.23 0.77 1.69E-03 
104 sp|P07091|S10A4_MOUSE 2.07 4.21 0.67 1.18E-03 
105 sp|P01864|GCAB_MOUSE 2.07 4.20 0.82 2.36E-02 
106 sp|P28654|PGS2_MOUSE 2.06 4.16 0.70 3.01E-02 
107 sp|Q08093|CNN2_MOUSE 2.04 4.11 0.84 3.60E-04 
108 sp|Q8R1G6|PDLI2_MOUSE 2.03 4.09 0.82 3.22E-01 
109 sp|P01869|IGH1M_MOUSE 2.03 4.08 0.50 1.86E-01 
110 sp|Q9Z2C6|UPK1B_MOUSE 2.03 4.07 0.71 8.95E-02 
111 sp|Q6IRU2|TPM4_MOUSE 2.02 4.06 0.91 7.97E-04 
112 sp|Q03350|TSP2_MOUSE 2.02 4.05 0.51 2.32E-02 
113 sp|P07309|TTHY_MOUSE 2.01 4.02 0.80 5.85E-04 
114 sp|Q80X19|COEA1_MOUSE 1.97 3.93 0.83 1.15E-03 
115 sp|Q99P72|RTN4_MOUSE 1.94 3.85 0.80 1.09E-02 
116 sp|O70591|PFD2_MOUSE 1.93 3.81 0.53 4.00E-01 
117 sp|Q7TPR4|ACTN1_MOUSE 1.89 3.72 0.96 3.26E-04 
118 sp|P16110|LEG3_MOUSE 1.89 3.71 0.86 1.05E-04 
119 sp|P28063|PSB8_MOUSE 1.87 3.66 0.54 1.61E-05 
120 sp|P97315|CSRP1_MOUSE 1.87 3.65 0.92 2.85E-03 
121 sp|Q61879|MYH10_MOUSE 1.86 3.63 0.84 4.47E-05 
122 sp|Q62523|ZYX_MOUSE 1.86 3.63 0.72 2.22E-05 
123 sp|O35682|MYADM_MOUSE 1.86 3.62 0.92 1.31E-04 
124 sp|Q3U7R1|ESYT1_MOUSE 1.85 3.60 0.83 5.53E-02 
125 sp|P54227|STMN1_MOUSE 1.84 3.59 0.51 1.25E-01 
126 sp|Q04857|CO6A1_MOUSE 1.82 3.52 0.89 3.20E-07 
127 sp|P63254|CRIP1_MOUSE 1.82 3.52 0.55 3.59E-03 
128 sp|Q91X72|HEMO_MOUSE 1.81 3.50 0.82 4.92E-02 
129 sp|Q8CFX1|G6PE_MOUSE 1.80 3.49 0.85 2.28E-06 
130 sp|Q61581|IBP7_MOUSE 1.79 3.46 0.73 2.79E-01 
131 sp|P58774|TPM2_MOUSE 1.78 3.44 0.82 4.72E-03 
132 sp|P43025|TETN_MOUSE 1.78 3.43 0.79 2.49E-06 
133 sp|P20491|FCERG_MOUSE 1.78 3.43 0.51 7.53E-05 
134 sp|Q640N1|AEBP1_MOUSE 1.78 3.43 0.73 7.59E-02 
135 sp|P11589|MUP2_MOUSE 1.78 3.43 1.00 5.29E-03 
136 sp|Q8C129|LCAP_MOUSE 1.78 3.43 0.56 3.99E-01 
137 sp|Q9DCV7|K2C7_MOUSE 1.78 3.43 0.88 2.46E-04 
138 sp|P50543|S10AB_MOUSE 1.77 3.40 0.88 1.14E-03 
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139 sp|Q02788|CO6A2_MOUSE 1.77 3.40 0.92 7.91E-05 
140 sp|P01837|IGKC_MOUSE 1.76 3.38 0.87 2.10E-03 
141 sp|P29391|FRIL1_MOUSE 1.75 3.36 0.86 7.26E-03 
142 sp|O08573|LEG9_MOUSE 1.75 3.36 0.55 4.02E-02 
143 sp|Q8C3W1|CA198_MOUSE 1.73 3.32 0.77 6.05E-03 
144 sp|Q9D8Y0|EFHD2_MOUSE 1.71 3.28 0.83 8.87E-06 
145 sp|Q07797|LG3BP_MOUSE 1.70 3.26 0.81 4.86E-03 
146 sp|O89086|RBM3_MOUSE 1.69 3.23 0.81 2.54E-02 
147 sp|O70318|E41L2_MOUSE 1.69 3.22 0.88 6.30E-05 
148 sp|P70460|VASP_MOUSE 1.68 3.21 0.74 1.72E-02 
149 sp|Q9R0P9|UCHL1_MOUSE 1.67 3.19 0.64 3.42E-03 
150 sp|P26645|MARCS_MOUSE 1.67 3.17 0.67 3.23E-01 
151 sp|Q9WVA4|TAGL2_MOUSE 1.66 3.16 0.87 8.36E-04 
152 sp|P20918|PLMN_MOUSE 1.64 3.13 0.72 3.82E-02 
153 sp|P18242|CATD_MOUSE 1.64 3.12 0.81 7.99E-03 
154 sp|P58771|TPM1_MOUSE 1.63 3.09 0.83 2.28E-03 
155 sp|P42225|STAT1_MOUSE 1.63 3.09 0.60 3.37E-02 
156 sp|Q9JJU8|SH3L1_MOUSE 1.63 3.09 0.89 4.69E-06 
157 sp|P07356|ANXA2_MOUSE 1.61 3.06 0.90 8.75E-06 
158 sp|P19221|THRB_MOUSE 1.61 3.05 0.78 1.27E-02 
159 sp|O35639|ANXA3_MOUSE 1.61 3.05 0.82 4.42E-04 
160 sp|Q3TZZ7|ESYT2_MOUSE 1.60 3.03 0.83 2.54E-05 
161 sp|Q8BHD7|PTBP3_MOUSE 1.59 3.01 0.60 6.62E-03 
162 sp|Q9R111|GUAD_MOUSE 1.58 3.00 0.52 4.18E-02 
163 sp|Q9QXS6|DREB_MOUSE 1.58 2.98 0.68 4.50E-01 
164 sp|Q9EPB4|ASC_MOUSE 1.57 2.97 0.73 1.35E-01 
165 sp|Q61147|CERU_MOUSE 1.56 2.95 0.77 3.65E-02 
166 sp|P46938|YAP1_MOUSE 1.56 2.94 0.53 4.84E-01 
167 sp|P28667|MRP_MOUSE 1.56 2.94 0.64 2.52E-03 
168 sp|P01867|IGG2B_MOUSE 1.56 2.94 0.77 9.32E-02 
169 sp|Q00898|A1AT5_MOUSE 1.55 2.94 0.51 7.08E-02 
170 sp|O35887|CALU_MOUSE 1.55 2.93 0.80 1.33E-03 
171 sp|P70202|LXN_MOUSE 1.55 2.93 0.67 1.21E-02 
172 sp|Q62465|VAT1_MOUSE 1.55 2.92 0.93 2.66E-04 
173 sp|Q9ES28|ARHG7_MOUSE 1.54 2.92 0.55 4.49E-02 
174 sp|Q9WV32|ARC1B_MOUSE 1.54 2.91 0.88 3.91E-07 
175 sp|O35206|COFA1_MOUSE 1.54 2.90 0.63 7.07E-04 
176 sp|O08638|MYH11_MOUSE 1.52 2.87 0.92 1.37E-04 
177 sp|P01899|HA11_MOUSE 1.52 2.86 0.79 9.40E-05 
178 sp|Q99M71|EPDR1_MOUSE 1.51 2.85 0.81 2.28E-05 
179 sp|Q9DBR7|MYPT1_MOUSE 1.50 2.83 0.67 1.30E-03 
180 sp|Q8VCM7|FIBG_MOUSE 1.50 2.82 0.74 2.80E-01 
181 sp|Q01339|APOH_MOUSE 1.49 2.82 0.85 5.32E-04 
182 sp|Q62048|PEA15_MOUSE 1.49 2.80 0.63 1.78E-01 
183 sp|Q00897|A1AT4_MOUSE 1.48 2.79 0.81 2.18E-02 
184 sp|P62737|ACTA_MOUSE 1.46 2.76 0.85 6.03E-02 
185 sp|P01029|CO4B_MOUSE 1.46 2.75 0.83 1.11E-02 
186 sp|O88531|PPT1_MOUSE 1.46 2.75 0.85 7.14E-04 
187 sp|P07758|A1AT1_MOUSE 1.45 2.74 0.81 1.46E-02 
188 sp|P08122|CO4A2_MOUSE 1.45 2.73 0.79 5.51E-05 
189 sp|P99024|TBB5_MOUSE 1.45 2.72 0.90 1.30E-04 
190 sp|P43275|H11_MOUSE 1.44 2.72 0.96 1.42E-03 
191 sp|P03987|IGHG3_MOUSE 1.42 2.68 0.54 3.92E-01 
192 sp|Q921I1|TRFE_MOUSE 1.42 2.67 0.89 5.42E-03 
193 sp|P14602|HSPB1_MOUSE 1.41 2.67 0.85 3.94E-04 
194 sp|P05784|K1C18_MOUSE 1.41 2.66 0.92 2.10E-04 
195 sp|Q7TMB8|CYFP1_MOUSE 1.39 2.63 0.66 8.83E-04 
196 sp|P42208|SEPT2_MOUSE 1.39 2.62 0.85 7.30E-06 
197 sp|Q9QXC1|FETUB_MOUSE 1.38 2.60 0.86 1.14E-02 
198 sp|Q64339|ISG15_MOUSE 1.37 2.59 0.89 6.35E-04 
199 sp|P48678|LMNA_MOUSE 1.36 2.57 0.94 9.84E-05 
200 sp|Q9CQ19|MYL9_MOUSE 1.35 2.56 0.98 1.27E-03 
201 sp|P17918|PCNA_MOUSE 1.35 2.55 0.81 2.16E-01 
202 sp|O08677|KNG1_MOUSE 1.35 2.54 0.92 4.70E-02 
203 sp|P29699|FETUA_MOUSE 1.35 2.54 0.94 7.51E-05 
204 sp|P43276|H15_MOUSE 1.34 2.54 0.91 8.85E-05 
205 sp|Q5SYD0|MYO1D_MOUSE 1.34 2.54 0.65 6.79E-03 
206 sp|Q60605|MYL6_MOUSE 1.34 2.53 0.94 2.47E-04 
207 sp|P23953|EST1C_MOUSE 1.34 2.52 0.94 5.33E-03 
208 sp|Q60854|SPB6_MOUSE 1.33 2.51 0.84 5.92E-04 
209 sp|Q8CC35|SYNPO_MOUSE 1.33 2.51 0.67 2.04E-03 
210 sp|Q8VDD5|MYH9_MOUSE 1.32 2.50 0.97 5.69E-04 
211 sp|P08226|APOE_MOUSE 1.32 2.49 0.94 1.93E-02 
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212 sp|P06728|APOA4_MOUSE 1.30 2.47 0.83 1.64E-03 
213 sp|Q8CCK0|H2AW_MOUSE 1.30 2.46 0.62 3.92E-02 
214 sp|P07724|ALBU_MOUSE 1.30 2.46 0.91 2.09E-06 
215 sp|P01027|CO3_MOUSE 1.29 2.45 0.87 1.41E-01 
216 sp|P30681|HMGB2_MOUSE 1.29 2.45 0.85 2.13E-03 
217 sp|Q06770|CBG_MOUSE 1.28 2.44 0.58 6.97E-02 
218 sp|Q9JIF0|ANM1_MOUSE 1.28 2.44 0.72 2.71E-01 
219 sp|Q9QWR8|NAGAB_MOUSE 1.28 2.43 0.82 6.47E-05 
220 sp|Q61160|FADD_MOUSE 1.28 2.43 0.53 8.47E-01 
221 sp|P47753|CAZA1_MOUSE 1.28 2.42 0.62 1.86E-03 
222 sp|P15864|H12_MOUSE 1.28 2.42 0.93 9.43E-06 
223 sp|O55131|SEPT7_MOUSE 1.27 2.41 0.80 2.32E-05 
224 sp|Q8CI51|PDLI5_MOUSE 1.27 2.40 0.61 2.40E-03 
225 sp|P40124|CAP1_MOUSE 1.26 2.40 0.92 3.84E-06 
226 sp|O35350|CAN1_MOUSE 1.26 2.40 0.50 1.96E-01 
227 sp|P63213|GBG2_MOUSE 1.25 2.39 0.78 9.71E-05 
228 sp|Q62219|TGFI1_MOUSE 1.25 2.38 0.57 9.14E-01 
229 sp|Q99KC8|VMA5A_MOUSE 1.24 2.36 0.86 2.46E-05 
230 sp|Q9Z247|FKBP9_MOUSE 1.23 2.35 0.51 1.31E-02 
231 sp|P08207|S10AA_MOUSE 1.23 2.35 0.74 1.19E-02 
232 sp|P01887|B2MG_MOUSE 1.23 2.34 0.89 6.25E-01 
233 sp|Q8C1B7|SEP11_MOUSE 1.22 2.33 0.83 1.09E-03 
234 sp|Q3THE2|ML12B_MOUSE 1.21 2.32 0.73 2.77E-01 
235 sp|P63163|RSMN_MOUSE 1.20 2.30 0.67 1.22E-04 
236 sp|P13020|GELS_MOUSE 1.20 2.30 0.87 5.00E-08 
237 sp|O54962|BAF_MOUSE 1.20 2.29 0.52 2.12E-01 
238 sp|Q6PDN3|MYLK_MOUSE 1.19 2.28 0.89 8.25E-04 
239 sp|P29351|PTN6_MOUSE 1.19 2.28 0.66 1.04E-03 
240 sp|P21614|VTDB_MOUSE 1.19 2.28 0.89 1.34E-04 
241 sp|Q61838|A2M_MOUSE 1.18 2.26 0.72 8.16E-02 
242 sp|P62500|T22D1_MOUSE 1.17 2.24 0.84 1.89E-03 
243 sp|Q9ESB3|HRG_MOUSE 1.15 2.22 0.77 1.57E-01 
244 sp|P97371|PSME1_MOUSE 1.14 2.21 0.81 3.26E-04 
245 sp|Q6ZWM4|LSM8_MOUSE 1.13 2.19 0.67 1.00E-01 
246 sp|Q61074|PPM1G_MOUSE 1.13 2.19 0.51 3.59E-03 
247 sp|P14733|LMNB1_MOUSE 1.13 2.19 0.88 6.74E-04 
248 sp|P48036|ANXA5_MOUSE 1.13 2.19 0.87 2.00E-03 
249 sp|P18760|COF1_MOUSE 1.13 2.18 0.83 6.23E-08 
250 sp|P28352|APEX1_MOUSE 1.13 2.18 0.60 1.29E-02 
251 sp|P27546|MAP4_MOUSE 1.12 2.17 0.81 1.23E-01 
252 sp|Q9JK48|SHLB1_MOUSE 1.12 2.17 0.62 5.48E-01 
253 sp|Q9DBG9|TX1B3_MOUSE 1.11 2.16 0.75 1.51E-04 
254 sp|P62962|PROF1_MOUSE 1.11 2.16 0.88 8.92E-03 
255 sp|Q9EQU5|SET_MOUSE 1.10 2.15 0.90 6.24E-04 
256 sp|Q9EST5|AN32B_MOUSE 1.10 2.14 0.91 1.33E-02 
257 sp|Q91XC8|DAP1_MOUSE 1.09 2.13 0.69 9.64E-02 
258 sp|Q921E2|RAB31_MOUSE 1.09 2.12 0.55 8.81E-03 
259 sp|P32261|ANT3_MOUSE 1.08 2.11 0.76 5.38E-01 
260 sp|Q9WUU7|CATZ_MOUSE 1.07 2.09 0.85 2.19E-02 
261 sp|Q9CPW4|ARPC5_MOUSE 1.06 2.09 0.90 8.18E-07 
262 sp|P39061|COIA1_MOUSE 1.06 2.08 0.94 8.49E-02 
263 sp|P07759|SPA3K_MOUSE 1.05 2.07 0.81 2.21E-01 
264 sp|P26350|PTMA_MOUSE 1.05 2.07 0.61 1.01E-01 
265 sp|P54923|ADPRH_MOUSE 1.04 2.06 0.84 1.92E-04 
266 sp|Q91VW3|SH3L3_MOUSE 1.04 2.06 0.72 4.48E-03 
267 sp|Q9JKF1|IQGA1_MOUSE 1.03 2.04 0.78 6.32E-03 
268 sp|P10493|NID1_MOUSE 1.03 2.04 0.94 5.23E-04 
269 sp|Q00623|APOA1_MOUSE 1.03 2.04 0.87 1.20E-01 
270 sp|O08529|CAN2_MOUSE 1.03 2.04 0.60 3.24E-01 
271 sp|P23198|CBX3_MOUSE 1.02 2.03 0.57 4.74E-02 
272 sp|P97372|PSME2_MOUSE 1.02 2.03 0.81 5.24E-05 
273 sp|P49312|ROA1_MOUSE 1.02 2.03 0.88 1.24E-03 
274 sp|Q64727|VINC_MOUSE 1.02 2.03 0.92 9.42E-04 
275 sp|Q9CX86|ROA0_MOUSE 1.01 2.01 0.69 1.65E-03 
276 sp|P06281|RENI1_MOUSE 1.01 2.01 0.84 3.71E-03 
277 sp|P02463|CO4A1_MOUSE 1.01 2.01 0.86 1.25E-04 
278 sp|Q63961|EGLN_MOUSE 1.00 2.00 0.64 3.94E-01 
279 sp|Q6WVG3|KCD12_MOUSE 1.00 2.00 0.66 9.52E-04 
280 sp|Q62318|TIF1B_MOUSE 0.99 1.99 0.81 6.65E-03 
281 sp|Q9DBG5|PLIN3_MOUSE 0.99 1.98 0.72 1.02E-02 
282 sp|P14824|ANXA6_MOUSE 0.99 1.98 0.91 1.27E-02 
283 sp|Q8VIJ6|SFPQ_MOUSE 0.98 1.97 0.81 1.13E-03 
284 sp|Q9CQW2|ARL8B_MOUSE 0.98 1.97 0.58 9.96E-02 
SUPPLEMENTARY DATA 
 
422 
 
285 sp|Q61001|LAMA5_MOUSE 0.97 1.96 0.89 7.33E-03 
286 sp|Q9WUM4|COR1C_MOUSE 0.97 1.95 0.82 9.46E-03 
287 sp|Q9DBC7|KAP0_MOUSE 0.96 1.95 0.79 1.18E-04 
288 sp|Q8K0E8|FIBB_MOUSE 0.96 1.95 0.71 2.06E-01 
289 sp|P68510|1433F_MOUSE 0.95 1.94 0.67 1.32E-02 
290 sp|Q9JM76|ARPC3_MOUSE 0.95 1.93 0.80 2.79E-03 
291 sp|P63280|UBC9_MOUSE 0.94 1.92 0.91 1.11E-08 
292 sp|Q80UG5|SEPT9_MOUSE 0.94 1.91 0.56 2.65E-03 
293 sp|Q62186|SSRD_MOUSE 0.93 1.91 0.54 6.78E-02 
294 sp|E9PV24|FIBA_MOUSE 0.93 1.91 0.69 2.16E-01 
295 sp|Q920E5|FPPS_MOUSE 0.93 1.91 0.53 2.12E-02 
296 sp|Q60749|KHDR1_MOUSE 0.93 1.90 0.52 5.83E-02 
297 sp|P10923|OSTP_MOUSE 0.92 1.90 0.60 1.95E-04 
298 sp|Q8BH43|WASF2_MOUSE 0.91 1.89 0.60 9.57E-04 
299 sp|O08553|DPYL2_MOUSE 0.91 1.88 0.83 7.44E-03 
300 sp|P56959|FUS_MOUSE 0.90 1.87 0.81 1.27E-04 
301 sp|Q9CR86|CHSP1_MOUSE 0.89 1.85 0.58 1.84E-01 
302 sp|Q9WVB0|RBPMS_MOUSE 0.89 1.85 0.71 1.58E-01 
303 sp|P51125|ICAL_MOUSE 0.89 1.85 0.50 1.55E-01 
304 sp|Q9JHU9|INO1_MOUSE 0.89 1.85 0.59 1.09E-01 
305 sp|P02468|LAMC1_MOUSE 0.87 1.83 0.90 6.38E-03 
306 sp|Q8C522|ENDD1_MOUSE 0.87 1.83 0.71 1.49E-04 
307 sp|P43406|ITAV_MOUSE 0.87 1.82 0.54 2.39E-04 
308 sp|Q3TEA8|HP1B3_MOUSE 0.86 1.82 0.89 5.42E-03 
309 sp|Q6GSS7|H2A2A_MOUSE 0.86 1.81 0.56 5.21E-03 
310 sp|Q9D8B3|CHM4B_MOUSE 0.85 1.81 0.59 6.21E-04 
311 sp|Q61292|LAMB2_MOUSE 0.85 1.81 0.78 8.92E-03 
312 sp|P08752|GNAI2_MOUSE 0.84 1.79 0.84 9.92E-03 
313 sp|Q3THW5|H2AV_MOUSE 0.84 1.79 0.84 3.13E-04 
314 sp|P50637|TSPO_MOUSE 0.84 1.79 0.56 6.94E-01 
315 sp|Q9QZR9|CO4A4_MOUSE 0.83 1.78 0.74 1.41E-03 
316 sp|O88322|NID2_MOUSE 0.83 1.77 0.87 2.47E-04 
317 sp|Q3UZ39|LRRF1_MOUSE 0.83 1.77 0.70 1.13E-03 
318 sp|Q07813|BAX_MOUSE 0.82 1.77 0.63 1.18E-01 
319 sp|Q921M3|SF3B3_MOUSE 0.82 1.76 0.73 4.47E-02 
320 sp|O70433|FHL2_MOUSE 0.82 1.76 0.71 7.81E-04 
321 sp|P24452|CAPG_MOUSE 0.81 1.76 0.81 5.76E-04 
322 sp|Q8BFZ3|ACTBL_MOUSE 0.81 1.75 0.91 1.48E-03 
323 sp|P45377|ALD2_MOUSE 0.80 1.74 0.73 1.26E-04 
324 sp|P47757|CAPZB_MOUSE 0.79 1.73 0.86 5.26E-03 
325 sp|Q91YH5|ATLA3_MOUSE 0.78 1.72 0.69 1.86E-03 
326 sp|Q8BH64|EHD2_MOUSE 0.78 1.72 0.57 1.56E-01 
327 sp|Q9Z1Q9|SYVC_MOUSE 0.78 1.72 0.52 3.91E-02 
328 sp|Q8VDW0|DX39A_MOUSE 0.78 1.71 0.57 6.26E-01 
329 sp|Q8C854|MYEF2_MOUSE 0.77 1.71 0.65 4.10E-02 
330 sp|Q99JY9|ARP3_MOUSE 0.77 1.71 0.93 5.66E-05 
331 sp|Q9QXA5|LSM4_MOUSE 0.77 1.70 0.73 1.27E-03 
332 sp|O88456|CPNS1_MOUSE 0.77 1.70 0.70 1.14E-03 
333 sp|Q61207|SAP_MOUSE 0.76 1.70 0.82 9.42E-03 
334 sp|Q60604|ADSV_MOUSE 0.76 1.69 0.58 9.73E-02 
335 sp|Q91VM5|RMXL1_MOUSE 0.76 1.69 0.58 7.20E-01 
336 sp|Q3U0V1|FUBP2_MOUSE 0.76 1.69 0.78 1.45E-03 
337 sp|Q9Z1N5|DX39B_MOUSE 0.76 1.69 0.81 6.73E-03 
338 sp|Q8BP92|RCN2_MOUSE 0.75 1.69 0.54 4.41E-02 
339 sp|P84104|SRSF3_MOUSE 0.75 1.68 0.61 7.48E-01 
340 sp|O54724|PTRF_MOUSE 0.74 1.67 0.69 1.96E-01 
341 sp|P02469|LAMB1_MOUSE 0.74 1.67 0.84 2.86E-03 
342 sp|P84089|ERH_MOUSE 0.73 1.66 0.71 5.27E-02 
343 sp|A2ASQ1|AGRIN_MOUSE 0.73 1.66 0.67 1.97E-01 
344 sp|Q3UTJ2|SRBS2_MOUSE 0.72 1.65 0.53 2.63E-02 
345 sp|Q9CXY6|ILF2_MOUSE 0.72 1.65 0.84 3.67E-05 
346 sp|P59999|ARPC4_MOUSE 0.72 1.65 0.85 4.33E-06 
347 sp|P26039|TLN1_MOUSE 0.72 1.65 0.89 1.43E-03 
348 sp|P97822|AN32E_MOUSE 0.72 1.65 0.68 3.30E-02 
349 sp|Q00612|G6PD1_MOUSE 0.72 1.65 0.76 9.08E-05 
350 sp|P27661|H2AX_MOUSE 0.72 1.64 0.83 3.13E-04 
351 sp|Q9ERG0|LIMA1_MOUSE 0.71 1.64 0.62 5.72E-03 
352 sp|Q62376|RU17_MOUSE 0.71 1.63 0.58 5.57E-03 
353 sp|O54879|HMGB3_MOUSE 0.70 1.63 0.64 7.37E-04 
354 sp|Q7TNC4|LC7L2_MOUSE 0.70 1.63 0.63 2.48E-03 
355 sp|Q501J6|DDX17_MOUSE 0.70 1.63 0.76 8.56E-02 
356 sp|Q7TMK9|HNRPQ_MOUSE 0.70 1.62 0.67 3.08E-01 
357 sp|Q99K48|NONO_MOUSE 0.69 1.62 0.89 4.81E-03 
SUPPLEMENTARY DATA 
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358 sp|Q91W90|TXND5_MOUSE 0.68 1.60 0.75 4.41E-02 
359 sp|P70168|IMB1_MOUSE 0.67 1.59 0.77 9.74E-02 
360 sp|Q8CGP2|H2B1P_MOUSE 0.67 1.59 0.88 2.15E-03 
361 sp|O88342|WDR1_MOUSE 0.67 1.59 0.65 5.67E-04 
362 sp|Q61166|MARE1_MOUSE 0.67 1.59 0.64 3.48E-05 
363 sp|Q922R8|PDIA6_MOUSE 0.67 1.59 0.88 9.34E-03 
364 sp|Q61029|LAP2B_MOUSE 0.67 1.59 0.78 9.92E-03 
365 sp|Q9D0T1|NH2L1_MOUSE 0.66 1.58 0.53 2.99E-02 
366 sp|Q9Z204|HNRPC_MOUSE 0.66 1.58 0.51 4.21E-01 
367 sp|Q9Z2N8|ACL6A_MOUSE 0.66 1.58 0.58 8.26E-04 
368 sp|P61161|ARP2_MOUSE 0.66 1.58 0.81 5.83E-01 
369 sp|Q9DCN2|NB5R3_MOUSE 0.66 1.58 0.58 5.37E-01 
370 sp|Q61937|NPM_MOUSE 0.66 1.58 0.83 1.75E-02 
371 sp|Q7TNG5|EMAL2_MOUSE 0.66 1.58 0.51 5.51E-01 
372 sp|Q8BG05|ROA3_MOUSE 0.66 1.58 0.88 1.78E-04 
373 sp|P62311|LSM3_MOUSE 0.65 1.57 0.91 1.64E-04 
374 sp|Q8VED5|K2C79_MOUSE 0.65 1.57 0.56 1.06E-01 
375 sp|P62315|SMD1_MOUSE 0.65 1.57 0.75 1.51E-03 
376 sp|Q8C166|CPNE1_MOUSE 0.64 1.56 0.63 6.52E-02 
377 sp|Q05793|PGBM_MOUSE 0.64 1.56 0.81 2.55E-03 
378 sp|Q60668|HNRPD_MOUSE 0.63 1.55 0.56 6.20E-02 
379 sp|Q4KML4|ABRAL_MOUSE 0.63 1.55 0.87 2.73E-02 
380 sp|Q9Z2W0|DNPEP_MOUSE 0.62 1.54 0.59 1.85E-02 
381 sp|Q8BL97|SRSF7_MOUSE 0.62 1.54 0.78 5.27E-06 
382 sp|P61957|SUMO2_MOUSE 0.62 1.54 0.56 8.02E-01 
383 sp|Q7TSV4|PGM2_MOUSE 0.62 1.54 0.65 3.71E-03 
384 sp|Q62093|SRSF2_MOUSE 0.62 1.53 0.74 5.89E-01 
385 sp|P63024|VAMP3_MOUSE 0.62 1.53 0.67 1.83E-02 
386 sp|Q9D1J3|SARNP_MOUSE 0.61 1.53 0.58 1.89E-02 
387 sp|O08807|PRDX4_MOUSE 0.61 1.53 0.89 1.02E-03 
388 sp|Q922Q8|LRC59_MOUSE 0.60 1.51 0.64 8.19E-03 
389 sp|Q9Z2D6|MECP2_MOUSE 0.60 1.51 0.73 4.42E-02 
390 sp|Q9CY50|SSRA_MOUSE 0.60 1.51 0.63 3.78E-03 
391 sp|Q9Z172|SUMO3_MOUSE 0.59 1.51 0.57 5.49E-01 
392 sp|Q9D0E1|HNRPM_MOUSE 0.59 1.50 0.82 3.36E-01 
393 sp|Q61792|LASP1_MOUSE 0.58 1.50 0.66 2.18E-01 
394 sp|Q99020|ROAA_MOUSE 0.58 1.50 0.84 3.06E-03 
395 sp|Q8CI94|PYGB_MOUSE 0.58 1.49 0.51 6.03E-01 
396 sp|P97447|FHL1_MOUSE 0.57 1.49 0.55 2.79E-01 
397 sp|P08003|PDIA4_MOUSE 0.57 1.48 0.88 1.81E-03 
398 sp|Q01730|RSU1_MOUSE 0.57 1.48 0.68 2.83E-02 
399 sp|P70372|ELAV1_MOUSE 0.57 1.48 0.63 1.14E-01 
400 sp|P60766|CDC42_MOUSE 0.57 1.48 0.75 3.19E-02 
401 sp|P30412|PPIC_MOUSE 0.56 1.48 0.69 1.83E-01 
402 sp|P05132|KAPCA_MOUSE 0.56 1.47 0.78 9.34E-01 
403 sp|P62806|H4_MOUSE 0.56 1.47 0.66 6.17E-01 
404 sp|Q99KF1|TMED9_MOUSE 0.55 1.47 0.71 3.49E-04 
405 sp|Q8BFY9|TNPO1_MOUSE 0.55 1.46 0.56 4.00E-02 
406 sp|P09405|NUCL_MOUSE 0.55 1.46 0.85 7.74E-02 
407 sp|P34022|RANG_MOUSE 0.55 1.46 0.51 2.87E-04 
408 sp|Q9CVB6|ARPC2_MOUSE 0.55 1.46 0.79 2.09E-04 
409 sp|O35737|HNRH1_MOUSE 0.55 1.46 0.71 6.93E-03 
410 sp|P62305|RUXE_MOUSE 0.54 1.45 0.80 2.29E-03 
411 sp|Q9Z2X1|HNRPF_MOUSE 0.54 1.45 0.74 7.75E-04 
412 sp|Q61102|ABCB7_MOUSE 0.54 1.45 0.89 5.19E-04 
413 sp|Q99JY3|GIMA4_MOUSE 0.53 1.45 0.54 3.91E-02 
414 sp|Q60972|RBBP4_MOUSE 0.53 1.45 0.56 7.08E-03 
415 sp|P47754|CAZA2_MOUSE 0.53 1.45 0.51 7.24E-01 
416 sp|O55222|ILK_MOUSE 0.53 1.45 0.78 8.58E-03 
417 sp|P63158|HMGB1_MOUSE 0.53 1.45 0.78 8.24E-02 
418 sp|O08583|THOC4_MOUSE 0.53 1.44 0.72 3.68E-02 
419 sp|Q8VEK3|HNRPU_MOUSE 0.53 1.44 0.84 8.83E-03 
420 sp|P63085|MK01_MOUSE 0.53 1.44 0.62 1.81E-01 
421 sp|Q9JHJ0|TMOD3_MOUSE 0.53 1.44 0.60 1.81E-03 
422 sp|Q9QZS0|CO4A3_MOUSE 0.52 1.44 0.51 1.68E-01 
423 sp|P60710|ACTB_MOUSE 0.52 1.43 0.90 6.17E-03 
424 sp|O70251|EF1B_MOUSE 0.52 1.43 0.53 5.43E-01 
425 sp|Q9R0P5|DEST_MOUSE 0.51 1.43 0.67 1.39E-02 
426 sp|Q6PDM2|SRSF1_MOUSE 0.51 1.42 0.71 1.09E-01 
427 sp|P26883|FKB1A_MOUSE 0.50 1.42 0.67 2.85E-02 
428 sp|Q9EPC1|PARVA_MOUSE 0.50 1.41 0.66 2.37E-03 
429 sp|Q99JI6|RAP1B_MOUSE 0.50 1.41 0.58 5.18E-01 
430 sp|P97314|CSRP2_MOUSE 0.50 1.41 0.71 1.45E-03 
SUPPLEMENTARY DATA 
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431 sp|Q8BFW7|LPP_MOUSE 0.49 1.41 0.72 1.04E-03 
432 sp|P62317|SMD2_MOUSE 0.48 1.40 0.82 2.16E-01 
433 sp|O89023|TPP1_MOUSE 0.48 1.40 0.54 9.46E-02 
434 sp|P97429|ANXA4_MOUSE 0.48 1.39 0.57 8.48E-02 
435 sp|Q9R0Y5|KAD1_MOUSE 0.48 1.39 0.81 7.91E-03 
436 sp|Q8VE37|RCC1_MOUSE 0.48 1.39 0.62 1.12E-03 
437 sp|Q9R0P6|SC11A_MOUSE 0.47 1.39 0.78 2.47E-03 
438 sp|Q62470|ITA3_MOUSE 0.47 1.39 0.52 3.05E-02 
439 sp|Q921F2|TADBP_MOUSE 0.47 1.39 0.82 2.50E-04 
440 sp|P17047|LAMP2_MOUSE 0.47 1.39 0.66 5.52E-03 
441 sp|P00493|HPRT_MOUSE 0.47 1.38 0.74 4.19E-02 
442 sp|Q80VD1|FA98B_MOUSE 0.47 1.38 0.57 2.42E-01 
443 sp|Q61656|DDX5_MOUSE 0.47 1.38 0.77 1.43E-02 
444 sp|P62320|SMD3_MOUSE 0.47 1.38 0.68 9.71E-03 
445 sp|Q9DAW9|CNN3_MOUSE 0.46 1.38 0.57 4.48E-01 
446 sp|Q8CIB5|FERM2_MOUSE 0.46 1.37 0.71 5.69E-02 
447 sp|P43274|H14_MOUSE 0.46 1.37 0.64 3.22E-02 
448 sp|P61750|ARF4_MOUSE 0.46 1.37 0.51 2.88E-02 
449 sp|O08547|SC22B_MOUSE 0.45 1.36 0.64 6.80E-02 
450 sp|P26041|MOES_MOUSE 0.44 1.36 0.57 9.75E-02 
451 sp|P61982|1433G_MOUSE 0.43 1.35 0.65 9.62E-01 
452 sp|P10605|CATB_MOUSE 0.43 1.35 0.85 1.33E-01 
453 sp|Q8CCS6|PABP2_MOUSE 0.43 1.35 0.66 1.33E-02 
454 sp|P46467|VPS4B_MOUSE 0.43 1.35 0.60 2.50E-01 
455 sp|Q9WUM3|COR1B_MOUSE 0.42 1.34 0.55 1.96E-03 
456 sp|Q61990|PCBP2_MOUSE 0.42 1.34 0.61 5.23E-04 
457 sp|Q91VC3|IF4A3_MOUSE 0.42 1.33 0.51 3.16E-01 
458 sp|P54823|DDX6_MOUSE 0.41 1.33 0.63 2.52E-03 
459 sp|P61979|HNRPK_MOUSE 0.41 1.33 0.77 1.44E-03 
460 sp|Q99K51|PLST_MOUSE 0.41 1.33 0.51 3.48E-01 
461 sp|P62307|RUXF_MOUSE 0.41 1.33 0.67 2.98E-02 
462 sp|Q99PT1|GDIR1_MOUSE 0.41 1.33 0.64 5.46E-03 
463 sp|Q61545|EWS_MOUSE 0.40 1.32 0.53 5.18E-02 
464 sp|Q9QZQ8|H2AY_MOUSE 0.40 1.32 0.70 2.88E-01 
465 sp|P09055|ITB1_MOUSE 0.39 1.31 0.60 2.62E-02 
466 sp|Q9R1Z8|VINEX_MOUSE 0.39 1.31 0.55 1.34E-01 
467 sp|Q64213|SF01_MOUSE 0.38 1.31 0.51 7.69E-02 
468 sp|Q8VDP6|CDIPT_MOUSE 0.38 1.30 0.67 2.30E-01 
469 sp|Q60598|SRC8_MOUSE 0.38 1.30 0.50 1.01E-01 
470 sp|P27773|PDIA3_MOUSE 0.37 1.29 0.65 3.09E-02 
471 sp|Q8BT60|CPNE3_MOUSE 0.37 1.29 0.52 8.90E-03 
472 sp|P58389|PTPA_MOUSE 0.36 1.29 0.62 2.88E-01 
473 sp|Q61735|CD47_MOUSE 0.36 1.29 0.60 9.20E-01 
474 sp|Q9CQU0|TXD12_MOUSE 0.35 1.28 0.56 2.21E-02 
475 sp|P62309|RUXG_MOUSE 0.35 1.27 0.54 6.12E-01 
476 sp|P62827|RAN_MOUSE 0.31 1.24 0.62 6.57E-01 
477 sp|P60867|RS20_MOUSE 0.29 1.23 0.51 7.74E-01 
478 sp|Q9D898|ARP5L_MOUSE -0.30 1.23 0.60 1.76E-02 
479 sp|P63017|HSP7C_MOUSE -0.31 1.24 0.80 4.21E-02 
480 sp|P14869|RLA0_MOUSE -0.32 1.25 0.51 1.08E-01 
481 sp|P17742|PPIA_MOUSE -0.33 1.25 0.76 2.99E-02 
482 sp|Q9CZ44|NSF1C_MOUSE -0.33 1.26 0.58 8.80E-02 
483 sp|Q01853|TERA_MOUSE -0.35 1.27 0.60 4.73E-01 
484 sp|P15626|GSTM2_MOUSE -0.35 1.28 0.54 4.49E-01 
485 sp|P84091|AP2M1_MOUSE -0.36 1.28 0.55 4.46E-01 
486 sp|P58021|TM9S2_MOUSE -0.41 1.33 0.54 4.92E-02 
487 sp|Q9Z1Q5|CLIC1_MOUSE -0.41 1.33 0.59 5.91E-01 
488 sp|Q8BGS7|CEPT1_MOUSE -0.42 1.34 0.60 6.55E-01 
489 sp|Q9Z1X4|ILF3_MOUSE -0.43 1.35 0.56 6.94E-01 
490 sp|Q61598|GDIB_MOUSE -0.43 1.35 0.75 3.04E-02 
491 sp|P23492|PNPH_MOUSE -0.45 1.36 0.53 6.82E-01 
492 sp|Q93092|TALDO_MOUSE -0.45 1.36 0.61 3.86E-01 
493 sp|Q61171|PRDX2_MOUSE -0.45 1.37 0.88 2.27E-02 
494 sp|P62259|1433E_MOUSE -0.45 1.37 0.74 6.98E-02 
495 sp|P62204|CALM_MOUSE -0.46 1.38 0.50 1.05E-01 
496 sp|P40142|TKT_MOUSE -0.47 1.38 0.84 2.33E-02 
497 sp|Q8C0C7|SYFA_MOUSE -0.47 1.39 0.55 4.55E-03 
498 sp|O70493|SNX12_MOUSE -0.48 1.39 0.53 9.56E-01 
499 sp|Q61469|LPP1_MOUSE -0.48 1.39 0.54 2.24E-01 
500 sp|Q11011|PSA_MOUSE -0.48 1.39 0.51 7.85E-02 
501 sp|P97384|ANX11_MOUSE -0.48 1.40 0.50 4.45E-02 
502 sp|P46471|PRS7_MOUSE -0.49 1.41 0.64 2.98E-01 
503 sp|P40237|CD82_MOUSE -0.50 1.41 0.54 9.25E-01 
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504 sp|P46412|GPX3_MOUSE -0.50 1.41 0.83 2.68E-03 
505 sp|Q3TDQ1|STT3B_MOUSE -0.50 1.42 0.58 3.95E-01 
506 sp|Q8R1Q8|DC1L1_MOUSE -0.51 1.42 0.58 8.84E-04 
507 sp|Q9QUI0|RHOA_MOUSE -0.51 1.42 0.70 3.31E-02 
508 sp|P51150|RAB7A_MOUSE -0.51 1.43 0.51 3.15E-01 
509 sp|Q9Z1Z0|USO1_MOUSE -0.51 1.43 0.65 1.82E-01 
510 sp|Q91WG5|AAKG2_MOUSE -0.52 1.43 0.58 2.08E-01 
511 sp|Q60770|STXB3_MOUSE -0.52 1.43 0.59 5.04E-03 
512 sp|Q7M6Y3|PICAL_MOUSE -0.52 1.44 0.52 3.14E-01 
513 sp|O54990|PROM1_MOUSE -0.53 1.44 0.56 2.87E-01 
514 sp|P42932|TCPQ_MOUSE -0.53 1.44 0.72 4.87E-01 
515 sp|Q6P8X1|SNX6_MOUSE -0.53 1.45 0.53 8.57E-02 
516 sp|P26638|SYSC_MOUSE -0.53 1.45 0.82 1.27E-03 
517 sp|P46460|NSF_MOUSE -0.54 1.45 0.52 5.97E-02 
518 sp|Q99KN9|EPN4_MOUSE -0.55 1.46 0.51 1.11E-02 
519 sp|P62821|RAB1A_MOUSE -0.55 1.46 0.64 8.96E-04 
520 sp|P07901|HS90A_MOUSE -0.55 1.46 0.82 5.95E-02 
521 sp|P53994|RAB2A_MOUSE -0.55 1.47 0.79 1.47E-02 
522 sp|P70195|PSB7_MOUSE -0.56 1.47 0.59 3.21E-02 
523 sp|P63276|RS17_MOUSE -0.57 1.48 0.58 2.85E-03 
524 sp|Q68FD5|CLH1_MOUSE -0.57 1.48 0.77 2.36E-04 
525 sp|P35293|RAB18_MOUSE -0.57 1.48 0.52 2.33E-02 
526 sp|P61205|ARF3_MOUSE -0.57 1.49 0.76 2.19E-03 
527 sp|Q9JHR7|IDE_MOUSE -0.59 1.51 0.53 2.13E-03 
528 sp|P80317|TCPZ_MOUSE -0.60 1.52 0.55 3.66E-01 
529 sp|P06151|LDHA_MOUSE -0.60 1.52 0.88 2.00E-02 
530 sp|Q9EQX4|AIF1L_MOUSE -0.60 1.52 0.57 6.06E-01 
531 sp|Q9JL35|HMGN5_MOUSE -0.61 1.52 0.57 1.29E-01 
532 sp|Q9D1G1|RAB1B_MOUSE -0.61 1.52 0.59 2.16E-01 
533 sp|P31428|DPEP1_MOUSE -0.61 1.53 0.86 2.94E-05 
534 sp|Q62446|FKBP3_MOUSE -0.63 1.55 0.81 4.23E-03 
535 sp|Q61249|IGBP1_MOUSE -0.63 1.55 0.54 1.27E-03 
536 sp|Q9QUH0|GLRX1_MOUSE -0.63 1.55 0.83 3.85E-03 
537 sp|Q9DBH5|LMAN2_MOUSE -0.64 1.55 0.59 9.89E-03 
538 sp|P80315|TCPD_MOUSE -0.64 1.56 0.51 3.43E-01 
539 sp|Q9JMH6|TRXR1_MOUSE -0.64 1.56 0.76 3.13E-03 
540 sp|Q9QYB1|CLIC4_MOUSE -0.67 1.59 0.54 2.13E-01 
541 sp|Q8BMA6|SRP68_MOUSE -0.67 1.59 0.56 1.27E-02 
542 sp|Q91V92|ACLY_MOUSE -0.67 1.60 0.85 6.47E-03 
543 sp|O09044|SNP23_MOUSE -0.68 1.60 0.52 5.57E-04 
544 sp|Q9EP69|SAC1_MOUSE -0.68 1.60 0.70 2.24E-02 
545 sp|Q61035|SYHC_MOUSE -0.68 1.61 0.53 2.73E-01 
546 sp|Q99L47|F10A1_MOUSE -0.68 1.61 0.85 6.55E-01 
547 sp|Q9R0N0|GALK1_MOUSE -0.69 1.61 0.64 1.41E-01 
548 sp|P05064|ALDOA_MOUSE -0.69 1.61 0.90 1.25E-04 
549 sp|Q9CQ89|CUTA_MOUSE -0.69 1.62 0.54 2.56E-01 
550 sp|Q9CPV4|GLOD4_MOUSE -0.70 1.62 0.87 5.87E-05 
551 sp|P30416|FKBP4_MOUSE -0.70 1.62 0.72 3.99E-04 
552 sp|Q9D1L9|LTOR5_MOUSE -0.70 1.62 0.62 3.17E-04 
553 sp|Q3TW96|UAP1L_MOUSE -0.70 1.63 0.84 1.54E-02 
554 sp|Q8R2Y8|PTH2_MOUSE -0.71 1.63 0.96 2.40E-03 
555 sp|O54984|ASNA_MOUSE -0.71 1.64 0.79 3.23E-01 
556 sp|O55143|AT2A2_MOUSE -0.72 1.64 0.75 7.17E-03 
557 sp|O55022|PGRC1_MOUSE -0.72 1.65 0.84 2.02E-02 
558 sp|Q9QYC0|ADDA_MOUSE -0.72 1.65 0.59 2.53E-02 
559 sp|Q9WUA2|SYFB_MOUSE -0.72 1.65 0.63 9.49E-02 
560 sp|Q6ZWY3|RS27L_MOUSE -0.73 1.65 0.86 2.19E-02 
561 sp|Q99KI3|EMC3_MOUSE -0.74 1.67 0.78 6.57E-01 
562 sp|Q91VH2|SNX9_MOUSE -0.74 1.67 0.75 1.30E-01 
563 sp|P68373|TBA1C_MOUSE -0.74 1.67 0.67 1.88E-01 
564 sp|Q6IRU5|CLCB_MOUSE -0.74 1.68 0.77 5.78E-05 
565 sp|Q80SU7|GVIN1_MOUSE -0.75 1.68 0.63 6.51E-02 
566 sp|P46638|RB11B_MOUSE -0.75 1.69 0.89 4.16E-04 
567 sp|P04117|FABP4_MOUSE -0.76 1.69 0.78 6.27E-02 
568 sp|P47964|RL36_MOUSE -0.76 1.69 0.66 1.81E-01 
569 sp|Q9Z2W1|STK25_MOUSE -0.77 1.70 0.58 7.55E-01 
570 sp|P63037|DNJA1_MOUSE -0.77 1.70 0.81 9.16E-03 
571 sp|P11881|ITPR1_MOUSE -0.77 1.70 0.83 2.03E-06 
572 sp|P62880|GBB2_MOUSE -0.77 1.70 0.63 7.34E-03 
573 sp|P40336|VP26A_MOUSE -0.78 1.72 0.92 1.63E-03 
574 sp|Q68FH4|GALK2_MOUSE -0.78 1.72 0.81 1.78E-01 
575 sp|Q8K021|SCAM1_MOUSE -0.78 1.72 0.66 8.54E-03 
576 sp|P54822|PUR8_MOUSE -0.79 1.73 0.69 2.87E-05 
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577 sp|O70492|SNX3_MOUSE -0.79 1.73 0.85 2.38E-04 
578 sp|Q9CQB5|CISD2_MOUSE -0.79 1.73 0.60 9.61E-03 
579 sp|Q8K2C9|HACD3_MOUSE -0.79 1.73 0.88 7.03E-03 
580 sp|P19157|GSTP1_MOUSE -0.80 1.74 0.93 1.03E-03 
581 sp|Q9D819|IPYR_MOUSE -0.81 1.76 0.79 6.78E-01 
582 sp|P50396|GDIA_MOUSE -0.82 1.76 0.55 7.57E-02 
583 sp|Q9CQM9|GLRX3_MOUSE -0.82 1.77 0.67 1.19E-03 
584 sp|P10639|THIO_MOUSE -0.82 1.77 0.79 9.40E-05 
585 sp|Q99LB6|MAT2B_MOUSE -0.83 1.78 0.96 1.81E-02 
586 sp|P35278|RAB5C_MOUSE -0.83 1.78 0.65 6.88E-02 
587 sp|P08556|RASN_MOUSE -0.84 1.79 0.81 1.66E-03 
588 sp|O88952|LIN7C_MOUSE -0.84 1.79 0.57 9.57E-04 
589 sp|Q9D1L0|CHCH2_MOUSE -0.84 1.79 0.67 1.16E-03 
590 sp|Q64133|AOFA_MOUSE -0.85 1.80 0.72 1.84E-01 
591 sp|Q91V64|ISOC1_MOUSE -0.86 1.81 0.85 5.02E-05 
592 sp|P27601|GNA13_MOUSE -0.86 1.82 0.64 6.58E-03 
593 sp|Q62261|SPTB2_MOUSE -0.87 1.83 0.85 2.49E-04 
594 sp|Q9CPU0|LGUL_MOUSE -0.87 1.83 0.83 9.27E-04 
595 sp|P16546|SPTN1_MOUSE -0.88 1.84 0.98 1.93E-05 
596 sp|Q64471|GSTT1_MOUSE -0.88 1.84 0.85 2.50E-02 
597 sp|D3Z7P3|GLSK_MOUSE -0.88 1.84 0.76 7.61E-04 
598 sp|Q9CS42|PRPS2_MOUSE -0.89 1.85 0.58 9.00E-03 
599 sp|P15947|KLK1_MOUSE -0.90 1.87 0.63 1.67E-03 
600 sp|Q8BFZ9|ERLN2_MOUSE -0.90 1.87 0.80 2.20E-04 
601 sp|Q99J56|DERL1_MOUSE -0.91 1.88 0.54 1.22E-01 
602 sp|Q9WV80|SNX1_MOUSE -0.92 1.89 0.64 5.36E-01 
603 sp|Q921Z5|TFIP8_MOUSE -0.92 1.90 0.68 1.02E-02 
604 sp|Q9DCL9|PUR6_MOUSE -0.92 1.90 0.75 5.29E-01 
605 sp|Q9CZW5|TOM70_MOUSE -0.93 1.90 0.60 3.70E-03 
606 sp|Q9D662|SC23B_MOUSE -0.93 1.91 0.68 5.68E-01 
607 sp|Q922B2|SYDC_MOUSE -0.94 1.92 0.57 1.01E-01 
608 sp|Q3UQ44|IQGA2_MOUSE -0.94 1.92 0.55 1.44E-03 
609 sp|B2RSH2|GNAI1_MOUSE -0.95 1.93 0.64 9.32E-04 
610 sp|O70404|VAMP8_MOUSE -0.95 1.94 0.83 2.12E-04 
611 sp|Q9ES97|RTN3_MOUSE -0.95 1.94 0.88 1.68E-03 
612 sp|Q3THS6|METK2_MOUSE -0.96 1.94 0.78 2.75E-03 
613 sp|P70296|PEBP1_MOUSE -0.96 1.95 0.95 1.59E-06 
614 sp|P68372|TBB4B_MOUSE -0.96 1.95 1.00 1.10E-06 
615 sp|Q9CQM5|TXD17_MOUSE -0.96 1.95 0.87 1.90E-05 
616 sp|O88587|COMT_MOUSE -0.96 1.95 0.82 4.04E-02 
617 sp|Q8R1V4|TMED4_MOUSE -0.97 1.95 0.86 1.74E-01 
618 sp|Q8K274|KT3K_MOUSE -0.97 1.96 0.66 7.16E-01 
619 sp|Q9D0M5|DYL2_MOUSE -0.98 1.97 0.50 5.24E-01 
620 sp|O09043|NAPSA_MOUSE -0.98 1.98 0.67 3.91E-01 
621 sp|Q9CR67|TMM33_MOUSE -0.99 1.99 0.83 1.86E-03 
622 sp|Q9D1A2|CNDP2_MOUSE -1.00 2.00 0.85 2.17E-02 
623 sp|Q9D358|PPAC_MOUSE -1.01 2.01 0.65 6.32E-01 
624 sp|P10630|IF4A2_MOUSE -1.01 2.01 0.68 5.20E-03 
625 sp|Q9Z0P4|PALM_MOUSE -1.01 2.02 0.78 6.81E-06 
626 sp|Q9ESE1|LRBA_MOUSE -1.02 2.03 0.51 2.53E-03 
627 sp|O08709|PRDX6_MOUSE -1.02 2.03 0.96 7.15E-09 
628 sp|Q9DBP5|KCY_MOUSE -1.03 2.04 0.83 6.50E-04 
629 sp|P12367|KAP2_MOUSE -1.03 2.05 0.51 1.12E-04 
630 sp|P28843|DPP4_MOUSE -1.04 2.05 0.80 1.81E-03 
631 sp|Q9R0X4|ACOT9_MOUSE -1.04 2.05 0.58 8.99E-03 
632 sp|P55258|RAB8A_MOUSE -1.04 2.06 0.82 5.53E-04 
633 sp|Q11136|PEPD_MOUSE -1.04 2.06 0.50 7.47E-02 
634 sp|Q9DCZ1|GMPR1_MOUSE -1.05 2.06 0.92 2.40E-05 
635 sp|P06745|G6PI_MOUSE -1.05 2.07 0.96 7.31E-07 
636 sp|Q9D6Z1|NOP56_MOUSE -1.06 2.08 0.57 1.29E-03 
637 sp|Q571I9|A16A1_MOUSE -1.06 2.08 0.76 5.46E-05 
638 sp|P22892|AP1G1_MOUSE -1.06 2.08 0.59 4.57E-02 
639 sp|Q9EQH3|VPS35_MOUSE -1.06 2.09 0.81 1.45E-01 
640 sp|O35345|IMA7_MOUSE -1.07 2.10 0.61 6.36E-02 
641 sp|Q9CY64|BIEA_MOUSE -1.07 2.10 0.81 1.35E-04 
642 sp|Q9CQU3|RER1_MOUSE -1.08 2.11 0.52 4.49E-04 
643 sp|O70475|UGDH_MOUSE -1.08 2.12 0.82 1.92E-05 
644 sp|Q9QXY6|EHD3_MOUSE -1.09 2.12 0.57 3.75E-03 
645 sp|O35643|AP1B1_MOUSE -1.09 2.13 0.69 4.37E-02 
646 sp|Q91V41|RAB14_MOUSE -1.09 2.13 0.83 2.28E-02 
647 sp|Q8R2K1|FUCM_MOUSE -1.11 2.15 0.88 1.27E-04 
648 sp|Q61699|HS105_MOUSE -1.11 2.16 0.52 1.85E-02 
649 sp|P09803|CADH1_MOUSE -1.11 2.17 0.62 5.31E-06 
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650 sp|Q9Z0N2|IF2H_MOUSE -1.12 2.17 0.57 4.45E-01 
651 sp|Q9QZ23|NFU1_MOUSE -1.12 2.18 0.67 1.18E-02 
652 sp|Q8BJY1|PSMD5_MOUSE -1.12 2.18 0.55 7.26E-04 
653 sp|P16858|G3P_MOUSE -1.13 2.18 0.90 2.07E-02 
654 sp|Q9QYG0|NDRG2_MOUSE -1.13 2.19 0.68 2.23E-04 
655 sp|Q9CPQ3|TOM22_MOUSE -1.13 2.19 0.56 2.09E-03 
656 sp|P35700|PRDX1_MOUSE -1.13 2.19 0.90 1.17E-03 
657 sp|Q01768|NDKB_MOUSE -1.14 2.20 0.90 3.54E-03 
658 sp|Q8BMF3|MAON_MOUSE -1.14 2.20 0.53 1.83E-01 
659 sp|P15532|NDKA_MOUSE -1.14 2.21 0.70 2.27E-03 
660 sp|P10649|GSTM1_MOUSE -1.15 2.22 0.89 5.92E-04 
661 sp|Q9CXA2|T3HPD_MOUSE -1.15 2.23 0.59 1.07E-02 
662 sp|Q9QYB5|ADDG_MOUSE -1.16 2.23 0.76 3.62E-04 
663 sp|Q3ULJ0|GPD1L_MOUSE -1.18 2.26 0.85 2.63E-04 
664 sp|Q80SW1|SAHH2_MOUSE -1.18 2.27 0.63 3.76E-06 
665 sp|P45878|FKBP2_MOUSE -1.19 2.28 0.64 8.36E-06 
666 sp|O55234|PSB5_MOUSE -1.19 2.29 0.76 1.76E-05 
667 sp|Q9CQX2|CYB5B_MOUSE -1.20 2.29 0.90 4.21E-02 
668 sp|Q9QYA2|TOM40_MOUSE -1.20 2.30 0.52 1.97E-05 
669 sp|P55264|ADK_MOUSE -1.21 2.31 0.83 2.10E-02 
670 sp|Q8CFV9|RIFK_MOUSE -1.21 2.31 0.53 8.25E-03 
671 sp|Q9CZ42|NNRD_MOUSE -1.21 2.32 0.82 3.33E-03 
672 sp|P62342|SELT_MOUSE -1.22 2.32 0.96 2.93E-04 
673 sp|Q8QZY2|GLCTK_MOUSE -1.23 2.34 0.74 3.91E-05 
674 sp|O35988|SDC4_MOUSE -1.23 2.34 0.61 1.20E-01 
675 sp|Q8K411|PREP_MOUSE -1.23 2.35 0.58 2.46E-04 
676 sp|P47915|RL29_MOUSE -1.24 2.37 0.54 4.11E-01 
677 sp|Q9D6U8|F162A_MOUSE -1.25 2.38 0.67 3.07E-02 
678 sp|Q91V12|BACH_MOUSE -1.25 2.38 0.81 7.23E-01 
679 sp|Q9DBJ1|PGAM1_MOUSE -1.26 2.39 0.95 2.08E-04 
680 sp|Q9DAS9|GBG12_MOUSE -1.26 2.39 0.94 2.16E-05 
681 sp|P28474|ADHX_MOUSE -1.26 2.40 0.84 6.84E-06 
682 sp|O88851|RBBP9_MOUSE -1.27 2.41 0.56 8.20E-03 
683 sp|P47791|GSHR_MOUSE -1.28 2.43 0.64 2.91E-03 
684 sp|O70439|STX7_MOUSE -1.30 2.46 0.76 1.00E-05 
685 sp|Q9WVE8|PACN2_MOUSE -1.30 2.46 0.88 1.83E-03 
686 sp|Q9ERN0|SCAM2_MOUSE -1.30 2.46 0.58 2.80E-01 
687 sp|P17182|ENOA_MOUSE -1.30 2.47 0.98 3.77E-04 
688 sp|Q6ZQI3|MLEC_MOUSE -1.32 2.49 0.55 3.56E-04 
689 sp|Q9WV85|NDK3_MOUSE -1.32 2.49 0.56 1.52E-01 
690 sp|P17710|HXK1_MOUSE -1.33 2.51 0.92 1.51E-03 
691 sp|P56565|S10A1_MOUSE -1.33 2.51 0.78 1.07E-01 
692 sp|Q99JB2|STML2_MOUSE -1.33 2.52 0.59 2.05E-02 
693 sp|Q99L04|DHRS1_MOUSE -1.34 2.53 0.71 4.08E-02 
694 sp|P10518|HEM2_MOUSE -1.34 2.54 0.91 5.02E-05 
695 sp|O70325|GPX41_MOUSE -1.35 2.55 0.66 6.14E-06 
696 sp|Q9CR98|F136A_MOUSE -1.35 2.56 0.58 2.60E-02 
697 sp|P17751|TPIS_MOUSE -1.36 2.56 0.83 2.72E-05 
698 sp|Q99LX0|PARK7_MOUSE -1.37 2.58 0.87 3.63E-02 
699 sp|P50247|SAHH_MOUSE -1.37 2.58 0.91 1.12E-04 
700 sp|Q8K4Z3|NNRE_MOUSE -1.38 2.60 0.76 2.55E-05 
701 sp|Q08857|CD36_MOUSE -1.38 2.60 0.67 2.17E-02 
702 sp|O35857|TIM44_MOUSE -1.38 2.61 0.83 4.82E-04 
703 sp|Q924M7|MPI_MOUSE -1.39 2.61 0.74 2.65E-04 
704 sp|Q99N23|CAH15_MOUSE -1.40 2.63 0.63 2.76E-03 
705 sp|Q9DCB8|ISCA2_MOUSE -1.40 2.64 0.71 2.34E-04 
706 sp|Q3UGR5|HDHD2_MOUSE -1.41 2.66 0.82 3.40E-01 
707 sp|P56393|COX7B_MOUSE -1.41 2.67 0.59 2.13E-03 
708 sp|B1AXP6|TOM5_MOUSE -1.43 2.69 0.88 1.10E-01 
709 sp|Q99LP6|GRPE1_MOUSE -1.43 2.69 0.78 2.89E-03 
710 sp|Q3UMF0|COBL1_MOUSE -1.43 2.70 0.50 1.77E-05 
711 sp|O09117|SYPL1_MOUSE -1.45 2.73 1.00 1.34E-04 
712 sp|P47740|AL3A2_MOUSE -1.45 2.74 0.86 3.41E-02 
713 sp|Q91ZJ5|UGPA_MOUSE -1.45 2.74 0.85 3.31E-04 
714 sp|P36552|HEM6_MOUSE -1.46 2.75 0.69 1.33E-01 
715 sp|A3KMP2|TTC38_MOUSE -1.46 2.75 0.79 1.13E-04 
716 sp|Q9CYR6|AGM1_MOUSE -1.47 2.76 0.59 1.36E-04 
717 sp|Q9D6Y9|GLGB_MOUSE -1.47 2.77 0.86 2.53E-06 
718 sp|Q9D8X1|CUTC_MOUSE -1.47 2.77 0.54 4.80E-01 
719 sp|P57016|LAD1_MOUSE -1.48 2.79 0.80 6.24E-04 
720 sp|Q921H8|THIKA_MOUSE -1.49 2.81 0.82 1.47E-02 
721 sp|P98197|AT11A_MOUSE -1.50 2.82 0.64 5.10E-02 
722 sp|Q9JKW0|AR6P1_MOUSE -1.50 2.83 0.56 1.84E-01 
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723 sp|Q14DH7|ACSS3_MOUSE -1.50 2.83 0.71 1.44E-01 
724 sp|Q06138|CAB39_MOUSE -1.51 2.85 0.62 4.41E-02 
725 sp|Q8BXK9|CLIC5_MOUSE -1.51 2.86 0.81 1.87E-03 
726 sp|P24472|GSTA4_MOUSE -1.53 2.89 0.87 7.48E-02 
727 sp|Q91W52|TMM19_MOUSE -1.53 2.89 0.69 1.41E-04 
728 sp|Q9CQ92|FIS1_MOUSE -1.54 2.91 0.88 9.45E-06 
729 sp|Q9D7N9|APMAP_MOUSE -1.55 2.93 0.85 3.51E-02 
730 sp|Q9Z1J3|NFS1_MOUSE -1.57 2.97 0.64 3.50E-03 
731 sp|P00920|CAH2_MOUSE -1.58 2.99 0.96 5.29E-05 
732 sp|Q8K183|PDXK_MOUSE -1.59 3.01 0.92 3.18E-02 
733 sp|Q3TMH2|SCRN3_MOUSE -1.60 3.02 0.72 7.29E-04 
734 sp|Q9CXJ4|ABCB8_MOUSE -1.60 3.02 0.64 6.02E-02 
735 sp|Q99KQ4|NAMPT_MOUSE -1.60 3.03 0.61 5.59E-05 
736 sp|Q6GQT9|NOMO1_MOUSE -1.60 3.03 0.81 6.15E-04 
737 sp|Q60973|RBBP7_MOUSE -1.60 3.04 0.71 5.54E-01 
738 sp|Q8BG51|MIRO1_MOUSE -1.61 3.06 0.71 1.23E-05 
739 sp|P70349|HINT1_MOUSE -1.62 3.06 0.95 1.68E-05 
740 sp|Q9CY27|TECR_MOUSE -1.63 3.10 0.66 4.03E-01 
741 sp|Q9QXE0|HACL1_MOUSE -1.64 3.11 0.60 1.72E-02 
742 sp|Q9WVK4|EHD1_MOUSE -1.64 3.11 0.77 2.56E-05 
743 sp|Q60930|VDAC2_MOUSE -1.64 3.13 0.93 9.19E-06 
744 sp|Q8VDQ1|PTGR2_MOUSE -1.66 3.15 0.92 1.19E-03 
745 sp|Q9D0F9|PGM1_MOUSE -1.66 3.15 0.85 1.05E-03 
746 sp|P70444|BID_MOUSE -1.66 3.16 0.64 4.10E-06 
747 sp|Q8JZQ2|AFG32_MOUSE -1.66 3.16 0.79 2.87E-08 
748 sp|Q9CYR0|SSBP_MOUSE -1.66 3.17 0.58 1.30E-02 
749 sp|P51863|VA0D1_MOUSE -1.67 3.19 0.87 6.43E-04 
750 sp|P70245|EBP_MOUSE -1.67 3.19 0.71 1.67E-02 
751 sp|Q9DCT1|AKCL2_MOUSE -1.67 3.19 0.82 4.52E-08 
752 sp|P56394|COX17_MOUSE -1.68 3.19 0.70 1.91E-01 
753 sp|Q60931|VDAC3_MOUSE -1.68 3.20 0.75 5.57E-03 
754 sp|Q9Z2Y8|PROSC_MOUSE -1.68 3.21 0.89 6.85E-05 
755 sp|P08228|SODC_MOUSE -1.69 3.22 0.95 3.31E-05 
756 sp|P51661|DHI2_MOUSE -1.69 3.22 0.88 4.33E-04 
757 sp|Q8JZU2|TXTP_MOUSE -1.69 3.23 0.83 2.65E-06 
758 sp|P56376|ACYP1_MOUSE -1.70 3.25 0.77 1.05E-01 
759 sp|Q8BIJ6|SYIM_MOUSE -1.71 3.27 0.83 1.27E-03 
760 sp|Q9D880|TIM50_MOUSE -1.71 3.27 0.89 1.17E-03 
761 sp|Q64105|SPRE_MOUSE -1.72 3.28 0.96 4.15E-09 
762 sp|Q9CYH2|F213A_MOUSE -1.73 3.31 0.83 7.88E-05 
763 sp|Q64331|MYO6_MOUSE -1.73 3.31 0.85 3.65E-02 
764 sp|O88958|GNPI1_MOUSE -1.74 3.33 0.88 1.61E-05 
765 sp|P61148|FGF1_MOUSE -1.74 3.34 0.64 6.21E-02 
766 sp|P09411|PGK1_MOUSE -1.74 3.35 0.97 2.49E-05 
767 sp|Q9D8Y1|T126A_MOUSE -1.76 3.38 0.58 4.01E-04 
768 sp|Q8BGC4|ZADH2_MOUSE -1.76 3.38 0.64 8.79E-01 
769 sp|P26043|RADI_MOUSE -1.76 3.39 0.89 7.42E-04 
770 sp|Q9DCJ9|NPL_MOUSE -1.77 3.41 0.86 1.12E-02 
771 sp|P26040|EZRI_MOUSE -1.77 3.41 0.96 4.48E-06 
772 sp|P31786|ACBP_MOUSE -1.77 3.42 0.96 3.64E-04 
773 sp|P82343|RENBP_MOUSE -1.78 3.43 0.62 2.38E-01 
774 sp|P67778|PHB_MOUSE -1.79 3.45 0.93 1.38E-07 
775 sp|Q9DCS3|MECR_MOUSE -1.79 3.45 0.57 2.52E-06 
776 sp|Q8R317|UBQL1_MOUSE -1.80 3.48 0.53 8.01E-01 
777 sp|Q91W43|GCSP_MOUSE -1.81 3.50 0.66 3.22E-02 
778 sp|P05201|AATC_MOUSE -1.81 3.51 0.89 2.12E-04 
779 sp|Q8VHF2|CDHR5_MOUSE -1.82 3.53 0.56 6.46E-02 
780 sp|O35969|GAMT_MOUSE -1.82 3.54 0.75 3.01E-04 
781 sp|P48193|41_MOUSE -1.83 3.55 0.83 7.63E-07 
782 sp|P55302|AMRP_MOUSE -1.83 3.55 0.58 1.74E-02 
783 sp|Q3UJU9|RMD3_MOUSE -1.83 3.56 0.67 2.43E-03 
784 sp|Q9D5T0|ATAD1_MOUSE -1.83 3.57 0.85 2.36E-07 
785 sp|Q8JZN5|ACAD9_MOUSE -1.84 3.59 0.67 2.40E-02 
786 sp|Q4VAE3|TMM65_MOUSE -1.84 3.59 0.91 2.83E-03 
787 sp|P56395|CYB5_MOUSE -1.85 3.60 0.89 5.08E-02 
788 sp|Q8R146|APEH_MOUSE -1.85 3.60 0.77 2.82E-04 
789 sp|Q8CAK1|CAF17_MOUSE -1.85 3.60 0.61 5.24E-05 
790 sp|P16406|AMPE_MOUSE -1.85 3.60 0.86 1.11E-03 
791 sp|P48774|GSTM5_MOUSE -1.86 3.62 0.89 7.07E-04 
792 sp|O35658|C1QBP_MOUSE -1.86 3.63 0.92 8.43E-04 
793 sp|Q9CPY7|AMPL_MOUSE -1.86 3.63 0.93 2.92E-02 
794 sp|Q8BTY1|KAT1_MOUSE -1.86 3.63 0.82 1.97E-02 
795 sp|P05063|ALDOC_MOUSE -1.87 3.66 0.62 3.88E-04 
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796 sp|Q9R0Q6|ARC1A_MOUSE -1.87 3.66 0.79 2.34E-04 
797 sp|Q64669|NQO1_MOUSE -1.88 3.67 0.52 8.49E-05 
798 sp|Q9CZU6|CISY_MOUSE -1.88 3.69 0.89 1.92E-05 
799 sp|O35143|ATIF1_MOUSE -1.89 3.71 0.83 2.41E-07 
800 sp|P17809|GTR1_MOUSE -1.91 3.75 0.72 1.80E-02 
801 sp|Q922H2|PDK3_MOUSE -1.92 3.77 0.69 1.03E-03 
802 sp|Q9JM63|KCJ10_MOUSE -1.92 3.79 0.77 5.64E-02 
803 sp|P63321|RALA_MOUSE -1.92 3.79 0.60 1.73E-03 
804 sp|P34884|MIF_MOUSE -1.92 3.79 0.89 2.62E-03 
805 sp|Q9R0P3|ESTD_MOUSE -1.92 3.80 0.88 3.21E-08 
806 sp|Q99M87|DNJA3_MOUSE -1.93 3.81 0.71 1.92E-04 
807 sp|Q9CZR8|EFTS_MOUSE -1.94 3.83 0.83 2.72E-04 
808 sp|O35129|PHB2_MOUSE -1.94 3.84 0.93 3.06E-06 
809 sp|Q8CGK3|LONM_MOUSE -1.95 3.87 0.90 6.16E-07 
810 sp|P51660|DHB4_MOUSE -1.95 3.87 0.94 3.07E-02 
811 sp|Q64521|GPDM_MOUSE -1.96 3.88 0.72 3.50E-02 
812 sp|P37040|NCPR_MOUSE -1.96 3.89 0.75 3.59E-04 
813 sp|P11352|GPX1_MOUSE -1.97 3.91 0.94 5.78E-03 
814 sp|Q9DCV4|RMD1_MOUSE -1.97 3.93 0.75 2.14E-05 
815 sp|Q99KB8|GLO2_MOUSE -1.97 3.93 0.70 1.04E-03 
816 sp|Q9Z1G3|VATC1_MOUSE -1.98 3.94 0.85 6.48E-05 
817 sp|Q99J39|DCMC_MOUSE -1.98 3.94 0.64 9.72E-01 
818 sp|Q8BGA8|ACSM5_MOUSE -2.00 4.00 0.60 2.06E-01 
819 sp|P62073|TIM10_MOUSE -2.00 4.01 0.74 1.58E-07 
820 sp|Q5SW19|CLU_MOUSE -2.01 4.02 0.57 4.45E-04 
821 sp|Q9WTN6|S22AL_MOUSE -2.01 4.03 0.63 3.16E-01 
822 sp|Q6P1B1|XPP1_MOUSE -2.02 4.05 0.85 7.74E-03 
823 sp|Q8CFA2|GCST_MOUSE -2.02 4.06 0.78 8.66E-06 
824 sp|O09172|GSH0_MOUSE -2.02 4.07 0.84 1.72E-03 
825 sp|P47934|CACP_MOUSE -2.04 4.11 0.82 4.37E-06 
826 sp|P48962|ADT1_MOUSE -2.04 4.11 0.85 1.43E-03 
827 sp|O35683|NDUA1_MOUSE -2.04 4.12 0.86 5.21E-04 
828 sp|Q91VT4|CBR4_MOUSE -2.05 4.13 0.72 1.82E-06 
829 sp|Q8K0C4|CP51A_MOUSE -2.05 4.14 0.78 4.60E-04 
830 sp|Q9DC61|MPPA_MOUSE -2.05 4.15 0.60 1.15E-03 
831 sp|P30275|KCRU_MOUSE -2.06 4.16 0.84 3.40E-05 
832 sp|Q8VHG0|FMO4_MOUSE -2.06 4.17 0.70 9.23E-01 
833 sp|Q8K010|OPLA_MOUSE -2.06 4.17 0.73 1.94E-04 
834 sp|Q924X2|CPT1B_MOUSE -2.06 4.17 0.53 1.84E-02 
835 sp|Q9JK42|PDK2_MOUSE -2.06 4.17 0.57 1.02E-04 
836 sp|Q811D0|DLG1_MOUSE -2.06 4.18 0.52 1.38E-02 
837 sp|Q9D939|ST1C2_MOUSE -2.07 4.19 0.50 3.91E-03 
838 sp|Q9JHW2|NIT2_MOUSE -2.07 4.19 0.90 2.70E-04 
839 sp|P97742|CPT1A_MOUSE -2.07 4.20 0.85 2.29E-03 
840 sp|Q80Y14|GLRX5_MOUSE -2.07 4.20 0.86 2.04E-07 
841 sp|Q5F285|TM256_MOUSE -2.07 4.21 0.58 2.86E-06 
842 sp|O55137|ACOT1_MOUSE -2.08 4.21 0.85 1.52E-04 
843 sp|P61110|ANRE_MOUSE -2.08 4.22 0.71 2.56E-02 
844 sp|P16125|LDHB_MOUSE -2.08 4.24 0.86 2.76E-04 
845 sp|P29758|OAT_MOUSE -2.09 4.26 0.86 1.70E-01 
846 sp|P97449|AMPN_MOUSE -2.09 4.26 0.94 3.67E-03 
847 sp|P53986|MOT1_MOUSE -2.10 4.28 0.80 8.36E-05 
848 sp|Q9CR62|M2OM_MOUSE -2.10 4.29 0.88 1.05E-08 
849 sp|Q99K30|ES8L2_MOUSE -2.10 4.29 0.65 4.43E-02 
850 sp|Q791V5|MTCH2_MOUSE -2.11 4.32 0.89 7.49E-06 
851 sp|Q925I1|ATAD3_MOUSE -2.11 4.33 0.87 9.83E-05 
852 sp|G5E8K5|ANK3_MOUSE -2.11 4.33 0.84 2.62E-05 
853 sp|Q9DB29|IAH1_MOUSE -2.12 4.35 0.82 3.41E-04 
854 sp|Q9EP89|LACTB_MOUSE -2.13 4.36 0.68 2.52E-04 
855 sp|Q922B1|MACD1_MOUSE -2.13 4.36 0.66 2.58E-04 
856 sp|Q9JLI6|SCLY_MOUSE -2.13 4.37 0.59 5.12E-01 
857 sp|Q8C5H8|NAKD2_MOUSE -2.13 4.39 0.65 8.94E-04 
858 sp|P58137|ACOT8_MOUSE -2.13 4.39 0.72 4.71E-03 
859 sp|Q9CPX8|QCR10_MOUSE -2.14 4.39 0.75 2.48E-03 
860 sp|Q99JY0|ECHB_MOUSE -2.15 4.43 0.89 1.86E-03 
861 sp|Q9DCU6|RM04_MOUSE -2.16 4.46 0.78 8.53E-05 
862 sp|Q9Z2I0|LETM1_MOUSE -2.16 4.47 0.86 8.05E-05 
863 sp|P70290|EM55_MOUSE -2.16 4.48 0.86 3.39E-05 
864 sp|O88451|RDH7_MOUSE -2.16 4.48 0.69 7.13E-02 
865 sp|Q8K157|GALM_MOUSE -2.16 4.48 0.78 1.51E-04 
866 sp|Q78IK4|MIC27_MOUSE -2.17 4.49 0.87 1.77E-01 
867 sp|Q9DCQ2|ASPD_MOUSE -2.17 4.50 0.67 1.05E-04 
868 sp|Q9JJW0|PXMP4_MOUSE -2.17 4.50 0.57 6.40E-03 
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869 sp|O88696|CLPP_MOUSE -2.17 4.51 0.87 3.01E-04 
870 sp|P00158|CYB_MOUSE -2.18 4.53 0.65 7.51E-03 
871 sp|P57746|VATD_MOUSE -2.18 4.54 0.86 4.39E-05 
872 sp|O89106|FHIT_MOUSE -2.18 4.54 0.79 3.05E-02 
873 sp|P46656|ADX_MOUSE -2.18 4.55 0.78 7.22E-04 
874 sp|P18572|BASI_MOUSE -2.19 4.56 0.82 4.64E-04 
875 sp|P51174|ACADL_MOUSE -2.19 4.56 0.95 3.30E-03 
876 sp|P97823|LYPA1_MOUSE -2.21 4.62 0.88 4.97E-03 
877 sp|P38647|GRP75_MOUSE -2.21 4.62 0.85 4.91E-04 
878 sp|Q8BGS1|E41L5_MOUSE -2.21 4.64 0.64 1.86E-03 
879 sp|P16331|PH4H_MOUSE -2.22 4.66 0.78 2.67E-05 
880 sp|Q8BMS1|ECHA_MOUSE -2.22 4.67 0.96 2.35E-03 
881 sp|Q8BFR5|EFTU_MOUSE -2.24 4.73 0.95 1.60E-05 
882 sp|Q8BMC1|VATG3_MOUSE -2.25 4.74 0.84 4.73E-04 
883 sp|Q9WTP7|KAD3_MOUSE -2.25 4.75 0.89 5.27E-05 
884 sp|P50431|GLYC_MOUSE -2.25 4.75 0.85 2.84E-05 
885 sp|P10637|TAU_MOUSE -2.26 4.79 0.77 2.71E-04 
886 sp|Q9D7P6|ISCU_MOUSE -2.27 4.82 0.71 5.80E-05 
887 sp|Q60676|PPP5_MOUSE -2.27 4.83 0.57 1.02E-04 
888 sp|Q61133|GSTT2_MOUSE -2.27 4.83 0.82 2.05E-04 
889 sp|Q9DB15|RM12_MOUSE -2.27 4.83 0.93 2.29E-05 
890 sp|P58281|OPA1_MOUSE -2.28 4.84 0.86 1.65E-09 
891 sp|Q9WV98|TIM9_MOUSE -2.28 4.85 0.81 2.08E-05 
892 sp|Q8VDK1|NIT1_MOUSE -2.28 4.86 0.89 5.74E-04 
893 sp|O88844|IDHC_MOUSE -2.28 4.87 0.91 6.87E-04 
894 sp|Q8VCR7|ABHEB_MOUSE -2.28 4.87 0.91 4.43E-05 
895 sp|Q8BP40|PPA6_MOUSE -2.28 4.87 0.69 6.19E-06 
896 sp|Q9DBL1|ACDSB_MOUSE -2.29 4.89 0.94 4.00E-04 
897 sp|Q9WV68|DECR2_MOUSE -2.30 4.92 0.79 6.73E-03 
898 sp|P62814|VATB2_MOUSE -2.30 4.92 0.91 9.32E-04 
899 sp|O55126|NIPS2_MOUSE -2.30 4.93 0.78 2.03E-02 
900 sp|P10852|4F2_MOUSE -2.31 4.94 0.93 5.34E-05 
901 sp|Q6PB66|LPPRC_MOUSE -2.31 4.96 0.85 2.81E-04 
902 sp|Q9QXG4|ACSA_MOUSE -2.31 4.97 0.75 1.69E-03 
903 sp|Q9D2R6|COA3_MOUSE -2.32 4.99 0.63 2.04E-04 
904 sp|O08756|HCD2_MOUSE -2.32 5.00 0.94 9.49E-02 
905 sp|Q8BH59|CMC1_MOUSE -2.32 5.01 0.86 4.67E-05 
906 sp|P97364|SPS2_MOUSE -2.33 5.03 0.84 2.59E-04 
907 sp|Q9R112|SQRD_MOUSE -2.33 5.04 0.89 1.43E-06 
908 sp|Q8BK72|RT27_MOUSE -2.34 5.05 0.71 5.71E-04 
909 sp|P97493|THIOM_MOUSE -2.34 5.05 0.95 6.36E-04 
910 sp|Q99J99|THTM_MOUSE -2.34 5.06 0.82 1.17E-06 
911 sp|Q8CAY6|THIC_MOUSE -2.34 5.08 0.81 5.93E-04 
912 sp|Q9DCC4|P5CR3_MOUSE -2.35 5.08 0.84 7.88E-04 
913 sp|O08691|ARGI2_MOUSE -2.35 5.10 0.52 7.12E-01 
914 sp|O35215|DOPD_MOUSE -2.35 5.10 0.95 1.11E-07 
915 sp|Q9CQZ5|NDUA6_MOUSE -2.35 5.11 0.87 5.55E-05 
916 sp|P26443|DHE3_MOUSE -2.37 5.15 0.93 1.27E-03 
917 sp|Q9DCN1|NUD12_MOUSE -2.37 5.15 0.63 3.67E-03 
918 sp|Q9D6R2|IDH3A_MOUSE -2.38 5.19 0.93 1.55E-04 
919 sp|Q9D2R0|AACS_MOUSE -2.38 5.22 0.81 6.81E-02 
920 sp|Q99LY9|NDUS5_MOUSE -2.39 5.22 0.85 9.03E-05 
921 sp|Q9WU84|CCS_MOUSE -2.39 5.23 0.83 9.89E-05 
922 sp|Q9DCS2|CP013_MOUSE -2.39 5.23 0.83 8.75E-03 
923 sp|P08905|LYZ2_MOUSE -2.39 5.25 0.87 1.53E-06 
924 sp|Q9Z2H7|GIPC2_MOUSE -2.39 5.26 0.55 2.08E-01 
925 sp|O35459|ECH1_MOUSE -2.40 5.27 0.95 1.18E-03 
926 sp|Q8K0D5|EFGM_MOUSE -2.40 5.27 0.50 1.87E-03 
927 sp|P28271|ACOC_MOUSE -2.41 5.32 0.88 1.33E-06 
928 sp|P62075|TIM13_MOUSE -2.41 5.33 0.89 1.83E-07 
929 sp|Q60648|SAP3_MOUSE -2.42 5.34 0.85 2.71E-06 
930 sp|Q8VCA8|SCRN2_MOUSE -2.43 5.37 0.83 5.11E-01 
931 sp|Q9D1K2|VATF_MOUSE -2.43 5.40 0.88 4.58E-06 
932 sp|P14152|MDHC_MOUSE -2.44 5.41 0.94 9.41E-08 
933 sp|Q8R086|SUOX_MOUSE -2.44 5.41 0.79 5.24E-05 
934 sp|Q8BVI4|DHPR_MOUSE -2.45 5.45 0.91 1.16E-04 
935 sp|Q8VEA4|MIA40_MOUSE -2.45 5.45 0.86 8.70E-03 
936 sp|Q9WVA2|TIM8A_MOUSE -2.45 5.45 0.84 1.63E-04 
937 sp|Q9D1H6|NDUF4_MOUSE -2.45 5.45 0.71 1.25E-04 
938 sp|P50518|VATE1_MOUSE -2.45 5.47 0.92 8.02E-05 
939 sp|Q9D517|PLCC_MOUSE -2.45 5.47 0.80 2.00E-04 
940 sp|Q9D1I5|MCEE_MOUSE -2.45 5.48 0.59 4.46E-04 
941 sp|P47738|ALDH2_MOUSE -2.45 5.48 0.94 2.65E-04 
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942 sp|Q9JHS4|CLPX_MOUSE -2.45 5.48 0.91 5.84E-04 
943 sp|Q7TMF3|NDUAC_MOUSE -2.46 5.49 0.70 8.33E-06 
944 sp|Q921G7|ETFD_MOUSE -2.46 5.49 0.90 3.66E-04 
945 sp|Q60932|VDAC1_MOUSE -2.46 5.49 0.96 6.12E-05 
946 sp|P42125|ECI1_MOUSE -2.46 5.51 0.90 2.47E-08 
947 sp|Q68FL4|SAHH3_MOUSE -2.47 5.54 0.83 1.46E-03 
948 sp|Q9DCU9|HOGA1_MOUSE -2.47 5.55 0.55 1.11E-01 
949 sp|Q99KR7|PPIF_MOUSE -2.47 5.55 0.77 1.04E-02 
950 sp|P50171|DHB8_MOUSE -2.47 5.55 0.81 7.84E-04 
951 sp|Q8BGH2|SAM50_MOUSE -2.49 5.60 0.90 4.03E-05 
952 sp|P50136|ODBA_MOUSE -2.49 5.61 0.75 1.02E-04 
953 sp|P98078|DAB2_MOUSE -2.49 5.62 0.80 6.54E-02 
954 sp|Q8VCF0|MAVS_MOUSE -2.49 5.62 0.75 6.43E-05 
955 sp|Q9CQ62|DECR_MOUSE -2.49 5.63 0.88 3.89E-03 
956 sp|Q8VDG7|PAFA2_MOUSE -2.49 5.64 0.55 5.67E-06 
957 sp|P00375|DYR_MOUSE -2.50 5.65 0.82 6.52E-04 
958 sp|Q91X52|DCXR_MOUSE -2.50 5.66 0.83 5.79E-04 
959 sp|P06801|MAOX_MOUSE -2.51 5.68 0.87 5.22E-02 
960 sp|Q8BJ64|CHDH_MOUSE -2.51 5.69 0.88 1.32E-03 
961 sp|Q9DBX3|SUSD2_MOUSE -2.52 5.75 0.93 5.04E-05 
962 sp|Q60597|ODO1_MOUSE -2.53 5.76 0.89 3.72E-07 
963 sp|Q8C3K6|SC5A1_MOUSE -2.53 5.77 0.57 1.68E-04 
964 sp|O88441|MTX2_MOUSE -2.53 5.78 0.74 1.15E-02 
965 sp|Q8VEM8|MPCP_MOUSE -2.53 5.78 0.94 5.33E-09 
966 sp|P50544|ACADV_MOUSE -2.53 5.79 0.85 1.62E-08 
967 sp|P99029|PRDX5_MOUSE -2.54 5.81 0.91 1.22E-04 
968 sp|Q8BWM0|PGES2_MOUSE -2.55 5.84 0.81 1.53E-07 
969 sp|Q9CRB9|MIC19_MOUSE -2.55 5.85 0.86 4.49E-03 
970 sp|O35286|DHX15_MOUSE -2.55 5.86 0.55 8.97E-01 
971 sp|Q64433|CH10_MOUSE -2.55 5.86 0.90 3.49E-04 
972 sp|Q9DCJ5|NDUA8_MOUSE -2.55 5.86 0.89 2.22E-05 
973 sp|Q9JKF7|RM39_MOUSE -2.55 5.87 0.56 2.17E-03 
974 sp|Q8BJZ4|RT35_MOUSE -2.55 5.87 0.68 9.07E-06 
975 sp|Q8BVE3|VATH_MOUSE -2.56 5.88 0.91 3.57E-07 
976 sp|Q8BWN8|ACOT4_MOUSE -2.56 5.92 0.69 1.80E-02 
977 sp|P56392|CX7A1_MOUSE -2.57 5.92 0.88 2.21E-04 
978 sp|P50516|VATA_MOUSE -2.57 5.96 0.93 1.90E-04 
979 sp|P52825|CPT2_MOUSE -2.58 5.99 0.85 1.83E-04 
980 sp|Q9EPL9|ACOX3_MOUSE -2.59 6.00 0.82 1.31E-01 
981 sp|Q9CQN1|TRAP1_MOUSE -2.59 6.02 0.89 7.18E-05 
982 sp|P20108|PRDX3_MOUSE -2.59 6.04 0.89 1.08E-04 
983 sp|Q9WTP6|KAD2_MOUSE -2.60 6.06 0.89 8.18E-05 
984 sp|P99028|QCR6_MOUSE -2.60 6.06 0.93 3.31E-05 
985 sp|P51855|GSHB_MOUSE -2.60 6.07 0.89 1.30E-04 
986 sp|Q9D051|ODPB_MOUSE -2.60 6.07 0.97 3.19E-05 
987 sp|Q91WT8|RBM47_MOUSE -2.61 6.09 0.63 3.25E-04 
988 sp|Q9CPQ1|COX6C_MOUSE -2.61 6.11 0.89 2.20E-09 
989 sp|Q9CR51|VATG1_MOUSE -2.61 6.13 0.78 1.61E-04 
990 sp|Q9WUZ9|ENTP5_MOUSE -2.62 6.15 0.80 3.48E-03 
991 sp|O08966|S22A1_MOUSE -2.62 6.17 0.79 4.04E-03 
992 sp|Q9D020|5NT3A_MOUSE -2.63 6.18 0.57 6.27E-01 
993 sp|Q91WK5|GCSH_MOUSE -2.63 6.19 0.71 5.39E-04 
994 sp|Q8K3J1|NDUS8_MOUSE -2.63 6.20 0.86 2.19E-04 
995 sp|Q9CXV1|DHSD_MOUSE -2.64 6.22 0.59 4.61E-05 
996 sp|Q922Q1|MARC2_MOUSE -2.64 6.22 0.91 2.55E-06 
997 sp|Q3UP75|UD3A1_MOUSE -2.64 6.24 0.84 4.17E-05 
998 sp|Q9CQZ6|NDUB3_MOUSE -2.64 6.24 0.77 9.57E-05 
999 sp|Q8BMF4|ODP2_MOUSE -2.65 6.28 0.94 3.65E-06 
1000 sp|P03911|NU4M_MOUSE -2.65 6.28 0.88 4.36E-06 
1001 sp|Q91YI0|ARLY_MOUSE -2.65 6.28 0.92 7.97E-07 
1002 sp|Q07417|ACADS_MOUSE -2.65 6.28 0.89 3.08E-03 
1003 sp|Q8CAQ8|MIC60_MOUSE -2.66 6.32 0.93 3.25E-08 
1004 sp|P28656|NP1L1_MOUSE -2.67 6.35 0.61 2.91E-01 
1005 sp|P03921|NU5M_MOUSE -2.67 6.35 0.86 3.70E-05 
1006 sp|Q9JLF6|TGM1_MOUSE -2.67 6.36 0.56 5.48E-04 
1007 sp|P30115|GSTA3_MOUSE -2.67 6.36 0.71 1.86E-03 
1008 sp|Q9D6J5|NDUB8_MOUSE -2.67 6.38 0.79 5.01E-04 
1009 sp|Q9JLT4|TRXR2_MOUSE -2.68 6.39 0.71 3.56E-03 
1010 sp|P05202|AATM_MOUSE -2.68 6.39 0.97 1.67E-04 
1011 sp|Q9D172|ES1_MOUSE -2.68 6.41 0.91 4.72E-05 
1012 sp|Q9DBL7|COASY_MOUSE -2.68 6.41 0.77 1.37E-02 
1013 sp|Q9ERS2|NDUAD_MOUSE -2.68 6.42 0.94 1.40E-07 
1014 sp|P03930|ATP8_MOUSE -2.68 6.43 0.81 3.91E-06 
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1015 sp|O55060|TPMT_MOUSE -2.69 6.43 0.93 3.65E-04 
1016 sp|Q9DCT2|NDUS3_MOUSE -2.70 6.51 0.94 3.46E-05 
1017 sp|Q9DCM0|ETHE1_MOUSE -2.70 6.52 0.93 8.66E-04 
1018 sp|P47802|MTX1_MOUSE -2.71 6.53 0.66 7.69E-05 
1019 sp|Q9DBE0|CSAD_MOUSE -2.71 6.56 0.91 6.18E-03 
1020 sp|P97494|GSH1_MOUSE -2.72 6.57 0.85 1.31E-06 
1021 sp|Q8BWF0|SSDH_MOUSE -2.72 6.57 0.71 7.86E-02 
1022 sp|P17665|COX7C_MOUSE -2.72 6.57 0.80 2.37E-04 
1023 sp|Q8R404|MIC13_MOUSE -2.72 6.57 0.92 1.30E-04 
1024 sp|Q91YP0|L2HDH_MOUSE -2.72 6.58 0.69 5.33E-03 
1025 sp|P50285|FMO1_MOUSE -2.73 6.63 0.78 1.30E-02 
1026 sp|O09111|NDUBB_MOUSE -2.74 6.67 0.93 5.21E-07 
1027 sp|Q9CZ13|QCR1_MOUSE -2.74 6.69 0.93 2.59E-05 
1028 sp|Q9CPU4|MGST3_MOUSE -2.74 6.70 0.76 1.62E-03 
1029 sp|P35486|ODPA_MOUSE -2.74 6.70 0.93 5.32E-06 
1030 sp|Q9DCX2|ATP5H_MOUSE -2.75 6.70 0.94 2.27E-05 
1031 sp|Q9CPP6|NDUA5_MOUSE -2.75 6.71 0.89 5.20E-04 
1032 sp|Q9D2G2|ODO2_MOUSE -2.75 6.71 0.91 3.59E-05 
1033 sp|Q9CXZ1|NDUS4_MOUSE -2.75 6.72 0.85 4.45E-07 
1034 sp|P32020|NLTP_MOUSE -2.75 6.73 0.91 5.64E-02 
1035 sp|P17426|AP2A1_MOUSE -2.75 6.75 0.65 6.59E-04 
1036 sp|P11404|FABPH_MOUSE -2.76 6.78 0.84 3.46E-06 
1037 sp|Q9QYR9|ACOT2_MOUSE -2.76 6.79 0.80 1.89E-03 
1038 sp|Q8VC69|S22A6_MOUSE -2.76 6.79 0.77 6.60E-02 
1039 sp|P70414|NAC1_MOUSE -2.77 6.80 0.59 7.11E-05 
1040 sp|O35409|FOLH1_MOUSE -2.77 6.81 0.80 1.46E-02 
1041 sp|P97807|FUMH_MOUSE -2.77 6.82 0.89 7.21E-08 
1042 sp|Q9DB20|ATPO_MOUSE -2.77 6.83 0.96 3.32E-05 
1043 sp|Q60866|PTER_MOUSE -2.78 6.85 0.94 2.33E-07 
1044 sp|Q9DC69|NDUA9_MOUSE -2.78 6.86 0.91 1.06E-05 
1045 sp|Q8BKZ9|ODPX_MOUSE -2.78 6.87 0.51 6.01E-04 
1046 sp|Q925N2|SFXN2_MOUSE -2.79 6.90 0.82 7.15E-05 
1047 sp|Q5M8N4|D39U1_MOUSE -2.79 6.91 0.69 9.10E-04 
1048 sp|Q78IK2|USMG5_MOUSE -2.79 6.93 0.97 4.94E-06 
1049 sp|Q9CWS0|DDAH1_MOUSE -2.79 6.93 0.78 4.63E-07 
1050 sp|Q9D6J6|NDUV2_MOUSE -2.79 6.94 0.79 5.41E-07 
1051 sp|Q922D8|C1TC_MOUSE -2.80 6.96 0.79 1.85E-05 
1052 sp|Q9Z1P6|NDUA7_MOUSE -2.80 6.97 0.87 6.83E-08 
1053 sp|Q9CYW4|HDHD3_MOUSE -2.80 6.97 0.61 1.08E-03 
1054 sp|P08249|MDHM_MOUSE -2.80 6.97 0.94 2.18E-05 
1055 sp|Q9CQJ8|NDUB9_MOUSE -2.81 7.01 0.84 2.95E-04 
1056 sp|Q03265|ATPA_MOUSE -2.81 7.02 0.96 2.09E-05 
1057 sp|Q9CQQ7|AT5F1_MOUSE -2.81 7.03 0.92 5.57E-07 
1058 sp|Q6ZQM8|UD17C_MOUSE -2.81 7.03 0.76 7.48E-01 
1059 sp|Q9R0M5|TPK1_MOUSE -2.81 7.03 0.72 6.12E-03 
1060 sp|Q8VCH0|THIKB_MOUSE -2.82 7.04 0.63 7.68E-04 
1061 sp|Q06185|ATP5I_MOUSE -2.82 7.06 0.86 2.20E-06 
1062 sp|P03899|NU3M_MOUSE -2.82 7.06 0.95 8.49E-04 
1063 sp|P63038|CH60_MOUSE -2.82 7.07 0.96 6.86E-04 
1064 sp|Q9Z2I9|SUCB1_MOUSE -2.82 7.07 0.93 1.72E-06 
1065 sp|Q99LB2|DHRS4_MOUSE -2.82 7.08 0.95 4.94E-02 
1066 sp|Q9JLJ2|AL9A1_MOUSE -2.83 7.09 0.92 1.06E-03 
1067 sp|Q3V0K9|PLSI_MOUSE -2.83 7.09 0.79 4.17E-04 
1068 sp|O08749|DLDH_MOUSE -2.83 7.11 0.93 8.43E-07 
1069 sp|Q9CQH3|NDUB5_MOUSE -2.84 7.15 0.79 4.95E-05 
1070 sp|P00405|COX2_MOUSE -2.84 7.15 0.86 4.27E-05 
1071 sp|Q9DBF1|AL7A1_MOUSE -2.84 7.15 0.87 3.10E-08 
1072 sp|Q91WD5|NDUS2_MOUSE -2.84 7.15 0.86 1.28E-05 
1073 sp|Q91Z53|GRHPR_MOUSE -2.84 7.17 0.77 7.36E-04 
1074 sp|Q9D7B6|ACAD8_MOUSE -2.84 7.17 0.78 9.18E-04 
1075 sp|P17563|SBP1_MOUSE -2.84 7.18 0.89 1.15E-03 
1076 sp|P51881|ADT2_MOUSE -2.84 7.18 0.88 6.34E-05 
1077 sp|P56480|ATPB_MOUSE -2.85 7.19 0.96 2.89E-05 
1078 sp|Q99JR1|SFXN1_MOUSE -2.85 7.20 0.86 3.54E-04 
1079 sp|Q9WV92|E41L3_MOUSE -2.86 7.24 0.67 9.04E-02 
1080 sp|Q9D855|QCR7_MOUSE -2.86 7.28 0.88 4.79E-06 
1081 sp|P68368|TBA4A_MOUSE -2.86 7.28 0.81 1.88E-04 
1082 sp|P97450|ATP5J_MOUSE -2.87 7.30 0.93 5.85E-05 
1083 sp|P48758|CBR1_MOUSE -2.87 7.30 0.94 6.51E-02 
1084 sp|Q9WV69|DEMA_MOUSE -2.87 7.31 0.75 1.48E-06 
1085 sp|Q920R6|VPP4_MOUSE -2.87 7.31 0.76 4.93E-05 
1086 sp|Q8R1G2|CMBL_MOUSE -2.87 7.32 0.80 1.69E-03 
1087 sp|P56391|CX6B1_MOUSE -2.87 7.32 0.88 1.74E-04 
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1088 sp|Q99LC3|NDUAA_MOUSE -2.87 7.33 0.90 2.03E-08 
1089 sp|Q9Z0S1|BPNT1_MOUSE -2.88 7.34 0.81 1.82E-05 
1090 sp|Q8BLF1|NCEH1_MOUSE -2.88 7.34 0.94 3.98E-03 
1091 sp|P60603|ROMO1_MOUSE -2.88 7.34 0.69 4.01E-06 
1092 sp|P56135|ATPK_MOUSE -2.88 7.34 0.83 3.96E-03 
1093 sp|O35855|BCAT2_MOUSE -2.88 7.36 0.89 1.16E-03 
1094 sp|Q71RI9|KAT3_MOUSE -2.88 7.36 0.82 1.07E-03 
1095 sp|P19783|COX41_MOUSE -2.88 7.37 0.93 1.81E-06 
1096 sp|P52503|NDUS6_MOUSE -2.89 7.39 0.82 8.62E-04 
1097 sp|Q62425|NDUA4_MOUSE -2.89 7.39 0.88 1.74E-04 
1098 sp|Q91VM9|IPYR2_MOUSE -2.90 7.47 0.90 6.01E-06 
1099 sp|P42925|PXMP2_MOUSE -2.90 7.48 0.55 4.26E-05 
1100 sp|Q9DC70|NDUS7_MOUSE -2.91 7.49 0.85 1.53E-05 
1101 sp|P62897|CYC_MOUSE -2.92 7.56 0.90 3.89E-04 
1102 sp|Q61767|3BHS4_MOUSE -2.92 7.58 0.81 1.15E-02 
1103 sp|Q91X91|NADC_MOUSE -2.92 7.59 0.65 3.17E-04 
1104 sp|O55125|NIPS1_MOUSE -2.93 7.62 0.90 2.14E-04 
1105 sp|Q9CZB0|C560_MOUSE -2.93 7.63 0.92 9.95E-05 
1106 sp|P56379|68MP_MOUSE -2.93 7.63 0.71 5.96E-05 
1107 sp|Q9CQX8|RT36_MOUSE -2.93 7.64 0.91 8.38E-06 
1108 sp|Q99KP3|CRYL1_MOUSE -2.93 7.64 0.89 4.23E-07 
1109 sp|Q91VR2|ATPG_MOUSE -2.94 7.65 0.92 5.23E-06 
1110 sp|Q91Y63|S13A3_MOUSE -2.94 7.65 0.84 7.64E-03 
1111 sp|Q9QXX4|CMC2_MOUSE -2.94 7.66 0.89 8.52E-06 
1112 sp|Q9CPQ8|ATP5L_MOUSE -2.94 7.67 0.71 1.52E-02 
1113 sp|Q9D3D9|ATPD_MOUSE -2.94 7.68 0.95 1.27E-04 
1114 sp|Q9D0M3|CY1_MOUSE -2.95 7.72 0.93 4.77E-05 
1115 sp|Q9QZD8|DIC_MOUSE -2.95 7.73 0.91 2.60E-03 
1116 sp|Q91VD9|NDUS1_MOUSE -2.95 7.74 0.90 1.02E-04 
1117 sp|P55096|ABCD3_MOUSE -2.95 7.75 0.90 2.14E-02 
1118 sp|Q9CQ75|NDUA2_MOUSE -2.96 7.78 0.83 1.80E-04 
1119 sp|Q61391|NEP_MOUSE -2.96 7.78 0.89 1.25E-02 
1120 sp|O35972|RM23_MOUSE -2.96 7.79 0.81 1.63E-04 
1121 sp|Q8K2B3|SDHA_MOUSE -2.96 7.80 0.97 9.18E-05 
1122 sp|Q99MR8|MCCA_MOUSE -2.97 7.81 0.82 1.09E-04 
1123 sp|Q7TNG8|LDHD_MOUSE -2.97 7.83 0.88 9.56E-02 
1124 sp|Q9D8I3|GLOD5_MOUSE -2.97 7.84 0.52 1.25E-02 
1125 sp|Q9DC50|OCTC_MOUSE -2.97 7.84 0.82 2.17E-01 
1126 sp|O88986|KBL_MOUSE -2.98 7.91 0.61 6.56E-02 
1127 sp|Q6DYE8|ENPP3_MOUSE -2.99 7.92 0.81 5.76E-03 
1128 sp|P56389|CDD_MOUSE -2.99 7.93 0.80 5.78E-02 
1129 sp|Q8BH95|ECHM_MOUSE -2.99 7.96 0.90 4.31E-05 
1130 sp|Q9Z0X1|AIFM1_MOUSE -2.99 7.96 0.92 5.94E-06 
1131 sp|Q9WUR2|ECI2_MOUSE -2.99 7.96 0.85 1.11E-02 
1132 sp|P56382|ATP5E_MOUSE -3.00 7.98 0.74 6.69E-04 
1133 sp|Q8VDT1|SC5A9_MOUSE -3.00 7.99 0.64 2.27E-01 
1134 sp|Q9CQA3|SDHB_MOUSE -3.00 8.00 0.83 7.55E-09 
1135 sp|Q9CQC7|NDUB4_MOUSE -3.01 8.03 0.83 2.86E-05 
1136 sp|Q9DD20|MET7B_MOUSE -3.01 8.04 0.65 6.36E-03 
1137 sp|Q8QZW3|F151A_MOUSE -3.01 8.04 0.76 1.21E-05 
1138 sp|Q9CR61|NDUB7_MOUSE -3.01 8.05 0.90 3.70E-04 
1139 sp|Q8K023|AKC1H_MOUSE -3.01 8.07 0.87 4.03E-04 
1140 sp|Q8C165|P20D1_MOUSE -3.02 8.10 0.77 1.71E-03 
1141 sp|P12787|COX5A_MOUSE -3.02 8.11 0.93 1.26E-04 
1142 sp|A2ARV4|LRP2_MOUSE -3.03 8.16 0.83 7.94E-04 
1143 sp|Q9DB77|QCR2_MOUSE -3.03 8.19 0.97 3.61E-09 
1144 sp|O70250|PGAM2_MOUSE -3.03 8.19 0.82 1.59E-03 
1145 sp|P70404|IDHG1_MOUSE -3.04 8.20 0.89 6.31E-05 
1146 sp|P11862|GAS2_MOUSE -3.04 8.24 0.60 2.51E-01 
1147 sp|Q9D9V3|ECHD1_MOUSE -3.04 8.24 0.86 6.69E-07 
1148 sp|P59158|S12A3_MOUSE -3.04 8.24 0.78 5.12E-03 
1149 sp|Q61847|MEP1B_MOUSE -3.05 8.27 0.80 8.60E-05 
1150 sp|Q02013|AQP1_MOUSE -3.05 8.29 0.88 1.47E-03 
1151 sp|P61458|PHS_MOUSE -3.05 8.31 0.82 2.08E-06 
1152 sp|Q91ZA3|PCCA_MOUSE -3.06 8.33 0.91 1.36E-04 
1153 sp|A2AJL3|FGGY_MOUSE -3.06 8.34 0.54 1.42E-04 
1154 sp|Q62433|NDRG1_MOUSE -3.06 8.36 0.98 9.87E-05 
1155 sp|Q8CI85|CAH12_MOUSE -3.07 8.37 0.62 4.99E-04 
1156 sp|Q9DBK0|ACO12_MOUSE -3.07 8.38 0.61 1.36E-01 
1157 sp|P48771|CX7A2_MOUSE -3.07 8.39 0.84 9.42E-04 
1158 sp|Q9DCS9|NDUBA_MOUSE -3.07 8.40 0.86 1.06E-04 
1159 sp|P47199|QOR_MOUSE -3.07 8.40 0.93 2.24E-04 
1160 sp|Q9CR21|ACPM_MOUSE -3.07 8.43 0.92 1.41E-04 
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1161 sp|P49429|HPPD_MOUSE -3.07 8.43 0.79 3.73E-03 
1162 sp|Q9JLB4|CUBN_MOUSE -3.08 8.45 0.74 8.02E-04 
1163 sp|Q9WVD5|ORNT1_MOUSE -3.09 8.51 0.79 5.66E-06 
1164 sp|Q9JMD3|PCTL_MOUSE -3.10 8.56 0.68 5.85E-07 
1165 sp|P54071|IDHP_MOUSE -3.10 8.56 0.93 1.41E-04 
1166 sp|Q8CC88|VWA8_MOUSE -3.10 8.58 0.80 1.77E-02 
1167 sp|Q8CG76|ARK72_MOUSE -3.10 8.60 0.85 3.84E-05 
1168 sp|P18894|OXDA_MOUSE -3.11 8.60 0.78 6.29E-04 
1169 sp|Q8BK30|NDUV3_MOUSE -3.11 8.61 0.54 4.50E-05 
1170 sp|O54749|CP2J5_MOUSE -3.11 8.61 0.58 3.19E-03 
1171 sp|Q8R0Y6|AL1L1_MOUSE -3.11 8.63 0.92 6.60E-06 
1172 sp|Q9CQ69|QCR8_MOUSE -3.11 8.65 0.92 1.50E-02 
1173 sp|Q9CR68|UCRI_MOUSE -3.13 8.74 0.84 2.41E-06 
1174 sp|P35802|GPM6A_MOUSE -3.13 8.74 0.65 5.76E-05 
1175 sp|Q8VIM4|BSND_MOUSE -3.13 8.77 0.75 7.61E-02 
1176 sp|Q8R1I1|QCR9_MOUSE -3.13 8.77 0.68 8.33E-04 
1177 sp|Q9DCW4|ETFB_MOUSE -3.13 8.78 0.92 5.83E-05 
1178 sp|P62077|TIM8B_MOUSE -3.14 8.79 0.71 4.50E-05 
1179 sp|Q80XL6|ACD11_MOUSE -3.14 8.83 0.77 1.26E-02 
1180 sp|Q9WVL0|MAAI_MOUSE -3.14 8.83 0.82 1.08E-05 
1181 sp|P15105|GLNA_MOUSE -3.14 8.84 0.83 9.22E-02 
1182 sp|P70441|NHRF1_MOUSE -3.14 8.85 0.91 9.72E-05 
1183 sp|Q9D0K2|SCOT1_MOUSE -3.15 8.85 0.91 2.78E-04 
1184 sp|Q9JI75|NQO2_MOUSE -3.15 8.86 0.55 6.12E-02 
1185 sp|Q64FW2|RETST_MOUSE -3.15 8.86 0.58 9.52E-06 
1186 sp|Q99KI0|ACON_MOUSE -3.15 8.88 0.88 3.72E-06 
1187 sp|Q8R519|ACMSD_MOUSE -3.15 8.90 0.70 5.11E-04 
1188 sp|P55014|S12A1_MOUSE -3.15 8.90 0.85 2.08E-05 
1189 sp|P00397|COX1_MOUSE -3.16 8.92 0.73 9.49E-03 
1190 sp|P09242|PPBT_MOUSE -3.16 8.93 0.70 8.50E-05 
1191 sp|Q8K370|ACD10_MOUSE -3.16 8.94 0.89 2.66E-06 
1192 sp|Q9D6Y7|MSRA_MOUSE -3.16 8.95 0.89 1.56E-05 
1193 sp|Q3TNA1|XYLB_MOUSE -3.16 8.96 0.72 5.17E-02 
1194 sp|O88428|PAPS2_MOUSE -3.16 8.97 0.77 1.50E-03 
1195 sp|Q91WR5|AK1CL_MOUSE -3.16 8.97 0.84 1.45E-01 
1196 sp|Q8R0N6|HOT_MOUSE -3.17 8.97 0.83 1.64E-01 
1197 sp|Q9WUM5|SUCA_MOUSE -3.17 9.00 0.93 2.05E-04 
1198 sp|Q8K1Z0|COQ9_MOUSE -3.17 9.02 0.81 2.51E-04 
1199 sp|Q61425|HCDH_MOUSE -3.18 9.04 0.89 5.29E-04 
1200 sp|P19536|COX5B_MOUSE -3.18 9.07 0.90 2.25E-04 
1201 sp|P16332|MUTA_MOUSE -3.18 9.08 0.83 1.77E-07 
1202 sp|P09671|SODM_MOUSE -3.18 9.08 0.88 1.31E-06 
1203 sp|Q8BWT1|THIM_MOUSE -3.18 9.09 0.88 2.59E-04 
1204 sp|Q91WG0|EST2C_MOUSE -3.20 9.16 0.57 2.05E-01 
1205 sp|Q59J78|MIMIT_MOUSE -3.20 9.17 0.66 1.77E-03 
1206 sp|O09174|AMACR_MOUSE -3.20 9.21 0.65 2.15E-01 
1207 sp|Q3UIU2|NDUB6_MOUSE -3.21 9.22 0.80 3.92E-07 
1208 sp|P09470|ACE_MOUSE -3.21 9.27 0.79 3.90E-03 
1209 sp|P38060|HMGCL_MOUSE -3.22 9.29 0.89 4.90E-06 
1210 sp|Q9ESG4|TMM27_MOUSE -3.22 9.30 0.85 1.67E-04 
1211 sp|Q9CQ54|NDUC2_MOUSE -3.22 9.30 0.84 6.09E-05 
1212 sp|Q8JZN7|MIRO2_MOUSE -3.23 9.35 0.87 6.91E-02 
1213 sp|P97478|COQ7_MOUSE -3.23 9.37 0.65 9.76E-01 
1214 sp|Q9JII6|AK1A1_MOUSE -3.23 9.38 0.92 3.89E-04 
1215 sp|Q8BH86|CN159_MOUSE -3.23 9.39 0.77 2.25E-03 
1216 sp|Q91VN4|MIC25_MOUSE -3.23 9.40 0.61 1.78E-03 
1217 sp|Q8QZT1|THIL_MOUSE -3.24 9.43 0.96 2.06E-02 
1218 sp|P52760|UK114_MOUSE -3.25 9.50 0.90 1.16E-03 
1219 sp|P24270|CATA_MOUSE -3.25 9.51 0.94 3.86E-02 
1220 sp|O35943|FRDA_MOUSE -3.25 9.53 0.66 3.23E-04 
1221 sp|Q99L13|3HIDH_MOUSE -3.26 9.57 0.93 2.16E-04 
1222 sp|Q7TNE1|SUCHY_MOUSE -3.26 9.59 0.85 6.59E-03 
1223 sp|P52196|THTR_MOUSE -3.26 9.59 0.89 8.09E-05 
1224 sp|Q8VC12|HUTU_MOUSE -3.26 9.60 0.58 1.54E-01 
1225 sp|Q9JLZ3|AUHM_MOUSE -3.27 9.63 0.89 2.02E-04 
1226 sp|Q9QXN5|MIOX_MOUSE -3.27 9.64 0.76 1.91E-04 
1227 sp|Q99LC5|ETFA_MOUSE -3.27 9.66 0.92 1.62E-05 
1228 sp|Q9JIL4|NHRF3_MOUSE -3.27 9.66 0.90 7.00E-07 
1229 sp|Q91YT0|NDUV1_MOUSE -3.29 9.81 0.92 2.47E-05 
1230 sp|Q80W22|THNS2_MOUSE -3.30 9.82 0.82 8.56E-07 
1231 sp|Q3UEG6|AGT2_MOUSE -3.30 9.85 0.78 2.69E-05 
1232 sp|P63030|MPC1_MOUSE -3.31 9.89 0.80 1.45E-05 
1233 sp|Q60825|NPT2A_MOUSE -3.31 9.93 0.59 1.88E-05 
SUPPLEMENTARY DATA 
 
435 
 
1234 sp|Q8C025|CHPT1_MOUSE -3.31 9.94 0.67 1.88E-03 
1235 sp|Q9JHI5|IVD_MOUSE -3.33 10.09 0.86 3.82E-04 
1236 sp|Q99KR3|LACB2_MOUSE -3.34 10.12 0.76 1.69E-02 
1237 sp|Q9CQ91|NDUA3_MOUSE -3.34 10.14 0.84 1.85E-05 
1238 sp|P41216|ACSL1_MOUSE -3.35 10.18 0.86 4.03E-03 
1239 sp|O88909|S22A8_MOUSE -3.35 10.19 0.80 1.36E-02 
1240 sp|Q9DCC7|ISC2B_MOUSE -3.35 10.22 0.72 5.81E-04 
1241 sp|Q3ULD5|MCCB_MOUSE -3.36 10.25 0.86 4.58E-06 
1242 sp|Q8BGD8|COA6_MOUSE -3.36 10.29 0.81 1.16E-01 
1243 sp|Q8BYF6|SC5A8_MOUSE -3.36 10.30 0.77 3.68E-03 
1244 sp|Q99JW2|ACY1_MOUSE -3.37 10.32 0.79 1.89E-03 
1245 sp|Q9DBT9|M2GD_MOUSE -3.37 10.33 0.83 5.64E-06 
1246 sp|Q91WS0|CISD1_MOUSE -3.37 10.36 0.94 5.52E-06 
1247 sp|Q8R4N0|CLYBL_MOUSE -3.38 10.40 0.83 4.10E-07 
1248 sp|O70577|S22A2_MOUSE -3.38 10.42 0.76 4.11E-03 
1249 sp|Q9Z2I8|SUCB2_MOUSE -3.39 10.47 0.92 6.43E-08 
1250 sp|Q91YD6|VILL_MOUSE -3.39 10.48 0.70 3.73E-01 
1251 sp|Q9DCZ4|MIC26_MOUSE -3.40 10.56 0.66 1.19E-03 
1252 sp|P00416|COX3_MOUSE -3.40 10.56 0.91 1.48E-02 
1253 sp|Q8R0Y8|S2542_MOUSE -3.40 10.58 0.71 1.62E-03 
1254 sp|Q60936|ADCK3_MOUSE -3.42 10.68 0.79 2.42E-04 
1255 sp|Q8VBW8|TTC36_MOUSE -3.42 10.69 0.77 6.20E-04 
1256 sp|P28825|MEP1A_MOUSE -3.43 10.75 0.89 5.03E-04 
1257 sp|Q9D0S9|HINT2_MOUSE -3.43 10.77 0.94 8.43E-03 
1258 sp|P35576|G6PC_MOUSE -3.43 10.79 0.83 6.92E-06 
1259 sp|Q9ERT9|PPR1A_MOUSE -3.44 10.83 0.88 1.95E-03 
1260 sp|P11930|NUD19_MOUSE -3.44 10.83 0.87 7.70E-02 
1261 sp|Q91V76|CK054_MOUSE -3.44 10.86 0.81 1.54E-07 
1262 sp|Q9D826|SOX_MOUSE -3.45 10.94 0.84 5.51E-02 
1263 sp|Q9Z2J0|S23A1_MOUSE -3.45 10.96 0.83 1.06E-02 
1264 sp|Q9D8B4|NDUAB_MOUSE -3.45 10.96 0.65 1.05E-01 
1265 sp|Q9QXD1|ACOX2_MOUSE -3.46 11.03 0.78 3.51E-04 
1266 sp|Q91VA0|ACSM1_MOUSE -3.47 11.05 0.89 1.31E-03 
1267 sp|P40936|INMT_MOUSE -3.47 11.06 0.85 6.12E-02 
1268 sp|Q923I7|SC5A2_MOUSE -3.47 11.10 0.81 4.52E-06 
1269 sp|Q8JZZ0|UD3A2_MOUSE -3.47 11.11 0.81 1.33E-02 
1270 sp|Q8K4F5|ABHDB_MOUSE -3.48 11.13 0.75 5.47E-03 
1271 sp|Q60759|GCDH_MOUSE -3.48 11.14 0.78 5.05E-07 
1272 sp|Q9D7X8|GGCT_MOUSE -3.48 11.16 0.79 1.11E-01 
1273 sp|Q8JZV9|BDH2_MOUSE -3.48 11.18 0.80 1.83E-04 
1274 sp|Q8R3P0|ACY2_MOUSE -3.49 11.20 0.78 3.56E-06 
1275 sp|Q9DCM2|GSTK1_MOUSE -3.49 11.23 0.85 2.47E-05 
1276 sp|Q9JIZ0|CMLO1_MOUSE -3.49 11.24 0.73 1.57E-03 
1277 sp|Q9WU79|PROD_MOUSE -3.49 11.25 0.80 2.03E-04 
1278 sp|Q8VCT4|CES1D_MOUSE -3.50 11.28 0.87 1.48E-06 
1279 sp|Q6P3A8|ODBB_MOUSE -3.50 11.28 0.81 3.58E-04 
1280 sp|Q8VCN5|CGL_MOUSE -3.50 11.29 0.83 2.45E-03 
1281 sp|Q9D023|MPC2_MOUSE -3.50 11.30 0.90 3.38E-05 
1282 sp|Q99NB1|ACS2L_MOUSE -3.50 11.31 0.83 2.51E-03 
1283 sp|Q91WN4|KMO_MOUSE -3.51 11.42 0.78 5.67E-05 
1284 sp|Q91XE4|ACY3_MOUSE -3.53 11.54 0.77 8.55E-02 
1285 sp|Q9WVM8|AADAT_MOUSE -3.54 11.59 0.80 1.14E-02 
1286 sp|Q99J27|ACATN_MOUSE -3.54 11.64 0.72 1.01E-04 
1287 sp|Q99K67|AASS_MOUSE -3.54 11.66 0.78 3.66E-04 
1288 sp|Q7TMS5|ABCG2_MOUSE -3.55 11.70 0.86 2.66E-04 
1289 sp|Q8VDN2|AT1A1_MOUSE -3.55 11.72 0.95 5.57E-04 
1290 sp|Q9DCX8|IYD1_MOUSE -3.55 11.72 0.86 5.50E-05 
1291 sp|Q99MN9|PCCB_MOUSE -3.55 11.73 0.90 1.84E-05 
1292 sp|Q62468|VILI_MOUSE -3.55 11.73 0.88 2.97E-09 
1293 sp|Q8CFZ5|S22AC_MOUSE -3.55 11.74 0.83 2.55E-04 
1294 sp|P97816|S100G_MOUSE -3.56 11.78 0.87 1.93E-03 
1295 sp|Q8CHT0|AL4A1_MOUSE -3.56 11.79 0.91 4.83E-05 
1296 sp|P10648|GSTA2_MOUSE -3.57 11.91 0.73 2.75E-02 
1297 sp|Q9CQR4|ACO13_MOUSE -3.60 12.10 0.88 5.84E-07 
1298 sp|A2AKK5|ACNT1_MOUSE -3.60 12.12 0.75 7.84E-02 
1299 sp|P85094|ISC2A_MOUSE -3.60 12.14 0.81 3.08E-03 
1300 sp|Q8R0F8|FAHD1_MOUSE -3.61 12.20 0.84 1.71E-03 
1301 sp|Q8BH00|AL8A1_MOUSE -3.61 12.21 0.89 5.29E-06 
1302 sp|P53395|ODB2_MOUSE -3.62 12.29 0.80 3.62E-07 
1303 sp|P61922|GABT_MOUSE -3.62 12.32 0.93 9.44E-04 
1304 sp|Q8QZS1|HIBCH_MOUSE -3.63 12.41 0.77 2.84E-04 
1305 sp|Q99LB7|SARDH_MOUSE -3.65 12.57 0.87 1.05E-04 
1306 sp|Q3UFF7|LYPL1_MOUSE -3.65 12.57 0.61 6.36E-02 
SUPPLEMENTARY DATA 
 
436 
 
1307 sp|Q8R2N1|AQP3_MOUSE -3.66 12.64 0.85 8.99E-05 
1308 sp|P14246|GTR2_MOUSE -3.66 12.65 0.59 2.88E-01 
1309 sp|Q3TLP5|ECHD2_MOUSE -3.68 12.79 0.88 3.17E-03 
1310 sp|O09173|HGD_MOUSE -3.70 13.01 0.76 2.36E-07 
1311 sp|Q99MZ7|PECR_MOUSE -3.71 13.10 0.92 2.98E-02 
1312 sp|Q60928|GGT1_MOUSE -3.74 13.34 0.86 1.52E-03 
1313 sp|Q9DBM2|ECHP_MOUSE -3.74 13.34 0.88 1.50E-02 
1314 sp|O35488|S27A2_MOUSE -3.76 13.57 0.84 2.47E-03 
1315 sp|P13707|GPDA_MOUSE -3.77 13.65 0.84 6.88E-05 
1316 sp|P35505|FAAA_MOUSE -3.79 13.80 0.90 6.23E-05 
1317 sp|Q64442|DHSO_MOUSE -3.80 13.96 0.85 2.78E-05 
1318 sp|Q80XN0|BDH_MOUSE -3.82 14.12 0.92 2.19E-05 
1319 sp|Q3TC72|FAHD2_MOUSE -3.83 14.19 0.81 6.59E-03 
1320 sp|Q8R164|BPHL_MOUSE -3.83 14.21 0.85 1.68E-04 
1321 sp|P97328|KHK_MOUSE -3.85 14.41 0.84 3.50E-05 
1322 sp|Q9R0H0|ACOX1_MOUSE -3.86 14.52 0.88 1.92E-01 
1323 sp|O88533|DDC_MOUSE -3.87 14.63 0.69 1.96E-02 
1324 sp|Q5SWY8|SC5AA_MOUSE -3.88 14.72 0.79 8.84E-04 
1325 sp|Q3UNZ8|QORL2_MOUSE -3.90 14.96 0.83 4.57E-05 
1326 sp|Q64516|GLPK_MOUSE -3.91 14.98 0.85 4.19E-05 
1327 sp|Q99J94|SO1A6_MOUSE -3.91 15.03 0.65 1.92E-03 
1328 sp|P62071|RRAS2_MOUSE -3.92 15.16 0.53 3.82E-01 
1329 sp|Q9DCG6|PBLD1_MOUSE -3.95 15.43 0.81 3.67E-04 
1330 sp|Q91Y97|ALDOB_MOUSE -3.95 15.47 0.93 1.32E-05 
1331 sp|Q3UZZ6|ST1D1_MOUSE -3.96 15.51 0.84 7.67E-06 
1332 sp|Q05920|PYC_MOUSE -3.97 15.62 0.84 2.15E-03 
1333 sp|Q04646|ATNG_MOUSE -3.97 15.63 0.89 2.75E-04 
1334 sp|Q9DCY0|KEG1_MOUSE -3.97 15.67 0.88 7.32E-02 
1335 sp|Q9EQ20|MMSA_MOUSE -3.98 15.74 0.89 1.00E-04 
1336 sp|O88338|CAD16_MOUSE -4.00 15.95 0.89 2.33E-04 
1337 sp|P45952|ACADM_MOUSE -4.02 16.23 0.87 2.07E-08 
1338 sp|P70691|UD12_MOUSE -4.04 16.44 0.72 8.34E-03 
1339 sp|P14094|AT1B1_MOUSE -4.05 16.52 0.87 1.61E-03 
1340 sp|Q91XE0|GLYAT_MOUSE -4.05 16.55 0.86 8.85E-04 
1341 sp|Q2TPA8|HSDL2_MOUSE -4.09 17.04 0.61 4.47E-01 
1342 sp|G3X9C2|FBX50_MOUSE -4.09 17.04 0.84 3.61E-04 
1343 sp|Q9Z2V4|PCKGC_MOUSE -4.10 17.10 0.85 1.47E-03 
1344 sp|Q78KK3|S22AI_MOUSE -4.12 17.38 0.78 2.76E-02 
1345 sp|P47955|RLA1_MOUSE -4.12 17.40 0.52 1.60E-02 
1346 sp|Q5U5V2|HYKK_MOUSE -4.14 17.57 0.64 1.62E-02 
1347 sp|Q49B93|SC5AC_MOUSE -4.14 17.68 0.66 8.26E-01 
1348 sp|Q8VC30|DHAK_MOUSE -4.16 17.82 0.79 7.06E-03 
1349 sp|Q9NYQ2|HAOX2_MOUSE -4.18 18.08 0.88 6.44E-02 
1350 sp|Q9QXD6|F16P1_MOUSE -4.19 18.22 0.90 1.02E-04 
1351 sp|O88343|S4A4_MOUSE -4.19 18.31 0.78 9.32E-05 
1352 sp|P03893|NU2M_MOUSE -4.21 18.52 0.51 3.27E-01 
1353 sp|O88576|S6A18_MOUSE -4.21 18.57 0.63 4.04E-03 
1354 sp|Q9WUR9|KAD4_MOUSE -4.24 18.93 0.91 1.57E-05 
1355 sp|Q78JT3|3HAO_MOUSE -4.26 19.13 0.82 6.74E-04 
1356 sp|Q99PG0|AAAD_MOUSE -4.27 19.31 0.91 1.47E-07 
1357 sp|Q8K0L3|ACSM2_MOUSE -4.32 19.94 0.89 5.35E-02 
1358 sp|Q9D964|GATM_MOUSE -4.39 20.94 0.88 3.33E-03 
1359 sp|P12658|CALB1_MOUSE -4.40 21.18 0.92 3.61E-03 
1360 sp|P16460|ASSY_MOUSE -4.43 21.51 0.87 2.53E-04 
1361 sp|P43024|CX6A1_MOUSE -4.43 21.54 0.80 3.67E-04 
1362 sp|Q9D687|S6A19_MOUSE -4.48 22.26 0.61 5.64E-03 
1363 sp|P34914|HYES_MOUSE -4.65 25.06 0.84 1.81E-01 
1364 sp|Q9JKZ2|SC5A3_MOUSE -4.79 27.69 0.86 2.89E-03 
1365 sp|Q9CQH0|PDZ1I_MOUSE -6.50 90.53 0.79 6.71E-03 
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S.1.2 List of overexpressed proteins in WT mice subjected to UUO 
Supplementary Table 3.5: List of proteins significantly overexpressed [C(FC)≥ 0.8] in WT kidneys 
subjected to UUO (21 days) and corresponding positive FC from Sham operated condition.  
 
Protein ID Name 
Abs(FC) 
UUO/Sham 
C(FC) 
UROM_MOUSE Uromodulin 16.34 0.85 
COCA1_MOUSE Collagen alpha-1(XII) chain 15.92 0.82 
FBN1_MOUSE Fibrillin-1 10.84 0.89 
FBLN2_MOUSE Fibulin-2 9.65 0.81 
K1C19_MOUSE Keratin, type I cytoskeletal 19 9.57 0.86 
TAGL_MOUSE Transgelin 9.27 0.89 
PGS1_MOUSE Biglycan 8.73 0.86 
CNN1_MOUSE Calponin-1 8.59 0.80 
VIME_MOUSE Vimentin 8.56 0.90 
HA2U_MOUSE H-2 class II histocompatibility antigen, A-U alpha chain 8.32 0.80 
ANXA1_MOUSE Annexin A1 8.17 0.84 
MT2_MOUSE Metallothionein-2 8.11 0.84 
POSTN_MOUSE Periostin 8.04 0.80 
A1AT2_MOUSE Alpha-1-antitrypsin 1-2 7.86 0.82 
FINC_MOUSE Fibronectin 7.85 0.84 
COR1A_MOUSE Coronin-1A 7.77 0.80 
CO3A1_MOUSE Collagen alpha-1(III) chain 7.72 0.92 
PLSL_MOUSE Plastin-2 7.63 0.85 
CO1A1_MOUSE Collagen alpha-1(I) chain 7.61 0.96 
KCRB_MOUSE Creatine kinase B-type 7.56 0.83 
FBN2_MOUSE Fibrillin-2 7.26 0.94 
MIME_MOUSE Mimecan 6.67 0.83 
CKAP4_MOUSE Cytoskeleton-associated protein 4 6.57 0.85 
LUM_MOUSE Lumican 6.55 0.87 
FBLN3_MOUSE EGF-containing fibulin-like extracellular matrix protein 1 6.33 0.80 
SERPH_MOUSE Serpin H1 6.19 0.94 
CNN2_MOUSE Calponin-2 6.15 0.80 
LEG1_MOUSE Galectin-1 6.15 0.87 
DESM_MOUSE Desmin 5.98 0.94 
FBLN5_MOUSE Fibulin-5 5.81 0.84 
RET1_MOUSE Retinol-binding protein 1 5.56 0.83 
PDLI7_MOUSE PDZ and LIM domain protein 7 5.40 0.81 
CLUS_MOUSE Clusterin 5.35 0.81 
K2C5_MOUSE Keratin, type II cytoskeletal 5 5.24 0.83 
FLNA_MOUSE Filamin-A 5.07 0.93 
MYOF_MOUSE Myoferlin 4.99 0.86 
K2C8_MOUSE Keratin, type II cytoskeletal 8 4.93 0.89 
CO6A1_MOUSE Collagen alpha-1(VI) chain 4.78 0.88 
CO6A2_MOUSE Collagen alpha-2(VI) chain 4.76 0.94 
ANXA3_MOUSE Annexin A3 4.73 0.83 
FIBA_MOUSE Fibrinogen alpha chain 4.64 0.90 
COEA1_MOUSE Collagen alpha-1(XIV) chain 4.62 0.81 
HEMO_MOUSE Hemopexin 4.60 0.86 
CSRP1_MOUSE Cysteine and glycine-rich protein 1 4.52 0.89 
CO4A2_MOUSE Collagen alpha-2(IV) chain 4.50 0.80 
FIBG_MOUSE Fibrinogen gamma chain 4.45 0.85 
EMIL1_MOUSE Emilin-1 4.42 0.82 
TBA1A_MOUSE Tubulin alpha-1A chain 4.41 0.96 
TYB4_MOUSE Thymosin beta-4 4.35 0.88 
TPM1_MOUSE Tropomyosin alpha-1 chain 4.28 0.84 
K2C7_MOUSE Keratin, type II cytoskeletal 7 4.27 0.88 
PEDF_MOUSE Pigment epithelium-derived factor 4.24 0.81 
ACTN1_MOUSE Alpha-actinin-1 4.22 0.96 
TPM4_MOUSE Tropomyosin alpha-4 chain 4.19 0.91 
IGKC_MOUSE Ig kappa chain C region 4.15 0.87 
FIBB_MOUSE Fibrinogen beta chain 4.00 0.86 
MYADM_MOUSE Myeloid-associated differentiation marker 4.00 0.87 
SH3L3_MOUSE SH3 domain-binding glutamic acid-rich-like protein 3 3.85 0.90 
TRFE_MOUSE Serotransferrin 3.78 0.91 
ANXA2_MOUSE Annexin A2 3.76 0.90 
G6PE_MOUSE GDH/6PGL endoplasmic bifunctional protein 3.71 0.90 
CALU_MOUSE Calumenin 3.69 0.84 
SPB6_MOUSE Serpin B6 3.56 0.89 
CRIP1_MOUSE Cysteine-rich protein 1 3.55 0.90 
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EFHD2_MOUSE EF-hand domain-containing protein D2 3.52 0.87 
ESYT1_MOUSE Extended synaptotagmin-1 3.52 0.82 
LMNA_MOUSE Prelamin-A/C 3.49 0.94 
CO4B_MOUSE Complement C4-B 3.44 0.86 
ARC1B_MOUSE Actin-related protein 2/3 complex subunit 1B 3.38 0.87 
TBB5_MOUSE Tubulin beta-5 chain 3.33 0.88 
APOE_MOUSE Apolipoprotein E 3.31 0.87 
MYH11_MOUSE Myosin-11 3.28 0.87 
MYH10_MOUSE Myosin-10 3.27 0.85 
FETUA_MOUSE Alpha-2-HS-glycoprotein 3.27 0.90 
ESYT2_MOUSE Extended synaptotagmin-2 3.23 0.86 
GCAB_MOUSE Ig gamma-2A chain C region secreted form 3.21 0.91 
ACTA_MOUSE Actin, aortic smooth muscle 3.17 0.94 
VTDB_MOUSE Vitamin D-binding protein 3.13 0.93 
EST1C_MOUSE Carboxylesterase 1C 3.11 0.95 
KNG1_MOUSE Kininogen-1 3.09 0.91 
MYL9_MOUSE Myosin regulatory light polypeptide 9 3.08 0.98 
S10AB_MOUSE Protein S100-A11 3.08 0.88 
A1AT1_MOUSE Alpha-1-antitrypsin 1-1 3.07 0.86 
IGG2B_MOUSE Ig gamma-2B chain C region 3.07 0.81 
SH3L1_MOUSE SH3 domain-binding glutamic acid-rich-like protein 3.06 0.86 
K2C79_MOUSE Keratin, type II cytoskeletal 79 3.05 0.91 
TAGL2_MOUSE Transgelin-2 3.04 0.88 
K1C18_MOUSE Keratin, type I cytoskeletal 18 2.99 0.94 
ALBU_MOUSE Serum albumin 2.98 0.92 
PTRF_MOUSE Polymerase I and transcript release factor 2.96 0.84 
VAT1_MOUSE Synaptic vesicle membrane protein VAT-1 homolog 2.96 0.90 
SEPT7_MOUSE Septin-7 2.95 0.82 
PSME2_MOUSE Proteasome activator complex subunit 2 2.91 0.88 
B2MG_MOUSE Beta-2-microglobulin 2.88 0.82 
CERU_MOUSE Ceruloplasmin 2.86 0.80 
SEPT2_MOUSE Septin-2 2.83 0.82 
COF1_MOUSE Cofilin-1 2.74 0.87 
A1AT4_MOUSE Alpha-1-antitrypsin 1-4 2.72 0.83 
ANXA6_MOUSE Annexin A6 2.71 0.89 
ADPRH_MOUSE [Protein ADP-ribosylarginine] hydrolase 2.71 0.86 
DPYL2_MOUSE Dihydropyrimidinase-related protein 2 2.68 0.88 
CO4A1_MOUSE Collagen alpha-1(IV) chain 2.67 0.88 
MAP4_MOUSE Microtubule-associated protein 4 2.66 0.82 
CATD_MOUSE Cathepsin D 2.65 0.82 
GBG2_MOUSE 
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-
2 
2.65 0.81 
ROA1_MOUSE Heterogeneous nuclear ribonucleoprotein A1 2.63 0.88 
ISG15_MOUSE Ubiquitin-like protein ISG15 2.62 0.84 
FETUB_MOUSE Fetuin-B 2.61 0.89 
MYH9_MOUSE Myosin-9 2.61 0.99 
CO3_MOUSE Complement C3 2.59 0.87 
MYLK_MOUSE Myosin light chain kinase, smooth muscle 2.59 0.80 
S10AA_MOUSE Protein S100-A10 2.59 0.86 
VMA5A_MOUSE von Willebrand factor A domain-containing protein 5A 2.58 0.86 
COIA1_MOUSE Collagen alpha-1(XVIII) chain 2.57 0.96 
MYL6_MOUSE Myosin light polypeptide 6 2.53 0.92 
CATZ_MOUSE Cathepsin Z 2.53 0.86 
SF3B3_MOUSE Splicing factor 3B subunit 3 2.51 0.83 
APOA4_MOUSE Apolipoprotein A-IV 2.50 0.82 
CAP1_MOUSE Adenylyl cyclase-associated protein 1 2.50 0.92 
APOH_MOUSE Beta-2-glycoprotein 1 2.50 0.80 
APOA1_MOUSE Apolipoprotein A-I 2.46 0.92 
SET_MOUSE Protein SET 2.46 0.83 
SFPQ_MOUSE Splicing factor, proline- and glutamine-rich 2.44 0.81 
RBM3_MOUSE RNA-binding protein 3 2.36 0.84 
T22D1_MOUSE TSC22 domain family protein 1 2.35 0.90 
TIF1B_MOUSE Transcription intermediary factor 1-beta 2.33 0.83 
GELS_MOUSE Gelsolin 2.33 0.84 
VINC_MOUSE Vinculin 2.33 0.94 
ML12B_MOUSE Myosin regulatory light chain 12B 2.33 0.83 
LMNB1_MOUSE Lamin-B1 2.30 0.86 
ANXA5_MOUSE Annexin A5 2.29 0.84 
PSME1_MOUSE Proteasome activator complex subunit 1 2.28 0.84 
ANT3_MOUSE Antithrombin-III 2.27 0.86 
LAMA5_MOUSE Laminin subunit alpha-5 2.26 0.83 
COR1C_MOUSE Coronin-1C 2.23 0.83 
CAPZB_MOUSE F-actin-capping protein subunit beta 2.23 0.89 
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FUS_MOUSE RNA-binding protein FUS 2.22 0.80 
AGRIN_MOUSE Agrin 2.16 0.92 
AN32B_MOUSE Acidic leucine-rich nuclear phosphoprotein 32 family member B 2.15 0.81 
KHDR1_MOUSE 
KH domain-containing, RNA-binding, signal transduction-associated 
protein 1 
2.14 0.84 
PROF1_MOUSE Profilin-1 2.10 0.89 
NID1_MOUSE Nidogen-1 2.10 0.92 
H2AV_MOUSE Histone H2A.V 2.07 0.86 
COR1B_MOUSE Coronin-1B 2.06 0.86 
A2M_MOUSE Pregnancy zone protein 2.05 0.85 
INO1_MOUSE Inositol-3-phosphate synthase 1 2.03 0.81 
LIMA1_MOUSE LIM domain and actin-binding protein 1 2.02 0.87 
GNAI2_MOUSE Guanine nucleotide-binding protein G(i) subunit alpha-2 2.02 0.83 
ARPC3_MOUSE Actin-related protein 2/3 complex subunit 3 2.01 0.87 
WDR1_MOUSE WD repeat-containing protein 1 2.01 0.83 
UBC9_MOUSE SUMO-conjugating enzyme UBC9 1.97 0.91 
HP1B3_MOUSE Heterochromatin protein 1-binding protein 3 1.94 0.83 
ACTBL_MOUSE Beta-actin-like protein 2 1.91 0.84 
ROA3_MOUSE Heterogeneous nuclear ribonucleoprotein A3 1.90 0.90 
NONO_MOUSE Non-POU domain-containing octamer-binding protein 1.90 0.91 
ABCB7_MOUSE ATP-binding cassette sub-family B member 7, mitochondrial 1.89 0.89 
ARP3_MOUSE Actin-related protein 3 1.89 0.95 
ARPC2_MOUSE Actin-related protein 2/3 complex subunit 2 1.87 0.83 
NH2L1_MOUSE NHP2-like protein 1 1.86 0.81 
LAMC1_MOUSE Laminin subunit gamma-1 1.85 0.93 
LAMB1_MOUSE Laminin subunit beta-1 1.85 0.85 
HNRPF_MOUSE Heterogeneous nuclear ribonucleoprotein F 1.82 0.83 
FABP4_MOUSE Fatty acid-binding protein, adipocyte 1.82 0.85 
LASP1_MOUSE LIM and SH3 domain protein 1 1.81 0.81 
PGBM_MOUSE 
Basement membrane-specific heparan sulfate proteoglycan core 
protein 
1.80 0.81 
TADBP_MOUSE TAR DNA-binding protein 43 1.80 0.81 
NUCL_MOUSE Nucleolin 1.79 0.83 
DX39B_MOUSE Spliceosome RNA helicase Ddx39b 1.78 0.81 
ANXA4_MOUSE Annexin A4 1.78 0.85 
TLN1_MOUSE Talin-1 1.78 0.82 
FUBP2_MOUSE Far upstream element-binding protein 2 1.78 0.80 
ARP2_MOUSE Actin-related protein 2 1.76 0.88 
RUXF_MOUSE Small nuclear ribonucleoprotein F 1.75 0.87 
HNRPM_MOUSE Heterogeneous nuclear ribonucleoprotein M 1.74 0.86 
CSRP2_MOUSE Cysteine and glycine-rich protein 2 1.72 0.82 
TGM2_MOUSE Transglutminase 2 1.71 0.90 
LAP2B_MOUSE 
Lamina-associated polypeptide 2, isoforms 
beta/delta/epsilon/gamma 
1.71 0.80 
SRSF2_MOUSE Serine/arginine-rich splicing factor 2 1.70 0.86 
PDIA6_MOUSE Protein disulfide-isomerase A6 1.68 0.90 
1433G_MOUSE 14-3-3 protein gamma 1.65 0.81 
SMAP_MOUSE Small acidic protein 1.64 0.88 
LSM3_MOUSE U6 snRNA-associated Sm-like protein LSm3 1.62 0.91 
RSU1_MOUSE Ras suppressor protein 1 1.59 0.84 
SC11A_MOUSE Signal peptidase complex catalytic subunit SEC11A 1.59 0.80 
ABRAL_MOUSE Costars family protein ABRACL 1.56 0.80 
ACTB_MOUSE Actin, cytoplasmic 1 1.56 0.93 
HNRPU_MOUSE Heterogeneous nuclear ribonucleoprotein U 1.53 0.85 
MOES_MOUSE Moesin 1.52 0.81 
GDIR1_MOUSE Rho GDP-dissociation inhibitor 1 1.51 0.84 
HNRH1_MOUSE Heterogeneous nuclear ribonucleoprotein H 1.48 0.87 
SMD2_MOUSE Small nuclear ribonucleoprotein Sm D2 1.47 0.81 
KAPCA_MOUSE cAMP-dependent protein kinase catalytic subunit alpha 1.44 0.89 
PDIA4_MOUSE Protein disulfide-isomerase A4 1.40 0.80 
HNRPK_MOUSE Heterogeneous nuclear ribonucleoprotein K 1.40 0.82 
LAMP1_MOUSE Lysosome-associated membrane glycoprotein 1 1.38 0.81 
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S.1.3 List of underexpressed proteins in WT mice subjected to UUO 
Supplementary Table 3.6: List of proteins significantly underexpressed [C(FC)≥ 0.8] in WT 
kidneys subjected to UUO (21 days) and corresponding negative FC from Sham operated 
condition.  
 
Protein ID Names 
Abs(FC) 
Sham/UUO 
C(FC) 
G6PC_MOUSE Glucose-6-phosphatase 72.24 0.86 
AADAT_MOUSE Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial 48.00 0.84 
PDZ1I_MOUSE PDZK1-interacting protein 1 45.76 0.84 
HAOX2_MOUSE Hydroxyacid oxidase 2 44.28 0.85 
CALB1_MOUSE Calbindin 32.07 0.91 
ASSY_MOUSE Argininosuccinate synthase 21.28 0.88 
ACSM1_MOUSE Acyl-coenzyme A synthetase ACSM1, mitochondrial 20.87 0.83 
F16P1_MOUSE Fructose-1,6-bisphosphatase 1 20.84 0.81 
ACSM2_MOUSE Acyl-coenzyme A synthetase ACSM2, mitochondrial 20.17 0.86 
ECHP_MOUSE Peroxisomal bifunctional enzyme 19.92 0.84 
KAD4_MOUSE Adenylate kinase 4, mitochondrial 19.83 0.89 
AT1B1_MOUSE Sodium/potassium-transporting ATPase subunit beta-1 19.55 0.87 
CAD16_MOUSE Cadherin-16 19.54 0.92 
PYC_MOUSE Pyruvate carboxylase, mitochondrial 18.04 0.87 
GSTA2_MOUSE Glutathione S-transferase A2 17.14 0.85 
AL8A1_MOUSE Aldehyde dehydrogenase family 8 member A1 17.11 0.88 
ATNG_MOUSE Sodium/potassium-transporting ATPase subunit gamma 16.80 0.90 
UD3A2_MOUSE UDP-glucuronosyltransferase 3A2 16.72 0.83 
S100G_MOUSE Protein S100-G 16.59 0.90 
ACS2L_MOUSE Acetyl-coenzyme A synthetase 2-like, mitochondrial 16.56 0.89 
KEG1_MOUSE Glycine N-acyltransferase-like protein Keg1 16.36 0.88 
SC5A2_MOUSE Sodium/glucose cotransporter 2 16.23 0.80 
ECHD2_MOUSE Enoyl-CoA hydratase domain-containing protein 2, mitochondrial 16.09 0.87 
CGL_MOUSE Cystathionine gamma-lyase 16.04 0.86 
3HAO_MOUSE 3-hydroxyanthranilate 3,4-dioxygenase 15.56 0.85 
S27A2_MOUSE Very long-chain acyl-CoA synthetase 14.88 0.81 
MEP1B_MOUSE Meprin A subunit beta 14.72 0.82 
ACADM_MOUSE Medium-chain specific acyl-CoA dehydrogenase, mitochondrial 14.48 0.86 
TMM27_MOUSE Collectrin 14.41 0.85 
ISC2A_MOUSE Isochorismatase domain-containing protein 2A 14.27 0.90 
BDH_MOUSE D-beta-hydroxybutyrate dehydrogenase, mitochondrial 14.24 0.89 
ALDOB_MOUSE Fructose-bisphosphate aldolase B 14.21 0.93 
HOT_MOUSE Hydroxyacid-oxoacid transhydrogenase, mitochondrial 14.07 0.84 
GATM_MOUSE Glycine amidinotransferase, mitochondrial 13.91 0.87 
GABT_MOUSE 4-aminobutyrate aminotransferase, mitochondrial 13.84 0.93 
KBL_MOUSE 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial 13.82 0.85 
MMSA_MOUSE Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial 13.79 0.88 
PXMP2_MOUSE Peroxisomal membrane protein 2 13.77 0.81 
ST1D1_MOUSE Sulfotransferase 1 family member D1 13.74 0.85 
GGT1_MOUSE Gamma-glutamyltranspeptidase 1 13.58 0.89 
MAAI_MOUSE Maleylacetoacetate isomerase 13.49 0.82 
PGAM2_MOUSE Phosphoglycerate mutase 2 13.44 0.88 
GLYAT_MOUSE Glycine N-acyltransferase 13.43 0.88 
S4A4_MOUSE Electrogenic sodium bicarbonate cotransporter 1 13.29 0.83 
FAAA_MOUSE Fumarylacetoacetase 13.16 0.92 
AT1A1_MOUSE Sodium/potassium-transporting ATPase subunit alpha-1 13.14 0.93 
DHSO_MOUSE Sorbitol dehydrogenase 13.11 0.82 
MPC1_MOUSE Mitochondrial pyruvate carrier 1 12.91 0.93 
UK114_MOUSE Ribonuclease UK114 12.69 0.94 
ACE_MOUSE Angiotensin-converting enzyme 12.66 0.91 
DECR2_MOUSE Peroxisomal 2,4-dienoyl-CoA reductase 12.62 0.90 
CATA_MOUSE Catalase 12.62 0.94 
ACY3_MOUSE N-acyl-aromatic-L-amino acid amidohydrolase (carboxylate-forming) 12.43 0.80 
S22A2_MOUSE Solute carrier family 22 member 2 12.29 0.81 
GSTK1_MOUSE Glutathione S-transferase kappa 1 12.27 0.82 
PCCB_MOUSE Propionyl-CoA carboxylase beta chain, mitochondrial 12.22 0.96 
AL4A1_MOUSE Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial 12.17 0.93 
CES1D_MOUSE Carboxylesterase 1D 11.96 0.83 
GLPK_MOUSE Glycerol kinase 11.89 0.86 
QORL2_MOUSE Quinone oxidoreductase-like protein 2 11.85 0.82 
AAAD_MOUSE Arylacetamide deacetylase 11.84 0.85 
VILI_MOUSE Villin-1 11.78 0.91 
DHAK_MOUSE Triokinase/FMN cyclase 11.77 0.80 
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COX1_MOUSE Cytochrome c oxidase subunit 1 11.70 0.90 
SODM_MOUSE Superoxide dismutase [Mn], mitochondrial 11.66 0.93 
S2542_MOUSE Mitochondrial coenzyme A transporter SLC25A42 11.63 0.86 
MPC2_MOUSE Mitochondrial pyruvate carrier 2 11.60 0.82 
ATP5L_MOUSE ATP synthase subunit g, mitochondrial 11.54 0.80 
OXDA_MOUSE D-amino-acid oxidase 11.38 0.81 
NUD19_MOUSE Nucleoside diphosphate-linked moiety X motif 19 11.28 0.90 
HINT2_MOUSE Histidine triad nucleotide-binding protein 2, mitochondrial 11.27 0.98 
BPHL_MOUSE Valacyclovir hydrolase 11.09 0.87 
MCCB_MOUSE Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial 10.95 0.90 
PBLD1_MOUSE Phenazine biosynthesis-like domain-containing protein 1 10.91 0.87 
DIC_MOUSE Mitochondrial dicarboxylate carrier 10.83 0.83 
ACD10_MOUSE Acyl-CoA dehydrogenase family member 10 10.77 0.86 
NHRF3_MOUSE Na(+)/H(+) exchange regulatory cofactor NHE-RF3 10.71 0.86 
GSTA3_MOUSE Glutathione S-transferase A3 10.63 0.81 
CK054_MOUSE Ester hydrolase C11orf54 homolog 10.61 0.82 
AK1A1_MOUSE Alcohol dehydrogenase [NADP(+)] 10.56 0.91 
3HIDH_MOUSE 3-hydroxyisobutyrate dehydrogenase, mitochondrial 10.55 0.94 
SUCB2_MOUSE Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial 10.42 0.94 
LACB2_MOUSE Beta-lactamase-like protein 2 10.39 0.82 
FAHD1_MOUSE Acylpyruvase FAHD1, mitochondrial 10.39 0.84 
FMO1_MOUSE Dimethylaniline monooxygenase [N-oxide-forming] 1 10.33 0.82 
IVD_MOUSE Isovaleryl-CoA dehydrogenase, mitochondrial 10.14 0.88 
THIL_MOUSE Acetyl-CoA acetyltransferase, mitochondrial 10.10 0.95 
PROD_MOUSE Proline dehydrogenase 1, mitochondrial 10.05 0.81 
SARDH_MOUSE Sarcosine dehydrogenase, mitochondrial 10.05 0.85 
INMT_MOUSE Indolethylamine N-methyltransferase 10.03 0.83 
AL1L1_MOUSE Cytosolic 10-formyltetrahydrofolate dehydrogenase 9.95 0.91 
KHK_MOUSE Ketohexokinase 9.90 0.83 
ARK72_MOUSE Aflatoxin B1 aldehyde reductase member 2 9.87 0.87 
S22AI_MOUSE Solute carrier family 22 member 18 9.86 0.90 
HCDH_MOUSE Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial 9.82 0.90 
NDUB6_MOUSE NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6 9.77 0.81 
CISD1_MOUSE CDGSH iron-sulfur domain-containing protein 1 9.75 0.95 
NDRG1_MOUSE Protein NDRG1 9.52 0.99 
S13A3_MOUSE Solute carrier family 13 member 3 9.52 0.88 
CYC_MOUSE Cytochrome c, somatic 9.49 0.92 
SSDH_MOUSE Succinate-semialdehyde dehydrogenase, mitochondrial 9.47 0.88 
SCOT1_MOUSE Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial 9.34 0.92 
HMGCL_MOUSE Hydroxymethylglutaryl-CoA lyase, mitochondrial 9.26 0.92 
ACPM_MOUSE Acyl carrier protein, mitochondrial 9.19 0.92 
ATPK_MOUSE ATP synthase subunit f, mitochondrial 9.17 0.80 
MSRA_MOUSE Mitochondrial peptide methionine sulfoxide reductase 9.12 0.83 
CBR1_MOUSE Carbonyl reductase [NADPH] 1 9.11 0.92 
LDHD_MOUSE Probable D-lactate dehydrogenase, mitochondrial 9.10 0.88 
COX5A_MOUSE Cytochrome c oxidase subunit 5A, mitochondrial 9.08 0.94 
ETFA_MOUSE Electron transfer flavoprotein subunit alpha, mitochondrial 9.07 0.93 
NDUB5_MOUSE 
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, 
mitochondrial 
9.01 0.85 
PLSI_MOUSE Plastin-1 9.01 0.86 
GPDA_MOUSE Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic 8.85 0.91 
NIPS1_MOUSE Protein NipSnap homolog 1 8.81 0.91 
NU4M_MOUSE NADH-ubiquinone oxidoreductase chain 4 8.79 0.89 
FAHD2_MOUSE umarylacetoacetate hydrolase domain-containing protein 2A 8.76 0.80 
CLYBL_MOUSE Citrate lyase subunit beta-like protein, mitochondrial 8.75 0.80 
FBX50_MOUSE F-box only protein 50 8.73 0.80 
NDUS6_MOUSE NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial 8.72 0.81 
THNS2_MOUSE Threonine synthase-like 2 8.70 0.83 
NDUB8_MOUSE 
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, 
mitochondrial 
8.67 0.86 
NU5M_MOUSE NADH-ubiquinone oxidoreductase chain 5 8.67 0.88 
PECR_MOUSE Peroxisomal trans-2-enoyl-CoA reductase 8.65 0.87 
SDHA_MOUSE 
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, 
mitochondrial 
8.64 0.98 
NDUBA_MOUSE NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 8.63 0.86 
SUCA_MOUSE Succinyl-CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial 8.55 0.94 
NDUV2_MOUSE NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial 8.50 0.84 
IPYR2_MOUSE Inorganic pyrophosphatase 2, mitochondrial 8.50 0.83 
NDUV1_MOUSE NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial 8.43 0.90 
NDUA9_MOUSE 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, 
mitochondrial 
8.38 0.89 
ABCD3_MOUSE ATP-binding cassette sub-family D member 3 8.36 0.88 
ATPD_MOUSE ATP synthase subunit delta, mitochondrial 8.32 0.98 
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QCR6_MOUSE Cytochrome b-c1 complex subunit 6, mitochondrial 8.31 0.93 
NDUA1_MOUSE NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 1 8.25 0.86 
COX5B_MOUSE Cytochrome c oxidase subunit 5B, mitochondrial 8.24 0.91 
IDHP_MOUSE Isocitrate dehydrogenase [NADP], mitochondrial 8.21 0.93 
SBP1_MOUSE Selenium-binding protein 1 8.19 0.92 
NDUS7_MOUSE NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial 8.16 0.94 
BDH2_MOUSE 3-hydroxybutyrate dehydrogenase type 2 8.13 0.82 
ETFB_MOUSE Electron transfer flavoprotein subunit beta 8.13 0.91 
NHRF1_MOUSE Na(+)/H(+) exchange regulatory cofactor NHE-RF1 8.07 0.94 
NEP_MOUSE Neprilysin 8.05 0.90 
NDUAD_MOUSE NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 8.00 0.89 
CSAD_MOUSE Cysteine sulfinic acid decarboxylase 8.00 0.90 
COX2_MOUSE Cytochrome c oxidase subunit 2 7.99 0.87 
SDHB_MOUSE Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial 7.99 0.89 
TPMT_MOUSE Thiopurine S-methyltransferase 7.98 0.93 
CY1_MOUSE Cytochrome c1, heme protein, mitochondrial 7.96 0.94 
TOM5_MOUSE Mitochondrial import receptor subunit TOM5 homolog 7.94 1.00 
COQ9_MOUSE Ubiquinone biosynthesis protein COQ9, mitochondrial 7.91 0.90 
IDHG1_MOUSE Isocitrate dehydrogenase [NAD] subunit gamma 1, mitochondrial 7.91 0.91 
THIM_MOUSE 3-ketoacyl-CoA thiolase, mitochondrial 7.90 0.91 
UCRI_MOUSE Cytochrome b-c1 complex subunit Rieske, mitochondrial 7.89 0.91 
NDUA3_MOUSE NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3 7.86 0.89 
AUHM_MOUSE Methylglutaconyl-CoA hydratase, mitochondrial 7.85 0.85 
COASY_MOUSE Bifunctional coenzyme A synthase 7.83 0.85 
NLTP_MOUSE Non-specific lipid-transfer protein 7.82 0.88 
NDUB7_MOUSE NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7 7.79 0.84 
TAU_MOUSE Microtubule-associated protein tau 7.76 0.83 
THTR_MOUSE Thiosulfate sulfurtransferase 7.75 0.89 
PPA6_MOUSE Lysophosphatidic acid phosphatase type 6 7.74 0.85 
QOR_MOUSE Quinone oxidoreductase 7.71 0.84 
ACSL1_MOUSE Long-chain-fatty-acid--CoA ligase 1 7.69 0.90 
CRYL1_MOUSE Lambda-crystallin homolog 7.62 0.90 
LRP2_MOUSE Low-density lipoprotein receptor-related protein 2 7.60 0.84 
CX7A1_MOUSE Cytochrome c oxidase subunit 7A1, mitochondrial 7.60 0.93 
HGD_MOUSE Homogentisate 1,2-dioxygenase 7.58 0.84 
CH60_MOUSE 60 kDa heat shock protein, mitochondrial 7.56 0.96 
C560_MOUSE Succinate dehydrogenase cytochrome b560 subunit, mitochondrial 7.55 0.83 
NDUS1_MOUSE NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial 7.55 0.94 
CP013_MOUSE UPF0585 protein C16orf13 homolog 7.48 0.87 
COX41_MOUSE Cytochrome c oxidase subunit 4 isoform 1, mitochondrial 7.46 0.94 
ACD11_MOUSE Acyl-CoA dehydrogenase family member 11 7.41 0.80 
CX7A2_MOUSE Cytochrome c oxidase subunit 7A2, mitochondrial 7.37 0.92 
NAKD2_MOUSE NAD kinase 2, mitochondrial 7.33 0.95 
VATG1_MOUSE V-type proton ATPase subunit G 1 7.31 0.83 
NDUA4_MOUSE Cytochrome c oxidase subunit NDUFA4 7.30 0.89 
AIFM1_MOUSE Apoptosis-inducing factor 1, mitochondrial 7.30 0.92 
CDD_MOUSE Cytidine deaminase 7.28 0.81 
MUTA_MOUSE Methylmalonyl-CoA mutase, mitochondrial 7.27 0.81 
MCCA_MOUSE Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial 7.25 0.82 
NDUB4_MOUSE NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 7.21 0.83 
ECHM_MOUSE Enoyl-CoA hydratase, mitochondrial 7.21 0.90 
ATP5H_MOUSE ATP synthase subunit d, mitochondrial 7.21 0.93 
OCTC_MOUSE Peroxisomal carnitine O-octanoyltransferase 7.20 0.80 
CMC2_MOUSE Calcium-binding mitochondrial carrier protein Aralar2 7.20 0.80 
NDUS4_MOUSE NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial 7.19 0.83 
CBR4_MOUSE Carbonyl reductase family member 4 7.19 0.85 
DLDH_MOUSE Dihydrolipoyl dehydrogenase, mitochondrial 7.18 0.94 
AL7A1_MOUSE Alpha-aminoadipic semialdehyde dehydrogenase 7.16 0.82 
MEP1A_MOUSE Meprin A subunit alpha 7.15 0.88 
QCR2_MOUSE Cytochrome b-c1 complex subunit 2, mitochondrial 7.14 0.94 
C1TC_MOUSE C-1-tetrahydrofolate synthase, cytoplasmic 7.12 0.87 
QCR8_MOUSE Cytochrome b-c1 complex subunit 8 7.12 0.91 
MGST3_MOUSE Microsomal glutathione S-transferase 3 7.12 0.84 
ADT2_MOUSE ADP/ATP translocase 2 7.06 0.81 
ATP8_MOUSE ATP synthase protein 8 6.97 0.90 
ATPG_MOUSE ATP synthase subunit gamma, mitochondrial 6.96 0.90 
NDUAA_MOUSE 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, 
mitochondrial 
6.92 0.93 
S12A1_MOUSE Solute carrier family 12 member 1 6.91 0.96 
AQP1_MOUSE Aquaporin-1 6.91 0.80 
ODO2_MOUSE 
Dihydrolipoyllysine-residue succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, mitochondrial 
6.89 0.89 
TBA4A_MOUSE Tubulin alpha-4A chain 6.89 0.88 
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ATPO_MOUSE ATP synthase subunit O, mitochondrial 6.84 0.96 
PCCA_MOUSE Propionyl-CoA carboxylase alpha chain, mitochondrial 6.83 0.84 
BPNT1_MOUSE 3'(2'),5'-bisphosphate nucleotidase 1 6.81 0.87 
PTER_MOUSE Phosphotriesterase-related protein 6.73 0.91 
FGGY_MOUSE FGGY carbohydrate kinase domain-containing protein 6.73 0.85 
ECI2_MOUSE Enoyl-CoA delta isomerase 2, mitochondrial 6.73 0.85 
NDUS2_MOUSE NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial 6.72 0.91 
ES1_MOUSE ES1 protein homolog, mitochondrial 6.71 0.92 
ACON_MOUSE Aconitate hydratase, mitochondrial 6.66 0.90 
NDUS3_MOUSE NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial 6.64 0.96 
MDHM_MOUSE Malate dehydrogenase, mitochondrial 6.63 0.96 
ATP5I_MOUSE ATP synthase subunit e, mitochondrial 6.62 0.90 
USMG5_MOUSE Up-regulated during skeletal muscle growth protein 5 6.60 0.97 
FUMH_MOUSE Fumarate hydratase, mitochondrial 6.56 0.89 
ATPB_MOUSE ATP synthase subunit beta, mitochondrial 6.55 0.94 
FABPH_MOUSE Fatty acid-binding protein, heart 6.53 0.88 
AQP3_MOUSE Aquaporin-3 6.51 0.90 
CX6B1_MOUSE Cytochrome c oxidase subunit 6B1 6.48 0.92 
NDUA5_MOUSE NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 6.48 0.90 
VWA8_MOUSE von Willebrand factor A domain-containing protein 8 6.46 0.82 
ATPA_MOUSE ATP synthase subunit alpha, mitochondrial 6.46 0.96 
DHRS4_MOUSE Dehydrogenase/reductase SDR family member 4 6.42 0.91 
SUSD2_MOUSE Sushi domain-containing protein 2 6.38 0.92 
QCR1_MOUSE Cytochrome b-c1 complex subunit 1, mitochondrial 6.37 0.94 
NDUA7_MOUSE NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7 6.36 0.91 
SFXN1_MOUSE Sideroflexin-1 6.35 0.83 
QCR7_MOUSE Cytochrome b-c1 complex subunit 7 6.34 0.89 
COX6C_MOUSE Cytochrome c oxidase subunit 6C 6.33 0.91 
ODB2_MOUSE 
Lipoamide acyltransferase component of branched-chain alpha-keto acid 
dehydrogenase complex, mitochondrial 
6.31 0.81 
ARLY_MOUSE Argininosuccinate lyase 6.31 0.91 
PRDX5_MOUSE Peroxiredoxin-5, mitochondrial 6.30 0.91 
PGES2_MOUSE Prostaglandin E synthase 2 6.29 0.89 
ATP5J_MOUSE ATP synthase-coupling factor 6, mitochondrial 6.29 0.97 
KAT3_MOUSE Kynurenine--oxoglutarate transaminase 3 6.29 0.81 
ACOX2_MOUSE Peroxisomal acyl-coenzyme A oxidase 2 6.24 0.84 
AT5F1_MOUSE ATP synthase F(0) complex subunit B1, mitochondrial 6.17 0.92 
NU3M_MOUSE NADH-ubiquinone oxidoreductase chain 3 6.15 0.95 
CH10_MOUSE 10 kDa heat shock protein, mitochondrial 6.15 0.90 
NDUB9_MOUSE NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 6.10 0.83 
AATM_MOUSE Aspartate aminotransferase, mitochondrial 6.10 0.97 
DHB8_MOUSE Estradiol 17-beta-dehydrogenase 8 6.07 0.87 
NDUA8_MOUSE NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8 6.07 0.91 
CHDH_MOUSE Choline dehydrogenase, mitochondrial 6.06 0.88 
ODPB_MOUSE Pyruvate dehydrogenase E1 component subunit beta, mitochondrial 6.05 0.96 
VATA_MOUSE V-type proton ATPase catalytic subunit A 6.04 0.92 
MRP2_MOUSE Canalicular multispecific organic anion transporter 1 6.03 0.82 
ETHE1_MOUSE Persulfide dioxygenase ETHE1, mitochondrial 5.99 0.92 
VATH_MOUSE V-type proton ATPase subunit H 5.94 0.90 
NDUC2_MOUSE NADH dehydrogenase [ubiquinone] 1 subunit C2 5.93 0.88 
DCXR_MOUSE L-xylulose reductase 5.92 0.88 
GSTT2_MOUSE Glutathione S-transferase theta-2 5.84 0.87 
ALDH2_MOUSE Aldehyde dehydrogenase, mitochondrial 5.82 0.95 
TRAP1_MOUSE Heat shock protein 75 kDa, mitochondrial 5.82 0.88 
AL9A1_MOUSE 4-trimethylaminobutyraldehyde dehydrogenase 5.76 0.94 
ETFD_MOUSE Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial 5.74 0.89 
CPT2_MOUSE Carnitine O-palmitoyltransferase 2, mitochondrial 5.70 0.88 
ANK3_MOUSE Ankyrin-3 5.70 0.85 
ACOT4_MOUSE Acyl-coenzyme A thioesterase 4 5.68 0.81 
MARC2_MOUSE Mitochondrial amidoxime reducing component 2 5.65 0.89 
ACOT1_MOUSE Acyl-coenzyme A thioesterase 1 5.63 0.85 
DOPD_MOUSE D-dopachrome decarboxylase 5.63 0.91 
TIM13_MOUSE Mitochondrial import inner membrane translocase subunit Tim13 5.58 0.96 
ODPA_MOUSE 
Pyruvate dehydrogenase E1 component subunit alpha, somatic form, 
mitochondrial 
5.58 0.92 
MPCP_MOUSE Phosphate carrier protein, mitochondrial 5.57 0.90 
ABHEB_MOUSE Protein ABHD14B 5.57 0.93 
GRP75_MOUSE Stress-70 protein, mitochondrial 5.56 0.82 
HIBCH_MOUSE 3-hydroxyisobutyryl-CoA hydrolase, mitochondrial 5.55 0.89 
NDUBB_MOUSE 
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 11, 
mitochondrial 
5.53 0.90 
MIC19_MOUSE MICOS complex subunit Mic19 5.53 0.90 
VATB2_MOUSE V-type proton ATPase subunit B, brain isoform 5.52 0.85 
SUPPLEMENTARY DATA 
 
444 
 
GSH1_MOUSE Glutamate--cysteine ligase catalytic subunit 5.49 0.86 
NCEH1_MOUSE Neutral cholesterol ester hydrolase 1 5.47 0.92 
ECH1_MOUSE Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial 5.46 0.97 
VATF_MOUSE V-type proton ATPase subunit F 5.45 0.90 
VATG3_MOUSE V-type proton ATPase subunit G 3 5.43 0.94 
CN159_MOUSE UPF0317 protein C14orf159 homolog, mitochondrial 5.41 0.83 
DECR_MOUSE 2,4-dienoyl-CoA reductase, mitochondrial 5.39 0.89 
CMBL_MOUSE Carboxymethylenebutenolidase homolog 5.38 0.85 
ACADS_MOUSE Short-chain specific acyl-CoA dehydrogenase, mitochondrial 5.36 0.89 
SUCB1_MOUSE Succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial 5.33 0.97 
VATE1_MOUSE V-type proton ATPase subunit E 1 5.32 0.91 
LPPRC_MOUSE Leucine-rich PPR motif-containing protein, mitochondrial 5.26 0.88 
ODP2_MOUSE 
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial 
5.25 0.98 
PRDX3_MOUSE Thioredoxin-dependent peroxide reductase, mitochondrial 5.23 0.90 
KAD2_MOUSE Adenylate kinase 2, mitochondrial 5.21 0.86 
SQRD_MOUSE Sulfide:quinone oxidoreductase, mitochondrial 5.20 0.92 
GSHB_MOUSE Glutathione synthetase 5.17 0.82 
LYPA1_MOUSE Acyl-protein thioesterase 1 5.13 0.90 
ACADV_MOUSE Very long-chain specific acyl-CoA dehydrogenase, mitochondrial 5.12 0.89 
KAD3_MOUSE GTP:AMP phosphotransferase AK3, mitochondrial 5.10 0.89 
DHPR_MOUSE Dihydropteridine reductase 5.07 0.88 
NIT1_MOUSE Nitrilase homolog 1 5.03 0.90 
ODO1_MOUSE 2-oxoglutarate dehydrogenase, mitochondrial 5.00 0.91 
E41L3_MOUSE Band 4.1-like protein 3 4.96 0.86 
SAP3_MOUSE Ganglioside GM2 activator 4.96 0.85 
MDHC_MOUSE Malate dehydrogenase, cytoplasmic 4.94 0.95 
SPS2_MOUSE Selenide, water dikinase 2 4.93 0.90 
THIOM_MOUSE Thioredoxin, mitochondrial 4.90 0.90 
RM12_MOUSE 39S ribosomal protein L12, mitochondrial 4.89 0.91 
NIT2_MOUSE Omega-amidase NIT2 4.88 0.90 
IDH3A_MOUSE Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial 4.86 0.91 
NDUA6_MOUSE NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6 4.86 0.84 
VDAC1_MOUSE Voltage-dependent anion-selective channel protein 1 4.85 0.96 
HYES_MOUSE Bifunctional epoxide hydrolase 2 4.85 0.81 
ACOC_MOUSE Cytoplasmic aconitate hydratase 4.84 0.94 
PH4H_MOUSE Cytoplasmic aconitate hydratase 4.83 0.84 
ECI1_MOUSE Enoyl-CoA delta isomerase 1, mitochondrial 4.80 0.91 
HCD2_MOUSE 3-hydroxyacyl-CoA dehydrogenase type-2 4.76 0.91 
IDHC_MOUSE Isocitrate dehydrogenase [NADP] cytoplasmic 4.75 0.90 
ISCA2_MOUSE Iron-sulfur cluster assembly 2 homolog, mitochondrial 4.73 0.82 
MIC27_MOUSE MICOS complex subunit Mic27 4.70 0.81 
SAM50_MOUSE Sorting and assembly machinery component 50 homolog 4.69 0.89 
LONM_MOUSE Lon protease homolog, mitochondrial 4.66 0.90 
MIC60_MOUSE MICOS complex subunit Mic60 4.65 0.92 
ATIF1_MOUSE ATPase inhibitor, mitochondrial 4.61 0.83 
LYZ2_MOUSE Lysozyme C-2 4.60 0.93 
OAT_MOUSE Ornithine aminotransferase, mitochondrial 4.59 0.86 
DDAH1_MOUSE N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 4.57 0.83 
EFTU_MOUSE Elongation factor Tu, mitochondrial 4.54 0.95 
CMC1_MOUSE Calcium-binding mitochondrial carrier protein Aralar1 4.51 0.84 
ECHA_MOUSE Trifunctional enzyme subunit alpha, mitochondrial 4.46 0.97 
RT35_MOUSE 28S ribosomal protein S35, mitochondrial 4.43 0.81 
THTM_MOUSE 3-mercaptopyruvate sulfurtransferase 4.41 0.83 
XPP1_MOUSE Xaa-Pro aminopeptidase 1 4.40 0.87 
VATD_MOUSE V-type proton ATPase subunit D 4.40 0.89 
BCAT2_MOUSE Branched-chain-amino-acid aminotransferase, mitochondrial 4.38 0.89 
DHE3_MOUSE Glutamate dehydrogenase 1, mitochondrial 4.37 0.92 
4F2_MOUSE 4F2 cell-surface antigen heavy chain 4.34 0.91 
ATAD3_MOUSE ATPase family AAA domain-containing protein 3 4.30 0.80 
TRXR2_MOUSE Thioredoxin reductase 2, mitochondrial 4.29 0.83 
ACADL_MOUSE Long-chain specific acyl-CoA dehydrogenase, mitochondrial 4.28 0.87 
CPT1A_MOUSE Carnitine O-palmitoyltransferase 1, liver isoform 4.27 0.84 
KCRU_MOUSE Creatine kinase U-type, mitochondrial 4.24 0.88 
AMPE_MOUSE Glutamyl aminopeptidase 4.21 0.87 
GLRX5_MOUSE Glutaredoxin-related protein 5, mitochondrial 4.20 0.93 
MAOX_MOUSE NADP-dependent malic enzyme 4.20 0.83 
M2OM_MOUSE Mitochondrial 2-oxoglutarate/malate carrier protein 4.19 0.83 
CLIC5_MOUSE Chloride intracellular channel protein 5 4.18 0.85 
ACDSB_MOUSE Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial 4.10 0.93 
BASI_MOUSE Basigin 4.09 0.87 
SCRN2_MOUSE Secernin-2 4.05 0.82 
TMM65_MOUSE Transmembrane protein 65 4.03 0.88 
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TIM10_MOUSE Mitochondrial import inner membrane translocase subunit Tim10 4.01 0.86 
MTCH2_MOUSE Mitochondrial carrier homolog 2 4.01 0.89 
PROSC_MOUSE Proline synthase co-transcribed bacterial homolog protein 4.01 0.90 
LDHB_MOUSE L-lactate dehydrogenase B chain 3.99 0.86 
MOT1_MOUSE Monocarboxylate transporter 1 3.98 0.91 
MAVS_MOUSE Mitochondrial antiviral-signaling protein 3.95 0.84 
T126A_MOUSE Transmembrane protein 126A 3.93 0.85 
GLNA_MOUSE Glutamine synthetase 3.91 0.83 
CYB5_MOUSE Cytochrome b5 3.87 0.86 
AT11A_MOUSE Probable phospholipid-transporting ATPase IH 3.85 0.81 
CISY_MOUSE Citrate synthase, mitochondrial 3.83 0.88 
AMPN_MOUSE Aminopeptidase N 3.83 0.95 
ADT1_MOUSE ADP/ATP translocase 1 3.82 0.83 
EM55_MOUSE 55 kDa erythrocyte membrane protein 3.82 0.91 
PTGR2_MOUSE Prostaglandin reductase 2 3.79 0.89 
NPL_MOUSE N-acetylneuraminate lyase 3.76 0.88 
PHB2_MOUSE Prohibitin-2 3.73 0.94 
MIF_MOUSE Macrophage migration inhibitory factor 3.71 0.92 
EBP_MOUSE 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase 3.70 0.91 
AATC_MOUSE Aspartate aminotransferase, cytoplasmic 3.68 0.88 
DHI2_MOUSE Corticosteroid 11-beta-dehydrogenase isozyme 2 3.67 0.83 
TSPO_MOUSE Translocator protein 3.66 0.98 
NCPR_MOUSE NADPH--cytochrome P450 reductase 3.64 0.81 
CYB5B_MOUSE Cytochrome b5 type B 3.62 0.93 
THIC_MOUSE Acetyl-CoA acetyltransferase, cytosolic 3.61 0.85 
GSTA4_MOUSE Glutathione S-transferase A4 3.61 0.86 
RM04_MOUSE 39S ribosomal protein L4, mitochondrial 3.59 0.91 
AMPL_MOUSE Cytosol aminopeptidase 3.57 0.93 
VATC1_MOUSE V-type proton ATPase subunit C 1 3.55 0.83 
GGCT_MOUSE Gamma-glutamylcyclotransferase 3.55 0.99 
C1QBP_MOUSE 
Complement component 1 Q subcomponent-binding protein, 
mitochondrial 
3.52 0.83 
ACBP_MOUSE Acyl-CoA-binding protein 3.51 0.93 
EFTS_MOUSE Elongation factor Ts, mitochondrial 3.50 0.85 
TXTP_MOUSE Tricarboxylate transport protein, mitochondrial 3.47 0.87 
SPRE_MOUSE Sepiapterin reductase 3.47 0.96 
GPX1_MOUSE Glutathione peroxidase 1 3.45 0.92 
F213A_MOUSE Redox-regulatory protein FAM213A 3.42 0.89 
DHB4_MOUSE Peroxisomal multifunctional enzyme type 2 3.39 0.95 
ECHB_MOUSE Trifunctional enzyme subunit beta, mitochondrial 3.37 0.87 
SODC_MOUSE Superoxide dismutase [Cu-Zn] 3.33 0.94 
NAPSA_MOUSE Napsin-A 3.32 0.84 
ESTD_MOUSE S-formylglutathione hydrolase 3.28 0.86 
APMAP_MOUSE Adipocyte plasma membrane-associated protein 3.28 0.84 
GSTM5_MOUSE Glutathione S-transferase Mu 5 3.27 0.87 
PGK1_MOUSE Phosphoglycerate kinase 1 3.27 0.97 
ISCU_MOUSE Iron-sulfur cluster assembly enzyme ISCU, mitochondrial 3.25 0.81 
VA0D1_MOUSE V-type proton ATPase subunit d 1 3.24 0.87 
GVIN1_MOUSE Interferon-induced very large GTPase 1 3.22 0.83 
PRPS2_MOUSE Ribose-phosphate pyrophosphokinase 2 3.20 0.85 
PGM1_MOUSE Phosphoglucomutase-1 3.13 0.90 
PHB_MOUSE Prohibitin 3.13 0.92 
EZRI_MOUSE Ezrin 3.13 0.96 
EHD1_MOUSE EH domain-containing protein 1 3.05 0.83 
HINT1_MOUSE Histidine triad nucleotide-binding protein 1 3.04 0.88 
SAHH_MOUSE Adenosylhomocysteinase 2.99 0.91 
GNPI1_MOUSE Glucosamine-6-phosphate isomerase 1 2.96 0.89 
CAH2_MOUSE Carbonic anhydrase 2 2.95 0.95 
THIKA_MOUSE 3-ketoacyl-CoA thiolase A, peroxisomal 2.95 0.91 
HDHD2_MOUSE Haloacid dehalogenase-like hydrolase domain-containing protein 2 2.90 0.82 
TTC38_MOUSE Tetratricopeptide repeat protein 38 2.87 0.87 
41_MOUSE Protein 4.1 2.84 0.85 
VDAC2_MOUSE Voltage-dependent anion-selective channel protein 2 2.84 0.94 
HEM2_MOUSE Delta-aminolevulinic acid dehydratase 2.82 0.91 
RADI_MOUSE Radixin 2.79 0.83 
CCS_MOUSE Copper chaperone for superoxide dismutase 2.75 0.99 
AKCL2_MOUSE 1,5-anhydro-D-fructose reductase 2.73 0.93 
GPD1L_MOUSE Glycerol-3-phosphate dehydrogenase 1-like protein 2.72 0.87 
TPIS_MOUSE Triosephosphate isomerase 2.71 0.95 
UGPA_MOUSE UTP--glucose-1-phosphate uridylyltransferase 2.66 0.87 
HXK1_MOUSE Hexokinase-1 2.66 0.91 
FIS1_MOUSE Mitochondrial fission 1 protein 2.65 0.89 
GLGB_MOUSE 1,4-alpha-glucan-branching enzyme 2.59 0.98 
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GTR1_MOUSE Solute carrier family 2, facilitated glucose transporter member 1 2.58 0.80 
NAMPT_MOUSE Nicotinamide phosphoribosyltransferase 2.57 0.82 
FUCM_MOUSE Fucose mutarotase 2.52 0.88 
ENOA_MOUSE Alpha-enolase 2.51 0.98 
SYPL1_MOUSE Synaptophysin-like protein 1 2.50 0.91 
S10A1_MOUSE Protein S100-A1 2.44 0.85 
PDXK_MOUSE Pyridoxal kinase 2.42 0.85 
PARK7_MOUSE Protein deglycase DJ-1 2.42 0.93 
PGAM1_MOUSE Phosphoglycerate mutase 1 2.41 0.97 
GMPR1_MOUSE GMP reductase 1 2.41 0.81 
GSTM1_MOUSE Glutathione S-transferase Mu 1 2.37 0.89 
EHD3_MOUSE EH domain-containing protein 3 2.37 0.86 
GSHR_MOUSE Glutathione reductase, mitochondrial 2.33 0.80 
G3P_MOUSE Glyceraldehyde-3-phosphate dehydrogenase 2.29 0.92 
TMM33_MOUSE Transmembrane protein 33 2.28 0.86 
TIM44_MOUSE Mitochondrial import inner membrane translocase subunit TIM44 2.25 0.83 
ARL1_MOUSE ADP-ribosylation factor-like protein 1 2.24 0.90 
PRDX6_MOUSE Peroxiredoxin-6 2.23 0.94 
NDKB_MOUSE Nucleoside diphosphate kinase B 2.11 0.95 
ADK_MOUSE Adenosine kinase 2.03 0.87 
PRDX1_MOUSE Peroxiredoxin-1 2.03 0.91 
G6PI_MOUSE Glucose-6-phosphate isomerase 2.03 0.93 
RS24_MOUSE 40S ribosomal protein S24 1.99 0.88 
NDKA_MOUSE Nucleoside diphosphate kinase A 1.98 0.88 
AP1B1_MOUSE AP-1 complex subunit beta-1 1.97 0.82 
PACN2_MOUSE Protein kinase C and casein kinase substrate in neurons protein 2 1.96 0.85 
MAT2B_MOUSE Methionine adenosyltransferase 2 subunit beta 1.94 0.89 
PEBP1_MOUSE Phosphatidylethanolamine-binding protein 1 1.92 0.92 
SPTN1_MOUSE Spectrin alpha chain, non-erythrocytic 1 1.85 0.88 
TMED4_MOUSE Transmembrane emp24 domain-containing protein 4 1.84 0.90 
SPTB2_MOUSE Spectrin beta chain, non-erythrocytic 1 1.80 0.87 
UGDH_MOUSE UDP-glucose 6-dehydrogenase 1.79 0.82 
GSTP1_MOUSE Glutathione S-transferase P 1 1.77 0.94 
UAP1L_MOUSE UDP-N-acetylhexosamine pyrophosphorylase-like protein 1 1.76 0.84 
SNX3_MOUSE Sorting nexin-3 1.72 0.84 
TBB4B_MOUSE Tubulin beta-4B chain 1.71 0.90 
GALK1_MOUSE Galactokinase 1.64 0.85 
ALDOA_MOUSE Fructose-bisphosphate aldolase A 1.57 0.84 
GPX3_MOUSE Glutathione peroxidase 3 1.54 0.83 
HS90A_MOUSE Heat shock protein HSP 90-alpha 1.50 0.81 
CLH1_MOUSE Clathrin heavy chain 1 1.47 0.88 
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S.1.4 List of GO Biological Process terms significantly enriched in UUO-
overexpressed proteins 
Supplementary Table 3.7: GO Biological Process overrepresentation test on UUO-overexpressed 
proteins, performed by DAVID. Statistical overrepresentation test was performed by DAVID 
(http://david.abcc.ncifcrf.gov) using the annotation term ontologies for Biological Process 
(GOTERM_BP_FAT). The number of proteins belonging to the annotation term and fold change from the 
expected value H0 are in increasing shades of red (the higher the more intense). The p-value is shown in 
increasing shades of blue (the more intense, the lower the p-value). A p-value lower than 0.05 was 
regarded as significant.  
GO Biological Process in UUO overexpressed Count % p-value 
Fold 
Enrichment 
GO:0030029~actin filament-based process 21 11.1 6.51E-15 10.6 
GO:0030036~actin cytoskeleton organization 20 10.6 2.54E-14 10.8 
GO:0007010~cytoskeleton organization 23 12.2 1.22E-11 6.3 
GO:0008064~regulation of actin polymerization or depolymerization 11 5.8 1.59E-10 19.5 
GO:0030832~regulation of actin filament length 11 5.8 1.97E-10 19.2 
GO:0032956~regulation of actin cytoskeleton organization 11 5.8 1.06E-09 16.3 
GO:0032970~regulation of actin filament-based process 11 5.8 1.26E-09 16.0 
GO:0051493~regulation of cytoskeleton organization 12 6.3 1.29E-08 10.8 
GO:0030833~regulation of actin filament polymerization 9 4.8 3.09E-08 17.8 
GO:0008380~RNA splicing 15 7.9 5.54E-08 6.6 
GO:0030198~extracellular matrix organization 11 5.8 1.83E-07 9.7 
GO:0032271~regulation of protein polymerization 9 4.8 2.12E-07 14.0 
GO:0043254~regulation of protein complex assembly 9 4.8 6.00E-07 12.3 
GO:0044087~regulation of cellular component biogenesis 10 5.3 6.42E-07 10.0 
GO:0043062~extracellular structure organization 12 6.3 8.77E-07 7.2 
GO:0033043~regulation of organelle organization 12 6.3 1.22E-06 6.9 
GO:0006397~mRNA processing 15 7.9 1.41E-06 5.1 
GO:0009611~response to wounding 17 9.0 1.70E-06 4.4 
GO:0032535~regulation of cellular component size 12 6.3 1.89E-06 6.6 
GO:0002526~acute inflammatory response 9 4.8 3.29E-06 9.9 
GO:0043933~macromolecular complex subunit organization 17 9.0 3.51E-06 4.1 
GO:0065003~macromolecular complex assembly 16 8.5 5.82E-06 4.2 
GO:0016071~mRNA metabolic process 15 7.9 7.37E-06 4.4 
GO:0006461~protein complex assembly 13 6.9 9.18E-06 5.1 
GO:0070271~protein complex biogenesis 13 6.9 9.18E-06 5.1 
GO:0034621~cellular macromolecular complex subunit organization 13 6.9 1.97E-05 4.7 
GO:0043623~cellular protein complex assembly 9 4.8 2.79E-05 7.4 
GO:0051235~maintenance of location 6 3.2 3.02E-05 16.1 
GO:0034622~cellular macromolecular complex assembly 12 6.3 3.23E-05 4.9 
GO:0007015~actin filament organization 7 3.7 3.63E-05 11.1 
GO:0051258~protein polymerization 6 3.2 7.87E-05 13.3 
GO:0006396~RNA processing 16 8.5 1.14E-04 3.3 
GO:0050729~positive regulation of inflammatory response 5 2.6 1.34E-04 18.5 
GO:0032101~regulation of response to external stimulus 8 4.2 1.54E-04 6.9 
GO:0007517~muscle organ development 10 5.3 1.61E-04 5.0 
GO:0007155~cell adhesion 18 9.5 1.79E-04 2.8 
GO:0022610~biological adhesion 18 9.5 1.83E-04 2.8 
GO:0051494~negative regulation of cytoskeleton organization 6 3.2 1.91E-04 11.1 
GO:0048584~positive regulation of response to stimulus 10 5.3 2.43E-04 4.8 
GO:0042060~wound healing 8 4.2 2.59E-04 6.3 
GO:0006953~acute-phase response 5 2.6 3.29E-04 14.8 
GO:0030865~cortical cytoskeleton organization 4 2.1 3.62E-04 27.3 
GO:0050727~regulation of inflammatory response 6 3.2 4.30E-04 9.3 
GO:0002891~positive regulation of immunoglobulin mediated immune 
response 
4 2.1 4.56E-04 25.4 
GO:0002714~positive regulation of B cell mediated immunity 4 2.1 4.56E-04 25.4 
GO:0002824~positive regulation of adaptive immune response based on 
somatic recombination of immune receptors built from immunoglobulin 
superfamily domains 
5 2.6 5.38E-04 13.1 
GO:0002821~positive regulation of adaptive immune response 5 2.6 5.38E-04 13.1 
GO:0010639~negative regulation of organelle organization 6 3.2 6.35E-04 8.6 
GO:0030155~regulation of cell adhesion 7 3.7 6.43E-04 6.6 
GO:0032103~positive regulation of response to external stimulus 5 2.6 9.13E-04 11.4 
GO:0006954~inflammatory response 10 5.3 9.66E-04 3.9 
GO:0002708~positive regulation of lymphocyte mediated immunity 5 2.6 1.01E-03 11.1 
GO:0002705~positive regulation of leukocyte mediated immunity 5 2.6 1.01E-03 11.1 
GO:0007596~blood coagulation 6 3.2 1.11E-03 7.6 
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GO:0050817~coagulation 6 3.2 1.11E-03 7.6 
GO:0007599~hemostasis 6 3.2 1.18E-03 7.5 
GO:0043244~regulation of protein complex disassembly 5 2.6 1.32E-03 10.3 
GO:0002699~positive regulation of immune effector process 5 2.6 1.70E-03 9.7 
GO:0050766~positive regulation of phagocytosis 4 2.1 2.06E-03 15.4 
GO:0030834~regulation of actin filament depolymerization 4 2.1 2.34E-03 14.8 
GO:0031032~actomyosin structure organization 4 2.1 2.63E-03 14.2 
GO:0030837~negative regulation of actin filament polymerization 4 2.1 2.63E-03 14.2 
GO:0051651~maintenance of location in cell 4 2.1 2.63E-03 14.2 
GO:0050764~regulation of phagocytosis 4 2.1 2.63E-03 14.2 
GO:0050878~regulation of body fluid levels 6 3.2 3.20E-03 6.0 
GO:0031333~negative regulation of protein complex assembly 4 2.1 3.30E-03 13.2 
GO:0000910~cytokinesis 4 2.1 3.30E-03 13.2 
GO:0032272~negative regulation of protein polymerization 4 2.1 3.30E-03 13.2 
GO:0002892~regulation of type II hypersensitivity 3 1.6 3.33E-03 33.3 
GO:0001798~positive regulation of type IIa hypersensitivity 3 1.6 3.33E-03 33.3 
GO:0002888~positive regulation of myeloid leukocyte mediated 
immunity 
3 1.6 3.33E-03 33.3 
GO:0001796~regulation of type IIa hypersensitivity 3 1.6 3.33E-03 33.3 
GO:0002894~positive regulation of type II hypersensitivity 3 1.6 3.33E-03 33.3 
GO:0002822~regulation of adaptive immune response based on somatic 
recombination of immune receptors built from immunoglobulin 
superfamily domains 
5 2.6 3.52E-03 7.9 
GO:0002819~regulation of adaptive immune response 5 2.6 3.52E-03 7.9 
GO:0045185~maintenance of protein location 4 2.1 3.66E-03 12.7 
GO:0019884~antigen processing and presentation of exogenous antigen 4 2.1 3.66E-03 12.7 
GO:0030334~regulation of cell migration 6 3.2 3.69E-03 5.8 
GO:0031349~positive regulation of defense response 5 2.6 3.75E-03 7.8 
GO:0051129~negative regulation of cellular component organization 6 3.2 3.87E-03 5.7 
GO:0050778~positive regulation of immune response 7 3.7 4.24E-03 4.6 
GO:0010033~response to organic substance 14 7.4 4.39E-03 2.5 
GO:0051604~protein maturation 6 3.2 4.43E-03 5.6 
GO:0002712~regulation of B cell mediated immunity 4 2.1 4.47E-03 11.8 
GO:0002889~regulation of immunoglobulin mediated immune response 4 2.1 4.47E-03 11.8 
GO:0006958~complement activation, classical pathway 4 2.1 4.47E-03 11.8 
GO:0006952~defense response 13 6.9 4.50E-03 2.6 
GO:0002866~positive regulation of acute inflammatory response to 
antigenic stimulus 
3 1.6 5.27E-03 26.6 
GO:0002885~positive regulation of hypersensitivity 3 1.6 5.27E-03 26.6 
GO:0034097~response to cytokine stimulus 4 2.1 5.37E-03 11.1 
GO:0016064~immunoglobulin mediated immune response 5 2.6 5.38E-03 7.0 
GO:0051605~protein maturation by peptide bond cleavage 5 2.6 6.01E-03 6.8 
GO:0002706~regulation of lymphocyte mediated immunity 5 2.6 6.01E-03 6.8 
GO:0019724~B cell mediated immunity 5 2.6 6.01E-03 6.8 
GO:0045807~positive regulation of endocytosis 4 2.1 6.37E-03 10.4 
GO:0002675~positive regulation of acute inflammatory response 3 1.6 6.40E-03 24.2 
GO:0043242~negative regulation of protein complex disassembly 4 2.1 6.91E-03 10.1 
GO:0002455~humoral immune response mediated by circulating 
immunoglobulin 
4 2.1 6.91E-03 10.1 
GO:0051270~regulation of cell motion 6 3.2 6.99E-03 5.0 
GO:0044057~regulation of system process 8 4.2 7.45E-03 3.5 
GO:0006956~complement activation 4 2.1 7.48E-03 9.9 
GO:0002541~activation of plasma proteins involved in acute 
inflammatory response 
4 2.1 7.48E-03 9.9 
GO:0002703~regulation of leukocyte mediated immunity 5 2.6 7.79E-03 6.3 
GO:0040012~regulation of locomotion 6 3.2 7.84E-03 4.8 
GO:0002684~positive regulation of immune system process 8 4.2 8.47E-03 3.4 
GO:0002864~regulation of acute inflammatory response to antigenic 
stimulus 
3 1.6 8.94E-03 20.5 
GO:0002863~positive regulation of inflammatory response to antigenic 
stimulus 
3 1.6 8.94E-03 20.5 
GO:0002883~regulation of hypersensitivity 3 1.6 8.94E-03 20.5 
GO:0030030~cell projection organization 10 5.3 9.71E-03 2.8 
GO:0010810~regulation of cell-substrate adhesion 4 2.1 1.00E-02 8.9 
GO:0042692~muscle cell differentiation 6 3.2 1.01E-02 4.6 
GO:0007044~cell-substrate junction assembly 3 1.6 1.04E-02 19.0 
GO:0002449~lymphocyte mediated immunity 5 2.6 1.04E-02 5.8 
GO:0032386~regulation of intracellular transport 4 2.1 1.15E-02 8.5 
GO:0002886~regulation of myeloid leukocyte mediated immunity 3 1.6 1.19E-02 17.8 
GO:0030048~actin filament-based movement 3 1.6 1.19E-02 17.8 
GO:0051017~actin filament bundle formation 3 1.6 1.19E-02 17.8 
GO:0051130~positive regulation of cellular component organization 6 3.2 1.19E-02 4.4 
GO:0045785~positive regulation of cell adhesion 4 2.1 1.22E-02 8.3 
GO:0014706~striated muscle tissue development 6 3.2 1.40E-02 4.2 
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GO:0002250~adaptive immune response 5 2.6 1.46E-02 5.3 
GO:0002460~adaptive immune response based on somatic 
recombination of immune receptors built from immunoglobulin 
superfamily domains 
5 2.6 1.46E-02 5.3 
GO:0008360~regulation of cell shape 4 2.1 1.55E-02 7.6 
GO:0051050~positive regulation of transport 6 3.2 1.63E-02 4.0 
GO:0019882~antigen processing and presentation 5 2.6 1.64E-02 5.1 
GO:0002861~regulation of inflammatory response to antigenic stimulus 3 1.6 1.69E-02 14.8 
GO:0002673~regulation of acute inflammatory response 3 1.6 1.69E-02 14.8 
GO:0002697~regulation of immune effector process 5 2.6 1.70E-02 5.0 
GO:0032989~cellular component morphogenesis 10 5.3 1.72E-02 2.5 
GO:0009719~response to endogenous stimulus 7 3.7 1.74E-02 3.4 
GO:0002443~leukocyte mediated immunity 5 2.6 1.76E-02 5.0 
GO:0016485~protein processing 5 2.6 1.83E-02 4.9 
GO:0032880~regulation of protein localization 5 2.6 1.83E-02 4.9 
GO:0060537~muscle tissue development 6 3.2 1.83E-02 3.9 
GO:0016477~cell migration 8 4.2 1.83E-02 3.0 
GO:0030100~regulation of endocytosis 4 2.1 2.03E-02 6.8 
GO:0050818~regulation of coagulation 3 1.6 2.07E-02 13.3 
GO:0043434~response to peptide hormone stimulus 5 2.6 2.19E-02 4.7 
GO:0032796~uropod organization 2 1.1 2.22E-02 88.8 
GO:0006959~humoral immune response 4 2.1 2.25E-02 6.6 
GO:0034329~cell junction assembly 3 1.6 2.27E-02 12.7 
GO:0030199~collagen fibril organization 3 1.6 2.27E-02 12.7 
GO:0030835~negative regulation of actin filament depolymerization 3 1.6 2.27E-02 12.7 
GO:0000902~cell morphogenesis 9 4.8 2.29E-02 2.6 
GO:0048738~cardiac muscle tissue development 4 2.1 2.59E-02 6.2 
GO:0006936~muscle contraction 4 2.1 2.95E-02 5.9 
GO:0010811~positive regulation of cell-substrate adhesion 3 1.6 3.63E-02 9.9 
GO:0009725~response to hormone stimulus 6 3.2 3.79E-02 3.2 
GO:0019725~cellular homeostasis 9 4.8 3.90E-02 2.3 
GO:0003012~muscle system process 4 2.1 3.91E-02 5.3 
GO:0031667~response to nutrient levels 5 2.6 4.01E-02 3.9 
GO:0048870~cell motility 8 4.2 4.05E-02 2.5 
GO:0051674~localization of cell 8 4.2 4.05E-02 2.5 
GO:0030031~cell projection assembly 4 2.1 4.36E-02 5.1 
GO:0030300~regulation of intestinal cholesterol absorption 2 1.1 4.40E-02 44.4 
GO:0033209~tumor necrosis factor-mediated signaling pathway 2 1.1 4.40E-02 44.4 
GO:0033157~regulation of intracellular protein transport 3 1.6 4.41E-02 8.9 
GO:0034330~cell junction organization 3 1.6 4.95E-02 8.3 
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S.1.5 List of GO Biological Process terms significantly enriched in UUO-
underexpressed proteins 
Supplementary Table 3.8: GO Biological Process overrepresentation test on UUO-
underexpressed proteins, performed by DAVID. Statistical overrepresentation test was performed 
by DAVID (http://david.abcc.ncifcrf.gov) using the annotation term ontologies for Biological Process 
(GOTERM_BP_FAT). The number of proteins belonging to the annotation term and fold change from the 
expected value H0 are in increasing shades of green (the higher the more intense). The p-value is shown 
in increasing shades of blue (the more intense, the lower the p-value). A p-value lower than 0.05 was 
regarded as significant.  
GO Biological Process in UUO underexpressed Count % p-value 
Fold 
Enrichment 
GO:0006091~generation of precursor metabolites and energy 105 24.14 1.50E-101 16.2 
GO:0055114~oxidation reduction 140 32.18 2.90E-94 8.4 
GO:0022900~electron transport chain 54 12.41 1.13E-55 19.4 
GO:0045333~cellular respiration 33 7.59 2.49E-36 22.5 
GO:0015980~energy derivation by oxidation of organic compounds 36 8.28 1.19E-31 14.8 
GO:0006119~oxidative phosphorylation 29 6.67 1.44E-30 20.8 
GO:0051186~cofactor metabolic process 44 10.11 3.16E-30 9.7 
GO:0006732~coenzyme metabolic process 40 9.20 4.68E-30 11.2 
GO:0044271~nitrogen compound biosynthetic process 49 11.26 1.87E-25 6.5 
GO:0006631~fatty acid metabolic process 38 8.74 1.82E-23 8.3 
GO:0006818~hydrogen transport 23 5.29 5.37E-22 17.4 
GO:0009144~purine nucleoside triphosphate metabolic process 29 6.67 1.97E-21 11.0 
GO:0009205~purine ribonucleoside triphosphate metabolic process 28 6.44 7.41E-21 11.1 
GO:0015992~proton transport 22 5.06 9.55E-21 17.0 
GO:0009199~ribonucleoside triphosphate metabolic process 28 6.44 9.85E-21 11.0 
GO:0009145~purine nucleoside triphosphate biosynthetic process 27 6.21 1.54E-20 11.5 
GO:0009142~nucleoside triphosphate biosynthetic process 27 6.21 2.07E-20 11.4 
GO:0009141~nucleoside triphosphate metabolic process 29 6.67 2.19E-20 10.1 
GO:0034220~ion transmembrane transport 20 4.60 4.89E-20 19.1 
GO:0046034~ATP metabolic process 26 5.98 7.61E-20 11.6 
GO:0015986~ATP synthesis coupled proton transport 19 4.37 9.03E-20 20.6 
GO:0015985~energy coupled proton transport, down electrochemical 
gradient 
19 4.37 9.03E-20 20.6 
GO:0009201~ribonucleoside triphosphate biosynthetic process 26 5.98 1.84E-19 11.2 
GO:0009206~purine ribonucleoside triphosphate biosynthetic process 26 5.98 1.84E-19 11.2 
GO:0009259~ribonucleotide metabolic process 29 6.67 2.45E-19 9.3 
GO:0022904~respiratory electron transport chain 17 3.91 3.29E-19 24.4 
GO:0044275~cellular carbohydrate catabolic process 22 5.06 3.29E-19 14.7 
GO:0009150~purine ribonucleotide metabolic process 28 6.44 7.67E-19 9.5 
GO:0016052~carbohydrate catabolic process 24 5.52 1.37E-18 11.9 
GO:0009260~ribonucleotide biosynthetic process 27 6.21 1.47E-18 9.8 
GO:0006754~ATP biosynthetic process 24 5.52 1.86E-18 11.8 
GO:0009152~purine ribonucleotide biosynthetic process 26 5.98 7.33E-18 9.8 
GO:0009060~aerobic respiration 16 3.68 7.91E-18 23.8 
GO:0016054~organic acid catabolic process 23 5.29 2.23E-17 11.4 
GO:0046395~carboxylic acid catabolic process 23 5.29 2.23E-17 11.4 
GO:0006163~purine nucleotide metabolic process 30 6.90 2.51E-17 7.5 
GO:0009165~nucleotide biosynthetic process 31 7.13 2.95E-17 7.2 
GO:0006164~purine nucleotide biosynthetic process 28 6.44 3.55E-17 8.2 
GO:0046164~alcohol catabolic process 21 4.83 4.32E-17 13.0 
GO:0006006~glucose metabolic process 28 6.44 6.33E-17 8.0 
GO:0034654~nucleobase, nucleoside, nucleotide and nucleic acid 
biosynthetic process 
31 7.13 6.66E-17 7.0 
GO:0034404~nucleobase, nucleoside and nucleotide biosynthetic 
process 
31 7.13 6.66E-17 7.0 
GO:0019318~hexose metabolic process 30 6.90 1.16E-16 7.1 
GO:0006084~acetyl-CoA metabolic process 16 3.68 1.24E-16 20.7 
GO:0046365~monosaccharide catabolic process 19 4.37 3.30E-16 14.1 
GO:0005996~monosaccharide metabolic process 31 7.13 5.30E-16 6.5 
GO:0006099~tricarboxylic acid cycle 14 3.22 9.60E-16 24.5 
GO:0046356~acetyl-CoA catabolic process 14 3.22 2.05E-15 23.5 
GO:0006096~glycolysis 17 3.91 3.18E-15 15.5 
GO:0006007~glucose catabolic process 18 4.14 3.35E-15 13.9 
GO:0019320~hexose catabolic process 18 4.14 3.35E-15 13.9 
GO:0009109~coenzyme catabolic process 14 3.22 5.07E-14 19.4 
GO:0051187~cofactor catabolic process 14 3.22 2.43E-13 17.6 
GO:0055085~transmembrane transport 42 9.66 9.51E-13 3.7 
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GO:0042773~ATP synthesis coupled electron transport 11 2.53 2.83E-12 24.6 
GO:0006749~glutathione metabolic process 12 2.76 3.48E-12 20.1 
GO:0006575~cellular amino acid derivative metabolic process 23 5.29 5.02E-12 6.6 
GO:0006518~peptide metabolic process 13 2.99 6.76E-11 13.8 
GO:0006790~sulfur metabolic process 18 4.14 1.27E-10 7.7 
GO:0046394~carboxylic acid biosynthetic process 21 4.83 2.79E-10 6.0 
GO:0016053~organic acid biosynthetic process 21 4.83 2.79E-10 6.0 
GO:0043648~dicarboxylic acid metabolic process 10 2.30 4.22E-10 20.1 
GO:0008652~cellular amino acid biosynthetic process 13 2.99 4.61E-10 11.9 
GO:0009063~cellular amino acid catabolic process 14 3.22 4.73E-10 10.4 
GO:0015672~monovalent inorganic cation transport 29 6.67 2.08E-09 3.8 
GO:0009310~amine catabolic process 14 3.22 5.48E-09 8.7 
GO:0010035~response to inorganic substance 16 3.68 7.05E-09 7.0 
GO:0006800~oxygen and reactive oxygen species metabolic process 12 2.76 1.46E-08 10.3 
GO:0042775~mitochondrial ATP synthesis coupled electron transport 8 1.84 1.60E-08 23.0 
GO:0009309~amine biosynthetic process 14 3.22 2.41E-08 7.7 
GO:0006979~response to oxidative stress 15 3.45 2.68E-08 6.9 
GO:0000302~response to reactive oxygen species 10 2.30 1.66E-07 11.2 
GO:0045454~cell redox homeostasis 12 2.76 3.05E-07 7.8 
GO:0042743~hydrogen peroxide metabolic process 8 1.84 3.18E-07 16.1 
GO:0051188~cofactor biosynthetic process 14 3.22 3.58E-07 6.2 
GO:0006811~ion transport 42 9.66 4.08E-07 2.4 
GO:0009064~glutamine family amino acid metabolic process 10 2.30 8.55E-07 9.3 
GO:0009062~fatty acid catabolic process 8 1.84 9.44E-07 14.0 
GO:0034637~cellular carbohydrate biosynthetic process 11 2.53 9.96E-07 7.9 
GO:0042542~response to hydrogen peroxide 8 1.84 1.31E-06 13.4 
GO:0006635~fatty acid beta-oxidation 7 1.61 1.45E-06 17.6 
GO:0006090~pyruvate metabolic process 8 1.84 1.77E-06 12.9 
GO:0019319~hexose biosynthetic process 8 1.84 1.77E-06 12.9 
GO:0046165~alcohol biosynthetic process 9 2.07 2.71E-06 9.8 
GO:0034614~cellular response to reactive oxygen species 7 1.61 3.21E-06 15.6 
GO:0009108~coenzyme biosynthetic process 11 2.53 3.55E-06 6.9 
GO:0006812~cation transport 32 7.36 4.74E-06 2.5 
GO:0006536~glutamate metabolic process 6 1.38 6.25E-06 20.1 
GO:0006094~gluconeogenesis 7 1.61 6.43E-06 14.1 
GO:0006766~vitamin metabolic process 11 2.53 7.15E-06 6.4 
GO:0046364~monosaccharide biosynthetic process 8 1.84 8.54E-06 10.4 
GO:0034599~cellular response to oxidative stress 7 1.61 1.19E-05 12.8 
GO:0019395~fatty acid oxidation 7 1.61 2.05E-05 11.7 
GO:0034440~lipid oxidation 7 1.61 2.05E-05 11.7 
GO:0009081~branched chain family amino acid metabolic process 6 1.38 2.23E-05 16.1 
GO:0006558~L-phenylalanine metabolic process 5 1.15 2.40E-05 25.1 
GO:0019400~alditol metabolic process 7 1.61 2.65E-05 11.3 
GO:0016051~carbohydrate biosynthetic process 11 2.53 3.76E-05 5.3 
GO:0006081~cellular aldehyde metabolic process 6 1.38 4.41E-05 14.2 
GO:0044242~cellular lipid catabolic process 9 2.07 6.63E-05 6.5 
GO:0006120~mitochondrial electron transport, NADH to ubiquinone 4 0.92 1.46E-04 32.2 
GO:0070301~cellular response to hydrogen peroxide 5 1.15 1.57E-04 16.8 
GO:0042744~hydrogen peroxide catabolic process 5 1.15 1.57E-04 16.8 
GO:0006767~water-soluble vitamin metabolic process 7 1.61 1.66E-04 8.3 
GO:0000096~sulfur amino acid metabolic process 6 1.38 2.12E-04 10.5 
GO:0006559~L-phenylalanine catabolic process 4 0.92 2.86E-04 26.8 
GO:0006733~oxidoreduction coenzyme metabolic process 7 1.61 3.14E-04 7.4 
GO:0043603~cellular amide metabolic process 7 1.61 3.64E-04 7.2 
GO:0009119~ribonucleoside metabolic process 7 1.61 3.64E-04 7.2 
GO:0006820~anion transport 12 2.76 3.89E-04 3.7 
GO:0019439~aromatic compound catabolic process 5 1.15 4.09E-04 13.4 
GO:0009084~glutamine family amino acid biosynthetic process 5 1.15 4.09E-04 13.4 
GO:0006796~phosphate metabolic process 39 8.97 4.33E-04 1.8 
GO:0006793~phosphorus metabolic process 39 8.97 4.33E-04 1.8 
GO:0009116~nucleoside metabolic process 8 1.84 4.43E-04 5.7 
GO:0016310~phosphorylation 34 7.82 4.72E-04 1.9 
GO:0006107~oxaloacetate metabolic process 4 0.92 4.91E-04 23.0 
GO:0019362~pyridine nucleotide metabolic process 6 1.38 5.60E-04 8.6 
GO:0019751~polyol metabolic process 7 1.61 6.26E-04 6.5 
GO:0030258~lipid modification 7 1.61 1.01E-03 6.0 
GO:0006637~acyl-CoA metabolic process 5 1.15 1.31E-03 10.1 
GO:0019748~secondary metabolic process 8 1.84 1.57E-03 4.7 
GO:0009072~aromatic amino acid family metabolic process 5 1.15 1.59E-03 9.6 
GO:0006570~tyrosine metabolic process 4 0.92 1.59E-03 16.1 
GO:0009065~glutamine family amino acid catabolic process 4 0.92 1.59E-03 16.1 
GO:0006106~fumarate metabolic process 3 0.69 1.81E-03 40.2 
GO:0000305~response to oxygen radical 4 0.92 2.15E-03 14.6 
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GO:0009074~aromatic amino acid family catabolic process 4 0.92 2.15E-03 14.6 
GO:0006071~glycerol metabolic process 5 1.15 2.27E-03 8.7 
GO:0046496~nicotinamide nucleotide metabolic process 5 1.15 2.67E-03 8.4 
GO:0009820~alkaloid metabolic process 5 1.15 2.67E-03 8.4 
GO:0006769~nicotinamide metabolic process 5 1.15 2.67E-03 8.4 
GO:0044272~sulfur compound biosynthetic process 6 1.38 3.28E-03 5.9 
GO:0006839~mitochondrial transport 6 1.38 3.65E-03 5.7 
GO:0019725~cellular homeostasis 18 4.14 5.38E-03 2.1 
GO:0009110~vitamin biosynthetic process 5 1.15 5.41E-03 6.9 
GO:0006572~tyrosine catabolic process 3 0.69 5.84E-03 24.1 
GO:0016042~lipid catabolic process 10 2.30 6.18E-03 3.0 
GO:0042398~cellular amino acid derivative biosynthetic process 6 1.38 6.51E-03 5.0 
GO:0009067~aspartate family amino acid biosynthetic process 4 0.92 6.66E-03 10.1 
GO:0018130~heterocycle biosynthetic process 6 1.38 8.41E-03 4.7 
GO:0006122~mitochondrial electron transport, ubiquinol to 
cytochrome c 
3 0.69 8.61E-03 20.1 
GO:0006108~malate metabolic process 3 0.69 8.61E-03 20.1 
GO:0006801~superoxide metabolic process 4 0.92 1.09E-02 8.5 
GO:0006534~cysteine metabolic process 3 0.69 1.19E-02 17.2 
GO:0006577~betaine metabolic process 3 0.69 1.19E-02 17.2 
GO:0019430~removal of superoxide radicals 3 0.69 1.19E-02 17.2 
GO:0006633~fatty acid biosynthetic process 7 1.61 1.52E-02 3.5 
GO:0015711~organic anion transport 5 1.15 1.54E-02 5.2 
GO:0009083~branched chain family amino acid catabolic process 3 0.69 1.56E-02 15.1 
GO:0046146~tetrahydrobiopterin metabolic process 3 0.69 1.56E-02 15.1 
GO:0006750~glutathione biosynthetic process 3 0.69 1.56E-02 15.1 
GO:0051881~regulation of mitochondrial membrane potential 3 0.69 1.56E-02 15.1 
GO:0009069~serine family amino acid metabolic process 4 0.92 1.64E-02 7.3 
GO:0042364~water-soluble vitamin biosynthetic process 4 0.92 1.64E-02 7.3 
GO:0009066~aspartate family amino acid metabolic process 4 0.92 1.64E-02 7.3 
GO:0042592~homeostatic process 24 5.52 1.93E-02 1.7 
GO:0006525~arginine metabolic process 3 0.69 1.97E-02 13.4 
GO:0006072~glycerol-3-phosphate metabolic process 3 0.69 1.97E-02 13.4 
GO:0008015~blood circulation 8 1.84 2.05E-02 2.9 
GO:0003013~circulatory system process 8 1.84 2.05E-02 2.9 
GO:0046128~purine ribonucleoside metabolic process 4 0.92 2.08E-02 6.7 
GO:0042278~purine nucleoside metabolic process 4 0.92 2.08E-02 6.7 
GO:0008217~regulation of blood pressure 6 1.38 2.24E-02 3.7 
GO:0043043~peptide biosynthetic process 3 0.69 2.42E-02 12.1 
GO:0000303~response to superoxide 3 0.69 2.42E-02 12.1 
GO:0007005~mitochondrion organization 7 1.61 3.35E-02 2.9 
GO:0015800~acidic amino acid transport 3 0.69 3.43E-02 10.1 
GO:0015813~L-glutamate transport 3 0.69 3.43E-02 10.1 
GO:0046942~carboxylic acid transport 7 1.61 3.65E-02 2.8 
GO:0015849~organic acid transport 7 1.61 3.81E-02 2.8 
GO:0051289~protein homotetramerization 3 0.69 3.99E-02 9.3 
GO:0010038~response to metal ion 5 1.15 4.21E-02 3.8 
GO:0000097~sulfur amino acid biosynthetic process 3 0.69 4.58E-02 8.6 
GO:0006739~NADP metabolic process 3 0.69 4.58E-02 8.6 
GO:0019563~glycerol catabolic process 2 0.46 4.90E-02 40.2 
GO:0019551~glutamate catabolic process to 2-oxoglutarate 2 0.46 4.90E-02 40.2 
GO:0006532~aspartate biosynthetic process 2 0.46 4.90E-02 40.2 
GO:0006097~glyoxylate cycle 2 0.46 4.90E-02 40.2 
GO:0043490~malate-aspartate shuttle 2 0.46 4.90E-02 40.2 
GO:0006551~leucine metabolic process 2 0.46 4.90E-02 40.2 
GO:0046168~glycerol-3-phosphate catabolic process 2 0.46 4.90E-02 40.2 
GO:0019550~glutamate catabolic process to aspartate 2 0.46 4.90E-02 40.2 
GO:0019405~alditol catabolic process 2 0.46 4.90E-02 40.2 
GO:0006059~hexitol metabolic process 2 0.46 4.90E-02 40.2 
GO:0015810~aspartate transport 2 0.46 4.90E-02 40.2 
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S.1.6 List of GO Molecular Function terms significantly enriched in UUO-
overexpressed proteins 
Supplementary Table 3.9: GO Molecular Function overrepresentation test on UUO-
overexpressed proteins, performed by DAVID. Statistical overrepresentation test was performed by 
DAVID (http://david.abcc.ncifcrf.gov) using the annotation term ontologies for Molecular Function 
(GOTERM_MF_FAT). The number of proteins belonging to the annotation term and fold change from the 
expected value H0 are in increasing shades of red (the higher the more intense). The p-value is shown in 
increasing shades of blue (the more intense, the lower the p-value). A p-value lower than 0.05 was 
regarded as significant 
GO Molecular Function in UUO overexpressed Count % PValue Fold Enrichment 
GO:0003779~actin binding 32 16.9 1.19E-20 8.9 
GO:0008092~cytoskeletal protein binding 34 18.0 6.34E-18 6.6 
GO:0005198~structural molecule activity 30 15.9 2.26E-13 5.3 
GO:0005201~extracellular matrix structural constituent 10 5.3 6.45E-11 26.7 
GO:0004857~enzyme inhibitor activity 16 8.5 3.53E-07 5.3 
GO:0004866~endopeptidase inhibitor activity 13 6.9 7.57E-07 6.5 
GO:0030414~peptidase inhibitor activity 13 6.9 1.95E-06 5.9 
GO:0051015~actin filament binding 8 4.2 2.22E-06 13.1 
GO:0005544~calcium-dependent phospholipid binding 6 3.2 9.76E-06 20.0 
GO:0005509~calcium ion binding 27 14.3 1.38E-05 2.6 
GO:0048407~platelet-derived growth factor binding 4 2.1 1.49E-04 35.6 
GO:0008289~lipid binding 14 7.4 3.71E-04 3.2 
GO:0004867~serine-type endopeptidase inhibitor activity 8 4.2 5.71E-04 5.6 
GO:0055102~lipase inhibitor activity 3 1.6 1.50E-03 48.0 
GO:0004859~phospholipase inhibitor activity 3 1.6 1.50E-03 48.0 
GO:0030898~actin-dependent ATPase activity 3 1.6 2.22E-03 40.0 
GO:0050840~extracellular matrix binding 4 2.1 3.54E-03 12.8 
GO:0003723~RNA binding 18 9.5 4.16E-03 2.1 
GO:0001871~pattern binding 7 3.7 5.23E-03 4.4 
GO:0030247~polysaccharide binding 7 3.7 5.23E-03 4.4 
GO:0005200~structural constituent of cytoskeleton 4 2.1 5.42E-03 11.0 
GO:0005539~glycosaminoglycan binding 6 3.2 1.38E-02 4.2 
GO:0005516~calmodulin binding 6 3.2 1.38E-02 4.2 
GO:0005543~phospholipid binding 6 3.2 1.63E-02 4.0 
GO:0008201~heparin binding 5 2.6 1.97E-02 4.8 
GO:0003774~motor activity 6 3.2 2.88E-02 3.5 
GO:0019834~phospholipase A2 inhibitor activity 2 1.1 3.68E-02 53.4 
GO:0008538~proteasome activator activity 2 1.1 4.88E-02 40.0 
GO:0043531~ADP binding 2 1.1 4.88E-02 40.0 
GO:0010860~proteasome regulator activity 2 1.1 4.88E-02 40.0 
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S.1.7 List of GO Molecular Function terms significantly enriched in UUO-
underexpressed proteins 
Supplementary Table 3.10: GO Molecular Function overrepresentation test on UUO-
underexpressed proteins, performed by DAVID. Statistical overrepresentation test was performed 
by DAVID (http://david.abcc.ncifcrf.gov) using the annotation term ontologies for Molecular Function 
(GOTERM_MF_FAT). The number of proteins belonging to the annotation term and fold change from the 
expected value H0 are in increasing shades of green (the higher the more intense). The p-value is shown 
in increasing shades of blue (the more intense, the lower the p-value). A p-value lower than 0.05 was 
regarded as significant 
GO Molecular Function in UUO underexpressed Count % p-value 
Fold 
Enrichment 
GO:0048037~cofactor binding 60 13.8 8.25E-41 9.4 
GO:0050662~coenzyme binding 47 10.8 6.11E-34 10.4 
GO:0015077~monovalent inorganic cation transmembrane transporter 
activity 
35 8.0 1.95E-30 14.2 
GO:0015078~hydrogen ion transmembrane transporter activity 34 7.8 4.50E-30 14.7 
GO:0022890~inorganic cation transmembrane transporter activity 35 8.0 3.60E-24 9.7 
GO:0016651~oxidoreductase activity, acting on NADH or NADPH 24 5.5 1.09E-22 16.6 
GO:0016655~oxidoreductase activity, acting on NADH or NADPH, 
quinone or similar compound as acceptor 
17 3.9 1.14E-18 22.3 
GO:0050136~NADH dehydrogenase (quinone) activity 16 3.7 4.44E-18 23.6 
GO:0003954~NADH dehydrogenase activity 16 3.7 4.44E-18 23.6 
GO:0008137~NADH dehydrogenase (ubiquinone) activity 16 3.7 4.44E-18 23.6 
GO:0009055~electron carrier activity 32 7.4 1.07E-14 5.6 
GO:0051287~NAD or NADH binding 17 3.9 2.39E-14 13.7 
GO:0042625~ATPase activity, coupled to transmembrane movement of 
ions 
19 4.4 3.98E-13 9.7 
GO:0046961~proton-transporting ATPase activity, rotational mechanism 11 2.5 7.54E-13 25.9 
GO:0015405~P-P-bond-hydrolysis-driven transmembrane transporter 
activity 
22 5.1 1.79E-12 7.3 
GO:0015399~primary active transmembrane transporter activity 22 5.1 2.17E-12 7.2 
GO:0016820~hydrolase activity, acting on acid anhydrides, catalyzing 
transmembrane movement of substances 
21 4.8 2.32E-12 7.7 
GO:0042626~ATPase activity, coupled to transmembrane movement of 
substances 
21 4.8 2.32E-12 7.7 
GO:0043492~ATPase activity, coupled to movement of substances 21 4.8 2.32E-12 7.7 
GO:0050660~FAD binding 17 3.9 9.16E-11 8.5 
GO:0016209~antioxidant activity 13 3.0 5.87E-10 11.5 
GO:0019829~cation-transporting ATPase activity 11 2.5 6.37E-10 15.5 
GO:0016620~oxidoreductase activity, acting on the aldehyde or oxo 
group of donors, NAD or NADP as acceptor 
11 2.5 3.53E-09 13.4 
GO:0003995~acyl-CoA dehydrogenase activity 9 2.1 3.95E-09 19.9 
GO:0046933~hydrogen ion transporting ATP synthase activity, rotational 
mechanism 
8 1.8 4.04E-09 25.7 
GO:0015002~heme-copper terminal oxidase activity 10 2.3 5.94E-09 15.4 
GO:0004129~cytochrome-c oxidase activity 10 2.3 5.94E-09 15.4 
GO:0016675~oxidoreductase activity, acting on heme group of donors 10 2.3 5.94E-09 15.4 
GO:0016676~oxidoreductase activity, acting on heme group of donors, 
oxygen as acceptor 
10 2.3 5.94E-09 15.4 
GO:0004364~glutathione transferase activity 10 2.3 2.11E-08 13.6 
GO:0019842~vitamin binding 18 4.1 4.83E-08 5.3 
GO:0051540~metal cluster binding 12 2.8 1.09E-07 8.5 
GO:0051536~iron-sulfur cluster binding 12 2.8 1.09E-07 8.5 
GO:0016408~C-acyltransferase activity 8 1.8 1.24E-07 17.7 
GO:0000166~nucleotide binding 102 23.4 1.24E-07 1.7 
GO:0016836~hydro-lyase activity 11 2.5 1.87E-07 9.3 
GO:0016684~oxidoreductase activity, acting on peroxide as acceptor 9 2.1 7.08E-07 11.4 
GO:0004601~peroxidase activity 9 2.1 7.08E-07 11.4 
GO:0008553~hydrogen-exporting ATPase activity, phosphorylative 
mechanism 
7 1.6 1.20E-06 17.7 
GO:0042623~ATPase activity, coupled 22 5.1 1.38E-06 3.5 
GO:0016769~transferase activity, transferring nitrogenous groups 9 2.1 2.17E-06 9.9 
GO:0003857~3-hydroxyacyl-CoA dehydrogenase activity 5 1.1 3.05E-06 35.3 
GO:0016878~acid-thiol ligase activity 7 1.6 4.61E-06 14.6 
GO:0016877~ligase activity, forming carbon-sulfur bonds 8 1.8 9.56E-06 10.1 
GO:0001882~nucleoside binding 73 16.8 1.39E-05 1.7 
GO:0005506~iron ion binding 26 6.0 1.44E-05 2.7 
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GO:0016765~transferase activity, transferring alkyl or aryl (other than 
methyl) groups 
10 2.3 1.52E-05 6.7 
GO:0030554~adenyl nucleotide binding 72 16.6 1.57E-05 1.7 
GO:0030170~pyridoxal phosphate binding 10 2.3 1.78E-05 6.5 
GO:0070279~vitamin B6 binding 10 2.3 1.78E-05 6.5 
GO:0051920~peroxiredoxin activity 5 1.1 2.04E-05 25.2 
GO:0016885~ligase activity, forming carbon-carbon bonds 5 1.1 2.04E-05 25.2 
GO:0001883~purine nucleoside binding 72 16.6 2.13E-05 1.6 
GO:0031406~carboxylic acid binding 12 2.8 2.56E-05 5.0 
GO:0015662~ATPase activity, coupled to transmembrane movement of 
ions, phosphorylative mechanism 
10 2.3 2.80E-05 6.2 
GO:0016667~oxidoreductase activity, acting on sulfur group of donors 8 1.8 3.05E-05 8.6 
GO:0051539~4 iron, 4 sulfur cluster binding 7 1.6 3.26E-05 10.8 
GO:0000287~magnesium ion binding 28 6.4 3.78E-05 2.4 
GO:0008483~transaminase activity 7 1.6 4.24E-05 10.3 
GO:0016887~ATPase activity 22 5.1 4.88E-05 2.8 
GO:0016645~oxidoreductase activity, acting on the CH-NH group of 
donors 
7 1.6 5.45E-05 9.9 
GO:0016405~CoA-ligase activity 5 1.1 7.03E-05 19.6 
GO:0004300~enoyl-CoA hydratase activity 4 0.9 8.73E-05 35.3 
GO:0016453~C-acetyltransferase activity 4 0.9 8.73E-05 35.3 
GO:0003988~acetyl-CoA C-acyltransferase activity 4 0.9 2.14E-04 28.3 
GO:0017076~purine nucleotide binding 78 17.9 3.34E-04 1.5 
GO:0008121~ubiquinol-cytochrome-c reductase activity 4 0.9 4.19E-04 23.6 
GO:0016681~oxidoreductase activity, acting on diphenols and related 
substances as donors, cytochrome as acceptor 
4 0.9 4.19E-04 23.6 
GO:0016679~oxidoreductase activity, acting on diphenols and related 
substances as donors 
4 0.9 4.19E-04 23.6 
GO:0016860~intramolecular oxidoreductase activity 7 1.6 6.24E-04 6.5 
GO:0015036~disulfide oxidoreductase activity 5 1.1 6.66E-04 11.8 
GO:0033293~monocarboxylic acid binding 6 1.4 8.43E-04 7.9 
GO:0016624~oxidoreductase activity, acting on the aldehyde or oxo 
group of donors, disulfide as acceptor 
4 0.9 1.65E-03 15.7 
GO:0016868~intramolecular transferase activity, phosphotransferases 4 0.9 2.31E-03 14.1 
GO:0004602~glutathione peroxidase activity 4 0.9 2.31E-03 14.1 
GO:0003985~acetyl-CoA C-acetyltransferase activity 3 0.7 2.34E-03 35.3 
GO:0050661~NADP or NADPH binding 5 1.1 2.55E-03 8.4 
GO:0015035~protein disulfide oxidoreductase activity 4 0.9 3.11E-03 12.9 
GO:0019205~nucleobase, nucleoside, nucleotide kinase activity 6 1.4 3.20E-03 5.9 
GO:0016866~intramolecular transferase activity 5 1.1 4.24E-03 7.4 
GO:0016833~oxo-acid-lyase activity 3 0.7 4.59E-03 26.5 
GO:0004774~succinate-CoA ligase activity 3 0.7 4.59E-03 26.5 
GO:0016776~phosphotransferase activity, phosphate group as acceptor 5 1.1 6.55E-03 6.5 
GO:0009374~biotin binding 3 0.7 7.51E-03 21.2 
GO:0031405~lipoic acid binding 3 0.7 7.51E-03 21.2 
GO:0016628~oxidoreductase activity, acting on the CH-CH group of 
donors, NAD or NADP as acceptor 
4 0.9 7.88E-03 9.4 
GO:0008430~selenium binding 5 1.1 1.08E-02 5.7 
GO:0004448~isocitrate dehydrogenase activity 3 0.7 1.11E-02 17.7 
GO:0016406~carnitine O-acyltransferase activity 3 0.7 1.11E-02 17.7 
GO:0016668~oxidoreductase activity, acting on sulfur group of donors, 
NAD or NADP as acceptor 
3 0.7 1.11E-02 17.7 
GO:0051537~2 iron, 2 sulfur cluster binding 4 0.9 1.54E-02 7.4 
GO:0005524~ATP binding 55 12.6 1.82E-02 1.3 
GO:0004029~aldehyde dehydrogenase (NAD) activity 3 0.7 1.99E-02 13.3 
GO:0016615~malate dehydrogenase activity 3 0.7 1.99E-02 13.3 
GO:0004017~adenylate kinase activity 3 0.7 1.99E-02 13.3 
GO:0032559~adenyl ribonucleotide binding 55 12.6 2.33E-02 1.3 
GO:0030145~manganese ion binding 10 2.3 2.45E-02 2.4 
GO:0016861~intramolecular oxidoreductase activity, interconverting 
aldoses and ketoses 
3 0.7 2.51E-02 11.8 
GO:0048038~quinone binding 3 0.7 2.51E-02 11.8 
GO:0010181~FMN binding 3 0.7 3.69E-02 9.6 
GO:0008237~metallopeptidase activity 11 2.5 3.95E-02 2.1 
GO:0004177~aminopeptidase activity 4 0.9 4.34E-02 5.0 
GO:0000062~acyl-CoA binding 3 0.7 4.35E-02 8.8 
GO:0008238~exopeptidase activity 6 1.4 4.75E-02 3.0 
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S.1.8 List of GO Cellular Component terms significantly enriched in UUO-
overexpressed proteins 
Supplementary Table 3.11: GO Cellular Component overrepresentation test on UUO-
overexpressed proteins, performed by DAVID. Statistical overrepresentation test was performed by 
DAVID (http://david.abcc.ncifcrf.gov) using the annotation term ontologies for Cellular Component 
(GOTERM_CC_FAT). The number of proteins belonging to the annotation term and fold change from the 
expected value H0 are in increasing shades of red (the higher the more intense). The p-value is shown in 
increasing shades of blue (the more intense, the lower the p-value). A p-value lower than 0.05 was 
regarded as significant. 
GO Cellular Compartment in UUO overexpressed Count % p-value Fold Enrichment 
GO:0015629~actin cytoskeleton 28 14.8 2.30E-20 10.88 
GO:0044421~extracellular region part 46 24.3 5.29E-19 4.73 
GO:0031012~extracellular matrix 30 15.9 1.02E-17 7.73 
GO:0005578~proteinaceous extracellular matrix 29 15.3 3.53E-17 7.78 
GO:0005856~cytoskeleton 52 27.5 4.71E-17 3.69 
GO:0005576~extracellular region 62 32.8 8.36E-16 2.94 
GO:0044420~extracellular matrix part 17 9.0 2.21E-14 14.72 
GO:0043232~intracellular non-membrane-bounded organelle 58 30.7 5.59E-11 2.41 
GO:0043228~non-membrane-bounded organelle 58 30.7 5.59E-11 2.41 
GO:0044430~cytoskeletal part 35 18.5 7.52E-11 3.60 
GO:0005604~basement membrane 13 6.9 8.87E-11 14.18 
GO:0005938~cell cortex 15 7.9 5.09E-10 9.48 
GO:0042383~sarcolemma 9 4.8 1.02E-07 15.25 
GO:0044448~cell cortex part 10 5.3 2.85E-07 10.91 
GO:0001725~stress fiber 7 3.7 2.90E-07 24.24 
GO:0032432~actin filament bundle 7 3.7 3.83E-07 23.23 
GO:0042641~actomyosin 7 3.7 8.16E-07 20.65 
GO:0030863~cortical cytoskeleton 8 4.2 9.09E-07 14.82 
GO:0031252~cell leading edge 11 5.8 1.30E-06 7.82 
GO:0005681~spliceosome 11 5.8 3.30E-06 7.07 
GO:0005615~extracellular space 21 11.1 5.55E-06 3.27 
GO:0042470~melanosome 9 4.8 1.05E-05 8.43 
GO:0048770~pigment granule 9 4.8 1.05E-05 8.43 
GO:0044449~contractile fiber part 9 4.8 1.14E-05 8.33 
GO:0005605~basal lamina 5 2.6 1.53E-05 30.63 
GO:0043292~contractile fiber 9 4.8 2.38E-05 7.55 
GO:0005882~intermediate filament 10 5.3 5.35E-05 5.81 
GO:0045111~intermediate filament cytoskeleton 10 5.3 6.33E-05 5.69 
GO:0030016~myofibril 8 4.2 1.38E-04 7.00 
GO:0043259~laminin-10 complex 3 1.6 4.60E-04 79.64 
GO:0005925~focal adhesion 6 3.2 7.04E-04 8.38 
GO:0005924~cell-substrate adherens junction 6 3.2 9.61E-04 7.83 
GO:0016459~myosin complex 6 3.2 9.61E-04 7.83 
GO:0030055~cell-substrate junction 6 3.2 1.37E-03 7.24 
GO:0005829~cytosol 17 9.0 1.38E-03 2.47 
GO:0005581~collagen 4 2.1 1.59E-03 16.77 
GO:0016323~basolateral plasma membrane 8 4.2 1.93E-03 4.52 
GO:0005912~adherens junction 7 3.7 2.10E-03 5.26 
GO:0005885~Arp2/3 protein complex 3 1.6 2.24E-03 39.82 
GO:0030018~Z disc 5 2.6 2.53E-03 8.66 
GO:0043256~laminin complex 3 1.6 3.12E-03 34.13 
GO:0030017~sarcomere 6 3.2 3.21E-03 5.97 
GO:0031674~I band 5 2.6 4.25E-03 7.51 
GO:0070161~anchoring junction 7 3.7 4.39E-03 4.53 
GO:0016023~cytoplasmic membrane-bounded vesicle 13 6.9 5.69E-03 2.50 
GO:0031988~membrane-bounded vesicle 13 6.9 6.36E-03 2.47 
GO:0001772~immunological synapse 3 1.6 1.10E-02 18.38 
GO:0031410~cytoplasmic vesicle 14 7.4 1.11E-02 2.19 
GO:0005788~endoplasmic reticulum lumen 5 2.6 1.24E-02 5.53 
GO:0042995~cell projection 15 7.9 1.28E-02 2.08 
GO:0030529~ribonucleoprotein complex 13 6.9 1.30E-02 2.24 
GO:0031982~vesicle 14 7.4 1.31E-02 2.15 
GO:0034364~high-density lipoprotein particle 3 1.6 1.65E-02 14.93 
GO:0001726~ruffle 4 2.1 2.07E-02 6.78 
GO:0034399~nuclear periphery 4 2.1 2.31E-02 6.50 
GO:0045177~apical part of cell 6 3.2 2.77E-02 3.51 
GO:0030864~cortical actin cytoskeleton 3 1.6 3.03E-02 10.86 
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GO:0031594~neuromuscular junction 3 1.6 3.03E-02 10.86 
GO:0016324~apical plasma membrane 5 2.6 3.53E-02 4.02 
GO:0030485~smooth muscle contractile fiber 2 1.1 3.70E-02 53.10 
GO:0008537~proteasome activator complex 2 1.1 3.70E-02 53.10 
GO:0005577~fibrinogen complex 2 1.1 3.70E-02 53.10 
GO:0045098~type III intermediate filament 2 1.1 3.70E-02 53.10 
GO:0030027~lamellipodium 4 2.1 4.39E-02 5.06 
GO:0032994~protein-lipid complex 3 1.6 4.43E-02 8.85 
GO:0034358~plasma lipoprotein particle 3 1.6 4.43E-02 8.85 
GO:0045095~keratin filament 4 2.1 4.57E-02 4.98 
GO:0001527~microfibril 2 1.1 4.90E-02 39.82 
GO:0005638~lamin filament 2 1.1 4.90E-02 39.82 
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S.1.9 List of GO Cellular Component terms significantly enriched in UUO-
underexpressed proteins 
Supplementary Table 3.12: GO Cellular Component overrepresentation test on UUO-
underexpressed proteins, performed by DAVID. Statistical overrepresentation test was performed 
by DAVID (http://david.abcc.ncifcrf.gov) using the annotation term ontologies for Cellular Component 
(GOTERM_CC_FAT). The number of proteins belonging to the annotation term and fold change from the 
expected value H0 are in increasing shades of green (the higher the more intense). The p-value is shown 
in increasing shades of blue (the more intense, the lower the p-value). A p-value lower than 0.05 was 
regarded as significant 
GO Cellular Compartment in UUO underexpressed 
Cou
nt 
% p-value 
Fold 
Enrich
ment 
GO:0005739~mitochondrion 269 61.8 2.12E-185 6.9 
GO:0044429~mitochondrial part 160 36.8 7.94E-126 10.3 
GO:0005743~mitochondrial inner membrane 112 25.7 1.66E-96 12.8 
GO:0031966~mitochondrial membrane 121 27.8 2.15E-96 11.1 
GO:0019866~organelle inner membrane 113 26.0 6.45E-95 12.3 
GO:0005740~mitochondrial envelope 122 28.0 3.88E-94 10.6 
GO:0031967~organelle envelope 123 28.3 6.23E-77 7.7 
GO:0031975~envelope 123 28.3 9.96E-77 7.7 
GO:0031090~organelle membrane 129 29.7 2.54E-61 5.4 
GO:0070469~respiratory chain 43 9.9 5.68E-49 22.4 
GO:0005759~mitochondrial matrix 56 12.9 7.35E-44 11.6 
GO:0031980~mitochondrial lumen 56 12.9 7.35E-44 11.6 
GO:0016469~proton-transporting two-sector ATPase complex 22 5.1 1.18E-21 17.7 
GO:0033178~proton-transporting two-sector ATPase complex, catalytic domain 12 2.8 1.31E-13 23.9 
GO:0042579~microbody 23 5.3 2.35E-13 7.5 
GO:0005777~peroxisome 23 5.3 2.35E-13 7.5 
GO:0044455~mitochondrial membrane part 17 3.9 3.17E-13 11.8 
GO:0045259~proton-transporting ATP synthase complex 12 2.8 7.57E-13 21.4 
GO:0005746~mitochondrial respiratory chain 8 1.8 9.49E-08 18.1 
GO:0000276~mitochondrial proton-transporting ATP synthase complex, coupling 
factor F(o) 
6 1.4 1.26E-07 33.9 
GO:0031968~organelle outer membrane 15 3.4 2.20E-07 5.8 
GO:0019867~outer membrane 15 3.4 3.39E-07 5.6 
GO:0031974~membrane-enclosed lumen 66 15.2 3.78E-07 1.9 
GO:0005753~mitochondrial proton-transporting ATP synthase complex 6 1.4 4.30E-07 29.0 
GO:0033176~proton-transporting V-type ATPase complex 8 1.8 4.35E-07 15.1 
GO:0005741~mitochondrial outer membrane 14 3.2 5.32E-07 5.9 
GO:0045263~proton-transporting ATP synthase complex, coupling factor F(o) 7 1.6 8.99E-07 18.2 
GO:0033177~proton-transporting two-sector ATPase complex, proton-
transporting domain 
8 1.8 2.10E-06 12.3 
GO:0005829~cytosol 38 8.7 2.17E-06 2.3 
GO:0005747~mitochondrial respiratory chain complex I 5 1.1 1.06E-05 28.2 
GO:0045261~proton-transporting ATP synthase complex, catalytic core F(1) 5 1.1 1.06E-05 28.2 
GO:0045271~respiratory chain complex I 5 1.1 1.06E-05 28.2 
GO:0030964~NADH dehydrogenase complex 5 1.1 1.06E-05 28.2 
GO:0043233~organelle lumen 59 13.6 2.14E-05 1.8 
GO:0070013~intracellular organelle lumen 58 13.3 3.85E-05 1.7 
GO:0033180~proton-transporting V-type ATPase, V1 domain 5 1.1 4.70E-05 21.2 
GO:0005758~mitochondrial intermembrane space 7 1.6 2.04E-04 7.9 
GO:0005625~soluble fraction 11 2.5 6.55E-04 3.8 
GO:0005792~microsome 15 3.4 7.06E-04 2.9 
GO:0042598~vesicular fraction 15 3.4 9.81E-04 2.8 
GO:0031970~organelle envelope lumen 7 1.6 1.03E-03 5.9 
GO:0045177~apical part of cell 12 2.8 2.25E-03 3.0 
GO:0016324~apical plasma membrane 10 2.3 2.53E-03 3.4 
GO:0017133~mitochondrial electron transfer flavoprotein complex 3 0.7 2.54E-03 33.9 
GO:0045251~electron transfer flavoprotein complex 3 0.7 2.54E-03 33.9 
GO:0000267~cell fraction 31 7.1 2.91E-03 1.8 
GO:0005903~brush border 6 1.4 3.37E-03 5.8 
GO:0042470~melanosome 9 2.1 3.49E-03 3.6 
GO:0048770~pigment granule 9 2.1 3.49E-03 3.6 
GO:0005902~microvillus 5 1.1 9.80E-03 5.8 
GO:0016471~vacuolar proton-transporting V-type ATPase complex 3 0.7 1.64E-02 14.5 
GO:0031903~microbody membrane 4 0.9 3.98E-02 5.2 
GO:0005778~peroxisomal membrane 4 0.9 3.98E-02 5.2 
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S.1.10 List of proteins significantly overexpressed/underexpressed upon 
UUO in the current SWATH-MS study which have been previously identified 
in the dame model by MS.  
Supplementary Table 3.13: Proteins detected in the current proteomic study that have been 
previously identified by MS in UUO models, according to recent literature (Yuan, Zhang et al. 
2015, Zhao, Yang et al. 2015).  Legend: +, red = overexpressed proteins in the study (positive fold 
change from the Sham operated control); -, green =underexpressed proteins in the study (positive fold 
change from the Sham operated control); bright yellow = confidence > 0.8 in the current study  
(considered significant in the current study); pale yellow = 0.5 > confidence < 0.8 in the current study. 
 
  
Current study 
  
Yuan et al., 2015 Zhao et al., 2015 
Protein Log2 FC (UUO/Sham) C(FC) 
Over/Under 
expressed 
Weeks 
post UUO 
Over/Under 
expressed 
Days Post 
cUUO 
VIME_MOUSE 3.10 0.90 + 3     
ANXA1_MOUSE 3.03 0.84 + 3 + 12 
A1AT2_MOUSE 2.97 0.82     + 72 
LUM_MOUSE 2.71 0.87 + 3     
LG3BP_MOUSE 2.53 0.67 + 1     
CLUS_MOUSE 2.42 0.81 + 3     
ACTN1_MOUSE 2.08 0.96 + 3     
A1AT5_MOUSE 2.04 0.65     + 72 
FIBB_MOUSE 2.00 0.86     + 12 
ALD1_MOUSE 1.98 0.44     + 24 
ANXA2_MOUSE 1.91 0.90     + 12 
ACTA_MOUSE 1.67 0.94     - 72 
A1AT1_MOUSE 1.62 0.86     + 72 
S10A9_MOUSE 1.60 0.54 + 1     
ALBU_MOUSE 1.58 0.92     + 72 
MUP6_MOUSE 1.56 0.62     - 72 
MUP2_MOUSE 1.48 0.77     - 72 
A1AT4_MOUSE 1.44 0.83     + 72 
CATD_MOUSE 1.41 0.82 + 1     
ANXA4_MOUSE 0.83 0.85     + 72 
PDIA6_MOUSE 0.75 0.90     + 12 
MOES_MOUSE 0.60 0.81 + 3     
ACTN4_MOUSE 0.55 0.70 + 3     
GSTM2_MOUSE 0.37 0.17     + 12 
ROA2_MOUSE 0.35 0.38     + 24 
SODE_MOUSE -0.38 0.31 + 3     
H14_MOUSE -0.40 0.18 + 3     
TALDO_MOUSE -0.42 0.57 + 3     
GBB2_MOUSE -0.47 0.47     + 12 
GSTP1_MOUSE -0.82 0.94     +/- 24 (+); 72 (-)  
PEBP1_MOUSE -0.94 0.92     + 12 
PRDX1_MOUSE -1.02 0.91     + 12 
MUP3_MOUSE -1.28 0.63     - 72 
VDAC2_MOUSE -1.50 0.94     + 12 
GPX1_MOUSE -1.79 0.92     - 72 
AMPN_MOUSE -1.94 0.95 + 1     
GPX41_MOUSE -2.06 0.52     + 12 
BCAT2_MOUSE -2.13 0.89     + 12 
IDH3A_MOUSE -2.28 0.91     - 24 
CMBL_MOUSE -2.43 0.85     - 72 
ABHEB_MOUSE -2.48 0.93     + 12 
AL9A1_MOUSE -2.53 0.94     - 24 
ODPB_MOUSE -2.60 0.96     - 72 
ATPB_MOUSE -2.71 0.94     + 12 
MEP1A_MOUSE -2.84 0.88     + 12 
ATP5H_MOUSE -2.85 0.93     + 12 
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THTR_MOUSE -2.95 0.89     + 12 
ETFB_MOUSE -3.02 0.91     + 12 
AGT2_MOUSE -3.17 0.71     + 12 
ODBA_MOUSE -3.36 0.64     + 12 
ACY3_MOUSE -3.64 0.80     - 72 
GGT1_MOUSE -3.76 0.89     + 24 
GATM_MOUSE -3.80 0.87     + 24 
3HAO_MOUSE -3.96 0.85     + 72 
KAD4_MOUSE -4.31 0.89     + 24 
 
 
Supplementary Table 3.14: Proteins detected as overexpressed in the current SWATHTM-MS 
study that have been previously found in other studies (Yuan, Zhang et al. 2015, Zhao, Yang et al. 
2015).  
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S.1.11 List of UUO-overexpressed proteins in TG2-KO mice 
Supplementary Table 3.15:  List of proteins significantly overexpressed (confidence ≥ 0.8) in 
TG2-KO kidneys subjected to UUO (21 days) and corresponding positive fold change from Sham 
operated condition.  
Protein ID Name 
Abs(FC) 
UUO/Sham 
C(FC) 
COCA1_MOUSE Collagen alpha-1(XII) chain 26.15 0.83 
FBN2_MOUSE Fibrillin-2 14.52 0.89 
S10A6_MOUSE Protein S100-A6 10.94 0.81 
PGS1_MOUSE Biglycan 9.86 0.87 
UROM_MOUSE Uromodulin 9.78 0.88 
RCN3_MOUSE Reticulocalbin-3 9.30 0.84 
ANXA1_MOUSE Annexin A1 8.24 0.94 
FBN1_MOUSE Fibrillin-1 8.05 0.89 
K1C19_MOUSE Keratin, type I cytoskeletal 19 7.95 0.89 
MUP6_MOUSE Major urinary protein 6 7.80 0.95 
CO5A1_MOUSE Collagen alpha-1(V) chain 7.56 0.83 
MIME_MOUSE Mimecan 7.40 0.86 
TAGL_MOUSE Transgelin 6.86 0.89 
COR1A_MOUSE Coronin-1A 6.83 0.82 
LUM_MOUSE Lumican 6.76 0.84 
TPSN_MOUSE Tapasin 6.71 0.89 
VIME_MOUSE Vimentin 6.67 0.91 
CO1A1_MOUSE Collagen alpha-1(I) chain 6.64 0.96 
GAPR1_MOUSE Golgi-associated plant pathogenesis-related protein 1 6.44 0.86 
FINC_MOUSE Fibronectin 6.31 0.89 
CFAH_MOUSE Complement factor H 6.17 0.81 
CO3A1_MOUSE Collagen alpha-1(III) chain 6.02 0.95 
KCRB_MOUSE Creatine kinase B-type 5.98 0.86 
ELN_MOUSE Elastin 5.78 0.83 
K1C14_MOUSE Keratin, type I cytoskeletal 14 5.55 0.81 
SERPH_MOUSE Serpin H1 5.45 0.96 
LEG1_MOUSE Galectin-1 5.44 0.93 
FBLN5_MOUSE Fibulin-5 5.38 0.87 
FBLN3_MOUSE EGF-containing fibulin-like extracellular matrix protein 1 5.35 0.87 
MYOF_MOUSE Myoferlin 5.21 0.81 
K2C5_MOUSE Keratin, type II cytoskeletal 5 5.15 0.84 
EMIL1_MOUSE Emilin-1 4.77 0.89 
PLSL_MOUSE Plastin-2 4.77 0.82 
SAMH1_MOUSE Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 4.70 0.84 
PRELP_MOUSE Prolargin 4.68 0.89 
TYB4_MOUSE Thymosin beta-4 4.65 0.90 
DESM_MOUSE Desmin 4.60 0.94 
FLNA_MOUSE Filamin-A 4.56 0.95 
H2A1H_MOUSE Histone H2A type 1-H 4.49 0.85 
C1QB_MOUSE Complement C1q subcomponent subunit B 4.35 0.91 
ASAH1_MOUSE Acid ceramidase 4.32 0.87 
CLUS_MOUSE Clusterin 4.30 0.86 
TBA1A_MOUSE Tubulin alpha-1A chain 4.28 0.91 
K2C8_MOUSE Keratin, type II cytoskeletal 8 4.26 0.94 
GCAB_MOUSE Ig gamma-2A chain C region secreted form 4.20 0.82 
CNN2_MOUSE Calponin-2 4.11 0.84 
PDLI2_MOUSE PDZ and LIM domain protein 2 4.09 0.82 
TPM4_MOUSE Tropomyosin alpha-4 chain 4.06 0.91 
COEA1_MOUSE Collagen alpha-1(XIV) chain 3.93 0.83 
ACTN1_MOUSE Alpha-actinin-1 3.72 0.96 
LEG3_MOUSE Galectin-3 3.71 0.86 
CSRP1_MOUSE Cysteine and glycine-rich protein 1 3.65 0.92 
MYH10_MOUSE Myosin-10 3.63 0.84 
MYADM_MOUSE Myeloid-associated differentiation marker 3.62 0.92 
ESYT1_MOUSE Extended synaptotagmin-1 3.60 0.83 
CO6A1_MOUSE Collagen alpha-1(VI) chain 3.52 0.89 
HEMO_MOUSE Hemopexin 3.50 0.82 
G6PE_MOUSE GDH/6PGL endoplasmic bifunctional protein 3.49 0.85 
TPM2_MOUSE Tropomyosin beta chain 3.44 0.82 
MUP2_MOUSE Major urinary protein 2 3.43 1.00 
K2C7_MOUSE Keratin, type II cytoskeletal 7 3.43 0.88 
S10AB_MOUSE Protein S100-A11 3.40 0.88 
CO6A2_MOUSE Collagen alpha-2(VI) chain 3.40 0.92 
IGKC_MOUSE Ig kappa chain C region 3.38 0.87 
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FRIL1_MOUSE Ferritin light chain 1 3.36 0.86 
EFHD2_MOUSE EF-hand domain-containing protein D2 3.28 0.83 
LG3BP_MOUSE Galectin-3-binding protein 3.26 0.81 
RBM3_MOUSE RNA-binding protein 3 3.23 0.81 
E41L2_MOUSE Band 4.1-like protein 2 3.22 0.88 
TAGL2_MOUSE Transgelin-2 3.16 0.87 
CATD_MOUSE Cathepsin D 3.12 0.81 
TPM1_MOUSE Tropomyosin alpha-1 chain 3.09 0.83 
SH3L1_MOUSE SH3 domain-binding glutamic acid-rich-like protein 3.09 0.89 
ANXA2_MOUSE Annexin A2 3.06 0.90 
ANXA3_MOUSE Annexin A3 3.05 0.82 
ESYT2_MOUSE Extended synaptotagmin-2 3.03 0.83 
VAT1_MOUSE Synaptic vesicle membrane protein VAT-1 homolog 2.92 0.93 
ARC1B_MOUSE Actin-related protein 2/3 complex subunit 1B 2.91 0.88 
MYH11_MOUSE Myosin-11 2.87 0.92 
EPDR1_MOUSE Mammalian ependymin-related protein 1 2.85 0.81 
APOH_MOUSE Beta-2-glycoprotein 1 2.82 0.85 
A1AT4_MOUSE Alpha-1-antitrypsin 1-4 2.79 0.81 
ACTA_MOUSE Actin, aortic smooth muscle 2.76 0.85 
CO4B_MOUSE Complement C4-B 2.75 0.83 
PPT1_MOUSE Palmitoyl-protein thioesterase 1 2.75 0.85 
A1AT1_MOUSE Alpha-1-antitrypsin 1-1 2.74 0.81 
TBB5_MOUSE Tubulin beta-5 chain 2.72 0.90 
H11_MOUSE Histone H1.1 2.72 0.96 
TRFE_MOUSE Serotransferrin 2.67 0.89 
HSPB1_MOUSE Heat shock protein beta-1 2.67 0.85 
K1C18_MOUSE Keratin, type I cytoskeletal 18 2.66 0.92 
SEPT2_MOUSE Septin-2 2.62 0.85 
FETUB_MOUSE Fetuin-B 2.60 0.86 
ISG15_MOUSE Ubiquitin-like protein ISG15 2.59 0.89 
LMNA_MOUSE Prelamin-A/C 2.57 0.94 
MYL9_MOUSE Myosin regulatory light polypeptide 9 2.56 0.98 
PCNA_MOUSE Proliferating cell nuclear antigen 2.55 0.81 
KNG1_MOUSE Kininogen-1 2.54 0.92 
FETUA_MOUSE Alpha-2-HS-glycoprotein 2.54 0.94 
H15_MOUSE Histone H1.5 2.54 0.91 
MYL6_MOUSE Myosin light polypeptide 6 2.53 0.94 
EST1C_MOUSE Carboxylesterase 1C 2.52 0.94 
SPB6_MOUSE Serpin B6 2.51 0.84 
MYH9_MOUSE Myosin-9 2.50 0.97 
APOE_MOUSE Apolipoprotein E 2.49 0.94 
APOA4_MOUSE Apolipoprotein A-IV 2.47 0.83 
ALBU_MOUSE Serum albumin 2.46 0.91 
CO3_MOUSE Complement C3 2.45 0.87 
HMGB2_MOUSE High mobility group protein B2 2.45 0.85 
NAGAB_MOUSE Alpha-N-acetylgalactosaminidase 2.43 0.82 
H12_MOUSE Histone H1.2 2.42 0.93 
SEPT7_MOUSE Septin-7 2.41 0.80 
CAP1_MOUSE Adenylyl cyclase-associated protein 1 2.40 0.92 
VMA5A_MOUSE von Willebrand factor A domain-containing protein 5A 2.36 0.86 
B2MG_MOUSE Beta-2-microglobulin 2.34 0.89 
SEP11_MOUSE Septin-11 2.33 0.83 
GELS_MOUSE Gelsolin 2.30 0.87 
MYLK_MOUSE Myosin light chain kinase, smooth muscle 2.28 0.89 
VTDB_MOUSE Vitamin D-binding protein 2.28 0.89 
T22D1_MOUSE TSC22 domain family protein 1 2.24 0.84 
PSME1_MOUSE Proteasome activator complex subunit 1 2.21 0.81 
LMNB1_MOUSE Lamin-B1 2.19 0.88 
ANXA5_MOUSE Annexin A5 2.19 0.87 
COF1_MOUSE Cofilin-1 2.18 0.83 
MAP4_MOUSE Microtubule-associated protein 4 2.17 0.81 
PROF1_MOUSE Profilin-1 2.16 0.88 
SET_MOUSE Protein SET 2.15 0.90 
AN32B_MOUSE Acidic leucine-rich nuclear phosphoprotein 32 family member B 2.14 0.91 
CATZ_MOUSE Cathepsin Z 2.09 0.85 
ARPC5_MOUSE Actin-related protein 2/3 complex subunit 5 2.09 0.90 
COIA1_MOUSE Collagen alpha-1(XVIII) chain 2.08 0.94 
SPA3K_MOUSE Serine protease inhibitor A3K 2.07 0.81 
ADPRH_MOUSE [Protein ADP-ribosylarginine] hydrolase 2.06 0.84 
NID1_MOUSE Nidogen-1 2.04 0.94 
APOA1_MOUSE Apolipoprotein A-I 2.04 0.87 
PSME2_MOUSE Proteasome activator complex subunit 2 2.03 0.81 
ROA1_MOUSE Heterogeneous nuclear ribonucleoprotein A1 2.03 0.88 
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VINC_MOUSE Vinculin 2.03 0.92 
RENI1_MOUSE Renin-1 2.01 0.84 
CO4A1_MOUSE Collagen alpha-1(IV) chain 2.01 0.86 
TIF1B_MOUSE Transcription intermediary factor 1-beta 1.99 0.81 
ANXA6_MOUSE Annexin A6 1.98 0.91 
SFPQ_MOUSE Splicing factor, proline- and glutamine-rich 1.97 0.81 
LAMA5_MOUSE Laminin subunit alpha-5 1.96 0.89 
COR1C_MOUSE Coronin-1C 1.95 0.82 
UBC9_MOUSE SUMO-conjugating enzyme UBC9 1.92 0.91 
DPYL2_MOUSE Dihydropyrimidinase-related protein 2 1.88 0.83 
FUS_MOUSE RNA-binding protein FUS 1.87 0.81 
LAMC1_MOUSE Laminin subunit gamma-1 1.83 0.90 
HP1B3_MOUSE Heterochromatin protein 1-binding protein 3 1.82 0.89 
GNAI2_MOUSE Guanine nucleotide-binding protein G(i) subunit alpha-2 1.79 0.84 
H2AV_MOUSE Histone H2A.V 1.79 0.84 
NID2_MOUSE Nidogen-2 1.77 0.87 
CAPG_MOUSE Macrophage-capping protein 1.76 0.81 
ACTBL_MOUSE Beta-actin-like protein 2 1.75 0.91 
CAPZB_MOUSE F-actin-capping protein subunit beta 1.73 0.86 
ARP3_MOUSE Actin-related protein 3 1.71 0.93 
SAP_MOUSE Prosaposin 1.70 0.82 
DX39B_MOUSE Spliceosome RNA helicase Ddx39b 1.69 0.81 
LAMB1_MOUSE Laminin subunit beta-1 1.67 0.84 
ILF2_MOUSE Interleukin enhancer-binding factor 2 1.65 0.84 
ARPC4_MOUSE Actin-related protein 2/3 complex subunit 4 1.65 0.85 
TLN1_MOUSE Talin-1 1.65 0.89 
H2AX_MOUSE Histone H2AX 1.64 0.83 
NONO_MOUSE Non-POU domain-containing octamer-binding protein 1.62 0.89 
H2B1P_MOUSE Histone H2B type 1-P 1.59 0.88 
PDIA6_MOUSE Protein disulfide-isomerase A6 1.59 0.88 
ARP2_MOUSE Actin-related protein 2 1.58 0.81 
NPM_MOUSE Nucleophosmin 1.58 0.83 
ROA3_MOUSE Heterogeneous nuclear ribonucleoprotein A3 1.58 0.88 
LSM3_MOUSE U6 snRNA-associated Sm-like protein LSm3 1.57 0.91 
PGBM_MOUSE Basement membrane-specific heparan sulfate proteoglycan core protein 1.56 0.81 
ABRAL_MOUSE Costars family protein ABRACL 1.55 0.87 
PRDX4_MOUSE Peroxiredoxin-4 1.53 0.89 
HNRPM_MOUSE Heterogeneous nuclear ribonucleoprotein M 1.50 0.82 
ROAA_MOUSE Heterogeneous nuclear ribonucleoprotein A/B 1.50 0.84 
PDIA4_MOUSE Protein disulfide-isomerase A4 1.48 0.88 
NUCL_MOUSE Nucleolin 1.46 0.85 
RUXE_MOUSE Small nuclear ribonucleoprotein E 1.45 0.80 
ABCB7_MOUSE ATP-binding cassette sub-family B member 7, mitochondrial 1.45 0.89 
HNRPU_MOUSE Heterogeneous nuclear ribonucleoprotein U 1.44 0.84 
ACTB_MOUSE Actin, cytoplasmic 1 1.43 0.90 
SMD2_MOUSE Small nuclear ribonucleoprotein Sm D2 1.40 0.82 
KAD1_MOUSE Adenylate kinase isoenzyme 1 1.39 0.81 
TADBP_MOUSE TAR DNA-binding protein 43 1.39 0.82 
CATB_MOUSE Cathepsin B 1.35 0.85 
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S.1.12 List of UUO-underexpressed proteins in TG2-KO mice 
Supplementary Table 3.16: List of proteins significantly underexpressed (confidence ≥ 0.8) in 
TG2-KO kidneys subjected to UUO (21 days) and corresponding negative fold change from Sham 
operated condition.  
 
Protein ID Name 
Abs(FC) 
Sham/UUO 
C(FC) 
SC5A3_MOUSE Sodium/myo-inositol cotransporter 27.69 0.86 
HYES_MOUSE Bifunctional epoxide hydrolase 2 25.06 0.84 
CX6A1_MOUSE Cytochrome c oxidase subunit 6A1, mitochondrial 21.54 0.80 
ASSY_MOUSE Argininosuccinate synthase 21.51 0.87 
CALB1_MOUSE Calbindin 21.18 0.92 
GATM_MOUSE Glycine amidinotransferase, mitochondrial 20.94 0.88 
ACSM2_MOUSE Acyl-coenzyme A synthetase ACSM2, mitochondrial 19.94 0.89 
AAAD_MOUSE Arylacetamide deacetylase 19.31 0.91 
3HAO_MOUSE 3-hydroxyanthranilate 3,4-dioxygenase 19.13 0.82 
KAD4_MOUSE Adenylate kinase 4, mitochondrial 18.93 0.91 
F16P1_MOUSE Fructose-1,6-bisphosphatase 1 18.22 0.90 
HAOX2_MOUSE Hydroxyacid oxidase 2 18.08 0.88 
PCKGC_MOUSE Phosphoenolpyruvate carboxykinase, cytosolic [GTP] 17.10 0.85 
FBX50_MOUSE F-box only protein 50 17.04 0.84 
GLYAT_MOUSE Glycine N-acyltransferase 16.55 0.86 
AT1B1_MOUSE Sodium/potassium-transporting ATPase subunit beta-1 16.52 0.87 
ACADM_MOUSE Medium-chain specific acyl-CoA dehydrogenase, mitochondrial 16.23 0.87 
CAD16_MOUSE Cadherin-16 15.95 0.89 
MMSA_MOUSE Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial 15.74 0.89 
KEG1_MOUSE Glycine N-acyltransferase-like protein Keg1 15.67 0.88 
ATNG_MOUSE Sodium/potassium-transporting ATPase subunit gamma 15.63 0.89 
PYC_MOUSE Pyruvate carboxylase, mitochondrial 15.62 0.84 
ST1D1_MOUSE Sulfotransferase 1 family member D1 15.51 0.84 
ALDOB_MOUSE Fructose-bisphosphate aldolase B 15.47 0.93 
PBLD1_MOUSE Phenazine biosynthesis-like domain-containing protein 1 15.43 0.81 
GLPK_MOUSE Glycerol kinase 14.98 0.85 
QORL2_MOUSE Quinone oxidoreductase-like protein 2 14.96 0.83 
ACOX1_MOUSE Peroxisomal acyl-coenzyme A oxidase 1 14.52 0.88 
KHK_MOUSE Ketohexokinase 14.41 0.84 
BPHL_MOUSE Valacyclovir hydrolase 14.21 0.85 
FAHD2_MOUSE umarylacetoacetate hydrolase domain-containing protein 2A 14.19 0.81 
BDH_MOUSE D-beta-hydroxybutyrate dehydrogenase, mitochondrial 14.12 0.92 
DHSO_MOUSE Sorbitol dehydrogenase 13.96 0.85 
FAAA_MOUSE Fumarylacetoacetase 13.80 0.90 
GPDA_MOUSE Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic 13.65 0.84 
S27A2_MOUSE Very long-chain acyl-CoA synthetase 13.57 0.84 
ECHP_MOUSE Peroxisomal bifunctional enzyme 13.34 0.88 
GGT1_MOUSE Gamma-glutamyltranspeptidase 1 13.34 0.86 
PECR_MOUSE Peroxisomal trans-2-enoyl-CoA reductase 13.10 0.92 
ECHD2_MOUSE Enoyl-CoA hydratase domain-containing protein 2, mitochondrial 12.79 0.88 
AQP3_MOUSE Aquaporin-3 12.64 0.85 
SARDH_MOUSE Sarcosine dehydrogenase, mitochondrial 12.57 0.87 
GABT_MOUSE 4-aminobutyrate aminotransferase, mitochondrial 12.32 0.93 
ODB2_MOUSE 
Lipoamide acyltransferase component of branched-chain alpha-keto acid 
dehydrogenase complex, mitochondrial 
12.29 0.80 
AL8A1_MOUSE Aldehyde dehydrogenase family 8 member A1 12.21 0.89 
FAHD1_MOUSE Acylpyruvase FAHD1, mitochondrial 12.20 0.84 
ISC2A_MOUSE Isochorismatase domain-containing protein 2A 12.14 0.81 
ACO13_MOUSE Acyl-coenzyme A thioesterase 13 12.10 0.88 
AL4A1_MOUSE Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial 11.79 0.91 
S100G_MOUSE Protein S100-G 11.78 0.87 
S22AC_MOUSE Solute carrier family 22 member 12 11.74 0.83 
VILI_MOUSE Villin-1 11.73 0.88 
PCCB_MOUSE Propionyl-CoA carboxylase beta chain, mitochondrial 11.73 0.90 
IYD1_MOUSE Iodotyrosine deiodinase 1 11.72 0.86 
AT1A1_MOUSE Sodium/potassium-transporting ATPase subunit alpha-1 11.72 0.95 
ABCG2_MOUSE ATP-binding cassette sub-family G member 2 11.70 0.86 
AADAT_MOUSE Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial 11.59 0.80 
ACS2L_MOUSE Acetyl-coenzyme A synthetase 2-like, mitochondrial 11.31 0.83 
MPC2_MOUSE Mitochondrial pyruvate carrier 2 11.30 0.90 
CGL_MOUSE Cystathionine gamma-lyase 11.29 0.83 
ODBB_MOUSE 2-oxoisovalerate dehydrogenase subunit beta, mitochondrial 11.28 0.81 
CES1D_MOUSE Carboxylesterase 1D 11.28 0.87 
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GSTK1_MOUSE Glutathione S-transferase kappa 1 11.23 0.85 
UD3A2_MOUSE UDP-glucuronosyltransferase 3A2 11.11 0.81 
SC5A2_MOUSE Sodium/glucose cotransporter 2 11.10 0.81 
INMT_MOUSE Indolethylamine N-methyltransferase 11.06 0.85 
ACSM1_MOUSE Acyl-coenzyme A synthetase ACSM1, mitochondrial 11.05 0.89 
S23A1_MOUSE Solute carrier family 23 member 1 10.96 0.83 
SOX_MOUSE Peroxisomal sarcosine oxidase 10.94 0.84 
CK054_MOUSE Ester hydrolase C11orf54 homolog 10.86 0.81 
NUD19_MOUSE Nucleoside diphosphate-linked moiety X motif 19 10.83 0.87 
PPR1A_MOUSE Protein phosphatase 1 regulatory subunit 1A 10.83 0.88 
G6PC_MOUSE Glucose-6-phosphatase 10.79 0.83 
HINT2_MOUSE Histidine triad nucleotide-binding protein 2, mitochondrial 10.77 0.94 
MEP1A_MOUSE Meprin A subunit alpha 10.75 0.89 
COX3_MOUSE Cytochrome c oxidase subunit 3 10.56 0.91 
SUCB2_MOUSE Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial 10.47 0.92 
CLYBL_MOUSE Citrate lyase subunit beta-like protein, mitochondrial 10.40 0.83 
CISD1_MOUSE CDGSH iron-sulfur domain-containing protein 1 10.36 0.94 
M2GD_MOUSE Dimethylglycine dehydrogenase, mitochondrial 10.33 0.83 
COA6_MOUSE Cytochrome c oxidase assembly factor 6 homolog 10.29 0.81 
MCCB_MOUSE Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial 10.25 0.86 
S22A8_MOUSE Solute carrier family 22 member 8 10.19 0.80 
ACSL1_MOUSE Long-chain-fatty-acid--CoA ligase 1 10.18 0.86 
NDUA3_MOUSE NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3 10.14 0.84 
IVD_MOUSE Isovaleryl-CoA dehydrogenase, mitochondrial 10.09 0.86 
MPC1_MOUSE Mitochondrial pyruvate carrier 1 9.89 0.80 
THNS2_MOUSE Threonine synthase-like 2 9.82 0.82 
NDUV1_MOUSE NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial 9.81 0.92 
NHRF3_MOUSE Na(+)/H(+) exchange regulatory cofactor NHE-RF3 9.66 0.90 
ETFA_MOUSE Electron transfer flavoprotein subunit alpha, mitochondrial 9.66 0.92 
AUHM_MOUSE Methylglutaconyl-CoA hydratase, mitochondrial 9.63 0.89 
THTR_MOUSE Thiosulfate sulfurtransferase 9.59 0.89 
SUCHY_MOUSE Succinate--hydroxymethylglutarate CoA-transferase 9.59 0.85 
3HIDH_MOUSE 3-hydroxyisobutyrate dehydrogenase, mitochondrial 9.57 0.93 
CATA_MOUSE Catalase 9.51 0.94 
UK114_MOUSE Ribonuclease UK114 9.50 0.90 
THIL_MOUSE Acetyl-CoA acetyltransferase, mitochondrial 9.43 0.96 
AK1A1_MOUSE Alcohol dehydrogenase [NADP(+)] 9.38 0.92 
MIRO2_MOUSE Mitochondrial Rho GTPase 2 9.35 0.87 
NDUC2_MOUSE NADH dehydrogenase [ubiquinone] 1 subunit C2 9.30 0.84 
TMM27_MOUSE Collectrin 9.30 0.85 
HMGCL_MOUSE Hydroxymethylglutaryl-CoA lyase, mitochondrial 9.29 0.89 
THIM_MOUSE 3-ketoacyl-CoA thiolase, mitochondrial 9.09 0.88 
SODM_MOUSE Superoxide dismutase [Mn], mitochondrial 9.08 0.88 
MUTA_MOUSE Methylmalonyl-CoA mutase, mitochondrial 9.08 0.83 
COX5B_MOUSE Cytochrome c oxidase subunit 5B, mitochondrial 9.07 0.90 
HCDH_MOUSE Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial 9.04 0.89 
COQ9_MOUSE Ubiquinone biosynthesis protein COQ9, mitochondrial 9.02 0.81 
SUCA_MOUSE Succinyl-CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial 9.00 0.93 
HOT_MOUSE Hydroxyacid-oxoacid transhydrogenase, mitochondrial 8.97 0.83 
AK1CL_MOUSE Aldo-keto reductase family 1 member C21 8.97 0.84 
MSRA_MOUSE Mitochondrial peptide methionine sulfoxide reductase 8.95 0.89 
ACD10_MOUSE Acyl-CoA dehydrogenase family member 10 8.94 0.89 
S12A1_MOUSE Solute carrier family 12 member 1 8.90 0.85 
ACON_MOUSE Aconitate hydratase, mitochondrial 8.88 0.88 
SCOT1_MOUSE Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial 8.85 0.91 
NHRF1_MOUSE Na(+)/H(+) exchange regulatory cofactor NHE-RF1 8.85 0.91 
GLNA_MOUSE Glutamine synthetase 8.84 0.83 
MAAI_MOUSE Maleylacetoacetate isomerase 8.83 0.82 
ETFB_MOUSE Electron transfer flavoprotein subunit beta 8.78 0.92 
UCRI_MOUSE Cytochrome b-c1 complex subunit Rieske, mitochondrial 8.74 0.84 
QCR8_MOUSE Cytochrome b-c1 complex subunit 8 8.65 0.92 
AL1L1_MOUSE Cytosolic 10-formyltetrahydrofolate dehydrogenase 8.63 0.92 
ARK72_MOUSE Aflatoxin B1 aldehyde reductase member 2 8.60 0.85 
IDHP_MOUSE Isocitrate dehydrogenase [NADP], mitochondrial 8.56 0.93 
ACPM_MOUSE Acyl carrier protein, mitochondrial 8.43 0.92 
QOR_MOUSE Quinone oxidoreductase 8.40 0.93 
NDUBA_MOUSE NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 8.40 0.86 
CX7A2_MOUSE Cytochrome c oxidase subunit 7A2, mitochondrial 8.39 0.84 
NDRG1_MOUSE Protein NDRG1 8.36 0.98 
PCCA_MOUSE Propionyl-CoA carboxylase alpha chain, mitochondrial 8.33 0.91 
PHS_MOUSE Pterin-4-alpha-carbinolamine dehydratase 8.31 0.82 
AQP1_MOUSE Aquaporin-1 8.29 0.88 
MEP1B_MOUSE Meprin A subunit beta 8.27 0.80 
SUPPLEMENTARY DATA 
 
466 
 
ECHD1_MOUSE Ethylmalonyl-CoA decarboxylase 8.24 0.86 
IDHG1_MOUSE Isocitrate dehydrogenase [NAD] subunit gamma 1, mitochondrial 8.20 0.89 
PGAM2_MOUSE Phosphoglycerate mutase 2 8.19 0.82 
QCR2_MOUSE Cytochrome b-c1 complex subunit 2, mitochondrial 8.19 0.97 
LRP2_MOUSE Low-density lipoprotein receptor-related protein 2 8.16 0.83 
COX5A_MOUSE Cytochrome c oxidase subunit 5A, mitochondrial 8.11 0.93 
AKC1H_MOUSE Aldo-keto reductase family 1 member C18 8.07 0.87 
NDUB7_MOUSE NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7 8.05 0.90 
NDUB4_MOUSE NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 8.03 0.83 
SDHB_MOUSE Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial 8.00 0.83 
ECI2_MOUSE Enoyl-CoA delta isomerase 2, mitochondrial 7.96 0.85 
AIFM1_MOUSE Apoptosis-inducing factor 1, mitochondrial 7.96 0.92 
ECHM_MOUSE Enoyl-CoA hydratase, mitochondrial 7.96 0.90 
ENPP3_MOUSE Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 7.92 0.81 
OCTC_MOUSE Peroxisomal carnitine O-octanoyltransferase 7.84 0.82 
LDHD_MOUSE Probable D-lactate dehydrogenase, mitochondrial 7.83 0.88 
MCCA_MOUSE Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial 7.81 0.82 
SDHA_MOUSE 
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, 
mitochondrial 
7.80 0.97 
RM23_MOUSE 39S ribosomal protein L23, mitochondrial 7.79 0.81 
NEP_MOUSE Neprilysin 7.78 0.89 
NDUA2_MOUSE NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2 7.78 0.83 
ABCD3_MOUSE ATP-binding cassette sub-family D member 3 7.75 0.90 
NDUS1_MOUSE NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial 7.74 0.90 
DIC_MOUSE Mitochondrial dicarboxylate carrier 7.73 0.91 
CY1_MOUSE Cytochrome c1, heme protein, mitochondrial 7.72 0.93 
ATPD_MOUSE ATP synthase subunit delta, mitochondrial 7.68 0.95 
CMC2_MOUSE Calcium-binding mitochondrial carrier protein Aralar2 7.66 0.89 
S13A3_MOUSE Solute carrier family 13 member 3 7.65 0.84 
ATPG_MOUSE ATP synthase subunit gamma, mitochondrial 7.65 0.92 
CRYL1_MOUSE Lambda-crystallin homolog 7.64 0.89 
RT36_MOUSE 28S ribosomal protein S36, mitochondrial 7.64 0.91 
C560_MOUSE Succinate dehydrogenase cytochrome b560 subunit, mitochondrial 7.63 0.92 
NIPS1_MOUSE Protein NipSnap homolog 1 7.62 0.90 
3BHS4_MOUSE 3 beta-hydroxysteroid dehydrogenase type 4 7.58 0.81 
CYC_MOUSE Cytochrome c, somatic 7.56 0.90 
NDUS7_MOUSE NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial 7.49 0.85 
IPYR2_MOUSE Inorganic pyrophosphatase 2, mitochondrial 7.47 0.90 
NDUA4_MOUSE Cytochrome c oxidase subunit NDUFA4 7.39 0.88 
NDUS6_MOUSE NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial 7.39 0.82 
COX41_MOUSE Cytochrome c oxidase subunit 4 isoform 1, mitochondrial 7.37 0.93 
KAT3_MOUSE Kynurenine--oxoglutarate transaminase 3 7.36 0.82 
BCAT2_MOUSE Branched-chain-amino-acid aminotransferase, mitochondrial 7.36 0.89 
ATPK_MOUSE ATP synthase subunit f, mitochondrial 7.34 0.83 
NCEH1_MOUSE Neutral cholesterol ester hydrolase 1 7.34 0.94 
BPNT1_MOUSE 3'(2'),5'-bisphosphate nucleotidase 1 7.34 0.81 
NDUAA_MOUSE 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, 
mitochondrial 
7.33 0.90 
CX6B1_MOUSE Cytochrome c oxidase subunit 6B1 7.32 0.88 
CMBL_MOUSE Carboxymethylenebutenolidase homolog 7.32 0.80 
CBR1_MOUSE Carbonyl reductase [NADPH] 1 7.30 0.94 
ATP5J_MOUSE ATP synthase-coupling factor 6, mitochondrial 7.30 0.93 
TBA4A_MOUSE Tubulin alpha-4A chain 7.28 0.81 
QCR7_MOUSE Cytochrome b-c1 complex subunit 7 7.28 0.88 
SFXN1_MOUSE Sideroflexin-1 7.20 0.86 
ATPB_MOUSE ATP synthase subunit beta, mitochondrial 7.19 0.96 
ADT2_MOUSE ADP/ATP translocase 2 7.18 0.88 
SBP1_MOUSE Selenium-binding protein 1 7.18 0.89 
NDUS2_MOUSE NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial 7.15 0.86 
AL7A1_MOUSE Alpha-aminoadipic semialdehyde dehydrogenase 7.15 0.87 
COX2_MOUSE Cytochrome c oxidase subunit 2 7.15 0.86 
DLDH_MOUSE Dihydrolipoyl dehydrogenase, mitochondrial 7.11 0.93 
AL9A1_MOUSE 4-trimethylaminobutyraldehyde dehydrogenase 7.09 0.92 
DHRS4_MOUSE Dehydrogenase/reductase SDR family member 4 7.08 0.95 
SUCB1_MOUSE Succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial 7.07 0.93 
CH60_MOUSE 60 kDa heat shock protein, mitochondrial 7.07 0.96 
NU3M_MOUSE NADH-ubiquinone oxidoreductase chain 3 7.06 0.95 
ATP5I_MOUSE ATP synthase subunit e, mitochondrial 7.06 0.86 
AT5F1_MOUSE ATP synthase F(0) complex subunit B1, mitochondrial 7.03 0.92 
ATPA_MOUSE ATP synthase subunit alpha, mitochondrial 7.02 0.96 
NDUB9_MOUSE NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 7.01 0.84 
MDHM_MOUSE Malate dehydrogenase, mitochondrial 6.97 0.94 
NDUA7_MOUSE NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7 6.97 0.87 
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USMG5_MOUSE Up-regulated during skeletal muscle growth protein 5 6.93 0.97 
SFXN2_MOUSE Sideroflexin-2 6.90 0.82 
NDUA9_MOUSE 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, 
mitochondrial 
6.86 0.91 
PTER_MOUSE Phosphotriesterase-related protein 6.85 0.94 
ATPO_MOUSE ATP synthase subunit O, mitochondrial 6.83 0.96 
FUMH_MOUSE Fumarate hydratase, mitochondrial 6.82 0.89 
FOLH1_MOUSE Glutamate carboxypeptidase 2 6.81 0.80 
ACOT2_MOUSE Acyl-coenzyme A thioesterase 2, mitochondrial 6.79 0.80 
FABPH_MOUSE Fatty acid-binding protein, heart 6.78 0.84 
NLTP_MOUSE Non-specific lipid-transfer protein 6.73 0.91 
NDUS4_MOUSE NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial 6.72 0.85 
ODO2_MOUSE 
Dihydrolipoyllysine-residue succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, mitochondrial 
6.71 0.91 
NDUA5_MOUSE NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 6.71 0.89 
ATP5H_MOUSE ATP synthase subunit d, mitochondrial 6.70 0.94 
ODPA_MOUSE 
Pyruvate dehydrogenase E1 component subunit alpha, somatic form, 
mitochondrial 
6.70 0.93 
QCR1_MOUSE Cytochrome b-c1 complex subunit 1, mitochondrial 6.69 0.93 
NDUBB_MOUSE 
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 11, 
mitochondrial 
6.67 0.93 
MIC13_MOUSE MICOS complex subunit MIC13 6.57 0.92 
COX7C_MOUSE Cytochrome c oxidase subunit 7C, mitochondrial 6.57 0.80 
GSH1_MOUSE Glutamate--cysteine ligase catalytic subunit 6.57 0.85 
CSAD_MOUSE Cysteine sulfinic acid decarboxylase 6.56 0.91 
ETHE1_MOUSE Persulfide dioxygenase ETHE1, mitochondrial 6.52 0.93 
NDUS3_MOUSE NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial 6.51 0.94 
TPMT_MOUSE Thiopurine S-methyltransferase 6.43 0.93 
ATP8_MOUSE ATP synthase protein 8 6.43 0.81 
NDUAD_MOUSE NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 6.42 0.94 
ES1_MOUSE ES1 protein homolog, mitochondrial 6.41 0.91 
AATM_MOUSE Aspartate aminotransferase, mitochondrial 6.39 0.97 
NU5M_MOUSE NADH-ubiquinone oxidoreductase chain 5 6.35 0.86 
MIC60_MOUSE MICOS complex subunit Mic60 6.32 0.93 
ACADS_MOUSE Short-chain specific acyl-CoA dehydrogenase, mitochondrial 6.28 0.89 
ARLY_MOUSE Argininosuccinate lyase 6.28 0.92 
NU4M_MOUSE NADH-ubiquinone oxidoreductase chain 4 6.28 0.88 
ODP2_MOUSE 
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial 
6.28 0.94 
UD3A1_MOUSE UDP-glucuronosyltransferase 3A1 6.24 0.84 
MARC2_MOUSE Mitochondrial amidoxime reducing component 2 6.22 0.91 
NDUS8_MOUSE NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial 6.20 0.86 
ENTP5_MOUSE Ectonucleoside triphosphate diphosphohydrolase 5 6.15 0.80 
COX6C_MOUSE Cytochrome c oxidase subunit 6C 6.11 0.89 
ODPB_MOUSE Pyruvate dehydrogenase E1 component subunit beta, mitochondrial 6.07 0.97 
GSHB_MOUSE Glutathione synthetase 6.07 0.89 
QCR6_MOUSE Cytochrome b-c1 complex subunit 6, mitochondrial 6.06 0.93 
KAD2_MOUSE Adenylate kinase 2, mitochondrial 6.06 0.89 
PRDX3_MOUSE Thioredoxin-dependent peroxide reductase, mitochondrial 6.04 0.89 
TRAP1_MOUSE Heat shock protein 75 kDa, mitochondrial 6.02 0.89 
ACOX3_MOUSE Peroxisomal acyl-coenzyme A oxidase 3 6.00 0.82 
CPT2_MOUSE Carnitine O-palmitoyltransferase 2, mitochondrial 5.99 0.85 
VATA_MOUSE V-type proton ATPase catalytic subunit A 5.96 0.93 
CX7A1_MOUSE Cytochrome c oxidase subunit 7A1, mitochondrial 5.92 0.88 
VATH_MOUSE V-type proton ATPase subunit H 5.88 0.91 
NDUA8_MOUSE NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8 5.86 0.89 
CH10_MOUSE 10 kDa heat shock protein, mitochondrial 5.86 0.90 
MIC19_MOUSE MICOS complex subunit Mic19 5.85 0.86 
PGES2_MOUSE Prostaglandin E synthase 2 5.84 0.81 
PRDX5_MOUSE Peroxiredoxin-5, mitochondrial 5.81 0.91 
ACADV_MOUSE Very long-chain specific acyl-CoA dehydrogenase, mitochondrial 5.79 0.85 
MPCP_MOUSE Phosphate carrier protein, mitochondrial 5.78 0.94 
ODO1_MOUSE 2-oxoglutarate dehydrogenase, mitochondrial 5.76 0.89 
SUSD2_MOUSE Sushi domain-containing protein 2 5.75 0.93 
CHDH_MOUSE Choline dehydrogenase, mitochondrial 5.69 0.88 
MAOX_MOUSE NADP-dependent malic enzyme 5.68 0.87 
DCXR_MOUSE L-xylulose reductase 5.66 0.83 
DYR_MOUSE Dihydrofolate reductase 5.65 0.82 
DECR_MOUSE 2,4-dienoyl-CoA reductase, mitochondrial 5.63 0.88 
DAB2_MOUSE Disabled homolog 2 5.62 0.80 
SAM50_MOUSE Sorting and assembly machinery component 50 homolog 5.60 0.90 
DHB8_MOUSE Estradiol 17-beta-dehydrogenase 8 5.55 0.81 
SAHH3_MOUSE Putative adenosylhomocysteinase 3 5.54 0.83 
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ECI1_MOUSE Enoyl-CoA delta isomerase 1, mitochondrial 5.51 0.90 
VDAC1_MOUSE Voltage-dependent anion-selective channel protein 1 5.49 0.96 
ETFD_MOUSE Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial 5.49 0.90 
CLPX_MOUSE 
ATP-dependent Clp protease ATP-binding subunit clpX-like, 
mitochondrial 
5.48 0.91 
ALDH2_MOUSE Aldehyde dehydrogenase, mitochondrial 5.48 0.94 
VATE1_MOUSE V-type proton ATPase subunit E 1 5.47 0.92 
TIM8A_MOUSE Mitochondrial import inner membrane translocase subunit Tim8 A 5.45 0.84 
MIA40_MOUSE Mitochondrial intermembrane space import and assembly protein 40 5.45 0.86 
DHPR_MOUSE Dihydropteridine reductase 5.45 0.91 
MDHC_MOUSE Malate dehydrogenase, cytoplasmic 5.41 0.94 
VATF_MOUSE V-type proton ATPase subunit F 5.40 0.88 
SCRN2_MOUSE Secernin-2 5.37 0.83 
SAP3_MOUSE Ganglioside GM2 activator 5.34 0.85 
TIM13_MOUSE Mitochondrial import inner membrane translocase subunit Tim13 5.33 0.89 
ACOC_MOUSE Cytoplasmic aconitate hydratase 5.32 0.88 
ECH1_MOUSE Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial 5.27 0.95 
LYZ2_MOUSE Lysozyme C-2 5.25 0.87 
CP013_MOUSE UPF0585 protein C16orf13 homolog 5.23 0.83 
CCS_MOUSE Copper chaperone for superoxide dismutase 5.23 0.83 
NDUS5_MOUSE NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 5.22 0.85 
AACS_MOUSE Acetoacetyl-CoA synthetase 5.22 0.81 
IDH3A_MOUSE Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial 5.19 0.93 
DHE3_MOUSE Glutamate dehydrogenase 1, mitochondrial 5.15 0.93 
NDUA6_MOUSE NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6 5.11 0.87 
DOPD_MOUSE D-dopachrome decarboxylase 5.10 0.95 
P5CR3_MOUSE Pyrroline-5-carboxylate reductase 3 5.08 0.84 
THIC_MOUSE Acetyl-CoA acetyltransferase, cytosolic 5.08 0.81 
THTM_MOUSE 3-mercaptopyruvate sulfurtransferase 5.06 0.82 
THIOM_MOUSE Thioredoxin, mitochondrial 5.05 0.95 
SQRD_MOUSE Sulfide:quinone oxidoreductase, mitochondrial 5.04 0.89 
SPS2_MOUSE Selenide, water dikinase 2 5.03 0.84 
CMC1_MOUSE Calcium-binding mitochondrial carrier protein Aralar1 5.01 0.86 
HCD2_MOUSE 3-hydroxyacyl-CoA dehydrogenase type-2 5.00 0.94 
LPPRC_MOUSE Leucine-rich PPR motif-containing protein, mitochondrial 4.96 0.85 
4F2_MOUSE 4F2 cell-surface antigen heavy chain 4.94 0.93 
VATB2_MOUSE V-type proton ATPase subunit B, brain isoform 4.92 0.91 
ACDSB_MOUSE Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial 4.89 0.94 
ABHEB_MOUSE Protein ABHD14B 4.87 0.91 
IDHC_MOUSE Isocitrate dehydrogenase [NADP] cytoplasmic 4.87 0.91 
NIT1_MOUSE Nitrilase homolog 1 4.86 0.89 
TIM9_MOUSE Mitochondrial import inner membrane translocase subunit Tim9 4.85 0.81 
OPA1_MOUSE Dynamin-like 120 kDa protein, mitochondrial 4.84 0.86 
RM12_MOUSE 39S ribosomal protein L12, mitochondrial 4.83 0.93 
GSTT2_MOUSE Glutathione S-transferase theta-2 4.83 0.82 
GLYC_MOUSE Serine hydroxymethyltransferase, cytosolic 4.75 0.85 
KAD3_MOUSE GTP:AMP phosphotransferase AK3, mitochondrial 4.75 0.89 
VATG3_MOUSE V-type proton ATPase subunit G 3 4.74 0.84 
EFTU_MOUSE Elongation factor Tu, mitochondrial 4.73 0.95 
ECHA_MOUSE Trifunctional enzyme subunit alpha, mitochondrial 4.67 0.96 
GRP75_MOUSE Stress-70 protein, mitochondrial 4.62 0.85 
LYPA1_MOUSE Acyl-protein thioesterase 1 4.62 0.88 
ACADL_MOUSE Long-chain specific acyl-CoA dehydrogenase, mitochondrial 4.56 0.95 
BASI_MOUSE Basigin 4.56 0.82 
VATD_MOUSE V-type proton ATPase subunit D 4.54 0.86 
CLPP_MOUSE ATP-dependent Clp protease proteolytic subunit, mitochondrial 4.51 0.87 
MIC27_MOUSE MICOS complex subunit Mic27 4.49 0.87 
EM55_MOUSE 55 kDa erythrocyte membrane protein 4.48 0.86 
LETM1_MOUSE LETM1 and EF-hand domain-containing protein 1, mitochondrial 4.47 0.86 
ECHB_MOUSE Trifunctional enzyme subunit beta, mitochondrial 4.43 0.89 
IAH1_MOUSE Isoamyl acetate-hydrolyzing esterase 1 homolog 4.35 0.82 
ANK3_MOUSE Ankyrin-3 4.33 0.84 
ATAD3_MOUSE ATPase family AAA domain-containing protein 3 4.33 0.87 
MTCH2_MOUSE Mitochondrial carrier homolog 2 4.32 0.89 
M2OM_MOUSE Mitochondrial 2-oxoglutarate/malate carrier protein 4.29 0.88 
MOT1_MOUSE Monocarboxylate transporter 1 4.28 0.80 
AMPN_MOUSE Aminopeptidase N 4.26 0.94 
OAT_MOUSE Ornithine aminotransferase, mitochondrial 4.26 0.86 
LDHB_MOUSE L-lactate dehydrogenase B chain 4.24 0.86 
ACOT1_MOUSE Acyl-coenzyme A thioesterase 1 4.21 0.85 
GLRX5_MOUSE Glutaredoxin-related protein 5, mitochondrial 4.20 0.86 
CPT1A_MOUSE Carnitine O-palmitoyltransferase 1, liver isoform 4.20 0.85 
NIT2_MOUSE Omega-amidase NIT2 4.19 0.90 
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KCRU_MOUSE Creatine kinase U-type, mitochondrial 4.16 0.84 
NDUA1_MOUSE NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 1 4.12 0.86 
ADT1_MOUSE ADP/ATP translocase 1 4.11 0.85 
CACP_MOUSE Carnitine O-acetyltransferase 4.11 0.82 
GSH0_MOUSE Glutamate--cysteine ligase regulatory subunit 4.07 0.84 
XPP1_MOUSE Xaa-Pro aminopeptidase 1 4.05 0.85 
VATC1_MOUSE V-type proton ATPase subunit C 1 3.94 0.85 
GPX1_MOUSE Glutathione peroxidase 1 3.91 0.94 
DHB4_MOUSE Peroxisomal multifunctional enzyme type 2 3.87 0.94 
LONM_MOUSE Lon protease homolog, mitochondrial 3.87 0.90 
PHB2_MOUSE Prohibitin-2 3.84 0.93 
EFTS_MOUSE Elongation factor Ts, mitochondrial 3.83 0.83 
ESTD_MOUSE S-formylglutathione hydrolase 3.80 0.88 
MIF_MOUSE Macrophage migration inhibitory factor 3.79 0.89 
ATIF1_MOUSE ATPase inhibitor, mitochondrial 3.71 0.83 
CISY_MOUSE Citrate synthase, mitochondrial 3.69 0.89 
KAT1_MOUSE Kynurenine--oxoglutarate transaminase 1 3.63 0.82 
AMPL_MOUSE Cytosol aminopeptidase 3.63 0.93 
C1QBP_MOUSE 
Complement component 1 Q subcomponent-binding protein, 
mitochondrial 
3.63 0.92 
GSTM5_MOUSE Glutathione S-transferase Mu 5 3.62 0.89 
AMPE_MOUSE Glutamyl aminopeptidase 3.60 0.86 
CYB5_MOUSE Cytochrome b5 3.60 0.89 
TMM65_MOUSE Transmembrane protein 65 3.59 0.91 
ATAD1_MOUSE ATPase family AAA domain-containing protein 1 3.57 0.85 
41_MOUSE Protein 4.1 3.55 0.83 
AATC_MOUSE Aspartate aminotransferase, cytoplasmic 3.51 0.89 
PHB_MOUSE Prohibitin 3.45 0.93 
ACBP_MOUSE Acyl-CoA-binding protein 3.42 0.96 
EZRI_MOUSE Ezrin 3.41 0.96 
NPL_MOUSE N-acetylneuraminate lyase 3.41 0.86 
RADI_MOUSE Radixin 3.39 0.89 
PGK1_MOUSE Phosphoglycerate kinase 1 3.35 0.97 
GNPI1_MOUSE Glucosamine-6-phosphate isomerase 1 3.33 0.88 
MYO6_MOUSE Unconventional myosin-VI 3.31 0.85 
F213A_MOUSE Redox-regulatory protein FAM213A 3.31 0.83 
SPRE_MOUSE Sepiapterin reductase 3.28 0.96 
TIM50_MOUSE Mitochondrial import inner membrane translocase subunit TIM50 3.27 0.89 
SYIM_MOUSE Isoleucine--tRNA ligase, mitochondrial 3.27 0.83 
TXTP_MOUSE Tricarboxylate transport protein, mitochondrial 3.23 0.83 
DHI2_MOUSE Corticosteroid 11-beta-dehydrogenase isozyme 2 3.22 0.88 
SODC_MOUSE Superoxide dismutase [Cu-Zn] 3.22 0.95 
PROSC_MOUSE Proline synthase co-transcribed bacterial homolog protein 3.21 0.89 
AKCL2_MOUSE 1,5-anhydro-D-fructose reductase 3.19 0.82 
VA0D1_MOUSE V-type proton ATPase subunit d 1 3.19 0.87 
PGM1_MOUSE Phosphoglucomutase-1 3.15 0.85 
PTGR2_MOUSE Prostaglandin reductase 2 3.15 0.92 
VDAC2_MOUSE Voltage-dependent anion-selective channel protein 2 3.13 0.93 
HINT1_MOUSE Histidine triad nucleotide-binding protein 1 3.06 0.95 
NOMO1_MOUSE Nodal modulator 1 3.03 0.81 
PDXK_MOUSE Pyridoxal kinase 3.01 0.92 
CAH2_MOUSE Carbonic anhydrase 2 2.99 0.96 
APMAP_MOUSE Adipocyte plasma membrane-associated protein 2.93 0.85 
FIS1_MOUSE Mitochondrial fission 1 protein 2.91 0.88 
GSTA4_MOUSE Glutathione S-transferase A4 2.89 0.87 
CLIC5_MOUSE Chloride intracellular channel protein 5 2.86 0.81 
THIKA_MOUSE 3-ketoacyl-CoA thiolase A, peroxisomal 2.81 0.82 
LAD1_MOUSE Ladinin-1 2.79 0.80 
GLGB_MOUSE 1,4-alpha-glucan-branching enzyme 2.77 0.86 
UGPA_MOUSE UTP--glucose-1-phosphate uridylyltransferase 2.74 0.85 
AL3A2_MOUSE Fatty aldehyde dehydrogenase 2.74 0.86 
SYPL1_MOUSE Synaptophysin-like protein 1 2.73 1.00 
TOM5_MOUSE Mitochondrial import receptor subunit TOM5 homolog 2.69 0.88 
HDHD2_MOUSE Haloacid dehalogenase-like hydrolase domain-containing protein 2 2.66 0.82 
TIM44_MOUSE Mitochondrial import inner membrane translocase subunit TIM44 2.61 0.83 
SAHH_MOUSE Adenosylhomocysteinase 2.58 0.91 
PARK7_MOUSE Protein deglycase DJ-1 2.58 0.87 
TPIS_MOUSE Triosephosphate isomerase 2.56 0.83 
HEM2_MOUSE Delta-aminolevulinic acid dehydratase 2.54 0.91 
HXK1_MOUSE Hexokinase-1 2.51 0.92 
ENOA_MOUSE Alpha-enolase 2.47 0.98 
PACN2_MOUSE Protein kinase C and casein kinase substrate in neurons protein 2 2.46 0.88 
ADHX_MOUSE Alcohol dehydrogenase class-3 2.40 0.84 
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GBG12_MOUSE Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-12 2.39 0.94 
PGAM1_MOUSE Phosphoglycerate mutase 1 2.39 0.95 
BACH_MOUSE Cytosolic acyl coenzyme A thioester hydrolase 2.38 0.81 
SELT_MOUSE Selenoprotein T 2.32 0.96 
NNRD_MOUSE ATP-dependent (S)-NAD(P)H-hydrate dehydratase 2.32 0.82 
ADK_MOUSE Adenosine kinase 2.31 0.83 
CYB5B_MOUSE Cytochrome b5 type B 2.29 0.90 
GPD1L_MOUSE Glycerol-3-phosphate dehydrogenase 1-like protein 2.26 0.85 
GSTM1_MOUSE Glutathione S-transferase Mu 1 2.22 0.89 
NDKB_MOUSE Nucleoside diphosphate kinase B 2.20 0.90 
PRDX1_MOUSE Peroxiredoxin-1 2.19 0.90 
G3P_MOUSE Glyceraldehyde-3-phosphate dehydrogenase 2.18 0.90 
FUCM_MOUSE Fucose mutarotase 2.15 0.88 
RAB14_MOUSE Ras-related protein Rab-14 2.13 0.83 
UGDH_MOUSE UDP-glucose 6-dehydrogenase 2.12 0.82 
BIEA_MOUSE Biliverdin reductase A 2.10 0.81 
VPS35_MOUSE Vacuolar protein sorting-associated protein 35 2.09 0.81 
G6PI_MOUSE Glucose-6-phosphate isomerase 2.07 0.96 
GMPR1_MOUSE GMP reductase 1 2.06 0.92 
RAB8A_MOUSE Ras-related protein Rab-8A 2.06 0.82 
KCY_MOUSE UMP-CMP kinase 2.04 0.83 
PRDX6_MOUSE Peroxiredoxin-6 2.03 0.96 
CNDP2_MOUSE Cytosolic non-specific dipeptidase 2.00 0.85 
TMM33_MOUSE Transmembrane protein 33 1.99 0.83 
TMED4_MOUSE Transmembrane emp24 domain-containing protein 4 1.95 0.86 
COMT_MOUSE Catechol O-methyltransferase 1.95 0.82 
TXD17_MOUSE Thioredoxin domain-containing protein 17 1.95 0.87 
TBB4B_MOUSE Tubulin beta-4B chain 1.95 1.00 
PEBP1_MOUSE Phosphatidylethanolamine-binding protein 1 1.95 0.95 
RTN3_MOUSE Reticulon-3 1.94 0.88 
VAMP8_MOUSE Vesicle-associated membrane protein 8 1.94 0.83 
ERLN2_MOUSE Erlin-2 1.87 0.80 
GSTT1_MOUSE Glutathione S-transferase theta-1 1.84 0.85 
SPTN1_MOUSE Spectrin alpha chain, non-erythrocytic 1 1.84 0.98 
LGUL_MOUSE Lactoylglutathione lyase 1.83 0.83 
SPTB2_MOUSE Spectrin beta chain, non-erythrocytic 1 1.83 0.85 
ISOC1_MOUSE Isochorismatase domain-containing protein 1 1.81 0.85 
RASN_MOUSE GTPase NRas 1.79 0.81 
MAT2B_MOUSE Methionine adenosyltransferase 2 subunit beta 1.78 0.96 
GSTP1_MOUSE Glutathione S-transferase P 1 1.74 0.93 
HACD3_MOUSE Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 3 1.73 0.88 
SNX3_MOUSE Sorting nexin-3 1.73 0.85 
GALK2_MOUSE N-acetylgalactosamine kinase 1.72 0.81 
VP26A_MOUSE Vacuolar protein sorting-associated protein 26A 1.72 0.92 
ITPR1_MOUSE Inositol 1,4,5-trisphosphate receptor type 1 1.70 0.83 
DNJA1_MOUSE DnaJ homolog subfamily A member 1 1.70 0.81 
RB11B_MOUSE Ras-related protein Rab-11B 1.69 0.89 
RS27L_MOUSE 40S ribosomal protein S27-like 1.65 0.86 
PGRC1_MOUSE Membrane-associated progesterone receptor component 1 1.65 0.84 
PTH2_MOUSE Peptidyl-tRNA hydrolase 2, mitochondrial 1.63 0.96 
UAP1L_MOUSE UDP-N-acetylhexosamine pyrophosphorylase-like protein 1 1.63 0.84 
GLOD4_MOUSE Glyoxalase domain-containing protein 4 1.62 0.87 
ALDOA_MOUSE Fructose-bisphosphate aldolase A 1.61 0.90 
F10A1_MOUSE Hsc70-interacting protein 1.61 0.85 
ACLY_MOUSE ATP-citrate synthase 1.60 0.85 
GLRX1_MOUSE Glutaredoxin-1 1.55 0.83 
FKBP3_MOUSE Peptidyl-prolyl cis-trans isomerase FKBP3 1.55 0.81 
DPEP1_MOUSE Dipeptidase 1 1.53 0.86 
LDHA_MOUSE L-lactate dehydrogenase A chain 1.52 0.88 
HS90A_MOUSE Heat shock protein HSP 90-alpha 1.46 0.82 
SYSC_MOUSE Serine--tRNA ligase, cytoplasmic 1.45 0.82 
GPX3_MOUSE Glutathione peroxidase 3 1.41 0.83 
TKT_MOUSE Transketolase 1.38 0.84 
PRDX2_MOUSE Peroxiredoxin-2 1.37 0.88 
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S.1.13 Comparison of UUO-differentially expressed proteins in WT and TG2-
null mice 
S.1.13.1 UUO-overexpressed proteins 
Supplementary Table 3.17. List of proteins significantly overexpressed (confidence ≥ 0.8) in 
either WT or TG2-KO kidneys subjected to UUO (21 days) and corresponding fold change from 
Sham operated condition in both phenotypes. In increasing shade of red the positive log2 (Log2FC) 
of fold change from the sham operated condition (the more intense, the more overexpressed), in 
decreasing shades of green the negative log2 (Log2FC) of fold change from the sham operated condition 
(the more intense, the more underexpressed), in increasing shades of grey the absolute fold change from 
the sham operated condition (Abs FC, absolute increase or decrease depending on the sign of Log2FC) 
while in shades of yellow the confidence of the change (refer to the colour legend below). A confidence 
≥ 0.8 was regarded as significant.  
 
Unique/ 
Common 
Protein 
ID 
_MOUSE 
Name 
WT TG2-KO 
Log2 
(FC) 
Abs 
(FC) 
C 
(FC) 
Log2 
(FC) 
Abs 
(FC) 
C 
(FC) 
WT ONLY FBLN2 Fibulin-2 3.27 9.65 0.81 2.32 4.99 0.54 
WT ONLY CNN1 Calponin-1 3.10 8.59 0.80 3.45 10.90 0.80 
WT ONLY HA2U 
H-2 class II histocompatibility antigen, A-U 
alpha chain 
3.06 8.32 0.80 2.95 7.75 0.74 
WT ONLY MT2 Metallothionein-2 3.02 8.11 0.84 -3.36 10.27 0.09 
WT ONLY POSTN Periostin 3.01 8.04 0.80 3.12 8.66 0.78 
WT ONLY A1AT2 Alpha-1-antitrypsin 1-2 2.97 7.86 0.82 1.31 2.48 0.48 
WT ONLY CKAP4 Cytoskeleton-associated protein 4 2.72 6.57 0.85 2.63 6.18 0.73 
WT ONLY RET1 Retinol-binding protein 1 2.48 5.56 0.83 2.31 4.95 0.78 
WT ONLY PDLI7 PDZ and LIM domain protein 7 2.43 5.40 0.81 2.36 5.13 0.64 
WT ONLY FIBA Fibrinogen alpha chain 2.21 4.64 0.90 0.93 1.91 0.69 
WT ONLY CO4A2 Collagen alpha-2(IV) chain 2.17 4.50 0.80 1.45 2.73 0.79 
WT ONLY FIBG Fibrinogen gamma chain 2.15 4.45 0.85 1.50 2.82 0.74 
WT ONLY PEDF Pigment epithelium-derived factor 2.09 4.24 0.81 2.37 5.16 0.55 
WT ONLY FIBB Fibrinogen beta chain 2.00 4.00 0.86 0.96 1.95 0.71 
WT ONLY SH3L3 
SH3 domain-binding glutamic acid-rich-like 
protein 3 
1.94 3.85 0.90 1.04 2.06 0.72 
WT ONLY CALU Calumenin 1.88 3.69 0.84 1.55 2.93 0.80 
WT ONLY CRIP1 Cysteine-rich protein 1 1.83 3.55 0.90 1.82 3.52 0.55 
WT ONLY IGG2B Ig gamma-2B chain C region 1.62 3.07 0.81 1.56 2.94 0.77 
WT ONLY K2C79 Keratin, type II cytoskeletal 79 1.61 3.05 0.91 0.65 1.57 0.56 
WT ONLY PTRF Polymerase I and transcript release factor 1.57 2.96 0.84 0.74 1.67 0.69 
WT ONLY CERU Ceruloplasmin 1.52 2.86 0.80 1.56 2.95 0.77 
WT ONLY GBG2 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(O) subunit gamma-2 
1.40 2.65 0.81 1.25 2.39 0.78 
WT ONLY S10AA Protein S100-A10 1.37 2.59 0.86 1.23 2.35 0.74 
WT ONLY SF3B3 Splicing factor 3B subunit 3 1.33 2.51 0.83 0.82 1.76 0.73 
WT ONLY ML12B Myosin regulatory light chain 12B 1.22 2.33 0.83 1.21 2.32 0.73 
WT ONLY ANT3 Antithrombin-III 1.18 2.27 0.86 1.08 2.11 0.76 
WT ONLY AGRIN Agrin 1.11 2.16 0.92 0.73 1.66 0.67 
WT ONLY KHDR1 
KH domain-containing, RNA-binding, signal 
transduction-associated protein 1 
1.10 2.14 0.84 0.93 1.90 0.52 
WT ONLY COR1B Coronin-1B 1.04 2.06 0.86 0.42 1.34 0.55 
WT ONLY A2M Pregnancy zone protein 1.03 2.05 0.85 1.18 2.26 0.72 
WT ONLY INO1 Inositol-3-phosphate synthase 1 1.02 2.03 0.81 0.89 1.85 0.59 
WT ONLY LIMA1 LIM domain and actin-binding protein 1 1.02 2.02 0.87 0.71 1.64 0.62 
WT ONLY ARPC3 Actin-related protein 2/3 complex subunit 3 1.01 2.01 0.87 0.95 1.93 0.80 
WT ONLY WDR1 WD repeat-containing protein 1 1.01 2.01 0.83 0.67 1.59 0.65 
WT ONLY ARPC2 Actin-related protein 2/3 complex subunit 2 0.91 1.87 0.83 0.55 1.46 0.79 
WT ONLY NH2L1 NHP2-like protein 1 0.90 1.86 0.81 0.66 1.58 0.53 
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WT ONLY HNRPF Heterogeneous nuclear ribonucleoprotein F 0.87 1.82 0.83 0.54 1.45 0.74 
WT ONLY FABP4 Fatty acid-binding protein, adipocyte 0.86 1.82 0.85 -0.76 1.69 0.78 
WT ONLY LASP1 LIM and SH3 domain protein 1 0.86 1.81 0.81 0.58 1.50 0.66 
WT ONLY ANXA4 Annexin A4 0.83 1.78 0.85 0.48 1.39 0.57 
WT ONLY FUBP2 Far upstream element-binding protein 2 0.83 1.78 0.80 0.76 1.69 0.78 
WT ONLY RUXF Small nuclear ribonucleoprotein F 0.81 1.75 0.87 0.41 1.33 0.67 
WT ONLY CSRP2 Cysteine and glycine-rich protein 2 0.78 1.72 0.82 0.50 1.41 0.71 
WT ONLY TGM2 Transglutminase 2 0.78 1.71 0.90 -1.49 2.81 0.17 
WT ONLY LAP2B 
Lamina-associated polypeptide 2, isoforms 
beta/delta/epsilon/gamma 
0.77 1.71 0.80 0.67 1.59 0.78 
WT ONLY SRSF2 Serine/arginine-rich splicing factor 2 0.76 1.70 0.86 0.62 1.53 0.74 
WT ONLY 1433G 14-3-3 protein gamma 0.72 1.65 0.81 0.43 1.35 0.65 
WT ONLY SMAP Small acidic protein 0.71 1.64 0.88 0.36 1.28 0.24 
WT ONLY RSU1 Ras suppressor protein 1 0.67 1.59 0.84 0.57 1.48 0.68 
WT ONLY SC11A 
Signal peptidase complex catalytic subunit 
SEC11A 
0.67 1.59 0.80 0.47 1.39 0.78 
WT ONLY MOES Moesin 0.60 1.52 0.81 0.44 1.36 0.57 
WT ONLY GDIR1 Rho GDP-dissociation inhibitor 1 0.60 1.51 0.84 0.41 1.33 0.64 
WT ONLY HNRH1 Heterogeneous nuclear ribonucleoprotein H 0.56 1.48 0.87 0.55 1.46 0.71 
WT ONLY KAPCA 
cAMP-dependent protein kinase catalytic 
subunit alpha 
0.53 1.44 0.89 0.56 1.47 0.78 
WT ONLY HNRPK Heterogeneous nuclear ribonucleoprotein K 0.49 1.40 0.82 0.41 1.33 0.77 
WT ONLY LAMP1 
Lysosome-associated membrane 
glycoprotein 1 
0.47 1.38 0.81 0.28 1.22 0.42 
COMMON UROM Uromodulin 4.03 16.34 0.85 3.29 9.78 0.88 
COMMON COCA1 Collagen alpha-1(XII) chain 3.99 15.92 0.82 4.71 26.15 0.83 
COMMON FBN1 Fibrillin-1 3.44 10.84 0.89 3.01 8.05 0.89 
COMMON K1C19 Keratin, type I cytoskeletal 19 3.26 9.57 0.86 2.99 7.95 0.89 
COMMON TAGL Transgelin 3.21 9.27 0.89 2.78 6.86 0.89 
COMMON PGS1 Biglycan 3.13 8.73 0.86 3.30 9.86 0.87 
COMMON VIME Vimentin 3.10 8.56 0.90 2.74 6.67 0.91 
COMMON ANXA1 Annexin A1 3.03 8.17 0.84 3.04 8.24 0.94 
COMMON FINC Fibronectin 2.97 7.85 0.84 2.66 6.31 0.89 
COMMON COR1A Coronin-1A 2.96 7.77 0.80 2.77 6.83 0.82 
COMMON CO3A1 Collagen alpha-1(III) chain 2.95 7.72 0.92 2.59 6.02 0.95 
COMMON PLSL Plastin-2 2.93 7.63 0.85 2.25 4.77 0.82 
COMMON CO1A1 Collagen alpha-1(I) chain 2.93 7.61 0.96 2.73 6.64 0.96 
COMMON KCRB Creatine kinase B-type 2.92 7.56 0.83 2.58 5.98 0.86 
COMMON FBN2 Fibrillin-2 2.86 7.26 0.94 3.86 14.52 0.89 
COMMON MIME Mimecan 2.74 6.67 0.83 2.89 7.40 0.86 
COMMON LUM Lumican 2.71 6.55 0.87 2.76 6.76 0.84 
COMMON FBLN3 
EGF-containing fibulin-like extracellular 
matrix protein 1 
2.66 6.33 0.80 2.42 5.35 0.87 
COMMON SERPH Serpin H1 2.63 6.19 0.94 2.45 5.45 0.96 
COMMON CNN2 Calponin-2 2.62 6.15 0.80 2.04 4.11 0.84 
COMMON LEG1 Galectin-1 2.62 6.15 0.87 2.44 5.44 0.93 
COMMON DESM Desmin 2.58 5.98 0.94 2.20 4.60 0.94 
COMMON FBLN5 Fibulin-5 2.54 5.81 0.84 2.43 5.38 0.87 
COMMON CLUS Clusterin 2.42 5.35 0.81 2.10 4.30 0.86 
COMMON K2C5 Keratin, type II cytoskeletal 5 2.39 5.24 0.83 2.37 5.15 0.84 
COMMON FLNA Filamin-A 2.34 5.07 0.93 2.19 4.56 0.95 
COMMON MYOF Myoferlin 2.32 4.99 0.86 2.38 5.21 0.81 
COMMON K2C8 Keratin, type II cytoskeletal 8 2.30 4.93 0.89 2.09 4.26 0.94 
COMMON CO6A1 Collagen alpha-1(VI) chain 2.26 4.78 0.88 1.82 3.52 0.89 
COMMON CO6A2 Collagen alpha-2(VI) chain 2.25 4.76 0.94 1.77 3.40 0.92 
COMMON ANXA3 Annexin A3 2.24 4.73 0.83 1.61 3.05 0.82 
COMMON COEA1 Collagen alpha-1(XIV) chain 2.21 4.62 0.81 1.97 3.93 0.83 
COMMON HEMO Hemopexin 2.20 4.60 0.86 1.81 3.50 0.82 
COMMON CSRP1 Cysteine and glycine-rich protein 1 2.18 4.52 0.89 1.87 3.65 0.92 
COMMON EMIL1 Emilin-1 2.15 4.42 0.82 2.25 4.77 0.89 
COMMON TBA1A Tubulin alpha-1A chain 2.14 4.41 0.96 2.10 4.28 0.91 
COMMON TYB4 Thymosin beta-4 2.12 4.35 0.88 2.22 4.65 0.90 
COMMON TPM1 Tropomyosin alpha-1 chain 2.10 4.28 0.84 1.63 3.09 0.83 
COMMON K2C7 Keratin, type II cytoskeletal 7 2.09 4.27 0.88 1.78 3.43 0.88 
COMMON ACTN1 Alpha-actinin-1 2.08 4.22 0.96 1.89 3.72 0.96 
COMMON TPM4 Tropomyosin alpha-4 chain 2.07 4.19 0.91 2.02 4.06 0.91 
COMMON IGKC Ig kappa chain C region 2.05 4.15 0.87 1.76 3.38 0.87 
COMMON MYADM Myeloid-associated differentiation marker 2.00 4.00 0.87 1.86 3.62 0.92 
COMMON TRFE Serotransferrin 1.92 3.78 0.91 1.42 2.67 0.89 
COMMON ANXA2 Annexin A2 1.91 3.76 0.90 1.61 3.06 0.90 
COMMON G6PE GDH/6PGL endoplasmic bifunctional protein 1.89 3.71 0.90 1.80 3.49 0.85 
COMMON SPB6 Serpin B6 1.83 3.56 0.89 1.33 2.51 0.84 
COMMON EFHD2 EF-hand domain-containing protein D2 1.82 3.52 0.87 1.71 3.28 0.83 
COMMON ESYT1 Extended synaptotagmin-1 1.81 3.52 0.82 1.85 3.60 0.83 
COMMON LMNA Prelamin-A/C 1.80 3.49 0.94 1.36 2.57 0.94 
COMMON CO4B Complement C4-B 1.78 3.44 0.86 1.46 2.75 0.83 
COMMON ARC1B Actin-related protein 2/3 complex subunit 1B 1.76 3.38 0.87 1.54 2.91 0.88 
COMMON TBB5 Tubulin beta-5 chain 1.74 3.33 0.88 1.45 2.72 0.90 
COMMON APOE Apolipoprotein E 1.73 3.31 0.87 1.32 2.49 0.94 
COMMON MYH11 Myosin-11 1.71 3.28 0.87 1.52 2.87 0.92 
COMMON MYH10 Myosin-10 1.71 3.27 0.85 1.86 3.63 0.84 
COMMON FETUA Alpha-2-HS-glycoprotein 1.71 3.27 0.90 1.35 2.54 0.94 
COMMON ESYT2 Extended synaptotagmin-2 1.69 3.23 0.86 1.60 3.03 0.83 
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COMMON GCAB Ig gamma-2A chain C region secreted form 1.68 3.21 0.91 2.07 4.20 0.82 
COMMON ACTA Actin, aortic smooth muscle 1.67 3.17 0.94 1.46 2.76 0.85 
COMMON VTDB Vitamin D-binding protein 1.65 3.13 0.93 1.19 2.28 0.89 
COMMON EST1C Carboxylesterase 1C 1.64 3.11 0.95 1.34 2.52 0.94 
COMMON KNG1 Kininogen-1 1.63 3.09 0.91 1.35 2.54 0.92 
COMMON MYL9 Myosin regulatory light polypeptide 9 1.62 3.08 0.98 1.35 2.56 0.98 
COMMON S10AB Protein S100-A11 1.62 3.08 0.88 1.77 3.40 0.88 
COMMON A1AT1 Alpha-1-antitrypsin 1-1 1.62 3.07 0.86 1.45 2.74 0.81 
COMMON SH3L1 
SH3 domain-binding glutamic acid-rich-like 
protein 
1.61 3.06 0.86 1.63 3.09 0.89 
COMMON TAGL2 Transgelin-2 1.60 3.04 0.88 1.66 3.16 0.87 
COMMON K1C18 Keratin, type I cytoskeletal 18 1.58 2.99 0.94 1.41 2.66 0.92 
COMMON ALBU Serum albumin 1.58 2.98 0.92 1.30 2.46 0.91 
COMMON VAT1 
Synaptic vesicle membrane protein VAT-1 
homolog 
1.56 2.96 0.90 1.55 2.92 0.93 
COMMON SEP7 Septin-7 1.56 2.95 0.82 1.27 2.41 0.80 
COMMON PSME2 Proteasome activator complex subunit 2 1.54 2.91 0.88 1.02 2.03 0.81 
COMMON B2MG Beta-2-microglobulin 1.52 2.88 0.82 1.23 2.34 0.89 
COMMON SEP2 Septin-2 1.50 2.83 0.82 1.39 2.62 0.85 
COMMON COF1 Cofilin-1 1.45 2.74 0.87 1.13 2.18 0.83 
COMMON A1AT4 Alpha-1-antitrypsin 1-4 1.44 2.72 0.83 1.48 2.79 0.81 
COMMON ANXA6 Annexin A6 1.44 2.71 0.89 0.99 1.98 0.91 
COMMON ADPRH [Protein ADP-ribosylarginine] hydrolase 1.44 2.71 0.86 1.04 2.06 0.84 
COMMON DPYL2 Dihydropyrimidinase-related protein 2 1.42 2.68 0.88 0.91 1.88 0.83 
COMMON CO4A1 Collagen alpha-1(IV) chain 1.42 2.67 0.88 1.01 2.01 0.86 
COMMON MAP4 Microtubule-associated protein 4 1.41 2.66 0.82 1.12 2.17 0.81 
COMMON CATD Cathepsin D 1.41 2.65 0.82 1.64 3.12 0.81 
COMMON ROA1 Heterogeneous nuclear ribonucleoprotein A1 1.40 2.63 0.88 1.02 2.03 0.88 
COMMON ISG15 Ubiquitin-like protein ISG15 1.39 2.62 0.84 1.37 2.59 0.89 
COMMON FETUB Fetuin-B 1.39 2.61 0.89 1.38 2.60 0.86 
COMMON MYH9 Myosin-9 1.39 2.61 0.99 1.32 2.50 0.97 
COMMON CO3 Complement C3 1.38 2.59 0.87 1.29 2.45 0.87 
COMMON MYLK Myosin light chain kinase, smooth muscle 1.37 2.59 0.80 1.19 2.28 0.89 
COMMON VMA5A 
von Willebrand factor A domain-containing 
protein 5A 
1.37 2.58 0.86 1.24 2.36 0.86 
COMMON COIA1 Collagen alpha-1(XVIII) chain 1.36 2.57 0.96 1.06 2.08 0.94 
COMMON MYL6 Myosin light polypeptide 6 1.34 2.53 0.92 1.34 2.53 0.94 
COMMON CATZ Cathepsin Z 1.34 2.53 0.86 1.07 2.09 0.85 
COMMON APOA4 Apolipoprotein A-IV 1.32 2.50 0.82 1.30 2.47 0.83 
COMMON CAP1 Adenylyl cyclase-associated protein 1 1.32 2.50 0.92 1.26 2.40 0.92 
COMMON APOH Beta-2-glycoprotein 1 1.32 2.50 0.80 1.49 2.82 0.85 
COMMON APOA1 Apolipoprotein A-I 1.30 2.46 0.92 1.03 2.04 0.87 
COMMON SET Protein SET 1.30 2.46 0.83 1.10 2.15 0.90 
COMMON SFPQ Splicing factor, proline- and glutamine-rich 1.28 2.44 0.81 0.98 1.97 0.81 
COMMON RBM3 RNA-binding protein 3 1.24 2.36 0.84 1.69 3.23 0.81 
COMMON T22D1 TSC22 domain family protein 1 1.23 2.35 0.90 1.17 2.24 0.84 
COMMON TIF1B Transcription intermediary factor 1-beta 1.22 2.33 0.83 0.99 1.99 0.81 
COMMON GELS Gelsolin 1.22 2.33 0.84 1.20 2.30 0.87 
COMMON VINC Vinculin 1.22 2.33 0.94 1.02 2.03 0.92 
COMMON LMNB1 Lamin-B1 1.20 2.30 0.86 1.13 2.19 0.88 
COMMON ANXA5 Annexin A5 1.20 2.29 0.84 1.13 2.19 0.87 
COMMON PSME1 Proteasome activator complex subunit 1 1.19 2.28 0.84 1.14 2.21 0.81 
COMMON LAMA5 Laminin subunit alpha-5 1.17 2.26 0.83 0.97 1.96 0.89 
COMMON COR1C Coronin-1C 1.16 2.23 0.83 0.97 1.95 0.82 
COMMON CAPZB F-actin-capping protein subunit beta 1.16 2.23 0.89 0.79 1.73 0.86 
COMMON FUS RNA-binding protein FUS 1.15 2.22 0.80 0.90 1.87 0.81 
COMMON AN32B 
Acidic leucine-rich nuclear phosphoprotein 32 
family member B 
1.11 2.15 0.81 1.10 2.14 0.91 
COMMON PROF1 Profilin-1 1.07 2.10 0.89 1.11 2.16 0.88 
COMMON NID1 Nidogen-1 1.07 2.10 0.92 1.03 2.04 0.94 
COMMON H2AV Histone H2A.V 1.05 2.07 0.86 0.84 1.79 0.84 
COMMON GNAI2 
Guanine nucleotide-binding protein G(i) 
subunit alpha-2 
1.01 2.02 0.83 0.84 1.79 0.84 
COMMON UBC9 SUMO-conjugating enzyme UBC9 0.98 1.97 0.91 0.94 1.92 0.91 
COMMON HP1B3 Heterochromatin protein 1-binding protein 3 0.95 1.94 0.83 0.86 1.82 0.89 
COMMON ACTBL Beta-actin-like protein 2 0.93 1.91 0.84 0.81 1.75 0.91 
COMMON ROA3 Heterogeneous nuclear ribonucleoprotein A3 0.93 1.90 0.90 0.66 1.58 0.88 
COMMON NONO 
Non-POU domain-containing octamer-binding 
protein 
0.92 1.90 0.91 0.69 1.62 0.89 
COMMON ABCB7 
ATP-binding cassette sub-family B member 
7, mitochondrial 
0.92 1.89 0.89 0.54 1.45 0.89 
COMMON ARP3 Actin-related protein 3 0.92 1.89 0.95 0.77 1.71 0.93 
COMMON LAMC1 Laminin subunit gamma-1 0.89 1.85 0.93 0.87 1.83 0.90 
COMMON LAMB1 Laminin subunit beta-1 0.89 1.85 0.85 0.74 1.67 0.84 
COMMON PGBM 
Basement membrane-specific heparan 
sulfate proteoglycan core protein 
0.85 1.80 0.81 0.64 1.56 0.81 
COMMON TADBP TAR DNA-binding protein 43 0.85 1.80 0.81 0.47 1.39 0.82 
COMMON NUCL Nucleolin 0.84 1.79 0.83 0.55 1.46 0.85 
COMMON DX39B Spliceosome RNA helicase Ddx39b 0.83 1.78 0.81 0.76 1.69 0.81 
COMMON TLN1 Talin-1 0.83 1.78 0.82 0.72 1.65 0.89 
COMMON ARP2 Actin-related protein 2 0.81 1.76 0.88 0.66 1.58 0.81 
COMMON HNRPM Heterogeneous nuclear ribonucleoprotein M 0.80 1.74 0.86 0.59 1.50 0.82 
COMMON PDIA6 Protein disulfide-isomerase A6 0.75 1.68 0.90 0.67 1.59 0.88 
COMMON LSM3 U6 snRNA-associated Sm-like protein LSm3 0.69 1.62 0.91 0.65 1.57 0.91 
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COMMON ABRAL Costars family protein ABRACL 0.64 1.56 0.80 0.63 1.55 0.87 
COMMON ACTB Actin, cytoplasmic 1 0.64 1.56 0.93 0.52 1.43 0.90 
COMMON HNRPU Heterogeneous nuclear ribonucleoprotein U 0.61 1.53 0.85 0.53 1.44 0.84 
COMMON SMD2 Small nuclear ribonucleoprotein Sm D2 0.56 1.47 0.81 0.48 1.40 0.82 
COMMON PDIA4 Protein disulfide-isomerase A4 0.49 1.40 0.80 0.57 1.48 0.88 
TG2-KO ONLY S10A6 Protein S100-A6 1.50 2.82 0.65 3.45 10.94 0.81 
TG2-KO ONLY RCN3 Reticulocalbin-3 2.73 6.65 0.74 3.22 9.30 0.84 
TG2-KO ONLY MUP6 Major urinary protein 6 1.56 2.94 0.62 2.96 7.80 0.95 
TG2-KO ONLY CO5A1 Collagen alpha-1(V) chain 3.74 13.34 0.78 2.92 7.56 0.83 
TG2-KO ONLY TPSN Tapasin 5.19 36.41 0.76 2.75 6.71 0.89 
TG2-KO ONLY GAPR1 
Golgi-associated plant pathogenesis-related 
protein 1 
2.52 5.72 0.64 2.69 6.44 0.86 
TG2-KO ONLY CFAH Complement factor H 2.12 4.35 0.72 2.63 6.17 0.81 
TG2-KO ONLY ELN Elastin 1.88 3.69 0.61 2.53 5.78 0.83 
TG2-KO ONLY K1C14 Keratin, type I cytoskeletal 14 2.75 6.75 0.75 2.47 5.55 0.81 
TG2-KO ONLY SAMH1 
Deoxynucleoside triphosphate 
triphosphohydrolase SAMHD1 
2.89 7.41 0.74 2.23 4.70 0.84 
TG2-KO ONLY PRELP Prolargin 2.13 4.38 0.79 2.23 4.68 0.89 
TG2-KO ONLY H2A1H Histone H2A type 1-H 1.45 2.73 0.64 2.17 4.49 0.85 
TG2-KO ONLY C1QB Complement C1q subcomponent subunit B 3.24 9.42 0.70 2.12 4.35 0.91 
TG2-KO ONLY ASAH1 Acid ceramidase 2.12 4.36 0.79 2.11 4.32 0.87 
TG2-KO ONLY PDLI2 PDZ and LIM domain protein 2 2.22 4.67 0.55 2.03 4.09 0.82 
TG2-KO ONLY LEG3 Galectin-3 1.90 3.73 0.73 1.89 3.71 0.86 
TG2-KO ONLY TPM2 Tropomyosin beta chain 1.67 3.19 0.79 1.78 3.44 0.82 
TG2-KO ONLY MUP2 Major urinary protein 2 1.48 2.79 0.77 1.78 3.43 1.00 
TG2-KO ONLY FRIL1 Ferritin light chain 1 1.82 3.54 0.64 1.75 3.36 0.86 
TG2-KO ONLY LG3BP Galectin-3-binding protein 2.53 5.78 0.67 1.70 3.26 0.81 
TG2-KO ONLY E41L2 Band 4.1-like protein 2 2.70 6.51 0.77 1.69 3.22 0.88 
TG2-KO ONLY EPDR1 Mammalian ependymin-related protein 1 0.46 1.38 0.55 1.51 2.85 0.81 
TG2-KO ONLY PPT1 Palmitoyl-protein thioesterase 1 1.18 2.26 0.70 1.46 2.75 0.85 
TG2-KO ONLY H11 Histone H1.1 0.86 1.81 0.68 1.44 2.72 0.96 
TG2-KO ONLY HSPB1 Heat shock protein beta-1 1.51 2.85 0.72 1.41 2.67 0.85 
TG2-KO ONLY PCNA Proliferating cell nuclear antigen 1.24 2.37 0.69 1.35 2.55 0.81 
TG2-KO ONLY H15 Histone H1.5 1.08 2.12 0.75 1.34 2.54 0.91 
TG2-KO ONLY HMGB2 High mobility group protein B2 1.46 2.75 0.52 1.29 2.45 0.85 
TG2-KO ONLY NAGAB Alpha-N-acetylgalactosaminidase 1.14 2.21 0.72 1.28 2.43 0.82 
TG2-KO ONLY H12 Histone H1.2 0.58 1.49 0.53 1.28 2.42 0.93 
TG2-KO ONLY SEP11 Septin-11 1.44 2.71 0.80 1.22 2.33 0.83 
TG2-KO ONLY ARPC5 Actin-related protein 2/3 complex subunit 5 1.60 3.03 0.76 1.06 2.09 0.90 
TG2-KO ONLY SPA3K Serine protease inhibitor A3K 1.11 2.15 0.79 1.05 2.07 0.81 
TG2-KO ONLY RENI1 Renin-1 1.47 2.77 0.78 1.01 2.01 0.84 
TG2-KO ONLY NID2 Nidogen-2 0.96 1.95 0.68 0.83 1.77 0.87 
TG2-KO ONLY CAPG Macrophage-capping protein 0.75 1.68 0.77 0.81 1.76 0.81 
TG2-KO ONLY SAP Prosaposin 0.91 1.88 0.75 0.76 1.70 0.82 
TG2-KO ONLY ILF2 Interleukin enhancer-binding factor 2 1.04 2.06 0.56 0.72 1.65 0.84 
TG2-KO ONLY ARPC4 Actin-related protein 2/3 complex subunit 4 0.77 1.71 0.66 0.72 1.65 0.85 
TG2-KO ONLY H2AX Histone H2AX 0.34 1.26 0.52 0.72 1.64 0.83 
TG2-KO ONLY H2B1P Histone H2B type 1-P 0.34 1.27 0.17 0.67 1.59 0.88 
TG2-KO ONLY NPM Nucleophosmin 0.67 1.59 0.57 0.66 1.58 0.83 
TG2-KO ONLY PRDX4 Peroxiredoxin-4 0.83 1.78 0.73 0.61 1.53 0.89 
TG2-KO ONLY ROAA Heterogeneous nuclear ribonucleoprotein A/B 0.50 1.41 0.74 0.58 1.50 0.84 
TG2-KO ONLY RUXE Small nuclear ribonucleoprotein E 0.43 1.35 0.79 0.54 1.45 0.80 
TG2-KO ONLY KAD1 Adenylate kinase isoenzyme 1 0.48 1.40 0.51 0.48 1.39 0.81 
TG2-KO ONLY CATB Cathepsin B 0.58 1.49 0.79 0.43 1.35 0.85 
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S.1.13.2 UUO-underexpressed proteins 
Supplementary Table 3.18: List of proteins significantly underexpressed (Confidence ≥ 0.8) in 
either WT or TG2-KO kidneys subjected to UUO (21 days) and corresponding fold change from 
Sham operated condition in both phenotypes. In increasing shade of red the positive log2 (Log2 FC) 
of fold change from the sham operated condition (the more intense, the more overexpressed), in 
decreasing shades of green the negative log2 (Log2 FC) of fold change from the sham operated condition 
(the more intense, the more underexpressed), in increasing shades of grey the absolute fold change from 
the sham operated condition (Abs FC, absolute increase or decrease depending of the sign of Log2 FC) 
while in shades of yellow the confidence of the change (refer to the colour legend below). A confidence 
≥ 0.8 was regarded as significant.  
 
 
Unique/Commo
n 
Protein 
ID 
_MOUSE 
Name 
WT TG2-KO 
Log2
(FC) 
Abs 
(FC) 
C 
(FC) 
Log2
(FC) 
Abs 
(FC) 
C 
(FC) 
WT ONLY PDZ1I PDZK1-interacting protein 1 -5.52 45.76 0.84 -6.50 90.53 0.79 
WT ONLY GSTA2 Glutathione S-transferase A2 -4.10 17.14 0.85 -3.57 11.91 0.73 
WT ONLY KBL 
2-amino-3-ketobutyrate coenzyme A ligase, 
mitochondrial 
-3.79 13.82 0.85 -2.98 7.91 0.61 
WT ONLY PXMP2 Peroxisomal membrane protein 2 -3.78 13.77 0.81 -2.90 7.48 0.55 
WT ONLY S4A4 
Electrogenic sodium bicarbonate 
cotransporter 1 
-3.73 13.29 0.83 -4.19 18.31 0.78 
WT ONLY ACE Angiotensin-converting enzyme -3.66 12.66 0.91 -3.21 9.27 0.79 
WT ONLY DECR2 Peroxisomal 2,4-dienoyl-CoA reductase -3.66 12.62 0.90 -2.30 4.92 0.79 
WT ONLY ACY3 
N-acyl-aromatic-L-amino acid 
amidohydrolase (carboxylate-forming) 
-3.64 12.43 0.80 -3.53 11.54 0.77 
WT ONLY S22A2 Solute carrier family 22 member 2 -3.62 12.29 0.81 -3.38 10.42 0.76 
WT ONLY DHAK Triokinase/FMN cyclase -3.56 11.77 0.80 -4.16 17.82 0.79 
WT ONLY COX1 Cytochrome c oxidase subunit 1 -3.55 11.70 0.90 -3.16 8.92 0.73 
WT ONLY S2542 
Mitochondrial coenzyme A transporter 
SLC25A42 
-3.54 11.63 0.86 -3.40 10.58 0.71 
WT ONLY ATP5L ATP synthase subunit g, mitochondrial -3.53 11.54 0.80 -2.94 7.67 0.71 
WT ONLY OXDA D-amino-acid oxidase -3.51 11.38 0.81 -3.11 8.60 0.78 
WT ONLY GSTA3 Glutathione S-transferase A3 -3.41 10.63 0.81 -2.67 6.36 0.71 
WT ONLY LACB2 Beta-lactamase-like protein 2 -3.38 10.39 0.82 -3.34 10.12 0.76 
WT ONLY FMO1 
Dimethylaniline monooxygenase [N-oxide-
forming] 1 
-3.37 10.33 0.82 -2.73 6.63 0.78 
WT ONLY PROD Proline dehydrogenase 1, mitochondrial -3.33 10.05 0.81 -3.49 11.25 0.80 
WT ONLY S22AI Solute carrier family 22 member 18 -3.30 9.86 0.90 -4.12 17.38 0.78 
WT ONLY NDUB6 
NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 6 
-3.29 9.77 0.81 -3.21 9.22 0.80 
WT ONLY SSDH 
Succinate-semialdehyde dehydrogenase, 
mitochondrial 
-3.24 9.47 0.88 -2.72 6.57 0.71 
WT ONLY NDUB5 
NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 5, mitochondrial 
-3.17 9.01 0.85 -2.84 7.15 0.79 
WT ONLY PLSI Plastin-1 -3.17 9.01 0.86 -2.83 7.09 0.79 
WT ONLY NDUB8 
NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 8, mitochondrial 
-3.12 8.67 0.86 -2.67 6.38 0.79 
WT ONLY NDUV2 
NADH dehydrogenase [ubiquinone] 
flavoprotein 2, mitochondrial 
-3.09 8.50 0.84 -2.79 6.94 0.79 
WT ONLY BDH2 3-hydroxybutyrate dehydrogenase type 2 -3.02 8.13 0.82 -3.48 11.18 0.80 
WT ONLY COASY Bifunctional coenzyme A synthase -2.97 7.83 0.85 -2.68 6.41 0.77 
WT ONLY TAU Microtubule-associated protein tau -2.96 7.76 0.83 -2.26 4.79 0.77 
WT ONLY PPA6 Lysophosphatidic acid phosphatase type 6 -2.95 7.74 0.85 -2.28 4.87 0.69 
WT ONLY HGD Homogentisate 1,2-dioxygenase -2.92 7.58 0.84 -3.70 13.01 0.76 
WT ONLY ACD11 Acyl-CoA dehydrogenase family member 11 -2.89 7.41 0.80 -3.14 8.83 0.77 
WT ONLY NAKD2 NAD kinase 2, mitochondrial -2.87 7.33 0.95 -2.13 4.39 0.65 
WT ONLY VATG1 V-type proton ATPase subunit G 1 -2.87 7.31 0.83 -2.61 6.13 0.78 
WT ONLY CDD Cytidine deaminase -2.86 7.28 0.81 -2.99 7.93 0.80 
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WT ONLY CBR4 Carbonyl reductase family member 4 -2.85 7.19 0.85 -2.05 4.13 0.72 
WT ONLY C1TC C-1-tetrahydrofolate synthase, cytoplasmic -2.83 7.12 0.87 -2.80 6.96 0.79 
WT ONLY MGST3 Microsomal glutathione S-transferase 3 -2.83 7.12 0.84 -2.74 6.70 0.76 
WT ONLY FGGY 
FGGY carbohydrate kinase domain-
containing protein 
-2.75 6.73 0.85 -3.06 8.34 0.54 
WT ONLY VWA8 
von Willebrand factor A domain-containing 
protein 8 
-2.69 6.46 0.82 -3.10 8.58 0.80 
WT ONLY ACOX2 Peroxisomal acyl-coenzyme A oxidase 2 -2.64 6.24 0.84 -3.46 11.03 0.78 
WT ONLY MRP2 
Canalicular multispecific organic anion 
transporter 1 
-2.59 6.03 0.82 -1.17 2.25 0.24 
WT ONLY ACOT4 Acyl-coenzyme A thioesterase 4 -2.51 5.68 0.81 -2.56 5.92 0.69 
WT ONLY HIBCH 
3-hydroxyisobutyryl-CoA hydrolase, 
mitochondrial 
-2.47 5.55 0.89 -3.63 12.41 0.77 
WT ONLY CN159 
UPF0317 protein C14orf159 homolog, 
mitochondrial 
-2.43 5.41 0.83 -3.23 9.39 0.77 
WT ONLY E41L3 Band 4.1-like protein 3 -2.31 4.96 0.86 -2.86 7.24 0.67 
WT ONLY PH4H Cytoplasmic aconitate hydratase -2.27 4.83 0.84 -2.22 4.66 0.78 
WT ONLY ISCA2 
Iron-sulfur cluster assembly 2 homolog, 
mitochondrial 
-2.24 4.73 0.82 -1.40 2.64 0.71 
WT ONLY DDAH1 
N(G),N(G)-dimethylarginine 
dimethylaminohydrolase 1 
-2.19 4.57 0.83 -2.79 6.93 0.78 
WT ONLY RT35 28S ribosomal protein S35, mitochondrial -2.15 4.43 0.81 -2.55 5.87 0.68 
WT ONLY TRXR2 Thioredoxin reductase 2, mitochondrial -2.10 4.29 0.83 -2.68 6.39 0.71 
WT ONLY TIM10 
Mitochondrial import inner membrane 
translocase subunit Tim10 
-2.00 4.01 0.86 -2.00 4.01 0.74 
WT ONLY MAVS Mitochondrial antiviral-signaling protein -1.98 3.95 0.84 -2.49 5.62 0.75 
WT ONLY T126A Transmembrane protein 126A -1.97 3.93 0.85 -1.76 3.38 0.58 
WT ONLY AT11A 
Probable phospholipid-transporting ATPase 
IH 
-1.94 3.85 0.81 -1.50 2.82 0.64 
WT ONLY EBP 
3-beta-hydroxysteroid-Delta(8),Delta(7)-
isomerase 
-1.89 3.70 0.91 -1.67 3.19 0.71 
WT ONLY TSPO Translocator protein -1.87 3.66 0.98 0.84 1.79 0.56 
WT ONLY NCPR NADPH--cytochrome P450 reductase -1.87 3.64 0.81 -1.96 3.89 0.75 
WT ONLY RM04 39S ribosomal protein L4, mitochondrial -1.84 3.59 0.91 -2.16 4.46 0.78 
WT ONLY GGCT Gamma-glutamylcyclotransferase -1.83 3.55 0.99 -3.48 11.16 0.79 
WT ONLY NAPSA Napsin-A -1.73 3.32 0.84 -0.98 1.98 0.67 
WT ONLY ISCU 
Iron-sulfur cluster assembly enzyme ISCU, 
mitochondrial 
-1.70 3.25 0.81 -2.27 4.82 0.71 
WT ONLY GVIN1 Interferon-induced very large GTPase 1 -1.69 3.22 0.83 -0.75 1.68 0.63 
WT ONLY PRPS2 Ribose-phosphate pyrophosphokinase 2 -1.68 3.20 0.85 -0.89 1.85 0.58 
WT ONLY EHD1 EH domain-containing protein 1 -1.61 3.05 0.83 -1.64 3.11 0.77 
WT ONLY TTC38 Tetratricopeptide repeat protein 38 -1.52 2.87 0.87 -1.46 2.75 0.79 
WT ONLY GTR1 
Solute carrier family 2, facilitated glucose 
transporter member 1 
-1.37 2.58 0.80 -1.91 3.75 0.72 
WT ONLY NAMPT Nicotinamide phosphoribosyltransferase -1.36 2.57 0.82 -1.60 3.03 0.61 
WT ONLY S10A1 Protein S100-A1 -1.28 2.44 0.85 -1.33 2.51 0.78 
WT ONLY EHD3 EH domain-containing protein 3 -1.24 2.37 0.86 -1.09 2.12 0.57 
WT ONLY GSHR Glutathione reductase, mitochondrial -1.22 2.33 0.80 -1.28 2.43 0.64 
WT ONLY ARL1 ADP-ribosylation factor-like protein 1 -1.16 2.24 0.90 -0.27 1.20 0.38 
WT ONLY RS24 40S ribosomal protein S24 -0.99 1.99 0.88 0.81 1.75 0.37 
WT ONLY NDKA Nucleoside diphosphate kinase A -0.99 1.98 0.88 -1.14 2.21 0.70 
WT ONLY AP1B1 AP-1 complex subunit beta-1 -0.97 1.97 0.82 -1.09 2.13 0.69 
WT ONLY GALK1 Galactokinase -0.71 1.64 0.85 -0.69 1.61 0.64 
WT ONLY CLH1 Clathrin heavy chain 1 -0.56 1.47 0.88 -0.57 1.48 0.77 
COMMON G6PC Glucose-6-phosphatase -6.17 72.24 0.86 -3.43 10.79 0.83 
COMMON AADAT 
Kynurenine/alpha-aminoadipate 
aminotransferase, mitochondrial 
-5.59 48.00 0.84 -3.54 11.59 0.80 
COMMON HAOX2 Hydroxyacid oxidase 2 -5.47 44.28 0.85 -4.18 18.08 0.88 
COMMON CALB1 Calbindin -5.00 32.07 0.91 -4.40 21.18 0.92 
COMMON ASSY Argininosuccinate synthase -4.41 21.28 0.88 -4.43 21.51 0.87 
COMMON ACSM1 
Acyl-coenzyme A synthetase ACSM1, 
mitochondrial 
-4.38 20.87 0.83 -3.47 11.05 0.89 
COMMON F16P1 Fructose-1,6-bisphosphatase 1 -4.38 20.84 0.81 -4.19 18.22 0.90 
COMMON ACSM2 
Acyl-coenzyme A synthetase ACSM2, 
mitochondrial 
-4.33 20.17 0.86 -4.32 19.94 0.89 
COMMON ECHP Peroxisomal bifunctional enzyme -4.32 19.92 0.84 -3.74 13.34 0.88 
COMMON KAD4 Adenylate kinase 4, mitochondrial -4.31 19.83 0.89 -4.24 18.93 0.91 
COMMON AT1B1 
Sodium/potassium-transporting ATPase 
subunit beta-1 
-4.29 19.55 0.87 -4.05 16.52 0.87 
COMMON CAD16 Cadherin-16 -4.29 19.54 0.92 -4.00 15.95 0.89 
COMMON PYC Pyruvate carboxylase, mitochondrial -4.17 18.04 0.87 -3.97 15.62 0.84 
COMMON AL8A1 
Aldehyde dehydrogenase family 8 member 
A1 
-4.10 17.11 0.88 -3.61 12.21 0.89 
COMMON ATNG 
Sodium/potassium-transporting ATPase 
subunit gamma 
-4.07 16.80 0.90 -3.97 15.63 0.89 
COMMON UD3A2 UDP-glucuronosyltransferase 3A2 -4.06 16.72 0.83 -3.47 11.11 0.81 
COMMON S100G Protein S100-G -4.05 16.59 0.90 -3.56 11.78 0.87 
COMMON ACS2L 
Acetyl-coenzyme A synthetase 2-like, 
mitochondrial 
-4.05 16.56 0.89 -3.50 11.31 0.83 
COMMON KEG1 Glycine N-acyltransferase-like protein Keg1 -4.03 16.36 0.88 -3.97 15.67 0.88 
COMMON SC5A2 Sodium/glucose cotransporter 2 -4.02 16.23 0.80 -3.47 11.10 0.81 
COMMON ECHD2 
Enoyl-CoA hydratase domain-containing 
protein 2, mitochondrial 
-4.01 16.09 0.87 -3.68 12.79 0.88 
COMMON CGL mmthionine gamma-lyase -4.00 16.04 0.86 -3.50 11.29 0.83 
SUPPLEMENTARY DATA 
 
477 
 
COMMON 3HAO 3-hydroxyanthranilate 3,4-dioxygenase -3.96 15.56 0.85 -4.26 19.13 0.82 
COMMON S27A2 Very long-chain acyl-CoA synthetase -3.90 14.88 0.81 -3.76 13.57 0.84 
COMMON MEP1B Meprin A subunit beta -3.88 14.72 0.82 -3.05 8.27 0.80 
COMMON ACADM 
Medium-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
-3.86 14.48 0.86 -4.02 16.23 0.87 
COMMON TMM27 Collectrin -3.85 14.41 0.85 -3.22 9.30 0.85 
COMMON ISC2A 
Isochorismatase domain-containing protein 
2A 
-3.84 14.27 0.90 -3.60 12.14 0.81 
COMMON BDH 
D-beta-hydroxybutyrate dehydrogenase, 
mitochondrial 
-3.83 14.24 0.89 -3.82 14.12 0.92 
COMMON ALDOB Fructose-bisphosphate aldolase B -3.83 14.21 0.93 -3.95 15.47 0.93 
COMMON HOT 
Hydroxyacid-oxoacid transhydrogenase, 
mitochondrial 
-3.82 14.07 0.84 -3.17 8.97 0.83 
COMMON GATM Glycine amidinotransferase, mitochondrial -3.80 13.91 0.87 -4.39 20.94 0.88 
COMMON GABT 
4-aminobutyrate aminotransferase, 
mitochondrial 
-3.79 13.84 0.93 -3.62 12.32 0.93 
COMMON MMSA 
Methylmalonate-semialdehyde 
dehydrogenase [acylating], mitochondrial 
-3.79 13.79 0.88 -3.98 15.74 0.89 
COMMON ST1D1 Sulfotransferase 1 family member D1 -3.78 13.74 0.85 -3.96 15.51 0.84 
COMMON GGT1 Gamma-glutamyltranspeptidase 1 -3.76 13.58 0.89 -3.74 13.34 0.86 
COMMON MAAI Maleylacetoacetate isomerase -3.75 13.49 0.82 -3.14 8.83 0.82 
COMMON PGAM2 Phosphoglycerate mutase 2 -3.75 13.44 0.88 -3.03 8.19 0.82 
COMMON GLYAT Glycine N-acyltransferase -3.75 13.43 0.88 -4.05 16.55 0.86 
COMMON FAAA Fumarylacetoacetase -3.72 13.16 0.92 -3.79 13.80 0.90 
COMMON AT1A1 
Sodium/potassium-transporting ATPase 
subunit alpha-1 
-3.72 13.14 0.93 -3.55 11.72 0.95 
COMMON DHSO Sorbitol dehydrogenase -3.71 13.11 0.82 -3.80 13.96 0.85 
COMMON MPC1 Mitochondrial pyruvate carrier 1 -3.69 12.91 0.93 -3.31 9.89 0.80 
COMMON UK114 Ribonuclease UK114 -3.67 12.69 0.94 -3.25 9.50 0.90 
COMMON CATA Catalase -3.66 12.62 0.94 -3.25 9.51 0.94 
COMMON GSTK1 Glutathione S-transferase kappa 1 -3.62 12.27 0.82 -3.49 11.23 0.85 
COMMON PCCB 
Propionyl-CoA carboxylase beta chain, 
mitochondrial 
-3.61 12.22 0.96 -3.55 11.73 0.90 
COMMON AL4A1 
Delta-1-pyrroline-5-carboxylate 
dehydrogenase, mitochondrial 
-3.61 12.17 0.93 -3.56 11.79 0.91 
COMMON CES1D Carboxylesterase 1D -3.58 11.96 0.83 -3.50 11.28 0.87 
COMMON GLPK Glycerol kinase -3.57 11.89 0.86 -3.91 14.98 0.85 
COMMON QORL2 Quinone oxidoreductase-like protein 2 -3.57 11.85 0.82 -3.90 14.96 0.83 
COMMON AAAD Arylacetamide deacetylase -3.57 11.84 0.85 -4.27 19.31 0.91 
COMMON VILI Villin-1 -3.56 11.78 0.91 -3.55 11.73 0.88 
COMMON SODM Superoxide dismutase [Mn], mitochondrial -3.54 11.66 0.93 -3.18 9.08 0.88 
COMMON MPC2 Mitochondrial pyruvate carrier 2 -3.54 11.60 0.82 -3.50 11.30 0.90 
COMMON NUD19 
Nucleoside diphosphate-linked moiety X 
motif 19 
-3.50 11.28 0.90 -3.44 10.83 0.87 
COMMON HINT2 
Histidine triad nucleotide-binding protein 2, 
mitochondrial 
-3.49 11.27 0.98 -3.43 10.77 0.94 
COMMON BPHL Valacyclovir hydrolase -3.47 11.09 0.87 -3.83 14.21 0.85 
COMMON MCCB 
Methylcrotonoyl-CoA carboxylase beta 
chain, mitochondrial 
-3.45 10.95 0.90 -3.36 10.25 0.86 
COMMON PBLD1 
Phenazine biosynthesis-like domain-
containing protein 1 
-3.45 10.91 0.87 -3.95 15.43 0.81 
COMMON DIC Mitochondrial dicarboxylate carrier -3.44 10.83 0.83 -2.95 7.73 0.91 
COMMON ACD10 Acyl-CoA dehydrogenase family member 10 -3.43 10.77 0.86 -3.16 8.94 0.89 
COMMON NHRF3 
Na(+)/H(+) exchange regulatory cofactor 
NHE-RF3 
-3.42 10.71 0.86 -3.27 9.66 0.90 
COMMON CK054 Ester hydrolase C11orf54 homolog -3.41 10.61 0.82 -3.44 10.86 0.81 
COMMON AK1A1 Alcohol dehydrogenase [NADP(+)] -3.40 10.56 0.91 -3.23 9.38 0.92 
COMMON 3HIDH 
3-hydroxyisobutyrate dehydrogenase, 
mitochondrial 
-3.40 10.55 0.94 -3.26 9.57 0.93 
COMMON SUCB2 
Succinyl-CoA ligase [GDP-forming] subunit 
beta, mitochondrial 
-3.38 10.42 0.94 -3.39 10.47 0.92 
COMMON FAHD1 Acylpyruvase FAHD1, mitochondrial -3.38 10.39 0.84 -3.61 12.20 0.84 
COMMON IVD 
Isovaleryl-CoA dehydrogenase, 
mitochondrial 
-3.34 10.14 0.88 -3.33 10.09 0.86 
COMMON THIL Acetyl-CoA acetyltransferase, mitochondrial -3.34 10.10 0.95 -3.24 9.43 0.96 
COMMON SARDH Sarcosine dehydrogenase, mitochondrial -3.33 10.05 0.85 -3.65 12.57 0.87 
COMMON INMT Indolethylamine N-methyltransferase -3.33 10.03 0.83 -3.47 11.06 0.85 
COMMON AL1L1 
Cytosolic 10-formyltetrahydrofolate 
dehydrogenase 
-3.31 9.95 0.91 -3.11 8.63 0.92 
COMMON KHK Ketohexokinase -3.31 9.90 0.83 -3.85 14.41 0.84 
COMMON ARK72 Aflatoxin B1 aldehyde reductase member 2 -3.30 9.87 0.87 -3.10 8.60 0.85 
COMMON HCDH 
Hydroxyacyl-coenzyme A dehydrogenase, 
mitochondrial 
-3.30 9.82 0.90 -3.18 9.04 0.89 
COMMON CISD1 
CDGSH iron-sulfur domain-containing 
protein 1 
-3.29 9.75 0.95 -3.37 10.36 0.94 
COMMON NDRG1 Protein NDRG1 -3.25 9.52 0.99 -3.06 8.36 0.98 
COMMON S13A3 Solute carrier family 13 member 3 -3.25 9.52 0.88 -2.94 7.65 0.84 
COMMON CYC Cytochrome c, somatic -3.25 9.49 0.92 -2.92 7.56 0.90 
COMMON SCOT1 
Succinyl-CoA:3-ketoacid coenzyme A 
transferase 1, mitochondrial 
-3.22 9.34 0.92 -3.15 8.85 0.91 
COMMON HMGCL 
Hydroxymethylglutaryl-CoA lyase, 
mitochondrial 
-3.21 9.26 0.92 -3.22 9.29 0.89 
COMMON ACPM Acyl carrier protein, mitochondrial -3.20 9.19 0.92 -3.07 8.43 0.92 
COMMON ATPK ATP synthase subunit f, mitochondrial -3.20 9.17 0.80 -2.88 7.34 0.83 
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COMMON MSRA 
Mitochondrial peptide methionine sulfoxide 
reductase 
-3.19 9.12 0.83 -3.16 8.95 0.89 
COMMON CBR1 Carbonyl reductase [NADPH] 1 -3.19 9.11 0.92 -2.87 7.30 0.94 
COMMON LDHD 
Probable D-lactate dehydrogenase, 
mitochondrial 
-3.19 9.10 0.88 -2.97 7.83 0.88 
COMMON COX5A 
Cytochrome c oxidase subunit 5A, 
mitochondrial 
-3.18 9.08 0.94 -3.02 8.11 0.93 
COMMON ETFA 
Electron transfer flavoprotein subunit alpha, 
mitochondrial 
-3.18 9.07 0.93 -3.27 9.66 0.92 
COMMON GPDA 
Glycerol-3-phosphate dehydrogenase 
[NAD(+)], cytoplasmic 
-3.15 8.85 0.91 -3.77 13.65 0.84 
COMMON NIPS1 Protein NipSnap homolog 1 -3.14 8.81 0.91 -2.93 7.62 0.90 
COMMON NU4M NADH-ubiquinone oxidoreductase chain 4 -3.14 8.79 0.89 -2.65 6.28 0.88 
COMMON FAHD2 
umarylacetoacetate hydrolase domain-
containing protein 2A 
-3.13 8.76 0.80 -3.83 14.19 0.81 
COMMON CLYBL 
Citrate lyase subunit beta-like protein, 
mitochondrial 
-3.13 8.75 0.80 -3.38 10.40 0.83 
COMMON FBX50 F-box only protein 50 -3.13 8.73 0.80 -4.09 17.04 0.84 
COMMON NDUS6 
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 6, mitochondrial 
-3.12 8.72 0.81 -2.89 7.39 0.82 
COMMON THNS2 Threonine synthase-like 2 -3.12 8.70 0.83 -3.30 9.82 0.82 
COMMON NU5M NADH-ubiquinone oxidoreductase chain 5 -3.12 8.67 0.88 -2.67 6.35 0.86 
COMMON PECR Peroxisomal trans-2-enoyl-CoA reductase -3.11 8.65 0.87 -3.71 13.10 0.92 
COMMON SDHA 
Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondrial 
-3.11 8.64 0.98 -2.96 7.80 0.97 
COMMON NDUBA 
NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 10 
-3.11 8.63 0.86 -3.07 8.40 0.86 
COMMON SUCA 
Succinyl-CoA ligase [ADP/GDP-forming] 
subunit alpha, mitochondrial 
-3.10 8.55 0.94 -3.17 9.00 0.93 
COMMON IPYR2 Inorganic pyrophosphatase 2, mitochondrial -3.09 8.50 0.83 -2.90 7.47 0.90 
COMMON NDUV1 
NADH dehydrogenase [ubiquinone] 
flavoprotein 1, mitochondrial 
-3.07 8.43 0.90 -3.29 9.81 0.92 
COMMON NDUA9 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 9, mitochondrial 
-3.07 8.38 0.89 -2.78 6.86 0.91 
COMMON ABCD3 
ATP-binding cassette sub-family D member 
3 
-3.06 8.36 0.88 -2.95 7.75 0.90 
COMMON ATPD ATP synthase subunit delta, mitochondrial -3.06 8.32 0.98 -2.94 7.68 0.95 
COMMON QCR6 
Cytochrome b-c1 complex subunit 6, 
mitochondrial 
-3.05 8.31 0.93 -2.60 6.06 0.93 
COMMON NDUA1 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 1 
-3.05 8.25 0.86 -2.04 4.12 0.86 
COMMON COX5B 
Cytochrome c oxidase subunit 5B, 
mitochondrial 
-3.04 8.24 0.91 -3.18 9.07 0.90 
COMMON IDHP 
Isocitrate dehydrogenase [NADP], 
mitochondrial 
-3.04 8.21 0.93 -3.10 8.56 0.93 
COMMON SBP1 Selenium-binding protein 1 -3.03 8.19 0.92 -2.84 7.18 0.89 
COMMON NDUS7 
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 7, mitochondrial 
-3.03 8.16 0.94 -2.91 7.49 0.85 
COMMON ETFB Electron transfer flavoprotein subunit beta -3.02 8.13 0.91 -3.13 8.78 0.92 
COMMON NHRF1 
Na(+)/H(+) exchange regulatory cofactor 
NHE-RF1 
-3.01 8.07 0.94 -3.14 8.85 0.91 
COMMON NEP Neprilysin -3.01 8.05 0.90 -2.96 7.78 0.89 
COMMON NDUAD 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 13 
-3.00 8.00 0.89 -2.68 6.42 0.94 
COMMON CSAD Cysteine sulfinic acid decarboxylase -3.00 8.00 0.90 -2.71 6.56 0.91 
COMMON COX2 Cytochrome c oxidase subunit 2 -3.00 7.99 0.87 -2.84 7.15 0.86 
COMMON SDHB 
Succinate dehydrogenase [ubiquinone] iron-
sulfur subunit, mitochondrial 
-3.00 7.99 0.89 -3.00 8.00 0.83 
COMMON TPMT Thiopurine S-methyltransferase -3.00 7.98 0.93 -2.69 6.43 0.93 
COMMON CY1 Cytochrome c1, heme protein, mitochondrial -2.99 7.96 0.94 -2.95 7.72 0.93 
COMMON TOM5 
Mitochondrial import receptor subunit TOM5 
homolog 
-2.99 7.94 1.00 -1.43 2.69 0.88 
COMMON COQ9 
Ubiquinone biosynthesis protein COQ9, 
mitochondrial 
-2.98 7.91 0.90 -3.17 9.02 0.81 
COMMON IDHG1 
Isocitrate dehydrogenase [NAD] subunit 
gamma 1, mitochondrial 
-2.98 7.91 0.91 -3.04 8.20 0.89 
COMMON THIM 3-ketoacyl-CoA thiolase, mitochondrial -2.98 7.90 0.91 -3.18 9.09 0.88 
COMMON UCRI 
Cytochrome b-c1 complex subunit Rieske, 
mitochondrial 
-2.98 7.89 0.91 -3.13 8.74 0.84 
COMMON NDUA3 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 3 
-2.98 7.86 0.89 -3.34 10.14 0.84 
COMMON AUHM 
Methylglutaconyl-CoA hydratase, 
mitochondrial 
-2.97 7.85 0.85 -3.27 9.63 0.89 
COMMON NLTP Non-specific lipid-transfer protein -2.97 7.82 0.88 -2.75 6.73 0.91 
COMMON NDUB7 
NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 7 
-2.96 7.79 0.84 -3.01 8.05 0.90 
COMMON THTR Thiosulfate sulfurtransferase -2.95 7.75 0.89 -3.26 9.59 0.89 
COMMON QOR Quinone oxidoreductase -2.95 7.71 0.84 -3.07 8.40 0.93 
COMMON ACSL1 Long-chain-fatty-acid--CoA ligase 1 -2.94 7.69 0.90 -3.35 10.18 0.86 
COMMON CRYL1 Lambda-crystallin homolog -2.93 7.62 0.90 -2.93 7.64 0.89 
COMMON LRP2 
Low-density lipoprotein receptor-related 
protein 2 
-2.93 7.60 0.84 -3.03 8.16 0.83 
COMMON CX7A1 
Cytochrome c oxidase subunit 7A1, 
mitochondrial 
-2.93 7.60 0.93 -2.57 5.92 0.88 
COMMON CH60 60 kDa heat shock protein, mitochondrial -2.92 7.56 0.96 -2.82 7.07 0.96 
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COMMON C560 
Succinate dehydrogenase cytochrome b560 
subunit, mitochondrial 
-2.92 7.55 0.83 -2.93 7.63 0.92 
COMMON NDUS1 
NADH-ubiquinone oxidoreductase 75 kDa 
subunit, mitochondrial 
-2.92 7.55 0.94 -2.95 7.74 0.90 
COMMON CP013 UPF0585 protein C16orf13 homolog -2.90 7.48 0.87 -2.39 5.23 0.83 
COMMON COX41 
Cytochrome c oxidase subunit 4 isoform 1, 
mitochondrial 
-2.90 7.46 0.94 -2.88 7.37 0.93 
COMMON CX7A2 
Cytochrome c oxidase subunit 7A2, 
mitochondrial 
-2.88 7.37 0.92 -3.07 8.39 0.84 
COMMON NDUA4 Cytochrome c oxidase subunit NDUFA4 -2.87 7.30 0.89 -2.89 7.39 0.88 
COMMON AIFM1 Apoptosis-inducing factor 1, mitochondrial -2.87 7.30 0.92 -2.99 7.96 0.92 
COMMON MUTA Methylmalonyl-CoA mutase, mitochondrial -2.86 7.27 0.81 -3.18 9.08 0.83 
COMMON MCCA 
Methylcrotonoyl-CoA carboxylase subunit 
alpha, mitochondrial 
-2.86 7.25 0.82 -2.97 7.81 0.82 
COMMON NDUB4 
NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 4 
-2.85 7.21 0.83 -3.01 8.03 0.83 
COMMON ECHM Enoyl-CoA hydratase, mitochondrial -2.85 7.21 0.90 -2.99 7.96 0.90 
COMMON ATP5H ATP synthase subunit d, mitochondrial -2.85 7.21 0.93 -2.75 6.70 0.94 
COMMON OCTC Peroxisomal carnitine O-octanoyltransferase -2.85 7.20 0.80 -2.97 7.84 0.82 
COMMON CMC2 
Calcium-binding mitochondrial carrier 
protein Aralar2 
-2.85 7.20 0.80 -2.94 7.66 0.89 
COMMON NDUS4 
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 4, mitochondrial 
-2.85 7.19 0.83 -2.75 6.72 0.85 
COMMON DLDH Dihydrolipoyl dehydrogenase, mitochondrial -2.84 7.18 0.94 -2.83 7.11 0.93 
COMMON AL7A1 
Alpha-aminoadipic semialdehyde 
dehydrogenase 
-2.84 7.16 0.82 -2.84 7.15 0.87 
COMMON MEP1A Meprin A subunit alpha -2.84 7.15 0.88 -3.43 10.75 0.89 
COMMON QCR2 
Cytochrome b-c1 complex subunit 2, 
mitochondrial 
-2.84 7.14 0.94 -3.03 8.19 0.97 
COMMON QCR8 Cytochrome b-c1 complex subunit 8 -2.83 7.12 0.91 -3.11 8.65 0.92 
COMMON ADT2 ADP/ATP translocase 2 -2.82 7.06 0.81 -2.84 7.18 0.88 
COMMON ATP8 ATP synthase protein 8 -2.80 6.97 0.90 -2.68 6.43 0.81 
COMMON ATPG 
ATP synthase subunit gamma, 
mitochondrial 
-2.80 6.96 0.90 -2.94 7.65 0.92 
COMMON NDUAA 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 10, mitochondrial 
-2.79 6.92 0.93 -2.87 7.33 0.90 
COMMON S12A1 Solute carrier family 12 member 1 -2.79 6.91 0.96 -3.15 8.90 0.85 
COMMON AQP1 Aquaporin-1 -2.79 6.91 0.80 -3.05 8.29 0.88 
COMMON ODO2 
Dihydrolipoyllysine-residue 
succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, 
mitochondrial 
-2.79 6.89 0.89 -2.75 6.71 0.91 
COMMON TBA4A Tubulin alpha-4A chain -2.79 6.89 0.88 -2.86 7.28 0.81 
COMMON ATPO ATP synthase subunit O, mitochondrial -2.77 6.84 0.96 -2.77 6.83 0.96 
COMMON PCCA 
Propionyl-CoA carboxylase alpha chain, 
mitochondrial 
-2.77 6.83 0.84 -3.06 8.33 0.91 
COMMON BPNT1 3'(2'),5'-bisphosphate nucleotidase 1 -2.77 6.81 0.87 -2.88 7.34 0.81 
COMMON PTER Phosphotriesterase-related protein -2.75 6.73 0.91 -2.78 6.85 0.94 
COMMON ECI2 Enoyl-CoA delta isomerase 2, mitochondrial -2.75 6.73 0.85 -2.99 7.96 0.85 
COMMON NDUS2 
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 2, mitochondrial 
-2.75 6.72 0.91 -2.84 7.15 0.86 
COMMON ES1 ES1 protein homolog, mitochondrial -2.75 6.71 0.92 -2.68 6.41 0.91 
COMMON ACON Aconitate hydratase, mitochondrial -2.74 6.66 0.90 -3.15 8.88 0.88 
COMMON NDUS3 
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 3, mitochondrial 
-2.73 6.64 0.96 -2.70 6.51 0.94 
COMMON MDHM Malate dehydrogenase, mitochondrial -2.73 6.63 0.96 -2.80 6.97 0.94 
COMMON ATP5I ATP synthase subunit e, mitochondrial -2.73 6.62 0.90 -2.82 7.06 0.86 
COMMON USMG5 
Up-regulated during skeletal muscle growth 
protein 5 
-2.72 6.60 0.97 -2.79 6.93 0.97 
COMMON FUMH Fumarate hydratase, mitochondrial -2.71 6.56 0.89 -2.77 6.82 0.89 
COMMON ATPB ATP synthase subunit beta, mitochondrial -2.71 6.55 0.94 -2.85 7.19 0.96 
COMMON FABPH Fatty acid-binding protein, heart -2.71 6.53 0.88 -2.76 6.78 0.84 
COMMON AQP3 Aquaporin-3 -2.70 6.51 0.90 -3.66 12.64 0.85 
COMMON CX6B1 Cytochrome c oxidase subunit 6B1 -2.70 6.48 0.92 -2.87 7.32 0.88 
COMMON NDUA5 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 5 
-2.69 6.48 0.90 -2.75 6.71 0.89 
COMMON ATPA ATP synthase subunit alpha, mitochondrial -2.69 6.46 0.96 -2.81 7.02 0.96 
COMMON DHRS4 
Dehydrogenase/reductase SDR family 
member 4 
-2.68 6.42 0.91 -2.82 7.08 0.95 
COMMON SUSD2 Sushi domain-containing protein 2 -2.67 6.38 0.92 -2.52 5.75 0.93 
COMMON QCR1 
Cytochrome b-c1 complex subunit 1, 
mitochondrial 
-2.67 6.37 0.94 -2.74 6.69 0.93 
COMMON NDUA7 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 7 
-2.67 6.36 0.91 -2.80 6.97 0.87 
COMMON SFXN1 Sideroflexin-1 -2.67 6.35 0.83 -2.85 7.20 0.86 
COMMON QCR7 Cytochrome b-c1 complex subunit 7 -2.66 6.34 0.89 -2.86 7.28 0.88 
COMMON COX6C Cytochrome c oxidase subunit 6C -2.66 6.33 0.91 -2.61 6.11 0.89 
COMMON ODB2 
Lipoamide acyltransferase component of 
branched-chain alpha-keto acid 
dehydrogenase complex, mitochondrial 
-2.66 6.31 0.81 -3.62 12.29 0.80 
COMMON ARLY Argininosuccinate lyase -2.66 6.31 0.91 -2.65 6.28 0.92 
COMMON PRDX5 Peroxiredoxin-5, mitochondrial -2.65 6.30 0.91 -2.54 5.81 0.91 
COMMON PGES2 Prostaglandin E synthase 2 -2.65 6.29 0.89 -2.55 5.84 0.81 
COMMON ATP5J 
ATP synthase-coupling factor 6, 
mitochondrial 
-2.65 6.29 0.97 -2.87 7.30 0.93 
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COMMON KAT3 Kynurenine--oxoglutarate transaminase 3 -2.65 6.29 0.81 -2.88 7.36 0.82 
COMMON AT5F1 
ATP synthase F(0) complex subunit B1, 
mitochondrial 
-2.62 6.17 0.92 -2.81 7.03 0.92 
COMMON NU3M NADH-ubiquinone oxidoreductase chain 3 -2.62 6.15 0.95 -2.82 7.06 0.95 
COMMON CH10 10 kDa heat shock protein, mitochondrial -2.62 6.15 0.90 -2.55 5.86 0.90 
COMMON NDUB9 
NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 9 
-2.61 6.10 0.83 -2.81 7.01 0.84 
COMMON AATM Aspartate aminotransferase, mitochondrial -2.61 6.10 0.97 -2.68 6.39 0.97 
COMMON DHB8 Estradiol 17-beta-dehydrogenase 8 -2.60 6.07 0.87 -2.47 5.55 0.81 
COMMON NDUA8 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 8 
-2.60 6.07 0.91 -2.55 5.86 0.89 
COMMON CHDH Choline dehydrogenase, mitochondrial -2.60 6.06 0.88 -2.51 5.69 0.88 
COMMON ODPB 
Pyruvate dehydrogenase E1 component 
subunit beta, mitochondrial 
-2.60 6.05 0.96 -2.60 6.07 0.97 
COMMON VATA V-type proton ATPase catalytic subunit A -2.59 6.04 0.92 -2.57 5.96 0.93 
COMMON ETHE1 
Persulfide dioxygenase ETHE1, 
mitochondrial 
-2.58 5.99 0.92 -2.70 6.52 0.93 
COMMON VATH V-type proton ATPase subunit H -2.57 5.94 0.90 -2.56 5.88 0.91 
COMMON NDUC2 
NADH dehydrogenase [ubiquinone] 1 
subunit C2 
-2.57 5.93 0.88 -3.22 9.30 0.84 
COMMON DCXR L-xylulose reductase -2.57 5.92 0.88 -2.50 5.66 0.83 
COMMON GSTT2 Glutathione S-transferase theta-2 -2.55 5.84 0.87 -2.27 4.83 0.82 
COMMON ALDH2 Aldehyde dehydrogenase, mitochondrial -2.54 5.82 0.95 -2.45 5.48 0.94 
COMMON TRAP1 Heat shock protein 75 kDa, mitochondrial -2.54 5.82 0.88 -2.59 6.02 0.89 
COMMON AL9A1 
4-trimethylaminobutyraldehyde 
dehydrogenase 
-2.53 5.76 0.94 -2.83 7.09 0.92 
COMMON ETFD 
Electron transfer flavoprotein-ubiquinone 
oxidoreductase, mitochondrial 
-2.52 5.74 0.89 -2.46 5.49 0.90 
COMMON CPT2 
Carnitine O-palmitoyltransferase 2, 
mitochondrial 
-2.51 5.70 0.88 -2.58 5.99 0.85 
COMMON ANK3 Ankyrin-3 -2.51 5.70 0.85 -2.11 4.33 0.84 
COMMON Mar-02 
Mitochondrial amidoxime reducing 
component 2 
-2.50 5.65 0.89 -2.64 6.22 0.91 
COMMON ACOT1 Acyl-coenzyme A thioesterase 1 -2.49 5.63 0.85 -2.08 4.21 0.85 
COMMON DOPD D-dopachrome decarboxylase -2.49 5.63 0.91 -2.35 5.10 0.95 
COMMON TIM13 
Mitochondrial import inner membrane 
translocase subunit Tim13 
-2.48 5.58 0.96 -2.41 5.33 0.89 
COMMON ODPA 
Pyruvate dehydrogenase E1 component 
subunit alpha, somatic form, mitochondrial 
-2.48 5.58 0.92 -2.74 6.70 0.93 
COMMON MPCP Phosphate carrier protein, mitochondrial -2.48 5.57 0.90 -2.53 5.78 0.94 
COMMON ABHEB Protein ABHD14B -2.48 5.57 0.93 -2.28 4.87 0.91 
COMMON GRP75 Stress-70 protein, mitochondrial -2.47 5.56 0.82 -2.21 4.62 0.85 
COMMON NDUBB 
NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 11, mitochondrial 
-2.47 5.53 0.90 -2.74 6.67 0.93 
COMMON MIC19 MICOS complex subunit Mic19 -2.47 5.53 0.90 -2.55 5.85 0.86 
COMMON VATB2 
V-type proton ATPase subunit B, brain 
isoform 
-2.47 5.52 0.85 -2.30 4.92 0.91 
COMMON GSH1 Glutamate--cysteine ligase catalytic subunit -2.46 5.49 0.86 -2.72 6.57 0.85 
COMMON NCEH1 Neutral cholesterol ester hydrolase 1 -2.45 5.47 0.92 -2.88 7.34 0.94 
COMMON ECH1 
Delta(3,5)-Delta(2,4)-dienoyl-CoA 
isomerase, mitochondrial 
-2.45 5.46 0.97 -2.40 5.27 0.95 
COMMON VATF V-type proton ATPase subunit F -2.45 5.45 0.90 -2.43 5.40 0.88 
COMMON VATG3 V-type proton ATPase subunit G 3 -2.44 5.43 0.94 -2.25 4.74 0.84 
COMMON DECR 2,4-dienoyl-CoA reductase, mitochondrial -2.43 5.39 0.89 -2.49 5.63 0.88 
COMMON CMBL Carboxymethylenebutenolidase homolog -2.43 5.38 0.85 -2.87 7.32 0.80 
COMMON ACADS 
Short-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
-2.42 5.36 0.89 -2.65 6.28 0.89 
COMMON SUCB1 
Succinyl-CoA ligase [ADP-forming] subunit 
beta, mitochondrial 
-2.42 5.33 0.97 -2.82 7.07 0.93 
COMMON VATE1 V-type proton ATPase subunit E 1 -2.41 5.32 0.91 -2.45 5.47 0.92 
COMMON LPPRC 
Leucine-rich PPR motif-containing protein, 
mitochondrial 
-2.40 5.26 0.88 -2.31 4.96 0.85 
COMMON ODP2 
Dihydrolipoyllysine-residue 
acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial 
-2.39 5.25 0.98 -2.65 6.28 0.94 
COMMON PRDX3 
Thioredoxin-dependent peroxide reductase, 
mitochondrial 
-2.39 5.23 0.90 -2.59 6.04 0.89 
COMMON KAD2 Adenylate kinase 2, mitochondrial -2.38 5.21 0.86 -2.60 6.06 0.89 
COMMON SQRD 
Sulfide:quinone oxidoreductase, 
mitochondrial 
-2.38 5.20 0.92 -2.33 5.04 0.89 
COMMON GSHB Glutathione synthetase -2.37 5.17 0.82 -2.60 6.07 0.89 
COMMON LYPA1 Acyl-protein thioesterase 1 -2.36 5.13 0.90 -2.21 4.62 0.88 
COMMON ACADV 
Very long-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
-2.36 5.12 0.89 -2.53 5.79 0.85 
COMMON KAD3 
GTP:AMP phosphotransferase AK3, 
mitochondrial 
-2.35 5.10 0.89 -2.25 4.75 0.89 
COMMON DHPR Dihydropteridine reductase -2.34 5.07 0.88 -2.45 5.45 0.91 
COMMON NIT1 Nitrilase homolog 1 -2.33 5.03 0.90 -2.28 4.86 0.89 
COMMON ODO1 
2-oxoglutarate dehydrogenase, 
mitochondrial 
-2.32 5.00 0.91 -2.53 5.76 0.89 
COMMON SAP3 Ganglioside GM2 activator -2.31 4.96 0.85 -2.42 5.34 0.85 
COMMON MDHC Malate dehydrogenase, cytoplasmic -2.30 4.94 0.95 -2.44 5.41 0.94 
COMMON SPS2 Selenide, water dikinase 2 -2.30 4.93 0.90 -2.33 5.03 0.84 
COMMON THIOM Thioredoxin, mitochondrial -2.29 4.90 0.90 -2.34 5.05 0.95 
COMMON RM12 39S ribosomal protein L12, mitochondrial -2.29 4.89 0.91 -2.27 4.83 0.93 
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COMMON NIT2 Omega-amidase NIT2 -2.29 4.88 0.90 -2.07 4.19 0.90 
COMMON IDH3A 
Isocitrate dehydrogenase [NAD] subunit 
alpha, mitochondrial 
-2.28 4.86 0.91 -2.38 5.19 0.93 
COMMON NDUA6 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 6 
-2.28 4.86 0.84 -2.35 5.11 0.87 
COMMON VDAC1 
Voltage-dependent anion-selective channel 
protein 1 
-2.28 4.85 0.96 -2.46 5.49 0.96 
COMMON HYES Bifunctional epoxide hydrolase 2 -2.28 4.85 0.81 -4.65 25.06 0.84 
COMMON ACOC Cytoplasmic aconitate hydratase -2.28 4.84 0.94 -2.41 5.32 0.88 
COMMON ECI1 Enoyl-CoA delta isomerase 1, mitochondrial -2.26 4.80 0.91 -2.46 5.51 0.90 
COMMON HCD2 3-hydroxyacyl-CoA dehydrogenase type-2 -2.25 4.76 0.91 -2.32 5.00 0.94 
COMMON IDHC 
Isocitrate dehydrogenase [NADP] 
cytoplasmic 
-2.25 4.75 0.90 -2.28 4.87 0.91 
COMMON MIC27 MICOS complex subunit Mic27 -2.23 4.70 0.81 -2.17 4.49 0.87 
COMMON SAM50 
Sorting and assembly machinery 
component 50 homolog 
-2.23 4.69 0.89 -2.49 5.60 0.90 
COMMON LONM Lon protease homolog, mitochondrial -2.22 4.66 0.90 -1.95 3.87 0.90 
COMMON MIC60 MICOS complex subunit Mic60 -2.22 4.65 0.92 -2.66 6.32 0.93 
COMMON ATIF1 ATPase inhibitor, mitochondrial -2.21 4.61 0.83 -1.89 3.71 0.83 
COMMON LYZ2 Lysozyme C-2 -2.20 4.60 0.93 -2.39 5.25 0.87 
COMMON OAT Ornithine aminotransferase, mitochondrial -2.20 4.59 0.86 -2.09 4.26 0.86 
COMMON EFTU Elongation factor Tu, mitochondrial -2.18 4.54 0.95 -2.24 4.73 0.95 
COMMON CMC1 
Calcium-binding mitochondrial carrier 
protein Aralar1 
-2.17 4.51 0.84 -2.32 5.01 0.86 
COMMON ECHA 
Trifunctional enzyme subunit alpha, 
mitochondrial 
-2.16 4.46 0.97 -2.22 4.67 0.96 
COMMON THTM 3-mercaptopyruvate sulfurtransferase -2.14 4.41 0.83 -2.34 5.06 0.82 
COMMON XPP1 Xaa-Pro aminopeptidase 1 -2.14 4.40 0.87 -2.02 4.05 0.85 
COMMON VATD V-type proton ATPase subunit D -2.14 4.40 0.89 -2.18 4.54 0.86 
COMMON BCAT2 
Branched-chain-amino-acid 
aminotransferase, mitochondrial 
-2.13 4.38 0.89 -2.88 7.36 0.89 
COMMON DHE3 Glutamate dehydrogenase 1, mitochondrial -2.13 4.37 0.92 -2.37 5.15 0.93 
COMMON 4F2 4F2 cell-surface antigen heavy chain -2.12 4.34 0.91 -2.31 4.94 0.93 
COMMON ATAD3 
ATPase family AAA domain-containing 
protein 3 
-2.10 4.30 0.80 -2.11 4.33 0.87 
COMMON ACADL 
Long-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
-2.10 4.28 0.87 -2.19 4.56 0.95 
COMMON CPT1A 
Carnitine O-palmitoyltransferase 1, liver 
isoform 
-2.09 4.27 0.84 -2.07 4.20 0.85 
COMMON KCRU Creatine kinase U-type, mitochondrial -2.08 4.24 0.88 -2.06 4.16 0.84 
COMMON AMPE Glutamyl aminopeptidase -2.07 4.21 0.87 -1.85 3.60 0.86 
COMMON GLRX5 
Glutaredoxin-related protein 5, 
mitochondrial 
-2.07 4.20 0.93 -2.07 4.20 0.86 
COMMON MAOX NADP-dependent malic enzyme -2.07 4.20 0.83 -2.51 5.68 0.87 
COMMON M2OM 
Mitochondrial 2-oxoglutarate/malate carrier 
protein 
-2.07 4.19 0.83 -2.10 4.29 0.88 
COMMON CLIC5 Chloride intracellular channel protein 5 -2.06 4.18 0.85 -1.51 2.86 0.81 
COMMON ACDSB 
Short/branched chain specific acyl-CoA 
dehydrogenase, mitochondrial 
-2.04 4.10 0.93 -2.29 4.89 0.94 
COMMON BASI Basigin -2.03 4.09 0.87 -2.19 4.56 0.82 
COMMON SCRN2 Secernin-2 -2.02 4.05 0.82 -2.43 5.37 0.83 
COMMON TMM65 Transmembrane protein 65 -2.01 4.03 0.88 -1.84 3.59 0.91 
COMMON MTCH2 Mitochondrial carrier homolog 2 -2.00 4.01 0.89 -2.11 4.32 0.89 
COMMON PROSC 
Proline synthase co-transcribed bacterial 
homolog protein 
-2.00 4.01 0.90 -1.68 3.21 0.89 
COMMON LDHB L-lactate dehydrogenase B chain -2.00 3.99 0.86 -2.08 4.24 0.86 
COMMON MOT1 Monocarboxylate transporter 1 -1.99 3.98 0.91 -2.10 4.28 0.80 
COMMON GLNA Glutamine synthetase -1.97 3.91 0.83 -3.14 8.84 0.83 
COMMON CYB5 Cytochrome b5 -1.95 3.87 0.86 -1.85 3.60 0.89 
COMMON CISY Citrate synthase, mitochondrial -1.94 3.83 0.88 -1.88 3.69 0.89 
COMMON AMPN Aminopeptidase N -1.94 3.83 0.95 -2.09 4.26 0.94 
COMMON ADT1 ADP/ATP translocase 1 -1.93 3.82 0.83 -2.04 4.11 0.85 
COMMON EM55 55 kDa erythrocyte membrane protein -1.93 3.82 0.91 -2.16 4.48 0.86 
COMMON PTGR2 Prostaglandin reductase 2 -1.92 3.79 0.89 -1.66 3.15 0.92 
COMMON NPL N-acetylneuraminate lyase -1.91 3.76 0.88 -1.77 3.41 0.86 
COMMON PHB2 Prohibitin-2 -1.90 3.73 0.94 -1.94 3.84 0.93 
COMMON MIF Macrophage migration inhibitory factor -1.89 3.71 0.92 -1.92 3.79 0.89 
COMMON AATC Aspartate aminotransferase, cytoplasmic -1.88 3.68 0.88 -1.81 3.51 0.89 
COMMON DHI2 
Corticosteroid 11-beta-dehydrogenase 
isozyme 2 
-1.88 3.67 0.83 -1.69 3.22 0.88 
COMMON CYB5B Cytochrome b5 type B -1.86 3.62 0.93 -1.20 2.29 0.90 
COMMON THIC Acetyl-CoA acetyltransferase, cytosolic -1.85 3.61 0.85 -2.34 5.08 0.81 
COMMON GSTA4 Glutathione S-transferase A4 -1.85 3.61 0.86 -1.53 2.89 0.87 
COMMON AMPL Cytosol aminopeptidase -1.84 3.57 0.93 -1.86 3.63 0.93 
COMMON VATC1 V-type proton ATPase subunit C 1 -1.83 3.55 0.83 -1.98 3.94 0.85 
COMMON C1QBP 
Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial 
-1.82 3.52 0.83 -1.86 3.63 0.92 
COMMON ACBP Acyl-CoA-binding protein -1.81 3.51 0.93 -1.77 3.42 0.96 
COMMON EFTS Elongation factor Ts, mitochondrial -1.81 3.50 0.85 -1.94 3.83 0.83 
COMMON TXTP 
Tricarboxylate transport protein, 
mitochondrial 
-1.80 3.47 0.87 -1.69 3.23 0.83 
COMMON SPRE Sepiapterin reductase -1.79 3.47 0.96 -1.72 3.28 0.96 
COMMON GPX1 Glutathione peroxidase 1 -1.79 3.45 0.92 -1.97 3.91 0.94 
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COMMON F213A Redox-regulatory protein FAM213A -1.77 3.42 0.89 -1.73 3.31 0.83 
COMMON DHB4 Peroxisomal multifunctional enzyme type 2 -1.76 3.39 0.95 -1.95 3.87 0.94 
COMMON ECHB 
Trifunctional enzyme subunit beta, 
mitochondrial 
-1.75 3.37 0.87 -2.15 4.43 0.89 
COMMON SODC Superoxide dismutase [Cu-Zn] -1.74 3.33 0.94 -1.69 3.22 0.95 
COMMON ESTD S-formylglutathione hydrolase -1.72 3.28 0.86 -1.92 3.80 0.88 
COMMON APMAP 
Adipocyte plasma membrane-associated 
protein 
-1.71 3.28 0.84 -1.55 2.93 0.85 
COMMON GSTM5 Glutathione S-transferase Mu 5 -1.71 3.27 0.87 -1.86 3.62 0.89 
COMMON PGK1 Phosphoglycerate kinase 1 -1.71 3.27 0.97 -1.74 3.35 0.97 
COMMON VA0D1 V-type proton ATPase subunit d 1 -1.70 3.24 0.87 -1.67 3.19 0.87 
COMMON PGM1 Phosphoglucomutase-1 -1.65 3.13 0.90 -1.66 3.15 0.85 
COMMON PHB Prohibitin -1.65 3.13 0.92 -1.79 3.45 0.93 
COMMON EZRI Ezrin -1.65 3.13 0.96 -1.77 3.41 0.96 
COMMON HINT1 Histidine triad nucleotide-binding protein 1 -1.60 3.04 0.88 -1.62 3.06 0.95 
COMMON SAHH Adenosylhomocysteinase -1.58 2.99 0.91 -1.37 2.58 0.91 
COMMON GNPI1 Glucosamine-6-phosphate isomerase 1 -1.56 2.96 0.89 -1.74 3.33 0.88 
COMMON CAH2 Carbonic anhydrase 2 -1.56 2.95 0.95 -1.58 2.99 0.96 
COMMON THIKA 3-ketoacyl-CoA thiolase A, peroxisomal -1.56 2.95 0.91 -1.49 2.81 0.82 
COMMON HDHD2 
Haloacid dehalogenase-like hydrolase 
domain-containing protein 2 
-1.53 2.90 0.82 -1.41 2.66 0.82 
COMMON 41 Protein 4.1 -1.51 2.84 0.85 -1.83 3.55 0.83 
COMMON VDAC2 
Voltage-dependent anion-selective channel 
protein 2 
-1.50 2.84 0.94 -1.64 3.13 0.93 
COMMON HEM2 Delta-aminolevulinic acid dehydratase -1.50 2.82 0.91 -1.34 2.54 0.91 
COMMON RADI Radixin -1.48 2.79 0.83 -1.76 3.39 0.89 
COMMON CCS 
Copper chaperone for superoxide 
dismutase 
-1.46 2.75 0.99 -2.39 5.23 0.83 
COMMON AKCL2 1,5-anhydro-D-fructose reductase -1.45 2.73 0.93 -1.67 3.19 0.82 
COMMON GPD1L 
Glycerol-3-phosphate dehydrogenase 1-like 
protein 
-1.44 2.72 0.87 -1.18 2.26 0.85 
COMMON TPIS Triosephosphate isomerase -1.44 2.71 0.95 -1.36 2.56 0.83 
COMMON UGPA 
UTP--glucose-1-phosphate 
uridylyltransferase 
-1.41 2.66 0.87 -1.45 2.74 0.85 
COMMON HXK1 Hexokinase-1 -1.41 2.66 0.91 -1.33 2.51 0.92 
COMMON FIS1 Mitochondrial fission 1 protein -1.41 2.65 0.89 -1.54 2.91 0.88 
COMMON GLGB 1,4-alpha-glucan-branching enzyme -1.37 2.59 0.98 -1.47 2.77 0.86 
COMMON FUCM Fucose mutarotase -1.33 2.52 0.88 -1.11 2.15 0.88 
COMMON ENOA Alpha-enolase -1.33 2.51 0.98 -1.30 2.47 0.98 
COMMON SYPL1 Synaptophysin-like protein 1 -1.32 2.50 0.91 -1.45 2.73 1.00 
COMMON PDXK Pyridoxal kinase -1.28 2.42 0.85 -1.59 3.01 0.92 
COMMON PARK7 Protein deglycase DJ-1 -1.27 2.42 0.93 -1.37 2.58 0.87 
COMMON PGAM1 Phosphoglycerate mutase 1 -1.27 2.41 0.97 -1.26 2.39 0.95 
COMMON GMPR1 GMP reductase 1 -1.27 2.41 0.81 -1.05 2.06 0.92 
COMMON GSTM1 Glutathione S-transferase Mu 1 -1.24 2.37 0.89 -1.15 2.22 0.89 
COMMON G3P 
Glyceraldehyde-3-phosphate 
dehydrogenase 
-1.19 2.29 0.92 -1.13 2.18 0.90 
COMMON TMM33 Transmembrane protein 33 -1.19 2.28 0.86 -0.99 1.99 0.83 
COMMON TIM44 
Mitochondrial import inner membrane 
translocase subunit TIM44 
-1.17 2.25 0.83 -1.38 2.61 0.83 
COMMON PRDX6 Peroxiredoxin-6 -1.16 2.23 0.94 -1.02 2.03 0.96 
COMMON NDKB Nucleoside diphosphate kinase B -1.08 2.11 0.95 -1.14 2.20 0.90 
COMMON ADK Adenosine kinase -1.02 2.03 0.87 -1.21 2.31 0.83 
COMMON PRDX1 Peroxiredoxin-1 -1.02 2.03 0.91 -1.13 2.19 0.90 
COMMON G6PI Glucose-6-phosphate isomerase -1.02 2.03 0.93 -1.05 2.07 0.96 
COMMON PACN2 
Protein kinase C and casein kinase 
substrate in neurons protein 2 
-0.97 1.96 0.85 -1.30 2.46 0.88 
COMMON MAT2B 
Methionine adenosyltransferase 2 subunit 
beta 
-0.96 1.94 0.89 -0.83 1.78 0.96 
COMMON PEBP1 Phosphatidylethanolamine-binding protein 1 -0.94 1.92 0.92 -0.96 1.95 0.95 
COMMON SPTN1 Spectrin alpha chain, non-erythrocytic 1 -0.89 1.85 0.88 -0.88 1.84 0.98 
COMMON TMED4 
Transmembrane emp24 domain-containing 
protein 4 
-0.88 1.84 0.90 -0.97 1.95 0.86 
COMMON SPTB2 Spectrin beta chain, non-erythrocytic 1 -0.84 1.80 0.87 -0.87 1.83 0.85 
COMMON UGDH UDP-glucose 6-dehydrogenase -0.84 1.79 0.82 -1.08 2.12 0.82 
COMMON GSTP1 Glutathione S-transferase P 1 -0.82 1.77 0.94 -0.80 1.74 0.93 
COMMON UAP1L 
UDP-N-acetylhexosamine 
pyrophosphorylase-like protein 1 
-0.81 1.76 0.84 -0.70 1.63 0.84 
COMMON SNX3 Sorting nexin-3 -0.78 1.72 0.84 -0.79 1.73 0.85 
COMMON TBB4B Tubulin beta-4B chain -0.77 1.71 0.90 -0.96 1.95 1.00 
COMMON ALDOA Fructose-bisphosphate aldolase A -0.65 1.57 0.84 -0.69 1.61 0.90 
COMMON GPX3 Glutathione peroxidase 3 -0.63 1.54 0.83 -0.50 1.41 0.83 
COMMON HS90A Heat shock protein HSP 90-alpha -0.58 1.50 0.81 -0.55 1.46 0.82 
TG2-KO ONLY SC5A3 Sodium/myo-inositol cotransporter -3.86 14.51 0.63 -4.79 27.69 0.86 
TG2-KO ONLY CX6A1 
Cytochrome c oxidase subunit 6A1, 
mitochondrial 
-3.57 11.91 0.74 -4.43 21.54 0.80 
TG2-KO ONLY PCKGC 
Phosphoenolpyruvate carboxykinase, 
cytosolic [GTP] 
-4.20 18.41 0.80 -4.10 17.10 0.85 
TG2-KO ONLY ACOX1 Peroxisomal acyl-coenzyme A oxidase 1 -2.33 5.01 0.78 -3.86 14.52 0.88 
TG2-KO ONLY ACO13 Acyl-coenzyme A thioesterase 13 -3.14 8.84 0.77 -3.60 12.10 0.88 
TG2-KO ONLY S22AC Solute carrier family 22 member 12 -3.15 8.90 0.78 -3.55 11.74 0.83 
TG2-KO ONLY IYD1 Iodotyrosine deiodinase 1 -5.13 35.04 0.44 -3.55 11.72 0.86 
TG2-KO ONLY ABCG2 
ATP-binding cassette sub-family G member 
2 
-4.12 17.42 0.79 -3.55 11.70 0.86 
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TG2-KO ONLY ODBB 
2-oxoisovalerate dehydrogenase subunit 
beta, mitochondrial 
-3.09 8.53 0.78 -3.50 11.28 0.81 
TG2-KO ONLY S23A1 Solute carrier family 23 member 1 -3.84 14.29 0.78 -3.45 10.96 0.83 
TG2-KO ONLY SOX Peroxisomal sarcosine oxidase -2.77 6.84 0.76 -3.45 10.94 0.84 
TG2-KO ONLY PPR1A 
Protein phosphatase 1 regulatory subunit 
1A 
-3.89 14.87 0.68 -3.44 10.83 0.88 
TG2-KO ONLY COX3 Cytochrome c oxidase subunit 3 -4.30 19.65 0.64 -3.40 10.56 0.91 
TG2-KO ONLY M2GD 
Dimethylglycine dehydrogenase, 
mitochondrial 
-3.27 9.68 0.78 -3.37 10.33 0.83 
TG2-KO ONLY COA6 
Cytochrome c oxidase assembly factor 6 
homolog 
-2.55 5.87 0.67 -3.36 10.29 0.81 
TG2-KO ONLY S22A8 Solute carrier family 22 member 8 -3.25 9.52 0.80 -3.35 10.19 0.80 
TG2-KO ONLY SUCHY 
Succinate--hydroxymethylglutarate CoA-
transferase 
-3.35 10.18 0.41 -3.26 9.59 0.85 
TG2-KO ONLY MIRO2 Mitochondrial Rho GTPase 2 -3.38 10.40 0.55 -3.23 9.35 0.87 
TG2-KO ONLY AK1CL Aldo-keto reductase family 1 member C21 -2.94 7.66 0.79 -3.16 8.97 0.84 
TG2-KO ONLY PHS Pterin-4-alpha-carbinolamine dehydratase -2.96 7.81 0.80 -3.05 8.31 0.82 
TG2-KO ONLY ECHD1 Ethylmalonyl-CoA decarboxylase -1.87 3.65 0.78 -3.04 8.24 0.86 
TG2-KO ONLY AKC1H Aldo-keto reductase family 1 member C18 -2.98 7.87 0.56 -3.01 8.07 0.87 
TG2-KO ONLY ENPP3 
Ectonucleotide 
pyrophosphatase/phosphodiesterase family 
member 3 
-2.57 5.94 0.71 -2.99 7.92 0.81 
TG2-KO ONLY RM23 39S ribosomal protein L23, mitochondrial -2.16 4.46 0.61 -2.96 7.79 0.81 
TG2-KO ONLY NDUA2 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 2 
-2.78 6.87 0.77 -2.96 7.78 0.83 
TG2-KO ONLY RT36 28S ribosomal protein S36, mitochondrial -2.92 7.55 0.67 -2.93 7.64 0.91 
TG2-KO ONLY 3BHS4 
3 beta-hydroxysteroid dehydrogenase type 
4 
-4.07 16.79 0.79 -2.92 7.58 0.81 
TG2-KO ONLY SFXN2 Sideroflexin-2 -3.49 11.27 0.65 -2.79 6.90 0.82 
TG2-KO ONLY FOLH1 Glutamate carboxypeptidase 2 -3.04 8.24 0.58 -2.77 6.81 0.80 
TG2-KO ONLY ACOT2 
Acyl-coenzyme A thioesterase 2, 
mitochondrial 
-2.43 5.38 0.79 -2.76 6.79 0.80 
TG2-KO ONLY MIC13 MICOS complex subunit MIC13 -2.90 7.47 0.72 -2.72 6.57 0.92 
TG2-KO ONLY COX7C 
Cytochrome c oxidase subunit 7C, 
mitochondrial 
-2.67 6.35 0.80 -2.72 6.57 0.80 
TG2-KO ONLY UD3A1 UDP-glucuronosyltransferase 3A1 -2.38 5.20 0.72 -2.64 6.24 0.84 
TG2-KO ONLY NDUS8 
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 8, mitochondrial 
-2.81 7.02 0.80 -2.63 6.20 0.86 
TG2-KO ONLY ENTP5 
Ectonucleoside triphosphate 
diphosphohydrolase 5 
-4.19 18.28 0.75 -2.62 6.15 0.80 
TG2-KO ONLY ACOX3 Peroxisomal acyl-coenzyme A oxidase 3 -3.46 11.01 0.41 -2.59 6.00 0.82 
TG2-KO ONLY DYR Dihydrofolate reductase -2.49 5.60 0.79 -2.50 5.65 0.82 
TG2-KO ONLY DAB2 Disabled homolog 2 -2.71 6.56 0.79 -2.49 5.62 0.80 
TG2-KO ONLY SAHH3 Putative adenosylhomocysteinase 3 -2.46 5.51 0.76 -2.47 5.54 0.83 
TG2-KO ONLY CLPX 
ATP-dependent Clp protease ATP-binding 
subunit clpX-like, mitochondrial 
-2.00 3.99 0.78 -2.45 5.48 0.91 
TG2-KO ONLY TIM8A 
Mitochondrial import inner membrane 
translocase subunit Tim8 A 
-2.15 4.45 0.67 -2.45 5.45 0.84 
TG2-KO ONLY MIA40 
Mitochondrial intermembrane space import 
and assembly protein 40 
-4.44 21.77 0.50 -2.45 5.45 0.86 
TG2-KO ONLY NDUS5 
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 5 
-2.96 7.78 0.67 -2.39 5.22 0.85 
TG2-KO ONLY AACS Acetoacetyl-CoA synthetase -2.64 6.24 0.60 -2.38 5.22 0.81 
TG2-KO ONLY P5CR3 Pyrroline-5-carboxylate reductase 3 -1.23 2.34 0.41 -2.35 5.08 0.84 
TG2-KO ONLY TIM9 
Mitochondrial import inner membrane 
translocase subunit Tim9 
-2.23 4.68 0.77 -2.28 4.85 0.81 
TG2-KO ONLY OPA1 Dynamin-like 120 kDa protein, mitochondrial -1.99 3.97 0.74 -2.28 4.84 0.86 
TG2-KO ONLY GLYC Serine hydroxymethyltransferase, cytosolic -2.22 4.67 0.77 -2.25 4.75 0.85 
TG2-KO ONLY CLPP 
ATP-dependent Clp protease proteolytic 
subunit, mitochondrial 
-2.29 4.89 0.73 -2.17 4.51 0.87 
TG2-KO ONLY LETM1 
LETM1 and EF-hand domain-containing 
protein 1, mitochondrial 
-2.27 4.84 0.79 -2.16 4.47 0.86 
TG2-KO ONLY IAH1 
Isoamyl acetate-hydrolyzing esterase 1 
homolog 
-2.03 4.10 0.76 -2.12 4.35 0.82 
TG2-KO ONLY CACP Carnitine O-acetyltransferase -2.31 4.95 0.74 -2.04 4.11 0.82 
TG2-KO ONLY GSH0 
Glutamate--cysteine ligase regulatory 
subunit 
-1.92 3.77 0.53 -2.02 4.07 0.84 
TG2-KO ONLY KAT1 Kynurenine--oxoglutarate transaminase 1 -2.34 5.05 0.69 -1.86 3.63 0.82 
TG2-KO ONLY ATAD1 
ATPase family AAA domain-containing 
protein 1 
-1.43 2.69 0.79 -1.83 3.57 0.85 
TG2-KO ONLY MYO6 Unconventional myosin-VI -1.84 3.59 0.80 -1.73 3.31 0.85 
TG2-KO ONLY TIM50 
Mitochondrial import inner membrane 
translocase subunit TIM50 
-2.06 4.18 0.49 -1.71 3.27 0.89 
TG2-KO ONLY SYIM Isoleucine--tRNA ligase, mitochondrial -1.99 3.98 0.73 -1.71 3.27 0.83 
TG2-KO ONLY NOMO1 Nodal modulator 1 -1.19 2.28 0.53 -1.60 3.03 0.81 
TG2-KO ONLY LAD1 Ladinin-1 -1.53 2.89 0.66 -1.48 2.79 0.80 
TG2-KO ONLY AL3A2 Fatty aldehyde dehydrogenase -1.38 2.61 0.79 -1.45 2.74 0.86 
TG2-KO ONLY ADHX Alcohol dehydrogenase class-3 -1.05 2.07 0.78 -1.26 2.40 0.84 
TG2-KO ONLY GBG12 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(O) subunit gamma-12 
-0.40 1.32 0.51 -1.26 2.39 0.94 
TG2-KO ONLY BACH 
Cytosolic acyl coenzyme A thioester 
hydrolase 
-1.01 2.02 0.30 -1.25 2.38 0.81 
TG2-KO ONLY SELT Selenoprotein T -1.43 2.70 0.76 -1.22 2.32 0.96 
TG2-KO ONLY NNRD 
ATP-dependent (S)-NAD(P)H-hydrate 
dehydratase 
-1.18 2.27 0.78 -1.21 2.32 0.82 
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TG2-KO ONLY RAB14 Ras-related protein Rab-14 -0.85 1.80 0.74 -1.09 2.13 0.83 
TG2-KO ONLY BIEA Biliverdin reductase A -0.96 1.94 0.63 -1.07 2.10 0.81 
TG2-KO ONLY VPS35 
Vacuolar protein sorting-associated protein 
35 
-1.06 2.09 0.50 -1.06 2.09 0.81 
TG2-KO ONLY RAB8A Ras-related protein Rab-8A -1.10 2.15 0.74 -1.04 2.06 0.82 
TG2-KO ONLY KCY UMP-CMP kinase -1.14 2.21 0.75 -1.03 2.04 0.83 
TG2-KO ONLY CNDP2 Cytosolic non-specific dipeptidase -0.93 1.90 0.77 -1.00 2.00 0.85 
TG2-KO ONLY COMT Catechol O-methyltransferase -0.62 1.54 0.49 -0.96 1.95 0.82 
TG2-KO ONLY TXD17 Thioredoxin domain-containing protein 17 -0.73 1.66 0.77 -0.96 1.95 0.87 
TG2-KO ONLY RTN3 Reticulon-3 -0.79 1.72 0.77 -0.95 1.94 0.88 
TG2-KO ONLY VAMP8 Vesicle-associated membrane protein 8 -1.27 2.41 0.77 -0.95 1.94 0.83 
TG2-KO ONLY ERLN2 Erlin-2 -0.69 1.62 0.66 -0.90 1.87 0.80 
TG2-KO ONLY GSTT1 Glutathione S-transferase theta-1 -0.91 1.87 0.80 -0.88 1.84 0.85 
TG2-KO ONLY LGUL Lactoylglutathione lyase -1.04 2.06 0.74 -0.87 1.83 0.83 
TG2-KO ONLY ISOC1 
Isochorismatase domain-containing protein 
1 
-0.66 1.58 0.71 -0.86 1.81 0.85 
TG2-KO ONLY RASN GTPase NRas -0.68 1.61 0.70 -0.84 1.79 0.81 
TG2-KO ONLY HACD3 
Very-long-chain (3R)-3-hydroxyacyl-CoA 
dehydratase 3 
-0.67 1.60 0.74 -0.79 1.73 0.88 
TG2-KO ONLY GALK2 N-acetylgalactosamine kinase -0.70 1.62 0.58 -0.78 1.72 0.81 
TG2-KO ONLY VP26A 
Vacuolar protein sorting-associated protein 
26A 
-0.70 1.63 0.79 -0.78 1.72 0.92 
TG2-KO ONLY ITPR1 Inositol 1,4,5-trisphosphate receptor type 1 -0.69 1.61 0.59 -0.77 1.70 0.83 
TG2-KO ONLY DNJA1 DnaJ homolog subfamily A member 1 -0.89 1.85 0.48 -0.77 1.70 0.81 
TG2-KO ONLY RB11B Ras-related protein Rab-11B -0.49 1.41 0.68 -0.75 1.69 0.89 
TG2-KO ONLY RS27L 40S ribosomal protein S27-like -1.07 2.10 0.77 -0.73 1.65 0.86 
TG2-KO ONLY PGRC1 
Membrane-associated progesterone 
receptor component 1 
-0.69 1.61 0.67 -0.72 1.65 0.84 
TG2-KO ONLY PTH2 Peptidyl-tRNA hydrolase 2, mitochondrial -0.86 1.82 0.57 -0.71 1.63 0.96 
TG2-KO ONLY GLOD4 Glyoxalase domain-containing protein 4 -0.67 1.59 0.71 -0.70 1.62 0.87 
TG2-KO ONLY F10A1 Hsc70-interacting protein -0.88 1.84 0.54 -0.68 1.61 0.85 
TG2-KO ONLY ACLY ATP-citrate synthase -0.80 1.74 0.76 -0.67 1.60 0.85 
TG2-KO ONLY GLRX1 Glutaredoxin-1 -0.72 1.65 0.54 -0.63 1.55 0.83 
TG2-KO ONLY FKBP3 Peptidyl-prolyl cis-trans isomerase FKBP3 -0.62 1.53 0.67 -0.63 1.55 0.81 
TG2-KO ONLY DPEP1 Dipeptidase 1 -0.51 1.43 0.76 -0.61 1.53 0.86 
TG2-KO ONLY LDHA L-lactate dehydrogenase A chain -0.52 1.44 0.72 -0.60 1.52 0.88 
TG2-KO ONLY SYSC Serine--tRNA ligase, cytoplasmic -0.53 1.45 0.57 -0.53 1.45 0.82 
TG2-KO ONLY TKT Transketolase -0.40 1.32 0.51 -0.47 1.38 0.84 
TG2-KO ONLY PRDX2 Peroxiredoxin-2 -0.36 1.28 0.64 -0.45 1.37 0.88 
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S.2 SUPPLEMENTARY DATA FOR CHAPTER IV 
 
S.2.1 Lists of TG2-associated proteins in the cytosolic fraction of UUO and 
Sham-operated kidneys at 21 days post-surgery 
Supplementary Table 4.1: List of proteins significantly associated with TG2 in UUO kidneys’ 
cytosolic fraction. This table shows all the proteins recognised as TG2-associated (z test, p≤0.05 N≥4) 
in the cytosolic fraction of UUO kidneys at 21 days post-operation. U = Uniquely expressed in UUO, C = 
common between UUO and Sham.  
 
TG2-associated proteins in UUO kidney cytosolic faction 
Sample ID Name N p-value 
Unique/ 
Common 
UBP24_MOUSE Ubiquitin carboxyl-terminal hydrolase 24 4 0.00E+00 U 
GPX41_MOUSE 
Phospholipid hydroperoxide glutathione peroxidase, 
mitochondrial 
5 0.00E+00 U 
HSPB1_MOUSE Heat shock protein beta-1 5 0.00E+00 U 
CKAP4_MOUSE Cytoskeleton-associated protein 4 4 2.88E-14 U 
FBLN1_MOUSE Fibulin-1 5 1.17E-10 U 
GBP2_MOUSE Guanylate-binding protein 1 5 1.69E-09 U 
DX39B_MOUSE Spliceosome RNA helicase Ddx39b 5 6.81E-09 C 
PP6R1_MOUSE Serine/threonine-protein phosphatase 6 regulatory subunit 1 4 8.59E-09 U 
RS18_MOUSE 40S ribosomal protein S18 5 9.03E-08 U 
IMB1_MOUSE Importin subunit beta-1 5 9.38E-08 U 
TES_MOUSE Testin 4 1.42E-07 U 
TCPQ_MOUSE T-complex protein 1 subunit theta 5 1.96E-07 C 
PMM2_MOUSE Phosphomannomutase 2 5 2.92E-07 U 
DCTN1_MOUSE Dynactin subunit 1 5 2.94E-07 U 
SEC13_MOUSE Protein SEC13 homolog 5 1.10E-06 U 
POSTN_MOUSE Periostin 4 1.88E-06 U 
RTN4_MOUSE Reticulon-4 5 4.52E-06 C 
PLST_MOUSE Plastin-3 5 6.60E-06 U 
DYHC1_MOUSE Cytoplasmic dynein 1 heavy chain 1 5 8.10E-06 U 
USP9X_MOUSE Probable ubiquitin carboxyl-terminal hydrolase FAF-X 5 1.07E-05 U 
ENPL_MOUSE Endoplasmin 5 1.64E-05 U 
SPTB2_MOUSE Spectrin beta chain, non-erythrocytic 1 5 1.95E-05 U 
MYO7B_MOUSE Unconventional myosin-VIIb 5 9.33E-05 U 
BAX_MOUSE Apoptosis regulator BAX 5 1.07E-04 C 
ATPA_MOUSE ATP synthase subunit alpha, mitochondrial 5 1.10E-04 U 
UB2D3_MOUSE Ubiquitin-conjugating enzyme E2 D3 5 1.24E-04 U 
RAN_MOUSE GTP-binding nuclear protein Ran 5 1.24E-04 C 
SRP68_MOUSE Signal recognition particle subunit SRP68 5 1.67E-04 U 
GRP75_MOUSE Stress-70 protein, mitochondrial 5 1.83E-04 U 
1433E_MOUSE 14-3-3 protein epsilon 5 2.07E-04 C 
CB39L_MOUSE Calcium-binding protein 39-like 5 3.18E-04 U 
RL11_MOUSE 60S ribosomal protein L11 5 3.84E-04 U 
HNRPM_MOUSE Heterogeneous nuclear ribonucleoprotein M 5 4.39E-04 U 
FINC_MOUSE Fibronectin 5 4.71E-04 U 
ACTA_MOUSE Actin, aortic smooth muscle 5 5.43E-04 U 
TGM2_MOUSE Transglutaminase 2 5 5.62E-04 C 
SNX12_MOUSE Sorting nexin-12 4 5.75E-04 U 
DPYL3_MOUSE Dihydropyrimidinase-related protein 3 5 6.82E-04 U 
GUAA_MOUSE GMP synthase [glutamine-hydrolyzing] 5 6.86E-04 U 
IST1_MOUSE IST1 homolog 5 9.25E-04 U 
SC31A_MOUSE Protein transport protein Sec31A 5 1.08E-03 U 
CTNB1_MOUSE Catenin beta-1 5 1.20E-03 U 
UBE2Z_MOUSE Ubiquitin-conjugating enzyme E2 Z 5 1.21E-03 U 
ANXA1_MOUSE Annexin A1 5 1.30E-03 U 
PLSL_MOUSE Plastin-2 5 1.50E-03 U 
RL15_MOUSE 60S ribosomal protein L15 5 3.27E-03 U 
SYEP_MOUSE Bifunctional glutamate/proline--tRNA ligase 5 3.63E-03 U 
DNJA1_MOUSE DnaJ homolog subfamily A member 1 5 3.98E-03 U 
VPS4B_MOUSE Vacuolar protein sorting-associated protein 4B 5 4.15E-03 U 
RS9_MOUSE 40S ribosomal protein S9 4 4.27E-03 C 
RS2_MOUSE 40S ribosomal protein S2 5 4.60E-03 U 
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1433T_MOUSE 14-3-3 protein theta 5 4.80E-03 U 
CC160_MOUSE Coiled-coil domain-containing protein 160 4 5.33E-03 U 
USO1_MOUSE General vesicular transport factor p115 5 5.63E-03 U 
MP2K2_MOUSE Dual specificity mitogen-activated protein kinase kinase 2 5 5.66E-03 C 
HS90A_MOUSE Heat shock protein HSP 90-alpha 5 5.73E-03 U 
MYH10_MOUSE Myosin-10 5 5.84E-03 U 
VINC_MOUSE Vinculin 5 6.30E-03 U 
AATM_MOUSE Aspartate aminotransferase, mitochondrial 5 6.41E-03 U 
BAF_MOUSE Barrier-to-autointegration factor 5 6.43E-03 U 
K1C18_MOUSE Keratin, type I cytoskeletal 18 5 6.51E-03 U 
TPM1_MOUSE Tropomyosin alpha-1 chain 5 7.36E-03 C 
TBA1A_MOUSE Tubulin alpha-1A chain 5 7.61E-03 U 
DESM_MOUSE Desmin 5 7.70E-03 U 
AT2B2_MOUSE Plasma membrane calcium-transporting ATPase 2 4 7.98E-03 U 
VATE1_MOUSE V-type proton ATPase subunit E 1 4 8.10E-03 C 
FA49B_MOUSE Protein FAM49B 5 8.18E-03 U 
RL27A_MOUSE 60S ribosomal protein L27a 5 8.35E-03 C 
VPS35_MOUSE Vacuolar protein sorting-associated protein 35 5 8.44E-03 U 
K2C8_MOUSE Keratin, type II cytoskeletal 8 5 8.88E-03 U 
BAG6_MOUSE Large proline-rich protein BAG6 5 9.34E-03 C 
ECHA_MOUSE Trifunctional enzyme subunit alpha, mitochondrial 5 9.52E-03 U 
UMPS_MOUSE Uridine 5'-monophosphate synthase 5 9.74E-03 C 
UBR4_MOUSE E3 ubiquitin-protein ligase UBR4 5 1.01E-02 U 
CTBP1_MOUSE C-terminal-binding protein 1 5 1.06E-02 U 
RL21_MOUSE 60S ribosomal protein L21 5 1.09E-02 U 
EF2_MOUSE Elongation factor 2 5 1.11E-02 C 
PNCB_MOUSE Nicotinate phosphoribosyltransferase 5 1.16E-02 U 
FLNA_MOUSE Filamin-A 5 1.20E-02 U 
HSP7C_MOUSE Heat shock cognate 71 kDa protein 5 1.22E-02 U 
RL3_MOUSE 60S ribosomal protein L3 5 1.23E-02 U 
MGST3_MOUSE Microsomal glutathione S-transferase 3 5 1.25E-02 U 
PSME1_MOUSE Proteasome activator complex subunit 1 5 1.25E-02 U 
TCPD_MOUSE T-complex protein 1 subunit delta 5 1.27E-02 U 
ATX10_MOUSE Ataxin-10 5 1.31E-02 U 
CTBP2_MOUSE C-terminal-binding protein 2 5 1.33E-02 U 
MEP1B_MOUSE Meprin A subunit beta 5 1.34E-02 U 
K1C14_MOUSE Keratin, type I cytoskeletal 14 5 1.36E-02 U 
KAD1_MOUSE Adenylate kinase isoenzyme 1 5 1.37E-02 C 
ROA3_MOUSE Heterogeneous nuclear ribonucleoprotein A3 5 1.38E-02 U 
PSME3_MOUSE Proteasome activator complex subunit 3 5 1.46E-02 U 
GCYB1_MOUSE Guanylate cyclase soluble subunit beta-1 5 1.47E-02 U 
ARL2_MOUSE ADP-ribosylation factor-like protein 2 5 1.49E-02 U 
UBE2N_MOUSE Ubiquitin-conjugating enzyme E2 N 5 1.50E-02 U 
MYO1E_MOUSE Unconventional myosin-Ie 5 1.54E-02 U 
PSD11_MOUSE 26S proteasome non-ATPase regulatory subunit 11 5 1.54E-02 C 
SNX6_MOUSE Sorting nexin-6 4 1.60E-02 U 
DC1L2_MOUSE Cytoplasmic dynein 1 light intermediate chain 2 5 1.60E-02 U 
RS14_MOUSE 40S ribosomal protein S14 5 1.64E-02 U 
PSMD5_MOUSE 26S proteasome non-ATPase regulatory subunit 5 4 1.73E-02 U 
MYL6_MOUSE Myosin light polypeptide 6 5 1.80E-02 U 
VP26B_MOUSE Vacuolar protein sorting-associated protein 26B 5 1.84E-02 U 
COPA_MOUSE Coatomer subunit alpha 5 1.95E-02 C 
TLN1_MOUSE Talin-1 5 1.96E-02 U 
MBB1A_MOUSE Myb-binding protein 1A 4 2.05E-02 U 
TPC2L_MOUSE Trafficking protein particle complex subunit 2-like protein 4 2.05E-02 U 
FIBG_MOUSE Fibrinogen gamma chain 5 2.10E-02 U 
PPAC_MOUSE Low molecular weight phosphotyrosine protein phosphatase 5 2.17E-02 U 
GLSK_MOUSE Glutaminase kidney isoform, mitochondrial 5 2.23E-02 U 
DDX5_MOUSE Probable ATP-dependent RNA helicase DDX5 5 2.29E-02 U 
DLDH_MOUSE Dihydrolipoyl dehydrogenase, mitochondrial 5 2.30E-02 U 
NIBL1_MOUSE Niban-like protein 1 5 2.37E-02 U 
CH60_MOUSE 60 kDa heat shock protein, mitochondrial 5 2.43E-02 C 
PRDX1_MOUSE Peroxiredoxin-1 5 2.55E-02 U 
CASP8_MOUSE Caspase-8 5 2.57E-02 U 
ACTH_MOUSE Actin, gamma-enteric smooth muscle 5 2.59E-02 U 
PLEC_MOUSE Plectin 5 2.68E-02 U 
DTX3L_MOUSE E3 ubiquitin-protein ligase DTX3L 5 2.74E-02 U 
PRS6A_MOUSE 26S protease regulatory subunit 6A 4 2.76E-02 U 
ARY2_MOUSE Arylamine N-acetyltransferase 2 5 2.78E-02 U 
EFHD2_MOUSE EF-hand domain-containing protein D2 5 2.78E-02 U 
S12A3_MOUSE Solute carrier family 12 member 3 5 2.85E-02 U 
K1C19_MOUSE Keratin, type I cytoskeletal 19 5 2.89E-02 U 
IPO8_MOUSE Importin-8 4 2.93E-02 U 
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IF4A2_MOUSE Eukaryotic initiation factor 4A-II 5 3.00E-02 C 
NUP98_MOUSE Nuclear pore complex protein Nup98-Nup96 4 3.02E-02 U 
RL13_MOUSE 60S ribosomal protein L13 5 3.04E-02 C 
ARHG1_MOUSE Rho guanine nucleotide exchange factor 1 5 3.18E-02 U 
CYGB_MOUSE Cytoglobin 4 3.41E-02 U 
KINH_MOUSE Kinesin-1 heavy chain 5 3.47E-02 U 
PDC6I_MOUSE Programmed cell death 6-interacting protein 5 3.51E-02 U 
VIME_MOUSE Vimentin 5 3.64E-02 U 
HS90B_MOUSE Heat shock protein HSP 90-beta 5 3.65E-02 U 
DPEP1_MOUSE Dipeptidase 1 5 3.68E-02 U 
API5_MOUSE Apoptosis inhibitor 5 5 3.79E-02 U 
LSP1_MOUSE Lymphocyte-specific protein 1 5 3.84E-02 U 
TCPA_MOUSE T-complex protein 1 subunit alpha 5 3.89E-02 U 
SAE2_MOUSE SUMO-activating enzyme subunit 2 5 3.90E-02 U 
NEDD4_MOUSE E3 ubiquitin-protein ligase NEDD4 5 3.98E-02 U 
MACF1_MOUSE Microtubule-actin cross-linking factor 1 5 4.01E-02 U 
SPTA1_MOUSE Spectrin alpha chain, erythrocytic 1 5 4.11E-02 U 
DNM1L_MOUSE Dynamin-1-like protein 5 4.11E-02 C 
ACY3_MOUSE 
N-acyl-aromatic-L-amino acid amidohydrolase (carboxylate-
forming) 
4 4.34E-02 U 
DJB11_MOUSE DnaJ homolog subfamily B member 11 4 4.35E-02 U 
ML12B_MOUSE Myosin regulatory light chain 12B 5 4.47E-02 U 
RAGP1_MOUSE Ran GTPase-activating protein 1 5 4.60E-02 U 
HBA_MOUSE Hemoglobin subunit alpha 5 4.63E-02 U 
TLN2_MOUSE Talin-2 5 4.64E-02 U 
CO6A2_MOUSE Collagen alpha-2(VI) chain 5 4.64E-02 U 
TPIS_MOUSE Triosephosphate isomerase 5 4.66E-02 C 
1433B_MOUSE 14-3-3 protein beta/alpha 5 4.71E-02 U 
PRS7_MOUSE 26S protease regulatory subunit 7 5 4.77E-02 U 
DPM1_MOUSE Dolichol-phosphate mannosyltransferase subunit 1 4 4.86E-02 C 
EPN4_MOUSE Clathrin interactor 1 4 5.09E-02 C 
AAKG1_MOUSE 5'-AMP-activated protein kinase subunit gamma-1 5 5.13E-02 C 
IPO9_MOUSE Importin-9 5 5.17E-02 U 
FLNB_MOUSE Filamin-B 5 5.25E-02 U 
CAP1_MOUSE Adenylyl cyclase-associated protein 1 5 5.28E-02 U 
DDX17_MOUSE Probable ATP-dependent RNA helicase DDX17 5 5.28E-02 U 
TRI25_MOUSE E3 ubiquitin/ISG15 ligase TRIM25 5 5.34E-02 C 
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Supplementary Table 4.2: List of proteins significantly associated with TG2 in Sham operated 
kidneys’ cytosolic fraction. This table shows all the proteins recognised as TG2-associated (z test, 
p≤0.05 N≥4) in the cytosolic fraction of sham operated kidneys at 21 days post-operation.  U = Uniquely 
expressed in Sham operated conditions, C = common between UUO and Sham. 
 
TG2-associated proteins in Sham operated kidney cytosolic faction 
Sample ID Name N P value 
Unique/ 
Common 
ACAD8_MOUSE Isobutyryl-CoA dehydrogenase, mitochondrial 4 0.00E+00 U 
PLSI_MOUSE Plastin-1 4 1.41E-07 U 
TGM2_MOUSE Transglutaminase 2 5 1.90E-07 C 
ARF2_MOUSE ADP-ribosylation factor 2 5 6.62E-07 U 
GPDA_MOUSE Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic 5 8.01E-07 U 
RS6_MOUSE 40S ribosomal protein S6 5 3.53E-05 U 
H4_MOUSE Histone H4 5 3.69E-05 U 
CYFP2_MOUSE Cytoplasmic FMR1-interacting protein 2 4 7.57E-05 U 
NPM_MOUSE Nucleophosmin 5 1.44E-04 U 
AP2A2_MOUSE AP-2 complex subunit alpha-2 5 1.99E-04 U 
MAAI_MOUSE Maleylacetoacetate isomerase 5 2.00E-04 U 
RL13A_MOUSE 60S ribosomal protein L13a 5 2.30E-04 U 
NFS1_MOUSE Cysteine desulfurase, mitochondrial 4 2.98E-04 U 
MON2_MOUSE Protein MON2 homolog 5 3.12E-04 U 
TPM3_MOUSE Tropomyosin alpha-3 chain 5 4.38E-04 U 
ISOC1_MOUSE Isochorismatase domain-containing protein 1 5 4.38E-04 U 
TRI25_MOUSE E3 ubiquitin/ISG15 ligase TRIM25 5 4.64E-04 C 
RS9_MOUSE 40S ribosomal protein S9 4 5.67E-04 C 
RS30_MOUSE 40S ribosomal protein S30 5 6.12E-04 U 
VATE1_MOUSE V-type proton ATPase subunit E 1 4 6.19E-04 C 
COPA_MOUSE Coatomer subunit alpha 5 7.76E-04 C 
VAT1_MOUSE Synaptic vesicle membrane protein VAT-1 homolog 5 8.32E-04 U 
RS13_MOUSE 40S ribosomal protein S13 5 9.74E-04 U 
DX39B_MOUSE Spliceosome RNA helicase Ddx39b 5 1.07E-03 C 
SQRD_MOUSE Sulfide:quinone oxidoreductase, mitochondrial 5 1.13E-03 U 
AP2M1_MOUSE AP-2 complex subunit mu 5 1.13E-03 U 
IF4A1_MOUSE Eukaryotic initiation factor 4A-I 5 1.41E-03 U 
RL27A_MOUSE 60S ribosomal protein L27a 5 1.43E-03 C 
PDIA6_MOUSE Protein disulfide-isomerase A6 5 1.64E-03 U 
RHG01_MOUSE Rho GTPase-activating protein 1 5 1.73E-03 U 
RCN1_MOUSE Reticulocalbin-1 4 2.06E-03 U 
RHOA_MOUSE Transforming protein RhoA 5 2.36E-03 U 
VATA_MOUSE V-type proton ATPase catalytic subunit A 5 2.47E-03 U 
IF4A2_MOUSE Eukaryotic initiation factor 4A-II 5 2.74E-03 C 
SORCN_MOUSE Sorcin 5 3.05E-03 U 
RL13_MOUSE 60S ribosomal protein L13 5 3.16E-03 C 
ZADH2_MOUSE Zinc-binding alcohol dehydrogenase domain-containing protein 2 4 3.40E-03 U 
VILL_MOUSE Villin-like protein 5 3.87E-03 U 
CO3_MOUSE Complement C3 4 4.10E-03 U 
COPE_MOUSE Coatomer subunit epsilon 5 4.20E-03 U 
CPNS1_MOUSE Calpain small subunit 1 5 5.68E-03 U 
TCPQ_MOUSE T-complex protein 1 subunit theta 5 6.01E-03 C 
UCK1_MOUSE Uridine-cytidine kinase 1 5 6.05E-03 U 
GGA1_MOUSE ADP-ribosylation factor-binding protein GGA1 5 6.25E-03 U 
BAX_MOUSE Apoptosis regulator BAX 5 7.33E-03 C 
H14_MOUSE Histone H1.4 5 7.61E-03 U 
SAE1_MOUSE SUMO-activating enzyme subunit 1 5 7.91E-03 U 
TPM1_MOUSE Tropomyosin alpha-1 chain 5 8.46E-03 C 
ETHE1_MOUSE Persulfide dioxygenase ETHE1, mitochondrial 5 8.87E-03 U 
UMPS_MOUSE Uridine 5'-monophosphate synthase 5 9.12E-03 C 
RS16_MOUSE 40S ribosomal protein S16 5 1.04E-02 U 
ESTD_MOUSE S-formylglutathione hydrolase 5 1.10E-02 U 
TPIS_MOUSE Triosephosphate isomerase 5 1.13E-02 C 
VMA5A_MOUSE von Willebrand factor A domain-containing protein 5A 5 1.25E-02 U 
DPM1_MOUSE Dolichol-phosphate mannosyltransferase subunit 1 4 1.39E-02 C 
SERA_MOUSE D-3-phosphoglycerate dehydrogenase 5 1.43E-02 U 
GRP78_MOUSE 78 kDa glucose-regulated protein 5 1.43E-02 U 
RAN_MOUSE GTP-binding nuclear protein Ran 5 1.57E-02 C 
RTN4_MOUSE Reticulon-4 5 1.67E-02 C 
SGK2_MOUSE Serine/threonine-protein kinase Sgk2 4 1.79E-02 U 
GLRX1_MOUSE Glutaredoxin-1 4 1.85E-02 U 
PRDX3_MOUSE Thioredoxin-dependent peroxide reductase, mitochondrial 5 1.86E-02 U 
CH60_MOUSE 60 kDa heat shock protein, mitochondrial 5 1.87E-02 C 
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RL40_MOUSE Ubiquitin-60S ribosomal protein L40 5 1.90E-02 U 
FAS_MOUSE Fatty acid synthase 5 1.94E-02 U 
ARL8B_MOUSE ADP-ribosylation factor-like protein 8B 5 1.97E-02 U 
TKT_MOUSE Transketolase 5 1.97E-02 U 
DNM1L_MOUSE Dynamin-1-like protein 5 2.08E-02 C 
1433Z_MOUSE 14-3-3 protein zeta/delta 5 2.10E-02 U 
IPO4_MOUSE Importin-4 5 2.14E-02 U 
ALBU_MOUSE Serum albumin 5 2.19E-02 U 
EPN4_MOUSE Clathrin interactor 1 4 2.20E-02 C 
EF2_MOUSE Elongation factor 2 5 2.31E-02 C 
ECHB_MOUSE Trifunctional enzyme subunit beta, mitochondrial 5 2.52E-02 U 
TOM1_MOUSE Target of Myb protein 1 4 2.55E-02 U 
PRS10_MOUSE 26S protease regulatory subunit 10B 5 2.66E-02 U 
COPB2_MOUSE Coatomer subunit beta' 5 2.93E-02 U 
RL7_MOUSE 60S ribosomal protein L7 5 2.99E-02 U 
DDX3Y_MOUSE ATP-dependent RNA helicase DDX3Y 5 3.03E-02 U 
ARP3_MOUSE Actin-related protein 3 5 3.04E-02 U 
ST1A1_MOUSE Sulfotransferase 1A1 5 3.10E-02 U 
ODO2_MOUSE 
Dihydrolipoyllysine-residue succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, mitochondrial 
5 3.20E-02 U 
SNTB2_MOUSE Beta-2-syntrophin 5 3.22E-02 U 
MP2K2_MOUSE Dual specificity mitogen-activated protein kinase kinase 2 5 3.22E-02 C 
ASSY_MOUSE Argininosuccinate synthase 5 3.22E-02 U 
LACTB_MOUSE Serine beta-lactamase-like protein LACTB, mitochondrial 5 3.24E-02 U 
CLH1_MOUSE Clathrin heavy chain 1 5 3.28E-02 U 
KAD1_MOUSE Adenylate kinase isoenzyme 1 5 3.33E-02 C 
CALB1_MOUSE Calbindin 5 3.38E-02 U 
THIKA_MOUSE 3-ketoacyl-CoA thiolase A, peroxisomal 5 3.41E-02 U 
ACADV_MOUSE Very long-chain specific acyl-CoA dehydrogenase, mitochondrial 5 3.53E-02 U 
GALK2_MOUSE N-acetylgalactosamine kinase 5 3.60E-02 U 
LYPL1_MOUSE Lysophospholipase-like protein 1 5 3.65E-02 U 
SCFD1_MOUSE Sec1 family domain-containing protein 1 5 3.94E-02 U 
ARPC4_MOUSE Actin-related protein 2/3 complex subunit 4 5 4.06E-02 U 
SYIM_MOUSE Isoleucine--tRNA ligase, mitochondrial 4 4.23E-02 U 
EHD1_MOUSE EH domain-containing protein 1 5 4.28E-02 U 
K1C20_MOUSE Keratin, type I cytoskeletal 20 4 4.36E-02 U 
1433E_MOUSE 14-3-3 protein epsilon 5 4.36E-02 C 
ETFB_MOUSE Electron transfer flavoprotein subunit beta 5 4.37E-02 U 
GRAN_MOUSE Grancalcin 5 4.58E-02 U 
PSD11_MOUSE 26S proteasome non-ATPase regulatory subunit 11 5 4.60E-02 C 
BAG6_MOUSE Large proline-rich protein BAG6 5 4.63E-02 C 
ANXA2_MOUSE Annexin A2 5 4.78E-02 U 
CDC42_MOUSE Cell division control protein 42 homolog 5 4.79E-02 U 
SC23B_MOUSE Protein transport protein Sec23B 4 4.85E-02 U 
ANS1A_MOUSE Ankyrin repeat and SAM domain-containing protein 1A 4 5.20E-02 U 
AAKG1_MOUSE 5'-AMP-activated protein kinase subunit gamma-1 5 5.31E-02 C 
H2B1P_MOUSE Histone H2B type 1-P 5 5.36E-02 U 
DDX1_MOUSE ATP-dependent RNA helicase DDX1 5 5.40E-02 U 
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S.2.2 Lists of TG2-associated proteins in the crude membrane fraction of  
UUO and Sham operated kidneys that have been removed from the analysis 
because nuclear, mitochondrial or ribosomal 
Supplementary Table 4.3: List of proteins significantly associated with TG2 in UUO or Sham 
operated kidney membranes (21-days) and exclusively located in the nuclear cellular 
compartment. This table shows all the proteins recognised as TG2-associated in UUO (A) or sham 
operated (B) kidney membranes at 21 days (z test, p≤0.05 N≥4) and identified as uniquely associated 
with the nuclei.  In increasing shades of blue, the p-value of TG2 association obtained by z-analysis. U = 
Uniquely expressed in UUO or Sham, C = common between UUO and Sham.  
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Supplementary Table 4.4: List of proteins significantly associated with TG2 in UUO or Sham 
operated kidney membranes (21-days) exclusively located in the mitochondrial and 
peroxisomal cellular compartment. This table shows all the proteins recognised as TG2-associated in 
UUO (A) or sham operated (B) kidney membranes at 21 days (z test, p≤0.05 N≥4) and identified as 
uniquely associated with mitochondria or peroxisomes.  In increasing shades of blue, the p-value of TG2 
association obtained by z-analysis. U = Uniquely expressed in UUO or Sham, C = common between UUO 
and Sham. 
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Supplementary Table 4.5: List of ribosomal and immunoglobulin proteins significantly 
associated with TG2 in UUO or Sham operated kidney membranes (21-days). (A,B) Proteins 
recognised as TG2-associated in UUO (A) or sham operated (B) kidney membranes at 21 days  (z test, 
p≤0.05 N≥4) and identified as ribosomal subunits.  (C) Proteins recognised as TG2-associated with UUO 
kidney membranes at 21 days  (z test, p≤0.05 N≥4) and identified immunoglobulins (Ig). In increasing 
shades of blue, the p-value of TG2 association obtained by z-analysis. U = Uniquely expressed in UUO or 
Sham, C = common between UUO and Sham. 
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S.2.3 Functional clustering of TG2-associated proteins in UUO or Sham 
operated kidney membranes 
Supplementary Table 4.6: Functional clustering of TG2-associated proteins identified uniquely 
in UUO kidney membranes. Proteins identified as significantly associated with TG2 uniquely in UUO 
kidney membranes at 21 days post operation (p≤0.05 N≥4, marked with “U” in Table 4.2) were manually 
associated with general functional clusters depending on their main biological role in the cell, 
investigated by manual search of protein IDs on UniProtKB database. Nuclear, mitochondrial and 
ribosomal proteins were removed from the list.  
  
TG2-associated proteins in UUO kidney membranes 
Protein ID Name N P Value Functional Cluster 
DESP Desmoplakin 5 1.22E-13 Cell Adhesion  
HSP7C Heat shock cognate 71 kDa protein 5 7.67E-10 Vesicular Trafficking  
CAZA2 F-actin-capping protein subunit alpha-2 5 1.97E-08 Cytoskeleton and Actin dynamics  
GPX1 Glutathione peroxidase 1 5 4.52E-07 Redox Regulation  
POSTN Periostin 4 1.03E-06 Cell Adhesion  
MYO1D Unconventional myosin-Id 5 3.52E-06 Vesicular Trafficking  
GLRX1 Glutaredoxin 1 4 5.61E-06 Redox Regulation  
GLRX3 Glutaredoxin-3 5 1.40E-05 Redox Regulation  
PROF1 Profilin-1 5 1.89E-05 Cytoskeleton and Actin dynamics  
HSPB1 Heat shock protein beta-1 5 3.68E-05 Signalling and Stress Response  
VATH V-type proton ATPase subunit H 5 5.98E-05 Vesicular Trafficking  
ADDG Gamma-adducin 5 6.66E-05 Cytoskeleton and Actin dynamics  
AT2A2 
Sarcoplasmic/endoplasmic reticulum calcium 
ATPase 2 
5 8.58E-05 Ion Transport  
SVIL Supervillin 4 1.01E-04 Cytoskeleton and Actin dynamics  
COR1C Coronin-1C 5 1.38E-04 Signalling and Stress Response  
TCPE T-complex protein 1 5 3.17E-04 Chaperone  
UBP5 Ubiquitin carboxyl-terminal hydrolase 5 5 4.59E-04 Ubiquitination and Proteasome  
FLOT2 Flotillin-2 4 5.38E-04 Vesicular Trafficking  
RAB1A Ras-related protein Rab-1A 5 9.16E-04 Vesicular Trafficking  
SDC4 Syndecan-4 5 9.34E-04 
Cell Adhesion + Extracellular 
Organisation 
 
LDHA L-lactate dehydrogenase A chain 4 1.04E-03 Metabolism  
MYO1G Unconventional myosin-Ig 5 1.21E-03 Vesicular Trafficking  
K1C20 Keratin, type I cytoskeletal 20 4 1.35E-03 Cytoskeleton and Actin dynamics  
COEA1 Collagen alpha-1(XIV) chain 5 1.64E-03 Extracellular Organisation  
COCA1 Collagen alpha-1(XII) chain 4 1.68E-03 Extracellular Organisation  
HIP1 Huntingtin-interacting protein 1 4 1.86E-03 Vesicular Trafficking  
SAR1B GTP-binding protein SAR1b 5 2.79E-03 Vesicular Trafficking  
FLNA Filamin-A 5 2.98E-03 Cytoskeleton and Actin dynamics  
ANK3 Ankyrin-3 5 3.03E-03 Cytoskeleton and Actin dynamics  
PSD11 
26S proteasome non-ATPase regulatory 
subunit 11 
5 3.09E-03 Ubiquitination and Proteasome  
PGBM 
Basement membrane-specific heparan 
sulfate proteoglycan core protein (Perlecan) 
5 3.16E-03 Extracellular Organisation  
LSP1 Lymphocyte-specific protein 1 5 3.53E-03 Signalling and Stress Response  
GELS Gelsolin 5 4.61E-03 Cytoskeleton and Actin dynamics  
YKT6 Synaptobrevin homolog YKT6 5 4.72E-03 Vesicular Trafficking  
FLNB Filamin-B 5 5.03E-03 Cytoskeleton and Actin dynamics  
TLN2 Talin-2 5 5.28E-03 Cell Adhesion  
KCC2D 
Calcium/calmodulin-dependent protein 
kinase type II subunit delta 
5 7.10E-03 Ion Transport  
RTN4 Reticulon-4 5 7.57E-03 Signalling and Stress Response  
KC1A Casein kinase I isoform alpha 5 8.06E-03 Signalling and Stress Response  
DCTN1 Dynactin subunit 1 5 8.52E-03 Vesicular Trafficking  
ADDA Alpha-adducin 5 8.61E-03 Cytoskeleton and Actin dynamics  
PGS2 Decorin 5 1.09E-02 Extracellular Organisation  
RHG18 Rho GTPase-activating protein 18 4 1.11E-02 Signalling and Stress Response  
CAPZB F-actin-capping protein subunit beta 5 1.11E-02 Cytoskeleton and Actin dynamics  
MVP Major vault protein 5 1.14E-02 Signalling and Stress Response  
ACTB Actin, cytoplasmic 1 5 1.24E-02 Cytoskeleton and Actin dynamics  
K1C14 Keratin, type I cytoskeletal 14 5 1.33E-02 Cytoskeleton and Actin dynamics  
PLSL Plastin-2 5 1.34E-02 Signalling and Stress Response  
AP2A2 AP-2 complex subunit alpha-2 5 1.52E-02 Vesicular Trafficking  
CLCB Clathrin light chain b 5 1.65E-02 Vesicular Trafficking  
SNX4 Sorting nexin-4 5 1.67E-02 Vesicular Trafficking  
SPTB1 Spectrin beta chain, erythrocytic 5 1.73E-02 Cytoskeleton and Actin dynamics  
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ZO1 Tight junction protein ZO-1 4 1.79E-02 Cell Adhesion  
DREB Drebrin 5 1.83E-02 Cytoskeleton and Actin dynamics  
CAN1 Calpain1 5 1.84E-02 Signalling and Stress Response  
PDLI5 PDZ and LIM domain protein 5 5 1.85E-02 Protein Binding  
PUR6 Multifunctional protein ADE2 5 1.88E-02 Metabolism  
MY18A Unconventional myosin-XVIIIa 5 1.93E-02 Vesicular Trafficking  
CLCA Clathrin light chain A 5 2.07E-02 Vesicular Trafficking  
IRGM1 Immunity-related GTPase family M protein 1 5 2.09E-02 Signalling and Stress Response  
NEB2 Neurabin-2 5 2.11E-02 Signalling and Stress Response  
K2C6B Keratin, type II cytoskeletal 6B 5 2.14E-02 Cytoskeleton and Actin dynamics  
AP2A1 AP-2 complex subunit alpha-1 5 2.15E-02 Vesicular Trafficking  
LYPA1 Acyl-protein thioesterase 1 5 2.18E-02 Metabolism  
AP2B1 AP-2 complex subunit beta 5 2.43E-02 Vesicular Trafficking  
K1C19 Keratin, type I cytoskeletal 19 5 2.58E-02 Cytoskeleton and Actin dynamics  
GRP78 78 kDa glucose-regulated protein 5 2.59E-02 Chaperone  
ARK72 Aflatoxin B1 aldehyde reductase member 2 5 2.61E-02 Metabolism  
SNTB2 Beta-2-syntrophin 5 2.63E-02 Protein Binding  
MYO1B Unconventional myosin-Ib 5 2.67E-02 Vesicular Trafficking  
K6PP 
ATP-dependent 6-phosphofructokinase, 
platelet type 
5 2.67E-02 Metabolism  
C1QB Complement C1q subcomponent subunit B 5 2.71E-02 Signalling and Stress Response  
HS90A Heat shock protein HSP 90-alpha 5 2.85E-02 Chaperone  
GAK Cyclin-G-associated kinase 5 2.86E-02 Vesicular Trafficking  
UCK1 Uridine-cytidine kinase 1 5 3.12E-02 Metabolism  
ES8L2 
Epidermal growth factor receptor kinase 
substrate 8-like protein 2 
4 3.29E-02 Cytoskeleton and Actin dynamics  
MOES Moesin 5 3.33E-02 Cytoskeleton and Actin dynamics  
PNCB Nicotinate phosphoribosyltransferase 5 3.34E-02 Metabolism  
MYH10 Myosin-10 5 3.59E-02 Cytoskeleton and Actin dynamics  
RBGPR 
Rab3 GTPase-activating protein non-
catalytic subunit 
5 3.65E-02 Vesicular Trafficking  
VIME Vimentin 5 3.66E-02 Cytoskeleton and Actin dynamics  
SERPH Serpin H1 5 3.81E-02 
Extracellular Organisation+ 
Chaperone 
 
RPN1 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1 
4 3.89E-02 Metabolism  
GSTT1 Glutathione S-transferase theta-1 5 3.95E-02 Redox Regulation  
TCPQ T-complex protein 1 5 3.96E-02 Chaperone  
IRAK4 Interleukin-1 receptor-associated kinase 4 5 4.24E-02 Signalling and Stress Response  
C1TC C-1-tetrahydrofolate synthase 5 4.28E-02 Metabolism  
ARC1B Actin-related protein 2/3 complex subunit 1B 5 4.28E-02 Cytoskeleton and Actin dynamics  
COPB2 Coatomer subunit beta 5 4.42E-02 Vesicular Trafficking  
FA49B Protein FAM49B 5 4.62E-02 Protein Binding  
MYH14 Myosin-14 5 4.79E-02 Cytoskeleton and Actin dynamics  
SNX1 Sorting nexin-1 4 4.81E-02 Vesicular Trafficking  
PLST Plastin-3 5 4.82E-02 Signalling and Stress Response  
GBP2 
Interferon-induced guanylate-binding protein 
2 
5 5.00E-02 Signalling and Stress Response  
SYEP Bifunctional glutamate/proline--tRNA ligase 5 5.17E-02 Translational Regulation  
TCPA T-complex protein 1 5 5.25E-02 Chaperone  
CLIC1 Chloride intracellular channel protein 1 5 5.33E-02 Ion Transport  
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Supplementary Table 4.7: Functional clustering of TG2-associated proteins identified uniquely 
in Sham-operated kidney membranes. Proteins identified as significantly associated with TG2 
uniquely in sham operated kidney membranes at 21 days post operation (p≤0.05 N≥4, marked with “U” 
in Table 4.3) were manually associated with general functional clusters depending on their main 
biological role in the cell, investigated by manual search of Protein IDs on UniProtKB database. Nuclear, 
mitochondrial and ribosomal proteins were removed from the list.   
 
TG2-associated proteins in Sham operated kidney membranes 
Protein ID Name N P Value Functional Cluster 
PRS4 26S protease regulatory subunit 4 5 5.22E-09 Ubiquitination and Proteasome  
PSME1 Proteasome activator complex subunit 1 5 8.91E-07 Ubiquitination and Proteasome  
NEDD4 E3 ubiquitin-protein ligase NEDD4 5 3.03E-05 Ubiquitination and Proteasome  
K2C1B Keratin, type II cytoskeletal 1b 4 8.40E-05 Cytoskeleton and Actin dynamics  
UN45A Protein unc-45 homolog A 5 1.04E-04 Cytoskeleton and Actin dynamics  
PRUNE Protein prune homolog 5 1.31E-04 Cell Regulation  
NIBL1 Niban-like protein 1 5 1.41E-04 Signalling and Stress Response  
PLEC Plectin 5 1.80E-04 Cytoskeleton and Actin dynamics  
PH4H Phenylalanine-4-hydroxylase 5 2.67E-04 Metabolism  
TOM1 Target of Myb protein 1 4 3.37E-04 Vesicular Trafficking  
ACY3 
N-acyl-aromatic-L-amino acid 
amidohydrolase 
4 5.54E-04 Metabolism  
DEST Destrin 5 8.51E-04 Cytoskeleton and Actin dynamics  
UB2D3 Ubiquitin-conjugating enzyme E2 D3 5 9.25E-04 Ubiquitination and Proteasome  
KAD1 Adenylate kinase isoenzyme 1 5 9.92E-04 Metabolism  
G3P 
Glyceraldehyde-3-phosphate 
dehydrogenase 
5 1.05E-03 Metabolism  
USP9X 
Probable ubiquitin carboxyl-terminal 
hydrolase FAF-X 
5 1.27E-03 Deubiquitination  
PDIA1 Protein disulfide-isomerase 4 1.40E-03 Metabolism  
CASP3 Caspase-3 4 1.42E-03 Signalling and Stress Response  
UBP24 Ubiquitin carboxyl-terminal hydrolase 24 4 1.43E-03 Deubiquitination  
MEP1A Meprin A subunit alpha 5 1.68E-03 Metabolism  
ARF6 ADP-ribosylation factor 6 5 1.88E-03 Vesicular Trafficking  
TM55B 
Type 1 phosphatidylinositol 4,5-
bisphosphate 4-phosphatase 
4 3.22E-03 Metabolism  
KCRB Creatine kinase B-type 5 4.11E-03 Metabolism  
RHEB GTP-binding protein Rheb 5 4.12E-03 Signalling and Stress Response  
ST1A1 Sulfotransferase 1A1 5 4.51E-03 Metabolism  
ANXA2 Annexin A2 5 5.38E-03 Vesicular Trafficking  
OLFM4 Olfactomedin-4 5 5.80E-03 Cell Adhesion  
IST1 IST1 homolog 5 6.01E-03 Vesicular Trafficking  
PP1A 
Serine/threonine-protein phosphatase 
PP1-alpha catalytic subunit 
4 6.08E-03 Cell Regulation  
NLTP Non-specific lipid-transfer protein 5 6.29E-03 Metabolism  
PPBT 
Alkaline phosphatase, tissue-nonspecific 
isozyme 
5 6.39E-03 Metabolism  
ENOA Alpha-enolase 4 6.90E-03 Metabolism  
FBLN1 Fibulin-1 5 7.33E-03 Cell Adhesion  
TCPG T-complex protein 1 subunit gamma 5 7.61E-03 Chaperone  
GGA1 
ADP-ribosylation factor-binding protein 
GGA1 
5 8.30E-03 Vesicular Trafficking  
IRF3 Interferon regulatory factor 3 4 8.39E-03 Signalling and Stress Response  
TBB5 Tubulin beta-5 chain 5 8.92E-03 Cytoskeleton and Actin dynamics  
FARP1 
FERM, RhoGEF and pleckstrin domain-
containing protein 1 
5 9.63E-03 Cell Regulation  
DJB11 DnaJ homolog subfamily B member 11 4 1.03E-02 Chaperone  
ARF5 ADP-ribosylation factor 5 5 1.03E-02 Vesicular Trafficking  
ARPC5 Actin-related protein 2/3 complex subunit 5 4 1.06E-02 Cytoskeleton and Actin dynamics  
ARHGC 
Rho guanine nucleotide exchange factor 
12 
5 1.10E-02 Signalling and Stress Response  
ARL2 ADP-ribosylation factor-like protein 2 5 1.14E-02 Cell Regulation  
AT1B1 
Sodium/potassium-transporting ATPase 
subunit beta-1 
5 1.21E-02 Ion Transport  
MGST3 Microsomal glutathione S-transferase 3 5 1.21E-02 Redox Regulation  
NSF Vesicle-fusing ATPase 5 1.28E-02 Vesicular Trafficking  
ARL1 ADP-ribosylation factor-like protein 1 5 1.42E-02 Cell Regulation  
AT1A1 
Sodium/potassium-transporting ATPase 
subunit alpha-1 
5 1.43E-02 Ion Transport  
CUL5 Cullin-5 5 1.43E-02 Ubiquitination and Proteasome  
VILI Villin-1 5 1.51E-02 Cytoskeleton and Actin dynamics  
S12A3 Solute carrier family 12 member 3 5 1.55E-02 Ion Transport  
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KS6A3 Ribosomal protein S6 kinase alpha-3 5 1.58E-02 Signalling and Stress Response  
TBA4A Tubulin alpha-4A chain 5 1.62E-02 Cytoskeleton and Actin dynamics  
VATA V-type proton ATPase catalytic subunit A 5 1.70E-02 Ion Transport  
SYWC Tryptophan--tRNA ligase 5 1.75E-02 Signalling and Stress Response  
CAH9 Carbonic anhydrase 9 4 1.76E-02 Metabolism  
RAC2 Ras-related C3 botulinum toxin substrate 2 5 1.85E-02 Signalling and Stress Response  
HBA Hemoglobin subunit alpha 5 1.88E-02 Metabolism  
RAB10 Ras-related protein Rab-10 5 1.98E-02 Vesicular Trafficking  
NRK1 Nicotinamide riboside kinase 1 5 2.11E-02 Metabolism  
VPS35 
Vacuolar protein sorting-associated protein 
35 
5 2.25E-02 Vesicular Trafficking  
SNX3 Sorting nexin-3 5 2.27E-02 Vesicular Trafficking  
ACSA Acetyl-coenzyme A synthetase 5 2.29E-02 Metabolism  
DNJA2 DnaJ homolog subfamily A member 2 5 2.29E-02 Chaperone  
ST1D1 Sulfotransferase 1 family member D1 5 2.40E-02 Metabolism  
ANFY1 Rabankyrin-5 5 2.42E-02 Vesicular Trafficking  
GLCTK Glycerate kinase 5 2.42E-02 Metabolism  
ARC1A 
Actin-related protein 2/3 complex subunit 
1A 
5 2.42E-02 Cytoskeleton and Actin dynamics  
PDIA6 Protein disulfide-isomerase A6 5 2.53E-02 Chaperone  
VATB2 V-type proton ATPase subunit B 5 2.59E-02 Ion Transport  
GCYA3 Guanylate cyclase soluble subunit alpha-3 5 2.67E-02 Metabolism  
LYPA2 Acyl-protein thioesterase 2 5 2.68E-02 Metabolism  
RUFY3 Protein RUFY3 4 2.72E-02 Cell Regulation  
TBC9B TBC1 domain family member 9B 5 2.78E-02 Vesicular Trafficking  
RCN1 Reticulocalbin-1 4 3.03E-02 Cell Regulation  
ARP3 Actin-related protein 3 5 3.04E-02 Cytoskeleton and Actin dynamics  
HS90B Heat shock protein HSP 90-beta 5 3.38E-02 Signalling and Stress Response  
ITM2B Integral membrane protein 2B 5 3.60E-02 Cell Regulation  
MP2K2 
Dual specificity mitogen-activated protein 
kinase kinase 2 
5 3.62E-02 Signalling and Stress Response  
DHRS4 
Dehydrogenase/reductase SDR family 
member 4 
4 3.62E-02 Metabolism  
TBA1A Tubulin alpha-1A chain 5 3.66E-02 Cytoskeleton and Actin dynamics  
IF4A1 Eukaryotic initiation factor 4A-I 5 3.68E-02 Traslational Regulation  
OXSR1 Serine/threonine-protein kinase OSR1 5 3.69E-02 Signalling and Stress Response  
CLIC4 Chloride intracellular channel protein 4 5 3.82E-02 Ion Transport  
VDAC1 
Voltage-dependent anion-selective 
channel protein 1 
5 3.87E-02 Ion Transport  
CAN2 Calpain-2 catalytic subunit 5 3.95E-02 Signalling and Stress Response  
NDRG3 Protein NDRG3 5 4.06E-02 Cell Regulation  
CLH1 Clathrin heavy chain 1 5 4.11E-02 Vesicular Trafficking  
TS101 Tumor susceptibility gene 101 protein 4 4.31E-02 Vesicular Trafficking  
DPYL3 Dihydropyrimidinase-related protein 3 5 4.39E-02 Cytoskeleton and Actin dynamics  
ISG15 Ubiquitin-like protein ISG15 5 4.53E-02 Signalling and Stress Response  
DRG2 
Developmentally-regulated GTP-binding 
protein 2 
5 4.71E-02 Cell Regulation  
RN213 E3 ubiquitin-protein ligase RNF213 4 4.73E-02 Ubiquitination and Proteasome  
BAX Apoptosis regulator BAX 5 4.73E-02 Signalling and Stress Response  
EF1A1 Elongation factor 1-alpha 1 5 5.34E-02 Traslational Regulation  
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Supplementary Table 4.8: Functional clustering of TG2-associated proteins identified in both 
UUO Sham-operated kidney membranes. Proteins identified as significantly associated with TG2 in 
both UUO and sham operated kidney membranes at 21 days post operation (p≤0.05 N≥4, marked with 
“C” in Tables 4.2 and 4.3) were manually associated with general functional clusters depending on their 
main biological role in the cell, investigated by manual search of Protein IDs on UniProtKB database. 
Nuclear, Mitochondrial and Ribosomal proteins were removed from the list.  
TG2-associated proteins in both UUO and Sham operated kidney membranes (Common) 
Protein 
ID 
Name N Sham UUO Functional Cluster 
TGM2 Transglutaminase 2 5 1.21E-04 3.31E-05 Transglutaminase  
IF4G3 Eukaryotic translation initiation factor 4 gamma 3 5 1.82E-04 1.11E-02 Traslational Regulation  
SERA D-3-phosphoglycerate dehydrogenase 5 1.85E-04 7.78E-03 Metabolism  
TERA Transitional endoplasmic reticulum ATPase 5 2.49E-04 1.21E-02 Vesicular Trafficking  
PTN6 Tyrosine-protein phosphatase non-receptor type 6 4 4.04E-04 4.84E-03 
Signalling and Stress 
Response 
 
TCPZ T-complex protein 1 5 6.52E-04 4.23E-02 Chaperone  
SPTA1 Spectrin alpha chain, erythrocytic 1 5 1.97E-03 2.92E-03 
Cytoskeleton and Actin 
dynamics 
 
SCFD1 Sec1 family domain-containing protein 1 5 4.24E-03 4.30E-02 Vesicular Trafficking  
CALM Calmodulin 5 5.39E-03 1.83E-08 Cell Regulation  
F120A Constitutive coactivator of PPAR-gamma-like protein 1 5 5.77E-03 6.27E-03 
Signalling and Stress 
Response 
 
PRDX2 Peroxiredoxin-2 4 6.07E-03 6.87E-03 Redox Regulation  
PDC6I Programmed cell death 6-interacting protein 5 6.41E-03 2.38E-02 Vesicular Trafficking  
LIMS1 
LIM and senescent cell antigen-like-containing domain 
protein 1 
5 7.55E-03 2.47E-03 
Cytoskeleton and Actin 
dynamics 
 
PGK1 Phosphoglycerate kinase 1 4 1.38E-02 5.39E-03 Metabolism  
PCKGC Phosphoenolpyruvate carboxykinase 5 2.08E-02 8.93E-04 Metabolism  
PICAL Phosphatidylinositol-binding clathrin assembly protein 4 2.73E-02 5.65E-03 Vesicular Trafficking  
IQGA1 Ras GTPase-activating-like protein IQGAP1 5 2.99E-02 1.50E-04 
Signaling and Stress 
Response 
 
PGS1 Biglycan 5 3.18E-02 1.30E-02 Extracellular Organisation  
NAMPT Nicotinamide phosphoribosyltransferase 5 3.20E-02 6.56E-04 Metabolism  
ECHP Peroxisomal bifunctional enzyme 5 3.21E-02 3.15E-02 Metabolism  
F213A Redox-regulatory protein FAM213A 5 3.76E-02 2.79E-02 
Stress Response + 
Redox Regulation 
 
LAMB2 Laminin subunit beta-2 4 4.21E-02 3.92E-02 Cell Adhesion  
FINC Fibronectin 5 4.27E-02 1.57E-02 
Cell Adhesion + 
Extracellular Organisation 
 
ADH1 Alcohol dehydrogenase 1 5 4.74E-02 9.40E-07 Metabolism  
SPTN1 Spectrin alpha chain, non-erythrocytic 1 5 5.25E-02 3.08E-02 
Cytoskeleton and Actin 
dynamics 
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S.2.4 DAVID statistical overrepresentation test on TG2-associated proteins 
in fibrotic and healthy conditions 
Supplementary Table 4.9: GO Biological Process overrepresentation test on TG2-associated 
proteins in UUO kidney membranes, performed by DAVID. Statistical overrepresentation test was 
performed by DAVID (http://david.abcc.ncifcrf.gov) using the annotation terms ontologies for Biological 
Process (GOTERM_BP_FAT). The number of proteins belonging to each annotation term and fold change 
from the expected value H0 are in increasing shades of red (the higher the more intense). The p-value is 
shown in increasing shades of blue (the more intense, the lower the p-value). A p-value lower than 0.05 
was regarded as significant. Grey arrows = Terms associated with intracellular trafficking and vesicular 
transport and enriched in UUO kidney membranes; Black arrows = terms associated with cytoskeletal 
organisation and actin binding and enriched in UUO kidney membranes.  
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Supplementary Table 4.10: GO Biological Process overrepresentation test on TG2-associated 
proteins in Sham operated kidney membranes, performed by DAVID. Statistical 
overrepresentation test was performed by DAVID (http://david.abcc.ncifcrf.gov) using the annotation 
terms ontologies for Biological Process (GOTERM_BP_FAT). The number of proteins belonging to the 
annotation term and fold change from the expected value H0 are in increasing shades of green (the higher 
the more intense). The p-value is shown in increasing shades of blue (the more intense, the lower the p-
value). A p-value lower than 0.05 was regarded as significant. * = Terms associated with intracellular 
trafficking and vesicular transport and enriched in sham operated kidney membranes; ** = terms 
associated with cytoskeletal organisation and actin binding and enriched in sham operated kidney 
membranes; o = terms associated with catalytic activity and enriched in sham operated kidney 
membranes; oo = terms associated with ion channel and enriched in sham operated kidney membranes; 
ooo = terms associated with G-proteins or Small GTPases and enriched in sham operated kidney 
membranes.  
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Supplementary Table 4.11: GO Molecular Function overrepresentation test on TG2-associated 
proteins in UUO kidney membranes, performed by DAVID. Statistical overrepresentation test was 
performed by DAVID (http://david.abcc.ncifcrf.gov) using the annotation terms ontologies for 
Molecular Function (GOTERM_MF_FAT). The number of proteins belonging to the annotation term and 
fold change from the expected value H0 are in increasing shades of red (the higher the more intense). 
The p-value is shown in increasing shades of blue (the more intense, the lower the p-value). A p-value 
lower than 0.05 was regarded as significant. Grey arrows = Terms associated with intracellular 
trafficking and vesicular transport and enriched in UUO kidney membranes; Black arrows = terms 
associated with cytoskeletal organisation and actin binding and enriched in UUO kidney membranes. 
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Supplementary Table 4.12: GO Molecular Function overrepresentation test on TG2-associated 
proteins in Sham-operated kidney membranes, performed on DAVID. Statistical 
overrepresentation test was performed by DAVID (http://david.abcc.ncifcrf.gov) using the annotation 
terms ontologies for Molecular Function (GOTERM_MF_FAT). The number of proteins belonging to the 
annotation term and fold change from the expected value H0 are in increasing shades of green (the higher 
the more intense). The p-value is shown in increasing shades of blue (the more intense, the lower the p-
value). A p-value lower than 0.05 was regarded as significant. o = terms associated with catalytic activity 
and enriched in sham operated kidney membranes; oo = terms associated with ion channel and enriched 
in sham operated kidney membranes; ooo = terms associated with G-proteins or Small GTPases and 
enriched in sham operated kidney membranes.  
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Supplementary Table 4.13: GO Cellular Component overrepresentation test on TG2-associated 
proteins in UUO kidney membranes, performed by DAVID. Statistical overrepresentation test was 
performed in DAVID (http://david.abcc.ncifcrf.gov) using the annotation terms ontologies for Cellular 
Component (GOTERM_CC_FAT). The number of proteins belonging to the annotation term and fold 
change from the expected value H0 are in increasing shades of red (the higher the more intense). The p-
value is shown in increasing shades of blue (the more intense, the lower the p-value). A p-value lower 
than 0.05 was regarded as significant. Grey arrows = Terms associated with intracellular trafficking and 
vesicular transport and enriched in UUO kidney membranes; Black arrows = terms associated with 
cytoskeletal organisation and actin binding and enriched in UUO kidney membranes. 
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Supplementary Table 4.14: GO Cellular Component overrepresentation test on TG2-associated 
proteins in UUO kidney membranes, performed by DAVID. Statistical overrepresentation test was 
performed by DAVID (http://david.abcc.ncifcrf.gov) using the annotation terms ontologies for Cellular 
Component (GOTERM_CC_FAT). The number of proteins belonging to the annotation term and fold 
change from the expected value H0 are in increasing shades of green (the higher the more intense). The 
p-value is shown in increasing shades of blue (the more intense, the lower the p-value). A p-value lower 
than 0.05 was regarded as significant. * = Terms associated with intracellular trafficking and vesicular 
transport and enriched in sham operated kidney membranes; ** = terms associated with cytoskeletal 
organisation and actin binding and enriched in sham operated kidney membranes. 
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S.2.5 Gene names corresponding to protein IDs of TG2-associated 
candidates 
Supplementary Table 4.15: Gene names corresponding to Protein IDs of TG2-associated 
candidates in UUO and/or Sham operated kidney membranes. Mouse gene names corresponding to 
the proteins IDs significantly associated with TG2 in UUO kidney membranes (p≤0.05 N≥4, reported in 
Table 4.2) and/or Sham operated kidney membranes (p≤0.05 N≥4, reported in Table 4.3).  
Gene Name Protein ID Name 
Unique/ 
Common 
Acss2 ACSA_MOUSE Acetyl-coenzyme A synthetase SHAM ONLY 
Actb ACTB_MOUSE Actin, cytoplasmic 1 UUO ONLY 
Actr3 ARP3_MOUSE Actin-related protein 3 SHAM ONLY 
Acy3 ACY3_MOUSE N-acyl-aromatic-L-amino acid amidohydrolase SHAM ONLY 
Add1 ADDA_MOUSE Alpha-adducin UUO ONLY 
Add3 ADDG_MOUSE Gamma-adducin UUO ONLY 
Adh1 ADH1_MOUSE Alcohol dehydrogenase 1 COMMON 
Ak1 KAD1_MOUSE Adenylate kinase isoenzyme 1 SHAM ONLY 
Akr7a2 ARK72_MOUSE Aflatoxin B1 aldehyde reductase member 2 UUO ONLY 
Alpl PPBT_MOUSE Alkaline phosphatase, tissue-nonspecific isozyme SHAM ONLY 
Ank3 ANK3_MOUSE Ankyrin-3 UUO ONLY 
Ankfy1 ANFY1_MOUSE Rabankyrin-5 SHAM ONLY 
Anxa2 ANXA2_MOUSE Annexin A2 SHAM ONLY 
Ap2a1 AP2A1_MOUSE AP-2 complex subunit alpha-1 UUO ONLY 
Ap2a2 AP2A2_MOUSE AP-2 complex subunit alpha-2 UUO ONLY 
Ap2b1 AP2B1_MOUSE AP-2 complex subunit beta UUO ONLY 
Arf5 ARF5_MOUSE ADP-ribosylation factor 5 SHAM ONLY 
Arf6 ARF6_MOUSE ADP-ribosylation factor 6 SHAM ONLY 
Arhgap18 RHG18_MOUSE Rho GTPase-activating protein 18 UUO ONLY 
Arhgef12 ARHGC_MOUSE Rho guanine nucleotide exchange factor 12 SHAM ONLY 
Arl1 ARL1_MOUSE ADP-ribosylation factor-like protein 1 SHAM ONLY 
Arl2 ARL2_MOUSE ADP-ribosylation factor-like protein 2 SHAM ONLY 
Arpc1a ARC1A_MOUSE Actin-related protein 2/3 complex subunit 1A SHAM ONLY 
Arpc1b ARC1B_MOUSE Actin-related protein 2/3 complex subunit 1B UUO ONLY 
Arpc5 ARPC5_MOUSE Actin-related protein 2/3 complex subunit 5 SHAM ONLY 
Atp1a1 AT1A1_MOUSE Sodium/potassium-transporting ATPase subunit alpha-1 SHAM ONLY 
Atp1b1 AT1B1_MOUSE Sodium/potassium-transporting ATPase subunit beta-1 SHAM ONLY 
Atp2a2 AT2A2_MOUSE Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 UUO ONLY 
Atp6v1a VATA_MOUSE V-type proton ATPase catalytic subunit A SHAM ONLY 
Atp6v1b2 VATB2_MOUSE V-type proton ATPase subunit B SHAM ONLY 
Atp6v1h VATH_MOUSE V-type proton ATPase subunit H UUO ONLY 
Bax BAX_MOUSE Apoptosis regulator BAX SHAM ONLY 
Bgn PGS1_MOUSE Biglycan COMMON 
C1qb C1QB_MOUSE Complement C1q subcomponent subunit B UUO ONLY 
Ca9 CAH9_MOUSE Carbonic anhydrase 9 SHAM ONLY 
Calm1 CALM_MOUSE Calmodulin COMMON 
Camk2d KCC2D_MOUSE Calcium/calmodulin-dependent protein kinase type II subunit delta UUO ONLY 
Capn1 CAN1_MOUSE Calpain1 UUO ONLY 
Capn2 CAN2_MOUSE Calpain-2 catalytic subunit SHAM ONLY 
Capza2 CAZA2_MOUSE F-actin-capping protein subunit alpha-2 UUO ONLY 
Capzb CAPZB_MOUSE F-actin-capping protein subunit beta UUO ONLY 
Casp3 CASP3_MOUSE Caspase-3 SHAM ONLY 
Cct3 TCPG_MOUSE T-complex protein 1 subunit gamma SHAM ONLY 
Cct5 TCPE_MOUSE T-complex protein 1 UUO ONLY 
Cct6a TCPZ_MOUSE T-complex protein 1 COMMON 
Cct8 TCPQ_MOUSE T-complex protein 1 UUO ONLY 
Ckb KCRB_MOUSE Creatine kinase B-type SHAM ONLY 
Clic1 CLIC1_MOUSE Chloride intracellular channel protein 1 UUO ONLY 
Clic4 CLIC4_MOUSE Chloride intracellular channel protein 4 SHAM ONLY 
Clta CLCA_MOUSE Clathrin light chain A UUO ONLY 
Cltb CLCB_MOUSE Clathrin light chain b UUO ONLY 
Cltc CLH1_MOUSE Clathrin heavy chain 1 SHAM ONLY 
Col12a1 COCA1_MOUSE Collagen alpha-1(XII) chain UUO ONLY 
Col14a1 COEA1_MOUSE Collagen alpha-1(XIV) chain UUO ONLY 
Copb2 COPB2_MOUSE Coatomer subunit beta UUO ONLY 
Coro1c COR1C_MOUSE Coronin-1C UUO ONLY 
Csnk1a1 KC1A_MOUSE Casein kinase I isoform alpha UUO ONLY 
Cul5 CUL5_MOUSE Cullin-5 SHAM ONLY 
Dbn1 DREB_MOUSE Drebrin UUO ONLY 
Dcn PGS2_MOUSE Decorin UUO ONLY 
Dctn1 DCTN1_MOUSE Dynactin subunit 1 UUO ONLY 
Dhrs4 DHRS4_MOUSE Dehydrogenase/reductase SDR family member 4 SHAM ONLY 
Dnaja2 DNJA2_MOUSE DnaJ homolog subfamily A member 2 SHAM ONLY 
Dnajb11 DJB11_MOUSE DnaJ homolog subfamily B member 11 SHAM ONLY 
Dpysl3 DPYL3_MOUSE Dihydropyrimidinase-related protein 3 SHAM ONLY 
Drg2 DRG2_MOUSE Developmentally-regulated GTP-binding protein 2 SHAM ONLY 
Dsp DESP_MOUSE Desmoplakin UUO ONLY 
Dstn DEST_MOUSE Destrin SHAM ONLY 
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Eef1a1 EF1A1_MOUSE Elongation factor 1-alpha 1 SHAM ONLY 
Ehhadh ECHP_MOUSE Peroxisomal bifunctional enzyme COMMON 
Eif4a1 IF4A1_MOUSE Eukaryotic initiation factor 4A-I SHAM ONLY 
Eif4g3 IF4G3_MOUSE Eukaryotic translation initiation factor 4 gamma 3 COMMON 
Eno1 ENOA_MOUSE Alpha-enolase SHAM ONLY 
Eprs SYEP_MOUSE Bifunctional glutamate/proline--tRNA ligase UUO ONLY 
Eps8l2 ES8L2_MOUSE Epidermal growth factor receptor kinase substrate 8-like protein 2 UUO ONLY 
FAM120A F120A_MOUSE Constitutive coactivator of PPAR-gamma-like protein 1 COMMON 
Fam129b NIBL1_MOUSE Niban-like protein 1 SHAM ONLY 
Fam213a F213A_MOUSE Redox-regulatory protein FAM213A COMMON 
Fam49b FA49B_MOUSE Protein FAM49B UUO ONLY 
Farp1 FARP1_MOUSE FERM, RhoGEF and pleckstrin domain-containing protein 1 SHAM ONLY 
Fbln1 FBLN1_MOUSE Fibulin-1 SHAM ONLY 
Flna FLNA_MOUSE Filamin-A UUO ONLY 
Flnb FLNB_MOUSE Filamin-B UUO ONLY 
Flot2 FLOT2_MOUSE Flotillin-2 UUO ONLY 
Fn1 FINC_MOUSE Fibronectin COMMON 
Gak GAK_MOUSE Cyclin-G-associated kinase UUO ONLY 
Gapdh G3P_MOUSE Glyceraldehyde-3-phosphate dehydrogenase SHAM ONLY 
Gbp2 GBP2_MOUSE Interferon-induced guanylate-binding protein 2 UUO ONLY 
Gga1 GGA1_MOUSE ADP-ribosylation factor-binding protein GGA1 SHAM ONLY 
Glrx GLRX1_MOUSE Glutaredoxin 1 UUO ONLY 
Glrx3 GLRX3_MOUSE Glutaredoxin-3 UUO ONLY 
Glyctk GLCTK_MOUSE Glycerate kinase SHAM ONLY 
Gpx1 GPX1_MOUSE Glutathione peroxidase 1 UUO ONLY 
Gsn GELS_MOUSE Gelsolin UUO ONLY 
Gstt1 GSTT1_MOUSE Glutathione S-transferase theta-1 UUO ONLY 
Gucy1a3 GCYA3_MOUSE Guanylate cyclase soluble subunit alpha-3 SHAM ONLY 
Hba HBA_MOUSE Hemoglobin subunit alpha SHAM ONLY 
Hip1 HIP1_MOUSE Huntingtin-interacting protein 1 UUO ONLY 
Hsp90aa1 HS90A_MOUSE Heat shock protein HSP 90-alpha UUO ONLY 
Hsp90ab1 HS90B_MOUSE Heat shock protein HSP 90-beta SHAM ONLY 
Hspa5 GRP78_MOUSE 78 kDa glucose-regulated protein UUO ONLY 
Hspa8 HSP7C_MOUSE Heat shock cognate 71 kDa protein UUO ONLY 
Hspb1 HSPB1_MOUSE Heat shock protein beta-1 UUO ONLY 
Hspg2 PGBM_MOUSE 
Basement membrane-specific heparan sulfate proteoglycan core protein 
(Perlecan) 
UUO ONLY 
Iqgap1 IQGA1_MOUSE Ras GTPase-activating-like protein IQGAP1 COMMON 
Irak4 IRAK4_MOUSE Interleukin-1 receptor-associated kinase 4 UUO ONLY 
Irf3 IRF3_MOUSE Interferon regulatory factor 3 SHAM ONLY 
Irgm1 IRGM1_MOUSE Immunity-related GTPase family M protein 1 UUO ONLY 
Isg15 ISG15_MOUSE Ubiquitin-like protein ISG15 SHAM ONLY 
Ist1 IST1_MOUSE IST1 homolog SHAM ONLY 
Itm2b ITM2B_MOUSE Integral membrane protein 2B SHAM ONLY 
Krt14 K1C14_MOUSE Keratin, type I cytoskeletal 14 UUO ONLY 
Krt19 K1C19_MOUSE Keratin, type I cytoskeletal 19 UUO ONLY 
Krt20 K1C20_MOUSE Keratin, type I cytoskeletal 20 UUO ONLY 
Krt6b K2C6B_MOUSE Keratin, type II cytoskeletal 6B UUO ONLY 
Krt77 K2C1B_MOUSE Keratin, type II cytoskeletal 1b SHAM ONLY 
Lamb2 LAMB2_MOUSE Laminin subunit beta-2 COMMON 
Lcp1 PLSL_MOUSE Plastin-2 UUO ONLY 
Ldha LDHA_MOUSE L-lactate dehydrogenase A chain UUO ONLY 
Lims1 LIMS1_MOUSE LIM and senescent cell antigen-like-containing domain protein 1 COMMON 
Lsp1 LSP1_MOUSE Lymphocyte-specific protein 1 UUO ONLY 
Lypla1 LYPA1_MOUSE Acyl-protein thioesterase 1 UUO ONLY 
Lypla2 LYPA2_MOUSE Acyl-protein thioesterase 2 SHAM ONLY 
Map2k2 MP2K2_MOUSE Dual specificity mitogen-activated protein kinase kinase 2 SHAM ONLY 
Mep1a MEP1A_MOUSE Meprin A subunit alpha SHAM ONLY 
Mgst3 MGST3_MOUSE Microsomal glutathione S-transferase 3 SHAM ONLY 
Msn MOES_MOUSE Moesin UUO ONLY 
Mthfd1 C1TC_MOUSE C-1-tetrahydrofolate synthase UUO ONLY 
Mvp MVP_MOUSE Major vault protein UUO ONLY 
Myh10 MYH10_MOUSE Myosin-10 UUO ONLY 
Myh14 MYH14_MOUSE Myosin-14 UUO ONLY 
Myo18a MY18A_MOUSE Unconventional myosin-XVIIIa UUO ONLY 
Myo1b MYO1B_MOUSE Unconventional myosin-Ib UUO ONLY 
Myo1d MYO1D_MOUSE Unconventional myosin-Id UUO ONLY 
Myo1g MYO1G_MOUSE Unconventional myosin-Ig UUO ONLY 
Nampt NAMPT_MOUSE Nicotinamide phosphoribosyltransferase COMMON 
Naprt PNCB_MOUSE Nicotinate phosphoribosyltransferase UUO ONLY 
Ndrg3 NDRG3_MOUSE Protein NDRG3 SHAM ONLY 
Nedd4 NEDD4_MOUSE E3 ubiquitin-protein ligase NEDD4 SHAM ONLY 
Nmrk1 NRK1_MOUSE Nicotinamide riboside kinase 1 SHAM ONLY 
Nsf NSF_MOUSE Vesicle-fusing ATPase SHAM ONLY 
Olfm4 OLFM4_MOUSE Olfactomedin-4 SHAM ONLY 
Oxsr1 OXSR1_MOUSE Serine/threonine-protein kinase OSR1 SHAM ONLY 
P4hb PDIA1_MOUSE Protein disulfide-isomerase SHAM ONLY 
Pah PH4H_MOUSE Phenylalanine-4-hydroxylase SHAM ONLY 
Paics PUR6_MOUSE Multifunctional protein ADE2 UUO ONLY 
Pck1 PCKGC_MOUSE Phosphoenolpyruvate carboxykinase COMMON 
Pdcd6ip PDC6I_MOUSE Programmed cell death 6-interacting protein COMMON 
Pdia6 PDIA6_MOUSE Protein disulfide-isomerase A6 SHAM ONLY 
Pdlim5 PDLI5_MOUSE PDZ and LIM domain protein 5 UUO ONLY 
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Pfkp K6PP_MOUSE ATP-dependent 6-phosphofructokinase, platelet type UUO ONLY 
Pfn1 PROF1_MOUSE Profilin-1 UUO ONLY 
Pgk1 PGK1_MOUSE Phosphoglycerate kinase 1 COMMON 
Phgdh SERA_MOUSE D-3-phosphoglycerate dehydrogenase COMMON 
Picalm PICAL_MOUSE Phosphatidylinositol-binding clathrin assembly protein COMMON 
Plec PLEC_MOUSE Plectin SHAM ONLY 
Pls3 PLST_MOUSE Plastin-3 UUO ONLY 
Postn POSTN_MOUSE Periostin UUO ONLY 
Ppp1ca PP1A_MOUSE Serine/threonine-protein phosphatase PP1-alpha catalytic subunit SHAM ONLY 
Ppp1r9b NEB2_MOUSE Neurabin-2 UUO ONLY 
Prdx2 PRDX2_MOUSE Peroxiredoxin-2 COMMON 
Prune PRUNE_MOUSE Protein prune homolog SHAM ONLY 
Psmc1 PRS4_MOUSE 26S protease regulatory subunit 4 SHAM ONLY 
Psmd11 PSD11_MOUSE 26S proteasome non-ATPase regulatory subunit 11 UUO ONLY 
Psme1 PSME1_MOUSE Proteasome activator complex subunit 1 SHAM ONLY 
Ptpn6 PTN6_MOUSE Tyrosine-protein phosphatase non-receptor type 6 COMMON 
Rab10 RAB10_MOUSE Ras-related protein Rab-10 SHAM ONLY 
Rab1A RAB1A_MOUSE Ras-related protein Rab-1A UUO ONLY 
Rab3gap2 RBGPR_MOUSE Rab3 GTPase-activating protein non-catalytic subunit UUO ONLY 
Rac2 RAC2_MOUSE Ras-related C3 botulinum toxin substrate 2 SHAM ONLY 
Rcn1 RCN1_MOUSE Reticulocalbin-1 SHAM ONLY 
Rheb RHEB_MOUSE GTP-binding protein Rheb SHAM ONLY 
Rnf213 RN213_MOUSE E3 ubiquitin-protein ligase RNF213 SHAM ONLY 
Rpn1 RPN1_MOUSE Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 UUO ONLY 
Rps6ka3 KS6A3_MOUSE Ribosomal protein S6 kinase alpha-3 SHAM ONLY 
Rtn4 RTN4_MOUSE Reticulon-4 UUO ONLY 
Rufy3 RUFY3_MOUSE Protein RUFY3 SHAM ONLY 
Sar1b SAR1B_MOUSE GTP-binding protein SAR1b UUO ONLY 
Scfd1 SCFD1_MOUSE Sec1 family domain-containing protein 1 COMMON 
Scp2 NLTP_MOUSE Non-specific lipid-transfer protein SHAM ONLY 
Sdc4 SDC4_MOUSE Syndecan-4 UUO ONLY 
Serpinh1 SERPH_MOUSE Serpin H1 UUO ONLY 
Slc12a3 S12A3_MOUSE Solute carrier family 12 member 3 SHAM ONLY 
Sntb2 SNTB2_MOUSE Beta-2-syntrophin UUO ONLY 
Snx1 SNX1_MOUSE Sorting nexin-1 UUO ONLY 
Snx3 SNX3_MOUSE Sorting nexin-3 SHAM ONLY 
Snx4 SNX4_MOUSE Sorting nexin-4 UUO ONLY 
Spna1 SPTA1_MOUSE Spectrin alpha chain, erythrocytic 1 COMMON 
Spna2 SPTN1_MOUSE Spectrin alpha chain, non-erythrocytic 1 COMMON 
Spnb1 SPTB1_MOUSE Spectrin beta chain, erythrocytic UUO ONLY 
Sult1a1 ST1A1_MOUSE Sulfotransferase 1A1 SHAM ONLY 
Sult1d1 ST1D1_MOUSE Sulfotransferase 1 family member D1 SHAM ONLY 
Svil SVIL_MOUSE Supervillin UUO ONLY 
Tbc1d9b TBC9B_MOUSE TBC1 domain family member 9B SHAM ONLY 
Tcp1 TCPA_MOUSE T-complex protein 1 UUO ONLY 
Tgm2 TGM2_MOUSE Transglutaminase 2 COMMON 
Tjp1 ZO1_MOUSE Tight junction protein ZO-1 UUO ONLY 
Tln2 TLN2_MOUSE Talin-2 UUO ONLY 
Tmem55b TM55B_MOUSE Type 1 phosphatidylinositol 4,5-bisphosphate 4-phosphatase SHAM ONLY 
Tom1 TOM1_MOUSE Target of Myb protein 1 SHAM ONLY 
Tsg101 TS101_MOUSE Tumor susceptibility gene 101 protein SHAM ONLY 
Tuba1a TBA1A_MOUSE Tubulin alpha-1A chain SHAM ONLY 
Tuba4a TBA4A_MOUSE Tubulin alpha-4A chain SHAM ONLY 
Tubb5 TBB5_MOUSE Tubulin beta-5 chain SHAM ONLY 
Ube2d3 UB2D3_MOUSE Ubiquitin-conjugating enzyme E2 D3 SHAM ONLY 
Uck1 UCK1_MOUSE Uridine-cytidine kinase 1 UUO ONLY 
Unc45a UN45A_MOUSE Protein unc-45 homolog A SHAM ONLY 
Usp24 UBP24_MOUSE Ubiquitin carboxyl-terminal hydrolase 24 SHAM ONLY 
Usp5 UBP5_MOUSE Ubiquitin carboxyl-terminal hydrolase 5 UUO ONLY 
Usp9x USP9X_MOUSE Probable ubiquitin carboxyl-terminal hydrolase FAF-X SHAM ONLY 
Vcp TERA_MOUSE Transitional endoplasmic reticulum ATPase COMMON 
Vdac1 VDAC1_MOUSE Voltage-dependent anion-selective channel protein 1 SHAM ONLY 
Vil1 VILI_MOUSE Villin-1 SHAM ONLY 
Vim VIME_MOUSE Vimentin UUO ONLY 
Vps35 VPS35_MOUSE Vacuolar protein sorting-associated protein 35 SHAM ONLY 
Wars SYWC_MOUSE Tryptophan--tRNA ligase SHAM ONLY 
Ykt6 YKT6_MOUSE Synaptobrevin homolog YKT6 UUO ONLY 
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S.2.6 Search for TG2-associated partners in kidney fibrotic membranes on 
the Exocarta database 
Supplementary Table 4.16: Analysis of presence of the TG2-associated proteins in kidney fibrotic 
membranes on the Exocarta database of exosomal proteins. The TG2-associated proteins identified 
in kidney fibrotic membranes were manually searched on the Exocarta database 
(http://www.exocarta.org/) of exosomal proteins in four different species: Homo sapiens, Mus musculus, 
Rattus norvegicus and Bos taurus. * = Identified only at mRNA level in the species.  
 
TG2 associated candidates in UUO Found in Exosomes 
Sample ID Name p value N 
Homo 
Sapiens 
Mus 
Muscus 
Rattus 
Norvegicus 
Bos 
Taurus 
DESP_MOUSE Desmoplakin 1.22E-13 5     
HSP7C_MOUSE Heat shock cognate 71 kDa protein 7.67E-10 5     
CALM_MOUSE Calmodulin 1.83E-08 5     
CAZA2_MOUSE F-actin-capping protein subunit alpha-2 1.97E-08 5     
GPX1_MOUSE Glutathione peroxidase 1 4.52E-07 5     
ADH1_MOUSE 
Alcohol dehydrogenase 
1;Adh1;ortholog 
9.40E-07 5     
POSTN_MOUSE Periostin 1.03E-06 4     
MYO1D_MOUSE Unconventional myosin-Id 3.52E-06 5     
GLRX1_MOUSE Glutaredoxin 1 5.61E-06 4     
GLRX3_MOUSE Glutaredoxin-3 1.40E-05 5     
PROF1_MOUSE Profilin-1 1.89E-05 5     
TGM2_MOUSE Transglutaminase 2 3.31E-05 5     
HSPB1_MOUSE Heat shock protein beta-1 3.68E-05 5     
VATH_MOUSE V-type proton ATPase subunit H 5.98E-05 5     
ADDG_MOUSE Gamma-adducin 6.66E-05 5     
AT2A2_MOUSE 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 
8.58E-05 5     
SVIL_MOUSE Supervillin;Svil;ortholog 1.01E-04 4     
COR1C_MOUSE Coronin-1C 1.38E-04 5     
IQGA1_MOUSE 
Ras GTPase-activating-like protein 
IQGAP1 
1.50E-04 5     
TCPE_MOUSE T-complex protein 1 3.17E-04 5     
UBP5_MOUSE Ubiquitin carboxyl-terminal hydrolase 5 4.59E-04 5     
FLOT2_MOUSE Flotillin-2 5.38E-04 4     
NAMPT_MOUSE 
Nicotinamide 
phosphoribosyltransferase 
6.56E-04 5     
PCKGC_MOUSE Phosphoenolpyruvate carboxykinase 8.93E-04 5     
RAB1A_MOUSE Ras-related protein Rab-1A 9.16E-04 5     
SDC4_MOUSE Syndecan 4 9.34E-04 5     
LDHA_MOUSE L-lactate dehydrogenase A  1.04E-03 4     
MYO1G_MOUSE Unconventional myosin-Ig 1.21E-03 5     
K1C20_MOUSE 
Keratin, type I cytoskeletal 
20;Krt20;ortholog 
1.35E-03 4     
COEA1_MOUSE Collagen alpha-1(XIV) chain 1.64E-03 5     
COCA1_MOUSE Collagen alpha-1(XII) chain 1.68E-03 4     
HIP1_MOUSE Huntingtin-interacting protein  1.86E-03 4     
LIMS1_MOUSE 
LIM and senescent cell antigen-like-
containing domain protein 1 
2.47E-03 5     
SAR1B_MOUSE GTP-binding protein SAR1b 2.79E-03 5     
SPTA1_MOUSE Spectrin alpha chain, erythrocytic 1 2.92E-03 5     
FLNA_MOUSE Filamin-A 2.98E-03 5     
ANK3_MOUSE Ankyrin-3 3.03E-03 5  *   
PSD11_MOUSE 
26S proteasome non-ATPase 
regulatory subunit 11 
3.09E-03 5     
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PGBM_MOUSE 
Basement membrane-specific heparan 
sulfate proteoglycan core protein 
(perlecan) 
3.16E-03 5     
LSP1_MOUSE Lymphocyte-specific protein 1 3.53E-03 5     
GELS_MOUSE Gelsolin 4.61E-03 5     
YKT6_MOUSE 
Synaptobrevin homolog 
YKT6;Ykt6;ortholog 
4.72E-03 5     
PTN6_MOUSE 
Tyrosine-protein phosphatase non-
receptor type 6 
4.84E-03 4     
FLNB_MOUSE Filamin-B 5.03E-03 5     
TLN2_MOUSE Talin-2 5.28E-03 5     
PGK1_MOUSE Phosphoglycerate kinase 1 5.39E-03 4     
PICAL_MOUSE 
Phosphatidylinositol-binding clathrin 
assembly protein 
5.65E-03 4     
F120A_MOUSE 
Constitutive coactivator of PPAR-
gamma-like protein 1 
6.27E-03 5     
PRDX2_MOUSE Peroxiredoxin-2 6.87E-03 4     
KCC2D_MOUSE 
Calcium/calmodulin-dependent protein 
kinase type II subunit delta 
7.10E-03 5     
RTN4_MOUSE Reticulon-4;Rtn4;ortholog 7.57E-03 5     
SERA_MOUSE D-3-phosphoglycerate dehydrogenase 7.78E-03 5     
KC1A_MOUSE Casein kinase I isoform alpha 8.06E-03 5     
DCTN1_MOUSE Dynactin subunit 1 8.52E-03 5     
ADDA_MOUSE Alpha-adducin 8.61E-03 5     
PGS2_MOUSE Decorin 1.09E-02 5     
IF4G3_MOUSE 
Eukaryotic translation initiation factor 4 
gamma 3 
1.11E-02 5     
RHG18_MOUSE Rho GTPase-activating protein 18 1.11E-02 4     
CAPZB_MOUSE F-actin-capping protein subunit beta 1.11E-02 5     
MVP_MOUSE Major vault protein 1.14E-02 5     
TERA_MOUSE 
Transitional endoplasmic reticulum 
ATPase 
1.21E-02 5     
ACTB_MOUSE Actin, cytoplasmic 1 1.24E-02 5     
PGS1_MOUSE Biglycan 1.30E-02 5     
K1C14_MOUSE Keratin, type I cytoskeletal 14 1.33E-02 5     
PLSL_MOUSE Plastin-2 1.34E-02 5     
AP2A2_MOUSE AP-2 complex subunit alpha-2 1.52E-02 5     
FINC_MOUSE Fibronectin 1.57E-02 5     
CLCB_MOUSE Clathrin light chain b 1.65E-02 5     
SNX4_MOUSE Sorting nexin-4 1.67E-02 5     
SPTB1_MOUSE Spectrin beta chain, erythrocytic 1.73E-02 5     
ZO1_MOUSE Tight junction protein ZO-1 1.79E-02 4     
DREB_MOUSE Drebrin 1.83E-02 5     
CAN1_MOUSE Calpain1 1.84E-02 5     
PDLI5_MOUSE PDZ and LIM domain protein 5 1.85E-02 5     
PUR6_MOUSE Multifunctional protein ADE2 1.88E-02 5     
MY18A_MOUSE Unconventional myosin-XVIIIa 1.93E-02 5     
CLCA_MOUSE Clathrin light chain A 2.07E-02 5     
IRGM1_MOUSE 
Immunity-related GTPase family M 
protein 1 
2.09E-02 5     
NEB2_MOUSE Neurabin-2 2.11E-02 5     
K2C6B_MOUSE Keratin, type II cytoskeletal 6B 2.14E-02 5     
AP2A1_MOUSE AP-2 complex subunit alpha-1 2.15E-02 5     
LYPA1_MOUSE Acyl-protein thioesterase 1 2.18E-02 5     
PDC6I_MOUSE 
Programmed cell death 6-interacting 
protein 
2.38E-02 5     
AP2B1_MOUSE AP-2 complex subunit beta 2.43E-02 5     
K1C19_MOUSE Keratin, type I cytoskeletal 19 2.58E-02 5     
GRP78_MOUSE 78 kDa glucose-regulated protein 2.59E-02 5     
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ARK72_MOUSE 
Aflatoxin B1 aldehyde reductase 
member 2 
2.61E-02 5     
SNTB2_MOUSE Beta-2-syntrophin 2.63E-02 5     
MYO1B_MOUSE Unconventional myosin-Ib 2.67E-02 5     
K6PP_MOUSE 
ATP-dependent 6-
phosphofructokinase, platelet type 
2.67E-02 5     
C1QB_MOUSE 
Complement C1q subcomponent 
subunit B 
2.71E-02 5     
F213A_MOUSE Redox-regulatory protein FAM213A 2.79E-02 5     
HS90A_MOUSE Heat shock protein HSP 90-alpha 2.85E-02 5     
GAK_MOUSE Cyclin-G-associated kinase 2.86E-02 5     
SPTN1_MOUSE Spectrin alpha chain, non-erythrocytic 1 3.08E-02 5     
UCK1_MOUSE Uridine-cytidine kinase 1 3.12E-02 5     
ECHP_MOUSE Peroxisomal bifunctional enzyme 3.15E-02 5     
ES8L2_MOUSE 
Epidermal growth factor receptor 
kinase substrate 8-like protein 2 
3.29E-02 4     
MOES_MOUSE Moesin 3.33E-02 5     
PNCB_MOUSE Nicotinate phosphoribosyltransferase 3.34E-02 5     
MYH10_MOUSE Myosin-10 3.59E-02 5     
RBGPR_MOUSE 
Rab3 GTPase-activating protein non-
catalytic subunit 
3.65E-02 5     
VIME_MOUSE Vimentin 3.66E-02 5     
SERPH_MOUSE Serpin H1 3.81E-02 5     
RPN1_MOUSE 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 1 
3.89E-02 4     
LAMB2_MOUSE Laminin subunit beta-2 3.92E-02 4     
GSTT1_MOUSE Glutathione S-transferase theta-1 3.95E-02 5     
TCPQ_MOUSE T-complex protein 1 3.96E-02 5     
TCPZ_MOUSE T-complex protein 1 4.23E-02 5     
IRAK4_MOUSE 
Interleukin-1 receptor-associated 
kinase 4 
4.24E-02 5     
C1TC_MOUSE 
C-1-tetrahydrofolate synthase, 
cytoplasmic 
4.28E-02 5     
ARC1B_MOUSE 
Actin-related protein 2/3 complex 
subunit 1B 
4.28E-02 5     
SCFD1_MOUSE 
Sec1 family domain-containing protein 
1 
4.30E-02 5     
COPB2_MOUSE Coatomer subunit beta' 4.42E-02 5     
FA49B_MOUSE Protein FAM49B;Fam49b;ortholog 4.62E-02 5     
MYH14_MOUSE Myosin-14 4.79E-02 5     
SNX1_MOUSE Sorting nexin-1 4.81E-02 4     
PLST_MOUSE Plastin-3 4.82E-02 5     
GBP2_MOUSE 
Interferon-induced guanylate-binding 
protein 2 
5.00E-02 5   *  
SYEP_MOUSE 
Bifunctional glutamate/proline--tRNA 
ligase 
5.17E-02 5     
TCPA_MOUSE T-complex protein 1 5.25E-02 5     
CLIC1_MOUSE Chloride intracellular channel protein 1 5.33E-02 5     
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S.2.7 Comparison between TG2-associated proteins in healthy kidney 
membranes and the proteomic analysis on the UUO model 
Supplementary Table 4.17. Comparison of TG2 interactome in Sham operated kidney 
membranes with the UUO Proteome: To see if the proteins significantly associated with TG2 in sham 
operated conditions were significantly altered in the healthy mice, the two analysis in were combined in 
this heat-map table. On the left side, the list of TG2-associated proteins in Sham operated kidney 
membranes (21 days); in scale of blue, the p-value of TG2 association as calculated by z-test. A p-value 
≤0.05 was regarded as significant. On the right, the fold change from sham and confidence values for the 
same proteins in the UUO proteomic analysis performed on whole tissue; in red, the positive fold change 
(FC) in the UUO, that means overexpression, and in green the negative fold change, that means 
underexpression. In yellow, the level of confidence of this second analysis, bright yellow ≥ 0.8 and light 
yellow 0.5 ≤ C < 0.8.  A confidence ≥ 0.8 was considered as significant. Legend: U=Unique; C= Common 
(associated with TG2 in both UUO and Sham operated mice).  
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S.3 SUPPLEMENTARY DATA FOR CHAPTER V  
S.3.1 Characterization of stable EGFP-TG2 overexpressing clones employed 
in this study 
In some experiments, a stable cell line of NRK52E clones overexpressing EGFP-tagged TG2 was 
employed (referred as EGFP-TG2 overexpressing clones or EGFP-TG2 clones). These clones 
were produced in Dr Verderio laboratory (NTU) by former research assistant Raghavendran 
Ramaswamy, by stably transfecting NRK52E cells with a specific pEGFP-N1-TG2 plasmid 
(Appendix, Fig. II), expressing a human TG2 cDNA chimeric protein with a C-terminal EGFP 
tag of 100 kDa size, with green fluorescence.  
These clones have already been fully characterized in Dr Verderio laboratory (NTU) and Prof 
Johnson laboratory (University of Sheffield) for a study of TG2 trafficking: they express an 
elevated level of exogenous EGFP-TG2 chimera antigen and transamidation activity, and they 
show a high TG2 export with a reaction to fibrotic stimuli that is comparable with the wild type 
(WT) cells (Huang et. al, unpublished). For the aims of this thesis, characterisation of TG2 
expression and activity was repeated in the clones employed to confirm the preservation of 
their characteristics.   
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Supplementary Figure 5.1: Characterisation of EGFP-TG2 overexpressing clones employed in this 
thesis. Stable EGFP-TG2 overexpressing clones #C5 and #E6, together with stable clones expressing 
EGFP alone (#B10 and #F3) and NRK52E WT cells, were cultured  as described in the general methods 
[2.2.1.2]. To maintain selection on stable clones, 700 µg/ml G418 (Geneticin) were added to the medium 
(A) Equal amounts of total protein lysates were separated by 12% (w/v) acrylamide/bis-acrylamide 
SDS PAGE and the expression  of TG2 and EGFP were analysed by Western blot using a rabbit polyclonal 
anti-TG2 antibody (ab80563, Abcam, dilution 1:1000) or an anti-EGFP antibody (ab290, Abcam, dilution 
1:2500). Actin (A2066, Sigma) was employed as a loading control. Immunoreactive bands were detected 
by enhanced chemiluminescence after incubation with appropriate donkey anti-rabbit IgG HRP-
conjugated secondary antibody  in blocking buffer. (B) Total TG2 was measured by biotin-cadaverine 
incorporation assay performed on equal amounts of total cell lysate (60 µg) in triplicates  as described 
in 2.2.8.1, and TG2 activity was detected through the enzyme’s ability of incorporating biotin-cadaverine 
into fibronectin for 2 h. The values are the average Abs (450 nm) of three independent experiments, 
each undertaken in triplicates, normalised for the WT control (equalised to 1) ± SD. (C) Extracellular 
TG2 was measured by biotin-cadaverine incorporation assay performed on 20,000 cells/well for 2 h as 
described in 2.2.8.2. Values are the average Abs (450 nm) of three or six independent experiments, each 
undertaken in triplicates, normalised for the WT control (equalised to 1) ±SD. Significance of the 
differences between treatments was determined by T-test: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = 
p<0.0001. 
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S.3.2 Optimisation of the experimental conditions 
S.3.2.1 Optimal number of cells for LDH cytotoxicity assay 
 
Supplementary Figure 5.2: Optimal number of cells/well for LDH cytotoxicity assay performed in 
a 96-well plate. In order to determine the optimal number of cells to employ using Pierce™ LDH 
cytotoxicity assay kit (Thermo Scientific), a serial dilution (0; 5,000; 10,000 and 20,000 cells/well)  of 
NRK52E cells (WT) and EGFP-TG2 overexpressing clone #C5 (C5) was seeded in a 96 well plate and 
cultured overnight (15 h). The day after medium was collected, or cells were lysed before medium 
collection following the manufacturer’s guidelines. Spontaneous and maximum LDH release in the 
medium was measured following the manufacturer’s protocol as described in 2.2.1.7. (A) Spontaneous 
and maximum LDH release was measured as Abs 490 nm – Abs 680 nm in both cell lines (WT and C5) at 
different concentration as well as in cell free serum free medium (SFM). A positive control provided by 
the kit was included. Data represent mean LDH release calculated as mean Abs 490 nm- mean Abs 680 
nm of three replicas, ±SD. (B) From the results, maximum LDH release – spontaneous LDH release ±SD 
was calculated for each initial cell concentration, and the optimal number of cells to employ for 
cytotoxicity assay was selected within the area of linear growth. 7,500 cells/well was chosen for the 
subsequent experiments.  
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S.3.2.2 Optimisation of conditions for extracellular TG2 activity assay 
 
 
Supplementary Figure 5.3: Optimisation of extracellular TG2 activity assay in NRK52E WT cells. 
NRK52E WT cells were cultured in T75 flask until 80% confluent and detached with a trypsin-free buffer 
[5 mM EDTA in sterile PBS pH7.4] in gentle shaking at 37°C. (A) Extracellular TG2 activity was measured 
through the enzyme’s ability of incorporating biotin cadaverine in fibronectin by 6,250 - 100,000 living 
cells/well (= 62,500 – 1 million living cells/ml) for 2 h as described in the general methods [2.2.9.2]. A 
number of 20,000 cells/well was chosen for the subsequent experiments (B) Extracellular TG2 activity 
was measured with the same method on 20,000 living cells/well for 2 h in presence or absence of DTT 
as reducing agent. Values are the average Abs (450 nm) of three replicas, normalised for the relative 
mock transfected control (equalised to 1) ± SD. Significance of the differences between treatments was 
determined by T-test: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
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S.3.3 Supplementary data for extracellular EGFP-TG2 immunofluorescent 
staining 
 
Supplementary Figure 5.4: Support data to the extracellular EGFP-TG2 immunofluorescent 
staining.  (A) EGFP-TG2 overexpressing NRK52E cells were grown in an 8 well chamber slide until 80% 
confluent, then medium was replaced with complete medium ± 10 ng/ml TGF-β1 for 16 h. Extracellular 
EGFP-TG2 chimera was detected on fixed (3%PFA) but not permeabilised cells using a rabbit polyclonal 
anti-GFP antibody (Abcam) followed by a donkey anti-rabbit Alexa Fluor® 568 antibody, with red 
fluorescence. Nuclei were stained with DAPI. Specimens (20 μm) where scanned by confocal microscopy 
every μm. Pictures are showing the staining of EGFP-TG2 from the apex to the basal level. (B) As a 
control, rabbit polyclonal anti-GFP antibody (Abcam) was omitted from the experiment, and fixed 
(3%PFA) but not permeabilised cells were incubated with only donkey anti-rabbit Alexa Fluor® 568 
antibody, with red fluorescence. Absence of the red signal after washing confirmed the specificity of the 
red staining observed in the experiments.  
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S.4 SUPPLEMENTARY DATA FOR CHAPTER VI 
S.4.1 Quality of the plasmid employed 
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Supplementary Figure 6.1: Quality control of mammalian expression vectors employed for 
transient transfection of rat TECs. (A) Restriction digestion of 1 µg pcDNA3_HA-Sdc4 and 
pcDNA3.1(+)Sdc4 purified plasmids following the general protocol reported in chapter II. pcDNA3_HA-
Sdc4 plasmid was digested using NdeI restriction enzyme (Promega) for 2 h at 37°C. pcDNA3 empty 
vector has only one restriction site for NdeI (cuts at 487-88); insertion of HA-Sdc4 the correct 
orientation introduces another NdeI restriction site, present on the N-terminal HA-tag (Appendix Fig. 
I), resulting band at 5527 bp and a lower band at 522 bp. As pcDNA3 empty vector has only one 
restriction site for NdeI (cuts at 487-88), insertion of HA-Sdc4 with the right orientation introduces 
another NdeI site, present on the HA-tag, resulting in two bands at 522 bp and 5527 bp upon digestion.  
pcDNA3.1(+)Sdc4 plasmid was digested using EcoRI and XhoI restriction enzymes (corresponding to 
cloning sites for Sdc4 cDNA, see Suppl. Figure 1B) for 2 h at 37°C. Expected bands are 5428 bp and 630 
bp. In both cases, the uncut plasmid was used as a control. The picture shows the product of the 
restriction digestion, separated by electrophoresis on 1.5% (w/v) agarose gel. For both plasmids, band 
comparison with standard DNA of known size (1Kb standard ladder, Promega) confirmed the presence 
of the insert and its right orientation. pcDNA3_HA-Sdc4 and pcDNA3.1(+)Sdc4 plasmids were produced 
by Dr Izhar Burhan and Dr Alessandra Scarpellini, respectively, starting from Sdc4cDNA and HA-Sdc4 
cDNA provided by Dr Mark Bass (The University of Sheffield). (B) Restriction digestion of pEGFP-N1 
empty plasmid and pEGFP-N1-TG2 (WT or Heparin binding mutants) plasmids: 1 µg of purified plasmid 
was digested using restriction enzyme EcoRI or the combination of EcoRV and XhoI. EcoRI restriction 
site is the cloning site of the plasmid used for the introduction of the insert, digestion with this enzyme 
was used to confirm the presence of the insert, producing expected bands of 4733 bp (plasmid) and 
2068 bp (TG2 cDNA insert)(Appendix Fig.II). Digestion with EcoRV and XhoI is instead used confirm 
the correct orientation of TG2 with EGFP. If the orientation is right the expected bands are 5456 bp and 
1345 bp. In all cases, the uncut plasmid was employed as a control. The picture shows the product of the 
restriction digestion, separated by electrophoresis on 1.5% (w/v) agarose gel. For all plasmids, band 
comparison with standard DNA of known size (1Kb standard ladder, Promega) confirmed the presence 
of the insert and its right orientation. (C) Confirmation of the heparin binding site mutation in pEGFP-
N1-EGFP-TG2(M1c) and pEGFP-N1-EGFP-TG2(M3) plasmids was performed by sequence alignment 
with wild-type full length TG2 cDNA: 100 ng/ul purified plasmids in 10 mM Tris HCl pH 8.5 were 
sequenced by Source Bioscience Sequencing (Nottingham UK). Sequencing results were aligned to wild 
type full length TG2 cDNA on ClustalW2 (EMBL-EBI) bioinformatics source. 
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S.4.2 Quality control and optimisation of transfections and treatments  
 
 
Supplementary Figure 6.2: Expression of HA-Tag and Sdc4 in NRK52E cells transfected with 
pcDNA3_HA-Sdc4 or pcDNA3.1(+)_Sdc4. (A) 1 million NRK52E WT cells were transfected by 
electroporation using 5 µg of either pcDNA3_HA-Sdc4 for 24 or 72 h. Mock transfected cells (24 h) were 
used as a control. Equal amounts of cell lysates (10 µg) were separated by 10% SDS-PAGE and 
immunoprobed with rabbit polyclonal anti-HA (Cell Technologies, dilution 1:1000) followed by Goat 
anti Rabbit IgG conjugated to HRP (Dako, dilution 1:2500). The immunoreactive bands were visualised 
by chemiluminescence after addition of ECL reagent (Biological Industries). 20 µg of proteins from the 
24 h transfected lysate were also screened for the expression of Sdc4 using a rabbit polyclonal anti-Sdc4 
antibody followed by goat anti-rabbit IgG conjugated to HRP. Image acquisition was performed with a 
LAS4000 imaging system (GE Heathcare). A representative blot is shown. (B) 200,000 NRK52E WT cells 
were transfected by electroporation with human Sdc4 cDNA using 5 µg of either pcDNA3_HA-Sdc4 or 
pcDNA3.1(+)_Sdc4 plasmid and seeded in an 8-well chamber slide. 48 h after transfection, cells were 
fixed (3%PFA/10 min) and immunostained with either a rabbit polyclonal anti-HA (C29F4, Cell 
Signalling Technology– dilution 1:500) in case of pcDNA3_HA-Sdc4 – transfected cells, or a rabbit 
polyclonal anti Sdc4 antibody (ab24511, Abcam -dilution 1:50) in case of pcDNA3.1(+)_Sdc4 – 
transfected cells.  Both antibodies were followed by a donkey anti-rabbit IgG H&L Alexa Fluor® 488 
antibody (dilution 1:1000), with green fluorescence, to detect cell surface HA-Sdc4 or cell surface Sdc4. 
Specimens (20 μm) where scanned by confocal microscopy every µm, and each picture combines all the 
20 levels observed. Representative pictures at 100X magnification are showed.  
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Supplementary Figure 6.3: Efficiency of NRK52E transfections. 1 million NRK52E WT cells were 
transfected by electroporation with 5 µg of pEGFP-N1 plasmid and seeded in a 6-well plate. 48 h after 
transfection, cells were detached, and ~20 µl of suspension was placed on a glass slide for direct 
observation by confocal microscopy. Specimens at 10X magnification were collected and transfection 
efficiency calculated as number of EGFP-expressing cells (green) over the total number of cells observed 
under bright light (bright field). Transfection efficiency was calculated as being typically between 60 and 
80%  
 
Supplementary Figure 6.4: Verification of an adequate knock down of Sdc4 from NRK52E cells by 
siRNA transfection. NRK52E WT cells were transfected once (single transfection for 24 h) or twice 
(double transfection for 24 h each) with 100 nM Rat Sdc4 – targeting siRNA as described in 6.3.4. The 
same cells transfected with 100 nM non-targeting scrambled siRNA were used as control. The relative 
expression of Sdc4 mRNA was measured by qRT-PCR (Table 4) by 2-ΔΔCt relative quantification method 
(CyclophilinA was employed as housekeeping gene). The experiment was performed in triplicates. 
Significance of the differences between treatments was determined by T-test: * = p<0.05, ** = p<0.01, 
*** = p<0.001, **** = p<0.0001. 
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Supplementary Figure 6.5: Analysis of Surfen effect on cell permeability/leakage and TG2 
expression. NRK52E WT and EGFP-TG2 overexpressing (clones #C5) cells were cultured in normal 
conditions until 80% confluent. At this stage, cells were incubated with 3 - 12 µM Surfen in serum free 
medium for 2 h at 37°C or for 10 min on ice. Incubation with serum free medium only was employed as 
a control. (A) After incubation, cell permeability was measured by LDH assay as described in the general 
methods (Chapter II). Data are presented as spontaneous LDH release (Abs  490 nm – Abs 680 nm) at 
each concentration for each cell line ± SD. Significance of the differences between treatments was 
determined by T-test: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. (B) After incubation with 
12 µM Surfen in serum free medium for 2 h at 37°C, equal amounts of protein lysate (35 µg) were 
separated by 10% SDS PAGE and immunoprobed with a rabbit polyclonal anti-TG2 antibody (ab80563, 
Abcam, dilution 1:1000) as well as with a rabbit polyclonal anti-β-tubulin antibody (ab6046 Abcam, 
dilution 1:5000), as a loading control. Immunoreactive bands were detected by enhanced 
chemiluminescence as described in the general methods after incubation with appropriate goat anti-
rabbit IgG HRP-conjugated secondary antibody (dilution 1:2000, Dako) in blocking buffer. Image 
acquisition was performed with a LAS4000 imaging system (GE Healthcare). Molecular weight of human 
TG2 immunoreactive bands is  ~75kDa (arrowhead).  
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Supplementary Figure 6.6: Efficiency of NRK52E TECs transfection with heparin binding mutant 
TG2 cDNA by employment of pEGFP-N1 plasmids. (A) 200,000 NRK52E WT cells were transiently 
transfected by electroporation with 5 µg of pEGFP-N1 plasmid containing either TG2(WT), TG2(M1c) 
and TG2(M3) as described in 6.3.3.2, and seeded in an 8-well chamber slide for 48 h. Cells were fixed 
(3%PFA) and nuclei were stained with DAPI. Representative pictures at 100X magnification are here 
shown. Transfection efficiency was quantified by direct count of EGFP-expressing cells (green) over the 
total number of cells (blue nuclei), and presented as mean percentage of transfected cells over the total 
cell number (on 8 non-overlapping images per section) ± SD, expressed relative to the TG2(WT) 
transfected cells (equalised to 1). Significance of the differences between transfections was determined 
by T-test: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
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Appendix 
 
A.1 THE KNOWN PARTNERS OF TRANSGLUTAMINASE 2 
 
Table I: List known and reported partners of transglutaminase-2. According to TransDab database 
(Csősz, Meskó and Fésüs 2009) 
 
TG2 partner Type of interaction 
26S proteasome non-ATPase regulatory subunit 4 BINDING 
40S ribosomial protein SA SUBSTRATE 
72 kDa type IV collagenase BINDING 
Abr (Active breakpoint cluster region-related protein) BINDING 
Acidic proline rich protein SUBSTRATE 
Aconitase SUBSTRATE 
ACTH (Adrenocorticotropic hormone) SUBSTRATE 
Actin  SUBSTRATE 
Adhesion G-protein coupled receptor G1 BINDING 
Adipocyte plasma membrane-assoiated protein BINDING 
ADP/ATP translocase 1 SUBSTRATE 
A-kinase anchor protein 13 BINDING 
Aldolase A SUBSTRATE 
Alpha lactalbumin  SUBSTRATE 
Alpha synuclein SUBSTRATE 
Alpha-1B adrenergic receptor BINDING 
Alpha-2 macroglobulin receptor SUBSTRATE 
Alpha-2 plasmin inhibitor  SUBSTRATE 
Alpha-2-HS-glycoprotein SUBSTRATE 
Alpha-gliadin BINDING 
Alpha-ketoglutarate dehydrogenase SUBSTRATE 
Amyloid beta A4 peptide SUBSTRATE 
Androgen receptor SUBSTRATE 
Angiocidin SUBSTRATE 
Ankyrin SUBSTRATE 
Annexin I SUBSTRATE 
Antileukoproteinase SUBSTRATE 
Arginase I SUBSTRATE 
Ataxin – 1 SUBSTRATE 
ATP synthase SUBSTRATE 
AT-rich interactive domain-containing protein 1A SUBSTRATE 
Band 3 anion transport protein SUBSTRATE 
Band 4.1 protein SUBSTRATE 
BAX BINDING 
Bcl-2 homologous antagonist/killer BINDING 
Bcr (Breakpoint cluster region protein) BINDING 
Bcr (Breakpoint cluster region protein) SUBSTRATE 
Beta casein SUBSTRATE 
Beta endorphin SUBSTRATE 
Beta lactoglobulin SUBSTRATE 
Beta tubulin BINDING 
Beta tubulin  SUBSTRATE 
Beta-2-microglobulin SUBSTRATE 
Betaine-homocysteine S-methyltransferase SUBSTRATE 
BiP protein SUBSTRATE 
Bone sialoprotein SUBSTRATE 
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C1 inhibitor SUBSTRATE 
C-1-tetrahydrofolate synthase BINDING 
Calbindin SUBSTRATE 
Calmodulin BINDING 
Calnexin BINDING 
Calpain SUBSTRATE 
Calreticulin BINDING 
Carboxypeptidase B2 SUBSTRATE 
Caspase-3 SUBSTRATE 
Cathepsin D SUBSTRATE 
C-CAM SUBSTRATE 
CD166 antigen/Activated leukocyte cell adhesion molecule BINDING 
CD38 SUBSTRATE 
CD44 antigen BINDING 
CD98 antigen/4F2 cell-surface antigen heavy chain BINDING 
Clathrin heavy chain SUBSTRATE 
Coatomer BINDING 
Collagen  SUBSTRATE 
Collagen alpha-1 (XVIII) BINDING 
Complement C3 SUBSTRATE 
Crystallin SUBSTRATE 
Cyclic Thymosin beta 4 SUBSTRATE 
Cytochrome C SUBSTRATE 
Deoxyribonuclease γ SUBSTRATE 
Dihydropyrimidinase-like 2 protein SUBSTRATE 
Dual leucine zipper-bearing kinase (DLK) SUBSTRATE 
E3 SUMO-protein ligase PIAS4 BINDING 
EGF Receptor SUBSTRATE 
Elafin  SUBSTRATE 
Elongation factor 1α SUBSTRATE 
Elongation factor 1γ SUBSTRATE 
Endostatin BINDING 
Enolase SUBSTRATE 
Envelope glycoprotein gp120 SUBSTRATE 
Envelope glycoprotein gp41 SUBSTRATE 
Ephrin A SUBSTRATE 
Epithelial-cadherin precursor BINDING 
Eucaryotic initiation factor 4F (eIF-4F) SUBSTRATE 
Eukaryotic translation initiation factor 5A-1 BINDING 
Exendin 4 SUBSTRATE 
Ezrin-Radixin-Moesin binding phosphoprotein 50 SUBSTRATE 
Fatty acid synthase SUBSTRATE 
F-box only protein SUBSTRATE 
Fibrillin-1 SUBSTRATE 
Fibrinogen alpha chain SUBSTRATE 
Fibrinogen gamma chain SUBSTRATE 
Fibronectin  BINDING 
Fibronectin SUBSTRATE 
Filamin 1 SUBSTRATE 
Fructose 1,6-bisphosphatase SUBSTRATE 
Galectin 3 SUBSTRATE 
Gliadin DEAMIDASE 
Gliadin SUBSTRATE 
Gliadoralin A SUBSTRATE 
Glucagon SUBSTRATE 
Glutathione S-transferase SUBSTRATE 
Glutathione S-transferase P BINDING 
Glyceraldehyde-3-phosphate dehydrogenase SUBSTRATE 
Glycogen debranching enzyme BINDING 
Hepatitis C virus core protein SUBSTRATE 
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Histamine SUBSTRATE 
Histatin SUBSTRATE 
Histone H1  KINASE 
Histone H1  SUBSTRATE 
Histone H2B type 1-C/E/F/G/I BINDING 
Histone H2B type 1-C/E/F/G/I  SUBSTRATE 
Histone H3.1 BINDING 
Histone octamer  KINASE 
Histone octamer  SUBSTRATE 
HIV-1 aspartyl protease  SUBSTRATE 
Hsp 27 SUBSTRATE 
Hsp27 BINDING 
Hsp60 SUBSTRATE 
Hsp70 SUBSTRATE 
Hsp70/90 organizing protein SUBSTRATE 
Hsp90 SUBSTRATE 
Human Clara-cell 10kDa protein SUBSTRATE 
Huntingtin SUBSTRATE 
Hyphal wall protein–1 SUBSTRATE 
Hypoxia inducible factor 1 BINDING 
Ig kappa chain C region SUBSTRATE 
Importin alpha3 BINDING 
Importin β1 subunit SUBSTRATE 
Insulin SUBSTRATE 
Insulin-like growth factor-binding protein-1 SUBSTRATE 
Insulin-like growth factor-binding protein-3  KINASE 
Insulin-like growth factor-binding protein-3  SUBSTRATE 
Insulin-like growth factor-binding protein-5 KINASE 
Integrin beta subunit BINDING 
Integrin beta3 BINDING 
Inter-alpha-inhibitor SUBSTRATE 
Intergrin alpha subunit BINDING 
Lamin A, C SUBSTRATE 
Latent transforming growth factor beta binding protein 1 SUBSTRATE 
Lipoprotein A  SUBSTRATE 
Long-chain-fatty-acid-CoA ligase BINDING 
Low-density lipoprotein receptor-related protein 5 BINDING 
Low-density lipoprotein receptor-related protein 6 SUBSTRATE 
Low-density lipoprotein receptor-related protein 6  BINDING 
Major vault protein BINDING 
Melittin SUBSTRATE 
Membrane-associated progesterone receptor component 2 BINDING 
Microfibril-associated glycoprotein (MAGP) SUBSTRATE 
Midkine SUBSTRATE 
Myelin basic protein SUBSTRATE 
Myoferlin BINDING 
Myosin  SUBSTRATE 
NADH-cytochrome b5 reductase 3 BINDING 
Neurofilament proteins SUBSTRATE 
Neuropeptide Y SUBSTRATE 
Neutral alpha-glucosidase BINDING 
NF-kappa-B inhibitor alpha SUBSTRATE 
Nidogen SUBSTRATE 
Nuclease sensitive element binding protein-1 SUBSTRATE 
Nucleophosmin SUBSTRATE 
Orexin B SUBSTRATE 
Osteonectin SUBSTRATE 
Osteopontin SUBSTRATE 
Oxysterol-binding protein BINDING 
Oxytocin receptor BINDING 
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Parkin SUBSTRATE 
Periphilin SUBSTRATE 
Periplakin SUBSTRATE 
Peroxiredoxin-1 BINDING 
Phosphoglycerate dehydrogenase SUBSTRATE 
Phospholipase A2  SUBSTRATE 
Phospholipase C delta1 BINDING 
Phosphorylase kinase SUBSTRATE 
Plasminogen SUBSTRATE 
Plasminogen activator inhibitor-2 SUBSTRATE 
Plasmodium falciparum liver stage antigen-1 SUBSTRATE 
Platelet-derived growth factor receptor beta BINDING 
Procarboxypeptidase B/U  SUBSTRATE 
Prohibitin SUBSTRATE 
Prolow-density lipoprotein receptor-related protein 1 BINDING 
Protein kinase A anchoring protein 13 BINDING 
Protein kinase C delta type SUBSTRATE 
Protein S100-A4 BINDING 
Protein synthesis initiation factor 5A  SUBSTRATE 
Proto-oncogene tyrosine-protein kinase Src BINDING 
PTEN (Phosphatase and tensin homolog) BINDING 
RAP - Alpha-2 macroglobulin related protein SUBSTRATE 
Ras GTPase-activating-like protein BINDING 
Ras-related C3 botulinum toxin substrate 1 BINDING 
Retinoblastoma protein  KINASE 
Retinoblastoma protein  SUBSTRATE 
Retinoblastoma-associated protein BINDING 
Rho associated, coiled coil, containing protein kinase 2 SUBSTRATE 
RhoA DEAMIDASE 
RhoA SUBSTRATE 
S100A10  SUBSTRATE 
S100A11  SUBSTRATE 
S100A7 SUBSTRATE 
Seminal vesicle secretory protein IV SUBSTRATE 
Ser/Thr protein phosphatase 2A BINDING 
Serotonin SUBSTRATE 
Single-stranded DNA-bindig protein BINDING 
Small ubiquitin-related modifier 1 BINDING 
SNAP-25 SUBSTRATE 
SP1 transcription factor SUBSTRATE 
Spectrin SUBSTRATE 
Statherin SUBSTRATE 
Substance P SUBSTRATE 
Suprabasin  SUBSTRATE 
Synapsin 1 SUBSTRATE 
Synapsin I SUBSTRATE 
Syndecan-4 BINDING 
Talin BINDING 
Tau protein SUBSTRATE 
T-complex protein 1ε subunit SUBSTRATE 
Thromboxane A2 receptor BINDING 
Thymosin beta 4 SUBSTRATE 
Thyroglobulin SUBSTRATE 
Transcription factor AP-1 BINDING 
Transcription factor p65 BINDING 
Transferrin receptor BINDING 
Troponin SUBSTRATE 
Tubulin alpha BINDING 
Tubulin beta-1 chain BINDING 
Tumor protein D54 BINDING 
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Tumor rejection antigen-1 SUBSTRATE 
Ubiquitin SUBSTRATE 
UDP-glucose:glycoprotein glucosyltransferase 1 BINDING 
Uteroglobin SUBSTRATE 
UV excision repair protein RAD23 homolog B SUBSTRATE 
Valosin SUBSTRATE 
Vasoactive intestinal peptide SUBSTRATE 
VEGFR-2 SUBSTRATE 
Very long-chain specific acyl-CoA dehydrogenase BINDING 
Vigilin SUBSTRATE 
Vimentin  SUBSTRATE 
Vinculin BINDING 
Vitronectin  SUBSTRATE 
Y-box binding protein SUBSTRATE 
Zyxin BINDING 
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Table II: List of binding partners for transglutaminase-2. Adapted from (Kanchan, Fuxreiter and 
Fésüs 2015) 
Name of the protein Site of interaction Proposed function 
Fibronectin  ECM, plasma  
Cell adhesion and migration 
Integrins b1 and b3 Membrane  
Syndecan-4 Membrane, ECM 
PDGFR  Membrane  
LRP5 and LRP6  Transmembrane Wnt/b catenin signalling pathway 
LRP1  Membrane  
Cell adhesion, migration, receptor mediated 
signalling 
ACAP 13  
Perinuclear, 
cytoplasmic areas 
Involved in Rho mediated change in cell polarity, 
potentiates interaction between PKA and TG2 
PTEN (tumor suppressor 
phosphatase) 
Cytoplasm  Regulation of cell survival signalling 
HSP 70  Membrane  Cell migration by targeting TG2 to cell surface 
Endostatin  ECM  Regulation of angiogenesis and tumour growth 
BCR and ABR Q12979 Cytoplasm  Cytoskeleton rearrangement through Rac activation 
GPR56  ECM  Tumour progression  
MMP2  ECM  
Regulation of matrix composition and migration / 
invasion of malignant cells 
Angiocidin  Cytoplasm  
Regulates cell migration and adhesion by inhibiting 
FN incorporation to ECM 
a1 adrenoceptor Membrane  
Regulates intracellular calcium signalling 
PLC d1  Cytoplasm  
Oxytocin receptor Membrane  
Intracellular calcium mobilization and muscle 
contraction 
Thromboxane receptor Membrane  Transmembrane signalling 
Calreticulin Cytoplasm  
Down-regulate both TG and GTPase activities of 
TG2 
Importin a3  Cytoplasm, nucleus Active transport of TG2 into the nucleus 
Eukaryotic initiation factor (eIF5A) Nucleus, cytoplasm TGs influence the cellular localization of eIF-5A 
c-Jun  Nucleus  ECM regulation and turnover 
cSrc  Membrane  Cell–matrix interactions and Wnt signalling 
Hypoxia-inducible factor (HIF1b) Cytoplasm, nucleus 
Protective role in the brain during its response to 
ischemia and stroke 
Reitnoblastoma  Nucleus, cytoplasm Transcriptional regulation 
SUMO 1 (small ubiquitin-like 
modifier) 
Nasal epithelium 
Regulating oxidative stress and inflammation 
PIASy (SUMO 1 ligase)  Nasal epithelium  
RAC1  Cytoplasm, membrane Regulates allergic inflammation 
Tubulin b1 Nucleus  Regulates intracellular calcium signalling 
Calmodulin Nucleus  
Regulation of TG2-mediated crosslinking of 
huntingtin and formation of stable aggregates in 
Huntington’s disease 
Histone H3 and H2B Nucleus  Chromatin remodelling  
BAX and BAK Cytoplasm  Stabilize efficient regulation of apoptosis 
14-3-3 binding protein  Cytoplasm  Regulation of apoptosis  
MFG E8  Cell surface  Phagocytosis of apoptotic cells 
P62/SQSTM 1  Cytoplasm  Recognition and recruitment of ubiquitinated proteins 
and organelles to pre-autophagic vesicles just before 
its degradation by autophagolysosomes NBR1  Cytoplasm  
HSP20  Whole cell lysate  
Regulation of apoptosis by interacting with 
Hsp20/Hsp27 complex 
Paxillin  Whole cell lysate  
Regulation of cell adhesion and migration by paxillin 
incorporation in focal adhesion complexes  
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A.2 BUFFER PREPARATIONS 
 
Table III: Buffer composition  
Buffer Composition 
500 mM Tris-HCl pH 7.4 (10X Tris buffer pH 7.4) 500 mM Tris, pH 7.4 (acidified using HCl) 
Blocking buffer for ELISA (3% BSA) 3% (w/v) BSA in 50mM Tris-HCl pH 7.4 
Blocking buffer for Immunosfluorescence (3% BSA) 3% (w/v) BSA in PBS pH 7.4 
Blocking buffer for Western blot (5% milk) 5% (w/v) non-fat milk in TBST 
Diethylpyrocarbonate (DEPC)- treated water or 
nuclease-free water 
Incubation of distilled H2O with 0.1% (v/v) DEPC overnight (15 
h), followed by autoclavation at 121 °C for 20 min 
Diethylpyrocarbonate (DEPC) water 0.1% (v/v) DEPC in distilled H2O 
Fixing solution - 3%PFA 3% (w/v) PFA in PBS pH 7.4 
Heparinase I Buffer 
200 mM Tris-HCl, 500 mM NaCl, 40 mM CaCl2, 0.1% (w/v) BSA, 
pH 7.5 
IGEPAL- containing Lysis Buffer 
20 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, 1% (v/v) IGEPAL 
CA-630, 0.5% (w/v) deoxycholic acid, 0.1% (w/v) SDS, pH 7.4 
Laemmli buffer (4X) 
250 mM Tris-HCl pH 6.8, 40% (v/v) glycerol, 8% (v/v) SDS, 
20%(v/v) β-mercaptoethanol, 0.008%(w/v) bromophenol blue 
Permeabilizing solution - Triton 0.1% (v/v) Triton X100 in PBS pH 7.4 
Phosphate buffered saline PBS 
137 mM NaCl , 2.7 mM KCl, 10 mM Na2HPO4, 1.8mM KH2PO4, 
pH 7.4 
Ponceau Red staining   0.1% (w/v) Ponceau S, 5% (v/v) glacial acetic acid 
Proteomics Lysis Buffer 
9.5 M urea, 2%(w/v) DTT, 1% (w/v) N-octyl-beta-
glucopyranoside (OGP)  
Radioimmunoprecipitation assay buffer (RIPA buffer) 
50 mM Tris-HCl, 150 mM NaCl, 1% (v/v) NP40, 0.5% sodium 
deoxicholate, 0.1% SDS, pH 8 
Resolving Buffer (4X) 1.5 mM Tris HCl, 0.4% SDS, pH 8.8 
Stacking buffer (4X) 0.5 M Tris HCl, 0.4% SDS, pH 6.8 
Sucrose – based Lysis buffer 250 mM Sucrose, 2 mM EDTA, and 50 mM Tris-HCl, pH 7.4 
Tank Buffer (Electrophoresis Buffer) (10X) 250mM Tris, 1.92M glycine, 1% (w/v) SDS 
Transfer Buffer (Transblot Buffer) (10X) 480mM Tris, 390mM Glycine,  0.375% (w/v) SDS 
Tris Buffer Saline - Tween (TBST) (10X) 
10 X Tris Buffer Saline [250mM Tris-HCl, 1-5M NaCl, 20mM 
KCl, pH 7.4], 1%(v/v) Tween-20 
Tris Buffer Saline (TBS) (10X) 250mM Tris-HCl, 1-5M NaCl, 20mM KCl, pH 7.4 
Tris-Acetate-EDTA (TAE) buffer 40mM Tris, 20mM acetic acid, 1mM EDTA, pH 8.5 
Tris-EDTA (TE) Buffer  10 mM Tris-HCl, 1 mM EDTA, pH 8.0 
Trypsin free cell detaching buffer (For extracellular 
activity assay) 
5 mM EDTA in sterile PBS pH 7.4 
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A.3 PLASMID MAPS 
 
Figure I: Plasmid maps of pcDNA3_HA-Sdc4 and pcDNA3.1(+)_Sdc4. pcDNA3_HA-Sdc4 plasmid (A) 
was produced by Dr Izhar Burhan (unpublished) and pcDNA3.1(+)Sdc4 (B) was produced by Dr 
Alessandra Scarpellini (Scarpellini 2009),  starting from Sdc4 cDNA and HA-Sdc4 cDNA provided by Dr 
Mark Bass (The Univesity of Sheffield). Plasmid map of pcDNA3.1(+)Sdc4 was obtained from Dr 
Scarpellini PhD thesis (Scarpellini 2009).  
APPENDIX 
 
531 
 
 
Figure II: Plasmid map of pEGFP-N1-TG2 plasmids. (A) pEGFP-N1 plasmid (ClonTech #6085-1). 
EcoRI restriction site was employed as cloning site for the introduction of the insert (TG2 cDNA) and the 
production of EGFP-TG2 chimera-expressing plasmid [pEGFP-N1-TG2(WT)] (Scarpellini 2009). Site 
directed mutagenesis of TG2 cDNA (Lortat-Jacob, et al. 2012) and subcloning employing the same EcoRI 
restriction site was performed to produce heparin binding mutant EGFP-TG2 expressing plasmid 
[pEGFP-N1-TG2(M1c) / pEGFP-N1-TG2(M3)]. Heparin binding mutant EGFP-TG2 expressing plasmids 
were produced by Dr Izhar Burhan (unpublished). (B) Restriction sites for diagnostic restriction 
digestion of pEGFP-N1-TG2 plasmids, to confirm correct orientation of TG2 with EGFP. Plasmid map of 
pEGFP-N1-TG2 was obtained from Dr Scarpellini PhD thesis (Scarpellini 2009).  
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A.4 DESCRIPTION OF THE TG2-ASSOCIATED MEMBRANE PARTNERS 
INVOLVED IN VESICULAR TRAFFICKING 
 
As reported in Chapter IV, a series of proteins identified as associated to with TG2 in kidney 
membranes (either fibrotic or healthy) by SWATHTM-MS analysis in the current study have 
been suggested to be involved in different steps of the cellular vesicular trafficking. These TG2-
associated partners are putative candidates that might play a role in a possible vesicular 
trafficking of the enzyme. In this section, a description of the functions of all TG2-associated 
proteins on kidney membranes will be provided. The proteins will not all be linked to a 
secretory route, as some of them are mostly involved in endocytic transport.  
 
A.4.1 Clathrin and clathrin associated proteins 
Among the TG2 associatedTG2-associated proteins on kidney membranes, both Sham operated 
or fibrotic, a series of proteins involved in cClathrin- mediated endocytosis were identified.  
 
A.4.1.1 Clathrin chains:  
Clathrin chains were detected as TG2 partners in kidney membranes in both fibrotic and 
healthy conditions: in particular, light chains were associated with to TG2 upon UUO 
(CLCA_MOUSE, CLCB_MOUSE) while the heavy chain CLH1_MOUSE was recognised in healthy 
conditions. Clathrin is the key protein involved in the formation of cytoplasmic coated vesicles 
(clathrin-coated vesicles, CCV),  that move in both direction, from the trans-Golgi network 
(TGN) to the secretory pathway, from the endosomes, and from the plasma membrane to the 
endosome by receptor-mediated endocytosis from of clathrin coated pits (CCP). Clathrin 
structure is called triskelion and is formed by 3 three heavy chains and 3 three light chains: the 
association of different triskelia to the membrane is mediated by specific adaptor proteins on 
the membrane, and together the triskelia associate to form a lattice (skelion), that drives the 
membrane budding and the formation of the rounded CCV.  Clathrin doesn’t does not bind the 
membrane or the cargo protein directly, but needs an adaptor complex on membranous 
compartment the vesicle will beis budding from. Adaptor complexes connect membrane lipids 
and cytosolic chains of protein cargos to clathrin during cytosolic vesicle formation. Two main 
type of adaptor complexes exist in nature: adaptor proteins (AP), that are associated to with 
different kind of membranes depending on the family, and the ADP-rybosilation factor (ARF)- 
binding protein GGA (Golgi-localised, gamma-adaptin hear containing), which is uniquely 
associated to with the TGN.  
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A.4.1.2 Adaptor complex-2 (AP2) 
Among the TG2-associated protein in fibrotic conditions, 3 three subunits of the aAdaptor 
complex-2 (AP2) were identified (AP2A1_MOUSE, AP2A2_MOUSE and AP2B1_MOUSE) while 
none was identified in Sham operated kidneys. Importantly, AP2 is characterised by being 
uniquely associated to with plasma membranes and to mediate in clathrin-mediated receptor-
mediated endocytosis (Nakatsu and Ohno 2003). The other AP complexes present in cells, AP1, 
AP3 and AP4, that are instead mainly associated toassociated with the budding of vesicles from 
the TGN to the endosome/lysosome and from the endosome(Nakatsu and Ohno 2003), were 
not identified in the list of TG2 associatedTG2-associated proteins. AP2 binds cell membrane 
phospholipids,  and  in particular to cell surface phosphoinositides PI(4,5)P2, targeting the 
adaptor to the plasma membrane (Höning, et al. 2005). Moreover AP2 might also play an 
additional role after endocytosis by interacting with Arf6.  
 
A.4.1.3 ADP-rybosilation factor (ARF) binding protein GGA 
The ADP-rybosilation factor (ARF) binding protein GGA (Golgi-localised, Gamma-adaptin 
hear containing) (GGA1_MOUSE) was identified as TG2 associated and is a known clathrin 
adaptor protein. This protein, however, is not involved in endocytosis, but is uniquely localised 
at the TGN, mediating the trafficking of proteins from the TGN to the endosomal/lysosomal 
system into clathrin coated vesicles (CCV) CCV. In particular, GGA adaptor proteins are 
involved in sorting of mannose 6-phosphate receptors/mannose-6-phospate modified 
proteins to the lysosome for degradation, by interaction of the receptor with the amino-
terminal VHS domain of GGA (Puertollano, et al. 2003) as well as sorting of ubiquitinated 
proteins to the endosome/lysosome though its GAT (GGA and Tom1) domain (Shiba, et al. 
2004).  
 
A.4.1.4 Target of myb protein 1 (Tom1) 
Target of myb protein 1 (Tom1), was as well detected as TG2 associated in healthy 
membranes (TOM1_MOUSE). This protein, similarly to GGA1, is VHS domain- and GAT domain-
containing adaptor protein and is localised normally on the endosomal membrane. It has been 
shown to bind clathrin and probably be a mediator of ubiquitinated protein binding to clathrin 
vesicles (Yamakami, Yoshimori and Yokosawa 2003, Katoh, et al. 2004, Katoh, et al. 2006). It 
plays an important role in protein targeting for degradation (Makioka, et al. 2016).   
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A.4.1.5 Phosphatidylinositol clathrin assembly protein Picalm 
Phosphatidylinositol clathrin assembly protein Picalm (PICAL_MOUSE) was identified as 
a TG2 associatedTG2-associated partner in both Sham and UUO kidney membranes. This 
protein interacts with both AP2 and clathrin and plays a role in the recruitment of these 
proteins to the plasma membrane, on the sites of formation of clathrin coated pits (Tebar, 
Bohlander and Sorkin 1999, Suzuki, et al. 2012).   
 
A.4.1.6 Huntingtin interacting protein 1 
Huntingtin interacting protein 1 (HIP1_MOUSE) was identified as TG2 associated in fibrotic 
kidney membranes. This protein is involved in the formation of CCV and receptor-mediated 
endocytosis, by interaction with the actin cytoskeleton (Waelter, et al. 2001, McPherson 2002). 
Interestingly, this protein is also involved in apoptosis by interaction with Caspase 3 (Hackam, 
et al. 2000, Kang, et al. 2005), a protein identified as TG2 associated in the TG2-interactome of 
Ssham operated kidney membranes.  
 
A.4.1.7 Proton pump component (H subunit) of vacuolar ATPase 
The proton pump component (H subunit) of vacuolar ATPase (VATH_MOUSE), a protein 
involved in endosomal compartments acidification, was a TG2-associated partner in fibrotic 
conditions only. VATH has been suggested to be involved in the acidification process that drives 
receptor-mediated endocytosis and to interact with AP2 (Forgac, et al. 1983, Mellman, Fuchs 
and Helenius 1986, Geyer, et al. 2002). On the other side, a role in exocytosis has also been 
suggested for the V0 subunit of vacuolar ATPase, which is independent from the H+-pump 
activity (Marshansky and Futai 2008, Raposo and Stoorvogel 2013).  
 
A.4.1.8 Cyclin-G associated kinase 
Cyclin-G associated kinase (GAK_MOUSE), also known as aAuxilin 2 (non-neuronal specific, 
ubiquitous) is another protein that interactsed with TG2 only in fibrotic condition. Auxillin is a 
DnaJ homolog that has been shown to mediate CCV uncoating after endocytosis, also performed 
by the molecular chaperone heat shock cognate 71 KDa protein Hsc70/Hspa8 (Greener, et al. 
2000, Wu 2016, Sousa and Lafer 2015), which is another TG2-associated protein in UUO kidney 
membranes (HSP7C_MOUSE).  
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A.4.2 Heat shock cognate 71 KDa protein 
Heat shock cognate 71 KDa protein (HSP7C_MOUSE) was identified as a TG2 associatedTG2-
associated protein in fibrotic conditions. This protein is a member of the heat shock 70 family 
of proteins (HSP70 family),  and it is a constitutively expressed protein that acts as a chaperone 
protein in a GTP/GDP-dependent manner (Stricher, et al. 2013). Generally, the chaperone 
activity is assisted by members of the HSP40/DNAJ family of chaperones, but also other 
proteins, such as HSP90, can act as a co-chaperone for this protein. As a chaperone, the protein 
is known to be involved in several mechanisms inside the cell, including protein folding, 
degradation, and translocation to the nucleus, mitochondria and ER (Ngosuwan, et al. 2003, 
Stricher, et al. 2013). In the context of degradation, Hsp7c also plays a role in different types of 
autophagy (Bandyopadhyay, et al. 2008, Sahu, et al. 2011, Stricher, et al. 2013). If we focus on 
vesicular trafficking, Hsp7c is known to act as an ATPase in mediating the uncoating of CCVs 
after clathrin-dependent endocytosis. Gak and DNAJ proteins are as well involved in the 
process (Sousa and Lafer 2015, Greener, et al. 2000, Wu 2016, Stricher, et al. 2013). In addition, 
some studies have suggested a role for Hsp7c in the regulation of vesicular transport along 
microtubules, by acting on kinesin function(Terada, et al. 2010). 
Beside the role in endocytosis and intracellular protein trafficking, the protein has also been 
strongly associated toassociated with the exosome compartment, being one of the most 
represented proteins in these extracellular vesicles, as reported on the Exocarta database of 
reported exosomal proteins (Mathivanan and Simpson 2009). Hsc70 is enriched within the 
exosome fraction upon cell stress/heat shock in different types of cells, and is detected in 
urinary exosomes after a stress such as kidney transplant  (Clayton, et al. 2005, Pisitkun, et al. 
2012).  
 
A.4.3 Flotillin 
Flottilin 2 (FLOT2_MOUSE), also known as rReggie-1, was identified as well in the TG2-
interactome in kidney fibrotic membranes, and is an interestinga marker of lipid rafts. Lipid 
rafts are specialized lipid-rich domains on the plasma membrane, characterized by abundant 
cholesterol, glycosphingolipids and integral/receptor proteins (Hooper 1999, Pike 2009). In 
particular, flotillin proteins characterize caveolar lipid rafts, specific membrane--invagination 
domains associated toassociated with caveolae-dependent, receptor-independent endocytosis 
and signal transduction (Hooper 1999, Pike 2009). Flotillins act as scaffolding protein in the 
caveolar rafts, participating, together with caveolins, in the formation of caveolar vesicles. 
Curiously, the protein homolog of Flot2, fFlotillin 1 or /reggie 2, has been reported to reach the 
plasma membrane by unconventional Golgi-independent secretion, in a process that depends 
on its acylation (Morrow, et al. 2002), and Flot2 association to the lipid rafts on the plasma 
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membrane has been shown to be dependent on Flot2 acylation (myristoylation, 
palmitoylation), and homo or hetero-oligomerisation with other caveolar proteins (Neumann-
Giesen, et al. 2004, Langhorst, et al. 2008).  
Similarly to Hsp7c, also flotillins have been associated toassociated with the exosome fraction 
of the cells, with a suggested role of lipid rafts in the protein loading into/on the exosomes, and 
are reported in the Exocarta database as well represented proteins of the exosomes (Phuyal, 
et al. 2014, Frick, et al. 2007).  
 
A.4.4 Rabankirin 5 (Rank-5) 
Rabankirin 5 (Rank-5) (ANFY_MOUSE) is a PI3P-binding effector of the small GTPase Rab5 
and was identified as TGg2 associated in healthy membranes. Rab GTPases are members of the 
Ras superfamily of G-proteins, are localised in different membranous compartments of the cell 
and involved in the regulation of different steps of membrane trafficking, from vesicle 
formation to movement and fusion, from the ER/Golgi network to the different endosomal 
compartments. In particular, Rab5 localises on the early endosomes and plays mostly a role in 
homotypic early endosomes fusion more than in heterotypic CCV-to-early endosome fusion. 
Both Rab5 and PI3P are known markers of early endosomes, and Rab5 plays not only a role in 
early endosomes lateral homotypic fusion, but also in clathrin- mediated endocytosis and 
liquid phase endocytosis by micropinocytosis (Bucci, et al. 1992). Together with its role in early 
endosome dynamics, Rank-5 has been demonstrated to play an important function as a Rab5 
effector in non-clathrin mediated fluid phase endocytosis, with particular significance in 
polarised cells such as kidney tubular epithelial cells (Schnatwinkel, et al. 2004). Moreover, 
Rank-5 has been demonstrated to play a role in retromer eEndosome-to-TGN transport and 
regulation, again as a Rab5 effector, by interacting with Eps15 homolog domain 1 (EHD1), a 
protein involved in both endocytic recycling and retromer transport, and the vacuolar sorting 
proteins Vps26 and Vps35, belonging to the cargo selective complex (Zhang, et al. 2012).  
 
A.4.5 ADP-ribosylation factors 5 and 6 (Arf5 and Arf6) 
ADP-ribosylation factors 5 and 6 (Arf5 and Arf6) were are two proteins identified as 
significantly associated toassociated with TG2 in healthy kidney membranes (ARF5_MOUSE, 
ARF6_MOUSE). Arf proteins are small GTP- binding proteins (GTPases) of the Ras superfamily, 
a superfamily of small GTPases involved in many cell functions (Goitre, et al. 2014). Also Rab 
GTPases proteins belong to the Ras superfamily, and, together with Arf proteins regulate 
membrane trafficking and vesicular transport (Goitre, et al. 2014). Arf6 GTPase is a member 
of the GTP-binding protein family of ARFs, and the only component of the class III of ARF 
protein. The peculiarity of this protein is that is localised at the plasma membrane and is 
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involved in endocytic pathways (both phagocytosis and receptor- mediated endocytosis), 
endosomal recycling and actin remodelling, with a role in cytokinesis (cell adhesion, migration 
etc…) (Souza-Schorey, et al. 1995, D'Souza-Schorey and Chavrier 2006). The role in clathrin 
vesicles formation is carried out by interaction with PI(4,5)P2 and AP2, but the protein is also 
involved in other endocytic pathways such as caveolar pathways and receptor- independent 
endocytosis such as phagocytosis (D'Souza-Schorey and Chavrier 2006, Souza-Schorey, et al. 
1995). The role in actin remodelling is itself important for localised phagocytic movements as 
well as for ARF6 function in cytokinesis (Balana, et al. 2005, D'Souza-Schorey and Chavrier 
2006).  
On the other side, Arf5 GTPase is a member of the class II of ARFs, together with Arf4. This 
class is less studied compared to the others, and has been mostly associated toassociated with 
Golgi trafficking and vesicles formation at the TGN (D'Souza-Schorey and Chavrier 2006). 
However, a work of Moravec and colleagues has suggested a role of Arf5 in clathrin-mediated 
endocytosis of α5β1 integrins, instead of the more likely to be involved Arf6 (Moravec, et al. 
2012).  
 
A.4.6 Annexin A2 (Anxa2) 
Annexin A2 (Anxa2) (ANXA2_MOUSE) was identified as significantly associated toassociated 
with TG2 in healthy kidney membranes. This protein has been already mentioned in Chapter 
V as a well-characterised unconventionally secreted protein: is a membrane- binding protein 
known to interact with membrane phosphoinositides in a calcium-dependent manner 
(Bharadwaj, et al. 2013) and to be an important regulator of actin dynamics in the proximity of 
membranes (Bharadwaj, et al. 2013, Grieve, Moss and Hayes 2012). Among its many roles, 
Annexin A2 has been shown to be involved in clathrin mediated endocytosis by interaction 
with AP2, and to interact with two specific Rab5 effectors involved in endocytosis  (Creutz and 
Snyder 2005, Urbanska, et al. 2011). At the same time, Anxa2 has also been suggested to be 
involved in receptor independent endocytosis by micropinocytosis, regulating the actin 
dynamics in the formation of the macropinosome (Hayes, et al. 2004, Grieve, Moss and Hayes 
2012). In general, Anxa2 is important in a number of processes involving actin regulation in 
the context of membrane dynamics, with a specific importance in membrane 
invagination/protrusion and vesicle formation (Grieve, Moss and Hayes 2012). Some studies 
have also associated Anxa2 to exosomal vesicles, and its release into these vesicular 
compartment was suggested to be part of a pathway starting from the formation of lipid rafts 
rich in cholesterol (Valapala and Vishwanatha 2011, Chasserot-Golaz, et al. 2005). 
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A.4.7 Exocytic proteins 
Moving to proteins mostly associated toassociated with exocytic pathways, two main proteins 
need to be mentioned, the first, programmed cell death 6 – interacting protein, better known 
as alix or AIP1 (PDC6I_MOUSE), was detected as TG2 associated in kidney membranes of both 
treatments, while the second, tumour susceptibility gene 101 protein (Tsg101) 
(TS101_MOUSE) was identified in Sham operated conditions only.  
 
A.4.7.1 Alix (or Programmed cell death 6 – interacting protein or AIP1) 
Alix (or Programmed cell death 6 – interacting protein or AIP1) (PDC6I_MOUSE) is a 
cytoplasmic vesicular protein sorting (Vps) protein involved in late endosomes/lysosomes 
regulation. The protein plays a role in the sorting of proteins into intraluminal vesicles of 
multivesicular bodies (MVB), generated by invagination of the limiting membrane of the late 
endosome, by connecting ESCRT complexes I to III and binding the atypical phospholipid 
lysobisphosphatidic acid (LBPA) (Matsuo, et al. 2004, Hurley and Odorizzi 2012, McCullough, 
Colf and Sundquist 2013). In this way, the protein regulatesd protein sorting into vesicles 
directed to the lysosome, but at the same time they areit is involved in the formation of 
exosomes, that are intraluminal vesicles released by fusion of the limiting membrane of the 
multivesicular exosome with the plasma membrane (Hurley and Odorizzi 2012, McCullough, 
Colf and Sundquist 2013). As a matter of facts, Alix is considered one of the main exosomal 
markers, as mentioned on Exocarta database (Mathivanan and Simpson 2009, Keerthikumar, 
et al. 2016). Particularly interesting is the involvement of sSyndecan HSPGs in the exosome 
biogenesis associated toin association with aAlix, and crucial in the process is the adaptor 
protein syntenin on the ectosome, that binds both alix and syndecan HSPGs in the formation of 
syntenin-containing exosomes. The process is probably dependent on the cytoplasmic domain 
of syndecan on the endosome, where syndecan can cluster and bind syntenin after the 
negatively charged extracellular domains have been cleaved (Baietti, et al. 2012, Ghossoub, et 
al. 2014). To confirm this, the process is favoured by the HS-Heparan sulphate digesting 
enzyme heparanase (David and Zimmermann 2015, Roucourt, et al. 2015). Interestingly, one 
ubiquitously expressed member of the syndecan family, syndecan- 4, was identified in the list 
of tg2-associated proteins in kidney membranes. Moreover, the abovementioned sSmall 
GTPase Arf6 and its effector phospholipase D (PLD) have been suggested to be involved in the 
process of syntenin/alix exosome formation, possibly by the regulation of specific phosphatidic 
acid (PA) domains (Ghossoub, et al. 2014).  
In addition to the direct functions in intraluminal vesicles / exosome formation, alix has been 
shown to be involved in actin dynamics on the cortical part of the cells, mediating regulation 
of actin polymerisation/depolymerisation and positioning of the endosome in the cell 
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(Cabezas, et al. 2005, Pan, et al. 2006b). Coronin, another TG2-associated protein in the kidney 
membrane interactome, co-localises with Alix alix in an actin depolymerisation process (Lin, 
et al. 2010).  
 
A.4.7.2 Tumour susceptibility gene 101 protein (Tsg101) 
Tumour susceptibility gene 101 protein (Tsg101) (TS101_MOUSE) is another protein 
involved in sorting of protein cargo into intraluminal vesicles of MVBs. It is a component of the 
ESCRT-I complex and recognises ubiquitinated proteins that need to be sorted into the late 
endosome (Babst, et al. 2000). Similarly to alix, it is likely to be required for the exosomal 
release of syndecan and its adaptor syntenin (Baietti, et al. 2012).  
Interestingly, both Tsg101 and the abovementioned Hsp7c heat shock protein 70protein, were 
also identified as associated with TG2 in a proteomic study of TG2-interactome, in a model of 
starvation mediated autophagy: the association of both proteins, together with a series of other 
molecular chaperones, was identified only in normal condition, and losts upon autophagy 
(Altuntas, et al. 2015). Moreover, as reported before in the context of  TG2 unconventional 
secretion hypothesis (Chapter V), the enzyme was suggested to interact with Tsg101 and aAlix 
in the regulation of its sorting,  and as well as other protein sorting, into secreted exosomes 
(Diaz-Hidalgo, et al. 2016).  
 
A.4.7.3 Ist1 homolog 
Ist1 homolog is another protein associated with the ESCRT machinery, and, similarly to 
Tsg101, was identified as associated toassociated with TG2 uniquely in Sham operated kidney 
membranes (IST_MOUSE). Ist1 has been shown to have an inhibitory effect on the ESCRT-III 
function (disassembly) with an important role in membrane abscission during cytokinesis 
(Xiao, et al. 2009, Babst, Davies and Katzmann 2011). Moreover, it has been seen to 
characterise a series of urinary exosome preparations (Li, et al. 2011, Raj, et al. 2012, Liu, et al. 
2015).  
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A.4.8 Vesicle fusion associated proteins 
A.4.8.1 Vesicle-fusing ATPase NSF (N-ethylmaleimide-sensitive factor) 
Vesicle-fusing ATPase NSF (N-ethylmaleimide-sensitive factor) (NSF_MOUSE), well 
known to be involved in membrane fusion events, was identified as TG2-associated in Ssham 
operated kidney membranes.  The protein is necessary for the process of membrane fusion and 
vesicle/cargo release mediated by SNAREs (vesicular and target membrane), hence is involved, 
in addition to its functions in intracellular fusion events, in exosome secretion by fusion of the 
limiting membrane (Zhao, Slevin and Whiteheart 2007, Fader, et al. 2009). As described before, 
TG2 secretion has been suggested to be dependent on NSF activity, as its inhibition has been 
shown to hamper the enzyme release (Zemskov, et al. 2011, Santhanam, Berkowitz and Belkin 
2011, Jandu, et al. 2013).  
 
A.4.8.2 Sec1 Family domain containing protein 1 
A protein strictly associated with NSF and SNAREs is Sec1 Family domain containing protein 
1, that was identified as TG2 associate in both fibrotic and healthy conditions (SCFD1_MOUSE). 
Sec1 is a protein specifically binding to syntaxin, a plasma membrane SNARE protein 
necessary, together with synaptobrevin and SNAP-25, for the formation of the SNARE complex 
necessary for plasma membrane fusion in constitutive and regulated exocytosis. Binding of 
Sec1 specifically regulates Syntaxin activity in the formation of the membrane SNARE complex 
(Halachmi and Lev 1996, Pevsner, et al. 1994).  
 
A.4.8.3 Synaptobrevin homolog YKT6 
Synaptobrevin homolog YKT6 was identified as TG2 associated in fibrotic conditions 
(YKT6_MOUSE). This protein has been shown to be involved in a vSNARE complex for 
membrane fusion and has mostly been associated toassociated with ER-to-Golgi transport as 
well as retrograde early endosome/recycling endosome to TGN transport (Zhang and Hong 
2001, Xu, et al. 2002, Tai, et al. 2004). However, a study on drosophila Wnt protein has 
suggested its role in exosome secretion (Gross, et al. 2012).  
 
A.4.8.4 Small GTPase Rab3 activating non catalytic protein subunit 2 (Rab3Gap2) 
Small GTPase Rab3 activating non catalytic protein subunit 2 (Rab3Gap2) was  identified 
as TG2 associated in fibrotic conditions (RBGPR_MOUSE). The protein is an activator of the 
Rab3 protein family, a family of small GTPases that controls the regulated, non-constitutive, 
exocytosis of neurotransmitters and hormones by associating to the area where Ca2+-regulated 
membrane fusion will happenhappens (Lledo, et al. 1994, Schluter, et al. 2002, Sakane, et al. 
2006). Rab3 proteins have been largely described in neural cells in the context of synaptic 
APPENDIX 
 
541 
 
secretion, but are also expressed in other cell types and in kidney cells (Liebenhoff and 
Rosenthal 1995, Schluter, et al. 2002). Rab3Gap complex performs the GTP-
hydrolysis/inactivation of GTP-bound Rab3 and subsequent dissociation of GDP-Rab3 from the 
fusion area, necessary for the exocytic process to continue by membrane fusion performed by 
the abovementioned SNARE/Syntaxin/Synaprobrevin complex (Sakane, et al. 2006).  
 
 
 
A.4.9 Sorting nexin 4 
Sorting Nexin 4 (Snx4) (SNX4_MOUSE) is a member of the sorting nexin family of 
phosphoinositide- binding proteins, and was identified as TG2 associated in kidney fibrotic 
membranes. This protein binds primarily PI3P on the endosomes and is involved in the 
recycling of proteins such as tTransferrin receptor (TfnR, endocytosed by clathrin-dependent 
receptor-mediated endocytosis) or E-cadherin. : iIt coordinates protein trafficking from the 
early endosome to the perinuclear endocytic recycling compartment by regulating minus-end 
directed trafficking along microtubules, in interaction with the motor protein dynein and with 
tubulin (Traer, et al. 2007). A more recent paper also suggested a possible interaction of Snx4 
with Flot2 in the regulation of recycling traffickingprotein recycling, a process that also 
involves the small GTPase Rab11a (Solis, et al. 2013).  
 
 
A.4.10 Unconventional myosins 
In fibrotic conditions, a series of uUnconventional myosins (myosin Ii class  - myosins 
MYO1B_MOUSE, MYO1D_MOUSE and MYO1G_MOUSE -  and myosin XVIII class - 
MY18A_MOUSE) were identified as associated toassociated with TG2, while no myosin was co-
precipitated with the enzyme in healthy conditions. While conventional myosins (Class class II 
myosins – muscle type myosins) mediate cytokinesis/cell motility in muscular and non-
muscular cells and obviously  contraction of muscular tissue, in association with actin filaments 
and in an ATP-dependent manner, unconventional myosins have different shapes and classes 
and can be associated toassociated with membrane trafficking. Myosins of class I are probably 
the more studied unconventional myosins and have been associated, among other functions, 
to the endocytic pathway. Raposo and colleagues, in 1999, have suggested that mMyosin I 
proteins localise in both endosome and lysosome and might mediate protein movement 
between the two compartments by interacting with actin and joininglinking the membranous 
domains to the actin cytoskeleton domains (Raposo, et al. 1999). Moreover, Mmyosin I has also 
been suggested to be involved also in secretory vesicles transport from the Golgi network 
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(DePina and Langford 1999), in endocytosis (micropinocytosis and phagocytosis),  and 
probably in some exocytic pathways (Mermall, Post and Mooseker 1998).  
The role of mMyosin I in membrane trafficking is possibly due to its role in mediating the 
adhesion between membrane and cytoskeleton, that stimulates membrane tension and its 
subsequent deformation in the processes of endocytosis, exocytosis and vesicle budding 
(Nambiar, McConnell and Tyska 2009).  
Myosin XVIII is another unconventional myosin possibly involved in vesicular movement. The 
protein, in fact, has been suggested to mediate the regulation of Golgi structures and vesicle 
budding from the Golgi network,  by tethering the Golgi membrane to the cytoskeleton and 
possibly generating membrane tension and /deformation (Dippold, et al. 2009, Taft, et al. 
2013).  
 
 
A.4.11 Retromer complex proteins 
A quite substantial portion of TG2-associated proteins was recognised to be involved in the 
rRetromer complex mechanism (Fig. III). 
 
Figure III: TG2-associated partners involved in retromer complex mechanisms. The figure above 
summarizes the main proteins involved in retromer transport from the endosome to the Golgi and from 
the eEndosome to the plasma membrane. In red are highlighted the proteins identified as TG2 associated 
in Fibrotic fibrotic (UUO) kidney membranes by SWATHTM.-MS in the current study, while in green are 
the TG2-associated partners in healthy conditions (Chapter IV). 
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A.4.11.1 Sorting nexins 1 and sorting nexin 3 
Two sorting nexin proteins, Snx1 and Snx3, were identified as associated toassociated with 
TG2 in kidney membranes, the first in mice subjected to UUO, and the second in Sham operated 
mice.  
Sorting nexin 1 (Snx1) (SNX1_MOUSE) is a known member of the Snx-BAR dimer involved in 
tubular endosome deformation/elongation,  necessary for the Snx-BAR retromer trafficking 
from the endosomal compartment to the TGN or to the plasma membrane.  
Sorting nexin 3 (Snx3) (SNX3_MOUSE) is involved as well in the retromer trafficking by 
mediating cargo-selective trimer (CST) recruitment to the endosomal membrane together with 
Rab7 (Harbour, et al. 2010). It is also likely to act as a component of an Snx-BAR-
independent/Snx3-dependent retromer complex, involved for examples in wWingless protein 
trafficking to the Golgi (Harterink, et al. 2011, Zhang, et al. 2011, Cullen and Korswagen 2012).  
 
A.4.11.2 Vacuolar sorting protein 35 
Vacuolar sorting protein 35 (Vps35) is a key component of the Cargo Selective Trimer 
(CST)CST of the retromer complex, and was identified as TG2 associated in healthy kidney 
membranes (VPS35_MOUSE). The protein is necessary for the selection of protein cargo to the 
complex; , as part of the trimer, it plays a key role acts in both SNX-BAR and Snx3 retromer 
trafficking,  and is also involved in binding to the WASH complex for endosome-to- plasma 
membrane recycling.  
 
A.4.11.3 Dynactin 
Dynactin subunit 1, also known as p150Glued, protein, was identified as TG2 associated in 
Fibrotic fibrotic conditions (DCTN1_MOUSE). This protein is a necessary component of the 
dynactin complex, that mediates the binding of vesicles or organelles to the motor protein 
dynamin, necessary for their retrograde transport along microtubules. Dynamin- mediated 
trafficking along microtubules goes from the plus-end (exposed β-tubulin subunits) of the 
microtubule towards the minus-end of the microtubule (exposed α-tubulin subunits), that 
means that the trafficking generally goes from the cell periphery towards the centrosome – 
microtubule organisation centre, close to the Golgi (Cooper 2000).  Dynactin interacts with 
dynein directly through DCTN1 and mediates the connection between the organelle/vesicle to 
the motor protein(Vaughan and Vallee 1995). As suggested before, retromer complex 
associates with dynactin, and the association is needed for endosomal tubules tracking along 
microtubules to the minus-end where the TGN is locateds (Wassmer, et al. 2009, Hong, et al. 
2009) .  
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A.4.12 Other vesicular-associated proteins 
A.4.12.1 Small GTPase Rab1 and small GTPase Sar1b 
Small GTPase Rab1 and Small GTPase Sar1b were both identified as TG2 associated in 
fibrotic kidney membranes. Rab1 (RAB1_MOUSE) is a small GTPase of the Rab family of 
trafficking regulators and is involved mainly in the regulation of the vesicular trafficking from 
the ER to the Ciscis-Golgi network, with a direct effect on the conventional protein secretion. 
The protein is involved in the budding of COPII vesicles from the ER, as well as tethering of the 
same vesicles at the cis-Golgi (Nuoffer, et al. 1994, Allan, Moyer and Balch 2000, Moyer, Allan 
and Balch 2001, Filipeanu, et al. 2004).  
Sar1b (SAR1B_MOUSE), on the other side, belongs to the ARF family of small GTPases. 
Similarly to Rab1, the protein has been suggested to be involved in ER-to-Golgi trafficking by 
mediating COPII recruitment and subsequent vesicle formation. The protein is a component of 
the COPII coat complex, which is necessary for coat formation and cargo loading into the 
vesicle. The GTP-bound form of the protein (activated by Sec12 protein) binds the ER 
membrane and recruits a complex of COPII-coat Sec proteins (Sec23/Sec24 + Sec13/Sec31), 
that determine cargo protein selection to the membrane,  and membrane deformation leading 
to vesicle budding (Szul and Sztul 2011).  
 
A.4.12.2 Coatomer 
Coatomer subunit β protein is a TG2-associated protein identified in fibrotic kidney 
membrane only (COPB2_MOUSE). Coatormer proteins are members of a coatomer complex 
that forms COPI vesicles, mediating both anterograde trafficking trough the Golgi cisternae and 
retrograde Golgi-to-ER transport of proteins. The recruitment of COPI complex (coatomer 
proteins) to the membranes is mediated by ARF proteins of class I (Arf1, Arf2 and Arf3) and 
possibly class II (Arf4 and Arf5) (Szul and Sztul 2011).  
 
A.4.12.3 Transitional endoplasmic reticulum ATPase TERA 
Transitional Endoplasmic Reticulum ATPase TERA, also known as valosin-containing 
protein Vcp (TERA_MOUSE),  was identified as TG2 associated in both UUO and Sham operated 
kidney membranes. This protein has mainly been associated toassociated with the formation 
of the transitional endoplasmic reticulum (tER), the area where the newly synthesized proteins 
leave the ER into vesicles. It acts as a molecular chaperone and plays a role in targeting of 
misfolded proteins from the ER  directly to the proteasome,  for degradation by endoplasmic-
reticulum-associated protein degradation (ERAD), and it generally plays a role in ubiquitin-
dependent protein degradation (Dai and Li 2001, Vij 2008). Moreover, it has been shown to 
bind both clathrin and Hsc70 (Pleasure, Black and Keen 1993).  
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A.4.12.4 Small GTPase Rab10 and TBC1 domain family member 9B 
Small GTPase Rab10 and TBC1-domain Family family member 9b were both detected as TG2 
associated in Sham operated kidneys.  
Small GTPase Rab10 (RAB10_MOUSE) is a known regulator of ER morphology (English and 
Voeltz 2013) and of conventional trafficking from TGN to the plasma membrane (Chen, et al. 
2012, Wang, et al. 2010), but has also been reported to be involved in the regulation of protein 
recycling in polarised cells (Babbey, et al. 2006, Schuck, et al. 2007).  
TBC1 domain family member 9B (TBC9B_MOUSE) is a protein characterised by the TBC-
domain, a well conserved ~200 aminoacids domain typical of Rab-inactivating proteins named 
GAPs (GTPase-activating proteins). GAP proteisproteins, in fact,  promote the hydrolysis GTP 
to GDP, that leads to Rab inactivation (Pan, et al. 2006a, Pfeffer 2013). 
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